PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DIAZ, P; GONZALEZ, C; GALLEGUILLOS, F; ANCIC, P; KAY, AB				DIAZ, P; GONZALEZ, C; GALLEGUILLOS, F; ANCIC, P; KAY, AB			EOSINOPHILS AND MACROPHAGES IN BRONCHIAL MUCUS AND BRONCHOALVEOLAR LAVAGE DURING ALLERGEN-INDUCED LATE-PHASE ASTHMATIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									BROMPTON HOSP,INST CARDIOTHORAC,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital	DIAZ, P (corresponding author), CLIN ENFERMEDADES RESP,SANTIAGO,CHILE.								0	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	2	S			244	244						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD38					2022-12-18	WOS:A1986AZD3800491
J	SPIEKSMA, FTM; VOOREN, PH; KRAMPS, JA; DIJKMAN, JH				SPIEKSMA, FTM; VOOREN, PH; KRAMPS, JA; DIJKMAN, JH			RESPIRATORY ALLERGY TO LABORATORY FRUIT-FLIES (DROSOPHILA-MELANOGASTER)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SPIEKSMA, FTM (corresponding author), STATE UNIV LEIDEN HOSP, DEPT PULMONOL, AEROBIOL LAB, RIJNSBURGERWEG 10, 2333 AA LEIDEN, NETHERLANDS.							ARBESMAN CE, 1977, INT ARCH ALLER A IMM, V53, P310, DOI 10.1159/000231767; BAGENSTOSE AH, 1980, J ALLERGY CLIN IMMUN, V65, P71, DOI 10.1016/0091-6749(80)90180-3; BERNSTEIN DI, 1983, J ALLERGY CLIN IMMUN, V72, P475, DOI 10.1016/0091-6749(83)90584-5; BERNTON HS, 1967, ANN ALLERGY, V25, P381; BESSOT JC, 1978, REV FR ALLERGOL, V18, P19, DOI 10.1016/S0335-7457(78)80043-4; BURGE PS, 1979, CLIN ALLERGY, V9, P185, DOI 10.1111/j.1365-2222.1979.tb01540.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; ELRAB MOG, 1980, J ALLERGY CLIN IMMUN, V66, P190; Figley KD, 1929, AM J MED SCI, V178, P338; FIGLEY KD, 1940, J ALLERGY, V11, P376; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P345, DOI 10.1016/0091-6749(83)90090-8; KINO T, 1978, J ALLERGY CLIN IMMUN, V61, P10, DOI 10.1016/0091-6749(78)90467-0; Klaschka F, 1976, Z Hautkr, V51, P177; LANGLOIS C, 1963, J ALLERGY, V34, P385, DOI 10.1016/0021-8707(63)90001-7; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MENON MPS, 1977, CLIN ALLERGY, V7, P365, DOI 10.1111/j.1365-2222.1977.tb01464.x; OSGOOD H, 1957, J ALLERGY, V28, P292, DOI 10.1016/0021-8707(57)90039-4; PARLATO SJ, 1930, J ALLERGY, V1, P307; PERLMAN F, 1958, J ALLERGY, V29, P302, DOI 10.1016/0021-8707(58)90037-6; RUDOLPH R, 1979, ALLERGOLOGIE, V2, P249; STOCKLEY RA, 1982, CLIN ALLERGY, V12, P151, DOI 10.1111/j.1365-2222.1982.tb01634.x; STORMS WW, 1981, CLIN ALLERGY, V11, P55, DOI 10.1111/j.1365-2222.1981.tb01566.x; VANDERPLAS K, 1982, EUR J RESPIR DIS, V63, P449	24	27	28	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				108	113		10.1016/0091-6749(86)90331-3	http://dx.doi.org/10.1016/0091-6749(86)90331-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3080509				2022-12-18	WOS:A1986AZD3600019
J	MEGGS, WJ; ATKINS, FM; WRIGHT, R; FISHMAN, M; KALINER, MA; METCALFE, DD				MEGGS, WJ; ATKINS, FM; WRIGHT, R; FISHMAN, M; KALINER, MA; METCALFE, DD			FAILURE OF SULFITES TO PRODUCE CLINICAL-RESPONSES IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS OR RECURRENT ANAPHYLAXIS - RESULTS OF A SINGLE-BLIND STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205; NATL JEWISH HOSP & RES CTR,NATL ASTHMA CTR,DEPT PEDIAT,DENVER,CO 80206	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Jewish Health	MEGGS, WJ (corresponding author), NIAID,MAST CELL PHYSIOL SECT,BLDG 10,RM 11C-208,BETHESDA,MD 20205, USA.							ALLEN DH, 1981, J ALLERGY CLIN IMMUN, V67, P71; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BAKER GJ, 1982, AUST NZ J MED, V12, P213; BAKER GJ, 1981, MED J AUSTRALIA, V2, P614, DOI 10.5694/j.1326-5377.1981.tb113018.x; CHICHESTER DF, 1972, HDB FOOD ADDITIVES, V1, P142; CLAYTON DE, 1980, CLIN ALLERGY, V10, P341, DOI 10.1111/j.1365-2222.1980.tb02116.x; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; FRIERI M, 1985, AM J MED, V78, P9, DOI 10.1016/0002-9343(85)90454-1; GUNNISON AF, 1977, TOXICOL APPL PHARM, V42, P99, DOI 10.1016/0041-008X(77)90200-9; HALD A, 1952, STATISTICAL TABLES F, P66; HUANG AS, 1984, NEW ENGL J MED, V311, P542; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; PRENNER BM, 1976, ANN ALLERGY, V37, P180; ROSENBAUM RC, 1984, J NUCL MED, V25, P859; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SIMON R A, 1982, Journal of Allergy and Clinical Immunology, V69, P118; SONIN L, 1985, J ALLERGY CLIN IMMUN, V75, P67, DOI 10.1016/0091-6749(85)90014-4; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V67, P3; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; WERTH GR, 1982, J ALLERGY CLIN IMMUN, V70, P143, DOI 10.1016/0091-6749(82)90243-3	24	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					840	846		10.1016/0091-6749(85)90758-4	http://dx.doi.org/10.1016/0091-6749(85)90758-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	3905921	Bronze			2022-12-18	WOS:A1985AWX9300014
J	BLEECKER, ER				BLEECKER, ER			AIRWAYS REACTIVITY AND ASTHMA - SIGNIFICANCE AND TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									JOHNS HOPKINS MED INST,FRANCIS SCOTT KEY MED CTR,DIV PULM MED,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine	BLEECKER, ER (corresponding author), JOHNS HOPKINS UNIV HOSP,SCH MED,BALTIMORE,MD 21205, USA.							BAHOUS J, 1984, AM REV RESPIR DIS, V129, P216; BAIGELMAN W, 1983, AM J MED, V75, P929, DOI 10.1016/0002-9343(83)90871-9; BARTER CE, 1976, AM REV RESPIR DIS, V113, P305; BICZKO GB, 1984, AM REV RESPIR DIS, V129, P12; BLEECKER ER, 1985, CHEST, V87; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRITT E J, 1980, Chest, V77, P260; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1983, CHEST, V84, P657, DOI 10.1378/chest.84.6.657; BURROWS B, 1982, J ALLERGY CLIN IMMUN, V70, P199, DOI 10.1016/0091-6749(82)90042-2; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CERRINA J, 1981, AM REV RESPIR DIS, V123, P156; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; COCKCROFT DW, 1977, AM REV RESPIR DIS, V119, P429; EASTON JG, 1981, J ALLERGY CLIN IMMUN, V67, P388, DOI 10.1016/0091-6749(81)90084-1; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GRIFFIN MP, 1983, J ALLERGY CLIN IMMUN, V71, P331, DOI 10.1016/0091-6749(83)90088-X; HARGREAVE FE, 1980, AIRWAY REACTIVITY ME, P216; ISLAM MS, 1972, INT ARCH ARBEITSMED, V29, P221, DOI 10.1007/BF00539250; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; KLEIN RC, 1966, J ALLERGY, V37, P158, DOI 10.1016/0021-8707(66)90090-6; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LEE LY, 1977, J APPL PHYSIOL, V43, P626, DOI 10.1152/jappl.1977.43.4.626; LEHRER SB, 1980, AM REV RESPIR DIS, V121, P168; MACKLEM PT, 1979, LUNG TRANSITION HLTH, P389; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; NADEL JA, 1984, J ALLERGY CLIN IMMUN, V73, P651, DOI 10.1016/0091-6749(84)90299-9; ORIE NGM, 1961, INT BRONCHITIS S, P43; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PERMUTT S, 1977, ASTHMA PHYSL IMMUNOP, P265; RANSDELL JW, 1982, AM REV RESPIR DIS, V128, P829; SILVERMAN H, 1982, PHYSIOLOGIST, V25, P307; SMITH JM, 1983, ALLERGY PRINCIPLES P, V2, P771; TATTERSFIELD AE, 1982, PHARMACOL THERAPEUT, V17, P299, DOI 10.1016/0163-7258(82)90019-5; WALDEN SM, 1984, AM REV RESPIR DIS, V130, P357; WEBBJOHNSON DC, 1977, NEW ENGL J MED, V297, P476; WOLFE JD, 1979, J ALLERGY CLIN IMMUN, V63, P162; 1983, RFPNHLBI8411 NIH NAT	43	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					21	24		10.1016/0091-6749(85)90006-5	http://dx.doi.org/10.1016/0091-6749(85)90006-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	3968325				2022-12-18	WOS:A1985ABF2600002
J	ORGEL, HA; KEMP, JP; TINKELMAN, DG; WEBB, DR				ORGEL, HA; KEMP, JP; TINKELMAN, DG; WEBB, DR			BITOLTEROL AND ALBUTEROL METERED-DOSE AEROSOLS - COMPARISON OF 2 LONG-ACTING BETA-2-ADRENERGIC BRONCHODILATORS FOR TREATMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BEREZUK GP, 1983, CLIN PHARMACY, V2, P129; CAMPBELL SC, UNPUB BRONCHODILATOR; CHOOKANG YF, 1973, PRACTITIONER, V211, P801; CHOOKANG YF, 1969, BMJ-BRIT MED J, V2, P287, DOI 10.1136/bmj.2.5652.287; CONWAY WD, 1968, J PHARM SCI-US, V57, P1135, DOI 10.1002/jps.2600570710; FALLIERS CJ, 1981, ANN ALLERGY, V47, P387; GEORGE RB, 1981, ANN ALLERGY, V47, P384; JENKINSON SG, 1977, ANN ALLERGY, V39, P423; Kanner R.E., 1975, CLIN PULMONARY FUNCT; KASS I, 1980, CHEST, V78, P283, DOI 10.1378/chest.78.2.283; KEMP JP, 1984, J ALLERGY CLIN IMMUN, V73, P32, DOI 10.1016/0091-6749(84)90481-0; KENNEDY M C S, 1969, British Journal of Diseases of the Chest, V63, P165, DOI 10.1016/S0007-0971(69)80014-8; LITTNER MR, 1983, ANN ALLERGY, V50, P309; MAHAJAN VK, 1977, ANN ALLERGY, V39, P319; MINATOYA H, 1978, J PHARMACOL EXP THER, V206, P515; MINATOYA H, 1974, PHARMACOLOGIST, V16, P211; RIDING W D, 1970, British Journal of Diseases of the Chest, V64, P37, DOI 10.1016/S0007-0971(70)80047-X; SHARGEL L, 1976, DRUG METAB DISPOS, V4, P65; SHEPHERD GL, 1981, BRIT J DIS CHEST, V75, P215, DOI 10.1016/0007-0971(81)90057-7; SNIDER GL, 1972, J AMER MED ASSOC, V221, P682, DOI 10.1001/jama.221.7.682; SPECTOR SL, 1977, J ALLERGY CLIN IMMUN, V59, P280, DOI 10.1016/0091-6749(77)90048-3; TALA E, 1971, POSTGRAD MED J, V47, P61; TATTERSFIELD AE, 1969, NEW ENGL J MED, V281, P1323, DOI 10.1056/NEJM196912112812402	23	27	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					55	62		10.1016/0091-6749(85)90012-0	http://dx.doi.org/10.1016/0091-6749(85)90012-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	3968329				2022-12-18	WOS:A1985ABF2600008
J	ELLIS, EF				ELLIS, EF			INHIBITION OF EXERCISE-INDUCED ASTHMA BY THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ELLIS, EF (corresponding author), SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY 14260, USA.							AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; AUBIER M, 1983, AM REV RESPIR DIS, V127, P148; BADIEI B, 1975, ANN ALLERGY, V35, P32; BIERMAN CW, 1975, JAMA-J AM MED ASSOC, V234, P295; BIERMAN CW, 1977, PEDIATRICS, V60, P845; CHRYSSANTHOPOULOS C, 1979, ANN ALLERGY, V42, P355; EGGLESTON PA, 1981, CHEST, V79, P399, DOI 10.1378/chest.79.4.399; GODFREY S, 1975, PEDIATRICS, V56, P930; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; MATTHAY RA, 1982, AM HEART J, V104, P1022, DOI 10.1016/0002-8703(82)90435-5; MATTHAY RA, 1978, AM J MED, V65, P903, DOI 10.1016/0002-9343(78)90741-6; MURPHY GW, 1968, CIRCULATION, V37, P361, DOI 10.1161/01.CIR.37.3.361; PARKER JO, 1967, CIRCULATION, V35, P365, DOI 10.1161/01.CIR.35.2.365; PARKER JO, 1966, CIRCULATION, V33, P17, DOI 10.1161/01.CIR.33.1.17; PHILLIPS MJ, 1981, BRIT J DIS CHEST, V75, P181, DOI 10.1016/0007-0971(81)90051-6; POLLOCK J, 1977, PEDIATRICS, V60, P840; SEALE JP, 1977, AUST NZ J MED, V7, P270, DOI 10.1111/j.1445-5994.1977.tb03685.x; SEALE JP, 1975, AUST NZ J MED, V5, P466; SIGRIST S, 1982, AM REV RESPIR DIS, V126, P46; 1983, GUIDELINES DOPING CO	20	27	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					690	692		10.1016/0091-6749(84)90307-5	http://dx.doi.org/10.1016/0091-6749(84)90307-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6715732				2022-12-18	WOS:A1984SS04600014
J	OWNBY, DR; ANDERSON, JA; JACOBS, GL; HOMBURGER, HA				OWNBY, DR; ANDERSON, JA; JACOBS, GL; HOMBURGER, HA			DEVELOPMENT AND COMPARATIVE-EVALUATION OF A MULTIPLE-ANTIGEN RAST AS A SCREENING-TEST FOR INHALANT ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HENRY FORD HOSP,DEPT PEDIAT,DETROIT,MI 48202; MAYO CLIN & MAYO FDN,DEPT LAB MED,ROCHESTER,MN 55901	Henry Ford Health System; Henry Ford Hospital; Mayo Clinic	OWNBY, DR (corresponding author), HENRY FORD HOSP,DIV ALLERGY & CLIN IMMUNOL,PEDIAT ALLERGY IMMUNOL LAB,DETROIT,MI 48202, USA.							FOX DJ, 1978, DOCUMENTATION MIDAS; FROMER JM, 1980, J ALLERGY CLIN IMMUN, V65, P203; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; HOMBURGER HA, 1982, J ALLERGY CLIN IMMUN, V70, P474, DOI 10.1016/0091-6749(82)90011-2; JACOB GL, 1983, J ALLERGY CLIN IMMUN, V71, P122, DOI 10.1016/0091-6749(83)90260-9; JOHNSTONE DE, 1983, NEW ENGL J MED, V308, P1598; KAJOSAARI M, 1981, ALLERGY, V36, P329, DOI 10.1111/j.1398-9995.1981.tb01584.x; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MERRETT J, 1978, CLIN ALLERGY, V8, P235, DOI 10.1111/j.1365-2222.1978.tb03219.x; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; ORTOLANI C, 1981, CLIN ALLERGY, V11, P249, DOI 10.1111/j.1365-2222.1981.tb01591.x; SAARINEN UM, 1982, ACTA PAEDIATR SCAND, V71, P489, DOI 10.1111/j.1651-2227.1982.tb09457.x; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P59; VECCHIO TJ, 1966, NEW ENGL J MED, V274, P1171, DOI 10.1056/NEJM196605262742104	15	27	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					466	472		10.1016/0091-6749(84)90356-7	http://dx.doi.org/10.1016/0091-6749(84)90356-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6608549	Bronze			2022-12-18	WOS:A1984SM08900007
J	SHEPPARD, D; EPSTEIN, J; SKOOGH, BE; BETHEL, RA; NADEL, JA; BOUSHEY, HA				SHEPPARD, D; EPSTEIN, J; SKOOGH, BE; BETHEL, RA; NADEL, JA; BOUSHEY, HA			VARIABLE INHIBITION OF HISTAMINE-INDUCED BRONCHOCONSTRICTION BY ATROPINE IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center					NHLBI NIH HHS [HL-24136, HL-07159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDOUVAKIS J, 1981, BRIT J DIS CHEST, V75, P295, DOI 10.1016/0007-0971(81)90009-7; BOUHUYS A, 1960, CLIN SCI, V19, P79; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GILMAN AG, 1980, GOODMAN GILMANS PHAR, P122; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GRIFFIN MP, 1982, J APPL PHYSIOL, V53, P1576, DOI 10.1152/jappl.1982.53.6.1576; HOLTZMAN MJ, 1983, J APPL PHYSIOL, V54, P134, DOI 10.1152/jappl.1983.54.1.134; HOLTZMAN MJ, 1980, AM REV RESPIR DIS, V122, P17; ITKIN IH, 1970, J ALLERGY, V45, P178, DOI 10.1016/0021-8707(70)90126-7; LEE LY, 1977, J APPL PHYSIOL, V43, P626, DOI 10.1152/jappl.1977.43.4.626; MARINI JJ, 1981, CHEST, V80, P285, DOI 10.1378/chest.80.3.285; MURLAS C, 1982, J APPL PHYSIOL, V52, P1084, DOI 10.1152/jappl.1982.52.4.1084; PEGELOW KO, 1974, ACTA ALLERGOL, V29, P365, DOI 10.1111/j.1398-9995.1974.tb01472.x; SCHILD HO, 1947, BRIT J PHARM CHEMOTH, V2, P189, DOI 10.1111/j.1476-5381.1947.tb00336.x; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169, DOI 10.1152/jappl.1982.53.1.169; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; VIDRUK EH, 1977, J APPL PHYSIOL, V43, P397, DOI 10.1152/jappl.1977.43.3.397; WOENNE R, 1978, J ALLERGY CLIN IMMUN, V62, P119, DOI 10.1016/0091-6749(78)90089-1; ZAR JH, 1974, BIOSTAT ANAL, P175	23	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					82	87		10.1016/0091-6749(84)90488-3	http://dx.doi.org/10.1016/0091-6749(84)90488-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6363488				2022-12-18	WOS:A1984SB99000012
J	CENTER, DM				CENTER, DM			IDENTIFICATION OF RAT MAST CELL-DERIVED CHEMOATTRACTANT FACTORS FOR LYMPHOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP BOSTON,DIV PULM MED,BOSTON,MA 02118; UNIV HOSP BOSTON,EVANS MEM DEPT CLIN RES,BOSTON,MA 02118					Center, David/0000-0002-5879-7978	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019717] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19717] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASKENASE PW, 1979, J ALLERGY CLIN IMMUN, V64, P79, DOI 10.1016/0091-6749(79)90041-1; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BOSWELL RN, 1978, J IMMUNOL, V120, P15; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; CENTER D M, 1980, American Review of Respiratory Disease, V121, P61; CENTER DM, 1982, J IMMUNOL, V128, P2563; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GOETZL E J, 1978, Journal of Immunology, V120, P526; GOETZL EJ, 1977, J CLIN INVEST, V59, P179, DOI 10.1172/JCI108617; KAY AB, 1973, IMMUNOLOGY, V24, P969; KELLER HU, 1977, CLIN EXP IMMUNOL, V27, P377; MCCARTY J, 1979, CELL IMMUNOL, V43, P103, DOI 10.1016/0008-8749(79)90154-0; OERTEL HL, 1981, J IMMUNOL, V127, P1398; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; SCHEFLER NC, 1979, STATISTICS BIOL SCI; SNYDERMAN R, 1972, J IMMUNOL, V108, P857; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; TILNEY NL, 1976, SURGERY, V79, P209; WARD PA, 1969, J IMMUNOL, V102, P93; WASSERMAN SI, 1974, J IMMUNOL, V112, P351; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; YURT RW, 1977, J IMMUNOL, V118, P1201; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	25	27	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					29	35		10.1016/0091-6749(83)90543-2	http://dx.doi.org/10.1016/0091-6749(83)90543-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6600464				2022-12-18	WOS:A1983PZ46100005
J	TING, S; ZWEIMAN, B; LAVKER, R				TING, S; ZWEIMAN, B; LAVKER, R			TERBUTALINE MODULATION OF HUMAN ALLERGIC SKIN REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT DERMATOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	TING, S (corresponding author), WILLIAM BEAUMONT ARMY MED CTR,DEPT MED,ALLERGY & IMMUNOL SERV,EL PASO,TX 79920, USA.				NIAID NIH HHS [AI401, 5T AI 07031, AI14332] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASSEM ESK, 1969, NATURE, V224, P1028, DOI 10.1038/2241028a0; FUGNER A, 1977, INT ARCH ALLER A IMM, V54, P78, DOI 10.1159/000231810; GRONNEBERG R, 1978, ALLERGY, V33, P334; GRONNEBERG R, 1980, ALLERGY, V34, P409; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P193, DOI 10.1016/0091-6749(78)90207-5; KALINER MA, 1974, CYCLIC AMP CELL GROW; Kazimierczak W, 1978, Prog Allergy, V24, P295, DOI 10.1159/000314421; LEVY DA, 1973, J LAB CLIN MED, V81, P291; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; RADERMECKER M, 1981, CLIN ALLERGY, V2, P79; SPECTOR SL, 1978, CHEST, V73, P976, DOI 10.1378/chest.73.6.976; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0	12	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					437	441		10.1016/0091-6749(83)90458-X	http://dx.doi.org/10.1016/0091-6749(83)90458-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6188770				2022-12-18	WOS:A1983QQ74200001
J	ASHMAN, RF; WHITE, RH; WIESENHUTTER, C; CANTOR, Y; LASAROW, E; LIEBLING, M; TALAL, N				ASHMAN, RF; WHITE, RH; WIESENHUTTER, C; CANTOR, Y; LASAROW, E; LIEBLING, M; TALAL, N			PANHYPOGAMMAGLOBULINEMIA IN SYSTEMIC LUPUS-ERYTHEMATOSUS - INVITRO DEMONSTRATION OF MULTIPLE CELLULAR DEFECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024; UNIV TEXAS,SCH MED,SAN ANTONIO,TX 78285	University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System					NIAID NIH HHS [AI15332, AI17990] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI015332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AISENBERG AC, 1978, IMMUNOLOGICAL DISEAS, V1, P530; AMMANN AJ, 1975, AUTOIMMUNITY, P479; ASHMAN RF, 1980, J ALLERGY CLIN IMMUN, V65, P242, DOI 10.1016/0091-6749(80)90151-7; BROOM BC, 1976, CLIN EXP IMMUNOL, V23, P77; DIXON WJ, 1977, BIOMEDICAL COMPUTER, P172; FAUCI AS, 1978, J IMMUNOL, V121, P1473; GINSBURG WW, 1979, CLIN EXP IMMUNOL, V35, P76; HAYNES BF, 1979, CELL IMMUNOL, V44, P169, DOI 10.1016/0008-8749(79)90037-6; KERSEY HL, 1975, BIRTH DEFECTS, V11, P189; KESSLER SW, 1975, J IMMUNOL, V115, P1617; LEVY J, 1972, J CLIN INVEST, V51, P2233, DOI 10.1172/JCI107031; MARKENSON JA, 1978, P SOC EXP BIOL MED, V158, P5; MOROZ C, 1980, CLIN IMMUNOL IMMUNOP, V15, P44, DOI 10.1016/0090-1229(80)90019-7; NIES KM, 1978, ARTHRITIS RHEUM, V21, P51, DOI 10.1002/art.1780210109; NIES KM, 1981, CLIN IMMUNOL IMMUNOP, V19, P118, DOI 10.1016/0090-1229(81)90053-2; RAVECHE ES, 1979, SEMIN HEMATOL, V16, P344; ROBBINS JB, 1966, N ENGL J MED, V274, P606; SAGAWA A, 1978, J CLIN INVEST, V62, P789, DOI 10.1172/JCI109190; SAKANE T, 1979, J CLIN INVEST, V63, P954, DOI 10.1172/JCI109396; SAKANE T, 1978, ARTHRITIS RHEUM, V21, P657, DOI 10.1002/art.1780210608; SAXON A, 1977, J IMMUNOL, V118, P1872; SAXON A, 1978, J CLIN INVEST, V61, P922, DOI 10.1172/JCI109017; Schaller J G, 1975, Birth Defects Orig Artic Ser, V11, P173; SEEGER RC, 1976, CLIN EXP IMMUNOL, V26, P1; SIEGAL FP, 1978, NEW ENGL J MED, V299, P172, DOI 10.1056/NEJM197807272990404; SIEGAL FP, 1976, J CLIN INVEST, V58, P109, DOI 10.1172/JCI108439; SMITH CK, 1970, AM J MED, V48, P113, DOI 10.1016/0002-9343(70)90105-1; TERASAKI PI, 1978, AM J CLIN PATHOL, V69, P103; WALDMANN TA, 1976, FED PROC, V35, P2067; WOLF JK, 1962, NEW ENGL J MED, V266, P473, DOI 10.1056/NEJM196203082661001	30	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					465	473		10.1016/0091-6749(82)90010-0	http://dx.doi.org/10.1016/0091-6749(82)90010-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6216277				2022-12-18	WOS:A1982PT74400010
J	FOX, RW; LOCKEY, RF; BUKANTZ, SC				FOX, RW; LOCKEY, RF; BUKANTZ, SC			NEUROLOGIC SEQUELAE FOLLOWING THE IMPORTED FIRE ANT STING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FOX, RW (corresponding author), UNIV S FLORIDA,COLL MED,JAMES A HALEY VET ADM HOSP,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,TAMPA,FL 33612, USA.							ADROUNY GA, 1959, SCIENCE, V130, P449, DOI 10.1126/science.130.3373.449; ASHWORTH B, 1964, J NEUROL NEUROSUR PS, V27, P542, DOI 10.1136/jnnp.27.6.542; BACHMAN DS, 1982, JAMA-J AM MED ASSOC, V247, P1443, DOI 10.1001/jama.247.10.1443; BAER H, 1979, TOXICON, V17, P397, DOI 10.1016/0041-0101(79)90267-8; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BARR SE, 1971, ANN ALLERGY, V29, P49; BRUMLIK J, 1976, JAMA-J AM MED ASSOC, V235, P2120, DOI 10.1001/jama.235.19.2120; BUFFKIN DC, 1972, TOXICON, V10, P526; CALCUTT CR, 1976, GEN PHARMACOL-VASC S, V7, P15, DOI 10.1016/0306-3623(76)90027-6; GILLIATT RW, 1981, MAYO CLIN PROC, V56, P361; GLASER GH, 1979, TXB NEUROLOGY, P851; GOLDSTEIN NP, 1960, JAMA-J AM MED ASSOC, V173, P1727, DOI 10.1001/jama.1960.73020330011014; HABERMANN E, 1975, TOXICON, V13, P465, DOI 10.1016/0041-0101(75)90176-2; JAMES FK, 1976, J ALLERGY CLIN IMMUN, V58, P110, DOI 10.1016/0091-6749(76)90112-3; JELLINGER K, 1953, WIEN KLIN WOCHENSCHR, V73, P726; JUNG RC, 1964, DERMATOLOGIC TROPICA, V5, P241; KAHN SN, 1981, NEW ENGL J MED, V304, P1430; KAPLAN AP, 1977, CLIN RES, V25, P361; KOCH RB, 1977, BIOCHEM PHARMACOL, V26, P983; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P391, DOI 10.1016/0091-6749(77)90024-0; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; LOFGREN CS, 1975, ANNU REV ENTOMOL, V20, P1, DOI 10.1146/annurev.en.20.010175.000245; MEANS ED, 1973, NEUROLOGY, V23, P881, DOI 10.1212/WNL.23.8.881; PARK AM, 1953, NEUROLOGY, V3, P227; PATERSON PY, 1978, IMMUNOLOGICAL DISEAS, P1411; PEPYS MB, 1979, NEUROIMMUNOLOGY, P155; PINNAS JL, 1977, J ALLERGY CLIN IMMUN, V59, P10, DOI 10.1016/0091-6749(77)90170-1; RHOADES RB, 1977, MED ASPECTS IMPORTED, P1; RHOADES RB, 1977, MED ASPECTS IMPORTED, P43; RHOADES RB, 1977, MED ASPECTS IMPORTED, P50; RODICHOK LD, 1979, HDB CLIN NEUROLOGY, P107; ROSS ALEXANDER T., 1939, JOUR ALLERGY, V10, P382, DOI 10.1016/S0021-8707(39)90154-1; SMITH JD, 1971, ARCH DERMATOL, V103, P438, DOI 10.1001/archderm.103.4.438; WALLACE T W, 1970, Cleveland Clinic Quarterly, V37, P117; YEH JZ, 1975, J PHARMACOL EXP THER, V194, P373	35	27	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	2					120	124		10.1016/0091-6749(82)90239-1	http://dx.doi.org/10.1016/0091-6749(82)90239-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PB591	6808047				2022-12-18	WOS:A1982PB59100008
J	MAGNUSSON, CGM; MASSON, PL				MAGNUSSON, CGM; MASSON, PL			PARTICLE COUNTING IMMUNOASSAY OF IMMUNOGLOBULIN-E ANTIBODIES AFTER THEIR ELUTION FROM ALLERGOSORBENTS BY PEPSIN - AN ALTERNATIVE TO THE RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MAGNUSSON, CGM (corresponding author), CATHOLIC UNIV LOUVAIN,INT INST CELLULAR & MOLEC PATHOL,EXPTL MED UNIT,B-1200 BRUSSELS,BELGIUM.							ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BERRENS L, 1979, ANN ALLERGY, V43, P38; CAMBIASO CL, 1977, J IMMUNOL METHODS, V18, P33, DOI 10.1016/0022-1759(77)90156-9; DEUSCHL H, 1977, CLIN ALLERGY, V7, P195, DOI 10.1111/j.1365-2222.1977.tb01442.x; DORRINGTON KJ, 1978, IMMUNOL REV, V41, P3, DOI 10.1111/j.1600-065X.1978.tb01458.x; ERIKSSON NE, 1977, INT ARCH ALLER A IMM, V54, P88, DOI 10.1159/000231811; GLEICH GJ, 1981, J IMMUNOL, V126, P575; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GUESDON JL, 1978, CLIN EXP IMMUNOL, V33, P430; HELLSING K, 1969, BIOCHEM J, V114, P151, DOI 10.1042/bj1140151; INGANAS M, 1981, INT ARCH ALLER A IMM, V65, P51, DOI 10.1159/000232737; KAISER H, 1965, Z ANAL CHEM FRESENIU, V209, P1; LUNDKVIST U, 1975, ADV DIAGNOSIS ALLERG, P85; MAGNUSSON CGM, 1981, CLIN ALLERGY, V11, P453, DOI 10.1111/j.1365-2222.1981.tb01619.x; Masson P L, 1981, Methods Enzymol, V74 Pt C, P106; MERRETT TG, 1981, IMMUNOL TODAY, V2, P13, DOI 10.1016/0167-5699(81)90005-0; PLATTSMILLS T, 1981, IMMUNOASSAYS 80S, P289; SANTRACH PJ, 1981, J ALLERGY CLIN IMMUN, V67, P97, DOI 10.1016/0091-6749(81)90003-8; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; VAERMAN JP, 1979, J CLIN LAB IMMUNOL, V2, P343; VERVLOET D, 1978, ALLERGY, V33, P203, DOI 10.1111/j.1398-9995.1978.tb01535.x; WIDE L, 1967, LANCET, V2, P1105; WILLIAMS RC, 1972, J CLIN INVEST, V51, P955, DOI 10.1172/JCI106890; Yman L, 1975, Dev Biol Stand, V29, P151; ZEISS CR, 1981, J ALLERGY CLIN IMMUN, V67, P105, DOI 10.1016/0091-6749(81)90004-X; ZEISS CR, 1973, J ALLERGY CLIN IMMUN, V62, P83	28	27	27	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					326	336		10.1016/0091-6749(82)90021-5	http://dx.doi.org/10.1016/0091-6749(82)90021-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	6813364				2022-12-18	WOS:A1982PQ10500003
J	SIEGEL, SC; KATZ, RM; RACHELEFSKY, GS; GELLER, BD; MONTAG, LL; BRANDON, ML; CANNON, SJ				SIEGEL, SC; KATZ, RM; RACHELEFSKY, GS; GELLER, BD; MONTAG, LL; BRANDON, ML; CANNON, SJ			MULTICENTRIC STUDY OF BECLOMETHASONE DIPROPIONATE NASAL AEROSOL IN ADULTS WITH SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									S MIAMI EAR NOSE & THROAT ASSOC,MIAMI,FL; ALLERGY & CLIN IMMUNOL MED GRP,LOS ANGELES,CA; ALLERGY MED GRP,SAN DIEGO,CA; ALLERGY MED CLIN,LOS ANGELES,CA									ANDERSEN JB, 1975, ACTA ALLERGOL, V30, P316, DOI 10.1111/j.1398-9995.1975.tb00208.x; BROWN HM, 1977, BRIT MED J, V1, P376; BROWN HM, 1977, BR J CLIN PHARM, V4, P287; CHATTERJEE S S, 1974, Clinical Allergy, V4, P343, DOI 10.1111/j.1365-2222.1974.tb01395.x; FOULDS WS, 1955, LANCET, V1, P234; GIBSON GJ, 1974, BRIT MED J, V4, P503, DOI 10.1136/bmj.4.5943.503; GODFREY MP, 1957, LANCET, V1, P767; HANSEN IB, 1974, ACTA ALLERGOL, V29, P281, DOI 10.1111/j.1398-9995.1974.tb01655.x; HARRIS DM, 1974, CLIN ALLERGY, V4, P291, DOI 10.1111/j.1365-2222.1974.tb01387.x; HERXHEIMER H, 1956, LANCET, V1, P537; KNIGHT A, 1979, CLIN ALLERGY, V9, P159, DOI 10.1111/j.1365-2222.1979.tb01537.x; MALM L, 1976, ACTA ALLERGOL, V31, P245, DOI 10.1111/j.1398-9995.1976.tb01685.x; MICHELS MI, 1967, ANN ALLERGY, V25, P569; MUNCH E, 1981, CLIN ALLERGY, V11, P303, DOI 10.1111/j.1365-2222.1981.tb01598.x; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; MYGIND N, 1977, BRIT J CLIN PHARMACO, V4, P287; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; NORMAN PS, 1966, J ALLERGY, V38, P93, DOI 10.1016/0021-8707(66)90048-7; POYNTER D, 1977, BRIT J PHARMACOL, V4, P295; SEEBOHM PM, 1978, ALLERGY PRINCIPLES P; SMITH JM, 1975, BRIT MED J, V2, P525; 1980, CLIN ALLERGY, V10, P239	23	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					345	353		10.1016/0091-6749(82)90144-0	http://dx.doi.org/10.1016/0091-6749(82)90144-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL280	7040528				2022-12-18	WOS:A1982NL28000003
J	GARAFALO, J; KAPLAN, AP				GARAFALO, J; KAPLAN, AP			HISTAMINE-RELEASE AND THERAPY OF SEVERE DERMATOGRAPHISM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY STONY BROOK,CTR HLTH SCI,DIV ALLERGY RHEUMATOL & CLIN IMMUN,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					PHS HHS [A1-68131072] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; CARINA N, 1970, J ALLERGY, V45, P266; Lewis T., 1927, BLOOD VESSELS HUMAN; MATTHEWS CN, 1973, BRIT J DERMATOL, V88, P279; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; ROSE BRAM, 1941, JOUR ALLERGY, V12, P327, DOI 10.1016/S0021-8707(41)90260-5; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3	7	27	30	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					103	105		10.1016/0091-6749(81)90166-4	http://dx.doi.org/10.1016/0091-6749(81)90166-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	6166647				2022-12-18	WOS:A1981MD16200004
J	METZGER, WJ; DORMINEY, HC; RICHERSON, HB; WEILER, JM; DONNELLY, A; MORAN, D				METZGER, WJ; DORMINEY, HC; RICHERSON, HB; WEILER, JM; DONNELLY, A; MORAN, D			CLINICAL AND IMMUNOLOGICAL EVALUATION OF GLUTARALDEHYDE-MODIFIED, TYROSINE-ADSORBED SHORT RAGWEED EXTRACT - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BEECHAM LABS,SURREY,ENGLAND	GlaxoSmithKline	METZGER, WJ (corresponding author), UNIV IOWA,HOSP & CLIN,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.				NCRR NIH HHS [RR59] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BUTLER JE, 1978, J IMMUNOL METHODS, V20, P365, DOI 10.1016/0022-1759(78)90272-7; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COCKCROFT DW, 1977, J ALLERGY CLIN IMMUN, V60, P56, DOI 10.1016/0091-6749(77)90083-5; FOUCARD T, 1978, CLIN ALLERGY, V8, P249, DOI 10.1111/j.1365-2222.1978.tb03221.x; JOHANSSON SG, 1974, CLIN ALLERGY, V4, P255, DOI 10.1111/j.1365-2222.1974.tb01383.x; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; MARSH DG, 1970, IMMUNOLOGY, V18, P705; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; METZGER WJ, CLIN ALLERGY; MILLER ACML, 1974, CLIN ALLERGY, V4, P49, DOI 10.1111/j.1365-2222.1974.tb01362.x; MORAN DM, 1976, INT ARCH ALLER A IMM, V50, P693, DOI 10.1159/000231548; MORAN DM, 1977, INT ARCH ALLER A IMM, V54, P315, DOI 10.1159/000231843; MORAN DM, 1978, J IMMUNOL METHODS, V24, P183, DOI 10.1016/0022-1759(78)90099-6; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1978, ALLERGY PRINCIPLES P, P256; NORMAN PS, 1968, J ALLERGY, V42, P94; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V64, P155, DOI 10.1016/0091-6749(79)90089-7; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	21	27	28	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					442	448		10.1016/0091-6749(81)90198-6	http://dx.doi.org/10.1016/0091-6749(81)90198-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	6796618				2022-12-18	WOS:A1981MU79000007
J	MUELLER, U; REISMAN, R; WYPYCH, J; ELLIOTT, W; STEGER, R; WALSH, S; ARBESMAN, C				MUELLER, U; REISMAN, R; WYPYCH, J; ELLIOTT, W; STEGER, R; WALSH, S; ARBESMAN, C			COMPARISON OF VESPID VENOMS COLLECTED BY ELECTROSTIMULATION AND BY VENOM SAC EXTRACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT MED,BUFFALO,NY 14214; SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214; BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center					NIAID NIH HHS [R01-AI14501] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014501] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; ESKRIDGE EM, 1981, TOXICON; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P367, DOI 10.1016/0091-6749(77)90020-3; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; MUELLER U, 1979, Allergy (Copenhagen), V34, P369; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; NAIR BC, 1976, J ALLERGY CLIN IMMUN, V58, P101, DOI 10.1016/0091-6749(76)90111-1; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P281, DOI 10.1016/0091-6749(79)90145-3; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P3, DOI 10.1016/0091-6749(79)90074-5; RICHMAN PG, 1981, ANAL BIOCH; SIMON RP, 1969, ANN ENTOMOL SOC AM, V62, P277, DOI 10.1093/aesa/62.2.277; TALKSDORF S, 1968, WORTHINGTON MANUAL, P35; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0; WYPYCH JI, 1979, J ALLERGY CLIN IMMUN, V63, P267, DOI 10.1016/0091-6749(79)90111-8; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V64, P1, DOI 10.1016/0091-6749(79)90073-3	19	27	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					254	261		10.1016/0091-6749(81)90148-2	http://dx.doi.org/10.1016/0091-6749(81)90148-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	7288046	Bronze			2022-12-18	WOS:A1981ML52500002
J	PATTERSON, R; FINK, JN; MILES, WB; BASICH, JE; SCHLEUTER, DB; TINKELMAN, DG; ROBERTS, M				PATTERSON, R; FINK, JN; MILES, WB; BASICH, JE; SCHLEUTER, DB; TINKELMAN, DG; ROBERTS, M			HYPERSENSITIVITY LUNG-DISEASE PRESUMPTIVELY DUE TO CEPHALOSPORIUM IN HOMES CONTAMINATED BY SEWAGE FLOODING OR BY HUMIDIFIER WATER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University	PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY SECT,CHICAGO,IL 60611, USA.				NHLBI NIH HHS [HL 15389] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		EDWARDS C, 1974, BRIT J DIS CHEST, V68, P57, DOI 10.1016/0007-0971(74)90010-2; FINK JN, 1978, ALLERGY PRINCIPLES P, P855; HUNTER WM, 1974, BRIT MED BULL, V30, P18, DOI 10.1093/oxfordjournals.bmb.a071161; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P67, DOI 10.1016/0091-6749(78)90227-0; MILLER MM, 1976, CLIN ALLERGY, V6, P451, DOI 10.1111/j.1365-2222.1976.tb01929.x; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V62, P103, DOI 10.1016/0091-6749(78)90086-6; PATTERSON R, 1976, AM J MED, V60, P144, DOI 10.1016/0002-9343(76)90543-X; SALMON GE, 1969, J IMMUNOL, V103, P139	9	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					128	132		10.1016/0091-6749(81)90171-8	http://dx.doi.org/10.1016/0091-6749(81)90171-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	6788828				2022-12-18	WOS:A1981MD16200009
J	SALE, SR; ROACH, DE; ZEISS, CR; PATTERSON, R				SALE, SR; ROACH, DE; ZEISS, CR; PATTERSON, R			CLINICAL AND IMMUNOLOGICAL CORRELATIONS IN TRIMELLITIC ANHYDRIDE AIRWAY SYNDROMES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; THREE M CO,DEPT MED,ST PAUL,MN 55101	Northwestern University; 3M					NHLBI NIH HHS [HL 15389] Funding Source: Medline; NIAID NIH HHS [AI 11759] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HERBERT FA, 1979, CHEST, V76, P546, DOI 10.1378/chest.76.5.546; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; PATTERSON R, 1980, CLIN IMMUNOL IMMUNOP, V15, P357, DOI 10.1016/0090-1229(80)90047-1; PATTERSON R, 1976, AM J MED, V60, P144, DOI 10.1016/0002-9343(76)90543-X; ZEISS CR, 1980, INT ARCH ALLER A IMM, V61, P380; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0; ZEISS CR, 1978, J ALLERGY CLIN IMMUN, V62, P83, DOI 10.1016/0091-6749(78)90083-0; ZEISS CR, 1973, J IMMUNOL, V110, P414; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P16	13	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					188	193		10.1016/0091-6749(81)90182-2	http://dx.doi.org/10.1016/0091-6749(81)90182-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	7264100	Bronze			2022-12-18	WOS:A1981MG54400004
J	BECKER, EL				BECKER, EL			CHEMOTAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BECKER, EL (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PATHOL,FARMINGTON,CT 06032, USA.							ALAN RB, 1978, EXP CELL RES, V111, P191; ASWANIKUMAR S, 1977, BIOCHEM BIOPH RES CO, V74, P810, DOI 10.1016/0006-291X(77)90375-8; ATKINS PC, 1979, J ALLERGY CLIN IMMUN, V64, P251, DOI 10.1016/0091-6749(79)90140-4; BECKER EL, 1978, J CELL BIOL, V77, P329, DOI 10.1083/jcb.77.2.329; BECKER EL, 1972, Z IMMUNITATSFORSCH, V143, P466; BECKER EL, 1979, J RETICULOENDOTH SOC, V26, P701; BECKER EL, 1980, CLIN IMMUNOLOGY, V1, P272; BECKER EL, 1980, 6TH P AM PEPT S ROCK; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BOUCEK MM, 1976, SCIENCE, V193, P905, DOI 10.1126/science.948752; BOXER LA, 1974, NEW ENGL J MED, V291, P1093, DOI 10.1056/NEJM197411212912101; BOXER LA, 1976, NEW ENGL J MED, V295, P1041, DOI 10.1056/NEJM197611042951904; CALEB M, 1977, N ENGL J MED, V297, P102; CHENOWETH DE, 1978, P NATL ACAD SCI USA, V75, P3943, DOI 10.1073/pnas.75.8.3943; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; GALLIN JI, 1974, J CELL BIOL, V62, P594, DOI 10.1083/jcb.62.3.594; GALLIN JI, 1978, LEUKOCYTE CHEMOCYTE; GOLDSTEIN I, 1973, P NATL ACAD SCI USA, V70, P2916, DOI 10.1073/pnas.70.10.2916; HILL HR, 1978, LEUKOCYTE CHEMOTAXIS, P179; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P2640, DOI 10.1073/pnas.76.6.2640; KORCHAK HM, 1978, P NATL ACAD SCI USA, V75, P3813; MALECH H, 1979, CLIN RES, V27, pA590; MALECH HL, 1977, J CELL BIOL, V75, P666, DOI 10.1083/jcb.75.3.666; MARCUS AJ, 1978, J LIPID RES, V19, P793; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; NACCACHE PH, 1977, J CELL BIOL, V73, P428, DOI 10.1083/jcb.73.2.428; NACCACHE PH, 1979, J CELL BIOL, V83, P179, DOI 10.1083/jcb.83.1.179; NACCACHE PH, 1979, BIOCHEM BIOPH RES CO, V87, P292, DOI 10.1016/0006-291X(79)91678-4; NACCACHE PH, 1979, BIOCHEM BIOPH RES CO, V89, P1224, DOI 10.1016/0006-291X(79)92139-9; NIEDEL J, 1979, J BIOL CHEM, V254, P700; ODEA RF, 1978, NATURE LOND, V272, P464; OLIVER JM, 1978, AM J PATHOL, V93, P221; OLIVER JM, 1979, J RETICULOENDOTHEL S, V25, P29; PETROSKI RJ, 1979, AM J PHYSIOL, V237, pC43, DOI 10.1152/ajpcell.1979.237.1.C43; PIKE MC, 1979, P NATL ACAD SCI USA, V76, P2922, DOI 10.1073/pnas.76.6.2922; QUIE PG, 1978, LEUKOCYTE CHEMOTAXIS, P307; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SELIGMANN B, 1980, MOL IMMUNOL, V17, P191, DOI 10.1016/0161-5890(80)90071-1; SHOWELL H J, 1979, Journal of Cell Biology, V83, p246A; SHOWELL HJ, 1976, J EXP MED, V143, P1154, DOI 10.1084/jem.143.5.1154; SHOWELL HJ, 1976, J IMMUNOL, V116, P99; SNYDERMAN R, 1977, J ALLERGY CLIN IMMUN, V60, P121, DOI 10.1016/0091-6749(77)90037-9; SODERSTROM UB, 1979, EXP CELL RES, V121, P325, DOI 10.1016/0014-4827(79)90011-9; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SPILBERG I, 1979, J CLIN INVEST, V63, P85, DOI 10.1172/JCI109282; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; VITKAUSKAS G, MOL IMMUNOL; WASSERMAN SI, 1979, J ALLERGY CLIN IMMUN, V64, P231, DOI 10.1016/0091-6749(79)90137-4; WILLIAMS LT, 1977, P NATL ACAD SCI USA, V74, P1204, DOI 10.1073/pnas.74.3.1204; ZIGMOND SH, 1978, J CELL BIOL, V77, P269, DOI 10.1083/jcb.77.2.269; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	53	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	2					97	105		10.1016/0091-6749(80)90055-X	http://dx.doi.org/10.1016/0091-6749(80)90055-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD119	6249863				2022-12-18	WOS:A1980KD11900002
J	FRANKLIN, EC				FRANKLIN, EC			THE ROLE OF CRYOGLOBULINS AND IMMUNE-COMPLEXES IN VASCULITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FRANKLIN, EC (corresponding author), NYU MED CTR,IRVINGTON HOUSE INST,DEPT MED,NEW YORK,NY 10016, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM002594, P01AM001431] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 02594, AM 01431] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; GOREVIC PD, AM J MED; GREY HM, 1973, SEMIN HEMATOL, V10, P87; Hamburger M I, 1979, Trans Assoc Am Physicians, V92, P104; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; LOCKWOOD CM, 1979, NEW ENGL J MED, V300, P524, DOI 10.1056/NEJM197903083001003; LOSPALLUTO J, 1962, AM J MED, V32, P142, DOI 10.1016/0002-9343(62)90191-2; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MELTZER M, 1966, AM J MED, V40, P828, DOI 10.1016/0002-9343(66)90199-9; THEOFILOPOULOS AN, CLIN IMMUNOLOGY UPDA; Wintrobe MM, 1933, B JOHNS HOPKINS HOSP, V52, P156	11	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	4					269	273		10.1016/0091-6749(80)90020-2	http://dx.doi.org/10.1016/0091-6749(80)90020-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KM254	7419829				2022-12-18	WOS:A1980KM25400002
J	WICHER, K; REISMAN, RE; WYPYCH, J; ELLIOTT, W; STEGER, R; MATHEWS, RS; ARBESMAN, CE				WICHER, K; REISMAN, RE; WYPYCH, J; ELLIOTT, W; STEGER, R; MATHEWS, RS; ARBESMAN, CE			COMPARISON OF THE VENOM IMMUNOGENICITY OF VARIOUS SPECIES OF YELLOW JACKETS (GENUS VESPULA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV GEORGIA,DEPT ENTOMOL,ATHENS,GA 30602; SUNY BUFFALO,DEPT MED,BUFFALO,NY 14214; BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14214; SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	University System of Georgia; University of Georgia; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014501] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI14501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; ELLIOTT WB, 1979, 1979 PITTSB C AN CHE; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; MILLER CDF, 1961, CAN ENTOMOL S, V22; NAIR BC, 1976, J ALLERGY CLIN IMMUN, V58, P101, DOI 10.1016/0091-6749(76)90111-1	5	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	3					244	249		10.1016/0091-6749(80)90047-0	http://dx.doi.org/10.1016/0091-6749(80)90047-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KH358	6774004				2022-12-18	WOS:A1980KH35800013
J	REED, C				REED, C			VARIABILITY OF ANTIGENICITY OF ASPERGILLUS-FUMIGATUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											REED, C (corresponding author), UNIV WISCONSIN,SCH MED,MADISON,WI 53706, USA.								0	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	4					227	229		10.1016/0091-6749(78)90189-6	http://dx.doi.org/10.1016/0091-6749(78)90189-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EV080	75900				2022-12-18	WOS:A1978EV08000014
J	FINDLAY, SR; GILLASPY, JE; LORD, R; WEINER, LS; GRANT, JA				FINDLAY, SR; GILLASPY, JE; LORD, R; WEINER, LS; GRANT, JA			POLISTES WASP HYPERSENSITIVITY - DIAGNOSIS BY VENOM-INDUCED RELEASE OF HISTAMINE INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DEPT MED,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT PEDIAT,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT HUMAN GENET,GALVESTON,TX 77550; TEXAS A&I UNIV,DEPT BIOL,KINGSVILLE,TX 78363	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Texas A&M University System; Texas A&M University Kingsville								BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BENSON RL, 1930, J ALLERGY, V1, P105; BERTON HS, 1965, J ALLERGY, V36, P315; DIRKS TF, 1972, TOXICON, V10, P381, DOI 10.1016/0041-0101(72)90062-1; DIRKS TF, 1971, THESIS U ILLINOIS; GRANT JA, 1975, J IMMUNOL, V114, P1101; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; KERN F, 1976, J ALLERGY CLIN IMMUN, V57, P554, DOI 10.1016/0091-6749(76)90006-3; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LIGHT WC, 1976, J ALLERGY CLIN IMMUN, V58, P322, DOI 10.1016/0091-6749(76)90138-X; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; LOVELESS MH, 1962, J IMMUNOL, V89, P204; MICKS D W, 1960, Tex Rep Biol Med, V18, P624; MUESBECK CFW, 1951, 2 US DEP AGR MON; NAIR BC, 1976, J ALLERGY CLIN IMMUN, V58, P101, DOI 10.1016/0091-6749(76)90111-1; OCONNOR R, 1965, ANN ALLERGY, V23, P151; PARISH HM, 1965, AM J MED SCI, V245, P129; PINNAS JL, 1977, J ALLERGY CLIN IMMUN, V59, P10, DOI 10.1016/0091-6749(77)90170-1; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V56, P443, DOI 10.1016/0091-6749(75)90062-7; REISMAN RE, 1976, J ALLERGY CLIN IMMUN, V57, P547, DOI 10.1016/0091-6749(76)90005-1; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; ZELEZNICK LD, 1977, J ALLERGY CLIN IMMUN, V59, P2, DOI 10.1016/0091-6749(77)90169-5	24	27	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	4					230	235		10.1016/0091-6749(77)90135-X	http://dx.doi.org/10.1016/0091-6749(77)90135-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DX458	71310				2022-12-18	WOS:A1977DX45800005
J	JAMES, FK; PENCE, HL; DRIGGERS, DP; JACOBS, RL; HORTON, DE				JAMES, FK; PENCE, HL; DRIGGERS, DP; JACOBS, RL; HORTON, DE			IMPORTED FIRE ANT HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USA, BROOKE MED CTR, ALLERGY & CLIN IMMUNOL SERV, DEPT MED, FT SAM HOUSTON, TX 78234 USA; USA, BROOKE MED CTR, ALLERGY & CLIN IMMUNOL SERV, DEPT CLINS, FT SAM HOUSTON, TX 78234 USA; WILFORD HALL MED CTR, ALLERGY & CLIN IMMUNOL SERV, LACKLAND AFB, TX USA									ADROUNY GA, 1959, SCIENCE, V130, P449, DOI 10.1126/science.130.3373.449; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BERNTON HS, 1965, J ALLERGY, V36, P315, DOI 10.1016/0021-8707(65)90038-9; BLUM MS, 1958, SCIENCE, V128, P306, DOI 10.1126/science.128.3319.306-a; BLUM MS, 1973, ANN ENTOMOL SOC AM, V66, P702, DOI 10.1093/aesa/66.3.702; BLUM MS, 1973, 7TH P INT C IUSSI LO, P23; BRAND JM, 1973, INSECT BIOCHEM, V3, P45, DOI 10.1016/0020-1790(73)90017-6; BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6; BUFFKIN DC, 1972, TOXICON, V10, P526; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; CARO MR, 1957, ARCH DERMATOL, V75, P475, DOI 10.1001/archderm.1957.01550160001001; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; CHARAVEJ.CC, 1974, J ALLERGY CLIN IMMUN, V53, P104; ELLIOTT WB, 1974, J ALLERGY CLIN IMMUN, V53, P103; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P73; HUNT KJ, 1975, J ALLERGY CLIN IMMUN, V55, P74; ILEA V, 1975, J ALLERGY CLIN IMMUN, V55, P74; JUNG R C, 1963, Dermatol Trop Ecol Geogr, V15, P241; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LOFGREN CS, 1975, ANNU REV ENTOMOL, V20, P1, DOI 10.1146/annurev.en.20.010175.000245; MACCONNELL JG, 1971, TETRAHEDRON, V27, P1129, DOI 10.1016/S0040-4020(01)90860-9; MACCONNELL JG, 1970, SCIENCE, V168, P840, DOI 10.1126/science.168.3933.840; REISMAN RE, 1974, J ALLERGY CLIN IMMUN, V53, P110, DOI 10.1016/0091-6749(74)90076-1; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V55, P79; REISMAN RE, 1973, J ALLERGY CLIN IMMUN, V52, P257, DOI 10.1016/0091-6749(73)90043-2; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V56, P84, DOI 10.1016/0091-6749(75)90112-8; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SOBOTKA A, 1974, J ALLERGY CLIN IMMUN, V53, P103; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; YUNGINGER JW, 1975, J ALLERGY CLIN IMMUN, V55, P74	33	27	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					110	120		10.1016/0091-6749(76)90112-3	http://dx.doi.org/10.1016/0091-6749(76)90112-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	947974				2022-12-18	WOS:A1976BX74200012
J	WEINSTEIN, RE; ANDERSON, JA; KVALE, P; SWEET, LC				WEINSTEIN, RE; ANDERSON, JA; KVALE, P; SWEET, LC			EFFECTS OF HUMIDIFICATION ON EXERCISED-INDUCED ASTHMA (EIA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	3					250	251						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BJ240					2022-12-18	WOS:A1976BJ24000150
J	WILBUR, RD; WARD, GW				WILBUR, RD; WARD, GW			IMMUNOLOGICAL STUDIES IN A CASE OF BAKERS ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY MED CTR,SERV IMMUNOL,ALLERGY CLIN,WASHINGTON,DC 20012	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DAVIES RJ, 1974, CLIN ALLERGY, V4, P227; GELL PGH, 1969, CLINICAL ASPECTS IMM; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; PATTERSON R, 1972, ALLERGIC DISEASES DI, P358; POPA A, 1970, ACTA ALLERGOL, V25, P159; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SCHWARTZ M, 1947, J ALLERGY, V18, P341, DOI 10.1016/0021-8707(47)90081-6; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P219	9	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					366	372		10.1016/0091-6749(76)90116-0	http://dx.doi.org/10.1016/0091-6749(76)90116-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	965616				2022-12-18	WOS:A1976CD45400002
J	MILLER, WL; DOPPMAN, JL; KAPLAN, AP				MILLER, WL; DOPPMAN, JL; KAPLAN, AP			RENAL ARTERIOGRAPHY FOLLOWING SYSTEMIC REACTION TO CONTRAST MATERIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,LAB CLIN INVEST,BETHESDA,MD 20014; NHLI,HYPERTENSION ENDOCRINE BRANCH,BETHESDA,MD 20014; NIH,CLIN CTR,DEPT DIAG RADIOL,BLDG 10,ROOM 11N 246,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)			Miller, Walter L/J-3696-2012					ANSELL G, 1970, INVEST RADIOL, V5, P373; BRASCH RC, 1970, INVEST RADIOL, V5, P510, DOI 10.1097/00004424-197011000-00017; BRYAN GT, 1965, J CLIN INVEST, V44, P957, DOI 10.1172/JCI105213; GATES DF, 1972, J UROLOGY, V108, P627, DOI 10.1016/S0022-5347(17)60821-8; KNOEFEL PE, 1965, DRILLS PHARMACOLOGY, P1434; LASSER EC, 1971, RADIOLOGY, V100, P683, DOI 10.1148/100.3.683; LASSER EC, 1974, RADIOLOGY, V110, P49, DOI 10.1148/110.1.49; LASSER EC, 1968, RADIOLOGY, V91, P63, DOI 10.1148/91.1.63; LASSER EC, 1971, AMER J ROENTGENOL RA, V113, P415; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; ROCKOFF SD, 1970, INVEST RADIOL, V5, P503, DOI 10.1097/00004424-197011000-00016; ROCKOFF SD, 1972, INVEST RADIOL, V7, P177; ROCKOFF SD, 1971, INVEST RADIOL, V6, P186; SANGER MAURY D., 1959, ANN ALLERGY, V17, P762; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; ZWEIMAN B, 1974, J ALLERGY CLIN IMMUN, V53, P97	16	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	4					291	295		10.1016/0091-6749(75)90103-7	http://dx.doi.org/10.1016/0091-6749(75)90103-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AS523					2022-12-18	WOS:A1975AS52300006
J	PATTERSON, R; SCHATZ, M				PATTERSON, R; SCHATZ, M			FACTITIOUS ALLERGIC EMERGENCIES - ANAPHYLAXIS AND LARYNGEAL EDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,MED SCH,DEPT MED,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University								BALLANTYNE J, 1971, SCOTT BROWNS DISEASE; BOOTH BH, 1972, ALLERGIC DISEASES DI, P63; CRAMER B, 1971, ARCH GEN PSYCHIAT, V24, P573; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; GOLBERT TM, 1972, ALLERGIC DISEASES DI, P362; HARVEY AM, 1972, PRINCIPLES PRACTICE; HAWKINGS JR, 1956, BMJ-BRIT MED J, V1, P361, DOI 10.1136/bmj.1.4963.361; HOLLENDER MH, 1973, SOUTH MED J, V66, P1279, DOI 10.1097/00007611-197311000-00020; IRELAND P, 1967, AM J MED, V43, P579, DOI 10.1016/0002-9343(67)90181-7; KELLY JF, 1974, JAMA-J AM MED ASSOC, V227, P1431, DOI 10.1001/jama.1974.03230250055038; MOORE GL, 1973, PSYCHIAT MED, V4, P301; PATTERSON R, 1974, CLIN ALLERGY, V4, P309; PETERSDORF RG, 1957, ANN INTERN MED, V46, P1039, DOI 10.7326/0003-4819-46-6-1039; ROSE E, 1969, ANN INTERN MED, V71, P309, DOI 10.7326/0003-4819-71-2-309; SERVICE FJ, 1974, ARCH INTERN MED, V134, P336, DOI 10.1001/archinte.134.2.336	15	27	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	2					152	159		10.1016/0091-6749(75)90120-7	http://dx.doi.org/10.1016/0091-6749(75)90120-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	AM325	1151010				2022-12-18	WOS:A1975AM32500009
J	RHOADES, RB; SCHAFER, WL; SCHMID, WH; WUBBENA, PF; DOZIER, RM; TOWNES, AW; WITTIG, HJ				RHOADES, RB; SCHAFER, WL; SCHMID, WH; WUBBENA, PF; DOZIER, RM; TOWNES, AW; WITTIG, HJ			HYPERSENSITIVITY TO IMPORTED FIRE ANT - REPORT OF 49 CASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32610	State University System of Florida; University of Florida								BLUM MS, 1972, TOXICON, V10, P259; BLUM MURRAY S., 1961, PSYCHE, V68, P73, DOI 10.1155/1961/80747; BOWEN R, 1951, South Med J, V44, P836, DOI 10.1097/00007611-195109000-00014; BROWN LL, 1972, SOUTHERN MED J, V65, P273, DOI 10.1097/00007611-197203000-00003; BUREN W F, 1972, Journal of the Georgia Entomological Society, V7, P1; BUREN W F, 1970, Journal of the Georgia Entomological Society, V5, P185; BUREN WF, 1974, COMMUNICATION; CARO MR, 1957, ARCH DERMATOL, V75, P475, DOI 10.1001/archderm.1957.01550160001001; FAVORITE FG, 1958, PUBLIC HEALTH REP, V73, P445, DOI 10.2307/4590149; Frazier CA, 1969, INSECT ALLERGY ALLER; Helmly R B, 1970, Hawaii Med J, V29, P368; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; LOCKEY RF, 1973, COMMUNICATION; MICKS D W, 1960, Tex Rep Biol Med, V18, P624; OLIVE AT, 1960, J ECON ENTOMOL, V53, P646, DOI 10.1093/jee/53.4.646; THOMAS J W, 1959, W V Med J, V55, P115; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019	17	27	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	2					84	93		10.1016/0091-6749(75)90112-8	http://dx.doi.org/10.1016/0091-6749(75)90112-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AM325	239051				2022-12-18	WOS:A1975AM32500001
J	FINK, JN				FINK, JN			HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,WOOD VET ADM HOSP,DEPT MED,RES SERV,ALLERGY SECT,MILWAUKEE,WI 53193	Medical College of Wisconsin								AVILA R, 1967, Jornal do Medico (Porto), V64, P789; BACH C, 1971, PRESSE MED, V79, P383; BARBORIAK JJ, 1965, J LAB CLIN MED, V65, P600; BOYD G., 1967, SCOT MED J, V12, P69; DINDA P, 1969, THORAX, V24, P374, DOI 10.1136/thx.24.3.374; ECKYMANS L, 1968, DIS CHEST, V53, P359; ELGEFORS B, 1971, SCAND J RESPIR DIS, V52, P167; FAUX J A, 1970, Clinical and Experimental Immunology, V7, P897; FAUX J A, 1971, Clinical Allergy, V1, P159, DOI 10.1111/j.1365-2222.1971.tb03015.x; FINK J, 1973, J ALLERGY CLIN IMMUN, V51, P125, DOI 10.1016/S0091-6749(73)80101-0; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; FINK JN, 1972, CHEST, V62, P277, DOI 10.1378/chest.62.3.277; FINK JN, 1969, J LAB CLIN MED, V71, P20; GERMUTH FG, 1961, AM REV RESP DIS, V34, P84; GODFREY S, 1967, P ROY SOC MED, V60, P1088, DOI 10.1177/003591576706011P112; HARGREAVE F, 1972, Clinical Radiology, V23, P1, DOI 10.1016/S0009-9260(72)80126-0; HARGREAVE FE, 1966, LANCET, V1, P446; HENSLEY GT, 1969, ARCH PATHOL, V87, P572; MAESEN FPV, 1972, DUIVENMELKERSLONG; Maloney P, 1967, Med J Aust, V1, P969; Nash E S, 1967, S Afr Med J, V41, P191; PARRISH WE, 1970, LANCET, V2, P591; PEARSALL MR, 1960, B MASON CLIN, V14, P127; Pepys J, 1969, HYPERSENSITIVITY DIS; PLESSNER M, 1960, Arch Mal Prof, V21, P67; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; RICHERSON HB, 1971, AM REV RESPIR DIS, V104, P568; SCHLUETER DP, 1969, ANN INTERN MED, V70, P457, DOI 10.7326/0003-4819-70-3-457; STEIHM ER, 1967, PEDIATRICS, V39, P904; UNGER JD, 1968, RADIOLOGY, V90, P683, DOI 10.1148/90.4.683; WARREN WP, 1972, CHEST, V62, P170, DOI 10.1378/chest.62.2.170; WARREN WP, 1972, CAN MED ASSOC J, V107, P1196	32	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	5					309	317		10.1016/0091-6749(73)90051-1	http://dx.doi.org/10.1016/0091-6749(73)90051-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2087	4270511				2022-12-18	WOS:A1973R208700009
J	NELSON, HS				NELSON, HS			EFFECT OF EPHEDRINE ON RESPONSE TO EPINEPHRINE IN NORMAL MEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS GEN HOSP,ALLERGY IMMUNOL SERV,DENVER,CO 80240									ANTONIS A, 1965, J LIPID RES, V6, P307; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; FIREMAN P, 1970, J ALLERGY, V45, P117; HARRIS WS, 1965, J CLIN INVEST, V44, P1058; HORNBROOK KR, 1970, FED PROC, V29, P1381; INNES IR, 1970, PHARMACOLOGICAL BASI, P481; INNES IR, 1970, PHARMACOL BASIS, P507; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; KIRKPATRICK CH, 1967, AM REV RESPIR DIS, V96, P692; LECKS HI, 1969, J ALLERGY, V44, P261, DOI 10.1016/0021-8707(69)90031-8; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; MASELLI R, 1970, J ALLERGY, V45, P117; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; PORTE D, 1967, J CLIN INVEST, V46, P86, DOI 10.1172/JCI105514; SCHOLZ R, 1959, BIOCHEM Z, V331, P71; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; Winer BJ, 1971, STATISTICAL PRINCIPL, P261	17	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	4					191	198		10.1016/0091-6749(73)90138-3	http://dx.doi.org/10.1016/0091-6749(73)90138-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P3010	4689137				2022-12-18	WOS:A1973P301000001
J	CARR, RI; WOLD, RT; FARR, RS				CARR, RI; WOLD, RT; FARR, RS			ANTIBODIES TO BOVINE GAMMA-GLOBULIN (BGG) AND OCCURRENCE OF A BGG-LIKE SUBSTANCE IN SYSTEMIC LUPUS-ERYTHEMATOSUS SERA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		CARR R I, 1970, Federation Proceedings, V29, P812; CEROTTINI JC, 1968, J IMMUNOL, V101, P433; DIXON FJ, 1958, ARCH PATHOL, V65, P18; DIXON FJ, 1961, J EXP MED, V113, P899, DOI 10.1084/jem.113.5.899; FAHEY JL, 1967, METHODS IMMUNOLOGY I, V1; FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; HOLLAND NH, 1962, J PEDIATR-US, V61, P181, DOI 10.1016/S0022-3476(62)80252-2; HUNTLEY CC, 1971, NEW ENGL J MED, V284, P7, DOI 10.1056/NEJM197101072840102; KOFFLER D, 1967, J EXP MED, V126, P607, DOI 10.1084/jem.126.4.607; KOFFLER D, 1968, AM J MED, V45, P165, DOI 10.1016/0002-9343(68)90034-X; LEDDY JP, 1963, 3 P INT S IMM BAS; LINSCOTT WD, 1963, SCIENCE, V142, P1170, DOI 10.1126/science.142.3596.1170; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MINDEN P, 1967, HDB EXPERIMENTAL IMM; NATVIG JB, 1967, NATURE, V215, P68, DOI 10.1038/215068a0; OSTERLAND CK, 1963, VOX SANG, V8, P133; PIERCE AE, 1965, IMMUNOLOGY, V8, P106; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; Quismorio F P, 1970, CRC Crit Rev Clin Lab Sci, V1, P639, DOI 10.3109/10408367009043922; ROTHBERG RM, 1967, J IMMUNOL, V98, P386; ROTHBERG RM, 1967, J IMMUNOL, V98, P792; ROTHBERG RM, 1965, J ALLERGY, V36, P450, DOI 10.1016/0021-8707(65)90139-5; ROTHBERG RM, 1969, J PEDIATR-US, V75, P391, DOI 10.1016/S0022-3476(69)80264-7; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; Schick B., 1951, SERUM KRANKHEIT; Siegel S., 1956, NONPARAMETRIC STAT B; TAN EM, 1966, J CLIN INVEST, V45, P1732, DOI 10.1172/JCI105479; TOMASI TB, 1969, SECRETORY IMMUNOLOGI	28	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	1					18	&		10.1016/0091-6749(72)90076-0	http://dx.doi.org/10.1016/0091-6749(72)90076-0			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M9284	4113506				2022-12-18	WOS:A1972M928400003
J	Dorgham, K; Quentric, P; Gokkaya, M; Marot, S; Parizot, C; Sauce, D; Guihot, A; Luyt, CE; Schmidt, M; Mayaux, J; Beurton, A; Le Guennec, L; Demeret, S; Ben Salah, E; Mathian, A; Yssel, H; Combadiere, B; Combadiere, C; Traidl-Hoffmann, C; Burrel, S; Marcelin, AG; Amoura, Z; Voiriot, G; Neumann, AU; Gorochov, G				Dorgham, Karim; Quentric, Paul; Gokkaya, Mehmet; Marot, Stephane; Parizot, Christophe; Sauce, Delphine; Guihot, Amelie; Luyt, Charles-Edouard; Schmidt, Matthieu; Mayaux, Julien; Beurton, Alexandra; Le Guennec, Loic; Demeret, Sophie; Ben Salah, Elyes; Mathian, Alexis; Yssel, Hans; Combadiere, Behazine; Combadiere, Christophe; Traidl-Hoffmann, Claudia; Burrel, Sonia; Marcelin, Anne-Genevieve; Amoura, Zahir; Voiriot, Guillaume; Neumann, Avidan U.; Gorochov, Guy			Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19 vaccine; mRNA vaccine; anaphylaxis; al-lergy; polyethylene glycol; PEGylated liposome; lipid nanoparticle; mast cells	INTERFERON; SYSTEM	Anaphylaxis to vaccines is historically a rare event. The coronavirus disease 2019 pandemic drove the need for rapid vaccine production applying a novel antigen delivery system: messenger RNA vaccines packaged in lipid nanoparticles. Unexpectedly, public vaccine administration led to a small number of severe allergic reactions, with resultant substantial public concern, especially within atopic individuals. We reviewed the constituents of the messenger RNA lipid nanoparticle vaccine and considered several contributors to these reactions: (1) contact system activation by nucleic acid, (2) complement recognition of the vaccine-activating allergic effector cells, (3) preexisting antibody recognition of polyethylene glycol, a lipid nanoparticle surface hydrophilic polymer, and (4) direct mast cell activation, coupled with potential genetic or environmental predispositions to hypersensitivity. Unfortunately, measurement of anti- polyethylene glycol antibodies in vitro is not clinically available,and the predictive value of skin testing to polyethylene glycol components as a coronavirus disease 2019 messenger RNA vaccine-specific anaphylaxis marker is unknown. Even less is known regarding the applicability of vaccine use for testing (in vitro/vivo) to ascertain pathogenesis or predict reactivity risk. Expedient and thorough research-based evaluation of patients who have suffered anaphylactic vaccine reactions and prospective clinical trials in putative at-risk individuals are needed to address these concerns during a public health crisis. (J Allergy Clin Immunol 2021;147:2075-82.)	[Dorgham, Karim; Quentric, Paul; Parizot, Christophe; Sauce, Delphine; Guihot, Amelie; Ben Salah, Elyes; Mathian, Alexis; Yssel, Hans; Combadiere, Behazine; Combadiere, Christophe; Amoura, Zahir; Gorochov, Guy] Sorbonne Univ, CIMI Paris, Ctr Immunol & Malad Infect, INSERM, Paris, France; [Gokkaya, Mehmet; Traidl-Hoffmann, Claudia; Neumann, Avidan U.] Univ Hosp Augsburg, Dept Environm Med, Fac Med, Augsburg, Germany; [Gokkaya, Mehmet; Traidl-Hoffmann, Claudia; Neumann, Avidan U.] Tech Univ Munich, Inst Environm Med IEM, Munich, Germany; [Gokkaya, Mehmet; Traidl-Hoffmann, Claudia; Neumann, Avidan U.] Helmholtz ZentrumM unchen, Augsburg, Germany; [Marot, Stephane; Burrel, Sonia; Marcelin, Anne-Genevieve] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ iPLESP, Hop Pitie Salpetriere, AP HP,Inserm,Dept Immunol, Paris, France; [Parizot, Christophe; Ben Salah, Elyes; Neumann, Avidan U.] Hop La Pitie Salpetriere, AP HP, Dept Immunol, Paris, France; [Luyt, Charles-Edouard; Schmidt, Matthieu] Hop La Pitie Salpetriere, AP HP, Serv Med Intens Reanimat, Inst Cardiol, Paris, France; [Luyt, Charles-Edouard; Schmidt, Matthieu] Sorbonne Univ, Inst Cardiometab & Nutr ICAN, INSERM, Paris, France; [Mayaux, Julien; Beurton, Alexandra] Hop La Pitie Salpetriere, AP HP, Serv Pneumol, Med Intens Reanimat, Paris, France; [Beurton, Alexandra] Sorbonne Univ, Neurophysiol Resp Expt & Clin, Inserm UMR S 1158, Paris, France; [Le Guennec, Loic; Demeret, Sophie] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Dept Neurol,Unite Med Intens & Reanimat Neurol, Paris, France; [Mathian, Alexis; Amoura, Zahir] Hop La Pitie Salpetriere, AP HP, Serv Med Interne 2, Inst E3M, Paris, France; [Traidl-Hoffmann, Claudia] Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland; [Voiriot, Guillaume] Hop Tenon, AP HP, Serv Med Intens Reanimat, Paris, France; [Neumann, Avidan U.] Czech Acad Sci, Inst Expt Med IEM, Prague, Czech Republic	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Technical University of Munich; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences	Gorochov, G (corresponding author), Hop La Pitie Salpetriere, Dept Immunol, 83 Bv Hop, F-75013 Paris, France.	guy.gorochov@sorbonne-universite.fr	Yssel, Hans/AFV-2907-2022; Voiriot, Guillaume/AIB-6833-2022; Combadiere, Behazine/S-8054-2019; Burrel, Sonia/GWV-5309-2022; Combadiere, Christophe/I-5639-2013; SAUCE, Delphine/ABE-5975-2020; Dorgham, karim/A-2241-2016; Marot, Stéphane/AAE-8974-2021	Yssel, Hans/0000-0001-7454-1836; Combadiere, Behazine/0000-0002-2353-4406; Combadiere, Christophe/0000-0002-1755-4531; SAUCE, Delphine/0000-0003-4596-7373; Dorgham, karim/0000-0001-9539-3203; Marot, Stéphane/0000-0003-4438-5793; Gorochov, Guy/0000-0003-2097-9677; PARIZOT, Christophe/0000-0001-5723-4471	Fondation de France; "Tous unis contre le virus" framework Alliance (Fondation de France, AP-HP, Institut Pasteur); Agence Nationale de la Recherche (ANR Flash COVID19 program); SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs; Programme Hospitalier de Recherche Clinique [PHRC-20-0375]; Christine Kuhne - Center for Allergy Research and Education; Initiative and Networking Fund (Immunology AMP; Inflammation) of the Helmholtz Association	Fondation de France(Fondation de France); "Tous unis contre le virus" framework Alliance (Fondation de France, AP-HP, Institut Pasteur); Agence Nationale de la Recherche (ANR Flash COVID19 program)(French National Research Agency (ANR)); SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs; Programme Hospitalier de Recherche Clinique; Christine Kuhne - Center for Allergy Research and Education; Initiative and Networking Fund (Immunology AMP; Inflammation) of the Helmholtz Association	This study was supported by the Fondation de France, "Tous unis contre le virus" framework Alliance (Fondation de France, AP-HP, Institut Pasteur) in collaboration with Agence Nationale de la Recherche (ANR Flash COVID19 program), by the SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs, by the Programme Hospitalier de Recherche Clinique PHRC-20-0375 COVID-19 (PI: G.G.), by the Christine Kuhne - Center for Allergy Research and Education (M.G., C.T.-H., and A.U.N.), and by the Initiative and Networking Fund (Immunology & Inflammation) of the Helmholtz Association (M.G., C.T.-H., and A.U.N.).	Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Chen J, 2007, ANNU REV IMMUNOL, V25, P443, DOI 10.1146/annurev.immunol.25.022106.141706; De Luca G, 2020, LANCET RHEUMATOL, V2, pE465, DOI 10.1016/S2665-9913(20)30170-3; Del Valle D.M., 2020, NAT MED, V26, P1636, DOI DOI 10.1038/s41591-020-1051-9; Dorgham K, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.00065-21; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Holly JMP, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.582870; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Liu BX, 2004, J GEN VIROL, V85, P423, DOI 10.1099/vir.0.19596-0; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Mariette X, 2021, LANCET RESP MED, V9, P295, DOI 10.1016/S2213-2600(20)30556-7; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; OLDHAM RR, 1983, SCIENCE, V219, P902, DOI 10.1126/science.6186027; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Schmidt M, 2020, LANCET RESP MED, V8, P1121, DOI 10.1016/S2213-2600(20)30328-3; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Teragawa H, 1996, JPN HEART J, V37, P905; Trouillet-Assant S, 2020, J ALLERGY CLIN IMMUN, V146, P206, DOI 10.1016/j.jaci.2020.04.029; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Yang Q, 2019, ACM T INTEL SYST TEC, V10, DOI 10.1145/3298981; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035	30	26	27	4	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2098	2107		10.1016/j.jaci.2021.03.047	http://dx.doi.org/10.1016/j.jaci.2021.03.047		JUN 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7YB	33894209	Green Published, Bronze, Green Submitted			2022-12-18	WOS:000657814800015
J	He, H; Del Duca, E; Diaz, A; Kim, HJ; Gay-Mimbrera, J; Zhang, N; Wu, JN; Beaziz, J; Estrada, Y; Krueger, JG; Pavel, AB; Ruano, J; Guttman-Yassky, E				He, Helen; Del Duca, Ester; Diaz, Aisleen; Kim, Hyun Je; Gay-Mimbrera, Jesus; Zhang, Ning; Wu, Jianni; Beaziz, Jessica; Estrada, Yeriel; Krueger, James G.; Pavel, Ana B.; Ruano, Juan; Guttman-Yassky, Emma			Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; mild; limited; severity; cytokines; qRT-PCR; OLINK; proteomics; systemic inflammation; immune tolerance	ACTIVATION-REGULATED CHEMOKINE; MACROPHAGE-DERIVED CHEMOKINE; DISEASE SEVERITY; GROWTH-FACTOR; SERUM THYMUS; T-CELLS; MARKERS; BIOMARKERS; BARRIER; MECHANISMS	Background: Molecular studies in atopic dermatitis (AD) are largely restricted to patients with moderate-to-severe disease. Objective: Our aim was to evaluate skin and blood abnormalities in mild, moderate, and severe AD. Methods: Skin and blood samples were obtained from 61 patients with AD (20 with mild or limited disease, 17 with moderate disease, and 24 with severe disease) and 20 healthy subjects. Immune and barrier markers were measured in lesional, nonlesional, and healthy skin by quantitative real-time PCR and immunohistochemistry, and in blood by using the OLINK proteomic assay. Results: Cellular markers of epidermal hyperplasia and T-cell/dendritic cell infiltration were increased in AD tissues of all patients in all severity groups versus in those of controls, whereas downstream T(H)2 cell-, T(H)22 cell-, T(H)1 cell-, and T(H)17 cell-related mediators demonstrated incremental elevations with increasing disease severity, in both lesional and nonlesional skin. Whereas the levels of the T(H)2 (IL13, CCL17, and CCL26) and T(H)22 (IL-22) cytokines were significantly elevated in both AD lesional and nonlesional skin of all patients regardless of the severity of their disease, patients with mild or limited AD showed increases in their levels of T(H)1 cell (IFNG, CXCL9, and CXCL10) and T(H)17 cell (IL-17A, CCL20, and CXCL1) markers in lesional but not nonlesional skin. Regulatory T-cell-related mediators (IL-10 and FOXP3) were comparably upregulated in all groups, without displaying the severity-based gradient in other immune axes. Unsupervised clustering aligned samples along a severity spectrum, where nonlesional mild or limited AD skin clustered with the samples from healthy controls. Furthermore, whereas the blood profiles of patients with moderate and severe AD showed gradual increases in the levels of T(H)1 cell-, T(H)2 cell-, and T(H)17 cell-related and atherosclerosis and/or cardiovascular risk (CCL7, FGF21, and IGFBP1) proteins, the blood profiles of patients with mild or limited AD lacked significant differences from those of the controls. Conclusion: Mild and limited AD show high levels of T(H)2/T(H)22 cell activation that is primarily localized to skin lesions and lacks the systemic inflammation of moderate and severe disease.	[He, Helen; Del Duca, Ester; Diaz, Aisleen; Kim, Hyun Je; Zhang, Ning; Wu, Jianni; Beaziz, Jessica; Estrada, Yeriel; Pavel, Ana B.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Gay-Mimbrera, Jesus; Ruano, Juan] Reina Sofia Univ Hosp, Dept Dermatol, Cordoba, Spain; [Krueger, James G.] Rockefeller Univ, Invest Dermatol Lab, 1230 York Ave, New York, NY 10021 USA; [Pavel, Ana B.] Univ Mississippi, Dept Biomed Engn, Oxford, MS USA	Icahn School of Medicine at Mount Sinai; Hospital Universitario Reina Sofia - Cordoba; Rockefeller University; University of Mississippi	Guttman-Yassky, E (corresponding author), Mt Sinai Med Ctr, Dept Dermatol, Icahn Sch Med, 5 E 98th St, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Mt Sinai Med Ctr, Lab Inflammatory Skin Dis, Icahn Sch Med, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org	Del Duca, Ester/AAC-2711-2022	Del Duca, Ester/0000-0001-7948-8536; Ruano, Juan/0000-0002-0286-4107; , Ana Brandusa/0000-0002-8155-8553	Pfizer ASPIRE Grant [52007983]	Pfizer ASPIRE Grant	Supported by the Pfizer ASPIRE Grant (no. 52007983).	Agrawal R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0433-9; Agrawal R, 2011, CURR PROBL DERMATOL, V41, P112, DOI 10.1159/000323305; Andersen YMF, 2019, DIABETES CARE, V42, P1095, DOI 10.2337/dc18-2158; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Berke R, 2012, AM FAM PHYSICIAN, V86, P35; Bissonnette R, 2019, BRIT J DERMATOL, V181, P733, DOI 10.1111/bjd.17932; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Brunner PM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09207-z; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P118, DOI 10.1016/j.jaci.2015.08.027; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Ellis KL, 2004, PEDIATR DERMATOL, V21, P619, DOI 10.1111/j.0736-8046.2004.21600.x; Fuxench ZCC, 2019, J INVEST DERMATOL, V139, P583, DOI 10.1016/j.jid.2018.08.028; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gu CY, 2015, INT J DERMATOL, V54, pE261, DOI 10.1111/ijd.12830; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hamza AM, 2017, INT J DERMATOL, V56, P534, DOI 10.1111/ijd.13579; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; He HL, 2020, J ALLERGY CLIN IMMUN, V145, P1615, DOI 10.1016/j.jaci.2020.01.042; He H, 2020, ANN ALLERG ASTHMA IM, V124, P70, DOI 10.1016/j.anai.2019.10.013; He H, 2019, AM J CLIN DERMATOL, V20, P181, DOI 10.1007/s40257-018-0413-2; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Huet F, 2019, ACTA DERM-VENEREOL, V99, P279, DOI 10.2340/00015555-3053; Jahnz-Rozyk K, 2005, ALLERGY, V60, P685, DOI 10.1111/j.1398-9995.2005.00774.x; Kakinuma T, 2003, J ALLERGY CLIN IMMUN, V111, P592, DOI 10.1067/mai.2003.114; Kakinuma T, 2002, CLIN EXP IMMUNOL, V127, P270, DOI 10.1046/j.1365-2249.2002.01727.x; Kim HS, 2017, ANN ALLERG ASTHMA IM, V119, P441, DOI 10.1016/j.anai.2017.06.022; Kim J, 2016, J INVEST DERMATOL, V136, P2173, DOI 10.1016/j.jid.2016.04.032; Lakhani I, 2018, METABOLISM, V83, P11, DOI 10.1016/j.metabol.2018.01.017; Leung TF, 2003, PEDIATR ALLERGY IMMU, V14, P296, DOI 10.1034/j.1399-3038.2003.00052.x; Lind L, 2015, ATHEROSCLEROSIS, V242, P205, DOI 10.1016/j.atherosclerosis.2015.07.023; Maarouf M, 2018, DERMATITIS, V29, P278, DOI 10.1097/DER.0000000000000406; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; Martel BC, 2016, EXP DERMATOL, V25, P453, DOI 10.1111/exd.12967; Nakazato J, 2008, PEDIAT ALLERG IMM-UK, V19, P605, DOI 10.1111/j.1399-3038.2007.00692.x; Nazarenko M S, 2011, Mol Biol (Mosk), V45, P610; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Ozceker D, 2018, ALLERGOL IMMUNOPATH, V46, P322, DOI 10.1016/j.aller.2017.10.005; Pavel AB, 2020, J AM ACAD DERMATOL, V82, P690, DOI 10.1016/j.jaad.2019.10.039; Pavel AB, 2019, J ALLERGY CLIN IMMUN, V144, P1011, DOI 10.1016/j.jaci.2019.07.013; Ramirez FD, 2019, JAMA PEDIATR, V173, DOI 10.1001/jamapediatrics.2019.0025; Roesner LM, 2015, ALLERGY, V70, P1656, DOI 10.1111/all.12712; Shen Y, 2018, CARDIOLOGY, V139, P212, DOI 10.1159/000486127; Silverberg JI, 2020, J ALLERGY CLIN IMMUN, V145, P173, DOI 10.1016/j.jaci.2019.08.013; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2018, J AM ACAD DERMATOL, V78, P863, DOI 10.1016/j.jaad.2018.01.017; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Sung M, 2017, PEDIAT ALLERG IMM-UK, V28, P543, DOI 10.1111/pai.12744; Szabo K, 2017, IMMUNOL LETT, V189, P101, DOI 10.1016/j.imlet.2017.04.010; Takamori A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25094-4; Thijs J, 2015, CURR OPIN ALLERGY CL, V15, P453, DOI 10.1097/ACI.0000000000000198; Thijs JL, 2018, J ALLERGY CLIN IMMUN, V141, P1523, DOI 10.1016/j.jaci.2017.12.991; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Toyoda M, 2002, BRIT J DERMATOL, V147, P71, DOI 10.1046/j.1365-2133.2002.04803.x; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wen HC, 2018, J ALLERGY CLIN IMMUN, V142, P324, DOI 10.1016/j.jaci.2018.02.047; Wolkerstorfer A, 1998, BRIT J DERMATOL, V138, P431; Wollenberg A, 2019, J ALLERGY CLIN IMMUN, V143, P135, DOI 10.1016/j.jaci.2018.05.029; Zhang Q, 2008, CYTOKINE GROWTH F R, V19, P347, DOI 10.1016/j.cytogfr.2008.08.003; Zheng W, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/1917291; Zhou LS, 2019, J ALLERGY CLIN IMMUN, V144, P144, DOI 10.1016/j.jaci.2019.01.015	68	26	26	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1369	1380		10.1016/j.jaci.2020.08.041	http://dx.doi.org/10.1016/j.jaci.2020.08.041		APR 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RX3VK	33011244				2022-12-18	WOS:000647154500002
J	Perkin, MR; Logan, K; Marrs, T; Radulovic, S; Craven, J; Boyle, RJ; Chalmers, JR; Williams, HC; Versteeg, SA; van Ree, R; Lack, G; Flohr, C				Perkin, Michael R.; Logan, Kirsty; Marrs, Tom; Radulovic, Suzana; Craven, Joanna; Boyle, Robert J.; Chalmers, Joanne R.; Williams, Hywel C.; Versteeg, Serge A.; van Ree, Ronald; Lack, Gideon; Flohr, Carsten		EAT Study Team	Association of frequent moisturizer use in early infancy with the development of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Moisturization; food allergy; allergy prevention; children; eczema; skin barrier; TEWL; filaggrin		Background: Food allergy is thought to develop through transcutaneous sensitization, especially in the presence of skin barrier impairment and inflammation. Regular moisturizer application to infant skin could potentially promote transcutaneous sensitization and the development of food allergy. Objectives: We tested this hypothesis in the Enquiring About Tolerance (EAT) study population. Methods: The EAT study was a population-based randomized clinical trial conducted from January 15, 2008, to August 31, 2015, and recruited 1303 exclusively breastfed 3-month-old infants and their families from England and Wales. At enrollment at 3 months, families completed a questionnaire that included questions about frequency and type of moisturizer applied, use of corticosteroid creams, and parental report of dry skin or eczema. Infants were examined for visible eczema at the enrollment visit. Results: A statistically significant dose-response relationship was observed between parent-reported moisturization frequency at 3 months of age and the subsequent development of food allergy. Each additional moisturization per week was associated with an adjusted odds ratio of 1.20 (95% CI, 1.131.27; P <.0005) for developing food allergy. For infants with no visible eczema at the enrollment visit, the corresponding adjusted odds ratio was 1.18 (95% CI, 1.07-1.30; P 5 .001) and for those with eczema at the enrollment visit, 1.20 (95% CI, 1.11-1.31; P < .0005). Moisturizer frequency showed similar dose-response relationships with the development of both food and aeroallergen sensitization at 36 months. Conclusions: These findings support the notion that regular application of moisturizers to the skin of young infants may promote the development of food allergy through transcutaneous sensitization. (J Allergy Clin Immunol 2021;147:967-76.) <comment>Superscript/Subscript Available</comment	[Perkin, Michael R.] St Georges Univ London, Populat Hlth Res Inst, Room 1-27,1st Floor,Jenner Wing, London SW17 0RE, England; [Logan, Kirsty; Marrs, Tom; Radulovic, Suzana; Craven, Joanna; Lack, Gideon] Kings Coll London, Sch Life Course Sci, Dept Women & Childrens Hlth, Paediat Allergy Res Grp, London, England; [Flohr, Carsten] Kings Coll London, Unit Populat Based Dermatol Res, St Johns Inst Dermatol, Sch Basic & Med Biosci,Fac Life Sci & Med, London, England; [Boyle, Robert J.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Chalmers, Joanne R.; Williams, Hywel C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England; [Versteeg, Serge A.; van Ree, Ronald] Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands; [van Ree, Ronald] Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands	St Georges University London; University of London; King's College London; University of London; King's College London; Imperial College London; University of Nottingham; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Perkin, MR (corresponding author), St Georges Univ London, Populat Hlth Res Inst, Room 1-27,1st Floor,Jenner Wing, London SW17 0RE, England.	m.perkin@sgul.ac.uk	Perkin, Michael/AID-7491-2022	Tonner, Sharon/0000-0002-7775-9926; Perkin, Michael/0000-0001-9272-2585; williams, hywel/0000-0002-5646-3093	UK Food Standards Agency [T07051]; Medical Research Council [MC_G1001205]; Clinician Scientist Award from the UK National Institute for Health Research [NIHRCS/01/2008/009]	UK Food Standards Agency; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Clinician Scientist Award from the UK National Institute for Health Research	The main components of the EAT Study were jointly funded by the UK Food Standards Agency (contract code T07051) and the Medical Research Council (grant MC_G1001205). Additionally we thank the Davis Foundation. The skin-related aspects of the study were supported by a Clinician Scientist Award from the UK National Institute for Health Research (NIHRCS/01/2008/009 [to C.F.]).	Brand RM, 2007, CUTAN OCUL TOXICOL, V26, P15, DOI 10.1080/15569520601182791; Brough HA, 2020, ALLERGY, V75, P2185, DOI 10.1111/all.14304; Chalmers JR, 2020, LANCET, V395, P962, DOI 10.1016/S0140-6736(19)32984-8; Chalmers JR, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2031-3; Cooke A, 2011, BR J MIDWIFERY, V19, P354, DOI [10.12968/bjom.2011.19.6.354, DOI 10.12968/BJOM.2011.19.6.354]; Cooke A, 2016, ACTA DERM-VENEREOL, V96, P323, DOI 10.2340/00015555-2279; Custovic A, 2015, CLIN EXP ALLERGY, V45, P54, DOI 10.1111/cea.12450; Deckers J, 2017, J ALLERGY CLIN IMMUN, V140, P1364, DOI 10.1016/j.jaci.2016.12.970; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Farahmand S, 2009, SKIN RES TECHNOL, V15, P392, DOI 10.1111/j.1600-0846.2009.00376.x; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Ierodiakonou D, 2016, JAMA-J AM MED ASSOC, V316, P1181, DOI 10.1001/jama.2016.12623; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kelleher MM, 2020, COCHRANE DB SYST REV; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Marrs T, 2020, J ALLER CL IMM-PRACT, V8, P2820, DOI 10.1016/j.jaip.2020.04.043; Miyaji Y, 2020, J ALLER CL IMM-PRACT, V8, P1721, DOI 10.1016/j.jaip.2019.11.036; Perkin MR, 2019, J ALLERGY CLIN IMMUN, V144, P1595, DOI 10.1016/j.jaci.2019.06.046; Perkin MR, 2019, J ALLERGY CLIN IMMUN, V144, P1606, DOI 10.1016/j.jaci.2019.06.045; Perkin MR, 2016, J ALLERGY CLIN IMMUN, V137, P1477, DOI 10.1016/j.jaci.2015.12.1322; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Sindher S, 2020, PEDIAT ALLERG IMM-UK, V31, P699, DOI 10.1111/pai.13253; Sindher S, 2020, ALLERGY, V75, P2662, DOI 10.1111/all.14275; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Torma H, 2008, J INVEST DERMATOL, V128, P1212, DOI 10.1038/sj.jid.5701170; Walker MT, 2018, J ALLERGY CLIN IMMUN, V141, P1711, DOI 10.1016/j.jaci.2018.02.003; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Yamamoto-Hanada K, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0233-8	31	26	26	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					967	+		10.1016/j.jaci.2020.10.044	http://dx.doi.org/10.1016/j.jaci.2020.10.044			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RG4QF	33678253	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000635524300001
J	Abdel-Aziz, MI; Brinkman, P; Vijverberg, SJH; Neerincx, AH; Riley, JH; Bates, S; Hashimoto, S; Kermani, NZ; Chung, KF; Djukanovic, R; Dahlen, SE; Adcock, IM; Howarth, PH; Sterk, PJ; Kraneveld, AD; Maitland-van der Zee, AH				Abdel-Aziz, Mahmoud, I; Brinkman, Paul; Vijverberg, Susanne J. H.; Neerincx, Anne H.; Riley, John H.; Bates, Stewart; Hashimoto, Simone; Kermani, Nazanin Zounemat; Chung, Kian Fan; Djukanovic, Ratko; Dahlen, Sven-Erik; Adcock, Ian M.; Howarth, Peter H.; Sterk, Peter J.; Kraneveld, Aletta D.; Maitland-van der Zee, Anke H.		U-BIOPRED Study Grp	Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sputum microbiome; metagenomics; asthma phenotypes; unbiased clusters; follow-up; neutrophils; macrophages; lung function	AIRWAY MICROBIOME; DISCOVERY; LIFE	Background: Asthma is a heterogeneous disease characterized by distinct phenotypes with associated microbial dysbiosis. Objectives: Our aim was to identify severe asthma phenotypes based on sputum microbiome profiles and assess their stability after 12 to 18 months. A further aim was to evaluate clusters' robustness after inclusion of an independent cohort of patients with mild-to-moderate asthma. Methods: In this longitudinal multicenter cohort study, sputum samples were collected for microbiome profiling from a subset of the Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes adult patient cohort at baseline and after 12 to 18 months of follow-up. Unsupervised hierarchical clustering was performed by using the Bray-Curtis b-diversity measure of microbial profiles. For internal validation, partitioning around medoids, consensus cluster distribution, bootstrapping, and topological data analysis were applied. Follow-up samples were studied to evaluate within-patient clustering stability in patients with severe asthma. Cluster robustness was evaluated by using an independent cohort of patients with mild-to-moderate asthma. Results: Data were available for 100 subjects with severe asthma (median age 55 years; 42% males). Two microbiome-driven clusters were identified; they were characterized by differences in asthma onset, smoking status, residential locations, percentage of blood and/or sputum neutrophils and macrophages, lung spirometry results, and concurrent asthma medications (all P values <.05). The cluster 2 patients displayed a commensal-deficient bacterial profile that was associated with worse asthma outcomes than those of the cluster 1 patients. Longitudinal clusters revealed high relative stability after 12 to 18 months in those with severe asthma. Further inclusion of an independent cohort of 24 patients with mild-to-moderate asthma was consistent with the clustering assignments. Conclusion: Unbiased microbiome-driven clustering revealed 2 distinct robust phenotypes of severe asthma that exhibited relative overtime stability. This suggests that the sputum microbiome may serve as a biomarker for better characterizing asthma phenotypes.	[Abdel-Aziz, Mahmoud, I; Brinkman, Paul; Vijverberg, Susanne J. H.; Neerincx, Anne H.; Hashimoto, Simone; Sterk, Peter J.; Maitland-van der Zee, Anke H.] Univ Amsterdam, Dept Resp Med, Amsterdam UMC, Meibergdreef 9, Amsterdam, Netherlands; [Abdel-Aziz, Mahmoud, I] Assiut Univ, Dept Clin Pharm, Fac Pharm, Assiut, Egypt; [Riley, John H.; Bates, Stewart] GlaxoSmithKline, Resp Therapeut Unit, Stockley Pk, Uxbridge, Middx, England; [Hashimoto, Simone; Maitland-van der Zee, Anke H.] Emma Childrens Hosp, Dept Pediat Resp Med, Amsterdam UMC, Amsterdam, Netherlands; [Kermani, Nazanin Zounemat] Imperial Coll London, Data Sci Inst, London, England; [Chung, Kian Fan; Adcock, Ian M.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Chung, Kian Fan; Adcock, Ian M.] Royal Brompton & Harefield NHS Trust, London, England; [Djukanovic, Ratko; Howarth, Peter H.] Univ Southampton, NIHR Southampton Resp Biomed Res Unit, Clin & Expt Sci & Human Dev & Hlth, Southampton, Hants, England; [Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, Ctr Allergy Res, Stockholm, Sweden; [Kraneveld, Aletta D.] Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Div Pharmacol, Utrecht, Netherlands; [Kraneveld, Aletta D.] Univ Utrecht, Fac Vet Med, Inst Risk Assessment Sci, Utrecht, Netherlands	University of Amsterdam; Egyptian Knowledge Bank (EKB); Assiut University; GlaxoSmithKline; Emma Children's Hospital; University of Amsterdam; Imperial College London; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; University of Southampton; Karolinska Institutet; Utrecht University; Utrecht University	Maitland-van der Zee, AH (corresponding author), Univ Amsterdam, Dept Resp Med, Amsterdam UMC, Meibergdreef 9, Amsterdam, Netherlands.	a.h.maitland@amsterdamumc.nl	kermani, nazanin/HGA-6347-2022; Brinkman, Paul/AAV-5110-2021; Maitland-van der Zee, Anke/I-9572-2016	Zounemat Kermani, Nazanin/0000-0003-2479-3861; Howarth, Peter/0000-0003-0619-7927; Maitland-van der Zee, Anke/0000-0002-0414-3442; Brinkman, Paul/0000-0003-4546-8478; Adcock, Ian/0000-0003-2101-8843; Hashimoto, Simone/0000-0001-8995-3817	Innovative Medicines Initiative Joint Undertaking [115010]; European Union; European Federation of Pharmaceutical Industries and Associations; Egyptian Government PhD Research Scholarships	Innovative Medicines Initiative Joint Undertaking; European Union(European Commission); European Federation of Pharmaceutical Industries and Associations; Egyptian Government PhD Research Scholarships	U-BIOPRED has received funding from the Innovative Medicines Initiative Joint Undertaking (under grant agreement No. 115010), the resources of which comprise financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations companies' in-kind contributions (www.imi.europa.eu).M.I.A.'s salary was sponsored by the Egyptian Government PhD Research Scholarships.	Abdel-Aziz MI, 2019, CLIN EXP ALLERGY, V49, P1067, DOI 10.1111/cea.13444; Barnes PJ, 2013, AM J RESP CRIT CARE, V188, P901, DOI 10.1164/rccm.201302-0388PP; Barnes PJ, 2010, SCIENCE, V330, P40, DOI 10.1126/science.1196017; Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BLASHFIELD RK, 1991, J CLASSIF, V8, P277; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; Brinkman P, 2019, J ALLERGY CLIN IMMUN, V143, P1811, DOI 10.1016/j.jaci.2018.10.058; Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698; Calinski T., 1974, COMMUN STAT-THEOR M, V3, P1, DOI [DOI 10.1080/03610927408827101, 10.1080/03610927408827101]; Chung KF, 2016, LANCET RESP MED, V4, P765, DOI 10.1016/S2213-2600(16)30232-6; Corren J, 2013, DISCOV MED, V15, P243; Gao H, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/3743048; Hartigan J.A., 1975, CLUSTERING ALGORITHM; Hennig C, 2007, COMPUT STAT DATA AN, V52, P258, DOI 10.1016/j.csda.2006.11.025; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Howarth P, 2019, AM J RESP CRIT CARE, V199; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kobayashi Y, 2014, CHEST, V145, P305, DOI 10.1378/chest.13-0835; Kuo Chih-Hsi Scott, 2017, Eur Respir J, V49, DOI 10.1183/13993003.02135-2016; Larsson K, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0719-x; Lee JJ, 2019, ALLERGY, V74, P709, DOI 10.1111/all.13608; Leitao FS, 2019, AM J RESP CRIT CARE, V199, P1205, DOI 10.1164/rccm.201806-1135OC; Li NJ, 2017, RESP MED, V131, P192, DOI 10.1016/j.rmed.2017.08.016; Liang ZK, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-72; Mariani J, 2018, ENVIRON RES, V162, P119, DOI 10.1016/j.envres.2017.12.016; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Munck C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158622; O'Neill S, 2015, THORAX, V70, P376, DOI 10.1136/thoraxjnl-2013-204114; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Pang ZQ, 2019, INT J MED SCI, V16, P477, DOI 10.7150/ijms.29433; Patarcic I, 2015, SCI REP-UK, V5, DOI 10.1038/srep16119; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; RAND WM, 1971, J AM STAT ASSOC, V66, P846, DOI 10.2307/2284239; Renz H, 2017, J ALLERGY CLIN IMMUN, V140, P24, DOI 10.1016/j.jaci.2017.05.015; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Schofield JPR, 2019, J ALLERGY CLIN IMMUN, V144, P70, DOI 10.1016/j.jaci.2019.03.013; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Siles RI, 2011, CLEV CLIN J MED, V78, P585, DOI 10.3949/ccjm.78a.11023; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Simpson JL, 2016, EUR RESPIR J, V47, P792, DOI 10.1183/13993003.00405-2015; Taylor SL, 2018, J ALLERGY CLIN IMMUN, V141, P94, DOI 10.1016/j.jaci.2017.03.044; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Weiszhar Z, 2013, BREATHE, V9, P301, DOI 10.1183/20734735.042912; Wheelock CE, 2013, EUR RESPIR J, V42, P802, DOI 10.1183/09031936.00078812; Xu XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071414; Yang X, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9230234; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724	53	26	27	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					123	134		10.1016/j.jaci.2020.04.018	http://dx.doi.org/10.1016/j.jaci.2020.04.018		JAN 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32353491	Green Submitted			2022-12-18	WOS:000613645900017
J	Caminati, M; Lombardi, C; Micheletto, C; Roca, E; Bigni, B; Furci, F; Girelli, D; Senna, G; Crisafulli, E				Caminati, Marco; Lombardi, Carlo; Micheletto, Claudio; Roca, Elena; Bigni, Barbara; Furci, Fabiana; Girelli, Domenico; Senna, Gianenrico; Crisafulli, Ernesto			Asthmatic patients in COVID-19 outbreak: Few cases despite many cases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Caminati, Marco; Senna, Gianenrico] Univ Verona, Dept Med, Allergy & Clin Immunol Sect, Verona, Italy; [Caminati, Marco; Senna, Gianenrico] Verona Univ Hosp, Verona, Italy; [Lombardi, Carlo; Roca, Elena; Bigni, Barbara] Ist Osped Fdn Poliambulanza, Dept Unit Allergol Immunol & Pneumol, Brescia, Italy; [Micheletto, Claudio] Integrated Univ Hosp, Cardiothorac Dept, Resp Unit, Verona, Italy; [Furci, Fabiana] Univ Messina, Univ Hosp G Martino, Allergy & Clin Immunol Unit, Dept Clin & Expt Med, Messina, Italy; [Girelli, Domenico; Crisafulli, Ernesto] Univ Verona, Dept Med, Sect Internal Med, Verona, Italy; [Girelli, Domenico; Crisafulli, Ernesto] Azienda Osped Univ Integrata Verona, Verona, Italy; [Crisafulli, Ernesto] Univ Verona, Dept Med, Resp Med Unit, Verona, Italy	University of Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; AOU Policlinico Gaetano Martino; University of Messina; University of Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona	Caminati, M (corresponding author), Univ Verona, Dept Med, Allergy & Clin Immunol Sect, Verona, Italy.; Caminati, M (corresponding author), Verona Univ Hosp, Verona, Italy.	ma.caminati@gmail.com	Caminati, Marco/AAC-6302-2022	Caminati, Marco/0000-0001-7383-1487; GIRELLI, Domenico/0000-0001-9684-1899; MICHELETTO, CLAUDIO/0000-0002-1138-3882	Cariverona Foundation, ENACT Project	Cariverona Foundation, ENACT Project	This work has been partially supported by the Cariverona Foundation, ENACT Project.	Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3; Jartti T, 2020, SEMIN IMMUNOPATHOL, V42, P61, DOI 10.1007/s00281-020-00781-5; Johnston SL, 2020, ALLERGY, V75, P1543, DOI 10.1111/all.14348; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Maggi E, 2020, J ALLERGY CLIN IMMUN, V146, P18, DOI 10.1016/j.jaci.2020.05.001	5	26	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					541	542		10.1016/j.jaci.2020.05.049	http://dx.doi.org/10.1016/j.jaci.2020.05.049			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32620309	Green Published			2022-12-18	WOS:000569168900017
J	Burte, E; Leynaert, B; Marcon, A; Bousquet, J; Benmerad, M; Bono, R; Carsin, AE; de Hoogh, K; Forsberg, B; Gormand, F; Heinrich, J; Just, J; Nieuwenhuijsen, M; Pin, I; Stempfelet, M; Sunyer, J; Villani, S; Kunzli, N; Siroux, V; Jarvis, D; Nadif, R; Jacquemin, B				Burte, Emilie; Leynaert, Benedicte; Marcon, Alessandro; Bousquet, Jean; Benmerad, Meriem; Bono, Roberto; Carsin, Anne-Elie; de Hoogh, Kees; Forsberg, Bertil; Gormand, Frederic; Heinrich, Joachim; Just, Jocelyne; Nieuwenhuijsen, Mark; Pin, Isabelle; Stempfelet, Morgane; Sunyer, Jordi; Villani, Simona; Kunzli, Nino; Siroux, Valerie; Jarvis, Deborah; Nadif, Rachel; Jacquemin, Benedicte			Long-term air pollution exposure is associated with increased severity of rhinitis in 2 European cohorts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis; allergic sensitization; air pollution; environment; severity; respiratory disease	USE REGRESSION-MODELS; ALLERGIC RHINITIS; BRONCHIAL HYPERRESPONSIVENESS; CLIMATE-CHANGE; ASTHMA; ESCAPE; IMPACT; ENVIRONMENT; POLLUTANTS; GENETICS	Background: Very few studies have examined the association between long-term outdoor air pollution and rhinitis severity in adults. Objective: We sought to assess the cross-sectional association between individual long-term exposure to air pollution and severity of rhinitis. Methods: Participants with rhinitis from 2 multicenter European cohorts (Epidemiological Study on the Genetics and Environment on Asthma and the European Community Respiratory Health Survey) were included. Annual exposure to NO2, PM10, PM2.5, and PMcoarse (calculated by subtracting PM2.5 from PM10) was estimated using land-use regression models derived from the European Study of Cohorts for Air Pollution Effects project, at the participants' residential address. The score of rhinitis severity (range, 0-12), based on intensity of disturbance due to symptoms reported by questionnaire, was categorized into low (reference), mild, moderate, and high severity. Polytomous logistic regression models with a random intercept for city were used. Results: A total of 1408 adults with rhinitis (mean age, 52 years; 46% men, 81% from the European Community Respiratory Health Survey) were included. The median (1st quartile-3rd quartile) score of rhinitis severity was 4 (2-6). Higher exposure to PM10 was associated with higher rhinitis severity (adjusted odds ratio [95% CI] for a 10 mu g/m(3) increase in PM10: for mild: 1.20 [0.88-1.64], moderate: 1.53 [1.07-2.19], and high severity: 1.72 [1.23-2.41]). Similar results were found for PM2.5. Higher exposure to NO2 was associated with an increased severity of rhinitis, with similar adjusted odds ratios whatever the level of severity. Adjusted odds ratios were higher among participants without allergic sensitization than among those with, but interaction was found only for NO2. Conclusions: People with rhinitis who live in areas with higher levels of pollution are more likely to report more severe nasal symptoms. Further work is required to elucidate the mechanisms of this association.	[Burte, Emilie; Bousquet, Jean; Nadif, Rachel; Jacquemin, Benedicte] VIMA, INSERM, U1168, Villejuif, France; [Burte, Emilie; Bousquet, Jean; Nadif, Rachel; Jacquemin, Benedicte] Epidemiol & Publ Hlth Approaches, Aging & Chron Dis, Villejuif, France; [Burte, Emilie; Marcon, Alessandro; Nadif, Rachel; Jacquemin, Benedicte] Univ Versailles St Quentin En Yvelines, UMR 1168, Montigny Le Bretonneux, France; [Burte, Emilie; Carsin, Anne-Elie; Nieuwenhuijsen, Mark; Sunyer, Jordi; Jacquemin, Benedicte] ISGLobal, Barcelona, Spain; [Burte, Emilie; Carsin, Anne-Elie; Nieuwenhuijsen, Mark; Sunyer, Jordi] Univ Pompeu Fabra, Barcelona, Spain; [Leynaert, Benedicte] INSERM, UMR 1152, Pathophysiol & Epidemiol Resp Dis, Paris, France; [Marcon, Alessandro] Univ Verona, Dept Diagnost & Publ Hlth, Unit Epidemiol & Med Stat, Verona, Italy; [Bousquet, Jean] Univ Hosp, Montpellier, France; [Bousquet, Jean] European Innovat Partnership Active & Hlth Ageing, MACVIA France MAlad Chron Vieillissement Actif Fr, Montpellier, France; [Benmerad, Meriem; Pin, Isabelle; Siroux, Valerie] Univ Grenoble Alpes, Team Environm Epidemiol Appl Reprod & Resp Hlth, IAB, CNRS,INSERM,U1209, Grenoble, France; [Bono, Roberto] Univ Turin, Dept Publ Hlth & Pediat, Turin, Italy; [Carsin, Anne-Elie; Nieuwenhuijsen, Mark; Sunyer, Jordi; Jacquemin, Benedicte] CIBERESP, Barcelona, Spain; [Carsin, Anne-Elie; Nieuwenhuijsen, Mark; Sunyer, Jordi] IMIM Hosp del Mar Med Res Inst, Barcelona, Spain; [de Hoogh, Kees; Kunzli, Nino] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [de Hoogh, Kees; Kunzli, Nino] Univ Basel, Basel, Switzerland; [Forsberg, Bertil] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden; [Gormand, Frederic] CHU Lyon, Dept Pneumol, Lyon, France; [Heinrich, Joachim] Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, Munich, Germany; [Heinrich, Joachim] German Ctr Lung Res, Comprehens Pneumol Ctr Munich CPC M, Munich, Germany; [Just, Jocelyne] Hop Armand Trousseau, AP HP, Dept Allergol, Paris, France; [Just, Jocelyne] Sorbonne Univ Paris 6, Paris, France; [Pin, Isabelle] CHU Grenoble Alpes, Pediatrie, Grenoble, France; [Stempfelet, Morgane] Sante Publ France, St Maurice, France; [Villani, Simona] Univ Pavia, Dept Publ Hlth Expt & Forens Med, Unit Biostat & Clin Epidemiol, Pavia, Italy; [Jarvis, Deborah] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Jarvis, Deborah] MRC Ctr Environm & Hlth, Sch Publ Hlth, London, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; ISGlobal; Pompeu Fabra University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Verona; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Turin; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Umea University; CHU Lyon; University of Munich; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; CHU Grenoble Alpes; Institute of Public Health Surveillance; University of Pavia; Imperial College London	Jacquemin, B (corresponding author), Irset Inserm UMR S 1085, 9 Ave Prof Leon Bernard, F-35000 Rennes, France.	benedicte.jacquemin@inserm.fr	Heinrich, Joachim/N-1720-2013; Marcon, Alessandro/C-3349-2012; de Hoogh, Kees/ABE-1274-2021; Nadif, Rachel/R-2876-2016; Sunyer, Jordi/G-6909-2014; Jacquemin, Benedicte/D-8948-2018; Carsin, Anne-Elie/AAF-6815-2021; Emilie, Burte/AAA-5048-2022; Nieuwenhuijsen, Mark/C-3914-2017	Heinrich, Joachim/0000-0002-9620-1629; Marcon, Alessandro/0000-0002-2778-658X; Nadif, Rachel/0000-0003-4938-9339; Sunyer, Jordi/0000-0002-2602-4110; Jacquemin, Benedicte/0000-0003-1273-9892; Carsin, Anne-Elie/0000-0003-3981-977X; Nieuwenhuijsen, Mark/0000-0001-9461-7981; Leynaert, Benedicte/0000-0001-5045-2492; Bousquet, Jean/0000-0002-4061-4766; Jarvis, Deborah/0000-0002-1753-3896	European Commission; local studies in ECRHS III; Belgium: Antwerp South, Antwerp City: Research Foundation Flanders (FWO) [G.0.410.08]; Ministere de la Sante, Programme Hospitalier de Recherche Clinique (PHRC); Paris: Agence Nationale de la Sante; Region Ile de France; Germany: Erfurt: German Research Foundation - Cariverona Foundation, Education Ministry; Spain: Fondo de Investigacion Sanitaria [PS09/02457, PS09/00716 09/01511, PS09/02185, PS09/03190]; Sociedad Espanola de Neumologia y Cirurgia Toracica [FIS PS09/00716]; Galdakao: Fondo de Investigacion Sanitaria [FIS 09/01511, FIS PS09/02185]; Swedish Heart and Lung Foundation; Swedish Asthma and Allergy Association; Heart Disease; Swedish Research Council for health, working life and welfare (FORTE); United Kingdom: Medical Research Council [92091]; National Institute for Health Research through the Primary Care Research Network; PHRC-Paris, PHRC-Grenoble, ANR [05-SEST-020-02/05-9-97, ANR-06-CEBS, ANR-CES-2009]; Region Nord Pas-de-Calais; Merck Sharp Dohme; European Study of Cohorts for Air Pollution Effects Funding; European Community [211250]; MRC [G0901214, MR/S019669/1] Funding Source: UKRI	European Commission(European CommissionEuropean Commission Joint Research Centre); local studies in ECRHS III; Belgium: Antwerp South, Antwerp City: Research Foundation Flanders (FWO); Ministere de la Sante, Programme Hospitalier de Recherche Clinique (PHRC); Paris: Agence Nationale de la Sante(French National Research Agency (ANR)); Region Ile de France(Region Ile-de-France); Germany: Erfurt: German Research Foundation - Cariverona Foundation, Education Ministry; Spain: Fondo de Investigacion Sanitaria; Sociedad Espanola de Neumologia y Cirurgia Toracica; Galdakao: Fondo de Investigacion Sanitaria; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Swedish Asthma and Allergy Association; Heart Disease; Swedish Research Council for health, working life and welfare (FORTE); United Kingdom: Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research through the Primary Care Research Network; PHRC-Paris, PHRC-Grenoble, ANR(French National Research Agency (ANR)); Region Nord Pas-de-Calais(Region Hauts-de-FranceEuropean Commission); Merck Sharp Dohme(Merck & Company); European Study of Cohorts for Air Pollution Effects Funding; European Community(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The European Community Respiratory Health Survey (ECRHS) was supported by the European Commission, as part of its Quality-of-Life program. The following bodies funded the local studies in ECRHS III in this article: Belgium: Antwerp South, Antwerp City: Research Foundation Flanders (FWO), grant code G.0.410.08.N.10 (both sites); France: (All) Ministere de la Sante, Programme Hospitalier de Recherche Clinique (PHRC) national 2010; Grenoble: Comite Scientifique AGIRadom 2011; Paris: Agence Nationale de la Sante, Region Ile de France, domaine d'interet majeur; Germany: Erfurt: German Research Foundation (HE 3294/10-1); Italy: All Italian centers were funded by the Italian Ministry of Health, Chiesi Farmaceutici SpA; in addition, Verona was funded by the Cariverona Foundation, Education Ministry (MIUR); Spain: Fondo de Investigacion Sanitaria (PS09/02457, PS09/00716 09/01511, PS09/02185, and PS09/03190), Servicio Andaluz de Salud, Sociedad Espanola de Neumologia y Cirurgia Toracica (SEPAR 1001/2010); Barcelona: Fondo de Investigacion Sanitaria (FIS PS09/00716); Galdakao: Fondo de Investigacion Sanitaria (FIS 09/01511); Huelva: Fondo de Investigacion Sanitaria (FIS PS09/02185) and Servicio Andaluz de Salud; Oviedo: Fondo de Investigacion Sanitaria (FIS PS09/03190); Sweden: All centers were funded by the Swedish Heart and Lung Foundation, the Swedish Asthma and Allergy Association, the Swedish Association against Lung and Heart Disease; the Swedish Research Council for health, working life and welfare (FORTE); and United Kingdom: Medical Research Council (grant no. 92091). Support also provided by the National Institute for Health Research through the Primary Care Research Network. The Epidemiological Study on the Genetics and Environment on Asthma is funded in part by PHRC-Paris, PHRC-Grenoble, ANR 05-SEST-020-02/05-9-97, ANR-06-CEBS, ANR-CES-2009, Region Nord Pas-de-Calais, and Merck Sharp & Dohme. European Study of Cohorts for Air Pollution Effects Funding: The research leading to these results has received funding from the European Community's Seventh Framework Program (FP7/2007-2011; under grant agreement no. 211250).	Adam M, 2015, EUR RESPIR J, V45, P38, DOI 10.1183/09031936.00130014; Annesi-Maesano I, 2012, INT ARCH ALLERGY IMM, V158, P397, DOI 10.1159/000332964; Basagana X, 2018, INT J EPIDEMIOL, V47, P1343, DOI 10.1093/ije/dyy117; Bates JT, 2019, ENVIRON SCI TECHNOL, V53, P4003, DOI 10.1021/acs.est.8b03430; Beelen R, 2013, ATMOS ENVIRON, V72, P10, DOI 10.1016/j.atmosenv.2013.02.037; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet Jean, 2002, Prim Care Respir J, V11, P18, DOI 10.1038/pcrj.2002.7; Bousquet PJ, 2013, INT ARCH ALLERGY IMM, V160, P393, DOI 10.1159/000342991; Bouzigon E, 2015, REV MAL RESPIR, V32, P822, DOI 10.1016/j.rmr.2014.12.005; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Burte E, 2018, ENVIRON INT, V115, P257, DOI 10.1016/j.envint.2018.03.021; D'Amato G, 2016, ALLERGY ASTHMA IMMUN, V8, P391, DOI 10.4168/aair.2016.8.5.391; D'Amato M, 2018, J INVEST ALLERG CLIN, V28, P91, DOI 10.18176/jiaci.0228; de Hoogh K, 2016, ENVIRON RES, V151, P1, DOI 10.1016/j.envres.2016.07.005; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Eeftens M, 2012, ENVIRON SCI TECHNOL, V46, P11195, DOI 10.1021/es301948k; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Hajat S, 2001, AM J EPIDEMIOL, V153, P704, DOI 10.1093/aje/153.7.704; Heinrich J., 2018, ALLERGO J INT, V28, P5; Huang KL, 2017, PLOS ONE, V12, P1; Jacquemin B, 2015, ENVIRON HEALTH PERSP, V123, P613, DOI 10.1289/ehp.1408206; Jang AS, 2016, CURR OPIN ALLERGY CL, V16, P13, DOI 10.1097/ACI.0000000000000235; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Katelaris CH, 2012, CLIN EXP ALLERGY, V42, P186, DOI 10.1111/j.1365-2222.2011.03891.x; Kauffmann F, 1999, CLIN EXP ALLERGY, V29, P17; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123, DOI 10.1164/ajrccm.156.4.12tac9; Leynaert Benedicte, 2000, Journal of Allergy and Clinical Immunology, V106, pS201; Mady LJ, 2018, INT FORUM ALLERGY RH, V8, P369, DOI 10.1002/alr.22060; Papadopoulos NG, 2015, ALLERGY, V70, P474, DOI 10.1111/all.12573; Quillen DM, 2006, AM FAM PHYSICIAN, V73, P1583; Rage E, 2009, OCCUP ENVIRON MED, V66, P182, DOI 10.1136/oem.2007.038349; Rouve S, 2010, RHINOLOGY, V48, P285, DOI [10.4193/Rhin09.208, 10.4193/Rhino09.208]; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Siroux V, 2009, J ALLERGY CLIN IMMUN, V124, P681, DOI 10.1016/j.jaci.2009.06.010; Wang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105125; Wu Jin-Zhun, 2018, Chronic Dis Transl Med, V4, P95, DOI 10.1016/j.cdtm.2018.04.001; Zhang FY, 2011, SCI TOTAL ENVIRON, V409, P2486, DOI 10.1016/j.scitotenv.2011.04.007	38	26	27	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					834	+		10.1016/j.jaci.2019.11.040	http://dx.doi.org/10.1016/j.jaci.2019.11.040			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31983528	Green Submitted, Green Published, Bronze, Green Accepted			2022-12-18	WOS:000518756700021
J	Goos, H; Fogarty, CL; Sahu, B; Plagnol, V; Rajamaki, K; Nurmi, K; Liu, XN; Einarsdottir, E; Jouppila, A; Pettersson, T; Vihinen, H; Krjutskov, K; Saavalainen, P; Jarvinen, A; Muurinen, M; Greco, D; Scala, G; Curtis, J; Nordstrom, D; Flaumenhaft, R; Vaarala, O; Kovanen, PE; Keskitalo, S; Ranki, A; Kere, J; Lehto, M; Notarangelo, LD; Nejentsev, S; Eklund, KK; Varjosalo, M; Taipale, J; Seppanen, MRJ				Goos, Helka; Fogarty, Christopher L.; Sahu, Biswajyoti; Plagnol, Vincent; Rajamaki, Kristiina; Nurmi, Katariina; Liu, Xiaonan; Einarsdottir, Elisabet; Jouppila, Annukka; Pettersson, Tom; Vihinen, Helena; Krjutskov, Kaarel; Saavalainen, Paivi; Jarvinen, Asko; Muurinen, Mari; Greco, Dario; Scala, Giovanni; Curtis, James; Nordstrom, Dan; Flaumenhaft, Robert; Vaarala, Outi; Kovanen, Panu E.; Keskitalo, Salla; Ranki, Annamari; Kere, Juha; Lehto, Markku; Notarangelo, Luigi D.; Nejentsev, Sergey; Eklund, Kari K.; Varjosalo, Markku; Taipale, Jussi; Seppanen, Mikko R. J.			Gain-of-function CEBPE mutation causes noncanonical autoinflammatory inflammasomopathy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunologic deficiency syndromes; autoinflammatory diseases; hereditary; chemotaxis; interferons; inflammasomes; NLR family; pyrin domain-containing 3 protein; gain-of-function mutation; neomorphic mutation	BINDING-PROTEIN-EPSILON; GRANULE DEFICIENCY; ABDOMINAL-PAIN; C/EBP-EPSILON; KAPPA-B; ACTIVATION; GENE; DIFFERENTIATION; INFECTION; ATTACKS	Background: CCAAT enhancer-binding protein epsilon (C/EBP epsilon) is a transcription factor involved in late myeloid lineage differentiation and cellular function. The only previously known disorder linked to C/EBP epsilon is autosomal recessive neutrophil-specific granule deficiency leading to severely impaired neutrophil function and early mortality. Objective: The aim of this study was to molecularly characterize the effects of C/EBP epsilon transcription factor Arg219His mutation identified in a Finnish family with previously genetically uncharacterized autoinflammatory and immunodeficiency syndrome. Methods: Genetic analysis, proteomics, genome-wide transcriptional profiling by means of RNA-sequencing, chromatin immunoprecipitation (ChIP) sequencing, and assessment of the inflammasome function of primary macrophages were performed. Results: Studies revealed a novel mechanism of genome-wide gain-of-function that dysregulated transcription of 464 genes. Mechanisms involved dysregulated noncanonical inflammasome activation caused by decreased association with transcriptional repressors, leading to increased chromatin occupancy and considerable changes in transcriptional activity, including increased expression of NLR family, pyrin domain-containing 3 protein (NLRP3) and constitutively expressed caspase-5 in macrophages. Conclusion: We describe a novel autoinflammatory disease with defective neutrophil function caused by a homozygous Arg219His mutation in the transcription factor C/EBP epsilon. Mutated C/EBPe acts as a regulator of both the inflammasome and interferome, and the Arg219His mutation causes the first human monogenic neomorphic and noncanonical inflammasomopathy/immunodeficiency. The mechanism, including widely dysregulated transcription, is likely not unique for C/EBP epsilon. Similar multiomics approaches should also be used in studying other transcription factor-associated diseases.	[Goos, Helka; Liu, Xiaonan; Greco, Dario; Scala, Giovanni; Keskitalo, Salla; Varjosalo, Markku] Univ Helsinki, HiLIFE, Inst Biotechnol, Helsinki, Finland; [Fogarty, Christopher L.; Lehto, Markku] Univ Helsinki, Diabet & Obes Res Program, Res Programs Unit, Helsinki, Finland; [Fogarty, Christopher L.] Univ Helsinki, Inst Clin Med, Helsinki, Finland; [Sahu, Biswajyoti; Taipale, Jussi] Univ Helsinki, Biomedicum Helsinki, Res Programs Unit, Genome Scale Biol, Helsinki, Finland; [Rajamaki, Kristiina; Nurmi, Katariina; Pettersson, Tom; Nordstrom, Dan; Eklund, Kari K.] Univ Helsinki, Fac Med, Clinicum, Helsinki, Finland; [Einarsdottir, Elisabet; Muurinen, Mari; Kere, Juha] Univ Helsinki, Res Programs Unit, Mol Neurol, Helsinki, Finland; [Vihinen, Helena] Univ Helsinki, Inst Biotechnol, Electron Microscopy Unit, Helsinki, Finland; [Saavalainen, Paivi] Univ Helsinki, Res Programs Unit, Immunobiol, Helsinki, Finland; [Saavalainen, Paivi] Univ Helsinki, Dept Med & Clin Genet, Helsinki, Finland; [Fogarty, Christopher L.; Lehto, Markku] Folkhalsan Res Ctr, Helsinki, Finland; [Fogarty, Christopher L.; Lehto, Markku] Univ Helsinki, Childrens Hosp, Abdominal Ctr Nephrol, Helsinki, Finland; [Jarvinen, Asko; Seppanen, Mikko R. J.] Univ Helsinki, Childrens Hosp, Adult Immunodeficiency Unit, Inflammat Ctr,Infect Dis, Helsinki, Finland; [Nordstrom, Dan; Eklund, Kari K.] Univ Helsinki, Childrens Hosp, Dept Rheumatol, Inflammat Ctr, Helsinki, Finland; [Vaarala, Outi] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland; [Ranki, Annamari] Univ Helsinki, Childrens Hosp, Dept Dermatol, Inflammat Ctr,Allergol & Venereal Dis, Helsinki, Finland; [Seppanen, Mikko R. J.] Univ Helsinki, Childrens Hosp, Rare Dis Ctr, Helsinki, Finland; [Seppanen, Mikko R. J.] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland; Helsinki Univ Hosp, Helsinki, Finland; [Plagnol, Vincent] UCL, Genet Inst, London, England; [Einarsdottir, Elisabet; Krjutskov, Kaarel; Muurinen, Mari; Kere, Juha] Folkhalsan Inst Genet, Helsinki, Finland; [Einarsdottir, Elisabet; Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Jouppila, Annukka; Krjutskov, Kaarel] Helsinki Univ Hosp, Res Inst, Helsinki, Finland; [Pettersson, Tom] Helsinki Univ Hosp, Dept Internal Med & Rehabil, Helsinki, Finland; [Krjutskov, Kaarel] Competence Ctr Hlth Technol, Tartu, Estonia; [Greco, Dario; Scala, Giovanni] Univ Tampere, Fac Med & Life Sci, Tampere, Finland; [Greco, Dario; Scala, Giovanni] Univ Tampere, Inst Biosci & Med Technol, Tampere, Finland; [Curtis, James; Nejentsev, Sergey] Univ Cambridge, Dept Med, Cambridge, England; [Flaumenhaft, Robert] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; [Vaarala, Outi] AstraZeneca, Resp Inflammat & Autoimmun, Innovat Med, Molndal, Sweden; [Kovanen, Panu E.] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Kovanen, Panu E.] Helsinki Univ Hosp, HUSLAB, Helsinki, Finland; [Kere, Juha] Kings Coll London, Guys Hosp, Sch Basic & Med Biosci, London, England; [Notarangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Eklund, Kari K.] Orton Orthopaed Hosp, Helsinki, Finland; [Eklund, Kari K.] Invalid Fdn, Res Inst, Helsinki, Finland; [Taipale, Jussi] Karolinska Inst, Dept Med Biochem & Biophys, Div Funct Genom & Syst Biol, Solna, Sweden; [Taipale, Jussi] Univ Cambridge, Dept Biochem, Cambridge, England	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Folkhalsan Research Center; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of London; University College London; Karolinska Institutet; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University; University of Cambridge; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; AstraZeneca; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Karolinska Institutet; University of Cambridge	Seppanen, MRJ (corresponding author), Univ Helsinki, Childrens Hosp, Rare Dis Ctr & Pediat Res Ctr, POB 281, FI-00029 Helsinki, Finland.; Seppanen, MRJ (corresponding author), Helsinki Univ Hosp, POB 281, FI-00029 Helsinki, Finland.	mikko.seppanen@hus.fi	Kere, Juha/A-9179-2008; Sahu, Biswajyoti/U-6724-2017; Kere, Juha/AAX-9117-2021; Saavalainen, Päivi M/E-8621-2011; Varjosalo, Markku/K-6424-2015	Kere, Juha/0000-0003-1974-0271; Sahu, Biswajyoti/0000-0001-6576-5440; Kere, Juha/0000-0003-1974-0271; Nurmi, Katariina/0000-0001-5406-5334; Varjosalo, Markku/0000-0002-1340-9732; Goos, Helka/0000-0002-6175-4872; Keskitalo, Salla/0000-0001-5555-1975; SCALA, GIOVANNI/0000-0002-9037-1782; Seppanen, Mikko/0000-0001-9733-3650; Einarsdottir, Elisabet/0000-0003-3101-2285; Vihinen, Helena/0000-0003-3862-9237; Rajamaki, Kristiina/0000-0001-5151-1220; Greco, Dario/0000-0001-9195-9003	Orion Research Foundation; Paulo Foundation ja Maire Lisko Foundation; Helsinki University Hospital Research funds; Academy of Finland Post-doctoral Fellowship [274555]; Paivikki and Sakari Sohlberg Foundation; Yrjo Jahnsson Foundation; Division of Intramural Research, National Institute of Health, National Institutes of Health, Bethesda, Maryland; Folkhalsan Research Foundation; Novo Nordisk; Academy of Finland [288475, 294173]; Sigrid Juselius Foundation; Finnish Foundation for Pediatric Research; University of Helsinki Three-year Research Grant; Biocentrum Helsinki; Biocentrum Finland; HiLIFE; Instrumentarium Research Foundation; Finska Lakaresallskapet; MRC [MR/M012328/2] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001222] Funding Source: NIH RePORTER	Orion Research Foundation; Paulo Foundation ja Maire Lisko Foundation; Helsinki University Hospital Research funds; Academy of Finland Post-doctoral Fellowship(Academy of Finland); Paivikki and Sakari Sohlberg Foundation; Yrjo Jahnsson Foundation; Division of Intramural Research, National Institute of Health, National Institutes of Health, Bethesda, Maryland(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Folkhalsan Research Foundation; Novo Nordisk(Novo Nordisk); Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Foundation for Pediatric Research; University of Helsinki Three-year Research Grant; Biocentrum Helsinki; Biocentrum Finland; HiLIFE; Instrumentarium Research Foundation; Finska Lakaresallskapet; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the Orion Research Foundation (to H.G.); the Paulo Foundation ja Maire Lisko Foundation (to K.R.); Helsinki University Hospital Research funds (to A.R. and M.R.J.S.), an Academy of Finland Post-doctoral Fellowship (274555, to B.S.); the Paivikki and Sakari Sohlberg Foundation and the Yrjo Jahnsson Foundation (to K.N.); the Division of Intramural Research, National Institute of Health, National Institutes of Health, Bethesda, Maryland (to L.D.N.); the Folkhalsan Research Foundation and the Novo Nordisk (to M.L.); the Academy of Finland (288475 and 294173, to M.V.); the Sigrid Juselius Foundation (to M.V.); the Finnish Foundation for Pediatric Research (to M.R.J.S.); a University of Helsinki Three-year Research Grant, Biocentrum Helsinki, Biocentrum Finland, and HiLIFE (to M.V.); the Instrumentarium Research Foundation (to M.V. and K.K.E.); and Finska Lakaresallskapet (to K.K.E. and D.N.).	Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; Bedi R, 2009, BLOOD, V113, P317, DOI 10.1182/blood-2008-02-139741; Boisson B, 2015, CURR OPIN IMMUNOL, V32, P90, DOI 10.1016/j.coi.2015.01.005; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Broz P, 2012, NATURE, V490, P288, DOI 10.1038/nature11419; Crisford H, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0883-z; Crow YJ, 2015, NAT REV IMMUNOL, V15, P429, DOI 10.1038/nri3850; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Gombart AF, 2001, BLOOD, V97, P2561, DOI 10.1182/blood.V97.9.2561; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Gurung P, 2012, J BIOL CHEM, V287, P34474, DOI 10.1074/jbc.M112.401406; Henry T, 2007, J EXP MED, V204, P987, DOI 10.1084/jem.20062665; Joosten LAB, 2009, ARTHRITIS RHEUM, V60, P3651, DOI 10.1002/art.25006; Kaustio M, 2017, J ALLERGY CLIN IMMUN, V140, P782, DOI 10.1016/j.jaci.2016.10.054; Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450; Khanna-Gupta A, 2007, BLOOD, V109, P4181, DOI 10.1182/blood-2005-05-022004; Kulkarni Meghana M, 2011, Curr Protoc Mol Biol, VChapter 25, DOI 10.1002/0471142727.mb25b10s94; Lekstrom-Himes J, 1999, BLOOD, V93, P3096; Lekstrom-Himes JA, 2001, STEM CELLS, V19, P125, DOI 10.1634/stemcells.19-2-125; Lillie RD, 1969, H J CONNS BIOL STAIN; Liu XN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03523-2; Lominadze G, 2005, MOL CELL PROTEOMICS, V4, P1503, DOI 10.1074/mcp.M500143-MCP200; Man SM, 2016, NAT REV IMMUNOL, V16, P7, DOI 10.1038/nri.2015.7; Meunier E, 2014, NATURE, V509, P366, DOI 10.1038/nature13157; MURROS J, 1974, BLOOD, V43, P871, DOI 10.1182/blood.V43.6.871.871; PASANEN AV, 1987, EUR J HAEMATOL, V39, P274; Pellegrini C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00036; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Rathinam VAK, 2012, CELL, V150, P606, DOI 10.1016/j.cell.2012.07.007; REPO H, 1979, CLIN EXP IMMUNOL, V36, P326; Schauvliege R, 2002, J BIOL CHEM, V277, P41624, DOI 10.1074/jbc.M207852200; Schipp C, 2016, HAEMATOLOGICA, V101, pE392, DOI 10.3324/haematol.2016.145136; Serwas NK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00588; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Vodovotz Y, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000014; Witzel M, 2017, NAT GENET, V49, P742, DOI 10.1038/ng.3833; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Zamoshnikova A, 2016, IMMUNOBIOLOGY, V221, P341, DOI 10.1016/j.imbio.2015.10.001; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	40	26	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1364	1376		10.1016/j.jaci.2019.06.003	http://dx.doi.org/10.1016/j.jaci.2019.06.003			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31201888	hybrid, Green Published			2022-12-18	WOS:000495004700027
J	Perkins, TN; Oczypok, EA; Dutz, RE; Donnell, ML; Myerburg, MM; Oury, TD				Perkins, Timothy N.; Oczypok, Elizabeth A.; Dutz, Regina E.; Donnell, Mason L.; Myerburg, Michael M.; Oury, Tim D.			The receptor for advanced glycation end products is a critical mediator of type 2 cytokine signaling in the lungs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Receptor for advanced glycation end products; asthma; mucus; inflammation; T(H)2; allergy	INNATE LYMPHOID-CELLS; ASTHMA; EXPRESSION; IL-13; RAGE; INTERLEUKIN-13; INFLAMMATION; EOSINOPHILS; MECHANISMS; DISEASE	Background: Asthma is estimated to effect more than 300 million persons worldwide, leading to nearly 250,000 deaths annually. The majority of patients with mild-to-severe asthma have what is deemed "type-2 high" asthma, which is driven by the prototypical type 2 cytokines IL-4, IL-5, and IL-13. Studies have indicated that the receptor for advanced glycation end products (RAGE) is a critical molecule in the pathogenesis of experimental asthma/allergic airway inflammation. More specifically, RAGE expressed on stromal cells, rather than hematopoietic cells, is critical to induction of asthma/allergic airway inflammation by driving type 2 inflammatory responses. However, the role of RAGE in directly mediating type 2 cytokine signaling has never been investigated. Objective: The goal of this study was to test the hypothesis that RAGE mediates type 2 cytokine-induced signal transduction, airway inflammation, and mucus metaplasia in the lungs. Methods: Wild-type (WT) and RAGE knockout (RAGE(-/-)) mice, were intranasally administered rIL-5/rIL-13 or rIL-4 alone, and signal transducer and activator of transcription 6 (STAT6) signaling, airway inflammation, and mucus metaplasia were assessed. A RAGE small-molecule antagonist was used to determine the effects of pharmacologically inhibiting RAGE on type 2 cytokine-induced effects. Results: Administration of type 2 cytokines induced pronounced airway inflammation and mucus metaplasia in WT mice, which was nearly completely abrogated in RAGE(-/-) mice. In addition, treatment with a RAGE-specific antagonist diminished the effects of type 2 cytokines in WT mice and in primary human bronchial epithelial cell cultures. Genetic ablation or pharmacologic inhibition of RAGE blocks the effects of IL-13 and IL-4 by inhibiting sustained STAT6 activation and downstream target gene expression in mice and in human bronchial epithelial cells. Conclusions: This study is the first to indicate that RAGE is a critical component of type 2 cytokine signal transduction mechanisms, which is a driving force behind type 2-high asthma.	[Perkins, Timothy N.; Dutz, Regina E.; Donnell, Mason L.; Oury, Tim D.] Univ Pittsburgh, Sch Med, Med Ctr, Dept Pathol, Pittsburgh, PA 15260 USA; [Oczypok, Elizabeth A.; Myerburg, Michael M.] Univ Pittsburgh, Sch Med, Med Ctr, Dept Med, Pittsburgh, PA 15260 USA; [Perkins, Timothy N.] UPMC, Childrens Hosp Pittsburgh, Div Pulm Allergy & Clin Immunol, Dept Pediat, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Perkins, TN; Oury, TD (corresponding author), 3550 Terrace St,S784 Scaife Hall, Pittsburgh, PA 15261 USA.	tnp16@pitt.edu; tdoury@pitt.edu			National Heart, Lung, and Blood Institute National Research Service Award [1T32HL129949-01A1]; American Heart Association (AHA) [19POST34370078]; National Institutes of Health [R01HL112863, P30DK072506]; Cystic Fibrosis Foundation (CFF)	National Heart, Lung, and Blood Institute National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association (AHA)(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation (CFF)	T.N.P. is funded by a National Heart, Lung, and Blood Institute National Research Service Award 1T32HL129949-01A1 and American Heart Association (AHA) 19POST34370078. M.M.M. is funded by the National Institutes of Health (R01HL112863 and P30DK072506) and the Cystic Fibrosis Foundation (CFF; Research Development Program to the University of Pittsburgh).	Anto JM, 2017, J ALLERGY CLIN IMMUN, V139, P388, DOI 10.1016/j.jaci.2016.12.940; Bamias G, 2015, CURR OPIN GASTROEN, V31, P471, DOI 10.1097/MOG.0000000000000212; Barnes PJ, 2018, NAT REV IMMUNOL, V18, P454, DOI 10.1038/s41577-018-0006-6; Barrios RJ, 2006, ARCH PATHOL LAB MED, V130, P447; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BRETT J, 1993, AM J PATHOL, V143, P1699; Chen G, 2014, AM J RESP CRIT CARE, V189, P301, DOI 10.1164/rccm.201306-1181OC; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030; Di Candia L, 2012, EUR RESPIR J, V39, P515, DOI 10.1183/09031936.00169511; Englert JM, 2008, AM J PATHOL, V172, P583, DOI 10.2353/ajpath.2008.070569; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; Ferhani N, 2010, AM J RESP CRIT CARE, V181, P917, DOI 10.1164/rccm.200903-0340OC; Godar M, 2018, MABS-AUSTIN, V10, P34, DOI 10.1080/19420862.2017.1392425; Gour N, 2015, CYTOKINE, V75, P68, DOI 10.1016/j.cyto.2015.05.014; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hanford LE, 2003, AM J RESP CELL MOL, V29, pS77; ISHIZAKA T, 1989, INT ARCH ALLER A IMM, V88, P46, DOI 10.1159/000234746; Kay A B, 1989, Prog Clin Biol Res, V297, P183; Kelly-Welch AE, 2004, J IMMUNOL, V172, P4545, DOI 10.4049/jimmunol.172.7.4545; Kim W, 2005, ANN NY ACAD SCI, V1043, P553, DOI 10.1196/annals.1338.063; Kuperman DA, 2008, CURR MOL MED, V8, P384, DOI 10.2174/156652408785161032; Lambrecht BN, 2013, EUR J IMMUNOL, V43, P3125, DOI 10.1002/eji.201343730; Lee H, 2017, FASEB J, V31, P2076, DOI 10.1096/fj.201601155R; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; Maes T, 2012, AM J RESP CELL MOL, V47, P261, DOI 10.1165/rcmb.2012-0080TR; Milutinovic PS, 2012, AM J PATHOL, V181, P1215, DOI 10.1016/j.ajpath.2012.06.031; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Moynihan B, 2008, AM J PHYSIOL-LUNG C, V295, pL171, DOI 10.1152/ajplung.00457.2007; Mukherjee TK, 2008, RESP PHYSIOL NEUROBI, V162, P210, DOI 10.1016/j.resp.2008.07.001; Munitz A, 2008, P NATL ACAD SCI USA, V105, P7240, DOI 10.1073/pnas.0802465105; Myerburg MM, 2010, AM J RESP CELL MOL, V43, P712, DOI 10.1165/rcmb.2009-0348OC; Oczypok EA, 2017, PAEDIATR RESPIR REV, V23, P40, DOI 10.1016/j.prrv.2017.03.012; Oczypok EA, 2015, J ALLERGY CLIN IMMUN, V136, P747, DOI 10.1016/j.jaci.2015.03.011; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P14, DOI 10.1016/S0091-6749(99)70107-7; Perkins TN, 2019, ALLERGY, V74, P89, DOI 10.1111/all.13500; Perkins TN, 2018, TOXICOL APPL PHARM, V348, P43, DOI 10.1016/j.taap.2018.04.011; Perkins TN, 2015, HUM MOL GENET, V24, P1374, DOI 10.1093/hmg/ddu551; Peters MC, 2019, J ALLERGY CLIN IMMUN, V143, P104, DOI 10.1016/j.jaci.2017.12.1009; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Reynaert NL, 2016, INT J BIOCHEM CELL B, V81, P403, DOI 10.1016/j.biocel.2016.06.016; Reynolds PR, 2011, AM J RESP CELL MOL, V45, P1195, DOI 10.1165/rcmb.2011-0170OC; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; Sukkar MB, 2012, BRIT J PHARMACOL, V167, P1161, DOI 10.1111/j.1476-5381.2012.01984.x; van der Velden VHJ, 1998, CYTOKINE, V10, P803, DOI 10.1006/cyto.1998.0365; van Zoelen MA, 2011, CRIT CARE, V15, DOI 10.1186/cc9990; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Winden DR, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-108; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Yan Shi Fang, 2007, Curr Diab Rep, V7, P146, DOI 10.1007/s11892-007-0024-4; Yao LH, 2016, BRIT J PHARMACOL, V173, P2600, DOI 10.1111/bph.13539; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhou ZM, 2003, CIRCULATION, V107, P2238, DOI 10.1161/01.CIR.0000063577.32819.23	60	26	26	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					796	+		10.1016/j.jaci.2019.03.019	http://dx.doi.org/10.1016/j.jaci.2019.03.019			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	30940519	Bronze			2022-12-18	WOS:000485222300024
J	Brokamp, C; Brandt, EB; Ryan, PH				Brokamp, Cole; Brandt, Eric B.; Ryan, Patrick H.			Assessing exposure to outdoor air pollution for epidemiological studies: Model-based and personal sampling strategies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exposure; outdoor air pollution; epidemiological studies; personal air sampling; traffic-related air pollution; asthma; allergic diseases	AEROSOL OPTICAL DEPTH; LAND-USE REGRESSION; ULTRAFINE PARTICLES; PM2.5 EXPOSURES; BLACK CARBON; CHILDREN; TRANSPORT; ASTHMA; IMPACT; MICROENVIRONMENTS	Epidemiologic studies have found air pollution to be causally linked to respiratory health including the exacerbation and development of childhood asthma. Accurately characterizing exposure is paramount in these studies to ensure valid estimates of health effects. Here, we provide a brief overview of the evolution of air pollution exposure assessment ranging from the use of ground-based, single-site air monitoring stations for population-level estimates to recent advances in spatiotemporal models, which use advanced machine learning algorithms and satellite-based data to accurately estimate individual-level daily exposures at high spatial resolutions. In addition, we review recent advances in sensor technology that enable the use of personal monitoring in epidemiologic studies, long-considered the "holy grail'' of air pollution exposure assessment. Finally, we highlight key advantages and uses of each approach including the generalizability and public health relevance of air pollution models and the accuracy of personal monitors that are useful to guide personalized prevention strategies. Investigators and clinicians interested in the effects of air pollution on allergic disease and asthma should carefully consider the pros and cons of each approach to guide their application in research and practice.	[Brokamp, Cole; Brandt, Eric B.; Ryan, Patrick H.] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA; [Brokamp, Cole; Ryan, Patrick H.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Brandt, Eric B.] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Ryan, PH (corresponding author), 3333 Burnet Ave,ML 5041, Cincinnati, OH 45229 USA.	patrick.ryan@cchmc.org	Ryan, Patrick/HDO-1133-2022	Brandt, Eric/0000-0003-0617-4100	National Institute of Environmental Health Sciences (NIEHS) [R33ES024713]	National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Support provided by grant funded by the National Institute of Environmental Health Sciences (NIEHS; grant no. R33ES024713).	Abellan R, 2010, ATHEROSCLEROSIS, V211, P203, DOI 10.1016/j.atherosclerosis.2010.01.030; Anenberg SC, 2018, ENVIRON HEALTH PERSP, V126, DOI [10.1289/EHP3766, 10.1289/ehp3766]; Bousquet J, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0221-z; Brandt EB, 2015, CURR OPIN PEDIATR, V27, P724, DOI 10.1097/MOP.0000000000000286; Brauer Michael, 2010, Proc Am Thorac Soc, V7, P111, DOI 10.1513/pats.200908-093RM; Brokamp C, 2018, ENVIRON SCI TECHNOL, V52, P4173, DOI 10.1021/acs.est.7b05381; Brokamp C, 2017, ATMOS ENVIRON, V151, P1, DOI 10.1016/j.atmosenv.2016.11.066; Buonanno G, 2014, SCI TOTAL ENVIRON, V468, P903, DOI 10.1016/j.scitotenv.2013.09.016; Buonanno G, 2013, ATMOS ENVIRON, V79, P53, DOI 10.1016/j.atmosenv.2013.06.041; Castell N, 2017, ENVIRON INT, V99, P293, DOI 10.1016/j.envint.2016.12.007; Cohen AJ, 2017, LANCET, V389, P1907, DOI [10.1016/S0140-6736(17)30505-6, 10.1016/s0140-6736(17)30505-6]; Cole-Hunter T, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-29; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; Di Q, 2016, ATMOS ENVIRON, V131, P390, DOI 10.1016/j.atmosenv.2016.02.002; Diapouli E, 2007, SCI TOTAL ENVIRON, V388, P128, DOI 10.1016/j.scitotenv.2007.07.063; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dons E, 2012, ATMOS ENVIRON, V55, P392, DOI 10.1016/j.atmosenv.2012.03.020; Enstrom JE, 2017, NEW ENGL J MED, V377, P1498, DOI 10.1056/NEJMc1709849; Gour N, 2018, ENVIRON RES, V161, P304, DOI 10.1016/j.envres.2017.10.041; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Hankey S, 2017, ENVIRON HEALTH PERSP, V125, P527, DOI 10.1289/EHP442; Hassoun Y, 2019, CLIN REV ALLERG IMMU, V57, P403, DOI 10.1007/s12016-019-08730-3; Haynes EN, 2012, SCI TOTAL ENVIRON, V427, P19, DOI 10.1016/j.scitotenv.2012.03.037; Health Effects Institute. (HEI), 2010, SPECIAL REPORT, V17, DOI DOI 10.1016/J.ENVINT.2019.104909; Hoek G, 2008, ATMOS ENVIRON, V42, P7561, DOI 10.1016/j.atmosenv.2008.05.057; Jerrett M, 2005, J EXPO ANAL ENV EPID, V15, P185, DOI 10.1038/sj.jea.7500388; Jung CR, 2019, J ALLERGY CLIN IMMUN, V143, P2254, DOI 10.1016/j.jaci.2019.03.024; Just AC, 2015, ENVIRON SCI TECHNOL, V49, P8576, DOI 10.1021/acs.est.5b00859; Kagen S, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0840-z; Khreis H, 2017, ENVIRON INT, V100, P1, DOI 10.1016/j.envint.2016.11.012; Kloog I, 2012, ENVIRON SCI TECHNOL, V46, P11913, DOI 10.1021/es302673e; Koehler K, 2019, INDOOR AIR, V29, P231, DOI 10.1111/ina.12533; Larkin A, 2017, Curr Environ Health Rep, V4, P463, DOI 10.1007/s40572-017-0163-y; Luyten LJ, 2018, ENVIRON RES, V166, P310, DOI 10.1016/j.envres.2018.03.025; Mazaheri M, 2014, ENVIRON SCI TECHNOL, V48, P113, DOI 10.1021/es403721w; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Morawska L, 2018, ENVIRON INT, V116, P286, DOI 10.1016/j.envint.2018.04.018; Murrison LB, 2019, J CLIN INVEST, V129, P1504, DOI 10.1172/JCI124612; Nieuwenhuijsen MJ, 2014, INT J ENV RES PUB HE, V11, P7805, DOI 10.3390/ijerph110807805; Nyhan M, 2016, ENVIRON SCI TECHNOL, V50, P9671, DOI 10.1021/acs.est.6b02385; Oteros J, 2019, J ALLERGY CLIN IMMUN, V143, P369, DOI 10.1016/j.jaci.2018.05.040; Poole JA, 2019, J ALLERGY CLIN IMMUN, V143, P1702, DOI 10.1016/j.jaci.2019.02.018; Ryan PH, 2007, INHAL TOXICOL, V19, P127, DOI 10.1080/08958370701495998; Ryan PH, 2015, SCI TOTAL ENVIRON, V508, P366, DOI 10.1016/j.scitotenv.2014.11.061; Stevens EL, 2019, J ALLERGY CLIN IMMUN, V143, P2016, DOI 10.1016/j.jaci.2019.04.011; Su JG, 2015, SCI TOTAL ENVIRON, V506, P518, DOI 10.1016/j.scitotenv.2014.11.022; Van Ryswyk K, 2014, J EXPO SCI ENV EPID, V24, P260, DOI 10.1038/jes.2013.20; Weisskopf MG, 2017, EPIDEMIOLOGY, V28, P635, DOI 10.1097/EDE.0000000000000686; Zuurbier M, 2011, EPIDEMIOLOGY, V22, P219, DOI 10.1097/EDE.0b013e3182093693	49	26	27	8	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2002	2006		10.1016/j.jaci.2019.04.019	http://dx.doi.org/10.1016/j.jaci.2019.04.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	31063735	Bronze			2022-12-18	WOS:000470113200003
J	Peng, C; Cardenas, A; Rifas-Shiman, SL; Hivert, MF; Gold, DR; Platts-Mills, TA; Lin, XH; Oken, E; Avila, L; Celedon, JC; Weiss, ST; Baccarelli, AA; Litonjua, AA; DeMeo, DL				Peng, Cheng; Cardenas, Andres; Rifas-Shiman, Sheryl L.; Hivert, Marie-France; Gold, Diane R.; Platts-Mills, Thomas A.; Lin, Xihong; Oken, Emily; Avila, Lydiana; Celedon, Juan C.; Weiss, Scott T.; Baccarelli, Andrea A.; Litonjua, Augusto A.; DeMeo, Dawn L.			Epigenetic age acceleration is associated with allergy and asthma in children in Project Viva	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epigenetic clock; allergy; asthma; DNA methylation	EPIGENOME-WIDE ASSOCIATION; DNA METHYLATION AGE; SERUM IMMUNOGLOBULIN-E; BLOOD; CLOCK; MORTALITY; EXPOSURE; RHINITIS; CELLS; IGE	Background: Epigenetic clocks have been suggested to capture one feature of the complexity between aging and the epigenome. However, little is known about the epigenetic clock in childhood allergy and asthma. Objective: We sought to examine associations of DNA methylation age (DNAmAge) and epigenetic age acceleration with childhood allergy and asthma. Methods: We calculated DNAmAge and age acceleration at birth, early childhood, and midchildhood based on the Illumina Human Methylation 450 Bead Chip in Project Viva. We evaluated epigenetic clock associations with allergy and asthma using covariate-adjusted linear and logistic regressions. We attempted to replicate our findings in the Genetics of Asthma in Costa Rica Study. Results: At midchildhood (mean age, 7.8 years) in Project Viva, DNAmAge and age acceleration were cross-sectionally associated with greater total serum IgE levels and greater odds of atopic sensitization. Every 1-year increase in intrinsic epigenetic age acceleration was associated with a 1.22 (95% CI, 1.07-1.39), 1.17 (95% CI, 1.03-1.34), and 1.29 (95% CI, 1.12-1.49) greater odds of atopic sensitization and environmental and food allergen sensitization. DNAmAge and extrinsic epigenetic age acceleration were also cross-sectionally associated with current asthma at midchildhood. DNAmAge and age acceleration at birth and early childhood were not associated with midchildhood allergy or asthma. The midchildhood association between age acceleration and atopic sensitization were replicated in an independent data set. Conclusions: Because the epigenetic clock might reflect immune and developmental components of biological aging, our study suggests pathways through which molecular epigenetic mechanisms of immunity, development, and maturation can interact along the age axis and associate with childhood allergy and asthma by midchildhood.	[Peng, Cheng; Gold, Diane R.; Weiss, Scott T.; Litonjua, Augusto A.; DeMeo, Dawn L.] Harvard Med Sch, Channing Div Network Med, Brigham & Womens Hosp, Boston, MA 02115 USA; [Litonjua, Augusto A.; DeMeo, Dawn L.] Harvard Med Sch, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Cardenas, Andres; Rifas-Shiman, Sheryl L.; Hivert, Marie-France; Oken, Emily] Harvard Med Sch, Dept Populat Med, Div Chron Dis Res Lifecourse, Boston, MA 02115 USA; [Cardenas, Andres; Rifas-Shiman, Sheryl L.; Hivert, Marie-France; Oken, Emily] Harvard Pilgr Hlth Care Inst, Boston, MA USA; [Hivert, Marie-France] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; [Gold, Diane R.] Harvard TH Chan Sch Publ Hlth, Environm Hlth, Boston, MA USA; [Lin, Xihong] Harvard TH Chan Sch Publ Hlth, Biostat, Boston, MA USA; [Platts-Mills, Thomas A.] Univ Virginia, Sch Med, Div Allergy & Clin Immunol, Charlottesville, VA 22908 USA; [Avila, Lydiana] Hosp Nacl Ninos Dr Carlos Saenz Herrera, Dept Pediat, San Jose, Costa Rica; [Celedon, Juan C.] Univ Pittsburgh, UPMC Childrens Hosp Pittsburgh, Div Pediat Pulm Med, Pittsburgh, PA USA; [Baccarelli, Andrea A.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Columbia University	Peng, C (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave,4th Floor, Boston, MA 02115 USA.	recpe@channing.harvard.edu	Avila, Lydiana/D-5638-2015; Hivert, Marie-France/GWN-0455-2022	Avila, Lydiana/0000-0002-9579-1591; Cardenas, Andres/0000-0003-2284-3298; Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health [R01 HL 111108, P01 HL 132825, R01 NR013945, R01 HD 034568, UG3OD023286, K23 ES022242, R01 AI102960]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117191, R01HL111108, P01HL132825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102960] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [UH3OD023286, UG3OD023286] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The Project Viva study is supported by grants from the National Institutes of Health (R01 HL 111108, P01 HL 132825, R01 NR013945, R01 HD 034568, UG3OD023286, K23 ES022242, and R01 AI102960).	Baccarelli A, 2012, EPIGENOMICS-UK, V4, P91, DOI [10.2217/EPI.11.106, 10.2217/epi.11.106]; Bakulski KM, 2016, EPIGENETICS-US, V11, P354, DOI 10.1080/15592294.2016.1161875; Barnetson RS, 2002, BRIT MED J, V324, P1376, DOI 10.1136/bmj.324.7350.1376; Binder AM, 2018, EPIGENETICS-US, V13, P85, DOI 10.1080/15592294.2017.1414127; Brehm JM, 2015, AM J RESP CRIT CARE, V192, P47, DOI 10.1164/rccm.201501-0037OC; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V137, P1063, DOI 10.1016/j.jaci.2015.11.031; Bunyavanich S, 2014, J ALLERGY CLIN IMMUN, V133, P1373, DOI 10.1016/j.jaci.2013.11.040; Cardenas A, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1467; Cardenas A, 2016, EPIGENETICS-US, V11, P773, DOI 10.1080/15592294.2016.1233091; Chen BH, 2016, AGING-US, V8, P1844, DOI 10.18632/aging.101020; Chen W, 2017, J ALLERGY CLIN IMMUN, V140, P571, DOI 10.1016/j.jaci.2016.11.030; Christiansen L, 2016, AGING CELL, V15, P149, DOI 10.1111/acel.12421; DeVries A, 2015, CURR OPIN ALLERGY CL, V15, P435, DOI 10.1097/ACI.0000000000000201; Everson TM, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0213-8; Gurnot C, 2015, EPIGENETICS-US, V10, P361, DOI 10.1080/15592294.2015.1026031; Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Horvath S, 2018, NAT REV GENET, V19, P371, DOI 10.1038/s41576-018-0004-3; Horvath S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1030-0; Horvath S, 2015, AGING-US, V7, P1130, DOI 10.18632/aging.100859; Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kim YJ, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-39; Klemera P, 2006, MECH AGEING DEV, V127, P240, DOI 10.1016/j.mad.2005.10.004; Knight AK, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1068-z; Levine ME, 2015, AGING-US, V7, P690, DOI 10.18632/aging.100809; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Lu AT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02697-5; Marioni RE, 2015, INT J EPIDEMIOL, V44, P1388, DOI 10.1093/ije/dyu277; Marioni RE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0584-6; Martino D, 2014, EPIGENETICS-US, V9, P998, DOI 10.4161/epi.28945; Martino DJ, 2011, EPIGENETICS-US, V6, P1085, DOI 10.4161/epi.6.9.16401; Miller GE, 2015, P NATL ACAD SCI USA, V112, P10325, DOI 10.1073/pnas.1505063112; Naumova OY, 2012, DEV PSYCHOPATHOL, V24, P143, DOI 10.1017/S0954579411000605; Non AL, 2014, EPIGENETICS-US, V9, P964, DOI 10.4161/epi.28853; Oken E, 2005, OBES RES, V13, P2021, DOI 10.1038/oby.2005.248; Oken E, 2015, INT J EPIDEMIOL, V44, P37, DOI 10.1093/ije/dyu008; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; Peng C, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0488-x; Perna L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0228-z; Quach A, 2017, AGING-US, V9, P419, DOI 10.18632/aging.101168; Simpkin AJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016708; Simpkin AJ, 2017, INT J EPIDEMIOL, V46, P549, DOI 10.1093/ije/dyw307; Simpkin AJ, 2016, HUM MOL GENET, V25, P191, DOI 10.1093/hmg/ddv456; Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680; Triche TJ, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt090; Urdinguio RG, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0913-x; van Aalderen WM, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/674204; Yang IV, 2017, J ALLERGY CLIN IMMUN, V139, P1478, DOI 10.1016/j.jaci.2016.07.036; Zheng T., 2014, J CLIN CELLULAR IMMU, V5, P2, DOI [10.4172/2155-9899.1000202, DOI 10.4172/2155-9899.1000202, 4172/2155-9899.1000202]; Zheng T, 2011, ALLERGY ASTHMA IMMUN, V3, P67, DOI 10.4168/aair.2011.3.2.67	53	26	27	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2263	+		10.1016/j.jaci.2019.01.034	http://dx.doi.org/10.1016/j.jaci.2019.01.034			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30738172	Green Accepted, Bronze			2022-12-18	WOS:000470113200029
J	Lu, HY; Biggs, CM; Blanchard-Rohner, G; Fung, SY; Sharma, M; Turvey, SE				Lu, Henry Y.; Biggs, Catherine M.; Blanchard-Rohner, Geraldine; Fung, Shan-Yu; Sharma, Mehul; Turvey, Stuart E.			Germline CBM-opathies: From immunodeficiency to atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						CBM-opathies; CARD9; CARD11; CARD14; BCL10; MALT1; primary immunodeficiencies; combined immunodeficiency; congenital B-cell lymphocytosis; primary atopic disease	NF-KAPPA-B; DOMAIN-CONTAINING PROTEIN; PITYRIASIS-RUBRA-PILARIS; LYMPHOID-TISSUE; T-CELL; MALT LYMPHOMA; 11 CARD11; GENETIC-HETEROGENEITY; SUSCEPTIBILITY LOCI; CLINICAL-FEATURES	Caspase recruitment domain (CARD) protein-B cell CLL/lymphoma 10 (BCL10)-MALT1 paracaspase (MALT1) [CBM] complexes are critical signaling adaptors that facilitate immune and inflammatory responses downstream of both cell surface and intracellular receptors. Germline mutations that alter the function of members of this complex (termed CBM-opathies) cause a broad array of clinical phenotypes, ranging from profound combined immunodeficiency to B-cell lymphocytosis. With an increasing number of patients being described in recent years, the clinical spectrum of diseases associated with CBM-opathies is rapidly expanding and becoming unexpectedly heterogeneous. Here we review major discoveries that have shaped our understanding of CBM complex biology, and we provide an overview of the clinical presentation, diagnostic approach, and treatment options for those carrying germline mutations affecting CARD9, CARD11, CARD14, BCL10, and MALT1.	[Lu, Henry Y.; Biggs, Catherine M.; Blanchard-Rohner, Geraldine; Sharma, Mehul; Turvey, Stuart E.] British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Lu, Henry Y.; Biggs, Catherine M.; Turvey, Stuart E.] Univ British Columbia, Fac Med, Expt Med Program, Vancouver, BC, Canada; [Fung, Shan-Yu] Tianjin Med Univ, Minist Educ, Dept Immunol, Tianjin, Peoples R China; [Fung, Shan-Yu] Tianjin Med Univ, Minist Educ, Key Lab Immune Microenvironm & Dis, Tianjin, Peoples R China	BC Childrens Hospital; University of British Columbia; University of British Columbia; Tianjin Medical University; Tianjin Medical University	Turvey, SE (corresponding author), BC Childrens Hosp, 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada.	sturvey@cw.bc.ca	Blanchard-Rohner, Geraldine/AAX-7643-2020; Fung, Shan-Yu/E-3477-2014; Lu, Henry/N-4567-2019; Blanchard-Rohner, Geraldine/AAO-7386-2020; Turvey, Stuart/HGV-1191-2022	Fung, Shan-Yu/0000-0002-4547-8740; Lu, Henry/0000-0002-1645-7748; Biggs, Catherine/0000-0002-4363-2660; Turvey, Stuart/0000-0003-1599-1065; Blanchard-Rohner, Geraldine/0000-0002-9974-2172	Canadian Institutes of Health Research (CIHR); Genome British Columbia [SIP007]; Canadian Allergy, Asthma and Immunology Foundation; British Columbia Children's Hospital Foundation; AllerGen Emerging Clinician-Scientist Research Fellowship; University of British Columbia Four Year Doctoral Fellowship	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Genome British Columbia; Canadian Allergy, Asthma and Immunology Foundation; British Columbia Children's Hospital Foundation; AllerGen Emerging Clinician-Scientist Research Fellowship; University of British Columbia Four Year Doctoral Fellowship	Supported in part by the Canadian Institutes of Health Research (CIHR); Genome British Columbia (SIP007 to S.E.T.); the Canadian Allergy, Asthma and Immunology Foundation; and the British Columbia Children's Hospital Foundation. S.E.T. holds the Canada Research Chair in Pediatric Precision Health and the Aubrey J. Tingle Professorship in Pediatric Immunology. C.M.B. is a Health Professional-Investigator of the Michael Smith Foundation for Health Research and is supported by the AllerGen Emerging Clinician-Scientist Research Fellowship. H.Y.L. is funded by a University of British Columbia Four Year Doctoral Fellowship.	Afonina IS, 2016, EMBO REP, V17, P914, DOI 10.15252/embr.201642109; Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Allen M, 2003, AM J HUM GENET, V73, P430; Arjunaraja S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00198; Arjunaraja S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00913; Bachelez H, 2018, BRIT J DERMATOL, V178, P614, DOI 10.1111/bjd.16232; Bedsaul JR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02105; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Biggs CM, 2017, NAT GENET, V49, P1162, DOI 10.1038/ng.3925; Biggs CM, 2017, CLIN IMMUNOL, V181, P75, DOI 10.1016/j.clim.2017.06.003; Bornancin F, 2015, J IMMUNOL, V194, P3723, DOI 10.4049/jimmunol.1402254; Brohl AS, 2015, J CLIN IMMUNOL, V35, P32, DOI 10.1007/s10875-014-0106-4; Buchbinder D, 2015, J ALLERGY CLIN IMMUN, V136, P819, DOI 10.1016/j.jaci.2015.03.008; Charbit-Henrion F, 2017, J PEDIATR GASTR NUTR, V64, P378, DOI 10.1097/MPG.0000000000001262; Cohen JI, 2011, BLOOD, V117, P5835, DOI 10.1182/blood-2010-11-316745; Corvilain E, 2018, J CLIN IMMUNOL, V38, P656, DOI 10.1007/s10875-018-0539-2; Craiglow BG, 2018, J AM ACAD DERMATOL, V79, P487, DOI 10.1016/j.jaad.2018.02.034; Almeida ACD, 2015, NAT GENET, V47, P1465, DOI 10.1038/ng.3442; Dadi H, 2018, J ALLERGY CLIN IMMUN, V141, P1818, DOI 10.1016/j.jaci.2017.06.047; DARTE JMM, 1971, NEW ENGL J MED, V284, P431, DOI 10.1056/NEJM197102252840807; De Bruyne M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02366; Desjardins M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02944; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Dorjbal B, 2019, J ALLERGY CLIN IMMUN, V143, P1482, DOI 10.1016/j.jaci.2018.08.013; Drummond RA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01836; Drummond RA, 2018, J ALLERGY CLIN IMMUN, V142, P1334, DOI 10.1016/j.jaci.2018.05.025; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Freeman AF, 2008, IMMUNOL ALLERGY CLIN, V28, P277, DOI 10.1016/j.iac.2008.01.005; Fuchs S, 2015, BLOOD, V126, P1658, DOI 10.1182/blood-2015-03-631374; Fuchs-Telem D, 2012, AM J HUM GENET, V91, P163, DOI 10.1016/j.ajhg.2012.05.010; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Gavino C, 2014, CLIN INFECT DIS, V59, P81, DOI 10.1093/cid/ciu215; Gehring T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01539; Gewies A, 2014, CELL REP, V9, P1292, DOI 10.1016/j.celrep.2014.10.044; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Grabiner BC, 2007, GENE DEV, V21, P984, DOI 10.1101/gad.1502507; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Gupta M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01049; Hamilton KS, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005169; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Howes A, 2016, BIOCHEM J, V473, P1759, DOI 10.1042/BCJ20160270; Hussell T, 1996, J PATHOL, V178, P122, DOI 10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; Israel L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02239; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Jattani RP, 2016, J BIOL CHEM, V291, P8338, DOI 10.1074/jbc.M116.717322; Jattani RP, 2016, J BIOL CHEM, V291, P8324, DOI 10.1074/jbc.M115.683714; Jaworski M, 2014, EMBO J, V33, P2765, DOI 10.15252/embj.201488987; Jeelall YS, 2012, J EXP MED, V209, P1907, DOI 10.1084/jem.20112744; Jordan CT, 2012, AM J HUM GENET, V90, P784, DOI 10.1016/j.ajhg.2012.03.012; Jordan CT, 2012, AM J HUM GENET, V90, P796, DOI 10.1016/j.ajhg.2012.03.013; Juilland M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01927; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Kim WB, 2017, CAN FAM PHYSICIAN, V63, P278; Klein T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9777; Lanternier F, 2013, CURR OPIN PEDIATR, V25, P736, DOI 10.1097/MOP.0000000000000031; Lee CH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12349-9; Lu HY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02078; Lu HY, 2018, PEDIAT ALLERG IMM-UK, V29, P663, DOI 10.1111/pai.12930; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; Lwin SM, 2018, BRIT J DERMATOL, V178, P969, DOI 10.1111/bjd.15462; Lyons JJ, 2018, J EXP MED, V215, P1009, DOI 10.1084/jem.20172306; Ma CA, 2017, NAT GENET, V49, P1192, DOI 10.1038/ng.3898; Torres JM, 2014, J CLIN INVEST, V124, P5239, DOI 10.1172/JCI77493; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; McAuley JR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01887; McKinnon ML, 2014, J ALLERGY CLIN IMMUN, V133, P1458, DOI 10.1016/j.jaci.2013.10.045; Moretta G, 2017, CLIN COSMET INV DERM, V10, P451, DOI 10.2147/CCID.S124351; Morgan JA, 1999, CANCER RES, V59, P6205; Nakaya M, 2014, IMMUNITY, V40, P692, DOI 10.1016/j.immuni.2014.04.007; Outinen T, 2016, CLIN IMMUNOL, V165, P19, DOI 10.1016/j.clim.2016.02.002; Peled A, 2019, J ALLERGY CLIN IMMUN, V143, P173, DOI 10.1016/j.jaci.2018.09.002; Punwani D, 2015, J CLIN IMMUNOL, V35, P135, DOI 10.1007/s10875-014-0125-1; Qiao Q, 2013, MOL CELL, V51, P766, DOI 10.1016/j.molcel.2013.08.032; Rieber N, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89890; Rozmus J, 2016, CLIN IMMUNOL, V168, P1, DOI 10.1016/j.clim.2016.04.011; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Ruland J, 2019, NAT REV IMMUNOL, V19, P118, DOI 10.1038/s41577-018-0087-2; Saba NS, 2017, CANCER RES, V77, P7038, DOI 10.1158/0008-5472.CAN-17-2485; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P1218, DOI 10.1016/j.jaad.2014.08.038; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P327, DOI 10.1016/j.jaad.2014.03.030; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Takeichi T, 2017, JAMA DERMATOL, V153, P66, DOI 10.1001/jamadermatol.2016.3601; Tanaka M, 2018, J IMMUNOL, V200, P71, DOI 10.4049/jimmunol.1700995; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(00)00094-0; Vaezi A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02434; Wang DY, 2018, AM J CLIN DERMATOL, V19, P377, DOI 10.1007/s40257-017-0338-1; Wang L, 2001, J BIOL CHEM, V276, P21405, DOI 10.1074/jbc.M102488200; Wang MC, 2018, IMMUNITY, V49, P66, DOI 10.1016/j.immuni.2018.05.012; Watt SA, 2015, AM J PATHOL, V185, P2354, DOI 10.1016/j.ajpath.2015.05.018; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; Wu CL, 2016, ONCOTARGET, V7, P38180, DOI 10.18632/oncotarget.9500; Yan QG, 2012, HAEMATOL-HEMATOL J, V97, P595, DOI 10.3324/haematol.2011.054080; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zotti T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02167; 2014, J ALLERGY CLIN IMMUN, V133, P1458; 2008, SCIENCE, V319, P1676	111	26	29	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1661	1673		10.1016/j.jaci.2019.03.009	http://dx.doi.org/10.1016/j.jaci.2019.03.009			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	31060714	Bronze			2022-12-18	WOS:000466784600001
J	Oksel, C; Granell, R; Mahmoud, O; Custovic, A; Henderson, AJ; Arshad, SH; Colicino, S; Cullinan, P; Curtin, J; Devereux, G; Holloway, J; Murray, CS; Roberts, G; Simpson, A; Turner, S; Bush, A; Ghazal, P; Grigg, J; Lloyd, CM; Marsland, B; Power, U; Saglani, S; Schwarze, J; Shields, M				Oksel, Ceyda; Granell, Raquel; Mahmoud, Osama; Custovic, Adnan; Henderson, A. John; Arshad, Syed Hasan; Colicino, Silvia; Cullinan, Paul; Curtin, John; Devereux, Graham; Holloway, John; Murray, Clare S.; Roberts, Graham; Simpson, Angela; Turner, Steve; Bush, Andrew; Ghazal, Peter; Grigg, Jonathan; Lloyd, Clare M.; Marsland, Benjamin; Power, Ultan; Saglani, Sejal; Schwarze, Jurgen; Shields, Mike		STELAR Investigators; Breathing Together Investigators	Causes of variability in latent phenotypes of childhood wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; wheeze phenotypes; longitudinal analysis; latent class analysis; Avon Longitudinal Study of Parents and Children	1ST 6 YEARS; LUNG-FUNCTION; CONFIRMED WHEEZE; ASTHMA; LIFE; ASSOCIATIONS; CHILDREN; OUTCOMES; ATOPY; RISK	Background: Latent class analysis (LCA) has been used extensively to identify (latent) phenotypes of childhood wheezing. However, the number and trajectory of discovered phenotypes differed substantially between studies. Objective: We sought to investigate sources of variability affecting the classification of phenotypes, identify key time points for data collection to understand wheeze heterogeneity, and ascertain the association of childhood wheeze phenotypes with asthma and lung function in adulthood. Methods: We used LCA to derive wheeze phenotypes among 3167 participants in the ALSPAC cohort who had complete information on current wheeze recorded at 14 time points from birth to age 161/2 years. We examined the effects of sample size and data collection age and intervals on the results and identified time points. We examined the associations of derived phenotypes with asthma and lung function at age 23 to 24 years. Results: A relatively large sample size (>2000) underestimated the number of phenotypes under some conditions (eg, number of time points < 11). Increasing the number of data points resulted in an increase in the optimal number of phenotypes, but an identical number of randomly selected follow-up points led to different solutions. A variable selection algorithm identified 8 informative time points (months 18, 42, 57, 81, 91, 140, 157, and 166). The proportion of asthmatic patients at age 23 to 24 years differed between phenotypes, whereas lung function was lower among persistent wheezers. Conclusions: Sample size, frequency, and timing of data collection have a major influence on the number and type of wheeze phenotypes identified by using LCA in longitudinal data.	[Oksel, Ceyda; Custovic, Adnan] Imperial Coll London, Paediat Sect, Dept Med, Norfolk Pl, London W2 1PG, England; [Granell, Raquel; Mahmoud, Osama; Henderson, A. John] Univ Bristol, Bristol Med Sch, Dept Populat Hlth Sci, Bristol, Avon, England	Imperial College London; University of Bristol	Custovic, A (corresponding author), Imperial Coll London, Paediat Sect, Dept Med, Norfolk Pl, London W2 1PG, England.	a.custovic@imperial.ac.uk	Öksel, Ceyda/AAS-5372-2020; Holloway, John W/B-5424-2009; Granell, Raquel/AAY-4846-2020; Granell, Raquel/AAB-5256-2022; Saglani, Sejal/AAE-5072-2019; Custovic, Adnan/A-2435-2012; Mahmoud, Osama/GRY-3702-2022; Schwarze, Jürgen/F-7396-2011	Holloway, John W/0000-0001-9998-0464; Granell, Raquel/0000-0002-4890-4012; Custovic, Adnan/0000-0001-5218-7071; Mahmoud, Osama/0000-0003-0342-6704; Roberts, Graham/0000-0003-2252-1248; Power, Ultan/0000-0003-3246-3774; Lloyd, Clare/0000-0001-8977-6726	Wellcome Trust Strategic Award [108818/15/Z]; UK Medical Research Council; Wellcome Trust [102215/2/13/2]; University of Bristol; UK Medical Research Council (MRC) [G0601361, MR/K002449/1]; MRC [G0401540, G0601361, MR/K002449/2, MC_PC_19009] Funding Source: UKRI	Wellcome Trust Strategic Award(Wellcome Trust); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); University of Bristol; UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	C.O. is funded through the Wellcome Trust Strategic Award 108818/15/Z. The UK Medical Research Council and the Wellcome Trust (grant 102215/2/13/2) and the University of Bristol provide core support for Avon Longitudinal Study of Parents and Children (ALSPAC). A comprehensive list of grants funding is available on the ALSPAC Web site (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). STELAR cohorts are funded by UK Medical Research Council (MRC) grants G0601361 and MR/K002449/1. This analysis was funded by the Wellcome Trust Strategic Award 108818/15/Z.	Arshad SH, 2018, INT J EPIDEMIOL, V47, P1043, DOI 10.1093/ije/dyy023; Belgrave D, 2017, J ALLERGY CLIN IMMUN, V139, P400, DOI 10.1016/j.jaci.2016.11.003; Belgrave D, 2014, AM J RESP CRIT CARE, V189, P121, DOI 10.1164/rccm.201312-2206ED; Belgrave DCM, 2018, LANCET RESP MED, V6, P526, DOI 10.1016/S2213-2600(18)30099-7; Belgrave DCM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001748; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Belgrave DCM, 2013, EXPERT REV CLIN IMMU, V9, P921, DOI 10.1586/1744666X.2013.836450; Belgrave DCM, 2013, J ALLERGY CLIN IMMUN, V132, P575, DOI 10.1016/j.jaci.2013.05.041; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Brand PLP, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00042-2018; Chen QX, 2012, ANN ALLERG ASTHMA IM, V108, P311, DOI 10.1016/j.anai.2012.02.016; Custovic A, 2015, THORAX, V70, P799, DOI 10.1136/thoraxjnl-2015-206781; Deliu M, 2017, EXPERT REV CLIN IMMU, V13, P705, DOI 10.1080/1744666X.2017.1257940; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Fop M, 2017, ANN APPL STAT, V11, P2080, DOI 10.1214/17-AOAS1061; Fraser A, 2013, INT J EPIDEMIOL, V42, P97, DOI 10.1093/ije/dys066; Grad R, 2012, J ALLERGY CLIN IMMUN, V130, P299, DOI 10.1016/j.jaci.2012.05.022; Granell R, 2016, J ALLERGY CLIN IMMUN, V138, P1060, DOI 10.1016/j.jaci.2016.01.046; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Howard R, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0542-0; Just J, 2017, CLIN EXP ALLERGY, V47, P848, DOI 10.1111/cea.12939; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Linzer DA, 2011, J STAT SOFTW, V42, P1, DOI 10.18637/jss.v042.i10; Lodge CJ, 2014, J PEDIATR-US, V164, P289, DOI 10.1016/j.jpeds.2013.09.056; Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Pike KC, 2011, PEDIATR PULM, V46, P75, DOI 10.1002/ppul.21327; Quanjer PH, 2010, EUR RESPIR J, V36, P1391, DOI 10.1183/09031936.00164109; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Sears MR, 2015, J ALLERGY CLIN IMMUN, V136, P829, DOI 10.1016/j.jaci.2015.04.048; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; van der Valk RJP, 2012, CLIN EXP ALLERGY, V42, P1329, DOI 10.1111/j.1365-2222.2012.04010.x; 2014, PRIM CARE RESP J, V23, P60, DOI DOI 10.4104/PCRJ.2014.00008	40	26	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1783	+		10.1016/j.jaci.2018.10.059	http://dx.doi.org/10.1016/j.jaci.2018.10.059			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30528616	hybrid, Green Accepted, Green Published, Green Submitted			2022-12-18	WOS:000466784600014
J	Gharib, SA; McMahan, RS; Eddy, WE; Long, ME; Parks, WC; Aitken, ML; Manicone, AM				Gharib, Sina A.; McMahan, Ryan S.; Eddy, William E.; Long, Matthew E.; Parks, William C.; Aitken, Moira L.; Manicone, Anne M.			Transcriptional and functional diversity of human macrophage repolarization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Macrophage; polarization; pathway; microarray; cystic fibrosis; asthma; efferocytosis; tolerance	GENE-EXPRESSION; ALTERNATIVE ACTIVATION; POLARIZATION; CELLS; AZITHROMYCIN; ASTHMA; INFLAMMATION; CLEARANCE; MONOCYTE; STRESS	Background: Macrophage plasticity allows cells to adopt different phenotypes, a property with important implications in disorders such as cystic fibrosis (CF) and asthma. Objective: We sought to examine the transcriptional and functional significance of macrophage repolarization from an M1 to an M2 phenotype and assess the role of a common human genetic disorder (CF) and a prototypical allergic disease (asthma) in this transformation. Methods: Monocyte-derived macrophages were collected from healthy subjects and patients with CF and polarized to an M2 state by using IL-4, IL-10, glucocorticoids, apoptotic PMNs, or azithromycin. We performed transcriptional profiling and pathway analysis for each stimulus. We assessed the ability of M2-repolarized macrophages to respond to LPS rechallenge and clear apoptotic neutrophils and used murine models to determine conserved functional responses to IL-4 and IL-10. We investigated whether M2 signatures were associated with alveolar macrophage phenotypes in asthmatic patients. Results: We found that macrophages exhibit highly diverse responses to distinct M2-polarizing stimuli. Specifically, IL-10 activated proinflammatory pathways and abrogated LPS tolerance, allowing rapid restoration of LPS responsiveness. In contrast, IL-4 enhanced LPS tolerance, dampening proinflammatory responses after repeat LPS challenge. A common theme observed across all M2 stimuli was suppression of interferon-associated pathways. We found that CF macrophages had intact reparative and transcriptional responses, suggesting that macrophage contributions to CFrelated lung disease are primarily shaped by their environment. Finally, we leveraged in vitro-derived signatures to show that allergen provocation induces distinct M2 state transcriptional patterns in alveolar macrophages. Conclusion: Our findings highlight the diversity of macrophage polarization, attribute functional consequences to different M2 stimuli, and provide a framework to phenotype macrophages in disease states.	[Gharib, Sina A.; Eddy, William E.; Long, Matthew E.; Aitken, Moira L.; Manicone, Anne M.] Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA; [McMahan, Ryan S.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; [Parks, William C.] Cedars Sinai Med Ctr, Womens Guild Lung Inst, Los Angeles, CA 90048 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Cedars Sinai Medical Center	Gharib, SA; Manicone, AM (corresponding author), Univ Washington, Div Pulm Crit Care & Sleep Med, Ctr Lung Biol, 850 Republican St, Seattle, WA 98109 USA.	sagharib@uw.edu; manicone@uw.edu	Parks, William C./AAH-6786-2021	GHARIB, SINA A./0000-0002-2480-4367; Long, Matthew/0000-0003-4485-019X	National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases [P30 DK089507]; NIH/National Heart, Lung, and Blood Institute (NHLBI) [R01 HL116514]; NIH/National Institute of Allergy and Infectious Diseases [R01 AI137111]; Cystic Fibrosis Foundation Research Development Program [CFF SINGH15R0]; NIH/NHLBI [T32 HL007828]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007828, R01HL144656, R01HL116514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI137111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK089507] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Cystic Fibrosis Foundation Research Development Program; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases P30 DK089507 (to A.M.M., R.S.M., and S.A.G.), NIH/National Heart, Lung, and Blood Institute (NHLBI) R01 HL116514 (to A.M.M.), NIH/National Institute of Allergy and Infectious Diseases R01 AI137111 (to S.A.G.), NIH/NHLBI T32 HL007828 (to M.E.L.), and the Cystic Fibrosis Foundation Research Development Program CFF SINGH15R0 (to M.E.L.).	Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Balhara J, 2012, MUCOSAL IMMUNOL, V5, P605, DOI 10.1038/mi.2012.74; Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733; Bhakta NR, 2018, AM J RESP CRIT CARE, V197, P313, DOI 10.1164/rccm.201706-1070OC; Brandt E, 2000, J LEUKOCYTE BIOL, V68, P125; Bruscia EM, 2011, J IMMUNOL, V186, P6990, DOI 10.4049/jimmunol.1100396; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Cory TJ, 2014, J CYST FIBROS, V13, P164, DOI 10.1016/j.jcf.2013.08.007; del Fresno C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002667; Del Porto P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019970; Di A, 2006, NAT CELL BIOL, V8, P933, DOI 10.1038/ncb1456; Draijer C, 2017, J ALLERGY CLIN IMMUN, V140, P280, DOI 10.1016/j.jaci.2016.11.020; Draijer C, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0681-6; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Gharib SA, 2014, J LEUKOCYTE BIOL, V95, P9, DOI 10.1189/jlb.1112587; Gibson PG, 2017, LANCET, V390, P659, DOI 10.1016/S0140-6736(17)31281-3; Girodet PO, 2016, AM J RESP CELL MOL, V55, P467, DOI 10.1165/rcmb.2015-0295OC; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Isserlin Ruth, 2014, F1000Res, V3, P141, DOI 10.12688/f1000research.4536.1; Jaresova I, 2007, MICROBES INFECT, V9, P1359, DOI 10.1016/j.micinf.2007.06.009; Jing J, 2013, J IMMUNOL, V190, P6360, DOI 10.4049/jimmunol.1202942; Johnston LK, 2012, AM J RESP CELL MOL, V47, P417, DOI 10.1165/rcmb.2012-0090OC; Kayala MA, 2012, NUCLEIC ACIDS RES, V40, pW553, DOI 10.1093/nar/gks420; Loke P, 2007, J IMMUNOL, V179, P3926, DOI 10.4049/jimmunol.179.6.3926; Long ME, 2017, J IMMUNOL, V198, P862, DOI 10.4049/jimmunol.1601059; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Manicone AM, 2009, J IMMUNOL, V182, P3866, DOI 10.4049/jimmunol.0713949; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murphy BS, 2008, J ANTIMICROB CHEMOTH, V61, P554, DOI 10.1093/jac/dkn007; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Park GY, 2013, AM J RESP CRIT CARE, V188, P928, DOI 10.1164/rccm.201306-1014OC; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sorio C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022212; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vallelian F, 2010, BLOOD, V116, P5347, DOI 10.1182/blood-2010-04-277319; Wojcik AJ, 2008, J IMMUNOL, V180, P4273, DOI 10.4049/jimmunol.180.6.4273; Yvan-Charvet L, 2010, CIRC RES, V106, P1861, DOI 10.1161/CIRCRESAHA.110.217281; Zhou DX, 2014, CELL SIGNAL, V26, P192, DOI 10.1016/j.cellsig.2013.11.004; Zizzo G, 2012, J IMMUNOL, V189, P3508, DOI 10.4049/jimmunol.1200662	41	26	31	5	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1536	1548		10.1016/j.jaci.2018.10.046	http://dx.doi.org/10.1016/j.jaci.2018.10.046			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30445062	Green Accepted, Bronze			2022-12-18	WOS:000463348900028
J	Nocera, AL; Mueller, SK; Stephan, JR; Hing, L; Seifert, P; Han, X; Lin, DT; Amiji, MM; Libermann, T; Bleier, BS				Nocera, Angela L.; Mueller, Sarina K.; Stephan, Jules R.; Hing, Loretta; Seifert, Philip; Han, Xue; Lin, Derrick T.; Amiji, Mansoor M.; Libermann, Towia; Bleier, Benjamin S.			Exosome swarms eliminate airway pathogens and provide passive epithelial immunoprotection through nitric oxide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exosome; innate immunity; CD81; epithelium; sinonasal mucus; nitric oxide; proteomics	DENSITY-GRADIENT SEPARATION; PSEUDOMONAS-AERUGINOSA; P-GLYCOPROTEIN; CELLS; INFLAMMATION; MECHANISM; DELIVERY; CAPTURE; INNATE; MODEL	Background: Nasal mucosa-derived exosomes (NMDEs) harbor immunodefensive proteins and are capable of rapid interepithelial protein transfer. Objectives: We sought to determine whether mucosal exposure to inhaled pathogens stimulates a defensive swarm of microbiocidal exosomes, which also donate their antimicrobial cargo to adjacent epithelial cells. Methods: We performed an institutional review board-approved study of healthy NMDE secretion after Toll-like receptor (TLR) 4 stimulation by LPS (12.5 mg/mL) in the presence of TLR4 inhibitors. Interepithelial transfer of exosomal nitric oxide (NO) synthase and nitric oxide was measured by using ELISAs and NO activity assays. Exosomal antimicrobial assays were performed with Pseudomonas aeruginosa. Proteomic analyses were performed by using SOMAscan. Results: In vivo and in vitro LPS exposure induced a 2-fold increase in NMDE secretion along with a 2-fold increase in exosomal inducible nitric oxide synthase expression and function through TLR4 and inhibitor of nuclear factor kB kinase activation. LPS stimulation increased exosomal microbiocidal activity against P aeruginosa by almost 2 orders of magnitude. LPS-stimulated exosomes induced a 4-fold increase in NO production within autologous epithelial cells with protein transfer within 5 minutes of contact. Pathway analysis of the NMDE proteome revealed 44 additional proteins associated with NO signaling and innate immune function. Conclusions: We provide direct in vivo evidence for a novel exosome-mediated innate immunosurveillance and defense mechanism of the human upper airway. These findings have implications for lower airway innate immunity, delivery of airway therapeutics, and host microbiome regulation.	[Nocera, Angela L.; Mueller, Sarina K.; Lin, Derrick T.; Bleier, Benjamin S.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA; [Seifert, Philip] Harvard Med Sch, Schepens Eye Res Inst, Boston, MA 02115 USA; [Seifert, Philip] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA; [Mueller, Sarina K.] Univ Erlangen Nurnberg, Dept Otolaryngol Head & Neck Surg, Erlangen, Germany; [Stephan, Jules R.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Hing, Loretta; Han, Xue] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; [Amiji, Mansoor M.] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA; [Libermann, Towia] Harvard Med Sch, Dept Med, BIDMC Genom Prote Bioinformat & Syst Biol Ctr, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Harvard Medical School; University of Erlangen Nuremberg; Massachusetts Institute of Technology (MIT); Boston University; Northeastern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Bleier, BS (corresponding author), 243 Charles St, Boston, MA 02114 USA.	benjamin_bleier@meei.harvard.edu	Bleier, Benjamin S/H-6726-2019; Amiji, Mansoor M/AAK-1531-2020; Mueller, Sarina K./AAJ-9925-2021	Bleier, Benjamin S/0000-0003-0783-8861; Amiji, Mansoor M/0000-0001-6170-881X; Mueller, Sarina K./0000-0001-5790-0841	National Institutes of Health's National Eye Institute [P30EY003790]; NATIONAL EYE INSTITUTE [P30EY003790] Funding Source: NIH RePORTER	National Institutes of Health's National Eye Institute; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Electron Microscopy work was supported through the National Institutes of Health's National Eye Institute, core grant P30EY003790.	Antunes MB, 2009, IMMUNOL ALLERGY CLIN, V29, P631, DOI 10.1016/j.iac.2009.07.004; Bebawy M, 2009, LEUKEMIA, V23, P1643, DOI 10.1038/leu.2009.76; Bebawy M, 2015, GASTROENTEROLOGY, V5, P1; Bendouah Z, 2006, OTOLARYNG HEAD NECK, V134, P991, DOI 10.1016/j.otohns.2006.03.001; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Bleier BS, 2012, J PHARM PHARMACOL, V64, P449, DOI 10.1111/j.2042-7158.2011.01409.x; Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x; Cai XW, 2017, MOL MED REP, V16, P7032, DOI 10.3892/mmr.2017.7492; Chennupati SK, 2009, AM J RHINOL ALLERGY, V23, P46, DOI 10.2500/ajra.2009.23.3261; Cho JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090683; Costantino HR, 2007, INT J PHARMACEUT, V337, P1, DOI 10.1016/j.ijpharm.2007.03.025; Ekman AK, 2009, INT ARCH ALLERGY IMM, V149, P154, DOI 10.1159/000189199; Greening DW, 2015, METHODS MOL BIOL, V1295, P179, DOI 10.1007/978-1-4939-2550-6_15; Hu G, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003261; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kim Seunggyu, 2017, Bioengineering-Basel, V4, P8, DOI 10.3390/bioengineering4010008; Kim YJ, 2017, BIOCHEM BIOPH RES CO, V493, P1102, DOI 10.1016/j.bbrc.2017.09.056; Kvarnhammar AM, 2012, RESP RES, P13; Lam JS, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00118; Lasser C, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0927-4; Lasser C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-9; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Lv MM, 2014, TUMOR BIOL, V35, P10773, DOI 10.1007/s13277-014-2377-z; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; Martinez-Castillo M, 2018, PARASITOL RES, V117, P75, DOI 10.1007/s00436-017-5666-9; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Molteni M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6978936; Monogue ML, 2018, J ANTIMICROB CHEMOTH, V73, P942, DOI 10.1093/jac/dkx483; Nocera AL, 2017, LARYNGOSCOPE, V127, pE295, DOI 10.1002/lary.26614; Nocera AL, 2016, AM J RHINOL ALLERGY, V30, P246, DOI 10.2500/ajra.2016.30.4330; Parthasarathi K, 2017, RHINOLOGY, V55, P332, DOI [10.4193/Rhin16.210, 10.4193/Rhino16.210]; Patki A, 2016, RESP PHYSIOL NEUROBI, V232, P66, DOI 10.1016/j.resp.2016.07.004; Pier GB, 2007, INT J MED MICROBIOL, V297, P277, DOI 10.1016/j.ijmm.2007.03.012; Skerrett SJ, 2017, PHYSL REP, P5; Tauro BJ, 2012, METHODS, V56, P293, DOI 10.1016/j.ymeth.2012.01.002; Thebaud B, 2012, CIRCULATION, V126, P2553, DOI 10.1161/CIRCULATIONAHA.112.146738; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Van Deun J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24858; Verbeurgt C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181302; Virtala R, 2012, CLIN EXP ALLERGY, V42, P590, DOI 10.1111/j.1365-2222.2011.03921.x; Wommack AJ, 2014, J AM CHEM SOC, V136, P13494, DOI 10.1021/ja505957w; Zhou R, 2010, NUCLEIC ACIDS RES, V38, P3222, DOI 10.1093/nar/gkq056; Zocco D, 2017, METHODS MOL BIOL, V1660, P269, DOI 10.1007/978-1-4939-7253-1_22	48	26	28	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1525	+		10.1016/j.jaci.2018.08.046	http://dx.doi.org/10.1016/j.jaci.2018.08.046			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30442371	Bronze			2022-12-18	WOS:000463348900027
J	Li, YP; Liu, B; Harmacek, L; Long, ZJ; Liang, JY; Lukin, K; Leach, SM; O'Connor, B; Gerber, AN; Hagman, J; Roers, A; Finkelman, FD; Huang, H				Li, Yapeng; Liu, Bing; Harmacek, Laura; Long, Zijie; Liang, Jinyi; Lukin, Kara; Leach, Sonia M.; O'Connor, Brian; Gerber, Anthony N.; Hagman, James; Roers, Axel; Finkelman, Fred D.; Huang, Hua			The transcription factors GATA2 and microphthalmia-associated transcription factor regulate Hdc gene expression in mast cells and are required for IgE/mast cell-mediated anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; connective tissue mast cell; GATA2; microphthalmia-associated transcription factor; histidine decarboxylase; enhancer; anaphylaxis; histamine synthesis	HISTIDINE-DECARBOXYLASE GENE; INTEGRATIVE GENOMICS VIEWER; MOUSE BONE-MARROW; UPSTREAM SP1 SITE; GRANULE MATURATION; PROMOTER REGION; MICE LACKING; HISTAMINE; ENHANCERS; DISTINCT	Background: Histamine is a critical mediator of IgE/mast cell-mediated anaphylaxis. Histamine is synthesized by decarboxylating the amino acid histidine, a reaction catalyzed by the histidine decarboxylase (Hdc) gene-encoded enzyme HDC. However, regulation of the Hdc gene in mast cells is poorly understood. Objective: We sought to investigate the in vivo regulation of IgE/ mast cell-mediated anaphylaxis by the transcription factors GATA2 and microphthalmia-associated transcription factor (MITF) and the mechanisms by which GATA2 and MITF regulate Hdc gene expression in mouse and human mast cells. Methods: Mice deficient in the transcription factors Gata2, aryl hydrocarbon receptor (Ahr), aryl hydrocarbon receptor repressor (Ahrr), or basic helix-loop-helix family member E40 (Bhlhe40) were assessed for anaphylactic reactions. Chromatin immunoprecipitation sequencing analysis identified putative Hdc enhancers. Luciferase reporter transcription assay confirmed enhancer activities of putative enhancers in the Hdc gene. The short hairpin RNA knockdown approach was used to determine the role of MITF in regulating mouse and human HDC gene expression. Results: Connective tissue mast cell-specific Gata2-deficient mice did not have IgE/mast cell-mediated anaphylaxis. GATA2 induced the expression of Mitf, Ahr, Ahrr, and Bhlhe40 in mast cells. MITF, but not AHR, AHRR, or BHLHE40, was required for anaphylaxis. MITF bound to an enhancer located 8.8 kb upstream of the transcription start site of the Hdc gene and directed enhancer activity. MITF overexpression largely restored Hdc gene expression in the Gata2-deficient mast cells. In the human mast cell line LAD2, MITF was required for the HDC gene expression and histamine synthesis. Conclusion: The transcription factors GATA2 and MITF regulate Hdc gene expression in mast cells and are required for IgE/mast cell-mediated anaphylaxis.	[Li, Yapeng; Liu, Bing; Long, Zijie; Liang, Jinyi; Lukin, Kara; Leach, Sonia M.; O'Connor, Brian; Gerber, Anthony N.; Hagman, James; Huang, Hua] Natl Jewish Hlth, Dept Biomed Res, 1400 Jackson St, Denver, CO 80206 USA; [Harmacek, Laura; Leach, Sonia M.; O'Connor, Brian] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA; [Gerber, Anthony N.] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Liu, Bing] Wuhan Univ, Zhongnan Hosp, Dept Resp Med, Wuhan, Hubei, Peoples R China; [Long, Zijie] Sun Yat Sen Univ, Affiliated Hosp 3, Inst Hematol, Dept Hematol, Guangzhou, Guangdong, Peoples R China; [Liang, Jinyi] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Parasitol, Guangzhou, Guangdong, Peoples R China; [Hagman, James; Huang, Hua] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Denver, CO USA; [Roers, Axel] Tech Univ Dresden, Inst Immunol, Dresden, Germany; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH 45221 USA	National Jewish Health; National Jewish Health; National Jewish Health; Wuhan University; Sun Yat Sen University; Sun Yat Sen University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Technische Universitat Dresden; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Huang, H (corresponding author), Natl Jewish Hlth, Dept Biomed Res, 1400 Jackson St, Denver, CO 80206 USA.	huangh@njhealth.org	Hagman, James/R-7013-2019	Hagman, James/0000-0002-5436-8455; Huang, Hua/0000-0001-7317-8983	National Institutes of Health [R01AI107022, RO1AI083986, R01 AI098417, R01AI113162]; China Scholarship Council [201606385033, 201406270087]; Sun Yet-Sen University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083986, R01AI113162, R01AI107022, R01AI098417] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council(China Scholarship Council); Sun Yet-Sen University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (R01AI107022 and RO1AI083986 to H.H., R01 AI098417 to J.H., and R01AI113162 to F.D.F.), funds provided by the China Scholarship Council (201606385033 to Z.L. and 201406270087 to B.L.), and funds provided by Sun Yet-Sen University (to J.L.).	Ai WD, 2006, AM J PHYSIOL-GASTR L, V290, pG1096, DOI 10.1152/ajpgi.00199.2005; Ai WD, 2004, J BIOL CHEM, V279, P8684, DOI 10.1074/jbc.M308278200; Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024; Calero-Nieto FJ, 2014, EMBO J, V33, P1212, DOI 10.1002/embj.201386825; Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038; Cildir G, 2017, J EXP MED, V214, P2491, DOI 10.1084/jem.20170910; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; GALLI SJ, 1982, J CELL BIOL, V95, P435, DOI 10.1083/jcb.95.2.435; Hallgren J, 2014, EUR J IMMUNOL, V44, P33, DOI 10.1002/eji.201344262; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hirasawa N, 2006, BIOCHEM BIOPH RES CO, V349, P833, DOI 10.1016/j.bbrc.2006.08.104; Hocker M, 1996, YALE J BIOL MED, V69, P21; Hogan SP, 2012, SEMIN IMMUNOPATHOL, V34, P643, DOI 10.1007/s00281-012-0320-1; Ichikawa A, 2010, P JPN ACAD B-PHYS, V86, P848, DOI 10.2183/pjab.86.848; Iwasaki H, 2006, GENE DEV, V20, P3010, DOI 10.1101/gad.1493506; Jiang XY, 2008, J NEUROSCI, V28, P1118, DOI 10.1523/JNEUROSCI.2262-07.2008; KATZ HR, 1987, J IMMUNOL, V139, P1640; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kitamura Y, 2002, INT ARCH ALLERGY IMM, V127, P106, DOI 10.1159/000048178; Kitamura Y, 2007, P JPN ACAD B-PHYS, V83, P164, DOI 10.2183/pjab.83.164; Komori H, 2012, J BIOL CHEM, V287, P29175, DOI 10.1074/jbc.M112.381897; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; Li YP, 2015, J IMMUNOL, V194, P4328, DOI 10.4049/jimmunol.1500018; Lim KC, 2012, J CLIN INVEST, V122, P3705, DOI 10.1172/JCI61619; Ling KW, 2004, J EXP MED, V200, P871, DOI 10.1084/jem.20031556; Makabe-Kobayashi Y, 2002, J ALLERGY CLIN IMMUN, V110, P298, DOI 10.1067/mai.2002.125977; Malbec O, 2007, J IMMUNOL, V178, P6465, DOI 10.4049/jimmunol.178.10.6465; Mangan S, 2003, P NATL ACAD SCI USA, V100, P11980, DOI 10.1073/pnas.2133841100; Morii E, 2004, AM J PATHOL, V165, P491, DOI 10.1016/S0002-9440(10)63314-7; Morii E, 2003, BLOOD, V101, P1344, DOI 10.1182/blood-2002-07-2213; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Nakazawa S, 2014, EUR J IMMUNOL, V44, P204, DOI 10.1002/eji.201343838; Ohmori S, 2015, BLOOD, V125, P3306, DOI 10.1182/blood-2014-11-612465; Ohtsu H, 2001, FEBS LETT, V502, P53, DOI 10.1016/S0014-5793(01)02663-1; Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957; Ottina E, 2015, J IMMUNOL, V194, P1316, DOI 10.4049/jimmunol.1400637; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; Qi XP, 2013, IMMUNITY, V39, P97, DOI 10.1016/j.immuni.2013.06.012; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rodrigues NP, 2008, BLOOD, V112, P4862, DOI 10.1182/blood-2008-01-136564; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; STECHSCHULTE DJ, 1987, J CELL PHYSIOL, V132, P565, DOI 10.1002/jcp.1041320321; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Suzuki-Ishigaki S, 2000, NUCLEIC ACIDS RES, V28, P2627, DOI 10.1093/nar/28.14.2627; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tong Q, 2016, FREE RADICAL BIO MED, V94, P185, DOI 10.1016/j.freeradbiomed.2016.02.036; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Vickery BP, 2011, PEDIATR CLIN N AM, V58, P363, DOI 10.1016/j.pcl.2011.02.012; Walisser JA, 2005, P NATL ACAD SCI USA, V102, P17858, DOI 10.1073/pnas.0504757102; Wastling JM, 1998, AM J PATHOL, V153, P491, DOI 10.1016/S0002-9440(10)65592-7; Yatsunami K, 1995, J BIOL CHEM, V270, P30813, DOI 10.1074/jbc.270.51.30813	61	26	26	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1173	1184		10.1016/j.jaci.2017.10.043	http://dx.doi.org/10.1016/j.jaci.2017.10.043			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29277702	Green Accepted, Bronze			2022-12-18	WOS:000446327300017
J	Gil-Krzewska, A; Saeed, MB; Oszmiana, A; Fischer, ER; Lagrue, K; Gahl, WA; Introne, WJ; Coligan, JE; Davis, DM; Krzewski, K				Gil-Krzewska, Aleksandra; Saeed, Mezida B.; Oszmiana, Anna; Fischer, Elizabeth R.; Lagrue, Kathryn; Gahl, William A.; Introne, Wendy J.; Coligan, John E.; Davis, Daniel M.; Krzewski, Konrad			An actin cytoskeletal barrier inhibits lytic granule release from natural killer cells in patients with Chediak-Higashi syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chediak-Higashi syndrome; lysosomal trafficking regulator; natural killer cell; cytotoxicity; cytotoxic lymphocyte; lysosomes; lytic granules; exocytosis; immune deficiency; actin cytoskeleton	CYTOTOXIC T-LYMPHOCYTES; IMMUNOLOGICAL SYNAPSE; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; ORGANELLE BIOGENESIS; GIANT ORGANELLES; CORTICAL ACTIN; HUMAN-DISEASE; NK CELLS; F-ACTIN; EXOCYTOSIS	Background: Chediak-Higashi syndrome (CHS) is a rare disorder caused by biallelic mutations in the lysosomal trafficking regulator gene (LYST), resulting in formation of giant lysosomes or lysosome-related organelles in several cell types. The disease is characterized by immunodeficiency and a fatal hemophagocytic lymphohistiocytosis caused by impaired function of cytotoxic lymphocytes, including natural killer (NK) cells. Objective: We sought to determine the underlying biochemical cause of the impaired cytotoxicity of NK cells in patients with CHS. Methods: We generated a human cell model of CHS using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. We used a combination of classical techniques to evaluate lysosomal function and cell activity in the model system and super-resolution microscopy to visualize F-actin and lytic granules in normal and LYST-deficient NK cells. Results: Loss of LYST function in a human NK cell line, NK92mi, resulted in inhibition of NK cell cytotoxicity and reproduced other aspects of the CHS cellular phenotype, including the presence of significantly enlarged lytic granules with defective exocytosis and impaired integrity of endolysosomal compartments. The large granules had an acidic pH and normal activity of lysosomal enzymes and were positive for the proteins essential for lytic granule exocytosis. Visualization of the actin meshwork openings at the immunologic synapse revealed that the cortical actin acts as a barrier for secretion of such large granules at the cell-cell contact site. Decreasing the cortical actin density at the immunologic synapse or decreasing the lytic granule size restored the ability of LYST-deficient NK cells to degranulate and kill target cells. Conclusion: The cortical actin and granule size play significant roles in NK cell cytotoxic function. We present evidence that the periodicity of subsynaptic actin is an important factor limiting the release of large lytic granules from NK cells from patients with CHS and could be a novel target for pharmaceutical intervention.	[Gil-Krzewska, Aleksandra; Coligan, John E.; Krzewski, Konrad] NIAID, Receptor Cell Biol Sect, Immunogenet Lab, NIH, Rockville, MD USA; [Saeed, Mezida B.; Oszmiana, Anna; Lagrue, Kathryn; Davis, Daniel M.] Univ Manchester, Manchester Collaborat Ctr Inflammat Res, Manchester, Lancs, England; [Fischer, Elizabeth R.] NIAID, Electron Microscopy Unit, Res Technol Branch, Rocky Mt Labs,NIH, Hamilton, MT USA; [Gahl, William A.; Introne, Wendy J.] NHGRI, Off Clin Director, NIH, Bethesda, MD 20892 USA; [Oszmiana, Anna] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia; [Oszmiana, Anna] Lions Eye Inst, Ctr Expt Immunol, Nedlands, WA, Australia	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Manchester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Western Australia; Lions Eye Institute; University of Western Australia	Krzewski, K (corresponding author), 12441 Parklawn Dr,Twinbrook 2,Rm 205, Rockville, MD 20852 USA.	krzewskikj@niaid.nih.gov	Oszmiana, Anna/F-6915-2015	Oszmiana, Anna/0000-0003-1501-4184; Saeed, Mezida/0000-0003-1921-6015; Davis, Daniel/0000-0002-9182-291X	Intramural Programs of the National Institute of Allergy and Infectious Diseases; Intramural Program of National Human Genome Research Institute; Medical Research Council [G1001044]; Wellcome Trust Investigator Award [110091]; Manchester Collaborative Centre for Inflammation Research - GlaxoSmithKline; AstraZeneca; University of Manchester, United Kingdom; Histiocytosis Association; MRC [G1001044] Funding Source: UKRI; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000215, ZIDHG200352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000962] Funding Source: NIH RePORTER	Intramural Programs of the National Institute of Allergy and Infectious Diseases; Intramural Program of National Human Genome Research Institute; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust Investigator Award(Wellcome Trust); Manchester Collaborative Centre for Inflammation Research - GlaxoSmithKline; AstraZeneca(AstraZeneca); University of Manchester, United Kingdom; Histiocytosis Association; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Intramural Programs of the National Institute of Allergy and Infectious Diseases (to A.G.-K., E.R.F., J.E.C, and K.K.), the Intramural Program of National Human Genome Research Institute (to W.A.G. and W.J.I.); the Medical Research Council (award G1001044 to D.M.D.), a Wellcome Trust Investigator Award (110091 to D.M.D.); the Manchester Collaborative Centre for Inflammation Research, funded by a pre-competitive open innovation award from GlaxoSmithKline, AstraZeneca, and the University of Manchester, United Kingdom (to A.O., M.B.S., K.L., and D.M.D.); and a grant award from the Histiocytosis Association (to K.K.).	ABO T, 1982, J CLIN INVEST, V70, P193, DOI 10.1172/JCI110592; Andzelm MM, 2007, J EXP MED, V204, P2285, DOI 10.1084/jem.20071143; BAETZ K, 1995, J IMMUNOL, V154, P6122; Barrett A, 2016, TRAFFIC, V17, P515, DOI 10.1111/tra.12381; Bhambhani V, 2013, MOVEMENT DISORD, V28, P127, DOI 10.1002/mds.25386; Brown ACN, 2012, BLOOD, V120, P3729, DOI 10.1182/blood-2012-05-429977; Brown ACN, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001152; Bryceson YT, 2012, BLOOD, V119, P2754, DOI 10.1182/blood-2011-08-374199; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; Casey JR, 2010, NAT REV MOL CELL BIO, V11, P50, DOI 10.1038/nrm2820; Clark RH, 2003, NAT IMMUNOL, V4, P1111, DOI 10.1038/ni1000; Cullinane AR, 2013, TRAFFIC, V14, P749, DOI 10.1111/tra.12069; Davis DM, 1999, P NATL ACAD SCI USA, V96, P15062, DOI 10.1073/pnas.96.26.15062; de Saint Basile G, 2010, NAT REV IMMUNOL, V10, P568, DOI 10.1038/nri2803; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; Elstak ED, 2011, BLOOD, V118, P1570, DOI 10.1182/blood-2011-02-339523; Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121; Falkenstein K, 2014, J CELL SCI, V127, P4356, DOI 10.1242/jcs.138123; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Filipovich AH, 2015, HEMATOL ONCOL CLIN N, V29, P895, DOI 10.1016/j.hoc.2015.06.007; Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938; Gil-Krzewska A, 2016, J ALLERGY CLIN IMMUN, V137, P1165, DOI 10.1016/j.jaci.2015.08.039; HALIOTIS T, 1980, J EXP MED, V151, P1039, DOI 10.1084/jem.151.5.1039; Ham H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00002; Holland P, 2014, TRAFFIC, V15, P1390, DOI 10.1111/tra.12227; Hsu HT, 2016, J CELL BIOL, V215, P875, DOI 10.1083/jcb.201604136; Huizing M, 2008, ANNU REV GENOM HUM G, V9, P359, DOI 10.1146/annurev.genom.9.081307.164303; Introne WJ, 1993, GENEREVIEWS; Jessen B, 2011, BLOOD, V118, P4620, DOI 10.1182/blood-2011-05-356113; Jog NR, 2007, AM J PHYSIOL-CELL PH, V292, pC1690, DOI 10.1152/ajpcell.00384.2006; Johnson JL, 2012, MOL BIOL CELL, V23, P1902, DOI 10.1091/mbc.E11-12-1001; Kaiserman D, 2006, J CELL BIOL, V175, P619, DOI 10.1083/jcb.200606073; Kaplan J, 2008, CURR OPIN HEMATOL, V15, P22, DOI 10.1097/MOH.0b013e3282f2bcce; Karim MA, 2002, AM J MED GENET, V108, P16, DOI 10.1002/ajmg.10184; Kjeldsen L, 1998, J LEUKOCYTE BIOL, V64, P72, DOI 10.1002/jlb.64.1.72; KLEIN M, 1980, J EXP MED, V151, P1049, DOI 10.1084/jem.151.5.1049; Krzewski K, 2008, CURR OPIN CELL BIOL, V20, P597, DOI 10.1016/j.ceb.2008.05.006; Krzewski K, 2013, BLOOD, V121, P4672, DOI 10.1182/blood-2012-08-453738; Krzewski K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00335; Krzewski K, 2011, EUR J IMMUNOL, V41, P3323, DOI 10.1002/eji.201141582; Kypri E, 2013, TRAFFIC, V14, P599, DOI 10.1111/tra.12058; Lagrue K, 2015, BLOOD, V126, P50, DOI 10.1182/blood-2015-01-625004; Lozano ML, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0132-6; Mace EM, 2014, IMMUNOL CELL BIOL, V92, P245, DOI 10.1038/icb.2013.96; Mace EM, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00421; Mace Emily M, 2012, Commun Integr Biol, V5, P184, DOI 10.4161/cib.18818; Meeths M, 2014, EXP CELL RES, V325, P10, DOI 10.1016/j.yexcr.2014.03.014; Menager MM, 2007, NAT IMMUNOL, V8, P257, DOI 10.1038/ni1431; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Mentlik AN, 2010, MOL BIOL CELL, V21, P2241, DOI 10.1091/mbc.E09-11-0930; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Perou CM, 1997, J BIOL CHEM, V272, P29790, DOI 10.1074/jbc.272.47.29790; PRIEUR DJ, 1978, AM J PATHOL, V90, P533; Rak GD, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001151; Ritter AT, 2017, P NATL ACAD SCI USA, V114, pE6585, DOI 10.1073/pnas.1710751114; Ritter AT, 2015, IMMUNITY, V42, P864, DOI 10.1016/j.immuni.2015.04.013; Robertson MJ, 2002, J LEUKOCYTE BIOL, V71, P173; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sepulveda FE, 2015, BLOOD, V125, P1427, DOI 10.1182/blood-2014-09-602946; Sepulveda FE, 2015, TRAFFIC, V16, P191, DOI 10.1111/tra.12244; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shiflett SL, 2004, TRAFFIC, V5, P700, DOI 10.1111/j.1600-0854.2004.00213.x; Sieni E, 2012, CELL MOL LIFE SCI, V69, P29, DOI 10.1007/s00018-011-0835-y; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; Stinchcombe JC, 2000, TRAFFIC, V1, P435, DOI 10.1034/j.1600-0854.2000.010508.x; Sungur CM, 2013, HEMATOL-AM SOC HEMAT, P227, DOI 10.1182/asheducation-2013.1.227; Tam YK, 1999, HUM GENE THER, V10, P1359, DOI 10.1089/10430349950018030; Trifaro JM, 2000, BIOCHIMIE, V82, P339, DOI 10.1016/S0300-9084(00)00193-0; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Ward DM, 2000, TRAFFIC, V1, P816; Weisfeld-Adams JD, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-46; Westbroek W, 2007, J INVEST DERMATOL, V127, P2674, DOI 10.1038/sj.jid.5700899; WHITE JG, 1980, AM J PATHOL, V98, P151; WINDHORST DB, 1966, SCIENCE, V151, P81, DOI 10.1126/science.151.3706.81; WOO JT, 1992, J ANTIBIOT, V45, P1108, DOI 10.7164/antibiotics.45.1108; Wood SM, 2011, CELL MOL LIFE SCI, V68, P3479, DOI 10.1007/s00018-011-0799-y; Wood SM, 2009, BLOOD, V114, P4117, DOI 10.1182/blood-2009-06-225359; ZELICKSON AS, 1967, J INVEST DERMATOL, V49, P575, DOI 10.1038/jid.1967.183	81	26	27	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					914	+		10.1016/j.jaci.2017.10.040	http://dx.doi.org/10.1016/j.jaci.2017.10.040			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29241728	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000443726500024
J	Chairakaki, AD; Saridaki, MI; Pyrillou, K; Mouratis, MA; Koltsida, O; Walton, RP; Bartlett, NW; Stavropoulos, A; Boon, L; Rovina, N; Papadopoulos, NG; Johnston, SL; Andreakos, E				Chairakaki, Aikaterini-Dimitra; Saridaki, Maria-Ioanna; Pyrillou, Katerina; Mouratis, Marios-Angelos; Koltsida, Ourania; Walton, Ross P.; Bartlett, Nathan W.; Stavropoulos, Athanasios; Boon, Louis; Rovina, Nikoletta; Papadopoulos, Nikolaos G.; Johnston, Sebastian L.; Andreakos, Evangelos			Plasmacytoid dendritic cells drive acute asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Plasmacytoid dendritic cells; asthma; animal models of allergic airway disease; rhinovirus; asthma exacerbations	ALLERGIC AIRWAY INFLAMMATION; T-HELPER-CELL; IN-VIVO; VIRAL-INFECTION; HUMAN TONSILS; OX40 LIGAND; DISEASE; DIFFERENTIATION; EXPRESSION; INDUCTION	Background: Although acute exacerbations, mostly triggered by viruses, account for the majority of hospitalizations in asthmatic patients, there is still very little known about the pathophysiologic mechanisms involved. Plasmacytoid dendritic cells (pDCs), prominent cells of antiviral immunity, exhibit proinflammatory or tolerogenic functions depending on the context, yet their involvement in asthma exacerbations remains unexplored. Objectives: We sought to investigate the role of pDCs in allergic airway inflammation and acute asthma exacerbations. Methods: Animal models of allergic airway disease (AAD) and virus-induced AAD exacerbations were used to dissect pDC function in vivo and unwind the potential mechanisms involved. Sputum from asthmatic patients with stable disease or acute exacerbations was further studied to determine the presence of pDCs and correlation with inflammation. Results: pDCs were key mediators of the immunoinflammatory cascade that drives asthma exacerbations. In animal models of AAD and rhinovirus-induced AAD exacerbations, pDCs were recruited to the lung during inflammation and migrated to the draining lymph nodes to boost T(H)2-mediated effector responses. Accordingly, pDC depletion after allergen challenge or during rhinovirus infection abrogated exacerbation of inflammation and disease. Central to this process was IL-25, which was induced by allergen challenge or rhinovirus infection and conditioned pDCs for proinflammatory function. Consistently, in asthmatic patients pDC numbers were markedly increased during exacerbations and correlated with the severity of inflammation and the risk for asthma attacks. Conclusions: Our studies uncover a previously unsuspected role of pDCs in asthma exacerbations with potential diagnostic and prognostic implications. They also propose the therapeutic targeting of pDCs and IL-25 for the treatment of acute asthma.	[Chairakaki, Aikaterini-Dimitra; Saridaki, Maria-Ioanna; Pyrillou, Katerina; Mouratis, Marios-Angelos; Koltsida, Ourania; Stavropoulos, Athanasios; Andreakos, Evangelos] Acad Athens, Biomed Res Fdn, Dept Immunol, Ctr Clin Expt Surg & Translat Res, Athens, Greece; [Koltsida, Ourania; Rovina, Nikoletta] Univ Athens, Sch Med, Dept Resp Med 1, Sotiria Reg Chest Dis Hosp, Athens, Greece; [Walton, Ross P.; Bartlett, Nathan W.; Johnston, Sebastian L.] Imperial Coll London, Natl Heart & Lung Inst, Airway Dis Infect Sect, London, England; [Bartlett, Nathan W.] Hunter Med Res Inst, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia; [Bartlett, Nathan W.] Univ Newcastle, Callaghan, NSW, Australia; [Boon, Louis] Bioceros, Utrecht, Netherlands; [Papadopoulos, Nikolaos G.] Univ Manchester, Inst Human Dev, Manchester, Lancs, England; [Papadopoulos, Nikolaos G.] Univ Athens, A Kyriakou Childrens Hosp, Athens, Greece	Academy of Athens; Athens Medical School; National & Kapodistrian University of Athens; Imperial College London; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; University of Manchester; National & Kapodistrian University of Athens	Andreakos, E (corresponding author), Acad Athens, Biomed Res Fdn, Soranou Efesiou 4, Athens, Greece.	vandreakos@bioacademy.gr	Johnston, Sebastian Lennox/I-2423-2012; Boon, Laurence/HCI-3629-2022; Rovina, Nikoletta/I-2527-2019; N.G., Papadopoulos/L-8670-2013	Johnston, Sebastian Lennox/0000-0003-3009-9200; N.G., Papadopoulos/0000-0002-4448-3468; Boon, Louis/0000-0002-0937-9171; Pyrillou, Katerina/0000-0003-0375-7810; Stavropoulos, Athanasios/0000-0002-5101-1899; Rovina, Nikoletta/0000-0003-0138-5582	Hellenic Ministries of Health and Education; Hellenic Ministry of Education ("Thalis'' Programme MIDAS and "Excellence'' Programme RESOLVE-ASTHMA); European Commission (FP7 Programmes PREDICTA, NILTHERA and TACIT); MRC [G1100168] Funding Source: UKRI	Hellenic Ministries of Health and Education; Hellenic Ministry of Education ("Thalis'' Programme MIDAS and "Excellence'' Programme RESOLVE-ASTHMA); European Commission (FP7 Programmes PREDICTA, NILTHERA and TACIT); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by core funding from the Hellenic Ministries of Health and Education and by grant awards from the Hellenic Ministry of Education ("Thalis'' Programme MIDAS and "Excellence'' Programme RESOLVE-ASTHMA) and the European Commission (FP7 Programmes PREDICTA, NILTHERA and TACIT).	Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Bratke K, 2007, THORAX, V62, P168, DOI 10.1136/thx.2006.067793; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Camelo A, 2012, J GASTROENTEROL, V47, P1198, DOI 10.1007/s00535-012-0591-2; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9; Dua B, 2010, J ALLERGY CLIN IMMUN, V126, P133, DOI 10.1016/j.jaci.2010.04.006; Edwards MR, 2012, NAT REV MICROBIOL, V10, P459, DOI 10.1038/nrmicro2801; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; Farkas L, 2004, J ALLERGY CLIN IMMUN, V114, P436, DOI 10.1016/j.jaci.2004.04.035; Gauthier M, 2015, AM J RESP CRIT CARE, V192, P660, DOI 10.1164/rccm.201504-0763PP; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Guery L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00059; Ito T, 2004, J IMMUNOL, V172, P4253, DOI 10.4049/jimmunol.172.7.4253; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Jenkins SJ, 2007, J IMMUNOL, V179, P3515, DOI 10.4049/jimmunol.179.6.3515; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Karrich JJ, 2014, J IMMUNOL, V193, P5772, DOI 10.4049/jimmunol.1401541; Kips JC, 1998, EUR RESPIR J, V11, p9S; Koltsida O, 2013, EMBO MOL MED, V5, P762, DOI 10.1002/emmm.201201891; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Kopecka J, 2013, MED SCI MONIT BASIC, V19, P291, DOI 10.12659/MSMBR.889791; Kucuksezer UC, 2013, J ALLERGY CLIN IMMUN, V131, P875, DOI 10.1016/j.jaci.2012.10.051; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Levy BD, 2015, AM J RESP CRIT CARE, V192, P1366, DOI 10.1164/rccm.201505-0963WS; Ma DY, 2009, SEMIN IMMUNOL, V21, P265, DOI 10.1016/j.smim.2009.05.010; Maazi H, 2017, IMMUNOL REV, V278, P192, DOI 10.1111/imr.12554; Mamessier E, 2008, ALLERGY, V63, P1202, DOI 10.1111/j.1398-9995.2008.01687.x; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Papadopoulos NG, 2007, ALLERGY, V62, P457, DOI 10.1111/j.1398-9995.2007.01341.x; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Shi LL, 2014, AM J RESP CRIT CARE, V190, P628, DOI 10.1164/rccm.201402-0234OC; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; Swiecki M, 2010, IMMUNOL REV, V234, P142, DOI 10.1111/j.0105-2896.2009.00881.x; Takagi H, 2011, IMMUNITY, V35, P958, DOI 10.1016/j.immuni.2011.10.014; Tworek D, 2016, AM J RESP CRIT CARE, V193, P957, DOI 10.1164/rccm.201509-1751OC; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Xirakia C, 2010, AM J RESP CRIT CARE, V181, P1207, DOI 10.1164/rccm.200908-1255OC	53	26	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					542	+		10.1016/j.jaci.2017.08.032	http://dx.doi.org/10.1016/j.jaci.2017.08.032			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29054692	Green Submitted, Bronze			2022-12-18	WOS:000440664400022
J	Urbano, PCM; Aguirre-Gamboa, R; Ashikov, A; van Heeswijk, B; Krippner-Heidenreich, A; Tijssen, H; Li, Y; Azevedo, VF; Smits, LJT; Hoentjen, F; Joosten, I; Koenen, HJPM				Urbano, Paulo C. M.; Aguirre-Gamboa, Raul; Ashikov, Angel; van Heeswijk, Bennie; Krippner-Heidenreich, Anja; Tijssen, Henk; Li, Yang; Azevedo, Valderilio F.; Smits, Lisa J. T.; Hoentjen, Frank; Joosten, Irma; Koenen, Hans J. P. M.			TNF-alpha-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-alpha blockade-driven IL-17A expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TNF-alpha; A20; TNF-alpha-induced protein 3; anti-TNF; IL-17A; inflammatory bowel disease	NF-KAPPA-B; INFLAMMATORY-BOWEL-DISEASE; KINASE-C-THETA; GENOME-WIDE ASSOCIATION; NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; AUTOIMMUNE ENCEPHALOMYELITIS; CELL ACTIVATION; TH17 CELLS; T-CELLS	Background: Anti-TNF inhibitors successfully improve the quality of life of patients with inflammatory disease. Unfortunately, not all patients respond to anti-TNF therapy, and some patients show paradoxical immune side effects, which are poorly understood. Surprisingly, anti-TNF agents were shown to promote IL-17A production with as yet unknown clinical implications. Objective: We sought to investigate the molecular mechanism underlying anti-TNF-driven IL-17A expression and the clinical implications of this phenomenon. Methods: Fluorescence-activated cell sorting, RNA sequencing, quantitative real-time PCR, Western blotting, small interfering RNA interference, and kinase inhibitors were used to study the molecular mechanisms in isolated human CD4(+) T cells from healthy donors. The clinical implication was studied in blood samples of patients with inflammatory bowel disease (IBD) receiving anti-TNF therapy. Results: Here we show that anti-TNF treatment results in inhibition of the anti-inflammatory molecule TNF-alpha-induced protein 3 (TNFAIP3)/A20 in memory CD4(+) T cells. We found an inverse relationship between TNFAIP3/A20 expression levels and IL-17A production. Inhibition of TNFAIP3/A20 promotes kinase activity of p38 mitogen-activated protein kinase and protein kinase C, which drives IL-17A expression. Regulation of TNFAIP3/A20 expression and cognate IL-17A production in T cells are specifically mediated through TNF receptor 2 signaling. Ex vivo, in patients with IBD treated with anti-TNF, we found further evidence for an inverse relationship between TNFAIP3/A20 expression levels and IL-17A-producing T cells. Conclusion: Anti-TNF treatment interferes in the TNFAIP3/A20-mediated anti-inflammatory feedback loop in CD4 1 T cells and promotes kinase activity. This puts TNFAIP3/A20, combined with IL-17A expression, on the map as a potential tool for predicting therapy responsiveness or side effects of anti-TNF therapy. Moreover, it provides novel targets related to TNFAIP3/A20 activity for superior therapeutic regimens in patients with IBD.	[Urbano, Paulo C. M.; van Heeswijk, Bennie; Tijssen, Henk; Joosten, Irma; Koenen, Hans J. P. M.] Radboud Univ Nijmegen Med Ctr, LMI, Dept Lab Med, Geert Grootepl Zuid 10,Route 469, NL-6500 HB Nijmegen, Netherlands; [Ashikov, Angel] Radboud Univ Nijmegen Med Ctr, Dept Neurol, Nijmegen, Netherlands; [Smits, Lisa J. T.; Hoentjen, Frank] Radboud Univ Nijmegen Med Ctr, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands; [Aguirre-Gamboa, Raul; Li, Yang] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Krippner-Heidenreich, Anja] Newcastle Univ, Northern Inst Canc Res, Wolfson Childhood Canc Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England; [Azevedo, Valderilio F.] Univ Fed Parana, Hosp Clin Curitiba, Dept Med Interna, Curitiba, Parana, Brazil	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; University of Groningen; Newcastle University - UK; Universidade Federal do Parana	Koenen, HJPM (corresponding author), Radboud Univ Nijmegen Med Ctr, LMI, Dept Lab Med, Geert Grootepl Zuid 10,Route 469, NL-6500 HB Nijmegen, Netherlands.	Hans.Koenen@radboudumc.nl	Azevedo, Valderílio Feijó/ABF-8713-2020; Tijssen, Henk/K-1376-2016; Koenen, Hans J.P.M./A-2852-2014; Joosten, Irma/N-4418-2013; Ashikov, Angel/N-7714-2015; Urbano, Paulo César Martins/M-5356-2015; Li, Yang/HGT-8446-2022	Azevedo, Valderílio Feijó/0000-0002-2346-388X; Joosten, Irma/0000-0003-2950-4977; Ashikov, Angel/0000-0001-9679-7955; Urbano, Paulo César Martins/0000-0002-5769-1573; Li, Yang/0000-0003-4022-7341; Hoentjen, Frank/0000-0001-5314-4452	Brazilian mobility program Science Without Borders [11920/13-0]	Brazilian mobility program Science Without Borders	The study and P.C.M.U. were supported by grant no. 11920/13-0 provided by the Brazilian mobility program Science Without Borders.	Aerts NE, 2010, RHEUMATOLOGY, V49, P2264, DOI 10.1093/rheumatology/keq224; Afonina IS, 2015, FEBS J, V282, P3286, DOI 10.1111/febs.13325; Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Bank S, 2014, PHARMACOGENOMICS J, V14, P526, DOI 10.1038/tpj.2014.19; Bartlett HS, 2015, NAT REV DRUG DISCOV, V14, P11, DOI 10.1038/nrd4518; Bikker R, 2017, CELL SIGNAL, V37, P123, DOI 10.1016/j.cellsig.2017.06.009; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Bowes J, 2010, DISCOV MED, V10, P177; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Catrysse L, 2014, TRENDS IMMUNOL, V35, P22, DOI 10.1016/j.it.2013.10.005; Chand S, 2012, CURR PHARM DESIGN, V18, P4725, DOI 10.2174/138161212802651625; Chapuy L, 2014, J ALLERGY CLIN IMMUN, V134, P978, DOI 10.1016/j.jaci.2014.05.025; Coornaert B, 2009, J BIOL CHEM, V284, P8217, DOI 10.1074/jbc.R800032200; Croft M, 2017, NAT REV RHEUMATOL, V13, P217, DOI 10.1038/nrrheum.2017.22; Davis BP, 2017, J ALLERGY CLIN IMMUN, V139, P1445, DOI 10.1016/j.jaci.2017.02.013; de Wit J, 2016, J ALLERGY CLIN IMMUN, V137, P960, DOI 10.1016/j.jaci.2015.09.048; Denadai R, 2013, J CROHNS COLITIS, V7, P517, DOI 10.1016/j.crohns.2012.08.007; Duwel M, 2009, J IMMUNOL, V182, P7718, DOI 10.4049/jimmunol.0803313; Evans HG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4199; Faustman D, 2010, NAT REV DRUG DISCOV, V9, P482, DOI 10.1038/nrd3030; Fischer JAA, 2015, ARTHRITIS RHEUMATOL, V67, P51, DOI 10.1002/art.38896; Fuss IJ, 2011, MUCOSAL IMMUNOL, V4, P366, DOI 10.1038/mi.2011.24; Galan-Arriero I, 2015, NEUROSCI LETT, V604, P69, DOI 10.1016/j.neulet.2015.07.044; Garg AV, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003699; Grinblat B, 2008, SEMIN ARTHRITIS RHEU, V37, P251, DOI 10.1016/j.semarthrit.2007.05.004; He XH, 2014, J INVEST DERMATOL, V134, P975, DOI 10.1038/jid.2013.459; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Huh JR, 2012, EUR J IMMUNOL, V42, P2232, DOI 10.1002/eji.201242740; Hull DN, 2015, CLIN EXP IMMUNOL, V181, P401, DOI 10.1111/cei.12626; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Kircik LH, 2009, J DRUGS DERMATOL, V8, P546; Ko JM, 2009, J DERMATOL TREAT, V20, P100, DOI 10.1080/09546630802441234; Konya V, 2017, J ALLERGY CLIN IMMUN; Kool M, 2011, IMMUNITY, V35, P82, DOI 10.1016/j.immuni.2011.05.013; Krippner-Heidenreich A, 2002, J BIOL CHEM, V277, P44155, DOI 10.1074/jbc.M207399200; Lee JS, 2015, IMMUNITY, V43, P727, DOI 10.1016/j.immuni.2015.09.003; Levin AD, 2016, J CROHNS COLITIS, V10, P989, DOI 10.1093/ecco-jcc/jjw053; Ma A, 2012, NAT REV IMMUNOL, V12, P774, DOI 10.1038/nri3313; Maggi L, 2014, ARTHRITIS RHEUMATOL, V66, P1372, DOI 10.1002/art.38355; Martin F, 2011, NAT GENET, V43, P822, DOI 10.1038/ng.916; Maxwell JR, 2015, IMMUNITY, V43, P739, DOI 10.1016/j.immuni.2015.08.019; Mihara K, 2008, BRIT J PHARMACOL, V154, P153, DOI 10.1038/bjp.2008.53; Monaco C, 2015, INT IMMUNOL, V27, P55, DOI 10.1093/intimm/dxu102; Musone SL, 2008, NAT GENET, V40, P1062, DOI 10.1038/ng.202; Xuan NT, 2015, EUR J IMMUNOL, V45, P818, DOI 10.1002/eji.201444795; Noubade R, 2011, BLOOD, V118, P3290, DOI 10.1182/blood-2011-02-336552; Peyrin-Biroulet L, 2016, CLIN GASTROENTEROL H, V14, P348, DOI 10.1016/j.cgh.2015.06.001; Plenge RM, 2007, NAT GENET, V39, P1477, DOI 10.1038/ng.2007.27; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; Seymour HE, 2001, BRIT J CLIN PHARMACO, V51, P201, DOI 10.1046/j.1365-2125.2001.00321.x; Shao L, 2013, PLOS ONE, V8; Shembade N, 2012, CELL MOL IMMUNOL, V9, P123, DOI 10.1038/cmi.2011.59; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751; Tan SL, 2006, J IMMUNOL, V176, P2872, DOI 10.4049/jimmunol.176.5.2872; Tejasvi T, 2012, J INVEST DERMATOL, V132, P593, DOI 10.1038/jid.2011.376; Upadhyay V, 2013, NAT REV IMMUNOL, V13, P270, DOI 10.1038/nri3406; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Whibley N, 2015, IMMUNITY, V43, P620, DOI 10.1016/j.immuni.2015.10.001	60	26	26	3	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					517	529		10.1016/j.jaci.2017.11.024	http://dx.doi.org/10.1016/j.jaci.2017.11.024			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29248493	Bronze, Green Published			2022-12-18	WOS:000440664400020
J	Drouillard, A; Mathieu, AL; Marcais, A; Belot, A; Viel, S; Mingueneau, M; Guckian, K; Walzer, T				Drouillard, Annabelle; Mathieu, Anne-Laure; Marcais, Antoine; Belot, Alexandre; Viel, Sebastien; Mingueneau, Michael; Guckian, Kevin; Walzer, Thierry			S1PR5 is essential for human natural killer cell migration toward sphingosine-1 phosphate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Drouillard, Annabelle; Mathieu, Anne-Laure; Marcais, Antoine; Belot, Alexandre; Viel, Sebastien; Walzer, Thierry] Int Ctr Infectiol Res, Ctr Int Rech Infectiol, Lyon, France; [Drouillard, Annabelle; Mathieu, Anne-Laure; Marcais, Antoine; Belot, Alexandre; Viel, Sebastien; Walzer, Thierry] Natl Inst Hlth & Med Res, U1111, Lyon, France; [Drouillard, Annabelle; Mathieu, Anne-Laure; Marcais, Antoine; Belot, Alexandre; Viel, Sebastien; Walzer, Thierry] Ecole Normale Super Lyon, Lyon, France; [Drouillard, Annabelle; Mathieu, Anne-Laure; Marcais, Antoine; Belot, Alexandre; Viel, Sebastien; Walzer, Thierry] Univ Lyon 1, Lyon, France; [Drouillard, Annabelle; Mathieu, Anne-Laure; Marcais, Antoine; Belot, Alexandre; Viel, Sebastien; Walzer, Thierry] CNRS, UMR5308, Lyon, France; [Marcais, Antoine; Belot, Alexandre; Viel, Sebastien] Hosp Civils Lyon, Lyon, France; [Mingueneau, Michael; Guckian, Kevin] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon; Biogen	Walzer, T (corresponding author), Int Ctr Infectiol Res, Ctr Int Rech Infectiol, Lyon, France.; Walzer, T (corresponding author), Natl Inst Hlth & Med Res, U1111, Lyon, France.; Walzer, T (corresponding author), Ecole Normale Super Lyon, Lyon, France.; Walzer, T (corresponding author), Univ Lyon 1, Lyon, France.; Walzer, T (corresponding author), CNRS, UMR5308, Lyon, France.	Thierry.walzer@inserm.fr	Viel, Sebastien/A-7258-2016; Mingueneau, Michael/O-5313-2019; Walzer, Thierry/L-9418-2014; Belot, Alexandre/C-7378-2013; Marçais, Antoine/F-4341-2017	Viel, Sebastien/0000-0002-5085-443X; Mingueneau, Michael/0000-0002-3873-7329; Walzer, Thierry/0000-0002-0857-8179; Belot, Alexandre/0000-0003-4902-5332; Marçais, Antoine/0000-0002-3591-6268; Mathieu, Anne-Laure/0000-0002-2893-7001	Association pour la Recherche sur le Cancer; Agence Nationale de la Recherche; European Research Council; Institut National de la Sante et de la Recherche Medicale; CNRS; Universite de Lyon; ENS de Lyon; Biogen	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Agence Nationale de la Recherche(French National Research Agency (ANR)); European Research Council(European Research Council (ERC)European Commission); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); CNRS(Centre National de la Recherche Scientifique (CNRS)); Universite de Lyon; ENS de Lyon; Biogen(Biogen)	The T.W. lab is supported by the Association pour la Recherche sur le Cancer, Agence Nationale de la Recherche, the European Research Council, Institut National de la Sante et de la Recherche Medicale, CNRS, Universite de Lyon, and ENS de Lyon. Biogen also sponsored this study.	Arnon TI, 2011, SCIENCE, V333, P1898, DOI 10.1126/science.1208248; Guerrero M, 2011, BIOORG MED CHEM LETT, V21, P3632, DOI 10.1016/j.bmcl.2011.04.097; Hobson AD, 2015, J MED CHEM, V58, P9154, DOI 10.1021/acs.jmedchem.5b00928; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Shah MV, 2008, BLOOD, V112, P770, DOI 10.1182/blood-2007-11-121871; Walzer T, 2007, NAT IMMUNOL, V8, P1337, DOI 10.1038/ni1523; Wang WG, 2005, FASEB J, V19, P1731, DOI 10.1096/fj.05-3730fje	9	26	27	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2265	2268		10.1016/j.jaci.2017.11.022	http://dx.doi.org/10.1016/j.jaci.2017.11.022			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29248494				2022-12-18	WOS:000434701600030
J	Lawless, D; Geier, CB; Farmer, JR; Allen, HL; Thwaites, D; Atschekzei, F; Brown, M; Buchbinder, D; Burns, SO; Butte, MJ; Csomos, K; Deevi, SVV; Egner, W; Ehl, S; Eibl, MM; Fadugba, O; Foldvari, Z; Green, DM; Henrickson, SE; Holland, SM; John, T; Klemann, C; Kuijpers, TW; Moreira, F; Piller, A; Rayner-Matthews, P; Romberg, ND; Sargur, R; Schmidt, RE; Schroder, C; Schuetz, C; Sharapova, SO; Smith, KGC; Sogkas, G; Speckmann, C; Stirrups, K; Thrasher, AJ; Wolf, HM; Notarangelo, LD; Anwar, R; Boyes, J; Ujhazi, B; Thaventhiran, J; Walter, JE; Savic, S				Lawless, Dylan; Geier, Christoph B.; Farmer, Jocelyn R.; Allen, Hana Lango; Thwaites, Daniel; Atschekzei, Faranaz; Brown, Matthew; Buchbinder, David; Burns, Siobhan O.; Butte, Manish J.; Csomos, Krisztian; Deevi, Sri V. V.; Egner, William; Ehl, Stephan; Eibl, Martha M.; Fadugba, Olajumoke; Foldvari, Zsofia; Green, Deanna M.; Henrickson, Sarah E.; Holland, Steven M.; John, Tami; Klemann, Christian; Kuijpers, Taco W.; Moreira, Fernando; Piller, Alexander; Rayner-Matthews, Paula; Romberg, Neil D.; Sargur, Ravishankar; Schmidt, Reinhold E.; Schroder, Claudia; Schuetz, Catharina; Sharapova, Svetlana O.; Smith, Ken G. C.; Sogkas, Georgios; Speckmann, Carsten; Stirrups, Kathleen; Thrasher, Adrian J.; Wolf, Hermann M.; Notarangelo, Luigi D.; Anwar, Rashida; Boyes, Joan; Ujhazi, Boglarka; Thaventhiran, James; Walter, Jolan E.; Savic, Sinisa		NIHR BioResource-Rare	Prevalence and clinical challenges among adults with primary immunodeficiency and recombination-activating gene deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RAG MUTATIONS		[Lawless, Dylan; Anwar, Rashida] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Biomed & Clin Sci, Leeds, W Yorkshire, England; [Geier, Christoph B.; Eibl, Martha M.; Piller, Alexander; Wolf, Hermann M.] Immunol Outpatient Clin, Vienna, Austria; [Farmer, Jocelyn R.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA; [Allen, Hana Lango; Brown, Matthew; Deevi, Sri V. V.; Rayner-Matthews, Paula; Speckmann, Carsten; Stirrups, Kathleen] Cambridge Univ Hosp, NIHR BioResource, Cambridge, England; [Allen, Hana Lango; Brown, Matthew; Deevi, Sri V. V.; Rayner-Matthews, Paula; Stirrups, Kathleen] Univ Cambridge, Dept Haematol, Cambridge Biomed Campus, Cambridge, England; [Thwaites, Daniel; Boyes, Joan] Univ Leeds, Sch Mol & Cellular Biol, Leeds, W Yorkshire, England; [Atschekzei, Faranaz; Schmidt, Reinhold E.; Schroder, Claudia; Sogkas, Georgios] Hannover Med Sch, Dept Clin Immunol & Rheumatol, Hannover, Germany; [Klemann, Christian] Hannover Med Sch, Dept Pediat Pneumol Allergy & Neonatol, Hannover, Germany; [Buchbinder, David] Childrens Hosp Orange Cty, Div Hematol, Orange, CA 92668 USA; [Burns, Siobhan O.; Moreira, Fernando] Royal Free London NHS Fdn Trust, Dept Immunol, London, England; [Burns, Siobhan O.] UCL, Inst Immun & Transplantat, London, England; [Butte, Manish J.] Univ Calif Los Angeles, Dept Pediat, Div Pediat Allergy Immunol, Los Angeles, CA 90024 USA; [Csomos, Krisztian; Ujhazi, Boglarka; Walter, Jolan E.] Univ S Florida, St Petersburg, FL 33701 USA; [Csomos, Krisztian; Ujhazi, Boglarka; Walter, Jolan E.] Johns Hopkins All Childrens Hosp, St Petersburg, FL 33701 USA; [Egner, William; Sargur, Ravishankar] Sheffield Teaching Hosp, Clin Immunol & Allergy Unit, Sheffield, S Yorkshire, England; [Ehl, Stephan] Univ Freiburg, Fac Med, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Ehl, Stephan; Speckmann, Carsten] Univ Freiburg, Ctr Pediat & Adolescent Med, Freiburg, Germany; [Eibl, Martha M.] Biomed Forsch GmbH, Vienna, Austria; [Fadugba, Olajumoke] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA; [Foldvari, Zsofia] Radiumhospitalet, Oslo Univ Hosp, Dept Canc Immunol, Inst Canc Res, Oslo, Norway; [Green, Deanna M.] Johns Hopkins All Childrens Hosp, Div Pediat Pulm, St Petersburg, FL USA; [Henrickson, Sarah E.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Allergy Immunol, Philadelphia, PA 19104 USA; [Henrickson, Sarah E.] Univ Penn, Inst Immunol, Philadelphia, PA 19104 USA; [Holland, Steven M.; Notarangelo, Luigi D.] NIAID, LCIM, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [John, Tami] CHOC Childrens Hosp, Div Hematol Oncol, Orange, CA USA; [Kuijpers, Taco W.] Emma Childrens Hosp, Acad Med Ctr, Dept Pediat Hematol Immunol & Infect Dis, Amsterdam, Netherlands; [Kuijpers, Taco W.] Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, Dept Blood Cell Res, Amsterdam, Netherlands; [Romberg, Neil D.] Yale Univ, Sch Med, Dept Pediat, Div Allergy & Clin Immunol, New Haven, CT 06510 USA; [Schuetz, Catharina] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Sharapova, Svetlana O.] Belarusian Res Ctr Pediat Oncol Hematol & Immunol, Res Dept, Minsk, BELARUS; [Smith, Ken G. C.; Thaventhiran, James] Univ Cambridge, Dept Med, Cambridge, England; [Thrasher, Adrian J.] Great Ormond St Inst Child Hlth, Mol & Cellular Immunol Sect, London, England; [Thrasher, Adrian J.] Great Ormond St Hosp NHS Trust, London, England; [Wolf, Hermann M.] Sigmund Freud Private Univ, Sch Med, Vienna, Austria; [Walter, Jolan E.] Massachusetts Gen Hosp Children, Div Allergy Immunol, Boston, MA 02114 USA; [Savic, Sinisa] St James Univ Hosp, Dept Clin Immunol & Allergy, Leeds, W Yorkshire, England; [Savic, Sinisa] St James Univ Hosp, Natl Inst Hlth Res, Leeds Musculoskeletal Biomed Res Ctr, Leeds, W Yorkshire, England; [Savic, Sinisa] St James Univ Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Cambridge; University of Cambridge; University of Leeds; Hannover Medical School; Hannover Medical School; Childrens Hospital of Orange County; University of London; University College London; Royal Free London NHS Foundation Trust; University of London; University College London; University of California System; University of California Los Angeles; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine; University of Sheffield; University of Freiburg; University of Freiburg; University of Pennsylvania; Pennsylvania Medicine; University of Oslo; Johns Hopkins University; Johns Hopkins Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Yale University; Ulm University; University of Cambridge; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Saint James's University Hospital; Saint James's University Hospital; Saint James's University Hospital	Walter, JE (corresponding author), Univ S Florida, St Petersburg, FL 33701 USA.; Walter, JE (corresponding author), Johns Hopkins All Childrens Hosp, St Petersburg, FL 33701 USA.; Walter, JE (corresponding author), Massachusetts Gen Hosp Children, Div Allergy Immunol, Boston, MA 02114 USA.; Savic, S (corresponding author), St James Univ Hosp, Dept Clin Immunol & Allergy, Leeds, W Yorkshire, England.; Savic, S (corresponding author), St James Univ Hosp, Natl Inst Hlth Res, Leeds Musculoskeletal Biomed Res Ctr, Leeds, W Yorkshire, England.; Savic, S (corresponding author), St James Univ Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.	jolanwalter@health.usf.edu; S.Savic@leeds.ac.uk	Klemann, Christian/AAQ-9301-2020; Savic, Sinisa/Q-6217-2019; Butte, Manish/T-8860-2019; Sharapova, Svetlana/ABF-3330-2020; Ehl, Stephan/AAM-6006-2020; Green, Deanna/HGU-5890-2022; Butte, Manish/AAM-8604-2020; Sargur, Ravishankar/C-2270-2009	Klemann, Christian/0000-0002-5639-8690; Savic, Sinisa/0000-0001-7910-0554; Butte, Manish/0000-0002-4490-5595; Butte, Manish/0000-0002-4490-5595; Burns, Siobhan/0000-0002-3356-9506; John, Tami/0000-0003-0632-3559; Boyes, Joan/0000-0002-8705-9827; Lango Allen, Hana/0000-0002-7803-8688; Deevi, Sri Vishnu Vardhan/0000-0002-0405-4335; Thwaites, Daniel/0000-0002-1504-7712; Romberg, Neil/0000-0002-1881-5318; Sargur, Ravishankar/0000-0002-8535-630X; Ehl, Stephan/0000-0002-9265-2721; Lawless, Dylan/0000-0001-8496-3725; Speckmann, Carsten/0000-0002-6217-1556; Bradley, John/0000-0002-7774-8805; Henrickson, Sarah/0000-0001-5569-4132; Thrasher, Adrian/0000-0002-6097-6115; Smith, Kenneth/0000-0003-3829-4326	National Institute of Allergy and Infectious Diseases/National Institutes of Health [5K08AI103035]; Jeffrey Modell Foundation; Robert A. Good Endowment; University of South Florida; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100887, K23AI115001, ZIAAI000646, ZIAAI001222, K08AI103035, ZIAAI000647] Funding Source: NIH RePORTER; Medical Research Council [MR/L006197/1] Funding Source: researchfish; MRC [MR/L006197/1] Funding Source: UKRI	National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Jeffrey Modell Foundation; Robert A. Good Endowment; University of South Florida; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported in part by National Institute of Allergy and Infectious Diseases/National Institutes of Health grant 5K08AI103035 (to J.E.W.), the Jeffrey Modell Foundation (to J.E.W.), the Robert A. Good Endowment, and the University of South Florida.	Buchbinder D, 2015, J CLIN IMMUNOL, V35, P119, DOI 10.1007/s10875-014-0121-5; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Geier CB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133220; Kumanovics A, 2017, J ALLERGY CLIN IMMUN, V139, P690, DOI 10.1016/j.jaci.2016.07.027; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Speckmann C, 2017, J ALLERGY CLIN IMMUN, V139, P1302, DOI 10.1016/j.jaci.2016.07.040; Tuijnenburg P, 2018, J ALLERGY CLIN IMMUN, V142, P1285, DOI 10.1016/j.jaci.2018.01.039; Walter JE, 2015, J CLIN INVEST, V125, P4135, DOI 10.1172/JCI80477	10	26	26	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2303	2306		10.1016/j.jaci.2018.02.007	http://dx.doi.org/10.1016/j.jaci.2018.02.007			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29477728	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000434701600043
J	Agache, I; Strasser, DS; Pierlot, GM; Farine, H; Izuhara, K; Akdis, CA				Agache, Ioana; Strasser, Daniel S.; Pierlot, Gabin M.; Farine, Herve; Izuhara, Kenji; Akdis, Cezmi A.			Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							AIRWAY; ORMDL3		[Agache, Ioana] Transylvania Univ, Fac Med, Brasov, Romania; [Strasser, Daniel S.; Pierlot, Gabin M.; Farine, Herve] Idorsia Pharmaceut Ltd, Dept Translat Sci, Basel, Switzerland; [Izuhara, Kenji] Saga Med Sch, Div Med Biochem, Dept Biomol Sci, Saga, Japan; [Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Akdis, Cezmi A.] CK CARE, Davos, Switzerland	Transylvania University of Brasov; Idorsia Pharmaceuticals Ltd; Saga University; Swiss Institute of Allergy & Asthma Research; University of Zurich	Agache, I (corresponding author), Transylvania Univ, Fac Med, Brasov, Romania.	ibrumaru@unitbv.ro	Akdis, Cezmi/AAV-4844-2020; Agache, Ioana/AAP-7403-2020	Akdis, Cezmi/0000-0001-8020-019X; Strasser, Daniel/0000-0002-0097-1937	 [PN-II-RU-TE-2014-4-2303]		I. A. developed the study protocol as part of the research project PN-II-RU-TE-2014-4-2303.	Adachi Y, 2008, CELL STRUCT FUNCT, V33, P75, DOI 10.1247/csf.07044; Agache I, 2016, ALLERGY, V71, P1192, DOI 10.1111/all.12906; Agache I, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0529-x; Brightling CE, 2015, LANCET RESP MED, V3, P692, DOI 10.1016/S2213-2600(15)00197-6; Doherty TA, 2011, NAT MED, V17, P596, DOI 10.1038/nm.2356; Hinks TSC, 2016, J ALLERGY CLIN IMMUN, V138, P61, DOI 10.1016/j.jaci.2015.11.020; Hoffman SM, 2016, J ALLERGY CLIN IMMUN, V137, P822, DOI 10.1016/j.jaci.2015.08.018; Hoffman SM, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-141; Lauer ME, 2009, J BIOL CHEM, V284, P5299, DOI 10.1074/jbc.M807965200; Lefaudeux D, 2017, J ALLERGY CLIN IMMUN, V139, P1797, DOI 10.1016/j.jaci.2016.08.048; Lum PY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01236; Malinovschi A, 2013, J ALLERGY CLIN IMMUN, V132, P821, DOI 10.1016/j.jaci.2013.06.007; Miller M, 2015, J IMMUNOL, V195, P3546, DOI 10.4049/jimmunol.1501105; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Stephan M, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.95; Xu WJ, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-14	18	26	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					442	+		10.1016/j.jaci.2017.08.027	http://dx.doi.org/10.1016/j.jaci.2017.08.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28987809	Bronze			2022-12-18	WOS:000419312200059
J	Yadlapati, R; Kahrilas, PJ				Yadlapati, Rena; Kahrilas, Peter J.			The "dangers'' of chronic proton pump inhibitor use	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Proton pump inhibitor; gastroesophageal reflux disease; adverse events; safety	LONG-TERM USE; ASSOCIATION; DEFICIENCY; BENEFITS; RISKS		[Yadlapati, Rena; Kahrilas, Peter J.] Northwestern Univ, Div Gastroenterol & Hepatol, Dept Med, Feinberg Sch Med, 676 N St Clair St,14th Floor, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Kahrilas, PJ (corresponding author), Northwestern Univ, Div Gastroenterol & Hepatol, Dept Med, Feinberg Sch Med, 676 N St Clair St,14th Floor, Chicago, IL 60611 USA.	p-kahrilas@northwestern.edu			Public Health Service [R01 DK092217]; National Institutes of Health [T32DK101363]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK101363, R01DK092217] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	P.J.K. was supported by grant R01 DK092217 from the Public Health Service. R.Y. was supported by National Institutes of Health grant T32DK101363.	Bhatt DL, 2010, NEW ENGL J MED, V363, P1909, DOI 10.1056/NEJMoa1007964; Blank ML, 2014, KIDNEY INT, V86, P837, DOI 10.1038/ki.2014.74; Freedberg DE, 2017, GASTROENTEROLOGY, V152, P706, DOI 10.1053/j.gastro.2017.01.031; Grimes DA, 2012, OBSTET GYNECOL, V120, P920, DOI 10.1097/AOG.0b013e31826af61a; Jung SB, 2015, INTERN MED J, V45, P409, DOI 10.1111/imj.12697; Kia L, 2016, NAT REV GASTRO HEPAT, V13, P253, DOI 10.1038/nrgastro.2016.44; Lam JR, 2017, GASTROENTEROLOGY, V152, P821, DOI 10.1053/j.gastro.2016.11.023; Lundell L, 2015, ALIMENT PHARM THER, V42, P649, DOI 10.1111/apt.13324; Scarpignato C, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0718-z; Sherwood MW, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002245	10	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					79	81		10.1016/j.jaci.2017.06.017	http://dx.doi.org/10.1016/j.jaci.2017.06.017			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28729001				2022-12-18	WOS:000419312200009
J	Regan, JA; Cao, Y; Dispenza, MC; Ma, S; Gordon, LI; Petrich, AM; Bochner, BS				Regan, Jennifer A.; Cao, Yun; Dispenza, Melanie C.; Ma, Shuo; Gordon, Leo I.; Petrich, Adam M.; Bochner, Bruce S.			Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC LYMPHOCYTIC-LEUKEMIA; TARGETING BTK; PCI-32765		[Regan, Jennifer A.; Cao, Yun; Dispenza, Melanie C.; Bochner, Bruce S.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Ma, Shuo; Gordon, Leo I.; Petrich, Adam M.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Ma, Shuo; Gordon, Leo I.; Petrich, Adam M.] Northwestern Univ, Feinberg Sch Med, Dept Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Petrich, Adam M.] Abbvie Inc, N Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; AbbVie	Bochner, BS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Chicago, IL 60611 USA.	bruce.bochner@northwestern.edu	Dispenza, Melanie/L-9123-2019	Dispenza, Melanie C/0000-0002-6655-3279; Bochner, Bruce S./0000-0002-9411-6009	Dixon Translational Innovation Award through the Northwestern University Clinical and Translational Sciences Institute; Northwestern Memorial Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001422] Funding Source: NIH RePORTER	Dixon Translational Innovation Award through the Northwestern University Clinical and Translational Sciences Institute; Northwestern Memorial Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was funded in part by a 2016 Dixon Translational Innovation Award through the Northwestern University Clinical and Translational Sciences Institute and Northwestern Memorial Foundation.	Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Chang BY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3400; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; MacGlashan D, 2011, INT IMMUNOPHARMACOL, V11, P475, DOI 10.1016/j.intimp.2010.12.018; Treon SP, 2015, NEW ENGL J MED, V372, P1430, DOI 10.1056/NEJMoa1501548; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220	9	26	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					875	+		10.1016/j.jaci.2017.03.013	http://dx.doi.org/10.1016/j.jaci.2017.03.013			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28389390	Bronze, Green Accepted			2022-12-18	WOS:000409241500032
J	Joseph, K; Tholanikunnel, BG; Kaplan, AP				Joseph, Kusumam; Tholanikunnel, Baby G.; Kaplan, Allen P.			Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hereditary angioedema; C1 inhibitor; bradykinin; heat shock protein 90	HUMAN FACTOR-XII; HAGEMAN-FACTOR; ORAL-CONTRACEPTIVES; CHRONIC URTICARIA; CONTACT SYSTEM; HUMAN-PLASMA; INHIBITOR; COLLAGEN; HEPARIN; PROTEIN	Background: When the prekallikrein-high molecular weight kininogen complex is bound to endothelial cells, prekallikrein is stoichiometrically converted to kallikrein because of release of heat shock protein-90 (Hsp90). Although bradykinin formation is typically initiated by factor XII autoactivation, it is also possible to activate factor XII either by kallikrein, thus formed, or by plasmin. Objective: Because attacks of hereditary angioedema can be related to infection and/or exposure to estrogen, we questioned whether estrogen or cytokine stimulation of endothelial cells could augment release of Hsp90 and prekallikrein activation. We also tested release of profibrinolytic enzymes, urokinase, and tissue plasminogen activator (TPA) as a source for plasmin formation. Methods: Cells were stimulated with agonists, and secretion of Hsp90, urokinase, and TPA was measured in the culture supernatants by ELISA. Activation of the prekallikrein-HK complex was measured by using pro-phe-arg-p-nitroanilide reflecting kallikrein formation. Results: Hsp90 release was stimulated with optimal doses of estradiol, IL-1, and TNF-alpha (10 ng/mL) from 15 minutes to 120 minutes. TPA release was not augmented by any of the agonists tested but urokinase was released by IL-1, TNF-alpha, and thrombin (positive control), but not estrogen. Augmented activation of the prekallikrein-HK complex to generate kallikrein was seen with each agonist that releases Hsp90. Addition of 0.1% factor XII relative to prekallikrein-HK leads to rapid formation of kallikrein; factor XII alone does not autoactivate. Conclusions: IL-1, TNF-alpha, and estrogen stimulate release of Hsp90 and augment activation of the prekallikrein-HK complex to generate kallikrein and bradykinin. IL-1 and TNF-alpha stimulate release of urokinase, which can convert plasminogen to plasmin and represents a possible source for plasmin generation in all types of hereditary angioedema, but particularly hereditary angioedema with normal C1 inhibitor with a factor XII mutation. Both kallikrein and plasmin activate factor XII; kallikrein is 20 times more potent on a molar basis.	[Joseph, Kusumam; Tholanikunnel, Baby G.] Med Univ South Carolina, Dept Biochem & Mol Biol, BSB 535B,173 Ashley Ave, Charleston, SC 29425 USA; [Kaplan, Allen P.] Med Univ South Carolina, Dept Med, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina	Joseph, K (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, BSB 535B,173 Ashley Ave, Charleston, SC 29425 USA.	josephk@musc.edu			Shire Human Genetics Therapies, Lexington, Mass	Shire Human Genetics Therapies, Lexington, Mass	This study was supported by Shire Human Genetics Therapies, Lexington, Mass.	Al-Ejeh F, 2004, EXP CELL RES, V297, P259, DOI 10.1016/j.yexcr.2004.03.030; [Anonymous], 2000, GEN PHARM, V35, P165; Asero R, 2013, J ALLERGY CLIN IMMUN, V132, P983, DOI 10.1016/j.jaci.2013.04.037; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bjorkqvist J, 2015, J CLIN INVEST, V125, P3132, DOI 10.1172/JCI77139; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Brown EW, 2002, BLOOD COAGUL FIBRIN, V13, P711, DOI 10.1097/00001721-200212000-00007; Brown NJ, 1999, HYPERTENSION, V33, P1431, DOI 10.1161/01.HYP.33.6.1431; Brunnee T, 1997, CLIN EXP ALLERGY, V27, P653; Citarella F, 1996, STEROIDS, V61, P270, DOI 10.1016/0039-128X(96)00037-2; de Maat S, 2016, J ALLERGY CLIN IMMUN, V138, P1414, DOI 10.1016/j.jaci.2016.02.021; GORDON EM, 1980, J LAB CLIN MED, V96, P762; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; HOEM NO, 1991, THROMB RES, V64, P427, DOI 10.1016/0049-3848(91)90343-U; HOJIMA Y, 1984, BLOOD, V63, P1453; HUISVELD IA, 1985, THROMB HAEMOSTASIS, V54, P102; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; JAFFE EA, 1980, TRANSPL P, V12, P49; Joseph K, 2005, ADV IMMUNOL, V86, P159, DOI 10.1016/S0065-2776(04)86005-X; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899; Joseph K, 2016, J ALLERGY CLIN IMMUN, V137, P1822, DOI 10.1016/j.jaci.2015.07.041; KAPLAN AP, 1971, J EXP MED, V133, P696, DOI 10.1084/jem.133.4.696; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MULLERTZ S, 1976, BIOCHEM J, V159, P545; Reshef A, 2015, ALLERGY, V70, P506, DOI 10.1111/all.12587; Riedl MA, 2013, J ALLER CL IMM-PRACT, V1, P427, DOI 10.1016/j.jaip.2013.06.004; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Shibayama Y, 1999, CLIN IMMUNOL, V90, P89, DOI 10.1006/clim.1998.4621; SILVERBERG M, 1980, J BIOL CHEM, V255, P7281; SILVERBERG M, 1980, THROMB RES, V20, P173, DOI 10.1016/0049-3848(80)90383-7; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; Tedeschi A, 2014, ALLERGY, V69, P683, DOI 10.1111/all.12389; van der Meijden PEJ, 2009, BLOOD, V114, P881, DOI 10.1182/blood-2008-07-171066; WILNER GD, 1968, J CLIN INVEST, V47, P2608, DOI 10.1172/JCI105943; ZACHARSKI LR, 1975, THROMB RES, V7, P929, DOI 10.1016/0049-3848(75)90097-3; Zuraw BL, 2012, ALLERGY ASTHMA PROC, V33, pS145, DOI 10.2500/aap.2012.33.3627	39	26	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					170	176		10.1016/j.jaci.2016.09.032	http://dx.doi.org/10.1016/j.jaci.2016.09.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27826093	Bronze			2022-12-18	WOS:000404542000017
J	Slovick, A; Douiri, A; Muir, R; Guerra, A; Tsioulos, K; Hay, E; Lam, EPS; Kelly, J; Peacock, JL; Ying, S; Shamji, MH; Cousins, DJ; Durham, SR; Till, SJ				Slovick, Anna; Douiri, Abdel; Muir, Rachel; Guerra, Andrea; Tsioulos, Konstantinos; Hay, Evie; Lam, Emily P. S.; Kelly, Joanna; Peacock, Janet L.; Ying, Sun; Shamji, Mohamed H.; Cousins, David J.; Durham, Stephen R.; Till, Stephen J.			Intradermal grass pollen immunotherapy increases T(H)2 and IgE responses and worsens respiratory allergic symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy; allergic rhinitis; grass pollen; Phleum pratense; immunotherapy; intradermal; low dose	MESSENGER-RNA EXPRESSION; ATOPIC-DERMATITIS; SKIN PREPARATION; HAY-FEVER; RHINITIS; RHINOCONJUNCTIVITIS; SENSITIZATION; INFILTRATION; INJECTIONS; EFFICACY	Background: Repeated low-dose grass pollen intradermal allergen injection suppresses allergen-induced cutaneous late-phase responses comparably with conventional subcutaneous and sublingual immunotherapy. Objective: We sought to evaluate the efficacy and safety of grass pollen intradermal immunotherapy in the treatment of allergic rhinitis. Methods: We randomly assigned 93 adults with grass pollen-induced allergic rhinitis to receive 7 preseasonal intradermal allergen injections (containing 7 ng of Phl p 5 major allergen) or a histamine control. The primary end point was daily combined symptom-medication scores during the 2013 pollen season (area under the curve). Analysis was by intention to treat. Skin biopsy specimens were collected after intradermal allergen challenges, and late-phase responses were measured 4 and 7, 10, or 13 months after treatment. Results: There was no significant difference in the primary end point between treatment arms (active, n = 46; control, n = 47; median difference, 14; 95% CI, -172.5 to 215.1; P = .80). Among secondary end points, nasal symptoms were worse in the intradermal treatment group, as measured based on daily (median difference, 35; 95% CI, 4.0-67.5; P = .03) and visual analog scale (median difference, 53; 95% CI, -11.6 to 125.2; P = .05) scores. In a per-protocol analysis intradermal immunotherapy was further associated with worse asthma symptoms and fewer symptom-free days. Intradermal immunotherapy increased serum Phleum pratense-specific IgE levels (P = .001) compared with those in the control arm. T cells cultured from biopsy specimens of subjects undergoing intradermal immunotherapy had higher expression of the T(H)2 surface marker CRTH2 (P = .04) and lower expression of the T(H)1 marker CXCR3 (P = .01), respectively. Late-phase responses remained inhibited 7 months after treatment (P = .03). Conclusion: Intradermal allergen immunotherapy suppressed skin late-phase responses but was not clinically effective and resulted in worsening of respiratory allergic symptoms.	[Slovick, Anna; Guerra, Andrea; Tsioulos, Konstantinos; Hay, Evie; Lam, Emily P. S.; Ying, Sun; Cousins, David J.; Till, Stephen J.] Kings Coll London, Div Asthma Allergy & Lung Biol, Guys Hosp, Sch Med, London, England; [Douiri, Abdel; Peacock, Janet L.] Kings Coll London, Div Hlth & Social Care Res, 4th Floor Addison House,Guys Campus, London, England; [Muir, Rachel] Guys Hosp, NIHR Biomed Res Ctr, Clin Res Facil, London, England; [Kelly, Joanna] Kings Coll London, Inst Psychiat, Kings Clin Trials Unit, London, England; [Shamji, Mohamed H.; Durham, Stephen R.] Imperial Coll, Fac Med, Natl Heart & Lung Inst, Allergy & Clin Immunol, London, England; [Cousins, David J.] Univ Leicester, Leicester Inst Lung Hlth, NIHR Leicester Resp Biomed Res Unit, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Slovick, Anna; Cousins, David J.; Till, Stephen J.] MRC Asthma UK Ctr Allerg Mech Asthma, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London; University of Leicester; University of London; King's College London	Till, SJ (corresponding author), Kings Coll London, Guys Hosp, Div Asthma Allergy & Lung Biol, London SE1 9R, England.	stephen.till@kcl.ac.uk	Muir, Rachel/AAB-9372-2019; Shamji, Mohamed/AAU-8811-2020; Shamji, Mohamed/AAD-1788-2019	Shamji, Mohamed/0000-0003-3425-3463; Cousins, David/0000-0003-3821-9596; Muir, Rachel/0000-0003-3345-9929; Peacock, Janet/0000-0002-0310-2518; Douiri, Abdel/0000-0002-4354-4433; Till, Stephen/0000-0003-4518-3093	Efficacy and Mechanism Evaluation Programme; Medical Research Council (MRC); King's College London; Guy's & St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; United Kingdom Clinical Research Collaboration-registered King's Clinical Trials Unit at King's Health Partners; NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust; NIHR Evaluation, Trials and Studies Coordinating Centre; HEFCE Clinical Senior Lectureship Award; MRC-Asthma UK; Athena SWAN; Royal College of Surgeons (England); NIHR Leicester Respiratory Biomedical Research Unit; Medical Research Council [MC_PC_12038, G1000758] Funding Source: researchfish; MRC [MC_PC_12038] Funding Source: UKRI	Efficacy and Mechanism Evaluation Programme; Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); King's College London; Guy's & St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; United Kingdom Clinical Research Collaboration-registered King's Clinical Trials Unit at King's Health Partners; NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust; NIHR Evaluation, Trials and Studies Coordinating Centre(National Institute for Health Research (NIHR)); HEFCE Clinical Senior Lectureship Award; MRC-Asthma UK; Athena SWAN; Royal College of Surgeons (England); NIHR Leicester Respiratory Biomedical Research Unit; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This project was awarded by the Efficacy and Mechanism Evaluation Programme and is funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership and jointly sponsored by King's College London and Guy's & St Thomas' NHS Foundation Trust. The funding source had no involvement in conduct of the research or preparation of the article. This work was also supported by the NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London and the United Kingdom Clinical Research Collaboration-registered King's Clinical Trials Unit at King's Health Partners, which is partially funded by the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR Evaluation, Trials and Studies Coordinating Centre. S.J.T. was supported a HEFCE Clinical Senior Lectureship Award. E.P.S.L. was funded by a MRC-Asthma UK funded PhD studentship. A.S. received funding from Athena SWAN and Royal College of Surgeons (England). D.J.C. acknowledges support from NIHR Leicester Respiratory Biomedical Research Unit.	Agbotounou W, 2013, J ALLERGY CLIN IMMUN, V131, pAB91, DOI 10.1016/j.jaci.2012.12.992; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P630, DOI 10.1016/j.jaci.2013.02.034; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Clausen BE, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00534; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; Dharmage SC, 2014, ALLERGY, V69, P17, DOI 10.1111/all.12268; Dupont C, 2014, J ALLERGY CLIN IMMUN, V133, pAB102, DOI 10.1016/j.jaci.2013.12.381; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; FREW AJ, 1988, J IMMUNOL, V141, P4158; GAGA M, 1991, J IMMUNOL, V147, P816; Hylander T, 2013, J ALLERGY CLIN IMMUN, V131, P412, DOI 10.1016/j.jaci.2012.10.056; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013; Lee CH, 2015, EXP DERMATOL, V24, P67, DOI 10.1111/exd.12583; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Mondoulet Lucie, 2012, Clin Transl Allergy, V2, P22, DOI 10.1186/2045-7022-2-22; Phillips E, 1933, J ALLERGY, V5, P29; Phillips EW, 1926, J AMER MED ASSOC, V86, P182, DOI 10.1001/jama.1926.02670290022008; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118; Rotiroti G, 2012, J ALLERGY CLIN IMMUN, V130, P918, DOI 10.1016/j.jaci.2012.06.052; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P128, DOI 10.1016/j.jaci.2011.08.036; Slovick Anna, 2013, Clin Transl Allergy, V3, P27, DOI 10.1186/2045-7022-3-27; Spina L, 2015, INT ARCH ALLERGY IMM, V167, P103, DOI 10.1159/000434681; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; von Moos S, 2014, J ALLERGY CLIN IMMUN, V134, P965, DOI 10.1016/j.jaci.2014.07.037; Winther L, 1999, ALLERGY, V54, P436, DOI 10.1034/j.1398-9995.1999.00910.x; Zuberbier T, 2010, ALLERGY, V65, P1525, DOI 10.1111/j.1398-9995.2010.02474.x	36	26	27	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1830	+		10.1016/j.jaci.2016.09.024	http://dx.doi.org/10.1016/j.jaci.2016.09.024			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27773851	Green Published, hybrid			2022-12-18	WOS:000402724600014
J	Frossi, B; Tripodo, C; Guarnotta, C; Carroccio, A; De Carli, M; De Carli, S; Marino, M; Calabro, A; Pucillo, CE				Frossi, Barbara; Tripodo, Claudio; Guarnotta, Carla; Carroccio, Antonio; De Carli, Marco; De Carli, Stefano; Marino, Marco; Calabro, Antonino; Pucillo, Carlo E.			Mast cells are associated with the onset and progression of celiac disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Celiac disease; mast cell; gliadin immunology; p31-43 fragment	NO-MANS-LAND; PLASMA-CELLS; GLUTEN SENSITIVITY; GLIADIN PEPTIDES; T-CELLS; KAPPA-B; IGA; ACTIVATION; EXPRESSION; DIFFERENTIATION	Background: Celiac disease (CD) is an immune-mediated disorder characterized by an accumulation of immune cells in the duodenal mucosa as a consequence of both adaptive and innate immune responses to undigested gliadin peptides. Mast cells (MCs) are innate immune cells that are a major source of costimulatory signals and inflammatory mediators in the intestinal mucosa. Although MCs have previously been associated with CD, functional studies have never been performed. Objective: We aimed at evaluating the role of MCs in the pathogenesis of CD. Methods: Intestinal biopsy specimens of patients with CD were scored according to the Marsh classification and characterized for leukocyte infiltration and MC distribution. Moreover, MC reactivity to gliadin and its peptides was characterized by using in vitro assays. Results: Infiltrating MCs were associated with the severity of mucosal damage, and their numbers were increased in patients with higher Marsh scores. MCs were found to directly respond to nonimmunodominant gliadin fragments by releasing proinflammatory mediators. Immunohistochemical characterization of infiltrating MCs and the effects of gliadin peptides on intestinal MCs indicated an increase in proinflammatory MC function in advanced stages of the disease. This was also associated with increased neutrophil accumulation, the prevalence of M1 macrophages, and the severity of tissue damage. Conclusion: We provide a description of the progressive stages of CD, in which MCs are the hallmark of the inflammatory process. Thus the view of CD should be revised, and the contribution of MCs in the onset and progression of CD should be reconsidered in developing new therapeutic approaches.	[Frossi, Barbara; Pucillo, Carlo E.] Univ Udine, Dept Med & Biol Sci, Ple Kolbe 4, I-33100 Udine, Italy; [Tripodo, Claudio; Guarnotta, Carla] Univ Hosp Palermo, Dept Hlth Sci, Palermo, Italy; [Carroccio, Antonio] Univ Hosp Palermo, Dept Internal Med & Specialist, Palermo, Italy; [De Carli, Marco; De Carli, Stefano] Univ Hosp Udine, Unit Internal Med 2, Udine, Italy; [Marino, Marco] Univ Hosp Udine, Dept Gastroenterol & Digest Endoscopy, Udine, Italy; [Calabro, Antonino] Univ Hosp Florence, Dept Expt & Clin Biomed Sci Mario Serio, Florence, Italy; [Calabro, Antonino] AOU Careggi, Tuscany Referral Ctr Adult Coeliac Dis, Florence, Italy	University of Udine; University of Palermo; Policlinico Paolo Giaccone; University of Palermo; Policlinico Paolo Giaccone; University of Udine; University Hospital of Udine; University of Udine; University Hospital of Udine; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi	Pucillo, CE (corresponding author), Univ Udine, Dept Med & Biol Sci, Ple Kolbe 4, I-33100 Udine, Italy.	carlo.pucillo@uniud.it	Pucillo, Carlo/A-5515-2008; Frossi, Barbara/AFL-0800-2022; Tripodo, Claudio/AAB-6004-2022	Pucillo, Carlo/0000-0002-4872-6156; Frossi, Barbara/0000-0001-9855-2396; Tripodo, Claudio/0000-0002-0821-6231	COST Action [BM1007]; Italian Ministry of Health [15561, 11843]; Ministero dell'Istruzione, Universita e Ricerca (PRIN); ASIMAS (ASsociazione Italiana MAStocitosi)	COST Action(European Cooperation in Science and Technology (COST)); Italian Ministry of Health(Ministry of Health, Italy); Ministero dell'Istruzione, Universita e Ricerca (PRIN); ASIMAS (ASsociazione Italiana MAStocitosi)	Supported by COST Action BM1007 "Mast cells and basophils: targets for innovative therapies,'' Italian Ministry of Health, (nos. 15561 and 11843), Ministero dell'Istruzione, Universita e Ricerca (PRIN2009), and ASIMAS (ASsociazione Italiana MAStocitosi).	[Anonymous], 2006, GASTROENTEROLOGY, V131, P1977, DOI 10.1053/j.gastro.2006.10.003; Ayyoub M, 2009, P NATL ACAD SCI USA, V106, P8635, DOI 10.1073/pnas.0900621106; Ball AJ, 2010, AM J GASTROENTEROL, V105, P222, DOI 10.1038/ajg.2009.565; Barone MV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012246; Brazowski E, 2010, PATHOBIOLOGY, V77, P328, DOI 10.1159/000322049; Broughton SE, 2012, IMMUNITY, V37, P611, DOI 10.1016/j.immuni.2012.07.013; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Cinova J, 2007, J CLIN IMMUNOL, V27, P201, DOI 10.1007/s10875-006-9061-z; Di Niro R, 2012, NAT MED, V18, P441, DOI 10.1038/nm.2656; Enoksson M, 2013, BLOOD, V121, P530, DOI 10.1182/blood-2012-05-434209; Han A, 2013, P NATL ACAD SCI USA, V110, P13073, DOI 10.1073/pnas.1311861110; HORVATH K, 1986, Acta Paediatrica Hungarica, V27, P311; Jelinkova L, 2004, FEBS LETT, V571, P81, DOI 10.1016/j.febslet.2004.06.057; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Leffler D, 2013, GUT, V62, P996, DOI 10.1136/gutjnl-2012-302196; Levesque MC, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000107; Maiuri L, 2003, LANCET, V362, P30, DOI 10.1016/S0140-6736(03)13803-2; Maiuri L, 2010, GUT, V59, P311, DOI 10.1136/gut.2009.183608; Maiuri MC, 2003, J MOL MED-JMM, V81, P373, DOI 10.1007/s00109-003-0440-0; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Meresse B, 2012, IMMUNITY, V36, P907, DOI 10.1016/j.immuni.2012.06.006; Merluzzi S, 2015, MOL IMMUNOL, V63, P94, DOI 10.1016/j.molimm.2014.02.016; Merluzzi S, 2010, BLOOD, V115, P2810, DOI 10.1182/blood-2009-10-250126; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Palova-Jelinkova L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062426; Piconese S, 2009, BLOOD, V114, P2639, DOI 10.1182/blood-2009-05-220004; Sibilano R, 2012, J IMMUNOL, V189, P120, DOI 10.4049/jimmunol.1200009; Steinsbo O, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5041; Stoinov SG, 2008, J GASTROINTEST LIVER, V17, P486; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; STROBEL S, 1983, GUT, V24, P222, DOI 10.1136/gut.24.3.222; Szebeni B, 2007, J PEDIATR GASTR NUTR, V45, P187, DOI 10.1097/MPG.0b013e318064514a; Thomas KE, 2006, J IMMUNOL, V176, P2512, DOI 10.4049/jimmunol.176.4.2512; Toellner KM, 2002, J EXP MED, V195, P383, DOI 10.1084/jem.20011112; van Bergen J, 2015, GASTROENTEROLOGY, V148, P1187, DOI 10.1053/j.gastro.2015.01.030; Verdu EF, 2009, AM J GASTROENTEROL, V104, P1587, DOI 10.1038/ajg.2009.188; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973	37	26	26	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1266	+		10.1016/j.jaci.2016.08.011	http://dx.doi.org/10.1016/j.jaci.2016.08.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27619824	Bronze			2022-12-18	WOS:000398771800021
J	Orgel, KA; Duan, ST; Wright, BL; Maleki, SJ; Wolf, JC; Vickery, BP; Burks, AW; Paulson, JC; Kulis, MD; Macauley, MS				Orgel, Kelly A.; Duan, Shiteng; Wright, Benjamin L.; Maleki, Soheila J.; Wolf, John C.; Vickery, Brian P.; Burks, A. Wesley; Paulson, James C.; Kulis, Mike D.; Macauley, Matthew S.			Exploiting CD22 on antigen-specific B cells to prevent allergy to the major peanut allergen Ara h 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CROSS-REACTIVITY; IGE; IMMUNOTHERAPY		[Orgel, Kelly A.; Wright, Benjamin L.; Vickery, Brian P.; Burks, A. Wesley; Kulis, Mike D.] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27514 USA; [Orgel, Kelly A.; Wright, Benjamin L.; Vickery, Brian P.; Burks, A. Wesley; Kulis, Mike D.] Univ N Carolina, UNC Food Allergy Initiat, Chapel Hill, NC 27514 USA; [Orgel, Kelly A.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC USA; [Duan, Shiteng; Paulson, James C.] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA; [Duan, Shiteng; Paulson, James C.; Macauley, Matthew S.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA; [Duan, Shiteng; Paulson, James C.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Wright, Benjamin L.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Maleki, Soheila J.; Wolf, John C.] ARS, USDA, Southern Reg Res Ctr, New Orleans, LA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Duke University; United States Department of Agriculture (USDA)	Kulis, MD (corresponding author), Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27514 USA.; Kulis, MD (corresponding author), Univ N Carolina, UNC Food Allergy Initiat, Chapel Hill, NC 27514 USA.	mike.kulis@unc.edu	Paulson, James/AAG-3565-2019; Duan, Shiteng/AAD-7109-2020	Macauley, Matthew/0000-0003-4579-1048; Vickery, Brian/0000-0002-7243-5543	National Institutes of Health [T32 AI007062, AI099141, AI050143]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007062, R01AI099141, P01AI058113, R01AI050143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008719] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health (grant no. T32 AI007062 to B.L.W.) and grants AI099141 and AI050143 (to J.C.P.).	Bublin M, 2013, J ALLERGY CLIN IMMUN, V132, P118, DOI 10.1016/j.jaci.2013.01.022; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P720, DOI 10.1111/cea.12412; Kulis M, 2012, CLIN EXP ALLERGY, V42, P326, DOI 10.1111/j.1365-2222.2011.03934.x; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; Macauley MS, 2013, J CLIN INVEST, V123, P3074, DOI 10.1172/JCI69187; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Smit JJ, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0056-9	9	26	27	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					366	+		10.1016/j.jaci.2016.06.053	http://dx.doi.org/10.1016/j.jaci.2016.06.053			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27554819	Green Accepted, Bronze			2022-12-18	WOS:000393996800042
J	Esaki, H; Czarnowicki, T; Gonzalez, J; Oliva, M; Talasila, S; Haugh, I; Rodriguez, G; Becker, L; Krueger, JG; Guttman-Yassky, E; Paller, AS				Esaki, Hitokazu; Czarnowicki, Tali; Gonzalez, Juana; Oliva, Margeaux; Talasila, Sreya; Haugh, Isabel; Rodriguez, Giselle; Becker, Lauren; Krueger, James G.; Guttman-Yassky, Emma; Paller, Amy S.			Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AGE-RELATED-CHANGES; CHILDREN; T(H)22/T(C)22; NEWBORNS; ALLERGY; MEMORY; ADULTS		[Esaki, Hitokazu; Czarnowicki, Tali; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Invest Dermatol Lab, 1230 York Ave, New York, NY 10021 USA; [Gonzalez, Juana] Rockefeller Univ, Translat Technol Core Lab, 1230 York Ave, New York, NY 10021 USA; [Esaki, Hitokazu; Oliva, Margeaux; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Talasila, Sreya; Haugh, Isabel; Rodriguez, Giselle; Becker, Lauren; Paller, Amy S.] Northwestern Univ Feinberg, Sch Med, Dept Dermatol, Chicago, IL USA; Northwestern Univ Feinberg, Sch Med, Dept Pediat, Chicago, IL USA	Rockefeller University; Rockefeller University; Icahn School of Medicine at Mount Sinai; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Paller, AS (corresponding author), Northwestern Univ Feinberg, Sch Med, Dept Dermatol, Chicago, IL USA.	apaller@northwestern.edu	Haugh, Isabel/AAW-9354-2020	Paller, Amy/0000-0001-6187-6549; Esaki, Hitokazu/0000-0002-3716-520X	NIAMS NIH HHS [P30 AR057216] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057216] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P1329, DOI 10.1016/j.jaci.2014.06.032; Cossarizza A, 1996, MECH AGEING DEV, V86, P173, DOI 10.1016/0047-6374(95)01691-0; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Ferran M, 2013, EXP DERMATOL, V22, P439, DOI 10.1111/exd.12154; Gasparoni A, 2003, BIOL NEONATE, V84, P297, DOI 10.1159/000073638; Gennery AR, 2008, CLIN EXP IMMUNOL, V153, P75, DOI 10.1111/j.1365-2249.2008.03681.x; Inoue H, 2010, EUR J PEDIATR, V169, P839, DOI 10.1007/s00431-009-1126-6; Kawamoto N, 2006, PEDIAT ALLERG IMM-UK, V17, P125, DOI 10.1111/j.1399-3038.2005.00363.x; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Ohtsuka Y, 2004, EUR J PEDIATR, V163, P747, DOI 10.1007/s00431-004-1524-8; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020	12	26	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1473	+		10.1016/j.jaci.2016.04.052	http://dx.doi.org/10.1016/j.jaci.2016.04.052			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27450726				2022-12-18	WOS:000389542700037
J	Griffith, LM; Cowan, MJ; Notarangelo, LD; Kohn, DB; Puck, JM; Shearer, WT; Burroughs, LM; Torgerson, TR; Decaluwe, H; Haddad, E				Griffith, Linda M.; Cowan, Morton J.; Notarangelo, Luigi D.; Kohn, Donald B.; Puck, Jennifer M.; Shearer, William T.; Burroughs, Lauri M.; Torgerson, Troy R.; Decaluwe, Helene; Haddad, Elie			Primary Immune Deficiency Treatment Consortium (PIDTC) update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allogeneic hematopoietic cell transplantation; gene therapy; primary immunodeficiency; clinical trial	SEVERE COMBINED IMMUNODEFICIENCY; STEM-CELL TRANSPLANTATION; GENE-THERAPY; NEUROCOGNITIVE FUNCTION; SEVERE INFECTIONS; T-CELLS; B-CELL; RECONSTITUTION; CHILDREN; DISEASES	The Primary Immune Deficiency Treatment Consortium (PIDTC) is a collaboration of 41 North American centers studying therapy for rare primary immune deficiency diseases (PIDs), including severe combined immune deficiency (SCID), Wiskott-Aldrich syndrome (WAS), and chronic granulomatous disease (CGD). An additional 3 European centers have partnered with the PIDTC to study CGD. Natural history protocols of the PIDTC analyze outcomes of treatment for rare PIDs in multicenter longitudinal retrospective, prospective, and cross-sectional studies. Since 2009, participating centers have enrolled more than 800 subjects on PIDTC protocols for SCID, and enrollment in the studies on WAS and CGD is underway. Four pilot projects have been funded, and 12 junior investigators have received fellowship awards. Important publications of the consortium describe the outcomes of hematopoietic cell transplantation for SCID during 2000-2009, diagnostic criteria for SCID, and the pilot project of newborn screening for SCID in the Navajo Nation. The PIDTC Annual Scientific Workshops provide an opportunity to strengthen collaborations with junior investigators, patient advocacy groups, and international colleagues. Funded by the National Institute of Allergy and Infectious Diseases and the Office of Rare Diseases Research, National Center for Advancing Translational Sciences, the PIDTC has recently received renewal for another 5 years. Here we review accomplishments of the group, projects underway, highlights of recent workshops, and challenges for the future.	[Griffith, Linda M.] NIAID, Div Allergy Immunol & Transplantat, NIH, 5601 Fishers Ln,Rm 7D49, Bethesda, MD 20892 USA; [Cowan, Morton J.; Puck, Jennifer M.] Univ Calif San Francisco, Div Allergy Immunol & Blood & Marrow Transplantat, Dept Pediat, San Francisco, CA 94143 USA; [Cowan, Morton J.; Puck, Jennifer M.] Univ Calif San Francisco, UCSF Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Notarangelo, Luigi D.] Harvard Med Sch, Childrens Hosp, Div Immunol, Boston, MA USA; [Notarangelo, Luigi D.] Harvard Med Sch, Harvard Stem Cell Inst, Boston, MA USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Microbiol, Los Angeles, CA 90024 USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Immunol & Mol Genet, Los Angeles, CA 90024 USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Shearer, William T.] Texas Childrens Hosp, Baylor Coll Med, Pediat Allergy & Immunol, Houston, TX 77030 USA; [Burroughs, Lauri M.] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Pediat Hematol Oncol, Seattle, WA 98195 USA; [Torgerson, Troy R.] Univ Washington, Sch Med, Seattle Childrens Res Inst, Pediat Rheumatol, Seattle, WA USA; [Decaluwe, Helene; Haddad, Elie] Univ Montreal, Mother & Child Ste Justine Hosp, Pediat Immunol & Pediat, Montreal, PQ H3C 3J7, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Baylor College of Medicine; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Universite de Montreal	Griffith, LM (corresponding author), NIAID, Div Allergy Immunol & Transplantat, NIH, 5601 Fishers Ln,Rm 7D49, Bethesda, MD 20892 USA.	LGriffith@niaid.nih.gov	Haddad, Elie/AAQ-4971-2020	Haddad, Elie/0000-0003-2446-6879; Decaluwe, Helene/0000-0001-6617-0633; Shearer, William/0000-0002-2483-2130	Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID); Intramural Research Program of the NIAID; Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Md [U54-AI082973, U54-NS064808, U01-TR001263, R13-AI094943]; Immune Deficiency Foundation, Towson, Md; Jeffrey Modell Foundation, New York, NY; David Center, Texas Children's Hospital, Houston, Tex; John P. McGovern Foundation, Houston, Tex; Seattle Cancer Care Alliance, Seattle, Wash; Seattle Children's Research Institute and Seattle Children's Hospital, Seattle, Wash; AbbVie, St-Laurent, Quebec, Canada; ADMA Biologics, Ramsey, NJ; Baxalta, Deerfield, Ill; Bristol-Myers Squibb Canada, St-Laurent, Quebec, Canada; CSL Behring, King of Prussia, Pa; CSL Behring, Ottawa, Ontario, Canada; GRI-FOLS Canada, Mississauga, Ontario, Canada; Horizon Pharma USA, Deerfield, Ill; Miltenyi Biotec, Auburn, Calif; Octapharma Canada, Toronto, Ontario, Canada; Otsuka Canada Pharmaceutical, St-Laurent, Quebec, Canada; Sigma-Tau Pharmaceuticals, Gaithersburg, Md; ORDR, NCATS; Division of Allergy Immunology and Transplantation (DAIT), NIAID; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [U01TR001263] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL122173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R13AI094943, U54AI082973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS064808] Funding Source: NIH RePORTER	Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID); Intramural Research Program of the NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Md; Immune Deficiency Foundation, Towson, Md; Jeffrey Modell Foundation, New York, NY; David Center, Texas Children's Hospital, Houston, Tex; John P. McGovern Foundation, Houston, Tex; Seattle Cancer Care Alliance, Seattle, Wash; Seattle Children's Research Institute and Seattle Children's Hospital, Seattle, Wash; AbbVie, St-Laurent, Quebec, Canada(AbbVie); ADMA Biologics, Ramsey, NJ; Baxalta, Deerfield, Ill; Bristol-Myers Squibb Canada, St-Laurent, Quebec, Canada(Bristol-Myers Squibb); CSL Behring, King of Prussia, Pa; CSL Behring, Ottawa, Ontario, Canada; GRI-FOLS Canada, Mississauga, Ontario, Canada; Horizon Pharma USA, Deerfield, Ill; Miltenyi Biotec, Auburn, Calif; Octapharma Canada, Toronto, Ontario, Canada; Otsuka Canada Pharmaceutical, St-Laurent, Quebec, Canada; Sigma-Tau Pharmaceuticals, Gaithersburg, Md; ORDR, NCATS; Division of Allergy Immunology and Transplantation (DAIT), NIAID; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID); the Intramural Research Program of the NIAID; and the Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Md: U54-AI082973 (PI: M. J. Cowan), U54-NS064808 and U01-TR001263 (PI: J. P. Krischer), and R13-AI094943 (PIs: M. J. Cowan, L. D. Notarangelo). The workshops were also supported in part by the Immune Deficiency Foundation, Towson, Md; the Jeffrey Modell Foundation, New York, NY; the David Center, Texas Children's Hospital, Houston, Tex; the John P. McGovern Foundation, Houston, Tex; Seattle Cancer Care Alliance, Seattle, Wash; Seattle Children's Research Institute and Seattle Children's Hospital, Seattle, Wash; AbbVie, St-Laurent, Quebec, Canada; ADMA Biologics, Ramsey, NJ; Baxalta, Deerfield, Ill; Bristol-Myers Squibb Canada, St-Laurent, Quebec, Canada; CSL Behring, King of Prussia, Pa; CSL Behring, Ottawa, Ontario, Canada; GRI-FOLS Canada, Mississauga, Ontario, Canada; Horizon Pharma USA, Deerfield, Ill; Miltenyi Biotec, Auburn, Calif; Octapharma Canada, Toronto, Ontario, Canada; Otsuka Canada Pharmaceutical, St-Laurent, Quebec, Canada; and Sigma-Tau Pharmaceuticals, Gaithersburg, Md. The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network (RDCRN) of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and is sponsored by the ORDR, NCATS, and the Division of Allergy Immunology and Transplantation (DAIT), NIAID. The opinions expressed are those of the authors and do not represent the position of the NIAID, the ORDR, the NCATS, the NIH, or the US Government.	Airoldi I, 2015, BLOOD, V125, P2349, DOI 10.1182/blood-2014-09-599423; Becker-Herman S, 2011, J EXP MED, V208, P2033, DOI 10.1084/jem.20110200; Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; Burroughs LM, 2014, BIOL BLOOD MARROW TR, V20, P1996, DOI 10.1016/j.bbmt.2014.08.020; Conley ME, 2003, CLIN IMMUNOL, V109, P272, DOI 10.1016/j.clim.2003.08.005; Cowan MJ, 2015, J ALLERGY CLIN IMMUN, V136, P1178, DOI 10.1016/j.jaci.2015.04.027; Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417; Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726; Dumont-Lagace M, 2014, J IMMUNOL, V192, P2219, DOI 10.4049/jimmunol.1302961; Dvorak CC, 2014, J ALLERGY CLIN IMMUN, V134, P935, DOI 10.1016/j.jaci.2014.06.021; Dvorak CC, 2013, J CLIN IMMUNOL, V33, P1156, DOI 10.1007/s10875-013-9917-y; Fathman JW, 2011, BLOOD, V118, P5439, DOI 10.1182/blood-2011-04-348912; Fuchs EJ, 2012, HEMATOL-AM SOC HEMAT, P230, DOI 10.1182/asheducation-2012.1.230; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Gennery AR, 2015, CLIN INFECT DIS, V60, P1184, DOI 10.1093/cid/ciu1155; Gratz IK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00333; Griffith LM, 2014, J ALLERGY CLIN IMMUN, V133, P335, DOI 10.1016/j.jaci.2013.07.052; Griffith LM, 2009, J ALLERGY CLIN IMMUN, V124, P1152, DOI 10.1016/j.jaci.2009.10.022; Griffith LM, 2008, J ALLERGY CLIN IMMUN, V122, P1087, DOI 10.1016/j.jaci.2008.09.045; Grunebaum E, 2013, CURR OPIN ALLERGY CL, V13, P630, DOI 10.1097/ACI.0000000000000006; Hacein-Bey-Abina S, 2014, NEW ENGL J MED, V371, P1407, DOI 10.1056/NEJMoa1404588; Hacein-Bey-Abina S, 2010, NEW ENGL J MED, V363, P355, DOI 10.1056/NEJMoa1000164; Haddad E, 2013, J ALLERGY CLIN IMMUN, V131, P994, DOI 10.1016/j.jaci.2013.01.047; Heimall J, 2015, BIOL BLOOD MARROW TR, V21, pS289, DOI 10.1016/j.bbmt.2014.11.459; Inlay MA, 2009, GENE DEV, V23, P2376, DOI 10.1101/gad.1836009; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Kanakry CG, 2014, BLOOD, V124, P3817, DOI 10.1182/blood-2014-07-587477; Kang EM, 2011, J ALLERGY CLIN IMMUN, V127, P1319, DOI 10.1016/j.jaci.2011.03.028; Koehne G, 2015, BIOL BLOOD MARROW TR, V21, P1663, DOI 10.1016/j.bbmt.2015.05.015; Kohn DB, 2014, HEMATOL-AM SOC HEMAT, P475, DOI 10.1182/asheducation-2014.1.475; Krenger W, 2011, BLOOD, V117, P6768, DOI 10.1182/blood-2011-02-334623; Kuo CY, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0615-8; Kwan A, 2015, CLIN IMMUNOL, V158, P29, DOI 10.1016/j.clim.2015.02.015; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Li B, 2011, CLIN IMMUNOL, V140, P244, DOI 10.1016/j.clim.2011.04.004; Lin M, 2009, J CLIN IMMUNOL, V29, P231, DOI 10.1007/s10875-008-9250-z; Long-Boyle JR, 2015, THER DRUG MONIT, V37, P236, DOI 10.1097/FTD.0000000000000131; Marciano BE, 2015, CLIN INFECT DIS, V60, P1176, DOI 10.1093/cid/ciu1154; Markert ML, 2010, CLIN IMMUNOL, V135, P236, DOI 10.1016/j.clim.2010.02.007; Matthews AJ, 2014, ADV IMMUNOL, V122, P1, DOI 10.1016/B978-0-12-800267-4.00001-8; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Saglio F, 2014, CYTOTHERAPY, V16, P149, DOI 10.1016/j.jcyt.2013.11.010; Savic RM, 2013, BIOL BLOOD MARROW TR, V19, P1608, DOI 10.1016/j.bbmt.2013.08.014; Shah AJ, 2008, J PEDIAT HEMATOL ONC, V30, P411, DOI 10.1097/MPH.0b013e318168e750; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Slatter MA, 2015, BONE MARROW TRANSPL, V50, P1536, DOI 10.1038/bmt.2015.171; Slatter MA, 2011, BLOOD, V117, P4367, DOI 10.1182/blood-2010-10-312082; Smigiel KS, 2014, IMMUNOL REV, V259, P40, DOI 10.1111/imr.12170; Straathof KC, 2009, LANCET, V374, P912, DOI 10.1016/S0140-6736(09)60945-4; Sullivan KE, 2014, J CLIN IMMUNOL, V34, P428, DOI 10.1007/s10875-014-0028-1; Vuong BQ, 2013, NAT IMMUNOL, V14, P1183, DOI 10.1038/ni.2732; Wehr C, 2015, J ALLERGY CLIN IMMUN, V135, P988, DOI 10.1016/j.jaci.2014.11.029; Williams DA, 2014, STEM CELL TRANSL MED, V3, P636, DOI 10.5966/sctm.2013-0206; Worth AJJ, 2015, EXPERT REV CLIN IMMU, V11, P1015, DOI 10.1586/1744666X.2015.1062366	57	26	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					375	385		10.1016/j.jaci.2016.01.051	http://dx.doi.org/10.1016/j.jaci.2016.01.051			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27262745	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000380835800006
J	Mendola, P; Wallace, M; Hwang, BS; Liu, DP; Robledo, C; Mannisto, T; Sundaram, R; Sherman, S; Ying, Q; Grantz, KL				Mendola, Pauline; Wallace, Maeve; Hwang, Beom Seuk; Liu, Danping; Robledo, Candace; Mannisto, Tuija; Sundaram, Rajeshwari; Sherman, Seth; Ying, Qi; Grantz, Katherine L.			Preterm birth and air pollution: Critical windows of exposure for women with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; pregnancy; preterm birth; air pollution	PREGNANCY OUTCOMES; PARTICULATE MATTER; CHILDREN BORN; PARTICLES; RISK; PRECONCEPTION; PENNSYLVANIA; POLLUTANTS; CALIFORNIA; GESTATION	Ambient air pollutants may increase preterm birth (PTB) risk, but critical exposure windows are uncertain. The interaction of asthma and pollutant exposure is rarely studied. Objective: We sought to assess the interaction of maternal asthma and air pollutant exposures in relation to PTB risk. Methods: Electronic medical records for 223,502 US deliveries were linked with modified Community Multiscale Air Quality model outputs. Logistic regression with generalized estimating equations estimated the odds ratio and 95% CIs for PTB on the basis of the interaction of maternal asthma and particulate matter with aerodynamic diameter of less than 2.5 microns and particulate matter with aerodynamic diameter of less than 10 microns, ozone (O-3), nitrogen oxides (NOx), sulfur dioxide (SO2), and carbon monoxide (CO) per interquartile range. For each gestational week 23 to 36, exposures among women who delivered were compared with those remaining pregnant. Three-month preconception, whole pregnancy, weeks 1 to 28, and the last 6 weeks of gestation averages were also evaluated. Results: On assessing PTB by gestational week, we found that significant asthma interactions were sporadic before 30 weeks but more common during weeks 34 to 36, with higher risk among mothers with asthma for NOx, CO, and SO2 exposure and an inverse association with O-3 in week 34. Odds of PTB were significantly higher among women with asthma for CO and NOx exposure preconception and early in pregnancy. In the last 6 weeks of pregnancy, PTB risk associated with particulate matter with aerodynamic diameter of less than 10 microns was higher among women with asthma. Conclusions: Mothers with asthma may experience a higher risk for PTB after exposure to traffic-related pollutants such as CO and NOx, particularly for exposures 3-months preconception and in the early weeks of pregnancy.	[Mendola, Pauline; Wallace, Maeve; Hwang, Beom Seuk; Liu, Danping; Sundaram, Rajeshwari; Grantz, Katherine L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, 6100 Execut Blvd,Rm 7B03F, Rockville, MD 20852 USA; [Robledo, Candace] Univ North Texas, Hlth Sci Ctr, Dept Behav & Community Hlth, Ft Worth, TX USA; [Mannisto, Tuija] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Oulu, Finland; [Mannisto, Tuija] Northern Finland Lab Ctr Nordlab, Oulu, Finland; [Mannisto, Tuija] Univ Oulu, Dept Clin Chem, Oulu, Finland; [Sherman, Seth] Emmes Corp, Rockville, MD USA; [Ying, Qi] Texas A&M Univ, Zachary Dept Civil Engn, College Stn, TX USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of North Texas System; University of North Texas Denton; Finland National Institute for Health & Welfare; University of Oulu; Emmes Corporation; Texas A&M University System; Texas A&M University College Station	Mendola, P (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, 6100 Execut Blvd,Rm 7B03F, Rockville, MD 20852 USA.	pauline.mendola@nih.gov	Ying, Qi/D-1985-2012	Ying, Qi/0000-0002-4560-433X; Grantz, Katherine/0000-0003-0276-8534; Sundaram, Rajeshwari/0000-0002-6918-5002; Mannisto, Tuija/0000-0002-6382-9153; Robledo, Candace A./0000-0002-1927-2335; Sherman, Seth/0000-0003-3667-9898; Liu, Danping/0000-0001-5483-6303; Mendola, Pauline/0000-0001-5330-2844	Intramural Research Program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Air Quality and Reproductive Health Study [HHSN275200800002I, HHSN27500008];  [HHSN267200603425C]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008794, ZIAHD008952, ZIAHD008953, ZIAHD008923] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Air Quality and Reproductive Health Study; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This research was supported by the Intramural Research Program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), including funding for the Consortium on Safe Labor (Contract No. HHSN267200603425C) and the Air Quality and Reproductive Health Study (Contract No. HHSN275200800002I, Task Order No. HHSN27500008). This article has been cleared for publication by the NICHD, but the funding source had no role in the design, analysis, interpretation, or writing of the manuscript. Disclosure of potential conflict of interest: T. Mannisto has received grants from Laboratoriolaaketieteen edistamissaatio and Paulo Foundation.	Akinbami Lara J, 2012, NCHS Data Brief, P1; Al-Gubory KH, 2010, INT J BIOCHEM CELL B, V42, P1634, DOI 10.1016/j.biocel.2010.06.001; Ancel PY, 2015, JAMA PEDIATR, V169, P230, DOI 10.1001/jamapediatrics.2014.3351; Ballester F, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-6; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bobak M, 2000, ENVIRON HEALTH PERSP, V108, P173, DOI 10.2307/3454517; Byun D, 2006, APPL MECH REV, V59, P51, DOI 10.1115/1.2128636; Chang HH, 2015, BIOSTATISTICS, V16, P509, DOI 10.1093/biostatistics/kxu060; Chen G, 2014, SCI TOTAL ENVIRON, V485, P563, DOI 10.1016/j.scitotenv.2014.03.107; Darrow LA, 2009, EPIDEMIOLOGY, V20, P689, DOI 10.1097/EDE.0b013e3181a7128f; Ferguson KK, 2013, J TOXICOL ENV HEAL B, V16, P69, DOI 10.1080/10937404.2013.775048; Gehring U, 2011, OCCUP ENVIRON MED, V68, P36, DOI 10.1136/oem.2009.053132; Gehring U, 2011, ENVIRON RES, V111, P125, DOI 10.1016/j.envres.2010.10.004; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Huang YCT, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-33; IHME, 2020, GBD COMP VIZ HUB; Lepeule J, 2012, ENVIRON HEALTH PERSP, V120, P965, DOI 10.1289/ehp.1104660; Liu SL, 2003, ENVIRON HEALTH PERSP, V111, P1773, DOI 10.1289/ehp.6251; Llop S, 2010, ENVIRON RES, V110, P778, DOI 10.1016/j.envres.2010.09.009; Mannucci PM, 2015, INTERN EMERG MED, V10, P657, DOI 10.1007/s11739-015-1276-7; Maroziene Ligita, 2002, Environ Health, V1, P6, DOI 10.1186/1476-069X-1-6; Martinelli N, 2013, EUR J INTERN MED, V24, P295, DOI 10.1016/j.ejim.2013.04.001; Mendola P, 2014, J ALLERGY CLIN IMMUN, V133, P85, DOI 10.1016/j.jaci.2013.06.012; Mendola P, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.11.007; Murphy VE, 2011, BJOG-INT J OBSTET GY, V118, P1314, DOI 10.1111/j.1471-0528.2011.03055.x; Nieuwenhuijsen MJ, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-6; Olsson D, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001955; Rappazzo KM, 2014, ENVIRON HEALTH PERSP, V122, P992, DOI 10.1289/ehp.1307456; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Ritz B, 2007, AM J EPIDEMIOL, V166, P1045, DOI 10.1093/aje/kwm181; Robledo CA, 2015, ENVIRON RES, V137, P316, DOI 10.1016/j.envres.2014.12.020; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Sagiv SK, 2005, ENVIRON HEALTH PERSP, V113, P602, DOI 10.1289/ehp.7646; Sapkota A, 2012, AIR QUAL ATMOS HLTH, V5, P369, DOI 10.1007/s11869-010-0106-3; Shah PS, 2011, ENVIRON INT, V37, P498, DOI 10.1016/j.envint.2010.10.009; Slama R, 2008, ENVIRON HEALTH PERSP, V116, P791, DOI 10.1289/ehp.11074; Stieb DM, 2012, ENVIRON RES, V117, P100, DOI 10.1016/j.envres.2012.05.007; The Dartmouth Institute for Health Policy and Clinical Practice, DARTMOUTH ATLAS HLTH; Woodruff TJ, 2009, ENVIRON RES, V109, P311, DOI 10.1016/j.envres.2008.12.012; Xu XP, 1995, ARCH ENVIRON HEALTH, V50, P407, DOI 10.1080/00039896.1995.9935976; Zhang J, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.058; Zhu YY, 2015, ENVIRON RES, V140, P714, DOI 10.1016/j.envres.2015.06.002	42	26	27	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					432	+		10.1016/j.jaci.2015.12.1309	http://dx.doi.org/10.1016/j.jaci.2015.12.1309			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	26944405	Bronze, Green Accepted, Green Submitted			2022-12-18	WOS:000380835800013
J	de Wit, J; Al-Mossawi, MH; Huhn, MH; Arancibia-Carcamo, CV; Doig, K; Kendrick, B; Gundle, R; Taylor, P; Mcclanahan, T; Murphy, E; Zhang, HJ; Barr, K; Miller, JR; Hu, X; Aicher, TD; Morgan, RW; Glick, GD; Zaller, D; Correll, C; Powrie, F; Bowness, P				de Wit, Jelle; Al-Mossawi, M. Hussein; Huehn, Michael H.; Arancibia-Carcamo, Carolina V.; Doig, Karen; Kendrick, Benjamin; Gundle, Roger; Taylor, Peter; Mcclanahan, Terri; Murphy, Erin; Zhang, Hongjun; Barr, Ken; Miller, J. Richard; Hu, Xiao; Aicher, Thomas D.; Morgan, Rodney W.; Glick, Gary D.; Zaller, Dennis; Correll, Craig; Powrie, Fiona; Bowness, Paul			ROR gamma t inhibitors suppress T(H)17 responses in inflammatory arthritis and inflammatory bowel disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXPRESSION; RECEPTOR; CELLS; DIFFERENTIATION		[de Wit, Jelle; Al-Mossawi, M. Hussein; Doig, Karen; Kendrick, Benjamin; Gundle, Roger; Bowness, Paul] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Huehn, Michael H.; Arancibia-Carcamo, Carolina V.; Powrie, Fiona] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Translat Gastroenterol Unit,Expt Med Div, Oxford OX3 9DU, England; [Taylor, Peter; Bowness, Paul] Univ Oxford, Nuffield Orthopaed Ctr, Natl Inst Hlth Res, Musculoskeletal Biomed Res Unit, Oxford, England; [Mcclanahan, Terri; Murphy, Erin] Merck Res Labs, Palo Alto, CA USA; [Zhang, Hongjun; Barr, Ken; Miller, J. Richard; Hu, Xiao; Zaller, Dennis; Correll, Craig] Merck Res Labs, Boston, MA USA; [Aicher, Thomas D.; Morgan, Rodney W.] Lycera Corp, Ann Arbor, MI USA; [Glick, Gary D.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; [Powrie, Fiona] Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England	University of Oxford; University of Oxford; Nuffield Orthopaedic Centre; University of Oxford; Merck & Company; Merck & Company; University of Michigan System; University of Michigan; University of Oxford	de Wit, J (corresponding author), Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England.	dewitjelle@gmail.com	Bowness, Paul/AAH-2484-2019; de Wit, Jelle/W-7035-2019	de Wit, Jelle/0000-0003-2444-6050; Al-Mossawi, Hussein/0000-0002-2312-3754; bowness, paul/0000-0003-4597-0484	Medical Research Council [MR/L022699/1] Funding Source: Medline; Wellcome Trust [095688] Funding Source: Medline; MRC [MR/L022699/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Antunes MB, 2007, BIOTECHNIQUES, V43, P195, DOI 10.2144/000112531; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Fransson M, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-17; Genovese MC, 2013, ANN RHEUM DIS, V72, P863, DOI 10.1136/annrheumdis-2012-201601; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Huh JR, 2011, NATURE, V472, P486, DOI 10.1038/nature09978; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Lees CW, 2011, GUT, V60, P1739, DOI 10.1136/gut.2009.199679; Mease PJ, 2014, NEW ENGL J MED, V370, P2295, DOI 10.1056/NEJMoa1315231; Rydberg C, 2009, IMMUNOLOGY, V128, pe600, DOI 10.1111/j.1365-2567.2008.03041.x; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Skepner J, 2014, J IMMUNOL, V192, P2564, DOI 10.4049/jimmunol.1302190; Xiao S, 2014, IMMUNITY, V40, P477, DOI 10.1016/j.immuni.2014.04.004	14	26	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					960	963		10.1016/j.jaci.2015.09.048	http://dx.doi.org/10.1016/j.jaci.2015.09.048			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26611672	Bronze, Green Submitted			2022-12-18	WOS:000371897500051
J	Campana, R; Moritz, K; Marth, K; Neubauer, A; Huber, H; Henning, R; Blatt, K; Hoermann, G; Brodie, TM; Kaider, A; Valent, P; Sallusto, F; Wohrl, S; Valenta, R				Campana, Raffaela; Moritz, Katharina; Marth, Katharina; Neubauer, Angela; Huber, Hans; Henning, Rainer; Blatt, Katharina; Hoermann, Gregor; Brodie, Tess M.; Kaider, Alexandra; Valent, Peter; Sallusto, Federica; Woehrl, Stefan; Valenta, Rudolf			Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen; recombinant hypoallergens; atopy patch testing; late-phase reaction; T-cell proliferation; cutaneous lymphocyte antigen; CCR4; birch pollen allergy; rBet v 1; rBet v 1 fragments; specific immunotherapy	ALLERGEN-SPECIFIC IMMUNOTHERAPY; BIRCH POLLEN ALLERGEN; SKIN; IGE; LYMPHOCYTES; EXPRESSION; DERMATITIS; OMALIZUMAB; RHINITIS; EPITOPE	Background: Late allergic reactions are common in the course of allergen-specific immunotherapy and even occur with allergy vaccines with reduced IgE reactivity. Objective: We sought to study atopy patch test (APT) reactions and T-cell responses to the recombinant birch pollen allergen Bet v 1 and recombinant hypoallergenic T-cell epitope-containing Bet v 1 fragments in patients with birch pollen allergy with and without atopic dermatitis (AD). Methods: A clinical study was conducted in 15 patients with birch pollen allergy with AD (group 1), 5 patients with birch pollen allergy without AD (group 2), 5 allergic patients without birch pollen allergy (group 3), and 5 nonallergic subjects (group 4) by performing skin prick tests and APTs with rBet v 1 and hypoallergenic rBet v 1 fragments. T-cell, cutaneous lymphocyte antigen (CLA) 1 and CCR4 1 T-cell and cytokine responses were studied by thymidine uptake, carboxyfluorescein diacetate succinimidyl ester staining, and Luminex technology, respectively. Results: rBet v 1 and hypoallergenic rBet v 1 fragments induced APT reactions in not only most of the patients with birch pollen allergy with AD (11/15) but also in most of those without AD (4/5). Patients with birch pollen allergy with AD had higher Bet v 1-specific proliferation of CLA 1 and CCR4 1 T cells compared with patients with birch pollen allergy without AD. There were no differences in Bet v 1-specific CLA 1 and CCR4 1 proliferation and cytokine secretion in patients with and without APT reactions. Conclusion: Hypoallergenic rBet v 1 fragments induce T cell-dependent late reactions not only in patients with birch pollen allergy with AD but also in those without AD, which can be determined based on APT results but not based on in vitro parameters.	[Campana, Raffaela; Marth, Katharina; Valenta, Rudolf] Med Univ Vienna, Vienna Gen Hosp AKH, Ctr Physiol & Pathophysiol, Dept Pathophysiol,Div Immunopathol, A-1090 Vienna, Austria; [Moritz, Katharina; Woehrl, Stefan] Med Univ Vienna, Vienna Gen Hosp AKH, Dept Dermatol, DIAID, A-1090 Vienna, Austria; [Blatt, Katharina; Valent, Peter] Med Univ Vienna, Vienna Gen Hosp AKH, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria; [Hoermann, Gregor] Med Univ Vienna, Vienna Gen Hosp AKH, Dept Lab Med, A-1090 Vienna, Austria; [Neubauer, Angela; Huber, Hans; Henning, Rainer] Vienna Competence Ctr, Biomay AG, Vienna, Austria; [Brodie, Tess M.; Sallusto, Federica] Univ Italian Switzerland, Inst Res Biomed, Cellular Immunol Lab, Bellinzona, Switzerland; [Kaider, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Sect Clin Biometr, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Universita della Svizzera Italiana; Medical University of Vienna	Valenta, R (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol,Gen Hosp Vie, AKH 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Wöhrl, Stefan/B-6954-2013; Gamperl, Susi/V-2715-2019; Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Hoermann, Gregor/B-8832-2016	Wöhrl, Stefan/0000-0002-6324-0007; Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365; Campana, Raffaela/0000-0001-9309-9908; Hoermann, Gregor/0000-0002-7374-4380	Austrian Science Fund (FWF) [F4605, F4611]; European Research Council [323183]; Biomay AG, Vienna, Austria	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); European Research Council(European Research Council (ERC)European Commission); Biomay AG, Vienna, Austria	Supported by grants F4605 and F4611 of the Austrian Science Fund (FWF), by grant 323183 from the European Research Council, and by a research grant from Biomay AG, Vienna, Austria.	Bohle B, 2006, J ALLERGY CLIN IMMUN, V118, P242, DOI 10.1016/j.jaci.2006.03.011; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; Campana R, 2008, J ALLERGY CLIN IMMUN, V121, P528, DOI 10.1016/j.jaci.2007.09.014; Campana R, 2010, J ALLERGY CLIN IMMUN, V126, P1024, DOI 10.1016/j.jaci.2010.05.023; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Cosmi L, 2011, ALLERGY, V66, P989, DOI 10.1111/j.1398-9995.2011.02576.x; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Focke-Tejkl M, 2015, J ALLERGY CLIN IMMUN, V135, P1207, DOI 10.1016/j.jaci.2014.09.012; Fuiano N, 2010, EUR J PEDIATR, V169, P819, DOI 10.1007/s00431-009-1118-6; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; Hennino A, 2007, J IMMUNOL, V178, P5571, DOI 10.4049/jimmunol.178.9.5571; Hennino A, 2011, J ALLERGY CLIN IMMUN, V127, P1064, DOI 10.1016/j.jaci.2010.11.022; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Murphy DM, 2010, CHEST, V137, P1417, DOI 10.1378/chest.09-1895; Nakatani T, 2001, J ALLERGY CLIN IMMUN, V107, P353, DOI 10.1067/mai.2001.112601; Niederberger V, 2015, J ALLERGY CLIN IMMUN, V136, P1101, DOI 10.1016/j.jaci.2015.03.034; Novak N, 2004, CURR ALLERGY ASTHM R, V4, P263, DOI 10.1007/s11882-004-0069-2; PICKER LJ, 1990, AM J PATHOL, V136, P1053; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Resch Y, 2011, CLIN EXP ALLERGY, V41, P1468, DOI 10.1111/j.1365-2222.2011.03798.x; Spertini F, 2014, J ALLERGY CLIN IMMUN, V134, P239, DOI 10.1016/j.jaci.2014.04.001; Turjanmaa K, 2006, ALLERGY, V61, P1377, DOI 10.1111/j.1398-9995.2006.01136.x; van Neerven RJ, 2006, INT ARCH ALLERGY IMM, V141, P119, DOI 10.1159/000094714; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2011, VACCINE, V29, P2140, DOI 10.1016/j.vaccine.2010.12.080; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Winther L, 2000, ALLERGY, V55, P827, DOI 10.1034/j.1398-9995.2000.00368.x; Winther L, 2006, CLIN EXP ALLERGY, V36, P254, DOI 10.1111/j.1365-2222.2006.02340.x	36	26	27	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					601	+		10.1016/j.jaci.2015.08.042	http://dx.doi.org/10.1016/j.jaci.2015.08.042			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26518092	Green Accepted, hybrid			2022-12-18	WOS:000369235500031
J	Frugoni, F; Dobbs, K; Felgentreff, K; Aldhekri, H; Al Saud, BK; Arnaout, R; Ali, AA; Abhyankar, A; Alroqi, F; Giliani, S; Ojeda, MM; Tsitsikov, E; Pai, SY; Casanova, JL; Notarangelo, LD; Manis, JP				Frugoni, Francesco; Dobbs, Kerry; Felgentreff, Kerstin; Aldhekri, Hasan; Al Saud, Bandar K.; Arnaout, Rand; Ali, Afshan Ashraf; Abhyankar, Avinash; Alroqi, Fayhan; Giliani, Silvia; Ojeda, Mayra Martinez; Tsitsikov, Erdyni; Pai, Sung-Yun; Casanova, Jean Laurent; Notarangelo, Luigi D.; Manis, John P.			A novel mutation in the POLE2 gene causing combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							REPAIR; EPSILON		[Frugoni, Francesco; Dobbs, Kerry; Felgentreff, Kerstin; Alroqi, Fayhan; Notarangelo, Luigi D.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Aldhekri, Hasan; Al Saud, Bandar K.; Arnaout, Rand] King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; [Ali, Afshan Ashraf] King Faisal Specialist Hosp & Res Ctr, Dept Pediat Hematol Oncol, Riyadh 11211, Saudi Arabia; [Abhyankar, Avinash] New York Genome Ctr, New York, NY USA; [Giliani, Silvia] Univ Brescia, Angelo Nocivelli Inst Mol Med, Brescia, Italy; [Ojeda, Mayra Martinez] Boston Childrens Hosp, Dept Genet, Boston, MA USA; [Tsitsikov, Erdyni; Manis, John P.] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA; [Pai, Sung-Yun] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA USA; [Casanova, Jean Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA; [Casanova, Jean Laurent] Univ Paris 05, Imagine Inst, Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Casanova, Jean Laurent] Howard Hughes Med Inst, New York, NY USA; [Casanova, Jean Laurent] Hop Necker Enfants Malad, Pediat Hematol Immunol, Paris, France; [Notarangelo, Luigi D.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA; [Manis, John P.] Boston Childrens Hosp, Joint Program Transfus Med, Dept Lab Med, Boston, MA USA; [Manis, John P.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; University of Brescia; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Notarangelo, LD (corresponding author), Boston Childrens Hosp, Div Immunol, Boston, MA USA.; Manis, JP (corresponding author), Boston Childrens Hosp, Dept Lab Med, Boston, MA USA.; Notarangelo, LD (corresponding author), Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.; Manis, JP (corresponding author), Boston Childrens Hosp, Joint Program Transfus Med, Dept Lab Med, Boston, MA USA.; Manis, JP (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.	luigi.notarangelo@childrens.harvard.edu; manis@enders.tch.harvard.edu	Notarangelo, Luigi D/F-9718-2016; Pai, Sung-Yun/AAH-7762-2019; Casanova, Jean-Laurent/I-3418-2017; Giliani, Silvia/AAX-8843-2020	Notarangelo, Luigi D/0000-0002-8335-0262; Pai, Sung-Yun/0000-0002-0158-8147; Giliani, Silvia/0000-0001-8137-4642; Casanova, Jean-Laurent/0000-0002-7782-4169; Frugoni, Francesco/0000-0002-1769-8121; Al-Dhekri, Hasan/0000-0003-2277-5782; ARNAOUT, RAND/0000-0003-3951-5880; Dobbs, Kerry/0000-0002-3432-3137	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100887] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI100887, R21AI87355, 5R01AI100887] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agbor AA, 2013, DNA REPAIR, V12, P954, DOI 10.1016/j.dnarep.2013.08.012; Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Bermudez VP, 2011, J BIOL CHEM, V286, P28963, DOI 10.1074/jbc.M111.256289; Callen E, 2007, ONCOGENE, V26, P7759, DOI 10.1038/sj.onc.1210873; Durandy A, 2013, NAT REV IMMUNOL, V13, P519, DOI 10.1038/nri3466; Helmink BA, 2012, ANNU REV IMMUNOL, V30, P175, DOI 10.1146/annurev-immunol-030409-101320; Kunkel TA, 2011, CURR OPIN CHEM BIOL, V15, P620, DOI 10.1016/j.cbpa.2011.07.025; Loeb LA, 2008, NAT REV GENET, V9, P594, DOI 10.1038/nrg2345; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Schmid JP, 2012, J EXP MED, V209, P2323, DOI 10.1084/jem.20121303	10	26	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					635	+		10.1016/j.jaci.2015.06.049	http://dx.doi.org/10.1016/j.jaci.2015.06.049			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26365386	Green Accepted			2022-12-18	WOS:000369235500042
J	Verhoef, PA; Constantinides, MG; McDonald, BD; Urban, JF; Sperling, AI; Bendelac, A				Verhoef, Philip A.; Constantinides, Michael G.; McDonald, Benjamin D.; Urban, Joseph F., Jr.; Sperling, Anne I.; Bendelac, Albert			Intrinsic functional defects of type 2 innate lymphoid cells impair innate allergic inflammation in promyelocytic leukemia zinc finger (PLZF)-deficient mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic mechanisms; innate lymphoid cells; mouse models	NATURAL HELPER-CELLS; T-CELLS; IMMUNE-RESPONSE; HOMEOSTASIS; INFECTION; ASTHMA	Background: The transcription factor promyelocytic leukemia zinc finger (PLZF) is transiently expressed during development of type 2 innate lymphoid cells (ILC2s) but is not present at the mature stage. We hypothesized that PLZF-deficient ILC2s have functional defects in the innate allergic response and represent a tool for studying innate immunity in a mouse with a functional adaptive immune response. Objective: We determined the consequences of PLZF deficiency on ILC2 function in response to innate and adaptive immune stimuli by using PLZF(-/-) mice and mixed wild-type:PLZF(-/-) bone marrow chimeras. Methods: PLZF(-/-) mice, wild-type littermates, or mixed bone marrow chimeras were treated with the protease allergen papain or the cytokines IL-25 and IL-33 or infected with the helminth Nippostrongylus brasiliensis to induce innate type 2 allergic responses. Mice were sensitized with intraperitoneal ovalbumin-alum, followed by intranasal challenge with ovalbumin alone, to induce adaptive T(H)2 responses. Lungs were analyzed for immune cell subsets, and alveolar lavage fluid was analyzed for ILC2-derived cytokines. In addition, ILC2s were stimulated ex vivo for their capacity to release type 2 cytokines. Results: PLZF-deficient lung ILC2s exhibit a cell-intrinsic defect in the secretion of IL-5 and IL-13 in response to innate stimuli, resulting in defective recruitment of eosinophils and goblet cell hyperplasia. In contrast, the adaptive allergic inflammatory response to ovalbumin and alum was unimpaired. Conclusions: PLZF expression at the innate lymphoid cell precursor stage has a long-range effect on the functional properties of mature ILC2s and highlights the importance of these cells for innate allergic responses in otherwise immunocompetent mice.	[Verhoef, Philip A.; Constantinides, Michael G.; McDonald, Benjamin D.; Sperling, Anne I.; Bendelac, Albert] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; [Verhoef, Philip A.; Sperling, Anne I.] Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637 USA; [Verhoef, Philip A.] Univ Chicago, Dept Pediat, Sect Pediat Crit Care, Chicago, IL 60637 USA; [Bendelac, Albert] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Urban, Joseph F., Jr.] ARS, Diet Genom & Immunol Lab, Beltsville Human Nutr Res Ctr, USDA, Beltsville, MD USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; United States Department of Agriculture (USDA)	Bendelac, A (corresponding author), Univ Chicago, Dept Pathol, Comm Immunol, 929 57th St,Gordon Ctr Integrat Sci W506, Chicago, IL 60637 USA.	abendela@bsd.uchicago.edu	Sperling, Anne/ACZ-2351-2022	Sperling, Anne I./0000-0002-4265-9212; Constantinides, Michael/0000-0003-4770-7751; Urban, Joseph/0000-0002-1590-8869	National Institutes of Health [T32 HL007605, R01HL118092, R01AI038339, AI108643]; University of Chicago Digestive Research Core Center Grant [P30DK42086]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007605, K12HL119995, R01HL118092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI108643, R01AI038339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Chicago Digestive Research Core Center Grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health grants T32 HL007605 (to P.A.V.) and R01HL118092, R01AI038339, and AI108643 (A.B.) and the University of Chicago Digestive Research Core Center Grant P30DK42086.	Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369; Caceres AI, 2009, P NATL ACAD SCI USA, V106, P9099, DOI 10.1073/pnas.0900591106; Camberis Mali, 2003, Curr Protoc Immunol, VChapter 19, DOI 10.1002/0471142735.im1912s55; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Constantinides MG, 2014, NATURE, V508, P397, DOI 10.1038/nature13047; Constantinides MG, 2013, CURR OPIN IMMUNOL, V25, P161, DOI 10.1016/j.coi.2013.01.003; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Fuchs A, 2013, CURR OPIN GASTROEN, V29, P581, DOI 10.1097/MOG.0b013e328365d339; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hung LY, 2013, P NATL ACAD SCI USA, V110, P282, DOI 10.1073/pnas.1206587110; Maazi H, 2015, IMMUNITY, V42, P538, DOI 10.1016/j.immuni.2015.02.007; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Savage AK, 2008, IMMUNITY, V29, P391, DOI 10.1016/j.immuni.2008.07.011; Scanlon ST, 2012, CURR OPIN IMMUNOL, V24, P707, DOI 10.1016/j.coi.2012.08.009; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Zeissig S, 2013, CURR OPIN IMMUNOL, V25, P690, DOI 10.1016/j.coi.2013.09.012	24	26	26	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					591	+		10.1016/j.jaci.2015.07.050	http://dx.doi.org/10.1016/j.jaci.2015.07.050			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26602165	Bronze, Green Accepted			2022-12-18	WOS:000369235500030
J	Munoz-Cano, R; Pascal, M; Bartra, J; Picado, C; Valero, A; Kim, DK; Brooks, S; Ombrello, M; Metcalfe, DD; Rivera, J; Olivera, A				Munoz-Cano, Rosa; Pascal, Mariona; Bartra, Joan; Picado, Cesar; Valero, Antonio; Kim, Do-Kyun; Brooks, Stephen; Ombrello, Michael; Metcalfe, Dean D.; Rivera, Juan; Olivera, Ana			Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; food allergy; lipid transfer protein syndrome; nonsteroidal anti-inflammatory drugs; transcriptome analysis	LIPID TRANSFER PROTEINS; FC-GAMMA-RI; AFFINITY IGG RECEPTOR; ADENOSINE RECEPTORS; BARRIER FUNCTION; MOUSE MODEL; MAST-CELLS; ASPIRIN; RESPONSES; IDENTIFICATION	Background: Lipid transfer protein (LTP), an abundant protein in fruits, vegetables, and nuts, is a common food allergen in Mediterranean areas causing diverse allergic reactions. Approximately 40% of food-related anaphylaxis induced by LTPs requires nonsteroidal anti-inflammatory drugs (NSAIDs) as a triggering cofactor. Objective: We sought to better understand the determinants of NSAID-dependent and NSAID-independent LTP-induced anaphylaxis (LTP-A). Methods: Selection of patients was based on a proved clinical history of NSAID-dependent or NSAID-independent anaphylaxis to LTPs, positive skin prick test response to LTPs, and serum LTP IgE. Whole-transcriptome (RNA sequencing) analysis of blood cells from 14 patients with NSAID-related LTP-A (NSAID-LTP-A), 7 patients with LTP-A, and 13 healthy control subjects was performed to identify distinct gene expression signatures. Results: Expression of genes regulating gastrointestinal epithelial renewal was altered in both patient sets, particularly in those with LTP-A, who also presented with gene expression profiles characteristic of an inflammatory syndrome. These included altered B-cell pathways, increased neutrophil activation markers, and increased reactive oxygen species levels. Increased expression of the IgG receptor (CD64) in patients with LTP-A was mirrored by the presence of LTP-specific IgG(1) and IgG(3). Conversely, patients with NSAID-LTP-A were characterized by reduced expression of IFN-gamma-regulated genes and IFN-gamma levels, as well as upregulated expression of adenosine receptor 3 (ADORA3) and genes related to adenosine metabolism. Conclusions: Gene ontology analysis suggests disturbances in gut epithelial homeostasis in both groups with LTP-A, with potential integrity breaches in patients with LTP-A that might explain their distinct inflammatory signatures. Differential regulation in patients with LTP-A and those with NSAID-LTP-A of the IFN-g pathway, IgG receptors, and ADORA3 might provide the pathogenic basis of their distinct responses.	[Munoz-Cano, Rosa; Kim, Do-Kyun; Metcalfe, Dean D.; Rivera, Juan] NIAID, Mast Cell Biol Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Munoz-Cano, Rosa; Bartra, Joan; Picado, Cesar; Valero, Antonio] Univ Barcelona, Unitat Al Lergia, Serv Neumol & Al Lergia Resp, Hosp Clin, Barcelona, Spain; [Munoz-Cano, Rosa; Pascal, Mariona; Bartra, Joan; Picado, Cesar; Valero, Antonio] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Pascal, Mariona] Univ Barcelona, Hosp Clin, CDB, Serv Immunol, Barcelona, Spain; [Pascal, Mariona; Bartra, Joan] Carlos III Hlth Inst, Spanish Res Network Adverse React Allergens & Dru, Madrid, Spain; [Rivera, Juan] NIAMSD, Immunogenet Mol Lab, Bethesda, MD 20892 USA; [Brooks, Stephen; Ombrello, Michael] NIAMSD, Off Sci & Technol, Bethesda, MD 20892 USA; [Brooks, Stephen; Ombrello, Michael] NIAMSD, Translat Genet & Genom Unit, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Munoz-Cano, R (corresponding author), NIAID, Mast Cell Biol Sect, Lab Allerg Dis, NIH, Bldg 10,Rm 11C205,10 Ctr Dr, Bethesda, MD 20892 USA.	rmunoz@clinic.ub.es	Muñoz, Rosa/AAC-7288-2020; Pascal, Mariona/HCG-9380-2022; /AAL-7347-2021; /AFX-9519-2022; Cano, Rosa Munoz/K-9413-2014	Muñoz, Rosa/0000-0001-8566-8285; Cano, Rosa Munoz/0000-0001-8566-8285; Ombrello, Michael/0000-0003-3322-4089	Division of Intramural Research Program within the National Institute of Allergy and Infectious Diseases; Ministerio de Economia y Competitividad-Instituto de Salud Carlos III, Spain [FIS-PI11/01326]; "Rio Hortega'' Fellowship, Ministerio de Economia y Competitividad, Instituto de Salud Carlos III, Spain; Division of Intramural Research Program within National Institute of Arthritis and Musculoskeletal and Skin Diseased, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000965, ZIAAI001206, ZIAAI001092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041198, ZIHAR041173] Funding Source: NIH RePORTER	Division of Intramural Research Program within the National Institute of Allergy and Infectious Diseases; Ministerio de Economia y Competitividad-Instituto de Salud Carlos III, Spain; "Rio Hortega'' Fellowship, Ministerio de Economia y Competitividad, Instituto de Salud Carlos III, Spain; Division of Intramural Research Program within National Institute of Arthritis and Musculoskeletal and Skin Diseased, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Division of Intramural Research Programs within the National Institute of Allergy and Infectious Diseases and the National Institute of Arthritis and Musculoskeletal and Skin Diseased, National Institutes of Health and by Ministerio de Economia y Competitividad-Instituto de Salud Carlos III (FIS-PI11/01326), Spain. R.M. C. was the recipient of the "Rio Hortega'' Fellowship, Ministerio de Economia y Competitividad, Instituto de Salud Carlos III, Spain.	Asero R, 2002, ALLERGY, V57, P900, DOI 10.1034/j.1398-9995.2002.t01-1-23541.x; Asero R, 2009, INT ARCH ALLERGY IMM, V150, P271, DOI 10.1159/000222679; Ben-Shoshan M, 2011, ALLERGY, V66, P1, DOI 10.1111/j.1398-9995.2010.02422.x; Bol-Schoenmakers M, 2011, CLIN EXP ALLERGY, V41, P424, DOI 10.1111/j.1365-2222.2010.03594.x; Cardona V, 2012, ALLERGY, V67, P1316, DOI [10.1111/j.1398-9995.2012.02877.x, 10.1111/j.1398-9995.2012.02877.x.]; Casadevall J, 2000, THORAX, V55, P921, DOI 10.1136/thorax.55.11.921; Chaussabel D, 2015, SEMIN IMMUNOL, V27, P58, DOI 10.1016/j.smim.2015.03.002; Cianferoni A, 2001, ANN ALLERG ASTHMA IM, V87, P27, DOI 10.1016/S1081-1206(10)62318-6; Cohen S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/708746; CRONSTEIN BN, 1994, INFLAMMATION, V18, P323, DOI 10.1007/BF01534273; Diesner SC, 2012, IMMUNOL LETT, V141, P210, DOI 10.1016/j.imlet.2011.10.006; Fasano A, 2012, ANN NY ACAD SCI, V1258, P25, DOI 10.1111/j.1749-6632.2012.06538.x; Fasano A, 2011, PHYSIOL REV, V91, P151, DOI 10.1152/physrev.00003.2008; Fishman P, 2012, DRUG DISCOV TODAY, V17, P359, DOI 10.1016/j.drudis.2011.10.007; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Ioan-Facsinay A, 2002, IMMUNITY, V16, P391, DOI 10.1016/S1074-7613(02)00294-7; Jin XW, 1997, J CLIN INVEST, V100, P2849, DOI 10.1172/JCI119833; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; Kim SH, 2010, BRIT J DERMATOL, V163, P977, DOI 10.1111/j.1365-2133.2010.09983.x; Kohane IS, 2012, BIOINFORMATICS, V28, P538, DOI 10.1093/bioinformatics/btr713; Leung CT, 2014, PURINERG SIGNAL, V10, P465, DOI 10.1007/s11302-014-9409-4; Mabley J, 2003, EUR J PHARMACOL, V466, P323, DOI 10.1016/S0014-2999(03)01570-X; Mancardi DA, 2008, J CLIN INVEST, V118, P3738, DOI 10.1172/JCI36452; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; Marchi LF, 2014, INT IMMUNOPHARMACOL, V18, P228, DOI 10.1016/j.intimp.2013.12.010; Matsukura S, 2010, CLIN EXP DERMATOL, V35, P233, DOI 10.1111/j.1365-2230.2009.03709.x; Matsuo H, 2005, CLIN EXP ALLERGY, V35, P461, DOI 10.1111/j.1365-2222.2005.02213.x; MIYAHARA JT, 1965, BIOCHEM J, V97, P194, DOI 10.1042/bj0970194; Moneret-Vautrin DA, 2005, CURR ALLERGY ASTHM R, V5, P80, DOI 10.1007/s11882-005-0060-6; NEWBY AC, 1983, BIOCHEM J, V214, P317, DOI 10.1042/bj2140317; Niggemann B, 2014, ALLERGY, V69, P1582, DOI 10.1111/all.12532; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; Olivera A, 2011, ADV EXP MED BIOL, V716, P123, DOI 10.1007/978-1-4419-9533-9_8; Palacin A, 2010, INT ARCH ALLERGY IMM, V152, P178, DOI 10.1159/000265539; Pascal M, 2012, CLIN EXP ALLERGY, V42, P1529, DOI 10.1111/j.1365-2222.2012.04071.x; Pascual V, 2010, ANNU REV IMMUNOL, V28, P535, DOI 10.1146/annurev-immunol-030409-101221; Pastorello EA, 2004, MOL NUTR FOOD RES, V48, P356, DOI 10.1002/mnfr.200400047; Paul E, 2000, J ALLERGY CLIN IMMUN, V105, P844, DOI 10.1067/mai.2000.105011; Perrier C, 2010, CLIN EXP ALLERGY, V40, P153, DOI 10.1111/j.1365-2222.2009.03329.x; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Romano A, 2012, CLIN EXP ALLERGY, V42, P1643, DOI 10.1111/cea.12011; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Stone SF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101409; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; van der Poel CE, 2011, J IMMUNOL, V186, P2699, DOI 10.4049/jimmunol.1003526; Vidal C, 2007, J INVEST ALLERG CLIN, V17, P113; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x; Yu M, 2011, J CLIN INVEST, V121, P3133, DOI 10.1172/JCI43598; Zhong H, 2003, J IMMUNOL, V171, P338, DOI 10.4049/jimmunol.171.1.338	52	26	26	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					137	146		10.1016/j.jaci.2015.05.042	http://dx.doi.org/10.1016/j.jaci.2015.05.042			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26194548	Bronze, Green Accepted			2022-12-18	WOS:000367724300004
J	de Jong, K; Vonk, JM; Timens, W; Bosse, Y; Sin, DD; Hao, K; Kromhout, H; Vermeulen, R; Postma, DS; Boezen, HM				de Jong, Kim; Vonk, Judith M.; Timens, Wim; Bosse, Yohan; Sin, Don D.; Hao, Ke; Kromhout, Hans; Vermeulen, Roel; Postma, Dirkje S.; Boezen, H. Marike			Genome-wide interaction study of gene-by-occupational exposure and effects on FEV1 levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Genetics; occupational exposures; interactions; gene expression; lung function	LUNG-FUNCTION DECLINE; ASSOCIATION; POPULATION; COPD; LIFELINES; VARIANTS; HEALTH; ASTHMA; ADULTS; LOCI	Background: Chronic obstructive pulmonary disease (COPD) is a complex disease characterized by impaired lung function and airway obstruction resulting from interactions between multiple genes and multiple environmental exposures. Thus far, genome-wide association studies have largely disregarded environmental factors that might trigger the development of lung function impairment and COPD, such as occupational exposures, which are thought to contribute to 15% to 20% of the COPD prevalence. Objectives: We performed a genome-wide interaction study to identify novel susceptibility loci for occupational exposure to biological dust, mineral dust, and gases and fumes in relation to FEV1 levels. Methods: We performed an identification analysis in 12,400 subjects from the LifeLines cohort study and verified our findings in 1436 subjects from a second independent cohort, the Vlagtwedde-Vlaardingen cohort. Additionally, we assessed whether replicated single nucleotide polymorphisms (SNPs) were cis-acting expression (mRNA) quantitative trait loci in lung tissue. Results: Of the 7 replicated SNPs that interacted with one of the occupational exposures, several identified loci were plausible candidates that might be involved in biological pathways leading to lung function impairment, such as PCDH9 and GALNT13. Two of the 7 replicated SNPs were cis-acting expression quantitative trait loci associated with gene expression of PDE4D and TMEM176A in lung tissue. Conclusion: This genome-wide interaction study on occupational exposures in relation to the level of lung function identified several novel genes. Further research should determine whether the identified genes are true susceptibility loci for occupational exposures and whether these SNP-by-exposure interactions consequently contribute to the development of COPD.	[de Jong, Kim; Vonk, Judith M.; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RB Groningen, Netherlands; [de Jong, Kim; Vonk, Judith M.; Timens, Wim; Postma, Dirkje S.; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD GRIAC, NL-9700 RB Groningen, Netherlands; [Timens, Wim] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, NL-9700 RB Groningen, Netherlands; [Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, NL-9700 RB Groningen, Netherlands; [Bosse, Yohan] Univ Laval, Dept Mol Med, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Sin, Don D.] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Sin, Don D.] Univ British Columbia, Ctr Heart Lung Innovat, Vancouver, BC V5Z 1M9, Canada; [Hao, Ke] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Kromhout, Hans; Vermeulen, Roel] Univ Utrecht, Div Environm Epidemiol, IRAS, NL-3508 TC Utrecht, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; Laval University; University of British Columbia; University of British Columbia; Icahn School of Medicine at Mount Sinai; Utrecht University	Boezen, HM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	h.m.boezen@umcg.nl	Kromhout, Hans/A-9159-2008; Sin, Don/AAC-2219-2021; Timens, Wim/K-5570-2013; Vonk, Judith/K-8477-2019; Vonk, Judith M/ABA-3009-2020; Vermeulen, Roel/F-8037-2011	Kromhout, Hans/0000-0002-4233-1890; Timens, Wim/0000-0002-4146-6363; Vonk, Judith/0000-0001-7531-4547; Vonk, Judith M/0000-0001-7531-4547; Vermeulen, Roel/0000-0003-4082-8163; de Jong, Kim/0000-0002-3948-1046	Research School GUIDE, University of Groningen, University Medical Center Groningen; Dutch Ministry of Health, Welfare and Sport; Ministry of Economic Affairs, Agriculture and Innovation; European Union; Northern Netherlands Provinces (SNN); Netherlands Organisation for Scientific Research (NWO); University Medical Center Groningen (UMCG); University of Groningen; de Nierstichting (the Dutch Kidney Foundation); Diabetes Fonds (the Diabetic Foundation); Ministry of Health and Environmental Hygiene of The Netherlands; Netherlands Asthma Fund [187, 3.2.02.51]; Stichting Astma Bestrijding; BBMRI-NL; European Respiratory Society COPD research award; Fonds de recherche Quebec-Sante (FRQS); Merck Research Laboratories; province of Groningen	Research School GUIDE, University of Groningen, University Medical Center Groningen; Dutch Ministry of Health, Welfare and Sport; Ministry of Economic Affairs, Agriculture and Innovation; European Union(European Commission); Northern Netherlands Provinces (SNN); Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); University Medical Center Groningen (UMCG); University of Groningen; de Nierstichting (the Dutch Kidney Foundation); Diabetes Fonds (the Diabetic Foundation); Ministry of Health and Environmental Hygiene of The Netherlands; Netherlands Asthma Fund; Stichting Astma Bestrijding; BBMRI-NL; European Respiratory Society COPD research award; Fonds de recherche Quebec-Sante (FRQS); Merck Research Laboratories(Merck & Company); province of Groningen	K.d.J. was funded by Research School GUIDE, University of Groningen, University Medical Center Groningen. The LifeLines cohort study was supported by the Dutch Ministry of Health, Welfare and Sport; the Ministry of Economic Affairs, Agriculture and Innovation; the province of Groningen; the European Union (regional development fund); the Northern Netherlands Provinces (SNN); the Netherlands Organisation for Scientific Research (NWO); University Medical Center Groningen (UMCG); the University of Groningen; de Nierstichting (the Dutch Kidney Foundation); and the Diabetes Fonds (the Diabetic Foundation). The Vlagtwedde-Vlaardingen cohort was supported by the Ministry of Health and Environmental Hygiene of The Netherlands and Netherlands Asthma Fund grant no. 187 and Netherlands Asthma Fund grant no. 3.2.02.51, the Stichting Astma Bestrijding, BBMRI-NL, and the European Respiratory Society COPD research award 2011 (to H.M.B.). Y.B. is the recipient of a Junior 2 Research Scholar award from the Fonds de recherche Quebec-Sante (FRQS). The lung tissue database was funded by Merck Research Laboratories. The sponsors of this study had no role in the design of the current study, data collection, analysis, and interpretation, or in writing and submitting of the manuscript.	Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Barnes PJ, 2004, LANCET, V364, P564, DOI 10.1016/S0140-6736(04)16866-9; Boezen H Marike, 2009, Proc Am Thorac Soc, V6, P701, DOI 10.1513/pats.200907-058DP; Bosse Y, 2012, INT J CHRONIC OBSTR, V7, P607, DOI 10.2147/COPD.S35294; Cho MH, 2014, LANCET RESP MED, V2, P214, DOI 10.1016/S2213-2600(14)70002-5; Cho MH, 2010, NAT GENET, V42, P200, DOI 10.1038/ng.535; Condamine T, 2010, J LEUKOCYTE BIOL, V88, P507, DOI 10.1189/jlb.1109738; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Cuajungco MP, 2012, ACTA HISTOCHEM, V114, P705, DOI 10.1016/j.acthis.2011.12.006; de Jong K, 2014, OCCUP ENVIRON MED, V71, P88, DOI 10.1136/oemed-2013-101639; Freeman CM, 2009, AM J RESP CRIT CARE, V180, P1179, DOI 10.1164/rccm.200904-0552OC; Gill DJ, 2010, J CELL BIOL, V189, P843, DOI 10.1083/jcb.201003055; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hang JQ, 2005, AM J RESP CRIT CARE, V171, P165, DOI 10.1164/rccm.200407-888OC; Hansen G, 2000, P NATL ACAD SCI USA, V97, P6751, DOI 10.1073/pnas.97.12.6751; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Imboden M, 2012, J ALLERGY CLIN IMMUN, V129, P1218, DOI 10.1016/j.jaci.2012.01.074; International Labour Organization, 1990, REV INT STAND CLASS; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; Leikauf GD, 2011, AM J RESP CRIT CARE, V183, P1499, DOI 10.1164/rccm.201006-0912OC; Liao SY, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-101; Manichaikul A, 2014, AM J RESP CRIT CARE, V189, P408, DOI 10.1164/rccm.201306-1061OC; Matheson MC, 2005, THORAX, V60, P645, DOI 10.1136/thx.2004.035170; Meigs JB, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S16; Obeidat M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019382; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Plant D, 2012, PHARMACOGENOMICS J, V12, P128, DOI 10.1038/tpj.2010.80; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Redies C, 2005, CELL MOL LIFE SCI, V62, P2840, DOI 10.1007/s00018-005-5320-z; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Richter W, 2005, BIOCHEM J, V388, P803, DOI 10.1042/BJ20050030; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Scholtens S, 2014, J ALLERGY CLIN IMMUN, V133, P885, DOI 10.1016/j.jaci.2013.08.049; Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941; Stolk RP, 2008, EUR J EPIDEMIOL, V23, P67, DOI 10.1007/s10654-007-9204-4; Sunyer J, 1998, AM J RESP CRIT CARE, V157, P512, DOI 10.1164/ajrccm.157.2.9705029; 't Mannetje A, 2003, INT J EPIDEMIOL, V32, P419, DOI 10.1093/ije/dyg080; Trynka G, 2009, GUT, V58, P1078, DOI 10.1136/gut.2008.169052; Van Pottelberge GR, 2009, COPD, V6, P284, DOI 10.1080/15412550903049124; Verhoeven VJM, 2013, NAT GENET, V45, P314, DOI 10.1038/ng.2554; Wilk JB, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S8; Wilk JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000429; Xia BY, 2005, GLYCOBIOLOGY, V15, P747, DOI 10.1093/glycob/cwi061; Ziegler A, 2012, CANCER LETT, V326, P1, DOI 10.1016/j.canlet.2012.07.021; Ziegler A, 2012, LUNG CANCER, V75, P189, DOI 10.1016/j.lungcan.2011.07.009; Zock JP, 2001, AM J RESP CRIT CARE, V163, P1572, DOI 10.1164/ajrccm.163.7.2004195	49	26	26	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1664	U368		10.1016/j.jaci.2015.03.042	http://dx.doi.org/10.1016/j.jaci.2015.03.042			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	25979521				2022-12-18	WOS:000366044300029
J	Blumenthal, KG; Youngster, I; Rabideau, DJ; Parker, RA; Manning, KS; Walensky, RP; Nelson, SB				Blumenthal, Kimberly G.; Youngster, Ilan; Rabideau, Dustin J.; Parker, Robert A.; Manning, Karen S.; Walensky, Rochelle P.; Nelson, Sandra B.			Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; antibiotic; drug; eosinophilia; hypersensitivity; drug rash with eosinophilia and systemic symptoms syndrome; vancomycin; metronidazole; outpatient parenteral antimicrobial therapy	TOXIC EPIDERMAL NECROLYSIS; SYSTEMIC SYMPTOMS; DRESS SYNDROME; DIFFERENTIAL-DIAGNOSIS; INTERSTITIAL NEPHRITIS; PRACTICE GUIDELINES; RENAL-FAILURE; DRUG RASH; VANCOMYCIN; MANAGEMENT	Background: Although drug-induced peripheral eosinophilia complicates antimicrobial therapy, little is known about its frequency and implications. Objective: We aimed to determine the frequency and predictors of antibiotic-induced eosinophilia and subsequent hypersensitivity reactions (HSRs). Methods: We evaluated a prospective cohort of former inpatients receiving intravenous antibiotic therapy as outpatients with at least 1 differential blood count. We used multivariate Cox proportional hazards models with time-varying antibiotic treatment indicators to assess the effect of demographic data and antibiotic exposures on eosinophilia and subsequent HSRs, including documented rash, renal injury, and liver injury. Possible drug rash with eosinophilia and systemic symptoms (DRESS) syndrome cases were identified and manually validated. Results: Of 824 patients (60% male; median age, 60 years; median therapy duration, 41 days), 210 (25%) had eosinophilia, with median peak absolute eosinophil counts of 726/mL (interquartile range, 594-990/mL). Use of vancomycin, penicillin, rifampin, and linezolid was associated with a higher hazard of having eosinophilia. There was a subsequent HSR in 64 (30%) of 210 patients with eosinophilia, including rash (n = 32), renal injury (n = 31), and liver injury (n = 13). Patients with eosinophilia were significantly more likely to have rash (hazard ratio [HR], 4.16; 95% CI, 2.54-6.83; P < .0001) and renal injury (HR, 2.13; 95% CI, 1.36-3.33; P = .0009) but not liver injury (HR, 1.75; 95% CI, 0.92-3.33; P = .09). Possible DRESS syndrome occurred in 7 (0.8%) of 824 patients; 4 (57%) were receiving vancomycin. Conclusions: Drug-induced eosinophilia is common with parenteral antibiotics. Although most patients with eosinophilia do not have an HSR, eosinophilia increases the hazard rate of having rash and renal injury. DRESS syndrome was more common than previously described.	[Blumenthal, Kimberly G.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Youngster, Ilan; Manning, Karen S.; Walensky, Rochelle P.; Nelson, Sandra B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Parker, Robert A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Med, Dept Med, Boston, MA 02114 USA; [Blumenthal, Kimberly G.; Parker, Robert A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA; [Rabideau, Dustin J.; Parker, Robert A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA; [Blumenthal, Kimberly G.; Youngster, Ilan; Parker, Robert A.; Walensky, Rochelle P.; Nelson, Sandra B.] Harvard Univ, Sch Med, Boston, MA USA; [Youngster, Ilan] Boston Childrens Hosp, Dept Pediat, Div Infect Dis, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Blumenthal, KG (corresponding author), Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Div Rheumatol Allergy & Immunol, 50 Staniford St,9th Floor, Boston, MA 02114 USA.	kblumenthal1@partners.org	Blumenthal, Kimberly/AAG-8290-2019; Youngster, Ilan/AAZ-1225-2020; Youngster, Ilan/J-5047-2014	Blumenthal, Kimberly/0000-0003-4773-9817; Youngster, Ilan/0000-0001-5233-1213; Youngster, Ilan/0000-0001-5233-1213	National Institutes of Health (NIH) [T32 HL116275]; National Center for Research Resources; National Center for Advancing Translational Sciences; NIH Award [8UL1TR000170-05]; Harvard University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000170] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL116275] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	K.G.B. is supported by the National Institutes of Health (NIH) (grant no. T32 HL116275). I.Y. received career support from Harvard Catalyst, Harvard Clinical and Translational Science Center, funded by the National Center for Research Resources and the National Center for Advancing Translational Sciences; NIH Award 8UL1TR000170-05; and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, the NIH, Harvard University, its affiliated academic health care centers, or its corporate contributors.	Abidi K, 2008, CRIT CARE, V12, DOI 10.1186/cc6883; An SY, 2011, ALLERGY ASTHMA IMMUN, V3, P194, DOI 10.4168/aair.2011.3.3.194; Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564; Baker RJ, 2004, NEPHROL DIAL TRANSPL, V19, P8, DOI 10.1093/ndt/gfg464; BALDWIN DS, 1968, NEW ENGL J MED, V279, P1245, DOI 10.1056/NEJM196812052792302; Bircher AJ, 2013, EXANTHEMATOUS MORBIL; Blumenthal KG, 2015, J ALLER CL IMM-PRACT, V3, P277, DOI 10.1016/j.jaip.2014.10.002; Blumenthal KG, 2012, ALLERGY ASTHMA PROC, V33, P165, DOI 10.2500/aap.2012.33.3498; Bocquet H, 1996, SEMIN CUTAN MED SURG, V15, P250, DOI 10.1016/S1085-5629(96)80038-1; Bouvresse S, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-72; Cacoub P, 2011, AM J MED, V124, P588, DOI 10.1016/j.amjmed.2011.01.017; CHAIKEN BH, 1950, NEW ENGL J MED, V242, P897, DOI 10.1056/NEJM195006082422304; Fridkin S, 2014, MMWR-MORBID MORTAL W, V63, P194; Jeung YJ, 2010, ALLERGY ASTHMA IMMUN, V2, P123, DOI 10.4168/aair.2010.2.2.123; Kardaun SH, 2007, BRIT J DERMATOL, V156, P609, DOI 10.1111/j.1365-2133.2006.07704.x; Kodner CM, 2003, AM FAM PHYSICIAN, V67, P2527; Lin YF, 2014, CLIN INFECT DIS, V58, P1377, DOI 10.1093/cid/ciu126; Macy E, 2012, ANN ALLERG ASTHMA IM, V108, P88, DOI 10.1016/j.anai.2011.11.006; Macy E, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.01.034; Marik PE, 1997, PHARMACOTHERAPY, V17, P1341; Mejia R, 2012, SEMIN HEMATOL, V49, P149, DOI 10.1053/j.seminhematol.2012.01.006; Mittal N, 2014, CUTAN OCUL TOXICOL, V33, P289, DOI 10.3109/15569527.2013.857678; Nandha Ruchika, 2011, Int J Appl Basic Med Res, V1, P50, DOI 10.4103/2229-516X.81982; Nutman TB, 2007, IMMUNOL ALLERGY CLIN, V27, P529, DOI 10.1016/j.iac.2007.07.008; O'Meara P, 2011, ALLERGY ASTHMA CL IM, V7, DOI 10.1186/1710-1492-7-16; OSMON D. R., 2012, EXECUTIVE SUMMARY DI, V56, P1, DOI DOI 10.1093/CID/CIS966; Roufosse F, 2010, J ALLERGY CLIN IMMUN, V126, P39, DOI 10.1016/j.jaci.2010.04.011; Roujeau JC, 2005, TOXICOLOGY, V209, P123, DOI 10.1016/j.tox.2004.12.022; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Terradas R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042860; Tice AD, 2004, CLIN INFECT DIS, V38, P1651, DOI 10.1086/420939; Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368; Vauthey L, 2008, PHARMACOLOGY, V82, P138, DOI 10.1159/000142729; Venning VA, 2011, DERMATOL CLIN, V29, P453, DOI 10.1016/j.det.2011.03.013; Verma Rajesh, 2013, Med J Armed Forces India, V69, P375, DOI 10.1016/j.mjafi.2013.01.007; Weller P., 2013, APPROACH PATIENT EOS; WHO, 2014, WHO ANT RES GLOB REP; Wibrow BA, 2011, ANAESTH INTENS CARE, V39, P224, DOI 10.1177/0310057X1103900211; Yang J, 2013, J INVEST ALLERG CLIN, V23, P248; Youngster I, 2014, CLIN INFECT DIS, V59, P369, DOI 10.1093/cid/ciu301; Zuliani E, 2005, CLIN NEPHROL, V64, P155	41	26	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1288	+		10.1016/j.jaci.2015.04.005	http://dx.doi.org/10.1016/j.jaci.2015.04.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	25981739	Green Accepted			2022-12-18	WOS:000364787200018
J	Lu, YX; Ho, R; Lim, TK; Kuan, WS; Goh, DYT; Mahadevan, M; Sim, TB; Van Bever, HPS; Larbi, A; Ng, TP				Lu, Yanxia; Ho, Roger; Lim, Tow Keang; Kuan, Win Sen; Goh, Daniel Yam Thiam; Mahadevan, Malcolm; Sim, Tiong Beng; Van Bever, Hugo P. S.; Larbi, Anis; Ng, Tze Pin			Neuropeptide Y may mediate psychological stress and enhance T(H)2 inflammatory response in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN; ONSET		[Lu, Yanxia; Ho, Roger; Ng, Tze Pin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Psychol Med, Singapore 117595, Singapore; [Goh, Daniel Yam Thiam; Van Bever, Hugo P. S.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pediat, Singapore 117595, Singapore; [Ho, Roger] Natl Univ Singapore, Dept Med, Div Resp & Crit Care Med, Singapore 117548, Singapore; [Lim, Tow Keang; Mahadevan, Malcolm; Sim, Tiong Beng] Natl Univ Singapore, Dept Emergency Med, Singapore 117548, Singapore; [Larbi, Anis] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN)	Ng, TP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Psychol Med, Singapore 117595, Singapore.	pcmngtp@nus.edu.sg	Van Bever, Hugo PS/D-8473-2015; Kuan, Win Sen/I-7684-2018; Ho, Roger/ABD-8859-2021; Yanxia, Lu/K-7383-2013; Ho, Roger C./ABD-9061-2021; Goh, Daniel/D-8573-2015; Larbi, Anis/ABE-5868-2020	Kuan, Win Sen/0000-0002-2134-7842; Yanxia, Lu/0000-0003-0878-7525; Ho, Roger C./0000-0001-9629-4493; 				Cohen S, 2007, JAMA-J AM MED ASSOC, V298, P1685, DOI 10.1001/jama.298.14.1685; Dreger LC, 2010, J ALLERGY CLIN IMMUN, V125, P116, DOI 10.1016/j.jaci.2009.09.051; Lietzen R, 2011, EUR RESPIR J, V37, P1360, DOI 10.1183/09031936.00164609; Makinde TO, 2013, EXP MOL PATHOL, V94, P45, DOI 10.1016/j.yexmp.2012.05.009; Marin TJ, 2009, PSYCHOSOM MED, V71, P378, DOI 10.1097/PSY.0b013e318199dbc3; Morgan CA, 2000, BIOL PSYCHIAT, V47, P902, DOI 10.1016/S0006-3223(99)00239-5; Rod NH, 2012, ALLERGY, V67, P1408, DOI 10.1111/j.1398-9995.2012.02882.x.; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Zollner EW, 2012, PEDIATRICS, V130, pE1512, DOI 10.1542/peds.2012-1147	9	26	26	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1061	1063		10.1016/j.jaci.2014.10.036	http://dx.doi.org/10.1016/j.jaci.2014.10.036			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25498790				2022-12-18	WOS:000352238600029
J	Tovey, ER; Stelzer-Braid, S; Toelle, BG; Oliver, BG; Reddel, HK; Willenborg, CM; Belessis, Y; Garden, FL; Jaffe, A; Strachan, R; Eyles, D; Rawlinson, WD; Marks, GB				Tovey, Euan R.; Stelzer-Braid, Sacha; Toelle, Brett G.; Oliver, Brian G.; Reddel, Helen K.; Willenborg, Christiana M.; Belessis, Yvonne; Garden, Frances L.; Jaffe, Adam; Strachan, Roxanne; Eyles, Darryl; Rawlinson, William D.; Marks, Guy B.			Rhinoviruses significantly affect day-to-day respiratory symptoms of children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Virus; rhinovirus; asthma; asthma control; children; mixed-model analysis; respiratory	DUST-MITE ALLERGEN; VIRAL-INFECTIONS; YOUNG-CHILDREN; PCR ASSAY; VITAMIN-D; EXACERBATIONS; VIRUSES; HEALTH; RISK; CHILDHOOD	Background: Viruses are frequently associated with acute exacerbations of asthma, but the extent to which they contribute to the level of day-to-day symptom control is less clear. Objective: We sought to explore the relationship between viral infections, host and environmental factors, and respiratory symptoms in children. Methods: Sixty-seven asthmatic children collected samples twice weekly for an average of 10 weeks. These included nasal wash fluid and exhaled breath for PCR-based detection of viral RNA, lung function measurements, and records of medication use and asthma and respiratory symptoms in the previous 3 days. Atopy, mite allergen exposure, and vitamin D levels were also measured. Mixed-model regression analyses were performed. Results: Human rhinoviruses (hRVs) were detected in 25.5% of 1232 nasal samples and 11.5% of breath samples. Non-hRV viruses were detected in less than 3% of samples. hRV in nasal samples was associated with asthma symptoms (cough and phlegm: odds ratio = 2.0; 95% CI = 1.4-2.86, P 5.0001; wheeze and chest tightness: odds ratio = 2.34, 95% CI = 1.55-3.52, P <.0001) and with cold symptoms, as reported concurrently with sampling and 3 to 4 days later. No differences were found between the 3 hRV genotypes (hRV-A, hRV-B, and hRV-C) in symptom risk. A history of inhaled corticosteroid use, but not atopic status, mite allergen exposure, or vitamin D levels, modified the association between viruses and asthma symptoms. Conclusion: The detection of nasal hRV was associated with a significantly increased risk of day-to-day asthma symptoms in children. Host, virus genotype, and environmental factors each had only a small or no effect on the relationship of viral infections to asthma symptoms.	[Tovey, Euan R.; Toelle, Brett G.; Oliver, Brian G.; Reddel, Helen K.; Garden, Frances L.; Marks, Guy B.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; [Stelzer-Braid, Sacha; Willenborg, Christiana M.; Rawlinson, William D.] Prince Wales Hosp, SEALS, Virol Res Lab, Sydney, NSW, Australia; [Stelzer-Braid, Sacha] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; [Toelle, Brett G.] Sydney Local Hlth Dist, Sydney, NSW, Australia; [Oliver, Brian G.] Univ Technol Sydney, Sydney, NSW 2007, Australia; [Belessis, Yvonne; Jaffe, Adam] Univ New S Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Belessis, Yvonne; Jaffe, Adam; Strachan, Roxanne; Rawlinson, William D.] Sydney Childrens Hosp, Sydney, NSW, Australia; [Garden, Frances L.] Ingham Inst Appl Med Res, Sydney, NSW, Australia; [Garden, Frances L.; Marks, Guy B.] Univ New S Wales, South Western Sydney Clin Sch, Sydney, NSW, Australia; [Eyles, Darryl] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia; [Eyles, Darryl] Pk Ctr Mental Hlth, Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia	University of Sydney; Woolcock Institute of Medical Research; University of New South Wales Sydney; University of Technology Sydney; University of New South Wales Sydney; University of Sydney; Ingham Institute for Applied Medical Research; University of New South Wales Sydney; University of Queensland; Queensland Centre for Mental Health Research	Tovey, ER (corresponding author), Woolcock Inst Med Res, POB M77,Missenden Rd Post Off, Glebe, NSW 2050, Australia.	euan.tovey@sydney.edu.au	Toelle, Brett G/B-1531-2008; Reddel, Helen/ABD-6338-2021; Oliver, Brian/E-7939-2010; Eyles, Darryl W/X-3386-2018; Reddel, Helen/AAC-3394-2020; Marks, Guy B./F-5058-2013; Tovey, Euan R/G-8604-2017	Toelle, Brett G/0000-0002-7375-0019; Oliver, Brian/0000-0002-7122-9262; Eyles, Darryl W/0000-0002-5023-7095; Reddel, Helen/0000-0002-6695-6350; Marks, Guy B./0000-0002-8976-8053; Tovey, Euan R/0000-0002-1802-7266; Garden, Frances/0000-0003-1653-3031; Rawlinson, William/0000-0003-0988-7827; Jaffe, Adam/0000-0002-1963-5415; Stelzer-Braid, Sacha/0000-0001-6037-9305	National Health and Medical Research Council of Australia [633238]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council of Australia (grant 633238).	Almstrand AC, 2010, J APPL PHYSIOL, V108, P584, DOI 10.1152/japplphysiol.00873.2009; Arden KE, 2010, J CLIN VIROL, V47, P219, DOI 10.1016/j.jcv.2010.01.001; Arden KE, 2010, J MED VIROL, V82, P1458, DOI 10.1002/jmv.21819; Bashir H, 2013, J ALLERGY CLIN IMMUN, V131, pAB232, DOI 10.1016/j.jaci.2012.12.1494; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Blakey JD, 2013, PRIM CARE RESP J, V22, P344, DOI 10.4104/pcrj.2013.00063; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Crisafulli D, 2007, ALLERGY, V62, P1394, DOI 10.1111/j.1398-9995.2007.01533.x; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Custovic A, 2013, ALLERGY, V68, P1520, DOI 10.1111/all.12275; Debiaggi M, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-247; Delfino RJ, 2013, J EXPO SCI ENV EPID, V23, P466, DOI 10.1038/jes.2013.25; DellaValle CT, 2012, EPIDEMIOLOGY, V23, P55, DOI 10.1097/EDE.0b013e31823b66b8; Effros RM, 2012, AM J RESP CRIT CARE, V185, P803, DOI 10.1164/rccm.201109-1702ED; Eyles D, 2009, CLIN CHIM ACTA, V403, P145, DOI 10.1016/j.cca.2009.02.005; Fabian P, 2011, J AEROSOL MED PULM D, V24, P137, DOI 10.1089/jamp.2010.0815; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Forno E, 2012, CURR OPIN PULM MED, V18, P63, DOI 10.1097/MCP.0b013e32834db288; Fry AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017780; Glasgow NJ, 2011, ARCH DIS CHILD, V96, P541, DOI 10.1136/adc.2010.189696; Gralton J, 2013, J MED VIROL, V85, P2151, DOI 10.1002/jmv.23698; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Hendley JO, 2004, J CLIN VIROL, V30, P326, DOI 10.1016/j.jcv.2004.02.011; Heymann PW, 2012, J ALLERGY CLIN IMMUN, V130, P1315, DOI 10.1016/j.jaci.2012.10.024; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Huynh KN, 2008, CLIN INFECT DIS, V46, P93, DOI 10.1086/523000; Iwane MK, 2011, J INFECT DIS, V204, P1702, DOI 10.1093/infdis/jir634; Jackson DJ, 2010, CURR OPIN ALLERGY CL, V10, P133, DOI 10.1097/ACI.0b013e3283352f7c; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Jacobs SE, 2013, CLIN MICROBIOL REV, V26, P135, DOI 10.1128/CMR.00077-12; Janssens T, 2013, CLIN EXP ALLERGY, V43, P1000, DOI 10.1111/cea.12138; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kloepfer KM, 2010, IMMUNOL ALLERGY CLIN, V30, P553, DOI 10.1016/j.iac.2010.08.002; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Linder JE, 2013, J ALLERGY CLIN IMMUN, V131, P69, DOI 10.1016/j.jaci.2012.09.033; Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07; Lysholm F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030875; Mann EH, 2014, ANN NY ACAD SCI, V1317, P57, DOI 10.1111/nyas.12410; Marks GB, 2010, ENVIRON HEALTH PERSP, V118, P1476, DOI 10.1289/ehp.1002186; McDevitt JJ, 2013, AEROSOL SCI TECH, V47, P444, DOI 10.1080/02786826.2012.762973; Miller EK, 2013, J CLIN VIROL, V57, P291, DOI 10.1016/j.jcv.2013.04.015; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nitschke M, 2006, J OCCUP ENVIRON MED, V48, P462, DOI 10.1097/01.jom.0000215802.43229.62; Nowson CA, 2012, MED J AUSTRALIA, V196, P686, DOI 10.5694/mja11.10301; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Peltola V, 2008, J INFECT DIS, V197, P382, DOI 10.1086/525542; Powell H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001802; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Stelzer-Braid S, 2008, EMERG INFECT DIS, V14, P1126, DOI 10.3201/eid1407.071098; Stelzer-Braid S, 2012, J VIROL METHODS, V186, P109, DOI 10.1016/j.jviromet.2012.08.008; Stelzer-Braid S, 2009, J MED VIROL, V81, P1674, DOI 10.1002/jmv.21556; Syrmis MW, 2004, J MOL DIAGN, V6, P125, DOI 10.1016/S1525-1578(10)60500-4; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Tarlo S M, 2000, Can Respir J, V7, P42; Thibaudon M, 2014, REV FR ALLERGOL, V54, P124, DOI 10.1016/j.reval.2014.01.025; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOVEY ER, 1992, CLIN EXP ALLERGY, V22, P67, DOI 10.1111/j.1365-2222.1992.tb00116.x; Turchiarelli V, 2011, ALLERGY, V66, P1099, DOI 10.1111/j.1398-9995.2011.02600.x; van der Zalm MM, 2011, J CLIN VIROL, V52, P317, DOI 10.1016/j.jcv.2011.09.003; van der Zalm MM, 2009, J PEDIATR-US, V154, P396, DOI 10.1016/j.jpeds.2008.08.036; Vernon MK, 2012, J ASTHMA, V49, P991, DOI 10.3109/02770903.2012.738268; WALTER SD, 1978, INT J EPIDEMIOL, V7, P175, DOI 10.1093/ije/7.2.175; Wisdom A, 2009, J CLIN MICROBIOL, V47, P3958, DOI 10.1128/JCM.00993-09	69	26	27	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					663	U124		10.1016/j.jaci.2014.10.020	http://dx.doi.org/10.1016/j.jaci.2014.10.020			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25476729	Bronze, Green Published			2022-12-18	WOS:000351065000009
J	Evans, H; Mitre, E				Evans, Holly; Mitre, Edward			Worms as therapeutic agents for allergy and asthma: Understanding why benefits in animal studies have not translated into clinical success	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; atopy; helminths; therapeutics; clinical trials; animal models; hygiene hypothesis	INDUCED AIRWAY INFLAMMATION; REGULATORY T-CELLS; INTESTINAL HELMINTH INFECTIONS; HETEROLOGOUS IMMUNE-RESPONSE; MANSONI ANTIGENS MODULATE; TRICHURIS-SUIS THERAPY; SERUM IGE LEVELS; HOOKWORM INFECTION; MURINE MODEL; SCHISTOSOMA-JAPONICUM	Helminth infections are associated with decreased rates of autoimmunity and allergy, and several clinical studies have demonstrated that intentional infection with helminths can reduce symptoms of autoimmune diseases. In contrast, though numerous animal studies have demonstrated that helminth infections ameliorate allergic diseases, clinical trials in humans have not shown benefit. In this article, we review in detail the 2 human studies that have prospectively tested whether helminth infections protect against allergy. We next review the research designs and results obtained from animal studies, and compare these to the human trials. We then postulate possible reasons for the lack of efficacy observed in clinical trials to date and discuss potential future areas of research in this field.	[Evans, Holly; Mitre, Edward] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Mitre, E (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	edward.mitre@usuhs.edu			National Institutes of Health	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	E. Mitre has received research support from the National Institutes of Health and has patents (US Patent Office Patents) submitted through the Henry Jackson Foundation. H. Evans declares that she has no relevant conflicts of interest.	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Attout T, 2008, PARASITOL INT, V57, P201, DOI 10.1016/j.parint.2008.01.001; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; Baqueiro T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-51; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; BEER RJS, 1971, BRIT MED J, V2, P44, DOI 10.1136/bmj.2.5752.44; BLACKWOOD LL, 1978, INT ARCH ALLER A IMM, V57, P8, DOI 10.1159/000232077; Blount D, 2009, AM J TROP MED HYG, V81, P911, DOI 10.4269/ajtmh.2009.09-0237; Boitelle A, 2005, INT J PARASITOL, V35, P765, DOI 10.1016/j.ijpara.2005.02.013; Broadhurst MJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001500; Camberis Mali, 2003, Curr Protoc Immunol, VChapter 19, DOI 10.1002/0471142735.im1912s55; Cardoso LS, 2010, CLIN EXP IMMUNOL, V160, P266, DOI 10.1111/j.1365-2249.2009.04084.x; Cheng LE, 2010, J IMMUNOL, V185, P5040, DOI 10.4049/jimmunol.1001900; Correale J, 2007, ANN NEUROL, V61, P97, DOI 10.1002/ana.21067; Demirturk N, 2007, ADV THER, V24, P1305, DOI 10.1007/BF02877777; Dittrich AM, 2008, J IMMUNOL, V180, P1792, DOI 10.4049/jimmunol.180.3.1792; Feary J, 2009, CLIN EXP ALLERGY, V39, P1060, DOI 10.1111/j.1365-2222.2009.03187.x; Feary JR, 2010, CLIN EXP ALLERGY, V40, P299, DOI 10.1111/j.1365-2222.2009.03433.x; Filbey KJ, 2014, IMMUNOL CELL BIOL, V92, P436, DOI 10.1038/icb.2013.109; GARB KS, 1984, INFECT IMMUN, V43, P1097, DOI 10.1128/IAI.43.3.1097-1099.1984; GERRARD JW, 1976, ANN ALLERGY, V37, P91; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; Grainger JR, 2010, J EXP MED, V207, P2331, DOI 10.1084/jem.20101074; Hartmann S, 2009, CLIN EXP ALLERGY, V39, P1585, DOI 10.1111/j.1365-2222.2009.03290.x; Hotez PJ, 2004, NEW ENGL J MED, V351, P799, DOI 10.1056/NEJMra032492; JARRETT E, 1980, NATURE, V283, P302, DOI 10.1038/283302a0; Jeong YI, 2011, BIOCHEM BIOPH RES CO, V407, P793, DOI 10.1016/j.bbrc.2011.03.102; Kitagaki K, 2006, J IMMUNOL, V177, P1628, DOI 10.4049/jimmunol.177.3.1628; Larson D, 2012, J ALLERGY CLIN IMMUN, V130, P270, DOI 10.1016/j.jaci.2012.04.017; Larson D, 2012, J IMMUNOL, V188, P4188, DOI 10.4049/jimmunol.1101859; Layland LE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002379; Lee KH, 2008, VET PARASITOL, V156, P216, DOI 10.1016/j.vetpar.2008.06.016; Lima C., 2002, Clinical and Experimental Allergy, V32, P1659, DOI 10.1046/j.1365-2222.2002.01506.x; Liu J, 2011, PROCEEDINGS OF THE ASME INTERNATIONAL MANUFACTURING SCIENCE AND ENGINEERING CONFERENCE 2011, VOL 2, P525, DOI 10.1111/j.1365-3024.2011.01308.x; Liu P, 2010, PARASITE IMMUNOL, V32, P57, DOI 10.1111/j.1365-3024.2009.01161.x; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Mangan NE, 2006, J IMMUNOL, V176, P138, DOI 10.4049/jimmunol.176.1.138; Mangan NE, 2004, J IMMUNOL, V173, P6346, DOI 10.4049/jimmunol.173.10.6346; McConchie BW, 2006, INFECT IMMUN, V74, P6632, DOI 10.1128/IAI.00720-06; McSorley HJ, 2013, INT J PARASITOL, V43, P301, DOI 10.1016/j.ijpara.2012.11.011; McSorley HJ, 2012, EUR J IMMUNOL, V43, P301; McSorley HJ, 2014, MUCOSAL IMMUNOL; Michels C, 2006, INFECT IMMUN, V74, P5926, DOI 10.1128/IAI.00207-06; Mitre E, 2005, INFECT IMMUN, V73, P4106, DOI 10.1128/IAI.73.7.4106-4111.2005; Mo HM, 2008, PARASITOL RES, V103, P1183, DOI 10.1007/s00436-008-1114-1; Mortimer K, 2006, AM J TROP MED HYG, V75, P914, DOI 10.4269/ajtmh.2006.75.914; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Negrao-Correa D, 2003, INFECT IMMUN, V71, P2607, DOI 10.1128/IAI.71.5.2607-2614.2003; Pacifico LGG, 2009, INFECT IMMUN, V77, P98, DOI 10.1128/IAI.00783-07; Park HK, 2011, EXP PARASITOL, V127, P539, DOI 10.1016/j.exppara.2010.10.004; Park SK, 2009, J IMMUNOL, V182, P6907, DOI 10.4049/jimmunol.0803533; Paterson JCM, 2002, INFECT IMMUN, V70, P6058, DOI 10.1128/IAI.70.11.6058-6067.2002; Pinelli E, 2008, CLIN EXP ALLERGY, V38, P649, DOI 10.1111/j.1365-2222.2007.02908.x; Pinto LA, 2004, PARASITE IMMUNOL, V26, P151, DOI 10.1111/j.0141-9838.2004.00694.x; Pochanke V, 2007, EUR J IMMUNOL, V37, P1275, DOI 10.1002/eji.200737135; PRICE P, 1986, AUST J EXP BIOL MED, V64, P127, DOI 10.1038/icb.1986.14; PRICE P, 1984, PARASITE IMMUNOL, V6, P499, DOI 10.1111/j.1365-3024.1984.tb00820.x; PRICE P, 1987, EXP PARASITOL, V63, P21, DOI 10.1016/0014-4894(87)90074-9; Reynolds LA, 2012, SEMIN IMMUNOPATHOL, V34, P829, DOI 10.1007/s00281-012-0347-3; Sahu N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011348; Schnoeller C, 2008, J IMMUNOL, V180, P4265, DOI 10.4049/jimmunol.180.6.4265; Schopf L, 2005, INVEST OPHTH VIS SCI, V46, P2772, DOI 10.1167/iovs.04-0899; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Smith KA, 2014, EUR J IMMUNOL, V44, P150, DOI 10.1002/eji.201343746; Smits HH, 2007, J ALLERGY CLIN IMMUN, V120, P932, DOI 10.1016/j.jaci.2007.06.009; STEWART GL, 1991, INT J PARASITOL, V21, P935, DOI 10.1016/0020-7519(91)90169-8; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Summers RW, 2003, AM J GASTROENTEROL, V98, P2034, DOI [10.1016/S0002-9270(03)00623-3, 10.1111/j.1572-0241.2003.07660.x]; Trujillo-Vargas CM, 2007, AM J RESP CRIT CARE, V175, P336, DOI 10.1164/rccm.200601-054OC; Turner JK, 1982, CLIN IMMUNOL IMMUNOP, V24, P440; Turner JK, 1985, INT ARCH ALLERGY IMM, V78, P329; Turner JK, 1982, AUST J EXP BIOL MED, V60, P147; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Wang CC, 2001, CLIN EXP ALLERGY, V31, P495, DOI 10.1046/j.1365-2222.2001.01044.x; Wilson MS, 2010, EUR J IMMUNOL, V40, P1682, DOI 10.1002/eji.200939721; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; Yang JH, 2007, IMMUNOLOGY, V120, P8, DOI 10.1111/j.1365-2567.2006.02472.x; ZAHNER H, 1989, PARASITOL RES, V75, P401, DOI 10.1007/BF00931137; 1976, LANCET, V1, P894	84	26	26	0	65	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					343	353		10.1016/j.jaci.2014.07.007	http://dx.doi.org/10.1016/j.jaci.2014.07.007			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25174866				2022-12-18	WOS:000349372300005
J	Campbell, BC; Gilding, EK; Timbrell, V; Guru, P; Loo, D; Zennaro, D; Mari, A; Solley, G; Hill, MM; Godwin, ID; Davies, JM				Campbell, Bradley C.; Gilding, Edward K.; Timbrell, Victoria; Guru, Preethi; Loo, Dorothy; Zennaro, Danila; Mari, Adriano; Solley, Graham; Hill, Michelle M.; Godwin, Ian D.; Davies, Janet M.			Total transcriptome, proteome, and allergome of Johnson grass pollen, which is important for allergic rhinitis in subtropical regions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergome; allergen components; allergic rhinitis; IgE; Johnson grass pollen; pollen allergy; proteome; transcriptome	PAS N 1; CROSS-REACTIVITY; IGE; ASTHMA; IMPACT; GUIDELINES; EFFICACY; TABLET; COMMON; SAFETY	Background: Genomic data are lacking for many allergen sources. To circumvent this limitation, we implemented a strategy to reveal the repertoire of pollen allergens of a grass with clinical importance in subtropical regions, where an increasing proportion of the world's population resides. Objective: We sought to identify and immunologically characterize the allergenic components of the Panicoideae Johnson grass pollen (JGP; Sorghum halepense). Methods: The total pollen transcriptome, proteome, and allergome of JGP were documented. Serum IgE reactivities with pollen and purified allergens were assessed in 64 patients with grass pollen allergy from a subtropical region. Results: Purified Sor h 1 and Sor h 13 were identified as clinically important allergen components of JGP with serum IgE reactivity in 49 (76%) and 28 (43.8%), respectively, of patients with grass pollen allergy. Within whole JGP, multiple cDNA transcripts and peptide spectra belonging to grass pollen allergen families 1, 2, 4, 7, 11, 12, 13, and 25 were identified. Pollen allergens restricted to subtropical grasses (groups 22-24) were also present within the JGP transcriptome and proteome. Mass spectrometry confirmed the IgE-reactive components of JGP included isoforms of Sor h 1, Sor h 2, Sor h 13, and Sor h 23. Conclusion: Our integrated molecular approach revealed qualitative differences between the allergenic components of JGP and temperate grass pollens. Knowledge of these newly identified allergens has the potential to improve specific diagnosis and allergen immunotherapy treatment for patients with grass pollen allergy in subtropical regions and reduce the burden of allergic respiratory disease globally.	[Campbell, Bradley C.; Gilding, Edward K.; Godwin, Ian D.] Univ Queensland, Sch Agr & Food Sci, Brisbane, Qld 4076, Australia; [Gilding, Edward K.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4076, Australia; [Timbrell, Victoria; Guru, Preethi; Davies, Janet M.] Univ Queensland, Sch Med, Translat Res Inst, Brisbane, Qld 4076, Australia; [Loo, Dorothy; Hill, Michelle M.] Univ Queensland, Univ Queensland Diamantina Inst, Translat Res Inst, Brisbane, Qld 4076, Australia; [Zennaro, Danila; Mari, Adriano] Ctr Associati Allergol Mol, Rome, Italy; [Mari, Adriano] Allergy Data Labs Sc, Latina, Italy; [Solley, Graham] Watkins Med Ctr, Brisbane, Qld, Australia	University of Queensland; University of Queensland; University of Queensland; University of Queensland	Davies, JM (corresponding author), Univ Queensland, Sch Med, Translat Res Inst, Brisbane, Qld 4076, Australia.	j.davies2@uq.edu.au	Campbell, Bradley C./AAV-7020-2020; Davies, Janet/C-7989-2009; Gilding, Edward/A-8630-2011; Hill, Michelle Mei Chih/G-4417-2010	Campbell, Bradley C./0000-0003-0815-930X; Gilding, Edward/0000-0003-1720-1282; Hill, Michelle Mei Chih/0000-0003-1134-0951; Davies, Janet/0000-0002-6378-4119; Godwin, Ian/0000-0002-4006-4426	University of Queensland Collaboration Industry Engagement Fund	University of Queensland Collaboration Industry Engagement Fund	Supported by the University of Queensland Collaboration Industry Engagement Fund and a cosponsorship from Stallergenes Pty Ltd. J. M. D. is supported by a National Health and Medical Research Council of Australia Development Grant (1017441). The University of Queensland Diamantina Institute proteomics facility was supported by the National Health and Medical Research Council of Australia Major Equipment and Infrastructure grant and a Ramaciotti Foundations Equipment Gift. M. M. H. is supported by Australian Research Council Future Fellowship (FT120100251). Disclosure of potential conflict of interest: E. K. Gilding has received salary and research support from the Australian Research Council (LP0883808) and has received payment for lectures from The University of Queensland. J. M. Davies has received research support from The University of Queensland Collaborative Industry Engagement Fund, the National Health and Medical Research Council, the Asthma Foundation of Queensland, and the Australian Society for Clinical Immunology and Allergy; has consultant arrangements with Stallergenes Australia; is employed by The University of Queensland; has received payment from Stallergenes Pty Ltd and GlaxoSmithKline for lectures delivered by J. M. Davies; the university has received travel support from Thermo Fisher; is the named inventor on patent granted in Australia and applied for in the United States for Novel immunogenic molecules and uses thereof: Immunogenic protein Pas n 1 from Bahia grass pollen; receives in- kind support for development of her research from Thermo Fisher by way of provision of materials; and receives in- kind support for development of her research from Sullivan Nicolaides Pathology by way of provision of pathology services. The rest of the authors declare that they have no relevant conflicts of interest.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 2007, EC IMPACT ALLERGIC D; AVJIOGLU A, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P161; Beggs PJ, 2011, ASIA-PAC J PUBLIC HE, V23, p46S, DOI 10.1177/1010539510391771; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Chabre H, 2010, CLIN EXP ALLERGY, V40, P505, DOI 10.1111/j.1365-2222.2009.03380.x; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Darrow LA, 2012, J ALLERGY CLIN IMMUN, V130, P630, DOI 10.1016/j.jaci.2012.06.020; Davies JM, 2014, CLIN EXP ALLERGY, V44, P790, DOI 10.1111/cea.12317; Davies JM, 2011, CLIN EXP ALLERGY, V41, P281, DOI 10.1111/j.1365-2222.2010.03670.x; Davies JM, 2011, MOL IMMUNOL, V48, P931, DOI 10.1016/j.molimm.2010.12.013; Davies JM, 2008, MOL IMMUNOL, V46, P286, DOI 10.1016/j.molimm.2008.08.267; Davies Janet Mary, 2012, Clin Transl Allergy, V2, P4, DOI 10.1186/2045-7022-2-4; Davies JM, 2005, ALLERGY, V60, P251, DOI 10.1111/j.1398-9995.2005.00663.x; De Canio M, 2009, J PROTEOME RES, V8, P4383, DOI 10.1021/pr900315a; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Drew AC, 2011, INT ARCH ALLERGY IMM, V154, P295, DOI 10.1159/000321821; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Erbas B, 2007, CLIN EXP ALLERGY, V37, P1641, DOI 10.1111/j.1365-2222.2007.02818.x; Erbas B, 2012, CLIN EXP ALLERGY, V42, P799, DOI 10.1111/j.1365-2222.2012.03995.x; Etto T, 2012, INT ARCH ALLERGY IMM, V159, P355, DOI 10.1159/000338290; Eusebius NP, 2002, INT ARCH ALLERGY IMM, V127, P234, DOI 10.1159/000053868; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; Focke-Tejkl M, 2014, J ALLERGY CLIN IMMUN, V133, P836, DOI 10.1016/j.jaci.2013.08.038; Fonseca C, 2012, J PROTEOMICS, V75, P2027, DOI 10.1016/j.jprot.2012.01.005; Galan C, 2013, ALLERGY, V68, P809, DOI 10.1111/all.12144; Gupta A, 2002, ENVIRON GEOL, V42, P736, DOI 10.1007/s00254-002-0551-x; HOLM LG, 1977, WORLDS WORST WEEDS D, P54; Inder K. L., 2012, J INTEGR OMICS, V2, P114; Kao SH, 2005, PROTEOMICS, V5, P3805, DOI 10.1002/pmic.200401229; Katelaris CH, 2012, CLIN EXP ALLERGY, V42, P186, DOI 10.1111/j.1365-2222.2011.03891.x; Kerim T, 2003, FUNCT PLANT BIOL, V30, P843, DOI 10.1071/FP03100; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Li ZW, 2005, BIOTECHNIQUES, V38, P872, DOI 10.2144/05386BM05; Mari A., 2004, Journal of Allergy and Clinical Immunology, V113, pS301; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Marth K, 2004, J ALLERGY CLIN IMMUN, V113, P470, DOI 10.1016/j.jaci.2003.11.042; MCWHORTER C G, 1989, Reviews of Weed Science, V4, P85; Meltzer EO, 2011, ANN ALLERG ASTHMA IM, V106, pS12, DOI 10.1016/j.anai.2010.10.014; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Morgan JA, 2011, NATURE, V476, P202, DOI 10.1038/nature10274; Paterson AH, 2009, NATURE, V457, P551, DOI 10.1038/nature07723; Pawankar R., 2011, WORLD ALLERGY ORG WA; Petersen A, 2006, PROTEOMICS, V6, P6317, DOI 10.1002/pmic.200600173; PHILLIPS JW, 1989, ANN ALLERGY, V63, P503; Prescott RA, 2001, S AFR MED J, V91, P237; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; Russell SD, 2008, MOL PLANT, V1, P751, DOI 10.1093/mp/ssn036; Schulten V, 2013, P NATL ACAD SCI USA, V110, P3459, DOI 10.1073/pnas.1300512110; Seidel DJ, 2008, NAT GEOSCI, V1, P21, DOI 10.1038/ngeo.2007.38; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; Smith PM, 1997, INT ARCH ALLERGY IMM, V114, P265, DOI 10.1159/000237678; SRIDHARA S, 1995, ANN ALLERG ASTHMA IM, V75, P73; Van Ree R, 2008, ALLERGY, V63, P310, DOI 10.1111/j.1398-9995.2007.01612.x; Weber RW, 2007, ANN ALLERG ASTHMA IM, V99, P203, DOI 10.1016/S1081-1206(10)60654-0; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425, DOI 10.1016/S1081-1206(10)61509-8; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893; 2011, GLOB ASTHM REP 2011	61	26	26	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					133	142		10.1016/j.jaci.2014.06.034	http://dx.doi.org/10.1016/j.jaci.2014.06.034			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25129679				2022-12-18	WOS:000347298200016
J	Kajdacsi, E; Jani, PK; Csuka, D; Varga, LA; Prohaszka, Z; Farkas, H; Cervenak, L				Kajdacsi, Erika; Jani, Peter K.; Csuka, Dorottya; Varga, Lilian Agnes; Prohaszka, Zoltan; Farkas, Henriette; Cervenak, Laszlo			Endothelial cell activation during edematous attacks of hereditary angioedema types I and II	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hereditary angioedema; C1-inhibitor deficiency; attack; endothelial cells; activation; von Willebrand factor; endothelin-1; soluble E-selectin; clinical study	VON-WILLEBRAND-FACTOR; SOLUBLE E-SELECTIN; RISK-FACTORS; EXPRESSION; BRADYKININ; DISEASE; MODEL; ATHEROSCLEROSIS; DYSFUNCTION; MECHANISMS	Background: Hereditary angioedema (HAE) caused by C1-inhibitor (C1-INH) deficiency (HAE-C1-INH) is a potentially life-threatening rare disease caused by the decreased activity of C1-INH. Lack of C1-INH leads to overproduction of bradykinin, a potent vasoactive peptide. Although angioedema is induced by bradykinin, the function and activation of endothelial cells (ECs), the targets of bradykinin, have not yet been studied during HAE attacks. Objective: We studied whether EC function is altered during HAE attacks in comparison with attack-free intervals. Methods: Forty-six consecutive samples obtained during attacks from 18 patients with HAE-C1-INH were compared with inter-attack samples of the same patients. The patients' sera were tested for von Willebrand factor (VWF) antigen, VWF collagen-binding activity, soluble E-selectin, and endothelin-1 levels by using ELISA and BRAHMS Kryptor technologies. Results: Levels of all 4 EC markers (VWF antigen, VWF collagen-binding activity, soluble E-selectin, and endothelin-1) were significantly increased during HAE attacks. Their increases were even more obvious in the subgroup of patients without any pre-existing risk factors for endothelial dysfunction. Conclusion: In this study we demonstrated that ECs are activated during HAE attacks. Our results might suggest the need for revising the knowledge on the pathogenesis of HAE-C1-INH and for reconsidering the role of ECs as a possible novel therapeutic target in patients with this disease.	[Kajdacsi, Erika; Jani, Peter K.; Csuka, Dorottya; Varga, Lilian Agnes; Prohaszka, Zoltan; Farkas, Henriette; Cervenak, Laszlo] Semmelweis Univ, Dept Internal Med 3, H-1125 Budapest, Hungary	Semmelweis University	Cervenak, L (corresponding author), Semmelweis Univ, Dept Internal Med 3, Kutvolgyi Ut 4, H-1125 Budapest, Hungary.	cela@kut.sote.hu	Csuka, Dorottya/F-2224-2010; Prohászka, Zoltán/F-2191-2010; Cervenak, Laszlo/F-1672-2010	Csuka, Dorottya/0000-0003-3610-9852; Prohászka, Zoltán/0000-0003-1761-7982; Varga, Lilian/0000-0002-5484-364X; Kajdacsi, Erika/0000-0003-0739-2193; Cervenak, Laszlo/0000-0003-0166-8697; Farkas, Henriette/0000-0003-2929-1721	National Scientific Research Fund [OTKA K 100886]; "Bolyai Janos" Research Fellowship [BO/00218/10/8]	National Scientific Research Fund; "Bolyai Janos" Research Fellowship(Hungarian Academy of Sciences)	Supported by the National Scientific Research Fund (grant no. OTKA K 100886, to H. F.). L.C. was granted the "Bolyai Janos" Research Fellowship (BO/00218/10/8).	Aird WC, 2004, CRIT CARE MED, V32, pS271, DOI 10.1097/01.CCM.0000129669.21649.40; BOOTH F, 1987, BRIT J HAEMATOL, V67, P71, DOI 10.1111/j.1365-2141.1987.tb02299.x; Bossi F, 2009, J ALLERGY CLIN IMMUN, V124, P1303, DOI 10.1016/j.jaci.2009.08.007; Bowen Tom, 2010, Allergy Asthma Clin Immunol, V6, P24, DOI 10.1186/1710-1492-6-24; Cardillo C, 1999, HYPERTENSION, V33, P753, DOI 10.1161/01.HYP.33.2.753; Cleator JH, 2006, BLOOD, V107, P2736, DOI 10.1182/blood-2004-07-2698; Czucz J, 2012, J CLIN IMMUNOL, V32, P61, DOI 10.1007/s10875-011-9606-7; Davenport A. P., 2006, V176, P295; Dias JP, 2012, J CARDIOVASC PHARM, V60, P61, DOI 10.1097/FJC.0b013e3182576277; Dong F, 2005, BRIT J PHARMACOL, V145, P323, DOI 10.1038/sj.bjp.0706193; Fan JL, 2000, ANN NY ACAD SCI, V902, P84; Fischer BE, 1998, ANN HEMATOL, V76, P159, DOI 10.1007/s002770050381; Hirase T, 2012, AM J PHYSIOL-HEART C, V302, pH499, DOI 10.1152/ajpheart.00325.2011; Judit C, 2011, CLIN RES CARDIOL, V100, P587, DOI 10.1007/s00392-011-0283-6; Kaplan AP, 2010, J ALLERGY CLIN IMMUN, V126, P918, DOI 10.1016/j.jaci.2010.08.012; Kaplan AP, 2010, MOL IMMUNOL, V47, P2161, DOI 10.1016/j.molimm.2010.05.010; Keleman Z, 2010, CLIN IMMUNOL, V134, P354, DOI 10.1016/j.clim.2009.11.002; Knipe L, 2010, BLOOD, V116, P2183, DOI 10.1182/blood-2010-03-276170; Lip GYH, 1997, CARDIOVASC RES, V34, P255, DOI 10.1016/S0008-6363(97)00039-4; Luo GP, 2012, ACTA HAEMATOL-BASEL, V128, P158, DOI 10.1159/000339426; MARSDEN PA, 1991, AM J PHYSIOL, V261, pF117, DOI 10.1152/ajprenal.1991.261.1.F117; Maurer M, 2011, ALLERGY, V66, P1397, DOI 10.1111/j.1398-9995.2011.02686.x; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; MOMOSE N, 1993, HYPERTENSION, V21, P921, DOI 10.1161/01.HYP.21.6.921; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Papassotiriou J, 2006, CLIN CHEM, V52, P1144, DOI 10.1373/clinchem.2005.065581; Popov J, 2006, CLIN CHEM, V52, P1965, DOI 10.1373/clinchem.2006.070730; Reriani MK, 2010, BIOMARK MED, V4, P351, DOI 10.2217/BMM.10.61; Roldan V, 2003, THROMB HAEMOSTASIS, V90, P1007, DOI 10.1160/TH02-09-0083; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Stow LR, 2011, FASEB J, V25, P16, DOI 10.1096/fj.10-161612; Szeplaki G, 2005, J ALLERGY CLIN IMMUN, V115, P864, DOI 10.1016/j.jaci.2004.12.1130; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Uzonyi B, 2006, P NATL ACAD SCI USA, V103, P6326, DOI 10.1073/pnas.0601223103; Valentijn KM, 2011, BLOOD, V117, P5033, DOI 10.1182/blood-2010-09-267492; Yu GY, 2005, BLOOD, V105, P3545, DOI 10.1182/blood-2004-07-2617	36	26	26	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1686	1691		10.1016/j.jaci.2013.12.1072	http://dx.doi.org/10.1016/j.jaci.2013.12.1072			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24522092				2022-12-18	WOS:000336672500022
J	Robert, V; Triffaux, E; Paulet, PE; Guery, JC; Pelletier, L; Savignac, M				Robert, Virginie; Triffaux, Emily; Paulet, Pierre-Emmanuel; Guery, Jean-Charles; Pelletier, Lucette; Savignac, Magali			Protein kinase C-dependent activation of Ca(V)1.2 channels selectively controls human T(H)2-lymphocyte functions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chemoattractant receptor-homologous molecule expressed on T(H)2 cells; asthma; calcium; voltage-dependent calcium channels; T(H)2 cytokines; protein kinase C alpha/beta	CALCIUM-CHANNEL; T-CELLS; SIGNALING PATHWAY; CA2+ CHANNELS; PHARMACOLOGY; LYMPHOCYTES; DEFICIENCY; SUBUNITS; TH1; RAT	Background: In addition to calcium release-activated calcium channel/ORAI calcium channels, the role of voltage-gated calcium (Ca(v)1) channels in T-cell calcium signaling is emerging. Ca(v)1 channels are formed by alpha 1 (Ca(V)1.1 to Ca(V)1.4) and auxiliary subunits. We previously demonstrated that mouse T(H)2 cells selectively overexpressed Ca(V)1.2 and Ca(V)1.3 channels. Knocking down these channels with Ca(v)1 antisense (AS) oligonucleotides inhibited T(H)2 functions and experimental asthma. Objective: We investigated the expression profile and role of Ca(v)1 channels in human T-cell subsets, with a focus on T(H)2 cells. Methods: We compared the profile of Ca(V)1 channel subunit expression in T-cell subsets isolated ex vivo from the blood of healthy donors, as well as in vitro-polarized T-cell subsets, and tested the effect of the Ca(v)1 inhibitors nicardipine and Ca(v)1.2AS on their functions. Results: Ca(V)1.4 expression was detectable in CD4+ T cells, ex vivo T(H)1 cells, and T(H)17 cells, whereas Ca(v)1.2 channels predominated in T(H)2 cells only. T-cell activation resulted in Ca(v)1.4 downregulation, whereas Ca(v)1.2 expression was selectively maintained in polarized T(H)2 cells and absent in T(H)1 or T(H)9 cells. Nicardipine and Ca(V)1.2AS decreased Ca2+ and cytokine responses in T(H)2, but not T(H)1, cells. Protein kinase C (PKC) alpha/beta inhibition decreased Ca2+ and cytokine responses, whereas both calcium and cytokine responses induced by PKC activation were inhibited by nicardipine or Cav1.2AS in T(H)2 cells. Conclusion: This study highlights the selective expression of Ca(v)1.2 channels in human T(H)2 cells and the role of PKC-dependent Ca(v)1.2 channel activation in T(H)2 cell function. Blocking PKC or Ca(v)1.2 channel activation in T(H)2 cells might represent new strategies to treat allergic diseases in human subjects.	[Robert, Virginie; Triffaux, Emily; Paulet, Pierre-Emmanuel; Guery, Jean-Charles; Pelletier, Lucette; Savignac, Magali] Univ Toulouse 3, Ctr Physiopathol Toulouse Purpan, CNRS, INSERM,U1043,U5282, F-31062 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Pelletier, L (corresponding author), CHU Purpan, INSERM, UMR1043, Pl Dr Baylac, F-31024 Toulouse 3, France.	lucette.pelletier@inserm.fr; magali.savignac@inserm.fr	Pelletier, Lucette/L-2956-2014; Savignac, Magali/K-1757-2014; GUERY, Jean-Charles/G-1452-2013	GUERY, Jean-Charles/0000-0003-4499-3270; Robert, Virginie/0000-0001-9998-6890	French National Institute for Health and Medical research (INSERM); Association 111 des Arts, ITMO IHP (INSERM); French Society of Allergology; MENRT	French National Institute for Health and Medical research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association 111 des Arts, ITMO IHP (INSERM); French Society of Allergology; MENRT	Supported by the French National Institute for Health and Medical research (INSERM) and by grants from the Association 111 des Arts, ITMO IHP (INSERM), and the French Society of Allergology. V. R. was supported by MENRT, and E. T. was supported by INSERM/DGOS allocation. L. P. is the recipient of Contrat d'Interface from Toulouse University Hospital and INSERM.	Badou A, 2006, P NATL ACAD SCI USA, V103, P15529, DOI 10.1073/pnas.0607262103; Bourdin B, 2010, J BIOL CHEM, V285, P22851, DOI 10.1074/jbc.M110.111062; Brereton HM, 1997, CELL CALCIUM, V22, P39, DOI 10.1016/S0143-4160(97)90088-9; Cabral MD, 2010, AM J RESP CRIT CARE, V181, P1310, DOI [10.1164/rccm.200907-1166oc, 10.1164/rccm.200907-1166OC]; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Fanger CM, 2000, J IMMUNOL, V164, P1153, DOI 10.4049/jimmunol.164.3.1153; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233; Gershon ES, 2013, MOL PSYCHIAT; Gomes B, 2007, AM J RESP CRIT CARE, V175, P1117, DOI 10.1164/rccm.200607-1026OC; Hogan PG, 2010, ANNU REV IMMUNOL, V28, P491, DOI 10.1146/annurev.immunol.021908.132550; Jabeen R, 2012, CURR OPIN IMMUNOL, V24, P303, DOI 10.1016/j.coi.2012.02.001; Jha MK, 2009, NAT IMMUNOL, V10, P1275, DOI 10.1038/ni.1793; Kim KD, 2011, J IMMUNOL, V187, P3620, DOI 10.4049/jimmunol.1100847; Liao P, 2010, PFLUG ARCH EUR J PHY, V460, P353, DOI 10.1007/s00424-009-0753-0; Matza D, 2009, P NATL ACAD SCI USA, V106, P9785, DOI 10.1073/pnas.0902844106; Navedo MF, 2006, J GEN PHYSIOL, V127, P611, DOI 10.1085/jgp.200609519; Navedo MF, 2005, P NATL ACAD SCI USA, V102, P11112, DOI 10.1073/pnas.0500360102; Omilusik K, 2011, IMMUNITY, V35, P349, DOI 10.1016/j.immuni.2011.07.011; Qui B, 2011, CELL CALCIUM, V50, P261, DOI 10.1016/j.ceca.2011.05.015; Richards MW, 2004, TRENDS PHARMACOL SCI, V25, P626, DOI 10.1016/j.tips.2004.10.008; Robert V, 2011, BIOCHIMIE, V93, P2087, DOI 10.1016/j.biochi.2011.06.016; Sallusto F, 2009, EUR J IMMUNOL, V39, P2076, DOI 10.1002/eji.200939722; Santana LF, 2010, J GEN PHYSIOL, V136, P143, DOI 10.1085/jgp.200910391; Savignac M, 2001, FASEB J, V15, P1577, DOI 10.1096/fj.00-0733fje; SloanLancaster J, 1997, J IMMUNOL, V159, P1160; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Stokes L, 2004, J BIOL CHEM, V279, P19566, DOI 10.1074/jbc.M401481200; Strauss O, 1997, FASEB J, V11, P859, DOI 10.1096/fasebj.11.11.9285484; Suzuki Y, 2010, MOL IMMUNOL, V47, P640, DOI 10.1016/j.molimm.2009.10.013; Tiwari S, 2006, IEEE T NANOTECHNOL, V5, P1, DOI 10.1109/TNANO.2005.861407; Tran-Van-Minh A, 2010, J NEUROSCI, V30, P12856, DOI 10.1523/JNEUROSCI.2700-10.2010; Triggle DJ, 2007, BIOCHEM PHARMACOL, V74, P1, DOI 10.1016/j.bcp.2007.01.016; Vig M, 2009, NAT IMMUNOL, V10, P21, DOI 10.1038/ni.f.220; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Weber KS, 2008, J IMMUNOL, V180, P1442, DOI 10.4049/jimmunol.180.3.1442	38	26	27	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1175	+		10.1016/j.jaci.2013.10.038	http://dx.doi.org/10.1016/j.jaci.2013.10.038			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24365142				2022-12-18	WOS:000333531700029
J	Schuetz, C; Pannicke, U; Jacobsen, EM; Burggraf, S; Albert, MH; Honig, M; Niehues, T; Feyen, O; Ehl, S; Debatin, KM; Friedrich, W; Schulz, AS; Schwarz, K				Schuetz, Catharina; Pannicke, Ulrich; Jacobsen, Eva-Maria; Burggraf, Siegfried; Albert, Michael H.; Hoenig, Manfred; Niehues, Tim; Feyen, Oliver; Ehl, Stephan; Debatin, Klaus-Michael; Friedrich, Wilhelm; Schulz, Ansgar S.; Schwarz, Klaus			Lesson from hypomorphic recombination-activating gene (RAG) mutations: Why asymptomatic siblings should also be tested	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LYMPHOPENIA; DEFICIENCY; DISEASE		[Schuetz, Catharina; Jacobsen, Eva-Maria; Hoenig, Manfred; Debatin, Klaus-Michael; Friedrich, Wilhelm; Schulz, Ansgar S.] Univ Hosp Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Pannicke, Ulrich; Schwarz, Klaus] Univ Ulm, Inst Transfus Med, D-89069 Ulm, Germany; [Burggraf, Siegfried] Lab Becker Olgemoller & Kollegen, Munich, Germany; [Albert, Michael H.] Dr von Hauner Univ, Childrens Hosp, Munich, Germany; [Niehues, Tim] Univ Dusseldorf, Acad Hosp, HELIOS Klinikum Krefeld, Ctr Child & Adolescent Hlth, Dusseldorf, Germany; [Feyen, Oliver] Univ Dusseldorf, Childrens Hosp, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany; [Feyen, Oliver] Tavarlin AG, Darmstadt, Germany; [Ehl, Stephan] Univ Hosp Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Schwarz, Klaus] German Red Cross Blood Serv, Inst Clin Transfus Med & Immunogenet Ulm, Baden Wurttemberg Hessen, Germany	Ulm University; Ulm University; University of Munich; Heinrich Heine University Dusseldorf; Helios Kliniken; Heinrich Heine University Dusseldorf; University of Freiburg	Schuetz, C (corresponding author), Univ Hosp Ulm, Dept Pediat & Adolescent Med, Ulm, Germany.	catharina.schuetz@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Ehl, Stephan/AAM-6006-2020	Debatin, Klaus-Michael/0000-0002-8397-1886; Ehl, Stephan/0000-0002-9265-2721				Abraham RS, 2013, J ALLERGY CLIN IMMUN, V131, P1421, DOI 10.1016/j.jaci.2012.09.016; Asai E, 2011, CLIN IMMUNOL, V138, P172, DOI 10.1016/j.clim.2010.11.005; Avila EM, 2010, PEDIATRICS, V126, pE1248, DOI 10.1542/peds.2009-3171; De Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583; Ehl S, 2005, J CLIN INVEST, V115, P3140, DOI 10.1172/JCI25221; Henderson LA, 2013, J ALLERGY CLIN IMMUN, V132, P969, DOI 10.1016/j.jaci.2013.06.032; Kuijpers TW, 2011, BLOOD, V117, P5892, DOI 10.1182/blood-2011-01-329052; McCusker C, 2009, CLIN IMMUNOL, V131, P447, DOI 10.1016/j.clim.2009.01.014; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Speckmann C, 2012, J ALLERGY CLIN IMMUN, V130, P991, DOI 10.1016/j.jaci.2012.04.004; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037	12	26	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1211	1215		10.1016/j.jaci.2013.10.021	http://dx.doi.org/10.1016/j.jaci.2013.10.021			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24331380				2022-12-18	WOS:000333531700035
J	Lukawska, JJ; Livieratos, L; Sawyer, BM; Lee, T; O'Doherty, M; Blower, PJ; Kofi, M; Ballinger, JR; Corrigan, CJ; Gnanasegaran, G; Sharif-Paghaleh, E; Mullen, GED				Lukawska, Joanna J.; Livieratos, Lefteris; Sawyer, Barbara M.; Lee, Tak; O'Doherty, Michael; Blower, Philip J.; Kofi, Martin; Ballinger, James R.; Corrigan, Christopher J.; Gnanasegaran, Gopinath; Sharif-Paghaleh, Ehsan; Mullen, Gregory E. D.			Real-time differential tracking of human neutrophil and eosinophil migration in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Granulocytes; eosinophils; neutrophils; kinetics; radiolabeled; lung; liver; spleen; bone marrow; technetium 99m-hexamethylpropyleneamine oxime	LABELED LEUKOCYTES; GRANULOCYTES; KINETICS; TC-99M-HMPAO; SEPARATION; CELLS; EXPRESSION; SPLEEN	Background: Hitherto, in vivo studies of human granulocyte migration have been based on indiscriminate labeling of total granulocyte populations. We hypothesized that the kinetics of isolated human neutrophil and eosinophil migration through major organs in vivo are fundamentally different, with the corollary that studying unseparated populations distorts measurement of both. Methods: Blood neutrophils and eosinophils were isolated on 2 separate occasions from human volunteers by using Current Good Manufacturing Practice CD16 CliniMACS isolation, labeled with technetium 99m-hexamethylpropyleneamine oxime, and then reinfused intravenously. The kinetics of cellular efflux were imaged over 4 hours. Results: Neutrophils and eosinophils were isolated to a mean purity of greater than 97% and greater than 95%, respectively. Activation of neutrophils measured as an increase in their CD11b mean fluorescence intensity in whole blood and after isolation and radiolabeling was 25.98 +/- 7.59 and 51.82 +/- 17.44, respectively, and was not significant (P = .052), but the mean fluorescence intensity of CD69 increased significantly on eosinophils. Analysis of the scintigraphic profile of lung efflux revealed exponential clearance of eosinophils, with a mean half-life of 4.16 +/- 0.11 minutes. Neutrophil efflux was at a significantly slower half-life of 13.72 +/- 4.14 minutes (P = .009). The migration of neutrophils and eosinophils was significantly different in the spleen at all time points (P = .014), in the liver at 15 minutes (P = .001), and in the bone marrow at 4 hours (P = .003). Conclusions: The kinetics of migration of neutrophils and eosinophils through the lung, spleen, and bone marrow of human volunteers are significantly different. Study of mixed populations might be misleading.	[Lukawska, Joanna J.; Livieratos, Lefteris; Sawyer, Barbara M.; O'Doherty, Michael; Blower, Philip J.; Ballinger, James R.; Sharif-Paghaleh, Ehsan; Mullen, Gregory E. D.] Kings Coll London, Div Imaging Sci & Bioengn, St Thomas Hosp, London SE1 7EH, England; [Lukawska, Joanna J.; Lee, Tak; Corrigan, Christopher J.] Kings Coll London, Dept Asthma Allergy & Resp Sci, Guys Hosp, London SE1 7EH, England; [Livieratos, Lefteris; O'Doherty, Michael; Kofi, Martin; Ballinger, James R.; Gnanasegaran, Gopinath] Guys Hosp, Dept Nucl Med, London SE1 9RT, England; [Livieratos, Lefteris; O'Doherty, Michael; Kofi, Martin; Ballinger, James R.; Gnanasegaran, Gopinath] St Thomas Hosp, London, England; [Blower, Philip J.] Kings Coll London, Div Chem, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Mullen, GED (corresponding author), Kings Coll London, Dept Imaging Chem & Biol, St Thomas Hosp, Div Imaging Sci & Bioengn, London SE1 7EH, England.	greg.mullen@kcl.ac.uk	Lee, Tak/AAA-9526-2020; Blower, Phil/GSD-5552-2022	Lee, Tak/0000-0002-7554-4059; Corrigan, Chris/0000-0002-0706-6534; Blower, Philip/0000-0001-6290-1590	Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; Lee Lu Cheung Fund; Medical Research Council [MR/J006742/1, G1000758, G1000758B] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish	Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; Lee Lu Cheung Fund; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Supported by the Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust and by the Lee Lu Cheung Fund.	ATHENS JW, 1961, J CLIN INVEST, V40, P159, DOI 10.1172/JCI104230; BECKER W, 1988, NUCL MED COMMUN, V9, P435, DOI 10.1097/00006231-198806000-00008; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; DOWNEY GP, 1990, J APPL PHYSIOL, V69, P1767, DOI 10.1152/jappl.1990.69.5.1767; Farahi N, 2012, BLOOD, V120, P4068, DOI 10.1182/blood-2012-07-443424; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; Huston JM, 2009, J IMMUNOL, V183, P552, DOI 10.4049/jimmunol.0802684; Jacobsen EA, 2011, J IMMUNOL, V187, P6059, DOI 10.4049/jimmunol.1102299; KUIJPERS TW, 1991, BLOOD, V78, P1105; MACEY MG, 1992, J IMMUNOL METHODS, V149, P37, DOI 10.1016/S0022-1759(12)80046-9; MAUER AM, 1960, J CLIN INVEST, V39, P1481, DOI 10.1172/JCI104167; Moberg L, 2001, BRIT J HAEMATOL, V114, P185, DOI 10.1046/j.1365-2141.2001.02889.x; OHGAMI M, 1989, J APPL PHYSIOL, V66, P1881, DOI 10.1063/1.344370; Oren A, 2005, J IMMUNOL METHODS, V303, P1, DOI 10.1016/j.jim.2005.04.022; PETERS AM, 1988, NUCL MED COMMUN, V9, P449, DOI 10.1097/00006231-198806000-00009; PETERS AM, 1985, SCAND J HAEMATOL, V34, P111; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; PUNCHER MRB, 1994, EUR J NUCL MED, V21, P1175; SAVERYMUTTU SH, 1985, BRIT J HAEMATOL, V61, P675, DOI 10.1111/j.1365-2141.1985.tb02882.x; SAVERYMUTTU SH, 1983, SCAND J HAEMATOL, V30, P151; SCHMIDSCHONBEIN GW, 1981, BIOPHYS J, V36, P243, DOI 10.1016/S0006-3495(81)84726-1; Stanciu LA, 1996, J IMMUNOL METHODS, V189, P107, DOI 10.1016/0022-1759(95)00240-5; Suratt BT, 2001, AM J PHYSIOL-LUNG C, V281, pL913, DOI 10.1152/ajplung.2001.281.4.L913; USSOV WY, 1995, J APPL PHYSIOL, V78, P1388, DOI 10.1152/jappl.1995.78.4.1388; USSOV WY, 1995, SCAND J CLIN LAB INV, V55, P87, DOI 10.3109/00365519509075382; Van TC, 2011, NAT IMMUNOL, V12, P151, DOI 10.1038/ni.1981; Wang HB, 2008, J LEUKOCYTE BIOL, V83, P817, DOI 10.1189/jlb.0607392	27	26	26	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					233	+		10.1016/j.jaci.2013.06.031	http://dx.doi.org/10.1016/j.jaci.2013.06.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23953710	Bronze			2022-12-18	WOS:000329105700031
J	Woessner, KM; White, AA				Woessner, Katharine M.; White, Andrew A.			Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							LEUKOTRIENE-MODIFIER DRUGS; INDUCED ASTHMA; SENSITIVE ASTHMATICS; CYSTEINYL-LEUKOTRIENES; INTOLERANT ASTHMA; NATURAL-HISTORY; NASAL POLYPS; PREVALENCE; CHALLENGES; RHINOSINUSITIS		[Woessner, Katharine M.; White, Andrew A.] Scripps Clin, Med Grp, Div Allergy Asthma & Immunol, San Diego, CA 92130 USA	Scripps Research Institute	Woessner, KM (corresponding author), Scripps Clin, Med Grp, Div Allergy Asthma & Immunol, 3811 Valley Ctr Dr, San Diego, CA 92130 USA.	Woessner.katharine@scrippshealth.org						Antczak A, 2002, AM J RESP CRIT CARE, V166, P301, DOI 10.1164/rccm.2101021; Berges-Gimeno MP, 2003, ANN ALLERG ASTHMA IM, V90, P338, DOI 10.1016/S1081-1206(10)61803-0; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Dahlen B, 2000, AM J RESP CRIT CARE, V161, pS137, DOI 10.1164/ajrccm.161.supplement_1.ltta-27; Dursun AB, 2008, ANN ALLERG ASTHMA IM, V100, P420, DOI 10.1016/S1081-1206(10)60465-6; Fahrenholz JM, 2003, CLIN REV ALLERG IMMU, V24, P113, DOI 10.1385/CRIAI:24:2:113; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Hope AP, 2009, J ALLERGY CLIN IMMUN, V123, P406, DOI 10.1016/j.jaci.2008.09.048; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; Katial RK, 2010, J ALLERGY CLIN IMMUN, V126, P738, DOI 10.1016/j.jaci.2010.06.036; KOWALSKI ML, 1986, EUR J RESPIR DIS, V69, P219; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Lee JY, 2007, J ALLERGY CLIN IMMUN, V119, P157, DOI 10.1016/j.jaci.2006.09.011; Lee RU, 2011, ALLERGY ASTHMA IMMUN, V3, P3, DOI 10.4168/aair.2011.3.1.3; Lee RU, 2010, ANN ALLERG ASTHMA IM, V105, P130, DOI 10.1016/j.anai.2010.05.020; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Steinke JW, 2009, J ALLERGY CLIN IMMUN, V124, P724, DOI 10.1016/j.jaci.2009.07.031; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Stevenson DD, 2004, IMMUNOL ALLERGY CLIN, V24, P491, DOI 10.1016/j.iac.2004.03.001; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; Stevenson DD, 2009, CURR ALLERGY ASTHM R, V9, P155, DOI 10.1007/s11882-009-0023-4; Szczeklik A, 2008, MIDDLETONS ALLERGY P, P1227; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0; White A, 2006, ANN ALLERG ASTHMA IM, V97, P688, DOI 10.1016/S1081-1206(10)61101-5; White A, 2006, ANN ALLERG ASTHMA IM, V97, P190, DOI 10.1016/S1081-1206(10)60012-9; White AA, 2013, ALLERGY ASTHMA PROC, V34, P378, DOI 10.2500/aap.2013.34.3670; White AA, 2013, ALLERGY ASTHMA PROC, V34, P138, DOI 10.2500/aap.2013.34.3644; Williams AN, 2007, J ALLERGY CLIN IMMUN, V120, P273, DOI 10.1016/j.jaci.2007.03.020; Woessner KM, 2013, IMMUNOL ALLERGY CLIN, V33, P263, DOI 10.1016/j.iac.2012.11.004; Woessner KM, 2002, ARTHRITIS RHEUM, V46, P2201, DOI 10.1002/art.10426	43	26	27	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					286	+		10.1016/j.jaci.2013.11.016	http://dx.doi.org/10.1016/j.jaci.2013.11.016			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24369807				2022-12-18	WOS:000329105700047
J	Barchuk, WT; Salapatek, AM; Ge, TT; D'Angelo, P; Liu, XJ				Barchuk, William T.; Salapatek, Anne Marie; Ge, Tingting; D'Angelo, Pina; Liu, Xuejun			A proof-of-concept study of the effect of a novel H-3-receptor antagonist in allergen-induced nasal congestion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; acoustic rhinometry; environmental exposure chamber; H-3-receptor antagonist; JNJ-39220675; pseudoephedrine; total nasal symptom scores	HISTAMINE H-3 RECEPTOR; RHINITIS; IDENTIFICATION; CHALLENGE; TARGET	Background: H-1-receptor inverse agonists are used effectively for treating several symptoms of allergic rhinitis, including nasal itching, rhinorrhea, and sneezing, although most agents are not very effective in treating nasal congestion. Objective: This study evaluated the relative efficacy of a novel selective H-3-receptor antagonist, JNJ-39220675, in preventing nasal congestion induced by exposing participants with ragweed allergy to ragweed allergen in an environmental exposure chamber model. Methods: In this single-dose, patient-blind, double-dummy, placebo-and active-controlled, phase IIa cross-over study, 53 participants were randomized to JNJ-39220675 plus placebo, placebo plus pseudoephedrine, or only placebo. The primary efficacy assessment was change in nasal patency assessed by measuring the minimal cross-sectional area of the nasal cavity by using acoustic rhinometry. Secondary assessment included total nasal symptom scores (TNSSs) over the 8-hour environmental exposure chamber exposure period. Results: Smaller decreases in minimal cross-sectional area were observed after JNJ-39220675 (least square mean difference, -0.126; P = .06) and pseudoephedrine (least square mean difference, -0.195; P = .004) treatment compared with placebo. The means for the baseline-adjusted area under the curve of TNSSs were significantly smaller for JNJ-39220675 (P = .0003) and pseudoephedrine (P = .04) versus placebo. JNJ-39220675 was significantly effective in treating all 4 individual symptoms (P <= .05 for all scores) compared with placebo, whereas pseudoephedrine only showed a trend for improvement in individual symptom scores of the TNSS. Insomnia was the most frequent adverse event (17.3%) associated with JNJ-39220675 treatment. Conclusion: Prophylactic treatment with the H-3-antagonist JNJ-39220675 relieved allergen-induced nasal congestion by using standard nasal symptom scoring; however, in contrast to pseudoephedrine, it only showed a trend for increasing nasal patency by using objective measures.	[Barchuk, William T.; Ge, Tingting; Liu, Xuejun] Janssen Res & Dev, San Diego, CA 92121 USA; [Salapatek, Anne Marie] McMaster Univ, Hamilton, ON, Canada; [D'Angelo, Pina] Cetero Res, Mississauga, ON, Canada	McMaster University	Barchuk, WT (corresponding author), Janssen Res & Dev, Immunol Translat Med Dev, 3210 Merryfield Row, San Diego, CA 92121 USA.	wbarchuk@its.jnj.com			Janssen Research & Development, LLC (formerly Johnson and Johnson Research and Development, LLC); Cetero Research; Janssen Research Development	Janssen Research & Development, LLC (formerly Johnson and Johnson Research and Development, LLC); Cetero Research; Janssen Research Development	Supported by Janssen Research & Development, LLC (formerly Johnson and Johnson Research and Development, LLC).; Disclosure of potential conflict of interest: W. T. Barchuk is employed by and owns stock/ stock options in Janssen Research & Development. A. M. Salapatek and P. D'Angelo have been supported by one or more grants from Cetero Research at the time of the study, which was sponsored by Janssen Research & Development. T. Ge and X. Liu are employed by Janssen Research & Development.	ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; Baroody FM, 2011, J ALLERGY CLIN IMMUN, V127, P927, DOI 10.1016/j.jaci.2011.01.037; Bonaventure P, 2007, BIOCHEM PHARMACOL, V73, P1084, DOI 10.1016/j.bcp.2006.10.031; Celanire S, 2005, DRUG DISCOV TODAY, V10, P1613, DOI 10.1016/S1359-6446(05)03625-1; Daley-Yates P, 2012, INT ARCH ALLERGY IMM, V158, P84, DOI 10.1159/000329738; Erin EM, 2005, ALLERGY, V60, P1524, DOI 10.1111/j.1398-9995.2005.00928.x; Esbenshade TA, 2008, BRIT J PHARMACOL, V154, P1166, DOI 10.1038/bjp.2008.147; Galici R, 2011, PSYCHOPHARMACOLOGY, V214, P829, DOI 10.1007/s00213-010-2092-4; Greiff L, 2001, CLIN EXP ALLERGY, V31, P1321, DOI 10.1046/j.1365-2222.2001.01029.x; Kuhne S, 2011, EXPERT OPIN INV DRUG, V20, P1629, DOI 10.1517/13543784.2011.625010; Latte J, 2004, CLIN EXP PHARMACOL P, V31, P429, DOI 10.1111/j.1440-1681.2004.04013.x; Letavic MA, 2006, PROGR MED CHEM, V44, P181, DOI 10.1016/S0079-6468(05)44405-7; Letavic MA, 2010, BIOORG MED CHEM LETT, V20, P4210, DOI 10.1016/j.bmcl.2010.05.041; Leurs R, 2005, NAT REV DRUG DISCOV, V4, P107, DOI 10.1038/nrd1631; Logan J, 2012, PSYCHOPHARMACOLOGY, V223, P447, DOI 10.1007/s00213-012-2733-x; Nakaya M, 2004, ANN OTO RHINOL LARYN, V113, P552, DOI 10.1177/000348940411300707; Nathan Robert A, 2005, J Allergy Clin Immunol, V115, pS442, DOI 10.1016/j.jaci.2004.12.015; Reed SD, 2004, PHARMACOECONOMICS, V22, P345, DOI 10.2165/00019053-200422060-00002; Saengpanich S, 2002, LARYNGOSCOPE, V112, P47, DOI 10.1097/00005537-200201000-00009; Salapatek AM, 2010, AM J RHINOL ALLERGY, V24, P433, DOI 10.2500/ajra.2010.24.3548; Sarin S, 2006, J ALLERGY CLIN IMMUN, V118, P999, DOI 10.1016/j.jaci.2006.09.013; Sekizawa SI, 2010, TOXICOL APPL PHARM, V247, P204, DOI 10.1016/j.taap.2010.06.014; Simons FER, 2011, J ALLERGY CLIN IMMUN, V128, P1139, DOI 10.1016/j.jaci.2011.09.005; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Stokes JR, 2012, J ALLERGY CLIN IMMUN, V129, P409, DOI 10.1016/j.jaci.2011.11.026; Thurmond RL, 2008, NAT REV DRUG DISCOV, V7, P41, DOI 10.1038/nrd2465; Undem Bradley J., 2000, Journal of Allergy and Clinical Immunology, V106, pS213; Varty LM, 2004, EUR J PHARMACOL, V484, P83, DOI 10.1016/j.ejphar.2003.10.051; Xie H, 2005, WORLD J GASTROENTERO, V11, P2851, DOI 10.3748/wjg.v11.i19.2851	29	26	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					838	+		10.1016/j.jaci.2013.05.001	http://dx.doi.org/10.1016/j.jaci.2013.05.001			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23791513	Bronze			2022-12-18	WOS:000325096500010
J	Kannan, AK; Sahu, N; Mohanan, S; Mohinta, S; August, A				Kannan, Arun K.; Sahu, Nisebita; Mohanan, Sunish; Mohinta, Sonia; August, Avery			IL-2-inducible T-cell kinase modulates T(H)2-mediated allergic airway inflammation by suppressing IFN-gamma in naive CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tec kinase; T(H)2; allergic asthma; T-bet; Eomesodermin; IFN-gamma	TEC-FAMILY KINASES; LYMPHOCYTE DEVELOPMENT; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; TYROSINE KINASE; MICE LACKING; ASTHMA; ITK; DIFFERENTIATION; RESPONSES	Background: Asthma is a predominantly T(H)2 cell-dominated inflammatory disease characterized by airway inflammation and a major public health concern affecting millions of persons. The Tec family tyrosine kinase IL-2-inducible T-cell kinase (Itk) is primarily expressed in T cells and critical for the function and differentiation of T-H cells. Itk (-/-) mice have a defective T(H)2 response and are not susceptible to allergic asthma. Objective: We sought to better understand the role of Itk signaling in TH differentiation programs and in the development and molecular pathology of allergic asthma. Methods: Using a murine model of allergic airway inflammation, we dissected the role of Itk in regulating TH cell differentiation through genetic ablation of critical genes, chromatin immunoprecipitation assays, and house dust mite-driven allergic airway inflammation. Results: Peripheral naive Itk (-/-) CD4 1 T cells have substantially increased transcripts and expression of the prototypic T(H)1 genes Eomesodermin, IFN-gamma, T-box transcription factor (T-bet), and IL-12R beta 1. Removal of IFN-gamma on the Itk (-/-) background rescues expression of TH2-related genes in TH cells and allergic airway inflammation in Itk (-/-) mice. Furthermore, small hairpin RNA-mediated knockdown of Itk in human peripheral blood T cells results in increased expression of mRNA for IFN-gamma and T-bet and reduction in expression of IL-4. Conclusion: Our results indicate that Itk signals suppress the expression of IFN-gamma in naive CD4 1 T cells, which in a positive feed-forward loop regulates the expression of T(H)1 factors, such as T-bet and Eomesodermin, and suppress development of T(H)2 cells and allergic airway inflammation.	[Kannan, Arun K.; Mohinta, Sonia; August, Avery] Cornell Univ, Dept Microbiol & Immunol, Ithaca, NY USA; [Sahu, Nisebita] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Mohanan, Sunish] Cornell Univ, Baker Inst Anim Hlth, Dept Biomed Sci, Ithaca, NY USA	Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Cornell University	August, A (corresponding author), Cornell Univ, Coll Vet Med, Dept Microbiol & Immunol, VMC 5171, Ithaca, NY 14853 USA.	averyaugust@cornell.edu			National Institutes of Health [AI051626, AI065566]; Ono Pharmaceuticals; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051626, R56AI065566, R01AI073955, R01AI065566] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ono Pharmaceuticals; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (AI051626 and AI065566). Disclosure of potential conflict of interest: A. August has received research support from the National Institutes of Health (NIH) and Ono Pharmaceuticals. The rest of the authors have received research support from the NIH.	Au-Yeung BB, 2006, J IMMUNOL, V176, P3895, DOI 10.4049/jimmunol.176.7.3895; Berg LJ, 2005, ANNU REV IMMUNOL, V23, P549, DOI 10.1146/annurev.immunol.22.012703.104743; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Denton AE, 2011, P NATL ACAD SCI USA, V108, P15306, DOI 10.1073/pnas.1112520108; Ferrara TJ, 2006, J ALLERGY CLIN IMMUN, V117, P780, DOI 10.1016/j.jaci.2005.12.1330; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamid Q, 2009, ANNU REV PHYSIOL, V71, P489, DOI 10.1146/annurev.physiol.010908.163200; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Kosaka Y, 2006, TRENDS IMMUNOL, V27, P453, DOI 10.1016/j.it.2006.08.006; Lewis MD, 2007, MOL CELL BIOL, V27, P8510, DOI 10.1128/MCB.01615-07; Miller AT, 2004, IMMUNITY, V21, P67, DOI 10.1016/j.immuni.2004.06.009; Mueller C, 2003, J IMMUNOL, V170, P5056, DOI 10.4049/jimmunol.170.10.5056; Nakayama T, 2010, SEMIN IMMUNOL, V22, P303, DOI 10.1016/j.smim.2010.04.010; Readinger JA, 2009, IMMUNOL REV, V228, P93, DOI 10.1111/j.1600-065X.2008.00757.x; Sahu N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011348; Schaeffer EM, 2001, NAT IMMUNOL, V2, P1183, DOI 10.1038/ni734; Schoenborn JR, 2007, NAT IMMUNOL, V8, P732, DOI 10.1038/ni1474; Schwartzberg PL, 2005, NAT REV IMMUNOL, V5, P284, DOI 10.1038/nri1591; Sprent J, 2008, IMMUNOL CELL BIOL, V86, P312, DOI 10.1038/icb.2008.12; Sugita M, 2003, INTERNAL MED, V42, P636, DOI 10.2169/internalmedicine.42.636; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Teixeira LK, 2005, MEM I OSWALDO CRUZ, V100, P137, DOI 10.1590/S0074-02762005000900024; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007	29	26	26	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					811	+		10.1016/j.jaci.2013.04.033	http://dx.doi.org/10.1016/j.jaci.2013.04.033			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23768572	Green Accepted			2022-12-18	WOS:000325096500005
J	Pahr, S; Constantin, C; Papadopoulos, NG; Giavi, S; Makela, M; Pelkonen, A; Ebner, C; Mari, A; Scheiblhofer, S; Thalhamer, J; Kundi, M; Vrtala, S; Mittermann, I; Valenta, R				Pahr, Sandra; Constantin, Claudia; Papadopoulos, Nikolaos G.; Giavi, Stavroula; Maekelae, Mika; Pelkonen, Anna; Ebner, Christof; Mari, Adriano; Scheiblhofer, Sandra; Thalhamer, Josef; Kundi, Michael; Vrtala, Susanne; Mittermann, Irene; Valenta, Rudolf			alpha-Purothionin, a new wheat allergen associated with severe allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GLIADIN; TOOL		[Pahr, Sandra; Constantin, Claudia; Vrtala, Susanne; Mittermann, Irene; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Pahr, Sandra; Vrtala, Susanne; Mittermann, Irene] Med Univ Vienna, Christian Doppler Lab Dev Allergen Chips, Vienna, Austria; [Papadopoulos, Nikolaos G.; Giavi, Stavroula] Univ Athens, Dept Allergy, GR-10679 Athens, Greece; [Maekelae, Mika; Pelkonen, Anna] Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, FIN-00014 Helsinki, Finland; [Ebner, Christof] Ambulatory Allergy & Clin Immunol, Vienna, Austria; [Mari, Adriano] IDIIRCCS, Ctr Mol Allergol, Rome, Italy; [Scheiblhofer, Sandra; Thalhamer, Josef] Salzburg Univ, Dept Mol Biol, Div Allergy & Immunol, A-5020 Salzburg, Austria; [Kundi, Michael] Med Univ Vienna, Inst Environm Hlth, Ctr Publ Hlth, Vienna, Austria; [Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; National & Kapodistrian University of Athens; University of Helsinki; Helsinki University Central Hospital; Salzburg University; Medical University of Vienna; Medical University of Vienna	Pahr, S (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Papadopoulos, Nikolaos/ABE-1774-2021; N.G., Papadopoulos/L-8670-2013; Thalhamer, Josef/E-5787-2011; Pelkonen, Anna/D-3153-2018	Papadopoulos, Nikolaos/0000-0002-4448-3468; N.G., Papadopoulos/0000-0002-4448-3468; Thalhamer, Josef/0000-0003-2285-6400; Pelkonen, Anna/0000-0002-1482-8947; Papadopoulos, Nikolaos/0000-0002-2508-3872; Valenta, Rudolf/0000-0001-5944-3365; Mittermann, Irene/0000-0002-6240-6730; Makela, Mika/0000-0002-2933-3111; Vrtala, Susanne/0000-0003-4250-8243; Scheiblhofer, Sandra/0000-0003-2867-9054				Constantin C, 2008, J IMMUNOL, V180, P7451, DOI 10.4049/jimmunol.180.11.7451; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; GOLDSTEIN GB, 1969, J ALLERGY, V44, P37, DOI 10.1016/0021-8707(69)90046-X; Helm Ricki M, 2008, Clin Allergy Immunol, V21, P219; Pahr S, 2012, CLIN EXP ALLERGY, V42, P597, DOI 10.1111/j.1365-2222.2012.03961.x; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Schocker F, 2004, J ALLERGY CLIN IMMUN, V113, P141, DOI 10.1016/j.jaci.2003.09.013; Stec B, 2004, J PEPT RES, V64, P210, DOI 10.1111/j.1399-3011.2004.00187.x; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x	10	26	27	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					1000	+		10.1016/j.jaci.2013.05.016	http://dx.doi.org/10.1016/j.jaci.2013.05.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23810762				2022-12-18	WOS:000325096500038
J	Watanabe, Y; Sasahara, Y; Ramesh, N; Massaad, MJ; Looi, CY; Kumaki, S; Kure, S; Geha, RS; Tsuchiya, S				Watanabe, Yuko; Sasahara, Yoji; Ramesh, Narayanaswamy; Massaad, Michel J.; Looi, Chung Yeng; Kumaki, Satoru; Kure, Shigeo; Geha, Raif S.; Tsuchiya, Shigeru			T-cell receptor ligation causes Wiskott-Aldrich syndrome protein degradation and F-actin assembly downregulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wiskott-Aldrich syndrome; Wiskott-Aldrich syndrome protein; T-cell receptor; calpain; ubiquitination; proteasome; F-actin; Cbl family proteins	X-LINKED NEUTROPENIA; TYROSINE PHOSPHORYLATION; IMMUNOLOGICAL SYNAPSE; NEGATIVE REGULATION; SYNDROME GENE; CBL-B; WASP; ACTIVATION; POLYMERIZATION; WIP	Background: Wiskott-Aldrich syndrome protein (WASP) links T-cell receptor (TCR) signaling to the actin cytoskeleton. WASP is normally protected from degradation by the Ca++-dependent protease calpain and by the proteasome because of its interaction with the WASP-interacting protein. Objective: We investigated whether WASP is degraded after TCR ligation and whether its degradation downregulates F-actin assembly caused by TCR ligation. Methods: Primary T cells, Jurkat T cells, and transfected 293T cells were used in immunoprecipitation experiments. Intracellular F-actin content was measured in splenic T cells from wild-type, WASP-deficient, and c-Casitas B-lineage lymphoma (Cbl)-b-deficient mice by using flow cytometry. Calpeptin and MG-132 were used to inhibit calpain and the proteasome, respectively. Results: A fraction of WASP in T cells was degraded by calpain and by the ubiquitin-proteasome pathway after TCR ligation. The Cbl-b and c-Cbl E3 ubiquitin ligases associated with WASP after TCR signaling and caused its ubiquitination. Inhibition of calpain and lack of Cbl-b resulted in a significantly more sustained increase in F-actin content after TCR ligation in wildtype T cells but not in WASP-deficient T cells. Conclusion: TCR ligation causes WASP to be degraded by calpain and to be ubiquitinated by Cbl family E3 ligases, which targets it for destruction by the proteasome. WASP degradation might provide a mechanism for regulating WASP-dependent TCR-driven assembly of F-actin.	[Watanabe, Yuko; Sasahara, Yoji; Looi, Chung Yeng; Kumaki, Satoru; Kure, Shigeo; Tsuchiya, Shigeru] Tohoku Univ, Grad Sch Med, Dept Pediat, Sendai, Miyagi 9808574, Japan; [Ramesh, Narayanaswamy; Massaad, Michel J.; Geha, Raif S.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; [Ramesh, Narayanaswamy; Massaad, Michel J.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Tohoku University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Sasahara, Y (corresponding author), Tohoku Univ, Grad Sch Med, Dept Pediat, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	ysasahara@med.tohoku.ac.jp	Looi, Chung Yeng/A-2623-2013	Looi, Chung Yeng/0000-0002-4830-3495	Japan Ministry of Education, Culture, Sports, Science and Technology; Japan Ministry of Health, Labour and Welfare; Japan Foundation for Pediatric Research; Mother and Child Health Foundation; US Public Health Service [HL059561]; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER	Japan Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Japan Foundation for Pediatric Research; Mother and Child Health Foundation(Mother and Child Health Foundation); US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants-in-aid from the Japan Ministry of Education, Culture, Sports, Science and Technology and a grant for research on intractable diseases from the Japan Ministry of Health, Labour and Welfare (to Y.S. and S.T.), grants from the Japan Foundation for Pediatric Research and the Mother and Child Health Foundation (to Y.S.) and by US Public Health Service grant HL059561.; The authors have been supported by one or more grants from the National Institutes of Health.	Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Anton IM, 2007, TRENDS CELL BIOL, V17, P555, DOI 10.1016/j.tcb.2007.08.005; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Badour K, 2004, SEMIN IMMUNOL, V16, P395, DOI 10.1016/j.smim.2004.08.019; Baud V, 2011, CURR TOP MICROBIOL, V349, P97, DOI 10.1007/82_2010_101; Beel K, 2009, BRIT J HAEMATOL, V144, P120, DOI 10.1111/j.1365-2141.2008.07416.x; Bronevetsky Y, 2013, J EXP MED, V210, P417, DOI 10.1084/jem.20111717; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; Chou HC, 2006, CURR BIOL, V16, P2337, DOI 10.1016/j.cub.2006.10.037; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; de la Fuente MA, 2007, P NATL ACAD SCI USA, V104, P926, DOI 10.1073/pnas.0610275104; DEJONGH KS, 1994, J NEUROCHEM, V63, P1558, DOI 10.1046/j.1471-4159.1994.63041558.x; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Devriendt K, 2001, NAT GENET, V27, P313, DOI 10.1038/85886; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; Du W, 2006, HUM MUTAT, V27, P370, DOI 10.1002/humu.20308; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Forneris F, 2012, CURR OPIN STRUC BIOL, V22, P333, DOI 10.1016/j.sbi.2012.04.001; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Huang YP, 2007, J CELL SCI, V120, P723, DOI 10.1242/jcs.000786; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Kawai S, 2002, J IMMUNOL METHODS, V260, P195, DOI 10.1016/S0022-1759(01)00549-X; Krawczyk C, 2001, TRENDS CELL BIOL, V11, P212, DOI 10.1016/S0962-8924(01)01981-X; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; Lanzi G, 2012, J EXP MED, V209, P29, DOI 10.1084/jem.20110896; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Massaad MJ, 2011, J ALLERGY CLIN IMMUN, V127, P998, DOI 10.1016/j.jaci.2011.01.015; Miyoshi-Akiyama T, 2001, ONCOGENE, V20, P4058, DOI 10.1038/sj.onc.1204528; Moratto Daniele, 2007, Expert Rev Clin Immunol, V3, P813, DOI 10.1586/1744666X.3.5.813; Ochs Hans D, 2005, Curr Opin Hematol, V12, P284, DOI 10.1097/01.moh.0000168520.98990.19; Ochs HD, 2009, IMMUNOL RES, V44, P84, DOI 10.1007/s12026-008-8084-3; Ochs HD, 2006, WISKOTT ALDRICH SYND; Paolino M, 2010, SEMIN IMMUNOPATHOL, V32, P137, DOI 10.1007/s00281-010-0197-9; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Razani B, 2011, IMMUNOL REV, V244, P44, DOI 10.1111/j.1600-065X.2011.01059.x; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Reicher B, 2012, MOL CELL BIOL, V32, P3153, DOI 10.1128/MCB.00161-12; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Schenone M, 2004, CURR OPIN HEMATOL, V11, P272, DOI 10.1097/01.moh.0000130308.37353.d4; Shcherbina A, 2001, BLOOD, V98, P2988, DOI 10.1182/blood.V98.10.2988; Sims TN, 2007, CELL, V129, P773, DOI 10.1016/j.cell.2007.03.037; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka Y, 2008, MOL CELL BIOL, V28, P4805, DOI 10.1128/MCB.01784-07; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P20849, DOI 10.1074/jbc.M010588200; Thrasher AJ, 2002, NAT REV IMMUNOL, V2, P635, DOI 10.1038/nri884; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; Westerberg LS, 2010, J EXP MED, V207, P1145, DOI 10.1084/jem.20091245; Wiedemann A, 2005, IMMUNOL LETT, V98, P57, DOI 10.1016/j.imlet.2004.10.014; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329	53	26	27	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					648	+		10.1016/j.jaci.2013.03.046	http://dx.doi.org/10.1016/j.jaci.2013.03.046			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23684068				2022-12-18	WOS:000323612000017
J	Rava, M; Tares, L; Lavi, I; Barreiro, E; Zock, JP; Ferrer, A; Muniozguren, N; Nadif, R; Cazzoletti, L; Kauffmann, F; Anto, JM; Guerra, S				Rava, Marta; Tares, Lluisa; Lavi, Iris; Barreiro, Esther; Zock, Jan-Paul; Ferrer, Anna; Muniozguren, Nerea; Nadif, Rachel; Cazzoletti, Lucia; Kauffmann, Francine; Anto, Josep M.; Guerra, Stefano			Serum levels of Clara cell secretory protein, asthma, and lung function in the adult general population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BIOMARKER; CC16; COPD		[Rava, Marta; Tares, Lluisa; Lavi, Iris; Zock, Jan-Paul; Anto, Josep M.; Guerra, Stefano] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Rava, Marta; Nadif, Rachel; Kauffmann, Francine] CESP Ctr Res Epidemiol & Populat Hlth, Resp & Environm Epidemiol Team, INSERM, U1018, Villejuif, France; [Rava, Marta; Nadif, Rachel; Kauffmann, Francine] Univ Paris 11, Villejuif, France; [Tares, Lluisa; Lavi, Iris; Zock, Jan-Paul; Anto, Josep M.; Guerra, Stefano] Hosp del Mar, Res Inst, IMIM, Barcelona, Spain; [Tares, Lluisa; Lavi, Iris; Zock, Jan-Paul; Anto, Josep M.; Guerra, Stefano] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain; [Barreiro, Esther] Hosp del Mar, IMIM, Dept Pulmonol, Muscle & Resp Syst Res Unit UR MAR, Barcelona, Spain; [Barreiro, Esther] Inst Salud Carlos III, Ctr Invest Red Enfermedades Resp CIBERES, Mallorca, Balearic Island, Spain; [Muniozguren, Nerea] Basque Govt, Dept Hlth, Bilbao, Basque Country, Spain; [Cazzoletti, Lucia] Univ Verona, Dept Publ Hlth & Community Med, Unit Epidemiol & Med Stat, I-37100 Verona, Italy; [Anto, Josep M.] Univ Pompeu Fabra, Barcelona, Spain; [Guerra, Stefano] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA	Pompeu Fabra University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Basque Government; University of Verona; Pompeu Fabra University; University of Arizona	Rava, M (corresponding author), Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.	marta.rava@inserm.fr	Barreiro, E/D-6919-2014; Zock, Jan-Paul/P-5034-2018; Rava, Marta/AAG-5923-2019; Nadif, Rachel/R-2876-2016; Anto, J M/H-2676-2014	Barreiro, E/0000-0003-2708-3443; Zock, Jan-Paul/0000-0002-2941-6259; Nadif, Rachel/0000-0003-4938-9339; Anto, J M/0000-0002-4736-8529; Rava, Marta/0000-0003-2260-9370				Broeckaert F, 2000, CLIN EXP ALLERGY, V30, P469; Cazzoletti L, 2010, INT ARCH ALLERGY IMM, V151, P70, DOI 10.1159/000232572; Greven F, 2011, BIOMARKERS, V16, P364, DOI 10.3109/1354750X.2011.578218; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Lakind JS, 2007, BIOMARKERS, V12, P445, DOI 10.1080/13547500701359327; Lomas DA, 2008, THORAX, V63, P1058, DOI 10.1136/thx.2008.102574; Shijubo N, 1999, LUNG, V177, P45, DOI 10.1007/PL00007626; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Ye Q, 2004, RESPIRATION, V71, P505, DOI 10.1159/000080636	9	26	28	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					230	232		10.1016/j.jaci.2013.01.023	http://dx.doi.org/10.1016/j.jaci.2013.01.023			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23473837	Green Submitted			2022-12-18	WOS:000321052300034
J	Kuo, CY; Chase, J; Lloret, MG; Stiehm, ER; Moore, T; Aguilera, MJM; Siles, JL; Church, JA				Kuo, Caroline Y.; Chase, John; Lloret, Maria Garcia; Stiehm, E. Richard; Moore, Theodore; Matas Aguilera, Maria J.; Lopez Siles, Juan; Church, Joseph A.			Newborn screening for severe combined immunodeficiency does not identify bare lymphocyte syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Kuo, Caroline Y.; Lloret, Maria Garcia; Stiehm, E. Richard] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Allergy & Immunol, Los Angeles, CA 90095 USA; [Chase, John] Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA; [Chase, John; Church, Joseph A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Moore, Theodore] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90095 USA; [Matas Aguilera, Maria J.; Lopez Siles, Juan] GENETAQ, Ctr Mol Genet, Malaga, Spain; [Church, Joseph A.] Childrens Hosp Los Angeles, Div Clin Immunol & Allergy, Los Angeles, CA 90027 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Children's Hospital Los Angeles; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Children's Hospital Los Angeles	Kuo, CY (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Allergy & Immunol, Los Angeles, CA 90095 USA.	ckuo@mednet.ucla.edu		Kuo, Caroline/0000-0002-9302-0187	PHS HHS [HHSN267200603430C] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Borte S, 2011, ANN NY ACAD SCI, V1246, P118, DOI 10.1111/j.1749-6632.2011.06350.x; Buckley RH, 2012, J ALLERGY CLIN IMMUN, V129, P597, DOI 10.1016/j.jaci.2011.12.964; Picard C, 2010, IMMUNOL ALLERGY CLIN, V30, P173, DOI 10.1016/j.iac.2010.01.001; Puck JM, 2012, J ALLERGY CLIN IMMUN, V129, P607, DOI 10.1016/j.jaci.2012.01.032; Puck JM, 2011, CURR OPIN PEDIATR, V23, P667, DOI 10.1097/MOP.0b013e32834cb9b0; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; Stiehm ER, 1996, IMMUNOLOGIC DISORDER, pxviii; TOURAINE JL, 1992, BONE MARROW TRANSPL, V9, P54	8	26	30	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1693	1695		10.1016/j.jaci.2013.01.019	http://dx.doi.org/10.1016/j.jaci.2013.01.019			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23453137				2022-12-18	WOS:000320532800031
J	Ben-Shoshan, M; Sheth, S; Harrington, D; Soller, L; Fragapane, J; Joseph, L; St Pierre, Y; La Vieille, S; Elliott, S; Waserman, S; Alizadehfar, R; Harada, L; Allen, M; Allen, MH; Clarke, AE				Ben-Shoshan, Moshe; Sheth, Shashank; Harrington, Daniel; Soller, Lianne; Fragapane, Joe; Joseph, Lawrence; St Pierre, Yvan; La Vieille, Sebastien; Elliott, Susan; Waserman, Susan; Alizadehfar, Reza; Harada, Laurie; Allen, Mary; Allen, Marilyn H.; Clarke, Ann E.			Effect of precautionary statements on the purchasing practices of Canadians directly and indirectly affected by food allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATTITUDES; CHILDREN		[Ben-Shoshan, Moshe; Alizadehfar, Reza] McGill Univ, Dept Pediat, Ctr Hlth, Div Pediat Allergy & Clin Immunol, Montreal, PQ H3A 2T5, Canada; [Sheth, Shashank; Clarke, Ann E.] McGill Univ, Div Allergy & Clin Immunol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada; [Soller, Lianne; Fragapane, Joe; Joseph, Lawrence; St Pierre, Yvan; Clarke, Ann E.] McGill Univ, Div Clin Epidemiol, Ctr Hlth, Dept Med, Montreal, PQ H3A 2T5, Canada; [Harrington, Daniel] McMaster Univ, Sch Geog & Earth Sci, Hamilton, ON, Canada; [Waserman, Susan] McMaster Univ, Dept Med, Div Clin Immunol Allergy, Hamilton, ON, Canada; [Joseph, Lawrence] McGill Univ, Dept Epidemiol, Montreal, PQ H3A 2T5, Canada; [Joseph, Lawrence] McGill Univ, Dept Biostat, Montreal, PQ H3A 2T5, Canada; [La Vieille, Sebastien] Hlth Canada, Food Directorate, Ottawa, ON K1A 0L2, Canada; [Elliott, Susan] Univ Waterloo, Fac Appl Hlth Sci, Waterloo, ON N2L 3G1, Canada; [Harada, Laurie; Allen, Marilyn H.] Anaphylaxis Canada, Toronto, ON, Canada; [Allen, Mary] Allergy Asthma Informat Assoc, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McMaster University; McMaster University; McGill University; McGill University; Health Canada; University of Waterloo	Ben-Shoshan, M (corresponding author), McGill Univ, Dept Pediat, Ctr Hlth, Div Pediat Allergy & Clin Immunol, Montreal, PQ H3A 2T5, Canada.	daliamoshebs@gmail.com	Soller, Lianne/AGR-7219-2022; La Vieille, Sébastien/AAC-5087-2019	La Vieille, Sebastien/0000-0001-5368-1266				Ben-Shoshan M, 2008, ANN ALLERG ASTHMA IM, V100, P570, DOI 10.1016/S1081-1206(10)60056-7; Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Crawford P, 2010, SOCIOL HEALTH ILL, V32, P745, DOI 10.1111/j.1467-9566.2010.01238.x; Ford LS, 2010, J ALLERGY CLIN IMMUN, V126, P384, DOI 10.1016/j.jaci.2010.05.034; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; Imamura T, 2008, PEDIAT ALLERG IMM-UK, V19, P270, DOI 10.1111/j.1399-3038.2007.00621.x; Noimark L, 2009, PEDIATR ALLERGY IMMU, V20, P500, DOI 10.1111/j.1399-3038.2008.00796.x; Sheth SS, 2010, ANN ALLERG ASTHMA IM, V104, P60, DOI 10.1016/j.anai.2009.11.008	8	26	26	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1401	1404		10.1016/j.jaci.2012.01.078	http://dx.doi.org/10.1016/j.jaci.2012.01.078			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22421266				2022-12-18	WOS:000303418000033
J	Wang, CH; Huang, CD; Lin, HC; Huang, TT; Lee, KY; Lo, YL; Lin, SM; Chung, KF; Kuo, HP				Wang, Chun-Hua; Huang, Chien-Da; Lin, Horng-Chyuan; Huang, Tzu-Ting; Lee, Kang-Yun; Lo, Yu-Lun; Lin, Shu-Min; Chung, Kian Fan; Kuo, Han-Pin			Increased activation of fibrocytes in patients with chronic obstructive asthma through an epidermal growth factor receptor-dependent pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fibrocytes; epidermal growth factor receptor; a disintegrin and metalloprotease domain 17; asthma; oxidative stress	SMOOTH-MUSCLE-CELLS; OXYGEN SPECIES GENERATION; AIR-FLOW OBSTRUCTION; CIRCULATING FIBROCYTES; SUBEPITHELIAL FIBROSIS; HYDROGEN-PEROXIDE; BRONCHIAL-ASTHMA; NITRIC-OXIDE; TRANSACTIVATION; EXPRESSION	Background: Fibrocytes are circulating progenitor cells that are increased in asthmatic patients with chronic obstructive asthma (COA) and rapid decrease in lung function. Fibrocytes from patients with COA have a greater capacity for proliferation and differentiation. Objective: We investigated whether epidermal growth factor receptor (EGFR) activation mediated the proliferation of fibrocytes in patients with COA and whether oxidative stress was involved in this activation. Methods: Circulating fibrocytes from nonadherent non-T-cell mononuclear cell fractions from healthy subjects, asthmatic patients with normal pulmonary function, and patients with COA were determined by using flow cytometric coexpression of collagen I, CD45, and CD34 or EGFR or a disintegrin and metalloprotease domain 17 and placed in culture. Results: Expression of EGFR was increased in fibrocytes from patients with COA compared with that seen in patients with NPF. AG1478 and gefitinib, inhibitors of EGFR tyrosine kinase, reduced fibrocyte proliferation and myofibroblast transformation. Increased expression of EGFR and fibrocyte proliferation and transformation were induced by hydrogen peroxide, and these effects were inhibited by N-acetylcysteine. Conclusions: Enhanced fibrocyte proliferation and transformation found in patients with COA might be mediated through an oxidant-sensitive EGFR-dependent pathway. (J Allergy Clin Immunol 2012;129:1367-76.)	[Wang, Chun-Hua; Huang, Chien-Da; Lin, Horng-Chyuan; Huang, Tzu-Ting; Lee, Kang-Yun; Lo, Yu-Lun; Lin, Shu-Min; Kuo, Han-Pin] Chang Gung Mem Hosp, Pulm Dis Res Ctr, Dept Thorac Med, Taipei, Taiwan; [Wang, Chun-Hua; Lin, Horng-Chyuan] Chang Gung Univ, Dept Chinese Med, Tao Yuan, Taiwan; [Kuo, Han-Pin] Chang Gung Univ, Dept Med, Tao Yuan, Taiwan; [Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Imperial College London	Kuo, HP (corresponding author), Chang Gung Mem Hosp, Pulm Dis Res Ctr, Dept Thorac Med, 199 Tun Hwa N Rd, Taipei, Taiwan.	q8828@ms11.hinet.net	Wang, Chun-Hua/V-9861-2019; Huang, Chien-Da/AAY-3771-2021; Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012; Wang, Chun-Hua/C-1488-2016	Wang, Chun-Hua/0000-0002-3514-9353; Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Huang, Chien-Da/0000-0002-4999-6019	National Science Council [NSC-96-2628-B-182-22-my3]; Chang Gung Research Project [CMRPG 371091]; UK Wellcome Trust [085935]; MRC UK; Asthma UK; Wellcome Trust; Medical Research Council [G0801056B, G1000758B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	National Science Council(Ministry of Science and Technology, Taiwan); Chang Gung Research Project; UK Wellcome Trust(Wellcome Trust); MRC UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by Taiwan National Science Council grant NSC-96-2628-B-182-22-my3, a Chang Gung Research Project grant (CMRPG 371091), and a UK Wellcome Trust grant (no. 085935).; C. H. Wang receives research support from the National Science Council, Taiwan. K. F. Chung has consultant arrangements with Gilead, is on advisory boards for Merck and GlaxoSmithKline, and receives research support from MRC UK, Asthma UK, and the Wellcome Trust. The rest of the authors declare that they have no relevant conflicts of interest.	Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Burgel PR, 2000, J ALLERGY CLIN IMMUN, V106, P705, DOI 10.1067/mai.2000.109823; Chen CH, 2006, MOL PHARMACOL, V69, P1347, DOI 10.1124/mol.105.017558; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Klapper LN, 2000, ADV CANCER RES, V77, P25; Koh YH, 2001, FASEB J, V15, P1472, DOI 10.1096/fj.00-0572fje; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; Lee E, 2010, CANCER LETT, V290, P43, DOI 10.1016/j.canlet.2009.08.022; Liu WH, 2010, J BIOL CHEM, V285, P30506, DOI 10.1074/jbc.M110.156257; Macedo P, 2009, CLIN EXP ALLERGY, V39, P1668, DOI 10.1111/j.1365-2222.2009.03319.x; Murray LA, 2011, INT J BIOCHEM CELL B, V43, P154, DOI 10.1016/j.biocel.2010.10.013; Nihlberg K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-50; Nishimura M, 2006, FREE RADICAL RES, V40, P589, DOI 10.1080/10715760600615094; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; ROCHE WR, 1989, LANCET, V1, P520; Samitas K, 2009, RESP MED, V103, P750, DOI 10.1016/j.rmed.2008.11.009; Saunders R, 2009, J ALLERGY CLIN IMMUN, V123, P376, DOI 10.1016/j.jaci.2008.10.048; Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380; Smirnova I S, 2010, Tsitologiia, V52, P357; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Takeyama K, 2000, J IMMUNOL, V164, P1546, DOI 10.4049/jimmunol.164.3.1546; Tamaoka M, 2008, EUR RESPIR J, V32, P1213, DOI 10.1183/09031936.00166907; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161, DOI 10.1164/ajrccm/146.5_Pt_1.1161; Wang CH, 1999, J ALLERGY CLIN IMMUN, V104, P803, DOI 10.1016/S0091-6749(99)70291-5; Wang CH, 2008, AM J RESP CRIT CARE, V178, P583, DOI 10.1164/rccm.200710-1557OC; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Xu PL, 2010, MOL CELL, V37, P551, DOI 10.1016/j.molcel.2010.01.034; Zheng XG, 2007, CANCER SCI, V98, P674, DOI 10.1111/j.1349-7006.2007.00440.x; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024; Zhou Q, 2006, FEBS LETT, V580, P5161, DOI 10.1016/j.febslet.2006.08.068	40	26	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1367	1376		10.1016/j.jaci.2012.01.038	http://dx.doi.org/10.1016/j.jaci.2012.01.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22325070				2022-12-18	WOS:000303418000028
J	Bohme, M; Soderhall, C; Kull, I; Bergstrom, A; van Hage, M; Wahlgren, CF				Bohme, Maria; Soderhall, Cilla; Kull, Inger; Bergstrom, Anna; van Hage, Marianne; Wahlgren, Carl-Fredrik			Filaggrin mutations increase the risk for persistent dry skin and eczema independent of sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; BIRTH COHORT; PREDISPOSE		[Bohme, Maria; Wahlgren, Carl-Fredrik] Karolinska Univ Hosp Solna, Dept Dermatol & Venereol, Stockholm, Sweden; [Bohme, Maria; Wahlgren, Carl-Fredrik] Karolinska Inst, Dept Med, Dermatol & Venereol Unit, Stockholm, Sweden; [Soderhall, Cilla] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Bergstrom, Anna] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [van Hage, Marianne] Karolinska Univ Hosp Solna, Dept Clin Immunol, Stockholm, Sweden; [van Hage, Marianne] Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Bohme, M (corresponding author), Karolinska Univ Hosp Solna, Dept Dermatol & Venereol, Stockholm, Sweden.	Maria.Bohme@ki.se	Söderhäll, Cilla/E-3940-2012; van Hage, Marianne/A-9678-2017	Söderhäll, Cilla/0000-0002-8397-3080; van Hage, Marianne/0000-0003-3091-1596; Kull, Inger/0000-0001-6096-3771				Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Bonnelykke K, 2010, PEDIAT ALLERG IMM-UK, V21, P954, DOI 10.1111/j.1399-3038.2010.01073.x; Cramer C, 2010, J ALLERGY CLIN IMMUN, V125, P1254, DOI 10.1016/j.jaci.2010.03.036; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x	8	26	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1153	1155		10.1016/j.jaci.2011.11.032	http://dx.doi.org/10.1016/j.jaci.2011.11.032			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22360978				2022-12-18	WOS:000302144600036
J	Slater, JE; Menzies, SL; Bridgewater, J; Mosquera, A; Zinderman, CE; Ou, AC; Maloney, D; Cook, CM; Rabin, RL				Slater, Jay E.; Menzies, Sandra L.; Bridgewater, Jennifer; Mosquera, Alexis; Zinderman, Craig E.; Ou, Alan C.; Maloney, Diane; Cook, Catherine M.; Rabin, Ronald L.			The US Food and Drug Administration review of the safety and effectiveness of nonstandardized allergen extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen extracts; immunotherapy; skin testing; safety; effectiveness		Background: Nonstandardized allergen extracts have been used for a century. Until 1972, these products were regulated by the National Institutes of Health, and products were not required to have an individualized showing of effectiveness. Jurisdiction was then transferred to the US Food and Drug Administration (FDA), which established external review panels to make recommendations regarding safety and effectiveness. Two external panels deliberated, the first from 1974-1979 and the second from 1982-1983. Objective: We sought to review external panels' recommendations and assess the safety and effectiveness of nonstandardized allergen extracts, FDA-reviewed available literature, and databases since 1972. Methods: Currently licensed nonstandardized allergen extracts were reviewed according to extract type. Available data were collected from medical and nonscientific search engines. Nomenclature was ascertained by consulting www.itis.gov or www.atcc.org. The FDA's Adverse Event Reporting System was probed for events associated with extract use. Provisional threshold levels of safety and effectiveness were established, and extracts were sorted according to whether they met the thresholds. Results: In the Adverse Event Reporting System, there were 178 adverse event reports, including 13 deaths, associatedwith allergen extract use over 23 years. Nosingle group of extracts predominated. Among 1269 allergen extracts reviewed, there were 480 for which use in the diagnosis and treatment of allergic disease were addressed in the literature, 207 for which only diagnostic use was addressed, 565 for which minimal or no supportive literature was identified, and 17 for which potential safety concerns were found. Conclusions: When used according to professional guidelines, almost all nonstandardized allergen extracts for diagnosis and therapy appear to be safe. Provisional thresholds of effectiveness were met by 54% of extracts reviewed. (J Allergy Clin Immunol 2012;129:1014-9.)	[Slater, Jay E.; Maloney, Diane; Cook, Catherine M.] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA; [Slater, Jay E.; Menzies, Sandra L.; Bridgewater, Jennifer; Rabin, Ronald L.] US FDA, Div Bacterial Parasit & Allergen Prod, Off Vaccines Res & Review, Rockville, MD 20852 USA; [Mosquera, Alexis; Zinderman, Craig E.; Ou, Alan C.] US FDA, Div Epidemiol, Off Biostat & Epidemiol, Rockville, MD 20852 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Slater, JE (corresponding author), US FDA, Ctr Biol Evaluat & Res, 1401 Rockville Pike,HFM-422, Rockville, MD 20852 USA.	jay.slater@fda.hhs.gov		Rabin, Ronald/0000-0003-3496-0504	US Food and Drug Administration; National Institute of Allergy and Infectious Diseases/National Institutes of Health	US Food and Drug Administration; National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the US Food and Drug Administration.; R. L. Rabin has received research support from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2011, FED REG          111, V76, P71045; [Anonymous], 1974, FED REG          010, V39, P1082; [Anonymous], ALL PROD ADV COMM M; [Anonymous], ALLERGENICS ADVISORY; [Anonymous], 2011, FED REG          092, V76, P59407; [Anonymous], 1985, FED REG          012, P3082; [Anonymous], 1983, PANEL REV ALLERGENIC; [Anonymous], 1994, FED REG          111, V59, P59228; [Anonymous], DNA BASED SEAFOOD ID; [Anonymous], 1982, FED REG          100, V47, P44062; [Anonymous], 1986, FDC REPORTS PINK SHE, V48, P17; [Anonymous], 1974, FED REG          061, V39, P21176; [Anonymous], MEDWATCH ONL VOL REP; Bernstein DI, 2011, IMMUNOL ALLERGY CLIN, V31, P241, DOI 10.1016/j.iac.2011.02.007; Cohen Sheldon G, 2008, Clin Allergy Immunol, V21, P1; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Morrow KS, 2001, CLIN REV ALLERG IMMU, V21, P141, DOI 10.1385/CRIAI:21:2-3:141; Till Stephen J, 2008, Clin Allergy Immunol, V21, P59	18	26	26	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1014	1019		10.1016/j.jaci.2012.01.066	http://dx.doi.org/10.1016/j.jaci.2012.01.066			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22341039				2022-12-18	WOS:000302144600017
J	Galanter, JM; Torgerson, D; Gignoux, CR; Sen, S; Roth, LA; Via, M; Aldrich, MC; Eng, C; Huntsman, S; Rodriguez-Santana, J; Rodriguez-Cintron, W; Chapela, R; Ford, JG; Burchard, EG				Galanter, Joshua M.; Torgerson, Dara; Gignoux, Christopher R.; Sen, Saunak; Roth, Lindsey A.; Via, Marc; Aldrich, Melinda C.; Eng, Celeste; Huntsman, Scott; Rodriguez-Santana, Jose; Rodriguez-Cintron, William; Chapela, Rocio; Ford, Jean G.; Burchard, Esteban G.			Cosmopolitan and ethnic-specific replication of genetic risk factors for asthma in 2 Latino populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; genetics; Hispanics; Latinos; Mexicans; Puerto Ricans; replication; genome-wide association; candidate genes; effect heterogeneity	GENOME-WIDE ASSOCIATION; PUERTO-RICAN; BRONCHODILATOR RESPONSIVENESS; HISPANIC/LATINO POPULATIONS; UNRELATED INDIVIDUALS; CHILDHOOD ASTHMA; CHILDREN; VARIANTS; DISEASES; EPIDEMIOLOGY	Background: Although Mexicans and Puerto Ricans are jointly classified as "Hispanic/Latino," there are significant differences in asthma prevalence, severity, and mortality between the 2 groups. We sought to examine the possibility that population-specific genetic risks contribute to this disparity. Objectives: More than 100 candidate genes have been associated with asthma and replicated in an independent population, and 7 genome-wide association studies in asthma have been performed. We compared the pattern of replication of these associations in Puerto Ricans and Mexicans. Methods: We genotyped Mexican and Puerto Rican trios using an Affymetrix 6.0 GeneChip and used a family-based analysis to test for genetic associations in 124 genes previously associated with asthma. Results: We identified 32 single nucleotide polymorphisms (SNPs) in 17 genes associated with asthma in at least 1 of the 2 populations. Twenty-two of these SNPs in 11 genes were significantly associated with asthma in the combined population and showed no significant heterogeneity of association, whereas 5 SNPs were associated in only 1 population and showed statistically significant heterogeneity. In a gene-based approach 2 additional genes were associated with asthma in the combined population, and 3 additional genes displayed ethnic-specific associations with heterogeneity. Conclusions: Our results show that only a minority of genetic association studies replicate in our population of Mexican and Puerto Rican asthmatic subjects. Among SNPs that were successfully replicated, most showed no significant heterogeneity across populations. However, we identified several population-specific genetic associations. (J Allergy Clin Immunol 2011; 128: 37-43.)	[Galanter, Joshua M.; Torgerson, Dara; Roth, Lindsey A.; Eng, Celeste; Huntsman, Scott; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Gignoux, Christopher R.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Sen, Saunak] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Via, Marc] Univ Barcelona, Fac Biol, E-08007 Barcelona, Spain; [Aldrich, Melinda C.] Vanderbilt Univ, Med Ctr, Dept Thorac Surg, Nashville, TN USA; [Rodriguez-Cintron, William] VA Med Ctr, San Juan, PR USA; [Rodriguez-Santana, Jose] Ctr Neumol Pediat, San Juan, PR USA; [Chapela, Rocio] INER, Mexico City, DF, Mexico; [Ford, Jean G.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Barcelona; Vanderbilt University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Galanter, JM (corresponding author), Univ Calif San Francisco, Dept Med, Box 2911, San Francisco, CA 94143 USA.	joshua.galanter@ucsf.edu	Aldrich, Melinda/C-7783-2013; Via, Marc/L-6511-2014	Via, Marc/0000-0002-9966-9921; Galanter, Joshua/0000-0002-2561-6384	National Institutes of Health [2T32GM007546, 1RC2 HL101651, ES015794, U19 AI077439, HL088133, HL078885]; Flight Attendant Medical Research Institute (FAMRI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088133, RC2HL101651, R01HL078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute (FAMRI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the National Institutes of Health (2T32GM007546, 1RC2 HL101651, ES015794, U19 AI077439, HL088133, and HL078885) and the Flight Attendant Medical Research Institute (FAMRI).; Disclosure of potential conflict of interest: J. M. Galanter receives research support from the National Institutes of Health. C. R. Gignoux owns stock in 23andMe, Inc. The rest of the authors have declared that they have no conflict of interest.	Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Aoki Takeshi, 2006, J Hum Genet, V51, P677, DOI 10.1007/s10038-006-0007-3; Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431; Browning BL, 2009, AM J HUM GENET, V84, P210, DOI 10.1016/j.ajhg.2009.01.005; Bryc K, 2010, P NATL ACAD SCI USA, V107, P8954, DOI 10.1073/pnas.0914618107; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Finkelstein Y, 2009, J ASTHMA, V46, P900, DOI 10.3109/02770900903199961; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554; Freeman NCG, 2003, J EXPO ANAL ENV EPID, V13, P169, DOI 10.1038/sj.jea.7500266; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474; Keen-Kim D, 2006, HUM MOL GENET, V15, P3324, DOI 10.1093/hmg/ddl408; Kleeberger SR, 2005, ANNU REV MED, V56, P383, DOI 10.1146/annurev.med.56.062904.144908; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; Lewis Cathryn M, 2002, Brief Bioinform, V3, P146, DOI 10.1093/bib/3.2.146; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Mao XY, 2007, AM J HUM GENET, V80, P1171, DOI 10.1086/518564; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Naqvi M, 2007, J ASTHMA, V44, P639, DOI 10.1080/02770900701554441; Nishimura Fumichika, 2006, Allergol Int, V55, P55, DOI 10.2332/allergolint.55.55; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ober C, 2005, J ALLERGY CLIN IMMUN, V116, P274, DOI 10.1016/j.jaci.2005.04.039; Ober C, 2005, CURR OPIN IMMUNOL, V17, P670, DOI 10.1016/j.coi.2005.09.009; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Siontis KCM, 2010, EUR J HUM GENET, V18, P832, DOI 10.1038/ejhg.2010.26; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Spencer CCA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000477; Tcheurekdjian H, 2010, J ALLERGY CLIN IMMUN, V126, P853, DOI 10.1016/j.jaci.2010.06.048; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wang S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000037; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007; Yu W, 2008, NAT GENET, V40, P124, DOI 10.1038/ng0208-124	44	26	26	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					37	U79		10.1016/j.jaci.2011.03.050	http://dx.doi.org/10.1016/j.jaci.2011.03.050			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21621256	Green Accepted, Bronze			2022-12-18	WOS:000292245600003
J	Clerisme-Beaty, EM; Bartlett, SJ; Teague, WG; Lima, J; Irvin, CG; Cohen, R; Castro, M; Wise, RA; Rand, CS				Clerisme-Beaty, Emmanuelle M.; Bartlett, Susan J.; Teague, W. Gerald; Lima, John; Irvin, Charles G.; Cohen, Rubin; Castro, Mario; Wise, Robert A.; Rand, Cynthia S.			The Madison Avenue effect: How drug presentation style influences adherence and outcome in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; medication adherence; electronic monitoring; outcome expectancy; behavioral intervention	INHALED CORTICOSTEROIDS; MEDICATION ADHERENCE; DECISION-MAKING; BELIEFS; ADULTS; INTERVENTION; MEDICINES; THERAPY; IMPACT	Background: Little is known about how drug presentation influences medication adherence. Objective: To examine the effect of an educational program aimed at increasing expectations of treatment benefit on medication adherence. Methods: Data are analyzed from 99 participants who underwent electronic drug monitoring during the Trial of Asthma Patient Education, a randomized, placebo-controlled, multicenter trial. Participants with suboptimally controlled asthma were randomized to placebo or montelukast in conjunction with a presentation mode that was either neutral or designed to increase outcome expectancy. Adherence was monitored electronically over 4 weeks and was defined as >= 80% use of prescribed doses. Outcome expectancy, peak expiratory flow, prebronchodilator FEV(1), asthma control (Juniper asthma control questionnaire), and asthma-related quality of life were assessed at baseline and at the 4-week follow-up. Results: Average electronic medication adherence was 69.9%. There was a significant interaction between presentation mode and drug assignment, with participants in the enhanced/montelukast group having a higher change in outcome expectancy (Delta 2.1 points; P < .001) and better medication adherence (odds ratio, 4.0; 95% CI, 1.1-14.3) compared with those in the neutral/placebo group. There was no difference in asthma symptoms, quality of life, or clinical outcomes on the basis of presentation mode. Rather, increased outcome expectancy was associated with modest improvements in asthma symptoms after adjusting for presentation mode, drug assignment, and medication adherence. Conclusion: The use of an enhanced presentation aimed at increasing outcome expectancy may lead to improved medication adherence. (J Allergy Clin Immunol 2011;127:406-11.)	[Bartlett, Susan J.] McGill Univ, Montreal, PQ, Canada; [Teague, W. Gerald] Univ Virginia, Charlottesville, VA 22903 USA; [Lima, John] Nemours Childrens Clin, Jacksonville, FL USA; [Irvin, Charles G.] Univ Vermont, Burlington, VT 05405 USA; [Cohen, Rubin] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Castro, Mario] Washington Univ, St Louis, MO 63130 USA; [Clerisme-Beaty, Emmanuelle M.; Wise, Robert A.; Rand, Cynthia S.] Johns Hopkins Univ, Baltimore, MD USA	McGill University; University of Virginia; University of Vermont; Yeshiva University; Albert Einstein College of Medicine; Washington University (WUSTL); Johns Hopkins University	Clerisme-Beaty, EM (corresponding author), Div Pulm Crit Care Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	crand@jhmi.edu	Cohen, Rubin I/ABC-2650-2021; Bartlett, Susan J./J-9864-2012; Bartlett, Susan Joan/AAD-4103-2020	Bartlett, Susan Joan/0000-0001-9755-2490; Wise, Robert/0000-0002-8353-2349; , Rubin/0000-0002-1257-391X	National Institutes of Health (National Heart, Lung, and Blood Institute) [R01HL073494]; American Lung Association; Centers for Disease Control and Prevention; Merck; Teva; NIH; Elsevier; Asthmatx; Amgen; Ception; GlaxoSmithKline; Genentech; MedImmune; Novartis; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007534, R01HL073494] Funding Source: NIH RePORTER	National Institutes of Health (National Heart, Lung, and Blood Institute)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Lung Association; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Merck(Merck & Company); Teva(Teva Pharmaceutical Industries); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Elsevier; Asthmatx; Amgen(Amgen); Ception; GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); MedImmune(AstraZenecaMedimmune); Novartis(Novartis); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Institutes of Health ( National Heart, Lung, and Blood Institute grant R01HL073494) and the American Lung Association.; S. J. Bartlett is the program chair for the Behavioral Sciences Assembly for the American Thoracic Society. W. G. Teague receives speakers' honoraria from Merck and Co; receives research support from the NIH/NHLBI, the American Lung Association, and the Centers for Disease Control and Prevention; has provided testimony on behalf of the American Thoracic Society relating to long-acting beta-agonists; is a volunteer for Not One More Life; and tithes to Genesis Bible Church, Bible Training Center for Pastors, and Cornerstone Church. C. G. Irvin receives speakers' fees from Merck and Teva, receives research support from the NIH and the American Lung Association, and is chairman of the American Lung Association Leadership Board in Vermont and the Vermont Department of Health. M. Castro is a consultant for Asthmatx, Schering, Electrocore, and NKTT; is on the advisory board for Genentech; receives speakers' honoraria from AstraZeneca, Boehringer-Ingelheim, Pfizer, and Merck; receives royalties from Elsevier; and receives research support from the American Lung Association, the NIH, Asthmatx, Amgen, Ception, GlaxoSmithKline, Genentech, MedImmune, Merck, and Novartis. R. A. Wise receives research support from the American Lung Association. C. S. Rand is on the advisory board for the Merck Foundation/MCAN, is on the leadership council for Schering-Plough, and is a consultant for GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.	Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; BANDURA A, 1989, J PERS SOC PSYCHOL, V56, P805, DOI 10.1037/0022-3514.56.5.805; Bender BG, 2004, CURR OPIN ALLERGY CL, V4, P191, DOI 10.1097/01.all.0000129449.73727.cf; Bender BG, 2010, J AM BOARD FAM MED, V23, P159, DOI 10.3122/jabfm.2010.02.090112; Borrelli B, 2007, J ALLERGY CLIN IMMUN, V120, P1023, DOI 10.1016/j.jaci.2007.08.017; Conn KM, 2007, PEDIATRICS, V120, pE521, DOI 10.1542/peds.2006-3023; Delea TE, 2008, CURR MED RES OPIN, V24, P3435, DOI [10.1185/03007990802557344, 10.1185/03007990802557344 ]; Horne R, 1999, J PSYCHOSOM RES, V47, P555, DOI 10.1016/S0022-3999(99)00057-4; Juniper E F, 1999, Curr Opin Pulm Med, V5, P105, DOI 10.1097/00063198-199903000-00005; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Le TT, 2008, J ASTHMA, V45, P33, DOI 10.1080/02770900701815552; Lee JY, 1996, AM J HYPERTENS, V9, P719, DOI 10.1016/0895-7061(96)00056-8; Menckeberg TT, 2008, J PSYCHOSOM RES, V64, P47, DOI 10.1016/j.jpsychores.2007.07.016; Olsen S, 2008, CLIN PSYCHOL REV, V28, P1355, DOI 10.1016/j.cpr.2008.07.004; Otsuki M, 2009, PEDIATRICS, V124, P1513, DOI 10.1542/peds.2008-2961; Ponieman D, 2009, ANN ALLERG ASTHMA IM, V103, P38, DOI 10.1016/S1081-1206(10)60141-X; Remington G, 2007, SCHIZOPHR RES, V90, P229, DOI 10.1016/j.schres.2006.11.015; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Wilson SR, 2010, AM J RESP CRIT CARE, V181, P566, DOI 10.1164/rccm.200906-0907OC; Wise RA, 2009, J ALLERGY CLIN IMMUN, V124, P436, DOI 10.1016/j.jaci.2009.05.041	20	26	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					406	411		10.1016/j.jaci.2010.11.038	http://dx.doi.org/10.1016/j.jaci.2010.11.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	714KH	21281871	Green Accepted			2022-12-18	WOS:000286808000014
J	Dreschler, K; Bratke, K; Petermann, S; Bier, A; Thamm, P; Kuepper, M; Virchow, JC; Lommatzsch, M				Dreschler, Katharina; Bratke, Kai; Petermann, Sebastian; Bier, Andrea; Thamm, Petra; Kuepper, Michael; Virchow, J. Christian; Lommatzsch, Marek			Impact of immunotherapy on blood dendritic cells in patients with Hymenoptera venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; Hymenoptera venom allergy; specific immunotherapy; flow cytometry	GRASS-POLLEN IMMUNOTHERAPY; IMMUNE-RESPONSES; ATOPIC-DERMATITIS; IN-VIVO; EFFICACY; DISEASE; INFLAMMATION; MECHANISMS; ACTIVATE; SUBSETS	Background: Modulation of T-cell differentiation, which is controlled by dendritic cells (DCs), plays a crucial role in specific immunotherapy (SIT). However, the number and the characteristics of blood DCs before and during immunotherapy are unknown. Objective: To analyze the number and the characteristics of blood DC subsets in patients with Hymenoptera venom allergy before and after initiation of SIT. Methods: In this clinical trial (NCT00947908), blood myeloid and plasmacytoid DCs were analyzed in 20 patients with Hymenoptera venom allergy (bee or wasp venom) by using 4-color flow cytometry at 3 time points: directly before SIT, and 52 hours and 12 months after initiation of SIT. In addition, 20 age-matched and sex-matched controls were examined. Results: In patients with Hymenoptera venom allergy, the number of plasmacytoid DCs before SIT was comparable to that of controls. Plasmacytoid DCs decreased markedly 52 hours after initiation of SIT and returned to control levels after 12 months of treatment. Myeloid DCs were elevated in patients with Hymenoptera venom allergy before, during, and after the first 12 months of SIT. In addition, there were changes in the expression of function-associated surface molecules on myeloid DCs (such as Fc g receptor 2 and Toll-like receptor 2) during SIT. Conclusion: Numbers of blood myeloid DCs are elevated in patients with Hymenoptera venom allergy, and there are specific changes in the expression of function-associated surface molecules on these cells during SIT. Numbers of plasmacytoid DCs in blood are profoundly but are only transiently decreased after initiation of SIT. (J Allergy Clin Immunol 2011;127:487-94.)	[Lommatzsch, Marek] Univ Rostock, Zentrum Innere Med, Abt Pneumol, D-18057 Rostock, Germany	University of Rostock	Lommatzsch, M (corresponding author), Univ Rostock, Zentrum Innere Med, Abt Pneumol, Ernst Heydemann Str 6, D-18057 Rostock, Germany.	marek.lommatzsch@med.uni-rostock.de			Deutsche Forschungsgemeinschaft [LO 1145/2-2]; University of Rostock	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Rostock	Supported by Deutsche Forschungsgemeinschaft (grant LO 1145/2-2), University of Rostock.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Bratke K, 2010, CLIN EXP ALLERGY, V40, P1015, DOI 10.1111/j.1365-2222.2010.03499.x; Bratke K, 2008, AM J RESP CELL MOL, V38, P655, DOI 10.1165/rcmb.2007-0400OC; Bratke K, 2007, THORAX, V62, P168, DOI 10.1136/thx.2006.067793; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; Bussmann C, 2010, ALLERGY, V65, P1558, DOI 10.1111/j.1398-9995.2010.02430.x; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; Gruchalla RS, 2004, NEW ENGL J MED, V351, P707, DOI 10.1056/NEJMe048168; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Jin HL, 2009, J ALLERGY CLIN IMMUN, V123, P875, DOI 10.1016/j.jaci.2009.02.007; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Lambrecht BN, 2008, CURR MOL MED, V8, P393, DOI 10.2174/156652408785160916; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lande R, 2010, ANN NY ACAD SCI, V1183, P89, DOI 10.1111/j.1749-6632.2009.05152.x; Lommatzsch M, 2010, EUR RESPIR J, V35, P1130, DOI 10.1183/09031936.00090109; Lommatzsch M, 2007, RESP MED, V101, P1493, DOI 10.1016/j.rmed.2007.01.003; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Novak N, 2008, J ALLERGY CLIN IMMUN, V121, pS370, DOI 10.1016/j.jaci.2007.06.001; Novak N, 2010, J ALLERGY CLIN IMMUN, V125, P50, DOI 10.1016/j.jaci.2009.11.019; O'Sullivan B, 2003, CRIT REV IMMUNOL, V23, P83, DOI 10.1615/CritRevImmunol.v23.i12.50; Poulsen LK, 2007, ANN MED, V39, P440, DOI 10.1080/07853890701449354; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; RING J, 1977, LANCET, V1, P466; Suzuki M, 2009, ALLERGY, V64, P387, DOI 10.1111/j.1398-9995.2008.01839.x; Ueno H, 2007, IMMUNOL REV, V219, P118, DOI 10.1111/j.1600-065X.2007.00551.x; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Yang D, 2008, J EXP MED, V205, P79, DOI 10.1084/jem.20062027	37	26	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					487	U1820		10.1016/j.jaci.2010.12.003	http://dx.doi.org/10.1016/j.jaci.2010.12.003			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281873				2022-12-18	WOS:000286808000024
J	Vince, N; Boutboul, D; Mouillot, G; Just, N; Peralta, M; Casanova, JL; Conley, ME; Bories, JC; Oksenhendler, E; Malphettes, M; Fieschi, C				Vince, Nicolas; Boutboul, David; Mouillot, Gael; Just, Nicolas; Peralta, Maria; Casanova, Jean-Laurent; Conley, Mary Ellen; Bories, Jean-Christophe; Oksenhendler, Eric; Malphettes, Marion; Fieschi, Claire		DEFI Study Grp	Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNODEFICIENCY; MUTATIONS; CELL		[Vince, Nicolas; Boutboul, David; Bories, Jean-Christophe; Oksenhendler, Eric; Malphettes, Marion; Fieschi, Claire] Univ Paris 07, EA3963, Ctr Hayem, Paris, France; [Oksenhendler, Eric; Malphettes, Marion; Fieschi, Claire] Hop St Louis, AP HP, Dept Clin Immunol, Paris, France; [Mouillot, Gael] Hop La Pitie Salpetriere, AP HP, Lab Immunol Cellulaire & Tissulaire, Paris, France; [Mouillot, Gael] INSERM, UMR S945, Paris, France; [Just, Nicolas] CH Roubaix, Dept Pneumoallergol, Roubaix, France; [Peralta, Maria] CH Mulhouse, Mulhouse, France; [Casanova, Jean-Laurent] Hop Necker Enfants Malad, AP HP, Unite Immunol & Hematol, Paris, France; [Conley, Mary Ellen] Univ Tennessee, Memphis, TN USA; [Conley, Mary Ellen] St Jude Childrens Hosp, Memphis, TN 38105 USA	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Vince, N (corresponding author), Univ Paris 07, EA3963, Ctr Hayem, Paris, France.	claire.fieschi@sls.aphp.fr	Vince, Nicolas/K-5882-2019; Casanova, Jean-Laurent/I-3418-2017; Amoura, Zahir/P-5325-2017; schleinitz, nicolas/AAL-6751-2020; HACHULLA, ERIC/R-8488-2018; AMOURA, Zahir/P-5324-2017; Bories, Jean-Christophe/L-6952-2017; Morisset, Martine/A-3084-2017	Vince, Nicolas/0000-0002-3767-6210; schleinitz, nicolas/0000-0001-9449-3392; HACHULLA, ERIC/0000-0001-7432-847X; AMOURA, Zahir/0000-0003-0292-9043; Soulas-Sprauel, Pauline/0000-0002-2058-4811; Morisset, Martine/0000-0002-4028-703X; Casanova, Jean-Laurent/0000-0002-7782-4169; Rohrlich, Pierre S/0000-0001-8801-4164; Borie, Raphael/0000-0002-9906-0024; bonnotte, bernard/0000-0002-1098-4598; BOUTBOUL, David/0000-0002-5006-8279; Martin, Thierry/0000-0002-2776-2641				Baker MW, 2009, J ALLERGY CLIN IMMUN, V124, P522, DOI 10.1016/j.jaci.2009.04.007; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; Kanegane H, 2007, GENES IMMUN, V8, P663, DOI 10.1038/sj.gene.6364431; Lacombe C, 1997, CLIN IMMUNOL IMMUNOP, V84, P194, DOI 10.1006/clin.1997.4386; Lokuta MA, 2007, MOL BIOL CELL, V18, P5069, DOI 10.1091/mbc.E07-05-0428; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Oksenhendler E, 2008, CLIN INFECT DIS, V46, P1547, DOI 10.1086/587669; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Watanabe R, 2010, J IMMUNOL, V184, P4801, DOI 10.4049/jimmunol.0902385	11	26	26	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					538	541		10.1016/j.jaci.2010.10.019	http://dx.doi.org/10.1016/j.jaci.2010.10.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21159371	Green Submitted			2022-12-18	WOS:000286808000036
J	Okano, M; Fujiwara, T; Higaki, T; Makihara, S; Haruna, T; Noda, Y; Kanai, K; Kariya, S; Yasueda, H; Nishizaki, K				Okano, Mitsuhiro; Fujiwara, Tazuko; Higaki, Takaya; Makihara, Seiichiro; Haruna, Takenori; Noda, Yohei; Kanai, Kengo; Kariya, Shin; Yasueda, Hiroshi; Nishizaki, Kazunori			Characterization of pollen antigen-induced IL-31 production by PBMCs in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T-CELLS; INTERLEUKIN-31; CYTOKINE		[Okano, Mitsuhiro; Fujiwara, Tazuko; Higaki, Takaya; Makihara, Seiichiro; Haruna, Takenori; Noda, Yohei; Kanai, Kengo; Kariya, Shin; Nishizaki, Kazunori] Okayama Univ, Dept Otolaryngol Head & Neck Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan; [Yasueda, Hiroshi] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan	Okayama University	Okano, M (corresponding author), Okayama Univ, Dept Otolaryngol Head & Neck Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.	mokano@cc.okayama-u.ac.jp						Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Ip WK, 2007, IMMUNOLOGY, V122, P532, DOI 10.1111/j.1365-2567.2007.02668.x; Lei Z, 2008, ALLERGY, V63, P327, DOI 10.1111/j.1398-9995.2007.01566.x; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Okubo Kimihiro, 2008, Allergol Int, V57, P265, DOI 10.2332/allergolint.O-07-514; Perrigoue JG, 2007, J EXP MED, V204, P481, DOI 10.1084/jem.20061791; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Sone Toshio, 2009, Allergology International, V58, P237, DOI 10.2332/allergolint.08-OA-0027	9	26	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					277	279		10.1016/j.jaci.2010.09.029	http://dx.doi.org/10.1016/j.jaci.2010.09.029			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211659	Bronze			2022-12-18	WOS:000285917300044
J	Schmetterer, KG; Haiderer, D; Leb-Reichl, VM; Neunkirchner, A; Jahn-Schmid, B; Kung, HJ; Schuch, K; Steinberger, P; Bohle, B; Pickl, WF				Schmetterer, Klaus G.; Haiderer, Daniela; Leb-Reichl, Victoria M.; Neunkirchner, Alina; Jahn-Schmid, Beatrice; Kueng, Hans J.; Schuch, Karina; Steinberger, Peter; Bohle, Barbara; Pickl, Winfried F.			Bet v 1-specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1-specific T-cell effector function in an activation-dependent manner	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immune regulation; regulatory T cells; allergen-specific T-cell receptor; FOXP3; type I allergy; birch pollen; Bet v 1	IMMUNOLOGICAL SELF-TOLERANCE; ALLERGEN-SPECIFIC IMMUNOTHERAPY; GRASS-POLLEN IMMUNOTHERAPY; RECEPTOR GENE-TRANSFER; REGULATORY-CELLS; IN-VITRO; TGF-BETA; AUTOIMMUNE-DISEASE; EXPRESSION; LYMPHOCYTES	Background: Regulatory T (Treg) cells establish and maintain tolerance to self-antigens and many foreign antigens, such as allergens, by suppressing effector T-cell proliferation and function. We have previously shown that human T-cell receptor (TCR) alpha beta-chains specific for allergen-derived epitopes confer allergen specificity on peripheral blood T cells of individuals with and without allergy. Objective: To study the feasibility of generating allergen-specific human Treg cells by retroviral transduction of a transcription unit encoding forkhead box protein 3 (FOXP3) and allergen-specific TCR alpha beta-chains. Methods: cDNAs encoding the a and beta-chains of a Bet v 1(142-153)-specific TCR (TCR alpha variable region 6/TCR beta variable region 20) and human FOXP3 were linked via picornaviral 2A sequences and expressed as single translational unit from an internal ribosomal entry site-green fluorescence protein-containing retroviral vector. Retrovirally transduced peripheral blood T cells were tested for expression of transgenes, Treg phenotype, and regulatory capacity toward allergen-specific effector T cells. Results: Transduced T cells displayed a Treg phenotype with clear-cut upregulation of CD25, CD39, and cytotoxic T-lymphocyte antigen 4. The transduced cells were hyporesponsive in cytokine production and secretion and, like naturally occurring Treg cells, did not proliferate after antigen-specific or antigen-mimetic stimulation. However, proliferation was inducible upon exposure to exogenous IL-2. In coculture experiments, TRAV6(+)TRBV20(+)FOXP3(+) transgenic T cells, unlike FOXP3(+) single transgenic T cells or naturally occurring Treg cells, highly significantly suppressed T cell cytokine production and proliferation of corresponding allergen-specific effector T cells in an allergen-specific, dose-dependent manner. Conclusion: We demonstrate a transgenic approach to engineer human allergen-specific Treg cells that exert their regulatory function in an activation-dependent manner. Customized Treg cells might become useful for tolerance induction therapies in individuals with allergic and other immune-mediated diseases. (J Allergy Clin Immunol 2011;127:238-45.)	[Schmetterer, Klaus G.; Haiderer, Daniela; Leb-Reichl, Victoria M.; Neunkirchner, Alina; Kueng, Hans J.; Schuch, Karina; Steinberger, Peter; Pickl, Winfried F.] Med Univ Vienna, Inst Immunol, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Jahn-Schmid, Beatrice; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Leb-Reichl, Victoria M.; Neunkirchner, Alina; Bohle, Barbara; Pickl, Winfried F.] Christian Doppler Lab Immunomodulat, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Pickl, WF (corresponding author), Med Univ Vienna, Inst Immunol, Ctr Pathophysiol Infectiol & Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.	winfried.pickl@meduniwien.ac.at	Pickl, Winfried F/E-5682-2011	Schmetterer, Klaus/0000-0001-9328-4871; Bohle, Barbara/0000-0002-5105-7985; Steinberger, Peter/0000-0001-6848-4097; Reichl, Victoria/0000-0001-7546-3438; Pickl, Winfried F./0000-0003-0430-4952	Austrian Science foundation [SFB F1816-B13, SFB F1807-B13, FWF 20011 B13]; Osterreichische Forschungsforderungsgesellschaft [812079]; Biomay AG; Christian Doppler Research Association, Austria; Austrian Science Fund; Christian Doppler Laboratory	Austrian Science foundation(Austrian Science Fund (FWF)); Osterreichische Forschungsforderungsgesellschaft; Biomay AG; Christian Doppler Research Association, Austria; Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Laboratory	Supported by grants from the Austrian Science foundation (SFB F1816-B13, SFB F1807-B13, and FWF 20011 B13), the Osterreichische Forschungsforderungsgesellschaft #812079 and Biomay AG, and the Christian Doppler Research Association, Austria.; B. Jahn-Schmid receives research support from the Austrian Science Fund. B. Bohle receives research support from the Austrian Science Fund and the Christian Doppler Laboratory. The rest of the authors have declared that they have no conflict of interest.	Aarts-Riemens T, 2008, EUR J IMMUNOL, V38, P1381, DOI 10.1002/eji.200737590; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Allan SE, 2008, MOL THER, V16, P194, DOI 10.1038/sj.mt.6300341; Arshad SH, 2001, J INVEST ALLERG CLIN, V11, P94; Baecher-Allan C, 2006, IMMUNOL REV, V212, P203, DOI 10.1111/j.0105-2896.2006.00417.x; Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; Clay TM, 1999, J IMMUNOL, V163, P507; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; Derdak SV, 2006, P NATL ACAD SCI USA, V103, P13144, DOI 10.1073/pnas.0602283103; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Fujio K, 2006, J IMMUNOL, V177, P8140, DOI 10.4049/jimmunol.177.11.8140; Godfrey WR, 2004, BLOOD, V104, P453, DOI 10.1182/blood-2004-01-0151; Heemskerk MHM, 2004, J EXP MED, V199, P885, DOI 10.1084/jem.20031110; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Hoffmann P, 2004, BLOOD, V104, P895, DOI 10.1182/blood-2004-01-0086; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kueng HJ, 2010, FASEB J, V24, P1572, DOI 10.1096/fj.09-137281; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Leb VM, 2008, J ALLERGY CLIN IMMUN, V121, P64, DOI 10.1016/j.jaci.2007.10.006; Leb VM, 2009, J ALLERGY CLIN IMMUN, V124, P121, DOI 10.1016/j.jaci.2009.04.008; Lefranc MP, 2005, NUCLEIC ACIDS RES, V33, pD593, DOI 10.1093/nar/gki065; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; O'Gorman WE, 2009, J IMMUNOL, V183, P332, DOI 10.4049/jimmunol.0900691; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Ozcan E, 2008, J ALLERGY CLIN IMMUN, V122, P1054, DOI 10.1016/j.jaci.2008.10.023; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Pfistershammer K, 2006, EUR J IMMUNOL, V36, P1104, DOI 10.1002/eji.200535344; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Rao PE, 2005, J IMMUNOL, V174, P1446, DOI 10.4049/jimmunol.174.3.1446; Sakaguchi S, 2009, EUR J IMMUNOL, V39, P2331, DOI 10.1002/eji.200939688; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Takahashi T, 1998, INT IMMUNOL, V10, P1969, DOI 10.1093/intimm/10.12.1969; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; van der Veken LT, 2005, GENE THER, V12, P1686, DOI 10.1038/sj.gt.3302586; Waldmann H, 2005, CURR TOP MICROBIOL, V293, P249, DOI 10.1007/3-540-27702-1_11; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1084/jem.20030422	50	26	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					238	U375		10.1016/j.jaci.2010.10.023	http://dx.doi.org/10.1016/j.jaci.2010.10.023			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211658				2022-12-18	WOS:000285917300034
J	Lemanske, RF; Busse, WW				Lemanske, Robert F., Jr.; Busse, William W.			The US Food and Drug Administration and long-acting beta(2)-agonists: The importance of striking the right balance between risks and benefits of therapy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; long-acting beta-agonists; asthma guidelines	INHALED CORTICOSTEROIDS; ASTHMA CONTROL; PERSISTENT ASTHMA; BETA-AGONISTS; FLUTICASONE PROPIONATE/SALMETEROL; DOUBLE-BLIND; SALMETEROL; METAANALYSIS; SAFETY		[Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Busse, William W.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin Hosp, Dept Med, K4-910 CSC,MC 9988,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu						Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P563, DOI 10.1016/j.jaci.2005.11.036; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman E, 2008, ANN INTERN MED, V149, P33, DOI 10.7326/0003-4819-149-1-200807010-00229; Chowdhury BA, 2010, NEW ENGL J MED, V362, P1169, DOI 10.1056/NEJMp1002074; DiSantostefano RL, 2008, ANN ALLERG ASTHMA IM, V100, P558, DOI 10.1016/S1081-1206(10)60048-8; Godard P, 2008, RESP MED, V102, P1124, DOI 10.1016/j.rmed.2008.03.014; Jaeschke R, 2008, AM J RESP CRIT CARE, V178, P1009, DOI 10.1164/rccm.200804-494OC; Koenig SM, 2008, J ASTHMA, V45, P681, DOI 10.1080/02770900802168695; Kramer JM, 2009, NEW ENGL J MED, V360, P1592, DOI 10.1056/NEJMp0810561; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Heart Lung and Blood Institute, GLOB STRAT ASTHM MAN; Nelson H, 2010, J ALLERGY CLIN IMMUN, V125, P390, DOI 10.1016/j.jaci.2009.11.036; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Weatherall M, 2010, THORAX, V65, P39, DOI 10.1136/thx.2009.116608	19	26	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					449	452		10.1016/j.jaci.2010.05.039	http://dx.doi.org/10.1016/j.jaci.2010.05.039			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20692690				2022-12-18	WOS:000281512500006
J	Kirstein, F; Horsnell, WGC; Kuperman, DA; Huang, XZ; Erle, DJ; Lopata, AL; Brombacher, F				Kirstein, Frank; Horsnell, William G. C.; Kuperman, Douglas A.; Huang, Xiaozhu; Erle, David J.; Lopata, Andreas L.; Brombacher, Frank			Expression of IL-4 receptor alpha on smooth muscle cells is not necessary for development of experimental allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Smooth muscle cell; allergy; asthma; cytokine receptors; IL-4; IL-13; gene-deficient mice	AIRWAY EPITHELIAL-CELLS; BAROMETRIC PLETHYSMOGRAPHY; EOTAXIN EXPRESSION; SIGNALING PATHWAYS; MUCUS PRODUCTION; INTERLEUKIN-13; RELEASE; MICE; LUNG; HYPERREACTIVITY	Background: Airflow in the lungs of patients with allergic asthma is impaired by excessive mucus production and airway smooth muscle contractions. Elevated levels of the cytokines IL-4 and IL-13 are associated with this pathology. In vitro studies have suggested that IL-4 receptor a (IL-4R alpha) signaling on smooth muscle cells is critical for airway inflammation and airway hyperresponsiveness. Objective: To define the contribution of IL-4 and IL-13 to the onset of asthmatic pathology, the role of their key receptor IL-4R alpha in smooth muscle cells was examined in vivo. Methods: By using transgenic smooth muscle myosin heavy chain(cre)IL-4R alpha(-/lox) mice deficient in IL-4R alpha in smooth muscle cells, in vivo effects of impaired IL-4R alpha signaling in smooth muscle cells on the outcome of asthmatic disease were investigated for the first time. Allergic asthma was introduced in mice by repeated sensitization with ovalbumin/aluminum hydroxide on days 0, 7, and 14, followed by intranasal allergen challenge on days 21 to 23. Mice were investigated for the presence of airway hyperresponsiveness, airway inflammation, allergen-specific antibody production, T(H)2-type cytokine responses, and lung pathology. Results: Airway hyperresponsiveness, airway inflammation, mucus production, T(H)2 cytokine production, and specific antibody responses were unaffected in smooth muscle myosin heavy chain(cre)IL-4R alpha(-/lox) mice compared with control animals. Conclusion: The impairment of IL-4R alpha on smooth muscle cells had no effect on major etiologic markers of allergic asthma. These findings suggest that IL-4R alpha responsiveness in airway smooth muscle cells during the early phase of allergic asthma is not, as suggested, necessary for the outcome of the disease. (J Allergy Clin Immunol 2010;126:347-54.)	[Kirstein, Frank; Horsnell, William G. C.; Lopata, Andreas L.; Brombacher, Frank] Univ Cape Town, Div Immunol, Inst Infect Dis & Mol Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa; [Kuperman, Douglas A.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL USA; [Huang, Xiaozhu; Erle, David J.] Univ Calif San Francisco, Dept Med, Lung Biol Ctr, San Francisco, CA USA; [Lopata, Andreas L.] RMIT Univ, Sch Appl Sci, Food Sci Allergy Res Grp, Melbourne, Vic, Australia	University of Cape Town; Northwestern University; Feinberg School of Medicine; University of California System; University of California San Francisco; Royal Melbourne Institute of Technology (RMIT)	Brombacher, F (corresponding author), IIDMM, Wernher & Beit Bldg S,Univ Cape Town Campus,Anzio, ZA-7925 Cape Town, South Africa.	fbrombac@mweb.co.za	Lopata, Andreas L/O-2143-2017; Horsnell, William GC/A-9512-2013; Lopata, Andreas L/C-3831-2012	Lopata, Andreas L/0000-0002-2940-9235; Lopata, Andreas L/0000-0002-2940-9235; Erle, David/0000-0002-2171-0648; Horsnell, William Gordon Charles/0000-0001-7172-408X	Wellcome Trust; National Institutes of Health [HL56835]; National Research Foundation (South Africa); Royal Society; MRC (South Africa); Australian Biological Resources Study; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085089] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome Trust); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Research Foundation (South Africa)(National Research Foundation - South AfricaSouth African Medical Research Council); Royal Society(Royal Society of London); MRC (South Africa); Australian Biological Resources Study; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the Wellcome Trust, the National Institutes of Health (HL56835), the National Research Foundation (South Africa), the Royal Society, and the MRC (South Africa).; D. J. Erle has received research support from the National Institutes of Health. A. L. Lopata has received research support from the Australian Biological Resources Study and the Medical Research Council (South Africa). The rest of the authors have declared that they have no conflict of interest.	Akiho H, 2002, AM J PHYSIOL-GASTR L, V282, pG226, DOI 10.1152/ajpgi.2002.282.2.G226; Bryborn M, 2004, CLIN EXP ALLERGY, V34, P1291, DOI 10.1111/j.1365-2222.2004.02031.x; Cohn L, 1999, J IMMUNOL, V162, P6178; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; Faffe DS, 2005, J ALLERGY CLIN IMMUN, V115, P514, DOI 10.1016/j.jaci.2004.11.033; Faffe DS, 2003, AM J PHYSIOL-LUNG C, V285, pL907, DOI 10.1152/ajplung.00120.2003; Finkelman FD, 2008, J ALLERGY CLIN IMMUN, V121, P334, DOI 10.1016/j.jaci.2007.11.028; Grunewald SM, 1998, J IMMUNOL, V160, P4004; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Grunstein MM, 2002, AM J PHYSIOL-LUNG C, V282, pL520, DOI 10.1152/ajplung.00343.2001; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Horsnell WGC, 2007, PLOS PATHOG, V3, P46, DOI 10.1371/journal.ppat.0030001; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Kuperman DA, 2005, J IMMUNOL, V175, P3746, DOI 10.4049/jimmunol.175.6.3746; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Li L, 1999, J IMMUNOL, V162, P2477; Matsukura S, 2001, AM J RESP CELL MOL, V24, P755, DOI 10.1165/ajrcmb.24.6.4351; Mohrs M, 1999, J IMMUNOL, V162, P7302; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Peng Q, 2004, AM J RESP CRIT CARE, V169, P596, DOI 10.1164/rccm.200307-888OC; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Regan CP, 2000, CIRC RES, V87, P363; STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tliba O, 2003, BRIT J PHARMACOL, V140, P1159, DOI 10.1038/sj.bjp.0705558; Wen FQ, 2003, J ALLERGY CLIN IMMUN, V111, P1307, DOI 10.1067/mai.2003.1455; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zuyderduyn S, 2004, J ALLERGY CLIN IMMUN, V114, P791, DOI 10.1016/j.jaci.2004.06.037	34	26	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					347	354		10.1016/j.jaci.2010.04.028	http://dx.doi.org/10.1016/j.jaci.2010.04.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20579713	Green Accepted			2022-12-18	WOS:000281203800021
J	Roy, SR; McGinty, EE; Hayes, SC; Zhang, L				Roy, Sitesh Ranen; McGinty, Emma Elizabeth; Hayes, Sandra Carr; Zhang, Lei			Regional and racial disparities in asthma hospitalizations in Mississippi	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; hospitalization; race; urban; rural; disparity	HEALTH-INSURANCE; UNITED-STATES; ADMISSIONS; CARE; READMISSIONS; CHILDREN; RISK	Background: In the United States, asthma hospitalization rates are disproportionately high among blacks compared with other racial/ethnic groups and vary by geographic region. These disparities among asthma hospitalizations might be affected by social, environmental, and health-care access factors. Objective: To determine demographic risk factors for asthma hospitalizations in urban versus rural areas of Mississippi. Methods: A cross-sectional study using data from the Mississippi Asthma Surveillance System was conducted to compare asthma hospitalizations in the urban Jackson metropolitan statistical area and rural Delta regions of Mississippi from 2003 to 2005. Factors including race, sex, age, and household income that might be associated with multiple hospitalizations for asthma (3 or more during the study period) were assessed using logistic regression. Results: Asthma hospitalization rates were significantly higher among all demographic groups in the rural Delta region compared with the urban Jackson Metropolitan Statistical Area (P < .001). In both regions, hospitalization rates were higher among blacks and females (P < .001). Asthma hospitalization rates were highest among children (0-17 years) and older adults (>= 65 years). In both regions, blacks were more likely to have 3 or more asthma hospitalizations (P < .001). Residents of the Delta had higher odds for multiple hospitalizations controlling for race, sex, age, and household income (P < .05). Conclusion: Blacks with asthma are more likely to have multiple asthma hospitalizations in Mississippi. Higher odds of multiple asthma discharges for Delta residents were not explained by race, sex, age, or income, indicating that other contributing factors (eg, environmental, social, and access to care factors) need further investigation. (J Allergy Clin Immunol 2010;125:636-42.)	[Zhang, Lei] Mississippi Dept Hlth, Off Hlth Data & Res, Jackson, MS 39215 USA; [Roy, Sitesh Ranen] Univ Mississippi, Dept Pediat, Med Ctr, Div Allergy Immunol, Jackson, MS USA; [McGinty, Emma Elizabeth] Ctr Dis Control & Prevent, Publ Hlth Prevent Serv, Atlanta, GA USA; [Hayes, Sandra Carr] Tougaloo Coll, Cent Mississippi Area Hlth Educ Ctr, Tougaloo, MS USA	University of Mississippi; University of Mississippi Medical Center; Centers for Disease Control & Prevention - USA; Tougaloo College	Zhang, L (corresponding author), Mississippi Dept Hlth, Off Hlth Data & Res, 570 E Woodrow Wilson,POB 1700, Jackson, MS 39215 USA.	Lei.Zhang@msdh.state.ms.us			Centers for Disease Control and Prevention (CDC), National Center for Environmental Health, Air Pollution and Respiratory Health Branch [5U59EH000208-03]; NATIONAL CENTER FOR ENVIRONMENTAL HEALTH [U59EH000208] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention (CDC), National Center for Environmental Health, Air Pollution and Respiratory Health Branch(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR ENVIRONMENTAL HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Collection of asthma hospital discharge data used in this research was supported by Cooperative Agreement Number 5U59EH000208-03 from the Centers for Disease Control and Prevention (CDC), National Center for Environmental Health, Air Pollution and Respiratory Health Branch. The contents of the article are solely responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi State Department of Health.	Adams K., 2003, PRIORITY AREAS NATL; Anderson R. C., 2000, Navigation. Journal of the Institute of Navigation, V47, P1; Ash M, 2006, AM J PUBLIC HEALTH, V96, P358, DOI 10.2105/AJPH.2004.050203; BENSON RH, 1995, PALEOCEANOGRAPHY, V10, P1, DOI 10.1029/94PA02581; BLACKWELL A, 2007, PUB GEORGIA DEP HUMA; Boudreaux ED, 2003, CHEST, V124, P803, DOI 10.1378/chest.124.3.803; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P802; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; *CTR MISS HLTH POL, 2008, CHILDR HLTH COV MISS; DAVIDOFF A, 2005, UN AM CHR HLTH COND; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; Halterman JS, 2000, PEDIATRICS, V105, P272; HILL AM, 1989, BRIT MED J, V289, P479; *HOUS ASS COUNC, 2002, TAK STOCK RUR PEOPL; Jones JA, 2001, PATIENT EDUC COUNS, V42, P67, DOI 10.1016/S0738-3991(00)00102-6; *KAIS COMM MED UN, 2003, CHARTB; Klein RJ, 2001, HLTH PEOPLE STAT NOT; Krishnan JA, 2001, ARCH INTERN MED, V161, P1660, DOI 10.1001/archinte.161.13.1660; Lara M, 2002, PEDIATRICS, V109, P919, DOI 10.1542/peds.109.5.919; Lave JR, 1998, JAMA-J AM MED ASSOC, V279, P1820, DOI 10.1001/jama.279.22.1820; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Minkovitz CS, 1999, ARCH PEDIAT ADOL MED, V153, P727, DOI 10.1001/archpedi.153.7.727; MITCHELL EA, 1994, THORAX, V49, P33, DOI 10.1136/thx.49.1.33; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Nelson A, 2002, J NATL MED ASSOC, V94, P666; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; *NY STAT DEP HLTH, 2007, NY STAT ASTHM SURV S; Perry TT, 2008, ANN ALLERG ASTHMA IM, V101, P375, DOI 10.1016/S1081-1206(10)60313-4; *PRACT MAN INF COR, 2006, ICD9CM PRACT MAN INF; Salamzadeh J, 2003, J ASTHMA, V40, P645, DOI 10.1081/JAS-120019035; Schaubel D, 1996, J ASTHMA, V33, P97, DOI 10.3109/02770909609054537; SENTHILSELVAN A, 1995, THORAX, V50, P934, DOI 10.1136/thx.50.9.934; Shone LP, 2005, PEDIATRICS, V115, pE697, DOI 10.1542/peds.2004-1726; STRUNK RC, 2009, J ALLERGY CLIN IMMUN, V109, P229; Sullivan SD, 2002, J ALLERGY CLIN IMMUN, V110, P576, DOI 10.1067/mai.2002.128009; To T, 1996, PEDIATRICS, V98, P191; *US BUR CENS, 2005, POP EST MISS; Valet RS, 2009, J ALLERGY CLIN IMMUN, V123, P1220, DOI 10.1016/j.jaci.2008.12.1131; WENNBERG JE, 1982, SOC SCI MED, V16, P811, DOI 10.1016/0277-9536(82)90234-9; Wever-Hess J, 2001, PEDIATR PULM, V31, P30, DOI 10.1002/1099-0496(200101)31:1<30::AID-PPUL1004>3.0.CO;2-L; Withy K, 2008, ETHNIC DIS, V18, P247	43	26	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					636	642		10.1016/j.jaci.2009.11.046	http://dx.doi.org/10.1016/j.jaci.2009.11.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	573BK	20226297	Bronze			2022-12-18	WOS:000275883200019
J	Tapiainen, T; Dunder, T; Mottonen, M; Pokka, T; Uhari, M				Tapiainen, Terhi; Dunder, Teija; Mottonen, Merja; Pokka, Tytti; Uhari, Matti			Adolescents with asthma or atopic eczema have more febrile days in early childhood: A possible explanation for the connection between paracetamol and asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DAY-CARE-CENTERS; ASSOCIATION; DERMATITIS; CHILDREN		[Tapiainen, Terhi; Dunder, Teija; Mottonen, Merja; Pokka, Tytti; Uhari, Matti] Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland	University of Oulu	Tapiainen, T (corresponding author), Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland.	terhi.tapiainen@oulu.fi		D, Teija/0000-0002-5159-1256				Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Dunder T, 2007, ARCH PEDIAT ADOL MED, V161, P972, DOI 10.1001/archpedi.161.10.972; Farquhar H, 2009, J ALLERGY CLIN IMMUN, V124, P649, DOI 10.1016/j.jaci.2009.07.037; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Koniman R, 2007, PEDIAT ALLERG IMM-UK, V18, P128, DOI 10.1111/j.1399-3038.2006.00484.x; Lesko SM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e20; Uhari M, 1999, PEDIATR INFECT DIS J, V18, P672, DOI 10.1097/00006454-199908000-00004	7	26	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					751	752		10.1016/j.jaci.2009.11.039	http://dx.doi.org/10.1016/j.jaci.2009.11.039			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20138352	Bronze			2022-12-18	WOS:000275883200038
J	Trifari, S; Scaramuzza, S; Catucci, M; Ponzoni, M; Mollica, L; Chiesa, R; Cattaneo, F; Lafouresse, F; Calvez, R; Vermi, W; Medicina, D; Castiello, MC; Marangoni, F; Bosticardo, M; Doglioni, C; Caniglia, M; Aiuti, A; Villa, A; Roncarolo, MG; Dupre, L				Trifari, Sara; Scaramuzza, Samantha; Catucci, Marco; Ponzoni, Maurilio; Mollica, Luca; Chiesa, Robert; Cattaneo, Federica; Lafouresse, Fanny; Calvez, Ronan; Vermi, William; Medicina, Daniela; Castiello, Maria Carmina; Marangoni, Francesco; Bosticardo, Marita; Doglioni, Claudio; Caniglia, Maurizio; Aiuti, Alessandro; Villa, Anna; Roncarolo, Maria-Grazia; Dupre, Loic			Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: Analysis of function and distribution in lymphoid organs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; Wiskott-Aldrich syndrome; secondary mutation	IN-VIVO REVERSION; SOCIETY-FOR-IMMUNODEFICIENCIES; SYNDROME PROTEIN WASP; SOMATIC MOSAICISM; SELECTIVE ADVANTAGE; 2ND-SITE MUTATION; CELL HOMEOSTASIS; DENDRITIC CELLS; GENE-THERAPY; DEFICIENCY	Background: The Wiskott-Aldrich syndrome (WAS) is a rare genetic disease characterized by thrombocytopenia, immunodeficiency, autoimmunity, and hematologic malignancies. Secondary mutations leading to re-expression of WAS protein (WASP) are relatively frequent in patients with WAS. Objective: The tissue distribution and function of revertant cells were investigated in a novel case of WAS gene secondary mutation. Methods: A vast combination of approaches was used to characterize the second-site mutation, to investigate revertant cell function, and to track their distribution over a 18-year clinical follow-up. Results: The WAS gene secondary mutation was a 4-nucleotide insertion, 4 nucleotides downstream of the original deletion. This somatic mutation allowed the T-cell-restricted expression of a stable, full-length WASP with a 3-amino acid change compared with the wild-type protein. WASP(+) T cells appeared early in the spleen (age 10 years) and were highly enriched in a mesenteric lymph node at a later time (age 23 years). Revertant T cells had a diversified T-cell-receptor repertoire and displayed in vitro and in vivo selective advantage. They proliferated and produced cytokines normally on T-cell-receptor stimulation. Consistently, the revertant WASP correctly localized to the immunologic synapse and to the leading edge of migrating T cells. Conclusion: Despite the high proportion of functional revertant T cells, the patient still has severe infections and autoimmune disorders, suggesting that re-expression of WASP in T cells is not sufficient to normalize immune functions fully in patients with WAS. (J Allergy Clin Immunol 2010;125:439-48.)	[Lafouresse, Fanny; Calvez, Ronan; Dupre, Loic] Purpan Univ Hosp, INSERM, U563, F-31300 Toulouse, France; [Trifari, Sara; Scaramuzza, Samantha; Catucci, Marco; Chiesa, Robert; Cattaneo, Federica; Castiello, Maria Carmina; Marangoni, Francesco; Bosticardo, Marita; Aiuti, Alessandro; Villa, Anna; Roncarolo, Maria-Grazia] San Raffaele Telethon Inst Gene Therapy HSR TIGET, Milan, Italy; [Catucci, Marco; Roncarolo, Maria-Grazia] Univ Vita Salute San Raffaele, Milan, Italy; [Ponzoni, Maurilio; Doglioni, Claudio] Ist Sci San Raffaele, Pathol Unit, Unit Lymphoid Malignancies, I-20132 Milan, Italy; [Mollica, Luca] Ist Sci San Raffaele, Biomol NMR Lab, Dulbecco Telethon Inst, I-20132 Milan, Italy; [Lafouresse, Fanny; Calvez, Ronan; Dupre, Loic] Univ Toulouse 3, Ctr Physiopathol Toulouse Purpan, F-31062 Toulouse, France; [Vermi, William; Medicina, Daniela] Univ Brescia, Dept Pathol, Brescia, Italy; [Caniglia, Maurizio] Bambino Gesu Childrens Hosp IRCCS, Bone Marrow Transplant Unit, Div Hematol, Rome, Italy; [Aiuti, Alessandro] Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, Rome, Italy; [Villa, Anna] CNR, ITB, Segrate, Italy	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Brescia; IRCCS Bambino Gesu; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Dupre, L (corresponding author), Purpan Univ Hosp, INSERM, U563, F-31300 Toulouse, France.	loic.dupre@inserm.fr	Lafouresse, Fanny/B-9017-2019; Marangoni, Francesco/I-9087-2012; Scaramuzza, Samantha/AAN-2204-2020; dupre, loic/L-8174-2014; Castiello, Maria Carmina/K-9767-2016; Bosticardo, Marita/ABA-2688-2021; AIUTI, ALESSANDRO/K-3918-2016; Lafouresse, Fanny/AAH-2069-2021; Catucci, Marco/AAC-3491-2019	Lafouresse, Fanny/0000-0001-6572-8631; Marangoni, Francesco/0000-0002-2490-849X; Scaramuzza, Samantha/0000-0003-2903-3650; dupre, loic/0000-0002-7278-6503; Castiello, Maria Carmina/0000-0003-2581-9648; Bosticardo, Marita/0000-0002-1771-4523; AIUTI, ALESSANDRO/0000-0002-5398-1717; Lafouresse, Fanny/0000-0001-6572-8631; Catucci, Marco/0000-0002-1037-5741; Calvez, Ronan/0000-0001-5762-1244; DOGLIONI, Claudio/0000-0002-4969-5216; Villa, Anna/0000-0003-4428-9013; VERMI, WILLIAM/0000-0002-2291-2997; MOLLICA, LUCA/0000-0001-8164-7663; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon Foundation; CARIPLO; Italian Health Ministry; European Community [MEXT-CT-2005-025032]	Telethon Foundation(Fondazione Telethon); CARIPLO(Fondazione Cariplo); Italian Health Ministry(Ministry of Health, Italy); European Community(European Commission)	Supported by the Telethon Foundation (A.V. and M.-G.R.). CARIPLO (NOBEL grant to A.V. and M.-G.R.), the Italian Health Ministry (RP2007: Giovani Ricercatori grant to M.B.), and the European Community (Marie Curie Excellence grant, contract MEXT-CT-2005-025032 to L.D.).	Ariga T, 1998, BLOOD, V92, P699, DOI 10.1182/blood.V92.2.699; Badolato R, 1998, J IMMUNOL, V161, P1026; Binks M, 1998, EUR J IMMUNOL, V28, P3259; Borg C, 2004, BLOOD, V104, P3267, DOI 10.1182/blood-2004-01-0380; Boztug K, 2007, HAEMATOLOGICA, V92, pE43, DOI 10.3324/haematol.11222; Boztug K, 2008, CLIN GENET, V74, P68, DOI 10.1111/j.1399-0004.2008.01019.x; Burns S, 2004, BLOOD, V104, P3454, DOI 10.1182/blood-2004-04-1678; Calle Y, 2004, J PATHOL, V204, P460, DOI 10.1002/path.1651; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Charrier S, 2007, GENE THER, V14, P415, DOI 10.1038/sj.gt.3302863; Cosmi L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397; Davis BR, 2008, BLOOD, V111, P5064, DOI 10.1182/blood-2007-06-095299; Davis BR, 2009, IMMUNOL RES, V44, P127, DOI 10.1007/s12026-008-8091-4; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Dewey RA, 2006, EXP HEMATOL, V34, P1162, DOI 10.1016/j.exphem.2006.04.021; Du W, 2006, HUM MUTAT, V27, P370, DOI 10.1002/humu.20308; Dupre L, 2006, HUM GENE THER, V17, P303, DOI 10.1089/hum.2006.17.303; Dupre L, 2002, IMMUNITY, V17, P157, DOI 10.1016/S1074-7613(02)00360-6; Greer WL, 1996, HUM GENET, V98, P685, DOI 10.1007/s004390050285; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; Hirschhorn R, 2003, J MED GENET, V40, P721, DOI 10.1136/jmg.40.10.721; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; Humblet-Baron S, 2007, J CLIN INVEST, V117, P407, DOI 10.1172/JCI29539; Imai K, 2004, BLOOD, V103, P456, DOI 10.1182/blood-2003-05-1480; Jin YZ, 2004, BLOOD, V104, P4010, DOI 10.1182/blood-2003-05-1592; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Konno A, 2004, BLOOD, V103, P676, DOI 10.1182/blood-2003-05-1739; Konno A, 2007, INT IMMUNOL, V19, P185, DOI 10.1093/intimm/dxl135; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Lutskiy MI, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003444; Lutskiy MI, 2005, BLOOD, V106, P2815, DOI 10.1182/blood-2004-12-4724; Marangoni F, 2007, J EXP MED, V204, P369, DOI 10.1084/jem.20061334; Marangoni F, 2009, MOL THER, V17, P1073, DOI 10.1038/mt.2009.31; Mazo IB, 2005, IMMUNITY, V22, P259, DOI 10.1016/j.immuni.2005.01.008; Meyer-Bahlburg A, 2008, BLOOD, V112, P4158, DOI 10.1182/blood-2008-02-140814; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; Stewart DM, 2007, J CLIN IMMUNOL, V27, P634, DOI 10.1007/s10875-007-9121-z; Tone Y, 2007, BLOOD, V109, P1182, DOI 10.1182/blood-2006-08-039057; Trifari S, 2006, J IMMUNOL, V177, P7451, DOI 10.4049/jimmunol.177.10.7451; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; VANBELZEN MJ, 2008, ANN M AM SOC HUM GEN; Wada T, 2005, BLOOD, V106, P3895, DOI 10.1182/blood-2005-06-2336; Wada T, 2004, BLOOD, V104, P1270, DOI 10.1182/blood-2004-03-0846; Wada T, 2003, J CLIN INVEST, V111, P1389, DOI 10.1172/JCI200315485; Wada T, 2001, P NATL ACAD SCI USA, V98, P8697, DOI 10.1073/pnas.151260498; Westerberg LS, 2008, BLOOD, V112, P4139, DOI 10.1182/blood-2008-02-140715	48	26	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					439	448		10.1016/j.jaci.2009.11.034	http://dx.doi.org/10.1016/j.jaci.2009.11.034			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159256				2022-12-18	WOS:000274764000024
J	Flicker, S; Marth, K; Kofler, H; Valenta, R				Flicker, Sabine; Marth, Katharina; Kofler, Heinz; Valenta, Rudolf			Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy-treated mother	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INHALANT ALLERGENS; ATOPIC DISEASE; LIFE; ANTIBODIES; EFFICACY; VACCINE		[Flicker, Sabine; Marth, Katharina; Valenta, Rudolf] Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Div Immunopathol, Vienna, Austria; [Marth, Katharina; Valenta, Rudolf] Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Christian Doppler Lab Allergy Res, Vienna, Austria; [Kofler, Heinz] Allergieambulatorium, Hall In Tirol, Austria	Medical University of Vienna; Medical University of Vienna	Flicker, S (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Div Immunopathol, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at		Valenta, Rudolf/0000-0001-5944-3365; Flicker, Sabine/0000-0003-4768-8693				AVRECH OM, 1994, INT ARCH ALLERGY IMM, V103, P160, DOI 10.1159/000236622; Bertino E, 2006, PEDIATR ALLERGY IMMU, V17, P484, DOI 10.1111/j.1399-3038.2006.00449.x; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; Constantin C, 2009, ALLERGY, V64, P1030, DOI 10.1111/j.1398-9995.2009.01955.x; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; GLOVSKY MM, 1991, ANN ALLERGY, V67, P21; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Jenmalm MC, 2000, CLIN EXP ALLERGY, V30, P34, DOI 10.1046/j.1365-2222.2000.00771.x; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; Uthoff H, 2003, J IMMUNOL, V171, P3485, DOI 10.4049/jimmunol.171.7.3485	16	26	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1358	1360		10.1016/j.jaci.2009.09.024	http://dx.doi.org/10.1016/j.jaci.2009.09.024			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004788				2022-12-18	WOS:000273071500034
J	Bogdanovic, J; Halsey, NA; Wood, RA; Hamilton, RG				Bogdanovic, Jelena; Halsey, Neal A.; Wood, Robert A.; Hamilton, Robert G.			Bovine and porcine gelatin sensitivity in children sensitized to milk and meat	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RUBELLA VACCINE; ANAPHYLAXIS; MEASLES; MUMPS; IGE		[Bogdanovic, Jelena; Wood, Robert A.; Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Bogdanovic, Jelena; Wood, Robert A.; Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Bogdanovic, Jelena; Wood, Robert A.; Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Halsey, Neal A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bogdanovic, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	rhamilt2@jhmi.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS058294] Funding Source: NIH RePORTER; NINDS NIH HHS [R21 NS058294-01] Funding Source: Medline; CIT NIH HHS [1406-04-08-CT-20000] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); CIT NIH HHS		KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Patja A, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.2.e27; Pool V, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e71; Sakaguchi M, 2000, VACCINE, V19, P431, DOI 10.1016/S0264-410X(00)00206-1; Sakaguchi M, 1999, IMMUNOLOGY, V96, P286, DOI 10.1046/j.1365-2567.1999.00696.x; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P535, DOI 10.1016/0091-6749(83)90433-5; Wang J, 2005, ANN ALLERG ASTHMA IM, V94, P530, DOI 10.1016/S1081-1206(10)61128-3; Yamada A, 2002, PEDIATR INT, V44, P87, DOI 10.1046/j.1442-200X.2002.01486.x	9	26	27	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1108	1110		10.1016/j.jaci.2009.06.021	http://dx.doi.org/10.1016/j.jaci.2009.06.021			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19665767	Green Accepted			2022-12-18	WOS:000272108000035
J	Senthilselvan, A; Dosman, JA; Chenard, L; Burch, LH; Predicala, BZ; Sorowski, R; Schneberger, D; Hurst, T; Kirychuk, S; Gerdts, V; Cormier, Y; Rennie, DC; Schwartz, DA				Senthilselvan, Ambikaipakan; Dosman, James A.; Chenard, Liliane; Burch, Lauranell H.; Predicala, Bernardo Z.; Sorowski, Randine; Schneberger, David; Hurst, Tom; Kirychuk, Shelley; Gerdts, Volker; Cormier, Yvon; Rennie, Donna C.; Schwartz, David A.			Toll-like receptor 4 variants reduce airway response in human subjects at high endotoxin levels in a swine facility	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway hyperresponsiveness; blood counts; cytokines; endotoxin; gene-environment interaction; lung function; swine confinement facility; Toll-like receptor 4 variants	GENE-ENVIRONMENT INTERACTIONS; LUNG-FUNCTION DECLINE; SOLUBLE CD14 LEVELS; SERUM IGE LEVELS; CONFINEMENT BUILDINGS; PIG FARMERS; PULMONARY-FUNCTION; DUST; POLYMORPHISMS; EXPOSURE	Background: Toll-like receptor 4 (TLR4) variants have been shown to reduce the respiratory responses to inhaled LPS in controlled experiments among healthy volunteers. Objective: We sought to investigate whether naive subjects with TLR4 variants showed reduced respiratory response to a complex aerosol including endotoxin as a major constituent. Methods: Twenty-nine nonsmoking, nonatopic healthy subjects with TLR4 299/399 polymorphisms and 29 age- and sex-matched, wild-type TLR4 control subjects were exposed for 5 hours each in a noncontaminated environment (baseline day) and in a swine confinement facility (exposure day). There were 16 men and 13 women in each of the 2 age- and sex-matched groups. Results: TLR4 polymorphic subjects who were exposed to high endotoxin levels (>= 1550 EU/m(3)) had less reduction in the percentage across-shift change in FEV1 from baseline than did wild-type subjects exposed to similar endotoxin levels. Among subjects exposed to higher endotoxin levels, the mean differences in the percentage across-shift changes between baseline and exposure days were significantly less in TLR4 polymorphic subjects compared with those seen in wild-type subjects in FEV1 (-8.48% +/- 1.52% [mean +/- SE] vs -11.46% +/- 1.79%, P = .001), forced expiratory flow between 25% and 75% of forced vital capacity (-18.30% +/- 1.99% vs -24.14% +/- 3.28%, P = .009), and FEV1/forced vital capacity ratio (-5.40% +/- 0.56% vs -8.53% +/- 1.51%, P = .04). These patterns were not observed in IL-6 levels from serum and nasal lavage fluid, IL-8 levels from nasal lavage fluid, white blood cell counts, or blood differential counts. Conclusion: The association between TLR4 variants and reduced airway responsiveness to inhaled particulate was observed at high endotoxin concentrations, creating the possibility of certain threshold phenomena for the apparent protective effect of TLR4 variants. (J Allergy Clin Immunol 2009;123:1034-40.)	[Senthilselvan, Ambikaipakan] Univ Alberta, Sch Publ Hlth, Dept Publ Hlth Sci, Edmonton, AB T6G 2G3, Canada; [Dosman, James A.; Chenard, Liliane; Sorowski, Randine; Schneberger, David; Kirychuk, Shelley; Rennie, Donna C.] Univ Saskatchewan, Candian Ctr Hlth & Safety Agr, Saskatoon, SK, Canada; [Gerdts, Volker] Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK, Canada; [Burch, Lauranell H.] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA; [Predicala, Bernardo Z.] Prairie Swine Ctr Inc, Saskatoon, SK, Canada; [Hurst, Tom] Univ Saskatchewan, Dept Med, Saskatoon, SK S7N 0W0, Canada; [Cormier, Yvon] Univ Laval, Quebec City, PQ, Canada; [Schwartz, David A.] Natl Jewish Hlth, Denver, CO USA	University of Alberta; University of Saskatchewan; University of Saskatchewan; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Saskatchewan; University of Saskatchewan; Laval University; National Jewish Health	Senthilselvan, A (corresponding author), Univ Alberta, Sch Publ Hlth, Dept Publ Hlth Sci, 13-106B Clin Sci Bldg, Edmonton, AB T6G 2G3, Canada.	sentil@ualberta.ca		Gerdts, Volker/0000-0001-8229-1611; Schneberger, David/0000-0002-6270-1502	Advancing Canadian Agriculture and Agri-Food Saskatchewan; National Science and Engineering Research Council (Canada); Saskatchewan Agriculture Development Fund; Alberta Agriculture and Food Council; Canadian Institutes for Health Research; Bill & Melinda Gates Foundation; Alberta Agriculture Funding Consortium; Canadian Lung Association; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZICES102546, Z01ES102546] Funding Source: NIH RePORTER	Advancing Canadian Agriculture and Agri-Food Saskatchewan; National Science and Engineering Research Council (Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Saskatchewan Agriculture Development Fund; Alberta Agriculture and Food Council; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Alberta Agriculture Funding Consortium; Canadian Lung Association; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Disclosure of potential conflict of interest: B. Predicala has received research support from Advancing Canadian Agriculture and Agri-Food Saskatchewan, the National Science and Engineering Research Council (Canada), the Saskatchewan Agriculture Development Fund, and the Alberta Agriculture and Food Council. S. Kirychuk has received research support from the Canadian Institutes for Health Research. V Gerdts has received research support from the Bill & Melinda Gates Foundation, the Canadian Institutes of Health Research, the National Sciences and Engineering Council (Canada), and the Alberta Agriculture Funding Consortium. D. C. Rennie has received research support from the Canadian Lung Association. D. A. Schwartz has patent rights through MedImmune. The rest of the authors have declared that they have no conflict of interest.	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Arbabi S, 2002, CRIT CARE MED, V30, pS74, DOI 10.1097/00003246-200201001-00010; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Awomoyi AA, 2007, J IMMUNOL, V179, P3171, DOI 10.4049/jimmunol.179.5.3171; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; CLARK S, 1983, AM IND HYG ASSOC J, V44, P537, DOI 10.1080/15298668391405265; DONHAM KJ, 1990, AM J IND MED, V17, P17; DONHAM KJ, 1986, AM IND HYG ASSOC J, V47, P404, DOI 10.1080/15298668691389955; Dosman JA, 2006, AM J IND MED, V49, P761, DOI 10.1002/ajim.20339; DOSMAN JA, 1988, J OCCUP ENVIRON MED, V30, P715; Dosman JA, 2000, CHEST, V118, P852, DOI 10.1378/chest.118.3.852; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; GLINDMEYER HW, 1982, AM REV RESPIR DIS, V125, P544, DOI 10.1164/arrd.1982.125.5.544; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; LARSSON KA, 1994, AM J RESP CRIT CARE, V150, P973, DOI 10.1164/ajrccm.150.4.7921472; Levan TD, 2008, J ALLERGY CLIN IMMUN, V121, P434, DOI 10.1016/j.jaci.2007.08.050; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Michel O, 2003, J ALLERGY CLIN IMMUN, V112, P923, DOI 10.1016/j.jaci.2003.05.001; PRELLER L, 1995, ANN OCCUP HYG, V39, P545, DOI 10.1093/annhyg/39.5.545; Reynolds SJ, 1996, AM J IND MED, V29, P33, DOI 10.1002/(SICI)1097-0274(199601)29:1<33::AID-AJIM5>3.0.CO;2-#; Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47, DOI 10.1164/ajrccm.151.1.7812571; Senthilselvan A, 1997, CHEST, V111, P1733, DOI 10.1378/chest.111.6.1733; Senthilselvan A, 1997, AM J RESP CRIT CARE, V156, P410, DOI 10.1164/ajrccm.156.2.9612069; Senthilselvan A, 2008, ANN ALLERG ASTHMA IM, V100, P463, DOI 10.1016/S1081-1206(10)60472-3; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Vogelzang PFJ, 1997, INT ARCH OCC ENV HEA, V70, P327, DOI 10.1007/s004200050226; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15, DOI 10.1164/ajrccm.157.1.9703087; Wang Z, 1997, EUR RESPIR J, V10, P381, DOI 10.1183/09031936.97.10020381; Williams LK, 2006, J ALLERGY CLIN IMMUN, V118, P851, DOI 10.1016/j.jaci.2006.07.007; ZEJDA JE, 1994, J OCCUP ENVIRON MED, V36, P49; ZHOU C, 1991, CHEST, V99, P941, DOI 10.1378/chest.99.4.941	34	26	26	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1034	1040		10.1016/j.jaci.2009.02.019	http://dx.doi.org/10.1016/j.jaci.2009.02.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19368968				2022-12-18	WOS:000266309400008
J	Tamagawa-Mineoka, R; Katoh, N; Kishimoto, S				Tamagawa-Mineoka, Risa; Katoh, Norito; Kishimoto, Saburo			Platelets play important roles in the late phase of the immediate hypersensitivity reaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; chemokine; immediate hypersensitivity reaction; late-phase reaction; platelet; P-selectin	AFFINITY IGE RECEPTOR; ACTIVATING-FACTOR; P-SELECTIN; INDUCED THROMBOCYTOPENIA; LEUKOCYTE RECRUITMENT; GLYCOPROTEIN IIB/IIIA; MAST-CELLS; EXPRESSION; RELEASE; ASPIRIN	Background: Recent studies have shown that platelets have a role in most inflammatory reactions, but involvement of platelets in the immediate hypersensitivity reaction (IHR) in skin has not been examined. Objective: To investigate the role of platelets in a mouse model of IgE-mediated IHR. Methods: Mice were sensitized by injecting ovalbumin intraperitoneally and challenged by injecting ovalbumin intradermally into ears, with or without platelet depletion. Results: Sensitized mice developed biphasic responses characterized by early-phase and late-phase reactions (LPRs). Degranulation of mast cells in skin did not differ between platelet-depleted mice and controls. The early phase reaction was not suppressed at I hour, but platelet depletion significantly reduced the LPR at 24 hours (P < .01). Flow cytometry showed that P-selectin expression on platelets and the number of plate] et-leukocyte aggregates were both higher in the blood of ovalbumin-challenged mice compared with sham-sensitized mice at 24 hours (P < .05). In platelet-depleted mice, the LPR was restored by infusing platelets from normal mice (P < .01). This effect did not occur by infusing platelets from P-selectin-deficient mice or by pretreating platelets with anti-P-selectin antibody. Injection of activated platelet supernatant into ears led to increased leukocyte infiltration at 24 hours, and this effect was blocked by pretreating the supernatant with several antichemokine antibodies. Systemic administration of antiplatelet compounds also suppressed the LPR significantly. Conclusion: These results show that platelets play important roles in the LPR of the IHR in skin by forming platelet-leukocyte complexes via P-selectin in blood and secreting several chemokines that attract leukocytes to skin. (J Allergy Clin Immunol 2009;123:581-7.)	[Tamagawa-Mineoka, Risa] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Dermatol, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine	Tamagawa-Mineoka, R (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Dermatol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	risat@koto.kpu-m.ac.jp	Inada, Mami/G-4783-2011		Japanese Ministry of Education, Science, Sports, and Culture; Shiseido Co Ltd; Cosmetology Research Foundation	Japanese Ministry of Education, Science, Sports, and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Shiseido Co Ltd; Cosmetology Research Foundation	Supported by a grant from the Japanese Ministry of Education, Science, Sports, and Culture (to R.T.-M. and N.K.), by a grant for Basic Dermatological Research from Shiseido Co Ltd (to R.T.-M.), and by a grant from the Cosmetology Research Foundation (to N.K.).	Andoh A, 2005, AM J GASTROENTEROL, V100, P2042, DOI 10.1111/j.1572-0241.2005.50381.x; Angiolillo DJ, 2004, EUR HEART J, V25, P1903, DOI 10.1016/j.ehj.2004.07.036; COYLE AJ, 1990, BRIT J PHARMACOL, V101, P31, DOI 10.1111/j.1476-5381.1990.tb12084.x; Danese S, 2003, GASTROENTEROLOGY, V124, P1249, DOI 10.1016/S0016-5085(03)00289-0; DEBRUIJNEADMIRAAL LG, 1992, BLOOD, V80, P134; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Fujisawa T, 2002, J ALLERGY CLIN IMMUN, V110, P139, DOI 10.1067/mai.2002.126079; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Gruber BL, 1997, J IMMUNOL, V158, P2310; Hasegawa S, 1999, BLOOD, V93, P2543, DOI 10.1182/blood.V93.8.2543.408k14_2543_2551; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; Katoh N, 2009, J DERMATOL SCI, V53, P89, DOI 10.1016/j.jdermsci.2008.08.019; KLINGER MHF, 1995, INT ARCH ALLERGY IMM, V107, P541, DOI 10.1159/000237097; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; LAPETINA EG, 1982, J BIOL CHEM, V257, P7314; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Ludwig RJ, 2004, J INVEST DERMATOL, V122, P830, DOI 10.1111/j.0022-202X.2004.22318.x; McKenzie ME, 2003, BLOOD COAGUL FIBRIN, V14, P249, DOI 10.1097/01.mbc.0000046182.72384.ab; Mitsuhashi M, 2001, J IMMUNOL, V166, P617, DOI 10.4049/jimmunol.166.1.617; Miyahara S, 2005, J ALLERGY CLIN IMMUN, V116, P1020, DOI 10.1016/j.jaci.2005.08.020; Nannizzi-Alaimo L, 2003, CIRCULATION, V107, P1123, DOI 10.1161/01.CIR.0000053559.46158.AD; PINCKARD RN, 1977, J IMMUNOL, V119, P2185; Pitchford SC, 2005, BLOOD, V105, P2074, DOI 10.1182/blood-2004-06-2282; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; Pitchford SC, 2008, AM J RESP CRIT CARE, V177, P604, DOI 10.1164/rccm.200702-214OC; ROTH GJ, 1994, BLOOD, V83, P885; SAVI P, 1994, THROMB HAEMOSTASIS, V72, P313; Sawada K, 1997, CLIN EXP ALLERGY, V27, P225; Schmitt-Sody M, 2005, RHEUMATOLOGY, V44, P885, DOI 10.1093/rheumatology/keh638; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; STENBERG PE, 1991, J CELL PHYSIOL, V147, P7, DOI 10.1002/jcp.1041470103; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Tamagawa-Mineoka R, 2007, AM J PATHOL, V170, P2019, DOI 10.2353/ajpath.2007.060881; Tamagawa-Mineoka Risa, 2008, Allergol Int, V57, P391, DOI 10.2332/allergolint.O-08-537; Tonnel AB, 1996, ANN NY ACAD SCI, V796, P9, DOI 10.1111/j.1749-6632.1996.tb32562.x; Uchida T, 2002, INT IMMUNOL, V14, P1431, DOI 10.1093/intimm/dxf109; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; von Hundelshausen P, 2007, CIRC RES, V100, P27, DOI 10.1161/01.RES.0000252802.25497.b7; Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9; Zeng S, 1999, ACTA PHARMACOL SIN, V20, P948	42	26	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					581	587		10.1016/j.jaci.2008.12.1114	http://dx.doi.org/10.1016/j.jaci.2008.12.1114			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19281907				2022-12-18	WOS:000264731200015
J	Sicherer, SH; Burks, AW				Sicherer, Scott H.; Burks, A. Wesley			Maternal and infant diets for prevention of allergic diseases: Understanding menu changes in 2008	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							SOLID FOOD INTRODUCTION; PEANUT ALLERGY; ATOPIC-DERMATITIS; ESPGHAN COMMITTEE; GOVERNMENT ADVICE; CHILDREN; RISK; ASTHMA; CHILDHOOD; PREGNANCY		[Burks, A. Wesley] Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA; [Sicherer, Scott H.] Mt Sinai Sch Med, Div Allergy & Immunol, Dept Pediat, New York, NY USA	Duke University; Icahn School of Medicine at Mount Sinai	Burks, AW (corresponding author), Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA.	wesley.burks@duke.edu						Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; Baker SS, 2000, PEDIATRICS, V106, P346; Boyle RJ, 2006, ALLERGY, V61, P1423, DOI 10.1111/j.1398-9995.2006.01113.x; Brand PLP, 2007, PEDIAT ALLERG IMM-UK, V18, P475, DOI 10.1111/j.1399-3038.2007.00541.x; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Calvani M, 2006, PEDIAT ALLERG IMM-UK, V17, P94, DOI 10.1111/j.1399-3038.2005.00367.x; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; Dean T, 2007, J HUM NUTR DIET, V20, P95, DOI 10.1111/j.1365-277X.2007.00751.x; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Fiocchi A, 2006, ANN ALLERG ASTHMA IM, V97, P10, DOI 10.1016/S1081-1206(10)61364-6; Flinterman AE, 2006, ALLERGY, V61, P370, DOI 10.1111/j.1398-9995.2006.01018.x; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; KRAMER MS, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000133.PUB2; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Liem JJ, 2007, J ALLERGY CLIN IMMUN, V119, P1203, DOI 10.1016/j.jaci.2006.12.671; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Osborn DA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003664.pub3; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P717, DOI 10.1016/j.jaci.2007.07.027; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Zutavern A, 2008, PEDIATRICS, V121, pE44, DOI 10.1542/peds.2006-3553	42	26	29	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					29	33		10.1016/j.jaci.2008.05.019	http://dx.doi.org/10.1016/j.jaci.2008.05.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18547624	Bronze			2022-12-18	WOS:000257605100004
J	Singh, KK; Lieser, A; Ruan, PK; Fenton, T; Spector, SA				Singh, Kurnud K.; Lieser, Alexis; Ruan, Ping K.; Fenton, Terry; Spector, Stephen A.			An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	14th Conference on Retroviruses and Opportunistic Infections	FEB 25-28, 2007	Los Angeles, CA			mannose binding lectin-2; polymorphisms; HIV-1 disease; central nervous system impairment; children	MENINGOCOCCAL DISEASE; HIV-1 INFECTION; MBL2 GENE; SUSCEPTIBILITY; PROGRESSION; DEFICIENCY; DIDANOSINE; ZIDOVUDINE; CHILDHOOD; MUTATIONS	Background: Mannose-binding lectin (MBL) is part of the lectin pathway of complement activation against various pathogens; however, its role in innate immune responses against HIV-1 infection in children is unknown. Objective: This study evaluated the effects of mannose-binding lectin-2 (MBL2) alleles on HIV-1 disease progression and central nervous system (CNS) impairment in children. Methods: A cohort of 1037 HIV-1-infected children enrolled in Pediatrics AIDS Clinical Trial Group protocols P152 and P300 before the availability of effective antiretroviral therapy was genotyped for MBL2 and evaluated for disease progression. Results: Children with the homozygous variant MBL2-O/O genotype were more likely to experience rapid disease progression and CNS impairment than those with the wildtype AA genotype. The effects were predominantly observed in children younger than 2 years. In unadjusted Cox proportional hazards models, children younger than 2 years with MBL2-O/O experienced more rapid disease progression (O/O vs AA: relative hazard [RH], 1.54; 95% CI, 1.07-2.22; P = .02; O/O vs A/O: RH, 2.28; 95% CI, 1.09-4.79; P = .029). Similarly, children with MBL2-O/O were more likely to experience rapid progression to CNS impairment (O/O vs A/A: RH, 2.78; 95% CI, 1.06-2.69, P = .027; O/O vs A/O: RH, 1.69; 95% CI, 1.07-7.21; P = .035). The effects remained significant after adjustment for CD4(+) lymphocyte count, plasma HIV-1 RNA, and other genotypes. Conclusions: MBL2-O/O genotypes, which result in lower expression of MBL, are associated with more rapid HIV-1-related disease progression, including CNS impairment, predominantly in children younger than 2 years. These data suggest that MBL2 variants are associated with altered HIV-1 disease progression, particularly in young children.	[Singh, Kurnud K.; Spector, Stephen A.] Univ Calif San Diego, Dept Pediat, Div Infect Dis, La Jolla, CA USA; [Lieser, Alexis] Univ Calif Irvine, Med Ctr, Orange, CA USA; [Ruan, Ping K.; Fenton, Terry] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA	University of California System; University of California San Diego; University of California System; University of California Irvine; Harvard University; Harvard T.H. Chan School of Public Health	Spector, SA (corresponding author), Univ Calif San Diego, Dept Pediat, Div Infect Dis, 9500 Gilman Dr, La Jolla, CA USA.	kusingh@ucsd.edu; saspector@ucsd.edu			NIAID NIH HHS [U01 AI068632, UM1 AI068632, U01 AI068632-03, AI068632, P30 AI036214, AI-36214] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI068632, UM1AI068632, P30AI036214] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bax WA, 1999, LANCET, V354, P1094, DOI 10.1016/S0140-6736(99)02563-5; Boldt ABW, 2006, HUM IMMUNOL, V67, P722, DOI 10.1016/j.humimm.2006.05.009; Boldt ABW, 2002, HUM MUTAT, V19, P296, DOI 10.1002/humu.10051; Boniotto M, 2000, GENES IMMUN, V1, P346, DOI 10.1038/sj.gene.6363685; Dommett RM, 2006, TISSUE ANTIGENS, V68, P193, DOI 10.1111/j.1399-0039.2006.00649.x; Dzwonek A, 2006, ANTIVIR THER, V11, P499; Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; Faber J, 2007, PEDIATR INFECT DIS J, V26, P243, DOI 10.1097/01.inf.0000256751.76218.7c; Fidler KJ, 2004, INTENS CARE MED, V30, P1438, DOI 10.1007/s00134-004-2303-8; Garred P, 1997, LANCET, V349, P236, DOI 10.1016/S0140-6736(96)08440-1; Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4; Heggelund L, 2003, JAIDS-J ACQ IMM DEF, V32, P354, DOI 10.1097/00126334-200304010-00002; Hibberd ML, 1999, LANCET, V353, P1049, DOI 10.1016/S0140-6736(98)08350-0; Ji X, 2005, MOL IMMUNOL, V42, P145, DOI 10.1016/j.molimm.2004.06.015; Kakkanaiah VN, 1998, CLIN DIAGN LAB IMMUN, V5, P319, DOI 10.1128/CDLI.5.3.319-321.1998; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P401, DOI 10.1016/S0304-4165(02)00321-5; Koch A, 2001, JAMA-J AM MED ASSOC, V285, P1316, DOI 10.1001/jama.285.10.1316; Lanzrein AS, 1998, NEUROREPORT, V9, P1491, DOI 10.1097/00001756-199805110-00045; McKinney RE, 1998, J PEDIATR-US, V133, P500, DOI 10.1016/S0022-3476(98)70057-5; Singh KK, 2003, J INFECT DIS, V188, P1461, DOI 10.1086/379038; Spear GT, 2003, IMMUNOLOGY, V110, P80, DOI 10.1046/j.1365-2567.2003.01707.x; Steffensen R, 2003, J IMMUNOL METHODS, V278, P191, DOI 10.1016/S0022-1759(03)00190-X; SUPER M, 1989, LANCET, V2, P1236; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Turner M W, 2000, Rev Immunogenet, V2, P305; Turner MW, 1998, IMMUNOBIOLOGY, V199, P327, DOI 10.1016/S0171-2985(98)80037-5; Valdimarsson H, 1998, SCAND J IMMUNOL, V48, P116; Verdu P, 2006, HUM MOL GENET, V15, P2650, DOI 10.1093/hmg/ddl193	29	26	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					173	180		10.1016/j.jaci.2008.05.025	http://dx.doi.org/10.1016/j.jaci.2008.05.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	325RD	18602571	Green Accepted			2022-12-18	WOS:000257605100028
J	Holt, EW; Cook, EF; Covar, RA; Spahn, J; Fuhlbrigge, AL				Holt, Elizabeth W.; Cook, Earl Francis; Covar, Ronina A.; Spahn, Joseph; Fuhlbrigge, Anne L.			Identifying the components of asthma health status in children with mild to moderate asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						factor analysis; asthma health status; components; associations; morbidity	EXHALED NITRIC-OXIDE; QUALITY-OF-LIFE; LUNG-FUNCTION; BRONCHIAL HYPERRESPONSIVENESS; AIRWAY HYPERRESPONSIVENESS; CHILDHOOD ASTHMA; SPUTUM ANALYSIS; SERUM IGE; SEVERITY; VALIDATION	Background: Weak and inconsistent correlations between measurements of asthma health status suggest that the disease is composed of nonoverlapping components. Objective: Factor analysis was used to explore the relationships between measures of asthma morbidity and to identify heterogeneous components of asthma health status in children 5 to 12 years old. Results were compared across time (baseline and 48-month visit) and treatment arms. Methods: Analyses were conducted in 7 different study windows in a database from a large clinical trial of children with mild to moderate asthma (n = 1041). Measurements of lung function, symptoms, and health care utilizations from daily diary cards, serum IgE levels, total eosinophil count, skin test positivity, and airway hyperresponsiveness were included. Data on fractional exhaled nitric oxide and sputum eosinophil cationic protein were included in a subgroup of patients. Results: In each of the study windows, factor analysis identified 5 factors that explained between 50% and 60% of the common variance. Factors identified included (1) inflammatory markers, (2) symptoms/medication use, (3) asthma exacerbations, and measures of lung function, which subdivided into (4) FEV1 and forced vital capacity, and (5) bronchodilator response and the FEV1/forced vital capacity ratio. Exploratory analyses suggest that fractional exhaled nitric oxide account for the atopy/inflammatory marker factor, and sputum measurements account for a sixth, separate factor. Conclusion: The consistent identification of a 5-factor structure across time and treatment arms suggests that each of these factors provides independent information in the assessment of asthma.	[Holt, Elizabeth W.; Fuhlbrigge, Anne L.] Harvard Univ, Channing Lab, Brigham & Womens Hosp, Boston, MA 02115 USA; [Cook, Earl Francis] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Spahn, Joseph; Fuhlbrigge, Anne L.] Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Holt, EW (corresponding author), Tulane Sch Publ Hlth & Trop Med, Dept Epidemiol, 1440 Canal St,SL 18, New Orleans, LA 70112 USA.	eholt@tulane.edu			NHLBI NIH HHS [U01 HL075419, N01-HR-16044-16052, N01HR16044, U01 HL075419-04] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016044] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL075419] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; APTER AJ, 1994, J ALLERGY CLIN IMMUN, V94, P732, DOI 10.1016/0091-6749(94)90181-3; ARMITAGE P, 2002, STAT METHODS MED RES, P455; Bacharier LB, 2003, PEDIATRICS, V112, pE85, DOI 10.1542/peds.112.2.e85; BAILEY WC, 1992, AM J MED, V93, P263, DOI 10.1016/0002-9343(92)90231-Y; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; Chan EY, 2005, PEDIATR PULM, V39, P558, DOI 10.1002/ppul.20227; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Covar RA, 2004, J ALLERGY CLIN IMMUN, V114, P575, DOI 10.1016/j.jaci.2004.06.036; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Grazzini M, 2001, RESP MED, V95, P246, DOI 10.1053/rmed.2000.1017; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Gronke L, 2002, CLIN EXP ALLERGY, V32, P57, DOI 10.1046/j.0022-0477.2001.01297.x; Hair J.F., 2006, MULTIVARIATE DATA AN, V87, P49; Juniper EF, 2004, EUR RESPIR J, V23, P287, DOI 10.1183/09031936.04.00064204; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Lapperre TS, 2004, AM J RESP CRIT CARE, V170, P499, DOI 10.1164/rccm.200401-112OC; Leung TF, 2005, THORAX, V60, P822, DOI 10.1136/thx.2004.039321; *NIH, 1997, PUB NIH; Osborne ML, 1999, CHEST, V115, P85, DOI 10.1378/chest.115.1.85; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Recruitment of participants in the childhood Asthma Management Program (CAMP), 1999, J ASTHMA, V36, P217; Ronchi MC, 1997, EUR RESPIR J, V10, P1809, DOI 10.1183/09031936.97.10081809; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P1049, DOI 10.1016/j.jaci.2005.02.008; Schatz M, 2007, QUAL LIFE RES, V16, P345, DOI 10.1007/s11136-006-9103-2; Schatz M, 2006, AM J MANAG CARE, V12, P478; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P995, DOI 10.1016/j.jaci.2006.01.053; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Sharek PJ, 2002, PEDIATRICS, V110, P797, DOI 10.1542/peds.110.4.797; Simeoni MC, 2007, QUAL LIFE RES, V16, P881, DOI 10.1007/s11136-007-9188-2; Smith AD, 2005, CURR OPIN ALLERGY CL, V5, P49, DOI 10.1097/00130832-200502000-00010; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Tantisira KG, 2006, J ALLERGY CLIN IMMUN, V117, P1264, DOI 10.1016/j.jaci.2006.01.050; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P1297, DOI 10.1164/ajrccm/144.6.1297	40	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1175	1180		10.1016/j.jaci.2008.02.015	http://dx.doi.org/10.1016/j.jaci.2008.02.015			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18466785	Green Accepted			2022-12-18	WOS:000255961700015
J	Small, CB; Stryszak, P; Danzig, M; Damiano, A				Small, Catherine Butkus; Stryszak, Paul; Danzig, Melvyn; Damiano, Angela			Onset of symptomatic effect of mometasone furoate nasal spray in the treatment of nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyposis; mometasone furoate; efficacy onset; intranasal corticosteroids; clinical trial	SEASONAL ALLERGIC RHINITIS; RANDOMIZED CONTROLLED-TRIAL; INTRANASAL BUDESONIDE; DOUBLE-BLIND; EFFICACY; FLUTICASONE; SINUSITIS; PLACEBO; TISSUE; POWDER	Background: The efficacy of the intranasal corticosteroid mometasone furoate nasal spray (MFNS) for treatment of nasal polyposis was demonstrated in 2 large clinical trials. Objective: To evaluate the onset of MFNS symptomatic effect, data from the 2 trials were pooled and analyzed to determine the first day subjects experienced significant symptom relief. Methods: Subjects with nasal polyposis randomized to MFNS 200 mu g twice daily or placebo scored symptoms on a 3-point scale (0 = none; 3 = severe) and measured peak nasal inspiratory flow immediately before the morning dose. Onset of symptomatic effect was defined as the first day a statistically significant (P < .05) lasting response was observed for MFNS compared with placebo. Results: A total of 447 subjects with bilateral nasal polyps and clinically significant nasal congestion/obstruction were analyzed. Compared with placebo, MFNS 200 mu g twice daily demonstrated statistically significant (P < .05) relief of anterior rhinorrhea by day 2 ( -10.9% vs +5.7%), nasal congestion by day 3 (45.1% vs -7.6%), postnasal drip by day 5 (+1.1% vs +4.6%), and sense of smell by day 13 (-9.6% vs -5.6%). Significant improvement in peak nasal inspiratory flow was seen by day 2 (increase of 6.22 L/min vs 1.48 L/min for placebo; P = .03). Conclusion: Mometasone furoate nasal spray 200 mu g twice daily rapidly improves the symptoms of nasal polyposis, leading to lasting relief of most major symptoms within 2 (24 hours after the first dose) to 5 days of initiating therapy.	[Small, Catherine Butkus] Westchester Cty Med Ctr, New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA; [Damiano, Angela] Westchester Cty Med Ctr, New York Med Coll, Div Otolaryngol, Valhalla, NY 10595 USA; [Stryszak, Paul; Danzig, Melvyn] Schering Plough Res Inst, Kenilworth, NJ USA	New York Medical College; Westchester Medical Center; New York Medical College; Westchester Medical Center; Merck & Company; Schering-Plough Research Institute	Small, CB (corresponding author), Westchester Cty Med Ctr, New York Med Coll, Div Infect Dis, Maunger Pavilion Rm 245, Valhalla, NY 10595 USA.	Catherine_Small@nymc.edu						Adcock IM, 1996, EUR RESPIR J, V9, P160, DOI 10.1183/09031936.96.09010160; Bachert C, 2003, CURR ALLERGY ASTHM R, V3, P523, DOI 10.1007/s11882-003-0065-y; Bachert C, 2003, ALLERGY, V58, P176, DOI 10.1034/j.1398-9995.2003.02172.x; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Badia L, 2001, DRUGS, V61, P573, DOI 10.2165/00003495-200161050-00003; Berkowitz RB, 1999, ALLERGY ASTHMA PROC, V20, P167, DOI 10.2500/108854199778553037; Berkowitz RB, 1999, ALLERGY, V54, P64, DOI 10.1034/j.1398-9995.1999.00713.x; Blomqvist EH, 2001, J ALLERGY CLIN IMMUN, V107, P224, DOI 10.1067/mai.2001.112124; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; DELANK KW, 1994, HNO, V42, P619; DEUSCHL H, 1977, Rhinology (Utrecht), V15, P17; Filiaci F, 2000, RHINOLOGY, V38, P185; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Holbrook Eric H, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P23, DOI 10.1097/01.moo.0000193174.77321.39; Holmberg K, 1997, ANN ALLERG ASTHMA IM, V78, P270, DOI 10.1016/S1081-1206(10)63180-8; Jankowski R, 2001, ARCH OTOLARYNGOL, V127, P447, DOI 10.1001/archotol.127.4.447; JOHANSEN LV, 1993, CLIN OTOLARYNGOL, V18, P524, DOI 10.1111/j.1365-2273.1993.tb00628.x; Johansson L, 2004, ACTA OTO-LARYNGOL, V124, P77, DOI 10.1080/00016480310016037; LILDHOLDT T, 1995, CLIN OTOLARYNGOL, V20, P26, DOI 10.1111/j.1365-2273.1995.tb00007.x; Lund VJ, 1998, ARCH OTOLARYNGOL, V124, P513, DOI 10.1001/archotol.124.5.513; MYGIND N, 1975, Clinical Allergy, V5, P159, DOI 10.1111/j.1365-2222.1975.tb01848.x; ROWEJONES JM, 1998, CURR OPIN OTOLARYNGO, V6, P41; RUHNO J, 1990, J ALLERGY CLIN IMMUN, V86, P946, DOI 10.1016/S0091-6749(05)80158-7; Simon HU, 1997, J IMMUNOL, V158, P3902; Small CB, 2005, J ALLERGY CLIN IMMUN, V116, P1275, DOI 10.1016/j.jaci.2005.07.027; Stjarne P, 2006, ARCH OTOLARYNGOL, V132, P179, DOI 10.1001/archotol.132.2.179; Tos M, 1998, AM J RHINOL, V12, P183, DOI 10.2500/105065898781390217	28	26	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					928	932		10.1016/j.jaci.2007.11.018	http://dx.doi.org/10.1016/j.jaci.2007.11.018			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18234321				2022-12-18	WOS:000254884000017
J	Casale, TB; Romero, FA; Spierings, ELH				Casale, Thomas B.; Romero, Francisco A.; Spierings, Egilius L. H.			Intranasal noninhaled carbon dioxide for the symptomatic treatment of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						carbon dioxide; topical nasal administration; clinical trial; allergic rhinitis	MIGRAINE HEADACHE; RHINOSINUSITIS; ANTIHISTAMINE; MANAGEMENT; CHALLENGE; RELEASE; PEPTIDE; CGRP	Background: Noninhaled intranasal carbon dioxide (CO2) has been shown to be effective in the abortive treatment of migraine headache. Migraine headache is associated with trigeminal neuronal activation and release of calcitonin gene-related peptide, events also implicated in allergic rhinitis. Intranasal CO2 might inhibit trigeminal neuronal activation and suppress the release of calcitonin gene-related peptide. Objective: We studied whether noninhaled intranasal CO2 would be effective in the treatment of seasonal allergic rhinitis. Methods: We conducted a single-center, randomized, double-blind, placebo-controlled, parallel-group study. Treatment consisted of either CO2 (verum) or air (placebo) at a 2:1 ratio administered in each nostril for 60 seconds per nostril at a flow rate of 10 mL/s. The primary efficacy end point was the change from baseline in total nasal symptom score (TNSS), the sum of congestion, rhinorrhea, itching, and sneezing scored on a 0- to 5-point scale, at 30 minutes. Results: Eighty-nine subjects received treatment, 60 with CO2 and 29 with placebo, and all subjects completed the study. CO2 resulted in a statistically significant improvement in TNSS at 30 minutes over placebo (absolute changes of 5.0 for CO2 and 2.2 for placebo, P =.00019). Improvement from baseline in TNSS (CO2 VS placebo) was statistically significant at 10 minutes and remained so for 24 hours. Conclusion: Two 60-second intranasal CO2 treatments resulted in rapid (10 minutes) and sustained (24 hours) relief of seasonal allergic rhinitis symptoms.	[Casale, Thomas B.; Romero, Francisco A.] Creighton Univ, Dept Internal Med, Div Allergy & Immunol, Omaha, NE 68178 USA; [Spierings, Egilius L. H.] Harvard Univ, Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA	Creighton University; Harvard University; Brigham & Women's Hospital	Casale, TB (corresponding author), Creighton Univ, Dept Internal Med, Div Allergy & Immunol, 601 N 30th St,Suite 5850, Omaha, NE 68178 USA.	tbcasale@creighton.edu	Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				Bauer O, 2000, NEWS PHYSIOL SCI, V15, P213, DOI 10.1152/physiologyonline.2000.15.5.213; Bellamy JL, 2006, HEADACHE, V46, P24, DOI 10.1111/j.1526-4610.2006.00294.x; Bowen EJ, 2005, HEADACHE, V45, P808; Dolen WK, 2004, ALLERGY ASTHMA PROC, V25, P85; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; GOADSBY PJ, 1990, ANN NEUROL, V28, P183, DOI 10.1002/ana.410280213; Juniper EF, 1997, CAN MED ASSOC J, V156, P1123; Lacroix FS, 2003, SWISS MED WKLY, V133, P560; Lai L, 2005, IMMUNOL ALLERGY CLIN, V25, P283, DOI 10.1016/j.iac.2005.02.003; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Schoenwetter WF, 2004, CURR MED RES OPIN, V20, P305, DOI 10.1185/030079903125003053; Spierings EL, 2005, HEADACHE, V45, P809; SPIERINGS ELH, 2005, 130 ANN M AM NEUR AS; Stempel David A, 2002, Curr Allergy Asthma Rep, V2, P223, DOI 10.1007/s11882-002-0023-0; UNDEM BJ, 2000, J ALLERGY CLIN IMMUN, V106, P213; WALKER KB, 1988, J CLIN IMMUNOL, V8, P108, DOI 10.1007/BF00917898; White P, 1998, CLIN EXP ALLERGY, V28, P266	18	26	34	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					105	109		10.1016/j.jaci.2007.08.056	http://dx.doi.org/10.1016/j.jaci.2007.08.056			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18028997				2022-12-18	WOS:000252372000015
J	Lejtenyi, D				Lejtenyi, Duncan			Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STREPTOCOCCUS-PNEUMONIAE; POLYSACCHARIDE; ANTIGENS; BLOOD		McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Div Allergy & Immunol, Quebec City, PQ, Canada	McGill University	Lejtenyi, D (corresponding author), McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Div Allergy & Immunol, Quebec City, PQ, Canada.	Bruce.Mazer@mcgill.ca						Farrell DJ, 2004, J MED MICROBIOL, V53, P1109, DOI 10.1099/jmm.0.45647-0; Inostroza J, 2005, CLIN DIAGN LAB IMMUN, V12, P722, DOI 10.1128/CDLI.12.6.722-726.2005; Lamari F, 1999, J PHARMACEUT BIOMED, V20, P913, DOI 10.1016/S0731-7085(99)00087-4; Mikolajczyk MG, 2004, CLIN DIAGN LAB IMMUN, V11, P1158, DOI 10.1128/CDLI.11.6.1158-1164.2004; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Siegel J, 2005, PHARMACOTHERAPY, V25, p78S, DOI 10.1592/phco.2005.25.11part2.78S; Simon HU, 2003, ALLERGY, V58, P543, DOI 10.1034/j.1398-9995.2003.00239.x	7	26	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					254	255		10.1016/j.jaci.2007.11.001	http://dx.doi.org/10.1016/j.jaci.2007.11.001			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206511				2022-12-18	WOS:000252372000040
J	Scott, JE; ElKhal, A; Freyschmidt, EJ; MacArthur, DH; McDonald, D; Howell, MD; Leung, DYM; Laouar, A; Manjunath, N; Bianchi, T; Boes, M; Oettgen, HC; Geha, RS				Scott, Jordan E.; ElKhal, Abdallah; Freyschmidt, Eva-Jasmin; MacArthur, Daniel H.; McDonald, Douglas; Howell, Michael D.; Leung, Donald Y. M.; Laouar, Amale; Manjunath, N.; Bianchi, Teresa; Boes, Marianne; Oettgen, Hans C.; Geha, Raif S.			Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema vaccinatum; allergy; vaccinia virus; smallpox vaccination; viral response; T(H)1/T(H)2 cells	INTERFERON-GAMMA; ATOPIC-DERMATITIS; SMALLPOX VACCINATION; EPICUTANEOUS SENSITIZATION; ECZEMA VACCINATUM; SKIN INFLAMMATION; DENDRITIC CELLS; MICE LACKING; T-CELLS; INFECTION	Background: Patients with atopic dermatitis (AD) exposed to the vaccinia virus (VV) smallpox vaccine have an increased risk of developing eczema vaccinatum. Objective: To investigate the effects of local allergic skin inflammation on vaccinia immunity. Methods: BALB/c mice were epicutaneously sensitized with ovalbumin (OVA) to induce allergic skin inflammation or with saline control, then inoculated with an attenuated VV strain by skin scarification or intraperitoneally. After 8 days, serum IgG anti-VV and cytokine secretion by splenocytes were measured. Results: Mice inoculated with VV at sites of epicutaneous sensitization with OVA, but not control mice inoculated at saline exposed sites, developed satellite pox lesions and had impaired secretion of T(H)1 cytokines in response to VV, decreased VV specific serum IgG(2a), increased VV specific serum IgG(1), and impaired upregulation of IFN-alpha, but not the cathelicidin-related antimicrobial peptide, at the infection site. The VV immune response of OVA-sensitized mice inoculated with VV at distant skin sites or intraperitoneally was normal. Conclusion: Local immune dysregulation at sites of allergic skin inflammation underlies the impaired T(H)1 immune response to VV introduced at these sites and the increased susceptibility to develop satellite pox lesions, a characteristic of eczema vaccinatum in patients with AD. Clinical implications: In a mouse model of AD, inoculation of VV at inflamed skin sites is associated with increased numbers of satellite pox lesions and an abnormal immune response to the virus. This may contribute to the susceptibility of patients with AD to virus dissemination after smallpox vaccination.	[Scott, Jordan E.; ElKhal, Abdallah; Freyschmidt, Eva-Jasmin; MacArthur, Daniel H.; McDonald, Douglas; Oettgen, Hans C.; Geha, Raif S.] Childrens Hosp, Div Allergy & Immunol, Dept Pediat, Boston, MA 02115 USA; [Laouar, Amale; Manjunath, N.] Harvard Univ, Sch Med, Ctr Blood Res, Inst Biomed Res, Boston, MA 02115 USA; [Howell, Michael D.; Leung, Donald Y. M.] Natl Jewish Ned & Res Ctr, Denver, CO USA; [Bianchi, Teresa; Boes, Marianne] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; [Bianchi, Teresa; Boes, Marianne] Harvard Univ, Sch Med, Dept Pediat & Dermatol, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, Karp 10th Floor,1 Blackfan St, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Laouar, Amale/AAO-2903-2020		NIAMS NIH HHS [R01 AR052810] Funding Source: Medline; PHS HHS [HHSN266200400030C] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052810] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; Davidson DJ, 2004, J IMMUNOL, V172, P1146, DOI 10.4049/jimmunol.172.2.1146; EARL PL, 1998, PREPARATION CELL CUL; Elkhal A, 2006, J ALLERGY CLIN IMMUN, V118, P1363, DOI 10.1016/j.jaci.2006.08.010; Ennis FA, 2002, J INFECT DIS, V185, P1657, DOI 10.1086/340517; Esposito JJ, 2001, FIELDS VIROLOGY, P2885; Freyschmidt EJ, 2007, J ALLERGY CLIN IMMUN, V119, P671, DOI 10.1016/j.jaci.2006.12.645; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Hogg KG, 2003, INFECT IMMUN, V71, P3563, DOI 10.1128/IAI.71.6.3563-3571.2003; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KARUPIAH G, 1990, J EXP MED, V172, P1495, DOI 10.1084/jem.172.5.1495; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KOHONENCORISH MRJ, 1990, EUR J IMMUNOL, V20, P157, DOI 10.1002/eji.1830200123; LANE JM, 1971, AM J EPIDEMIOL, V93, P238, DOI 10.1093/oxfordjournals.aje.a121252; LANE JM, 1970, J AMER MED ASSOC, V212, P441, DOI 10.1001/jama.212.3.441; Laouini D, 2005, J ALLERGY CLIN IMMUN, V116, P390, DOI 10.1016/j.jaci.2005.03.042; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; MANETTI R, 1995, EUR J IMMUNOL, V25, P2656, DOI 10.1002/eji.1830250938; Marris E, 2007, NAT MED, V13, P517, DOI 10.1038/nm0507-517; Neff JM, 2002, JAMA-J AM MED ASSOC, V288, P1901, DOI 10.1001/jama.288.15.1901; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Phelps AL, 2007, VACCINE, V25, P34, DOI 10.1016/j.vaccine.2006.07.022; Sharma DP, 1996, J VIROL, V70, P7103, DOI 10.1128/JVI.70.10.7103-7107.1996; SHIRASAWA K, 1979, ACTA PATHOL JAPON, V29, P435; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; van den Broek M, 2000, J IMMUNOL, V164, P371, DOI 10.4049/jimmunol.164.1.371; vandenBroek MF, 1995, IMMUNOL REV, V148, P5; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Xu R, 2004, J IMMUNOL, V172, P6265, DOI 10.4049/jimmunol.172.10.6265	33	26	27	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1382	1388		10.1016/j.jaci.2007.08.004	http://dx.doi.org/10.1016/j.jaci.2007.08.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17889291				2022-12-18	WOS:000251653800021
J	Persson, H; Sadegh, MK; Greiff, L; Ohlin, M				Persson, Helena; Sadegh, Mardjaneh Karbalaei; Greiff, Lennart; Ohlin, Mats			Delineating the specificity of an IgE-encoding transcriptome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; antibody library; antibody repertoire; diversity; grass pollen allergen; IgE; phage display; specificity	PHLEUM-PRATENSE POLLEN; IMMUNOGLOBULIN-E ANTIBODIES; PHAGE-DISPLAY LIBRARIES; GRASS-POLLEN; V-H; ATOPIC-DERMATITIS; GENE USAGE; IN-VIVO; P 5; ALLERGEN	Background: Although much is known about the reactivity of polyclonal populations of antibodies targeting the wide array of allergens produced by timothy (Phleum pratense) and other grass species, little is known about the finer details at the level of individual antibody specificities. Objective: We sought to investigate the IgE repertoire as it occurs in a patient with grass pollen allergy. Methods: For this purpose, a human IgE library was used, constructed from peripheral blood B cells of an individual with timothy allergy. The library was screened by using phage display against a panel of 6 timothy allergens (Phi p 1, Phi p 2, Phi p 4, Phi p 5, Phi p 6, and Phi p 11). Results: Highly diverse antibody fragments with respect to gene usage were identified. The binders were specific for their respective target antigen, except for clones selected on Phi p 6 that also recognized Phi p 5, most likely reflecting the high sequence homology between these allergens. Interestingly, by using this approach, we were able to determine the specificity of more than 25% of all IgE-producing transcripts in this individual with allergy. Conclusion: The human IgE repertoire is produced by a limited number of highly related B-cell clones and as such is restricted in its recognition of a limited number of antigens. Clinical implications: Human allergen-specific antibodies can, by defining the specificity of IgE responses, aid in the development of allergy vaccines or even by themselves be used in passive immunotherapy.	Lund Univ, Dept Immunotechnol, SE-22184 Lund, Sweden; Univ Lund Hosp, Dept Otorhinolaryngol, Lund, Sweden	Lund University; Lund University; Skane University Hospital	Ohlin, M (corresponding author), Lund Univ, Dept Immunotechnol, BMC D13, SE-22184 Lund, Sweden.	mats.ohlin@immun.lth.se	Ohlin, Mats/A-7307-2010	Ohlin, Mats/0000-0002-5105-1938; Persson, Helena/0000-0002-2965-0395				Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Andreasson U, 2006, J MOL BIOL, V362, P212, DOI 10.1016/j.jmb.2006.06.062; Davies JM, 2004, CLIN EXP ALLERGY, V34, P429, DOI 10.1111/j.1365-2222.2004.01900.x; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; Edwards MR, 2002, J IMMUNOL, V168, P6305, DOI 10.4049/jimmunol.168.12.6305; EFREMOV DG, 1993, J IMMUNOL, V151, P2195; Eibensteiner P, 2000, IMMUNOLOGY, V101, P112, DOI 10.1046/j.1365-2567.2000.00078.x; Engberg J, 1995, Methods Mol Biol, V51, P355; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Flicker S, 2006, J ALLERGY CLIN IMMUN, V117, P1336, DOI 10.1016/j.jaci.2006.02.012; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; Giudicelli V, 2004, NUCLEIC ACIDS RES, V32, pW435, DOI 10.1093/nar/gkh412; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; Jakobsen CG, 2004, MOL IMMUNOL, V41, P941, DOI 10.1016/j.molimm.2004.05.009; Janezic A, 1998, J ALLERGY CLIN IMMUN, V101, P391, DOI 10.1016/S0091-6749(98)70253-2; Laffer S, 2001, INT ARCH ALLERGY IMM, V124, P29, DOI 10.1159/000053660; Laukkanen ML, 2003, J IMMUNOL METHODS, V278, P271, DOI 10.1016/S0022-1759(03)00070-X; Lefranc MP, 2003, DEV COMP IMMUNOL, V27, P55, DOI 10.1016/S0145-305X(02)00039-3; Lindstedt M, 2005, INT IMMUNOL, V17, P401, DOI 10.1093/intimm/dxh220; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; MATTHIESEN F, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P189; Meijer PJ, 2006, J MOL BIOL, V358, P764, DOI 10.1016/j.jmb.2006.02.040; Monod MY, 2004, BIOINFORMATICS, V20, P379, DOI 10.1093/bioinformatics/bth945; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Niederberger V, 2007, INT ARCH ALLERGY IMM, V142, P133, DOI 10.1159/000096439; PETERSEN A, 1995, INT ARCH ALLERGY IMM, V108, P55, DOI 10.1159/000237118; SNOW RE, 1995, J IMMUNOL, V154, P5576; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; Steinberger P, 1996, J BIOL CHEM, V271, P10967, DOI 10.1074/jbc.271.18.10967; Tilgner J, 1997, CLIN EXP IMMUNOL, V107, P528, DOI 10.1046/j.1365-2249.1997.d01-960.x; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; Vrtala S, 1999, J IMMUNOL, V163, P5489; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6	34	26	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1186	1192		10.1016/j.jaci.2007.06.041	http://dx.doi.org/10.1016/j.jaci.2007.06.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17825890	Bronze, Green Submitted			2022-12-18	WOS:000250973400031
J	Kuiper, S; Muris, JWM; Dompeling, E; Kester, ADM; Wesseling, G; Knottnerus, JA; van Schayck, CP				Kuiper, Sandra; Muris, Jean W. M.; Dompeling, Edward; Kester, Arnold D. M.; Wesseling, Geertjan; Knottnerus, J. Andre; van Schayck, Constant P.			Interactive effect of family history and environmental factors on respiratory tract-related morbidity in infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetic predisposition to asthma; risk factors; respiratory signs and symptoms; infants; parental smoking; house dust mite; breast-feeding	CHILDHOOD ASTHMA; MATERNAL HISTORY; PARENTAL HISTORY; PRIMARY-CARE; RISK-FACTOR; EARLY-LIFE; CHILDREN; EXPOSURE; PREVALENCE; ATOPY	Background: Family and environmental factors affect the development of respiratory morbidity. How these factors interact is unclear. Objective: We sought to clarify the interactive effect of family history of asthma and environmental factors on the occurrence of respiratory morbidity. Methods: Two hundred twenty-one infants with a positive family history of asthma (PFH) and 308 with a negative family history of asthma (NFH) were prenatally selected and followed until the age of 2 years. Exposure to environmental factors and the occurrence of respiratory morbidity were recorded. By using multiple logistic regression analysis, increased risk was expressed in odds ratios (ORs) adjusted for relevant covariables. Results: Infants with a PFH had more respiratory morbidity than infants with an NFH. Adjusted ORs ranged from 1.7 (95% CI, 1.0-2.8) for expiratory wheezing to 4.9 (95% CI, 1.7-13.6) for croup. Parental smoking increased the OR of a PFH for wheezing ever (OR, 5.8 [95% CI, 2.5-13.8]) and attacks of wheezing (OR, 6.8 [95% CI, 2.7-16.9]), as did Der p 1 (OR, 10.2 [95% CI, 2.8-36.3] and OR, 7.1 [95% CI, 7.1-21.0], respectively). Exposure to both parental smoking and Der p 1 further increased this OR (OR, 30.8 [95%, CI, 6.9-137.2] and OR, 26.2 [95% CI, 5.9-115.6], respectively). Breast-feeding decreased the ORs of PFH for tonsillitis and acute otitis media: the increased ORs for these diagnoses in formula-fed infants with PFHs versus those with NFHs (OR, 9.2 [95% CI, 2.1-39.7] and OR, 2.9 [95% CI, 1.1-7.2], respectively) was attenuated in breast-fed infants (OR, 1.8 [95 % CI, 0.8-3.8] and OR, 0.7 [95 % CI, 0.4-1.3]). Conclusion: Parental smoking and Der p 1 increase the effect of a PFH on respiratory morbidity. Breast-feeding reduces this effect. Clinical implications: Extra attention should be given to stimulate mothers to breast-feed their children in case they cannot stop smoking or taking sanitation measures.	Univ Maastricht, Care & Publ Hlth Res Inst, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Care & Publ Hlth Res Inst, Dept Methodol & Stat, NL-6200 MD Maastricht, Netherlands; Maastricht Univ Hosp, Care & Publ Hlth Res Inst, Dept Paediat, Maastricht, Netherlands; Maastricht Univ Hosp, Care & Publ Hlth Res Inst, Dept Pulmonol, Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Kuiper, S (corresponding author), Univ Maastricht, Care & Publ Hlth Res Inst, Dept Gen Practice, POB 616, NL-6200 MD Maastricht, Netherlands.	Sandra.Kuiper@HAG.unimaas.nl	Knottnerus, Johannes A/A-3829-2009; Knottnerus, Andre/F-4866-2013	Muris, Jean/0000-0002-8780-476X				ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; Austin JB, 2004, SCOT MED J, V49, P18, DOI 10.1177/003693300404900105; Baraibar Roman, 1997, Clin Microbiol Infect, V3 Suppl 3, pS13; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bosken CH, 2000, AM J RESP CRIT CARE, V161, P1810, DOI 10.1164/ajrccm.161.6.9903030; Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; CAMERON P, 1967, J ALLERGY, V40, P12, DOI 10.1016/0021-8707(67)90054-8; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chantry CJ, 2006, PEDIATRICS, V117, P425, DOI 10.1542/peds.2004-2283; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403, DOI 10.1164/ajrccm.159.2.9712029; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Dirksen W, 1998, HUISARTS WET, V41, P130; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Eldeirawi K, 2004, CHEST, V125, P1685, DOI 10.1378/chest.125.5.1685; Gray L, 2000, CLIN EXP ALLERGY, V30, P393; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Knottnerus JA, 2002, J CLIN EPIDEMIOL, V55, P1201, DOI 10.1016/S0895-4356(02)00528-0; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Kuiper S, 2005, PEDIAT ALLERG IMM-UK, V16, P321, DOI 10.1111/j.1399-3038.2005.00278.x; Lindgren C, 1998, ACTA PAEDIATR, V87, P1028, DOI 10.1080/080352598750031329; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; McCunney RJ, 2005, J OCCUP ENVIRON MED, V47, P1285, DOI 10.1097/01.jom.0000188561.75578.bf; Mommers M, 2005, THORAX, V60, P97, DOI 10.1136/thx.2004.024786; Nelson EAS, 2001, EARLY HUM DEV, V62, P43, DOI 10.1016/S0378-3782(01)00116-5; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLDER JJ, 2007, 2707510052002 RIVM; Polk S, 2004, AM J RESP CRIT CARE, V170, P273, DOI 10.1164/rccm.200310-1348OC; Rodrigo Carlos, 1997, Clin Microbiol Infect, V3 Suppl 3, pS55; Schonberger HJAM, 1998, CLIN EXP ALLERGY, V28, P1325; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; van der Heide S, 1999, J ALLERGY CLIN IMMUN, V104, P447, DOI 10.1016/S0091-6749(99)70391-X; van Schayck CP, 2005, EUR RESPIR J, V26, P647, DOI 10.1183/09031936.05.00019805; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; VONMUTIUS E, 2000, ARCH DIS CHILD, V2; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WILLATT DJ, 1986, CLIN OTOLARYNGOL, V11, P317, DOI 10.1111/j.1365-2273.1986.tb00132.x; *WONCA, 1998, INT CLASS HLTH PROBL; Wright AL, 2000, ADV EXP MED BIOL, V478, P131	47	26	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					388	395		10.1016/j.jaci.2007.03.038	http://dx.doi.org/10.1016/j.jaci.2007.03.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17498791	Bronze			2022-12-18	WOS:000248654900026
J	Wang, L; Joad, JP; Abel, K; Spinner, A; Smiley-Jewell, S; Liu, H; Pinkerton, KE				Wang, Lei; Joad, Jesse P.; Abel, Kristina; Spinner, Abigail; Smiley-Jewell, Suzette; Liu, Hao; Pinkerton, Kent E.			Effects of environmental tobacco smoke on the developing immune system of infant monkeys	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						environmental tobacco smoke; immune system maturation; leukocytes; cytokine; gene expression	CIGARETTE-SMOKE; 1ST YEAR; CYTOKINE PRODUCTION; MATERNAL SMOKING; LUNG-FUNCTION; PARENTAL SMOKING; DENDRITIC CELLS; RHESUS MACAQUES; EXPOSURE; LIFE	Background: Exposure to environmental tobacco smoke (ETS) is associated with an increased incidence of allergic and infectious diseases among children that is thought to be partly due to the immaturity of the immune system. Objective: We sought to investigate the effects of ETS exposure on immune development during the first year of life in the nonhuman primate. Methods: Fifteen neonatal rhesus monkeys studied to 13 months of postnatal age were randomized into 3 groups: (1) exposure to filtered air, (2) continuous ETS exposure beginning at gestation day 50 (perinatal ETS); and (3) exposure to ETS beginning at 6 months of age (6-month ETS). Complete blood counts, lymphocyte subsets, and mRNA levels of 12 cytokines in PBMCs were measured. Results: Fetal/infant exposure to ETS altered the normal maturation of mRNA levels of IFN-gamma, IL-2, and IL-10, as well as the ratio of CD4 to CD8 lymphocytes, compared with filtered-air control levels. Blood lymphocyte subset distribution also significantly differed based on the onset of exposure to ETS. Subacute exposure to ETS for 2 weeks in 6-month-old infants was found to increase levels of peripheral blood neutrophils and IL-6 mRNA. Conclusions: Short-term exposure to ETS can induce an acute systemic inflammatory response in the neonatal nonhuman primate, and long-term exposure to ETS beginning in utero or at 6 months of postnatal age can significantly alter immune effectors. Clinical implications: Normal immune system development is compromised by in utero and postnatal exposure to ETS and might contribute to ETS-related childhood diseases.	Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA; Univ Calif Davis, Dept Pediat, Davis, CA 95616 USA; Calif Natl Primate Res Ctr, Davis, CA USA; Baylor Coll Med, Div Biostat, Houston, TX 77030 USA	University of California System; University of California Davis; University of California System; University of California Davis; Baylor College of Medicine	Pinkerton, KE (corresponding author), Univ Calif Davis, Ctr Hlth & Environm, Old Davis Rd, Davis, CA 95616 USA.	kepinkerton@ucdavis.edu	De Paris, Kristina/H-8174-2019	De Paris, Kristina/0000-0001-5199-3004	NCRR NIH HHS [P51 RR00169] Funding Source: Medline; NIEHS NIH HHS [R01 ES011634, ES05707] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011634] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abel K, 2001, CYTOKINE, V16, P191, DOI 10.1006/cyto.2001.0961; Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5; Adkins P, 2001, J IMMUNOL, V166, P918, DOI 10.4049/jimmunol.166.2.918; Balding DJ, 2004, APPL LONGITUDINAL AN; Chipeta J, 1998, CELL IMMUNOL, V183, P149, DOI 10.1006/cimm.1998.1244; de Vries E, 2000, PEDIATR RES, V47, P528, DOI 10.1203/00006450-200004000-00019; DeMaria MA, 2000, EUR J HAEMATOL, V65, P245, DOI 10.1034/j.1600-0609.2000.065004245.x; *DEP HLTH HUM SER, 2006, HLTH CONS INV EXP TO; Dietert RR, 2006, ENVIRON HEALTH PERSP, V114, P477, DOI 10.1289/ehp.8566; FINKLEA JF, 1971, AM REV RESPIR DIS, V104, P368, DOI 10.1164/arrd.1971.104.3.368; Floreani A A, 1999, Curr Opin Pulm Med, V5, P38, DOI 10.1097/00063198-199901000-00007; Gasparoni A, 2003, BIOL NEONATE, V84, P297, DOI 10.1159/000073638; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; GORTMAKER SL, 1982, AM J PUBLIC HEALTH, V72, P574, DOI 10.2105/AJPH.72.6.574; Hartel C, 2005, CLIN EXP IMMUNOL, V142, P446, DOI 10.1111/j.1365-2249.2005.02928.x; HOIDAL JR, 1982, AM REV RESPIR DIS, V126, P548; HOLBERG CJ, 1993, PEDIATRICS, V91, P885; Holladay SD, 2000, ENVIRON HEALTH PERSP, V108, P463, DOI 10.2307/3454538; HOLT PG, 1994, J IMMUNOL, V153, P256; HOLT PG, 1987, THORAX, V42, P241, DOI 10.1136/thx.42.4.241; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; Lannero E, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-3; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097, DOI 10.1164/ajrccm.162.6.2004178; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; PEDREIRA FA, 1985, PEDIATRICS, V75, P594; Phaybouth V, 2006, AM J PHYSIOL-LUNG C, V290, pL222, DOI 10.1152/ajplung.00148.2005; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; R Development Core Team, 2006, R LANG ENV STAT COMP; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Seymour BWP, 1997, J IMMUNOL, V159, P6169; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136, DOI 10.1164/ajrccm/145.5.1136; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Singh SP, 2006, TOXICOL LETT, V167, P231, DOI 10.1016/j.toxlet.2006.10.001; Sopori M., 1994, IMMUNOTOXICOLOGY IMM, V413, P434; Sopori ML, 1998, J NEUROIMMUNOL, V83, P148, DOI 10.1016/S0165-5728(97)00231-2; TASHKIN DP, 1984, AM REV RESPIR DIS, V129, P891; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; Vassallo R, 2004, CHEST, V125, p107S, DOI 10.1378/chest.125.5_suppl.107S; WANG L, 2006, AM J RESP CRIT CARE, V132, pA657; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383; Zhang J, 2002, EXP BIOL MED, V227, P823, DOI 10.1177/153537020222700916; Zhong CY, 2006, AM J RESP CRIT CARE, V174, P428, DOI 10.1164/rccm.200503-509OC	45	26	28	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					445	451		10.1016/j.jaci.2007.03.028	http://dx.doi.org/10.1016/j.jaci.2007.03.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17482667				2022-12-18	WOS:000248654900034
J	Coifman, RE				Coifman, Robert E.			2006 American Academy of Allergy, Asthma & Immunology member immunotherapy practice patterns and concerns	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INHIBITORS		Allergy & Asthma S Jersey, Millville, NJ 08332 USA; Ctr Asthma & Allergy, Ft Lauderdale, FL USA		Coifman, RE (corresponding author), Allergy & Asthma S Jersey, Millville, NJ 08332 USA.	rcoifman@comcast.net	Coifman, Robert/F-6647-2015	Coifman, Robert/0000-0002-8472-3374				Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Stumpf JL, 2006, ANN PHARMACOTHER, V40, P699, DOI 10.1345/aph.1G295; TUNONDELARA JM, 1992, LANCET, V340, P908, DOI 10.1016/0140-6736(92)93314-D	3	26	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					1012	1013		10.1016/j.jaci.2007.01.029	http://dx.doi.org/10.1016/j.jaci.2007.01.029			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17418663				2022-12-18	WOS:000245729500034
J	de Blic, J; Scheinmann, P				de Blic, Jacques; Scheinmann, Pierre			The use of imaging techniques for assessing severe childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; child HRCT scan; remodeling; bronchial wall thickening; small airway	RESOLUTION COMPUTED-TOMOGRAPHY; SMALL AIRWAYS; DIFFICULT ASTHMA; PEDIATRIC ASTHMA; CHILDREN; CT	Computed tomography (CT) scans are usually performed in children with asthma to exclude alternative diagnoses. Technical improvements of high-resolution CT (HRCT) scans have increased the spatial resolution sufficiently for the theoretical quantification of bronchial wall thickening of the proximal airways and the assessment of small airway disease by the extent and degree of low attenuation areas, which are believed to represent air trapping. In contrast with adults, very few studies have been performed in children. The results suggest that the HRCT scan might be useful as a noninvasive technique for airway inflammation and airway remodeling. In the future, the potential use of HRCT scans for determining optimal treatment should be evaluated. However, several issues remain to be resolved, including the validity of algorithm reconstruction, the imaging parameters to be used, and the application of this technique to young children. Furthermore, because of its cost and the irradiation involved, this examination is highly unlikely to be used routinely for the management and follow-up of all children with asthma but will likely be restricted to patients with severe asthma.	Univ Paris 05, Serv Pneumol & Allergol Pediat, Hop Necker Enfants Malad, Assistance Publ Hop Paris, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	de Blic, J (corresponding author), Univ Paris 05, Serv Pneumol & Allergol Pediat, Hop Necker Enfants Malad, Assistance Publ Hop Paris, 149 Rue de Sevres, F-75015 Paris, France.	j.deblic@nck.aphp.fr						Apter AJ, 2006, J ALLERGY CLIN IMMUN, V117, P512, DOI 10.1016/j.jaci.2005.12.1353; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; de Jong PA, 2005, EUR RESPIR J, V26, P140, DOI 10.1183/09031936.05.00007105; de Jongste J C, 2000, Paediatr Respir Rev, V1, P354; Jain N, 2005, PEDIATR PULM, V40, P211, DOI 10.1002/ppul.20215; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Ketai L, 2005, J ASTHMA, V42, P667, DOI 10.1080/02770900500264978; Ketai L, 2001, ACAD RADIOL, V8, P257, DOI 10.1016/S1076-6332(03)80535-4; Marchac V, 2002, AM J ROENTGENOL, V179, P1245, DOI 10.2214/ajr.179.5.1791245; Matsumoto H, 2005, THORAX, V60, P277, DOI 10.1136/thx.2004.028936; Mitsunobu F, 2005, CURR OPIN ALLERGY CL, V5, P85, DOI 10.1097/00130832-200502000-00015; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Pifferi M, 2002, J PEDIATR-US, V141, P104, DOI 10.1067/mpd.2002.125006; Saglani S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-46; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Ueda T, 2006, J ALLERGY CLIN IMMUN, V118, P1019, DOI 10.1016/j.jaci.2006.07.032; Vignola AM, 2004, EUR RESPIR J, V24, P910, DOI 10.1183/09031936.04.00032603; Wenzel S, 2006, J ALLERGY CLIN IMMUN, V117, P508, DOI 10.1016/j.jaci.2005.12.1316; Zeidler MR, 2006, J ALLERGY CLIN IMMUN, V118, P1075, DOI 10.1016/j.jaci.2006.06.042; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605	20	26	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					808	810		10.1016/j.jaci.2006.12.657	http://dx.doi.org/10.1016/j.jaci.2006.12.657			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17289134				2022-12-18	WOS:000245729500006
J	Prieto, A; De Barrio, M; Martin, E; Fernandez-Bohorquez, M; de Castro, FJ; Ruiz, FJ; Herrero, T; Tornero, P; Rubio, M				Prieto, Alicia; De Barrio, Manuel; Martin, Elena; Fernandez-Bohorquez, Maria; de Castro, Francisco Javier; Ruiz, Francisco Javier; Herrero, Teresa; Tornero, Pilar; Rubio, Maria			Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nonsteroidal anti-inflammatory drug intolerance; nabumetone; meloxican	ASPIRIN; SAFETY; ROFECOXIB; OSTEOARTHRITIS; HYPERSENSITIVITY; NIMESULIDE; DICLOFENAC; EFFICACY	Background: Because nonsteroidal anti-inflammatory drug (NSAID) intolerance depends on COX-1 inhibition, preferential or selective COX-2 inhibitors have been thought to be well tolerated by these patients. Objective: The aim of this study is to evaluate tolerability to nabumetone and meloxicam in patients with NSAID intolerance. Methods: Seventy patients intolerant to NSAIDs were selected. Thirty subjects were patients with asthma with respiratory (rhinitis-asthma) intolerance to NSAIDs (group A); 40 patients (group B) had cutaneous-mucous (urticaria-angioedema) NSAID intolerance. Diagnosis was based on clinical histories in all patients, and it was confirmed by positive single-blind placebo-controlled oral challenge test in 36 patients. After written informed consent, a single-blind placebo-controlled oral challenge test with nabumetone in all patients (2 g except for 11 patients who reached 1 g) and meloxicam (15 mg) in 51 patients was performed. Results: Of the total selected, 94.3% tolerated 1 g nabumetone. In those who reached the 2-g dose, the tolerability was 83.6%. With respect to meloxicam, 96.1% of patients, tolerated 15 mg. No significant difference in nabumetone and meloxicam tolerability was observed between groups A and B. Conclusion: The results of this study confirm a high percentage of tolerability to the maximum therapeutic dosage of nabumetone and meloxicam in patients with NSAID intolerance, both in those with cutaneous/mucous manifestations and in those with respiratory disease. Clinical implications: Nabumetone and meloxicam are safe alternatives in NSAID-intolerant patients.	Hosp Gen Univ Gregorio Maranon, Serv Alergia, Madrid 28007, Spain	General University Gregorio Maranon Hospital	Prieto, A (corresponding author), Hosp Gen Univ Gregorio Maranon, Serv Alergia, Dr Esquerdo 46, Madrid 28007, Spain.	aprieto.hgugm@salud.madrid.org		Prieto-Garcia, Alicia/0000-0003-3915-1941				Bavbek S, 2004, J ASTHMA, V41, P67, DOI 10.1081/JAS-120026063; Bavbek S, 2007, INT ARCH ALLERGY IMM, V142, P64, DOI 10.1159/000096000; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Confino-Cohen R, 2003, ALLERGY ASTHMA PROC, V24, P281; Davies NM, 2000, DRUGS, V59, P25, DOI 10.2165/00003495-200059991-00004; Degner F, 2000, CLIN THER, V22, P400, DOI 10.1016/S0149-2918(00)89009-8; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Gala G, 2003, ALERGOL INMUNOL CLIN, V18, P275; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Hedner T, 2004, DRUGS, V64, P2315, DOI 10.2165/00003495-200464200-00004; Karakaya G, 2000, Allergol Immunopathol (Madr), V28, P319; Kosnik M, 1998, ALLERGY, V53, P1231, DOI 10.1111/j.1398-9995.1998.tb03854.x; Lister B J, 1993, Am J Med, V95, p2S, DOI 10.1016/0002-9343(93)90390-B; Mastalerz L, 2004, J ALLERGY CLIN IMMUN, V113, P771, DOI 10.1016/j.jaci.2003.12.323; Morgan GJ, 2001, J CLIN GASTROENTEROL, V32, P310, DOI 10.1097/00004836-200104000-00006; Nettis E, 2001, ALLERGY, V56, P803, DOI 10.1034/j.1398-9995.2001.056008803.x; Quaratino D, 2000, ANN ALLERG ASTHMA IM, V84, P613, DOI 10.1016/S1081-1206(10)62412-X; Santiago AV, 2003, ALLERGY, V58, P367; SENNA G, 2004, ALLERG IMMUNOL PARIS, V36, P215; SENNA GE, 2003, ALLERG IMMUNOL PARIS, V35, P393; SETTIPANE RA, 1989, J ALLERGY CLIN IMMUN, V84, P26, DOI 10.1016/0091-6749(89)90174-7; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Szczeklik A, 2006, EUR J PHARMACOL, V533, P145, DOI 10.1016/j.ejphar.2005.12.053; Szczeklik A, 2004, CURR OPIN PULM MED, V10, P51, DOI 10.1097/00063198-200401000-00009; Valat JP, 2001, INFLAMM RES, V50, pS30; Weaver AL, 2006, JCR-J CLIN RHEUMATOL, V12, P17, DOI 10.1097/01.rhu.0000200384.79405.33; Woessner KM, 2004, ANN ALLERG ASTHMA IM, V93, P339, DOI 10.1016/S1081-1206(10)61392-0	28	26	27	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					960	964		10.1016/j.jaci.2006.12.616	http://dx.doi.org/10.1016/j.jaci.2006.12.616			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17292954				2022-12-18	WOS:000245729500027
J	Martinez, FD				Martinez, Fernando D.			Asthma treatment and asthma prevention: A tale of 2 parallel pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial; hyperresponsiveness; inhaled corticosteroids; lung function; remodeling	NEWLY-DIAGNOSED ASTHMA; LONG-TERM TREATMENT; LUNG-FUNCTION; INHALED CORTICOSTEROIDS; AIRWAY HYPERRESPONSIVENESS; PULMONARY-FUNCTION; CHILDREN; GROWTH; INFLAMMATION; FLUTICASONE	Three recent clinical trials used different study designs to test the hypothesis that early introduction of inhaled corticosteroids in infants and young children at high risk for the development of asthma could change the natural course of the disease. All 3 trials reached the same conclusion: treatment requirement, symptom frequency while off treatment, and lung function did not differ between children receiving active drug or placebo, with outcomes measured 2 to 4 years after randomization. These findings challenge the concept that the inflammatory processes that cause asthma symptoms and are responsive to inhaled corticosteroids are also responsible for the chronic changes in airway structure and function that are believed to predispose to the development of persistent asthma. This conclusion is supported by studies showing that bronchial hyperresponsiveness, independent of current asthma symptoms, is associated with subsequent deficits in airway function growth during childhood. Successful strategies for the prevention of asthma will require a better understanding of the genetic, environmental, and developmental factors that predispose toward inappropriate responses to airway injury. Abnormal airway remodeling and persistent dysregulation of airway tone might be the final common pathway for different disease mechanisms, and this might explain the heterogeneity of clinical phenotypic syndromes that go under the common label of "asthma."	Univ Arizona, Arizona Resp Ctr, Coll Med, Tucson, AZ 85724 USA	University of Arizona	Martinez, FD (corresponding author), Univ Arizona, Arizona Resp Ctr, Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	fernando@arc.arizona.edu			NHLBI NIH HHS [U10HL64307, U10HL56177, P02HL67672, R01HL04029] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067672, U10HL064307, R01HL056177, P50HL067672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Chetta A, 2003, AM J RESP CRIT CARE, V167, P751, DOI 10.1164/rccm.200207-710OC; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; FONG EW, 2005, P AM THORAC SOC, V2, pA606; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Holgate ST, 2003, EUR RESPIR J, V22, p24S, DOI 10.1183/09031936.03.00000803; Homer RJ, 2005, PHYSIOLOGY, V20, P28, DOI 10.1152/physiol.00035.2004; Hoshino M, 1998, CLIN EXP ALLERGY, V28, P568; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; Lange P, 2006, THORAX, V61, P100, DOI 10.1136/thx.2004.037978; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Martinez FD, 2003, NEW ENGL J MED, V349, P1473, DOI 10.1056/NEJMe030041; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; O'Byrne PM, 2006, CHEST, V129, P1478, DOI 10.1378/chest.129.6.1478; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tanaka H, 2003, AM J RESP CRIT CARE, V168, P1495, DOI 10.1164/rccm.200306-727OC; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820, DOI 10.1164/ajrccm.161.6.9809118	26	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					30	33		10.1016/j.jaci.2006.10.020	http://dx.doi.org/10.1016/j.jaci.2006.10.020			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17125825				2022-12-18	WOS:000243622200005
J	Glezen, WP				Glezen, W. Paul			Asthma, influenza, and vaccination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma in children; influenza-triggered asthma exacerbations; influenza vaccines; inactivated and live attenuated; safety and efficacy of influenza vaccines in children with asthma	HUMAN METAPNEUMOVIRUS; VIRUS VACCINE; LARGE-COHORT; CHILDREN; TRIVALENT; SAFETY; EXACERBATION; IMMUNIZATION; INFECTIONS; PREVENTION	Exacerbations of asthma in children are usually triggered by. virus infections. Many different respiratory viruses are associated with these exacerbations, but influenza viruses are frequently associated with those requiring hospitalization and are the only ones for which specific treatment and prophylaxis are available. Current studies have shown that influenza vaccines are safe for patients with asthma. The efficacy of inactivated influenza vaccines in preventing exacerbations of asthma has been questioned. The live attenuated influenza vaccine has been licensed recently in the United States, and studies have shown it to be safe and protective. A direct comparison of the inactivated and live attenuated influenza vaccines in children with asthma demonstrated superior protection by the latter. Live attenuated influenza vaccine, given by nasal spray, is better accepted by children for annual vaccination and is easier to administer. Universal vaccination of all children in school-based clinics will facilitate control of epidemic influenza and provide an infrastructure for control of future influenza pandemics.	Baylor Coll Med, MVM Dept, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Glezen, WP (corresponding author), Baylor Coll Med, MVM Dept, 1 Baylor Pl,MS-BCM-280, Houston, TX 77030 USA.	wglezen@bcm.edu						ASHKENAZI S, 2006, IN PRESS PEDIAT INFE; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; BEISHE R, 2006, PED AC SOC M APR 29; Bergen R, 2004, PEDIATR INFECT DIS J, V23, P138, DOI 10.1097/01.inf.0000109392.96411.4f; Bueving HJ, 2004, AM J RESP CRIT CARE, V169, P488, DOI 10.1164/rccm.200309-1251OC; Christy C, 2004, ARCH DIS CHILD, V89, P734, DOI 10.1136/adc.2003.030999; CLOVER RD, 1991, J INFECT DIS, V163, P300, DOI 10.1093/infdis/163.2.300; EGGLESTON PA, 2006, OSKIS PEDIAT, P2404; Esper F, 2004, J INFECT DIS, V189, P1388, DOI 10.1086/382482; FLEMING DM, 2006, IN PRESS PEDIAT INFE; Gaglani MJ, 2004, ARCH PEDIAT ADOL MED, V158, P65, DOI 10.1001/archpedi.158.1.65; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; Glezen WP, 2004, PEDIATR ANN, V33, P545, DOI 10.3928/0090-4481-20040801-12; GLEZEN WP, 1984, CLIN CHEST MED, V5, P635; Glezen WP, 2004, TXB PEDIAT INFECT DI, P2252; GLEZEN WP, 2004, PEDIATR INFECT DIS J, V23, P202; Govorkova EA, 2006, J INFECT DIS, V194, P159, DOI 10.1086/505225; Hak E, 2003, AM J EPIDEMIOL, V157, P692, DOI 10.1093/aje/kwg027; Halloran ME, 2003, AM J EPIDEMIOL, V158, P305, DOI 10.1093/aje/kwg163; Hanania NA, 2004, J ALLERGY CLIN IMMUN, V113, P717, DOI 10.1016/j.jaci.2003.12.584; Harper Scott A., 2005, Morbidity and Mortality Weekly Report, V54, P1; Heymann PW, 2005, PEDIATR INFECT DIS J, V24, P217; Johnston SL, 2005, PEDIATR INFECT DIS J, V24, P225, DOI 10.1097/01.inf.0000154322.38267.ce; Kramarz P, 2001, J PEDIATR-US, V138, P306, DOI 10.1067/mpd.2001.112168; Kramarz P, 2000, ARCH FAM MED, V9, P617, DOI 10.1001/archfami.9.7.617; Laham FR, 2004, J INFECT DIS, V189, P2047, DOI 10.1086/383350; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Neuzil KM, 2000, J PEDIATR-US, V137, P856, DOI 10.1067/mpd.2000.110445; Park CL, 1996, PEDIATRICS, V98, P196; Piedra PA, 2002, PEDIATRICS, V110, P662, DOI 10.1542/peds.110.4.662; Piedra PA, 2005, PEDIATRICS, V116, pE397, DOI 10.1542/peds.2004-2258; PIEDRA PA, 1991, SEMIN PEDIAT INFECT, V2, P140; Redding G, 2002, PEDIATR INFECT DIS J, V21, P44, DOI 10.1097/00006454-200201000-00010; Reichert TA, 2001, NEW ENGL J MED, V344, P889, DOI 10.1056/NEJM200103223441204; Smith CB, 2002, J INFECT DIS, V185, P980, DOI 10.1086/339416; SUGAYA N, 1994, JAMA-J AM MED ASSOC, V272, P153; Sumino KC, 2005, J INFECT DIS, V192, P1052, DOI 10.1086/432728; Tan WC, 2005, CURR OPIN PULM MED, V11, P21; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350	43	26	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1199	1206		10.1016/j.jaci.2006.08.032	http://dx.doi.org/10.1016/j.jaci.2006.08.032			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157648				2022-12-18	WOS:000242880300001
J	Arbes, SJ; Sever, ML; Vaughn, B; Cohen, EA; Zeldin, DC				Arbes, Samuel J., Jr.; Sever, Michelle L.; Vaughn, Ben; Cohen, Eric A.; Zeldin, Darryl C.			Oral pathogens and allergic disease: Results from the Third National Health and Nutrition Examination Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; wheeze; hay fever; hygiene hypothesis; periodontal disease; epidemiology; survey; antibodies; oral pathogens; Actinobacillus actinomycetemcomitans; Porphyromonas gingivalis	SERUM ANTIBODY-LEVELS; PORPHYROMONAS-GINGIVALIS; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; PERIODONTAL PATHOGENS; HAY-FEVER; RESPONSES; MICROBIOTA; COLONIZATION; POPULATION; PREVALENCE	Background: The hygiene hypothesis contends that fewer opportunities for infection have led to increases in the prevalences of asthma and other allergic diseases. Objective: This study evaluated the association between asthma, wheeze, and hay fever and antibodies to 2 oral bacteria associated with periodontal disease. Methods: Data were obtained from the Third National Health and Nutrition Examination Survey. Serum levels of IgG antibodies to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis were quantified by enzyme-linked immunoassays in 9385 subjects age 12 years and older. The outcomes were current asthma, wheeze, and hay fever. Odds ratios (ORs) representing a 1-log-unit increase in IgG concentrations were estimated with logistic regression. ORs were adjusted for 8 confounders and weighted to represent the US population. Results: For each disease outcome, geometric mean antibody concentrations were higher in persons without the disease outcome than with the disease outcome. For a I-log-unit increase in P gingivalis antibody concentration, adjusted ORs were 0.41 (95% CI, 0.20-0.87) for asthma, 0.43 (0.23-0.78) for wheeze, and 0.45 (0.23-0.93) for hay fever. For A actinomytetemcomitans, those ORs were 0.56 (0.19-1.72), 0.39 (0.17-0.86), and 0.48 (0.23-1.03), respectively. Conclusion: Consistent with the hygiene hypothesis, higher concentrations of IgG antibodies to P gingivalis were significantly associated with lower prevalences of asthma, wheeze, and hay fever, and higher concentrations of IgG antibodies to A actinomycetemcomitans were significantly associated with a lower prevalence of wheeze. Clinical implications: Colonization of the oral cavity by bacteria and other microbes might play a protective role in the etiology of allergic disease.	NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Rho Inc, Durham, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Rho	Zeldin, DC (corresponding author), NIEHS, NIH, POB 12233,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Sever, Michelle/0000-0002-2435-1214	Intramural NIH HHS [Z01 ES025041-10] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025041] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 1994, VITAL HLTH STAT, P1; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Beck JD, 2005, CIRCULATION, V112, P19, DOI 10.1161/CIRCULATIONAHA.104.511998; BECK JD, 2002, CARRANZAS CLIN PERIO, P74; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; Burt BA., 1999, DENT DENT PRACTICE C; Darby I, 2001, PERIODONTOL 2000, V26, P33, DOI 10.1034/j.1600-0757.2001.2260103.x; Dye BA, 2005, J CLIN PERIODONTOL, V32, P1189, DOI 10.1111/j.1600-051X.2005.00856.x; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Haake S.K., 2002, CARRANZAS CLIN PERIO, V6, P96; Haake SK, 2002, CARRANZAS CLIN PERIO, P132; Hoppin AA, 2004, AM J RESP CRIT CARE, V169, P1308, DOI 10.1164/rccm.200309-1228OC; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kojima T, 1997, J PERIODONTOL, V68, P618, DOI 10.1902/jop.1997.68.7.618; Kuramitsu H.K., 2000, ORAL BACTERIAL ECOLO; Lamell CW, 2000, J CLIN MICROBIOL, V38, P1196, DOI 10.1128/JCM.38.3.1196-1199.2000; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Mattila KJ, 2005, J PERIODONTOL, V76, P2085, DOI 10.1902/jop.2005.76.11-S.2085; McClellan DL, 1996, J CLIN MICROBIOL, V34, P2017, DOI 10.1128/JCM.34.8.2017-2019.1996; MOUTON C, 1981, INFECT IMMUN, V31, P182, DOI 10.1128/IAI.31.1.182-192.1981; NAKAGAWA S, 1994, J PERIODONTAL RES, V29, P9, DOI 10.1111/j.1600-0765.1994.tb01085.x; Novak MJ, 2002, CARRANZAS CLIN PERIO, P64; Noverr MC, 2005, INFECT IMMUN, V73, P30, DOI 10.1128/IAI.73.1.30-38.2005; Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Papapanou PN, 2000, J PERIODONTOL, V71, P885, DOI 10.1902/jop.2000.71.6.885; Pussinen PJ, 2005, ARTERIOSCL THROM VAS, V25, P833, DOI 10.1161/01.ATV.0000157982.69663.59; Pussinen PJ, 2004, EUR J CARDIOV PREV R, V11, P408, DOI 10.1097/00149831-200410000-00008; Pussinen PJ, 2003, ARTERIOSCL THROM VAS, V23, P1250, DOI 10.1161/01.ATV.0000072969.71452.87; Sheikh Aziz, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P232, DOI 10.1097/01.moo.0000122311.13359.30; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sudo N, 1997, J IMMUNOL, V159, P1739; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; 1998, NHANES 3 PRESCRIPTIO	36	26	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1169	1175		10.1016/j.jaci.2006.07.029	http://dx.doi.org/10.1016/j.jaci.2006.07.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088145	Green Accepted			2022-12-18	WOS:000244282300025
J	Thottingal, TB; Stefura, BP; Simons, FER; Bannon, GA; Burks, W; HayGlass, KT				Thottingal, Tina B.; Stefura, Bill P.; Simons, F. Estelle R.; Bannon, Gary A.; Burks, Wesley; HayGlass, Kent T.		Canadian Inst Hlth Res	Human subjects without peanut allergy demonstrate T cell-dependent, T(H)2-biased, peanut-specific cytokine and chemokine responses independent of T(H)1 expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; peanut allergy; anaphylaxis; T cell; cytokine; chemokine; costimulation	IGE-BINDING EPITOPES; ARA H-II; ATOPIC-DERMATITIS; FOOD ALLERGY; SKIN PRICK; POLYCLONAL STIMULATION; LYMPHOCYTE-RESPONSES; PERIPHERAL-BLOOD; CHILDREN; IDENTIFICATION	Background: Peanut allergy is a major cause of anaphylaxis. Regulation of immune responses to peanut allergen, particularly why sensitization does not usually progress to allergic reactions, is not well investigated. Most studies focus exclusively on serologic responses and individuals with peanut allergy. Objective: We sought to determine the existence, prevalence, and nature of peanut-specific, T cell-dependent cytokine and chemokine responses of adults who eat peanut without having symptoms. Methods: We developed systems to examine specific immunity in peanut-tolerant individuals who had (1) negative histories and negative peanut skin test responses, (2) negative histories and positive peanut skin test responses, and (3) clinically apparent peanut allergy. After primary culture of PBMCs restimulated with whole peanut extract, we quantified responses characteristic of TO (IFN-gamma and CXCL10) and T(H)2-like immunity (IL-5, IL-13, CCL17, and CCL22) using ultrasensitive ELISAs. Antigen-presenting cell costimulatory requirements (CD4, HLA-DR, CD80/86, and cytotoxic T lymphocyte-associated antigen 4 [CTLA4] Ig) were determined. Results: T cell-dependent, peanut-specific IL-5, IL-13, and CCL22 were common in peanut-tolerant individuals, regardless of whether they had positive or negative skin test responses. These were blocked by anti-CD4 and were dependent on CD28/CD86 costimulation. None of the 70 individuals studied had demonstrable IFN-gamma or CXCL10 responses to peanut. All demonstrated T(H)1 and T(H)2 responses to the ubiquitous recall antigen streptokinase. Conclusions: Qualitatively similar and quantitatively increasing peanut-specific T(H)2 responses in the consistent absence of putatively protective T(H)1 immunity were found in both peanut-tolerant individuals and those with peanut allergy. Clinical implications: The continuum of responses between individuals with negative and individuals with positive skin test results, rather than T(H)1 versus T(H)2 bias, might be important in peanut allergy.	Univ Manitoba, Dept Immunol, Canada Res Chair Immune Regulat, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Duke Univ, Dept Pediat, Div Allergy & Immunol, Durham, NC 27706 USA	University of Manitoba; University of Manitoba; University of Arkansas System; University of Arkansas Medical Sciences; Duke University	HayGlass, KT (corresponding author), Univ Manitoba, Dept Immunol, Canada Res Chair Immune Regulat, Winnipeg, MB R3E 0W3, Canada.	Hayglass@ms.umanitoba.ca	Bigotanov, Kaisar/B-5917-2017	Bigotanov, Kaisar/0000-0002-2266-4647; HayGlass, Kent/0000-0002-4621-7737				Appelt G. K., 2004, Journal of Allergy and Clinical Immunology, V113, pS99, DOI 10.1016/j.jaci.2003.12.345; Barre A, 2005, BIOCHIMIE, V87, P499, DOI 10.1016/j.biochi.2005.02.011; Boehncke WH, 1998, CLIN EXP ALLERGY, V28, P434, DOI 10.1046/j.1365-2222.1998.00246.x; Braunstahl GJ, 2005, J ALLERGY CLIN IMMUN, V115, P142, DOI 10.1016/j.jaci.2004.10.041; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P889, DOI 10.1016/0091-6749(92)90461-A; Castro R. R., 2004, Journal of Allergy and Clinical Immunology, V113, pS251, DOI 10.1016/j.jaci.2004.01.370; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Clarke MCA, 1998, CLIN EXP ALLERGY, V28, P1251, DOI 10.1046/j.1365-2222.1998.00386.x; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; DELEON MP, 2006, MOL IMMUNOL     0329; DORION BJ, 1994, J ALLERGY CLIN IMMUN, V93, P93, DOI 10.1016/0091-6749(94)90237-2; Eigenmann PA, 2003, CURR OPIN ALLERGY CL, V3, P199, DOI [10.1097/00130832-200306000-00008, 10.1097/01.all.0000072715.82112.5e]; Glaspole IN, 2005, ALLERGY, V60, P35, DOI 10.1111/j.1398-9995.2004.00608.x; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Hong SJ, 1999, J ALLERGY CLIN IMMUN, V104, P473, DOI 10.1016/S0091-6749(99)70396-9; Hourihane JO, 1998, CLIN EXP ALLERGY, V28, P163, DOI 10.1046/j.1365-2222.1998.00213.x; Howell WM, 1998, CLIN EXP ALLERGY, V28, P156, DOI 10.1046/j.1365-2222.1998.00224.x; IMADA M, 1995, INT IMMUNOL, V7, P229, DOI 10.1093/intimm/7.2.229; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Kolopp-Sarda MN, 2001, CLIN EXP ALLERGY, V31, P47, DOI 10.1046/j.1365-2222.2001.733/ca1804.x; Laan MP, 1998, CLIN EXP ALLERGY, V28, P35, DOI 10.1046/j.1365-2222.1998.00168.x; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Li XM, 2005, CURR OPIN ALLERGY CL, V5, P287, DOI 10.1097/01.all.0000168796.20324.bd; Li Y, 1998, J IMMUNOL, V161, P7007; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Piersma SR, 2005, MOL NUTR FOOD RES, V49, P744, DOI 10.1002/mnfr.200500020; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Pons L, 2005, CURR OPIN ALLERGY CL, V5, P558; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 2005, ALLERGY, V60, P19, DOI 10.1111/j.1398-9995.2005.00853.x; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P139, DOI 10.1016/j.jaci.2004.11.003; Sampson HA, 2002, CURR OPIN ALLERGY CL, V2, P257, DOI 10.1097/00130832-200206000-00017; Scott-Taylor TH, 2005, CLIN EXP ALLERGY, V35, P1473, DOI 10.1111/j.1365-2222.2005.02355.x; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Turcanu V. H., 2004, Journal of Allergy and Clinical Immunology, V113, pS48, DOI 10.1016/j.jaci.2003.12.132; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207, DOI 10.1016/S0091-6749(98)70410-5; van Wijk F, 2005, J IMMUNOL, V174, P174, DOI 10.4049/jimmunol.174.1.174; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.2324.x; Wilson MS, 2006, CHEM IMMUNOL ALLERGY, V90, P176, DOI 10.1159/000088892; Zhang Y, 2004, FASEB J, V18, pA232	51	26	27	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					905	914		10.1016/j.jaci.2006.06.016	http://dx.doi.org/10.1016/j.jaci.2006.06.016			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030245				2022-12-18	WOS:000241434200019
J	Benson, M; Langston, MA; Adner, M; Andersson, B; Torinssson-Naluai, A; Cardell, LO				Benson, Mikael; Langston, Michael A.; Adner, Mikael; Andersson, Bengt; Torinssson-Naluai, Asa; Cardell, Lars Olaf			A network-based analysis of the late-phase reaction of the skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DNA microarrays; gene expression; late-phase reaction	DNA MICROARRAY ANALYSIS; ALLERGIC RHINITIS; GENE-EXPRESSION; GROWTH-FACTOR; T-CELLS; RECEPTOR EXPRESSION; EOSINOPHILS; IGE; ASTHMA; PROTEIN	Background: The late-phase reaction (LPR) of the skin is an in vivo model of allergic inflammation. Objective: We sought to identify disease-associated pathways in the LPR using a network-based analysis. Methods: The LPR was examined by means of DNA microarray analysis of skin biopsy specimens from 10 patients with allergic rhinitis and 10 healthy control subjects. The results were further analyzed in 2 different materials consisting of nasal fluids and allergen-challenged CD4(+) T cells from patients with allergic rhinitis. Results: The DNA microarray analysis revealed several genes of known relevance to allergy. The eosinophil marker Charcot-Leyden crystal protein (CLC) that encodes Charcot-Leyden crystal protein differed most in expression. A network-based analysis showed upregulation of IL-4- and CCL4-dependent pathways and downregulation of a TGF-beta-induced pathway. CCL4 is expressed by CD4(+) T cells and chemotactic for eosinophils. We hypothesized that allergen induces release of CCL4 from TH2 cells and that this contributes to influx of eosinophils. Further analysis showed increase of CCL4 protein in nasal fluids from allergic patients during the season. Allergen challenge of PBMCs resulted in proliferation of TH2 cells and increased production of CCL4 in CD4(+) T cells from allergic patients. An analysis of the DNA microarray data revealed a significant correlation between CCL4 and the eosinophil marker CLC. Conclusion: A network-based analysis of the LPR showed increased activity of IL-4- and CCL4-dependent pathways and downregulation of the TGF-beta-induced pathway. Allergen-induced release of CCL4 from T(H)2 cells might contribute to influx of eosinophils during the LPR. Clinical implications: Involvement of multiple interacting pathways indicates that it might be difficult to identify one single mediator as a biomarker or drug target in allergic inflammation.	Queen Silvia Childrens Hosp, Dept Pediat, SE-41685 Gothenburg, Sweden; Univ Tennessee, Dept Comp Sci, Knoxville, TN 37996 USA; Lund Univ, Malmo Univ Hosp, Dept Otorhinolaryngol, Lab Clin & Expt Allergy Res, Malmo, Sweden; Sahlgrens Acad, Dept Clin Immunol, Gothenburg, Sweden; Sahlgrens Acad, Dept Clin Genet & Goteborg Genom, Gothenburg, Sweden	Queen Silvia Children's Hospital; University of Tennessee System; University of Tennessee Knoxville; Lund University; Skane University Hospital; University of Gothenburg; University of Gothenburg	Benson, M (corresponding author), Queen Silvia Childrens Hosp, Dept Pediat, SE-41685 Gothenburg, Sweden.	mikael.benson@vgregion.se	Naluai, Åsa Torinsson/AAB-2166-2021; Naluai, Åsa Torinsson/P-3269-2015; Langston, Michael/A-9484-2011	Naluai, Åsa Torinsson/0000-0002-0504-6492; Naluai, Åsa Torinsson/0000-0002-0504-6492; 				ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Benson M, 2004, J ALLERGY CLIN IMMUN, V113, P1137, DOI 10.1016/j.jaci.2004.02.028; Benson M, 2000, ALLERGY ASTHMA PROC, V21, P89, DOI 10.2500/108854100778250932; Benson M, 2002, CYTOKINE, V20, P268, DOI 10.1006/cyto.2002.1997; Benson M, 2002, CYTOKINE, V18, P20, DOI 10.1006/cyto.2002.1012; Benson M, 2000, J ALLERGY CLIN IMMUN, V106, P307, DOI 10.1067/mai.2000.108111; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Borchers MT, 2002, J LEUKOCYTE BIOL, V71, P1033; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; Groneberg DA, 2003, J ALLERGY CLIN IMMUN, V111, P1099, DOI 10.1067/mai.2003.1477; Hansen I, 2004, CURR OPIN ALLERGY CL, V4, P159, DOI 10.1097/01.all.0000129444.81350.23; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/88213; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398; Menzies-Gow A, 2002, J IMMUNOL, V169, P2712, DOI 10.4049/jimmunol.169.5.2712; Nakajima T, 2002, BLOOD, V100, P3861, DOI 10.1182/blood-2002-02-0602; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Phipps S, 2002, J IMMUNOL, V169, P4604, DOI 10.4049/jimmunol.169.8.4604; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; Plewako H, 2002, J ALLERGY CLIN IMMUN, V110, P68, DOI 10.1067/mai.2002.125488; Sallusto F, 1999, EUR J IMMUNOL, V29, P2037, DOI 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Stout BA, 2004, J IMMUNOL, V173, P6409, DOI 10.4049/jimmunol.173.10.6409; Wills-Karp M, 2004, SCIENCE, V305, P1726, DOI 10.1126/science.1104134; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	31	26	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					220	225		10.1016/j.jaci.2006.03.006	http://dx.doi.org/10.1016/j.jaci.2006.03.006			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815159				2022-12-18	WOS:000239184800027
J	Fahy, JV				Fahy, John V.			Anti-IgE: Lessons learned from effects on airway inflammation and asthma exacerbation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; anti-IgE; Xolair; exacerbation; remodeling; mast cells	FC-EPSILON-RI; MONOCLONAL-ANTIBODY; CYTOKINE PRODUCTION; OMALIZUMAB; CELLS; EXPRESSION; RECEPTOR	Omalizumab is an mAb that binds free IgE and ultimately reduces the density of IgE-loaded receptors on IgE effector cells. Because IgE effector cells, such as mast cells and basophils, are a source of proinflammatory chemokines, cytokines, and proteases, it is not surprising that omalizumab has antiinflammatory effects, most notably large effects in reducing airway eosinophilia. What has been surprising is the nature of the clinical effects of omalizumab. Rates of exacerbation in omalizumab-treated patients are approximately half those in placebo-treated patients. This important clinical effect has occurred despite the fact that omalizumab does not improve nonspecific bronchial hyperesponsiveness and does not have large effects on airflow. The unsuspected dissociations among asthma outcomes uncovered during clinical trials of omalizumab remind us that mysteries remain for how inflammation, remodeling, and airway function are linked in asthma.	Univ Calif San Francisco, Cardiovasc Res Inst, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Fahy, JV (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Div Pulm & Crit Care Med, 505 Parnassus Ave,Box 0111, San Francisco, CA 94143 USA.	john.fahy@ucsf.edu						Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Gounni AS, 2005, J IMMUNOL, V175, P2613, DOI 10.4049/jimmunol.175.4.2613; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, pS1, DOI 10.1164/ajrccm.164.supplement_1.2103024; Plewako H, 2002, J ALLERGY CLIN IMMUN, V110, P68, DOI 10.1067/mai.2002.125488; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101	18	26	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1230	1232		10.1016/j.jaci.2006.01.046	http://dx.doi.org/10.1016/j.jaci.2006.01.046			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750979				2022-12-18	WOS:000238332300004
J	Plante, S; Semlali, A; Joubert, P; Bissonnette, E; Laviolette, M; Hamid, Q; Chakir, J				Plante, Sophie; Semlali, AbdelHabib; Joubert, Philippe; Bissonnette, Elyse; Laviolette, Michel; Hamid, Qutayba; Chakir, Jamila			Mast cells regulate procollagen I (alpha(1)) production by bronchial fibroblasts derived from subjects with asthma through IL-4/IL-4 delta 2 ratio	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; collagen; fibroblasts; mast cells; remodeling	ALTERNATIVE SPLICE VARIANT; IL-13 RECEPTOR ALPHA-2; SUBEPITHELIAL FIBROSIS; COLLAGEN-SYNTHESIS; MESSENGER-RNA; INTERLEUKIN-4; GROWTH; PROLIFERATION; EXPRESSION; CYTOKINES	Background: Asthma is characterized by inflammation and remodeling. Mast cells are generally increased in bronchial mucosa of subjects with asthma. These cells release a wide variety of cytokines and mediators that have the capacity to stimulate other resident cells such as smooth muscle cells and fibroblasts. Objective: This study was designed to evaluate whether mast cells modulate collagen production by bronchial fibroblasts isolated from subjects with asthma and normal subjects through cytokine production. Methods: Human mast cells were cocultured for 72 hours with primary bronchial fibroblasts isolated from bronchial biopsies of subjects with mild asthma and normal controls. Procollagen I (alpha(1)), IL-4R alpha, IL-13R alpha(1), and IL-13R alpha(2) gene expression by bronchial fibroblasts and IL-4 and IL-4 delta 2 gene expression by mast cells were quantified by real-time RT-PCR. IL-4 production was also measured by ELISA in culture supernatants. Results: Procollagen I (oil) gene expression by fibroblasts from subjects with asthma was significantly higher compared with cells from normal controls when cocultured with mast cells. Mast cells expressed IL-4 isoform and IL-4 delta 2, an alternative splice variant of IL-4. Coculture significantly increased the expression of IL-4 but not IL-4 delta 2 by mast cells when they were cultured with fibroblasts from subjects with asthma compared with cells from normal controls. Neutralization of IL-4 abrogated collagen mRNA expression. There was no significant change in IL-4R alpha or IL-13R alpha(1). However, IL-13R alpha(2) gene expression was significantly reduced in fibroblasts from subjects with asthma. Conclusion: These results suggest that inflammatory process may regulate airway remodelling through crosstalk between inflammatory and structural cells. Targeting this crosstalk may have therapeutic application. Clinical implications: Understanding mechanisms that govern airway remodeling and collagen deposition in asthma is a step toward therapeutic management of this disease. In this work, we found that mast cell-fibroblast crosstalk may be a potential future target to control some aspects of airway remodeling.	Hop Laval, Ctr Rech, Inst Univ Cardiol & Pneumol, Ste Foy, PQ G1V 4G5, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	Laval University; McGill University	Chakir, J (corresponding author), Hop Laval, Ctr Rech, Inst Univ Cardiol & Pneumol, 2725 Chemin St Foy, Ste Foy, PQ G1V 4G5, Canada.	jamila.chakir@med.ulaval.ca	Semlali, Abdelhabib/AAP-7043-2020	Semlali, Abdelhabib/0000-0002-1643-0377; Plante, Sophie/0000-0003-1069-239X; Joubert, Philippe/0000-0001-7784-6387				Abe M, 2000, J ALLERGY CLIN IMMUN, V106, pS78, DOI 10.1067/mai.2000.106058; Alms WJ, 1996, MOL IMMUNOL, V33, P361, DOI 10.1016/0161-5890(95)00154-9; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; Arinobu Y, 1999, CELL IMMUNOL, V191, P161, DOI 10.1006/cimm.1998.1431; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Atamas SP, 1996, J IMMUNOL, V156, P435; Atamas SP, 1999, ARTHRITIS RHEUM, V42, P1168, DOI 10.1002/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L; Bergeron C, 2003, CLIN EXP ALLERGY, V33, P1389, DOI 10.1046/j.1365-2222.2003.01785.x; Berton A, 2000, CLIN EXP ALLERGY, V30, P485; BRADDING P, 1995, J IMMUNOL, V155, P297; Bradding P, 2003, CURR OPIN ALLERGY CL, V3, P45, DOI 10.1097/01.all.0000053267.39029.fd; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Chakir J, 1996, LAB INVEST, V75, P735; CHAKIR J, 1999, METHODS MOL MED ASTH, P53; David MD, 2003, ONCOGENE, V22, P3386, DOI 10.1038/sj.onc.1206352; Doucet C, 2002, EUR J IMMUNOL, V32, P2437, DOI 10.1002/1521-4141(200209)32:9<2437::AID-IMMU2437>3.0.CO;2-N; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Dube J, 2000, INT J EXP PATHOL, V81, P429, DOI 10.1046/j.1365-2613.2000.00173.x; Dube J, 1998, LAB INVEST, V78, P297; FERTIN C, 1991, CELL MOL BIOL, V37, P823; Garbuzenko E, 2002, CLIN EXP ALLERGY, V32, P237, DOI 10.1046/j.1365-2222.2002.01293.x; Gebhardt T, 2005, GUT, V54, P928, DOI 10.1136/gut.2004.054650; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Glare EM, 1999, J ALLERGY CLIN IMMUN, V104, P978, DOI 10.1016/S0091-6749(99)70078-3; Goulet F, 1996, AM J RESP CELL MOL, V15, P312, DOI 10.1165/ajrcmb.15.3.8810634; Gruber Barry L, 2003, Curr Rheumatol Rep, V5, P147, DOI 10.1007/s11926-003-0043-3; Gruber BL, 1997, J IMMUNOL, V158, P2310; HOLGATE ST, 1991, CLIN EXP ALLERGY, V21, P11, DOI 10.1111/j.1365-2222.1991.tb01758.x; JORDANA M, 1993, AM J RESP CELL MOL, V8, P7, DOI 10.1165/ajrcmb/8.1.7; Kashyap M, 2005, EXP HEMATOL, V33, P1281, DOI 10.1016/j.exphem.2005.07.001; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KIKUCHI K, 1995, DERMATOLOGY, V190, P4, DOI 10.1159/000246625; Laliberte R, 2001, MATRIX BIOL, V19, P743, DOI 10.1016/S0945-053X(00)00120-7; Liebler JM, 1998, THORAX, V53, P823, DOI 10.1136/thx.53.10.823; Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Mekori YA, 2004, J ALLERGY CLIN IMMUN, V114, P52, DOI 10.1016/j.jaci.2004.04.015; Mentink-Kane MM, 2004, IMMUNOL REV, V202, P191, DOI 10.1111/j.0105-2896.2004.00210.x; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; Prieto J, 2001, CLIN EXP ALLERGY, V31, P791, DOI 10.1046/j.1365-2222.2001.01078.x; REED JA, 1995, LAB INVEST, V72, P215; ROCHE WR, 1989, LANCET, V1, P520; Seah GT, 2001, AM J RESP CRIT CARE, V164, P1016, DOI 10.1164/ajrccm.164.6.2012138; Seah GT, 1999, J IMMUNOL METHODS, V228, P139, DOI 10.1016/S0022-1759(99)00084-8; Trautmann A, 1998, J IMMUNOL, V160, P5053; Yamamoto T, 2001, J DERMATOL SCI, V26, P106, DOI 10.1016/S0923-1811(00)00164-X; Yoshikawa M, 2003, BIOCHEM BIOPH RES CO, V312, P1248, DOI 10.1016/j.bbrc.2003.11.077	48	26	29	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1321	1327		10.1016/j.jaci.2005.12.1349	http://dx.doi.org/10.1016/j.jaci.2005.12.1349			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750993	Bronze			2022-12-18	WOS:000238332300018
J	Saadane, A; Soltys, J; Berger, M				Saadane, Aicha; Soltys, Jindrich; Berger, Melvin			Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cystic fibrosis; bronchoalveolar lavage; Pseudomonas aeruginosa; nuclear factor-kappa B; 1-kappa B; lung; PMN	BRONCHIAL EPITHELIAL-CELLS; KNOCKOUT MICE; IL-10 DEFICIENCY; INTERLEUKIN-10; EXPRESSION; INFECTION; ALPHA; MACROPHAGES; AERUGINOSA; ENDOTOXIN	Background: Cystic fibrosis (CF) is characterized by an excessive and prolonged inflammatory response to Pseudomonas aeruginosa in the lung. There are high levels of cytokines and chemokines and an exaggerated PMN influx causing significant morbidity and mortality. Objective: To compare the kinetics of the inflammatory response with the kinetics of clearance of acute bacterial challenge in the lungs of CF and wild-type (WT) mice. Methods: We challenged CF knockout (KO) and WT mice intratracheally with P aeruginosa in suspension and evaluated bacteria counts, nuclear factor-kappa B (NF-kappa B), and inhibitor of NF-kappa B alpha protein (I-kappa B alpha) in lung tissue, cytokines, and PMN in bronchoalveolar lavage (BAL). Results: Both groups of mice cleared the infection with the same kinetics. CF-KO mice had more PMN in BAL than WT mice. CF-KO mice had high concentrations of proinflammatory cytokines in BAL on days 2 and 4, whereas cytokines in BAL from WT mice were only slightly elevated. CF-KO mice failed to regenerate I-kappa B alpha once it was degraded, and consequently had prolonged and excessive activation of NF-kappa B for the entire 6-day duration or the study. In contrast, WT mice showed only slight NF-kappa B activation, which plateaued at day 4. Conclusion: These data suggest that NF-kappa B is dysregulated in CIF lung infection and could be a good target for therapy. Prolonged responses to initial acute infections may contribute to the eventual establishment of chronic persistent inflammation. Clinical implications: Dysregulation of the I-kappa B/NF-kappa B pathway in cystic fibrosis leads to prolonged cytokine secretion and persistent inflammation in response to acute challenges and may be important in the development of chronic lung inflammation and infection.	Case Western Reserve Univ, Dept Pediat, Rainbow Babies & Childrens Hosp, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Berger, M (corresponding author), Case Western Reserve Univ, Dept Pediat, Rainbow Babies & Childrens Hosp, Sch Med, 11100 Euclid Ave, Cleveland, OH 44106 USA.	mxb12@po.cwru.edu	Soltys, Jindrich/C-2399-2011; Soltys, Jindrich/P-3576-2019	Soltys, Jindrich/0000-0002-4490-3151; Saadane, Aicha/0000-0001-9985-2147				BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; Berger M, 1999, CYSTIC FIBROSIS IN ADULTS, P115; Bonfield TL, 1999, J ALLERGY CLIN IMMUN, V104, P72, DOI 10.1016/S0091-6749(99)70116-8; BONFIELD TL, 1995, AM J RESP CRIT CARE, V152, P2111, DOI 10.1164/ajrccm.152.6.8520783; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; Chmiel James F, 2002, Methods Mol Med, V70, P495; Chmiel JF, 2002, AM J RESP CRIT CARE, V165, P1176, DOI 10.1164/ajrccm.165.8.2107051; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; ECKMAN EA, 1995, AM J PHYSIOL-LUNG C, V269, pL625, DOI 10.1152/ajplung.1995.269.5.L625; ELBORN JS, 1993, CLIN SCI, V85, P563, DOI 10.1042/cs0850563; Freedman SD, 2002, J APPL PHYSIOL, V92, P2169, DOI 10.1152/japplphysiol.00927.2001; Joseph T, 2005, AM J PHYSIOL-LUNG C, V288, pL471, DOI 10.1152/ajplung.00066.2004; Knorre A, 2002, BIOL CHEM, V383, P271, DOI 10.1515/BC.2002.029; Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786; Li J, 2003, AM J PHYSIOL-LUNG C, V284, pL307, DOI 10.1152/ajplung.00086.2002; McMorran BJ, 2001, AM J PHYSIOL-LUNG C, V281, pL740, DOI 10.1152/ajplung.2001.281.3.L740; Muhlebach MS, 2002, AM J RESP CRIT CARE, V165, P911, DOI 10.1164/ajrccm.165.7.2107114; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; Poynter ME, 2003, J IMMUNOL, V170, P6257, DOI 10.4049/jimmunol.170.12.6257; Saadane A, 2005, J ALLERGY CLIN IMMUN, V115, P405, DOI 10.1016/j.jaci.2004.10.044; Skerrett SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL143, DOI 10.1152/ajplung.00030.2004; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Soltys J, 2002, J IMMUNOL, V168, P1903, DOI 10.4049/jimmunol.168.4.1903; Tabary O, 2003, AM J PATHOL, V162, P293, DOI 10.1016/S0002-9440(10)63820-5; Tabary O, 2001, PFLUG ARCH EUR J PHY, V443, pS40, DOI 10.1007/s004240100642; Thomas GR, 2000, J IMMUNOL, V164, P3870, DOI 10.4049/jimmunol.164.7.3870; van Heeckeren AM, 2000, AM J RESP CRIT CARE, V161, P271, DOI 10.1164/ajrccm.161.1.9903019; Venkatakrishnan A, 2000, AM J RESP CELL MOL, V23, P396, DOI 10.1165/ajrcmb.23.3.3949; Weber AJ, 2001, AM J PHYSIOL-LUNG C, V281, pL71, DOI 10.1152/ajplung.2001.281.1.L71	30	26	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1163	1169		10.1016/j.jaci.2006.01.052	http://dx.doi.org/10.1016/j.jaci.2006.01.052			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675347				2022-12-18	WOS:000237436300031
J	Matsuda, K; Nishi, Y; Okamatsu, Y; Kojima, M; Matsuishi, T				Matsuda, K; Nishi, Y; Okamatsu, Y; Kojima, M; Matsuishi, T			Ghrelin and leptin: A link between obesity and allergy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY; ASTHMA; PEPTIDE; MICE		Kurume Univ, Sch Med, Dept Pediat, Fukuoka 8300011, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 830, Japan	Kurume University; Kurume University	Matsuda, K (corresponding author), Kurume Univ, Sch Med, Dept Pediat, 67 Asahi Machi, Fukuoka 8300011, Japan.			Nishi, Yoshihiro/0000-0001-7529-1103				Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; Guler N, 2004, J ALLERGY CLIN IMMUN, V114, P254, DOI 10.1016/j.jaci.2004.03.053; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Sood A, 2005, J ALLERGY CLIN IMMUN, V115, P921, DOI 10.1016/j.jaci.2005.02.033; Xia Q, 2004, REGUL PEPTIDES, V122, P173, DOI 10.1016/j.regpep.2004.06.016	11	26	32	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					705	706		10.1016/j.jaci.2005.11.007	http://dx.doi.org/10.1016/j.jaci.2005.11.007			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522475				2022-12-18	WOS:000236263100031
J	Schatz, M; Leung, DYM; Goldstein, S				Schatz, M; Leung, DYM; Goldstein, S			Consultation and referral guidelines citing the evidence: How the allergist-immunologist can help	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							DUST MITE AVOIDANCE; NATURAL-RUBBER LATEX; IMPORTED FIRE ANT; EXERCISE-INDUCED ANAPHYLAXIS; PLACEBO-CONTROLLED TRIAL; SKIN PRICK TESTS; QUALITY-OF-LIFE; DISCONTINUING VENOM IMMUNOTHERAPY; ASTHMA MANAGEMENT GUIDELINES; SEVERE ATOPIC-DERMATITIS		Amer Acad Allergy Asthma & Immunol, Milwaukee, WI 53202 USA		Schatz, M (corresponding author), Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53202 USA.							AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Abramson MJ, 2001, AM J RESP CRIT CARE, V163, P12, DOI 10.1164/ajrccm.163.1.9910042; ABRAMSON MJ, 2003, COCHRANE DATABASE SY; ABRAMSON MJ, 2002, COCHRANE LIB; ADAMS RM, 1990, ALLERGY PROC, V11, P117, DOI 10.2500/108854190778880259; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Aihara Y, 2001, J ALLERGY CLIN IMMUN, V108, P1035, DOI 10.1067/mai.2001.119914; Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Altman DR, 1996, J ALLERGY CLIN IMMUN, V97, P1247, DOI 10.1016/S0091-6749(96)70192-6; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; *AM AC ALL, 2000, ASTHM IMM TASK FORC, V1; *AM THOR SOC, 2001, AM J RESP CRIT CARE, V161, P646; AMAIZVILLENA A, 1995, CRIT REV ONCOL HEMAT, V19, P131; Anderson SD, 1995, SPUMS, V25, P233; [Anonymous], 1998, J Allergy Clin Immunol, V101, pS465; [Anonymous], 1999, CLIN EXP IMMUNOL, V118, P1; Antonicelli L, 2002, CURR OPIN ALLERGY CL, V2, P341, DOI 10.1097/00130832-200208000-00008; ASAR N, 1994, J ALLERGY CLIN IMMUN, V93, P1001; Bachert C, 2002, ALLERGY, V57, P1208; Bagenstose SE, 1999, ANN ALLERG ASTHMA IM, V83, P524, DOI 10.1016/S1081-1206(10)62863-3; Baker SS, 2000, PEDIATRICS, V106, P346; Ballow M, 2002, J ALLERGY CLIN IMMUN, V109, P581, DOI 10.1067/mai.2002.122466; BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BAUR X, 1995, J ALLERGY CLIN IMMUN, V95, P1004, DOI 10.1016/S0091-6749(95)70101-X; Baur X, 1998, AM J IND MED, V33, P114; BelchiHernandez J, 1996, ANN ALLERG ASTHMA IM, V76, P355, DOI 10.1016/S1081-1206(10)60037-3; BERNSTEIN DI, 1995, CHEST, V108, P636, DOI 10.1378/chest.108.3.636; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Bernstein JA, 1999, J ALLERGY CLIN IMMUN, V103, P1153, DOI 10.1016/S0091-6749(99)70192-2; Bittner A, 2004, ALLERGY ASTHMA PROC, V25, P161; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; Blais R, 2001, CHEST, V119, P1316, DOI 10.1378/chest.119.5.1316; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1987, PEDIATRICS, V79, P683; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; BONER AL, 1985, ANN ALLERGY, V54, P42; Bonfanti P, 2000, BIOMED PHARMACOTHER, V54, P45, DOI 10.1016/S0753-3322(00)88640-0; Bonini S, 1999, CURR PROBL DERMATOL, V28, P88; Bonini S, 2000, OPHTHALMOLOGY, V107, P1157, DOI 10.1016/S0161-6420(00)00092-0; BORISH L, 1987, J ALLERGY CLIN IMMUN, V80, P314, DOI 10.1016/0091-6749(87)90037-6; Borish L, 2002, J ALLERGY CLIN IMMUN, V109, P606, DOI 10.1067/mai.2002.123024; Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brockow K, 2004, IMMUNOL ALLERGY CLIN, V24, P287, DOI 10.1016/j.iac.2004.01.002; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2002, J ALLERGY CLIN IMMUN, V109, P747, DOI 10.1067/mai.2002.123617; BUCKNALL CE, 1988, LANCET, V1, P748; Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, P1001, DOI 10.1067/mai.2002.124999; Cakmak S, 2002, LANCET, V359, P947, DOI 10.1016/S0140-6736(02)08045-5; CARMONA JGB, 1992, ALLERGY, V47, P190, DOI 10.1111/j.1398-9995.1992.tb00964.x; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; CARTIER A, 1984, CLIN ALLERGY, V14, P193, DOI 10.1111/j.1365-2222.1984.tb02652.x; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; Champi Catherine, 2002, J Pediatr Health Care, V16, P16; Chang AB, 2000, MED J AUSTRALIA, V172, P122, DOI 10.5694/j.1326-5377.2000.tb127937.x; CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; CHARPIN D, 1994, CLIN EXP ALLERGY, V24, P1010, DOI 10.1111/j.1365-2222.1994.tb02736.x; Cianferoni A, 2001, ANN ALLERG ASTHMA IM, V87, P27, DOI 10.1016/S1081-1206(10)62318-6; Cicardi M, 2003, MEDICINE, V82, P274, DOI 10.1097/00005792-200307000-00006; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; COCKCROFT DW, 1979, CAN MED ASSOC J, V121, P602; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; *COR CURR SUBC TRA, 1996, J ALLERGY CLIN IMMUN, V98, P1012; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; Crespo JF, 2002, ALLERGY, V57, P946, DOI 10.1034/j.1398-9995.2002.23626.x; Cunningham-Rundles C, 2001, CLIN IMMUNOL, V100, P181, DOI 10.1006/clim.2001.5052; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Dales RE, 2000, AM J RESP CRIT CARE, V162, P2087, DOI 10.1164/ajrccm.162.6.2001020; Davis MDP, 2004, IMMUNOL ALLERGY CLIN, V24, P183, DOI 10.1016/j.iac.2004.01.007; de Gracia J, 2004, INT IMMUNOPHARMACOL, V4, P745, DOI 10.1016/j.intimp.2004.02.011; Demoly P, 1998, J ALLERGY CLIN IMMUN, V102, P1033, DOI 10.1016/S0091-6749(98)70343-4; Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x; Demoly P, 2002, ALLERGY, V57, P546, DOI 10.1034/j.1398-9995.2002.t01-1-13370.x; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Devillers ACA, 2002, DERMATOLOGY, V204, P50, DOI 10.1159/000051810; Dibbern DA, 2004, IMMUNOL ALLERGY CLIN, V24, P141, DOI 10.1016/j.iac.2004.01.008; Diette GB, 2001, PEDIATRICS, V108, P432, DOI 10.1542/peds.108.2.432; Donahue JG, 2000, J ALLERGY CLIN IMMUN, V106, P1108, DOI 10.1067/mai.2000.111432; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; Drake LA, 1996, J AM ACAD DERMATOL, V34, P110, DOI 10.1016/S0190-9622(96)90842-7; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; DYKEWICZ MS, 1988, J ALLERGY CLIN IMMUN, V81, P455, DOI 10.1016/0091-6749(88)90917-7; DYKEWICZ MS, 1994, J ALLERGY CLIN IMMUN, V93, P117, DOI 10.1016/0091-6749(94)90240-2; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Elberink JNGO, 2003, CURR OPIN ALLERGY CL, V3, P287, DOI [10.1097/00130832-200308000-00009, 10.1097/01.all.0000083957.99396.b7]; ENGEL W, 1989, MED CARE, V27, P306, DOI 10.1097/00005650-198903000-00009; Epton MJ, 1997, THORAX, V52, P528, DOI 10.1136/thx.52.6.528; Farber HJ, 2003, J ASTHMA, V40, P17, DOI 10.1081/JAS-120017203; FEINGOLD BF, 1961, ANN ALLERGY, V19, P1275; Finn AF, 1999, J ALLERGY CLIN IMMUN, V104, P1071, DOI 10.1016/S0091-6749(99)70091-6; Fleisher TA, 1996, ADV INTERNAL MED, V41, P1; Fonacier L, 2003, CURR ALLERGY ASTHM R, V3, P283, DOI 10.1007/s11882-003-0088-4; FONACIER LS, 2002, AM J CONTACT DERMATI, V14, P164; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; FREUND DA, 1988, ANN ALLERGY, V60, P3; FREUND DA, 1989, J ALLERGY CLIN IMMUN, V84, P401, DOI 10.1016/0091-6749(89)90428-4; Gall H, 1996, J ALLERGY CLIN IMMUN, V97, P933, DOI 10.1016/S0091-6749(96)80067-4; Gallin JI, 2003, NEW ENGL J MED, V348, P2416, DOI 10.1056/NEJMoa021931; GANNON PFG, 1993, BRIT J IND MED, V50, P491; Gardulf A, 2004, J ALLERGY CLIN IMMUN, V114, P936, DOI 10.1016/j.jaci.2004.06.053; GAUCI M, 1990, ANN ALLERGY, V64, P297; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; Gibson PG, 2003, COCHRANE DATABASE SY; Goldberg A, 2001, J ALLERGY CLIN IMMUN, V107, P902, DOI 10.1067/mai.2001.114986; GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GOSSAIN VV, 1985, ANN ALLERGY, V55, P116; Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7; GRAMMER LC, 1984, JAMA-J AM MED ASSOC, V251, P1459, DOI 10.1001/jama.251.11.1459; GRAMMER LC, 1988, CLIN ORTHOP RELAT R, V234, P12; GREENE SL, 1985, J AM ACAD DERMATOL, V12, P669, DOI 10.1016/S0190-9622(85)70092-8; Grootendorst DC, 2001, CLIN EXP ALLERGY, V31, P400, DOI 10.1046/j.1365-2222.2001.01022.x; Gruchalla RS, 2000, ALLERGY ASTHMA PROC, V21, P39, DOI 10.2500/108854100778249015; Gutgesell C, 2001, BRIT J DERMATOL, V145, P70, DOI 10.1046/j.1365-2133.2001.04283.x; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Harper JI, 2001, DERMATOLOGY, V203, P3, DOI 10.1159/000051694; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; HAUGUARD L, 1991, J ALLERGY CLIN IMMUN, V87, P702; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786, DOI 10.1164/ajrccm.151.6.7767521; Henderson RL, 2000, J AM ACAD DERMATOL, V43, P1084, DOI 10.1067/mjd.2000.109305; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; Hermann K, 1997, INT ARCH ALLERGY IMM, V112, P251, DOI 10.1159/000237462; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; Hoare C, 2000, Health Technol Assess, V4, P1; Hoffman Donald R, 2004, Clin Allergy Immunol, V18, P355; Hoffman DR., 2003, MONOGRAPH INSECT ALL, P161; Holgate S, 2001, CURR MED RES OPIN, V17, P233; Holm L, 2001, ALLERGY, V56, P152, DOI 10.1034/j.1398-9995.2001.056002152.x; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Horwitz ME, 2001, NEW ENGL J MED, V344, P881, DOI 10.1056/NEJM200103223441203; Host A, 2003, ALLERGY, V58, P559, DOI 10.1034/j.1398-9995.2003.00238.x; Huang JL, 2001, PEDIATR ALLERGY IMMU, V12, P11, DOI 10.1034/j.1399-3038.2001.012001011.x; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Iacono G, 1996, J ALLERGY CLIN IMMUN, V97, P822, DOI 10.1016/S0091-6749(96)80160-6; Irwin RS, 1998, CHEST, V114, p133S, DOI 10.1378/chest.114.2_Supplement.133S; Janson S, 2004, J ASTHMA, V41, P343, DOI 10.1081/JAS-120026093; *JOINT TASK FORC P, 2004, ANN ALLERG ASTHMA S, V93, pS1; Joint Task Force On Practice Parameter, 2003, ANN ALLERGY ASTHM S1, V90, pS1; Joint Task Force on Practice Parameters, 2000, Ann Allergy Asthma Immunol, V85, P521; Joint Task Force on Practice Parameters, 2003, Ann Allergy Asthma Immunol, V90, P1; KALIVAS J, 1990, J ALLERGY CLIN IMMUN, V86, P1014, DOI 10.1016/S0091-6749(05)80246-5; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; Kastelik JA, 2005, EUR RESPIR J, V25, P235, DOI 10.1183/09031936.05.00140803; KAWAI T, 1984, CHEST, V85, P311, DOI 10.1378/chest.85.3.311; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; Kelly CS, 2000, PEDIATRICS, V105, P1029, DOI 10.1542/peds.105.5.1029; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; KIVITY S, 1993, J ALLERGY CLIN IMMUN, V91, P844, DOI 10.1016/0091-6749(93)90341-C; LAKE AM, 1982, J PEDIATR-US, V101, P906, DOI 10.1016/S0022-3476(82)80008-5; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V91, P154, DOI 10.1016/S1081-1206(10)62170-9; Larsen FS, 2002, IMMUNOL ALLERGY CLIN, V22, P1, DOI 10.1016/S0889-8561(03)00066-3; Lee CW, 2004, GYNECOL ONCOL, V95, P370, DOI 10.1016/j.ygyno.2004.08.002; Lee JM, 2000, PEDIATRICS, V106, P762, DOI 10.1542/peds.106.4.762; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; Leonard PA, 2002, TRANSPLANTATION, V74, P1697, DOI 10.1097/01.TP.0000038316.61592.28; Leoung GS, 2001, J INFECT DIS, V184, P992, DOI 10.1086/323353; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; Leung DYM, 1997, ANN ALLERG ASTHMA IM, V79, P197, DOI 10.1016/S1081-1206(10)63003-7; LEUNG FW, 1983, WESTERN J MED, V138, P565; Lever R, 1998, PEDIATR ALLERGY IMMU, V9, P13, DOI 10.1111/j.1399-3038.1998.tb00294.x; Li JT, 2003, ANN ALLERG ASTHMA IM, V90, P1, DOI 10.1016/S1081-1206(10)63600-9; Li LF, 2003, CONTACT DERMATITIS, V49, P189, DOI 10.1111/j.0105-1873.2003.0218.x; Light WC, 2001, J ALLERGY CLIN IMMUN, V107, P925, DOI 10.1067/mai.2001.114985; Lindberg M, 2004, ACTA DERM-VENEREOL, V84, P291, DOI 10.1080/00015550410025921; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Mabry RL, 1998, OTOLARYNG HEAD NECK, V119, P648, DOI 10.1016/S0194-5998(98)70027-0; Macy E, 2004, IMMUNOL ALLERGY CLIN, V24, P533, DOI 10.1016/j.iac.2004.03.002; Macy E, 2003, J ALLERGY CLIN IMMUN, V111, P1111, DOI 10.1067/mai.2003.1385; Macy E, 2002, ALLERGY, V57, P1151, DOI 10.1034/j.1398-9995.2002.23700.x; Macy E, 2002, PERM J, V6, P17; MAHR TA, 1993, ANN ALLERGY, V71, P115; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; MALO JL, 1982, AM REV RESPIR DIS, V125, P113; Markman M, 2000, J CLIN ONCOL, V18, P102, DOI 10.1200/JCO.2000.18.1.102; MARKS GB, 1995, CLIN EXP ALLERGY, V25, P114, DOI 10.1111/j.1365-2222.1995.tb01015.x; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Marks J, 1993, PATCH TESTING CONTAC; Marks JG, 1998, J AM ACAD DERMATOL, V38, P911, DOI 10.1016/S0190-9622(98)70587-0; Martin A, 2003, J INVEST ALLERG CLIN, V13, P232; MCCORMACK DR, 1995, ANN ALLERG ASTHMA IM, V74, P39; McNally PA, 1997, ALLERGY ASTHMA PROC, V18, P169, DOI 10.2500/108854197778984374; MEHREGAN DR, 1992, J AM ACAD DERMATOL, V26, P441, DOI 10.1016/0190-9622(92)70069-R; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; Meng YY, 1999, J EVAL CLIN PRACT, V5, P213, DOI 10.1046/j.1365-2753.1999.00177.x; Mimura T, 2004, OCUL IMMUNOL INFLAMM, V12, P45, DOI 10.1076/ocii.12.1.45.28067; MITCHELL EB, 1982, LANCET, V1, P127; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Moffitt JE, 1997, ANN ALLERG ASTHMA IM, V79, P125, DOI 10.1016/S1081-1206(10)63098-0; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moore CM, 1997, ANN ALLERG ASTHMA IM, V78, P373, DOI 10.1016/S1081-1206(10)63199-7; Morice AH, 2004, EUR RESPIR J, V24, P481, DOI 10.1183/09031936.04.00027804; Moscato G, 1999, CHEST, V115, P249, DOI 10.1378/chest.115.1.249; MOSCATO G, 1995, J ALLERGY CLIN IMMUN, V96, P295; *MRC, 1956, LANCET, V2, P803; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; NACLERIO R, 1983, J ALLERGY CLIN IMMUN, V71, P294, DOI 10.1016/0091-6749(83)90083-0; Nathan RA, 2004, ANN ALLERG ASTHMA IM, V92, P668, DOI 10.1016/S1081-1206(10)61435-4; Neas LM, 1996, AM J EPIDEMIOL, V143, P797, DOI 10.1093/oxfordjournals.aje.a008818; Nettis E, 2003, ALLERGY, V58, P1304, DOI 10.1046/j.1398-9995.2003.00346.x; Newson R, 1997, THORAX, V52, P680, DOI 10.1136/thx.52.8.680; Nguyen B, 2003, J ALLERGY CLIN IMMUN, V111, P807, DOI 10.1067/mai.2003.1341; NGUYEN MT, 1995, AIDS, V9, P573, DOI 10.1097/00002030-199506000-00007; Niggemann B, 2001, J ALLERGY CLIN IMMUN, V108, P1053, DOI 10.1067/mai.2001.120192; Nugent JS, 2003, ANN ALLERG ASTHMA IM, V90, P398, DOI 10.1016/S1081-1206(10)61823-6; NYDAHLPERSSON A, 1995, ACTA PAEDIATR, V84, P1007, DOI 10.1111/j.1651-2227.1995.tb13816.x; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Osborn DA, 2003, COCHRANE DB SYST REV, V4; PAGGIARO PL, 1987, B EUR PHYSIOPATH RES, V23, P565; Palmer RA, 2001, BRIT J DERMATOL, V144, P912, DOI 10.1046/j.1365-2133.2001.04163.x; Panjo GB, 2001, CLIN EXP ALLERGY, V31, P1392; Peng Z, 1998, J ALLERGY CLIN IMMUN, V101, pS32; PENG ZK, 1995, ANN ALLERG ASTHMA IM, V74, P259; Perfetti L, 1998, CHEST, V114, P398, DOI 10.1378/chest.114.2.398; PINNAS JL, 1978, FED PROC, V37, P1555; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; REUNALA T, 1994, J ALLERGY CLIN IMMUN, V94, P902, DOI 10.1016/0091-6749(94)90158-9; REUNALA T, 1994, INT ARCH ALLERGY IMM, V104, P366, DOI 10.1159/000236693; Ricci G, 2000, BRIT J DERMATOL, V143, P379, DOI 10.1046/j.1365-2133.2000.03666.x; Rich JD, 1997, ANN ALLERG ASTHMA IM, V79, P409, DOI 10.1016/S1081-1206(10)63034-7; Rietschel Robert L, 2002, Am J Contact Dermat, V13, P170, DOI 10.1053/ajcd.2002.36635; Robinson JB, 2001, GYNECOL ONCOL, V82, P550, DOI 10.1006/gyno.2001.6331; Rodier F, 2003, J ALLERGY CLIN IMMUN, V112, P1105, DOI 10.1016/j.jaci.2003.08.011; ROHR AS, 1984, J ALLERGY CLIN IMMUN, V73, P369, DOI 10.1016/0091-6749(84)90410-X; Romano A, 2001, INT ARCH ALLERGY IMM, V125, P264, DOI 10.1159/000053825; ROSENBERG N, 1987, CLIN ALLERGY, V17, P55, DOI 10.1111/j.1365-2222.1987.tb02319.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Ross RN, 2000, CLIN THER, V22, P329, DOI 10.1016/S0149-2918(00)80037-5; Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9; ROTSKOFF B, 2004, ALLERGY ASTHMA PROC, V25, P449; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; Rueff F, 2001, ALLERGY, V56, P889, DOI 10.1034/j.1398-9995.2001.00021.x; SALEK MS, 1993, BRIT J DERMATOL, V129, P422, DOI 10.1111/j.1365-2133.1993.tb03170.x; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 2001, GASTROENTEROLOGY, V120, P1026, DOI 10.1053/gast.2001.23031; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2000, J PEDIATR GASTR NUTR, V30, pS87, DOI 10.1097/00005176-200001001-00013; SASVARY T, 1994, SCHWEIZ MED WSCHR, V124, P1887; Schatz M, 2005, J ALLERGY CLIN IMMUN, V116, P1307, DOI 10.1016/j.jaci.2005.09.027; Schatz M, 2003, J ALLERGY CLIN IMMUN, V111, P503, DOI 10.1067/mai.2003.178; SCHATZ M, 1984, J ALLERGY CLIN IMMUN, V74, P606, DOI 10.1016/0091-6749(84)90114-3; Schubert MS, 2004, DRUGS, V64, P363, DOI 10.2165/00003495-200464040-00002; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P387, DOI 10.1016/S0091-6749(98)70125-3; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; Shan En-Zhi, 1995, Journal of Dermatology (Tokyo), V22, P411, DOI 10.1111/j.1346-8138.1995.tb03415.x; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; Shirai T, 2005, CHEST, V127, P1565, DOI 10.1378/chest.127.5.1565; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Simon P, 1996, NEPHROLOGIE, V17, P163; Simon RA, 2003, CLIN REV ALLERG IMMU, V24, P189, DOI 10.1385/CRIAI:24:2:189; SIMONS FER, 2003, MONOGRAPH INSECT ALL, P161; SJOSTEDT L, 1989, AM J IND MED, V16, P199, DOI 10.1002/ajim.4700160211; SLOAN AE, 1986, J ALLERGY CLIN IMMUN, V78, P127, DOI 10.1016/0091-6749(86)90002-3; Solensky R, 2000, ANN ALLERG ASTHMA IM, V85, P195, DOI 10.1016/S1081-1206(10)62466-0; Solensky R, 2002, ARCH INTERN MED, V162, P822, DOI 10.1001/archinte.162.7.822; Solensky Roland, 2004, Clin Allergy Immunol, V18, P585; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; SPERBER K, 1995, J ASTHMA, V32, P335, DOI 10.3109/02770909509082758; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; STARK BJ, 1987, J ALLERGY CLIN IMMUN, V79, P523, DOI 10.1016/0091-6749(87)90371-X; Steinke JW, 2004, IMMUNOL ALLERGY CLIN, V24, P45, DOI 10.1016/S0889-8561(03)00108-5; Stempel DA, 1997, ANN ALLERG ASTHMA IM, V79, P517, DOI 10.1016/S1081-1206(10)63059-1; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; SUBIZA J, 1994, CLIN EXP ALLERGY, V24, P1123, DOI 10.1111/j.1365-2222.1994.tb03317.x; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Tarlo S M, 1998, Can Respir J, V5, P289; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P628, DOI 10.1067/mai.2001.118792; Tarlo SM, 1997, OCCUP ENVIRON MED, V54, P756, DOI 10.1136/oem.54.10.756; Tarlo SM, 2000, CHEST, V118, P1309, DOI 10.1378/chest.118.5.1309; THIEL H, 1980, CHEST, V78, P400, DOI 10.1378/chest.78.2.400; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7; Tripathi A, 2001, ANN ALLERG ASTHMA IM, V86, P425, DOI 10.1016/S1081-1206(10)62489-1; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; TRUDEAU WL, 1993, CLIN EXP ALLERGY, V23, P377, DOI 10.1111/j.1365-2222.1993.tb00342.x; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; Valent P, 2004, J ALLERGY CLIN IMMUN, V114, P3, DOI 10.1016/j.jaci.2004.02.045; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VALENTINE MD, 1993, ANN ALLERGY, V70, P427; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; van der Heide S, 1999, J ALLERGY CLIN IMMUN, V104, P447, DOI 10.1016/S0091-6749(99)70391-X; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; Vandenplas O, 1997, EUR RESPIR J, V10, P2612, DOI 10.1183/09031936.97.10112612; VANDENPLAS O, 1993, AM REV RESPIR DIS, V147, P338, DOI 10.1164/ajrccm/147.2.338; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; VANWYE JE, 1991, J ALLERGY CLIN IMMUN, V88, P968, DOI 10.1016/0091-6749(91)90257-O; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; VEDAL S, 1986, ARCH ENVIRON HEALTH, V41, P179, DOI 10.1080/00039896.1986.9935774; VEMUIR P, 2004, ALLERGY ASTHMA PROC, V25, P349; VERVLOET D, 1991, ALLERGY, V46, P554, DOI 10.1111/j.1398-9995.1991.tb00620.x; Vilar MEB, 2000, ANN ALLERG ASTHMA IM, V84, P299, DOI 10.1016/S1081-1206(10)62777-9; Vollmer WM, 1997, ARCH INTERN MED, V157, P1201, DOI 10.1001/archinte.157.11.1201; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; Wartenberg D, 2001, AM J EPIDEMIOL, V153, P523, DOI 10.1093/aje/153.6.523; Wasserman RL, 1999, PEDIATR INFECT DIS J, V18, P157, DOI 10.1097/00006454-199902000-00016; WEINSTEIN AG, 1992, J ALLERGY CLIN IMMUN, V90, P66, DOI 10.1016/S0091-6749(06)80012-6; Weinstein AG, 1996, J ALLERGY CLIN IMMUN, V98, P264, DOI 10.1016/S0091-6749(96)70149-5; Weltermann BM, 1998, AM J IND MED, V34, P499, DOI 10.1002/(SICI)1097-0274(199811)34:5&lt;499::AID-AJIM11&gt;3.0.CO;2-X; Westley CR, 1997, ALLERGY ASTHMA PROC, V18, P15, DOI 10.2500/108854197778612835; WHEATLEY LM, 2000, ALLERGIC SKIN DIS MU, P423; Williams PB, 2003, ANN ALLERG ASTHMA IM, V91, P26; WOLF FM, 2003, COCHRANE DATABASE SY; WOLLE JM, 1995, J ASTHMA, V32, P309, DOI 10.3109/02770909509044839; WONG S, 1990, ARCH INTERN MED, V150, P1323, DOI 10.1001/archinte.150.6.1323; WOODELL DA, 2004, NATL AMBULATORY MED; Woodmansee DP, 2001, J ALLERGY CLIN IMMUN, V108, P309, DOI 10.1067/mai.2001.116986; Wu AW, 2001, ARCH INTERN MED, V161, P2554, DOI 10.1001/archinte.161.21.2554; YASSIN MS, 1992, ANN ALLERGY, V69, P207; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; YOUNG E, 1987, J ROY COLL PHYS LOND, V21, P241; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8; Zacharisen MC, 1998, J OCCUP ENVIRON MED, V40, P640, DOI 10.1097/00043764-199807000-00010; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T; 2005, TRENDS ASTHMA MORBID; 2005, ANN ALLERGY S, V94, pS1; 2003, ANN ALLERGY ASTHMA S, V90, pS1; 2002, J ALLERGY CLIN IMMUN, V98, P1012; 1998, ANN ALLERGY ASTHMA S, V81, P478; 1999, J ALLERGY CLIN IMMUN, V103, P963	368	26	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		2			S495	S521		10.1016/j.jaci.2005.10.047	http://dx.doi.org/10.1016/j.jaci.2005.10.047			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VT	16553071	Bronze			2022-12-18	WOS:000235865500001
J	Volz, T; Berner, D; Weigert, C; Rocken, M; Biedermann, T				Volz, T; Berner, D; Weigert, C; Rocken, M; Biedermann, T			Fixed food eruption caused by asparagus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POPULATION		Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Volz, T (corresponding author), Univ Tubingen, Dept Dermatol, Liebermeisterstr 25, D-72076 Tubingen, Germany.			Rocken, Martin/0000-0003-3795-7001; Biedermann, Tilo/0000-0002-5352-5105				HINDSEN M, 1987, BRIT J DERMATOL, V116, P351, DOI 10.1111/j.1365-2133.1987.tb05849.x; Kelso JM, 1996, J AM ACAD DERMATOL, V35, P638, DOI 10.1016/S0190-9622(96)90698-2; Niggemann B, 2002, CURR OPIN ALLERGY CL, V2, P253, DOI 10.1097/00130832-200206000-00016; Rieker J, 2004, J ALLERGY CLIN IMMUN, V113, P354, DOI 10.1016/j.jaci.2003.10.066; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sanchez MC, 1997, CONTACT DERMATITIS, V37, P181, DOI 10.1111/j.1600-0536.1997.tb00194.x; Shiohara T, 2002, CURR OPIN ALLERGY CL, V2, P317, DOI 10.1097/00130832-200208000-00005; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Yanguas I, 1998, J AM ACAD DERMATOL, V38, P640, DOI 10.1016/S0190-9622(98)70136-7; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8; Zuberbier T, 2004, ALLERGY, V59, P338, DOI 10.1046/j.1398-9995.2003.00403.x	11	26	26	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1390	1392		10.1016/j.jaci.2005.09.032	http://dx.doi.org/10.1016/j.jaci.2005.09.032			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337479				2022-12-18	WOS:000235687000038
J	Appleton, SL; Adams, RJ; Wilson, DH; Taylor, AW; Ruffin, RE				Appleton, SL; Adams, RJ; Wilson, DH; Taylor, AW; Ruffin, RE		NW Adelaide Cohort Hlth Study Team	Spirometric criteria for asthma: Adding further evidence to the debate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; spirometry; bronchodilator response; asthma epidemiology; asthma diagnosis	OBSTRUCTIVE PULMONARY-DISEASE; SHORT-TERM VARIABILITY; CHRONIC LUNG-DISEASE; RESPIRATORY SYMPTOMS; BRONCHODILATOR REVERSIBILITY; RESPONSIVENESS; METHACHOLINE; COMBINATION; SEVERITY; FEV1	Background: Objective assessments of pulmonary function are considered essential for the diagnosis of asthma. The degree of reversibility of FEV1 considered supportive of asthma varies between international asthma guidelines. Objective: We sought to compare the relative performance of international guideline reversibility criteria for identifying impairment in persons with a significant bronchodilator response (SBR) without an asthma diagnosis. Methods: The North West Adelaide Health (Cohort) Study, a population biomedical study of 4060 subjects, conducted spirometry according to American Thoracic Society criteria. SBR was defined as postbronchodilator FEV1 responses of at least 12% or 15% of baseline values, 9% of predicted values, or 400 mL. A self-completed questionnaire assessed current asthma (CA), respiratory symptoms, and participant demographics. Results: The prevalence of CA was 9.4% (n = 380), whereas 1.3% (>= 400 mL) to 4.5% (>= 9% of predicted value) of participants demonstrated an SBR in the absence of CA. With the exception of the 9% predicted criterion, prebronchodilator mean FEV1 (percent predicted) in those demonstrating an SBR but no CA was significantly worse than that in the CA group. Significantly more respiratory symptoms were experienced by the SBR groups than the group without asthma. Logistic regression analyses identified different characteristics of those classified by the following criteria: 12% and 15 %, age of 40 years or greater and household income of less than $40,000; 9% predicted, household income of less than $40,000; 400 mL, male sex (odds ratio, 4.5; 95% CL 2.1-9.3). Conclusions: Different criteria identify different persons, but SBR by any criteria was associated with significant respiratory impairment, some of which might be attributable to asthma. Postbronchodilator change as a percentage of predicted value was the least biased of the criteria.	Univ Adelaide, Hlth Observ, Dept Med, Woodville, SA 5011, Australia; S Australian Dept Hlth, Populat Res & Outcomes Studies Unit, Adelaide, SA, Australia	University of Adelaide	Adams, RJ (corresponding author), Univ Adelaide, Hlth Observ, Dept Med, Queen Elizabeth Hosp Campus,Woodville Rd, Woodville, SA 5011, Australia.	robert.adams@adelaide.edu.au	Appleton, Sarah/Y-5206-2019; Adams, Robert/Z-3197-2019; Taylor, Anne w/F-5708-2010; Appleton, Sarah/E-9149-2017	Taylor, Anne w/0000-0002-4422-7974; Appleton, Sarah/0000-0001-7292-9714				Adams RJ, 2003, THORAX, V58, P846, DOI 10.1136/thorax.58.10.846; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; ANTHONISEN N, 1989, AM REV RESPIR DIS, V133, P14; BANERJEE DK, 1987, BRIT J DIS CHEST, V81, P23, DOI 10.1016/0007-0971(87)90104-5; BERGER R, 1988, CHEST, V93, P541, DOI 10.1378/chest.93.3.541; BERGER R, 1988, CHEST, V94, P674, DOI 10.1016/S0012-3692(16)30213-6; BRAND PLP, 1992, THORAX, V47, P429, DOI 10.1136/thx.47.6.429; BRAND PLP, 1991, AM REV RESPIR DIS, V143, P916, DOI 10.1164/ajrccm/143.5_Pt_1.916; Burge PS, 2003, THORAX, V58, P654, DOI 10.1136/thorax.58.8.654; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CONNOLLY MJ, 1992, THORAX, V47, P410, DOI 10.1136/thx.47.6.410; DALES RE, 1988, AM REV RESPIR DIS, V138, P317, DOI 10.1164/ajrccm/138.2.317; Dorinsky PM, 1999, CHEST, V115, P966, DOI 10.1378/chest.115.4.966; Dow L, 1998, CLIN EXP ALLERGY, V28, P195; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; GREENSPON LW, 1992, CHEST, V102, P1419, DOI 10.1378/chest.102.5.1419; GREENSPON LW, 1986, AM REV RESPIR DIS, V133, P735; GUYATT GH, 1988, ARCH INTERN MED, V148, P1949, DOI 10.1001/archinte.148.9.1949; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; Hosmer DW, 1989, APPL LOGISTIC REGRES; Joyce DP, 1996, CHEST, V109, P697, DOI 10.1378/chest.109.3.697; Lewis SA, 2001, EUR RESPIR J, V18, P921, DOI 10.1183/09031936.01.00211801; LORBER DB, 1978, AM REV RESPIR DIS, V118, P855; Mahler DA, 2002, AM J RESP CRIT CARE, V166, P1084, DOI 10.1164/rccm.2112055; MARABINI M, 2001, MONALDI ARCH CHEST D, V564, P299; MCIVOR RA, 2001, CAN RESPIR J, V83, P153; MENDELLA LA, 1982, ANN INTERN MED, V96, P17, DOI 10.7326/0003-4819-96-1-17; Moody A, 2004, THORAX, V59, P1; National Heart Lung and Blood Institute, 2003, NIH PUBL, V02-5074; *NIH NAT HEART LUN, 1997, NIH PUBL; PALMEIRO EM, 1992, CHEST, V101, P630, DOI 10.1378/chest.101.3.630; Parameswaran K, 1998, RESP MED, V92, P573, DOI 10.1016/S0954-6111(98)90311-0; Peat JK, 2001, THORAX, V56, P406, DOI 10.1136/thorax.56.5.406; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Reid DW, 2003, INTERN MED J, V33, P572, DOI 10.1111/j.1445-5994.2003.00485.x; Rossi A, 2002, CHEST, V121, P1058, DOI 10.1378/chest.121.4.1058; Ruffin RE, 2000, QUAL LIFE RES, V9, P1031, DOI 10.1023/A:1016689729722; RUSSELL NJ, 1986, THORAX, V41, P360, DOI 10.1136/thx.41.5.360; Selim AJ, 1997, CHEST, V111, P1607, DOI 10.1378/chest.111.6.1607; SHIM CS, 1980, AM J MED, V68, P11, DOI 10.1016/0002-9343(80)90155-2; SPARROW D, 1987, AM REV RESPIR DIS, V135, P1255; Tashkin D, 2003, CHEST, V123, P1441, DOI 10.1378/chest.123.5.1441; Taylor AW, 1998, AUST NZ J PUBL HEAL, V22, P223, DOI 10.1111/j.1467-842X.1998.tb01177.x; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; TWEEDDALE PM, 1987, THORAX, V42, P487, DOI 10.1136/thx.42.7.487; TWEEDDALE PM, 1984, THORAX, V39, P928, DOI 10.1136/thx.39.12.928; VanSchayck CP, 1996, BRIT J GEN PRACT, V46, P193; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; [No title captured]; 2001, NIH PUBLICATION, V2701	53	26	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					976	982		10.1016/j.jaci.2005.08.034	http://dx.doi.org/10.1016/j.jaci.2005.08.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275363	Bronze			2022-12-18	WOS:000235686700004
J	Liossis, SNC; Tsokos, GC				Liossis, SNC; Tsokos, GC			Monoclonal antibodies and fusion proteins in medicine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						cancer; lymphoma; transplantation; rheumatoid arthritis; systemic lupus erythematosus; psoriasis	TUMOR-NECROSIS-FACTOR; B-CELL DEPLETION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; RECEIVING CONCOMITANT METHOTREXATE; ANTI-CD40 LIGAND ANTIBODY; METASTATIC BREAST-CANCER; GROWTH-FACTOR RECEPTOR; MOLECULE CD40 LIGAND; RHEUMATOID-ARTHRITIS	Humanized antibodies and decoy receptors have been introduced in clinical practice to treat malignancies and systemic autoimmune disease because they ablate specific cells or disrupt pathogenic processes at distinct points. Reported clinical responses offer hope to treatment-resistant patients, particularly those with lymphomas and rheumatic diseases. Side effects from the use of biologic agents include lymphokine release syndrome, reactivation of tuberculosis, and immunosuppression. Further insights are needed regarding limitation of adverse effects, correct use in conjunction with existing drugs, and treatment of patients in whom resistance develops.	Univ Patras, Sch Med, Dept Internal Med, Div Rheumatol, GR-26110 Patras, Greece; Walter Reed Army Inst Res, Dept Cellular Injury, Silver Spring, MD USA	University of Patras; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Liossis, SNC (corresponding author), Patras Univ Hosp, Dept Internal Med, Patras 26504, Greece.	sliossis@med.upatras.gr	tsokos, george C/O-3360-2013; Liossis, Stamatis-Nick/K-5383-2019	tsokos, george C/0000-0001-9589-2360; Liossis, Stamatis-Nick/0000-0003-2511-8083				Ahrens N, 2001, BRIT J HAEMATOL, V114, P244; Anolik JH, 2004, ARTHRITIS RHEUM-US, V50, P3580, DOI 10.1002/art.20592; Anolik JH, 2003, ARTHRITIS RHEUM, V48, P455, DOI 10.1002/art.10764; Antoni C, 2002, ARTHRITIS RHEUM-US, V46, pS381; Antoni CE, 2003, ANN RHEUM DIS, V62, P90; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Berney T, 2002, TRANSPLANTATION, V74, P1000, DOI 10.1097/00007890-200210150-00018; Borchmann P, 2003, BLOOD, V102, P3737, DOI 10.1182/blood-2003-02-0515; Boumpas DT, 2003, ARTHRITIS RHEUM-US, V48, P719, DOI 10.1002/art.10856; Braun J, 2002, LANCET, V359, P1187, DOI 10.1016/S0140-6736(02)08215-6; BRAUN J, 1995, ARTHRITIS RHEUM, V38, P499, DOI 10.1002/art.1780380407; BURNSTEIN H, 2001, J CLIN ONCOL, V19, P2722; Chamian F, 2005, P NATL ACAD SCI USA, V102, P2075, DOI 10.1073/pnas.0409569102; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier B, 1998, BLOOD, V92, P1927; Colombat P, 2001, BLOOD, V97, P101, DOI 10.1182/blood.V97.1.101; Cooper N, 2004, BRIT J HAEMATOL, V125, P232, DOI 10.1111/j.1365-2141.2004.04889.x; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Czuczman MS, 2001, ANN ONCOL, V12, P109, DOI 10.1023/A:1008395214584; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; DesaiMehta A, 1996, J CLIN INVEST, V97, P2063, DOI 10.1172/JCI118643; Dimopoulos MA, 2002, J CLIN ONCOL, V20, P2327, DOI 10.1200/JCO.2002.09.039; Dinarello CA, 2005, J RHEUMATOL, V32, P40; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Ekstrand BC, 2003, BLOOD, V101, P4285, DOI 10.1182/blood-2002-08-2644; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308; GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337; Gordon KB, 2003, JAMA-J AM MED ASSOC, V290, P3073, DOI 10.1001/jama.290.23.3073; Gordon LI, 2004, BLOOD, V103, P4429, DOI 10.1182/blood-2003-11-3883; GOTTLIEB AB, 2003, AM AC DERM 61 ANN M; Grammer AC, 2003, J CLIN INVEST, V112, P1506, DOI 10.1172/JCI200319301; GUEME PA, 1989, J CLIN INVEST, V83, P582; Hainsworth JD, 2002, J CLIN ONCOL, V20, P4261, DOI 10.1200/JCO.2002.08.674; Horning SJ, 2005, J CLIN ONCOL, V23, P712, DOI 10.1200/JCO.2005.07.040; Huang WQ, 2002, ARTHRITIS RHEUM-US, V46, P1554, DOI 10.1002/art.10273; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kahan BD, 1999, TRANSPLANTATION, V67, P276, DOI 10.1097/00007890-199901270-00016; Kalunian KC, 2002, ARTHRITIS RHEUM, V46, P3251, DOI 10.1002/art.10681; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; Katsiari CG, 2002, CLIN IMMUNOL, V103, P54, DOI 10.1006/clim.2001.5172; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Keating MJ, 2002, BLOOD, V99, P3554, DOI 10.1182/blood.V99.10.3554; Keating MJ, 2002, J CLIN ONCOL, V20, P205, DOI 10.1200/JCO.20.1.205; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Keogh KA, 2005, ARTHRITIS RHEUM-US, V52, P262, DOI 10.1002/art.20718; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Krueger GG, 2002, J AM ACAD DERMATOL, V47, P821, DOI 10.1067/mjd.2002.127247; Leandro MJ, 2002, ARTHRITIS RHEUM-US, V46, P2673, DOI 10.1002/art.10541; Lebwohl M, 2003, ARCH DERMATOL, V139, P719, DOI 10.1001/archderm.139.6.719; Leonard JP, 2003, J CLIN ONCOL, V21, P3051, DOI 10.1200/JCO.2003.01.082; Leonardi CL, 2005, J AM ACAD DERMATOL, V52, P425, DOI 10.1016/j.jaad.2004.09.029; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Liu MF, 1999, SCAND J IMMUNOL, V50, P68; Liu MF, 1996, ARTHRITIS RHEUM, V39, P110, DOI 10.1002/art.1780390115; Looney RJ, 2004, ARTHRITIS RHEUM, V50, P2580, DOI 10.1002/art.20430; Lundin J, 2002, BLOOD, V100, P768, DOI 10.1182/blood-2002-01-0159; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Maini RN, 2004, ARTHRITIS RHEUM-US, V50, P1051, DOI 10.1002/art.20159; Mannon PJ, 2004, NEW ENGL J MED, V351, P2069, DOI 10.1056/NEJMoa033402; Mass R, 2000, SEMIN ONCOL, V27, P46; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Mease PJ, 2004, ARTHRITIS RHEUM-US, V50, P2264, DOI 10.1002/art.20335; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; Moreland LW, 2002, ARTHRITIS RHEUM, V46, P1470, DOI 10.1002/art.10294; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; Nashan B, 1999, TRANSPLANTATION, V67, P110, DOI 10.1097/00007890-199901150-00019; NEIDEL J, 1995, INFLAMM RES, V44, P217, DOI 10.1007/BF01782262; Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303; Norman DJ, 2000, TRANSPLANTATION, V70, P1707, DOI 10.1097/00007890-200012270-00008; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Nussenblatt RB, 2005, OPHTHALMOLOGY, V112, P764, DOI 10.1016/j.ophtha.2004.12.034; Panayi G. S., 1997, Current Opinion in Rheumatology, V9, P236, DOI 10.1097/00002281-199705000-00010; Papadakis KA, 2005, AM J GASTROENTEROL, V100, P75, DOI 10.1111/j.1572-0241.2005.40647.x; Perez-Simon JA, 2002, BLOOD, V100, P3121, DOI 10.1182/blood-2002-03-0701; Piro LD, 1999, ANN ONCOL, V10, P655, DOI 10.1023/A:1008389119525; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; Rutgeerts P, 2004, GASTROENTEROLOGY, V126, P1593, DOI 10.1053/j.gastro.2004.02.070; Sands BE, 2004, NEW ENGL J MED, V350, P876, DOI 10.1056/NEJMoa030815; Schnell R, 2002, CLIN CANCER RES, V8, P1779; Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215; Sfikakis PP, 2005, ARTHRITIS RHEUM-US, V52, P501, DOI 10.1002/art.20858; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Spina M, 2005, BLOOD, V105, P1891, DOI 10.1182/blood-2004-08-3300; Sridhar SS, 2003, LANCET ONCOL, V4, P397, DOI 10.1016/S1470-2045(03)01137-9; Susman E, 2004, LANCET ONCOL, V5, P647, DOI 10.1016/S1470-2045(04)01627-4; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Treon SP, 2000, SEMIN ONCOL, V27, P79, DOI 10.1053/sonc.2000.20425; Tsokos GC, 2004, ARTHRITIS RHEUM-US, V50, P3404, DOI 10.1002/art.20602; Tsokos GC, 1999, IMMUNOL TODAY, V20, P119, DOI 10.1016/S0167-5699(98)01395-4; Tsokos GC, 2004, NEW ENGL J MED, V350, P2546, DOI 10.1056/NEJMp048114; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; Vogel CL, 2001, ONCOLOGY-BASEL, V61, P37, DOI 10.1159/000055400; Walker S, 2004, COCHRANE DB SYST REV; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; Witzig TE, 2002, J CLIN ONCOL, V20, P3262, DOI 10.1200/JCO.2002.11.017; Wolfe F, 2004, ARTHRITIS RHEUM-US, V50, P1740, DOI 10.1002/art.20311; Xiong HQ, 2004, J CLIN ONCOL, V22, P2610, DOI 10.1200/JCO.2004.12.040; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Younes A, 2003, CLIN LYMPHOMA, V3, P257, DOI 10.3816/CLM.2003.n.008; Zecca M, 2001, BLOOD, V97, P3995, DOI 10.1182/blood.V97.12.3995	109	26	32	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					721	729		10.1016/j.jaci.2005.06.035	http://dx.doi.org/10.1016/j.jaci.2005.06.035			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210042				2022-12-18	WOS:000235686600001
J	Fontaine, C; Bousquet, PJ; Demoly, P				Fontaine, C; Bousquet, PJ; Demoly, P			Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Hosp Montpellier, Hosp Arnaud Villeneuve, INSERM, U454, F-34295 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Fontaine, C (corresponding author), Univ Hosp Montpellier, Hosp Arnaud Villeneuve, INSERM, U454, F-34295 Montpellier, France.		Bousquet, Philippe Jean/AAW-8608-2021; Demoly, Pascal/Y-9938-2019; Bousquet, Jean/O-4221-2019	Bousquet, Philippe Jean/0000-0002-0217-5483; Demoly, Pascal/0000-0001-7827-7964; 				Gagnon R, 2003, J ALLERGY CLIN IMMUN, V111, P1404, DOI 10.1067/mai.2003.1465; Grob M, 2002, ALLERGY, V57, P264, DOI 10.1034/j.1398-9995.2002.1n3581.x; LAYTON D, 2004, EUR J CLIN PHARM; Levy MB, 2001, ANN ALLERG ASTHMA IM, V87, P72, DOI 10.1016/S1081-1206(10)62327-7; Messaad D, 2004, ANN INTERN MED, V140, P1001, DOI 10.7326/0003-4819-140-12-200406150-00009; Schellenberg RR, 2001, NEW ENGL J MED, V345, P1856, DOI 10.1056/NEJM200112203452518; Schuster C, 2003, ALLERGY, V58, P1072, DOI 10.1034/j.1398-9995.2003.00116.x; Stevenson DD, 2004, IMMUNOL ALLERGY CLIN, V24, P491, DOI 10.1016/j.iac.2004.03.001	8	26	26	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					633	634		10.1016/j.jaci.2004.10.045	http://dx.doi.org/10.1016/j.jaci.2004.10.045			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753917	Bronze			2022-12-18	WOS:000227687000032
J	Szefler, SJ; Apter, A				Szefler, SJ; Apter, A			Advances in pediatric and adult asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; biomarkers; corticosteroids; genetics; immunomodulators; long-term control therapy	AIRWAY INFLAMMATION; CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; BRONCHIAL-ASTHMA; NITRIC-OXIDE; CHILDREN; ATOPY; ASSOCIATION; RISK; OUTCOMES	Last year's review on adult and pediatric asthma highlighted reports related to asthma genetics, the importance of upper airway management, the costs of asthma, and the importance of early recognition and intervention. This year we will organize our discussion to review recent reports related to the origins and persistence of asthma in both adults and children. We highlight Journal publications from 2004, along with recent key publications from other medical journals, to provide a perspective on the rapidly developing areas of genetics, including pharmacogenetics, respiratory infection, biomarker measurements, and asthma pharmacotherapy. This new understanding of the pathogenesis of asthma combined with clinical applications of genetics and biomarkers should lead to new management strategies. Asthma management is likely to change in the coming years from a strategy directed to the best outcome in groups of patients to an individualized approach to assessment and management.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Pharmacol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Immunol, Denver, CO 80206 USA; Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	National Jewish Health; National Jewish Health; University of Pennsylvania	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Pharmacol, 1400 Jackson St,Room J304 Molly Blank Bldg, Denver, CO 80206 USA.	szeflers@njc.org			DIVISION OF LUNG DISEASES [N01HR016048] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL051834, K23HL004337, P01HL036577] Funding Source: NIH RePORTER; NCRR NIH HHS [5 M01 RR00051] Funding Source: Medline; NHLBI NIH HHS [HL 51834, HL04337-01, HL36577, 1NO1-HR-16048] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347; Al-Mousawi MSH, 2004, J ALLERGY CLIN IMMUN, V114, P1389, DOI 10.1016/j.jaci.2004.09.005; Alford SH, 2004, J ALLERGY CLIN IMMUN, V114, P1046, DOI 10.1016/j.jaci.2004.08.036; Apter AJ, 2004, J ALLERGY CLIN IMMUN, V113, P407, DOI 10.1016/j.jaci.2003.12.002; APTER AJ, 2003, J ALLERGY CLIN IMM S, V11, pS780; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Becker JM, 2004, J ALLERGY CLIN IMMUN, V113, P264, DOI 10.1016/j.jaci.2003.10.052; Bogen D, 2004, J ALLERGY CLIN IMMUN, V114, P863, DOI 10.1016/j.jaci.2004.07.017; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; Busse W, 2004, AM J RESP CRIT CARE, V170, P683, DOI 10.1164/rccm.200311-1539WS; Cabana MD, 2004, J ALLERGY CLIN IMMUN, V114, P352, DOI 10.1016/j.jaci.2004.04.047; Camara AA, 2004, J ALLERGY CLIN IMMUN, V113, P551, DOI 10.1016/j.jaci.2003.11.027; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; Cookson W, 2004, NEW ENGL J MED, V351, P1794, DOI 10.1056/NEJMe048232; Corren J, 2004, J ALLERGY CLIN IMMUN, V113, P415, DOI 10.1016/j.jaci.2003.11.034; Covar RA, 2004, J ALLERGY CLIN IMMUN, V114, P575, DOI 10.1016/j.jaci.2004.06.036; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; De Swert LF, 2004, NEW ENGL J MED, V350, P1157, DOI 10.1056/NEJM200403113501122; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gern JE, 2004, PEDIATR INFECT DIS J, V23, pS78, DOI 10.1097/01.inf.0000108196.46134.a6; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Hanania NA, 2004, J ALLERGY CLIN IMMUN, V113, P717, DOI 10.1016/j.jaci.2003.12.584; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Hederos CA, 2004, J ALLERGY CLIN IMMUN, V114, P451, DOI 10.1016/j.jaci.2004.03.045; Heinzmann A, 2004, J ALLERGY CLIN IMMUN, V114, P671, DOI 10.1016/j.jaci.2004.06.038; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Hoffjan S, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-14; Hoffjan S, 2002, CURR OPIN IMMUNOL, V14, P709, DOI 10.1016/S0952-7915(02)00393-X; Howard TD, 2003, J ALLERGY CLIN IMMUN, V112, P717, DOI 10.1016/S0091-6749(03)01939-0; Hunt LW, 2004, J ALLERGY CLIN IMMUN, V113, P853, DOI 10.1016/j.jaci.2004.02.039; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Joseph-Bowen J, 2004, J ALLERGY CLIN IMMUN, V114, P1040, DOI 10.1016/j.jaci.2004.07.051; Kawano T, 2004, J ALLERGY CLIN IMMUN, V114, P1278, DOI 10.1016/j.jaci.2004.09.003; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Lazaar AL, 2003, AM J MED, V115, P652, DOI 10.1016/j.amjmed.2003.07.010; Lee KS, 2004, J ALLERGY CLIN IMMUN, V113, P902, DOI 10.1016/j.jaci.2004.03.008; Lemanske RF, 2004, J ALLERGY CLIN IMMUN, V114, P1023, DOI 10.1016/j.jaci.2004.08.031; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung TF, 2004, J ALLERGY CLIN IMMUN, V114, P199, DOI 10.1016/j.jaci.2004.03.048; Mahut B, 2004, J ALLERGY CLIN IMMUN, V113, P252, DOI 10.1016/j.jaci.2003.10.038; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Nowak-Wegrzyn A, 2004, J ALLERGY CLIN IMMUN, V113, P558, DOI 10.1016/j.jaci.2003.11.015; O'Connor GT, 2004, J ALLERGY CLIN IMMUN, V114, P599, DOI 10.1016/j.jaci.2004.05.064; Oba Y, 2004, J ALLERGY CLIN IMMUN, V114, P265, DOI 10.1016/j.jaci.2004.05.049; Oguma T, 2004, NEW ENGL J MED, V351, P1752, DOI 10.1056/NEJMoa031785; Openshaw PJM, 2004, J ALLERGY CLIN IMMUN, V114, P1275, DOI 10.1016/j.jaci.2004.08.024; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Piacentini GL, 2004, J ALLERGY CLIN IMMUN, V114, P202, DOI 10.1016/j.jaci.2004.04.010; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rabinovitch N, 2004, J ALLERGY CLIN IMMUN, V114, P1131, DOI 10.1016/j.jaci.2004.08.026; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rccm.200207-634OC; Raby BA, 2004, J ALLERGY CLIN IMMUN, V113, P1071, DOI 10.1016/j.jaci.2004.03.035; Saito J, 2004, J ALLERGY CLIN IMMUN, V114, P512, DOI 10.1016/j.jaci.2004.05.033; Schatz M, 2004, J ALLERGY CLIN IMMUN, V113, P1040, DOI 10.1016/j.jaci.2004.03.017; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Szczeklik W, 2004, J ALLERGY CLIN IMMUN, V114, P248, DOI 10.1016/j.jaci.2004.05.030; Szema AM, 2004, J ALLERGY CLIN IMMUN, V113, P420, DOI 10.1016/j.jaci.2003.12.015; Tsitoura DC, 2004, J CLIN INVEST, V113, P619, DOI 10.1172/JCI200418975; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Vargas PA, 2004, J ALLERGY CLIN IMMUN, V114, P499, DOI 10.1016/j.jaci.2004.05.025; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Zanconato S, 2004, J ALLERGY CLIN IMMUN, V113, P257, DOI 10.1016/j.jaci.2003.10.046	80	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					470	477		10.1016/j.jaci.2004.12.1123	http://dx.doi.org/10.1016/j.jaci.2004.12.1123			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753890				2022-12-18	WOS:000227687000005
J	Laitinen, A; Lindqvist, A; Halme, M; Altraja, A; Laitinen, LA				Laitinen, A; Lindqvist, A; Halme, M; Altraja, A; Laitinen, LA			Leukotriene E-4-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airways; biopsies; CysLT(1); receptor; LTE4; inflammation; eosinophilia	RECEPTOR ANTAGONIST; INDUCED BRONCHOCONSTRICTION; CYSTEINYL LEUKOTRIENES; SUSCEPTIBILITY LOCUS; BASEMENT-MEMBRANE; EXPRESSION; D-4; CELLS; INFILTRATION; INFLAMMATION	Background: We have shown that inhalation of leukotriene (LT) E-4 contributes to specific recruitment of eosinophils to the airway mucosa in patients with asthma at the time of maximal decrease in airway-specific conductance. Objective: We examined the ability of the cysteinyl LT1 receptor antagonist, zafirlukast, to improve or prevent LT-mediated eosinophilia and airway obstruction in asthma. Methods: Bronchial biopsies were taken and pulmonary function was measured before and 4 to 6 hours after the dose of inhaled LTE4 causing a greater than or equal to15% fall in FEV1 at baseline both at week 0 and after 6-week randomly assigned treatment with a high dose of zafirlukast, 80 mg twice daily. Results: Leukotriene E-4 inhalation at week 0 doubled the number of eosinophils in the airway mucosa in 21 of 25 patients with mild asthma, increased the numbers of neutrophils and lymphocytes, and decreased FEV1 (-17%). Zafirlukast reduced both airway eosinophilia and obstruction in FEV1, whereas with a double-blind placebo treatment, the effect of LTE4 on both parameters persisted for 6 weeks. On repeat LTE4 inhalation challenge after 6 weeks, zafirlukast treatment prevented further airway eosinophilia and decrease in FEV1 seen in the placebo group. Conclusion: Persistent LTE4-induced airway eosinophilia may form the basis of an amplification mechanism for further eosinophil recruitment. Zafirlukast prevents LTE4-induced eosinophilic airway inflammation in mild asthma.	Univ Helsinki, Inst Biomed, Dept Anat, Helsinki, Finland; Univ Helsinki, Cent Hosp, Clin Res Unit Pulm Med, Helsinki, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Laitinen, A (corresponding author), Hosp Dist Helsinki & Uusimaa, POB 100, FIN-00029 Helsinki, Finland.	lauri.lautinen@hus.fi						[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Busse WW, 1996, CLIN EXP ALLERGY, V26, P868, DOI 10.1111/j.1365-2222.1996.tb00621.x; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; Dahlen SE, 2000, AM J RESP CRIT CARE, V161, pS41, DOI 10.1164/ajrccm.161.supplement_1.ltta-9; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; Evans JF, 2003, PROSTAG LEUKOTR ESS, V69, P117, DOI 10.1016/S0952-3278(03)00072-3; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Holgate ST, 2000, AM J RESP CRIT CARE, V161, pS147, DOI 10.1164/ajrccm.161.supplement_1.ltta-29; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; JONES TR, 1982, CAN J PHYSIOL PHARM, V60, P638, DOI 10.1139/y82-087; Kato M, 1998, ANAT REC, V252, P418, DOI 10.1002/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; Nicosia S, 2001, PULM PHARMACOL THER, V14, P3, DOI 10.1006/pupt.2000.0262; OHICKEY SP, 1991, AM REV RESPIR DIS, V144, P1053, DOI 10.1164/ajrccm/144.5.1053; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; Zhang XZ, 2003, J ALLERGY CLIN IMMUN, V112, P93, DOI 10.1067/mai.2003.1587	35	26	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					259	265		10.1016/j.jaci.2004.10.021	http://dx.doi.org/10.1016/j.jaci.2004.10.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696079				2022-12-18	WOS:000227043600008
J	Beier, KC; Hutloff, A; Lohning, M; Kallinich, T; Kroczek, RA; Hamelmann, E				Beier, KC; Hutloff, A; Lohning, M; Kallinich, T; Kroczek, RA; Hamelmann, E			Inducible costimulator-positive T cells are required for allergen-induced local B-cell infiltration and antigen-specific IgE production in lung tissue	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; IgE; ICOS; T cell; B cell	IMMUNE-RESPONSES; AIRWAY DISEASE; ICOS; ASTHMA; DIFFERENTIATION; EXPRESSION; RECEPTOR; IDENTIFICATION; CHALLENGE; ANTIBODY	Background: Airway inflammation plays a critical role in the pathogenesis of asthma. In susceptible individuals, airway allergen exposure results in the recruitment of inflammatory cells into lung tissue, leading to a local inflammatory response. Central to the induction and regulation of this process are T lymphocytes. Objective: Blocking of the newly discovered costimulatory T-cell molecule inducible costimulator (ICOS) with monoclonal antibodies was shown to ameliorate allergic airway inflammation in models of murine asthma. Although these observations indirectly support an association between ICOS and the development of allergic inflammation, the role of the ICOS+ T cell in the pathogenesis of allergic airway disease remains unclear. Methods: We used an adoptive transfer model to analyze further the role of antigen-specific ICOS+ T cells during the effector phase of allergic airway inflammation. In vitro stimulated CD4(+) T cells from mice transgenic for an ovalbumin-specific T-cell receptor (DO11.10) were sorted into ICOS-enriched and ICOS-depleted T-cell fractions and transferred into BALB/c recipient mice. Results: Transfer of the ICOS-enriched T-cell population followed by allergen airway challenges induced pronounced infiltration of recipient T and B cells and local production of allergen-specific IgE by intrapulmonary plasma cells. In contrast, transfer of the ICOS-depleted T-cell fraction resulted in the recruitment of significantly lower numbers of B cells and no local IgE production. Conclusion: These data indicate that expression of ICOS defines a subset of T effector cells that are required for B-cell infiltration and local IgE production in lung tissues on allergen airway exposure.	Univ Med Berlin, Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Robert Koch Inst, D-1000 Berlin, Germany; Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Robert Koch Institute; University of Zurich; University Zurich Hospital	Hamelmann, E (corresponding author), Univ Med Berlin, Charite, Dept Pediat Pneumol & Immunol, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	eckard.hamelmann@charite.de	Löhning, Max/AAL-2967-2021; Hutloff, Andreas/D-1781-2014; Hamelmann, Eckard/AAJ-9124-2021	Löhning, Max/0000-0001-6382-7281; Hutloff, Andreas/0000-0002-0572-8151; 				Beier KC, 2000, EUR J IMMUNOL, V30, P3707, DOI 10.1002/1521-4141(200012)30:12<3707::AID-IMMU3707>3.0.CO;2-Q; Bonhagen K, 2003, EUR J IMMUNOL, V33, P392, DOI 10.1002/immu.200310013; BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; Burr JS, 2001, AM J RESP CELL MOL, V24, P563, DOI 10.1165/ajrcmb.24.5.4375; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Frauwirth KA, 2002, J CLIN INVEST, V109, P295, DOI 10.1172/JCI200214941; GASCAN H, 1992, EUR J IMMUNOL, V22, P1133, DOI 10.1002/eji.1830220505; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; Kobayashi N, 2002, CLIN EXP IMMUNOL, V129, P446, DOI 10.1046/j.1365-2249.2002.01932.x; LARSON KA, 1995, J IMMUNOL, V155, P3002; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632; London CA, 2000, J IMMUNOL, V164, P265, DOI 10.4049/jimmunol.164.1.265; Mages HW, 2000, EUR J IMMUNOL, V30, P1040, DOI 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; OHNISHI T, 1993, J ALLERGY CLIN IMMUN, V92, P607, DOI 10.1016/0091-6749(93)90085-T; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; PABST R, 1995, ANAT EMBRYOL, V192, P293, DOI 10.1007/BF00710098; Pape KA, 2003, J EXP MED, V197, P1677, DOI 10.1084/jem.20012065; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113, DOI 10.1165/ajrcmb.14.2.8630259; Schweitzer AN, 1998, J IMMUNOL, V161, P2762; Shinall SM, 2000, J IMMUNOL, V164, P5729, DOI 10.4049/jimmunol.164.11.5729; Sporici RA, 2001, CLIN IMMUNOL, V100, P263, DOI 10.1006/clim.2001.5093; Tesciuba AG, 2001, J IMMUNOL, V167, P1996, DOI 10.4049/jimmunol.167.4.1996; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson DR, 2002, AM J RESP CRIT CARE, V165, P22, DOI 10.1164/ajrccm.165.1.2010112; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	44	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					775	782		10.1016/j.jaci.2004.06.024	http://dx.doi.org/10.1016/j.jaci.2004.06.024			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480315				2022-12-18	WOS:000224439100009
J	Evans, DM; Zhu, G; Duffy, DL; Montgomery, GW; Frazer, IH; Martin, NG				Evans, DM; Zhu, G; Duffy, DL; Montgomery, GW; Frazer, IH; Martin, NG			Major quantitative trait locus for eosinophil count is located on chromosome 2q	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; asthma; genetics; linkage; QTL; twins	GENOME-WIDE SEARCH; LINKAGE ANALYSIS; SCHISTOSOMA-MANSONI; VARIANCE-COMPONENTS; ASTHMA; GENE; SUSCEPTIBILITY; EXTENSIONS; INTENSITY; INFECTION	Background: Eosinophils are granulocytic white blood cells implicated in asthma and atopic disease. The degree of eosinophilia in the blood of patients with asthma correlates with the severity of asthmatic symptoms. Quantitative trait loci (QTL) linkage analysis of eosinophil count may be a more powerful strategy of mapping genes involved in asthma than linkage analysis using affected relative pairs. 1 Objective: To identify QTLs responsible for variation in eosinophil count in adolescent twins. Methods: We measured eosinophil count longitudinally in 738 pairs of twins at 12, 14, and 16 years of age. We typed 757 highly polymorphic microsatellite markers at an average spacing of similar to5 centimorgans across the genome. We then used multipoint variance components linkage analysis to test for linkage between marker loci and eosinophil concentrations at each age across the genome. Results: We found highly significant linkage on chromosome 2q33 in 12-year-old twins (logarithm of the odds = 4.6; P = .000002) and suggestive evidence of linkage in the same region in 14-year-olds (logarithm of the odds = 1.0; P = .016). We also found suggestive evidence of linkage at other areas of the genome, including regions on chromosomes 2, 3, 4, 8, 9, 11, 12, 17, 20, and 22. Conclusion: A QTL for eosinophil count is present on chromosome 2q33. This QTL might represent a gene involved in asthma pathophysiology.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Queensland, Queensland Inst Med Res, Brisbane, Qld, Australia; Univ Queensland, Joint Genet Program, Brisbane, Qld, Australia; Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Brisbane, Qld, Australia	University of Oxford; Wellcome Centre for Human Genetics; QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; University of Queensland	Evans, DM (corresponding author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	davide@well.ox.ac.uk	Evans, David M/H-6325-2013; Duffy, David L/B-7392-2013; Montgomery, Grant W/B-7148-2008; Frazer, Ian/A-1137-2007	Evans, David M/0000-0003-0663-4621; Duffy, David L/0000-0001-7227-632X; Montgomery, Grant W/0000-0002-4140-8139; Frazer, Ian/0000-0002-8002-4680; Martin, Nicholas/0000-0003-4069-8020	NATIONAL CANCER INSTITUTE [R01CA088363] Funding Source: NIH RePORTER; NCI NIH HHS [CA88363] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Aitken JF, 1996, CANCER, V78, P252, DOI 10.1002/(SICI)1097-0142(19960715)78:2<252::AID-CNCR10>3.0.CO;2-V; Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; AMOS CI, 1994, AM J HUM GENET, V54, P535; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; Eaves LJ, 1996, BEHAV GENET, V26, P519, DOI 10.1007/BF02359757; Evans D M, 1999, Twin Res, V2, P250, DOI 10.1375/136905299320565735; EVANS DM, 2003, THESIS U QUEENSLAND; Fulker DW, 1996, BEHAV GENET, V26, P527, DOI 10.1007/BF02359758; HOPPER JL, 1982, ANN HUM GENET, V46, P373, DOI 10.1111/j.1469-1809.1982.tb01588.x; JACQUARD A, 1972, BIOMETRICS, V28, P1101, DOI 10.2307/2528643; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P423, DOI 10.1164/ajrccm/143.2.423; LANGE K, 1976, ANN HUM GENET, V39, P485, DOI 10.1111/j.1469-1809.1976.tb00156.x; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; Martin N, 1997, NAT GENET, V17, P387, DOI 10.1038/ng1297-387; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; McGregor B, 1999, GENET EPIDEMIOL, V16, P40, DOI 10.1002/(SICI)1098-2272(1999)16:1<40::AID-GEPI4>3.3.CO;2-T; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Palmer LJ, 2001, GENET EPIDEMIOL, V20, P356, DOI 10.1002/gepi.6; Palmer LJ, 1998, AM J RESP CRIT CARE, V158, P1825, DOI 10.1164/ajrccm.158.6.9804037; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; RISCH N, 1990, AM J HUM GENET, V46, P229; SELF SG, 1987, J AM STAT ASSOC, V82, P605, DOI 10.2307/2289471; Williams JT, 1999, ANN HUM GENET, V63, P545, DOI 10.1017/S0003480099007848; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Zhu G, 2004, TWIN RES, V7, P197, DOI 10.1375/136905204323016186; Zhu G, 1999, AM J HUM GENET, V65, P483, DOI 10.1086/302494	34	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					826	830		10.1016/j.jaci.2004.05.060	http://dx.doi.org/10.1016/j.jaci.2004.05.060			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480322				2022-12-18	WOS:000224439100016
J	Pappalardo, E; Zingale, LC; Cicardi, M				Pappalardo, E; Zingale, LC; Cicardi, M			C1 inhibitor gene expression in patients with hereditary angioedema: Quantitative evaluation by means of real-time RT-PCR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; C1 inhibitor; mRNA; gene expression; real-time PCR	C1-INHIBITOR MESSENGER-RNA; ANGIONEUROTIC-EDEMA; QUALITY-CONTROL; FC-GAMMA; MUTATIONS; FIBROBLASTS; PENETRANCE; COMPLEXES; DANAZOL; DENSITY	Background: Hereditary angioedema (HAE) is caused by heterozygous defects in the C1 inhibitor (C1-INH) gene (SERPING1/C1NH). In patients' plasma C1-INH levels range between 5% and 30% of normal levels (ie, far from the 50% expected for an autosomal dominant defect). Most patients have antigenic and functional deficiency (type I HAE), and 15% have reduced C1-INH function but normal to increased antigen because of the presence of a dysfunctional protein (type II HAE). Objective: We sought to contribute to the understanding of the pattern of C1-INH gene expression in patients with HAE. Methods: We used real-time quantitative RT-PCR to measure C1-INH mRNA levels in PBMCs of 57 patients with HAE typed for mutations in the SERPING1/C1NH gene. Results: Thirty-six different mutations were identified in genomic DNA. Compared with healthy control subjects, C1-INH mRNA was significantly and similarly reduced in patients with type I and type II HAE (40% and 47%, respectively; P < .0001). By means of direct sequencing of cDNAs, we found that 74% of patients with type I HAE carrying small mutations presented significant amounts of mutated transcripts at the mRNA level, suggesting that both allelic mRNA products were reduced to approximately 50%. In 4 patients carrying large deletions expected to fully inactivate expression from the mutant allele, C1-INH mRNA was 23% on average compared with that seen in control subjects, confirming that normal mRNA was strongly underexpressed. Conclusions: These new findings, combined with previous evidence of increased C1-INH consumption, might explain the plasma levels of normal C1-INH that are markedly less than the expected 50%.	Univ Milan, Osped S Giuseppe, Dipartimento Med Interna, I-20123 Milan, Italy	University of Milan	Cicardi, M (corresponding author), Univ Milan, Osped S Giuseppe, Dipartimento Med Interna, Via S Vittore 12, I-20123 Milan, Italy.	Marco.Cicardi@unimi.it	cicardi, marco/K-9219-2016; Zingale, Lorenza Chiara/AAB-8598-2020	cicardi, marco/0000-0003-1251-225X; Zingale, Lorenza Chiara/0000-0001-8577-7449	Telethon [GGP030403] Funding Source: Medline	Telethon(Fondazione Telethon)		AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; Bowen B, 2001, CLIN IMMUNOL, V98, P157, DOI 10.1006/clim.2000.4947; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; CICARDI M, 1987, J CLIN INVEST, V79, P698, DOI 10.1172/JCI112873; CUGNO M, 1990, J CLIN INVEST, V85, P1215, DOI 10.1172/JCI114555; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; FRANGI D, 1991, J CLIN INVEST, V88, P755, DOI 10.1172/JCI115373; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gouya L, 2002, NAT GENET, V30, P27, DOI 10.1038/ng809; GRAGEGRIEBENOW E, 1993, EUR J IMMUNOL, V23, P3126, DOI 10.1002/eji.1830231213; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; JOHNSON AM, 1971, SCIENCE, V173, P553, DOI 10.1126/science.173.3996.553; KATZ Y, 1989, J IMMUNOL, V142, P2041; KRAMER J, 1991, J CLIN INVEST, V87, P1614, DOI 10.1172/JCI115175; KRAMER J, 1993, J CLIN INVEST, V91, P1258, DOI 10.1172/JCI116290; LACHMANN PJ, 1984, ACTA PATH MICRO IM C, V92, P35; Loseke S, 2003, J IMMUNOL METHODS, V276, P207, DOI 10.1016/S0022-1759(03)00072-3; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Mocellin S, 2003, J IMMUNOL METHODS, V280, P1, DOI 10.1016/S0022-1759(03)00274-6; Ohnmacht GA, 2001, J IMMUNOL, V167, P1809, DOI 10.4049/jimmunol.167.3.1809; Pappalardo E, 2003, IMMUNOL LETT, V86, P271, DOI 10.1016/S0165-2478(03)00029-4; Pappalardo E, 2000, J ALLERGY CLIN IMMUN, V106, P1147, DOI 10.1067/mai.2000.110471; Pickford AS, 2003, CELL MOL LIFE SCI, V60, P871, DOI 10.1007/s00018-003-2245-2; QUASTEL M, 1983, J CLIN INVEST, V71, P1041, DOI 10.1172/JCI110831; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; SCHMAIER AH, 1993, BLOOD, V82, P465; Stordeur P, 2003, J IMMUNOL METHODS, V276, P69, DOI 10.1016/S0022-1759(03)00074-7; Storm D, 1997, J BIOL CHEM, V272, P31043, DOI 10.1074/jbc.272.49.31043; SUTTER U, 1990, COMPLEMENT INFLAMM, V7, P157; Torsteinsdottir I, 1999, CLIN EXP IMMUNOL, V115, P554; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VERPY E, 1995, J CLIN INVEST, V95, P350, DOI 10.1172/JCI117663; Vithana EN, 2003, INVEST OPHTH VIS SCI, V44, P4204, DOI 10.1167/iovs.03-0253; Zuraw BL, 2000, J ALLERGY CLIN IMMUN, V105, P541, DOI 10.1067/mai.2000.104780	38	26	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					638	644		10.1016/j.jaci.2004.06.021	http://dx.doi.org/10.1016/j.jaci.2004.06.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356570				2022-12-18	WOS:000223799600026
J	Swierczynska, M; Nizankowska-Mogilnicka, E; Zarychta, J; Gielicz, A; Szczeklik, A				Swierczynska, M; Nizankowska-Mogilnicka, E; Zarychta, J; Gielicz, A; Szczeklik, A			Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin-induced asthma/rhinitis; aspirin challenge; leukotriene E-4; prostaglandin D-2; 9 alpha; 11 beta-prostaglandin F-2	PROSTAGLANDIN D-2 METABOLITE; URINARY LEUKOTRIENE E-4; MAST-CELL ACTIVATION; SENSITIVE RHINOSINUSITIS; NATURAL-HISTORY; INDUCED ASTHMA; DIAGNOSIS; PROVOCATION; PLASMA	Background: Aspirin-induced asthma/rhinitis (AIAR) is characterized by the altered metabolism of leukotrienes and proinflammatory prostaglandins. The basal and postchallenge levels of eicosanoids might reflect the clinical and biochemical characteristics of patients with distinct types of hypersensitive responses to aspirin. Objective: We compared clinical and eicosanoid profiles of patients with AIAR showing both bronchial and nasal versus isolated nasal responses to aspirin challenge. Methods: Twenty-three patients with AIAR underwent the single-blind, oral, placebo-controlled aspirin challenge. The bronchial response (BR) was evidenced by dyspnea and spirometry, whereas the nasal response (NR) was evidenced by nasal symptoms and acoustic rhinometry and/or rhinomanometry. Urinary leukotriene E-4 (uLTE(4)), serum and urinary stable prostaglandin D-2 metabolite, and 9alpha,11beta-prostaglandin F-2 (9alpha,11beta-PGF(2)), were determined at baseline and after the aspirin challenge. Results: Fifteen subjects showed BR and NR (BNR), whereas 8 showed NR only. Basal uLTE(4) in the BNR group was significantly higher than in the NR group. After aspirin challenge, it increased significantly in both groups. Serum 9alpha,11beta-PGF(2) increased after aspirin challenge in the BNR group only. The patients with BNR had more severe AIAR. Conclusions: BNR to aspirin in AIAR indicates a more advanced disease and more profound underlying eicosanoid metabolism disturbances.	Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Krakow, Poland	Jagiellonian University	Szczeklik, A (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, Ul Skawinska 8, PL-31066 Krakow, Poland.							Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Casadevall J, 2000, THORAX, V55, P921, DOI 10.1136/thorax.55.11.921; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; KANNY G, 2002, ACI INT, V14, P201; Kumlin M, 2000, AM J RESP CRIT CARE, V161, pS102, DOI 10.1164/ajrccm.161.supplement_1.ltta-20; Kurokawa K, 2001, CHEST, V120, P1822, DOI 10.1378/chest.120.6.1822; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; Mita H, 2001, ALLERGY, V56, P1061; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; NIZANKOWSKA E, 2003, TRAITE ALLERGOLOGIE, P791; OBATA T, 1994, J CHROMATOGR B, V655, P173, DOI 10.1016/0378-4347(94)00100-6; Oosaki R, 1997, ALLERGY, V52, P470, DOI 10.1111/j.1398-9995.1997.tb01032.x; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; SETTIPANE GA, 1988, BIOMED PHARMACOTHER, V42, P493; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Szczeklik A, 2001, CURR OPIN ALLERGY CL, V1, P27, DOI 10.1097/01.all.0000010981.95396.58	21	26	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					995	1001		10.1016/S0091-6749(03)02015-3	http://dx.doi.org/10.1016/S0091-6749(03)02015-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610494	Bronze, Green Published			2022-12-18	WOS:000186553300025
J	Timonen, M; Jokelainen, J; Herva, A; Zitting, P; Meyer-Rochow, VB; Rasanen, P				Timonen, M; Jokelainen, J; Herva, A; Zitting, P; Meyer-Rochow, VB; Rasanen, P			Presence of atopy in first-degree relatives as a predictor of a female proband's depression: Results from the Northern Finland 1966 Birth Cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; allergy; depression; cohort study; inheritance	GLUCOCORTICOID RECEPTOR-BINDING; 28-YEAR FOLLOW-UP; MAJOR DEPRESSION; MATERNAL SMOKING; MITOCHONDRIAL-DNA; BIPOLAR DISORDER; SEX-DIFFERENCES; MOOD DISORDERS; FAMILY HISTORY; SEVERE ASTHMA	Background: Recent investigations suggest a common genetic rather than environmental cause to explain the association between IgE-mediated atopic allergies and depression. Objective: Taking into account psychosocial confounding factors, we investigated separately and at the epidemiologic level the effects of maternal, paternal, and sibling atopy on the cumulative incidence of a child's depression. Methods: We used an unselected, genetically homogenous, general population birth cohort of 12,058 live-born children in Finland. The 31-year prospective follow-up included questionnaire information on atopic disorders of the cohort members' parents and siblings. The probands' own atopic conditions were evaluated by means of skin prick tests, and information on lifetime depression diagnoses was gleaned from postal questionnaires and national hospital discharge registers. Potential confounders were mother's parity, father's social class, maternal smoking during pregnancy, proband's regular daily smoking, and proband's dwelling place. Total variable information was available from 4068 cohort members. Results: Among female probands, the presence of atopy in parents was the strongest predictor for lifetime depression (P < .001), and sibling atopy and parental atopy were the strongest predictors for hospital-treated depression (P = .018 and P = .036, respectively). After controlling for confounders, it was noticed that maternal atopy increased a female proband's risk of lifetime depression up to 1.9-fold (odds ratio, 1.9; 95% CI, 1.1-3.0). The corresponding risk increased over 4-fold if parental-maternal atopy was combined with proband's own atopy. Conclusions: Our findings suggest that maternal inheritance could be a significant causative factor in the association between atopy and depression of female probands.	Oulu Univ, Dept Psychiat, FIN-90014 Oulu, Finland; Oulu Hlth Ctr, Oulu, Finland; Oulu Univ, Dept Publ Hlth Sci & Gen Practice, Oulu, Finland; Oulu Univ Hosp, Unit Gen Practice, Oulu, Finland; Oulu Univ Hosp, Dept Psychiat, Oulu, Finland; IUB, Sch Sci & Engn, Bremen, Germany; Oulu Univ, Dept Physiol, Oulu, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu	Timonen, M (corresponding author), Oulu Univ, Dept Psychiat, Box 5000, FIN-90014 Oulu, Finland.		MEYER-ROCHOW, Victor Benno/AAJ-7258-2020	MEYER-ROCHOW, V. Benno/0000-0003-1531-9244; Jokelainen, Jari/0000-0003-4629-0560				Abbas A., 2017, CELLULAR MOL IMMUNOL, P281; Arborelius L, 1999, J ENDOCRINOL, V160, P1, DOI 10.1677/joe.0.1600001; Backer V, 2002, ANN ALLERG ASTHMA IM, V89, P148, DOI 10.1016/S1081-1206(10)61930-8; BELL IR, 1991, PSYCHOTHER PSYCHOSOM, V55, P24, DOI 10.1159/000288404; Bierut LJ, 1999, ARCH GEN PSYCHIAT, V56, P557, DOI 10.1001/archpsyc.56.6.557; Brown ES, 2000, INT J PSYCHIAT MED, V30, P319, DOI 10.2190/7U7P-EJYL-5BKG-6106; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; CLAYTON MH, 1995, J ALLERGY CLIN IMMUN, V96, P421, DOI 10.1016/S0091-6749(95)70062-5; Cuffel B, 1999, PSYCHOSOMATICS, V40, P491, DOI 10.1016/S0033-3182(99)71187-4; Davies W, 2001, ANN MED, V33, P428, DOI 10.3109/07853890108995956; DAVIS JB, 1977, PSYCHOL MED, V7, P305, DOI 10.1017/S0033291700029408; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Dierker LC, 2002, AM J PSYCHIAT, V159, P947, DOI 10.1176/appi.ajp.159.6.947; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Elenkov IJ, 1999, ANN NY ACAD SCI, V876, P1, DOI 10.1111/j.1749-6632.1999.tb07618.x; Fergusson DM, 1998, ARCH GEN PSYCHIAT, V55, P721, DOI 10.1001/archpsyc.55.8.721; Hashiro M, 1998, J DERMATOL SCI, V16, P231, DOI 10.1016/S0923-1811(97)00074-1; Hashiro M, 1997, J DERMATOL SCI, V14, P63, DOI 10.1016/S0923-1811(96)00553-1; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; Holsboer F, 2001, J AFFECT DISORDERS, V62, P77, DOI 10.1016/S0165-0327(00)00352-9; Horrobin DF, 1999, PROSTAG LEUKOTR ESS, V60, P217, DOI 10.1054/plef.1999.0037; Irwin M, 1999, ADV EXP MED BIOL, V461, P1; Isohanni I, 2001, SCAND J PUBLIC HEALT, V29, P87, DOI 10.1177/14034948010290020501; Isohanni M, 1997, SOC PSYCH PSYCH EPID, V32, P303, DOI 10.1007/BF00789044; Ito C, 2000, BIOMED PHARMACOTHER, V54, P263, DOI 10.1016/S0753-3322(00)80069-4; Ito C, 1999, NEUROSCI LETT, V262, P143, DOI 10.1016/S0304-3940(99)00052-X; Jarvelin MR, 1997, BRIT J AUDIOL, V31, P165, DOI 10.3109/03005364000000019; Jiang HK, 2000, PSYCHIAT CLIN NEUROS, V54, P227, DOI 10.1046/j.1440-1819.2000.00663.x; Karvonen SL, 1999, BRIT J DERMATOL, V140, P634; Kato T, 2001, NEUROSCI RES, V40, P105, DOI 10.1016/S0168-0102(01)00221-8; Kemppainen L, 2000, SOC PSYCH PSYCH EPID, V35, P104, DOI 10.1007/s001270050191; Kendler KS, 2001, PSYCHOL MED, V31, P605, DOI 10.1017/S0033291701003907; Kendler KS, 2001, PSYCHOL MED, V31, P617, DOI 10.1017/S0033291701003798; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; LEHTINEN V, 1994, ACTA PSYCHIAT SCAND, V89, P7, DOI 10.1111/j.1600-0447.1994.tb05794.x; LENZI A, 1993, SOC PSYCH PSYCH EPID, V28, P56, DOI 10.1007/BF00802092; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Mahonen M, 2000, EUR J EPIDEMIOL, V16, P701, DOI 10.1023/A:1026599805969; MCMAHON FJ, 1995, AM J HUM GENET, V157, P1058; Moles D R, 1997, Prim Dent Care, V4, P61; NASR S, 1981, J AFFECT DISORDERS, V3, P291, DOI 10.1016/0165-0327(81)90030-6; NAYHA S, 1992, INT J EPIDEMIOL, V21, P30, DOI 10.1093/ije/21.1.30; Nejtek VA, 2001, ANN ALLERG ASTHMA IM, V87, P129, DOI 10.1016/S1081-1206(10)62206-5; Nimmagadda SR, 1997, AM J RESP CRIT CARE, V155, P87, DOI 10.1164/ajrccm.155.1.9001294; OSSOFSKY HJ, 1976, COMPR PSYCHIAT, V17, P335, DOI 10.1016/0010-440X(76)90008-0; Pariante CM, 2001, BIOL PSYCHIAT, V49, P391, DOI 10.1016/S0006-3223(00)01088-X; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; POIKOLAINEN K, 1983, DRUG ALCOHOL DEPEN, V12, P315, DOI 10.1016/0376-8716(83)90002-9; RANTAKALLIO P, 1995, SOC PSYCH PSYCH EPID, V30, P113, DOI 10.1007/BF00802039; RANTAKALLIO P, 1992, INT J EPIDEMIOL, V21, P1106, DOI 10.1093/ije/21.6.1106; Rantakallio P, 1988, Paediatr Perinat Epidemiol, V2, P59, DOI 10.1111/j.1365-3016.1988.tb00180.x; RANTAKALLIO P, 1969, ACTA PAEDIAT SC S193, V0193; Rantakallio P, 1997, INT J EPIDEMIOL, V26, P837, DOI 10.1093/ije/26.4.837; Rasanen P, 1999, AM J PSYCHIAT, V156, P857; REMES S, 1998, KUOPIO U PUBLICATION, V141; *SPSS LTD, 1998, ANSW TREE 2 0 US GUI; *SPSS UK LTD, 1994, INTR SASS CHAID WIND; Strauch K, 2001, GENET EPIDEMIOL, V21, pS204, DOI 10.1002/gepi.2001.21.s1.s204; SUGERMAN AA, 1982, ANN ALLERGY, V48, P166; TEIRAMAA E, 1979, J PSYCHOSOM RES, V23, P209, DOI 10.1016/0022-3999(79)90006-0; Timonen M, 2002, BIOL PSYCHIAT, V52, P349, DOI 10.1016/S0006-3223(01)01364-6; Timonen M, 2001, AM J MED GENET, V105, P216, DOI 10.1002/ajmg.1199; VAISANEN E, 1975, ACTA PSYCHIAT SCAND, P22; Wamboldt MZ, 1998, J CHILD PSYCHOL PSYC, V39, P1007, DOI 10.1111/1469-7610.00403; Wamboldt MZ, 1996, J AM ACAD CHILD PSY, V35, P1042, DOI 10.1097/00004583-199608000-00015; Wamboldt MZ, 2000, AM J MED GENET, V96, P146, DOI 10.1002/(SICI)1096-8628(20000403)96:2<146::AID-AJMG4>3.0.CO;2-J; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132; Xu BZ, 2000, J ALLERGY CLIN IMMUN, V105, P393, DOI 10.1016/S0091-6749(00)90095-2	69	26	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1249	1254		10.1067/mai.2003.1546	http://dx.doi.org/10.1067/mai.2003.1546			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	688FZ	12789225	Bronze			2022-12-18	WOS:000183424700013
J	Quirce, S; Swanson, MC; Fernandez-Nieto, M; de las Heras, M; Cuesta, J; Sastre, J				Quirce, S; Swanson, MC; Fernandez-Nieto, M; de las Heras, M; Cuesta, J; Sastre, J			Quantified environmental challenge with absorbable dusting powder aerosol from natural rubber latex gloves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aeroallergen; immunochemical assay; natural rubber latex; occupational asthma; specific inhalation challenge	OCCUPATIONAL ASTHMA; AEROALLERGEN; ALLERGENS; WORKERS; SURVEILLANCE; AGENTS	Background: There are few data that link quantified natural rubber latex (NRL) absorbable dusting powder aerosol to biologic responses in NRIL-sensitized subjects. Methods: We conducted a study on 30 health care workers with possible occupational asthma. All the subjects but 2 had a positive skin prick test result with NRL extract. Quantified environmental challenge (QEC) with powdered NRL gloves was performed in a 7-m(3) chamber. The patients would don and discard a pair of gloves every 3 minutes up to a maximum of 60 minutes. The concentrations of NRL aeroallergen were measured by a competitive IgE immunoassay. Ocular and respiratory symptoms and pulmonary function were monitored. Results: Twenty-six patients (87%) had rhinoconjunctivitis, 19 (63%) had an asthmatic response (responders), and 1 patient developed eosinophilic bronchitis on QEC. The asthmatic responses were of the early type in 15 patients, dual in 3, and isolated late in 1 patient. The duration of exposures sufficient to elicit asthmatic responses varied from 3 to 114 cumulative minutes. Time-weighted average NRL aeroallergen concentrations during QEC with responders ranged between 199 and 1107 ng/m(3). NRL concentrations measured at various time points during exposure were reproducible. Measured concentrations of NRL aeroallergen between responders (677 +/- 281 ng.m(3)) and nonresponders (611 +/- 351 ng/m(3)) were not statistically different. The cumulative inhaled NRL aeroallergen dose required for an asthmatic response ranged between 25 to 515 ng. Conclusion: The total dose of latex aeroallergen eliciting an asthmatic response during QEC was mostly affected by the duration of exposure and varied widely from person to person.	Fdn Jimenez Diaz, Dept Allergy, Sevicio Alergia, E-28040 Madrid, Spain; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Quirce, S (corresponding author), Fdn Jimenez Diaz, Dept Allergy, Sevicio Alergia, Av Reyes Catolicos 2, E-28040 Madrid, Spain.		s, q/AAD-7171-2020					AHMED T, 1981, J ALLERGY CLIN IMMUN, V67, P135, DOI 10.1016/0091-6749(81)90009-9; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; Baur X, 1998, AM J IND MED, V33, P114; Bernstein David I., 1993, P103; Charous BL, 2000, ANN ALLERG ASTHMA IM, V85, P285, DOI 10.1016/S1081-1206(10)62531-8; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; Hnizdo E, 2001, CLIN EXP ALLERGY, V31, P32, DOI 10.1046/j.1365-2222.2001.00981.x; Ho A, 1996, THORAX, V51, P1280, DOI 10.1136/thx.51.12.1280; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; Kujala V, 2002, CLIN EXP ALLERGY, V32, P1077, DOI 10.1046/j.1365-2222.2002.01413.x; Kurtz KM, 2001, J ALLERGY CLIN IMMUN, V107, P178, DOI 10.1067/mai.2001.112125; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P967, DOI 10.1016/0091-6749(93)90207-V; MARCOS C, 1991, ANN ALLERGY, V67, P319; ORFAN NA, 1994, J ALLERGY CLIN IMMUN, V94, P826, DOI 10.1016/0091-6749(94)90149-X; PISATI G, 1994, EUR RESPIR J, V7, P332, DOI 10.1183/09031936.94.07020332; Pisati G, 1998, J ALLERGY CLIN IMMUN, V101, P327, DOI 10.1016/S0091-6749(98)70243-X; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; Poulos LM, 2002, J ALLERGY CLIN IMMUN, V109, P701, DOI 10.1067/mai.2002.122463; Quirce S, 1999, ALLERGY, V54, P1121, DOI 10.1034/j.1398-9995.1999.00388.x; Quirce S, 2000, CLIN EXP ALLERGY, V30, P839; Quirce S, 2001, J ALLERGY CLIN IMMUN, V108, P143, DOI 10.1067/mai.2001.116120; Ross DJ, 1998, OCCUP MED-OXFORD, V48, P481, DOI 10.1093/occmed/48.8.481; Swanson M, 2001, ANN ALLERG ASTHMA IM, V87, P307, DOI 10.1016/S1081-1206(10)62245-4; SWANSON MC, 1990, AM REV RESPIR DIS, V141, P1578, DOI 10.1164/ajrccm/141.6.1578; Swanson MC, 2002, J ALLERGY CLIN IMMUN, V110, pS15, DOI 10.1067/mai.2002.125338; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; SWANSON MC, 1999, P 8 INT C IND AIR QU, P290; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Vandenplas O, 1997, EUR RESPIR J, V10, P2612, DOI 10.1183/09031936.97.10112612; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; Weytjens K, 1999, ALLERGY, V54, P290, DOI 10.1034/j.1398-9995.1999.00000.x	40	26	28	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					788	794		10.1067/mai.2003.166	http://dx.doi.org/10.1067/mai.2003.166			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704359				2022-12-18	WOS:000182258500019
J	Tabar-Purroy, AI; Alvarez-Puebla, MJ; Acero-Sainz, S; Garcia-Figueroa, BE; Echechipia-Madoz, S; Olaguibel-Rivera, JM; Quirce-Gancedo, S				Tabar-Purroy, AI; Alvarez-Puebla, MJ; Acero-Sainz, S; Garcia-Figueroa, BE; Echechipia-Madoz, S; Olaguibel-Rivera, JM; Quirce-Gancedo, S			Carmine (E-120)-induced occupational asthma revisited	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; specific inhalation challenge; prevalence; cumulative incidence; natural gas; carmine; cochineal; healthy worker effect	BRONCHIAL RESPONSIVENESS; IDENTIFICATION; SENSITIZATION; ANAPHYLAXIS; ALLERGENS; EMPLOYEES	Background: Occupational asthma (OA) caused by carmine (E-120) has been reported. Objective: We sought to evaluate the prevalence of sensitization and OA at a natural dye processing factory in which 2 workers had been given a diagnosis of carmine-induced OA 6 years previously. Methods: The 24 current employees and one worker who had recently left work because of asthma completed a questionnaire and underwent skin testing (carmine, cochineal, carminic acid, curcuma, annato, and chlorophyll), car me g dot-blot analysis, and methacholine inhalation testing. Workers exhibiting positive occupational skin test responses, work-related asthma, or bronchial hyperresponsiveness underwent specific inhalation challenge and serial peak expiratory flow rate recording. Results: Positive skin test responses to carmine (41.7%), cochineal (29.2%), and carminic acid (4.2%) were observed. Carmine IgE dot-blot results were positive in 4 subjects. No difference in atopy or smoking was observed between occupationally sensitized and nonsensitized subjects. Among the 5 employees reporting work-related asthma, 2 had positive skin test responses, and 4 had bronchial hyperresponsiveness. Five subjects underwent specific inhalation challenges: 2 workers had early asthma responses to carmine and cochineal challenges, and the remaining subjects did not have suggestive peak expiratory flow recordings. The subject who had left his job was given a diagnosis of carmine-induced OA. Conclusion: The prevalence of sensitization and OA caused by carmine was 41.6% and 8.3%, respectively. When the 3 workers who had left their jobs were included, the cumulative incidence of sensitization and OA was 48.1% and 18.5%, resembling the healthy worker effect. Prevention programs to establish the permissible levels of airborne allergen should be implemented.	Hosp Virgen Camino, Serv Alergol, Pamplona, Spain; Fdn Jimenez Diaz, Serv Alergol, E-28040 Madrid, Spain	Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea	Tabar-Purroy, AI (corresponding author), Serv Alergol, CS Conde Oliveto,Plaza Paz SN, Pamplona 31002, Spain.		RIVERA, JOSE MARIA OLAGUIBEL/AAK-3845-2020	RIVERA, JOSE MARIA OLAGUIBEL/0000-0002-9126-4559				Acero S, 1998, ALLERGY, V53, P897, DOI 10.1111/j.1398-9995.1998.tb03998.x; Alvarez MJ, 2000, ALLERGY, V55, P355, DOI 10.1034/j.1398-9995.2000.00312.x; [Anonymous], 1989, ALLERGY S10, V10, P1; Baldwin JL, 1997, ANN ALLERG ASTHMA IM, V79, P415, DOI 10.1016/S1081-1206(10)63035-9; BARDY JD, 1987, AM REV RESPIR DIS, V135, P1033; BEAUDOUIN E, 1995, ANN ALLERG ASTHMA IM, V74, P427; Bernstein IL, 1999, ASTHMA WORKPLACE; BURGE PS, 1979, CLIN ALLERGY, V9, P185, DOI 10.1111/j.1365-2222.1979.tb01540.x; CHATHAM M, 1982, CHEST, V82, P15, DOI 10.1378/chest.82.1.15; Chung K, 2001, ALLERGY, V56, P73, DOI 10.1034/j.1398-9995.2001.00693.x; Gannon PFG, 1997, EUR RESPIR J, V10, pS57; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CY, 1999, OCCUP MED-OXFORD, V49, P225, DOI 10.1093/occmed/49.4.225; Lizaso MT, 2000, ANN ALLERG ASTHMA IM, V84, P549, DOI 10.1016/S1081-1206(10)62521-5; MALO JL, 1990, J ALLERGY CLIN IMMUN, V86, P562, DOI 10.1016/S0091-6749(05)80213-1; PERRIN B, 1992, EUR RESPIR J, V5, P40; QUIRCE S, 1994, J ALLERGY CLIN IMMUN, V93, P44, DOI 10.1016/0091-6749(94)90231-3; RODRIGUEZ A, 1990, Clinical and Experimental Allergy, V20, P43; SPECTOR SL, 1995, PROVOCATION TESTING; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TENABENE A, 1987, Archives des Maladies Professionnelles de Medecine du Travail et de Securite Sociale, V48, P569; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; Wuthrich B, 1997, ALLERGY, V52, P1133, DOI 10.1111/j.1398-9995.1997.tb00189.x	24	26	28	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					415	419		10.1067/mai.2003.51	http://dx.doi.org/10.1067/mai.2003.51			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589365				2022-12-18	WOS:000180942700029
J	Cohen, SG; Zelaya-Quesada, M				Cohen, SG; Zelaya-Quesada, M			Portier, Richet, and the discovery of anaphylaxis: A centennial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID, Bethesda, MD 20892 USA; NIH, Natl Lib Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Cohen, SG (corresponding author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.							AKUTAGAWA K, 1952, RASHOMON OTHER STORI; ALBERT, 2002, ENCY BRITTANICA, P243; Arthus M, 1903, CR SOC BIOL, V55, P817; BEHRING EA, 1893, GESAMMELTE ABHANDLUN; Behring EKS., 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI [10.1055/s-0029-1207589, DOI 10.1055/S-0029-1207589]; BOUQUET H, 1935, MONDE MED, V24, P111; BRAIN WS, 1993, RICHET ORIGINS PHYSL; CALLERYRADOT R, 1924, VILLE PASTEUR, P88; Conradt C.., 2014, PRIX NOBEL 1913, P1; FLEXNER S, 1894, MED NEWS, V65, P116; GOTTSTEIN A, 1896, THER MH, V10, P269; Halstead B. W., 1988, POISONOUS VENOMOUS M, P99; HERICOURT J, 1898, C R SOC BIOL, V50, P137; HOLMES FL, 1975, DICT SCI BIOGRAPHY, P425; JONSSON B, 1640, WORKS, V2; MAGENDIE F, 1839, LECTURES BLOOD, P244; MASEFIELD J, 2002, SALT WATER BALLADS; MAY CD, 1985, J ALLERGY CLIN IMMUN, V75, P485, DOI 10.1016/S0091-6749(85)80022-1; MONNIER AM, 1975, DICT SCI BIOGRAPHY, P101; PORTIER J, 1985, J ALLERGY CLIN IMMUN, V75, P485; PORTIER P, 1952, PRESSE MED, V60, P679; Portier P, 1902, CR HEBD ACAD SCI, V134, P247; PORTIER P, 1936, NAISSANCE TITRES TRA; PORTIER P, 1962, SEMAINE HOPITAU 0214, P7; PORTIER P, 1985, J ALLERGY CLIN IMMUN, V75, P485; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; RICHARD J, 1910, B I OCEANOGR, V7, P162; RICHET C, 1952, PRESSE MED, V60, P685; RICHET C, 1956, PATHOLOGIE DEPORTATI; RICHET C, 1913, ANAPHYLAXIS; Richet G, 1998, CR ACAD SCI III-VIE, V321, P261, DOI 10.1016/S0764-4469(98)80049-8; RICHET G, 1999, COMMUNICATION   1221; WOLF S, 1993, C RICHET ORIGINS PHY	33	26	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					331	336	UNSP 1/54/126565					6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170279				2022-12-18	WOS:000177509800025
J	Creticos, PS; Eiden, JJ; Broide, D; Balcer-Whaley, SL; Schroeder, JT; Khattignavong, A; Li, HM; Norman, PS; Hamilton, RG				Creticos, PS; Eiden, JJ; Broide, D; Balcer-Whaley, SL; Schroeder, JT; Khattignavong, A; Li, HM; Norman, PS; Hamilton, RG			Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a 1 allergen: Effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Johns Hopkins Univ, Dynavax Technol Corp, Baltimore, MD 21218 USA; Univ Calif San Diego, La Jolla, CA 92093 USA	Johns Hopkins University; University of California System; University of California San Diego									0	26	29	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4				3	743	744						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ					2022-12-18	WOS:000175132600035
J	Tovey, ER; Taylor, DJ; Mitakakis, TZ; De Lucca, SD				Tovey, ER; Taylor, DJ; Mitakakis, TZ; De Lucca, SD			Effectiveness of laundry washing agents and conditions in the removal of cat and dust mite allergen from bedding dust	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; dust mite; Der p 1; cat; Fel d 1; bedding; halogen	FEL-D-I; TEMPERATURE; EXPOSURE	Background: There is limited information about the removal of allergens by laundry washing. Objective: The purpose of this investigation was to determine the dynamics of the removal of mite allergen (Der p 1) and cat allergen (Fel d 1) from bed dust during simulated laundry processes. Methods: Three studies were performed. The first compared combinations of 4 laundry agents (water alone, soap, detergent with enzymes, and detergent without enzymes), 4 temperatures (15 degrees, 25 degrees, 45 degrees, and 60 degreesC), and 3 extraction times (5, 20, and 60 minutes). The second study examined allergen extraction by 11 common brands of detergents at 25 degrees and 45 degreesC for 5 minutes. The third study compared 4 detergents containing enzymes before and after the denaturation of their enzymes. To measure the quantity of allergens extracted, each study used an ELISA assay as well as a more sensitive but semiquantitative Halogen immunoassay to detect any allergens remaining after the simulated laundry extraction. Results: Study 1 showed that detergents extracted more of both Fel d 1 and Der p 1 than either soap or water alone and that almost all allergens were extracted within 5 minutes at 25 degrees. However, washing at 60 degreesC extracted slightly more Fel d 1 and denatured Der p 1, resulting in lower residual amounts of both allergens. Study 2 showed that all of the commercial detergents performed similarly. Study 3 showed that the presence of enzymes in detergent formulations did not produce a significant effect on the extraction of allergens. Conclusion: Using detergent solutions at 25 degrees for at least 5 minutes was sufficient to extract most mite and cat allergen from dust of bedding.	Royal Prince Alfred Hosp, Inst Resp Med, Sydney, NSW, Australia	University of Sydney	Tovey, ER (corresponding author), Univ Sydney, Inst Resp Med, Allergen Unit, Room 461,Blackburn Bldg,D06, Sydney, NSW 2006, Australia.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; Cain G, 1998, ALLERGY, V53, P1213, DOI 10.1111/j.1398-9995.1998.tb03844.x; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1243, DOI 10.1111/j.1365-2222.1996.tb00520.x; HASHIMOTO M, 1994, J VET MED SCI, V56, P597, DOI 10.1292/jvms.56.597; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MATTHEW DJ, 1977, LANCET, V1, P321; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; Rachelefsky GS, 1999, ANN ALLERG ASTHMA IM, V82, P296, DOI 10.1016/S1081-1206(10)62612-9; Razmovski V, 2000, J ALLERGY CLIN IMMUN, V105, P725, DOI 10.1067/mai.2000.105222; SAKAGUCHI M, 1991, Japanese Journal of Allergology, V40, P439; Siebers R, 1997, J ALLERGY CLIN IMMUN, V100, P580; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213	16	26	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					369	374		10.1067/mai.2001.117799	http://dx.doi.org/10.1067/mai.2001.117799			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544455				2022-12-18	WOS:000171215400007
J	Sandford, AJ; Zhu, SK; Bai, TR; FitzGerald, JM; Pare, PD				Sandford, AJ; Zhu, SK; Bai, TR; FitzGerald, JM; Pare, PD			The role of the C-C chemokine receptor-5 Delta 32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokine; receptor; deletion; asthma	BRONCHOALVEOLAR LAVAGE FLUID; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; HIV-1 INFECTION; CCR5; RANTES; GENE; MIP-1-ALPHA; INFLAMMATION; EOSINOPHILS	Background: There are conflicting data regarding the role of a deletion in the C-C chemokine receptor-5 gene (CCR5*D32) in the pathogenesis of asthma and whether this deletion influences the production of regulated on activation, normal T cells expressed and secreted (RANTES). RANTES is a chemokine that is known to play an important role in the pathogenesis of allergic asthma. Objective: We sought to determine whether CCR5*D32 is associated with increased RANTES production, the presence of asthma, and the severity of asthma. Methods: A PCR assay for CCR5*D32 was developed. The prevalence of CCR5*D32 was determined in a group of patients with mild-to-moderate asthma, a group of subjects with severe asthma who had fatal or near-fatal asthma attacks, and a group of nonasthmatic control subjects. The level of RANTES produced by stimulated and unstimulated T cells was measured by using a commercially available immunoassay. Results: The frequency of CCR5*D32 was not significantly increased in the severe asthma group compared with in the mild-to-moderate asthma group. CCR5*D32 was not increased in the asthmatic subjects versus in the control subjects. There was no significant increase in RANTES levels from T cells heterozygous for CCR5*D32 compared with wild-type cells. Conclusion: These data indicate that the CCR5*D32 allele is not a genetic risk factor for the development of asthma and does not influence disease severity. The CCR5*D32 allele does not influence RANTES production in the heterozygous state.	St Pauls Hosp, UBC McDonald Res Labs, Vancouver, BC V6Z 1Y6, Canada; Vancouver Gen Hosp, Div Resp, Vancouver, BC, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia	Sandford, AJ (corresponding author), St Pauls Hosp, UBC Pulm Res Lab, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.		Pare, Peter D/C-7425-2011					Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; COOPER CS, 1991, METHOD MOL BIOL, V9, P133; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Hall IP, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03425-X; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kurashima K, 1996, J LEUKOCYTE BIOL, V59, P313, DOI 10.1002/jlb.59.3.313; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lukacs NW, 1997, J IMMUNOL, V158, P4398; Mitchell TJ, 2000, LANCET, V356, P1491, DOI 10.1016/S0140-6736(00)03144-5; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PLATTSMILLS TAE, 1994, ANN ALLERGY, V72, P381; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Sambrook J, 1989, MOL CLONING LAB MANU; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Sanford Andrew, 1996, American Journal of Respiratory and Critical Care Medicine, V153, P1749; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Yang JY, 1999, CYTOKINE, V11, P1, DOI 10.1006/cyto.1998.0396; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153	27	26	29	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					69	73						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447384				2022-12-18	WOS:000170171200009
J	Reitamo, S				Reitamo, S			Tacrolimus: A new topical immunomodulatory therapy for atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							LANGERHANS CELLS; OINTMENT; FK506; EXOTOXINS; FK-506; TRIAL; SKIN; IGE		Univ Helsinki, Cent Hosp, Hosp Skin & Allerg Dis, Dept Dermatol, Helsinki 00250, Finland	University of Helsinki; Helsinki University Central Hospital	Reitamo, S (corresponding author), Univ Helsinki, Cent Hosp, Dept Dermatol, Meilahdentie 2, Helsinki 00250, Finland.			Reitamo, Sakari/0000-0002-7819-9844				Akdis CA, 1999, CURR PROBL DERMATOL, V28, P37; Alaiti S, 1998, J AM ACAD DERMATOL, V38, P69, DOI 10.1016/S0190-9622(98)70541-9; Anjuere F, 2000, BLOOD, V96, P1633, DOI 10.1182/blood.V96.5.1633.h8001633_1633_1637; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; GOTO T, 1987, TRANSPLANT P, V19, P4; Hauk PJ, 2001, J ALLERGY CLIN IMMUN, V107, P391, DOI 10.1067/mai.2001.112848; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; Panhans-Gross A, 2001, J ALLERGY CLIN IMMUN, V107, P345, DOI 10.1067/mai.2001.112600; Reitamo S, 2000, ARCH DERMATOL, V136, P999, DOI 10.1001/archderm.136.8.999; Reitamo S, 1998, J INVEST DERMATOL, V111, P396, DOI 10.1046/j.1523-1747.1998.00323.x; Remitz A, 2001, J ALLERGY CLIN IMMUN, V107, P196, DOI 10.1067/mai.2001.112131; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; TOCCI MJ, 1989, J IMMUNOL, V143, P718; Tsytsykova AV, 2000, J EXP MED, V192, P581, DOI 10.1084/jem.192.4.581; Werfel T, 1999, CURR PROBL DERMATOL, V28, P29; WIERENGA EA, 1993, BLOOD, V82, P1471; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942	25	26	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					445	448		10.1067/mai.2001.113521	http://dx.doi.org/10.1067/mai.2001.113521			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240943	Bronze			2022-12-18	WOS:000167793300004
J	Polosa, R; Prosperini, G; Tomaselli, V; Howarth, PH; Holgate, ST; Davies, DE				Polosa, R; Prosperini, G; Tomaselli, V; Howarth, PH; Holgate, ST; Davies, DE			Expression of c-erbB receptors and ligands in human nasal epithelium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal epithelium; epidermal growth factor; c-erbB receptors; heterodimers	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR-ALPHA; OLFACTORY EPITHELIUM; MESSENGER-RNA; CELLS; MUCOSA; RAT; AMPHIREGULIN; ACTIVATION	Background: The epidermal growth fatter (EGF) family of growth factors plays an important role in maintenance and repair in a variety of epithelial tissues. However, very little is known about coexpression of these factors and their receptors, the c-erbB family of receptor tyrosine kinases, in human nasal epithelium. Objective: we sought to investigate the expression of these molecules in cultured nasal epithelial cells and nasal mucosa from healthy individuals. Methods: Identification of c-erbB receptors and their ligands was sought by using reverse transcription PCR, Western blotting, and immunohistochemistry. Results: Messenger RNA encoding the EGF receptors (EGFR) c-erbB2 and c-erbB3, but not c-erbB4, was detected in primary cultures of human nasal epithelial cells. Transcripts encoding EGF, heparin-binding EGF, transforming growth factor (TGF) alpha, and amphiregulin were also detected. Receptor and ligand expression was confirmed by using immunocytochemical staining of the cells and Western blotting of the cell lysates, Immunohistochemical analysis of tissue sections obtained from biopsy specimens of nasal mucosa revealed intense membrane staining for the EGFR within the respiratory nasal epithelium, which was predominantly localized at the level of the columnar epithelial layers. Similar staining patterns were observed for c-erbB2 and c-erbB3 in the respiratory nasal epithelium. Evidence for EGF, transforming growth factor alpha, heparin-binding EGF, amphiregulin, and betacellulin immunostaining in the nasal epithelium nas also obtained; their staining patterns paralleled that of EGFR immunostaining. Conclusion: Colocalization of c-erbB receptors and ligands establishes a basis on which to investigate c-erbB receptor-mediated effects in human nasal epithelium.	Univ Southampton, Southampton Gen Hosp, Div Resp Cell & Mol Biol, Fac Med, Southampton SO16 6YD, Hants, England	University of Southampton	Davies, DE (corresponding author), Univ Southampton, Southampton Gen Hosp, Div Resp Cell & Mol Biol, Fac Med, Tremona Rd, Southampton SO16 6YD, Hants, England.		Davies, Donna E/H-2993-2012	Howarth, Peter/0000-0003-0619-7927; Davies, Donna/0000-0002-5117-2991				ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Chamberlin SG, 1998, BBA-PROTEIN STRUCT M, V1384, P223, DOI 10.1016/S0167-4838(97)00203-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; Davies DE, 1999, ALLERGY, V54, P771; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; DEVALIA JL, 1990, RESP MED, V84, P303, DOI 10.1016/S0954-6111(08)80058-3; Ezeh PI, 1998, J NEUROBIOL, V37, P199, DOI 10.1002/(SICI)1097-4695(19981105)37:2<199::AID-NEU1>3.0.CO;2-F; GarciaSuarez O, 1997, ANAT RECORD, V247, P299, DOI 10.1002/(SICI)1097-0185(199703)247:3<299::AID-AR1>3.0.CO;2-Q; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOLBROOK EH, 1995, J COMP NEUROL, V363, P129, DOI 10.1002/cne.903630111; HWANG DL, 1992, REGUL PEPTIDES, V37, P95, DOI 10.1016/0167-0115(92)90658-H; Krishna NSR, 1996, J COMP NEUROL, V373, P297, DOI 10.1002/(SICI)1096-9861(19960916)373:2<297::AID-CNE11>3.0.CO;2-I; LAWRENCE WT, 1994, CLIN DERMATOL, V12, P157, DOI 10.1016/0738-081X(94)90266-6; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; McCarthy DW, 1996, J INVEST DERMATOL, V106, P49, DOI 10.1111/1523-1747.ep12327214; MYGIND N, 1975, Rhinology (Utrecht), V13, P57; Polosa R, 1999, AM J RESP CRIT CARE, V159, pA493; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; POWELL PP, 1993, AM J PATHOL, V143, P784; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; PROCTOR DF, 1977, AM REV RESPIR DIS, V115, P97; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; SalehiAshtiani K, 1996, INT J DEV NEUROSCI, V14, P801, DOI 10.1016/S0736-5748(96)00039-1; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SOLIC N, 1995, INT J CANCER, V62, P48, DOI 10.1002/ijc.2910620111; TONNESEN P, 1990, SCAND J CLIN LAB INV, V50, P187, DOI 10.3109/00365519009089152; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; [No title captured]	33	26	26	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1124	1131						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112896				2022-12-18	WOS:000165930300015
J	Vanlaar, CH; Peat, JK; Marks, GB; Rimmer, J; Tovey, ER				Vanlaar, CH; Peat, JK; Marks, GB; Rimmer, J; Tovey, ER			Domestic control of house dust mite allergen in children's beds	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen avoidance; allergens; mites; encasing; occlusive covers; acaricides; laundry additives	ASTHMATIC-PATIENTS; LIVING MITES; P-I; TEMPERATURE; REDUCTION; AVOIDANCE; DERMATOPHAGOIDES; ELIMINATION; EXPOSURE; COVERS	Background: House dust mite allergen levels in humid coastal regions of Australia are high, particularly in beds. Because high allergen levels in beds are associated with more severe asthma, reduction of levels may be important for asthma control. Objective: We tested the effectiveness of an acaricidal treatment of bedding in combination with occlusive mattress and pillow encasings in reducing allergen levels in children's beds in a community setting. Methods: A total of 14 beds of children were selected for the active intervention. In each home the bed of a sibling of nearest age was selected as the control. Dust was vacuumed from beds by using a standard protocol, and Der p 1 levels mere measured by using ELISA. Adjacent settling dust was collected by using opened Petri dishes. The intervention consisted of encasing mattresses and pillows in occlusive covers and washing all bedding with Acaril, an acaricidal additive. The acaricidal wash mas repeated twice in 7 households at 2-month inter vals. Control beds mere not treated. Results: The mean Der p 1 concentration at baseline was 27.9 mu g/g in the active beds and 18.1 mu g/g in the control beds. At 4 days after intervention, Der p 1 decreased to 32 mu g/g and 15.7 mu g/g in active and control beds, respectively. The average difference (active minus control) over the first 1-week cycle was 78.5% (P < .0001), and the difference over 3 washing cycles was 125.1% (P < .05). The mean rate of settling Der p 1 adjacent to the actively treated beds decreased from 24.4 ng.m(-2).d(-1) at baseline to 10.0 ng.m(-2).d(-1) after intervention (P < .01). Conclusion: A substantial reduction in Der p 1 levels in beds and in airborne dust in a humid region with naturally high house dust mite allergen levels can be achieved and sustained in a community setting with use of occlusive covers and a rigorous washing routine.	Royal Prince Alfred Hosp, Inst Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Vanlaar, CH (corresponding author), Royal Prince Alfred Hosp, Inst Resp Med, Level 8,Bldg 82, Camperdown, NSW 2050, Australia.		Tovey, Euan R/G-8604-2017; Marks, Guy B./F-5058-2013	Tovey, Euan R/0000-0002-1802-7266; Marks, Guy B./0000-0002-8976-8053				ANDERSEN A, 1989, ALLERGY, V44, P396, DOI 10.1111/j.1398-9995.1989.tb04170.x; Bischoff ERC, 1996, CLIN EXP ALLERGY, V26, P945, DOI 10.1111/j.1365-2222.1996.tb00631.x; Bischoff ERC, 1998, CLIN EXP ALLERGY, V28, P60, DOI 10.1046/j.1365-2222.1998.00192.x; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; CHANYEUNG M, 1998, AM J RESP CRIT CARE, V157, pA12; Custovic A, 1998, J ALLERGY CLIN IMMUN, V101, pS81; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Frederick JM, 1998, J ALLERGY CLIN IMMUN, V101, pS26; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Hayden ML, 1997, ANN ALLERG ASTHMA IM, V79, P437, DOI 10.1016/S1081-1206(10)63040-2; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MARKS GB, 1995, CLIN EXP ALLERGY, V25, P114, DOI 10.1111/j.1365-2222.1995.tb01015.x; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; MCDONALD LG, 1993, J ALLERGY CLIN IMMUN, V92, P771, DOI 10.1016/0091-6749(93)90022-8; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Sporik R, 1998, J ALLERGY CLIN IMMUN, V101, P451, DOI 10.1016/S0091-6749(98)70352-5; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; TOVEY E, 1993, LANCET, V342, P126, DOI 10.1016/0140-6736(93)91334-I; TOVEY ER, 1992, CLIN EXP ALLERGY, V22, P67, DOI 10.1111/j.1365-2222.1992.tb00116.x; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; vanderHeide S, 1997, ALLERGY, V52, P921, DOI 10.1111/j.1398-9995.1997.tb01252.x; Weeks J, 1995, CLIN EXP ALLERGY, V25, P1179, DOI 10.1111/j.1365-2222.1995.tb03041.x; WICKMAN M, 1994, ALLERGY, V49, P114, DOI 10.1111/j.1398-9995.1994.tb00810.x	29	26	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1130	1133		10.1067/mai.2000.106213	http://dx.doi.org/10.1067/mai.2000.106213			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856146				2022-12-18	WOS:000087781800013
J	de Silva, HD; Sutherland, MF; Suphioglu, C; McLellan, SC; Slater, JE; Rolland, JM; O'Hehir, RE				de Silva, HD; Sutherland, MF; Suphioglu, C; McLellan, SC; Slater, JE; Rolland, JM; O'Hehir, RE			Human T-cell epitopes of the latex allergen Hev b 5 in health care workers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; latex; Hev b 5; peptides; T-cell epitopes; allergen; allergy	RUBBER ELONGATION-FACTOR; HOUSE-DUST MITE; SPINA-BIFIDA; IGE ANTIBODIES; IDENTIFICATION; CLONING; PREVALENCE; BINDING; PEPTIDES; HEV-B-5	Background: Latex allergy affects health care workers as a high-risk cohort. Hev b 5 is a major latex allergen reacting with serum IgE from 92% of later-allergic health care workers, Because CD4(+) T-cell recognition is central to the specific immune response to allergens, identification of dominant T-cell epitopes is important for the development of specific immunotherapy for latex allergy. Objective: Our purpose was to map T-cell epitopes of Hev b 5 in health care workers. Methods: Six later-allergic health care workers (grade 3 to 4 enzyme allergosorbent test score) were studied. Peripheral blood latex specific 3-week T-cell lines were generated and screened for proliferative response to overlapping 20-mer peptides of Hev b 5, Supernatants collected at 48 hours were analyzed by ELISA for IL-5 and IFN-gamma. Results: Dot immunoblotting with use of recombinant Hev b 5/maltose-binding protein indicated serum-specific IgE in 5 of 6 patients. T-cell reactivity to one or more Hev b 5 peptides was identified in these 5 donors, but not in the sixth. Hev b 5 (46-65) induced T-cell proliferation in all 5 donors. Hev b 5 (109-128) stimulated T cells from 3 of these patients. Proliferative responses were accompanied by substantial IL-5 secretion and minimal IFN-gamma, indicating a T(H)2-predominant cytokine profile. Conclusions: Five of 6 latex-allergic patients demonstrated T-cell responsiveness to Hev b 5 consistent with a major T-cell reactive latex allergen. Two T-cell immunodominant regions of Hev b 5 were identified, and reactivity to these sites was associated with strong IL-5 but minimal IFN-gamma production.	Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Prahran, Vic 3181, Australia; Alfred Hosp, Dept Pathol & Immunol, Prahran, Vic 3181, Australia; Monash Univ, Clayton, Vic 3168, Australia; US FDA, Ctr Biol Evaluat & Res, Lab Immunobiochem, Rockville, MD 20857 USA	Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health; Monash University; US Food & Drug Administration (FDA)	O'Hehir, RE (corresponding author), Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Commercial Rd, Prahran, Vic 3181, Australia.		Rolland, Jennifer/E-7543-2011; O'Hehir, Robyn E/H-3627-2011	O'Hehir, Robyn E/0000-0002-3489-7595				Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; Beezhold DH, 1999, J ALLERGY CLIN IMMUN, V103, P1166, DOI 10.1016/S0091-6749(99)70194-6; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BREITENEDER H, 1998, ALLERGY CLIN IMMUNOL, V10, P101; Brown RH, 1998, ANESTHESIOLOGY, V89, P292, DOI 10.1097/00000542-199808000-00004; BRUGNAMI G, 1995, J ALLERGY CLIN IMMUN, V96, P457, DOI 10.1016/S0091-6749(95)70287-3; Chen Z, 1996, CLIN EXP ALLERGY, V26, P406, DOI 10.1046/j.1365-2222.1996.d01-327.x; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; de Lalla C, 1999, J IMMUNOL, V163, P1725; Douglas R, 1997, AUST NZ J MED, V27, P165, DOI 10.1111/j.1445-5994.1997.tb00933.x; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; Hoyne GF, 1997, INT IMMUNOL, V9, P1165, DOI 10.1093/intimm/9.8.1165; KELLY KJ, 1995, IMMUNOL ALLERGY CLIN, V15, P139; Kibby T, 1997, ANN ALLERG ASTHMA IM, V78, P41, DOI 10.1016/S1081-1206(10)63370-4; Kostyal DA, 1998, CLIN EXP IMMUNOL, V112, P355; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Michael T, 1996, CLIN EXP ALLERGY, V26, P934; Moller M, 1998, ALLERGY, V53, P289, DOI 10.1111/j.1398-9995.1998.tb03889.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; OHehir R, 1993, METHODS IMMUNOLOGICA, V3, P120; OHEHIR RE, 1993, EUR J CLIN INVEST, V23, P763, DOI 10.1111/j.1365-2362.1993.tb00729.x; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; Posch A, 1998, CLIN EXP ALLERGY, V28, P134; Ramachandran S, 1998, J INFECT DIS, V177, P196, DOI 10.1086/513817; Raulf-Heimsoth M, 1998, CLIN EXP ALLERGY, V28, P339; Scheiner O, 1999, INT ARCH ALLERGY IMM, V118, P311, DOI 10.1159/000024113; Schramm G, 1999, J IMMUNOL, V162, P2406; Sette A, 1998, CURR OPIN IMMUNOL, V10, P478, DOI 10.1016/S0952-7915(98)80124-6; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; Slater JE, 1999, MOL IMMUNOL, V36, P135, DOI 10.1016/S0161-5890(99)00021-8; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; SUPHIOGLU C, 1993, ALLERGY, V48, P273, DOI 10.1111/j.1398-9995.1993.tb00728.x; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0	37	26	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					1017	1024		10.1067/mai.2000.105806	http://dx.doi.org/10.1067/mai.2000.105806			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808185	Bronze			2022-12-18	WOS:000087185000023
J	Kornfeld, SJ; Zeffren, B; Christodoulou, CS; Day, NK; Cawkwell, G; Good, RA				Kornfeld, SJ; Zeffren, B; Christodoulou, CS; Day, NK; Cawkwell, G; Good, RA			DiGeorge anomaly: A comparative study of the clinical and immunologic characteristics of patients positive and negative by fluorescence in situ hybridization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DiGeorge anomaly; microdeletion; chromosome; immunodeficiencies; fluorescence in situ hybridization positive; fluorescence in situ hybridization negative; hypoparathyroidism; thymic aplasia; congenital heart disease; neonatal hypocalcemia	DELETIONS; MICRODELETIONS; CHROMOSOME-22; DEFICIENCY; SPECTRUM; DISEASE	Background: DiGeorge anomaly (DGA) is defined as a field defect characterized by dysmorphic facies, hypoparathyroidism, congenital heart defects, and a deficiency in cell-mediated immunity, usually associated with a microdeletion in chromosome 22q11.2. Data correlating clinical and genetic information, especially in terms of the extent of the immunodeficiency and infectious complications, are scant. Objective: The goal of this study was to define the severity of the immunodeficiency and infectious illnesses in DGA patients with characteristic clinical and genetic findings and compare them with a similar group of patients without a microdeletion in chromosome 22q11.2. Methods: A retrospective chart review of patients referred for evaluation of DGA to our immunology service from 1989 to 1995 was conducted, Clinical and immunologic data were collected from their initial evaluation. Patients meeting at least 3 of 4 of these criteria were considered to meet strict clinical diagnostic criteria for DGA, and the results of analysis for a microdeletion in chromosome 22q11.2 for each patient was noted. Results: Sixteen of the 22 patients meeting strict clinical criteria for DGA were available for analysis for the microdeletion at chromosome 22q.11.2. Of these, 13 (81%) were positive by fluorescence in situ hybridization (FISH); 9 of 13 (69%) had low CD3 numbers, 6 of 10 assayed (60%) had low thymulin levels; 10 of 13 (77%) had low CD4 numbers, and 10 of 12 (83%) had absent or small thymus glands. B cells were increased in 9 of 13 (69%) patients. Mitogen and antigen responses were normal in 6 of 7 (86%) patients tested. Eight of 13 (62%) had a history of increased frequency of infectious illnesses. All had recurrent respiratory infections, including sinusitis, otitis media, and pneumonia. Three of the 16 patients tested (19%) were FISH negative. Two of 3 (67%) had low CD3 and CD4 numbers. B cells were elevated in all patients. All had recurrent respiratory infections, low thymulin levels, and absent thymus glands. Conclusions: Contrary to traditional descriptions, this group of clinically and genetically defined patients with DGA had a predominantly mild cell-mediated immunodeficiency syndrome usually associated with infections characteristic of humoral immunodeficiencies, The patients who were FISH positive did not differ significantly from those that were FISH negative in terms of clinical and immunologic findings or infectious complications.	Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA	State University System of Florida; University of South Florida	Kornfeld, SJ (corresponding author), Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA.							AMMANN AJ, 1986, IMMUNOLOGIC DISORDER, P257; BARRETT DJ, 1981, J CLIN LAB IMMUNOL, V6, P1; BASTIAN J, 1989, J PEDIATR-US, V115, P391, DOI 10.1016/S0022-3476(89)80837-6; BOCKMAN DE, 1984, SCIENCE, V223, P498, DOI 10.1126/science.6606851; CONLEY ME, 1979, J PEDIATR-US, V94, P883, DOI 10.1016/S0022-3476(79)80207-3; COOPER MD, 1965, J PEDIATR-US, V67, P907, DOI 10.1016/S0022-3476(65)81796-6; DELACHAPELLE A, 1981, HUM GENET, V57, P253, DOI 10.1007/BF00278938; DEMCZUK S, 1994, ANN GENET-PARIS, V37, P60; DEMCZUK S, 1995, ANN GENET-PARIS, V38, P59; DiGeorge A. M., 1968, BIRTH DEFECTS OAS, V4, P116; DRISCOLL DA, 1992, AM J HUM GENET, V50, P924; FREEDOM RM, 1972, CIRCULATION, V46, P165, DOI 10.1161/01.CIR.46.1.165; HAIRE RN, 1993, J EXP MED, V178, P825, DOI 10.1084/jem.178.3.825; Hong R, 1996, TRANSPLANTATION, V61, P444, DOI 10.1097/00007890-199602150-00023; KRETSCHM.R, 1968, NEW ENGL J MED, V279, P1295, DOI 10.1056/NEJM196812122792401; Lammer E J, 1986, Am J Med Genet Suppl, V2, P113, DOI 10.1002/ajmg.1320250615; LISCHNER HW, 1972, J PEDIATR-US, V81, P1042, DOI 10.1016/S0022-3476(72)80575-4; LISCHNER HW, 1969, LANCET, V2, P1044; LODBELL DH, 1959, ARCH PATHOL, V67, P412; MULLER W, 1989, EUR J PEDIATR, V149, P96, DOI 10.1007/BF01995856; PABST HF, 1976, AM J DIS CHILD, V130, P316, DOI 10.1001/archpedi.1976.02120040094018; PALACIOS J, 1993, AM J MED GENET, V46, P641, DOI 10.1002/ajmg.1320460608; SCAMBLER PJ, 1991, GENOMICS, V10, P201, DOI 10.1016/0888-7543(91)90501-5; SCAMBLER PJ, 1992, LANCET, V339, P1138, DOI 10.1016/0140-6736(92)90734-K; SCHUBERT MS, 1992, ANN ALLERGY, V69, P231; Smith CA, 1998, CLIN DIAGN LAB IMMUN, V5, P415, DOI 10.1128/CDLI.5.3.415-417.1998; TAITZ LS, 1966, PEDIATRICS, V38, P412; WILSON DI, 1992, LANCET, V340, P573, DOI 10.1016/0140-6736(92)92107-Q; WILSON DI, 1991, BRIT HEART J, V66, P308; WILSON DI, 1993, J MED GENET, V30, P852, DOI 10.1136/jmg.30.10.852	30	26	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					983	987		10.1067/mai.2000.105527	http://dx.doi.org/10.1067/mai.2000.105527			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808180				2022-12-18	WOS:000087185000018
J	Shida, K; Hachimura, S; Ametani, A; Ishimori, M; Ling, M; Hashiguchi, M; Ueda, Y; Sato, T; Kumagai, Y; Takamizawa, K; Habu, S; Kaminogawa, S				Shida, K; Hachimura, S; Ametani, A; Ishimori, M; Ling, M; Hashiguchi, M; Ueda, Y; Sato, T; Kumagai, Y; Takamizawa, K; Habu, S; Kaminogawa, S			Serum IgE response to orally ingested antigen: A novel IgE response model with allergen-specific T-cell receptor transgenic mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; food allergy; TCR transgenic mouse; ovalbumin; oral tolerance; T-H2; antibody response to orally ingested antigen; animal model	LIVED PLASMA-CELLS; CYTOKINE PRODUCTION; B-CELLS; TOLERANCE; MILK; SECRETION; CULTURES; EPSILON; MOUSE; DIET	Background: The mechanism by which orally ingested allergens elicit an IgE response remains unclear because there are few animal models available for investigation of this response. Objective: We tried to develop a murine model suitable for investigation of the IgE response to orally ingested allergens, which would allow us to identify T cells that could promote IgE production. Methods: Ovalbumin (OVA)-specific T-cell receptor transgenic mice were fed a diet containing OVA, and both the serum antibody response and cytokine production by splenocytes were examined. Results: Oral administration of OVA to transgenic mice Led to an increase in the levels of both antigen-specific IgE and total IgE in the sera. Subsequent intravenous challenge of OVA-fed transgenic mice with OVA resulted in anaphylactic shock. Analysis of cytokine production by splenocytes revealed that high IL-4-producing T cells appeared in the spleen 1 week after the start of feeding the OVA diet. T cells from these mice were found to promote IgE secretion by BALB/c B cells in vitro. This helper activity and the levels of IL-4 secretion were diminished after long-term feeding. These findings suggest the possibility that the orally ingested antigen elicited a response by a subpopulation of T cells that produce high levels of T-H2-type cytokines and that promote IgE secretion, and these same T cells were tolerized by the orally ingested antigen. Conclusion: This experimental model with transgenic mice may be a useful tool for further studies of the cellular and molecular mechanisms of the T-cell and IgE responses to orally ingested antigens.	Yakult Cent Inst Microbiol Res, Kunitachi, Tokyo 1868650, Japan; Univ Tokyo, Dept Appl Biol Chem, Tokyo, Japan; Tokai Univ, Sch Med, Dept Immunol, Isehara, Kanagawa 25911, Japan; Res Dev Corp Japan, Precursory Res Embryon Sci & Technol, Yokohama, Kanagawa, Japan	Yakult Honsha Company, Limited; University of Tokyo; Tokai University; Japan Science & Technology Agency (JST)	Shida, K (corresponding author), Yakult Cent Inst Microbiol Res, 1796 Yaho, Kunitachi, Tokyo 1868650, Japan.		Eckhardt, Erik/G-1567-2010	Hashiguchi, Masaaki/0000-0002-3359-4488				BEAGLEY KW, 1988, J IMMUNOL, V141, P2035; Chen YH, 1997, CELL IMMUNOL, V178, P62, DOI 10.1006/cimm.1997.1119; ENOMOTO A, 1993, CLIN IMMUNOL IMMUNOP, V66, P136, DOI 10.1006/clin.1993.1017; HALTEREN AGS, 1997, J ALLERGY CLIN IMMUN, V99, P94; Ito K, 1997, EUR J IMMUNOL, V27, P3427, DOI 10.1002/eji.1830271243; KIM SM, 1993, INT ARCH ALLERGY IMM, V101, P260, DOI 10.1159/000236455; Manz RA, 1998, INT IMMUNOL, V10, P1703, DOI 10.1093/intimm/10.11.1703; Melamed D, 1996, INT IMMUNOL, V8, P717, DOI 10.1093/intimm/8.5.717; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; POULSEN OM, 1987, CLIN ALLERGY, V17, P449, DOI 10.1111/j.1365-2222.1987.tb02039.x; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; RUSSELL GJ, 1995, IMMUNOLOGY IMMUNOPAT, P15; Sampson HA, 1996, ANNU REV NUTR, V16, P161, DOI [10.1146/annurev.nu.16.070196.001113, 10.1146/annurev.nutr.16.1.161]; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SATO T, 1994, EUR J IMMUNOL, V24, P1512, DOI 10.1002/eji.1830240708; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; SCHULTZ CL, 1992, J IMMUNOL, V149, P60; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; YOSHIDA K, 1990, P NATL ACAD SCI USA, V87, P7829, DOI 10.1073/pnas.87.20.7829; Yoshida T, 1997, CLIN IMMUNOL IMMUNOP, V82, P207, DOI 10.1006/clin.1996.4319; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0	28	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					788	795		10.1067/mai.2000.104934	http://dx.doi.org/10.1067/mai.2000.104934			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756231				2022-12-18	WOS:000086604100019
J	Siebers, R				Siebers, R			The accuracy of references of three allergy journals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						references; accuracy; medline			Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, Wellington, New Zealand	University of Otago	Siebers, R (corresponding author), Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, POB 7343, Wellington, New Zealand.		Siebers, Robert/A-4102-2009	Siebers, Robert/0000-0002-6359-3144				Clever L, 1997, NEW ENGL J MED, V336, P309; DELACEY G, 1985, BRIT MED J, V291, P884, DOI 10.1136/bmj.291.6499.884; Kee WDN, 1997, AUST NZ J SURG, V67, P417, DOI 10.1111/j.1445-2197.1997.tb02005.x; Roach VJ, 1997, AM J OBSTET GYNECOL, V177, P973, DOI 10.1016/S0002-9378(97)70303-X; Siebers R, 1999, NZ J MED LAB SCI, V53, P46	5	26	26	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					837	838		10.1067/mai.2000.104935	http://dx.doi.org/10.1067/mai.2000.104935			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756238				2022-12-18	WOS:000086604100026
J	Bolos, AM; Bochner, BS; Togias, A; Schleimer, RP; Beck, LA				Bolos, AM; Bochner, BS; Togias, A; Schleimer, RP; Beck, LA			Surface expression of CCR3 and CD49d on eosinophils is not increased in allergic asthma and allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine									0	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	2	S		770	S259	S259		10.1016/S0091-6749(00)91198-9	http://dx.doi.org/10.1016/S0091-6749(00)91198-9			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	287WR					2022-12-18	WOS:000085530100766
J	Barry, PW; O'Callaghan, C				Barry, PW; O'Callaghan, C			The output of budesonide from spacer devices assessed under simulated breathing conditions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Congress of the European-Respiratory-Society	SEP 07-11, 1996	STOCKHOLM, SWEDEN	European Resp Soc		drug administration; inhalation; spacer devices; static charge; budesonide; corticosteroids	METERED DOSE INHALER; IN-VITRO DELIVERY; MULTIPLE ACTUATIONS; ELECTROSTATIC CHARGE; DRUG-DELIVERY; INHALATION; SALBUTAMOL; AEROSOL; ASTHMA; CORTICOSTEROIDS	Background: Spacer devices are increasingly used to aid inhalational therapy, and many different devices are available. Patient and spacer size and spacer static charge may affect drug delivery, brit the optimum spacer size and method of reducing static charge is not certain Objective: We sought to determine the output of budesonide from 3 different spacer devices when assessed by using simulated breathing at different tidal volumes and to assess the effect of washing and handling the spacer on drug output, Methods: Three spacer types were assessed: 2 polycarbonate spacers, the Aerochamber and the Nebuhaler, and the metal Nebuchamber or Non-Electrostatic-Spacer. Breathing was simulated by using a sinus flow pump. Metered-dose inhalers of budesonide 200 mu g were actuated into the spacer, which was attached to the breathing simulator for 5 simulated breathing cycles. Budesonide was collected on a filter placed between the spacer and breathing simulator and was assayed by HPLC, Spacers were assessed after they had been washed briefly in water, after they had been washed briefly in cetrimide solution in an attempt to reduce their static charge, and after they had been handled to simulate normal use, Zn separate experiments budesonide particle size from the spacers was measured by using a multistage liquid impinger, Results: Drug output from the Nebuchamber was greater than that from the other 2 spacers, especially at lower tidal volumes, With 150 mt of tidal volume, the Nebuchamber delivered 36% of the nominal dose to the filter versus 13% from the Nebuhaler and 7% from the Aerochamber. The output from the Aerochamber and Nebuhaler increased linearly with tidal volume, but this was not the case with the Nebuchamber, in which output was constant at tidal volumes of 150 mt and above. Compared with washing in tap water, neither washing the spacers in 0.1% cetrimide solution nor vigorous wiping with a paper towel changed their output. Thirty-eight percent of the drug from the Nebuchamber was contained in particles smaller than 4.7 mu m in diameter compared with 47% from the Nebuhaler and 53% from the Aerochamber, Conclusions: The Nebuchamber increases in vitro budesonide delivery compared with the polycarbonate spacers tested but delivers a greater percentage of the drug in large particles. No increase in delivery with tidal volume was seen with the Nebuchamber, which would deliver a higher dose of drug per kilogram of body weight to smaller patients. Briefly washing the polycarbonate spacers in water or in a weak detergent solution, simulating household washing, did not make them as effective as the metal spacer, Further research is needed to determine a practical washing and handling method to reduce static charge on polycarbonate spacers.	Univ Leicester, Dept Child Hlth, Leicester, Leics, England	University of Leicester	Barry, PW (corresponding author), Univ Leicester, Dept Child Hlth, Leicester, Leics, England.							Barry PW, 1996, THORAX, V51, P835, DOI 10.1136/thx.51.8.835; BARRY PW, 1995, BRIT J CLIN PHARMACO, V40, P76, DOI 10.1111/j.1365-2125.1995.tb04538.x; BARRY PW, 1993, ARCH DIS CHILD, V69, P693, DOI 10.1136/adc.69.6.693; Barry PW, 1999, BRIT J CLIN PHARMACO, V47, P357; BARRY PW, 1996, EUR RESP J S23, V9, P432; BARRY PW, 1995, PAEDIAT REV COMMUN, V8, P210; BISGAARD H, 1995, EUR RESPIR J, V8, P856; BISGAARD H, 1995, ARCH DIS CHILD, V73, P226, DOI 10.1136/adc.73.3.226; Bisgaard H, 1997, EUR RESPIR REV, V7, P376; BROWN PH, 1990, THORAX, V45, P736, DOI 10.1136/thx.45.10.736; CARLSEN KCL, 1992, ARCH DIS CHILD, V67, P1077; Clark DJ, 1996, THORAX, V51, P981, DOI 10.1136/thx.51.10.981; CONNER WT, 1989, PEDIATR PULM, V6, P263, DOI 10.1002/ppul.1950060410; Devadason SG, 1997, EUR RESPIR J, V10, P2479, DOI 10.1183/09031936.97.10112479; Dewsbury NJ, 1996, INT J PHARM, V137, P261, DOI 10.1016/0378-5173(96)04500-0; Dluhy RG, 1998, J ALLERGY CLIN IMMUN, V101, pS447, DOI 10.1016/S0091-6749(98)70157-5; KEELEY D, 1992, BRIT MED J, V305, P598, DOI 10.1136/bmj.305.6854.598; Lipworth BJ, 1996, PULM PHARMACOL THER, V9, P19, DOI 10.1006/pulp.1996.0002; MAY KR, 1966, BACTERIOL REV, V30, P559, DOI 10.1128/MMBR.30.3.559-570.1966; O'Callaghan C, 1999, BRIT MED J, V318, P410, DOI 10.1136/bmj.318.7181.410; OCALLAGHAN C, 1993, THORAX, V48, P603, DOI 10.1136/thx.48.6.603; OCALLAGHAN C, 1989, BRIT MED J, V298, P160, DOI 10.1136/bmj.298.6667.160; PRAHL P, 1987, CLIN ALLERGY, V17, P393, DOI 10.1111/j.1365-2222.1987.tb02031.x; SELROOS O, 1991, THORAX, V46, P891, DOI 10.1136/thx.46.12.891; SHIM C, 1980, AM J MED, V69, P891, DOI 10.1016/S0002-9343(80)80016-7; SMALDONE GC, 1991, J AEROSOL MED, V4, P229, DOI 10.1089/jam.1991.4.229; Wildhaber JH, 1996, THORAX, V51, P985, DOI 10.1136/thx.51.10.985; Wildhaber JH, 1996, EUR RESPIR J, V9, P1943, DOI 10.1183/09031936.96.09091943	28	26	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1205	1210		10.1016/S0091-6749(99)70014-X	http://dx.doi.org/10.1016/S0091-6749(99)70014-X			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589002				2022-12-18	WOS:000084289200014
J	Sowka, S; Hafner, C; Radauer, C; Focke, M; Brehler, R; Astwood, JD; Arif, SAM; Kanani, A; Sussman, GL; Scheiner, O; Beezhold, DH; Breiteneder, H				Sowka, S; Hafner, C; Radauer, C; Focke, M; Brehler, R; Astwood, JD; Arif, SAM; Kanani, A; Sussman, GL; Scheiner, O; Beezhold, DH; Breiteneder, H			Molecular and immunologic characterization of new isoforms of the Hevea brasiliensis latex allergen Hev b 7: Evidence of no cross-reactivity between Hev b 7 isoforms and potato patatin and proteins from avocado and banana	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type 1 allergy; natural rubber latex; Hev b 7; isoforms; polymorphism; patatins; cross-reactivity; recombinant allergens	NATURAL-RUBBER LATEX; AMINO-ACID SUBSTITUTION; 4 RECOMBINANT ISOFORMS; BIRCH POLLEN ALLERGEN; YEAST PICHIA-PASTORIS; MAJOR ALLERGEN; IGE ANTIBODIES; POTENTIAL USE; HAZEL POLLEN; GRASS-POLLEN	Background: Hev b 7 is a Hevea brasiliensis latex allergen with sequence identities of 39% to 42% to patatins recently identified as potato allergens. The complementary DNAs encoding 2 different Hev b 7 isoforms were previously reported. Objective: The aim of this study was to determine the sequence variation of Hev b 7 and to compare the IgE reactivity of individual isoforms in vitro and in vivo. A further objective was to evaluate possible cross-reactivities between Hev b 7 and patatins and proteins from banana and avocado. Methods: An H brasiliensis lambda ZAP complementary DNA (cDNA) Library was screened with use of a Hev b 7 cDNA probe. Four Hev b 7 isoforms Here produced in recombinant form and their IgE-binding capacities a ere compared. IgE immunoblot inhibitions and ELISA inhibition assays were used to investigate the possible cross-reactivity between Hev b 7 and recombinant potato patatin and proteins from avocado and banana. Results: Two new isoforms, S2 and D-2, were identified by sequencing 32 cDNA clones with full-length coding regions. All 4 recombinant isoforms displayed esterase activity and identical IgE-binding capacities. The new isoforms S2 and D-2 were evaluated in skin prick tests and provoked responses equivalent to natural Hev b 7, No cross-reactivity was observed between Hev b 7 isoforms and potato patatin and proteins from avocado and banana. Conclusions: All 4 recombinant Hev b 7 Isoforms have equivalent IgE-binding capacity and therefore represent suitable reagents for the development of in vitro and in vivo diagnostic tests. Hev b 7, patatins, and their homologs appear not to contribute to cross-reactivity in the Inter-fruit syndrome.	Univ Vienna, Dept Gen & Expt Pathol, Vienna, Austria; Univ Munster, Dept Dermatol & Venerol, D-4400 Munster, Germany; Monsanto Co, St Louis, MO USA; Rubber Res Inst Malaysia, Kuala Lumpur, Malaysia; Univ Toronto, Dept Allergy & Clin Immunol, Toronto, ON, Canada; Guthrie Res Inst, Sayre, PA USA	University of Vienna; University of Munster; Monsanto; Institute Penyelidikan Getah Malaysia; University of Toronto	Breiteneder, H (corresponding author), Univ Hosp Vienna, Dept Gen & Expt Pathol, AKH EBO 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Radauer, Christian/AAN-6260-2021	Radauer, Christian/0000-0001-9920-4449; Beezhold, Donald/0000-0001-5543-5747				AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; Alenius H, 1996, CLIN EXP ALLERGY, V26, P341, DOI 10.1046/j.1365-2222.1996.d01-312.x; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BLANCO C, 1994, ANN ALLERGY, V73, P309; BLANCO C, 1994, ALLERGY, V49, P454, DOI 10.1111/j.1398-9995.1994.tb00839.x; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Breiteneder H, 1998, INT ARCH ALLERGY IMM, V116, P83, DOI 10.1159/000023930; CARMICHAEL AJ, 1989, CONTACT DERMATITIS, V20, P64, DOI 10.1111/j.1600-0536.1989.tb03103.x; CASTELLS MC, 1986, J ALLERGY CLIN IMMUN, V78, P1110, DOI 10.1016/0091-6749(86)90258-7; Chua KY, 1996, CLIN EXP ALLERGY, V26, P829, DOI 10.1111/j.1365-2222.1996.tb00615.x; DECORRES LF, 1993, ANN ALLERGY, V70, P35; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; FRANKLAND AW, 1995, CLIN EXP ALLERGY, V25, P580, DOI 10.1111/j.1365-2222.1995.tb01103.x; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; Kostyal DA, 1998, CLIN EXP IMMUNOL, V112, P355; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; LIU Z, 1991, J IMMUNOL, V146, P438; LIU ZR, 1993, J IMMUNOL, V151, P1852; Mace SR, 1998, ANN ALLERG ASTHMA IM, V80, P252, DOI 10.1016/S1081-1206(10)62966-3; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; MERRETT TG, 1995, J ALLERGY CLIN IMMUN, V95, P154; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62, DOI 10.1159/000236804; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; Posch A, 1998, CLIN EXP ALLERGY, V28, P134; Reese G, 1996, ADV EXP MED BIOL, V409, P225; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; Sambrook J, 1989, MOL CLONING LAB MANU, V1, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENK S, 1994, EUR J BIOCHEM, V224, P717, DOI 10.1111/j.1432-1033.1994.00717.x; Seppala U, 1999, J ALLERGY CLIN IMMUN, V103, P165, DOI 10.1016/S0091-6749(99)70541-5; Seppala U, 1999, J ALLERGY CLIN IMMUN, V103, pS103; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; WAHL R, 1990, INT ARCH ALLER A IMM, V92, P168, DOI 10.1159/000235209; Yusof F., 1998, Journal of Rubber Research, V1, P95	47	26	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1302	1310		10.1016/S0091-6749(99)70028-X	http://dx.doi.org/10.1016/S0091-6749(99)70028-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589016				2022-12-18	WOS:000084289200028
J	Barnes, KC; Freidhoff, LR; Horowitz, EM; Mathias, RA; Mulkern, DM; Bonacum, JT; Goldman, MH; Polito, AJ; Saini, SS; Marsh, DG; Beaty, TH; Togias, A				Barnes, KC; Freidhoff, LR; Horowitz, EM; Mathias, RA; Mulkern, DM; Bonacum, JT; Goldman, MH; Polito, AJ; Saini, SS; Marsh, DG; Beaty, TH; Togias, A			Physician-derived asthma diagnoses made on the basis of questionnaire data are in good agreement with interview-based diagnoses and are not affected by objective tests	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma questionnaire; Collaborative Study on the Genetics of Asthma; interjudge reliability; intraclass correlation coefficient		Background: Defining the phenotype is critical for investigating the genetic etiology of asthma. As part of the Collaborative Study on the Genetics of Asthma (CSGA), the primary objective of which is to identify asthma susceptibility loci, an algorithm was designed to determine diagnoses of definite asthma, probable asthma, less than probable asthma, or no asthma, A respiratory questionnaire was designed to assist in the process of characterizing the asthma phenotype. Objective: This study was designed to determine the validity of the CSGA algorithm for the diagnosis of asthma, to determine agreement in assessing an asthma diagnosis between the information obtained by the CSGA questionnaire versus a patient interview by a panel of specialist physicians, and to determine the degree to which objective tests would alter the questionnaire-based certainty of asthma diagnosis. Methods: An expert panel of asthma clinicians (n = 4) indicated to what degree they were certain that a subject (n = 48) had asthma as determined by using a 6-point Likert scale based on a 20-minute interview (phase I), a review of the CSGA questionnaire (phase II), a review of the questionnaire plus skin test and peripheral blood eosinophilia data (phase III), and a review of phase III information plus pulmonary data (spirometry and methacholine-reversibility testing; IV), Intraclass correlation coefficients (ICCs) were calculated between the physicians' interpretation of the likelihood of asthma based on the information they received during each of the phases and between the CSGA algorithm and each of the phases. Results: Interjudge reliability with regard to the degree of certainty with which an asthma diagnosis could be made by interview was excellent (ICC, 98; 95% confidence intervals [95% CIs], 0.87-0.99). We also found that the agreement between the physicians' interview with the patients (phase I) and the CSGA algorithm was good and at least as good with the addition of the CSGA questionnaire data and objective data (ICC, 0.65-0.75). Good agreement was also observed between the average. certainty score from the interview and the CSGA questionnaire (ICC, 92; 95% CI, 0.76-0.93), and ICCs determining the agreement on asthma diagnosis between phase I and phases III and IV, in which objective data were introduced, did not change from the ICCs comparing phase I with phase II (ICC of 0.93 [95% CI, 0.79-0.96] and ICC of 0.91 [95% CI 0.73-0.95], respectively). Conclusion: We conclude that the CSGA algorithm is a valid tool for which the diagnosis of asthma can be made at an acceptable level of certainty and that the CSGA questionnaire, interpreted by an asthma specialist, is a useful tool for the diagnosis of asthma in clinical or epidemiologic studies.	Johns Hopkins Sch Hyg & Publ Hlth, Div Clin Immunol, Dept Med, Baltimore, MD USA; Johns Hopkins Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Pulm Med, Dept Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49612-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; Britton J, 1998, CLIN EXP ALLERGY, V28, P2; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; HOROWITZ E, 1995, J ALLERGY CLIN IMMUN, V95, P269; Jeyaseelan L, 1992, Natl Med J India, V5, P286; Marsh DG, 1997, NAT GENET, V15, P389; OCONNOR GT, 1994, AM J RESP CRIT CARE, V149, pS21, DOI 10.1164/ajrccm/149.2_Pt_2.S21; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; Postma DS, 1998, CLIN EXP ALLERGY, V28, P62; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Weissert CS, 1998, PUBLIUS J FEDERALISM, V28, P1	16	26	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				791	796		10.1016/S0091-6749(99)70289-7	http://dx.doi.org/10.1016/S0091-6749(99)70289-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	248NG	10518823				2022-12-18	WOS:000083281200010
J	Yu, CK; Shieh, CM; Lei, HY				Yu, CK; Shieh, CM; Lei, HY			Repeated intratracheal inoculation of house dust mite (Dermatophagoides farinae) induces pulmonary eosinophilic inflammation and IgE antibody production in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dermatophagoides farinae; pulmonary inflammation; eosinophil; IgE; mouse	T-CELL; AIRWAY RESPONSIVENESS; SENSITIZED MICE; SERINE-PROTEASE; MAST-CELLS; ALLERGEN; COSTIMULATION; INDUCTION; ASTHMA; CLEAVAGE	Background: In vitro studies have shown that the biologic activities of dust mite allergens probably contribute to their allergenicity, However, little is known about their in vivo effect, which may lead to allergic inflammation and sensitization. Objective: In this study we characterized the pathologic and immunologic responses of mice after repetitive challenge with dust mite Dermatophagoides farinae. Methods: Der f crude extract was intratracheally instilled into female BALB/c mice either once or a total of 10 times at 1-week intervals. The inflammatory responses, morphologic changes, IgE antibody and cytokine levels, and costimulatory molecular B7 expression in the airways were then monitored. Results: We demonstrated that single Der f challenge provoked an acute neutrophilic inflammation in the airways. After repeated Der f challenge, there was chronic inflammation characterized by increased numbers of lymphocytes and eosinophils in bronchoalveolar lavage (BAL) fluids. Histopathologically, the numbers of goblet cells and mast cells were significantly increased in the airways of these mire. Repetitive challenge elicited Der f-specific IgE antibody, increased IL-5 and IFN-gamma level in BAL fluids, and enhanced costimulatory B7 molecule expression on BAL cells. Conclusions: Our findings are in agreement with those of other in vitro studies concerning the properties of dust mite allergens. Prolonged inhalation of Der f without adjuvant may represent an optimal condition to develop experimental animal models of allergic lung diseases.	Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan	National Cheng Kung University	Yu, CK (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan.							Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; CARSWELL F, 1988, IMMUNOLOGY, V65, P497; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; DAVIS PB, 1995, AM J RESP CELL MOL, V12, P367, DOI 10.1165/ajrcmb.12.4.7695915; GALLI SJ, 1991, CURR OPIN IMMUNOL, V3, P865, DOI 10.1016/S0952-7915(05)80005-6; GANT V, 1992, AM REV RESPIR DIS, V146, P900, DOI 10.1164/ajrccm/146.4.900; Harris N, 1997, J EXP MED, V185, P177, DOI 10.1084/jem.185.1.177; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; HO W, 1973, ONCOLOGY-BASEL, V27, P385, DOI 10.1159/000224748; Holtzman MJ, 1996, AM J RESP CELL MOL, V14, P316, DOI 10.1165/ajrcmb.14.4.8600934; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Keane-Myers AM, 1998, J IMMUNOL, V160, P1036; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83, DOI 10.1159/000236807; MAGGI E, 1994, ANN NY ACAD SCI, V725, P2, DOI 10.1111/j.1749-6632.1994.tb39784.x; Maruo K, 1997, J ALLERGY CLIN IMMUN, V100, P253, DOI 10.1016/S0091-6749(97)70233-1; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; Rumsaeng V, 1997, J IMMUNOL, V159, P2904; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; STEWART GA, 1994, AM J IND MED, V25, P105, DOI 10.1002/ajim.4700250128; TAKAHASHI K, 1990, INT ARCH ALLER A IMM, V91, P80, DOI 10.1159/000235094; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137; Yu CK, 1996, J IMMUNOL, V156, P1923; Yu CK, 1997, INT ARCH ALLERGY IMM, V112, P73, DOI 10.1159/000237434; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661, DOI 10.1164/ajrccm.155.2.9032210	28	26	27	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					228	236		10.1016/S0091-6749(99)70140-5	http://dx.doi.org/10.1016/S0091-6749(99)70140-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400866				2022-12-18	WOS:000081738900036
J	Jacobi, HH; Skov, PS; Poulsen, LK; Malling, HJ; Mygind, N				Jacobi, HH; Skov, PS; Poulsen, LK; Malling, HJ; Mygind, N			Histamine and tryptase in nasal lavage fluid after allergen challenge: Effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; nasal allergen challenge; nasal mucosa; histamine; tryptase; cetirizine; azelastine	MAST-CELLS; HUMAN-LUNG; DOUBLE-BLIND; RELEASE; RHINITIS; METHACHOLINE; LORATADINE; EFFICACY; QUANTITATION; ANTAGONISTS	Background: Antihistamines (H-1-receptor antagonists) act by competitive antagonism of histamine at H-1-receptors, In addition, high concentrations of some antihistamines inhibit allergen-induced histamine release from mast cells in vitro, Objective: The purpose of this study was to determine the effect of intranasal azelastine or systemic cetirizine (both potent antihistamines) on the allergen-induced release of mast-cell mediators from the human nasal mucosa in vivo. Methods: Patients allergic to birch pollen (n = 11)and control subjects not allergic to birch pollen (n = 5) were included in a randomized, double-blind, placebo-controlled, 3-way crossover study outside the pollen season. Each subject was treated with azelastine nasal spray 0.14 mg per nostril twice daily, cetirizine tablets 10 mg every day, or placebo for 1 week using a double-dummy design. At the end of each treatment period, nasal allergen challenges were performed, and the number of sneezes were counted. In addition, nasal lavage fluid was collected, and the-levels of mast-cell mediators (histamine and tryptase) were measured. Results: The allergen challenge of patients allergic to pollen produced sneezing and a significant increase in the Levels of histamine and tryptase. The challenge of subjects not allergic to pollen produced no such response. Azelastine and cetirizine significantly reduced allergen-induced sneezing and the associated increase in histamine and tryptase levels. No significant differences were found between the azelastine and cetirizine treatments. Conclusion: Pretreatment with azelastine or cetirizine inhibits the allergen-induced release of mast-cell mediators from the human nasal mucosa, Our results are consistent with the hypothesis that both antihistamines reduce mediator release from nasal mucosa mast cells in vivo. However, further studies are necessary to test this hypothesis.	Natl Univ Hosp, Allergy Unit, Copenhagen, Denmark; Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark	Aarhus University	Jacobi, HH (corresponding author), Rigshosp, Allergiklinikken 7511, Tagensvej 20, DK-2200 Copenhagen, Denmark.		Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X				ANDERSSON M, 1990, J ALLERGY CLIN IMMUN, V86, P815, DOI 10.1016/S0091-6749(05)80188-5; ANDERSSON M, 1991, ALLERGY, V46, P540, DOI 10.1111/j.1398-9995.1991.tb00618.x; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661, DOI 10.1152/jappl.1993.74.6.2661; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; CHURCH MK, 1980, BRIT J PHARMACOL, V69, P663, DOI 10.1111/j.1476-5381.1980.tb07919.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; Genovese A, 1997, CLIN EXP ALLERGY, V27, P559, DOI 10.1111/j.1365-2222.1997.tb00745.x; GREIFF L, 1995, J ALLERGY CLIN IMMUN, V96, P97, DOI 10.1016/S0091-6749(95)70038-2; Jacobi HH, 1998, CLIN EXP ALLERGY, V28, P83; LITTLE MM, 1989, AGENTS ACTIONS, V28, P16, DOI 10.1007/BF02022975; LITTLE MM, 1989, J ALLERGY CLIN IMMUN, V83, P862, DOI 10.1016/0091-6749(89)90096-1; MANSMANN HC, 1992, ANN ALLERGY, V68, P348; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P447, DOI 10.1016/0091-6749(88)90018-8; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; NOLTE H, 1989, ALLERGY, V44, P543, DOI 10.1111/j.1398-9995.1989.tb04199.x; OKAYAMA Y, 1994, ALLERGY, V49, P246, DOI 10.1111/j.1398-9995.1994.tb02657.x; PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6; RIMMER SJ, 1990, CLIN EXP ALLERGY, V20, P3, DOI 10.1111/j.1365-2222.1990.tb02456.x; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; SHIN MH, 1992, CLIN EXP ALLERGY, V22, P289, DOI 10.1111/j.1365-2222.1992.tb03085.x; SIMONS FER, 1995, J ALLERGY CLIN IMMUN, V95, P759, DOI 10.1016/S0091-6749(95)70183-4; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840; Walsh GM, 1997, CLIN EXP ALLERGY, V27, P47, DOI 10.1111/j.1365-2222.1997.tb02583.x; WEILER JM, 1988, J ALLERGY CLIN IMMUN, V82, P801, DOI 10.1016/0091-6749(88)90082-6	28	26	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				768	772		10.1016/S0091-6749(99)70418-5	http://dx.doi.org/10.1016/S0091-6749(99)70418-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329808				2022-12-18	WOS:000080470200009
J	Shi, HZ; Sun, JJ; Pan, HL; Lu, JQ; Zhang, JL; Jiang, JD				Shi, HZ; Sun, JJ; Pan, HL; Lu, JQ; Zhang, JL; Jiang, JD			Alterations of T-lymphocyte subsets, soluble IL-2 receptor, and IgE in peripheral blood of children with acute asthma attacks	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; asthma; acute attack; remission; T-cell subsets; activation; IL-2R; IgE	INTERLEUKIN-2 RECEPTOR; BRONCHOALVEOLAR LAVAGE; AIRWAY INFLAMMATION; DISEASE SEVERITY; CELL CLONES; ACTIVATION; CYTOKINES	Background: T-cell activation and alteration of cytokines are involved in the pathogenesis of atopic asthma. However, the profile of circulating T-lymphocyte subsets, related cytokines, and plasma IgE during acute asthma attacks is still unclear. Objective: In an attempt to illustrate the dynamics of these parameters in asthma attacks, He investigated the changes of T-cell subsets, lymphocyte activation, soluble IL-2R, and IgE in peripheral blood in children during and after acute asthma attach. Methods: This study was carried out in a cohort of Chinese children (n = 59) with acute asthma attacks. Immunoassays were performed when the patients had acute attacks before treatment, and the patients were reexamined in the 3 weeks after the resolution of acute attacks with therapy. Paired t tests were used for the statistical analysis of these patients to compare the data obtained during and after the acute attacks. Twenty healthy, age-matched subjects sere used as normal control subjects. Nine children with long-term stable asthma were used as control subjects with stable asthma. Results: CD3+, CD4+, CD8+, and IL-2R+ (CD25+) cells; plasma soluble IL-2 receptor; and IgE were significantly higher in patients with acute attacks than in control subjects. (P <.05, P <.05, P <.001, P <.05, P <.0001, and P<.0001, respectively). Immunoelectron microscopy exhibited an increased expression of IL-2R on lymphocytes in acute attacks as compared to control subjects. The abnormalities returned to normal, with the exception of IgE, when clinical remission was achieved after treatment. Correlation analyses revealed a positive relationship between plasma IgE and soluble IL-2R in asthma attacks (r = 0.83, P=.0001). plasma IgE and soluble IL-2R of those who Here in remission positively correlated with their production in acute attacks (r = 0.58, P =.001 and r = 0.71, P =.0001, respectively). Conclusion: This study suggests that (1) the percentage of CD4+, CD8+, or IL-2R+ lymphocytes in peripheral blood was significantly elevated during acute attacks and returned to normal ranges after complete remission was achieved; (3) plasma soluble IL-2R is a sensitive marker for asthma activity; and (3) atopic asthmatic children seem to have a hereditary predisposition of having higher revels of soluble IL-2R in asthma attacks, coinherited with the trait of IgE.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Nanjing Med Univ, Cent Immunol Lab, Nanjing, Peoples R China; Nanjing Med Univ, Hosp Nanjing City 1, Dept Pediat, Nanjing, Peoples R China; Nanjing Med Univ, Electron Microscopy Lab, Nanjing, Peoples R China	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Jiang, JD (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1131, New York, NY 10029 USA.							Abbas A.K., 1994, CYTOKINES CELLULAR M, P240; BROWN PH, 1991, LANCET, V338, P590, DOI 10.1016/0140-6736(91)90605-O; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; CORRIGAN CJ, 1991, INT ARCH ALLER A IMM, V94, P270, DOI 10.1159/000235380; Gemou-Engesaeth V, 1994, Pediatr Allergy Immunol, V5, P170, DOI 10.1111/j.1399-3038.1994.tb00234.x; HASHIMOTO S, 1993, ANN ALLERGY, V71, P455; HUANG DS, 1993, CHIN J PEDIAT, V31, P195; KOBZIK L, 1994, PATHOLOGIC BASIS DIS, P673; Koning H, 1996, PEDIATR RES, V40, P363, DOI 10.1203/00006450-199609000-00001; LAI CKW, 1993, CHEST, V103, P782, DOI 10.1378/chest.103.3.782; Lai CKW, 1996, CLIN EXP ALLERGY, V26, P5, DOI 10.1111/j.1365-2222.1996.tb00050.x; Lasky JA, 1997, RES IMMUNOL, V148, P39, DOI 10.1016/S0923-2494(97)86273-6; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mori A, 1997, BLOOD, V89, P2891, DOI 10.1182/blood.V89.8.2891; MORI A, 1995, INT ARCH ALLERGY IMM, V107, P220, DOI 10.1159/000236983; MOTOJIMA S, 1995, J ASTHMA, V32, P151, DOI 10.3109/02770909509083237; NELSON DL, 1986, J CLIN IMMUNOL, V6, P114, DOI 10.1007/BF00918743; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922, DOI 10.1164/ajrccm/145.4_Pt_1.922; PARK CS, 1994, CHEST, V106, P400, DOI 10.1378/chest.106.2.400; Pretolani M, 1997, RES IMMUNOL, V148, P33, DOI 10.1016/S0923-2494(97)86272-4; RICCI M, 1994, CLIN EXP ALLERGY, V24, P801, DOI 10.1111/j.1365-2222.1994.tb01803.x; URBANOISPIZUA A, 1992, BRIT J HAEMATOL, V81, P178, DOI 10.1111/j.1365-2141.1992.tb08204.x; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958, DOI 10.1164/ajrccm/145.4_Pt_1.958; ZHANG YM, 1992, CHIN J PEDIAT, V30, P100	26	26	30	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				388	394		10.1016/S0091-6749(99)70461-6	http://dx.doi.org/10.1016/S0091-6749(99)70461-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069870				2022-12-18	WOS:000079175700005
J	Cousins, L				Cousins, L			Fetal oxygenation, assessment of fetal well-being, and obstetric management of the pregnant patient with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CEREBRAL OXYGENATION; BLOOD-FLOW; EXERCISE; REST; PREDICTION; LABOR	Asthma is the most common chronic respiratory disease affecting pregnant women. To provide the best obstetric care, it is necessary to understand fetal oxygenation and how it can be affected by maternal asthma, During pregnancy, fetal well-being should be closely monitored, and asthma care should be carefully integrated with obstetric care. Optimal fetal assessment includes establishing gestational age, assessment of fetal growth, and monitoring fetal activity, Evaluation for high-risk patients may include the non-stress test, contraction stress test, or biophysical profile.	Sharp Mem & Sharp Perinatal Ctr, Mary Birch Hosp Women, San Diego, CA 92123 USA		Cousins, L (corresponding author), Sharp Mem & Sharp Perinatal Ctr, Mary Birch Hosp Women, San Diego, CA 92123 USA.							ADAMSONS K, 1971, AM J OBSTET GYNECOL, V109, P248, DOI 10.1016/0002-9378(71)90873-8; AHLQUIST RP, 1947, FED PROC, V6, P305; ALDRICH CJ, 1995, BRIT J OBSTET GYNAEC, V102, P14, DOI 10.1111/j.1471-0528.1995.tb09019.x; ALDRICH CJ, 1994, BRIT J OBSTET GYNAEC, V101, P509, DOI 10.1111/j.1471-0528.1994.tb13152.x; AWE RJ, 1979, OBSTET GYNECOL, V53, P182; CAMPBELL S, 1985, OBSTET GYNECOL, V65, P613; COUSINS LM, 1989, ENDOCRINE DISORDERS, P345; CRANE JP, 1980, AM J OBSTET GYNECOL, V138, P518, DOI 10.1016/0002-9378(80)90279-3; CRAWFORD JS, 1980, ANAESTHESIA, V35, P397, DOI 10.1111/j.1365-2044.1980.tb05138.x; FREEMAN RK, 1975, AM J OBSTET GYNECOL, V121, P481, DOI 10.1016/0002-9378(75)90079-4; GILSTRAP LC, 1987, OBSTET GYNECOL, V69, P328; GORDON M, 1970, AM J OBSTET GYNECOL, V106, P421, DOI 10.1016/0002-9378(70)90371-6; HAGEN E, 1993, OBSTET GYNECOL, V82, P1004; HOBBINS JC, 1978, J REPROD MED, V21, P319; JOBE A, 1989, MATERNAL FETAL MED P, P426; KNUTTGEN HG, 1974, J APPL PHYSIOL, V36, P549, DOI 10.1152/jappl.1974.36.5.549; Mabie WC, 1996, CLIN OBSTET GYNECOL, V39, P56, DOI 10.1097/00003081-199603000-00007; MABIE WC, 1992, J MATERNAL FETAL MED, V1, P45; MANNING FA, 1985, AM J OBSTET GYNECOL, V151, P343, DOI 10.1016/0002-9378(85)90301-1; MESCHIA G, 1989, MATERNAL FETAL MED, P303; MOORE TR, 1989, AM J OBSTET GYNECOL, V160, P1075, DOI 10.1016/0002-9378(89)90164-6; MOTOYAMA EK, 1967, ANESTHESIOLOGY, V28, P891, DOI 10.1097/00000542-196709000-00026; *NAT ASTHM ED PROG, 1993, NIH PUBL; PEETERS LLH, 1979, AM J OBSTET GYNECOL, V135, P637, DOI 10.1016/S0002-9378(16)32989-1; PERNOLL ML, 1975, RESP PHYSIOL, V25, P295, DOI 10.1016/0034-5687(75)90005-5; PERNOLL ML, 1975, RESP PHYSIOL, V25, P285, DOI 10.1016/0034-5687(75)90004-3; PROWSE CM, 1965, ANESTHESIOLOGY, V26, P381, DOI 10.1097/00000542-196507000-00003; Robson JM, 1938, J PHYSIOL-LONDON, V92, P9, DOI 10.1113/jphysiol.1938.sp003579; ROCHARD F, 1976, AM J OBSTET GYNECOL, V126, P699, DOI 10.1016/0002-9378(76)90523-8; ROSENFELD CR, 1976, AM J OBSTET GYNECOL, V124, P156, DOI 10.1016/S0002-9378(16)33292-6; Schnider SM, 1987, ANESTHESIA OBSTETRIC, P159; WULF KH, 1972, NIH PUBL	32	26	26	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	2	S			S343	S349		10.1016/S0091-6749(99)70260-5	http://dx.doi.org/10.1016/S0091-6749(99)70260-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	171KA	9949335	Bronze			2022-12-18	WOS:000078861500004
J	Fushimi, T; Okayama, H; Shimura, S; Saitoh, H; Shirato, K				Fushimi, T; Okayama, H; Shimura, S; Saitoh, H; Shirato, K			Dexamethasone suppresses gene expression and production of IL-13 by human mast cell line and lung mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; dexamethasone; mast cells; RNA	TUMOR-NECROSIS-FACTOR; HUMAN IGE SYNTHESIS; HUMAN B-CELLS; MESSENGER-RNA; ATOPIC ASTHMA; GLUCOCORTICOIDS SUPPRESS; BRONCHOALVEOLAR LAVAGE; HUMAN-MONOCYTES; T-CELLS; GM-CSF	Background: IL-13 has been shown to induce IgE production in B cells by promoting class switching to IgE. Mast cells are known to play an important role in the pathogenesis of allergic diseases. We evaluated the ability of human mast cells to produce IL-13 using human mast cell line HMC-1 and freshly isolated lung mast cells and then examined the effect of dexamethasone on the gene expression and production of IL-13 by these cells. Methods: HMC-1 cells and lung mast cells were cultured with 10 ng/ml phorbol l2-myristate U-acetate (PMA) and 1 mu mol/L ionomycin and with 5 mu g/ml phytohemagglutinin (PHA) and 10 ng/ml PMA, respectively, in the presence of dexamethasone. The gene expression of IL-13 at 3 hours (HMC-1 cells) or 12 hours (human lung mast cells) after stimulation was assessed semiquantitatively by sequential reverse transcription-polymerase chain reaction and Southern blot analysis. IL-13 production at 12 hours after stimulation was assayed by ELISA. Results: The gene expression of IL-13 by HMC-1 cells and human lung mast cells, which was detected at a low level in an unstimulated condition, was increased by PMA/ionomycin and suppressed by dexamethasone. The supernatant of HMC-1 cells and human lung mast cells showed a low level of IL-13, which was increased by the stimulation and suppressed by dexamethasone, Conclusion: These findings indicate that HMC-1 cells and human lung mast cells produce IL-13 and that dexamethasone suppresses the production of IL-13 by these cells through an inhibitory action on the gene expression.	Tohoku Univ, Sch Med, Dept Internal Med 1, Aoba Ku, Sendai, Miyagi 9808574, Japan	Tohoku University	Shirato, K (corresponding author), Tohoku Univ, Sch Med, Dept Internal Med 1, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.							ARYA SK, 1984, J IMMUNOL, V133, P273; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOUMPAS DT, 1991, J CLIN INVEST, V87, P1739, DOI 10.1172/JCI115192; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; DEVRIES JE, 1972, CURR OPIN IMMUNOL, V3851, P91; Fushimi T, 1997, INT ARCH ALLERGY IMM, V112, P13, DOI 10.1159/000237425; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEW W, 1988, J IMMUNOL, V140, P1895; LOEW D, 1986, EUR J CLIN PHARMACOL, V30, P225, DOI 10.1007/BF00614309; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOLLER A, 1993, J IMMUNOL, V151, P3261; OKAYAMA H, 1994, J ALLERGY CLIN IMMUN, V93, P1006, DOI 10.1016/S0091-6749(94)70049-4; OKAYAMA Y, 1994, J IMMUNOL METHODS, V169, P153, DOI 10.1016/0022-1759(94)90259-3; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PUNNONEN J, 1994, J IMMUNOL, V152, P1094; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SPAHN JD, 1995, J ALLERGY CLIN IMMUN, V95, P385; TOBLER A, 1992, BLOOD, V79, P45; TSUEI SE, 1979, J PHARMACOKINET BIOP, V7, P249, DOI 10.1007/BF01060016; WAAGE A, 1988, IMMUNOLOGY, V63, P299; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WASSIM YA, 1996, J LEUKOCYTE BIOL, V60, P563; WERSHIL BK, 1995, J IMMUNOL, V154, P1391; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053; YOUNG MC, 1989, EUR J CLIN PHARMACOL, V37, P75; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	43	26	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					134	142		10.1016/S0091-6749(98)70064-8	http://dx.doi.org/10.1016/S0091-6749(98)70064-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679857				2022-12-18	WOS:000074909500019
J	Lara-Marquez, ML; Deykin, A; Krinzman, S; Listman, J; Israel, E; He, HZ; Christiani, DC; Perkins, DL; Finn, PW				Lara-Marquez, ML; Deykin, A; Krinzman, S; Listman, J; Israel, E; He, HZ; Christiani, DC; Perkins, DL; Finn, PW			Analysis of T-cell activation after bronchial allergen challenge in patients with atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen challenge; T helper cells; CD45 R isoforms; interleukin-2R; MHC class II	PERIPHERAL-BLOOD; BRONCHOALVEOLAR LAVAGE; CD45 ISOFORMS; AIRWAY HYPERREACTIVITY; LYMPHOCYTE SUBSETS; MEMORY; EXPRESSION; ANTIGEN; PHENOTYPE; UCHL1	Background: T helper cells are a heterogeneous group of cells that have phenotypic and functional differences. Activated T helper cells have been found in peripheral blood after allergen challenge of subjects with atopic asthma, but the phenotypes of specific T helper subpopulation involved remains to be identified. Objective: To characterize the T cell activation markers that may be regulated by allergens, we analyzed peripheral blood lymphocytes obtained before and after allergen challenge from subjects with atopic asthma. Methods: We analyzed the distribution of the cell surface activation markers, interleukin 2 receptor (IL-2R) and major histocompatibility complex class Ii antigens (MHC II) among T helper subpopulations classified as naive (CD45RA) or memory (CD45RO) phenotypes. Nine adult subjects with atopic asthma underwent bronchoprovacative allergen inhalation and isocapnic cold air hyperventilation (ISH) challenge followed by serial spirometry. Peripheral blood mononuclear cells (PBMC) were isolated at baseline and 2 and 24 hours after challenge. Four color how cytometry was used to analyze the expression and distribution in vivo of IL-2R and MHC LI activation markers on naive and memory T cell subsets after challenge. Results: At 2 and 24 hours after allergen challenge, there was a significant increase in the CD45RO+IL-2R+ T helper cells compared with baseline (mean +/- SE, baseline, 12.5% +/- 1% versus 2 hours, 18.1% +/- 1% and 24 hours, 17.8% +/- 2%, p < 0.025). MHC II expression was not significantly increased after challenge on naive and memory T helper cells and coexpression of IL-PR and MHC II was only found in a small proportion of CD45RO+ T helper cells (2.7% +/- 1%). No changes of IL-2R or MBC II expression on T helper subsets were observed after ISH challenge in the same patients. We also found that 31% to 46% of T helper cells coexpress CD45RA and CD45RO simultaneously, and upregulation of IL-2-R and MHC II expression occurs only on those T helper cells that express CD45RO. Conclusions: We have found that T helper cells express both CD45RA and CD45RO isoforms, which suggests the existence of a transitional phenotype among naive and memory T helper cells in peripheral blood. In subjects with atopic asthma, our in vivo analysis characterizes two populations of activated memory T helper cells based on the expression of IL-2R or MHC II surface molecules after allergen challenge.	Brigham & Womens Hosp, Div Resp, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Nephrol, Boston, MA 02115 USA; Beth Israel Hosp, Div Resp, Boston, MA USA; Massachusetts Gen Hosp, Div Pulm, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Finn, PW (corresponding author), Brigham & Womens Hosp, Div Resp, 75 Francis St, Boston, MA 02115 USA.			Lara-Marquez, Maria Luz/0000-0003-1014-6524	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, R01ES006568] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33100] Funding Source: Medline; NIEHS NIH HHS [ES06568, ES00002] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKBAR AN, 1991, IMMUNOL TODAY, V12, P184, DOI 10.1016/0167-5699(91)90050-4; AKBAR AN, 1988, J IMMUNOL, V140, P2171; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOIS RMD, 1992, AM REV RESPIR DIS, V145, P1205; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; Chheda S, 1996, BIOL NEONATE, V69, P128; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; DEROSE V, 1994, J CLIN INVEST, V94, P1840, DOI 10.1172/JCI117533; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; FINN PW, 1991, J IMMUNOL, V146, P4011; GARSSEN J, 1991, AM REV RESPIR DIS, V144, P931, DOI 10.1164/ajrccm/144.4.931; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; JOHANNISSON A, 1995, CYTOMETRY, V19, P343, DOI 10.1002/cyto.990190409; KANEGANE H, 1991, INT IMMUNOL, V3, P1349, DOI 10.1093/intimm/3.12.1349; Krinzman SJ, 1996, AM J PHYSIOL-LUNG C, V271, pL476, DOI 10.1152/ajplung.1996.271.3.L476; Krinzman SJ, 1996, J CLIN INVEST, V98, P2693, DOI 10.1172/JCI119093; LASALLE JM, 1994, FASEB J, V8, P601, DOI 10.1096/fasebj.8.9.8005388; Listman JA, 1996, CELL IMMUNOL, V167, P44, DOI 10.1006/cimm.1996.0006; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MORIMOTO C, 1988, EUR J IMMUNOL, V18, P731, DOI 10.1002/eji.1830180512; Nasert S, 1996, J IMMUNOL, V157, P441; NEWMAN I, 1993, IMMUNOLOGY, V78, P92; Patel HR, 1996, J IMMUNOL, V156, P1781; Perkins DL, 1996, J IMMUNOL, V156, P4961; PLEBANSKI M, 1992, IMMUNOLOGY, V75, P86; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHAUER U, 1991, CLIN EXP IMMUNOL, V83, P25; Shanafelt MC, 1996, J ALLERGY CLIN IMMUN, V98, P433, DOI 10.1016/S0091-6749(96)70168-9; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WALKER C, 1991, INT ARCH ALLER A IMM, V94, P241, DOI 10.1159/000235370; WERFEL S, 1995, J ALLERGY CLIN IMMUN, V96, P57, DOI 10.1016/S0091-6749(95)70033-1; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958, DOI 10.1164/ajrccm/145.4_Pt_1.958; ZOLA H, 1992, CELL IMMUNOL, V145, P175, DOI 10.1016/0008-8749(92)90321-F	41	26	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					699	708		10.1016/S0091-6749(98)70180-0	http://dx.doi.org/10.1016/S0091-6749(98)70180-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600509				2022-12-18	WOS:000073697400020
J	Barnes, N				Barnes, N			Relative safety and efficacy of inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhaled corticosteroids; asthma; safety; efficacy	FLUTICASONE PROPIONATE; BECLOMETHASONE DIPROPIONATE; SEVERE ASTHMA; GLUCOCORTICOID RECEPTOR; MODERATE ASTHMA; ADULT PATIENTS; BUDESONIDE; POWDER	Inhaled corticosteroids are the main treatment for controlling asthma in adults and children. However, there is still some concern over the safety of these drugs when used at high doses and for long periods of time. Hence issues relating to the efficacy and safety of inhaled corticosteroids have been extensively researched over the past 5 years. General considerations, such as use of an appropriate dose of inhaled corticosteroid in an appropriate asthma population, are discussed. Studies comparing the efficacy and safety of fluticasone propionate, beclomethasone dipropionate, and budesonide are highlighted, and a systematic review of these studies suggests that fluticasone propionate has a better efficacy:safety therapeutic ratio than either beclomethasone dipropionate or budesonide.	London Chest Hosp, Dept Resp Med, London E2 9JX, England	University of London; Queen Mary University London	Barnes, N (corresponding author), London Chest Hosp, Dept Resp Med, Bonner Rd,Victoria Pk, London E2 9JX, England.							Agertoft L, 1997, J ALLERGY CLIN IMMUN, V99, P773, DOI 10.1016/S0091-6749(97)80011-5; ANDERSSON N, 1994, AM J RESP CRIT CARE, V149, pA467; [Anonymous], 1990, BRIT MED J, V301, P651; AYRES JG, 1995, EUR RESPIR J, V8, P579; Backman R, 1996, J ALLERGY CLIN IMMUN, V97, P267; BARNES NC, 1993, EUR RESPIR J, V6, P877; Barnes NC, 1998, RESP MED, V92, P95, DOI 10.1016/S0954-6111(98)90039-7; BARNES NC, 1992, INT MONITOR, V3, P1; BONER AL, 1993, DRUG SAFETY, V9, P9, DOI 10.2165/00002018-199309010-00002; BOOTSMA GP, 1995, AM J RESP CRIT CARE, V151, pA275; BOOTSMA M, 1996, EUR RESPIR J, V9, P1427; BOYCE JA, PNC ASTHMA; BOYD G, 1996, INPHARMA S, V3, P1; Clark DJ, 1997, THORAX, V52, P55, DOI 10.1136/thx.52.1.55; CONNOLLY A, 1995, EUR J CLIN RES, V7, P15; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; ENGLISH AF, 1994, AM J RESP CRIT CAR S, V149; Falcoz C., 1997, British Journal of Clinical Pharmacology, V43, p541P; GEDDES DM, 1992, THORAX, V47, P404, DOI 10.1136/thx.47.6.404; GRAHNEN A, 1994, BR J CLIN PHARM, V38, P1; GROVE A, 1994, BRIT J CLIN PHARMACO, V38, P527, DOI 10.1111/j.1365-2125.1994.tb04394.x; GUSTAFSSON P, 1993, ARCH DIS CHILD, V69, P206, DOI 10.1136/adc.69.2.206; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; LANGDON CG, 1994, BR J CLIN RES, V5, P73; LANGDON CG, 1994, BR J CLIN RES, V5, P85; LEBLANC P, 1994, ALLERGY, V49, P380, DOI 10.1111/j.1398-9995.1994.tb02286.x; Lonnebo A, 1996, EUR J CLIN PHARMACOL, V49, P459; LUNDBACK B, 1993, RESP MED, V87, P609, DOI 10.1016/S0954-6111(05)80264-1; Mackie A. E., 1997, British Journal of Clinical Pharmacology, V43, p540P; Meibohm B, 1997, J CLIN PHARMACOL, V37, P704, DOI 10.1002/j.1552-4604.1997.tb04357.x; MONSON JP, 1993, THORAX, V48, P955, DOI 10.1136/thx.48.10.955; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; PAUWELS RA, 1995, AM J RESP CRIT CARE, V151, pA276; Ringdal N, 1996, MEDIAT INFLAMM, V5, P382, DOI 10.1155/S0962935196000555; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; STEINMETZ KO, 1996, AM J RESP CRIT CARE, V153, pA338; Williams J, 1997, BRIT J CLIN PRACT, V51, P147; WURTHWEIN G, 1990, BIOPHARM DRUG DISPOS, V11, P381, DOI 10.1002/bdd.2510110503; 1992, CLIN EXP ALLERGY S1, V22, P1	39	26	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	2	S			S460	S464		10.1016/S0091-6749(98)70160-5	http://dx.doi.org/10.1016/S0091-6749(98)70160-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZK101	9563373				2022-12-18	WOS:000073285000007
J	Slavin, RG				Slavin, RG			Complications of allergic rhinitis: Implications for sinusitis and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	21st Century Management of Upper Respiratory Allergic Diseases - a Focus on Allergy and Asthma	JAN 13-14, 1997	CHICAGO, ILLINOIS				BRONCHIAL-ASTHMA; CHILDREN; SURGERY; RESPONSIVENESS; EOSINOPHILIA; DISEASE		St Louis Univ, Sch Med, Div Allergy & Immunol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Microbiol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University; Saint Louis University	Slavin, RG (corresponding author), St Louis Univ, Sch Med, Div Allergy & Immunol, 1402 S Grand Blvd, St Louis, MO 63104 USA.							BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; BRUGMAN SM, 1993, AM REV RESPIR DIS, V147, P314, DOI 10.1164/ajrccm/147.2.314; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; BULLEN SS, 1932, J ALLERGY, V4, P402; DIXON WE, 1903, J PHYSIOL-LONDON, V29, P93; ENGLISH GM, 1986, LARYNGOSCOPE, V96, P374; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; FULLER C, 1990, Journal of Allergy and Clinical Immunology, V85, P222; FURUKAWA CT, 1992, J ALLERGY CLIN IMMUN, V90, P515, DOI 10.1016/0091-6749(92)90177-4; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KRATCHMER I, 1966, LARYNGOSCOPE, V76, P30; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; MINGS R, 1988, AM J RHINOL, V71, P123; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; NISHIOKA GJ, 1994, OTOLARYNG HEAD NECK, V110, P494, DOI 10.1177/019459989411000604; PARSONS DS, 1993, LARYNGOSCOPE, V103, P899; RACHELEFSKY G S, 1991, Journal of Allergy and Clinical Immunology, V87, P219, DOI 10.1016/0091-6749(91)91603-Q; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; ROSSI OVJ, 1994, INT ARCH ALLERGY IMM, V103, P209, DOI 10.1159/000236629; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SLAVIN RG, 1991, J AM GERIATR SOC, V39, P212, DOI 10.1111/j.1532-5415.1991.tb01630.x; STONE BD, 1990, J ALLERGY CLIN IMMUN, V85, P22; VANDISHOECK HAE, 1961, ADV OTORHINOLARYNGOL, V10, P1; Weille FL, 1936, NEW ENGL J MED, V215, P235, DOI 10.1056/NEJM193608062150602	32	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	2	S			S357	S360		10.1016/S0091-6749(98)70219-2	http://dx.doi.org/10.1016/S0091-6749(98)70219-2			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZA245	9500727				2022-12-18	WOS:000072343900003
J	Kanny, G; de Hauteclocque, C; Moneret-Vautrin, DA				Kanny, G; de Hauteclocque, C; Moneret-Vautrin, DA			Food anaphylaxis to bovine serum albumin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Ctr Hosp Univ Nancy, Hop Cent, Serv Med D Med Interne Immunol Clin & Allergol, F-54035 Nancy, France	CHU de Nancy	Kanny, G (corresponding author), Ctr Hosp Univ Nancy, Hop Cent, Serv Med D Med Interne Immunol Clin & Allergol, 29 Ave Lattre Tassigny, F-54035 Nancy, France.		Kanny, Gisèle/AHA-8910-2022					Drouet M, 1994, Allerg Immunol (Paris), V26, P166; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; MATA E, 1992, ALLERGY, V47, P471, DOI 10.1111/j.1398-9995.1992.tb00667.x; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; Werfel SJ, 1997, J ALLERGY CLIN IMMUN, V99, P293, DOI 10.1016/S0091-6749(97)70045-9	5	26	28	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				137	139		10.1016/S0091-6749(98)70210-6	http://dx.doi.org/10.1016/S0091-6749(98)70210-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449518				2022-12-18	WOS:000071539800026
J	Kowalczyk, D; Mytar, B; Zembala, M				Kowalczyk, D; Mytar, B; Zembala, M			Cytokine production in transient hypogammaglobulinemia and isolated IgA deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						transient hypogammaglobulinemia; isolated IgA deficiency; tumor necrosis factor; cytokines	TUMOR-NECROSIS-FACTOR; COMMON VARIABLE IMMUNODEFICIENCY; X-LINKED AGAMMAGLOBULINEMIA; MHC CLASS-II; GENE-EXPRESSION; HUMAN MONOCYTES; CELL DIFFERENTIATION; FACTOR TNF; T-CELLS; LYMPHOCYTES	Background: Transient hypogammaglobulinemia of infancy and isolated IgA deficiency are characterized by normal numbers of circulating B lymphocytes. It is likely that no single abnormality, but rather different factors, may be relevant for the delayed onset of Ige synthesis in transient hypogammaglobulinemia or for the differentiation defect of B cells in IgA deficiency. These factors mag include defective production of cytokines or an abnormal response of B cells to various mediators. Alternatively, some cytokines may act as inhibitory factors of B-cell function. Methods: The ability of peripheral blood mononuclear cells from children with proved or probable transient hypogammaglobulinemia (30 patients) and IgA deficiency (ii patients) to secrete several cytokines on stimulation with phytohemagglutinin in vitro was analyzed. Results: An enhanced production of tumor necrosis factor (TNF)-alpha, TNF-beta, and IL-10 was observed in transient hypogammaglobulinemia; whereas secretion of IL-1, IL-4, and IL-6 was essentially similar in the control and patient groups. Increased frequency of mononuclear sells secreting TNF-alpha was seen in the patient groups. Apart from elevated production of TNF-alpha, no other abnormalities in cytokine synthesis in selective IgA deficiency were observed. In vitro observations showed that exogenously added TNF-alpha and TNF-beta inhibited IgG and IgA secretion by pokeweed mitogen-stimulated mononuclear cells. During follow-up of 10 children, normalization of serum IgG level mas associated with a decrease in previously elevated TNF-alpha and TNF-beta production, but IL-10 production remained unchanged, Conclusion: These results suggest that TNF may he involved in the regulation of IgG and IgA production and can be associated with an arrest of IgG and IgA snitch of B cells in hypogammaglobulinemia. The balance between TNF and IL-10 may be important for the normal development of IgG-secreting B cells.	JAGIELLONIAN UNIV, COLL MED, POLISH AMER INST PEDIAT, DEPT CLIN IMMUNOL, PL-30663 KRAKOW, POLAND	Jagiellonian University; Collegium Medicum Jagiellonian University								AUKRUST P, 1994, CLIN IMMUNOL IMMUNOP, V70, P217, DOI 10.1006/clin.1994.1032; CALLARD RE, 1986, LYMPHOKINE RES, V5, pS151; CANO F, 1990, J ALLERGY CLIN IMMUN, V85, P510, DOI 10.1016/0091-6749(90)90163-X; EISENSTEIN EM, 1993, J CLIN IMMUNOL, V13, P247, DOI 10.1007/BF00919383; FRENCH MAH, 1990, IMMUNOL TODAY, V11, P271, DOI 10.1016/0167-5699(90)90110-U; GORDON JM, 1993, P SOC PHOTO-OPT INS, V2016, P27, DOI 10.1117/12.161943; HAYAKAWA H, 1981, J CLIN IMMUNOL, V1, P31, DOI 10.1007/BF00915474; JASINSKI M, 1995, J CLIN IMMUNOL, V15, P185, DOI 10.1007/BF01541088; KASHIWA H, 1987, J IMMUNOL, V138, P1383; KOWALCZYK D, 1994, ACTA PAEDIATR, V83, P1310, DOI 10.1111/j.1651-2227.1994.tb13024.x; KRUGER G, 1984, J CLIN IMMUNOL, V4, P295, DOI 10.1007/BF00915297; Malisan F, 1996, J EXP MED, V183, P937, DOI 10.1084/jem.183.3.937; MATHESON DS, 1994, J ALLERGY CLIN IMMUN, V93, P126, DOI 10.1016/0091-6749(94)90241-0; MCGHEE JR, 1989, J CLIN IMMUNOL, V9, P175, DOI 10.1007/BF00916814; MCGREADY SJ, 1987, J PEDIATR, V110, P47; MULLER F, 1995, CLIN IMMUNOL IMMUNOP, V76, P203, DOI 10.1006/clin.1995.1116; North ME, 1996, CLIN EXP IMMUNOL, V105, P517, DOI 10.1046/j.1365-2249.1996.d01-795.x; PASTORELLI G, 1989, CLIN EXP IMMUNOL, V78, P334; RILEY RJ, 1995, CLIN EXP IMMUNOL, V99, P1; ROSEN FS, 1984, NEW ENGL J MED, V311, P300, DOI 10.1056/NEJM198408023110506; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SIEGEL RL, 1981, NEW ENGL J MED, V305, P1307, DOI 10.1056/NEJM198111263052202; SNELLER MC, 1990, J IMMUNOL, V144, P3762; SPLAWSKI JB, 1991, J CLIN INVEST, V88, P967, DOI 10.1172/JCI115400; STROBER W, 1990, J CLIN IMMUNOL, V10, pS56, DOI 10.1007/BF00918692; TILLER TL, 1978, J PEDIATR-US, V92, P347, DOI 10.1016/S0022-3476(78)80417-X; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VANDERPOLL T, 1994, J EXP MED, V180, P1985, DOI 10.1084/jem.180.5.1985; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WALKER A, 1994, ARCH DIS CHILD, V70, P183, DOI 10.1136/adc.70.3.183; WANIDWORANUN C, 1993, J IMMUNOL, V151, P6853; ZEMBALA M, 1994, INT J CANCER, V56, P269, DOI 10.1002/ijc.2910560221; ZEMBALA M, 1990, INT IMMUNOL, V2, P337, DOI 10.1093/intimm/2.4.337; ZEMBALA M, 1994, IMMUNOL INVEST, V23, P189, DOI 10.3109/08820139409087799; ZEMBALA M, 1984, J IMMUNOL, V133, P1293	35	26	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					556	562		10.1016/S0091-6749(97)70150-7	http://dx.doi.org/10.1016/S0091-6749(97)70150-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338552				2022-12-18	WOS:A1997YA52900021
J	Ikeda, K; Oshima, T; Furukawa, M; Katori, Y; Shimomura, A; Takasaka, T; Maruoka, S				Ikeda, K; Oshima, T; Furukawa, M; Katori, Y; Shimomura, A; Takasaka, T; Maruoka, S			Restoration of the mucociliary clearance of the maxillary sinus after endoscopic sinus surgery	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endoscopic sinus surgery; mucociliary clearance; chronic sinusitis; radionuclide; cilia; maxillary sinus	FOLLOW-UP; MANAGEMENT; RHINOSINUSITIS; ANTROSTOMY	Background: Whether endoscopic sinus surgery (ESS) restores the mucociliary cl Methods: We evaluated the mucociliary clearance of the maxillary sinus by using a radionuclide technique in 12 patients with chronic sinusitis (sinusitis group) and in six patients who had undergone ESS 6 to 14 months after. the surgery (post-ESS group). The mucosal cilia taken from the maxillary sinus in 12 patients with sinusitis before and after ESS (paired experiments) were examined by light and electron microscopy. Results: The radionuclide placed endoscopically in the maxillary sinus in eight patients immediately after ESS maintained 81.2% +/- 16.3% of its radioactivity after 30 minutes. This result was consistent with results in four patients with untreated chronic sinusitis in whom the radionuclide had been instilled by antral puncture (86.9% +/- 3.5%). On the other hand in six patients in the post-ESS group the radionucleotide maintained only 25.9% +/- 11.6% of its radioactivity, demonstrating statistically significant differences from those of both the sinusitis group without ESS (p < 0.005) and the group 4 days after ESS (p < 0.005). The absence of the cilia in the sinusitis condition was recognized in 35.5% +/- 12.1% (n = 12) of the epithelial cells. On the other hand the absence of cilia was significantly (p < 0.01) reduced to 5.3% +/- 3.7% of the epithelial cells in the post-ESS condition. Electron microscopic observation also revealed abnormal cilia in the sinusitis condition, whereas the mucosal cilia were regularly arranged in the post-ESS condition. Conclusions: The mucociliary clearance of the maxillary sinus disturbed by chronic inflammation was restored by ESS, indicating the clinical effectiveness of ESS for the treatment of chronic sinusitis.	TOHOKU UNIV, SCH MED, DEPT RADIOL, SENDAI, MIYAGI 980, JAPAN	Tohoku University	Ikeda, K (corresponding author), TOHOKU UNIV, SCH MED, DEPT OTORHINOLARYNGOL, SENDAI, MIYAGI 980, JAPAN.							BENNINGER MS, 1993, OTOLARYNG HEAD NECK, V109, P1034; FRIEDRICH JP, 1984, MED HYG, V41, P3410; Kennedy D W, 1992, Laryngoscope, V102, P1; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; KENNEDY DW, 1987, LARYNGOSCOPE, V97, P1, DOI 10.1288/00005537-198708002-00001; King E., 1935, ANN OTO RHINOL LARYN, V44, P480, DOI [DOI 10.1177/000348943504400220, 10.1177/000348943504400220]; KING JM, 1994, LARYNGOSCOPE, V104, P404; LANZA DC, 1992, J ALLERGY CLIN IMMUN, V90, P505, DOI 10.1016/0091-6749(92)90175-2; LEVINE HL, 1990, LARYNGOSCOPE, V100, P79; LUND VJ, 1991, J LARYNGOL OTOL, V105, P832, DOI 10.1017/S0022215100117463; MAJIMA Y, 1986, CLIN OTOLARYNGOL, V11, P55, DOI 10.1111/j.1365-2273.1986.tb00108.x; Messerklinger W, 1966, Monatsschr Ohrenheilkd Laryngorhinol, V100, P56; OHASHI Y, 1983, ACTA OTO-LARYNGOL, P3; OHASHI Y, 1983, ACTA OTO-LARYNGOL, P11; RICE DH, 1989, OTOLARYNG HEAD NECK, V101, P476, DOI 10.1177/019459988910100412; SHARPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417; STAMMBERGER H, 1990, EUR ARCH OTO-RHINO-L, V247, P63; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P143, DOI 10.1177/019459988609400202; TAKASAKA T, 1980, ANN OTO RHINOL LARYN, V89, P37, DOI 10.1177/000348948008900110; WARNER A, 1977, AM REV RESPIR DIS, V116, P73	20	26	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				48	52		10.1016/S0091-6749(97)70299-9	http://dx.doi.org/10.1016/S0091-6749(97)70299-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003210				2022-12-18	WOS:A1997WD06100007
J	Gschwentner, M; Susanna, A; Schmarda, A; Laich, A; Nagl, UO; Ellemunter, H; Deetjen, P; Frick, J; Paulmichl, M				Gschwentner, M; Susanna, A; Schmarda, A; Laich, A; Nagl, UO; Ellemunter, H; Deetjen, P; Frick, J; Paulmichl, M			I-Cln: A chloride channel paramount for cell volume regulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chloride channel; cromolyn sodium; epithelial cell; fibroblast; nedocromil sodium; regulatory volume decrease		Cell volume regulation is a ubiquitous cell regulatory mechanism based on meticulously controlled ion transport mechanisms. Keeping the absolute volume constant seems to be of the highest priority for most cells and is achieved at the expense of altered intracellular ion concentrations. We have been able to demonstrate that I-Cln, a chloride channel cloned from epithelial cells, is paramount for the ability of swollen cells to regulate their volume back to that under resting conditions. A unique feature of I-Cln is the distinct sensitivity bf these channels for nucleotides and nucleoside analogues added to the extracellular fluid. In addition, cromolyn sodium and nedocromil sodium, drugs used by patients with asthma, are able to impede the function of these channels.	UNIV INNSBRUCK, DEPT PHYSIOL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, DEPT PEDIAT, A-6020 INNSBRUCK, AUSTRIA; SALZBURGER LANDESKRANKENANSTALTEN, DEPT UROL, SALZBURG, AUSTRIA	University of Innsbruck; University of Innsbruck			Susanna, Alfonso/C-1683-2013	Susanna, Alfonso/0000-0003-4717-9063				Alton EWFW, 1996, J ALLERGY CLIN IMMUN, V98, pS102, DOI 10.1016/S0091-6749(96)80136-9; ALTON EWFW, 1991, J PHYSIOL-LONDON, V443, P137, DOI 10.1113/jphysiol.1991.sp018827; Gschwentner M, 1996, BRIT J PHARMACOL, V118, P41, DOI 10.1111/j.1476-5381.1996.tb15364.x; GSCHWENTNER M, 1994, RENAL PHYSIOL BIOCH, V17, P148; GSCHWENTNER M, 1995, MOL MED, V1, P407, DOI 10.1007/BF03401578; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; GSTRAUNTHALER G, 1993, RENAL DISPOSITION NE, P2761; HAMASAKI Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P37, DOI 10.1016/0005-2760(85)90173-0; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LAMBERT IH, 1987, J MEMBRANE BIOL, V98, P247, DOI 10.1007/BF01871187; Lang F., 1990, Comparative Physiology, V4, P1; Marty A., 1983, SINGLE CHANNEL RECOR, P107; PAULMICHL M, 1989, PFLUG ARCH EUR J PHY, V413, P456, DOI 10.1007/BF00594173; PAULMICHL M, 1993, CELL PHYSIOL BIOCHEM, V3, P374, DOI 10.1159/000154699; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; VANGLARIK CJ, 1993, J GEN PHYSIOL, V101, P545; WANGEMANN P, 1986, PFLUG ARCH EUR J PHY, V407, pS128, DOI 10.1007/BF00584942; ZHANG J, 1992, PHYSIOLOGIST, V35, P18	18	26	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S98	S101		10.1016/S0091-6749(96)80135-7	http://dx.doi.org/10.1016/S0091-6749(96)80135-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939183				2022-12-18	WOS:A1996VW14000021
J	Noma, T; Mori, A; Yoshizawa, I				Noma, T; Mori, A; Yoshizawa, I			Induction of allergen-specific IL-2 responsiveness of lymphocytes after respiratory syncytial virus infection and prediction of onset of recurrent wheezing and bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Recurrent wheezing; respiratory syncytial virus; ovalbumin; alpha-casein; Dermatophagoides farinae; propidium iodide staining; allergen-induced IL-2 responsiveness; bronchial asthma	HEN EGG ALLERGY; INITIAL EVENTS; T-CELLS; ANTIGEN; BRONCHIOLITIS; OVALBUMIN; RESPONSES; MICE	Background: In pediatric patients with bronchial asthma and/or atopic dermatitis, peripheral lymphocytes are activated if they are stimulated with the responsible antigen, resulting in induction of responsiveness to IL-2. Because some nursing infants experience recurrent wheezing after respiratory syncytial virus (RSV) infection, attention is being directed to progression of the disease to bronchial asthma. Objectives: The study was designed to elucidate the mechanism of the onset of allergic diseases after RSV infection. Methods: We examined allergen-specific IL-2 responsiveness induced in lymphocytes in the peripheral blood of infants after infection by RSV. The relationship between the onset of recurrent wheezing and antigen-specific IL-2 responsiveness was analyzed in 25 pediatric patients who could be followed up for 3 years after RSV infection. Results: Stimulation of lymphocytes with ovalbumin, alpha-casein, and mite (Dermatophagoides farinae) antigens induced significantly higher responsiveness to IL-2 in the RSV-infected infant group than in the healthy infant and disease control groups of the same age. There was no clear correlation between the IgE RAST scores for D. farinae, ovalbumin, and alpha-casein and IL-2 responsiveness. The D. farinae-specific IL-2 responsiveness was significantly increased in the group with the symptom (16 patients) for a value of 1.64 +/- 0.13 (mean +/- SEM) compared with the value of 1.31 +/- 0.21 in the asymptomatic group (9 patients). The incidence of patients with positive test results for IL-2 responsiveness was 68.8% in the symptomatic group and 44.4% in the asymptomatic group. Similarly, the ovalbumin-specific IL-2 responsiveness was significantly increased in the symptomatic group (1.63 +/- 0.17) compared with the asymptomatic group (1.12 +/- 0.26). The incidence of patients with positive test results was 62.5% and 22.2%, respectively. alpha-Casein-specific IL-2 responsiveness was also higher in the symptomatic group than in the asymptomatic group, but the difference was not statistically significant. In the patient groups with RSV infection, on the other hand, the D. farinae-, ovalbumin-, and alpha-casein-specific IL-2 responsiveness in the symptomatic group were all similar to that in the asymptomatic group were all similar to that in the asymptomatic group; no significant increases were detected. Conclusion: The results indicated that after RSV infection, lymphocytes acquire specific susceptibility to D. farinae, a mite antigen, and food antigens, particularly ovalbumin. Hence, it is thought that positive IL-2 responsiveness specific for D. farinae and/or ovalbumin, detected several months after RSV infection, can be a prediction factor for the onset of allergic diseases, such as received wheezing and bronchial asthma.	SAITAMA MED SCH,DEPT PEDIAT,MOROYAMA,SAITAMA,JAPAN	Saitama Medical University								AHLSTEDT S, 1983, IMMUNOLOGY, V48, P247; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; CHANOCK RM, 1961, JAMA-J AM MED ASSOC, V176, P647; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; LEIBOVITZ E, 1988, INT ARCH ALLER A IMM, V86, P112, DOI 10.1159/000234615; MAGGI E, 1992, J IMMUNOL, V148, P2142; MONTO AS, 1974, AM J EPIDEMIOL, V100, P458, DOI 10.1093/oxfordjournals.aje.a112058; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NOMA T, 1987, Japanese Journal of Allergology, V36, P1075; NOMA T, 1994, ANN ALLERGY, V73, P76; NOMA T, 1990, ANN ALLERGY, V64, P33; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; SAKAMOTO M, 1984, J IMMUNOL, V132, P2614; SANDIFOLD BR, 1961, BRIT MED J, V2, P881; SHU U, 1994, J CLIN INVEST, V94, P1352, DOI 10.1172/JCI117469; WELLIVER RC, 1979, J PEDIATR-US, V94, P370, DOI 10.1016/S0022-3476(79)80573-9; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; YOSHIZAWA I, 1989, J ALLERGY CLIN IMMUN, V84, P246, DOI 10.1016/0091-6749(89)90332-1	20	26	27	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					816	826		10.1016/S0091-6749(96)70131-8	http://dx.doi.org/10.1016/S0091-6749(96)70131-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876558				2022-12-18	WOS:A1996VM66500015
J	Caraballo, L; Avjioglu, A; Marrugo, J; Puerta, L; Marsh, D				Caraballo, L; Avjioglu, A; Marrugo, J; Puerta, L; Marsh, D			Cloning and expression of complementary DNA coding for an allergen with common antibody-binding specificities with three allergens of the house dust mite Blomia tropicalis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Blomia tropicalis; cDNA cloning; recombinant allergen; epitopes; major allergen; IgE; immunoblotting	ASTHMA; SENSITIZATION; REACTIVITY; PROTEINS; FAUNA	The mite Blomia tropicalis is a potent source of allergens in tropical and subtropical regions. So far most of these allergens have only been studied by immunoblotting. To characterize them at the molecular level a lambda gt11 complementary DNA library was constructed from messenger RNA isolated from whole B. tropicalis mites. This library was screened by using pooled sera from patients allergic to B. tropicalis in a plaque IgE radioimmunoassay. A B. tropicalis IgE-positive clone (Bt-M) was selected for immunologic studies. After subcloning into pBluescript (Stratagene, La Jolla, Calif.), it produced a sequence of 310 bp, with a probable amino acid sequence of 72 residues for the expressed peptide. The recombinant protein was transferred to nitrocellulose filters and probed with 100 sera from patients allergic to B. tropicalis. Forty-seven percent of sera reacted with the recombinant allergen. Immunoblottings performed with allergic serum and B. tropicalis-affinity-purified IgE demonstrated that the recombinant protein shares allergenic epitopes with the 11-13, 14, and 16 kd native allergens of B. tropicalis, which are known to be important allergens of this mite.	UNIV CARTAGENA, IMMUNOL RES INST, CARTAGENA, COLOMBIA; JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD USA	Universidad de Cartagena; Johns Hopkins University; Johns Hopkins Medicine					NIAID NIH HHS [AI19727] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019727, R55AI019727] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1042, DOI 10.1016/0091-6749(93)90218-5; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; BRONSWIJK JEM, 1973, ACAROLOGIA, V15, P477; BUSSE WW, 1988, ALLERGY PRINCIPLES P, P969; CARABALLO L, 1994, CLIN EXP ALLERGY, V24, P1056, DOI 10.1111/j.1365-2222.1994.tb02743.x; CARABALLO L, 1990, Journal of Allergy and Clinical Immunology, V85, P248; CARABALLO L, 1993, J ALLERGY CLIN IMMUN, V91, P335; CARABALLO LR, 1992, TISSUE ANTIGENS, V39, P128, DOI 10.1111/j.1399-0039.1992.tb01922.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FERNANDEZCALDAS E, 1993, CLIN EXP ALLERGY, V23, P292, DOI 10.1111/j.1365-2222.1993.tb00325.x; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; FERNANDEZCALDAS E, 1986, THESIS U LA LAGUNA T; GUERIN B, 1993, J ALLERGY CLIN IMMUN, V91, P356; HURTADO I, 1987, ANN ALLERGY, V59, P128; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JORGE N, 1980, REV BRAS ALERG IMUNO, V2, P140; Krantz GW, 1978, MANUAL ACAROLOGY, P77; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; MERCADO D, 1992, J ALLERGY CLIN IMMUN, V89, P150; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; ONEILL GM, 1994, MOL IMMUNOL, V31, P1447, DOI 10.1016/0161-5890(94)90161-9; PEARSON R S B, 1973, Clinical Allergy, V3, P299, DOI 10.1111/j.1365-2222.1973.tb01337.x; PUERTA L, 1996, IN PRESS J ALLERGY C; SAMBROOK J, 1989, MOL CLONING LAB MANU, V1, P62; SAMBROOK J, 1989, MOL CLONING LAB MANU, V2, P67; SCHUHL JF, 1977, ALLERGOL IMMUNOPATH, V5, P117; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; SOMORIN AO, 1978, IRISH J MED SCI, V147, P26, DOI 10.1007/BF02939363; STANALAND BE, 1994, J ALLERGY CLIN IMMUN, V94, P452, DOI 10.1016/0091-6749(94)90200-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Bronswijk J.E.M.H., 1972, Entomologische Berichten, V32, P162; [No title captured]	35	26	31	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					573	579		10.1016/S0091-6749(96)70091-X	http://dx.doi.org/10.1016/S0091-6749(96)70091-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828535				2022-12-18	WOS:A1996VJ42800014
J	MerayoLloves, J; Zhao, TZ; Dutt, JE; Foster, CS				MerayoLloves, J; Zhao, TZ; Dutt, JE; Foster, CS			A new murine model of allergic conjunctivitis and effectiveness of nedocromil sodium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; hay fever conjunctivitis; histopathology; IgE; nedocromil sodium; ragweed	MAST-CELL; OCULAR ANAPHYLAXIS; TRANSGENIC MICE; EOSINOPHILS; IL-4; DISEASE; RESPONSIVENESS; MODULATION; CYTOKINES; ANTIGEN	Background: Allergic conjunctivitis is the most common atopic disease affecting the eye. To study the pathophysiology and effectiveness of antiallergic drugs, it is necessary to develop animal models that closely mimic human allergic conjunctivitis. Objective: The study was performed to develop an experimental murine model of ocular allergic conjunctivitis to an airborne allergen. Methods: SWR/J mice were divided into the following groups: group 1, untreated, experimental; group 2, phosphate-buffered saline-treated; group 3, nedocromil sodium-treated; and group 4, unmanipulated controls. Groups 1, 2, and 3 were exposed to ragweed by topical contact with the nasal and conjunctival mucosae. Allergic conjunctivitis was evaluated by scoring of clinical signs, serum IgE levels, and histologic findings. Results: Mice exposed to ragweed had clinicopathologic signs of allergic conjunctivitis and specific anti-ragweed IgE. Allergic conjunctivitis was modulated by nedocromil sodium. Treated mice had fewer clinical signs of allergy, lower levels of ragweed-specific IgE, reduction of conjunctival eosinophil infiltration, decrease in the number of intact and degranulating mast cells, and reduction of cytokine release. Conclusion: This is the first report of a murine model of allergic conjunctivitis to an airborne allergen that can be used to study the disease pathophysiology and its response to treatment.	HARVARD UNIV, SCH MED,DEPT OPHTHALMOL, MASSACHUSETTS EYE & EAR INFIRM,OCULAR IMMUNOL SER, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	MerayoLloves, J (corresponding author), HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, MASSACHUSETTS EYE & EAR INFIRM, HILLES IMMUNOL LAB, BOSTON, MA 02115 USA.							ABELSON MB, 1993, SURV OPHTHALMOL, V38, P115, DOI 10.1016/0039-6257(93)90036-7; ABELSON MB, 1983, ARCH OPHTHALMOL-CHIC, V101, P555; ABELSON MB, 1994, PRINCIPLES PRACTICE, V1, P77; ALLANSMITH MR, 1981, IMMUNOLOGY, V44, P623; ALLANSMITH MR, 1981, AM J OPHTHALMOL, V91, P71, DOI 10.1016/0002-9394(81)90351-2; ALLANSMITH MR, 1985, J ALLERGY CLIN IMMUN, V76, P200, DOI 10.1016/0091-6749(85)90702-X; ALLANSMITH R, 1980, INVEST OPHTH VIS SCI, V19, P1521; *ARVO, 1993, HDB US AN BIOM RES A, P15; AUSDENMOORE RW, 1988, MANUAL ALLERGY IMMUN, P36; AUSTEN KF, 1994, HARRISONS PRINCIPLES, P1422; BALLAS Z, 1993, SURV OPHTHALMOL, V38, P141, DOI 10.1016/0039-6257(93)90038-9; BENAURER WB, 1993, GRAEFES ARCH CLIN EX, V231, P563; BRADDING P, 1993, J IMMUNOL, V151, P3853; BURSTEIN HJ, 1991, J IMMUNOL, V147, P2950; BUTRUS SI, 1988, INT OPHTHALMOL CLIN, V28, P324, DOI 10.1097/00004397-198802840-00015; CALONGE M, 1990, ACTA OPHTHALMOL, V68, P470; CALONGE MC, 1990, INVEST OPHTH VIS SCI, V31, P176; Coca AF, 1923, J IMMUNOL, V8, P163; DOHERTY MJ, 1989, MODERN TRENDS IMMUNO, P136; DONSHIK PC, 1988, INT OPHTHALMOL CLIN, V28, P294, DOI 10.1097/00004397-198802840-00007; DVORAK AM, 1990, LAB INVEST, V62, P590; DVORAK AM, 1994, BLOOD, V83, P3600; ELNER VM, 1991, AM J PATHOL, V138, P525; ELNER VM, 1991, AM J PATHOL, V139, P977; FRIEDLAENDER MH, 1984, ANIMALS MODELS OCULA, P263; GALLI SJ, 1990, LAB INVEST, V62, P5; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; HENRIQUEZ AS, 1981, ARCH OPHTHALMOL-CHIC, V99, P1266, DOI 10.1001/archopht.1981.03930020140019; ISO T, 1980, OPHTHALMIC RES, V12, P9, DOI 10.1159/000265056; KIMATA H, 1993, J IMMUNOL, V151, P6723; LEDERER JA, 1994, J IMMUNOL, V152, P77; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; LOH RKS, 1994, J ALLERGY CLIN IMMUN, V93, P219; MERAYOLLOVES J, 1995, CURR EYE RES, V14, P487, DOI 10.3109/02713689509003760; MERAYOLLOVES J, 1994, INT CONGR SER, V1068, P107; MORGAN SJ, 1991, J ALLERGY CLIN IMMUN, V87, P111, DOI 10.1016/0091-6749(91)90221-9; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; RESLER B, 1992, J ALLERGY CLIN IMMUN, V89, P235; REVOLTELLA R, 1969, IMMUNOLOGY, V17, P45; ROTHENBERG ME, 1988, INT OPHTHALMOL CLIN, V28, P267, DOI 10.1097/00004397-198802840-00004; Saruya S., 1968, ACTA SOC OPHTHALMOL, V72, P833; SCHWARTZMAN RM, 1971, CLIN EXP IMMUNOL, V9, P549; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; THANH HX, 1990, OPHTHALMOLOGY, V97, P1468; VAZ EM, 1971, IMMUNOLOGY, V21, P11; von Pirquet CE, 1911, ARCH INTERN MED, V7, P259	47	26	26	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1129	1140		10.1016/S0091-6749(96)70268-3	http://dx.doi.org/10.1016/S0091-6749(96)70268-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626992				2022-12-18	WOS:A1996UL26100015
J	Jacobsen, L; Dreborg, S; Moller, C; Valovirta, E; Wahn, U; Niggemann, B; Koller, D; Urbanek, R; Halken, S; Host, A; Lowenstein, H				Jacobsen, L; Dreborg, S; Moller, C; Valovirta, E; Wahn, U; Niggemann, B; Koller, D; Urbanek, R; Halken, S; Host, A; Lowenstein, H			Immunotherapy as preventive allergy treatment (PAT).	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	3				198	198						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TV536					2022-12-18	WOS:A1996TV53600198
J	Saeki, H; Kuwata, S; Nakagawa, H; Etoh, T; Yanagisawa, M; Miyamoto, M; Tokunaga, K; Juji, T; Shibata, Y				Saeki, H; Kuwata, S; Nakagawa, H; Etoh, T; Yanagisawa, M; Miyamoto, M; Tokunaga, K; Juji, T; Shibata, Y			Analysis of disease-associated amino acid epitopes on HLA class Is molecules in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL 23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		HLA; epitope; amino acid; atopic dermatitis; IgE	CLASS-II; PRIMERS; GENE	We investigated the association between HLA class II alleles and severe atopic dermatitis with high serum IgE levels (greater than 8000 U/ml). The frequencies of HLA-DRB1*1302 and DQB1*0604 were increased, whereas the frequency of HLA-DQB1*0302 was decreased. A strong haplotype, HLA-DRB1*1302-DQB1*0604, has been reported in the Japanese population, and this haplotype is conserved in patients with AD. Further analysis of the amino acid epitopes on the HLA-DR beta 1 and DQ beta 1 domains revealed that DR beta 1 (77)Glu (RR = 5.71, p < 0.05) and DQ beta 1 (30)His (RR = 3.25 p < 0.01), and (57)Val (RR = 3.13, p < 0.05) were increased in frequency. DR beta 1 (71)Glu was exclusively unique to DRB1*1302. DQ beta 1 (30)His was shared by the following alleles: DQ beta 1*0501, *0502, *0503, and *0604, which were all increased in patients with AD. DQ beta 1 (57)Val was shared by DQB1*0501 and *0604. A well-known haplotype, HLA-DRB1*1302-DQB1*O604, contains DR beta 1 (71)Glu and DQ beta 1 (30)His and (57)Val. Therefore HLA-DR beta 1 (71)Glu and/or DQ beta 1 (30)His/(57)Val considered to play the most important role in the development of atopic dermatitis.	UNIV TOKYO, FAC MED, DEPT TRANSFUS MED & IMMUNOHEMATOL, TOKYO 113, JAPAN; JAPANESE RED CROSS, CENT BLOOD CTR, TOKYO, JAPAN	University of Tokyo; Japanese Red Cross Medical Center	Saeki, H (corresponding author), UNIV TOKYO, FAC MED, DEPT DERMATOL, BUNKYO KU, HONGO 7-3-1, TOKYO 113, JAPAN.							ANSARI AA, 1991, IMMUNOGENETICS, V33, P24; BODMER JG, 1994, TISSUE ANTIGENS, V44, P1, DOI 10.1111/j.1399-0039.1994.tb02351.x; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; Kitao Y, 1987, Acta Paediatr Jpn, V29, P654; KUMAI M, 1990, AM J RHINOL, V4, P273; LARSEN FS, 1987, TISSUE ANTIGENS, V29, P1; MITSUNAGA S, 1995, HUM IMMUNOL, V42, P307, DOI 10.1016/0198-8859(94)00118-A; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; OTA M, 1992, TISSUE ANTIGENS, V39, P187, DOI 10.1111/j.1399-0039.1992.tb01935.x; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; SAEKI H, 1994, J ALLERGY CLIN IMMUN, V94, P575, DOI 10.1016/0091-6749(94)90133-3; SENGAR DPS, 1994, TISSUE ANTIGENS, V43, P242, DOI 10.1111/j.1399-0039.1994.tb02332.x; SENGAR DPS, 1994, TISSUE ANTIGENS, V43, P286, DOI 10.1111/j.1399-0039.1994.tb02342.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; SVEJGAARD E, 1985, ACTA DERM-VENEREOL, P72; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; VERHOEF A, 1993, INT IMMUNOL, V5, P1589, DOI 10.1093/intimm/5.12.1589; YSSEL H, 1992, J IMMUNOL, V148, P738	21	26	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1061	1068		10.1016/S0091-6749(95)70191-5	http://dx.doi.org/10.1016/S0091-6749(95)70191-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	TQ509	8543763				2022-12-18	WOS:A1995TQ50900002
J	EINARSSON, R; MUNIR, AKM; DREBORG, SKG				EINARSSON, R; MUNIR, AKM; DREBORG, SKG			ALLERGENS IN SCHOOL DUST .2. MAJOR MITE (DER-P-I, DER-F-I) ALLERGENS IN DUST FROM SWEDISH SCHOOLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							CHILDREN; SENSITIZATION; ASTHMA; CAT		LINKOPING UNIV HOSP,DEPT PEDIAT,S-58185 LINKOPING,SWEDEN	Linkoping University								DYBENDAL T, 1993, CLIN EXP ALLERGY, V22, P1100; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; MUNIR AKM, 1995, ALLERGY, V50, P55, DOI 10.1111/j.1398-9995.1995.tb02483.x; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; MUNIR AKM, 1994, LINKOPING U MED DISS, V412, P1; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1982, LANCET, V2, P675; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	10	26	26	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				1049	1053		10.1016/S0091-6749(95)70108-7	http://dx.doi.org/10.1016/S0091-6749(95)70108-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751503				2022-12-18	WOS:A1995QY91700019
J	FUJISHIMA, H; OKAMOTO, Y; SAITO, I; TSUBOTA, K				FUJISHIMA, H; OKAMOTO, Y; SAITO, I; TSUBOTA, K			RESPIRATORY SYNCYTIAL VIRUS AND ALLERGIC CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC CONJUNCTIVITIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR); NESTED PCR; BRUSH CYTOLOGY	IMMUNE-RESPONSES; AIRWAY DISEASE; BRUSH CYTOLOGY; OTITIS-MEDIA; RS-VIRUS; INFECTION; IGE; ANTIBODIES; CHILDREN; EPITHELIUM	The pathogenesis of allergic conjunctivitis is largely conjectural. We investigated the possible involvement of respiratory syncytial virus (RSV), a ubiquitous respiratory pathogen, in the development of allergic conjunctivitis through immune mechanisms. A new technique of brush cytology was used to obtain conjunctival cells from 30 patients with allergic conjunctivitis and 20 control subjects. Samples were assayed for the presence of RSV sequences with the reverse-transcription polymerase chain reaction and the nested polymerase chain reaction. Specific primers and inner primers were synthesized on the basis of RNA sequences previously identified. RSV sequences were defected in 7 of 30 (23%) patient samples and 1 of 20 (5%) control samples. Our results proved that polymerase chain reaction could detect RSV sequences in conjunctival samples. RSV may be a significant pathogenic factor in allergic conjunctivitis.	KEIO UNIV,SCH MED,DEPT OPHTHALMOL,TOKYO,JAPAN; AKITA UNIV,SCH MED,DEPT OTOLARYNGOL,AKITA 010,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT VIROL & IMMUNOL,DIV IMMUNOL DIS,TOKYO,JAPAN	Keio University; Akita University; Tokyo Medical & Dental University (TMDU)	FUJISHIMA, H (corresponding author), TOKYO DENT COLL,DEPT OPHTHALMOL,5-11-13 SUGANO,ICHIKAWA,CHIBA 272,JAPAN.							ANESTAD G, 1981, ACTA PATH MICRO IM B, V89, P285; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BECKER S, 1991, J IMMUNOL, V147, P4307; BERNSTEIN JM, 1985, ANN ALLERGY, V55, P544; BUCKLEY RH, 1982, ANN ALLERGY, V49, P67; CARSON JL, 1985, NEW ENGL J MED, V312, P463, DOI 10.1056/NEJM198502213120802; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS PL, 1984, P NATL ACAD SCI-BIOL, V81, P7683, DOI 10.1073/pnas.81.24.7683; DOLIN R, 1977, J INFECT DIS, V135, P714, DOI 10.1093/infdis/135.5.714; FISER PM, 1979, J IMMUNOL, V123, P1788; Frankland A W, 1971, Trans Ophthalmol Soc U K, V91, P479; FREIHORST J, 1988, P SOC EXP BIOL MED, V188, P191; FUJISHIMA H, 1992, ATARASHII GANKA, V9, P2097; FUJISHIMA H, 1993, ATARASHII GANKA, V10, P1404; GERSHWIN LJ, 1990, INT ARCH ALLER A IMM, V92, P293, DOI 10.1159/000235192; HENDERSON FW, 1982, NEW ENGL J MED, V306, P1377, DOI 10.1056/NEJM198206103062301; HORNSLETH A, 1985, J MED VIROL, V16, P329, DOI 10.1002/jmv.1890160405; ISHIZAKA K, 1978, IMMUNOL REV, V41, P109; KATZ DH, 1980, IMMUNOLOGY, V41, P1; KATZ DH, 1980, J IMMUNOL, V124, P819; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; LESCHINSKAYA NP, 1988, EPIDEMIOL INFECT, V101, P565, DOI 10.1017/S0950268800029435; MUFSON MA, 1988, J INFECT DIS, V157, P143, DOI 10.1093/infdis/157.1.143; OKAMOTO Y, 1991, LANCET, V19, P1025; SALKIND AR, 1991, J INFECT DIS, V163, P71, DOI 10.1093/infdis/163.1.71; SAMPSON HA, 1981, J IMMUNOL, V127, P829; STEWART RS, 1989, VET IMMUNOL IMMUNOP, V20, P313, DOI 10.1016/0165-2427(89)90077-9; TSUBOTA K, 1991, CORNEA, V10, P525, DOI 10.1097/00003226-199111000-00011; TSUBOTA K, 1990, ACTA CYTOL, V34, P233; VOLOVITZ B, 1988, PEDIATR RES, V24, P504, DOI 10.1203/00006450-198810000-00018; WELLIVER R, 1982, J PEDIATR, V10, P889; WELLIVER RC, 1984, J IMMUNOL, V133, P1925; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WELLIVER RC, 1979, J PEDIATR-US, V94, P370, DOI 10.1016/S0022-3476(79)80573-9; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501	35	26	28	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					663	667		10.1016/S0091-6749(95)70169-9	http://dx.doi.org/10.1016/S0091-6749(95)70169-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897147				2022-12-18	WOS:A1995QM01700004
J	KOBAYASHI, Y; KONDO, N; SHINODA, S; AGATA, H; FUKUTOMI, O; ORII, T				KOBAYASHI, Y; KONDO, N; SHINODA, S; AGATA, H; FUKUTOMI, O; ORII, T			PREDICTIVE VALUES OF CORD-BLOOD IGE AND CORD-BLOOD LYMPHOCYTE-RESPONSES TO FOOD ANTIGENS IN ALLERGIC DISORDERS DURING INFANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC DISORDERS; CORD BLOOD IGE; CORD BLOOD LYMPHOCYTES; PROLIFERATIVE RESPONSES; FOOD ANTIGENS; NEWBORN INFANTS; PREDICTION; INTERLEUKIN-2	ATOPIC-DERMATITIS; MILK-PROTEINS; CHILDREN; DISEASE; ANTIBODIES	Proliferative response of cord blood lymphocytes stimulated twice by food antigens and cord blood IgE concentration were measured in 131 full-term newborn infants for the prediction of allergic disorders. Through the follow-up study for 2 1/2 years, the value of stimulation index in proliferative response of cord blood lymphocytes to ovalbumin or bovine serum albumin was greater than 1.5 in 17 (sensitivity 53.1%) of 32 infants in whom allergic disorders developed and less and an 1.5 in 81 (specificity 81.8%) of 99 infants who had no allergic disorders (cutoff limit of stimulation index 1.5). The sensitivity was increased (71.9%) by the combination of the cord blood IgE concentration (cutoff limit 1.0 IU/ml) and proliferative response of cord blood lymphocytes to food antigens (cutoff limit of stimulation index 1.5). The combination of the cord blood IgE concentration and proliferative response of cord blood lymphocytes to food antigens is useful for the prediction of allergic disorders. Interleukin-2 production of cord blood lymphocytes stimulated with food antigens was also measured in 24 newborn infants. Interleukin-2 activity in culture supernatants of ovalbumin- or bovine serum albumin-stimulated cord blood lymphocytes correlated well with proliferative response of cord blood lymphocytes to ovalbumin or bovine serum albumin.			KOBAYASHI, Y (corresponding author), GIFU UNIV,SCH MED,DEPT PEDIAT,TSUKASA MACHI 40,GIFU 500,JAPAN.							AGATA H, 1992, ARCH DIS CHILD, V67, P280, DOI 10.1136/adc.67.3.280; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; GOLDMAN AS, 1963, PEDIATRICS, V32, P572; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; KONDO N, 1992, ARCH DIS CHILD, V67, P1003, DOI 10.1136/adc.67.8.1003; KUROUME T, 1976, ANN ALLERGY, V37, P41; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MAY CD, 1977, CLIN ALLERGY, V7, P583, DOI 10.1111/j.1365-2222.1977.tb01489.x; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; ORGEL HA, 1975, J ALLERGY CLIN IMMUN, V56, P296, DOI 10.1016/0091-6749(75)90104-9; PEARLMAN DS, 1989, IMMUNOLOGIC DISORDER, P439; PEARSON JR, 1983, PEDIATR RES, V17, P406, DOI 10.1203/00006450-198305000-00017; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; RAWLE FC, 1984, J IMMUNOL, V133, P195; RUIZ RGG, 1991, CLIN EXP ALLERGY, V21, P467, DOI 10.1111/j.1365-2222.1991.tb01687.x	26	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					907	916		10.1016/0091-6749(94)90159-7	http://dx.doi.org/10.1016/0091-6749(94)90159-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963159				2022-12-18	WOS:A1994PR24000016
J	FUCHS, T				FUCHS, T			LATEX ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GLOVES				FUCHS, T (corresponding author), UNIV GOTTINGEN,SKIN & OUTPATIENTS HOSP,DEPT ALLERGY,VON SIEBOLD STR 3,D-37075 GOTTINGEN,GERMANY.							Dreborg S., 1989, ALLERGY S10, V44, P31; FROSCH PJ, 1990, HAUTARZT S10, V41, P129; FUCHS T, 1992, ALLERGY PROC, V13, P61, DOI 10.2500/108854192778878881; FUCHS T, 1992, MED KLIN, V87, P355; Grimm A., 1927, KLIN WOCHENSCHR, V6, P1479, DOI 10.1007/BF017185344.; Hansen K, 1957, ALLERGIE; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; STERN G, 1927, KLIN WOCHENSCHR, V6, P2096; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x	9	26	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					951	952		10.1016/0091-6749(94)90393-X	http://dx.doi.org/10.1016/0091-6749(94)90393-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8018192	Bronze			2022-12-18	WOS:A1994NL91900024
J	BURNS, M; SHANAMAN, JE; SHELLENBERGER, CH				BURNS, M; SHANAMAN, JE; SHELLENBERGER, CH			A LABORATORY STUDY OF PATIENTS WITH CHRONIC ALLERGIC RHINITIS - ANTIHISTAMINE EFFECTS ON SKILLED PERFORMANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; ALLERGIC RHINITIS; ANTIHISTAMINE; ATTENTION; DIPHENHYDRAMINE; PERFORMANCE SYMPTOM CONDITION; VIGILANCE		Twenty-four patients with chronic allergic rhinitis participated in a study of antihistamine effects on skilled performance. They were tested while experiencing symptoms and when they were free of symptoms. Within each symptom condition they attended two sessions; each patient received a placebo capsule at one session and a 50 mg diphenhydramine capsule at the other. Subjects performed a battery of skilled performance tests, which included the Divided-Attention, Visual Backward Masking, Stimulus Response Conflict, and Vigilance tests. They rated the treatments and their performance. Affective states were assessed with the Profile of Mood States. Symptoms did not affect performance. Diphenhydramine impaired vigilance performance and measures of Divided Attention and Stimulus Response Conflict, Visual Backward Masking performance was not affected. The largest performance changes occurred when dephenhydramine was administered to subjects when they were free of symptoms.	WARNER LAMBERT PARKE DAVIS,ANN ARBOR,MI; SO CALIF RES INST,ENCINO,CA	Pfizer								BURNS M, 1990, J OCCUP ENVIRON MED, V32, P320, DOI 10.1097/00043764-199004000-00012; BURNS M, 1980, EUR J CLIN PHARMACOL, V17, P259, DOI 10.1007/BF00625799; BURNS M, 1990, 11TH P T89 INT C ALC, P470; BURNS M, 1991, VULNERABLE ROAD USER, P69; MOSKOWITZ H, 1988, CUTIS, V42, P14; MOSKOWITZ H, 1987, 2ND P S MED DRUGS DR	6	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					716	724		10.1016/0091-6749(94)90251-8	http://dx.doi.org/10.1016/0091-6749(94)90251-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163781				2022-12-18	WOS:A1994NH49700004
J	DOYLE, WJ; SKONER, DP; SEROKY, JT; FIREMAN, P; GWALTNEY, JM				DOYLE, WJ; SKONER, DP; SEROKY, JT; FIREMAN, P; GWALTNEY, JM			EFFECT OF EXPERIMENTAL RHINOVIRUS-39 INFECTION ON THE NASAL RESPONSE TO HISTAMINE AND COLD-AIR CHALLENGES IN ALLERGIC AND NONALLERGIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PRIMING; NASAL HYPERRESPONSIVENESS; ALLERGY; VIRAL INFECTION; HISTAMINE CHALLENGE	INFLAMMATORY MEDIATORS; RHINITIS PATIENTS; METHACHOLINE; REACTIVITY; HYPERREACTIVITY; RESPONSIVENESS; PHENTOLAMINE	To determine whether a viral upper respiratory tract infection can alter the responsiveness of the nasal mucosa, Paired intranasal histamine and cold air challenge sessions were performed before and after (8 to 13 days) experimental rhinovirus infection in 18 nonallergic subjects and 20 subjects with seasonal allergic rhinitis. The nasal response to the challenges was measured as symptom scores for rhinorrhea and congestion, counts for sneezing weight for expelled secretions, and inspiratory conductance for nasal patency. For both sessions, a greater response was observed in allergic subjects for sneezing, symptoms of rhinorrhea and congestion, secretion weights provoked by histamine challenge, and secretion weights provoked by cold air challenge when compared with the nonallergic subjects. A comparison of the responses to the paired challenge sessions showed greater responses for sneezing secretion weight and rhinorrhea to histamine and for secretion weight to cold air challenges performed after rhinovirus infection. No differences were observed between allergic and nonallergic subjects with respect to the degree of enhanced responsiveness secondary to viral infection These results document an increased responsiveness of the nose to these stimuli during the postsymptomatic period of a rhinovirus infection in both allergic and nonallergic subjects.	CHILDRENS HOSP PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA; CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT,DIV ALLERGY IMMUNOL RHEUMATOL,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA; UNIV VIRGINIA,SCH MED,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Virginia					NCRR NIH HHS [MO/RR 000 84] Funding Source: Medline; NIAID NIH HHS [AI 19262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019262] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON M, 1989, ACTA OTO-LARYNGOL, V107, P270, DOI 10.3109/00016488909127508; ASAKURA K, 1984, ARCH OTO-RHINO-LARYN, V239, P273, DOI 10.1007/BF00464255; BACON JR, 1981, J ALLERGY CLIN IMMUN, V67, P111, DOI 10.1016/0091-6749(81)90005-1; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; CONNELL JT, 1968, J ALLERGY, V41, P101; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CORRADO OJ, 1986, THORAX, V41, P863, DOI 10.1136/thx.41.11.863; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; GRONBORG H, 1983, EUR J RESPIR DIS, V64, P406; GRONBORG H, 1986, CLIN ALLERGY, V16, P597, DOI 10.1111/j.1365-2222.1986.tb01999.x; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; KLEMENTSSON H, 1990, CLIN EXP ALLERGY, V20, P539, DOI 10.1111/j.1365-2222.1990.tb03147.x; KONNO A, 1987, J ALLERGY CLIN IMMUN, V79, P620, DOI 10.1016/S0091-6749(87)80158-6; KRAYENBUHL MC, 1988, CLIN ALLERGY, V18, P157, DOI 10.1111/j.1365-2222.1988.tb02855.x; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P65; MULLINS RJ, 1989, J ALLERGY CLIN IMMUN, V83, P955, DOI 10.1016/0091-6749(89)90111-5; OKUDA M, 1983, ANN ALLERGY, V51, P51; SILBER G, 1988, AM REV RESPIR DIS, V137, P606, DOI 10.1164/ajrccm/137.3.606; SKONER DP, 1989, AM J RHINOL, V3, P53; TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133; van Wijk R G, 1987, Rhinology, V25, P41; VANWIJK RG, 1991, CLIN EXP ALLERGY, V21, P661; VANWIJK RG, 1991, CLIN OTOLARYNGOL, V16, P133; VANWIJK RG, 1987, CLIN ALLERGY, V17, P563; VANWIJK RG, 1989, CLIN EXP ALLERGY, V19, P283	31	26	26	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					534	542		10.1016/0091-6749(94)90364-6	http://dx.doi.org/10.1016/0091-6749(94)90364-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120280	Bronze			2022-12-18	WOS:A1994MY58100016
J	LOONEY, RJ; PUDIAK, D; ROSENFELD, SI				LOONEY, RJ; PUDIAK, D; ROSENFELD, SI			CYTOKINE PRODUCTION BY MITE-SPECIFIC T-CELLS FROM DONORS WITH MILD ATOPIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; HOUSE DUST MITE; T CELLS; INTERLEUKIN-4; INTERFERON-GAMMA; CYTOKINES	MESSENGER-RNA EXPRESSION; COLONY-STIMULATING FACTOR; FUNCTIONAL SUBSETS; IFN-GAMMA; HUMAN TH1; IL-4; CLONES	This study was designed to determine whether allergen-specific T cells from patients with mild atopic disease were similar to T-H2 cells. Tetanus-specific and house mite-specific T-cell clones were derived from peripheral blood of donors with strong immediate epicutaneous skin tests to Dermatophagoides farinae but with mild allergic disease. Overall, the tetanus- and mite-specific clones produced similar amounts of interleukin-4 (IL-4) and gamma interferon (INF-gamma). However, when donors were divided into those with high and low serum levels of mite-specific IgE as determined by RAST, mite-specific clones from donors with high specific IgE produced significantly more IL-4 and less IFN-gamma than mite-specific clones from donors with low levels of specific IgE. These results suggest that circulating allergen-specific T cells from patients who do not have severe allergic disease may nonetheless be skewed toward a T-H2 profile. We also examined IL-4 and IFN-gamma production during primary culture of antigen-stimulated peripheral blood mononuclear cells. Detectable amounts of IL-4 were not produced. Stimulation with tetanus antigen induced two to three times as much IFN-gamma as did stimulation with mite antigen. However, the amount of IFN-gamma produced during primary culture did not correlate with the cytokine production of the T-cell clones subsequently generated.			LOONEY, RJ (corresponding author), UNIV ROCHESTER,MED CTR,DEPT MED,BOX 695,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.							DURHAM SR, 1992, J IMMUNOL, V148, P2390; FONG TAT, 1989, J IMMUNOL, V143, P2887; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; MAGGI E, 1992, J IMMUNOL, V148, P2142; MASMANN TR, 1986, J IMMUNOL, V136, P2348; MOSSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145; PARRONCHI P, 1991, IMMUNOLOGY, V68, P1538; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; STREET NE, 1990, J IMMUNOL, V144, P1629; TSICOPOULOS A, 1992, J IMMUNOL, V148, P2058; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	14	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					476	483		10.1016/0091-6749(94)90357-3	http://dx.doi.org/10.1016/0091-6749(94)90357-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120275				2022-12-18	WOS:A1994MY58100009
J	TEDESCHI, A; PALUMBO, G; MILAZZO, N; MIADONNA, A				TEDESCHI, A; PALUMBO, G; MILAZZO, N; MIADONNA, A			NASAL NEUTROPHILIA AND EOSINOPHILIA INDUCED BY CHALLENGE WITH PLATELET-ACTIVATING-FACTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC INFLAMMATION; EOSINOPHILS; LYSO-PAF; NASAL AIRWAYS; NEUTROPHILS; PLATELET ACTIVATING FACTOR	PHASE ASTHMATIC REACTIONS; PAF-ACETHER; ANTIGEN CHALLENGE; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE; INFLAMMATORY CELLS; ALLERGEN; HUMANS; RESPONSIVENESS; ACCUMULATION	Background: It has been demonstrated that in vitro platelet activating factor-acether (1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine; PAF) has the capacity to attract eosinophils and neutrophils. We investigated whether the same applies when human nasal airways are stimulated with PAF. Methods: Symptom scores and cytologic changes in nasal lavage fluids were evaluated in 10 atopic and 10 nonatopic subjects after nasal challenge with PAF, its precursor and metabolite, 1-O-hexadecyl-sn-glycero-3-phosphorylcholine (lyso-PAF), or saline solution. Results: Nasal obstruction was reported by all the atopic subjects and seven of the 10 nonatopic subjects after nasal challenge with PAF; other symptoms such as rhinorrhea, itching, and sneezing were generally mild. PAF induced neutrophilia, which appeared after 30 minutes in atopic subjects and after 1 hour in nonatopic subjects, and peaked at 3 hours in both. Less neutrophilia was found 3 hours after stimulation with lyso-PAF in both groups of subjects. PAF also induced eosinophilia, which appeared after 30 minutes in atopic subjects and only after 3 hours in nonatopic subjects. An increase in eosinophil counts was observed 3 hours after lyso-PAF stimulation in atopic but not in nonatopic subjects. Conculsion: PAF can attract neutrophils and eosinophils into human nasal airways; however, the recruitment of inflammatory cells is more rapid in atopic than in nonatopic subjects, suggesting a different degree of responsiveness to PAF challenge in the two groups of subjects.	UNIV MILAN,OSPED POLICLIN,DEPT INTERNAL MED INFECT DIS & IMMUNOPATHOL,I-20122 MILAN,ITALY	University of Milan			Palumbo, Giuseppe/W-7072-2019	Palumbo, Giuseppe/0000-0003-1859-6319				ARNOUX B, 1988, AM REV RESPIR DIS, V137, P855, DOI 10.1164/ajrccm/137.4.855; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BENVENISTE J, 1987, AM REV RESPIR DIS, V135, pS2; BENVENISTE J, 1983, INSERM S, V23; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671; CHARO IF, 1986, J IMMUNOL, V136, P3412; CUSS FM, 1986, LANCET, V2, P189; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENIZOT Y, 1989, BIOCHEM BIOPH RES CO, V161, P939, DOI 10.1016/0006-291X(89)92689-2; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DUPUIS R, 1992, J ALLERGY CLIN IMMUN, V89, P850, DOI 10.1016/0091-6749(92)90441-4; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; EWANS TW, 1987, J APPL PHYSIOL, V63, P479; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; HENOCQ E, 1986, LANCET, V1, P1378; KAY AB, 1985, CLIN EXP IMMUNOL, V62, P1; KIMANI G, 1988, J IMMUNOL, V140, P3161; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LARSEN GL, 1987, ALLERGY INFLAMMATION, P225; LEGGIERI E, 1991, ALLERGY, V46, P466, DOI 10.1111/j.1398-9995.1991.tb04363.x; LIU M, 1990, Journal of Allergy and Clinical Immunology, V85, P263; MENCIAHUERTA JM, 1989, CLIN EXP ALLERGY, V19, P125, DOI 10.1111/j.1365-2222.1989.tb02356.x; MIADONNA A, 1986, Folia Allergologica et Immunologica Clinica, V33, P279; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; MIADONNA A, 1989, AM REV RESPIR DIS, V140, P142, DOI 10.1164/ajrccm/140.1.142; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MULLINS RJ, 1989, J ALLERGY CLIN IMMUN, V83, P955, DOI 10.1016/0091-6749(89)90111-5; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NINIO E, 1983, BIOCHIM BIOPHYS ACTA, V710, P23; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P1068, DOI 10.1016/0091-6749(89)90448-X; RANDOLPH TG, 1949, J LAB CLIN MED, V34, P1696; RUBIN AHE, 1987, AM REV RESPIR DIS, V136, P1145, DOI 10.1164/ajrccm/136.5.1145; SHAW JO, 1981, J IMMUNOL, V127, P1250; WARDLAW AJ, 1987, ALLERGY, V42, P321, DOI 10.1111/j.1398-9995.1987.tb02218.x; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WARDLAW AJ, 1990, AM REV RESPIR DIS, V141, P386, DOI 10.1164/ajrccm/141.2.386; Wrighl D.G., 1982, ADV HOST DEFENSE MEC, P75	41	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					526	533		10.1016/0091-6749(94)90363-8	http://dx.doi.org/10.1016/0091-6749(94)90363-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120279				2022-12-18	WOS:A1994MY58100015
J	SCHWARTZ, HA; ZUROWSKI, D				SCHWARTZ, HA; ZUROWSKI, D			ANAPHYLAXIS TO LATEX IN INTRAVENOUS FLUIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							RUBBER		ALEXANDRIA HOSP,DEPT MED & ANAESTHESIOL,ALEXANDRIA,VA 22304				Schwartz, H. Andrew/AAE-7276-2021					KWITTKEN PL, 1992, ALLERGY PROC, V13, P123, DOI 10.2500/108854192778878782; NGUYEN DH, 1991, J UROLOGY, V146, P571, DOI 10.1016/S0022-5347(17)37858-8; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; SLATER JE, 1992, ANN ALLERGY, V68, P203; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TURJANMAA K, 1984, ALLERGY S2, V39, pA35; WARPINSKI JR, 1991, ALLERGY PROC, V12, P95, DOI 10.2500/108854191779011846	7	26	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					358	359		10.1016/0091-6749(93)90181-E	http://dx.doi.org/10.1016/0091-6749(93)90181-E			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349946				2022-12-18	WOS:A1993LT46900018
J	MATLOFF, SM				MATLOFF, SM			LOCAL INTRAVAGINAL DESENSITIZATION TO SEMINAL FLUID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							HYPERSENSITIVITY REACTIONS; IMMUNOTHERAPY				MATLOFF, SM (corresponding author), HARVARD UNIV,HARVARD COMMUNITY HLTH PLAN,DEPT ALLERGY,291 INDEPENDENCE DR,BOSTON,MA 02167, USA.							Bernstein I L, 1985, Contrib Gynecol Obstet, V14, P151; BERNSTEIN IL, 1981, ANN INTERN MED, V94, P459, DOI 10.7326/0003-4819-94-4-459; BOSSO JV, 1991, ALLERGY PROC, V12, P113, DOI 10.2500/108854191779011828; FRIEDMAN SA, 1984, JAMA-J AM MED ASSOC, V251, P2684, DOI 10.1001/jama.251.20.2684; MATHIAS CGT, 1980, ARCH DERMATOL, V116, P209, DOI 10.1001/archderm.116.2.209; OHMAN JL, 1990, J ALLERGY CLIN IMMUN, V85, P103, DOI 10.1016/0091-6749(90)90230-2; SPECKEN, 1958, Ned Tijdschr Verloskd Gynaecol, V58, P314	7	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1230	1231		10.1016/0091-6749(93)90328-D	http://dx.doi.org/10.1016/0091-6749(93)90328-D			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509583				2022-12-18	WOS:A1993LG74000017
J	TWENTYMAN, OP; OLLIER, S; HOLGATE, ST				TWENTYMAN, OP; OLLIER, S; HOLGATE, ST			THE EFFECT OF H1-RECEPTOR BLOCKADE ON THE DEVELOPMENT OF EARLY-PHASE AND LATE-PHASE BRONCHOCONSTRICTION AND INCREASED BRONCHIAL RESPONSIVENESS IN ALLERGEN-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; LATE-PHASE RESPONSE; ANTIHISTAMINE; BRONCHIAL HYPERRESPONSIVENESS; AZELASTINE	PERITONEAL MAST-CELLS; HISTAMINE-INDUCED BRONCHOCONSTRICTION; ANTIALLERGIC DRUGS; ATOPIC ASTHMA; AZELASTINE HYDROCHLORIDE; INHALED ALLERGEN; INHIBITION; RELEASE; RESPONSES; ANAPHYLAXIS	Background: Allergen challenge of subjects with asthma produces an early asthmatic response, late asthmatic response, and increases bronchial responsiveness. Histamine partly mediates the early asthmatic response, and may play a role in late-phase responses. Azelastine has antiallergic properties and has been proposed as a treatment for asthma. We therefore investigated the contribution of histamine to late-phase responses with the use of the potent H-1-receptor antagonist azelastine. Methods: Ten subjects with atopic asthma were studied in a double-blind, randomized, placebo-controlled trial. Azelastine was administered over 4 days before allergen challenge. Changes in airway caliber were followed with measurements of forced expiratory volume in 1 second, and changes in bronchial responsiveness were followed by methacholine and prostaglandin D2 bronchial provocation tests. Results: Azelastine significantly inhibited the development of the early asthmatic response. Azelastine had no effect on the late asthmatic response or on the development of allergen-induced increases in bronchial responsiveness. The power of the study was sufficient to have had a high probability of detecting any important differences between placebo and azelastine during the late phase. Conclusions: Azelastine had no significant effect on the late-phase response model of asthma. This study does not support the hypothesis that histamine is an important mediator of the late asthmatic response or allergen-induced increases in bronchial responsiveness.	ADVISORY SERV CLIN & GEN LTD,LONDON,ENGLAND; UNIV SOUTHAMPTON,DEPT MED 1,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton	TWENTYMAN, OP (corresponding author), PETERBOROUGH DIST GEN HOSP,THORPE RD,PETERBOROUGH PE3 6DA,ENGLAND.							ALBAZZAZ MK, 1988, THORAX, V43, P306, DOI 10.1136/thx.43.4.306; ARMITAGE P, 1987, STATISTICAL METHODS; BUSSE WW, 1989, J ALLERGY CLIN IMMUN, V84, P658, DOI 10.1016/0091-6749(89)90293-5; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAND N, 1986, AGENTS ACTIONS, V19, P164, DOI 10.1007/BF01966201; CHAND N, 1986, ALLERGY, V41, P473, DOI 10.1111/j.1398-9995.1986.tb00331.x; CHAND N, 1985, INT J IMMUNOPHARMACO, V7, P833, DOI 10.1016/0192-0561(85)90045-1; CHAND N, 1986, BRIT J PHARMACOL, V87, P443, DOI 10.1111/j.1476-5381.1986.tb10835.x; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1985, INT ARCH ALLER A IMM, V77, P451, DOI 10.1159/000233825; CHAND N, 1985, AGENTS ACTIONS, V16, P318, DOI 10.1007/BF01982866; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEMONCHY JGR, 1985, AGENTS ACTIONS, V16, P252; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DJUKANOVIC R, 1991, EUR RESPIR J S14, V4, pS340; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; FITZPATRICK FA, 1981, BIOCHEMISTRY-US, V20, P6129, DOI 10.1021/bi00524a033; GOULD CAL, 1988, BRIT J CLIN PHARMACO, V26, P515, DOI 10.1111/j.1365-2125.1988.tb05291.x; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V76, P375, DOI 10.1016/0091-6749(85)90657-8; HOLGATE ST, 1988, Q J MED, P5; HOWARTH PH, 1987, J ALLERGY CLIN IMMUN, V80, P703, DOI 10.1016/0091-6749(87)90291-0; KARLIN JM, 1972, ANN ALLERGY, V30, P342; KATAYAMA S, 1987, INT ARCH ALLER A IMM, V83, P284, DOI 10.1159/000234309; KAUFFMAN HF, 1983, CLIN ALLERGY, V13, P219, DOI 10.1111/j.1365-2222.1983.tb02591.x; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; LIU M, 1990, Journal of Allergy and Clinical Immunology, V85, P263; MACHIN D, 1987, STATISTICAL TABLES D, P79; MAGNUSSEN H, 1989, J ALLERGY CLIN IMMUN, V83, P467, DOI 10.1016/0091-6749(89)90135-8; MAGNUSSEN H, 1987, CHEST, V91, P855, DOI 10.1378/chest.91.6.855; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MOTOJIMA S, 1985, ASIAN PAC J ALLERGY, V3, P174; NAKAZAWA T, 1976, J ALLERGY CLIN IMMUN, V58, P1, DOI 10.1016/0091-6749(76)90101-9; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; PAGANO RR, 1986, UNDERSTANDING STATIS; PHILLIPS MJ, 1984, THORAX, V39, P345, DOI 10.1136/thx.39.5.345; RAFFERTY P, 1989, J ALLERGY CLIN IMMUN, V84, P649, DOI 10.1016/0091-6749(89)90292-3; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1989, CLIN EXP ALLERGY, V19, P315, DOI 10.1111/j.1365-2222.1989.tb02389.x; SPECTOR SL, 1987, J ALLERGY CLIN IMMUN, V80, P75, DOI 10.1016/S0091-6749(87)80194-X; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; TOWN GI, 1990, J ALLERGY CLIN IMMUN, V86, P886, DOI 10.1016/S0091-6749(05)80151-4; WEILER JM, 1988, J ALLERGY CLIN IMMUN, V82, P801, DOI 10.1016/0091-6749(88)90082-6	48	26	26	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1169	1178		10.1016/0091-6749(93)90320-F	http://dx.doi.org/10.1016/0091-6749(93)90320-F			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8099592				2022-12-18	WOS:A1993LG74000009
J	GAGNON, R; AKOUM, A; HEBERT, J				GAGNON, R; AKOUM, A; HEBERT, J			LOL-P I-INDUCED IL-4 AND IFN-GAMMA PRODUCTION BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS OF ATOPIC AND NONATOPIC SUBJECTS DURING AND OUT OF THE POLLEN SEASON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LOL P-I; IL-4; IFN-GAMMA; ATOPIC	STIMULATORY FACTOR-I; HUMAN IGE SYNTHESIS; T-HELPER CELL; HUMAN B-CELLS; INTERFERON-GAMMA; MONOCLONAL-ANTIBODIES; CYTOKINE PRODUCTION; INTERLEUKIN-4; CLONES; LYMPHOCYTES	The reciprocal effects of IL-4 and IFN-gamma on IgE synthesis have been well established. It has also been shown that these two lymphokines are secreted by different subsets of CD4+ T cells (T(H1) and T(H2), and that T(H2) helper T lymphocytes could be involved in the pathophysiology of allergic diseases. But little is known about the effects of an allergen on the profile of lymphokine synthesis by human peripheral blood mononuclear cells (PBMCs) of allergic and nonallergic subjects. We studied the production of IL-4 and IFN-gamma by PBMCs of atopic and nonatopic donors after in vitro stimulation by the group 1 allergen from Lolium perenne pollen (Lol p I), during and out of the grass pollen season. On natural exposure to pollen, Lol p I-induced IL-4 production was observed only with atopic donors (6 of 8), whereas the synthesis of IFN-gamma was observed for all nonatopic donors (7 of 7) and most allergic patients (5 of 7). At the time of the study, higher amounts of IFN-gamma were produced by PBMCs of nonatopic donors than by PBMCs of atopic patients. Out of the pollen season the production of IL-4 was not observed either by atopic (n = 11) or by nonatopic subjects (n = 5). On the other hand, IFN-gamma was produced by PBMCs of most subjects (atopic, 10 of 11; nonatopic, 5 of 5), but at the time of the study no difference was observed between the two groups. These results show that Lol p I induces different profiles of IL-4 and IFN-gamma production by PBMCs of atopic and nonatopic subjects. In atopic subjects this profile of lymphokine synthesis is influenced by the natural exposure to pollen, which is in keeping with the seasonal rise of IgE antibodies.	CHU LAVAL, CTR RECH,CTR RECH INFLAMMAT IMMUNOL & RHUMATOL, ROOM 9800,2705 BLVD LAURIER, Ste Foy G1V 4G2, PQ, CANADA	Laval University								CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; HEBERT J, 1981, CELL IMMUNOL, V58, P366, DOI 10.1016/0008-8749(81)90230-6; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; ISHIZAKA A, 1990, CLIN EXP IMMUNOL, V79, P392; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; KATZ DH, 1978, J ALLERGY CLIN IMMUN, V62, P44, DOI 10.1016/0091-6749(78)90072-6; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KILLAR L, 1987, J IMMUNOL, V138, P1674; LITCHMAN AH, 1987, P NATL ACAD SCI USA, V84, P824; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOURAD W, 1988, MOL IMMUNOL, V25, P899, DOI 10.1016/0161-5890(88)90127-7; MOURAD W, 1989, MOL IMMUNOL, V26, P1051, DOI 10.1016/0161-5890(89)90069-2; MOURAD W, 1986, J IMMUNOL METHODS, V89, P53, DOI 10.1016/0022-1759(86)90031-1; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PENE J, 1989, INT ARCH ALLER A IMM, V90, P32, DOI 10.1159/000235073; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, pS13, DOI 10.1016/0090-1229(89)90110-4; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SNAPPER CM, 1988, J IMMUNOL, V140, P2121; SPIEGELBERG HL, 1991, INT ARCH ALLER A IMM, V94, P181, DOI 10.1159/000235357; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; VERCELLI D, 1990, J IMMUNOL, V144, P570; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YANG XD, 1988, EUR J IMMUNOL, V18, P1699, DOI 10.1002/eji.1830181107	41	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					950	956		10.1016/0091-6749(93)90353-H	http://dx.doi.org/10.1016/0091-6749(93)90353-H			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473684				2022-12-18	WOS:A1993KY25100016
J	MULLER, BA; LEICK, CA; SMITH, RM; SUELZER, MT; RICHERSON, HB				MULLER, BA; LEICK, CA; SMITH, RM; SUELZER, MT; RICHERSON, HB			COMPARISONS OF SPECIFIC AND NONSPECIFIC BRONCHOPROVOCATION IN SUBJECTS WITH ASTHMA, RHINITIS, AND HEALTHY-SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHOPROVOCATION; METHACHOLINE; ALLERGEN; ASTHMA; RHINITIS	ALLERGEN-INDUCED ASTHMA; DOSE-RESPONSE CURVE; BRONCHIAL RESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; INHALED HISTAMINE; METHACHOLINE; REACTIVITY; CHALLENGE; DISTINCTION; SENSITIVITY	Background: We studied subjects with atopic asthma, atopic rhinitis, and nonatopic healthy subjects to evaluate responsiveness to bronchoprovocation with both methacholine and allergen. Methods: Subjects with a demonstrable FEV1 PD20 to methacholine or allergen (responders) were further analyzed for putative sensitivity (PD20 FEV1) and reactivity (dose-response slopes) to determine whether any characteristics could distinguish individuals with asthma from other responders. Subjects were recruited without sex restrictions and were between the ages of 18 and 45 years old. They were nonsmokers, had no other medical problems, and were free of upper respiratory infection for at least 6 weeks before challenge. All had a history taken, physical examination, limited laboratory screening, chest radiography, pulmonary function testing, and intradermal skin testing before admission to the study. Results: Although the groups were significantly different in both sensitivity and reactivity to methacholine, responses to allergen bronchoprovocation were sufficiently similar between responders with asthma and those with rhinitis to prevent separation on the basis of either sensitivity or reactivity. The fall in FEV1 at the nadir of the late response, which was greater in the asthma group, was significantly correlated with sensitivity and reactivity of the immediate response to allergen but not to methacholine. Regression analysis demonstrated a stronger association between allergen and methacholine responsiveness in subjects with rhinitis than in subjects with asthma. Conclusion: We concluded that (1) nonspecific bronchial hyperresponsiveness fails to explain why patients with allergic asthma have clinical asthma as a result of allergen exposure and patients with allergic rhinitis do not; (2) hyperresponsiveness to allergen does not simply reflect quantitative or qualitative airway nonspecific hyperresponsiveness; and (3) clinical asthma may involve mechanisms difficult to elucidate by laboratory bronchoprovocation techniques.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA	University of Iowa					NCRR NIH HHS [RR59] Funding Source: Medline; NIAID NIH HHS [AI 19093] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019093] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BOULET LP, 1984, CLIN ALLERGY, V14, P379, DOI 10.1111/j.1365-2222.1984.tb02219.x; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; CAMPAGNE JG, 1969, SCAND J RESPIR DIS, V50, P76; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1983, THORAX, V38, P55, DOI 10.1136/thx.38.1.55; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Colton T, 1974, STAT MED, P211; EISER NM, 1987, BRONCHIAL HYPERRESPO, P173; FICK RB, 1987, AM REV RESPIR DIS, V135, P1204; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; HOPP RJ, 1987, J ALLERGY CLIN IMMUN, V80, P821, DOI 10.1016/S0091-6749(87)80272-5; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; KREUKNIET J, 1973, RESPIRATION, V30, P345, DOI 10.1159/000193049; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; PERMUTT S, 1977, ASTHMA PHYSL IMMUNOP, P265; ROSENTHAL RR, 1975, INT ARCH ALLER A IMM, V49, P89, DOI 10.1159/000231381; SEPPALA OP, 1991, RESP MED, V85, P365, DOI 10.1016/S0954-6111(06)80179-4; STERK PJ, 1989, EUR RESPIR J, V2, P267; STEVENS WJ, 1980, EUR J RESPIR DIS, V61, P203; SUELZER M, 1991, American Review of Respiratory Disease, V143, pA426; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; WOOLCOCK AJ, 1983, EUR J RESPIR DIS, V64, P181; [No title captured]; 1982, STATISTICS 1982, P169	35	26	26	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					758	772		10.1016/0091-6749(93)90196-M	http://dx.doi.org/10.1016/0091-6749(93)90196-M			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454799				2022-12-18	WOS:A1993KU20300009
J	ENGLER, DB; DEJARNATT, AC; SIM, TC; LEE, JL; GRANT, JA				ENGLER, DB; DEJARNATT, AC; SIM, TC; LEE, JL; GRANT, JA			COMPARISON OF THE SENSITIVITY AND PRECISION OF 4 SKIN-TEST DEVICES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SKIN TESTING; ALLERGY TESTING; HISTAMINE	STANDARDIZATION	Twenty volunteers were skin tested with seven concentrations of histamine phosphate and a glycerosaline control to determine the relative sensitivity and precision of four skin test devices: Greer Pen (GP), Greer DermaPIK (DP), Center Multi-Test (MT), and Morrow Brown needle (MB). The end points of the study were (1) wheal and flare response of each device, with a dose-response curve, (2) the time required to apply each set of eight tests, and (3) the volunteers' subjective assessment of each device. On a different day, 10 of the volunteers were tested to determine the precision of each device. Dose-response curves for half-log dilutions of histamine phosphate were produced with a glycerosaline control. The DP and GP induced wheal and flare responses discernible from that of the glycerosaline control at a lower concentration of histamine phosphate than the MB and MT The DP took a shorter time to apply eight samples than any other device. The MB was preferred by the most volunteers, but any device tested on the upper half of the back was usually preferred over that tested on the lower half. When 5 mg/ml histamine phosphate was used, coefficients of variation for each device demonstrated that for wheals the precision of the DP, GP, and MT was similar (mean, 21.1 23.1%, and 24.5%, respectively). The MB was larger (mean, 59.9%). For flares, the precision of GP and DP was similar (mean, 22.0% and 23.5%, respectively), with the MT and MB larger (mean, 35.5% and 58.2%, respectively). Repeating the analysis for the MB with 10 mg/ml histamine phosphate, we found a mean coefficient of variation of 16.5% for wheals and 19.6% for flares. We conclude that the DP is equal to the GP in precision and sensitivity for wheal and flare, but it has the advantage of allowing allergy skin testing to be performed more quickly. The MT has similar precision for wheals but has less precision for flares. The MB device is more precise only with higher concentrations of histamine phosphate than those routinely used in the clinical practice of allergy.	UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston								AAS K, 1980, ALLERGY, V35, P250, DOI 10.1111/j.1398-9995.1980.tb01763.x; ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; BASOMBA A, 1985, ALLERGY, V40, P395, DOI 10.1111/j.1398-9995.1985.tb02677.x; GARIBALDI E, 1990, J ALLERGY CLIN IMMUN, V86, P137; HAVNEN J, 1974, ACTA ALLERGOL, V29, P225; NELSON HS, 1983, ANN ALLERGY, V51, P411; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; TURKELTAUB PC, 1989, ALLERGOL IMMUNOPATH, V17, P53; VANARSDEL PP, 1989, ANN INTERN MED, V110, P304, DOI 10.7326/0003-4819-110-4-304; VOORHORST R, 1973, ANN ALLERGY, V31, P137; VOORHORST R, 1980, ALLERGY, V35, P247, DOI 10.1111/j.1398-9995.1980.tb01762.x	12	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				985	991		10.1016/0091-6749(92)90472-E	http://dx.doi.org/10.1016/0091-6749(92)90472-E			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1460202				2022-12-18	WOS:A1992KD19000016
J	SLAVIN, RG; GLEICH, GJ; HUTCHESON, PS; KEPHART, GM; KNUTSEN, AP; TSAI, CC				SLAVIN, RG; GLEICH, GJ; HUTCHESON, PS; KEPHART, GM; KNUTSEN, AP; TSAI, CC			LOCALIZATION OF IGE TO LUNG GERMINAL LYMPHOID FOLLICLES IN A PATIENT WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							MAJOR BASIC-PROTEIN; IMMUNOFLUORESCENCE		ST LOUIS UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63104; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905	Saint Louis University; Mayo Clinic	SLAVIN, RG (corresponding author), ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,1402 S GRAND DOISY R209,ST LOUIS,MO 63104, USA.				NHLBI NIH HHS [HL30652] Funding Source: Medline; NIAID NIH HHS [AI15231] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, R37AI015231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adolphson C. R., 1986, MANUAL CLIN LABORATO, P652; FILLEY WV, 1982, LANCET, V2, P11; GOLBERT TM, 1970, ANN INTERN MED, V72, P395, DOI 10.7326/0003-4819-72-3-395; GREENBERGER PA, 1988, J ALLERGY CLIN IMMUN, V82, P164, DOI 10.1016/0091-6749(88)90995-5; KRENIK KD, 1989, J IMMUNOL METHODS, V117, P91, DOI 10.1016/0022-1759(89)90122-1; NAKAJIMA S, 1975, CLIN EXP IMMUNOL, V21, P306; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P718, DOI 10.1016/0091-6749(88)91044-5; SLAVIN RG, 1978, INT ARCH ALLER A IMM, V56, P325, DOI 10.1159/000232038	10	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				1006	1008		10.1016/0091-6749(92)90479-L	http://dx.doi.org/10.1016/0091-6749(92)90479-L			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1460191				2022-12-18	WOS:A1992KD19000023
J	FISHER, AA				FISHER, AA			ALLERGIC CONTACT REACTIONS IN HEALTH PERSONNEL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MEDIATED ANAPHYLACTOID REACTIONS; RUBBER GLOVES; LATEX GLOVES; INTRAOPERATIVE ANAPHYLAXIS; BENZALKONIUM CHLORIDE; URTICARIA; CHLORHEXIDINE; DERMATITIS; ARTHROPLASTY		NYU,POSTGRAD MED SCH,DEPT DERMATOL,NEW YORK,NY 10003	New York University								AARONS J, 1974, SURG GYNECOL OBSTET, V138, P385; AFZELIUS H, 1979, CONTACT DERMATITIS, V5, P60, DOI 10.1111/j.1600-0536.1979.tb05546.x; AXELSSON IGK, 1988, ACTA PAEDIATR SCAND, V77, P314, DOI 10.1111/j.1651-2227.1988.tb10652.x; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BERGQVISTKARLSSON A, 1988, CONTACT DERMATITIS, V18, P84, DOI 10.1111/j.1600-0536.1988.tb02745.x; BOHLING HG, 1977, ARCH TOXICOL, V38, P307, DOI 10.1007/BF00352035; CHEUNG J, 1985, ANAESTH INTENS CARE, V13, P429, DOI 10.1177/0310057X8501300419; COHEN SR, 1987, OCCUP MED, V2, P565; CUEVAS M, 1986, CONTACT DERMATITIS, V15, P69; DEGROOT AC, 1990, CONTACT DERMATITIS, V23, P263; EDWARDS PM, 1975, BRIT J IND MED, V32, P31; FISHER AA, 1972, ARCH DERMATOL, V106, P169, DOI 10.1001/archderm.106.2.169; FISHER AA, 1987, CUTIS, V39, P281; FISHER AA, 1954, JAMA-J AM MED ASSOC, V156, P238, DOI 10.1001/jama.1954.02950030030010; FISHER AA, 1991, CUTIS, V47, P301; FISHER AA, 1991, CUTIS, V47, P226; FISHER AA, 1987, OCCUPATIONAL IND DER, P271; FISHER AA, 1973, J DERMATOL SURG, V113, P6; FISHER AA, 1986, CUTIS, V39, P291; FISHER AA, 1986, NITROGEN MUSTARD CON, P696; FISHER AA, 1990, CUTIS, V45, P327; FISHER AA, 1987, CUTIS, V44, P365; FISHER AA, 1972, MED WORLD NEWS, V67, P121; FISHER AA, 1986, CUTIS, V47, P425; FISHER AA, 1973, CUTIS, V12, P333; FITZGERALD RH, 1979, MAYO CLIN PROC, V54, P590; FREGERT S, 1963, J ALLERGY, V34, P404, DOI 10.1016/0021-8707(63)90003-0; FRIES IB, 1975, J BONE JOINT SURG AM, VA 57, P547, DOI 10.2106/00004623-197557040-00020; FROSCH PJ, 1986, CONTACT DERMATITIS, V14, P241, DOI 10.1111/j.1600-0536.1986.tb01233.x; GELLIN GA, 1987, OCCUPATIONAL IND DER, P88; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; GONCALO S, 1984, CONTACT DERMATITIS, V10, P185; GRANT JBF, 1976, BRIT J SURG, V63, P864, DOI 10.1002/bjs.1800631107; HOGARO DJ, 1991, ENV DERMATITIS, P392; KIRSHEN EJ, 1974, AM J OBSTET GYNECOL, V118, P799, DOI 10.1016/0002-9378(74)90491-8; LAMMINTAUSTA K, 1982, CONTACT DERMATITIS, V8, P84, DOI 10.1111/j.1600-0536.1982.tb04151.x; LAYNADIER F, 1989, ANAESTHESIA, V44, P547; LOZYNSKY OA, 1986, ANN ALLERGY, V56, P62; MAILBACH H, 1975, CONTACT DERMATITIS, V1, P327; MARKS JG, 1982, J AM ACAD DERMATOL, V6, P43; MARTINSCOTT I, 1960, BRIT J DERMATOL, V72, P372; MEDING B, 1984, CONTACT DERMATITIS, V10, P52, DOI 10.1111/j.1600-0536.1984.tb00071.x; MONTENY E, 1978, ACTA ORTHOP SCAND, V49, P554, DOI 10.3109/17453677808993237; MORIKAWA F, 1974, J SOC COSMET CHEM, V25, P113; OHTOSHI T, 1986, CLIN ALLERGY, V16, P155, DOI 10.1111/j.1365-2222.1986.tb00759.x; PEGUM JS, 1971, BMJ-BRIT MED J, V2, P141, DOI 10.1136/bmj.2.5754.141; RAPAPORT MJ, 1980, CONTACT DERMATITIS, V6, P229, DOI 10.1111/j.1600-0536.1980.tb05617.x; Richardson DR, 1969, CUTIS, V5, P1115; RODGERS B, 1987, OCCUP MED, V2, P513; ROGERS B, 1987, OCCUP MED, V2, P513; ROSTENBERG A, 1952, J INVEST DERMATOL, V19, P456; SAXEN L, 1970, ACTA PATHOL MIC SC, V64, P55; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SNEDDON IB, 1969, BMJ, V1, P183; SODERBER.CH, 1973, AM J SURG, V125, P455, DOI 10.1016/0002-9610(73)90081-0; SWARTZ J, 1990, CAN J ANAESTH, V37, P589, DOI 10.1007/BF03006333; TAYLOR JS, 1989, J AM ACAD DERMATOL, V21, P874, DOI 10.1016/S0190-9622(89)70271-1; TAYLOR JS, 1986, CONTACT DERMATITIS, P603; TAYLOR JS, 1986, CONTACT DERMATITIS, P631; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, DERMATOL CLIN, V6, P47, DOI 10.1016/S0733-8635(18)30688-0; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029; TURJANMAA K, 1989, CONTACT DERMATITIS, V20, P360, DOI 10.1111/j.1600-0536.1989.tb03173.x; VALSECCHI R, 1991, CONTACT DERMATITIS, V24, P70, DOI 10.1111/j.1600-0536.1991.tb01645.x; van Ketel W G, 1975, Contact Dermatitis, V1, P7; VANDERMEEREN HLM, 1986, CONTACT DERMATITIS, V14, P190, DOI 10.1111/j.1600-0536.1986.tb01213.x; WATERMAN AH, 1985, CONTACT DERMATITIS, V13, P294, DOI 10.1111/j.1600-0536.1985.tb02581.x; WRANGSJO K, 1986, CONTACT DERMATITIS, V15, P79, DOI 10.1111/j.1600-0536.1986.tb01281.x; 1986, CONTACT DERMATITIS, P525	71	26	28	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					729	738		10.1016/0091-6749(92)90095-J	http://dx.doi.org/10.1016/0091-6749(92)90095-J			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1430699	Bronze			2022-12-18	WOS:A1992JZ31900001
J	BINKLEY, K; CHEEMA, A; SUSSMAN, G; MOUDGIL, G; OCONNOR, M; EVANS, S; DOLOVICH, J				BINKLEY, K; CHEEMA, A; SUSSMAN, G; MOUDGIL, G; OCONNOR, M; EVANS, S; DOLOVICH, J			GENERALIZED ALLERGIC REACTIONS DURING ANESTHESIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANESTHESIA; ANAPHYLAXIS; THIOPENTAL; SUCCINYLCHOLINE; LATEX SKIN TESTS; RAST	ANAPHYLACTOID REACTIONS; MUSCLE-RELAXANTS; ADVERSE REACTIONS; INDUCTION; DIAGNOSIS; DRUGS	Twenty-eight adults with a history of a generalized allergic reaction during anesthesia were investigated. The reactions were systemic in 23 adults, urticaria/angioedema in four, and bronchial obstruction in one adult. The study population and an additional 35 subjects with a history of use of thiopental during anesthesia but without reactions were investigated by methods including thiopental skin test, succinylcholine skin test, and IgE RAST for antibodies to thiopental, succinylcholine, or latex. Among the 28 patients with reactions, 17 had positive thiopental skin tests; 14/28 reactors and 1/35 of the control group had an IgE thiopental RAST value > 2 SD above the mean for control sera from ragweed-allergic subjects. The one control subject with a positive thiopental RAST also was the only control subject with a positive thiopental skin test. IgE succinylcholine RAST was negative in all 23 reactor sera tested. The IgE latex RAST was strongly positive in one reactor. In conclusion, evidence of allergy, particularly allergy to thiopental as a possible basis for the reactions, was obtained in > 50% of the patients who were investigated. No allergy to succinylcholine was found.	MCMASTER UNIV,MED CTR,DEPT PEDIAT,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT ANESTHESIA,HAMILTON L8N 3Z5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA	McMaster University; McMaster University; University of Toronto								BALDWIN AC, 1979, ANAESTHESIA, V34, P333, DOI 10.1111/j.1365-2044.1979.tb04930.x; CLARKE RSJ, 1981, DRUGS, V22, P26, DOI 10.2165/00003495-198122010-00002; CLARKE RSJ, 1985, INT ANESTHESIOL CLIN, V23, P1; EVANS JM, 1977, BRIT MED J, V2, P735, DOI 10.1136/bmj.2.6089.735; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P226, DOI 10.1177/0310057X8100900304; FISHER MM, 1983, ANESTH ANALG, V62, P559; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P242, DOI 10.1177/0310057X8100900306; FISHER MM, 1985, INT ANESTHESIOL CLIN, V23, P161; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; HARLE DG, 1986, CLIN ALLERGY, V16, P493, DOI 10.1111/j.1365-2222.1986.tb01984.x; KELLY JF, 1978, J ALLERGY CLIN IMMUN, V62, P181, DOI 10.1016/0091-6749(78)90104-5; MONERETVAUTRIN DA, 1988, J ALLERGY CLIN IMMUN, V82, P745, DOI 10.1016/0091-6749(88)90074-7; MOSCICKI RA, 1990, J ALLERGY CLIN IMMUN, V86, P325, DOI 10.1016/S0091-6749(05)80095-8; MOSS J, 1983, ANESTHESIOLOGY, V59, P330, DOI 10.1097/00000542-198310000-00011; MOUDGIL GC, 1986, CAN J ANAESTH, V33, P400, DOI 10.1007/BF03010757; SCHWARTZ HJ, 1965, JAMA-J AM MED ASSOC, V194, P113; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P552, DOI 10.1016/0091-6749(83)90436-0; WATKINS J, 1979, BRIT J ANAESTH, V51, P51, DOI 10.1093/bja/51.1.51; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x	21	26	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					768	774		10.1016/0091-6749(92)90386-G	http://dx.doi.org/10.1016/0091-6749(92)90386-G			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545098				2022-12-18	WOS:A1992HJ34000018
J	WILLIAMS, PB; NOLTE, H; DOLEN, WK; KOEPKE, JW; SELNER, JC				WILLIAMS, PB; NOLTE, H; DOLEN, WK; KOEPKE, JW; SELNER, JC			THE HISTAMINE CONTENT OF ALLERGEN EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGENS; DRUG CONTAMINATION; TISSUE EXTRACTS; POLLEN; SKIN TESTS; BASOPHIL HISTAMINE RELEASE; HISTAMINE; DIAMINE OXIDASE	DOSE-RESPONSE CURVE; WHEAL	The histamine content of 108 inhalant, food, and venom extracts from four commercial sources was measured by chemical (glass fiber-based) and immunologic (competitive RIA) methods. Histamine was present in 64 of 76 inhalant extracts (range, 0.005 to 7.4-mu-g/ml), 20 of 26 food extracts (range, 0.16 to 23-mu-g/ml), and six of six venoms, 100-mu-g/ml (range, 1.0 to 38-mu-g/ml). Histamine was removed by treatment with diamine oxidase or dialysis of an extract. Repeat assay of selected extracts after addition of known amounts of histamine in the glass fiber-based method produced additive results, and glycerin- or phenol-extract preservatives did not affect assay performance. Timed extractions of dried-pollen grains demonstrated maximal histamine content at 30 seconds, suggesting that histamine is an inherent component of at least some pollens. Histamine found in some allergen extracts could, under extreme circumstances, produce false-positive results in skin testing and in basophil histamine release assays, and could affect the result of research that uses intact pollen or allergen extracts.	ELON COLL,ELON,NC 27244	Elon University	WILLIAMS, PB (corresponding author), ALLERGY RESP INST COLORADO,5800 E EVANS AVE,DENVER,CO 80222, USA.							ANDERSSON M, 1990, J ALLERGY CLIN IMMUN, V86, P815, DOI 10.1016/S0091-6749(05)80188-5; BECKER CG, 1981, BLOOD, V58, P861; BOUSQUET J, 1980, ANN ALLERGY, V45, P316; BREDE S, 1983, ARB P EHRLICH I G SP, V78, P195; DJUKANOVIC R, 1989, J ALLERGY CLIN IMMUN, V84, P373, DOI 10.1016/0091-6749(89)90423-5; DREBORG S, 1987, ALLERGY, V42, P117, DOI 10.1111/j.1398-9995.1987.tb02369.x; ESCH RE, 1989, ADV BIOSCI, V74, P3; Freed D. L. J., 1979, PROTEIN TRANSMISSION, P411; FREED DLJ, 1983, ALLERGY, V38, P477, DOI 10.1111/j.1398-9995.1983.tb02356.x; GUERIN B, 1979, CLIN ALLERGY, V9, P283, DOI 10.1111/j.1365-2222.1979.tb01555.x; HARRIS RI, 1988, ALLERGY, V43, P565, DOI 10.1111/j.1398-9995.1988.tb00928.x; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; MALLING HJ, 1987, ALLERGY, V42, P196, DOI 10.1111/j.1398-9995.1987.tb02200.x; MALONE MH, 1986, NEW ENGL REG ALLERGY, V7, P241; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; NELSON HS, 1983, ANN ALLERGY, V51, P411; Richman P. G., 1986, Monograph on insect allergy, P13; SELTZER JM, 1982, J IMMUNOL METHODS, V55, P355, DOI 10.1016/0022-1759(82)90095-3; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P55; VERBURG KM, 1984, AGENTS ACTIONS, V14, P633, DOI 10.1007/BF01978899; WILLOUGHBY JW, 1988, AM ACADEMY OTOLARYNG, V1, P151; [No title captured]	25	26	26	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					738	745		10.1016/0091-6749(92)90382-C	http://dx.doi.org/10.1016/0091-6749(92)90382-C			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545095				2022-12-18	WOS:A1992HJ34000014
J	WIEBICKE, W; JORRES, R; MAGNUSSEN, H				WIEBICKE, W; JORRES, R; MAGNUSSEN, H			COMPARISON OF THE EFFECTS OF INHALED CORTICOSTEROIDS ON THE AIRWAY RESPONSE TO HISTAMINE, METHACHOLINE, HYPERVENTILATION, AND SULFUR-DIOXIDE IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BECLOMETHASONE DIPROPIONATE; BRONCHIAL RESPONSIVENESS; SODIUM CROMOGLYCATE; COLD AIR; HYPERREACTIVITY; BUDESONIDE; REACTIVITY; REPRODUCIBILITY; TERBUTALINE; INHALATION	To investigate whether inhaled steroids modulate the airway response to different bronchoconstrictive stimuli, we studied 25 subjects with mild asthma with a double-blind, noncrossover design to compare the effect of a 3-week treatment with salbutamol (0.2 mg, four times a day [q.i.d.]) and placebo (N = 11) to the effect of salbutamol (0.2 mg q.i.d.) and inhaled beclomethasone dipropionate (BDP, 0.5 mg q.i.d.) (N = 14). Airway response to histamine and methacholine was assessed as the provocative concentration (in milligrams per milliliter) necessary to increase the specific airway resistance (SR(aw)) (in centimeters of H2O times second) by 100% (PC100 SR(aw)). Airway response to hyperventilation of air and to hyperventilation of 0.75 ppm of sulfur dioxide (SO2) was determined as the provocative ventilation (in liters per minute) necessary to increase SR(aw) by 75% (PV75 SR(aw)). Challenges were performed on separate days before and after treatment, and salbutamol inhalation was withheld at least 6 hours before each challenge. Salbutamol and placebo did not change prechallenge baseline SR(aw) nor did they have any significant effect on the airway response to the stimuli. Salbutamol and BDP decreased the mean prechallenge baseline SR(aw) (SEM) from 7.7 (0.37) to 5.9 (0.28) (p < 0.01) and significantly (p < 0.01) increased geometric mean (SEM) PC100 SR(aw) for histamine from 0.5 (1.42) to 0.9 (1.53) mg/ml; for metacholine, from 0.2 (1.47) to 0.5 (1.51) mg/ml; and mean (SEM) PV75 SR(aw) for hyperventilation of air from 51.8 (2.32) to 58.4 (1.86) L/min. In contrast, the change of PV75 SR(aw) during hyperventilation of SO2 from 26.2 (2.29) to 31.4 (3.30) L/min was not significant. Our observations confirm previously reported effects of inhaled steroids on metacholine and histamine challenges. However, since BDP had no consistent effect on the SO2 hyperventilation test, we suggest that the efficacy of inhaled steroids depends on the nature of the provoking stimulus.	KRANKENHAUS GROSSHANSDORF,CTR PULM DIS & THORAC SURG,WOHRENDAMM 80,W-2070 GROSSHANSDORF,GERMANY	Grosshansdorf Hospital								CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CROPP GJA, 1980, ATS NEWS         SPR, P11; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; EASTON JG, 1981, J ALLERGY CLIN IMMUN, V67, P388, DOI 10.1016/0091-6749(81)90084-1; HENRIKSEN JM, 1983, AM REV RESPIR DIS, V128, P993; HORSTMAN D, 1986, Toxicology and Industrial Health, V2, P289; JENKINS CR, 1988, THORAX, V43, P378, DOI 10.1136/thx.43.5.378; JORRES R, 1990, EUR RESPIR J, V3, P132; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KALINER M, 1985, J ALLERGY CLIN IMMUN, V76, P321, DOI 10.1016/0091-6749(85)90648-7; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KOHLER W, 1984, BIOMETRIE, P96; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; MAGNUSSEN H, 1987, American Review of Respiratory Disease, V135, pA442; MALO JL, 1986, AM REV RESPIR DIS, V134, P990, DOI 10.1164/arrd.1986.134.5.990; MAPP C, 1987, AM REV RESPIR DIS, V136, P1403, DOI 10.1164/ajrccm/136.6.1403; MYERS DJ, 1986, AM REV RESPIR DIS, V133, P1154; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; TATTERSFIELD AE, 1987, AM REV RESPIR DIS, V136, P564; TESSIER P, 1986, J ALLERGY CLIN IMMUN, V78, P379, DOI 10.1016/0091-6749(86)90021-7; VATHENEN A S, 1989, American Review of Respiratory Disease, V139, pA109; 1983, B EUR PHYSIOPATHOL S, V19, P7	29	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				915	923		10.1016/S0091-6749(05)80155-1	http://dx.doi.org/10.1016/S0091-6749(05)80155-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262646				2022-12-18	WOS:A1990EQ04500013
J	HANIFIN, JM				HANIFIN, JM			THE ROLE OF ANTIHISTAMINES IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	MEETING ON HISTAMINE AND DISEASE : A FORUM ON CURRENT AND FUTURE MANAGEMENT	AUG 25-26, 1989	CARLSBAD, CA	MERRELL DOW PHARM							HANIFIN, JM (corresponding author), OREGON HLTH SCI UNIV,DERMATOL,3181 SW SAM JACKSON PARK RD,PORTLAND,OR 97201, USA.							ARNOLD AJ, 1979, J AM ACAD DERMATOL, V1, P509, DOI 10.1016/S0190-9622(79)80094-8; BUTLER JM, 1983, J ALLERGY CLIN IMMUN, V71, P490, DOI 10.1016/0091-6749(83)90467-0; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; DOHERTY V, 1989, BRIT MED J, V298, P96, DOI 10.1136/bmj.298.6666.96; EPSTEIN E, 1946, ARCH DERMATOL SYPH, V53, P281, DOI 10.1001/archderm.1946.01510320071012; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FIOCCHI A, 1985, CURR THER RES CLIN E, V37, P1113; FROSCH PJ, 1984, ARCH DERMATOL RES, V276, P36, DOI 10.1007/BF00412560; GIUSTINA TA, 1984, J ALLERGY CLIN IMMUN, V74, P252, DOI 10.1016/0091-6749(84)90254-9; GRAHAM DT, 1953, J LAB CLIN MED, V42, P238; HACHISUKA H, 1988, ARCH DERMATOL RES, V280, P158, DOI 10.1007/BF00456847; HAGERMARK O, 1974, ACTA DERM-VENEREOL, V54, P397; HANIFIN JM, 1977, ANN ALLERGY, V39, P153; HANIFIN JM, 1986, CLIN REV ALLERG, V4, P43; ISHIBASHI Y, 1989, CLIN EVAL, V17, P77; KLEIN GL, 1980, ANN ALLERGY, V44, P142; KODA A, 1976, J ALLERGY CLIN IMMUN, V57, P396, DOI 10.1016/0091-6749(76)90054-3; KOMATSU H, 1988, JPN J PHARMACOL, V46, P53, DOI 10.1254/jjp.46.53; KRAUSE L, 1983, BRIT MED J, V287, P1199, DOI 10.1136/bmj.287.6400.1199; LEBEL B, 1980, ACTA DERM-VENEREOL, V92, P57; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEIFERMAN KM, 1989, CLIN RES, V37, pA737; LITTLE MM, 1989, J ALLERGY CLIN IMMUN, V83, P862, DOI 10.1016/0091-6749(89)90096-1; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SLADEK WA, 1989, ANN ALLERGY, V62, P249; SOBOTKA AK, 1978, IMMUNOL REV, V41, P171, DOI 10.1111/j.1600-065X.1978.tb01464.x	29	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			666	669		10.1016/S0091-6749(05)80237-4	http://dx.doi.org/10.1016/S0091-6749(05)80237-4			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	1699988				2022-12-18	WOS:A1990EH09300018
J	BARTHELSON, R; VALONE, F				BARTHELSON, R; VALONE, F			INTERACTION OF PLATELET-ACTIVATING FACTOR WITH INTERFERON-GAMMA IN THE STIMULATION OF INTERLEUKIN-1 PRODUCTION BY HUMAN MONOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BARTHELSON, R (corresponding author), VET ADM MED CTR,111H,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NIAID NIH HHS [AI22141, AI19784] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022141, P01AI019784] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCHER CB, 1985, BRIT J DERMATOL, V112, P285, DOI 10.1111/j.1365-2133.1985.tb04855.x; BARTHELSON RA, 1990, CLIN RES, V38, pA111; BARTHELSON RA, 1990, CELL IMMUNOL, V125, P142, DOI 10.1016/0008-8749(90)90069-4; BONAVIDA B, 1989, INT ARCH ALLER A IMM, V88, P157, DOI 10.1159/000234772; Braquet P, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P822; BRAQUET P, 1987, IMMUNOL TODAY, V8, P345, DOI 10.1016/0167-5699(87)90010-7; BROWN KM, 1986, P NATL ACAD SCI USA, V83, P9119, DOI 10.1073/pnas.83.23.9119; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; CUSS FM, 1986, LANCET, V2, P189; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; DOEBBER TW, 1986, J IMMUNOL, V136, P4659; DUBOIS C, 1989, J IMMUNOL, V143, P964; FUHLBRIGGE RC, 1987, J IMMUNOL, V138, P3799; HERRMANN F, 1989, J IMMUNOL, V142, P139; LACEY DL, 1987, J IMMUNOL, V138, P1680; LE JM, 1987, LAB INVEST, V56, P234; LEE TC, 1987, PLATELET ACTIVATING, P116; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; MIZEL SB, 1978, J IMMUNOL, V120, P1497; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NEWTON RC, 1985, IMMUNOLOGY, V56, P441; PIGNOL B, 1989, INT ARCH ALLER A IMM, V88, P161, DOI 10.1159/000234773; PIGNOL B, 1987, PROSTAGLANDINS, V33, P931, DOI 10.1016/0090-6980(87)90120-1; PRETOLANI M, 1987, EUR J PHARMACOL, V140, P311, DOI 10.1016/0014-2999(87)90288-3; RUIS N, IN PRESS LIPIDS; SECKINGER P, 1987, J IMMUNOL, V139, P1541; SUN XM, 1988, J CLIN INVEST, V81, P1328, DOI 10.1172/JCI113459; TIFFANY CW, 1989, FEBS LETT, V247, P189, DOI 10.1016/0014-5793(89)81331-6; TOWNLEY RG, 1989, J ALLERGY CLIN IMMUN, V83, P997, DOI 10.1016/0091-6749(89)90437-5; VALONE F, 1990, PAF IMMUNE RESPONSES, P42; VALONE FH, 1988, J IMMUNOL, V141, P3945; WARD S, 1989, PLATELET ACTIVATING, P37; WARNER SJC, 1987, J IMMUNOL, V139, P1911	34	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					193	201		10.1016/S0091-6749(05)80066-1	http://dx.doi.org/10.1016/S0091-6749(05)80066-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2117030	Bronze			2022-12-18	WOS:A1990DV31600009
J	VENGE, P; HENRIKSEN, J; DAHL, R; HAKANSSON, L				VENGE, P; HENRIKSEN, J; DAHL, R; HAKANSSON, L			EXERCISE-INDUCED ASTHMA AND THE GENERATION OF NEUTROPHIL CHEMOTACTIC ACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									AARHUS UNIV HOSP,DEPT LUND MED,DK-8000 AARHUS C,DENMARK	Aarhus University	VENGE, P (corresponding author), UNIV HOSP UPPSALA,DEPT CLIN CHEM,INFLAMMAT RES LAB,S-75185 UPPSALA,SWEDEN.		Dahl, Ronahl/F-8170-2013					ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; GODFREY S, 1986, EUR J RESPIR DIS, V68, P81; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; HAKANSSON L, 1980, SCAND J IMMUNOL, V11, P271, DOI 10.1111/j.1365-3083.1980.tb00235.x; LEE TH, 1985, THORAX, V40, P481, DOI 10.1136/thx.40.7.481; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MCFADDEN ER, 1987, NEW ENGL J MED, V317, P502, DOI 10.1056/NEJM198708203170809; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; RAK S, IN PRESS J ALLERGY C; RUBENSTEIN I, 1987, NEW ENGL J MED, V317, P482; VENGE P, 1982, ALLERGY, V37, P55, DOI 10.1111/j.1398-9995.1982.tb04117.x; VENGE P, 1987, J ALLERGY CLIN IMMUN, V80, P679, DOI 10.1016/0091-6749(87)90287-9; WILKINSON PC, 1974, CHEMOTAXIS INFLAMMAT	14	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					498	504		10.1016/0091-6749(90)90161-V	http://dx.doi.org/10.1016/0091-6749(90)90161-V			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2105990				2022-12-18	WOS:A1990CP51100012
J	KIM, KS				KIM, KS			HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN IMPAIRS ANTIBACTERIAL ACTIVITY OF ANTIBIOTICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033	University of Southern California	KIM, KS (corresponding author), CHILDRENS HOSP LOS ANGELES,DEPT PEDIAT,DIV INFECT DIS,4660 SUNSET BLVD,LOS ANGELES,CA 90027, USA.							KIM KS, 1987, PEDIATR RES, V21, P289, DOI 10.1203/00006450-198703000-00018; KIM KS, 1987, J INFECT DIS, V155, P1233, DOI 10.1093/infdis/155.6.1233; KIM KS, 1986, J INFECT DIS, V153, P1092, DOI 10.1093/infdis/153.6.1092; SCHREIBER J, 1987, PEDIATR RES, V21, pA334, DOI 10.1203/00006450-198704010-00999; SHIGEOKA AO, 1978, LANCET, V1, P636; SIEGEL G, 1985, CLIN RES, V333, pA419	6	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	2	S			579	588		10.1016/0091-6749(89)90194-2	http://dx.doi.org/10.1016/0091-6749(89)90194-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ398	2677094				2022-12-18	WOS:A1989AZ39800003
J	REED, CE; YUNGINGER, JW; EVANS, R				REED, CE; YUNGINGER, JW; EVANS, R			QUALITY ASSURANCE AND STANDARDIZATION OF ALLERGY EXTRACTS IN ALLERGY PRACTICE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									CHILDRENS MEM HOSP,DIV ALLERGY & IMMUNOL,CHICAGO,IL 60614	Ann & Robert H. Lurie Children's Hospital of Chicago	REED, CE (corresponding author), MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905, USA.							ANDERSON MC, 1986, CLIN REV ALLERG, V4, P363; ANDERSON MC, 1987, ARB P EHRLICH I, V80, P41; ANDERSON MS, 1987, ARB P EHRLICH I, V80, P1; AUKRUST L, 1987, ARB P EHRLICH I, V80, P7; BAER H, 1988, ARB P EHRLICH I, V82, P9; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; DREBORG S, 1987, ALLERGY, V42, P109, DOI 10.1111/j.1398-9995.1987.tb02368.x; FORD AW, 1987, CLIN REV ALLERG, V5, P49; HOFFMAN DR, 1987, CLIN REV ALLERG, V5, P75; ISHIZAKA K, 1988, ALLERGY PRINCIPLES P, V1, P52; KING TP, 1986, CLIN REV ALLERG, V4, P425; LOWENSTEIN H, 1986, CLIN REV ALLERG, V4, P405; Lowenstein H, 1987, ARB P EHRLICH I, V80, P75; MARSH DG, 1988, ALLERGY PRINCIPLES P, V1, P94; MARSH DG, 1987, ARB P EHRLICH I, V80, P47; NORMAN PS, 1986, J ALLERGY CLIN IMMUN, V77, P405, DOI 10.1016/0091-6749(86)90173-9; NORMAN PS, 1988, ARB P EHRLICH I BUND, V82, P45; OHMAN JL, 1987, CLIN REV ALLERG, V5, P37; OHMAN JL, 1987, ARB P EHRLICH I, V80, P25; PHILLIPS PV, 1987, ARB P EHRLICH I, V80, P59; SJOKOLM I, 1988, ARB P EHRLICH I, V82, P41; SPIEKSMA FTM, 1987, ARB P EHRLICH I, V80, P15; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; TURKELTAUB PC, 1988, ARB P EHRLICH I BUND, V82, P19; YUNGINGER JW, 1984, J ALLERGY CLIN IMMUN, V73, P316, DOI 10.1016/0091-6749(84)90402-0; YUNGINGER JW, 1988, ARB P EHRLICH I, V82, P129; METHODS LABORATORY A	28	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					4	8		10.1016/0091-6749(89)90171-1	http://dx.doi.org/10.1016/0091-6749(89)90171-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2666483				2022-12-18	WOS:A1989AG12000002
J	SOMVILLE, MA; MACHIELS, J; GILLES, JGG; SAINTREMY, JMR				SOMVILLE, MA; MACHIELS, J; GILLES, JGG; SAINTREMY, JMR			SEASONAL-VARIATION IN SPECIFIC IGE ANTIBODIES OF GRASS-POLLEN HYPERSENSITIVE PATIENTS DEPENDS ON THE STEADY-STATE IGE CONCENTRATION AND IS NOT RELATED TO CLINICAL SYMPTOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CATHOLIC UNIV LOUVAIN,INST CELLULAR & MOLEC PATHOL,EXPTL MED UNT,1CP 7430,B-1200 BRUSSELS,BELGIUM; CLIN ST PIERRE,OTTIGNIES,BELGIUM	Universite Catholique Louvain								AAS K, 1982, ALLERGY, V37, P1, DOI 10.1111/j.1398-9995.1982.tb04111.x; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; CERNY J, 1984, IMMUNOL TODAY, V5, P3; DEUSCHL H, 1977, CLIN ALLERGY, V7, P315, DOI 10.1111/j.1365-2222.1977.tb01459.x; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P499; FRIEDHOFF L R, 1987, Journal of Allergy and Clinical Immunology, V80, P646; GILLES JGG, 1988, J ALLERGY CLIN IMMUN, V82, P35, DOI 10.1016/0091-6749(88)90048-6; GLEICH GJ, 1976, J ALLERGY CLIN IMMUN, V57, P203; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; JOHANSSON SGO, 1986, 13 P C EUR AC ALL CL; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MAGNUSSON CGM, 1981, CLIN ALLERGY, V11, P453, DOI 10.1111/j.1365-2222.1981.tb01619.x; MAGNUSSON CGM, 1985, J ALLERGY CLIN IMMUN, V75, P513, DOI 10.1016/S0091-6749(85)80026-9; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MEYERS DA, 1987, AM J HUM GENET, V41, P51; NICKELSEN JA, 1986, J ALLERGY CLIN IMMUN, V77, P43, DOI 10.1016/0091-6749(86)90320-9; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; WALDMANN TA, 1976, J IMMUNOL, V117, P1139; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	25	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				486	494		10.1016/0091-6749(89)90138-3	http://dx.doi.org/10.1016/0091-6749(89)90138-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2918188				2022-12-18	WOS:A1989T448900019
J	SHEPPARD, D				SHEPPARD, D			SULFUR-DIOXIDE AND ASTHMA - A DOUBLE-EDGED SWORD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											SHEPPARD, D (corresponding author), SAN FRANCISCO GEN HOSP,CTR LUNG BIOL,BLDG 1,ROOM 150,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.							AMDUR M O, 1969, Journal of the Air Pollution Control Association, V19, P638; AMDUR MO, 1966, ARCH ENVIRON HEALTH, V12, P729, DOI 10.1080/00039896.1966.10664472; BALMES JR, 1987, AM REV RESPIR DIS, V136, P1117, DOI 10.1164/ajrccm/136.5.1117; BETHEL RA, 1983, AM REV RESPIR DIS, V128, P987; FRANK NR, 1962, J APPL PHYSIOL, V17, P252, DOI 10.1152/jappl.1962.17.2.252; FRANK NR, 1965, ARCH ENVIRON HEALTH, V11, P624, DOI 10.1080/00039896.1965.10664271; Hahn H L, 1983, Prax Klin Pneumol, V37 Suppl 1, P666; HOLLAND WW, 1979, AM J EPIDEMIOL, V110, P527; HORSTMAN DH, 1988, AM IND HYG ASSOC J, V49, P38, DOI 10.1202/0002-8894(1988)049<0038:TRBEDA>2.0.CO;2; IBRAHIM AL, 1980, J ENVIRON PATHOL TOX, V3, P251; KERHL HR, 1987, AM REV RESPIR DIS, V135, P1124; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; LINN WS, 1983, AM REV RESPIR DIS, V127, P278; LOGAN WPD, 1953, LANCET, V1, P336; MATSUMURA Y, 1970, AM REV RESPIR DIS, V102, P430; MATSUMURA Y, 1970, AM REV RESPIR DIS, V102, P438; MATSUMURA Y, 1970, AM REV RESPIR DIS, V102, P444; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; OSEBOLD JW, 1980, J ENVIRON PATHOL TOX, V3, P221; PAYAN DG, 1984, J IMMUNOL, V132, P1601; RIEDEL F, 1988, J ALLERGY CLIN IMMUN, V82, P527, DOI 10.1016/0091-6749(88)90961-X; ROGER LJ, 1985, J APPL PHYSIOL, V59, P784, DOI 10.1152/jappl.1985.59.3.784; SCHACHTER EN, 1984, ARCH ENVIRON HEALTH, V39, P34, DOI 10.1080/00039896.1984.10545831; SCHRENK HH, 1949, PUBLIC HLTH B, P306; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHY CM, 1978, HLTH EFFECTS AIR POL	26	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					961	964		10.1016/0091-6749(88)90131-5	http://dx.doi.org/10.1016/0091-6749(88)90131-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3060513				2022-12-18	WOS:A1988R631100002
J	MIDDLETON, E				MIDDLETON, E			CHRONIC RHINITIS IN ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MIDDLETON, E (corresponding author), SUNY BUFFALO,100 HIGH ST,BUFFALO,NY 14203, USA.							ARBESMAN C, 1983, J ALLERGY CLIN IMMUN, V71, P597, DOI 10.1016/0091-6749(83)90442-6; BALLOW M, 1984, POSTGRAD MED, V76, P197, DOI 10.1080/00325481.1984.11698675; BROIDE D, 1986, PHARMACOTHERAPY, V65, P47; CORRADO OJ, 1986, THORAX, V41, P863, DOI 10.1136/thx.41.11.863; DOLOVICH J, 1987, J ALLERGY CLIN IMMUN, V80, P274, DOI 10.1016/0091-6749(87)90031-5; HENDELES L, 1980, AM J HOSP PHARM, V37, P1496, DOI 10.1093/ajhp/37.11.1496; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; KIRKEGAARD J, 1987, J ALLERGY CLIN IMMUN, V79, P585, DOI 10.1016/S0091-6749(87)80153-7; KNIGHT A, 1986, ANN ALLERGY, V57, P348; KONNO A, 1987, J ALLERGY CLIN IMMUN, V79, P620, DOI 10.1016/S0091-6749(87)80158-6; MATHEWS KP, 1985, ALLERGY, P323; MAYEUX D, 1986, CURR MED RES OPIN, V10, P330, DOI 10.1185/03007998609111099; MCLEAN JA, 1982, N ENGL SOC ALLERGY P, V3, P397; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; Mygind N., 1979, NASAL ALLERGY; NACLERIO RM, 1986, CLIN ALLERGY, V16, P101, DOI 10.1111/j.1365-2222.1986.tb00753.x; NACLERIO RM, 1987, J RESPIR DIS, V8, P29; SETTIPANE GA, 1984, NEW ENGLAND REGIONAL; SIMONS FER, 1984, CLIN REV ALLERG, V2, P237; SPECTOR SL, 1983, ALLERGY PRINCIPLES P, P1249; SPIESMAN I. G., 1937, American Journal of Digestive Diseases, V4, P438; STAFFORD CT, 1987, POSTGRAD MED, V81, P147, DOI 10.1080/00325481.1987.11699668; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; WIHL JA, 1985, J ALLERGY CLIN IMMUN, V75, P720, DOI 10.1016/0091-6749(85)90100-9; Zeiger R., 1982, IMMUNOL ALLERGY PRAC, V4, P26; ZEIGER RS, 1982, IMMUNOL ALLERGY PRAC, V4, P17	26	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			971	975		10.1016/0091-6749(88)90163-7	http://dx.doi.org/10.1016/0091-6749(88)90163-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3286737				2022-12-18	WOS:A1988N703700008
J	SLAVIN, RG				SLAVIN, RG			SINUSITIS IN ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST LOUIS UNIV, SCH MED, DEPT INTERNAL MED & MICROBIOL, ST LOUIS, MO 63104 USA	Saint Louis University								AFZELIUS B A, 1976, Science (Washington D C), V193, P317; AUST R, 1976, Rhinology (Utrecht), V14, P43; AUST R, 1976, ACTA OTO-LARYNGOL, V81, P468, DOI 10.3109/00016487609107502; AUST R, 1974, Rhinology (Utrecht), V12, P25; BULLEN SS, 1932, J ALLERGY, V4, P402; CAPLAN ES, 1982, JAMA-J AM MED ASSOC, V247, P639, DOI 10.1001/jama.247.5.639; CARENFELT C, 1978, ACTA OTO-LARYNGOL, V85, P116, DOI 10.3109/00016487809121431; CARENFELT C, 1977, ACTA OTO-LARYNGOL, V84, P138, DOI 10.3109/00016487709123952; CLEVELAND HH, 1979, ACTA OTOLARYNGOL S, V368; DRETTNER B, 1980, CLIN OTOLARYNGOL, V5, P277, DOI 10.1111/j.1365-2273.1980.tb01658.x; Drettner B., 1965, ACTA OTO-LARYNGOL, V60, P304; FRIEDMAN WH, 1984, CLIN REV ALLERG, V2, P409; GOTTLIEB MS, 1932, JAMA-J AM MED ASSOC, V85, P105; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P643, DOI 10.1001/archotol.1985.00800120037003; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; MINGS RD, 1987, J ALLERGY CLIN IMMUN, V79, P247; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; PHIPATAN.CS, 1974, ARCH OTOLARYNGOL, V100, P109; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; REINER A, 1978, ACTA OTOLARYNGOL S, V355; ROHR AS, 1984, CLIN REV ALLERG, V2, P387; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SLAVIN RG, 1983, J ALLERGY CLIN IMMUN, V71, P156, DOI 10.1016/0091-6749(83)90394-9; STAMMBERGER H, 1985, ANN OTO RHINO 2 S119, V94; STEHIM ER, 1980, IMMUNOLOGIC DISORDER, P183; 1971, DIGEST HLTH STATISTI; 1984, NIH DATA BOOK, P51	27	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			1028	1032		10.1016/0091-6749(88)90174-1	http://dx.doi.org/10.1016/0091-6749(88)90174-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3286729				2022-12-18	WOS:A1988N703700019
J	KAKUTA, Y; OKAYAMA, H; AIKAWA, T; KANNO, T; OHYAMA, T; SASAKI, H; KATO, T; TAKISHIMA, T				KAKUTA, Y; OKAYAMA, H; AIKAWA, T; KANNO, T; OHYAMA, T; SASAKI, H; KATO, T; TAKISHIMA, T			K-CHANNELS OF HUMAN ALVEOLAR MACROPHAGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,1-1 SEIRYO MACHI,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT DERMATOL,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University								BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENJEAN A, 1983, J APPL PHYSIOL, V55, P799, DOI 10.1152/jappl.1983.55.3.799; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; DOSREIS GA, 1979, BIOCHIM BIOPHYS ACTA, V552, P331, DOI 10.1016/0005-2736(79)90287-6; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GALLIN EK, 1984, FED PROC, V43, P2385; GALLIN EK, 1975, J CELL PHYSIOL, V86, P653, DOI 10.1002/jcp.1040860510; GALLIN EK, 1977, J CELL BIOL, V75, P277, DOI 10.1083/jcb.75.1.277; GALLIN EK, 1984, BIOPHYS J, V46, P821, DOI 10.1016/S0006-3495(84)84080-1; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; HAMILL OP, 1981, J PHYSIOL-LONDON, V319, pP97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTSHORNE RP, 1985, P NATL ACAD SCI USA, V82, P240, DOI 10.1073/pnas.82.1.240; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HOIDAL JR, 1978, AM J PATHOL, V91, P469; HOLIAN A, 1982, J CELL PHYSIOL, V113, P87, DOI 10.1002/jcp.1041130115; HOLROYDE MC, 1981, LANCET, V2, P17; JOSEPH M, 1980, CLIN EXP IMMUNOL, V40, P416; JOSEPH M, 1985, AGENTS ACTIONS, V16, P27, DOI 10.1007/BF01999635; KAKUTA Y, 1988, J ALLERGY CLIN IMMUN, V81, P469, DOI 10.1016/0091-6749(88)90919-0; KAKUTA Y, 1984, PFLUG ARCH EUR J PHY, V400, P72, DOI 10.1007/BF00670539; KAKUTA Y, 1987, American Review of Respiratory Disease, V135, pA345; KAKUTA Y, 1985, AM REV RESPIR DIS, V131, pA390; KATO T, 1986, BIOL ROLE REACTIVE O, P171; KITAGAWA S, 1986, J IMMUNOL, V136, P2605; KITAGAWA S, 1985, J IMMUNOL, V135, P3417; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; Lee T H, 1985, Prog Biochem Pharmacol, V20, P1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX HD, 1981, PFLUG ARCH EUR J PHY, V389, P293, DOI 10.1007/BF00584792; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; MOREY J, 1984, LANCET, V2, P1142; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; PALLOTTA BS, 1985, J PHYSIOL-LONDON, V363, P501, DOI 10.1113/jphysiol.1985.sp015724; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; RANKIN JA, 1984, J IMMUNOL, V132, P1993; SALTINI C, 1984, AM REV RESPIR DIS, V130, P650; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SCHOPF RE, 1984, J IMMUNOL METHODS, V67, P109, DOI 10.1016/0022-1759(84)90090-5; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; WELSH MJ, 1985, J CLIN INVEST, V76, P1155, DOI 10.1172/JCI112071; WILLIAMS AJ, 1981, THORAX, V36, P866, DOI 10.1136/thx.36.11.866; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034	49	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					460	468		10.1016/0091-6749(88)90918-9	http://dx.doi.org/10.1016/0091-6749(88)90918-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	2448360				2022-12-18	WOS:A1988M099300016
J	BELCHER, NG; MURDOCH, R; DALTON, N; CLARK, TJH; REES, PJ; LEE, TH				BELCHER, NG; MURDOCH, R; DALTON, N; CLARK, TJH; REES, PJ; LEE, TH			CIRCULATING CONCENTRATIONS OF HISTAMINE, NEUTROPHIL CHEMOTACTIC ACTIVITY, AND CATECHOLAMINES DURING THE REFRACTORY PERIOD IN EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, DEPT MED, LONDON SE1 9RT, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, DEPT RESP MED, LONDON SE1 9RT, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1983, EUR J RESPIR DIS, V64, P225; ANDERSON SD, 1985, CHEST, V87, pS191, DOI 10.1378/chest.87.5_Supplement.191S; BARNES PJ, 1981, THORAX, V36, P435, DOI 10.1136/thx.36.6.435; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BARYISHAY E, 1983, AM REV RESPIR DIS, V127, P572, DOI 10.1164/arrd.1983.127.5.572; BELCHER NG, 1987, J ALLERGY CLIN IMMUN, V79, P128; BENDOV I, 1982, AM REV RESPIR DIS, V125, P530, DOI 10.1164/arrd.1982.125.5.530; BERKIN KE, 1985, Q J EXP PHYSIOL CMS, V70, P203, DOI 10.1113/expphysiol.1985.sp002903; BERKIN KE, 1986, CLIN SCI, V70, P347, DOI 10.1042/cs0700347; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHURCH MK, 1982, J IMMUNOL, V129, P2116; CUNDELL DR, IN PRESS B EUR PHYSI; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FEHR J, 1979, J CLIN INVEST, V64, P8, DOI 10.1172/JCI109466; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; GUILLOUX L, 1981, CLIN CHIM ACTA, V116, P269, DOI 10.1016/0009-8981(81)90046-2; HAHN AG, 1984, THORAX, V39, P919, DOI 10.1136/thx.39.12.919; HARRIES MG, 1979, CLIN ALLERGY, V9, P437, DOI 10.1111/j.1365-2222.1979.tb02506.x; HARTLEY JPR, 1981, CLIN SCI, V61, P151, DOI 10.1042/cs0610151; HOWARTH PH, 1984, J ALLERGY CLIN IMMUN, V73, P391, DOI 10.1016/0091-6749(84)90414-7; HOWARTH PH, 1984, THORAX, V39, P698; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; Howarth pH, 1985, PROG RESPIR RES, V19, P30; IND PW, 1983, BRIT J CLIN PHARMACO, V15, pP145; KAY AB, 1982, J ALLERGY CLIN IMMUN, V70, P317, DOI 10.1016/0091-6749(82)90019-7; LARSSON K, 1982, CHEST, V82, P560, DOI 10.1378/chest.82.5.560; LEE TH, 1984, J ALLERGY CLIN IMMUN, V73, P634, DOI 10.1016/0091-6749(84)90296-3; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1985, THORAX, V40, P481, DOI 10.1136/thx.40.7.481; LEE TH, 1984, AM REV RESPIR DIS, V129, P409; LEE TH, 1983, LANCET, V2, P164; LEE TH, 1984, J CLIN INVEST, V74, P1922, DOI 10.1172/JCI111612; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MCFADDEN ER, 1980, J ALLERGY CLIN IMMUN, V66, P472, DOI 10.1016/0091-6749(80)90008-1; NACLERIO RM, 1984, ARCH OTOLARYNGOL, V110, P25; NAGAKURA T, 1983, AM REV RESPIR DIS, V128, P294; NAGY L, 1983, EUR J RESPIR DIS, V64, P161; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; PICHURKO BM, 1986, J ALLERGY CLIN IMMUN, V77, P796, DOI 10.1016/0091-6749(86)90376-3; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; STEARNS DR, 1981, J APPL PHYSIOL, V50, P503, DOI 10.1152/jappl.1981.50.3.503; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; WEILERRAVELL D, 1981, J ALLERGY CLIN IMMUN, V67, P391, DOI 10.1016/0091-6749(81)90085-3	47	26	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					100	110		10.1016/0091-6749(88)90227-8	http://dx.doi.org/10.1016/0091-6749(88)90227-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3339187				2022-12-18	WOS:A1988M027400016
J	LEE, TM; GREENBERGER, PA; OH, S; PATTERSON, R; ROBERTS, M; LIOTTA, JL				LEE, TM; GREENBERGER, PA; OH, S; PATTERSON, R; ROBERTS, M; LIOTTA, JL			ALLERGIC BRONCHOPULMONARY CANDIDIASIS - CASE-REPORT AND SUGGESTED DIAGNOSTIC-CRITERIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA K, 1984, CHEST, V85, P699, DOI 10.1378/chest.85.5.699; BAUM GL, 1960, NEW ENGL J MED, V263, P70, DOI 10.1056/NEJM196007142630204; BENATAR SR, 1980, THORAX, V34, P515; CHEW WH, 1967, J IMMUNOL, V98, P220; EDGE G, 1980, CLIN ALLERGY, V10, P47, DOI 10.1111/j.1365-2222.1980.tb02079.x; EDGE G, 1977, BR J CLIN PHARM, V4, P303; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GORDON EH, 1986, IMMUNOL ALLERGY PRAC, V8, P163; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; HALWIG JM, 1985, AM REV RESPIR DIS, V132, P186; HENRICK DJ, 1982, AM REV RESPIR DIS, V126, P935; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; KABE J, 1971, AM REV RESPIR DIS, V104, P348, DOI 10.1164/arrd.1971.104.3.348; KOCHWESE.J, 1968, ARCH INTERN MED, V121, P255, DOI 10.1001/archinte.121.3.255; LEE TM, 1987, ARCH INTERN MED, V147, P319, DOI 10.1001/archinte.147.2.319; LIRSAC B, 1986, ALLERGY CLIN IMMUNOL, V77, P167; MATHIESSON AM, 1981, THORAX, V36, P719; MULLINS J, 1978, CLIN ALLERGY, V8, P525, DOI 10.1111/j.1365-2222.1978.tb01506.x; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; PEPYS J, 1968, J ALLERGY, V41, P305, DOI 10.1016/0021-8707(68)90073-7; REID MJ, 1985, J ALLERGY CLIN IMMUN, V76, P172, DOI 10.1016/0091-6749(85)90697-9; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SANDHU RS, 1979, SCAND J RESPIR DIS, V60, P235; SCADDING JG, 1967, SCAND J RESPIR DIS, V48, P372; SHIZAMA K, 1981, CLIN ALLERGY, V11, P343; SQUIRE EN, 1986, ANN ALLERGY, V56, P22; VOISIN C, 1976, REV FR ALLERGOL, V16, P279, DOI 10.1016/S0335-7457(76)80023-8	28	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					816	820		10.1016/S0091-6749(87)80271-3	http://dx.doi.org/10.1016/S0091-6749(87)80271-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	3693760				2022-12-18	WOS:A1987L502000008
J	KROUTIL, LA; BUSH, RK				KROUTIL, LA; BUSH, RK			DETECTION OF ALTERNARIA ALLERGENS BY WESTERN BLOTTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM S MIDDLETON MEM VET ADM HOSP,2500 OVERLOOK TERRACE,MADISON,WI 53705; UNIV WISCONSIN,MADISON,WI 53706	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSH RK, 1983, J ALLERGY CLIN IMMUN, V71, P239, DOI 10.1016/0091-6749(83)90105-7; DEWAIR M, 1985, J ALLERGY CLIN IMMUN, V76, P537, DOI 10.1016/0091-6749(85)90772-9; GOODERHAM K, 1983, TECHNIQUES MOL BIOL, P49; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN H, 1980, ADV ALLERGOLOGY APPL, P573; PETRY RW, 1985, J ALLERGY CLIN IMMUN, V75, P268, DOI 10.1016/0091-6749(85)90056-9; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; TOVEY ER, 1984, INT ARCH ALLER A IMM, V75, P322, DOI 10.1159/000233641; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	13	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					170	176		10.1016/0091-6749(87)90126-6	http://dx.doi.org/10.1016/0091-6749(87)90126-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3611538				2022-12-18	WOS:A1987J657500008
J	ELIASSON, O; DENSMORE, MJ; SCHERZER, HH; DEGRAFF, AC				ELIASSON, O; DENSMORE, MJ; SCHERZER, HH; DEGRAFF, AC			THE EFFECT OF SODIUM MECLOFENAMATE IN PREMENSTRUAL ASTHMA - A CONTROLLED CLINICAL-TRIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARTFORD HOSP, DIV PULM MED, HARTFORD, CT 06115 USA; UNIV CONNECTICUT, CTR HLTH, DIV PULM MED, FARMINGTON, CT 06032 USA; NEW BRITAIN GEN HOSP, NEW BRITAIN, CT 06050 USA	Hartford Hospital; University of Connecticut								AXELROD L, 1984, PROSTAG OTH LIPID M, V28, P333, DOI 10.1016/0090-6980(84)90021-2; BARKMAN RP, 1981, MED J AUSTRALIA, V1, P316; BONNER JR, 1984, CLIN CHEST MED, V5, P557; BUDOFF PW, 1982, NEW ENGL J MED, V307, P714, DOI 10.1056/NEJM198209163071203; DALTON K, 1984, PREMENSTRUAL SYNDROM, P46; DOWNIE J, 1981, AM J OBSTET GYNECOL, V141, P313; ELIASSON O, 1986, J ALLERGY CLIN IMMUN, V77, P87, DOI 10.1016/0091-6749(86)90328-3; ELIASSON O, 1986, J ASTHMA, V23, P309, DOI 10.3109/02770908609073178; Eliasson O, 1984, Conn Med, V48, P777; ELIASSON O, 1985, American Review of Respiratory Disease, V131, pA110; FOSTER PS, 1983, BRIT J PHARMACOL, V78, P441, DOI 10.1111/j.1476-5381.1983.tb09409.x; GIBBS CJ, 1984, THORAX, V39, P833, DOI 10.1136/thx.39.11.833; GIBBS CJ, 1984, THORAX, V39, P232; HANLEY SP, 1981, BRIT J DIS CHEST, V75, P306, DOI 10.1016/0007-0971(81)90010-3; HYMAN AL, 1978, AM REV RESPIR DIS, V117, P111; KOULLAPIS EN, 1980, ACTA ENDOCRINOL-COP, V93, P123, DOI 10.1530/acta.0.0930123; Lindner H R, 1980, Adv Prostaglandin Thromboxane Res, V8, P1371; MAGOS A, 1985, BRIT J HOSP MED, V33, P68; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MURAD F, 1975, PHARMACOL BASIS, P1423; PETERS SP, 1985, AM REV RESPIR DIS, V132, P367; PICKLES VR, 1979, ACTA OBSTET GYN SCAN, P7; REES L, 1963, J PSYCHOSOM RES, V7, P191, DOI 10.1016/0022-3999(63)90003-5; ROSENBAUM MS, 1983, PEDIATRICS, V71, P359; SHENFIELD GM, 1975, THORAX, V30, P430, DOI 10.1136/thx.30.4.430; SLEPIAN IK, 1985, CHEST, V87, P386, DOI 10.1378/chest.87.3.386; SPECTOR SL, 1981, CHEST, V80, P676, DOI 10.1378/chest.80.6.676; WALLENSTEIN S, 1977, BIOMETRICS, V33, P261, DOI 10.2307/2529321; WALLENSTEIN S, 1981, BIOMETRICS, V37, P875; WEINMANN G G, 1985, American Review of Respiratory Disease, V131, pA5; WILKS JW, 1972, J REPROD MED, V9, P271	33	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					909	918		10.1016/0091-6749(87)90240-5	http://dx.doi.org/10.1016/0091-6749(87)90240-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3584746				2022-12-18	WOS:A1987H904400012
J	MCFADDEN, ER				MCFADDEN, ER			GLOTTIC FUNCTION AND DYSFUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV HOSP, DEPT MED, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital	MCFADDEN, ER (corresponding author), CASE WESTERN RESERVE UNIV HOSP, CTR AIRWAY DIS, 2074 ABINGTON RD, CLEVELAND, OH 44106 USA.				NCRR NIH HHS [MOIRR-0080-25] Funding Source: Medline; NHLBI NIH HHS [HL 33791, HL 36156] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036156, R01HL033791] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELBLATT NH, 1981, ARCH OTOLARYNGOL, V107, P305; BAIER H, 1977, Journal of Applied Physiology Respiratory Environmental and Exercise Physiology, V43, P603; BARTLETT D, 1973, RESP PHYSIOL, V18, P197, DOI 10.1016/0034-5687(73)90050-9; BOUSHEY HA, 1974, J PHYSIOL-LONDON, V240, P153, DOI 10.1113/jphysiol.1974.sp010605; BRANCATISANO TP, 1985, J APPL PHYSIOL, V58, P605, DOI 10.1152/jappl.1985.58.2.605; CAMPBELL AH, 1976, BRIT J DIS CHEST, V70, P58, DOI 10.1016/0007-0971(76)90006-1; CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605; COLLETT PW, 1983, AM REV RESPIR DIS, V128, P719; CORMIER YF, 1980, AM REV RESPIR DIS, V121, P147; DOWNING ET, 1982, JAMA-J AM MED ASSOC, V248, P2878, DOI 10.1001/jama.248.21.2878; ENGLAND SJ, 1982, J APPL PHYSIOL, V52, P780, DOI 10.1152/jappl.1982.52.3.780; ENGLAND SJ, 1982, J APPL PHYSIOL, V52, P773, DOI 10.1152/jappl.1982.52.3.773; ENGLAND SJ, 1985, J APPL PHYSIOL, V58, P352, DOI 10.1152/jappl.1985.58.2.352; GAUTIER H, 1973, RESP PHYSIOL, V18, P205, DOI 10.1016/0034-5687(73)90051-0; HIGENBOTTAM T, 1982, AM REV RESPIR DIS, V125, P746; HIGENBOTTAM T, 1980, J APPL PHYSIOL, V49, P403, DOI 10.1152/jappl.1980.49.3.403; KELLMAN RM, 1982, LARYNGOSCOPE, V92, P58; LISBOA C, 1980, AM REV RESPIR DIS, V122, P115; MARTIN J, 1980, AM REV RESPIR DIS, V121, P441, DOI 10.1164/arrd.1980.121.3.441; MCFADDEN ER, 1983, ALLERGY PRINCIPLES P, P843; MULLER N, 1981, J APPL PHYSIOL, V50, P279, DOI 10.1152/jappl.1981.50.2.279; MYEARS DW, 1985, LARYNGOSCOPE, V95, P1235; PATTERSON R, 1974, CLIN ALLERGY, V4, P307, DOI 10.1111/j.1365-2222.1974.tb01390.x; REMMERS JE, 1977, J APPL PHYSIOL, V42, P80, DOI 10.1152/jappl.1977.42.1.80; RODENSTEIN DO, 1983, AM REV RESPIR DIS, V127, P354; ROGERS JH, 1978, J LARYNGOL OTOL, V92, P157, DOI 10.1017/S0022215100085169; SELNER JC, 1987, J ALLERGY CLIN IMMUN, V79, P726, DOI 10.1016/0091-6749(87)90203-X; SHINDOH C, 1985, AM REV RESPIR DIS, V132, P671; STANESCU DC, 1972, J APPL PHYSIOL, V32, P460, DOI 10.1152/jappl.1972.32.4.460; STARKMAN MN, 1984, PSYCHOSOMATICS, V25, P327, DOI 10.1016/S0033-3182(84)73049-0; STROHL KP, 1986, AM REV RESPIR DIS, V134, P791; WIDDICOMBE JG, 1973, VENTILATION PHONATIO, P131; WYKE BD, 1976, SCI F OTOLARYNGOLOGY, P546	33	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					707	710		10.1016/0091-6749(87)90200-4	http://dx.doi.org/10.1016/0091-6749(87)90200-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3571764				2022-12-18	WOS:A1987H434900003
J	DEWECK, AL				DEWECK, AL			DRUGS AS ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DEWECK, AL (corresponding author), UNIV BERN, INSELSPITAL, INST CLIN IMMUNOL, CH-3010 BERN, SWITZERLAND.							ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V73, P411, DOI 10.1016/0091-6749(84)90417-2; AHLSTEDT S, 1984, ALLERGY, V39, P151, DOI 10.1111/j.1398-9995.1984.tb02619.x; BALDO BA, 1983, NATURE, V306, P262, DOI 10.1038/306262a0; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P798; De Weck A. L., 1974, ANTIGENS, V2, P141; DEHAAN P, 1983, ALLERGY, V38, P319; DEWECK AL, 1983, HDB EXPT PHARM, V63, P227; DEWECK AL, 1983, HDB EXPT PHARM, V63, P423; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; GRUBER UF, 1982, SCHWEIZ MED WSCHR, V112, P605; HOIGNE R, 1983, HDB EXPT PHARM, V63, P188; KATZ DH, 1984, ALLERGY, V39, P81, DOI 10.1111/j.1398-9995.1984.tb01940.x; KLEIN U, 1976, INT J CLIN PHARM BI, V13, P187; LEVINE B, 1967, INT ARCH ALLER A IMM, V31, P594, DOI 10.1159/000229906; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; MESSMER K, 1980, LANCET, V1, P975; MILLER FF, 1967, J ALLERGY, V40, P46, DOI 10.1016/0021-8707(67)90058-5; NEFTEL KA, 1982, LANCET, V1, P986; NEFTEL KA, 1984, KLIN WOCHENSCHR, V62, P25, DOI 10.1007/BF01725189; NEFTEL KA, 1983, BRIT J HAEMATOL, V54, P255, DOI 10.1111/j.1365-2141.1983.tb02093.x; NEFTEL KA, 1981, KLIN WOCHENSCHR, V59, P877, DOI 10.1007/BF01721921; NEFTEL KA, 1981, INT C S SERIES ROYAL, V47, P223; RAJKA G, 1965, ACTA ALLERGOL, V20, P387, DOI 10.1111/j.1398-9995.1965.tb03071.x; SCHLUMBERGER HD, 1980, PSEUDO ALLERGIC REAC, V1, P125; SMITH JW, 1966, NEW ENGL J MED, V274, P998, DOI 10.1056/NEJM196605052741804; WECK ALD, 1975, Z IMMUNITATSFORSCH, V150, P138	26	26	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			1047	1050						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	2431022				2022-12-18	WOS:A1986E971900023
J	MARONE, G; POTO, S; GIUGLIANO, R; CELESTINO, D; BONINI, S				MARONE, G; POTO, S; GIUGLIANO, R; CELESTINO, D; BONINI, S			CONTROL MECHANISMS OF HUMAN BASOPHIL RELEASABILITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV NAPLES,SCH MED 2,DEPT CHEM,I-80138 NAPLES,ITALY; UNIV ROME LA SAPIENZA,SCH MED,DEPT MED,I-00185 ROME,ITALY; UNIV ROME LA SAPIENZA,SCH MED,DEPT INFECT & TROP DIS,I-00185 ROME,ITALY	University of Naples Federico II; Sapienza University Rome; Sapienza University Rome			Bonini, Sergio/T-6594-2019	Bonini, Sergio/0000-0003-0079-3031				Adkinson J, 1920, GENETICS, V5, P363; AUSTEN KF, 1965, P SOC EXP BIOL MED, V120, P542; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BIAS WB, 1978, GENETIC DETERMINANTS, P127; BLACK PL, 1976, BRONCHIAL ASTHMA MEC, P53; CHURCH MK, 1982, J IMMUNOL, V129, P2116; CONDORELLI M, 1984, ADV CLIN IMMUNOLOGY; CONROY MC, 1977, J IMMUNOL, V118, P1317; COOKE RA, 1916, J IMMUNOL, V1, P216; CZARNETZKI BM, 1976, J INVEST DERMATOL, V67, P276, DOI 10.1111/1523-1747.ep12514261; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FLEISCH JH, 1978, BIOCH PHARM, V27, P211; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GLOVSKY MM, 1979, J CLIN INVEST, V64, P804, DOI 10.1172/JCI109527; ISHIZAKA T, 1982, FED PROC, V41, P17; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; Lichtenstein LM., 1979, MAST CELL ITS ROLE H, P83; LICHTENSTEIN LM, 1976, 9TH P INT C ALL BUEN, P109; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MARONE G, 1983, CLIN IMMUNOL IMMUNOP, V28, P334, DOI 10.1016/0090-1229(83)90100-9; MARONE G, 1979, J IMMUNOL, V123, P1473; MARONE G, 1984, J IMMUNOL, V133, P1542; MARONE G, 1984, 13TH P M EUR HIST RE, P91; MARONE G, 1983, 12TH P C EUR AC ALL, P293; MARONE G, 1983, PROGR CLIN IMMUNOLOG, P290; MARONE G, J ALLERGY CLIN IMMUN; MARONE G, 1983, PROGR CLIN IMMUNOLOG, P139; MAY CD, 1972, PEDIATRICS, V49, P536; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; ORIDA N, 1982, FED PROC, V41, P822; PARISI P, 1983, NATURE, V304, P626, DOI 10.1038/304626a0; RICCI M, 1983, PROGR CLIN IMMUNOLOG; SCHLEIMER RP, 1984, ADV CLIN IMMUNOLOGY, P65; Schwartz M, 1952, ACTA ALLERGOL S2, V5, P1; TUNG R, 1982, J IMMUNOL, V128, P2067; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259	40	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			974	980		10.1016/0091-6749(86)90288-5	http://dx.doi.org/10.1016/0091-6749(86)90288-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	2431024				2022-12-18	WOS:A1986E971900009
J	AUBIER, M				AUBIER, M			EFFECT OF THEOPHYLLINE ON DIAPHRAGMATIC AND OTHER SKELETAL-MUSCLE FUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											AUBIER, M (corresponding author), HOP BEAUJON,FAC XAVIER BICHAT,PNEUMOL CLIN,INSERM,U226,100 AVE GEN LECLERC,F-92110 CLICHY,FRANCE.							ALLYA I, 1978, J PHARMACOL EXP THER, V199, P208; AUBIER M, 1983, J APPL PHYSIOL, V54, P460, DOI 10.1152/jappl.1983.54.2.460; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; AUBIER M, 1981, J APPL PHYSIOL, V50, P538, DOI 10.1152/jappl.1981.50.3.538; AUBIER M, 1983, AM REV RESPIR DIS, V127, P148; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; BUKOWSKYJ M, 1984, ANN INTERN MED, V101, P63, DOI 10.7326/0003-4819-101-1-63; DOWELL AR, 1963, NEW ENGL J MED, V273, P1447; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; ESTENNE M, 1980, AM REV RESPIR DIS, V121, P967; FABIATO A, 1977, CIRC RES, V40, P119, DOI 10.1161/01.RES.40.2.119; FITTS RH, 1976, AM J PHYSIOL, V231, P430, DOI 10.1152/ajplegacy.1976.231.2.430; GOODMAN LS, 1980, PHARM BASIS THERAPEU, P598; GRASSINO A, 1978, J APPL PHYSIOL, V44, P829, DOI 10.1152/jappl.1978.44.6.829; HOWELL S, 1984, AM REV RESPIR DIS, V129, P118; JONES DA, 1982, CLIN SCI, V63, P161, DOI 10.1042/cs0630161; KENTERA D, 1975, BRIT J PHARMACOL, V54, P375, DOI 10.1111/j.1476-5381.1975.tb07578.x; LAKSHMINARAYAN S, 1978, AM REV RESPIR DIS, V117, P33; MURCIANO D, 1984, NEW ENGL J MED, V311, P349, DOI 10.1056/NEJM198408093110601; NOCHOMOVITZ ML, 1984, AM REV RESPIR DIS, V130, P685; PANNIER JL, 1970, PFLUG ARCH EUR J PHY, V320, P120, DOI 10.1007/BF00588547; POTREAU D, 1979, J PHYSL, V307, P9; PROSDOCINI M, 1981, J PHARMACOL EXP THER, V218, P87; ROCHESTER DF, 1979, B EUR PHYSIOPATH RES, V15, P951; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; ROUSSOS CS, 1977, J APPL PHYSIOL, V43, P189, DOI 10.1152/jappl.1977.43.2.189; SANCHEZ JA, 1978, J PHYSIOL-LONDON, V283, P197, DOI 10.1113/jphysiol.1978.sp012496; SAWYNOK J, 1976, J PHARMACOL EXP THER, V197, P379; SIGRIST S, 1982, AM REV RESPIR DIS, V126, P46; SMITH PA, 1979, NATURE, V280, P400, DOI 10.1038/280400a0; STANDAERT FG, 1976, J PHARMACOL EXP THER, V199, P553; STROUD MW, 1955, J PHARMACOL EXP THER, V114, P461; SUPINSKI GS, 1984, AM REV RESPIR DIS, V130, P429; TRIPPENBACH T, 1980, RESP PHYSIOL, V40, P211, DOI 10.1016/0034-5687(80)90094-8; VARAGIC VM, 1978, N-S ARCH PHARMACOL, V303, P47, DOI 10.1007/BF00496184; VARAGIC VM, 1979, EUR J PHARMACOL, V55, P1, DOI 10.1016/0014-2999(79)90141-9; VIIRES N, 1984, AM REV RESPIR DIS, V129, P396; WEINBERGER M, 1953, N ENGL J MED, V291, P151; WILES CM, 1983, CLIN SCI, V64, P547, DOI 10.1042/cs0640547	39	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				787	792		10.1016/0091-6749(86)90062-X	http://dx.doi.org/10.1016/0091-6749(86)90062-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3534059	Bronze			2022-12-18	WOS:A1986E568400020
J	GOLDBERG, MJ; PARK, GD; BERLINGER, WG				GOLDBERG, MJ; PARK, GD; BERLINGER, WG			TREATMENT OF THEOPHYLLINE INTOXICATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL PHARM,DIV CLIN HOSP PHARM,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242; VET ADM MED CTR,IOWA CITY,IA 52240; AMER COLL PHYSICIANS,PHILADELPHIA,PA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); American College of Physicians								BERLINGER WG, 1983, CLIN PHARMACOL THER, V33, P351, DOI 10.1038/clpt.1983.44; BROWN GS, 1981, AM J KIDNEY DIS, V1, P24, DOI 10.1016/S0272-6386(81)80007-8; BUCKLEY BM, 1983, LANCET, V2, P618; CHANG TMS, 1980, PEDIATRICS, V65, P811; COLLIER HOJ, 1974, NATURE, V249, P471, DOI 10.1038/249471a0; Culberson C G, 1979, Trans Am Neurol Assoc, V104, P224; DELGADOESCUETA AV, 1982, NEW ENGL J MED, V306, P1337, DOI 10.1056/NEJM198206033062205; EHLERS SM, 1978, JAMA-J AM MED ASSOC, V240, P474, DOI 10.1001/jama.240.5.474; GAL P, 1984, JAMA-J AM MED ASSOC, V251, P3130, DOI 10.1001/jama.251.23.3130; GOLDBERG MJ, 1986, CLIN TOXICOL, V24, P203; GOLDBERG MJ, CLIN PHARM THER; GREENBERG A, 1984, AM J MED, V76, P854, DOI 10.1016/0002-9343(84)90997-5; HALL KW, 1984, ANN INTERN MED, V101, P457, DOI 10.7326/0003-4819-101-4-457; HELLIWELL M, 1979, BRIT MED J, V2, P1114, DOI 10.1136/bmj.2.6198.1114; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; KEARNEY TE, 1985, ANN INTERN MED, V102, P766, DOI 10.7326/0003-4819-102-6-766; KRENZELOK EP, 1984, VET HUM TOXICOL, V26, P402; KULIG K, 1985, ANN EMERG MED, V14, P562, DOI 10.1016/S0196-0644(85)80780-0; LEE CS, 1979, J CLIN PHARMACOL, V19, P219, DOI 10.1002/j.1552-4604.1979.tb01655.x; LEVY G, 1977, JAMA-J AM MED ASSOC, V237, P1466, DOI 10.1001/jama.237.14.1466; MAHUTTE CK, 1983, AM REV RESPIR DIS, V128, P820; MASSANARI M, 1985, DRUG INTEL CLIN PHAR, V19, P462; MINOCHA A, 1984, J TOXICOL-CLIN TOXIC, V22, P529, DOI 10.3109/15563658408992582; NEUVONEN PJ, 1983, EUR J CLIN PHARMACOL, V24, P557, DOI 10.1007/BF00609903; OLSON KR, 1983, VET HUM TOXICOL, V25, P269; PARK GD, 1983, CLIN PHARMACOL THER, V34, P663, DOI 10.1038/clpt.1983.229; PARK GD, 1983, AM J MED, V74, P961, DOI 10.1016/0002-9343(83)90790-8; PARK GD, 1984, J CLIN PHARMACOL, V24, P289, DOI 10.1002/j.1552-4604.1984.tb01835.x; POLLACK MM, 1981, ANN EMERG MED, V10, P528, DOI 10.1016/S0196-0644(81)80009-1; POND S, 1979, CLIN PHARMACOKINET, V4, P329, DOI 10.2165/00003088-197904050-00001; RADOMSKI L, 1984, CLIN PHARMACOL THER, V35, P402, DOI 10.1038/clpt.1984.50; SAHNEY S, 1983, PEDIATRICS, V71, P615; SESSLER CN, 1985, CHEST, V87, P325, DOI 10.1378/chest.87.3.325; SLAUGHTER RL, 1982, THER DRUG MONIT, V4, P191, DOI 10.1097/00007691-198206000-00006; SPYKER DA, 1985, ARCH INTERN MED, V145, P43, DOI 10.1001/archinte.145.1.43; TRUE RJ, 1984, CRIT CARE MED, V12, P113, DOI 10.1097/00003246-198402000-00006; WALKER JE, 1981, J PHARM PHARMACOL, V33, P479, DOI 10.1111/j.2042-7158.1981.tb13842.x; WOO OF, 1984, J TOXICOL-CLIN TOXIC, V22, P411, DOI 10.3109/15563658408992572; YARNELL PR, 1975, NEUROLOGY, V25, P819, DOI 10.1212/WNL.25.9.819; ZWILLICH CW, 1975, ANN INTERN MED, V82, P784, DOI 10.7326/0003-4819-82-6-784; 1985, LANCET, V1, P146	41	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				811	817		10.1016/0091-6749(86)90066-7	http://dx.doi.org/10.1016/0091-6749(86)90066-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3534061				2022-12-18	WOS:A1986E568400024
J	GOETZL, EJ; VALACER, DJ; PAYAN, DG; WONG, MYS				GOETZL, EJ; VALACER, DJ; PAYAN, DG; WONG, MYS			ABNORMAL RESPONSES TO ASPIRIN OF LEUKOCYTE OXYGENATION OF ARACHIDONIC-ACID IN ADULTS WITH ASPIRIN INTOLERANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,DIV ALLERGY & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	GOETZL, EJ (corresponding author), UNIV CALIF SAN FRANCISCO,MED CTR,HOWARD HUGHES MED INST LABS,U-426,SAN FRANCISCO,CA 94143, USA.				NIAID NIH HHS [AI 19784] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019784] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRINDLEY LL, 1983, J CLIN INVEST, V72, P1218, DOI 10.1172/JCI111077; GOETZL EJ, 1972, J EXP MED, V136, P1564, DOI 10.1084/jem.136.6.1564; GOETZL EJ, 1984, J IMMUNOL, V133, P3255; GOETZL EJ, 1984, J ALLERGY CLIN IMMUN, V74, P309, DOI 10.1016/0091-6749(84)90121-0; LEE JY, 1984, BIOCHEM BIOPH RES CO, V123, P944, DOI 10.1016/S0006-291X(84)80225-9; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; LINDGREN JA, 1983, FEBS LETT, V152, P83, DOI 10.1016/0014-5793(83)80487-6; MAROM Z, 1984, PROSTAGLANDINS, V28, P79, DOI 10.1016/0090-6980(84)90115-1; MATTHAY MA, 1984, J CLIN IMMUNOL, V4, P479, DOI 10.1007/BF00916578; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V72, P462, DOI 10.1016/0091-6749(83)90582-1; SPECTOR SL, 1983, ALLERGY PRINCIPLES P, P1249; SZCZEKLIK A, 1983, DRUGS, V25, P533, DOI 10.2165/00003495-198325060-00001; VOIGTLANDER V, 1981, INT ARCH ALLER A IMM, V66, P154, DOI 10.1159/000232891; WASSERMAN SI, 1978, J ALLERGY CLIN IMMUN, V61, P139, DOI 10.1016/0091-6749(78)90276-2	15	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					693	698		10.1016/0091-6749(86)90412-4	http://dx.doi.org/10.1016/0091-6749(86)90412-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	2422239				2022-12-18	WOS:A1986C390300010
J	JUNIPER, EF; ROBERTS, RS; KENNEDY, LK; OCONNOR, J; SYTYGOLDA, M; DOLOVICH, J; HARGREAVE, FE				JUNIPER, EF; ROBERTS, RS; KENNEDY, LK; OCONNOR, J; SYTYGOLDA, M; DOLOVICH, J; HARGREAVE, FE			POLYETHYLENE-GLYCOL MODIFIED RAGWEED POLLEN EXTRACT IN RHINOCONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,FIRESTONE REG CHEST & ALLERGY UNIT,50 CHARLTON AVE E,HAMILTON L8N 4A6,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University								CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHATTERJEE J, 1974, CAN MED ASSOC J, V110, P659; COCKCROFT DW, 1977, J ALLERGY CLIN IMMUN, V60, P56, DOI 10.1016/0091-6749(77)90083-5; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FOUCARD T, 1976, CLIN ALLERGY, V6, P429, DOI 10.1111/j.1365-2222.1976.tb01927.x; LEE WY, 1978, IMMUNOL REV, V41, P200, DOI 10.1111/j.1600-065X.1978.tb01466.x; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; WIE SI, 1981, INT ARCH ALLER A IMM, V64, P84, DOI 10.1159/000232678	10	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					578	585		10.1016/0091-6749(85)90033-8	http://dx.doi.org/10.1016/0091-6749(85)90033-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	3989142				2022-12-18	WOS:A1985AHV0700007
J	NAGAYA, H				NAGAYA, H			INDUCTION OF ANTIGEN-SPECIFIC SUPPRESSOR CELLS IN PATIENTS WITH HAY-FEVER RECEIVING IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM MED CTR,ALLERGY IMMUNOL SECT,LONG BEACH,CA 90822; UNIV CALIF IRVINE,COLL MED,DEPT MED,IRVINE,CA 92717	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine								ANDERSON JA, 1974, CELL IMMUNOL, V10, P442, DOI 10.1016/0008-8749(74)90135-X; BEER DJ, 1982, NEW ENGL J MED, V306, P454, DOI 10.1056/NEJM198202253060804; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GAITEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P553; MAGE MG, 1977, J IMMUNOL METHODS, V15, P47, DOI 10.1016/0022-1759(77)90016-3; NAGAYA H, 1980, ANN ALLERGY, V44, P193; NAGAYA H, 1977, ANN ALLERGY, V39, P246; NAGAYA H, 1966, P SOC EXP BIOL MED, V121, P722; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROMAGNANI S, 1975, CLIN EXP IMMUNOL, V19, P83; TANIGUCHI M, 1977, J EXP MED, V146, P1450, DOI 10.1084/jem.146.5.1450; WALTER H, 1975, CELL IMMUNOL, V19, P158, DOI 10.1016/0008-8749(75)90302-0; WALTER H, 1979, EXP CELL RES, V122, P380, DOI 10.1016/0014-4827(79)90314-8	20	26	26	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					388	394		10.1016/0091-6749(85)90077-6	http://dx.doi.org/10.1016/0091-6749(85)90077-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	2579117				2022-12-18	WOS:A1985AEB4600011
J	REID, MJ; KWASNICKI, JM; MOSS, RB; CHEUNG, NKV				REID, MJ; KWASNICKI, JM; MOSS, RB; CHEUNG, NKV			UNDERESTIMATION OF SPECIFIC IMMUNOGLOBULIN-E BY MICROTITER PLATE ENZYME-LINKED IMMUNOSORBENT ASSAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DAVID GRANT USAF MED CTR,ALLERGY CLIN,TRAVIS AFB,CA 94535				Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				AALBERSE RC, 1973, INT ARCH ALLER A IMM, V45, P46, DOI 10.1159/000230999; ALI M, 1979, ANN ALLERGY, V42, P231; CHEUNG NKV, 1983, J ALLERGY CLIN IMMUN, V71, P283, DOI 10.1016/0091-6749(83)90082-9; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; HAMILTON RG, 1981, J IMMUNOL METHODS, V44, P101, DOI 10.1016/0022-1759(81)90111-3; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; LYNCH NR, 1975, CLIN EXP IMMUNOL, V22, P35; PAULL BR, 1978, J IMMUNOL, V120, P1917; REID MJ, 1982, J ALLERGY CLIN IMMUN, V70, P191, DOI 10.1016/0091-6749(82)90041-0; Tsay Y, 1984, IMMUNOL ALLERGY PRAC, V6, P169; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; ZEISS CR, 1981, J ALLERGY CLIN IMMUN, V67, P105, DOI 10.1016/0091-6749(81)90004-X; ZIMMERMAN EM, 1980, J ALLERGY CLIN IMMUN, V65, P386	13	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					172	176		10.1016/0091-6749(85)90697-9	http://dx.doi.org/10.1016/0091-6749(85)90697-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	3894478				2022-12-18	WOS:A1985APE8800009
J	ROBINSON, C; HOLGATE, ST				ROBINSON, C; HOLGATE, ST			NEW PERSPECTIVES ON THE PUTATIVE ROLE OF EICOSANOIDS IN AIRWAY HYPERRESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											ROBINSON, C (corresponding author), SOUTHAMPTON GEN HOSP, CTR BLOCK, LEVEL D, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.			Robinson, Clive/0000-0001-6253-7864				ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; BARNES PJ, 1984, THORAX, V39, P561, DOI 10.1136/thx.39.8.561; BARNES PJ, 1984, RECEPTORS CHRONIC OB, P72; DELEHUNT JC, 1984, AM REV RESPIR DIS, V130, P748; DUNNILL MS, 1971, IDENTIFICATION ASTHM, P35; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; FABBRI LM, 1985, J ALLERGY CLIN IMMUN, V76, P162, DOI 10.1016/0091-6749(85)90695-5; FABBRI LM, 1983, AM REV RESPIR DIS, V127, P244; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GOETZL EJ, 1980, EOSINOPHIL HLTH DISE, P167; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HAMMARSTROM S, 1983, ANNU REV BIOCHEM, V52, P355, DOI 10.1146/annurev.bi.52.070183.002035; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HIGGS GA, 1979, BIOCHEM PHARMACOL, V28, P1959, DOI 10.1016/0006-2952(79)90651-8; HOGG JC, 1984, AM REV RESPIR DIS, V129, P207; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; ISLAM MS, 1972, INT ARCH ARBEITSMED, V29, P221, DOI 10.1007/BF00539250; LAITINEN L A, 1976, American Review of Respiratory Disease, V113, P194; LARSEN GL, 1984, ASTHMA PHYSL IMMUNOP, P245; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MCFADDEN ER, 1984, J ALLERGY CLIN IMMUN, V73, P413, DOI 10.1016/0091-6749(84)90347-6; MONCADA S, 1978, PHARMACOL REV, V30, P293; NADEL JA, 1984, ASTHMA PHYSL IMMUNOP, P129; OBYRNE P, 1983, PHYSIOLOGIST, V26, pA35; PIPER PJ, 1981, J PHARM PHARMACOL, V33, P384, DOI 10.1111/j.2042-7158.1981.tb13810.x; RADMARK O, 1980, FEBS LETT, V110, P213, DOI 10.1016/0014-5793(80)80075-5; RICHARDSON J, 1976, J APPL PHYSIOL, V41, P764, DOI 10.1152/jappl.1976.41.5.764; SCHEEL LD, 1959, J APPL PHYSIOL, V14, P67, DOI 10.1152/jappl.1959.14.1.67; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; SHEPPARD MN, 1983, THORAX, V38, P330; SHIMASAKI H, 1976, BIOCHEM BIOPH RES CO, V68, P1256, DOI 10.1016/0006-291X(76)90332-6; SIEGEL MI, 1981, PROSTAGLANDINS, V21, P123, DOI 10.1016/0090-6980(81)90202-1; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TAKIZAWA T, 1971, AM REV RESPIR DIS, V104, P331, DOI 10.1164/arrd.1971.104.3.331; VANDERHOEK JY, 1982, BIOCHEM PHARMACOL, V31, P3463, DOI 10.1016/0006-2952(82)90627-X; VIDRUK EH, 1977, J APPL PHYSIOL, V43, P397, DOI 10.1152/jappl.1977.43.3.397; WALKER JR, 1984, ADV INFLAMMAT RES, V6, P227	42	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					140	144		10.1016/0091-6749(85)90691-8	http://dx.doi.org/10.1016/0091-6749(85)90691-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	3926850				2022-12-18	WOS:A1985APE8800003
J	WALKER, SB; SHAPIRO, GG; BIERMAN, CW; MORGAN, MS; MARSHALL, SG; FURUKAWA, CT; PIERSON, WE				WALKER, SB; SHAPIRO, GG; BIERMAN, CW; MORGAN, MS; MARSHALL, SG; FURUKAWA, CT; PIERSON, WE			INDUCTION OF EUSTACHIAN-TUBE DYSFUNCTION WITH HISTAMINE NASAL PROVOCATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											WALKER, SB (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PEDIAT RD-20,SEATTLE,WA 98195, USA.							BERNSTEIN JM, 1983, AM J OTOL, V5, P66; BLUESTONE CD, 1981, ANN OTO RHINOL LARYN, V90, P552, DOI 10.1177/000348948109000608; BLUESTONE CD, 1977, LARYNGOSCOPE, V87, P493; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; COOK DA, 1980, J ALLERGY CLIN IMMUN, V65, P215; DOYLE WJ, 1984, ARCH OTOLARYNGOL, V110, P508; FRIEDMAN PA, 1983, J ALLERGY CLIN IMMUN, V71, P442; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; Otis, 1964, HANDBOOK PHYSIOLOG 3, VI, P463; PIERSON WE, 1983, J ALLERGY CLIN IMMUN, V71, P156, DOI 10.1016/0091-6749(83)90393-7; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6	12	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					158	162		10.1016/0091-6749(85)90694-3	http://dx.doi.org/10.1016/0091-6749(85)90694-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	4019948				2022-12-18	WOS:A1985APE8800006
J	BLECHER, M; LEWIS, S; HICKS, JM; JOSEPHS, S				BLECHER, M; LEWIS, S; HICKS, JM; JOSEPHS, S			BETA-BLOCKING AUTOANTIBODIES IN PEDIATRIC BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,NATL MED CTR,DEPT LAB MED,WASHINGTON,DC 20010; CHILDRENS HOSP,NATL MED CTR,DEPT ALLERGY & IMMUNOL,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED,DEPT CHILD HLTH & DEV,WASHINGTON,DC 20052	Children's National Health System; Children's National Health System; George Washington University	BLECHER, M (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM,WASHINGTON,DC 20007, USA.							AHO K, 1982, ACTA MED SCAND, V211, P213; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; FLIER JS, 1976, J CLIN INVEST, V58, P1442, DOI 10.1172/JCI108600; FRASER CM, 1981, NEW ENGL J MED, V305, P1165, DOI 10.1056/NEJM198111123052001; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; KNIGHT JG, 1982, RECEPTORS ANTIBODIES, P35; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; MAGUIRE ME, 1976, J BIOL CHEM, V251, P1221; MCFADDEN ER, 1983, PRINCIPLES INTERNAL, P1512; MEHDI SQ, 1978, ENDOCRINOLOGY, V103, P296, DOI 10.1210/endo-103-1-296; MISHELL BB, 1980, SELECTED METHODS CEL, P278; NEWSOMDAVIS J, 1982, CLIN IMMUNOL ALLERGY, V2, P405; NEWSOMDAVIS J, 1982, RECEPTORS ANTIBODIES, P225; PARKER CW, 1981, NEW ENGL J MED, V305, P1212, DOI 10.1056/NEJM198111123052009; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; SMITH LJ, 1980, J ALLERGY CLIN IMMUN, V66, P374, DOI 10.1016/0091-6749(80)90116-5; STRAUSS WL, 1979, ARCH BIOCH BIOPHYS, V196, P556; VAUGHAN J, 1982, JAMA, V248, P2646; VENTER JC, 1980, SCIENCE, V207, P1361, DOI 10.1126/science.6153472	22	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					246	251		10.1016/0091-6749(84)90253-7	http://dx.doi.org/10.1016/0091-6749(84)90253-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6147371				2022-12-18	WOS:A1984TJ80800005
J	KAPLAN, AP				KAPLAN, AP			DRUG-INDUCED SKIN-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KAPLAN, AP (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,DEPT MED,DIV ALLERGY RHEUMATOL & CLIN IMMUNOL,STONY BROOK,NY 11794, USA.							Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; DESWARTE RD, 1972, ALLERGIC DISEASES DI, P393; DEWECK AL, 1971, INT ARCH ALLER A IMM, V41, P393, DOI 10.1159/000230534; DVORAK HF, 1974, CONTACT HYPERSENSITI, P54; GODFREY HP, 1982, IMMUNOLOGY, V46, P115; KAPLAN AP, 1983, ALLERGY PRINCIPLES P, V2, P1341; KAZMIEROWSKI JA, 1978, J INVEST DERMATOL, V71, P366, DOI 10.1111/1523-1747.ep12556746; LIM HW, 1983, J CLIN INVEST, V71, P1326; LUGER TA, 1982, J CLIN INVEST, V70, P470, DOI 10.1172/JCI110637; LUGER TA, 1983, ADV INFLAMMAT RES, V5, P1; PARKER CW, 1980, CLIN IMMUNOLOGY, V2, P1219; SHELLEY WB, 1976, NATURE, V261, P46, DOI 10.1038/261046a0; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; WEISER WY, 1981, J IMMUNOL, V126, P1958; YURCHAK AM, 1970, J ALLERGY, V46, P245, DOI 10.1016/0021-8707(70)90028-6; ZEISS CR, 1980, AM J MED, V68, P867, DOI 10.1016/0002-9343(80)90216-8	17	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					573	579		10.1016/0091-6749(84)90109-X	http://dx.doi.org/10.1016/0091-6749(84)90109-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6238077				2022-12-18	WOS:A1984TQ16300006
J	SLY, RM				SLY, RM			BETA-ADRENERGIC DRUGS IN THE MANAGEMENT OF ASTHMA IN ATHLETES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GEORGE WASHINGTON UNIV, SCH MED & HLTH SCI, DEPT CHILD HLTH & DEV, WASHINGTON, DC 20052 USA	George Washington University	SLY, RM (corresponding author), CHILDRENS HOSP, NATL MED CTR, DEPT ALLERGY & IMMUNOL, WASHINGTON, DC 20010 USA.							ANDERSON SD, 1975, AUST NZ J MED, V5, P544, DOI 10.1111/j.1445-5994.1975.tb03860.x; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; BACHUS BF, 1977, JAMA-J AM MED ASSOC, V238, P2277; BADIEI B, 1975, ANN ALLERGY, V35, P32; BARNES PJ, 1983, BRIT J CLIN PHARMACO, V15, P677, DOI 10.1111/j.1365-2125.1983.tb01549.x; BERKOWITZ R, 1983, OCT P SECT ALL IMM A; BIERMAN CW, 1977, PEDIATRICS, V60, P845; BILLING B, 1982, EUR J RESPIR DIS, V63, P399; BLUMBERG MZ, 1977, PEDIATRICS, V60, P14; CHOOKANG YF, 1969, BMJ-BRIT MED J, V2, P287, DOI 10.1136/bmj.2.5652.287; DAVIS C, 1977, CLIN SCI MOL MED, V52, pP28; DOLOVICH M, 1983, CHEST, V84, P36, DOI 10.1378/chest.84.1.36; ELLULMICALLEF R, 1975, THORAX, V30, P312, DOI 10.1136/thx.30.3.312; FRANCIS PWJ, 1980, PEDIATRICS, V66, P103; GALANT SP, 1978, J ALLERGY CLIN IMMUN, V61, P73, DOI 10.1016/0091-6749(78)90228-2; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; HEIMER D, 1980, J ALLERGY CLIN IMMUN, V66, P75, DOI 10.1016/0091-6749(80)90141-4; HENRIKSEN JM, 1983, AM REV RESPIR DIS, V128, P993; HIGGS CMB, 1983, BRIT J DIS CHEST, V77, P262; HODGES IGC, 1981, ARCH DIS CHILD, V56, P787, DOI 10.1136/adc.56.10.787; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; KONIG P, 1981, CLIN ALLERGY, V11, P597, DOI 10.1111/j.1365-2222.1981.tb02180.x; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440, DOI 10.1164/arrd.1983.128.3.440; MORSE JLC, 1976, AM REV RESPIR DIS, V113, P89; NELSON HS, 1982, CHEST, V82, pS33; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; NEWHOUSE MT, 1978, CHEST, V73, P936, DOI 10.1378/chest.73.6.936; NEWMAN SP, 1981, AM REV RESPIR DIS, V124, P317; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; POLLOCK J, 1977, PEDIATRICS, V60, P840; POPPIUS H, 1973, SCAND J RESPIR DIS, V54, P142; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; ROSENTHAL RR, 1979, AM REV RESPIR DIS, V119, P79; SCHOEFFEL RE, 1981, ANN ALLERGY, V46, P273; SHAPIRO GG, 1981, PEDIATRICS, V67, P508; SILVERMAN M, 1973, THORAX, V28, P574, DOI 10.1136/thx.28.5.574; SLY RM, 1968, ANN ALLERGY, V26, P253; SLY RM, 1975, ANN ALLERGY, V34, P7; SLY RM, 1969, ANN ALLERGY, V27, P158; SLY RM, 1967, ANN ALLERGY, V25, P324; SMITH JA, 1980, CHEST, V78, P816, DOI 10.1378/chest.78.6.816; SPECTOR SL, 1977, J ALLERGY CLIN IMMUN, V59, P280, DOI 10.1016/0091-6749(77)90048-3; STURANI C, 1983, EUR J RESPIR DIS, V64, P526; SVEDMYR K, 1982, ALLERGY, V37, P101, DOI 10.1111/j.1398-9995.1982.tb01883.x; SVEDMYR K, 1982, ALLERGY, V37, P119, DOI 10.1111/j.1398-9995.1982.tb01885.x; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1; WILSON JD, 1981, LANCET, V1, P1235	52	26	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					680	685		10.1016/0091-6749(84)90305-1	http://dx.doi.org/10.1016/0091-6749(84)90305-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6143770				2022-12-18	WOS:A1984SS04600012
J	BEDARD, PM; ATKINS, PC; ZWEIMAN, B				BEDARD, PM; ATKINS, PC; ZWEIMAN, B			ANTIGEN-INDUCED LOCAL MEDIATOR RELEASE AND CELLULAR INFLAMMATORY RESPONSES IN ATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 14332-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; BEDARD PM, J CLIN IMMUNOL; DUNSKY EH, 1978, J ALLERGY CLIN IMMUN, V62, P127, DOI 10.1016/0091-6749(78)90091-X; LEVY DA, 1973, J LAB CLIN MED, V81, P291; TERR AI, 1974, TXB PULMONARY DISEAS, P423; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; TING S, 1981, J ALLERGY CLIN IMMUN, V68, P65, DOI 10.1016/0091-6749(81)90125-1; TING S, 1981, J IMMUNOL, V127, P557	9	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					394	398		10.1016/0091-6749(83)90068-4	http://dx.doi.org/10.1016/0091-6749(83)90068-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QL121	6300213				2022-12-18	WOS:A1983QL12100007
J	BUCKLEY, RH				BUCKLEY, RH			IMMUNODEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University; Duke University	BUCKLEY, RH (corresponding author), DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710, USA.		Buckley, Rebecca/AAB-1578-2019					BERGSMA D, 1975, ORIGINAL ARTICLE SER, V11; BORTIN MM, 1977, JAMA-J AM MED ASSOC, V238, P591, DOI 10.1001/jama.238.7.591; BUCKLEY RH, 1976, J CLIN INVEST, V58, P130, DOI 10.1172/JCI108441; BUCKLEY RH, 1977, CLIN IMMUNOL IMMUNOP, V7, P305, DOI 10.1016/0090-1229(77)90061-7; BUCKLEY RH, 1983, PRIMARY IMMUNODEFICI; BUCKLEY RH, 1981, CLIN IMMUNOLOGY UPDA, P147; BUCKLEY RH, 1982, CECIL TXB MED; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; GIBLETT ER, 1975, LANCET, V1, P1010, DOI 10.1016/S0140-6736(75)91950-9; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; HARADA S, 1982, J IMMUNOL, V129, P2532; LAWLOR GJ, 1974, J PEDIATR-US, V84, P183, DOI 10.1016/S0022-3476(74)80599-8; LINDSTEN T, 1982, J IMMUNOL, V129, P2536; MCKUSIK VA, 1964, B JOHNS HOPKINS HOSP, V116, P285; OWNBY DR, 1976, J PEDIATR-US, V89, P382, DOI 10.1016/S0022-3476(76)80532-X; PIERCE GF, 1982, CLIN EXP IMMUNOL, V50, P621; POLMAR SH, 1976, NEW ENGL J MED, V295, P1337, DOI 10.1056/NEJM197612092952402; REISNER Y, 1983, BLOOD, V61, P341; SALVAGGIO JE, 1982, JAMA, V248; SPECTOR BD, 1978, CLIN IMMUNOL IMMUNOP, V11, P12, DOI 10.1016/0090-1229(78)90200-3; STIEHM ER, 1980, IMMUNOLOGIC DISORDER; TILLER TL, 1978, J PEDIATR-US, V92, P347, DOI 10.1016/S0022-3476(78)80417-X; TOURAINE JL, 1981, LANCET, V1, P319; WALDMANN TA, 1982, ADV IMMUNOL, V32, P1, DOI 10.1016/S0065-2776(08)60720-8; WALDMANN TA, 1983, J CLIN INVEST, V71, P282, DOI 10.1172/JCI110768; WEBSTER ADB, 1982, CLIN EXP IMMUNOL, V49, P1; WILFERT CM, 1977, NEW ENGL J MED, V296, P1485, DOI 10.1056/NEJM197706302962601; 1971, MED RES COUNCIL SPEC, V310; 1982, N ENGL J MED, V306, P248	29	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	6					627	641		10.1016/0091-6749(83)90619-X	http://dx.doi.org/10.1016/0091-6749(83)90619-X			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RW048	6417214	Bronze			2022-12-18	WOS:A1983RW04800001
J	MATSON, SC; SWANSON, MC; REED, CE; YUNGINGER, JW				MATSON, SC; SWANSON, MC; REED, CE; YUNGINGER, JW			IGE AND IGG-IMMUNE MECHANISMS DO NOT MEDIATE OCCUPATION-RELATED RESPIRATORY OR SYSTEMIC SYMPTOMS IN HOG FARMERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,406 GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO MED SCH,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								Donham K, 1982, ANN AM C GOVT IND HY, V2, P137; DONHAM KJ, 1977, J OCCUP ENVIRON MED, V19, P383, DOI 10.1097/00043764-197706000-00004; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HARRIES MG, 1982, BRIT MED J, V284, P867, DOI 10.1136/bmj.284.6319.867; KATILA ML, 1981, BRIT J IND MED, V38, P334; KROLL J, 1973, SCAND J IMMUNOL, V2, P79, DOI 10.1111/j.1365-3083.1973.tb03783.x; MACY NE, 1968, P SOC EXP BIOL MED, V128, P1098; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; OLENCHOCK SA, 1980, ANN ALLERGY, V44, P23; PERNIS B, 1961, BRIT J IND MED, V18, P120; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778	13	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					299	304		10.1016/0091-6749(83)90035-0	http://dx.doi.org/10.1016/0091-6749(83)90035-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	RH938	6886262				2022-12-18	WOS:A1983RH93800011
J	PATTERSON, R; ZEISS, CR; HARRIS, KE				PATTERSON, R; ZEISS, CR; HARRIS, KE			IMMUNOLOGICAL AND RESPIRATORY RESPONSES TO AIRWAY CHALLENGES OF DOGS WITH TOLUENE DIISOCYANATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.				NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P25; KAROL MH, 1980, TOXICOL APPL PHARM, V53, P260, DOI 10.1016/0041-008X(80)90425-1; KELLY JF, 1974, J LAB CLIN MED, V83, P738; Oppenheim J. J., 1976, MANUAL CLIN IMMUNOLO, P81; PATTERSON R, 1980, J ALLERGY CLIN IMMUN, V65, P269, DOI 10.1016/0091-6749(80)90154-2; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; PATTERSON R, 1974, CHEST, V65, P488, DOI 10.1378/chest.65.5.488; PATTERSON R, 1978, J LAB CLIN MED, V92, P283; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; PATTERSON R, 1980, CLIN IMMUNOL IMMUNOP, V15, P357, DOI 10.1016/0090-1229(80)90047-1; PATTERSON R, 1982, J LAB CLIN MED, V99, P615; SALE SR, 1982, INT ARCH ALLER A IMM, V67, P329, DOI 10.1159/000233042; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; THORSBY E, 1970, HISTOCOMPATIBILITY T, P655; VERSCHUEREN K, 1977, HDB ENV DATA ORGANIC, P596; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0; ZEISS CR, 1982, J ALLERGY CLIN IMMUN, V70, P15, DOI 10.1016/0091-6749(82)90195-6	19	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					604	611		10.1016/0091-6749(83)90443-8	http://dx.doi.org/10.1016/0091-6749(83)90443-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6304178				2022-12-18	WOS:A1983QV13900013
J	AGARWAL, MK; JONES, RT; YUNGINGER, JW				AGARWAL, MK; JONES, RT; YUNGINGER, JW			IMMUNOCHEMICAL AND PHYSICOCHEMICAL CHARACTERIZATION OF COMMERCIAL ALTERNARIA EXTRACTS - A MODEL FOR STANDARDIZATION OF MOLD ALLERGEN EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO MED SCH,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI-16791] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016791] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P437, DOI 10.1016/0091-6749(82)90006-9; ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; AWDEH ZL, 1968, NATURE, V219, P66, DOI 10.1038/219066a0; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; EDWARDS M, 1982, Journal of Allergy and Clinical Immunology, V69, P160; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GOLDFARB A R, 1964, J Asthma Res, V2, P7, DOI 10.3109/02770906409107690; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V69, P1, DOI 10.1016/0091-6749(82)90079-3; RODBARD D, 1974, CLIN CHEM, V20, P1255; SIMMONS EG, 1967, MYCOLOGIA, V59, P67, DOI 10.2307/3756943; VAUGHN WT, 1954, PRACTICE ALLERGY, P657; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X	18	26	26	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					432	436		10.1016/0091-6749(82)90005-7	http://dx.doi.org/10.1016/0091-6749(82)90005-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6890564				2022-12-18	WOS:A1982PT74400005
J	BROOKS, CD; BUTLER, D; METZLER, C				BROOKS, CD; BUTLER, D; METZLER, C			EFFECT OF H2-BLOCKADE IN THE CHALLENGED ALLERGIC NOSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UPJOHN CO,KALAMAZOO,MI 49001	Pfizer	BROOKS, CD (corresponding author), BRONSON CLIN INVEST UNIT,252 E LOVELL ST,KALAMAZOO,MI 49007, USA.							BROOKS CD, 1981, ANN ALLERGY, V47, P316; CARPENTER GB, 1980, J ALLERGY CLIN IMMUN, V65, P187; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P335; EDVINSSON L, 1975, NEUROLOGY, V25, P271, DOI 10.1212/WNL.25.3.271; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HUTCHCROFT BJ, 1979, J ALLERGY CLIN IMMUN, V63, P376, DOI 10.1016/0091-6749(79)90209-4; LEOPOLD JD, 1979, BR J CLIN PHARM, V8, P749; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V57, P153, DOI 10.1016/0091-6749(76)90034-8; NATHAN RA, 1979, AM REV RESPIR DIS, V120, P1251; NOGRADY SG, 1981, THORAX, V36, P268, DOI 10.1136/thx.36.4.268; PLAUT M, 1979, J ALLERGY CLIN IMMUN, V63, P371, DOI 10.1016/0091-6749(79)90208-2; SEEBOHM PM, 1978, ALLERGY PRINCIPLES P, P875	13	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					373	376		10.1016/0091-6749(82)90027-6	http://dx.doi.org/10.1016/0091-6749(82)90027-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	6127360	Bronze			2022-12-18	WOS:A1982PQ10500009
J	WERTH, GR				WERTH, GR			INHALED METABISULFITE SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter											WERTH, GR (corresponding author), GEORGE WASHINGTON UNIV,DIV PULM DIS & ALLERGY,WASHINGTON,DC 20037, USA.								0	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	2					143	143		10.1016/0091-6749(82)90243-3	http://dx.doi.org/10.1016/0091-6749(82)90243-3			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PB591	7096821	Bronze			2022-12-18	WOS:A1982PB59100011
J	EDWARDS, JH; DAVIES, BH				EDWARDS, JH; DAVIES, BH			INHALATION CHALLENGE AND SKIN TESTING IN FARMERS LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											EDWARDS, JH (corresponding author), LLANDOUGH HOSP,MRC,PNEUMOCONIOSIS UNIT,PENARTH CF6 1XW,GLAMORGANSHIRE,WALES.							ARNOW PM, 1978, AM J MED, V64, P236, DOI 10.1016/0002-9343(78)90051-7; ARTHUS M, 1903, C R SOC BIOL, V55, P871; BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BARROWCLIFF DF, 1968, THORAX, V23, P490, DOI 10.1136/thx.23.5.490; CHAO P, 1977, J EXP MED, V145, P1288, DOI 10.1084/jem.145.5.1288; DERIDDER G, 1979, SCAND J RESPIR DIS, V60, P243; DEUSCHL H, 1974, CLIN EXP IMMUNOL, V16, P401; EDWARDS J H, 1974, Clinical Allergy, V4, P379, DOI 10.1111/j.1365-2222.1974.tb01399.x; EDWARDS JH, 1976, CLIN ALLERGY, V6, P19, DOI 10.1111/j.1365-2222.1976.tb01408.x; EDWARDS JH, 1972, J LAB CLIN MED, V79, P683; EDWARDS JH, 1972, CLIN EXP IMMUNOL, V11, P341; EDWARDS JH, 1976, CLIN ALLERGY, V6, P155, DOI 10.1111/j.1365-2222.1976.tb01893.x; EDWARDS JH, 1979, IMMUNOLOGY, V37, P91; EDWARDS JH, 1968, THESIS U WALES; EDWARDS JH, CLIN ALLERGY; EDWARDS JH, 1980, BRIT J IND MED, V57, P35; Gell PGH, 1968, CLIN ASPECTS IMMUNOL, VSecond, P580; GHOSE T, 1974, CLIN ALLERGY, V4, P119, DOI 10.1111/j.1365-2222.1974.tb01369.x; GRANT IWB, 1972, BRIT MED J, V1, P530, DOI 10.1136/bmj.1.5799.530; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HAWKINS D, 1972, J IMMUNOL, V108, P310; HUGGINS KG, 1975, LANCET, V2, P148; HUNNINGHAKE GW, 1977, J IMMUNOL, V118, P1728; Kabat E., 1961, EXPT IMMUNOCHEMISTRY; KAWAI T, 1973, CLIN EXP IMMUNOL, V15, P123; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; OVARY Z, 1953, J IMMUNOL, V71, P6; PATTERSON R, 1976, AM REV RESPIR DIS, V114, P315; PEPYS J, 1961, ACTA ALLERGOL, V16, P76; PEPYS J, 1963, LANCET, V2, P607; PEPYS J, 1965, THORAX, V20, P21, DOI 10.1136/thx.20.1.21; PEPYS J, 1969, MONOGRAPHS ALLERGY; RAMAZZINI B, 1940, MORBUS ARTIFICUM; REED CE, 1965, JAMA-J AM MED ASSOC, V193, P81; RICHERSON HB, 1972, J LAB CLIN MED, V79, P745; RIDDLE HFV, 1968, THORAX, V23, P271, DOI 10.1136/thx.23.3.271; SALVAGGIO J, 1975, J ALLERGY CLIN IMMUN, V56, P364, DOI 10.1016/0091-6749(75)90130-X; SCHORLEMMER HU, 1977, CLIN EXP IMMUNOL, V27, P198; SCHUYLER MR, 1978, ANN INTERN MED, V88, P355, DOI 10.7326/0003-4819-88-3-355; TEISBERG P, 1975, AM J MED, V59, P563, DOI 10.1016/0002-9343(75)90263-6; VIJAY HM, 1977, INT ARCH ALLER A IMM, V53, P78, DOI 10.1159/000231734; WEISSMANN G, 1971, J EXP MED, V134, pS149; WENZEL FJ, 1971, J ALLERGY CLIN IMMUN, V48, P224, DOI 10.1016/0091-6749(71)90069-8; WILLIAMS J. V., 1963, THORAX, V18, P182, DOI 10.1136/thx.18.2.182	44	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					58	64		10.1016/0091-6749(81)90124-X	http://dx.doi.org/10.1016/0091-6749(81)90124-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	7240600				2022-12-18	WOS:A1981LY10100010
J	HALLGREN, R; ARRENDAL, H; HIESCHE, K; LUNDQUIST, G; NOU, E; ZETTERSTROM, O				HALLGREN, R; ARRENDAL, H; HIESCHE, K; LUNDQUIST, G; NOU, E; ZETTERSTROM, O			ELEVATED SERUM IMMUNOGLOBULIN-E IN BRONCHIAL-CARCINOMA - ITS RELATION TO THE HISTOLOGY AND PROGNOSIS OF THE CANCER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV UPPSALA HOSP,DEPT LUNG MED,S-75014 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75014 UPPSALA,SWEDEN; PHARMACIA DIAGNOST,UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Pfizer; Pharmacia Corporation	HALLGREN, R (corresponding author), UNIV UPPSALA HOSP,DEPT INTERNAL MED,S-75014 UPPSALA,SWEDEN.							AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; ALDERSON M, 1974, LANCET, V2, P1475; COCKCROFT DW, 1979, ANN ALLERGY, V43, P345; DELLON AL, 1975, CANCER, V35, P687, DOI 10.1002/1097-0142(197503)35:3<687::AID-CNCR2820350322>3.0.CO;2-U; DWORIN M, 1955, CANCER, V8, P128, DOI 10.1002/1097-0142(1955)8:1<128::AID-CNCR2820080117>3.0.CO;2-T; FORD RM, 1978, ANN ALLERGY, V40, P240; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V59, P377, DOI 10.1016/0091-6749(77)90022-7; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; JOHANSSON SG, 1968, LANCET, V1, P1118; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; JOHANSSON SGO, 1975, LABORATORY DIAGNOSIS, P225; KREYBERG L, 1967, HISTOLOGICAL TYPING; LOGAN J, 1953, N Z Med J, V52, P210; LUTHGENS M, 1977, FORTSCHR MED, V95, P278; MACKAY WD, 1966, BRIT J CANCER, V20, P434, DOI 10.1038/bjc.1966.52; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; Nou E, 1979, Scand J Respir Dis Suppl, V104, P43; PAUWELL R, 1975, LANCET, V1, P396; SERROU B, 1975, LANCET, V1, P582; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; TWOMEY PL, 1974, CANCER, V33, P435, DOI 10.1002/1097-0142(197402)33:2<435::AID-CNCR2820330219>3.0.CO;2-A; URE D M J, 1969, Scottish Medical Journal, V14, P51; WALDMANN TA, 1974, J IMMUNOL, V113, P379; WATKINS SM, 1973, CLIN EXP IMMUNOL, V14, P69; WINTERS WD, 1976, J ALLERGY CLIN IMMUN, V57, P181, DOI 10.1016/0091-6749(76)90039-7	25	26	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					398	406		10.1016/0091-6749(81)90086-5	http://dx.doi.org/10.1016/0091-6749(81)90086-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	6164710				2022-12-18	WOS:A1981LQ56300011
J	HENDRIX, S; SALE, S; ZEISS, CR; UTLEY, J; PATTERSON, R				HENDRIX, S; SALE, S; ZEISS, CR; UTLEY, J; PATTERSON, R			FACTITIOUS HYMENOPTERA ALLERGIC EMERGENCY - A REPORT OF A NEW VARIANT OF MUNCHAUSENS SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; NORTHWESTERN UNIV,DEPT PSYCHIAT,CHICAGO,IL 60611	Northwestern University; Northwestern University					NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER JC, 1962, J MENT SCI, V108, P167, DOI 10.1192/bjp.108.453.167; CRAMER B, 1971, ARCH GEN PSYCHIAT, V24, P573; FERGUSON EE, 1978, HOSP PRACT, V13, P111, DOI 10.1080/21548331.1978.11707300; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; IRELAND P, 1967, AM J MED, V43, P579, DOI 10.1016/0002-9343(67)90181-7; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; PATTERSON R, 1975, J ALLERGY CLIN IMMUN, V56, P152, DOI 10.1016/0091-6749(75)90120-7; PATTERSON R, 1973, J IMMUNOL, V110, P1402; PATTERSON R, 1974, CLIN ALLERGY, V4, P307, DOI 10.1111/j.1365-2222.1974.tb01390.x; PRUZANSK.JJ, 1965, J IMMUNOL, V95, P48; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P3, DOI 10.1016/0091-6749(79)90074-5; SCHATZ M, 1976, J ALLERGY CLIN IMMUN, V58, P198, DOI 10.1016/0091-6749(76)90155-X; YUNGINGER J, 1978, J ALLERGY CLIN IMMUN, V61, P213, DOI 10.1016/0091-6749(78)90183-5; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1978, J ALLERGY CLIN IMMUN, V62, P83, DOI 10.1016/0091-6749(78)90083-0	16	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					8	13		10.1016/0091-6749(81)90038-5	http://dx.doi.org/10.1016/0091-6749(81)90038-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	7451774	Bronze			2022-12-18	WOS:A1981KZ17300003
J	PATTERSON, R; HARRIS, KE				PATTERSON, R; HARRIS, KE			INHIBITION OF IMMUNOGLOBULIN-E-MEDIATED, ANTIGEN-INDUCED MONKEY ASTHMA AND SKIN REACTIONS BY 5,8,11,14-EICOSATETRAYNOIC ACID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.				NIAID NIH HHS [AI 11759] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMDUR MO, 1958, AM J PHYSIOL, V192, P364, DOI 10.1152/ajplegacy.1958.192.2.364; ELAZAB J, 1977, INT ARCH ALLER A IMM, V55, P350, DOI 10.1159/000231946; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; GOTH A, 1978, FED PROC, V37, P590; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HOGARTHS.RS, 1967, IMMUNOLOGY, V13, P535; HYMAN AL, 1978, AM REV RESPIR DIS, V117, P111; JAKSCHIK BA, 1977, P NATL ACAD SCI USA, V74, P4577, DOI 10.1073/pnas.74.10.4577; JOHNSON HG, 1978, INT ARCH ALLER A IMM, V56, P481, DOI 10.1159/000232062; KELLY JF, 1974, J LAB CLIN MED, V83, P738; KRELL RD, 1976, LIFE SCI, V19, P1777, DOI 10.1016/0024-3205(76)90086-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER MM, 1976, J LAB CLIN MED, V88, P995; PATTERSON R, 1976, J LAB CLIN MED, V87, P1016; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P261, DOI 10.1016/0091-6749(78)90201-4; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; PATTERSON R, 1971, INT ARCH ALLER A IMM, V41, P592, DOI 10.1159/000230552; PATTERSON R, 1969, J LAB CLIN MED, V73, P924; PATTERSON R, 1977, J LAB CLIN MED, V90, P18; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V62, P371, DOI 10.1016/0091-6749(78)90139-2; PATTERSON R, 1978, LIFE SCI, V22, P389, DOI 10.1016/0024-3205(78)90285-0; PATTERSON R, 1978, J LAB CLIN MED, V92, P283; PATTERSON R, 1979, J CLIN INVEST, V64, P49, DOI 10.1172/JCI109462; PATTERSON R, 1976, J LAB CLIN MED, V87, P65; PATTERSON R, 1974, ANNU REV MED, V25, P53, DOI 10.1146/annurev.me.25.020174.000413; PATTERSON R, 1980, J ALLERGY CLIN IMMUN, V65, P273; SNEDECOR GW, 1973, STATISTICAL METHODS, P59; TOBIAS LD, 1979, LIPIDS, V14, P181, DOI 10.1007/BF02533870; WEISZER I, 1968, J ALLERGY, V41, P14, DOI 10.1016/0021-8707(68)90004-X	29	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					146	152		10.1016/0091-6749(81)90010-5	http://dx.doi.org/10.1016/0091-6749(81)90010-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	6161146				2022-12-18	WOS:A1981LB94700010
J	KELLY, JF; ZEISS, CR; PATTERSON, R; LEVITZ, D; SUSZKO, IM				KELLY, JF; ZEISS, CR; PATTERSON, R; LEVITZ, D; SUSZKO, IM			POLYMERIZED WHOLE RAGWEED - HUMAN SAFETY AND IMMUNE-RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University								BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; Cooke RA, 1947, ALLERGY THEORY PRACT; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; IRONS JS, 1975, J ALLERGY CLIN IMMUN, V56, P64, DOI 10.1016/0091-6749(75)90035-4; JOHANSSON SGO, 1978, ALLERGY PRINCIPLES P; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; MELAM HL, 1972, ALLERGIC DISEASES DI; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; PATTERSON R, 1974, J IMMUNOL, V112, P1855; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1973, J IMMUNOL, V110, P1402; PATTERSON R, 1976, J ALLERGY CLIN IMMUN, V57, P168, DOI 10.1016/0091-6749(76)90036-1; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; PATTERSON R, 1973, J IMMUNOL, V110, P1412; PATTERSON R, 1977, EXCERPTA MEDICA  414, P492; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; ZEISS CR, 1979, J ALLERGY CLIN IMMUN, V63, P273, DOI 10.1016/0091-6749(79)90112-X; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1973, J IMMUNOL, V110, P414	20	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					50	56		10.1016/0091-6749(80)90176-1	http://dx.doi.org/10.1016/0091-6749(80)90176-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	6153084				2022-12-18	WOS:A1980JB45900008
J	LEMAO, J; WEYER, A; PAULI, G; LEBEL, B; DAVID, B				LEMAO, J; WEYER, A; PAULI, G; LEBEL, B; DAVID, B			STUDIES ON DERMATOPHAGOIDES-PTERONYSSINUS ALLERGENS - MEASUREMENT OF THE RELATIVE POTENCIES OF DERMATOPHAGOIDES-PTERONYSSINUS PURIFIED EXTRACTS BY INVITRO AND INVIVO METHODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FAC MED PARIS,INSERM,FRA 3,F-75006 PARIS,FRANCE; FAC MED STRASBOURG,DEPT PNEUMOPHTISIOL,STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	LEMAO, J (corresponding author), INST PASTEUR,DEPT IMMUNOL,IMMUNO ALLERGY SECT,IMMUNO ALLERGIE UNITE,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AALBERSE RC, 1974, THESIS U AMSTERDAM; AAS K, 1972, ACTA ALLERGOL, V27, P439; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BECKER EL, 1948, J ALLERGY, V19, P108, DOI 10.1016/0021-8707(48)90097-5; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; LEMAO J, 1978, ANN INST PASTEUR IMM, VC129, P63; LICHTENSTEIN LM, 1966, J ALLERGY, V38, P174, DOI 10.1016/0021-8707(66)90040-2; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; PAULI G, 1972, REV FR ALLERGOL, V12, P141, DOI 10.1016/S0035-2845(72)80014-3; PAULI G, 1973, REV FR MAL RESP, V5, P711; Pepys J, 1975, Dev Biol Stand, V29, P284; PHILIPPE J, 1967, METHODES STATISTIQUE, P263; Shore PA, 1971, METHODS BIOCH ANAL S, P89, DOI [10.1002/9780470110409.ch3, DOI 10.1002/9780470110409.CH3]; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SWAIN HH, 1952, J ALLERGY, V23, P441, DOI 10.1016/0021-8707(52)90008-7; VOORHORST R, 1969, HOUSE DUST ATOPY HOU, P120; Yman L, 1975, Dev Biol Stand, V29, P151; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; 1971, PHARMACOPEE EUROPEEN, V2	21	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	5					381	388		10.1016/0091-6749(80)90217-1	http://dx.doi.org/10.1016/0091-6749(80)90217-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV955	6154726	Bronze			2022-12-18	WOS:A1980JV95500011
J	SHAPIRO, GG; PIERSON, WE; FURUKAWA, CT; BIERMAN, CW				SHAPIRO, GG; PIERSON, WE; FURUKAWA, CT; BIERMAN, CW			COMPARISON OF THE EFFECTIVENESS OF FREE-RUNNING AND TREADMILL EXERCISE FOR ASSESSING EXERCISE-INDUCED BRONCHOSPASM IN CLINICAL PRACTICE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SHAPIRO, GG (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195, USA.							GODFREY S, 1975, PEDIATRICS, V56, P893; KATTAN M, 1978, J PEDIATR-US, V92, P718, DOI 10.1016/S0022-3476(78)80135-8; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; PIERSON WE, 1975, PEDIATRICS, V56, P890	4	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					609	611		10.1016/0091-6749(79)90023-X	http://dx.doi.org/10.1016/0091-6749(79)90023-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512256				2022-12-18	WOS:A1979HX84300011
J	BIERMAN, CW; SHAPIRO, GG; CHRISTIE, DL; VANARSDEL, PP; FURUKAWA, CT; WARD, BH				BIERMAN, CW; SHAPIRO, GG; CHRISTIE, DL; VANARSDEL, PP; FURUKAWA, CT; WARD, BH			ALLERGY GRAND ROUNDS - ECZEMA, RICKETS, AND FOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion									CHILDRENS ORTHOPED HOSP & MED CTR,DEPT RADIOL,SEATTLE,WA 98105; CHILDRENS ORTHOPED HOSP & MED CTR,DIV ALLERGY,SEATTLE,WA 98105; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,DIV ALLERGY,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								AAS K, 1966, INT ARCH ALLER A IMM, V29, P346, DOI 10.1159/000229716; AMENT ME, 1972, GASTROENTEROLOGY, V62, P227; ANAND BS, 1977, LANCET, V118; ASCOLI M, 1902, MUNCH MED WSCHR, V49, P398; BROWN EB, 1963, AM J DIS CHILD, V117, P693; CALDWELL JH, 1975, NEW ENGL J MED, V292, P1388, DOI 10.1056/NEJM197506262922608; CHRISTAKIS G, 1972, NUTRITIONAL ASSESSME; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P477, DOI 10.1016/0091-6749(76)90191-3; COOKE RA, 1944, J ALLERGY, V15, P203; ENGMAN MF, 1936, MED CLIN N AM, V20, P651; FONTAINE JL, 1975, ARCH DIS CHILD, V50, P357, DOI 10.1136/adc.50.5.357; Freeman J, 1925, P ROY SOC MED, V18, P29; FRY L, 1966, ARCH DERMATOL, V93, P647, DOI 10.1001/archderm.1966.01600240013002; FURUKAWA CT, 1977, ANN ALLERGY, V38, P308; GANGHOFNER, 1904, MUNCHEN MED WOCHEN, V51, P1497; GLASER J, 1953, JAMA-J AM MED ASSOC, V153, P620, DOI 10.1001/jama.1953.02940240012003; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; GRYBOSKI JD, 1966, PEDIATRICS, V38, P299; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HARRISON M, 1976, BRIT MED J, V1, P1501, DOI 10.1136/bmj.1.6024.1501; HEINER DC, 15TH ROSS C PED RES; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; JOHNSTONE DE, 1966, NEW ENGL J MED, V274, P715, DOI 10.1056/NEJM196603312741305; JOHNSTONE DE, 1972, ANN ALLERGY, V30, P173; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351, DOI 10.1136/adc.50.5.351; LOWELL FC, 1954, J ALLERGY, V25, P57; MATTHEW DJ, 1977, LANCET, V1, P321; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MUELLER JL, 1963, NEW ENGL J MED, V268, P1220; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; ROY CC, 1975, PEDIATRIC CLINICAL G, P202; ROY CC, 1975, PEDIATRIC CLINICAL G, P227; Schloss OM, 1916, AM J DIS CHILD, V11, P342; SCHWACHMAN H, 1973, AM J DIS CHILD, V125, P365; SCOGGINS RB, 1965, NEW ENGL J MED, V273, P831, DOI 10.1056/NEJM196510142731601; SHINER M, 1975, LANCET, V1, P136; SNYDERMAN R, 1977, J ALLERGY CLIN IMMUN, V60, P121, DOI 10.1016/0091-6749(77)90037-9; VOWLES M, 1955, BRIT J DERMATOL, V67, P53, DOI 10.1111/j.1365-2133.1955.tb12687.x; WALDMANN TA, 1967, NEW ENGL J MED, V276, P761, DOI 10.1056/NEJM196704062761401; WILSON JF, 1974, J PEDIATR-US, V84, P335, DOI 10.1016/S0022-3476(74)80713-4	41	26	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	2					119	127						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EL413	621348				2022-12-18	WOS:A1978EL41300009
J	PATTERSON, R; ORANGE, R; HARRIS, KE				PATTERSON, R; ORANGE, R; HARRIS, KE			STUDY OF EFFECT OF SLOW-REACTING SUBSTANCES OF ANAPHYLAXIS ON RHESUS-MONKEY AIRWAY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,DEPT IMMUNOL,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611, USA.							AMDUR MO, 1958, AM J PHYSIOL, V192, P364, DOI 10.1152/ajplegacy.1958.192.2.364; BACH MK, 1974, J IMMUNOL, V113, P2040; DRAZEN JM, 1974, J CLIN INVEST, V53, P1679, DOI 10.1172/JCI107719; DRAZEN JM, 1975, J APPL PHYSIOL, V38, P834, DOI 10.1152/jappl.1975.38.5.834; HOGARTHS.RS, 1967, IMMUNOLOGY, V13, P535; KELLY JF, 1974, J LAB CLIN MED, V83, P738; MICHOUD M C, 1977, American Review of Respiratory Disease, V115, P66; MILLER MM, 1976, J LAB CLIN MED, V88, P995; ORANGE RP, 1973, J IMMUNOL, V110, P760; ORANGE RP, 1976, J IMMUNOL, V116, P392; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; PATTERSON R, 1971, INT ARCH ALLER A IMM, V41, P592, DOI 10.1159/000230552; PATTERSON R, 1969, J LAB CLIN MED, V73, P924; PATTERSON R, 1975, INT ARCH ALLER A IMM, V49, P381, DOI 10.1159/000231419; PATTERSON R, 1976, J LAB CLIN MED, V87, P65; PATTERSON R, 1974, ANNU REV MED, V25, P53, DOI 10.1146/annurev.me.25.020174.000413; STECHSCHULTE DJ, 1967, J EXP MED, V125, P127, DOI 10.1084/jem.125.1.127	17	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	6					371	377		10.1016/0091-6749(78)90139-2	http://dx.doi.org/10.1016/0091-6749(78)90139-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GA292	101573	Bronze			2022-12-18	WOS:A1978GA29200010
J	SLY, RM; IMSEIS, M; FRAZER, M; JOSEPH, F				SLY, RM; IMSEIS, M; FRAZER, M; JOSEPH, F			TREATMENT OF ASTHMA IN CHILDREN WITH TRIAMCINOLONE ACETONIDE AEROSOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LOUISIANA STATE UNIV,MED CTR,DEPT PEDIAT,NEW ORLEANS,LA 70122	Louisiana State University System								BOLDON DP, 1977, ANN ALLERGY, V39, P71; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CAYTON RM, 1974, LANCET, V2, P303; CHAMPION P, 1975, CAN MED ASSOC J, V113, P213; CHERVINSKY P, 1977, ANN ALLERGY, V38, P192; CHERVINSKY P, 1977, ANN ALLERGY, V39, P71; CHOO-KANG Y F J, 1972, British Journal of Diseases of the Chest, V66, P101, DOI 10.1016/S0007-0971(72)80031-7; EASTON JG, 1971, J ALLERGY CLIN IMMUN, V48, P355, DOI 10.1016/0091-6749(71)90081-9; FALLIERS CJ, 1976, J ALLERGY CLIN IMMUN, V57, P1, DOI 10.1016/0091-6749(76)90073-7; FALLIERS CJ, 1977, ANN ALLERGY, V39, P71; KLEIN R, 1977, PEDIATRICS, V60, P7; KRIZ RJ, 1976, CHEST, V69, P455, DOI 10.1378/chest.69.4.455; KRIZ RJ, 1977, CHEST, V72, P36, DOI 10.1378/chest.72.1.36; LIDDLE GW, 1959, J CLIN ENDOCR METAB, V19, P875, DOI 10.1210/jcem-19-8-875; MATTINGLY D, 1964, LANCET, V2, P1046; MEIKLE AW, 1975, J CLIN ENDOCR METAB, V40, P290, DOI 10.1210/jcem-40-2-290; MORRIS HG, 1974, J ALLERGY CLIN IMMUN, V54, P350, DOI 10.1016/0091-6749(74)90025-6; MORRIS HG, 1971, J PEDIATR-US, V79, P480, DOI 10.1016/S0022-3476(71)80163-4; PLUMPTON FS, 1969, BRIT J SURG, V56, P216, DOI 10.1002/bjs.1800560315; SIEGEL SC, 1964, PEDIATRICS, V33, P245; SIEGEL SC, 1965, J PEDIATR-US, V66, P927, DOI 10.1016/S0022-3476(65)80069-5; SILBER RH, 1958, CLIN CHEM, V4, P278; SPARK RF, 1971, ANN INTERN MED, V75, P717, DOI 10.7326/0003-4819-75-5-717; TOOGOOD J, 1977, ANN ALLERGY, V39, P70; WEBB DR, 1976, J ALLERGY CLIN IMMUN, V57, P257; WILLIAMS MH, 1974, AM REV RESPIR DIS, V109, P538; WILLIAMS MH, 1975, CHEST, V68, P765, DOI 10.1378/chest.68.6.765	27	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					76	82		10.1016/0091-6749(78)90082-9	http://dx.doi.org/10.1016/0091-6749(78)90082-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	670608				2022-12-18	WOS:A1978FL83500002
J	COGEN, FC; MAYOCK, RL; ZWEIMAN, B				COGEN, FC; MAYOCK, RL; ZWEIMAN, B			CHRONIC EOSINOPHILIC PNEUMONIA FOLLOWED BY POLYARTERITIS NODOSA COMPLICATING COURSE OF BRONCHIAL-ASTHMA - REPORT OF A CASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP UNIV PENN, DEPT MED, ALLERGY CLIN IMMUNOL SECT, PHILADELPHIA, PA 19174 USA; HOSP UNIV PENN, DEPT MED, PULM DIS SECT, PHILADELPHIA, PA 19174 USA	University of Pennsylvania; University of Pennsylvania								CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; CHURG J, 1951, AM J PATHOL, V27, P277; CROFTON JW, 1952, THORAX, V7, P1, DOI 10.1136/thx.7.1.1; DIVERTIE MB, 1960, DIS CHEST, V37, P340, DOI 10.1378/chest.37.3.340; FORD RM, 1966, AM REV RESPIR DIS, V93, P797; GAENSLER EA, 1977, AM J ROENTGENOL, V128, P1; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; KINSELLA DL, 1967, J AMER MED ASSOC, V202, P867; Kussmaul A., 1866, DTSCH ARCH KLIN MED, V1, P484; PATTERSON R, 1974, J ALLERGY CLIN IMMUN, V53, P245, DOI 10.1016/0091-6749(74)90088-8; RODGERS R, 1975, CHEST, V68, P665; ROSE GA, 1957, Q J MED, V26, P43; ROSENBERG TF, 1975, J ALLERGY CLIN IMMUN, V55, P56, DOI 10.1016/S0091-6749(75)80008-X; SCADDING JG, 1971, P ROY SOC MED, V64, P381, DOI 10.1177/003591577106400419; SERGENT JS, 1976, MEDICINE, V55, P1, DOI 10.1097/00005792-197601000-00001; WILSON KS, 1945, J LAB CLIN MED, V30, P195	16	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	6					377	382		10.1016/0091-6749(77)90069-0	http://dx.doi.org/10.1016/0091-6749(77)90069-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ED834	21898				2022-12-18	WOS:A1977ED83400007
J	GALANT, SP; FLOD, N; SHIMIZU, I; GRANGER, GA; GRONCY, CE				GALANT, SP; FLOD, N; SHIMIZU, I; GRANGER, GA; GRONCY, CE			RELATIONSHIP BETWEEN CUTANEOUS DELAYED-HYPERSENSITIVITY AND CELL-MEDIATED-IMMUNITY INVITRO RESPONSES ASSESSED BY DIPHTHERIA AND TETANUS TOXOIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,MED CTR,DEPT PEDIAT,ORANGE,CA 92668	University of California System; University of California Irvine								ASTOR S H, 1973, Journal of Immunology, V110, P1174; CHAPARAS SD, 1975, AM REV RESPIR DIS, V101, P67; CHESS L, 1974, J IMMUNOL, V113, P1122; CLAUSEN JE, 1971, ACTA ALLERGOL, V26, P56, DOI 10.1111/j.1398-9995.1971.tb01399.x; DEAN JH, 1975, J IMMUNOL, V115, P1449; FACKTOR MA, 1973, J ALLERGY CLIN IMMUN, V52, P1, DOI 10.1016/0091-6749(73)90115-2; FRANZ ML, 1976, J PEDIATR-US, V88, P975, DOI 10.1016/S0022-3476(76)81053-0; LING NR, 1964, LANCET, V1, P363; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P835; ROSENBERG SA, 1970, J IMMUNOL, V105, P1447; SCHIFF RI, 1974, J IMMUNOL, V112, P376; SLAVIN SB, 1960, J EXP MED, V111, P465; SPOFFORD BT, 1974, J IMMUNOL, V112, P2111; STEELE RW, 1976, AM J DIS CHILD, V130, P1218, DOI 10.1001/archpedi.1976.02120120052008; STIEHM ER, 1973, IMMUNOLOGIC DISORDER, P145; WASMAN J, 1973, AM REV RESPIR DIS, V107, P661	16	26	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	4					247	253		10.1016/0091-6749(77)90139-7	http://dx.doi.org/10.1016/0091-6749(77)90139-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DX458	332750	Green Submitted			2022-12-18	WOS:A1977DX45800009
J	YUNGINGER, JW; ROBERTS, GD; GLEICH, GJ				YUNGINGER, JW; ROBERTS, GD; GLEICH, GJ			STUDIES ON ALTERNARIA ALLERGENS .1. ESTABLISHMENT OF RADIOALLERGOSORBENT TEST FOR MEASUREMENT OF ALTERNARIA ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & FDN,ALLERGIC DIS RES LAB,ROCHESTER,MN 55901; MAYO CLIN & FDN,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & FDN,DEPT LAB MED,ROCHESTER,MN 55901; MAYO CLIN & FDN,DEPT INTERN MED,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; BONIL.O, 1961, J ALLERGY, V32, P246, DOI 10.1016/0021-8707(61)90055-7; DIXON WJ, 1957, INTRO STATISTICAL AN, P209; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FAGERBERG E, 1970, INT ARCH ALLER A IMM, V39, P301, DOI 10.1159/000230356; FOUCARD T, 1973, J ALLERGY CLIN IMMUN, V51, P39, DOI 10.1016/0091-6749(73)90007-9; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HOFFMAN DR, 1974, PEDIATRICS, V54, P151; KABAT EA, 1967, EXPT IMMUNOCHEMISTRY, P559; LEBEAU LJ, 1952, THESIS U ILLINOIS; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Prince H. E., 1947, ANN ALLERGY, V5, P434; RANCOUR JM, COMMUNICATION; STENIUS B, 1969, LANCET, V2, P455; WIDE L, 1971, Clinical Allergy, V1, P171, DOI 10.1111/j.1365-2222.1971.tb03016.x; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1969, ACTA ENDOCRINOL-COP, VS 63, P207; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	19	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					293	301		10.1016/0091-6749(76)90085-3	http://dx.doi.org/10.1016/0091-6749(76)90085-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	944203				2022-12-18	WOS:A1976BM68900002
J	KIRKPATRICK, CH				KIRKPATRICK, CH			PROPERTIES AND ACTIVITIES OF TRANSFER-FACTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,LAB CLIN INVEST,SECT CLIN ALLERGY & HYPERSENSITIV,BLDG 10,ROOM 11B-13,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ARALACHAVES MP, 1974, CELL IMMUNOL, V10, P371, DOI 10.1016/0008-8749(74)90129-4; ASCHER MS, 1974, P NATL ACAD SCI USA, V71, P1178, DOI 10.1073/pnas.71.4.1178; BLOOM BR, 1967, PROG ALLERGY, V10, P151; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BURNET FM, 1974, J ALLERGY CLIN IMMUN, V54, P1, DOI 10.1016/S0091-6749(74)80002-3; CHASE MW, 1945, P SOC EXP BIOL MED, V59, P134, DOI 10.3181/00379727-59-15006P; COOPER MD, 1968, IMMUNOL DEFICIENCY, V4, P7; DAVID JR, 1975, PHAGOCYTIC CELL HOST, P143; DUPONT B, 1974, P NATL ACAD SCI USA, V71, P867, DOI 10.1073/pnas.71.3.867; ESTENSEN RD, 1973, NATURE, V245, P458, DOI 10.1038/245458a0; GALLIN JI, 1974, P NATL ACAD SCI USA, V71, P498, DOI 10.1073/pnas.71.2.498; GOLDBLUM RM, 1973, CELL IMMUNOL, V9, P297, DOI 10.1016/0008-8749(73)90081-6; GRISCELLI C, 1973, BIOMEDICINE, V18, P220; IGNARRO LJ, 1974, P NATL ACAD SCI USA, V71, P2027, DOI 10.1073/pnas.71.5.2027; JONDAL M, 1973, TRANSPLANT REV, V16, P163; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KHAN A, 1973, AM J DIS CHILD, V126, P797, DOI 10.1001/archpedi.1973.02110190643012; KIRKPATRICK CH, 1974, ONCOLOGY-BASEL, V29, P46, DOI 10.1159/000224888; KIRKPATRICK CH, 1971, ANN INTERN MED, V74, P955, DOI 10.7326/0003-4819-74-6-955; KIRKPATRICK CH, 1972, J CLIN INVEST, V51, P2948, DOI 10.1172/JCI107119; KIRKPATRICK CH, 1974, DERMATOL DIG, V13, P15; KIRKPATRICK CH, 1975, PHAGOCYTIC CELL HOST, P155; Landsteiner K, 1942, P SOC EXP BIOL MED, V49, P688, DOI 10.3181/00379727-49-13670; Lawrence H S, 1969, Adv Immunol, V11, P195, DOI 10.1016/S0065-2776(08)60480-0; Lawrence H S, 1968, Trans Assoc Am Physicians, V81, P240; LAWRENCE HS, 1956, J EXP MED, V104, P321, DOI 10.1084/jem.104.3.321; LAWRENCE HS, 1955, J CLIN INVEST, V34, P219, DOI 10.1172/JCI103075; LAWRENCE HS, 1949, P SOC EXP BIOL MED, V71, P516, DOI 10.3181/00379727-71-17242; LAWRENCE HS, 1963, T ASSOC AM PHYSICIAN, V76, P84; LAWRENCE HS, 1960, J CLIN INVEST, V39, P185, DOI 10.1172/JCI104018; LEVIN AS, 1970, P NATL ACAD SCI USA, V67, P821, DOI 10.1073/pnas.67.2.821; MACKANESS GB, 1971, J INFECT DIS, V123, P439, DOI 10.1093/infdis/123.4.439; MAURER PH, 1961, J EXP MED, V113, P1029, DOI 10.1084/jem.113.6.1029; ORANGE RP, 1971, J EXP MED          S, V134, P136; PABST HF, 1972, BRIT MED J, V2, P442, DOI 10.1136/bmj.2.5811.442; PACHMAN LM, 1974, J PEDIATR-US, V84, P681, DOI 10.1016/S0022-3476(74)80009-0; RAPAPORT FT, 1960, J IMMUNOL, V84, P358; ROCKLIN RE, 1973, J IMMUNOL, V110, P674; SANDLER J, COMMUNICATION; SANDLER J, TO BE PUBLISHED; SANDLER JA, 1975, J CLIN INVEST, V55, P431, DOI 10.1172/JCI107948; SCHULKIN.ML, 1972, CELL IMMUNOL, V3, P606, DOI 10.1016/0008-8749(72)90122-0; SPITLER LE, 1972, J CLIN INVEST, V51, P3216, DOI 10.1172/JCI107148; SPITLER LE, 1973, METHOD CANCER RES, V8, P59; STROM TB, 1973, J EXP MED, V138, P381, DOI 10.1084/jem.138.2.381; VALDIMARSSON H, 1974, CLIN EXP IMMUNOL, V16, P141; WATSON J, 1975, J EXP MED, V141, P97, DOI 10.1084/jem.141.1.97; WATSON J, 1973, NATURE, V246, P405, DOI 10.1038/246405a0; WYBRAN J, 1973, NEW ENGL J MED, V288, P710, DOI 10.1056/NEJM197304052881405; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; ZUCKERMAN KS, 1974, J CLIN INVEST, V54, P997, DOI 10.1172/JCI107841; ZURIER RB, 1974, J CLIN INVEST, V53, P297, DOI 10.1172/JCI107550	52	26	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	6					411	421		10.1016/0091-6749(75)90080-9	http://dx.doi.org/10.1016/0091-6749(75)90080-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AE593	48524				2022-12-18	WOS:A1975AE59300008
J	LAKIN, JD; GRACE, WR; SELL, KW				LAKIN, JD; GRACE, WR; SELL, KW			IGE ANTIPOLYMYXIN-B ANTIBODY-FORMATION IN A T-CELL-DEPLETED BONE-MARROW TRANSPLANT PATIENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USN,MED RES INST,BETHESDA,MD 20014	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy								DESWARTE RD, 1972, ALLERGIC DISEASES DI, P393; GOODFRIEND L, 1973, CONTROL MECHANISMS R; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; GUBAREV EA, 1965, FED PROC, V24, P1116; HAMOKA T, 1973, J EXP MED, V138, P538; HERBERT WJ, 1973, HDB EXPT IMMUNOLOGY, V1, P20; HOEPRICH PD, 1970, MED CLIN N AM, V54, P1257, DOI 10.1016/S0025-7125(16)32591-3; ISHIZAKA K, 1973, Journal of Immunology, V110, P1067; KALCKAR HM, 1947, J BIOL CHEM, V167, P461; Katz D H, 1972, Adv Immunol, V15, P1, DOI 10.1016/S0065-2776(08)60683-5; KIND LS, 1973, INT ARCH ALLER A IMM, V45, P780, DOI 10.1159/000231077; LAKIN JD, 1969, J IMMUNOL, V102, P253; LAKIN JD, 1967, J IMMUNOL, V98, P745; LANGUNOFF D, 1960, J EXP MED, V112, P571; LEWIS JE, 1972, NATURE-NEW BIOL, V239, P214, DOI 10.1038/newbio239214a0; MARSCHKE G, 1971, ANN INTERN MED, V74, P296, DOI 10.7326/0003-4819-74-2-296_3; MELNIKOV.EA, 1971, ANTIBIOT MED BIOTEK, V16, P911; TADA T, 1973, J IMMUNOL, V111, P952; TADA T, 1971, J IMMUNOL, V107, P1682; 1971, AEROSPORIN BRAND POL	20	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	2					94	103		10.1016/0091-6749(75)90113-X	http://dx.doi.org/10.1016/0091-6749(75)90113-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AM325	168239	Bronze			2022-12-18	WOS:A1975AM32500002
J	SCHLICHTING, HE				SCHLICHTING, HE			EJECTION OF MICROALGAE INTO AIR VIA BURSTING BUBBLES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									N CAROLINA STATE UNIV, DEPT BOT, RALEIGH, NC 27007 USA	University of North Carolina; North Carolina State University								ADAMS AP, 1970, SCIENCE, V169, P1218, DOI 10.1126/science.169.3951.1218; BENAIMPINTO C, 1972, J ALLERGY CLIN IMMUN, V49, P356, DOI 10.1016/0091-6749(72)90135-2; BERNSTEIN IL, 1970, NATURE, V227, P851, DOI 10.1038/227851a0; BERNSTEIN IL, 1966, J ALLERGY, V38, P166, DOI 10.1016/0021-8707(66)90039-6; BERNSTEIN IL, 1973, USIBP AEROBIOLOGY PR; BEZDEK HF, 1972, LIMNOL OCEANOGR, V17, P566, DOI 10.4319/lo.1972.17.4.0566; BEZDEK HF, 1971, J PHYS CHEM-US, V75, P3623, DOI 10.1021/j100692a024; BLANCHARD DC, 1970, SCIENCE, V170, P626, DOI 10.1126/science.170.3958.626; BLANCHARD DC, 1972, SATURDAY REV, V1, P60; LEDBETTER JO, 1964, WATER SEWAGE WORKS, V111, P62; LOEB GI, 1972, PERSONAL COMMUNICATI; MACINTYRE F, 1968, J PHYS CHEM-US, V72, P589, DOI 10.1021/j100848a034; MAHONEY JL, 1968, THESIS N TEXAS STATE; MASON BJ, 1954, NATURE, V174, P957, DOI 10.1038/174957a0; MAYNARD NG, 1968, Z ALLG MIKROBIOL, V8, P119, DOI 10.1002/jobm.3630080205; MCELHENNEY TR, 1962, ANN ALLERGY, V20, P739; MCGOVERN JP, 1966, ANN ALLERGY, V24, P145; NAPALITANO PJ, 1966, WATER SEWAGE WORKS, V113, P480; PARKER B, 1970, BIOSCIENCE, V20, P87, DOI 10.2307/1294827; SCHLICHTING HE, 1971, BOT MAR, V14, P24; SCHLICHTING HE, 1969, AIR POLLUT CONTROL, V19, P945; WOLFE HW, 1959, SAMPLING MICROBIOLOG, P686; WOODCOCK AH, 1955, SEWAGE IND WASTES, V27, P1189; WOODCOCK AH, 1948, J MAR RES, V7, P56	24	26	26	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	3					185	188		10.1016/0091-6749(74)90006-2	http://dx.doi.org/10.1016/0091-6749(74)90006-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S3550	4813890				2022-12-18	WOS:A1974S355000006
J	DAVIS, DJ				DAVIS, DJ			NIAID INITIATIVES IN ALLERGY RESEARCH	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		HAGH GW, 1966, J ALLERGY, V37, P107; MATERNOWSKI CJ, 1962, J ALLERGY, V33, P130; RHYNE MB, 1971, HEW212 CHILDR BUR PR; RHYNE MB, 1971, H188R HEW CHILD BUR; SHERRY MN, 1968, ANN ALLERGY, V26, P335; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; VANCE VJ, 1971, ANN ALLERGY, V29, P455; 1971, J AM HOSP ASSOC    2, V45, P462; 1971, I CAMPS ASTHMATIC CH; 1970, PRIVATE PRACTICE AST; 1971, 1000 US PUBL HEAL 10	11	26	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	6					323	&		10.1016/0091-6749(72)90130-3	http://dx.doi.org/10.1016/0091-6749(72)90130-3			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6593	5025094				2022-12-18	WOS:A1972M659300001
J	FREEDMAN, SO				FREEDMAN, SO			CARCINOEMBRYONIC ANTIGEN - CURRENT CLINICAL APPLICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		EGAN ML, 1972, IMMUNOCHEMISTRY, V9, P289, DOI 10.1016/0019-2791(72)90093-6; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; HANSEN HJ, 1971, CLIN RES, V19, P53; LOGERFO P, 1971, NEW ENGL J MED, V285, P138, DOI 10.1056/NEJM197107152850302; REYNOSO G, 1972, J AMER MED ASSOC, V220, P361, DOI 10.1001/jama.220.3.361; THOMSON DMP, 1969, P NATL ACAD SCI USA, V64, P161, DOI 10.1073/pnas.64.1.161; ZAMCHECK N, 1972, NEW ENGL J MED, V286, P83, DOI 10.1056/NEJM197201132860207	7	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	6					348	&		10.1016/0091-6749(72)90038-3	http://dx.doi.org/10.1016/0091-6749(72)90038-3			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O2043	4117803				2022-12-18	WOS:A1972O204300004
J	MOORE, RB; PINNEY, MA; COTTON, EK				MOORE, RB; PINNEY, MA; COTTON, EK			EFFECT OF INTERMITTENT POSITIVE-PRESSURE BREATHING ON AIRWAY RESISTANCE IN NORMAL AND ASTHMATIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BRISCOE WA, 1958, J CLIN INVEST, V37, P1279, DOI 10.1172/JCI103715; COHEN AA, 1965, AM J MED SCI, V249, P309, DOI 10.1097/00000441-196503000-00010; Dixon WE, 1903, J PHYSIOL-LONDON, V29, P97; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1958, J CLIN INVEST, V37, P1746, DOI 10.1172/JCI103767; FRANK NR, 1962, J APPL PHYSIOL, V17, P252, DOI 10.1152/jappl.1962.17.2.252; GODDARD RF, 1957, JAMA-J AM MED ASSOC, V163, P1125, DOI 10.1001/jama.1957.02970480029006; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; NADEL JA, 1962, J APPL PHYSIOL, V17, P861, DOI 10.1152/jappl.1962.17.6.861; NADEL JA, 1961, J APPL PHYSIOL, V16, P717, DOI 10.1152/jappl.1961.16.4.717; PETTY TL, 1968, J AMER MED ASSOC, V203, P871, DOI 10.1001/jama.203.10.871; RICHARDS W, 1969, PEDIATR CLIN N AM, V16, P9; SAFAR P, 1965, RESPIRATORY THERAPY; SEGAL MS, 1959, JAMA-J AM MED ASSOC, V169, P1063, DOI 10.1001/jama.1959.73000270005011; SEGAL MS, 1954, NEW ENGL J MED, V250, P225, DOI 10.1056/NEJM195402112500601; SIMMONSSON BG, 1967, J CLIN INVEST, V46, P1812; SLONIM NB, 1967, RESPIRATORY PHYSIOLO; TAYLOR WF, 1966, J ALLERGY, V38, P257, DOI 10.1016/0021-8707(66)90018-9; WELLS RE, 1960, MED CLIN N AM, V44, P1279, DOI 10.1016/S0025-7125(16)33962-1; WELLS RE, 1960, NEW ENGL J MED, V263, P268, DOI 10.1056/NEJM196008112630602; WIDDICOMBE JG, 1962, J APPL PHYSIOL, V17, P613, DOI 10.1152/jappl.1962.17.4.613; WU N, 1954, CLIN RES P, V2, P106; ZOHMAN L, 1958, J ALLERGY, V29, P72, DOI 10.1016/0021-8707(58)90057-1	23	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	3					137	&		10.1016/0091-6749(72)90107-8	http://dx.doi.org/10.1016/0091-6749(72)90107-8			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L8566	4551707				2022-12-18	WOS:A1972L856600001
J	EASTON, JG; BUSSER, RJ; HEIMLICH, EM				EASTON, JG; BUSSER, RJ; HEIMLICH, EM			EFFECT OF ALTERNATE-DAY STEROID ADMINISTRATION ON ADRENAL FUNCTION IN ALLERGIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BUYTENDIJK HJ, 1964, ACTA ENDOCRINOL-COP, V47, P613, DOI 10.1530/acta.0.0470613; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; IMURA H, 1965, J CLIN ENDOCR METAB, V25, P1361, DOI 10.1210/jcem-25-10-1361; LANDON J, 1964, J CLIN ENDOCR METAB, V24, P1206, DOI 10.1210/jcem-24-11-1206; LANGE K, 1958, J AM MED ASS, V168, P337; LANGE K, 1951, NEPHROTIC SYNDROME; MATTINGLY D, 1962, J CLIN PATHOL, V15, P374, DOI 10.1136/jcp.15.4.374; MILBY JC, 1961, AM PRACT, V12, P156; PORTNER MM, 1970, J ALLERGY, V45, P109; SIEGEL SC, 1965, J ALLERGY, V36, P209; SIEGEL SC, 1969, PEDIATR CLIN N AM, V16, P287; SIEGEL SC, 1959, PEDIATRICS, V24, P434; SPENCERP.J, 1965, J ENDOCRINOL, V31, P235, DOI 10.1677/joe.0.0310235; STEENBURG RW, 1964, J CLIN ENDOCR METAB, V24, P875, DOI 10.1210/jcem-24-9-875	14	26	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	6					355	&		10.1016/0091-6749(71)90081-9	http://dx.doi.org/10.1016/0091-6749(71)90081-9			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L0384	4330394				2022-12-18	WOS:A1971L038400004
J	MALLEY, A; WILSON, BJ; BARNETT, M; PERLMAN, F				MALLEY, A; WILSON, BJ; BARNETT, M; PERLMAN, F			SITE OF ACTION OF ANTIGEN-D IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		CAMPBELL DH, 1963, METHOD IMMUNOL, P141; CLAMAN HN, 1966, P SOC EXP BIOL MED, V122, P1167; FANGER MW, 1970, J IMMUNOL, V105, P1484; FRANCIS TC, 1970, NATURE, V226, P173, DOI 10.1038/226173a0; GIRARD JP, 1967, J ALLERGY, V39, P65, DOI 10.1016/0021-8707(67)90113-X; GREY I, 1969, IMMUNOLOGY, V16, P381; MACKLER BF, 1970, FED PROC, V29, pA369; MACKLER BF, IN PRESS; MACKLER BF, 1970, THESIS U OREGON; MALLEY A, 1970, J ALLERGY, V45, P14, DOI 10.1016/0021-8707(70)90013-4; MALLEY A, 1967, J IMMUNOL, V99, P825; METZGER H, 1970, ANNU REV BIOCHEM, V39, P889, DOI 10.1146/annurev.bi.39.070170.004325; MITCHELL BG, 1968, P NATL ACAD SCI USA, V59, P296, DOI 10.1073/pnas.59.1.296; MOSIER DE, 1968, P NATL ACAD SCI USA, V61, P542, DOI 10.1073/pnas.61.2.542; OPPENHEIM JJ, 1967, IMMUNOLOGY, V12, P89; PERLMAN F, 1968, J ALLERGY, V41, P114; RICHTER M, 1968, J ALLERGY, V41, P140, DOI 10.1016/0021-8707(68)90054-3; SELL S, 1970, FED PROC, V29, pA301; SELL S, 1967, J IMMUNOL, V98, P786; SHEARER GM, 1969, J EXP MED, V129, P185, DOI 10.1084/jem.129.1.185; WIENER S, 1965, Med J Aust, V1, P148; WOODRUFF MF, 1967, NATURE, V215, P591, DOI 10.1038/215591a0; ZEITZ SJ, 1966, J ALLERGY, V38, P321, DOI 10.1016/0021-8707(66)90030-X	23	26	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	5					267	+		10.1016/0091-6749(71)90027-3	http://dx.doi.org/10.1016/0091-6749(71)90027-3			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K7978	5285776				2022-12-18	WOS:A1971K797800003
J	SLAVIN, RG; LEWIS, CR				SLAVIN, RG; LEWIS, CR			SENSITIVITY TO ENZYME ADDITIVES IN LAUNDRY DETERGENT WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BELIN L, 1970, LANCET, V2, P1153; FLINDT MLH, 1969, LANCET, V1, P1177; FRANZ J, 1971, J ALLERGY, V47, P170; MONTE V, 1970, EXCERPTA MEDICA  211, P14; NEWHOUSE ML, 1970, LANCET, V1, P689; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PEPYS J, 1969, LANCET, V1, P1181; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160	8	26	26	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	5					262	&		10.1016/0091-6749(71)90026-1	http://dx.doi.org/10.1016/0091-6749(71)90026-1			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K7978	4255272	Bronze			2022-12-18	WOS:A1971K797800002
J	Thalhammer, J; Kindle, G; Nieters, A; Rusch, S; Seppanen, MRJ; Fische, A; Grimbacher, B; Edgar, D; Buckland, M; Mahlaoui, N; Ehl, S				Thalhammer, Julian; Kindle, Gerhard; Nieters, Alexandra; Rusch, Stephan; Seppanen, Mikko R. J.; Fische, Alain; Grimbacher, Bodo; Edgar, David; Buckland, Matthew; Mahlaoui, Nizar; Ehl, Stephan			Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; inborn error of immunity; presenting symptom; immune dysregulation; autoimmune; inflamma-tory; syndromic; warning signs; registry	PRIMARY IMMUNODEFICIENCY DISEASES; 10 WARNING SIGNS; DEFICIENCY; REGISTRY; COMMON; TIME	Background: Inborn errors of immunity (IEI) are rare diseases, which makes diagnosis a challenge. A better description of the initial presenting manifestations should improve awareness and avoid diagnostic delay. Although increased infection susceptibility is a well-known initial IEI manifestation, less is known about the frequency of other presenting manifestations. Objective: We sought to analyze age-related initial presenting manifestations of IEI including different IEI disease cohorts. Methods: We analyzed data on 16,486 patients of the European Society for Immunodeficiencies Registry. Patients with autoinflammatory diseases were excluded because of the limited number registered. Results: Overall, 68% of patients initially presented with infections only, 9% with immune dysregulation only, and 9% with a combination of both. Syndromic features were the presenting feature in 12%, 4% had laboratory abnormalities only, 1.5% were diagnosed because of family history only, and 0.8% presented with malignancy. Two-third of patients with IEI presented before the age of 6 years, but a quarter of patients developed initial symptoms only as adults. Immune dysregulation was most frequently recognized as an initial IEI manifestation between age 6 and 25 years, with male predominance until age 10 years, shifting to female predominance after age 40 years. Infections were most prevalent as a first manifestation in patients presenting after age 30 years. Conclusions: An exclusive focus on infection-centered warning signs would have missed around 25% of patients with IEI who initially present with other manifestations. (J Allergy Clin Immunol 2021;148:1332-41.)	[Thalhammer, Julian; Kindle, Gerhard; Nieters, Alexandra; Rusch, Stephan; Grimbacher, Bodo; Ehl, Stephan] Univ Freiburg, Fac Med, Ctr Chron Immunodeficiency, Inst Immunodeficiency,Med Ctr, Freiburg, Germany; [Thalhammer, Julian] Univ Freiburg, Ctr Pediat, Med Ctr, Fac Med, Freiburg, Germany; [Seppanen, Mikko R. J.] Univ Helsinki, Hosp Children, Rare Dis & Pediat Res Ctr, Helsinki, Finland; [Seppanen, Mikko R. J.] Univ Helsinki, Adolescents & Adult Immunodeficiency Unit, Inflammat Ctr, Helsinki, Finland; [Seppanen, Mikko R. J.] Univ Hosp, HUS Helsinki, Helsinki, Finland; [Fische, Alain; Mahlaoui, Nizar] Necker Enfants Malad Univ Hosp, AP HP, Pediat Immunohaematol & Rheumatol Unit, Paris, France; [Fische, Alain; Mahlaoui, Nizar] Necker Enfants Malad Univ Hosp, AP HP, French Natl Reference Ctr Primary Immune Deficien, Paris, France; [Grimbacher, Bodo] Satellite Ctr Freiburg, DZIF German Ctr Infect Res, Freiburg, Germany; [Grimbacher, Bodo; Ehl, Stephan] Albert Ludwigs Univ, CIBSS Ctr Integrat Biol Signalling Studies, Freiburg, Germany; [Grimbacher, Bodo] Hanover Med Sch, RESIST Cluster Excellence 2155, Satellite Ctr Freiburg, Freiburg, Germany; [Edgar, David] St James Hosp, Dublin, Ireland; [Edgar, David] Trinity Coll Dublin, Dublin, Ireland; [Buckland, Matthew] UCL, Inst Immun & Transplantat, London, England; [Buckland, Matthew] Royal Free London NHS Fdn Trust, Dept Immunol, London, England	University of Freiburg; University of Freiburg; University of Helsinki; University of Helsinki; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; German Center for Infection Research; University of Freiburg; Hannover Medical School; Trinity College Dublin; Trinity College Dublin; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust	Ehl, S (corresponding author), Univ Med Ctr, Inst Immunodeficiency, Breisacher Str 115, D-79106 Freiburg, Germany.	stephan.ehl@uniklinik-freiburg.de	Körholz, Julia/ABA-2133-2020; Olbrich, Peter/AAV-3601-2021; Abolhassani, Hassan/B-3465-2014; Binder, Nadine/AAP-6261-2021; Buckland, Matthew/H-7049-2019; Scheible, Raphael/R-1731-2019; Gambineri, Eleonora/J-8747-2016; Müller, Ingo/AAW-9025-2021; Farmaki, Evangelia/AAA-6768-2022; Boyarchuk, Oksana/GSD-2473-2022; Metzler, Markus/AAS-2066-2021; Sobh, Ali/Q-6160-2016; Richter, Darko/AAJ-8861-2020; Kostyuchenko, Larysa/P-1827-2019; Sanchez-Ramon, Silvia/AAZ-7670-2020; /K-2737-2018; Seidel, Markus G/N-9951-2017; Reichenbach, Janine/U-2171-2018; Cesaro, Simone/F-8118-2019	Olbrich, Peter/0000-0001-9853-7903; Abolhassani, Hassan/0000-0002-4838-0407; Binder, Nadine/0000-0002-1919-4154; Buckland, Matthew/0000-0002-5646-4707; Scheible, Raphael/0000-0003-2067-5569; Gambineri, Eleonora/0000-0002-4676-6541; Müller, Ingo/0000-0002-7477-6632; Boyarchuk, Oksana/0000-0002-1234-0040; Metzler, Markus/0000-0002-4523-1676; Sobh, Ali/0000-0001-7047-076X; Richter, Darko/0000-0002-6559-9056; Kostyuchenko, Larysa/0000-0002-0262-1359; Sanchez-Ramon, Silvia/0000-0001-9585-6167; Ekwall, Olov/0000-0002-4506-9955; Maccari, Maria Elena/0000-0001-6488-7622; Litzman, Jiri/0000-0002-1926-5426; /0000-0001-7140-1694; Landwehr-Kenzel, Sybille/0000-0002-4836-7659; Yong, Patrick/0000-0003-1736-2756; Fasth, Anders/0000-0002-0033-740X; Thalhammer, Julian/0000-0002-0226-1955; Goda, Vera/0000-0002-0757-538X; Hanitsch, Leif G./0000-0002-8181-0093; Garcez, Tomaz/0000-0002-8106-0480; Seidel, Markus G/0000-0003-0981-8661; Danieli, Maria Giovanna/0000-0002-9608-2252; Klemann, Christian/0000-0002-5639-8690; Kolios, Antonios/0000-0002-3897-4578; Hilfanova, Anna/0000-0002-2541-0327; Schneider, Dominik T./0000-0001-8153-1601; Bredius, Robbert/0000-0001-8151-1539; Reichenbach, Janine/0000-0002-9008-1312; Seppanen, Mikko/0000-0001-9733-3650; Gabzdilova, Juliana/0000-0002-8125-1885; Leahy, Timothy Ronan/0000-0001-6419-9328; Cesaro, Simone/0000-0002-8698-9547; Antoli Gil, Arnau/0000-0003-4576-1308; El Hawary, Rabab/0000-0001-6244-0288; Solanich, Xavier/0000-0002-2572-2187	German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung [BMBF]) [01GM0896, 01GM1111B, 01GM1517C, 01EO1303, 01ZZ1801B]; European Union [HEALTH-F2-2008-201549]; Novartis; GlaxoSmithKline; LFB; UCB UK; Pharming; Plasma Protein Therapeutics Association; Care-for-Rare Foundation; PROimmune e.V.; ERN RITA; European Society for Immunodeficiencies	German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung [BMBF])(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); LFB; UCB UK; Pharming; Plasma Protein Therapeutics Association; Care-for-Rare Foundation; PROimmune e.V.; ERN RITA; European Society for Immunodeficiencies	The European Society for Immunodeficiencies Registry was supported by the German Federal Ministry of Education and Research (Bundesministerium f_ur Bildung und Forschung [BMBF] grant nos. 01GM0896, 01GM1111B, 01GM1517C, 01EO1303, and 01ZZ1801B), the European Union (grant no. HEALTH-F2-2008-201549 [EUROPADnet]), the pharmaceutical companies Novartis, GlaxoSmithKline, LFB, UCB UK, and Pharming, the Plasma Protein Therapeutics Association, the Care-for-Rare Foundation, PROimmune e.V., ERN RITA, and the European Society for Immunodeficiencies (www.ESID.org).	Abolhassani H, 2020, EXPERT REV CLIN IMMU, V16, P717, DOI 10.1080/1744666X.2020.1801422; Al-Herz W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01754; Arkwright PD, 2011, ANN NY ACAD SCI, V1238, P7, DOI 10.1111/j.1749-6632.2011.06206.x; Arslan S, 2016, ANN ALLERG ASTHMA IM, V116, P151, DOI 10.1016/j.anai.2015.12.001; Baumann U, 2010, PRIMARE IMMUNDEFEKTE; Bjelac JA, 2019, J CLIN IMMUNOL, V39, P90, DOI 10.1007/s10875-018-0582-z; Bousfiha AA, 2013, J CLIN IMMUNOL, V33, P1, DOI 10.1007/s10875-012-9751-7; Chellapandian D, 2020, IMMUNOL ALLERGY CLIN, V40, P511, DOI 10.1016/j.iac.2020.04.001; Costa-Carvalho BT, 2014, J CLIN IMMUNOL, V34, P10, DOI 10.1007/s10875-013-9954-6; Cunningham-Rundles C, 2011, CLIN EXP IMMUNOL, V164, P6, DOI 10.1111/j.1365-2249.2011.04388.x; El-Helou SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01272; Elsink K, 2020, CLIN IMMUNOL, V213, DOI 10.1016/j.clim.2020.108359; Erjaee A, 2019, SAMJ S AFR MED J, V109, pS4, DOI 10.7196/SAMJ.2019.v109i8b.13820; Farmand S, 2011, KLIN PADIATR, V223, P378, DOI 10.1055/s-0031-1287835; Farmand S, 2017, ABKLARUNG INFEKTIONS; Fischer A, 2017, J ALLERGY CLIN IMMUN, V140, P1388, DOI 10.1016/j.jaci.2016.12.978; Gambineri E, 2012, CELL MOL LIFE SCI, V69, P49, DOI 10.1007/s00018-011-0838-8; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Grimbacher Bodo, 2016, J Allergy Clin Immunol, V137, P3, DOI 10.1016/j.jaci.2015.11.004; Heitzeneder S, 2012, CLIN IMMUNOL, V143, P22, DOI 10.1016/j.clim.2011.11.002; Joshi AY, 2009, MAYO CLIN PROC, V84, P16, DOI [10.4065/84.1.16, 10.1016/S0025-6196(11)60802-1]; Lankisch P, 2015, J CLIN IMMUNOL, V35, P273, DOI 10.1007/s10875-015-0149-1; Mahlaoui N, 2017, J ALLERGY CLIN IMMUN, V140, P1731, DOI 10.1016/j.jaci.2017.06.020; Mauracher AA, J ALLERGY CLIN IMMUN, V9; Modell V, 2011, IMMUNOL RES, V51, P61, DOI 10.1007/s12026-011-8241-y; O'Sullivan MD, 2012, CURR OPIN ALLERGY CL, V12, P588, DOI 10.1097/ACI.0b013e3283591534; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Pilania RK, 2020, GENES DIS, V7, P3, DOI 10.1016/j.gendis.2019.09.004; Puck JM, 2019, IMMUNOL REV, V287, P241, DOI 10.1111/imr.12729; Schatorje E, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0492-1; Scheible R, 2019, BIOINFORMATICS, V35, P5367, DOI 10.1093/bioinformatics/btz525; Shillitoe B, 2018, CLIN EXP IMMUNOL, V192, P284, DOI 10.1111/cei.13125; Subbarayan A, 2011, PEDIATRICS, V127, P810, DOI 10.1542/peds.2010-3680; Tangye SG, 2020, J CLIN IMMUNOL, V40, P65, DOI 10.1007/s10875-020-00763-0; Toplak N, 2012, ANN RHEUM DIS, V71, P1177, DOI 10.1136/annrheumdis-2011-200549	35	25	25	4	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2021	148	5					1332	+		10.1016/j.jaci.2021.04.015	http://dx.doi.org/10.1016/j.jaci.2021.04.015		NOV 2021	15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WV8FQ	33895260	Green Submitted			2022-12-18	WOS:000717466600004
J	Dribin, TE; Schnadower, D; Spergel, JM; Campbell, RL; Shaker, M; Neuman, MI; Michelson, KA; Capucilli, PS; Camargo, CA; Brousseau, DC; Rudders, SA; Assa'ad, AH; Risma, KA; Castells, M; Schneider, LC; Wang, J; Lee, J; Mistry, RD; Vyles, D; Pistiner, M; Witry, JK; Zhang, Y; Sampson, HA				Dribin, Timothy E.; Schnadower, David; Spergel, Jonathan M.; Campbell, Ronna L.; Shaker, Marcus; Neuman, Mark I.; Michelson, Kenneth A.; Capucilli, Peter S.; Camargo, Carlos A., Jr.; Brousseau, David C.; Rudders, Susan A.; Assa'ad, Amal H.; Risma, Kimberly A.; Castells, Mariana; Schneider, Lynda C.; Wang, Julie; Lee, Juhee; Mistry, Rakesh D.; Vyles, David; Pistiner, Michael; Witry, John K.; Zhang, Yin; Sampson, Hugh A.			Severity grading system for acute allergic reactions: A multidisciplinary Delphi study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic reactions; anaphylaxis; Delphi; emergency department; severity	INTERNATIONAL CONSENSUS DEFINITIONS; ANAPHYLACTIC REACTIONS; SEPTIC SHOCK; SEPSIS; FOOD; RISK	Background: There is no widely adopted severity grading system for acute allergic reactions, including anaphylactic and nonanaphylactic reactions, thus limiting the ability to optimize and standardize management practices and advance research. Objective: The aim of this study was to develop a severity grading system for acute allergic reactions for use in clinical care and research. Methods: From May to September 2020, we convened a 21 member multidisciplinary panel of allergy and emergency care experts; 9 members formed a writing group to critically appraise and assess the strengths and limitations of prior severity grading systems and develop the structure and content for an optimal severity grading system. The entire study panel then revised the grading system and sought consensus by utilizing Delphi methodology. Results: The writing group recommended that an optimal grading system encompass the severity of acute allergic reactions on a continuum from mild allergic reactions to anaphylactic shock. Additionally, the severity grading system must be able to discriminate between clinically important & nbsp;differences in reaction severity to be relevant in research while also being intuitive and straightforward to apply in clinical care. Consensus was reached for all elements of the proposed severity grading system. Conclusion: We developed a consensus severity grading system for acute allergic reactions, including anaphylactic and nonanaphylactic reactions. Successful international validation, refinement, dissemination, and application of the grading system will improve communication among providers and patients about the severity of allergic reactions and will help advance future research. (J Allergy Clin Immunol 2021;148:173-81.)	[Dribin, Timothy E.; Schnadower, David; Witry, John K.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Assa'ad, Amal H.; Risma, Kimberly A.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Zhang, Yin] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Dribin, Timothy E.; Schnadower, David; Assa'ad, Amal H.; Risma, Kimberly A.] Univ Cincinnati Coll Med, Dept Pediat, Cincinnati, OH USA; [Spergel, Jonathan M.; Lee, Juhee] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Campbell, Ronna L.] Mayo Clin, Dept Emergency Med, Rochester, MN USA; [Shaker, Marcus] Dartmouth Geisel Sch Med, Hanover, NH USA; [Shaker, Marcus] Dartmouth Hitchcock Med Ctr, Hanover, NH USA; [Neuman, Mark I.; Michelson, Kenneth A.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Rudders, Susan A.; Schneider, Lynda C.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Neuman, Mark I.; Michelson, Kenneth A.; Schneider, Lynda C.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Camargo, Carlos A., Jr.] Harvard Med Sch, Dept Emergency Med, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Pistiner, Michael] Harvard Med Sch, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Castells, Mariana] Harvard Med Sch, Brigham & Womens Hosp, Div Allergy & Clin Immunol, Dept Med, Boston, MA 02115 USA; [Capucilli, Peter S.] Rochester Reg Hlth, Rochester, NY USA; [Brousseau, David C.; Vyles, David] Med Coll Wisconsin, Dept Pediat, Sect Pediat Emergency Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Wang, Julie; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Div Allergy & Immunol, New York, NY 10029 USA; [Mistry, Rakesh D.] Childrens Hosp Colorado, Sect Emergency Med, Dept Pediat, Aurora, CO USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Mayo Clinic; Dartmouth College; Dartmouth College; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Medical College of Wisconsin; Icahn School of Medicine at Mount Sinai; Children's Hospital Colorado	Dribin, TE (corresponding author), Cincinnati Childrens Hosp, 3244 Burnet Ave, Cincinnati, OH 45229 USA.	Timothy.Dribin@cchmc.org	Schneider, Lynda C/AAY-6545-2021; Camargo, Carlos A./C-2145-2008	Schneider, Lynda C/0000-0002-5633-0178; Camargo, Carlos A./0000-0002-5071-7654; Zhang, Yin/0000-0002-6127-7535	Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center	Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center	Supported by the Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center.	Andorf S, 2018, LANCET GASTROENTEROL, V3, P85, DOI 10.1016/S2468-1253(17)30392-8; Bilaver LA, 2019, ANN ALLERG ASTHMA IM, V122, P373, DOI 10.1016/j.anai.2019.01.014; Boateng GO, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00149; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Cox LS, 2017, J ALLER CL IMM-PRACT, V5, P58, DOI 10.1016/j.jaip.2016.11.009; Dribin TE, 2020, J ALLERGY CLIN IMMUN, V146, P1089, DOI 10.1016/j.jaci.2020.08.015; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fitch K, 2001, RAND UCLA APPROPRIAT; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252, DOI 10.1016/S1081-1206(10)60714-4; Greenhawt M, 2019, J ALLER CL IMM-PRACT, V7, P1148, DOI 10.1016/j.jaip.2018.10.052; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Ishoo E, 1999, OTOLARYNG HEAD NECK, V121, P263, DOI 10.1016/S0194-5998(99)70182-8; Korosec P, 2017, J ALLERGY CLIN IMMUN, V140, P750, DOI 10.1016/j.jaci.2016.12.989; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Mehta S, 2017, AM J RESP CRIT CARE, V196, P425, DOI 10.1164/rccm.201701-0076CP; Michelson KA, 2020, J ALLER CL IMM-PRACT, V8, P767, DOI 10.1016/j.jaip.2019.07.018; Muraro A, 2018, ALLERGY, V73, P1792, DOI 10.1111/all.13408; Niggemann B, 2016, ALLERGY, V71, P135, DOI 10.1111/all.12765; Pistiner M, 2021, J ALLER CL IMM-PRACT, V9, DOI 10.1016/j.jaip.2020.11.005; Sampson HA, 2003, PEDIATRICS, V111, P1601; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Shaker MS, 2020, J ALLERGY CLIN IMMUN, V145, P1082, DOI 10.1016/j.jaci.2020.01.017; Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Stone SF, 2009, J ALLERGY CLIN IMMUN, V124, P786, DOI 10.1016/j.jaci.2009.07.055; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Turner PJ, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100066; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Ye YM, 2015, ALLERGY ASTHMA IMMUN, V7, P22, DOI 10.4168/aair.2015.7.1.22	38	25	25	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2021	148	1					173	181		10.1016/j.jaci.2021.01.003	http://dx.doi.org/10.1016/j.jaci.2021.01.003		JUL 2021	9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE3IE	33476673	Green Accepted			2022-12-18	WOS:000669906700025
J	Navrazhina, K; Frew, JW; Gilleaudeau, P; Sullivan-Whalen, M; Garcet, S; Krueger, JG				Navrazhina, Kristina; Frew, John W.; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Garcet, Sandra; Krueger, James G.			Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hidradenitis suppurativa; IL-17; neutrophils; brodalumab	EXPRESSION; REGULATOR; PATHWAY; LESIONS; SKIN	Background: Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, painful, and burdensome inflammatory disease manifesting in nodules and abscesses, with progression to chronically draining tunnels in later-stage disease. Objective: We sought to determine whether HS tunnels are immunologically active participants in disease activity. Methods: Skin biopsy specimens were obtained by using ultrasound guidance in untreated patients with HS and those enrolled in an open-label study of brodalumab (ClinicalTrials.gov identifier NCT03960268) for patients with moderate-to-severe HS. Results: Immunohistochemistry of HS biopsy specimens demonstrated that the epithelialized HS tunnels recapitulate the psoriasiform epidermal hyperplasia morphology of the overlying epidermis, displaying molecular inflammation, including S100A7 (psoriasin) positivity, as well as features of epidermal skin, including loricrin, filaggrin, lipocalin-2, and Melan-A positive cells. Tunnels were associated with increased infiltration of T cells, dendritic cells, and neutrophils; formation of neutrophil extracellular traps, and increased expression of psoriasiform proinflammatory cytokines. Unsupervised hierarchical clustering demonstrated a separation of HS samples based on the presence or absence of tunnels. Tunnels isolated by microdissection had higher levels of epithelium derived inflammatory cytokines compared with the overlying epidermis and healthy controls. Clinically, the size and draining of the tunnels were decreased with treatment with the IL-17RA antagonist brodalumab. Conclusion: These data suggest that tunnels are a source of inflammation in HS. (J Allergy Clin Immunol 2021;147:2213-24.)	[Navrazhina, Kristina; Frew, John W.; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Garcet, Sandra; Krueger, James G.] Rockefeller Univ, Lab Investigative Dermatol, 1230 York Ave, New York, NY 10065 USA; [Navrazhina, Kristina] Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY USA	Rockefeller University	Krueger, JG (corresponding author), Rockefeller Univ, Lab Investigative Dermatol, 1230 York Ave, New York, NY 10065 USA.	jgk@rockefeller.edu			Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health [T32GM007739]; National Center for Advancing Translational Sciences, National Institutes of Health Clinical and Translational Science Award Program [UL1 TR001866]; Shapiro-Silverberg Fund for the Advancement of Translational Research; Hidradenitis Suppurativa Foundation Danby Grant	Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health; National Center for Advancing Translational Sciences, National Institutes of Health Clinical and Translational Science Award Program; Shapiro-Silverberg Fund for the Advancement of Translational Research; Hidradenitis Suppurativa Foundation Danby Grant	K.N. was supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health under award number T32GM007739 to the Weill Cornell/Rockefeller/Sloan Kettering TriInstitutional MD-PhD Program. J.W.F. and J.G.K. were supported in part by grant UL1 TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health Clinical and Translational Science Award Program. J.W.F. was supported by the Shapiro-Silverberg Fund for the Advancement of Translational Research and the Hidradenitis Suppurativa Foundation Danby Grant.	Berends ETM, 2010, J INNATE IMMUN, V2, P576, DOI 10.1159/000319909; Byrd AS, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5908; Byrd AS, 2013, J IMMUNOL, V190, P4136, DOI 10.4049/jimmunol.1202671; Coates M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216249; Deckers IE, 2016, DERMATOL CLIN, V34, P17, DOI 10.1016/j.det.2015.07.003; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Folgueras AR, 2013, CELL STEM CELL, V13, P314, DOI 10.1016/j.stem.2013.06.018; Frew JW, 2019, BRIT J DERMATOL, V181, P1339, DOI 10.1111/bjd.18309; Frew JW, 2020, J INVEST DERMATOL, V140, P1323, DOI 10.1016/j.jid.2020.02.014; Frew JW, 2020, J AM ACAD DERMATOL, V83, P1341, DOI 10.1016/j.jaad.2020.05.007; Frew JW, 2020, J AM ACAD DERMATOL, V82, P1150, DOI 10.1016/j.jaad.2019.12.044; Frew JW, 2019, EXP DERMATOL, V28, P886, DOI 10.1111/exd.13978; Frew John W, 2018, F1000Res, V7, P1930, DOI 10.12688/f1000research.17267.1; Garg A, 2018, J INVEST DERMATOL, V138, P2152, DOI 10.1016/j.jid.2018.04.001; Garg A, 2017, JAMA DERMATOL, V153, P760, DOI 10.1001/jamadermatol.2017.0201; Garg A, 2017, J AM ACAD DERMATOL, V77, P118, DOI 10.1016/j.jaad.2017.02.005; Ge YJ, 2017, CELL, V169, P636, DOI 10.1016/j.cell.2017.03.042; Gill Liza, 2014, F1000Prime Rep, V6, P112, DOI 10.12703/P6-112; Goldburg SR, 2020, J AM ACAD DERMATOL, V82, P1061, DOI 10.1016/j.jaad.2019.08.089; Goldburg SR, 2020, J AM ACAD DERMATOL, V82, P1045, DOI 10.1016/j.jaad.2019.08.090; Gooderham M, 2015, J AM ACAD DERMATOL, V73, pS19, DOI 10.1016/j.jaad.2015.07.054; Grand D, 2021, BRIT J DERMATOL, V184, P688, DOI 10.1111/bjd.19343; Hawkes JE, 2018, J IMMUNOL, V201, P1605, DOI 10.4049/jimmunol.1800013; Jemec GBE, 2015, J AM ACAD DERMATOL, V73, pS4, DOI 10.1016/j.jaad.2015.07.052; Jenei A, 2019, J INVEST DERMATOL, V139, P964, DOI 10.1016/j.jid.2018.10.020; Juneau RA, 2011, INFECT IMMUN, V79, P431, DOI 10.1128/IAI.00660-10; Kadaja M, 2014, GENE DEV, V28, P328, DOI 10.1101/gad.233247.113; Kidacki M, 2019, BRIT J DERMATOL, V181, P192, DOI 10.1111/bjd.17541; Kimball AB, 2016, NEW ENGL J MED, V375, P422, DOI 10.1056/NEJMoa1504370; Kokolakis G, 2020, DERMATOLOGY, V236, P421, DOI 10.1159/000508787; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Krueger JG, 2019, J ALLERGY CLIN IMMUN, V144, P750, DOI 10.1016/j.jaci.2019.04.029; Kurzen H, 1999, BRIT J DERMATOL, V141, P231; Margesson LJ, 2014, BEST PRACT RES CL OB, V28, P1013, DOI 10.1016/j.bpobgyn.2014.07.012; Navrazhina K, 2020, BRIT J DERMATOL, V182, P1045, DOI 10.1111/bjd.18556; Ofenloch RF, 2017, BRIT J DERMATOL, V176, P861, DOI 10.1111/bjd.15448; Quartey QQ, 2020, CLIN EXP DERMATOL, V45, P202, DOI 10.1111/ced.14054; Ring HC, 2017, BRIT J DERMATOL, V176, P993, DOI 10.1111/bjd.15007; Sabat R, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0149-1; Saunte DML, 2017, JAMA-J AM MED ASSOC, V318, P2019, DOI 10.1001/jama.2017.16691; Schlapbach C, 2011, J AM ACAD DERMATOL, V65, P790, DOI 10.1016/j.jaad.2010.07.010; Schneider MR, 2014, CELL TISSUE RES, V358, P697, DOI 10.1007/s00441-014-1999-1; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; Suarez-Farinas M, 2012, J INVEST DERMATOL, V132, P2552, DOI 10.1038/jid.2012.184; van der Zee HH, 2012, DERMATOLOGY, V225, P9, DOI 10.1159/000339773; Vanlaerhoven AMJD, 2018, DERMATOLOGY, V234, P232, DOI 10.1159/000491547; von Laffert M, 2011, BRIT J DERMATOL, V164, P367, DOI 10.1111/j.1365-2133.2010.10034.x; von Laffert M, 2010, EXP DERMATOL, V19, P533, DOI 10.1111/j.1600-0625.2009.00915.x; Vossen ARJV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02965; Witte-Handel E, 2019, J INVEST DERMATOL, V139, P1294, DOI 10.1016/j.jid.2018.11.018; Wolk K, 2017, BRIT J DERMATOL, V177, P1385, DOI 10.1111/bjd.15424; Zouboulis CC, 2020, J EUR ACAD DERMATOL, V34, P846, DOI 10.1111/jdv.16147; Zouboulis CC, 2015, J EUR ACAD DERMATOL, V29, P619, DOI 10.1111/jdv.12966	54	25	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2213	2224		10.1016/j.jaci.2020.12.651	http://dx.doi.org/10.1016/j.jaci.2020.12.651		JUN 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7MD	33548397	Green Accepted			2022-12-18	WOS:000657783800002
J	Demoly, P; Corren, J; Creticos, P; De Blay, F; Gevaert, P; Hellings, P; Kowal, K; Le Gall, M; Nenasheva, N; Passalacqua, G; Pfaar, O; Tortajada-Girbes, M; Vidal, C; Worm, M; Casale, TB				Demoly, Pascal; Corren, Jonathan; Creticos, Peter; De Blay, Frederic; Gevaert, Philippe; Hellings, Peter; Kowal, Krzysztof; Le Gall, Martine; Nenasheva, Natalia; Passalacqua, Giovanni; Pfaar, Oliver; Tortajada-Girbes, Miguel; Vidal, Carmen; Worm, Margitta; Casale, Thomas B.			A 300 IR sublingual tablet is an effective, safe treatment for house dust mite?induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen immunotherapy; allergic rhinitis; allergy; house-dust mite; sublingual immunotherapy; tablet; total combined score; symptom score; medication score	IMMUNOTHERAPY TABLET; EFFICACY; RHINOCONJUNCTIVITIS; ADULTS; GUIDELINES; CONSENSUS; IMPACT; STANDARDIZATION; OUTCOMES; BENEFIT	Background: Allergic rhinitis induced by house dust mites (HDMs) is a highly prevalent but often underdiagnosed and undertreated/untreated chronic disease. It often has a negative impact on sleep, work, leisure activities, and health-related quality of life. Allergen immunotherapy is a proven, safe treatment for respiratory allergies. Objective: We sought to assess the efficacy and safety of a 300 index of reactivity (IR) sublingual tablet formulation of Dermatophagoides pteronyssinus:Dermatophagoides farinae 1:1 extract in adolescents (aged >_12) and adults with moderate to severe HDM-induced allergic rhinitis. Methods: In a phase III, international, double-blind, placebo controlled, randomized clinical trial, participants received approximately 12 months of treatment with placebo or the 300 IR tablet. The primary end point was the average total combined score during 4 weeks at the end of the treatment period. Results: A total of 1607 participants were randomized, and 1476 (including 555 [37.6%] with concomitant mild controlled asthma at inclusion) comprised the full analysis set. Over the primary evaluation period, the least squares mean average total combined score in the 300 IR group (3.62) was significantly lower (P <.0001) than in the placebo group (4.35), with a relative least squares mean difference of -16.9% (95% CI, -24.0% to -9.2%). All prespecified secondary end points were consistently improved in the 300 IR group, relative to placebo. The 300 IR tablet was generally well tolerated. Treatment related adverse events (mainly mild or moderate local reactions) were reported for 51.0% of the patients in the 300 IR group and 14.9% in the placebo group. Conclusions: The 300 IR sublingual HDM tablet is an effective, safe treatment for HDM-induced allergic rhinitis. (J Allergy Clin Immunol 2021;147:1020-30.) <comment>Superscript/Subscript Available</comment	[Demoly, Pascal] Montpellier Univ, Arnaud Villeneuve Hosp, Dept Pulmonol & Addictol, Montpellier, France; [Demoly, Pascal] Sorbonne Univ, EPAR Team, IPLESP, INSERM,UMR S 1136, Paris, France; [Corren, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Corren, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; [Creticos, Peter] Johns Hopkins Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Creticos, Peter] Creticos Res Grp Charleston Allergy & Asthma, Charleston, SC USA; [De Blay, Frederic] Strasbourg Univ Hosp, Div Allergy, Chest Dis Dept, Strasbourg, France; [Gevaert, Philippe] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Hellings, Peter] Univ Hosp Leuven, Dept Otorhinolaryngol, Leuven, Belgium; [Kowal, Krzysztof] Med Univ Bialystok, Dept Expt Allergol & Immunol, Bialystok, Poland; [Le Gall, Martine] Stallergenes Greer, Global Clin Dev Dept, Antony, France; [Nenasheva, Natalia] Minist Hlth, Russian Med Acad Continuous Profess Educ, Moscow, Russia; [Passalacqua, Giovanni] Univ Genoa, IRCCS Policlin S Martino, Allergy & Resp Dis, Genoa, Italy; [Pfaar, Oliver] Philipps Univ Marburg, Univ Hosp Marburg, Sect Rhinol & Allergy, Dept Otorhinolaryngol Head & Neck Surg, Marburg, Germany; [Tortajada-Girbes, Miguel] Dr Peset Univ Hosp, Dept Pediat, Pediat Pulmonol & Allergy Unit, Valencia, Spain; [Tortajada-Girbes, Miguel] Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia, Spain; [Tortajada-Girbes, Miguel] IVI Fdn, Valencia, Spain; [Vidal, Carmen] Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Dept Allergy, Fac Med, Santiago De Compostela, Spain; [Worm, Margitta] Charite, Div Allergy & Immunol, Dept Dermatol Allergy & Venerol, Berlin, Germany; [Casale, Thomas B.] Univ S Florida, Div Allergy & Immunol, Tampa, FL 33620 USA	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Johns Hopkins Medicine; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Ghent University; KU Leuven; University Hospital Leuven; Medical University of Bialystok; Stallergenes Greer; Ministry of Health of the Russian Federation; University of Genoa; Philipps University Marburg; University Hospital of Giessen & Marburg; University of Valencia; University of Valencia; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; State University System of Florida; University of South Florida	Demoly, P (corresponding author), Hop Arnaud Villeneuve, Dept Pneumol & Addictol, 371 Rue Doyen Gaston Giraud, F-34295 Montpellier 5, France.	pascal.demoly@inserm.fr	Demoly, Pascal/Y-9938-2019; Gevaert, Philippe/ABA-4588-2021	Demoly, Pascal/0000-0001-7827-7964; /0000-0002-0910-1292; Worm, Margitta/0000-0002-3449-1245	Stallergenes Greer (Antony, France)	Stallergenes Greer (Antony, France)	The study was sponsored and funded by Stallergenes Greer (Antony, France).	Asthma G., 2020, GLOB STRAT ASTHM MAN; Batard T, 2016, ALLERGY, V71, P220, DOI 10.1111/all.12796; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Blaiss MS, 2018, ANN ALLERG ASTHMA IM, V121, P43, DOI 10.1016/j.anai.2018.03.028; Bonertz A, 2018, ALLERGY, V73, P64, DOI 10.1111/all.13266; Bousquet J, 2008, ALLERGY, V63, P1, DOI 10.1111/j.1398-9995.2007.01594.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Calderon MA, 2012, ALLERGY, V67, P302, DOI 10.1111/j.1398-9995.2011.02761.x; Calderon MA, 2019, J ALLER CL IMM-PRACT, V7, P1450, DOI 10.1016/j.jaip.2019.01.015; Calderon MA, 2015, J ALLER CL IMM-PRACT, V3, P843, DOI 10.1016/j.jaip.2015.06.019; Calderon MA, 2013, J ALLERGY CLIN IMMUN, V132, P1322, DOI 10.1016/j.jaci.2013.09.004; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Demoly P, 2017, J ALLERGY CLIN IMMUN, V140, P614, DOI 10.1016/j.jaci.2017.01.037; Demoly P, 2016, EXPERT REV CLIN IMMU, V12, P1141, DOI 10.1080/1744666X.2016.1237288; Demoly P, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0246-9; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Devillier P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-71; Didier A, 2011, J ALLERGY CLIN IMMUN, V128, P559, DOI 10.1016/j.jaci.2011.06.022; Durham SR, 2016, J ALLERGY CLIN IMMUN, V138, P1081, DOI 10.1016/j.jaci.2016.04.061; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Feng ML, 2018, J IMMUNOL, V200, P3897, DOI 10.4049/jimmunol.1701690; Frew AJ, 2018, ALLERGO J, V27, P31, DOI 10.1007/s40629-018-0065-z; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; Jutel M, 2016, ANN AGR ENV MED, V23, P44, DOI 10.5604/12321966.1196851; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Leger D, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0208-7; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; Linneberg A, 2016, Clin Mol Allergy, V14, P12; Meltzer Eli O, 2012, Allergy Asthma Proc, V33 Suppl 1, pS113, DOI 10.2500/aap.2012.33.3603; Nelson HS, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0687-0; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Nolte H, 2017, J ALLER CL IMM-PRACT, V5, P84, DOI 10.1016/j.jaip.2016.08.017; Nolte H, 2016, J ALLERGY CLIN IMMUN, V138, P1631, DOI 10.1016/j.jaci.2016.06.044; Okamoto Y, 2017, ALLERGY, V72, P435, DOI 10.1111/all.12996; Okamoto Y, 2019, PEDIAT ALLERG IMM-UK, V30, P66, DOI 10.1111/pai.12984; Ozdoganoglu T, 2012, THER ADV RESPIR DIS, V6, P11, DOI 10.1177/1753465811431975; Penagos Martin, 2018, Curr Treat Options Allergy, V5, P275, DOI 10.1007/s40521-018-0176-2; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Pitsios C, 2015, ALLERGY, V70, P897, DOI 10.1111/all.12638; Portnoy J, 2017, J ALLER CL IMM-PRACT, V5, P90, DOI 10.1016/j.jaip.2016.11.008; Rodrigo GJ, 2011, CLIN EXP ALLERGY, V41, P160, DOI 10.1111/j.1365-2222.2010.03654.x; Roux M, 2016, J ALLERGY CLIN IMMUN, V138, P451, DOI 10.1016/j.jaci.2016.03.039; Scadding GK, 2000, CLIN OTOLARYNGOL, V25, P551, DOI 10.1046/j.1365-2273.2000.00417.x; Thomas WR, 2010, ASIAN PAC J ALLERGY, V28, P211; Thomas WR, 2010, TRENDS MOL MED, V16, P321, DOI 10.1016/j.molmed.2010.04.008; Udaka T, 2006, LARYNGOSCOPE, V116, P2129, DOI 10.1097/01.mlg.0000239111.24094.a3; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; Vuurman EFPM, 2014, ALLERGY, V69, P906, DOI 10.1111/all.12418; Worm M, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-7; Zock JP, 2006, J ALLERGY CLIN IMMUN, V118, P682, DOI 10.1016/j.jaci.2006.04.060	55	25	25	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					1020	+		10.1016/j.jaci.2020.07.036	http://dx.doi.org/10.1016/j.jaci.2020.07.036		MAR 2021	21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RG4QF	32890575	Green Submitted			2022-12-18	WOS:000635524300007
J	Sousa-Pinto, B; Tarrio, I; Blumenthal, KG; Araujo, L; Azevedo, LF; Delgado, L; Fonseca, JA				Sousa-Pinto, Bernardo; Tarrio, Isabel; Blumenthal, Kimberly G.; Araujo, Luis; Azevedo, Luis Filipe; Delgado, Luis; Fonseca, Joao Almedia			Accuracy of penicillin allergy diagnostic tests: A systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Diagnostic accuracy; drug provocation test; IgE quantification; penicillin allergy; skin tests	BETA-LACTAM ANTIBIOTICS; DRUG PROVOCATION TESTS; HYPERSENSITIVITY REACTIONS; NONIMMEDIATE REACTIONS; AMOXICILLIN ALLERGY; ORAL CHALLENGE; IMMEDIATE HYPERSENSITIVITY; HOSPITALIZED-PATIENTS; CLINICAL HISTORY; CROSS-REACTIVITY	Background: Having a penicillin allergy label associates with a higher risk for antibiotic resistance and increased health care use. Objective: We sought to assess the accuracy of skin tests and specific IgE quantification in the diagnostic evaluation of patients reporting a penicillin/B-lactam allergy. Methods: We performed a systematic review and diagnostic accuracy meta-analysis, searching on MEDLINE, Scopus, and Web of Science. We included studies conducted in patients reporting a penicillin allergy and in whom skin tests and/or specific IgE quantification were performed and compared with drug challenge results. We quantitatively assessed the accuracy of diagnostic tests with bivariate random-effects meta-analyses. Meta-regression and subgroup analyses were performed to explore causes of heterogeneity. Studies' quality was evaluated using QUADAS-2 criteria. Results: We included 105 primary studies, assessing 31,761 participants. Twenty-seven studies were assessed by bivariate meta-analysis. Skin tests had a summary sensitivity of 30.7% (95% CI, 18.9%-45.9%) and a specificity of 96.8% (95% CI, 94.2%-98.3%), with a partial area under the summary receiver operating characteristic curve of 0.686 (I-2 = 38.2%). Similar results were observed for subanalyses restricted to patients reporting nonimmediate maculopapular exanthema or urticaria/angioedema. Specific IgE had a summary sensitivity of 19.3% (95% CI, 12.0%-29.4%) and a specificity of 97.4% (95% CI, 95.2%-98.6%), with a partial area under the summary receiver-operating characteristic curve of 0.420 (I-2 = 8.5%). Projected predictive values mainly reflect the low frequency of true penicillin allergy. Conclusions: Skin tests and specific IgE quantification appear to have low sensitivity and high specificity. Because current evidence is insufficient for assessing the role of these tests in stratifying patients for delabeling, we identified key requirements needed for future studies.	[Sousa-Pinto, Bernardo; Tarrio, Isabel; Azevedo, Luis Filipe; Fonseca, Joao Almedia] Univ Porto, MEDCIDS, Dept Community Med Informat & Hlth Decis Sci, Fac Med, Porto, Portugal; [Sousa-Pinto, Bernardo; Araujo, Luis; Azevedo, Luis Filipe; Delgado, Luis; Fonseca, Joao Almedia] Ctr Hlth Technol & Serv Res, CINTESIS, Rua Dr Placido da Costa, Porto, Portugal; [Sousa-Pinto, Bernardo; Araujo, Luis; Delgado, Luis] Univ Porto, Basic & Clin Immunol Unit, Dept Pathol, Fac Med, Porto, Portugal; [Blumenthal, Kimberly G.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Blumenthal, Kimberly G.] Harvard Med Sch, Boston, MA 02115 USA	Universidade do Porto; Universidade do Porto; Universidade do Porto; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Sousa-Pinto, B (corresponding author), Ctr Hlth Technol & Serv Res, CINTESIS, Rua Dr Placido da Costa, Porto, Portugal.	bernardo@med.up.pt	Fonseca, João A./B-7562-2008; Blumenthal, Kimberly/AAG-8290-2019; Azevedo, Luís/J-7819-2012; Delgado, Luis/L-8035-2013; Sousa-Pinto, Bernardo/O-2846-2014	Fonseca, João A./0000-0002-0887-8796; Blumenthal, Kimberly/0000-0003-4773-9817; Azevedo, Luís/0000-0002-8421-2937; Delgado, Luis/0000-0003-2375-9071; Sousa-Pinto, Bernardo/0000-0002-1277-3401; Araujo, Luis/0000-0001-8511-2930	Portuguese Ministry for Science, Technology and Higher Education (Ministerio da Ciencia, Tecnologia e Ensino Superior), through the Portuguese Foundation for Science and Technology (Fundacao para a Ciencia e a Tecnologia) [PD/BD/129836/2017]; National Institutes of Health [NIH K01AI125631]; American Academy of Audiology, Asthma & Immunology Foundation; Massachusetts General Hospital (MGH) Claflin Distinguished Scholar Award	Portuguese Ministry for Science, Technology and Higher Education (Ministerio da Ciencia, Tecnologia e Ensino Superior), through the Portuguese Foundation for Science and Technology (Fundacao para a Ciencia e a Tecnologia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Audiology, Asthma & Immunology Foundation; Massachusetts General Hospital (MGH) Claflin Distinguished Scholar Award	This work was supported by the Portuguese Ministry for Science, Technology and Higher Education (Ministerio da Ciencia, Tecnologia e Ensino Superior), through the Portuguese Foundation for Science and Technology (Fundacao para a Ciencia e a Tecnologia; grant no. PD/BD/129836/2017). K.G.B. receives career development support from the National Institutes of Health (grant no. NIH K01AI125631), the American Academy of Audiology, Asthma & Immunology Foundation, and the Massachusetts General Hospital (MGH) Claflin Distinguished Scholar Award.	Abrams EM, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0165-6; Al-Ahmad M, 2014, ASIA PAC ALLERGY, V4, P106, DOI 10.5415/apallergy.2014.4.2.106; Astin MP, 2008, RADIOLOGY, V247, P365, DOI 10.1148/radiol.2472070101; Atanaskovic-Markovic M, 2016, PEDIAT ALLERG IMM-UK, V27, P533, DOI 10.1111/pai.12565; Barni S, 2015, CLIN EXP ALLERGY, V45, P1472, DOI 10.1111/cea.12596; BASOMBA A, 1979, CLIN ALLERGY, V9, P515, DOI 10.1111/j.1365-2222.1979.tb02516.x; BLANCA M, 1990, CLIN EXP ALLERGY, V20, P475, DOI 10.1111/j.1365-2222.1990.tb03139.x; Blanca M, 2009, ALLERGY, V64, P183, DOI [10.1111/j.1398-9995.2008.01924.x, 10.1111/j.1398-9995.2008.01916.x]; Blanca M, 2001, ALLERGY, V56, P862, DOI 10.1034/j.1398-9995.2001.00995.x; Blanca-Lopez N, 2015, ALLERGY, V70, P1013, DOI 10.1111/all.12636; Blumenthal Kimberly G, 2019, JAMA, V321, P216, DOI 10.1001/jama.2018.20470; Blumenthal KG, 2019, LANCET, V393, P183, DOI 10.1016/S0140-6736(18)32218-9; Blumenthal KG, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2400; Borch JE, 2006, BASIC CLIN PHARMACOL, V98, P357, DOI 10.1111/j.1742-7843.2006.pto_230.x; Bourke J, 2015, J ALLER CL IMM-PRACT, V3, P365, DOI 10.1016/j.jaip.2014.11.002; Bousquet PJ, 2008, CLIN EXP ALLERGY, V38, P185, DOI 10.1111/j.1365-2222.2007.02867.x; Bousquet PJ, 2007, ALLERGY, V62, P872, DOI 10.1111/j.1398-9995.2007.01463.x; BROWN BC, 1964, JAMA-J AM MED ASSOC, V189, P599; Brusca I, 2007, RIV ITALIANA MED LAB, V3, P196; Caubet JC, 2015, PEDIAT ALLERG IMM-UK, V26, P80, DOI 10.1111/pai.12314; Caubet JC, 2011, J ALLERGY CLIN IMMUN, V127, P218, DOI 10.1016/j.jaci.2010.08.025; Juri MC, 2017, MEDICINA-BUENOS AIRE, V77, P180; Cederbrant K, 1998, ALLERGY, V53, P1155, DOI 10.1111/j.1398-9995.1998.tb03835.x; Celik GE, 2012, INT ARCH ALLERGY IMM, V157, P311, DOI 10.1159/000328212; Chambel M, 2010, ALLERGOL IMMUNOPATH, V38, P300, DOI 10.1016/j.aller.2010.01.005; Chen JR, 2017, J ALLER CL IMM-PRACT, V5, P686, DOI 10.1016/j.jaip.2016.09.045; Chiriac AM, 2017, ALLERGY, V72, P552, DOI 10.1111/all.13037; Chiriac AM, 2019, J ALLER CL IMM-PRACT, V7, P46, DOI 10.1016/j.jaip.2018.07.037; Chiriac AM, 2019, J ALLER CL IMM-PRACT, V7, P2404, DOI 10.1016/j.jaip.2019.01.060; Colas H, 2014, REV FR ALLERGOL, V54, P300, DOI 10.1016/j.reval.2014.01.038; Confino-Cohen R, 2017, J ALLER CL IMM-PRACT, V5, P669, DOI 10.1016/j.jaip.2017.02.023; del Real GA, 2007, J ALLERGY CLIN IMMUN, V117, pS224; Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350; Deville Walter L, 2002, BMC Med Res Methodol, V2, P9, DOI 10.1186/1471-2288-2-9; Ibanez MD, 2018, ANN ALLERG ASTHMA IM, V121, P235, DOI 10.1016/j.anai.2018.05.013; Erkocoglu M, 2013, PEDIAT ALLERG IMM-UK, V24, P160, DOI 10.1111/pai.12047; Faitelson Y, 2018, J ALLER CL IMM-PRACT, V6, P1363, DOI 10.1016/j.jaip.2017.11.015; Fazlollahi MR, 2017, ARCH IRAN MED, V20, P34, DOI 0172001/AIM.008; Ferre-Ybarz L, 2015, ALLERGOL IMMUNOPATH, V43, P369, DOI 10.1016/j.aller.2014.04.009; Fontaine C, 2007, ALLERGY, V62, P47, DOI 10.1111/j.1398-9995.2006.01268.x; Forrest DM, 2001, CLIN INFECT DIS, V32, P1685, DOI 10.1086/320752; Fox SJ, 2014, J ALLER CL IMM-PRACT, V2, P439, DOI 10.1016/j.jaip.2014.04.013; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; Nunez IG, 2012, J INVEST ALLERG CLIN, V22, P41; Goldberg A, 2008, ANN ALLERG ASTHMA IM, V100, P37, DOI 10.1016/S1081-1206(10)60402-4; Gomes E, 2004, CLIN EXP ALLERGY, V34, P1597, DOI 10.1111/j.1365-2222.2004.02070.x; Gomes ER, 2008, CLIN EXP ALLERGY, V38, P191, DOI 10.1111/j.1365-2222.2007.02870.x; GRAFFLONNEVIG V, 1988, ARCH DIS CHILD, V63, P1342, DOI 10.1136/adc.63.11.1342; Harandian F, 2016, POSTGRAD MED, V128, P557, DOI 10.1080/00325481.2016.1191319; Harbord RM, 2007, BIOSTATISTICS, V8, P239, DOI 10.1093/biostatistics/kxl004; Hershkovich J, 2009, CLIN EXP ALLERGY, V39, P726, DOI 10.1111/j.1365-2222.2008.03180.x; Herve M, 1998, ARCH PEDIATRIE, V5, P503, DOI 10.1016/S0929-693X(99)80314-5; Hjortlund J, 2013, ALLERGY, V68, P1057, DOI 10.1111/all.12195; Hjortlund J, 2012, ACTA DERM-VENEREOL, V92, P307, DOI 10.2340/00015555-1254; Holm A, 2011, ALLERGY ASTHMA IMMUN, V3, P118, DOI 10.4168/aair.2011.3.2.118; Iammatteo M, 2019, J ALLER CL IMM-PRACT, V7, P236, DOI 10.1016/j.jaip.2018.05.008; Iglesias-Souto J, 2012, PEDIATR INFECT DIS J, V31, P1091, DOI 10.1097/INF.0b013e3182624d03; Torres MJ, 2019, ALLERGY, V74, P1052, DOI 10.1111/all.13721; JUCHET A, 1994, REV FR ALLERGOL, V34, P369, DOI 10.1016/S0335-7457(05)80241-2; Kamboj S, 2011, ALLERGY ASTHMA PROC, V32, P99, DOI 10.2500/aap.2011.32.3433; King EA, 2016, ANN ALLERG ASTHMA IM, V117, P67, DOI 10.1016/j.anai.2016.04.021; Kopac P, 2012, ACTA DERMATOVENEROL, V21, P5; Lebel B, 2001, ALLERGY, V56, P688, DOI 10.1034/j.1398-9995.2001.00103.x; Lee CE, 2000, ARCH INTERN MED, V160, P2819, DOI 10.1001/archinte.160.18.2819; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; Lipsey MW, 2003, ANN AM ACAD POLIT SS, V587, P69, DOI 10.1177/0002716202250791; Lopez Tiro J J, 2001, Rev Alerg Mex, V48, P80; Loza Cortina C., 1998, AN ESP PEDIAT, V49, P359; Macy E, 1997, J ALLERGY CLIN IMMUN, V100, P586, DOI 10.1016/S0091-6749(97)70159-3; Macy E, 2018, ANN ALLERG ASTHMA IM, V121, P523, DOI 10.1016/j.anai.2018.07.041; Macy E, 2013, J ALLER CL IMM-PRACT, V1, P258, DOI 10.1016/j.jaip.2013.02.002; Macy E, 2010, ANN ALLERG ASTHMA IM, V105, P136, DOI 10.1016/j.anai.2010.06.014; Macy E, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.01.034; Manuyakorn W, 2016, ASIAN PAC J ALLERGY, V34, P242, DOI 10.12932/AP0750; Marraccini P, 2018, INT ARCH ALLERGY IMM, V177, P160, DOI 10.1159/000490116; Marwood J, 2017, EMERG MED AUSTRALAS, V29, P509, DOI 10.1111/1742-6723.12774; Mattingly TJ, 2018, J ALLER CL IMM-PRACT, V6, P1649, DOI 10.1016/j.jaip.2017.12.033; Mawhirt SL, 2017, ANN ALLERG ASTHMA IM, V118, P73, DOI 10.1016/j.anai.2016.10.003; McDanel DL, 2017, J ARTHROPLASTY, V32, pS101, DOI 10.1016/j.arth.2017.01.012; McInnes MDF, 2018, JAMA-J AM MED ASSOC, V319, P388, DOI 10.1001/jama.2017.19163; Meng J, 2016, ANN ALLERG ASTHMA IM, V117, P273, DOI 10.1016/j.anai.2016.07.009; Mill C, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0033; Misirlioglu ED, 2017, ALLERGY ASTHMA PROC, V38, P38, DOI [10.2500/aap.2017.38.4065, 10.2500/aap.2017.38.4009]; Moral L, 2011, ALLERGOL IMMUNOPATH, V39, P337, DOI 10.1016/j.aller.2010.10.002; Moreno E, 2016, ALLERGY, V71, P1787, DOI 10.1111/all.13032; Mori F, 2015, J ALLER CL IMM-PRACT, V3, P375, DOI 10.1016/j.jaip.2014.11.001; Mota I, 2016, EUR ANN ALLERGY CLIN, V48, P212; Moussa Y, 2018, SURGERY, V164, P117, DOI 10.1016/j.surg.2018.03.004; Na Hye Ran, 2011, Korean J Pediatr, V54, P304, DOI 10.3345/kjp.2011.54.7.304; Nolan RC, 2008, INTERN MED J, V38, P357, DOI 10.1111/j.1445-5994.2008.01657.x; Novalbos A, 2001, CLIN EXP ALLERGY, V31, P438, DOI 10.1046/j.1365-2222.2001.00992.x; Padial A, 2008, CLIN EXP ALLERGY, V38, P822, DOI 10.1111/j.1365-2222.2008.02961.x; Picard M, 2014, ANN ALLERG ASTHMA IM, V113, P75, DOI 10.1016/j.anai.2014.04.017; Pichichero ME, 1998, J PEDIATR-US, V132, P137, DOI 10.1016/S0022-3476(98)70499-8; Ponvert C, 2011, PEDIAT ALLERG IMM-UK, V22, P411, DOI 10.1111/j.1399-3038.2011.01169.x; Ramsey A, 2018, J ALLER CL IMM-PRACT, V6, P1349, DOI 10.1016/j.jaip.2017.11.012; Ratzon R, 2016, ANN ALLERG ASTHMA IM, V116, P329, DOI 10.1016/j.anai.2016.01.018; Reitsma JB, 2005, J CLIN EPIDEMIOL, V58, P982, DOI 10.1016/j.jclinepi.2005.02.022; RESNIK SS, 1965, J INVEST DERMATOL, V45, P269, DOI 10.1038/jid.1965.128; Richter AG, 2011, J CLIN PATHOL, V64, P1014, DOI 10.1136/jcp.2010.088203; Rimawi RH, 2013, J HOSP MED, V8, P341, DOI 10.1002/jhm.2036; Rodriguez-Alvarez M, 2008, ALLERGOL IMMUNOPATH, V36, P201, DOI 10.1016/S0301-0546(08)72550-3; ROMANO A, 1995, ALLERGY, V50, P113; Romano A, 2002, INT ARCH ALLERGY IMM, V129, P169, DOI 10.1159/000065876; Rosenfield L, 2015, ALLERGY ASTHMA CL IM, V11, DOI 10.1186/s13223-015-0098-5; Sastre J, 1996, ALLERGY, V51, P383, DOI 10.1111/j.1398-9995.1996.tb04634.x; Sedlackova Lenka, 2018, Prague Med Rep, V119, P30, DOI 10.14712/23362936.2018.3; Seitz CS, 2011, PEDIAT ALLERG IMM-UK, V22, P405, DOI 10.1111/j.1399-3038.2011.01134.x; Shenoy ES, 2019, JAMA-J AM MED ASSOC, V321, P188, DOI 10.1001/jama.2018.19283; Silva R, 2009, ALLERGOL IMMUNOPATH, V37, P193, DOI 10.1016/j.aller.2009.01.001; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; Solensky R, 2002, ARCH INTERN MED, V162, P822, DOI 10.1001/archinte.162.7.822; Soria A, 2017, ANN MED, V49, P710, DOI 10.1080/07853890.2017.1370125; Soto L, 2012, ALLERGY, V67, P429; Sousa-Pinto B, 2020, ALLERGY, V75, P436, DOI 10.1111/all.13951; Sousa-Pinto B, 2018, ANN ALLERG ASTHMA IM, V120, P190, DOI 10.1016/j.anai.2017.11.022; Sousa-Pinto B, 2017, ANN ALLERG ASTHMA IM, V119, P362, DOI 10.1016/j.anai.2017.07.009; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; Sundquist BK, 2017, POSTGRAD MED, V129, P915, DOI 10.1080/00325481.2017.1370360; SURTEES SJ, 1991, BRIT MED J, V302, P1051, DOI 10.1136/bmj.302.6784.1051; Tannert LK, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0179-2; Tantikul C, 2008, ASIAN PAC J ALLERGY, V26, P77; Torres MJ, 2002, CLIN EXP ALLERGY, V32, P270, DOI 10.1046/j.1365-2222.2002.01296.x; Trautmann A, 2014, CLIN EXP ALLERGY, V44, P1531, DOI 10.1111/cea.12437; VANARSDEL PP, 1986, WESTERN J MED, V144, P311; Vyles D, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0471; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; WIDE L, 1971, Clinical Allergy, V1, P171, DOI 10.1111/j.1365-2222.1971.tb03016.x; Wong BBL, 2006, ANN ALLERG ASTHMA IM, V97, P169, DOI 10.1016/S1081-1206(10)60008-7; Zambonino MA, 2014, PEDIAT ALLERG IMM-UK, V25, P80, DOI 10.1111/pai.12155; Zhou Y, 2014, STAT MED, V33, P2701, DOI 10.1002/sim.6115	132	25	25	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					296	308		10.1016/j.jaci.2020.04.058	http://dx.doi.org/10.1016/j.jaci.2020.04.058		JAN 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PS2UA	32446963	Green Accepted			2022-12-18	WOS:000607781700004
J	Van Singer, M; Brahier, T; Ngai, M; Wright, J; Weckman, AM; Erice, C; Meuwly, JY; Hugli, O; Kain, KC; Boillat-Blanco, N				Van Singer, Mathias; Brahier, Thomas; Ngai, Michelle; Wright, Julie; Weckman, Andrea M.; Erice, Clara; Meuwly, Jean-Yves; Hugli, Olivier; Kain, Kevin C.; Boillat-Blanco, Noemie			COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Endothelial dysfunction; immune activation; biomarkers; COVID-19	TREM-1	Background: The coronavirus disease 2019 (COVID-19) pandemic has led to surges of patients presenting to emergency departments (EDs) and potentially overwhelming health systems. Objective: We sought to assess the predictive accuracy of host biomarkers at clinical presentation to the ED for adverse outcome. Methods: Prospective observational study of PCR-confirmed COVID-19 patients in the ED of a Swiss hospital. Concentrations of inflammatory and endothelial dysfunction biomarkers were determined at clinical presentation. We evaluated the accuracy of clinical signs and these biomarkers in predicting 30-day intubation/mortality, and oxygen requirement by calculating the area under the receiver-operating characteristic curve and by classification and regression tree analysis. Results: Of 76 included patients with COVID-19, 24 were outpatients or hospitalized without oxygen requirement, 35 hospitalized with oxygen requirement, and 17 intubated/died. We found that soluble triggering receptor expressed on myeloid cells had the best prognostic accuracy for 30-day intubation/mortality (area under the receiver-operating characteristic curve, 0.86; 95% CI, 0.77-0.95) and IL-6 measured at presentation to the ED had the best accuracy for 30-day oxygen requirement (area under the receiver-operating characteristic curve, 0.84; 95% CI, 0.74-0.94). An algorithm based on respiratory rate and sTREM-1 predicted 30-day intubation/mortality with 94% sensitivity and 0.1 negative likelihood ratio. An IL-6-based algorithm had 98% sensitivity and 0.04 negative likelihood ratio for 30-day oxygen requirement. Conclusions: sTREM-1 and IL-6 concentrations in COVID-19 in the ED have good predictive accuracy for intubation/ mortality and oxygen requirement. sTREM-1- and IL-6-based algorithms are highly sensitive to identify patients with adverse outcome and could serve as early triage tools.	[Van Singer, Mathias; Brahier, Thomas; Boillat-Blanco, Noemie] Univ Hosp Lausanne, Infect Dis Serv, Rue Bugnon 46, CH-1011 Lausanne, Switzerland; [Ngai, Michelle; Wright, Julie; Weckman, Andrea M.; Erice, Clara; Kain, Kevin C.] Univ Toronto, Sandra Rotman Ctr Global Hlth, Univ Hlth Network Toronto Gen, Trop Dis Unit,Dept Med, Toronto, ON, Canada; [Meuwly, Jean-Yves] Univ Hosp Lausanne, Dept Radiol, Lausanne, Switzerland; [Hugli, Olivier] Univ Hosp Lausanne, Emergency Dept, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Brahier, T (corresponding author), Univ Hosp Lausanne, Infect Dis Serv, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	thomas.brahier@chuv.ch	Erice, Clara/ABI-5816-2020; Boillat-Blanco, Noémie/GLT-5579-2022	Erice, Clara/0000-0001-9681-6861; Van Singer, Mathias/0000-0002-1858-8661; Boillat-Blanco, Noemie/0000-0002-2490-8174; Brahier, Thomas/0000-0002-9256-641X	Leenaards Foundation; Foundation of Lausanne University Hospital; Canadian Institutes of Health Research (Foundation) [FDN-148439]; CIHR COVID-19 grant [447092, VR3-172649]; National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) [947684]; GeoSentinel Foundation; FAST grants Thistledown Foundation; Slaight Family Foundation; Tesari Foundation; Canada Research Chair program	Leenaards Foundation; Foundation of Lausanne University Hospital; Canadian Institutes of Health Research (Foundation)(Canadian Institutes of Health Research (CIHR)); CIHR COVID-19 grant(Canadian Institutes of Health Research (CIHR)); National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP); GeoSentinel Foundation; FAST grants Thistledown Foundation; Slaight Family Foundation; Tesari Foundation; Canada Research Chair program(Canada Research Chairs)	This work was supported in part by an academic award of the Leenaards Foundation (to N.B.-B.) and by the Foundation of Lausanne University Hospital (to N.B.-B.); Canadian Institutes of Health Research (Foundation grant no. FDN-148439 to K.C.K.); CIHR COVID-19 grant (grant nos. 447092 and VR3-172649 to K.C.K.); National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) (grant no. 947684 to K.C.K.); GeoSentinel Foundation (to K.C.K.); FAST grants Thistledown Foundation (to K.C.K); Slaight Family Foundation (to K.C.K.); Tesari Foundation (to K.C.K); and the Canada Research Chair program (to K.C.K.). The funding bodies had no role in the design of the study and collection, analysis and interpretation of data, and writing the manuscript.	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Arango C, 2020, BIOL PSYCHIAT, V88, pE33, DOI 10.1016/j.biopsych.2020.04.003; ARTS RJW, 2013, CELL MOL IMMUNOL, V93, P209; Bauer TT, 2006, J INTERN MED, V260, P93, DOI 10.1111/j.1365-2796.2006.01657.x; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; BOUCHON A, 2001, MED MALADIES INFECT, V410, P1103; Brenner T, 2017, BIOMARKERS, V22, P63, DOI 10.1080/1354750X.2016.1204005; CARRASCO K, 2019, NATURE, V16, P460; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Erdman LK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017440; Eubank S, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00726-x; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Gomez-Pina V, 2007, J IMMUNOL, V179, P4065, DOI 10.4049/jimmunol.179.6.4065; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Hosmer W. D., 2000, APPL LOGISTIC REGRES, P143, DOI [10.1002/0471722146.ch5, DOI 10.1002/0471722146.CH5]; Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2; Leligdowicz A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175130; Lewis RJ, 2000, 200 SOC ACAD EMERGEN, P1; Li SH, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138070; Liu T, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012421; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Richard-Greenblatt M, 2020, CLIN INFECT DIS, V70, P1304, DOI 10.1093/cid/ciz419; Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Saglietto A, 2020, LANCET, V395, P1110, DOI 10.1016/S0140-6736(20)30690-5; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; SMADJA DM, 2020, NEW ENGL J MED, V23, P611; Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Tanne JH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1090; Thachil J, 2020, J THROMB HAEMOST, V18, P1795, DOI 10.1111/jth.14841; Vaquero LM, C REACTIVE PROTEIN A, DOI [10.1101/2020.05.22, DOI 10.1101/2020.05.22]; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Vergano M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02891-w; Wang CS, 2020, INTENS CARE MED, V46, P1475, DOI 10.1007/s00134-020-06065-8; Wang L, 2020, MED MALADIES INFECT, V50, P332, DOI 10.1016/j.medmal.2020.03.007; WHO, HOME CARE PATIENTS C; WOODHEAD M, 2011, ANGIOGENESIS, V17, pE1; Wright SW, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01627-5; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328; Yan Q., 2020, LONGITUDINAL PERIPHE, DOI [10.1101/2020.05.05.20091355, DOI 10.1101/2020.05.05.20091355]; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	47	25	26	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					99	+		10.1016/j.jaci.2020.10.001	http://dx.doi.org/10.1016/j.jaci.2020.10.001		JAN 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	33045281	Green Published, Bronze			2022-12-18	WOS:000613645900013
J	Lai, JF; Thompson, LJ; Ziegler, SF				Lai, Jen-Feng; Thompson, Lucas J.; Ziegler, Steven F.			TSLP drives acute T(H)2-cell differentiation in lungs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TSLP; T(H)2; interstitial macrophages; dendritic cells; lung; lymph node	THYMIC STROMAL LYMPHOPOIETIN; T-CELL DIFFERENTIATION; HOUSE-DUST MITE; DENDRITIC CELL; ANTIGEN PRESENTATION; AIRWAY INFLAMMATION; MONOCYTES; RESPONSES; SURVIVAL; RECEPTOR	Background: Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine that is important for the development of type 2 inflammatory responses at mucosal surfaces. Objective: In humans, TSLP level has been found to be elevated in the lungs of patients with asthma, and in mouse models, TSLP can promote type 2 airway inflammation, primarily through the activation of dendritic cells. However, the mechanisms underlying its role remain unclear. The objective of this study was to provide a mechanistic analysis of TSLP-mediated type 2 airway inflammation Methods: To dissect the mechanisms of TSLP-mediated type 2 responses, mice were treated with TSLP and antigen to evaluate cellular immune responses. Flow cytometric analyses were used to follow responses in the airways, and conditional deletion of TSLP receptor and adoptive transfer were used to identify the cellular subsets involved in this inflammatory response. Results: We showed that TSLP can directly promote T(H)2-cell differentiation in the lung, independent of the draining lymph nodes. We also identified a population of patrolling monocytes/interstitial macrophages (IMs) (CD11c-expressing IMs) that are both necessary and sufficient for TSLP-mediated T(H)2-cell differentiation and airway inflammation. T(H)2-cell-driven airway eosinophilia is attenuated by ablation of CD11c-expressing IMs or by selective deficiency of TSLP receptor signaling in these cells. More importantly, CD11c-expressing IMs are sufficient for the induction of acute T(H)2-cell responses in the lungs that is independent of dendritic cells and T-cell priming in the draining lymph nodes. Conclusion: These findings indicate a novel mechanistic role for TSLP and CD11c-expressing IMs in the development of acute T(H)2-cell-dependent allergic airway inflammation. This work also demonstrates a new role for TSLP in promoting type 2 responses directly in the lung.	[Lai, Jen-Feng; Thompson, Lucas J.; Ziegler, Steven F.] Virginia Mason, Benaroya Res Inst, Seattle, WA USA; [Thompson, Lucas J.] Juno Therapeut, Seattle, WA USA	Benaroya Research Institute; Virginia Mason Medical Center	Ziegler, SF (corresponding author), Benaroya Res Inst, 1201 9th Ave, Seattle, WA 98101 USA.	sziegler@benaroyaresearch.org		Ziegler, Steven/0000-0003-0657-5529	US National Institutes of Health [AI068731, HL098067]	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by US National Institutes of Health grants AI068731 and HL098067 (to S.F.Z.).	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Bedoret D, 2009, J CLIN INVEST, V119, P3723, DOI 10.1172/JCI39717; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JCI200216109; Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064; Davies LC, 2013, NAT IMMUNOL, V14, P986, DOI 10.1038/ni.2705; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Han HW, 2014, J CLIN INVEST, V124, P5442, DOI 10.1172/JCI77798; Hanna RN, 2015, SCIENCE, V350, P985, DOI 10.1126/science.aac9407; Hanna RN, 2011, NAT IMMUNOL, V12, P778, DOI 10.1038/ni.2063; Hashimoto D, 2011, IMMUNITY, V35, P323, DOI 10.1016/j.immuni.2011.09.007; Headley MB, 2009, J IMMUNOL, V182, P1641, DOI 10.4049/jimmunol.182.3.1641; Hohl TM, 2009, CELL HOST MICROBE, V6, P470, DOI 10.1016/j.chom.2009.10.007; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760; Itano AA, 2003, NAT IMMUNOL, V4, P733, DOI 10.1038/ni957; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kitajima M, 2013, J IMMUNOL, V191, P4903, DOI 10.4049/jimmunol.1302175; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Landsman L, 2009, BLOOD, V113, P963, DOI 10.1182/blood-2008-07-170787; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Medoff BD, 2008, ANNU REV IMMUNOL, V26, P205, DOI 10.1146/annurev.immunol.26.021607.090312; Mionnet C, 2010, NAT MED, V16, P1305, DOI 10.1038/nm.2253; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Quentmeier H, 2001, LEUKEMIA, V15, P1286, DOI 10.1038/sj.leu.2402175; Rochman Y, 2010, P NATL ACAD SCI USA, V107, P19455, DOI 10.1073/pnas.1008271107; Rodero MP, 2015, ELIFE, V4, DOI 10.7554/eLife.07847; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Turner DL, 2014, MUCOSAL IMMUNOL, V7, P501, DOI 10.1038/mi.2013.67; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	41	25	26	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2020	146	6					1406	1418		10.1016/j.jaci.2020.03.032	http://dx.doi.org/10.1016/j.jaci.2020.03.032			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC3XH	32304753	Green Accepted, hybrid			2022-12-18	WOS:000596937900022
J	Passerini, L; Barzaghi, F; Curto, R; Sartirana, C; Barera, G; Tucci, F; Albarello, L; Mariani, A; Testoni, PA; Bazzigaluppi, E; Bosi, E; Lampasona, V; Neth, O; Zama, D; Hoenig, M; Schulz, A; Seidel, MG; Rabbone, I; Olek, S; Roncarolo, MG; Cicalese, MP; Aiuti, A; Bacchetta, R				Passerini, Laura; Barzaghi, Federica; Curto, Rosalia; Sartirana, Claudia; Barera, Graziano; Tucci, Francesca; Albarello, Luca; Mariani, Alberto; Testoni, Pier Alberto; Bazzigaluppi, Elena; Bosi, Emanuele; Lampasona, Vito; Neth, Olaf; Zama, Daniele; Hoenig, Manfred; Schulz, Ansgar; Seidel, Markus G.; Rabbone, Ivana; Olek, Sven; Roncarolo, Maria G.; Cicalese, Maria P.; Aiuti, Alessandro; Bacchetta, Rosa			Treatment with rapamycin can restore regulatory T-cell function in IPEX patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						autoimmunity; Ebi3; FOXP3; GITR; IPEX; mTOR; rapamycin; regulatory T cells; suppression	SIROLIMUS; ENTEROPATHY; POLYENDOCRINOPATHY; INHIBITION; INDUCTION; BLOCKADE	Background: Immune-dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a lethal disease caused by mutations in a transcription factor critical for the function of thymus-derived regulatory T (Treg) cells (ie, FOXP3), resulting in impaired Treg function and autoimmunity. At present, hematopoietic stem cell transplantation is the therapy of choice for patients with IPEX syndrome. If not available, multiple immunosuppressive regimens have been used with poor disease-free survival at long-term follow-up. Rapamycin has been shown to suppress peripheral T cells while sparing Treg cells expressing wild-type FOXP3, thereby proving beneficial in the clinical setting of immune dysregulation. However, the mechanisms of immunosuppression selective to Treg cells in patients with IPEX syndrome are unclear. Objective: We sought to determine the cellular and molecular basis of the clinical benefit observed under rapamycin treatment in 6 patients with IPEX syndrome with different FOXP3 mutations. Methods: Phenotype and function of FOXP3-mutated Treg cells from rapamycin-treated patients with IPEX syndrome were tested by flow cytometry and in vitro suppression assays, and the gene expression profile of rapamycin-conditioned Treg cells by droplet-digital PCR. Results: Clinical and histologic improvements in patients correlated with partially restored Treg function, independent of FOXP3 expression or Treg frequency. Expression of TNF-receptor-superfamily-member 18 (TNFRSF18, glucocorticoidinduced TNF-receptor-related) and EBV-induced-3 (EBI3, an IL-35 subunit) in patients' Treg cells increased during treatment as compared with that of Treg cells from untreated healthy subjects. Furthermore inhibition of glucocorticoid-induced TNF-receptor-related and Ebi3 partially reverted in vitro suppression by in vivo rapamycin-conditioned Treg cells. Conclusions: Rapamycin is able to affect Treg suppressive function via a FOXP3-independent mechanism, thus sustaining the clinical improvement observed in patients with IPEX syndrome under rapamycin treatment.	[Passerini, Laura; Barzaghi, Federica; Curto, Rosalia; Sartirana, Claudia; Cicalese, Maria P.; Aiuti, Alessandro; Bacchetta, Rosa] San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy; [Barzaghi, Federica; Tucci, Francesca; Cicalese, Maria P.; Aiuti, Alessandro] IRCCS San Raffaele Sci Inst, Dept Paediat Immunohematol, Milan, Italy; [Barera, Graziano] IRCCS San Raffaele Sci Inst, Dept Paediat, Milan, Italy; [Albarello, Luca] IRCCS San Raffaele Sci Inst, Pathol Unit, Milan, Italy; [Mariani, Alberto; Testoni, Pier Alberto] IRCCS San Raffaele Sci Inst, Gastroenterol Unit, Milan, Italy; [Bazzigaluppi, Elena; Bosi, Emanuele; Lampasona, Vito] IRCCS San Raffaele Sci Inst, Diabet Res Inst, Milan, Italy; [Bosi, Emanuele; Aiuti, Alessandro] Univ Vita Salute San Raffaele, Milan, Italy; [Neth, Olaf] Univ Seville, CSIC, Inst Biomed Sevilla, Dept Paediat Infect Dis Rheumatol & Immunodeficie, Seville, Spain; [Zama, Daniele] Univ Bologna, S Orsola Malpighi Hosp, Dept Pediat, Bologna, Italy; [Hoenig, Manfred; Schulz, Ansgar] Ulm Univ, Clin Pediat & Adolescent Med, Ulm, Germany; [Seidel, Markus G.] Med Univ Graz, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Graz, Austria; [Rabbone, Ivana] Univ Turin, Dept Pediat, Turin, Italy; [Olek, Sven] Epiontis GmbH, Berlin, Germany; [Roncarolo, Maria G.; Bacchetta, Rosa] Stanford Univ, Sch Med, Dept Pediat, Div Stem Cell Transplantat & Regenerat Med, Stanford, CA 94305 USA	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; Ulm University; Medical University of Graz; University of Turin; Epiontis GmbH; Stanford University	Bacchetta, R (corresponding author), Stanford Sch Med, Dept Pediat, 265 Campus Dr, Stanford, CA 94305 USA.	rosab@stanford.edu	Neth, Olaf/F-1167-2015; Lampasona, Vito/E-8999-2012; bazzigaluppi, elena/AAN-5052-2020; barera, graziano/AAN-5041-2020; Zama, Daniele/B-7055-2013; Rabbone, Ivana/ABF-2203-2020; Tucci, Francesca/AAB-2184-2022; ALBARELLO, LUCA/AAN-3876-2020; Seidel, Markus G/N-9951-2017; Passerini, Laura/J-7791-2016	Neth, Olaf/0000-0001-5018-0466; Lampasona, Vito/0000-0001-5162-8445; bazzigaluppi, elena/0000-0002-6715-7454; Zama, Daniele/0000-0002-9895-5942; Rabbone, Ivana/0000-0003-4173-146X; Tucci, Francesca/0000-0001-8798-8987; ALBARELLO, LUCA/0000-0003-4846-5096; Seidel, Markus G/0000-0003-0981-8661; Passerini, Laura/0000-0002-4020-7386; Bacchetta, Rosa/0000-0002-0606-6268	Telethon Foundation; Italian Ministry of Health [GR-2011-02346941]	Telethon Foundation(Fondazione Telethon); Italian Ministry of Health(Ministry of Health, Italy)	This work was supported by Telethon Foundation (Tele10-A4 to R.B.) and the Italian Ministry of Health (GR-2011-02346941 to L.P.).	Apostolidis SA, 2016, NAT IMMUNOL, V17, P556, DOI 10.1038/ni.3390; Araki K, 2011, CURR OPIN CELL BIOL, V23, P707, DOI 10.1016/j.ceb.2011.08.006; Azizi G, 2017, EUR ANN ALLERGY CLIN, V49, P235, DOI 10.23822/EurAnnACI.1764-1489.22; Bacchetta R, 2018, ANN NY ACAD SCI, V1417, P5, DOI 10.1111/nyas.13011; Badami E, 2011, DIABETES, V60, P2120, DOI 10.2337/db10-1201; Bardel E, 2008, J IMMUNOL, V181, P6898, DOI 10.4049/jimmunol.181.10.6898; Barzaghi F, 2012, J AUTOIMMUN, V38, P49, DOI 10.1016/j.jaut.2011.12.009; Barzaghi F, 2018, J ALLERGY CLIN IMMUN, V141, P1036, DOI 10.1016/j.jaci.2017.10.041; Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338; Bindl L, 2005, J PEDIATR-US, V147, P256, DOI 10.1016/j.jpeds.2005.04.017; Charbonnier LM, 2019, NAT IMMUNOL, V20, P1208, DOI 10.1038/s41590-019-0442-x; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Gabrysova L, 2011, EUR J IMMUNOL, V41, P1242, DOI 10.1002/eji.201041073; Kang J, 2008, J LEUKOCYTE BIOL, V83, P1230, DOI 10.1189/jlb.1207851; Lampasona V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078664; Lu YJ, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/989434; Mitsuiki N, 2019, IMMUNOL REV, V287, P33, DOI 10.1111/imr.12721; Monti P, 2008, DIABETES, V57, P2341, DOI 10.2337/db08-0138; Passerini L, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007320; Passerini L, 2011, J ALLERGY CLIN IMMUN, V128, P1376, DOI 10.1016/j.jaci.2011.09.010; Passerini L, 2011, EUR J IMMUNOL, V41, P1120, DOI 10.1002/eji.201040909; Sabbatini M, 2015, CLIN EXP IMMUNOL, V182, P230, DOI 10.1111/cei.12669; Sakaguchi S, 2013, NAT REV IMMUNOL, V13, P461, DOI 10.1038/nri3464; Schmetterer KG, 2012, FASEB J, V26, P2253, DOI 10.1096/fj.11-193672; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; Seidel MG, 2009, BLOOD, V113, P5689, DOI 10.1182/blood-2009-02-206359; Seyer M, 2010, EUR J IMMUNOL, V40, P321, DOI 10.1002/eji.200939527; Vignesh P, 2017, CLIN REV ALLERG IMMU, V52, P287, DOI 10.1007/s12016-016-8591-2; Wirtz S, 2011, GASTROENTEROLOGY, V141, P1875, DOI 10.1053/j.gastro.2011.07.040; Yang JF, 2008, EUR J IMMUNOL, V38, P1204, DOI 10.1002/eji.200838145; Yong PL, 2008, J CLIN IMMUNOL, V28, P581, DOI 10.1007/s10875-008-9196-1; Zama D, 2014, ITAL J PEDIATR, V40, DOI 10.1186/s13052-014-0068-4; Zheng Y, 2007, J IMMUNOL, V178, P2163, DOI 10.4049/jimmunol.178.4.2163	34	25	25	3	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1262	+		10.1016/j.jaci.2019.11.043	http://dx.doi.org/10.1016/j.jaci.2019.11.043			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31874182	Bronze			2022-12-18	WOS:000523633400022
J	Kottyan, LC; Parameswaran, S; Weirauch, MT; Rothenberg, ME; Martin, LJ				Kottyan, Leah C.; Parameswaran, Sreeja; Weirauch, Matthew T.; Rothenberg, Marc E.; Martin, Lisa J.			The genetic etiology of eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; genetics; single nucleotide polymorphism; heritability; genome-wide association study	GENOME-WIDE ASSOCIATION; VARIANTS; DIFFERENTIATION; SUSCEPTIBILITY; FAMILY	Eosinophilic esophagitis (EoE) is a chronic allergic disease associated with marked mucosal eosinophil accumulation. Multiple studies have reported a strong familial component to EoE, with the presence of EoE increasing the risk for other family members with EoE. Epidemiologic studies support an important role for environmental risk factors as modulators of genetic risk. In a small percentage of cases, including patients who have Mendelian diseases with co-occurrent EoE, rare genetic variation with large effect sizes could mediate EoE and explain multigenerational incidence in families. Common genetic risk variants mediate genetic risk for the majority of patients with EoE. Across the 31 reported independent EoE risk loci (P < 10(-5)), most of the EoE risk variants are located in between genes (36.7%) or within the introns of genes (42.4%). Although some variants do change the amino acid sequence of genes (2.2%), only 3 of the 31 EoE risk loci harbor an amino acid-changing variant. Thus most EoE risk loci are outside of the coding regions of genes, suggesting a key role for gene regulation in patients with EoE, which is consistent with most other complex diseases.	[Kottyan, Leah C.; Weirauch, Matthew T.; Rothenberg, Marc E.; Martin, Lisa J.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Kottyan, Leah C.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Kottyan, Leah C.; Parameswaran, Sreeja; Weirauch, Matthew T.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA; [Weirauch, Matthew T.] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA; [Weirauch, Matthew T.] Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; [Martin, Lisa J.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Kottyan, LC (corresponding author), 3333 ML 15026 Burnet Ave, Cincinnati, OH 45229 USA.	Leah.Kottyan@cchmc.org	Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946; Kottyan, Leah/0000-0003-3979-2220	Cincinnati Children's Hospital Medical Center (CCHMC) Center for Pediatrics Genomics (CpG) award; Cincinnati Children's Research Foundation Endowed Scholar Award; CCHMC CpG award; National Institutes of Health grants [R01 DK107502, R37 AI045898, R01 AI057803, U19 AI070235, U54 AI117804, R01 AI124355]; Campaign Urging Research for Eosinophilic Disease (CURED); Sunshine Charitable Foundation	Cincinnati Children's Hospital Medical Center (CCHMC) Center for Pediatrics Genomics (CpG) award; Cincinnati Children's Research Foundation Endowed Scholar Award; CCHMC CpG award; National Institutes of Health grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Disease (CURED); Sunshine Charitable Foundation	L.C.K. is funded by grant R01 DK107502 and a Cincinnati Children's Hospital Medical Center (CCHMC) Center for Pediatrics Genomics (CpG) award. M.T.W. is supported by a Cincinnati Children's Research Foundation Endowed Scholar Award and a CCHMC CpG award. M.E.R.'s work is funded by National Institutes of Health grants R37 AI045898, U19 AI070235, R01 AI057803, and R01 DK107502; the Campaign Urging Research for Eosinophilic Disease (CURED); the Sunshine Charitable Foundation and its supporters, Denise and David Bunning. L.J.M. is supported by National Institutes of Health grants U19 AI070235, U54 AI117804, R01 AI124355, and R01 DK107502.	Alexander ES, 2014, J ALLERGY CLIN IMMUN, V134, P1084, DOI 10.1016/j.jaci.2014.07.021; Allen-Brady K, 2017, J ALLERGY CLIN IMMUN, V140, P1138, DOI 10.1016/j.jaci.2016.12.979; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Azouz NP, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap9736; Azouz Nurit P, 2015, J Vis Exp, P52505, DOI 10.3791/52505; Baye TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016522; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Dashti MJS, 2017, BIOTECHNIQUES, V62, P18, DOI 10.2144/000114492; de Guia RM, 2010, INT J MOL EPIDEMIOL, V1, P67; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; Jensen ET, 2018, J ALLERGY CLIN IMMUN, V142, P32, DOI 10.1016/j.jaci.2018.04.015; Jensen ET, 2018, J ALLERGY CLIN IMMUN, V141, P632, DOI 10.1016/j.jaci.2017.07.010; Jensen ET, 2018, J ALLERGY CLIN IMMUN, V141, P214, DOI 10.1016/j.jaci.2017.05.018; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Kohli MA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000041; Kottyan LC, 2017, MUCOSAL IMMUNOL, V10, P580, DOI 10.1038/mi.2017.4; Kottyan L, 2019, ANN ALLERG ASTHMA IM, V122, P443, DOI 10.1016/j.anai.2018.10.026; Kottyan LC, 2019, GENES IMMUN, V20, P281, DOI 10.1038/s41435-018-0034-z; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Litosh VA, 2017, J ALLERGY CLIN IMMUN, V139, P1762, DOI 10.1016/j.jaci.2016.09.027; Lu MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027363; Lyles J, 2019, CURR OPIN IMMUNOL, V60, P46, DOI 10.1016/j.coi.2019.04.004; Mansoor E, 2016, DIGEST DIS SCI, V61, P2928, DOI 10.1007/s10620-016-4204-4; Martin LJ, 2018, J ALLERGY CLIN IMMUN, V141, P1690, DOI 10.1016/j.jaci.2017.09.046; Martin LJ, 2015, J ALLERGY CLIN IMMUN, V135, P1519, DOI 10.1016/j.jaci.2015.03.004; Miller DE, 2019, G3-GENES GENOM GENET, V9, P729, DOI 10.1534/g3.118.200901; Namjou B, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00401; Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646; O'Shea KM, 2018, GASTROENTEROLOGY, V154, P333, DOI 10.1053/j.gastro.2017.06.065; Peng G, 2013, P NATL ACAD SCI USA, V110, P3985, DOI 10.1073/pnas.1222158110; Rochman M, 2018, J ALLERGY CLIN IMMUN, V142, P10, DOI 10.1016/j.jaci.2018.05.008; Rochman M, 2017, J ALLERGY CLIN IMMUN, V140, P738, DOI 10.1016/j.jaci.2016.11.042; Rothenberg ME, 2015, GASTROENTEROLOGY, V148, P1143, DOI 10.1053/j.gastro.2015.02.002; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Russo A, 2018, INT J MOL SCI, V19; Schwartz JT, 2019, J ALLERGY CLIN IMMUN, V143, P1221, DOI 10.1016/j.jaci.2018.10.036; Sherrill JD, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99922; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; So HC, 2017, BIOINFORMATICS, V33, P886, DOI 10.1093/bioinformatics/btw745; Toma C, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0113-y; Visscher PM, 2012, AM J HUM GENET, V90, P7, DOI 10.1016/j.ajhg.2011.11.029; Wagner MJ, 2013, PHARMACOGENOMICS, V14, P413, DOI [10.2217/PGS.13.36, 10.2217/pgs.13.36]; Weissenkampen J Dylan, 2019, Curr Protoc Hum Genet, V101, pe83, DOI 10.1002/cphg.83; Wen T, 2019, J CLIN INVEST, V129, P2014, DOI 10.1172/JCI125917	46	25	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					9	15		10.1016/j.jaci.2019.11.013	http://dx.doi.org/10.1016/j.jaci.2019.11.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31910986	Bronze, Green Accepted			2022-12-18	WOS:000505590800002
J	Gilhar, A; Laufer-Britva, R; Keren, A; Paus, R				Gilhar, Amos; Laufer-Britva, Rimma; Keren, Aviad; Paus, Ralf			Frontiers in alopecia areata pathobiology research	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Autoantigens; IFN-gamma; invariant natural killer T cell 10; severe combined immune deficiency mice; regulatory T cells	REGULATORY T-CELLS; JANUS KINASE INHIBITOR; HUMAN SCALP EXPLANTS; HUMAN HAIR FOLLICLE; HUMANIZED MOUSE MODEL; NATURAL-KILLER-CELLS; CLASS-I EXPRESSION; IMMUNE PRIVILEGE; ATOPIC-DERMATITIS; INTERFERON-GAMMA	This current review explores selected and as yet insufficiently investigated frontiers in current alopecia areata (AA) pathobiology research, with an emphasis on potential "new'' players in AA pathobiology that deserve more systematic exploration and therapeutic targeting. Indeed, new evidence suggests that CD8(+) T cells, which have long been thought to be the central players in AA pathobiology, are not the only drivers of disease. Instead, subsets of natural killer (NK) and so-called "unconventional'' T cells (invariant NK T cells, gamma delta T cells, classic NK cells, and type 1 innate lymphoid cells), all of which can produce large amounts of IFN-gamma, might also drive AA pathobiology independent of classical, autoantigen-dependent CD8(+) T-cell functions. Another important new frontier is the role of regulatory lymphocyte subsets, such as regulatory T cells, gamma delta regulatory T cells, NKT10 cells, and perifollicular mast cells, in maintaining physiologic hair follicle immune privilege (IP); the extent to which these functions are defective in patients with AA; and how this IP-protective role could be restored therapeutically in patients with established AA. Broadening our AA research horizon along the lines suggested above promises not only to open the door to innovative and even more effective immunotherapy strategies for AA but will also likely be relevant for other autoimmune disorders in which pathobiology, ectopic MHC class I expression, and IP collapse play an important role.	[Gilhar, Amos; Keren, Aviad] Technion Israel Inst Technol, Rappaport Fac Med, Skin Res Lab, Haifa, Israel; [Laufer-Britva, Rimma] Rambam Hlth Care Campus, Dept Dermatol, Haifa, Israel; [Paus, Ralf] Univ Miami, Miller Sch Med, Dr Philipp Frost Dept Dermatol & Cutaneous Surg, Coral Gables, FL 33124 USA; [Paus, Ralf] Univ Manchester, Dermatol Res Ctr, Manchester, Lancs, England; [Paus, Ralf] NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; University of Miami; University of Manchester	Gilhar, A (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Skin Res Lab, Haifa, Israel.	doritg2000@gmail.com						Aleisa A, 2019, PEDIATR DERMATOL, V36, pE44, DOI 10.1111/pde.13699; Ali N, 2017, CELL, V169, P1119, DOI 10.1016/j.cell.2017.05.002; Antonelli A, 2014, CYTOKINE GROWTH F R, V25, P57, DOI 10.1016/j.cytogfr.2014.01.006; Arenas R., 2019, J AM ACAD DERMATOL; Attia EAS, 2010, DERMAT RES PRACT, V2010, DOI 10.1155/2010/503587; Bain KA, 2020, BRIT J DERMATOL, V182, P130, DOI 10.1111/bjd.18008; Barahmani N, 2009, J AM ACAD DERMATOL, V61, P581, DOI 10.1016/j.jaad.2009.04.031; Becker JC, 1996, J INVEST DERMATOL, V107, P627, DOI 10.1111/1523-1747.ep12584237; Bertolini M, 2016, BRIT J DERMATOL, V175, P531, DOI 10.1111/bjd.14645; Bertolini Marta, 2015, J Investig Dermatol Symp Proc, V17, P9, DOI 10.1038/jidsymp.2015.31; Bertolini M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094260; Bertolini M, 2013, EXP DERMATOL, V22, P593, DOI 10.1111/exd.12205; Betz RC, 2007, J INVEST DERMATOL, V127, P2539, DOI 10.1038/sj.jid.5700915; Betz RC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6966; Borde A, 2018, EXPERT OPIN THER TAR, V22, P503, DOI 10.1080/14728222.2018.1481504; Boy MG, 2009, J INVEST DERMATOL, V129, P2299, DOI 10.1038/jid.2009.25; Bracke S, 2014, EXP DERMATOL, V23, P199, DOI 10.1111/exd.12321; Britva RL, 2020, BRIT J DERMATOL, V182, P227, DOI 10.1111/bjd.18264; Britva RL, 2019, J INVEST DERMATOL, V139, pS88; Carretero M, 2016, J INVEST DERMATOL, V136, P136, DOI 10.1038/JID.2015.362; Castela E, 2014, JAMA DERMATOL, V150, P748, DOI 10.1001/jamadermatol.2014.504; Christoph T, 2000, BRIT J DERMATOL, V142, P862, DOI 10.1046/j.1365-2133.2000.03464.x; Coda AB, 2011, GENOMICS, V98, P431, DOI 10.1016/j.ygeno.2011.08.009; Collins PL, 2019, CELL, V176, P348, DOI 10.1016/j.cell.2018.11.045; Corbera-Bellalta M, 2016, ANN RHEUM DIS, V75, P1177, DOI 10.1136/annrheumdis-2015-208371; Crispin MK, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89776; Czarnowicki T, 2018, ALLERGY, V73, P713, DOI 10.1111/all.13346; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P2095, DOI 10.1016/j.jaci.2018.11.031; Dai YX, 2019, J AM ACAD DERMATOL, V80, P1164, DOI 10.1016/j.jaad.2018.12.041; Darrigade AS, 2018, BRIT J DERMATOL, V179, P534, DOI 10.1111/bjd.16711; de Jong A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121949; De Luca F, 2019, CLIN EXP IMMUNOL, V195, P74, DOI 10.1111/cei.13158; Eberl G, 2016, NAT REV IMMUNOL, V16, P524, DOI 10.1038/nri.2016.75; Ebrahim Adel Ali, 2019, Int J Trichology, V11, P26, DOI 10.4103/ijt.ijt_80_18; Eleftheriadis T, 2016, INT J MOL MED, V37, P1412, DOI 10.3892/ijmm.2016.2547; Fischer J, 2017, EXP DERMATOL, V26, P536, DOI 10.1111/exd.13123; Freyschmidt-Paul P, 2006, BRIT J DERMATOL, V155, P515, DOI 10.1111/j.1365-2133.2006.07377.x; Fu BQ, 2014, IMMUNOLOGY, V141, P483, DOI 10.1111/imm.12224; Fuentes-Duculan J, 2016, EXP DERMATOL, V25, P282, DOI 10.1111/exd.12918; Gao Z, 2017, ONCOTARGET, V8, P33432, DOI 10.18632/oncotarget.16504; Ghraieb A, 2018, J AUTOIMMUN, V91, P61, DOI 10.1016/j.jaut.2018.04.001; Gilhar A, 2005, J INVEST DERMATOL, V124, P288, DOI 10.1111/j.0022-202X.2004.23580.x; Gilhar A, 1998, J CLIN INVEST, V101, P62, DOI 10.1172/JCI551; Gilhar A, 2003, CLIN IMMUNOL, V106, P181, DOI 10.1016/S1521-6616(02)00042-6; GILHAR A, 1993, CLIN IMMUNOL IMMUNOP, V66, P120, DOI 10.1006/clin.1993.1015; Gilhar A, 2001, J INVEST DERMATOL, V117, P1357, DOI 10.1046/j.0022-202x.2001.01583.x; Gilhar A, 2002, ARCH DERMATOL, V138, P916, DOI 10.1001/archderm.138.7.916; Gilhar A, 2019, LANCET, V393, P318, DOI 10.1016/S0140-6736(18)32987-8; Gilhar A, 2016, AUTOIMMUN REV, V15, P726, DOI 10.1016/j.autrev.2016.03.008; Gilhar A, 2013, J INVEST DERMATOL, V133, P2088, DOI 10.1038/jid.2013.141; Gilhar A, 2013, J INVEST DERMATOL, V133, P844, DOI 10.1038/jid.2012.365; Gilhar A, 2012, NEW ENGL J MED, V366, P1515, DOI 10.1056/NEJMra1103442; Gilhar A, 2010, J INVEST DERMATOL, V130, P2535, DOI 10.1038/jid.2010.260; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Gong Y, 2018, EXP DERMATOL; Aspizua SG, 2010, AM J PATHOL, V177, P3112, DOI 10.2353/ajpath.2010.100078; Guttman-Yassky E, 2018, ARCH DERMATOL RES, V310, P607, DOI 10.1007/s00403-018-1853-5; Han YM, 2015, J DERMATOL, V42, P981, DOI 10.1111/1346-8138.12978; Hua J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25384-x; Huang KP, 2013, JAMA DERMATOL, V149, P789, DOI 10.1001/jamadermatol.2013.3049; Ikeda T, 1965, Hifuka Kiyo, V60, P110; Inui S, 2013, J DERMATOL, V40, P881, DOI 10.1111/1346-8138.12273; Ito T, 2004, AM J PATHOL, V164, P623, DOI 10.1016/S0002-9440(10)63151-3; Ito T, 2008, J INVEST DERMATOL, V128, P1196, DOI 10.1038/sj.jid.5701183; Ito T, 2013, J DERMATOL SCI, V72, P327, DOI 10.1016/j.jdermsci.2013.07.014; Ito Taisuke, 2008, V10, P27, DOI 10.1159/000131412; Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5; Kanameishi S, 2017, J EUR ACAD DERMATOL, V31, pE137, DOI 10.1111/jdv.13879; Kang H, 2010, J INVEST DERMATOL, V130, P2677, DOI 10.1038/jid.2010.180; Kaufman G, 2010, EXP DERMATOL, V19, pE347, DOI 10.1111/j.1600-0625.2010.01106.x; Keino H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1679197; Keren A, 2018, J ALLERGY CLIN IMMUN, V142, P305, DOI 10.1016/j.jaci.2018.02.015; Kinori M, 2011, INVEST OPHTH VIS SCI, V52, P4447, DOI 10.1167/iovs.10-7154; Le Poole I Caroline, 2017, J Investig Dermatol Symp Proc, V18, pS38, DOI 10.1016/j.jisp.2016.10.023; Lee S, 2019, J AM ACAD DERMATOL, V80, P466, DOI 10.1016/j.jaad.2018.07.013; Leung MC, 2010, J PROTEOME RES, V9, P5153, DOI 10.1021/pr100422u; Li J, 2016, J INVEST DERMATOL, V136, P715, DOI 10.1016/j.jid.2015.12.003; Lindstrom E, 2007, J PHARMACOL EXP THER, V322, P1286, DOI 10.1124/jpet.107.124958; Liu LY, 2019, J AM ACAD DERMATOL, V80, P566, DOI 10.1016/j.jaad.2018.08.040; Loh SH, 2018, J EUR ACAD DERMATOL, V32, P1028, DOI 10.1111/jdv.14775; Ma EH, 2017, CELL METAB, V25, P482, DOI 10.1016/j.cmet.2017.01.014; McElwee KJ, 2013, EXP DERMATOL, V22, P609, DOI 10.1111/exd.12209; McElwee KJ, 2005, J INVEST DERMATOL, V124, P947, DOI 10.1111/j.0022-202X.2005.23692.x; Meyer KC, 2008, BRIT J DERMATOL, V159, P1077, DOI 10.1111/j.1365-2133.2008.08818.x; Mikhaylov D, 2019, ARCH DERMATOL RES, V311, P29, DOI 10.1007/s00403-018-1876-y; Minder EI, 2017, CLIN PHARMACOKINET, V56, P815, DOI 10.1007/s40262-016-0501-5; Mitchell Krystal, 2018, JAAD Case Rep, V4, P143, DOI 10.1016/j.jdcr.2017.11.020; Moftah NH, 2016, ARCH DERMATOL RES, V308, P415, DOI 10.1007/s00403-016-1652-9; Mohan GC, 2015, JAMA DERMATOL, V151, P522, DOI 10.1001/jamadermatol.2014.3324; Nagai H, 2006, ARCH DERMATOL RES, V298, P131, DOI 10.1007/s00403-006-0668-y; Nickoloff BJ, 2000, J DERMATOL SCI, V24, P212, DOI 10.1016/S0923-1811(00)00120-1; Nickoloff BJ, 1999, ARCH DERMATOL, V135, P546, DOI 10.1001/archderm.135.5.546; Niederkorn JY, 2003, J INVEST DERM SYMP P, V8, P168, DOI 10.1046/j.1087-0024.2003.00803.x; Ocampo-Garza J, 2019, EXPERT OPIN INV DRUG, V28, P275, DOI 10.1080/13543784.2019.1568989; Papp KA, 2012, BRIT J DERMATOL, V167, P668, DOI 10.1111/j.1365-2133.2012.11168.x; Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646; PAUS R, 1993, YALE J BIOL MED, V66, P541; Paus R, 2005, TRENDS IMMUNOL, V26, P32, DOI 10.1016/j.it.2004.09.014; Paus R, 2003, J INVEST DERM SYMP P, V8, P188, DOI 10.1046/j.1087-0024.2003.00807.x; PAUS R, 1991, BRIT J DERMATOL, V124, P415, DOI 10.1111/j.1365-2133.1991.tb00618.x; PAUS R, 1994, BRIT J DERMATOL, V131, P177; Paus Ralf, 2018, J Investig Dermatol Symp Proc, V19, pS12, DOI 10.1016/j.jisp.2017.10.014; Penzi LR, 2018, JAMA DERMATOL, V154, P1358, DOI 10.1001/jamadermatol.2018.2976; Peters EMJ, 2007, AM J PATHOL, V171, P1872, DOI 10.2353/ajpath.2007.061206; Petukhova L, 2010, NATURE, V466, P113, DOI 10.1038/nature09114; Ports WC, 2013, BRIT J DERMATOL, V169, P137, DOI 10.1111/bjd.12266; Pratt CH, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.11; Price VH, 2005, J AM ACAD DERMATOL, V52, P138, DOI 10.1016/j.jaad.2004.05.019; Punwani N, 2012, J AM ACAD DERMATOL, V67, P658, DOI 10.1016/j.jaad.2011.12.018; Putterman E, 2019, J AM ACAD DERMATOL, V80, P1389, DOI 10.1016/j.jaad.2018.12.051; Rankin LC, 2018, CELL, V173, P554, DOI 10.1016/j.cell.2018.03.013; Prado MJR, 2018, J INVEST ALLERG CLIN, V28, P420, DOI 10.18176/jiaci.0301; Rodriguez RS, 2014, J CLIN INVEST, V124, P1027, DOI 10.1172/JCI72932; Ruckert R, 1998, J INVEST DERMATOL, V111, P25, DOI 10.1046/j.1523-1747.1998.00228.x; Seidel JA, 2018, CLIN EXP IMMUNOL, V194, P79, DOI 10.1111/cei.13189; Shin BS, 2013, J DERMATOL SCI, V70, P141, DOI 10.1016/j.jdermsci.2013.01.006; Shin JM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30997-3; Siebenhaar F, 2007, J INVEST DERMATOL, V127, P1489, DOI 10.1038/sj.jid.5700704; Smogorzewski Jan, 2019, JAAD Case Rep, V5, P116, DOI 10.1016/j.jdcr.2018.11.007; Smyth JR, 1999, J INVEST DERM SYMP P, V4, P211, DOI 10.1038/sj.jidsp.5640213; Song T, 2018, J ALLERGY CLIN IMMUN, V142, P1631, DOI 10.1016/j.jaci.2018.06.029; Strazzulla LC, 2018, J AM ACAD DERMATOL, V78, P1, DOI 10.1016/j.jaad.2017.04.1141; Strober B, 2013, BRIT J DERMATOL, V169, P992, DOI 10.1111/bjd.12517; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V136, P1277, DOI 10.1016/j.jaci.2015.06.032; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Sundberg John P., 2007, Journal of Experimental Animal Science, V43, P265, DOI 10.1016/j.jeas.2006.10.005; Tan PH, 2009, EXPERT OPIN THER TAR, V13, P987, DOI 10.1517/14728220903018940; Taylor AW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00037; Trueb Ralph Michel, 2018, Int J Trichology, V10, P193, DOI 10.4103/ijt.ijt_62_18; Uchida Y, 2016, J INVEST DERMATOL, V136, pS9, DOI 10.1016/j.jid.2016.02.076; Waldmann H, 2006, NATURE, V442, P987, DOI 10.1038/nature05165; Wambier CG, 2019, J AM ACAD DERMATOL, V80, pE45, DOI 10.1016/j.jaad.2018.08.059; Wang EHC, 2018, J INVEST DERMATOL, V138, P1911, DOI 10.1016/j.jid.2018.05.027; Wang EHC, 2016, J INVEST DERMATOL, V136, P1617, DOI 10.1016/j.jid.2016.04.004; Wang ECE, 2018, J ALLERGY CLIN IMMUN, V141, P499, DOI 10.1016/j.jaci.2017.10.028; Wang LL, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12710; Wang XJ, 2014, J INVEST DERMATOL, V134, P736, DOI 10.1038/jid.2013.368; Wei YL, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00118; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645; Yazdanyar S, 2019, DERMATITIS, V30, P175, DOI 10.1097/DER.0000000000000458; Yoon TY, 2014, JAMA DERMATOL, V150, P952, DOI 10.1001/jamadermatol.2014.62; Yoshiga Y, 2008, INT J MOL MED, V22, P369, DOI 10.3892/ijmm_00000032; Zhang XT, 2015, ARCH DERMATOL RES, V307, P319, DOI 10.1007/s00403-015-1539-1; Zhang YY, 2016, EUR J DERMATOL, V26, P240, DOI 10.1684/ejd.2015.2709; Zohar Y, 2014, J CLIN INVEST, V124, P2009, DOI 10.1172/JCI71951; Zoller M, 2002, J INVEST DERMATOL, V118, P983, DOI 10.1046/j.1523-1747.2002.01745.x	147	25	27	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1478	1489		10.1016/j.jaci.2019.08.035	http://dx.doi.org/10.1016/j.jaci.2019.08.035			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31606262	Bronze			2022-12-18	WOS:000500694900003
J	Wang, M; Zhang, N; Zheng, M; Li, Y; Meng, LL; Ruan, Y; Han, JB; Zhao, N; Wang, XD; Zhang, L; Bachert, C				Wang, Min; Zhang, Nan; Zheng, Ming; Li, Ying; Meng, Lingling; Ruan, Yu; Han, Jinbo; Zhao, Na; Wang, Xiangdong; Zhang, Luo; Bachert, Claus			Cross-talk between T(H)2 and T(H)17 pathways in patients with chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis with nasal polyps; T(H)2; T(H)17; endotypes; shift	GROWTH-FACTOR-BETA; T-CELLS; AIRWAY INFLAMMATION; TGF-BETA; EXPRESSION; IL-4; EOSINOPHIL; DEVELOP; IL-17A; SENSITIZATION	Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease with a spectrum of endotypes. T(H)2- and T(H)17-related cytokines are 2 central regulators involved in the inflammation associated with CRSwNP. Objective: We sought to investigate the interregulation of T(H)2 and T(H)17 pathways in Chinese patients with CRSwNP. Methods: Levels of key T(H)2- and T(H)17-related factors were measured in homogenates of polyp tissue obtained from patients with CRSwNP. The relationship of these factors and their expression in groups classified according to tissue IL-5 and IL-17 concentrations were analyzed. Cross-regulation of T(H)2 and T(H)17 cytokines and the effects of dexamethasone treatment were studied in dispersed nasal polyp cells. Associations between T(H)2- and T(H)17 related factors and comorbid atopic status and asthma, disease recurrence, and edema scores were also explored. Results: Four CRSwNP groups were classified based on expression or nonexpression of mutually exclusive T(H)2- and T(H)17-related factors. The T(H)2 cytokines IL-4 and IL-13 inhibited expression of T(H)17-related factors, whereas the T(H)17 cytokines IL-17 and TGF-beta 1 enhanced expression of T(H)2-related factors. Dexamethasone treatment inhibited both the T(H)2 and T(H)17 pathways. A patient's atopic status was related to their T(H)2 immune response. Edema scores were positively correlated with the T(H)2 pathway and negatively correlated with the T(H)17 pathway. Conclusion: The T(H)2 and T(H)17 pathways are mutually exclusive and regulate each other, favoring the development of a T(H)2 immune response in Chinese patients with CRSwNP.	[Wang, Min; Zheng, Ming; Han, Jinbo; Wang, Xiangdong; Zhang, Luo] Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Wang, Min; Li, Ying; Ruan, Yu; Han, Jinbo; Wang, Xiangdong; Zhang, Luo] Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China; [Zhang, Nan; Bachert, Claus] Ghent Univ Hosp, Upper Airways Res Lab, Dept Otorhinolaryngol, Ghent, Belgium; [Meng, Lingling] Bayan Nur Hosp, Dept Otolaryngol, Bayan Nur, Peoples R China; [Zhao, Na] Capital Med Univ, Dept Otolaryngol, Yanqing Dist Hosp, Gen Practice & Continuing Educ, Beijing, Peoples R China; [Wang, Xiangdong; Zhang, Luo] Capital Med Univ, Dept Allergy, Beijing Tongren Hosp, Beijing, Peoples R China; [Bachert, Claus] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div ENT Dis, Stockholm, Sweden; [Bachert, Claus] Karolinska Univ Hosp, Dept Ear Nose & Throat Dis, Stockholm, Sweden	Capital Medical University; Ghent University; Ghent University Hospital; Capital Medical University; Capital Medical University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Wang, XD; Zhang, L (corresponding author), Beijing Inst Otolaryngol, 17 HouGouHuTong, Beijing 100005, Peoples R China.	entwxd@vip.sina.com; dr.luozhang@139.com	Zhang, Nan/AAQ-3944-2020; Wang, Xiangdong/AAF-9148-2020; Bachert, Claus/J-8825-2012	Zhang, Luo/0000-0002-0910-9884	National Key R&D Program of China [2016YFC20160905200]; Program for the Changjiang scholars and Innovative Research Team [IRT13082]; National Natural Science Foundation of China [81420108009, 81630023, 81570893, 81570894]; Beijing Municipal Administration of Hospitals' Mission Plan [SML20150203]; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Beijing Technology and Business University) [20181045]; Capital Health Research and Development of Special [2014-41092]; Beijing Natural Science Foundation [7162042, 7172054]	National Key R&D Program of China; Program for the Changjiang scholars and Innovative Research Team(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Administration of Hospitals' Mission Plan; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Beijing Technology and Business University); Capital Health Research and Development of Special; Beijing Natural Science Foundation(Beijing Natural Science Foundation)	Supported by grants from the National Key R&D Program of China (2016YFC20160905200), the Program for the Changjiang scholars and Innovative Research Team (IRT13082), the National Natural Science Foundation of China (81420108009, 81630023, 81570893, and 81570894), Beijing Municipal Administration of Hospitals' Mission Plan (SML20150203), Beijing Advanced Innovation Center for Food Nutrition and Human Health (Beijing Technology and Business University, 20181045), the Capital Health Research and Development of Special (2014-41092), and the Beijing Natural Science Foundation (7162042 and 7172054).	Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Aravindan KP, 2010, INDIAN J PATHOL MICR, V53, P258, DOI 10.4103/0377-4929.64343; Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004; Banuelos J, 2017, ALLERGY, V72, P331, DOI 10.1111/all.13051; Casale TB, 2017, J ALLERGY CLIN IMMUN, V139, P1411, DOI 10.1016/j.jaci.2017.03.006; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Cooney LA, 2011, J IMMUNOL, V187, P4440, DOI 10.4049/jimmunol.1002860; Derycke L, 2012, J CYST FIBROS, V11, P193, DOI 10.1016/j.jcf.2011.11.007; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Gorelik L, 2000, J IMMUNOL, V165, P4773, DOI 10.4049/jimmunol.165.9.4773; Gupta A, 2014, THORAX, V69, P508, DOI 10.1136/thoraxjnl-2013-203421; Gurrola J, 2017, J ALLERGY CLIN IMMUN, V140, P1499, DOI 10.1016/j.jaci.2017.10.006; Hall SL, 2017, J ALLERGY CLIN IMMUN, V139, P462, DOI 10.1016/j.jaci.2016.04.037; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; He R, 2009, J ALLERGY CLIN IMMUN, V124, P761, DOI 10.1016/j.jaci.2009.07.040; Katotomichelakis M, 2013, AM J RHINOL ALLERGY, V27, P354, DOI 10.2500/ajra.2013.27.3922; Kim SJ, 2013, OTOLARYNG HEAD NECK, V149, P431, DOI 10.1177/0194599813495363; Kirstein F, 2016, J ALLERGY CLIN IMMUN, V137, P1852, DOI 10.1016/j.jaci.2015.10.036; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Patou J, 2008, J ALLERGY CLIN IMMUN, V121, P110, DOI 10.1016/j.jaci.2007.08.059; Ray S, 2014, CURR OPIN GASTROEN, V30, P531, DOI 10.1097/MOG.0000000000000119; SAD S, 1994, J IMMUNOL, V153, P3514; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Shin SH, 2014, AM J RHINOL ALLERGY, V28, P95, DOI 10.2500/ajra.2014.28.4003; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; SWAIN SL, 1991, J IMMUNOL, V147, P2991; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; Verrecchia F, 2007, WORLD J GASTROENTERO, V13, P3056, DOI 10.3748/wjg.v13.i22.3056; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wang CS, 2015, J ALLERGY CLIN IMMUN, V135, P922, DOI 10.1016/j.jaci.2014.10.018; Wang M, 2015, J ALLERGY CLIN IMMUN, V136, P1700, DOI 10.1016/j.jaci.2015.09.005; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Wenzel SE, 2002, J IMMUNOL, V169, P4613, DOI 10.4049/jimmunol.169.8.4613; Yang LY, 2017, ALLERGY ASTHMA IMMUN, V9, P142, DOI 10.4168/aair.2017.9.2.142; Zeng M, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0096-x; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zhang Y, 2017, J ALLERGY CLIN IMMUN, V140, P1230, DOI 10.1016/j.jaci.2017.09.009	42	25	27	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1254	1264		10.1016/j.jaci.2019.06.023	http://dx.doi.org/10.1016/j.jaci.2019.06.023			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31271788	hybrid			2022-12-18	WOS:000495004700017
J	Liang, YS; Yu, BH; Chen, JC; Wu, HJ; Xu, YP; Yang, B; Lu, QJ				Liang, Yunsheng; Yu, Bihui; Chen, Junchen; Wu, Haijin; Xu, Yingping; Yang, Bin; Lu, Qianjin			Thymic stromal lymphopoietin epigenetically upregulates Fc receptor gamma subunit-related receptors on antigen-presenting cells and induces T(H)2/T(H)17 polarization through dectin-2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; thymic stromal lymphopoietin; signal transducer and activator of transcription 5; ten-eleven translocation protein 2; DNA demethylation; FcR gamma-related receptors; dectin-2; allergen uptake; IL-33; IL-25; T(H)2/T(H)17 polarization	DENDRITIC CELLS; ATOPIC-DERMATITIS; EPSILON-RI; EXPRESSION; ALLERGEN; STAT5; T(H)2; DNA; DEMETHYLATION; INFLAMMATION	Background: Fc receptor gamma subunit (FcR gamma)-related receptors expressed on antigen-presenting cells (APCs) enhance allergen sensitization and allergic inflammation. DNA demethylation of the high-affinity IgE receptor gamma subunit gene (FCER1G) leads to FcR gamma and Fc epsilon RI overexpression on monocytes from patients with atopic dermatitis. Objective: We investigated epigenetic mechanisms underlying FCER1G demethylation and upregulation of FcR gamma-related receptors on APCs and the consequent effect on allergic responses. Methods: Effects of thymic stromal lymphopoietin (TSLP) on expression of FcR gamma and its related receptors and methylation or hydroxymethylation of FCER1G in human monocytes were assessed. Recruitment of ten-eleven translocation protein (TET) 2 to FCER1G by TSLP-activated phosphorylated signal transducer and activator of transcription 5 (pSTAT5) was evaluated. Effects of TSLP on expression of FcR gamma-related receptors and costimulatory receptors on monocyte-derived dendritic cells (DCs) and the ability of DCs to take up ovalbumin were analyzed. TSLP-induced T-H polarization and related cytokine production were also analyzed. Results: pSTAT5 activation by TSLP resulted in TET2 recruitment to FCER1G, leading to FCER1G demethylation and subsequent upregulation of FcR gamma-related receptors on monocytes. TSLP not only stimulated monocyte-derived DC maturation but also maintained their allergen uptake ability, likely through maintenance and upregulation of FcR gamma-related receptors. Allergen sensitization and upregulation of T(H)2/T(H)17-related cytokines contributed to TSLP-DC-induced T(H)2/T(H)17 polarization. The latter was attenuated on neutralization with a dectin-2 antibody. Conclusions: TSLP mediated upregulation of FcR gamma-related receptors on APCs through activation of pSTAT5, which recruited TET2 to induce FCER1G demethylation. TSLP-induced allergic T(H)2/T(H)17 polarization likely depends on dectin-2-mediated allergen sensitization and upregulation of T(H)2/T(H)17-related cytokines.	[Liang, Yunsheng; Yu, Bihui; Chen, Junchen; Xu, Yingping; Yang, Bin] Southern Med Univ, Dermatol Hosp, Dept Dermatol, 2 Lujing Rd, Guangzhou 510091, Guangdong, Peoples R China; [Yu, Bihui; Wu, Haijin; Lu, Qianjin] Cent S Univ, Xiangya Hosp 2, Hunan Key Lab Med Epigen, Changsha, Hunan, Peoples R China; [Yu, Bihui; Wu, Haijin; Lu, Qianjin] Cent S Univ, Xiangya Hosp 2, Dept Dermatol, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China	Southern Medical University - China; Central South University; Central South University	Liang, YS; Yang, B (corresponding author), Southern Med Univ, Dermatol Hosp, Dept Dermatol, 2 Lujing Rd, Guangzhou 510091, Guangdong, Peoples R China.; Lu, QJ (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Dermatol, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.	yunshengliang@aliyun.com; yangbin101@hotmail.com; qianliu5860@csu.edu.cn		Yang, Bin/0000-0002-7155-6079	National Natural Science Foundation of China [81371742, 81573052]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Supported by the National Natural Science Foundation of China (grant nos. 81371742 and 81573052 to Y.L.).	Abboud G, 2009, J IMMUNOL, V182, P6517, DOI 10.4049/jimmunol.0801055; Bandukwala HS, 2007, J EXP MED, V204, P1875, DOI 10.1084/jem.20061134; Bell BD, 2013, NAT IMMUNOL, V14, P364, DOI 10.1038/ni.2541; Booth MJ, 2014, NAT CHEM, V6, P435, DOI [10.1038/nchem.1893, 10.1038/NCHEM.1893]; Booth MJ, 2013, NAT PROTOC, V8, P1841, DOI 10.1038/nprot.2013.115; Borriello F, 2017, J IMMUNOL, V198, P3426, DOI 10.4049/jimmunol.1601497; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Hanifin JM, 1999, ARCH DERMATOL, V135, P1551, DOI 10.1001/archderm.135.12.1551; Hubo M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00082; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Humeniuk P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071491; Ichiyama K, 2015, IMMUNITY, V42, P613, DOI 10.1016/j.immuni.2015.03.005; Ito T, 2012, ALLERGOL INT, V61, P35, DOI 10.2332/allergolint.11-RAI-0376; Kitamura K, 2007, J IMMUNOL, V178, P480, DOI 10.4049/jimmunol.178.1.480; Klug M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-5-r46; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Liang Y, 2012, ALLERGY, V67, P424, DOI 10.1111/j.1398-9995.2011.02760.x; Lin JX, 2012, IMMUNITY, V36, P586, DOI 10.1016/j.immuni.2012.02.017; Moniuszko M, 2009, CLIN IMMUNOL, V130, P338, DOI 10.1016/j.clim.2008.09.011; Norimoto A, 2014, AM J RESP CELL MOL, V51, P201, DOI 10.1165/rcmb.2013-0522OC; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2002, ALLERGY, V57, P931, DOI 10.1034/j.1398-9995.2002.23737.x; Novak N, 2012, J ALLERGY CLIN IMMUN, V129, P879, DOI 10.1016/j.jaci.2012.01.062; Pulendran B, 2010, NAT IMMUNOL, V11, P647, DOI 10.1038/ni.1894; Putiri EL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r81; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Tan L, 2012, DEVELOPMENT, V139, P1895, DOI 10.1242/dev.070771; Tjota MY, 2014, J ALLERGY CLIN IMMUN, V134, P706, DOI 10.1016/j.jaci.2014.06.013; Tjota MY, 2013, J CLIN INVEST, V123, P2287, DOI 10.1172/JCI63802; Tomoki I., 2005, J EXP MED, V202, P1213; Verstraete K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14937; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	34	25	28	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					1025	+		10.1016/j.jaci.2019.06.011	http://dx.doi.org/10.1016/j.jaci.2019.06.011			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31251950	Bronze			2022-12-18	WOS:000488803900018
J	Sharif, H; Singh, I; Kouser, L; Mosges, R; Bonny, MA; Karamani, A; Parkin, RV; Bovy, N; Kishore, U; Robb, A; Katotomichelakis, M; Holtappels, G; Derycke, L; Corazza, F; von Frenckell, R; Wathelet, N; Duchateau, J; Legon, T; Pirotton, S; Durham, SR; Bachert, C; Shamji, MH				Sharif, Hanisah; Singh, Iesha; Kouser, Lubna; Moesges, Ralph; Bonny, Marie-Alix; Karamani, Angeliki; Parkin, Rebecca V.; Bovy, Nicolas; Kishore, Uday; Robb, Abigail; Katotomichelakis, Michael; Holtappels, Gabriele; Derycke, Lara; Corazza, Francis; von Frenckell, Remy; Wathelet, Nathalie; Duchateau, Jean; Legon, Thierry; Pirotton, Sabine; Durham, Stephen R.; Bachert, Claus; Shamji, Mohamed H.			Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; peptide immunotherapy; follicular helper T cells; regulatory T cells; regulatory B cells	GRASS-POLLEN IMMUNOTHERAPY; SEASONAL ALLERGIC RHINITIS; T FOLLICULAR HELPER; B-CELLS; RESPONSES; IGE; EXPRESSION; PERSISTENCE; PREVALENCE; TOLERANCE	Background: A 3-week short-course of adjuvant-free hydrolysates of Lolium perenne peptide (LPP) immunotherapy for rhinoconjunctivitis with or without asthma over 4 physician visits is safe, well tolerated, and effective. Objective: We sought to investigate immunologic mechanisms of LPP immunotherapy in a subset of patients who participated in a phase III, multicenter, randomized, double-blind, placebo controlled trial (clinicaLgovNCT02560948). Methods: Participants were randomized to receive LPP (n = 21) or placebo (n = 11) for 3 weeks over 4 visits. Grass pollen induced basophil, T-cell, and B-cell responses were evaluated before treatment (visit [V] 2), at the end of treatment (V6), and after the pollen season (V8). Results: Combined symptom and rescue medication scores (CSMS) were lower during the peak pollen season (-35.1%, P = .03) and throughout the pollen season (-53.7%, P = .03) in the LPP-treated group compared with those in the placebo treated group. Proportions of CD63(+) and CD203c(bright)CRTH2(+) basophils were decreased following LPP treatment at V6 (10 ngl mL, P < .0001) and V8 (10 ng/mL, P <.001) compared to V2. No change in the placebo-treated group was observed. Blunting of seasonal increases in levels of grass pollen-specific IgE was observed in LPP-treated but not placebo-treated group. LPP immunotherapy, but not placebo, was associated with a reduction in proportions of IL-4(+) T(H)2 (V6, P =.02), IL-4(+) (V6, P =.003; V8, P =.004), and IL-21(+) (V6, P =.003; V8, P =.002) follicular helper T cells. Induction of FoxP3(+), follicular regulatory T, and IL-10+ regulatory B cells were observed at V6 (all P < .05) and V8 (all P < .05) in LPP-treated group. Induction of regulatory B cells was associated with allergen-neutralizing IgG4-blocking antibodies. Conclusion: For the first time, we demonstrate that the immunologic mechanisms of LPP immunotherapy are underscored by immune modulation in the T-and B-cell compartments, which is necessary for its effect.	[Sharif, Hanisah; Singh, Iesha; Kouser, Lubna; Karamani, Angeliki; Parkin, Rebecca V.; Robb, Abigail; Durham, Stephen R.; Shamji, Mohamed H.] Imperial Coll London, Immunomodulat & Tolerance Grp, Asthma UK Ctr Allerg Mech Asthma, Allergy & Clin Immunol,Inflammat Repair & Dev, London, England; [Moesges, Ralph] Inst Med Stat Informat & Epidemiol IMSIE, Cologne, Germany; [Bonny, Marie-Alix; Bovy, Nicolas; Wathelet, Nathalie; Duchateau, Jean; Legon, Thierry; Pirotton, Sabine] ASIT Biotech SA, Brussels, Belgium; [Katotomichelakis, Michael; Holtappels, Gabriele; Derycke, Lara; Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Corazza, Francis] CHU Brugmann, Lab Clin Biol, Brussels, Belgium; [Kishore, Uday] Brunel Univ, Uxbridge, Middx, England	Imperial College London; University of London; King's College London; Ghent University; Brunel University	Shamji, MH (corresponding author), Imperial Coll London, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol, Inflammat Repair & Dev,Natl Heart & Lung Inst, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	m.shamji@imperial.ac.uk	Sharif, Hanisah/AAZ-5132-2021; Shamji, Mohamed/AAU-8811-2020; Corazza, Francis V/O-1262-2013; Katotomichelakis, Michael/AAL-7657-2021; Shamji, Mohamed/AAD-1788-2019; Bachert, Claus/J-8825-2012	Sharif, Hanisah/0000-0002-2620-906X; Shamji, Mohamed/0000-0003-3425-3463; Corazza, Francis V/0000-0001-9487-2712; 	ASIT Biotech S.A., Brussels, Belgium	ASIT Biotech S.A., Brussels, Belgium	Supported by ASIT Biotech S.A., Brussels, Belgium.	Avery DT, 2008, BLOOD, V112, P1784, DOI 10.1182/blood-2008-02-142745; Avery DT, 2008, J IMMUNOL, V181, P1767, DOI 10.4049/jimmunol.181.3.1767; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Beyer M, 2011, NAT IMMUNOL, V12, P898, DOI 10.1038/ni.2084; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Couroux P, 2015, CLIN EXP ALLERGY, V45, P974, DOI 10.1111/cea.12488; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Katelaris CH, 2012, CLIN EXP ALLERGY, V42, P186, DOI 10.1111/j.1365-2222.2011.03891.x; Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013; Kitagawa Y, 2017, NAT IMMUNOL, V18, P474, DOI 10.1038/ni0417-474d; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Larche Mark, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS292, DOI 10.1513/AnnalsATS.201402-090AW; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Matsuoka T, 2013, ALLERGOL INT, V62, P403, DOI 10.2332/allergolint.13-RAI-0650; Mosges R, 2018, ALLERGY, V73, P1254, DOI 10.1111/all.13392; Mosges R, 2018, ALLERGY, V73, P896, DOI 10.1111/all.13358; Mosges R, 2018, ALLERGY, V73, P1842, DOI 10.1111/all.13433; Noble A, 2016, CLIN EXP ALLERGY, V46, P1075, DOI 10.1111/cea.12750; Pfaar O, 2018, ALLERGY, V73, P187, DOI 10.1111/all.13240; Rosewich M, 2010, CLIN EXP IMMUNOL, V160, P403, DOI 10.1111/j.1365-2249.2010.04106.x; Sage PT, 2014, IMMUNITY, V41, P1026, DOI 10.1016/j.immuni.2014.12.005; Sage PT, 2014, J CLIN INVEST, V124, P5191, DOI 10.1172/JCI76861; Scadding GW, 2017, JAMA-J AM MED ASSOC, V317, P615, DOI 10.1001/jama.2016.21040; Schulten V, 2018, J ALLERGY CLIN IMMUN, V141, P775, DOI 10.1016/j.jaci.2017.04.032; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Shamji MH, 2019, J ALLERGY CLIN IMMUN, V143, P1131, DOI 10.1016/j.jaci.2018.06.041; Shamji MH, 2018, J ALLERGY CLIN IMMUN, V141, P448, DOI 10.1016/j.jaci.2017.09.013; Shamji MH, 2017, J ALLERGY CLIN IMMUN, V140, P1485, DOI 10.1016/j.jaci.2017.10.010; Shamji MH, 2015, J ALLERGY CLIN IMMUN, V135, P913, DOI 10.1016/j.jaci.2014.09.049; Valenta R, 2011, J ALLERGY CLIN IMMUN, V127, P860, DOI 10.1016/j.jaci.2011.02.016; Varricchi G, 2016, ALLERGY, V71, P1086, DOI 10.1111/all.12878; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Wang RX, 2014, NAT MED, V20, P633, DOI 10.1038/nm.3554; Wang R, 2009, P NATL ACAD SCI USA, V106, P13439, DOI 10.1073/pnas.0901965106; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683	44	25	25	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					738	749		10.1016/j.jaci.2019.02.023	http://dx.doi.org/10.1016/j.jaci.2019.02.023			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	30844425	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000485222300019
J	Thio, CLP; Lai, ACP; Chi, PY; Webster, G; Chang, YJ				Thio, Christina Li -Ping; Lai, Alan Chuan-Ping; Chi, Po -Yu; Webster, Gill; Chang, Ya-Jen			Toll-like receptor 9-dependent interferon production prevents group 2 innate lymphoid cell-driven airway hyperreactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor 9; CpG A; group 2 innate lymphoid cells; allergic asthma; MIS416; interferons	REGULATORY T-CELLS; DENDRITIC CELLS; IFN-GAMMA; CPG OLIGODEOXYNUCLEOTIDE; MURINE MODEL; ALLERGIC INFLAMMATION; ALVEOLAR MACROPHAGES; PERIPHERAL-BLOOD; TYPE-2 IMMUNITY; TH1 CELLS	Background: Group 2 innate lymphoid cells (ILC2s) are important mediators of allergic asthma. Bacterial components, such as unmethylated CpG DNA, a Toll-like receptor (TLR) 9 agonist, are known to possess beneficial immunomodulatory effects in patients with T cell mediated chronic asthma. However, their roles in regulating ILC2s remain unclear. Objective: We sought to determine the role of TLR9 activation in regulating ILC2 function and to evaluate the therapeutic utility of an immunomodulatory microparticle containing natural TLR9 ligand (MIS416). Methods: We evaluated the immunomodulatory effects of CpG A in IL-33 induced airway hyperreactivity (AHR) and airway inflammation. The roles of interferons were examined in vivo and in vitro by using signal transducer and activator of transcription 1 (Stat1)(-/-) mice and neutralizing antibodies against IFN-gamma and IFN-alpha/beta receptor subunit 1, and their cellular sources were identified. The therapeutic utility of MIS416 was investigated in the Alternaria alternata model of allergic asthma and in humanized NSG mice. Results: We show that TLR9 activation by CpG A suppresses IL-33-mediated AHR and airway inflammation through inhibition of ILC2s. Activation of TLR9 leads to production of IFN-alpha, which drives IFN-gamma production by natural killer cells. Importantly, IFN-gamma is essential for TLR9-driven suppression, and IFN-alpha cannot compensate for impaired IFN-gamma signaling. We further show that IFN-gamma directly inhibits ILC2 function through a STAT1-dependent mechanism. Finally, we demonstrate the therapeutic potential of MIS416 in A alternata-induced airway inflammation and validated these findings in human subjects. Conclusion: TLR9 activation alleviates ILC2-driven AHR and airway inflammation through direct suppression of cell function. Microparticle-based delivery of TLR9 ligands might serve as a therapeutic strategy for asthma treatment.	[Thio, Christina Li -Ping; Lai, Alan Chuan-Ping; Chi, Po -Yu; Chang, Ya-Jen] Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan; [Webster, Gill] Innate Immunotherapeut, Auckland, New Zealand	Academia Sinica - Taiwan	Chang, YJ (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	yajchang@ibms.sinica.edu.tw	Chang, Ya-Jen/O-1584-2018	Chang, Ya-Jen/0000-0003-1377-6142	Ministry of Science and Technology [105-2628-B-001-009-MY3, 106-2320-B-001-001]; Academia Sinica Career Development Award [104-CDA-L05]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Academia Sinica Career Development Award	Supported in part by the Ministry of Science and Technology (105-2628-B-001-009-MY3 and 106-2320-B-001-001 to Y.-J.C.) and by the Academia Sinica Career Development Award (104-CDA-L05 to Y.-J.C.) in Taiwan.	Angelov GS, 2005, J IMMUNOL, V175, P189, DOI 10.4049/jimmunol.175.1.189; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Ashino S, 2008, INT IMMUNOL, V20, P259, DOI 10.1093/intimm/dxm138; Baban B, 2009, J IMMUNOL, V183, P2475, DOI 10.4049/jimmunol.0900986; Ballester M, 2015, SCI REP-UK, V5, DOI 10.1038/srep14274; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Beeh KM, 2013, J ALLERGY CLIN IMMUN, V131, P866, DOI 10.1016/j.jaci.2012.12.1561; Brasel K, 2000, BLOOD, V96, P3029, DOI 10.1182/blood.V96.9.3029.h8003029_3029_3039; Califano D, 2018, MUCOSAL IMMUNOL, V11, P209, DOI 10.1038/mi.2017.41; Campbell JD, 2014, THORAX, V69, P565, DOI 10.1136/thoraxjnl-2013-204605; Casale TB, 2015, ALLERGY, V70, P1160, DOI 10.1111/all.12663; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cheung DOY, 2000, INFECT IMMUN, V68, P4585, DOI 10.1128/IAI.68.8.4585-4592.2000; Duechs MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091223; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Fantuzzi G, 1999, J CLIN INVEST, V104, P761, DOI 10.1172/JCI7501; Fanucchi MV, 2004, AM J RESP CRIT CARE, V170, P1153, DOI 10.1164/rccm.200404-533OC; Furusawa J, 2013, J IMMUNOL, V191, P1818, DOI 10.4049/jimmunol.1300379; Girvan RC, 2011, VACCINE, V29, P545, DOI 10.1016/j.vaccine.2010.10.040; Gramzinski RA, 2001, INFECT IMMUN, V69, P1643, DOI 10.1128/IAI.69.3.1643-1649.2001; Halim TYF, 2016, NAT IMMUNOL, V17, P57, DOI 10.1038/ni.3294; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Huang TJ, 2001, J IMMUNOL, V166, P207, DOI 10.4049/jimmunol.166.1.207; Hunter CA, 1997, IMMUNOL LETT, V59, P1, DOI 10.1016/S0165-2478(97)00091-6; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; Jain VV, 2003, AM J PHYSIOL-LUNG C, V285, pL1137, DOI 10.1152/ajplung.00073.2003; Jain VV, 2002, J ALLERGY CLIN IMMUN, V110, P867, DOI 10.1067/mai.2002.129371; Jeske S, 2013, NUCLEIC ACID THER, V23, P118, DOI 10.1089/nat.2012.0384; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; Kim DH, 2016, ALLERGY ASTHMA IMMUN, V8, P264, DOI 10.4168/aair.2016.8.3.264; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kline JN, 2002, AM J PHYSIOL-LUNG C, V283, pL170, DOI 10.1152/ajplung.00402.2001; Kranzer K, 2000, IMMUNOLOGY, V99, P170, DOI 10.1046/j.1365-2567.2000.00964.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Luckey A. M., 2015, MULT SCLER J, V1, P1; Lund Sean, 2013, Current Immunology Reviews, V9, P214; Maazi H, 2018, J ALLERGY CLIN IMMUN, V141, P893, DOI 10.1016/j.jaci.2017.04.043; Mack EA, 2011, MBIO, V2, DOI 10.1128/mBio.00169-11; Mansson A, 2009, ALLERGY, V64, P1292, DOI 10.1111/j.1398-9995.2009.02012.x; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Puig M, 2012, J LEUKOCYTE BIOL, V91, P147, DOI 10.1189/jlb.0711371; Racila DM, 2005, J ALLERGY CLIN IMMUN, V116, P1202, DOI 10.1016/j.jaci.2005.08.050; Rubtsova K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166322; Sabatel C, 2017, IMMUNITY, V46, P457, DOI 10.1016/j.immuni.2017.02.016; Salmond RJ, 2012, J ALLERGY CLIN IMMUN, V130, P1159, DOI 10.1016/j.jaci.2012.05.018; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Singh PB, 2017, J EXP MED, V214, P3627, DOI 10.1084/jem.20170545; Suzuki K, 2005, AM J RESP CRIT CARE, V171, P707, DOI 10.1164/rccm.200408-1078OC; Suzuki M, 2015, J IMMUNOL, V195, P1273, DOI 10.4049/jimmunol.1500531; Tayyari F, 2005, EUR RESPIR J, V25, P295, DOI 10.1183/09031936.05.00016304; Thio CLP, 2018, J ALLERGY CLIN IMMUN, V142, P1867, DOI 10.1016/j.jaci.2018.02.032; Thorburn AN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156402; Urry Z, 2009, J CLIN INVEST, V119, P387, DOI 10.1172/JCI32354; Valladao AC, 2016, J IMMUNOL, V197, P4541, DOI 10.4049/jimmunol.1600007; Webster G, 2009, BIOPHARM INT, V2009; Webster Gill A, 2017, Pilot Feasibility Stud, V3, P60, DOI 10.1186/s40814-017-0201-4; Yasuda H, 2008, AM J PHYSIOL-RENAL, V294, pF1050, DOI 10.1152/ajprenal.00461.2007; Yu S, 2014, J ALLERGY CLIN IMMUN, V133, P943, DOI 10.1016/j.jaci.2014.02.015; Yu X, 2014, MUCOSAL IMMUNOL, V7, P730, DOI 10.1038/mi.2013.92	69	25	25	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					682	+		10.1016/j.jaci.2019.03.008	http://dx.doi.org/10.1016/j.jaci.2019.03.008			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	30914379	Bronze			2022-12-18	WOS:000485222300014
J	Guttman-Yassky, E; Zhou, L; Krueger, JG				Guttman-Yassky, Emma; Zhou, Lisa; Krueger, James G.			The skin as an immune organ: Tolerance versus effector responses and applications to food allergy and hypersensitivity reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; inflammation; tolerance; dendritic cell; Langerhans cell; regulatory T cell; epicutaneous immunotherapy; immunotherapy	REGULATORY T-CELLS; INFLAMMATORY DENDRITIC CELLS; PEDIATRIC ATOPIC-DERMATITIS; INNATE LYMPHOID-CELLS; LANGERHANS CELLS; EPICUTANEOUS IMMUNOTHERAPY; PEANUT ALLERGY; CONTACT HYPERSENSITIVITY; BETA-CATENIN; TGF-BETA	Skin is replete with immunocompetent cells that modulate signaling pathways to maintain a salubrious immunogenic/tolerogenic balance. This fertile immune environment plays a significant role in the development of allergic responses and sensitivities, but the mechanisms underlying these pathways have been underappreciated and underused with respect to developing therapeutics. Among the complex repertoire of cells that promote tolerogenic pathways in the periphery, 2 key classes include dendritic cells and regulatory T (Treg) cells. Immature dendritic cells are the first line of defense, patrolling the periphery, sampling antigens, and secreting cytokines that suppress immune cells and promote the survival of Treg cells. Skin-homing Treg cells also play a critical role in mitigating the reactivity of immune cells, secreting high levels of cytokines that promote tolerance. Therapeutic approaches that capitalize on our knowledge of the rich cellular and molecular environment are emerging and show great promise. We will discuss the advantages and challenges of 5 such strategies and how these therapies might mitigate the atopic march by facilitating tolerance. We conclude that skin is a multifaceted structure that provides a fertile ground for therapeutic discovery. Accordingly, ongoing work in this domain will no doubt continue to deliver exciting progress for improved health outcomes.	[Guttman-Yassky, Emma] Mt Sinai Med Ctr, Icahn Sch Med, Dept Dermatol, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA; [Zhou, Lisa] Columbia Univ, Med Ctr, New York, NY 10027 USA; [Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Columbia University; Rockefeller University	Guttman-Yassky, E (corresponding author), Mt Sinai Med Ctr, Icahn Sch Med, Dept Dermatol, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org			IMPRINT Science, New York, NY - DBV Technologies	IMPRINT Science, New York, NY - DBV Technologies	Editorial support was provided by IMPRINT Science, New York, NY, and funded by DBV Technologies. DBV Technologies reviewed the manuscript for scientific accuracy but did not play a role in the design, analysis, interpretation of the data, or decision to publish.	ABERER W, 1981, J INVEST DERMATOL, V76, P202, DOI 10.1111/1523-1747.ep12525745; Achtman JC, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0706-2; Alvarez D, 2008, IMMUNITY, V29, P325, DOI 10.1016/j.immuni.2008.08.006; Birmingham NP, 2007, INT ARCH ALLERGY IMM, V144, P203, DOI 10.1159/000103993; Blanco JL, 2008, VET IMMUNOL IMMUNOP, V125, P47, DOI 10.1016/j.vetimm.2008.04.020; Brocker T, 1997, J EXP MED, V185, P541, DOI 10.1084/jem.185.3.541; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2018, ANN ALLERG ASTHMA IM, V120, P34, DOI 10.1016/j.anai.2017.09.055; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Burks AW, 2018, J ALLERGY CLIN IMMUN, V141, P1, DOI 10.1016/j.jaci.2017.11.004; Bursch LS, 2007, J EXP MED, V204, P3147, DOI 10.1084/jem.20071966; Cavani A, 1998, J INVEST DERMATOL, V111, P621, DOI 10.1046/j.1523-1747.1998.00334.x; Chambers SJ, 2004, IMMUNOLOGY, V112, P72, DOI 10.1111/j.1365-2567.2004.01846.x; Charles J, 2010, EUR J DERMATOL, V20, P16, DOI 10.1684/ejd.2010.0816; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Chu CC, 2012, J EXP MED, V209, P935, DOI 10.1084/jem.20112583; Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247; Clausen BE, 2010, IMMUNOL CELL BIOL, V88, P351, DOI 10.1038/icb.2010.40; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Collin M, 2013, IMMUNOLOGY, V140, P22, DOI 10.1111/imm.12117; Conti P, 2017, IMMUNOL RES, V65, P982, DOI 10.1007/s12026-017-8938-7; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V140, P134, DOI 10.1016/j.jaci.2016.09.060; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P118, DOI 10.1016/j.jaci.2015.08.027; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; da Rosa JC, 2015, J ALLERGY CLIN IMMUN, V135, P712, DOI 10.1016/j.jaci.2014.11.017; de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9; Deckers J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00093; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Dhingra N, 2013, J INVEST DERMATOL, V133, P2311, DOI 10.1038/jid.2013.239; Dinarello CA, 2016, EUR J IMMUNOL, V46, P1067, DOI 10.1002/eji.201545828; Dioszeghy V, 2017, CELL MOL IMMUNOL, V14, P770, DOI 10.1038/cmi.2016.14; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Divekar R, 2015, CURR OPIN ALLERGY CL, V15, P98, DOI 10.1097/ACI.0000000000000133; Domogalla MP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01764; Dudek AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00438; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1473, DOI 10.1016/j.jaci.2016.04.052; Fainaru O, 2007, GENES IMMUN, V8, P239, DOI 10.1038/sj.gene.6364380; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1010/J.JACL2011.05.016; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Fyhrquist N, 2014, J ALLERGY CLIN IMMUN, V134, P1301, DOI 10.1016/j.jaci.2014.07.059; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; GODFREY VL, 1991, AM J PATHOL, V138, P1379; Gorelik M, 2015, CURR OPIN ALLERGY CL, V15, P575, DOI 10.1097/ACI.0000000000000213; Gratz IK, 2013, J IMMUNOL, V190, P4483, DOI 10.4049/jimmunol.1300212; Guilloteau K, 2010, J IMMUNOL, V184, P5263, DOI 10.4049/jimmunol.0902464; Gurung P, 2016, CELL MOL LIFE SCI, V73, P3035, DOI 10.1007/s00018-016-2212-3; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2018, J INVEST DERMATOL, V138, P1467, DOI 10.1016/j.jid.2018.02.037; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Haniffa M, 2015, J DERMATOL SCI, V77, P85, DOI 10.1016/j.jdermsci.2014.08.012; Hofmann AM, 2009, CURR OPIN IMMUNOL, V21, P679, DOI 10.1016/j.coi.2009.09.007; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Idoyaga J, 2013, J CLIN INVEST, V123, P844, DOI 10.1172/JCI65260; Ilarregui JM, 2009, NAT IMMUNOL, V10, P981, DOI 10.1038/ni.1772; Jakob T, 1999, J INVEST DERMATOL, V112, P102, DOI 10.1046/j.1523-1747.1999.00475.x; Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Kang ZZ, 2012, IMMUNITY, V36, P821, DOI 10.1016/j.immuni.2012.03.021; Kaplan DH, 2007, J EXP MED, V204, P2545, DOI 10.1084/jem.20071401; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kel JM, 2010, J IMMUNOL, V185, P3248, DOI 10.4049/jimmunol.1000981; Kim T.G., 2017, INT J MOL SCI, V19; King JK, 2015, J IMMUNOL, V195, P464, DOI 10.4049/jimmunol.1402735; Kissenpfennig A, 2006, TRENDS IMMUNOL, V27, P132, DOI 10.1016/j.it.2006.01.003; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Komiya Yuko, 2008, Organogenesis, V4, P68; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kornete M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00165; Kreutz M, 2012, J INVEST DERMATOL, V132, P179, DOI 10.1038/jid.2011.255; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lawrence MG, 2016, ANN ALLERG ASTHMA IM, V117, P138, DOI 10.1016/j.anai.2016.06.027; Leon B, 2008, IMMUNOL CELL BIOL, V86, P320, DOI 10.1038/icb.2008.14; Leonard A, 2019, CLIN REV ALLERG IMMU, V56, P1, DOI 10.1007/s12016-018-8685-0; Levin C, 2015, HUM VACC IMMUNOTHER, V11, P27, DOI 10.4161/hv.34299; Levings MK, 2000, J ALLERGY CLIN IMMUN, V106, pS109, DOI 10.1067/mai.2000.106635; Luckey U, 2012, J ALLERGY CLIN IMMUN, V130, P781, DOI 10.1016/j.jaci.2012.06.022; Luo YC, 2014, P NATL ACAD SCI USA, V111, P15178, DOI 10.1073/pnas.1416714111; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Lv J, 2018, ALLERGY, V73, P1642, DOI 10.1111/all.13395; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Mahnke K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00063; Malik K, 2017, CLIN EXP ALLERGY, V47, P1648, DOI 10.1111/cea.13040; Manicassamy S, 2011, IMMUNOL REV, V241, P206, DOI 10.1111/j.1600-065X.2011.01015.x; Manicassamy S, 2010, SCIENCE, V329, P849, DOI 10.1126/science.1188510; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Mascanfroni ID, 2013, NAT IMMUNOL, V14, P1054, DOI 10.1038/ni.2695; Matsushima H, 2010, J CLIN INVEST, V120, P653, DOI 10.1172/JCI42280; Mondoulet L, 2015, IMMUNOTHERAPY-UK, V7, P1293, DOI 10.2217/imt.15.86; Mondoulet L, 2015, J ALLERGY CLIN IMMUN, V135, P1546, DOI 10.1016/j.jaci.2014.11.028; Mondoulet Lucie, 2012, Clin Transl Allergy, V2, P22, DOI 10.1186/2045-7022-2-22; Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132; Mukherjee G, 2010, CLIN EXP IMMUNOL, V161, P197, DOI 10.1111/j.1365-2249.2010.04157.x; Nagaraj S, 2013, J IMMUNOL, V191, P17, DOI 10.4049/jimmunol.1300654; Nestle FO, 2009, NAT REV IMMUNOL, V9, P679, DOI 10.1038/nri2622; Noordegraaf M, 2010, J INVEST DERMATOL, V130, P2752, DOI 10.1038/jid.2010.223; Ohtani T, 2009, IMMUNOLOGY, V126, P485, DOI 10.1111/j.1365-2567.2008.02919.x; Paller AS, 2017, J ALLERGY CLIN IMMUN, V139, P152, DOI 10.1016/j.jaci.2016.07.019; Peebles RS, 2015, J LEUKOCYTE BIOL, V97, P469, DOI 10.1189/jlb.3BT0814-383R; Peiser M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/261037; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; Pishesha N, 2017, P NATL ACAD SCI USA, V114, P3157, DOI 10.1073/pnas.1701746114; Polak ME, 2012, J INVEST DERMATOL, V132, P1636, DOI 10.1038/jid.2012.26; Qu CF, 2014, INT J INFECT DIS, V19, P1, DOI 10.1016/j.ijid.2013.09.023; Rimoldi M, 2005, BLOOD, V106, P2818, DOI 10.1182/blood-2004-11-4321; Rodriguez RS, 2014, J CLIN INVEST, V124, P1027, DOI 10.1172/JCI72932; Romani N, 2003, APMIS, V111, P725, DOI 10.1034/j.1600-0463.2003.11107805.x; Romani N, 2010, IMMUNOL REV, V234, P120, DOI 10.1111/j.0105-2896.2009.00886.x; Rudloff I, 2017, J LEUKOCYTE BIOL, V101, P901, DOI 10.1189/jlb.3MA0616-287R; Ruiter B, 2012, J ALLERGY CLIN IMMUN, V129, P921, DOI 10.1016/j.jaci.2012.01.080; SALMON JK, 1994, WESTERN J MED, V160, P146; Sampson HA, 2017, JAMA-J AM MED ASSOC, V318, P1798, DOI 10.1001/jama.2017.16591; Schulke S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00455; Schwarz A, 2010, J INVEST DERMATOL, V130, P1419, DOI 10.1038/jid.2009.429; Segura E, 2013, TRENDS IMMUNOL, V34, P440, DOI 10.1016/j.it.2013.06.001; Segura E, 2013, IMMUNITY, V38, P336, DOI 10.1016/j.immuni.2012.10.018; Sells RE, 2010, J INVEST DERMATOL, V130, P2697, DOI 10.1038/jid.2010.292; Seneschal J, 2012, IMMUNITY, V36, P873, DOI 10.1016/j.immuni.2012.03.018; Senti G, 2015, ALLERGY, V70, P707, DOI 10.1111/all.12600; Senti G, 2016, IMMUNOL ALLERGY CLIN, V36, P25, DOI 10.1016/j.iac.2015.08.006; Shay T, 2013, P NATL ACAD SCI USA, V110, P2946, DOI 10.1073/pnas.1222738110; Shevach EM, 2014, IMMUNOL REV, V259, P88, DOI 10.1111/imr.12160; Shin JS, 2015, CELL MOL LIFE SCI, V72, P2349, DOI 10.1007/s00018-015-1870-x; Silvestre MC, 2018, AN BRAS DERMATOL, V93, P242, DOI 10.1590/abd1806-4841.20186340; Steele L, 2012, IMMUNOL RES, V54, P75, DOI 10.1007/s12026-012-8308-4; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Stier MT, 2018, J EXP MED, V215, P263, DOI 10.1084/jem.20170449; Tan YH, 2014, MOL CELL, V54, P212, DOI 10.1016/j.molcel.2014.03.012; TOEWS GB, 1980, J IMMUNOL, V124, P445; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Torres-Aguilar H, 2010, J IMMUNOL, V184, P1765, DOI 10.4049/jimmunol.0902133; Tsakok T, 2016, J ALLERGY CLIN IMMUN, V137, P1071, DOI 10.1016/j.jaci.2015.10.049; Ungar B, 2017, EXP DERMATOL, V26, P272, DOI 10.1111/exd.13148; van der Aar AMG, 2013, J INVEST DERMATOL, V133, P1240, DOI 10.1038/jid.2012.500; Vander Lugt B, 2017, J CELL BIOL, V216, P779, DOI 10.1083/jcb.201512012; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, pAB26, DOI 10.1016/j.jaci.2010.12.114; Wakim LM, 2008, SCIENCE, V319, P198, DOI 10.1126/science.1151869; Wei XD, 2017, CELL REP, V21, P1853, DOI 10.1016/j.celrep.2017.10.090; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Wu J, 2014, BURNS TRAUMA, V2, DOI [10.4103/2321-3868.124771, 10.4103/2321-3868.113326]; Xia MC, 2014, J ALLERGY CLIN IMMUN, V134, P634, DOI 10.1016/j.jaci.2014.03.010; Yamazaki S, 2006, IMMUNOL REV, V212, P314, DOI 10.1111/j.0105-2896.2006.00422.x; Yamazaki S, 2009, J DERMATOL SCI, V54, P69, DOI 10.1016/j.jdermsci.2009.02.001; Yasmin N, 2013, J INVEST DERMATOL, V133, P1250, DOI 10.1038/jid.2012.481; Yoshino M, 2003, INT IMMUNOL, V15, P773, DOI 10.1093/intimm/dxg075; Zaba LC, 2007, J CLIN INVEST, V117, P2517, DOI 10.1172/JCI32282; Zaba LC, 2010, J ALLERGY CLIN IMMUN, V125, P1261, DOI 10.1016/j.jaci.2010.03.018; Zaba LC, 2009, J INVEST DERMATOL, V129, P302, DOI 10.1038/jid.2008.225; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194; Zeng HY, 2015, CELL MOL IMMUNOL, V12, P566, DOI 10.1038/cmi.2015.44; Zhang R, 2015, J IMMUNOL, V195, P4154, DOI 10.4049/jimmunol.1500945; Zhang R, 2013, J CLIN INVEST, V123, P580, DOI 10.1172/JCI65013	160	25	25	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					362	374		10.1016/j.jaci.2019.03.021	http://dx.doi.org/10.1016/j.jaci.2019.03.021			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	30954522	hybrid			2022-12-18	WOS:000478789300002
J	Jimenez-Saiz, R; Ellenbogen, Y; Bruton, K; Spill, P; Sommer, DD; Lima, H; Waserman, S; Patil, SU; Shreffler, WG; Jordana, M				Jimenez-Saiz, Rodrigo; Ellenbogen, Yosef; Bruton, Kelly; Spill, Paul; Sommer, Doron D.; Lima, Hermenio; Waserman, Susan; Patil, Sarita U.; Shreffler, Wayne G.; Jordana, Manel			Human BCR analysis of single-sorted, putative IgE(+) memory B cells in food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ANTIBODIES; EXPRESSION		[Jimenez-Saiz, Rodrigo; Ellenbogen, Yosef; Bruton, Kelly; Spill, Paul; Jordana, Manel] McMaster Univ, Dept Pathol & Mol Med, McMaster Immunol Res Ctr MIRC, Hamilton, ON, Canada; [Sommer, Doron D.] McMaster Univ, Dept Surg, Hamilton, ON, Canada; [Lima, Hermenio; Waserman, Susan] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Jimenez-Saiz, Rodrigo; Ellenbogen, Yosef; Patil, Sarita U.; Shreffler, Wayne G.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; [Jimenez-Saiz, Rodrigo; Ellenbogen, Yosef; Patil, Sarita U.; Shreffler, Wayne G.] Harvard Med Sch, Boston, MA 02115 USA	McMaster University; McMaster University; McMaster University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Jordana, M (corresponding author), McMaster Univ, Dept Pathol & Mol Med, McMaster Immunol Res Ctr MIRC, Hamilton, ON, Canada.	jordanam@mcmaster.ca	Jimenez-Saiz, Rodrigo/O-7384-2019; Sommer, Doron/AAQ-1761-2021	Jimenez-Saiz, Rodrigo/0000-0002-0606-3251; Sommer, Doron/0000-0001-9692-7414; Bruton, Kelly/0000-0003-0817-6134	Food Allergy Canada; Delaney family; Zych family; Walter and Maria Schroeder Foundation; AllerGen NCE [16CanFAST5]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI121491] Funding Source: NIH RePORTER	Food Allergy Canada; Delaney family; Zych family; Walter and Maria Schroeder Foundation; AllerGen NCE; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by grants from Food Allergy Canada, the Delaney family, the Zych family, the Walter and Maria Schroeder Foundation and AllerGen NCE (grant 16CanFAST5 to DrsWaserman and Jordana, International Visit Award to Dr Jimenez-Saiz and Summer studenship to Yosef Ellenbogen).	Berkowska MA, 2014, J ALLERGY CLIN IMMUN, V134, P688, DOI 10.1016/j.jaci.2014.03.036; Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017; Croote D, 2018, SCIENCE, V362, P1306, DOI 10.1126/science.aau2599; Heeringa JJ, 2018, ALLERGY, V73, P1331, DOI 10.1111/all.13421; Heeringa JJ, 2018, CLIN EXP ALLERGY, V48, P679, DOI 10.1111/cea.13136; Jimenez-Saiz R, 2018, J ALLERGY CLIN IMMUN, V142, P1441, DOI 10.1016/j.jaci.2018.08.029; Oliveria JP, 2017, J ALLERGY CLIN IMMUN, V140, P590, DOI 10.1016/j.jaci.2016.12.981; Oliveria JP, 2017, AM J RESP CRIT CARE, V196, P107, DOI 10.1164/rccm.201611-2274LE; Patil SU, 2015, J ALLERGY CLIN IMMUN, V136, P125, DOI 10.1016/j.jaci.2015.03.026; Shade KTC, 2015, J EXP MED, V212, P457, DOI 10.1084/jem.20142182; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Tiller T, 2009, J IMMUNOL METHODS, V350, P183, DOI 10.1016/j.jim.2009.08.009; Wang XW, 2000, J IMMUNOL METHODS, V244, P217, DOI 10.1016/S0022-1759(00)00260-X	13	25	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					336	+		10.1016/j.jaci.2019.04.001	http://dx.doi.org/10.1016/j.jaci.2019.04.001			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30959060	Green Accepted, Bronze			2022-12-18	WOS:000473432800042
J	Ke, X; Do, DC; Li, CJ; Zhao, YL; Kollarik, M; Fu, QL; Wan, M; Gao, PS				Ke, Xia; Do, Danh C.; Li, Changjun; Zhao, Yilin; Kollarik, Marian; Fu, Qingling; Wan, Mei; Gao, Peisong			Ras homolog family member A/Rho-associated protein kinase 1 signaling modulates lineage commitment of mesenchymal stem cells in asthmatic patients through lymphoid enhancer-binding factor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cockroach allergen; Ras homolog family member A/Rho-associated protein kinase 1; mesenchymal stem cell; Lef1	EPITHELIAL-CELLS; AIRWAY EPITHELIUM; RHO-KINASE; SELF-RENEWAL; LUNG; INFLAMMATION; TRANSITION; MODEL; FIBROSIS; GROWTH	Background: Numbers of mesenchymal stem cells (MSCs) are increased in the airways after allergen challenge. Ras homolog family member A (RhoA)/Rho-associated protein kinase 1 (ROCK) signaling is critical in determining the lineage fate of MSCs in tissue repair/remodeling. Objectives: We sought to investigate the role of RhoA/ROCK signaling in lineage commitment of MSCs during allergen-induced airway remodeling and delineate the underlying mechanisms. Methods: Active RhoA expression in lung tissues of asthmatic patients and its role in cockroach allergen-induced airway inflammation and remodeling were investigated. RhoA/ROCK signaling-mediated MSC lineage commitment was assessed in an asthma mouse model by using MSC lineage tracing mice (nestin-Cre; ROSA26-EYFP). The role of RhoA/ROCK in MSC lineage commitment was also examined by using MSCs expressing constitutively active RhoA (RhoA-L63) or dominant negative RhoA (RhoA-N19). Downstream RhoA-regulated genes were identified by using the Stem Cell Signaling Array. Results: Lung tissues from asthmatic mice showed increased expression of active RhoA when compared with those from control mice. Inhibition of RhoA/ROCK signaling with fasudil, a RhoA/ROCK inhibitor, reversed established cockroach allergen-induced airway inflammation and remodeling, as assessed based on greater collagen deposition/fibrosis. Furthermore, fasudil inhibited MSC differentiation into fibroblasts/myofibroblasts but promoted MSC differentiation into epithelial cells in asthmatic nestin-Cre; ROSA26-EYFP mice. Consistently, expression of RhoA-L63 facilitated differentiation of MSCs into fibroblasts/myofibroblasts, whereas expression of RhoA-19 switched the differentiation toward epithelial cells. The gene array identified the Wnt signaling effector lymphoid enhancer-binding factor 1 (Lef1) as the most upregulated gene in RhoA-L63-transfected MSCs. Knockdown of Lef1 induced MSC differentiation away from fibroblasts/myofibroblasts but toward epithelial cells. Conclusions: These findings uncover a previously unrecognized role of RhoA/ROCK signaling in MSC-involved airway repair/remodeling in the setting of asthma.	[Ke, Xia; Do, Danh C.; Zhao, Yilin; Kollarik, Marian; Gao, Peisong] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Li, Changjun; Wan, Mei] Johns Hopkins Univ, Sch Med, Dept Orthoped Surg, Baltimore, MD USA; [Ke, Xia] Chongqing Med Univ, Affiliated Hosp 1, Dept Otorhinolaryngol, Chongqing, Peoples R China; [Zhao, Yilin] Fourth Mil Med Univ, Dept Resp Med, Xian, Shaanxi, Peoples R China; [Fu, Qingling] Sun Yat Sen Univ, Affiliated Hosp 1, Otorhinolaryngol Hosp, Guangzhou, Guangdong, Peoples R China	Johns Hopkins University; Johns Hopkins University; Chongqing Medical University; Air Force Military Medical University; Sun Yat Sen University	Gao, PS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Rm 3B-71, Baltimore, MD 21224 USA.	pgao1@jhmi.edu	C, Danh/I-1527-2019	C, Danh/0000-0002-1065-7140	US National Institutes of Health [RO1ES021739, R21 AI109062, R21 AI121768, R21 AI137547]; National Science Foundation of China [N81628001]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI109062, R21AI137547, R21AI088406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES021739] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants from the US National Institutes of Health (RO1ES021739, R21 AI109062, R21 AI121768, and R21 AI137547) and the National Science Foundation of China (N81628001 to P.G.).	Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; Aloysius A, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan3000; Asaduzzaman M, 2018, ALLERGY, V73, P416, DOI 10.1111/all.13313; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Bentley JK, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-127; Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028; Boras-Granic K, 2006, DEV BIOL, V295, P219, DOI 10.1016/j.ydbio.2006.03.030; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bryan BA, 2010, FASEB J, V24, P3186, DOI 10.1096/fj.09-145102; Cai SX, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0060-y; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Danchuk S, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt68; Desai LP, 2004, AM J PHYSIOL-LUNG C, V287, P44; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fehrenbach H, 2017, CELL TISSUE RES, V367, P551, DOI 10.1007/s00441-016-2566-8; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Ganesan S, 2013, CURR RESP CARE REP, V2; Gao PS, 2014, J IMMUNOL, V192, P4560, DOI 10.4049/jimmunol.1303461; Ghosh M, 2018, AM J RESP CRIT CARE, V197, P1645, DOI 10.1164/rccm.201801-0103LE; Gilles C, 2003, CANCER RES, V63, P2658; Goodwin M, 2011, STEM CELLS, V29, P1137, DOI 10.1002/stem.656; Goto K, 2010, BIOL PHARM BULL, V33, P710, DOI 10.1248/bpb.33.710; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; Han XP, 2018, J CELL BIOCHEM, V119, P1008, DOI 10.1002/jcb.26268; Holgate ST, 2011, IMMUNOL REV, V242, P205, DOI 10.1111/j.1600-065X.2011.01030.x; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Holvoet T, 2017, GASTROENTEROLOGY, V153, P1054, DOI 10.1053/j.gastro.2017.06.013; Huang C, 2010, J GENET GENOMICS, V37, P441, DOI 10.1016/S1673-8527(09)60063-1; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Ke HN, 2016, SCI REP-UK, V6, DOI 10.1038/srep23987; Knipe RS, 2018, AM J RESP CELL MOL, V58, P471, DOI 10.1165/rcmb.2017-0075OC; Kokubun K, 2016, J TISSUE ENG REGEN M, V10, pE73, DOI 10.1002/term.1758; Krause Diane S, 2008, Proc Am Thorac Soc, V5, P323, DOI 10.1513/pats.200712-169DR; Kume H, 2008, CURR MED CHEM, V15, P2876, DOI 10.2174/092986708786242831; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Li CJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11455; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Love JJ, 2004, BIOCHEMISTRY-US, V43, P8725, DOI 10.1021/bi049591m; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Lynch TJ, 2018, CELL STEM CELL, V22, P653, DOI 10.1016/j.stem.2018.03.017; Marinas-Pardo L, 2014, ALLERGY, V69, P730, DOI 10.1111/all.12392; McAnulty RJ, 2007, INT J BIOCHEM CELL B, V39, P666, DOI 10.1016/j.biocel.2006.11.005; Murphy JM, 2003, ARTHRITIS RHEUM-US, V48, P3464, DOI 10.1002/art.11365; Nabhan AN, 2018, SCIENCE, V359, P1118, DOI 10.1126/science.aam6603; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; Naveed SUN, 2017, AM J RESP CRIT CARE, V195, P1000, DOI 10.1164/rccm.201604-0822OC; Nawshad A, 2007, J CELL SCI, V120, P1646, DOI 10.1242/jcs.003129; Ogulur I, 2014, INT IMMUNOPHARMACOL, V20, P101, DOI 10.1016/j.intimp.2014.02.028; Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104; Ou-Yang HF, 2011, EXP BIOL MED, V236, P1461, DOI 10.1258/ebm.2011.011221; Qi XJ, 2015, INT J CLIN EXP PATHO, V8, P12140; Qiu LP, 2018, J IMMUNOL, V201, P916, DOI 10.4049/jimmunol.1701167; Qu JJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90139; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Santiago L, 2017, AM J CANCER RES, V7, P1389; Schaafsma D, 2004, BRIT J PHARMACOL, V143, P477, DOI 10.1038/sj.bjp.0705903; Schilders KAA, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0358-z; Shentu TP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18288-9; Spees JL, 2008, FASEB J, V22, P1226, DOI 10.1096/fj.07-8076com; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Sun ZR, 2012, CELL BIOL INT, V36, P169, DOI 10.1042/CBI20110121; Takeda K, 2018, J IMMUNOL, V200, P1261, DOI 10.4049/jimmunol.1700562; Takeda N, 2006, AM J RESP CELL MOL, V35, P722, DOI 10.1165/rcmb.2006-0034OC; Tang N, 2014, J CELL MOL MED, V18, P156, DOI 10.1111/jcmm.12178; Tata A, 2018, CELL STEM CELL, V22, P668, DOI 10.1016/j.stem.2018.03.018; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Volckaert T, 2014, FIBROGENESIS TISSUE, V7, DOI 10.1186/1755-1536-7-8; Wan M, 2012, STEM CELLS, V30, P2498, DOI 10.1002/stem.1208; Wang GS, 2005, P NATL ACAD SCI USA, V102, P186, DOI 10.1073/pnas.0406266102; Wang H, 2018, J ALLERGY CLIN IMMUN, V141, P586, DOI 10.1016/j.jaci.2017.06.013; Wang L, 2017, STEM CELL TRANSL MED, V6, P394, DOI 10.5966/sctm.2015-0411; Wang WS, 2014, STEM CELLS DEV, V23, P1392, DOI 10.1089/scd.2013.0528; Wang YJ, 2009, BIOCHEM BIOPH RES CO, V390, P1309, DOI 10.1016/j.bbrc.2009.10.143; Wong AP, 2009, J CLIN INVEST, V119, P336, DOI 10.1172/JCI36882; Xie L, 2016, ANN NY ACAD SCI, V1376, P53, DOI 10.1111/nyas.13000; Xie L, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/762098; Xu T, 2015, J IMMUNOL, V195, P5539, DOI 10.4049/jimmunol.1501198; Yang JQ, 2016, J ALLERGY CLIN IMMUN, V137, P231, DOI 10.1016/j.jaci.2015.05.004; Zhang H, 2014, GENET MOL RES, V13, P8320, DOI [10.4238/2014.October.20.8, 10.4238/2014.January.22.2]; Zhang SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033773; Zhao W, 2016, SCI REP-UK, V6, DOI 10.1038/srep21176; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638; Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143; Zhou YF, 2018, J ALLERGY CLIN IMMUN, V141, P350, DOI 10.1016/j.jaci.2017.04.049	85	25	26	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1560	+		10.1016/j.jaci.2018.08.023	http://dx.doi.org/10.1016/j.jaci.2018.08.023			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30194990	Bronze, Green Accepted			2022-12-18	WOS:000463348900030
J	Lougaris, V; Chou, J; Beano, A; Wallace, JG; Baronio, M; Gazzurelli, L; Lorenzini, T; Moratto, D; Tabellini, G; Parolini, S; Seleman, M; Stafstrom, K; Xu, HM; Harris, C; Geha, RS; Plebani, A				Lougaris, Vassilios; Chou, Janet; Beano, Abdallah; Wallace, Jacqueline G.; Baronio, Manuela; Gazzurelli, Luisa; Lorenzini, Tiziana; Moratto, Daniele; Tabellini, Giovanna; Parolini, Silvia; Seleman, Michael; Stafstrom, Kelsey; Xu, Haiming; Harris, Chad; Geha, Raif S.; Plebani, Alessandro			A monoallelic activating mutation in RAC2 resulting in a combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FRAMEWORK; GTPASES		[Lougaris, Vassilios; Baronio, Manuela; Gazzurelli, Luisa; Lorenzini, Tiziana; Plebani, Alessandro] Univ Brescia, Pediat Clin, Brescia, Italy; [Lougaris, Vassilios; Baronio, Manuela; Gazzurelli, Luisa; Lorenzini, Tiziana; Plebani, Alessandro] Univ Brescia, Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, Brescia, Italy; [Lougaris, Vassilios; Baronio, Manuela; Gazzurelli, Luisa; Lorenzini, Tiziana; Plebani, Alessandro] ASST Spedali Civili Brescia, Brescia, Italy; [Chou, Janet; Beano, Abdallah; Wallace, Jacqueline G.; Seleman, Michael; Stafstrom, Kelsey; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Chou, Janet; Beano, Abdallah; Wallace, Jacqueline G.; Seleman, Michael; Stafstrom, Kelsey; Geha, Raif S.] Harvard Med Sch, Boston, MA 02115 USA; [Moratto, Daniele] Univ Brescia, Inst Mol Med A Nocivelli, Dept Pathol,ASST Spedali Civili Brescia, Lab Genet Disorders Childhood,Dept Mol & Translat, Brescia, Italy; [Tabellini, Giovanna; Parolini, Silvia] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Xu, Haiming; Harris, Chad] Harvard Med Sch, Boston Childrens Hosp, Boston, MA 02115 USA; [Xu, Haiming; Harris, Chad] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Xu, Haiming; Harris, Chad] Harvard Stem Cell Inst, Boston, MA USA	University of Brescia; University of Brescia; Hospital Spedali Civili Brescia; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Hospital Spedali Civili Brescia; University of Brescia; University of Brescia; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University	Lougaris, V (corresponding author), Univ Brescia, Pediat Clin, Brescia, Italy.; Lougaris, V (corresponding author), Univ Brescia, Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, Brescia, Italy.; Lougaris, V (corresponding author), ASST Spedali Civili Brescia, Brescia, Italy.	vlougarisbs@yahoo.com; Raif.Geha@childrens.harvard.edu		Wallace, Jacqueline/0000-0001-6565-2534; PAROLINI, Silvia/0000-0003-1968-7765	European Community's Seventh Framework Programme [FP7/2007-2013 201549]; EURO-PADnet HEALTH [F2-2008-201549]; Italian Ministerial Grant [GR-2010-2315762]; Fondazione C. Golgi, Brescia, Italy; Jeffrey Modell Foundation; Perkin Fund; National Institutes of Health [AI124101, AI139633, 5K08AI116979]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI116979] Funding Source: NIH RePORTER	European Community's Seventh Framework Programme(European Commission); EURO-PADnet HEALTH; Italian Ministerial Grant; Fondazione C. Golgi, Brescia, Italy; Jeffrey Modell Foundation; Perkin Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by the European Community's Seventh Framework Programme (grant no. FP7/2007-2013 201549 to V.L. and A.P.), EURO-PADnet HEALTH (grant no. F2-2008-201549 to V.L. and A.P.), Italian Ministerial Grant (grant no. GR-2010-2315762 to V.L. and A.P.), Fondazione C. Golgi, Brescia, Italy (V.L. and A.P.), the Jeffrey Modell Foundation (V.L. and A.P.); the Perkin Fund (R.S.G. and J.C.); and the National Institutes of Health (grant nos. AI124101 and AI139633 to R.S.G. and grant no. 5K08AI116979 to J.C.).	Accetta D, 2011, J ALLERGY CLIN IMMUN, V127, P535, DOI 10.1016/j.jaci.2010.10.013; Alkhairy OK, 2015, J ALLERGY CLIN IMMUN, V135, P1380, DOI 10.1016/j.jaci.2014.10.039; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Cannons JL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01758; Chen Y, 2012, METHODS MOL BIOL, V844, P115, DOI 10.1007/978-1-61779-527-5_8; Daball PC, 2018, IMMUNOL CELL BIOL, V96, P1060, DOI 10.1111/imcb.12169; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Desouza Melissa, 2012, Bioarchitecture, V2, P75; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Lanzi G, 2012, J EXP MED, V209, P29, DOI 10.1084/jem.20110896; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Pai SY, 2010, DIS MARKERS, V29, P177, DOI [10.1155/2010/380291, 10.3233/DMA-2010-0738]; Williams DA, 2000, BLOOD, V96, P1646	14	25	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1649	+		10.1016/j.jaci.2019.01.001	http://dx.doi.org/10.1016/j.jaci.2019.01.001			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30654050	Bronze			2022-12-18	WOS:000463348900047
J	Nobs, SP; Kayhan, M; Kopf, M				Nobs, Samuel Philip; Kayhan, Merve; Kopf, Manfred			GM-CSF intrinsically controls eosinophil accumulation in the setting of allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; asthma; allergic airway inflammation; GM-CSF; chemokinesis	COLONY-STIMULATING FACTOR; FETAL MONOCYTES; MURINE MODEL; PPAR-GAMMA; MACROPHAGES; CELLS; TISSUE; DIFFERENTIATION; INDUCTION; RESPONSES	Background: Eosinophils are a therapeutic target in asthmatic patients, and GM-CSF has been suggested to control various aspects of eosinophil biology, including development, function, and survival. However, to date, the role of GM-CSF signaling in eosinophils in vivo is largely unclear. Objective: We sought to elucidate the role of GM-CSF signaling in asthmatic inflammation. Methods: Wild-type and GM-CSF receptor a (Csf2ra)-deficient mice reconstituted with Csf2ra-proficient alveolar macrophages were subjected to different models of airway inflammation to evaluate the effect of GM-CSF signaling deficiency on asthmatic inflammation in general and on eosinophils in particular. Results: We demonstrate that GM-CSF signaling, although being largely dispensable for eosinophil development at steady state, intrinsically promotes accumulation of eosinophils in the lung during allergic airway inflammation. In contrast, chitin-induced eosinophil accumulation in the peritoneal cavity occurs independent of GM-CSF, indicating organ specificity. We show that GM-CSF induces chemokinesis and promotes eosinophil survival in vitro, which likely contribute to eosinophil accumulation in the airways in vivo. Conclusion: GM-CSF intrinsically promotes eosinophil accumulation in the setting of pulmonary allergic inflammation.	[Nobs, Samuel Philip; Kayhan, Merve; Kopf, Manfred] Swiss Fed Inst Technol, Mol Biomed, Inst Mol Hlth Sci, Dept Biol, Zurich, Switzerland; [Nobs, Samuel Philip] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel	Swiss Federal Institutes of Technology Domain; ETH Zurich; Weizmann Institute of Science	Kopf, M (corresponding author), Swiss Fed Inst Technol, Inst Mol Hlth Sci, Otto Stern Weg 7, CH-8093 Zurich, Switzerland.	manfred.kopf@ethz.ch	Nobs, Samuel Philip/N-4819-2019; Kopf, Manfred/B-6907-2009	Nobs, Samuel Philip/0000-0003-0627-892X; Kopf, Manfred/0000-0002-0628-7140	Swiss National Science Foundation (SNCF) Grant [310030_163443]	Swiss National Science Foundation (SNCF) Grant	Supported by Swiss National Science Foundation (SNCF) Grant 310030_163443.	Asquith KL, 2008, J IMMUNOL, V180, P1199, DOI 10.4049/jimmunol.180.2.1199; Bergeron Celine, 2009, Proc Am Thorac Soc, V6, P301, DOI 10.1513/pats.200808-089RM; Bogunovic M, 2009, IMMUNITY, V31, P513, DOI 10.1016/j.immuni.2009.08.010; Carlens J, 2009, J IMMUNOL, V183, P5600, DOI 10.4049/jimmunol.0801581; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Dyer KD, 2008, J IMMUNOL, V181, P4004, DOI 10.4049/jimmunol.181.6.4004; Dyer KD, 2011, J IMMUNOL METHODS, V369, P91, DOI 10.1016/j.jim.2011.04.009; Gouon-Evans V, 2000, DEVELOPMENT, V127, P2269; Greter M, 2012, IMMUNITY, V36, P1031, DOI 10.1016/j.immuni.2012.03.027; Griseri T, 2015, IMMUNITY, V43, P187, DOI 10.1016/j.immuni.2015.07.008; Guilliams M, 2013, J EXP MED, V210, P1977, DOI 10.1084/jem.20131199; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Liu LY, 2015, ALLERGY, V70, P805, DOI 10.1111/all.12624; Lloyd CM, 2013, NAT MED, V19, P976, DOI 10.1038/nm.3296; Nobs SP, 2017, J EXP MED, V214, P3015, DOI 10.1084/jem.20162069; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Roberts AW, 2017, IMMUNITY, V47, P913, DOI 10.1016/j.immuni.2017.10.006; Schneider C, 2017, J LEUKOCYTE BIOL, V101, P367, DOI 10.1189/jlb.4HI0316-157R; Schneider C, 2014, NAT IMMUNOL, V15, P1026, DOI 10.1038/ni.3005; Schneider C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004053; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Su YC, 2008, J IMMUNOL, V180, P2600, DOI 10.4049/jimmunol.180.4.2600; Valencia HA, 2016, ALLERGY, V71, P267, DOI 10.1111/all.12776; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Willebrand R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163751; Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P97, DOI 10.1067/mai.2003.3	29	25	26	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1513	+		10.1016/j.jaci.2018.08.044	http://dx.doi.org/10.1016/j.jaci.2018.08.044			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30244025				2022-12-18	WOS:000463348900026
J	Pfaar, O; Bachert, C; Kuna, P; Panzner, P; Dzupinova, M; Klimek, L; van Nimwegen, MJ; Boot, JD; Yu, DH; Opstelten, DJE; de Kam, PJ				Pfaar, Oliver; Bachert, Claus; Kuna, Piotr; Panzner, Petr; Dzupinova, Maria; Klimek, Ludger; van Nimwegen, Maroesja J.; Boot, Johan D.; Yu, Donghui; Opstelten, Dirk Jan E.; de Kam, Pieter-Jan			Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birch pollen allergy; allergic rhinoconjunctivitis; sublingual immunotherapy; allergen immunotherapy; efficacy; safety; combined symptom and medication score; pivotal phase III trial; quality of life	INTERNATIONAL CONSENSUS; CLINICAL-TRIALS; RHINITIS; STANDARDIZATION; RECOMMENDATIONS; ORGANIZATION; MECHANISMS; CHILDHOOD; EFFICACY; IMPACT	Background: Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both clinically efficacious and safe. However, in line with the current regulatory guidance from the European Medicines Agency, allergen immunotherapy (AIT) products must demonstrate their efficacy and safety in pivotal phase III trials for registration. Objective: We sought to investigate the efficacy and safety of sublingual high-dose liquid birch pollen extract (40,000 allergy units native [AUN]/mL) in adults with birch pollen allergy. Methods: A randomized, double-blind, placebo-controlled, parallel-group multicenter trial was conducted in 406 adult patients with moderate-to-severe birch pollen-induced allergic rhinoconjunctivitis with or without mild-to-moderate controlled asthma. Treatment was started 3 to 6 months before the birch pollen season and continued during the season in 40 clinical study centers in 5 European countries. For primary end point assessment, the recommended combined symptom and medication score of the European Academy of Allergy and Clinical Immunology was used. Secondary end points included quality-of-life assessments, immunologic parameters, and safety. Results: Primary efficacy results demonstrated a significant (P < .0001) and clinically relevant (32%) reduction in the combined symptom and medication score compared with placebo after 3 to 6 months of SLIT. Significantly better rhinoconjunctivitis quality-of-life scores (P < .0001) and the patient's own overall assessment of his or her health status, including the visual analog scale score (Euro Quality of Life Visual Analogue Scale; P = .0025), were also demonstrated. In total, a good safety profile of SLIT was observed. Conclusion: This study confirmed both the clinical efficacy and safety of a sublingual liquid birch pollen extract in adults with birch pollen allergy in a pivotal phase III trial (EudraCT: 2013-005550-30; ClinicalTrials. gov: NCT02231307).	[Pfaar, Oliver] Philipps Univ Marburg, Univ Hosp Marburg, Dept Otorhinolaryngol Head & Neck Surg, Sect Rhinol & Allergy, Marburg, Germany; [Pfaar, Oliver] Heidelberg Univ, Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Med Fac Mannheim, Mannheim, Germany; [Pfaar, Oliver; Klimek, Ludger] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Kuna, Piotr] Med Univ Lodz, Div Internal Med Asthma & Allergy, Lodz, Poland; [Panzner, Petr] Charles Univ Prague, Dept Immunol & Allergol, Fac Med Pilsen, Plzen, Czech Republic; [Dzupinova, Maria] ALIAN Sro, Ambulancia Alergol & Klin Imunol, Bardejov, Slovakia; [van Nimwegen, Maroesja J.; Boot, Johan D.; Yu, Donghui; Opstelten, Dirk Jan E.; de Kam, Pieter-Jan] HAL Allergy BV, Leiden, Netherlands	Philipps University Marburg; University Hospital of Giessen & Marburg; Ruprecht Karls University Heidelberg; Ghent University; Medical University Lodz; Charles University Prague; HAL Allergy Group	Pfaar, O (corresponding author), Philipps Univ Marburg, Univ Hosp Marburg, Dept Otorhinolaryngol Head & Neck Surg, Sect Rhinol & Allergy, Marburg, Germany.	oliver@pfaar.org	Bachert, Claus/J-8825-2012; Panzner, Petr/I-7034-2017	Kuna, Piotr/0000-0003-2401-0070; Panzner, Petr/0000-0002-1291-450X	HAL Allergy B.V., Leiden, The Netherlands	HAL Allergy B.V., Leiden, The Netherlands(Netherlands Government)	The authors acknowledge medical writing and editorial support for the preparation of this article from Bernd Renner, which was funded by HAL Allergy B.V., Leiden, The Netherlands. Moreover, we thank Annemie Narkus for her helpful reviewof the final draft of this manuscript. The authors thank all the patients and investigators of this study.	Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bagnasco M, 2003, CHEM IMMUNOL, V82, P33; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet PJ, 2010, J ALLERGY CLIN IMMUN, V126, P666, DOI 10.1016/j.jaci.2010.06.034; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-6; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; De Weger L.A., 2013, ALLERGENIC POLLEN RE; Dhami S, 2017, ALLERGY, V72, P1825, DOI 10.1111/all.13208; Dhami S, 2017, ALLERGY, V72, P1597, DOI 10.1111/all.13201; Durham SR, 2011, ALLERGY, V66, P120, DOI 10.1111/j.1398-9995.2010.02434.x; European Medicines Agency, CHMPEWP185042006 EUR; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; Muraro A, 2017, ALLERGEN IMMUNOTHE 1; Pfaar O, 2018, ALLERGY, V73, P1775, DOI 10.1111/all.13429; Pfaar O, 2018, ALLERGY, V73, P5, DOI 10.1111/all.13355; Pfaar O, 2016, ALLERGY, V71, P99, DOI 10.1111/all.12760; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Pfaar O, 2011, IMMUNOL ALLERGY CLIN, V31, P289, DOI 10.1016/j.iac.2011.02.004; Pfaar Oliver, 2014, Allergo J Int, V23, P282; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; Roberts G, 2018, ALLERGY, V73, P765, DOI 10.1111/all.13317; Schmitt J, 2015, J ALLERGY CLIN IMMUN, V136, P1511, DOI 10.1016/j.jaci.2015.07.038; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Shamji MH, 2017, J ALLERGY CLIN IMMUN, V140, P1485, DOI 10.1016/j.jaci.2017.10.010	34	25	25	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					970	977		10.1016/j.jaci.2018.11.018	http://dx.doi.org/10.1016/j.jaci.2018.11.018			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30508538	hybrid, Green Published			2022-12-18	WOS:000460272900017
J	Huls, A; Abramson, MJ; Sugiri, D; Fuks, K; Kramer, U; Krutmann, J; Schikowski, T				Huls, Anke; Abramson, Michael J.; Sugiri, Dorothea; Fuks, Kateryna; Kramer, Ursula; Krutmann, Jean; Schikowski, Tamara			Nonatopic eczema in elderly women: Effect of air pollution and genes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic eczema; atopic dermatitis; adults; allergy; serum IgE; hay fever; gene-environment interactions	ENVIRONMENTAL TOBACCO-SMOKE; USE REGRESSION-MODELS; ATOPIC-DERMATITIS; ALLERGIC SENSITIZATION; EXPOSURE; PREVALENCE; ASTHMA; SKIN; ASSOCIATION; MECHANISMS	Background: Although many risk factors have been described for atopic eczema in children, little is known about the eczema phenotype in middle-aged or elderly adults. Objective: We sought to examine the association between air pollution, atopy, and eczema in adulthood. Methods: This analysis was based on 834 women from the Study on the influence of Air pollution on Lung Function, Inflammation and Ageing cohort in Germany. Incident symptoms of eczema after age 55 years and prevalent symptoms of eczema 12 months or less before investigation were assessed by means of questionnaire at the second follow-up (2007-2010). Total serum IgE levels were measured at baseline (1985-1994) and in 2007-2010. Exposure to air pollution was assessed by using land-use regression. Adjusted logistic regression models were applied to estimate the association between air pollution and incident and prevalent symptoms of eczema. Weighted genetic risk scores were used to investigate the effect of atopic eczema-related risk alleles on this association. Results: Exposures to oxides of nitrogen (nitrogen dioxide and nitrogen oxides) and particulate matter (fine particulate matter with an aerodynamic diameter of <= 2.5 mu m [PM2.5] and particulate matter with an aerodynamic diameter of < 10 mu m) were significantly associated with increased odds of incident eczema (eg, with PM2.5 per 4.7 mg/m(3); odds ratio, 1.45; 95% CI, 1.06-1.99). These associations were slightly more pronounced with nonatopic eczema (eg, with PM2.5; odds ratio of 1.65 and 95% CI of 1.15-2.34 for participants without hay fever or increased IgE levels). Associations with air pollution were stronger in carriers of fewer risk alleles for atopic eczema. Conclusion: Nonatopic eczema in the elderly is associated with traffic-related air pollutants, and this phenotype differs from genetically driven atopic eczema.	[Huls, Anke; Abramson, Michael J.; Sugiri, Dorothea; Fuks, Kateryna; Kramer, Ursula; Krutmann, Jean; Schikowski, Tamara] IUF Leibniz Res Inst Environm Med, Aufm Hennekamp 50, D-40225 Dusseldorf, Germany; [Abramson, Michael J.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Krutmann, Jean] Heinrich Heine Univ, Fac Med, Dusseldorf, Germany	Leibniz Institut fur Umweltmedizinische Forschung (IUF); Monash University; Heinrich Heine University Dusseldorf	Schikowski, T (corresponding author), IUF Leibniz Res Inst Environm Med, Aufm Hennekamp 50, D-40225 Dusseldorf, Germany.	Tamara.Schikowski@IUF-Duesseldorf.de	Huels, Anke/J-8743-2019; Abramson, Michael/AAQ-2671-2020	Huels, Anke/0000-0002-6005-417X; Abramson, Michael/0000-0002-9954-0538; Fuks, Kateryna/0000-0003-1860-0197	Deutsche Forschungsgemeinschaft (DFG) [HE-4510/2-1, KR 1938/3-1, LU 691/4-1, SCHI 1358/3-1]; Ministry of the Environment of the State of North Rhine-Westphalia (Dusseldorf, Germany); Federal Ministry of the Environment (Berlin, Germany); European Community's Seventh Framework Program (FP7/2007-2011) [211250]; German Federal Ministry of Education and Research (BMBF); Research Commission of the Medical Faculty of the Heinrich-Heine University of Dusseldorf [12/2011]; DGUV [VT 266.1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Ministry of the Environment of the State of North Rhine-Westphalia (Dusseldorf, Germany); Federal Ministry of the Environment (Berlin, Germany); European Community's Seventh Framework Program (FP7/2007-2011); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Research Commission of the Medical Faculty of the Heinrich-Heine University of Dusseldorf; DGUV	Supported by the Deutsche Forschungsgemeinschaft (DFG; HE-4510/2-1, KR 1938/3-1, LU 691/4-1, and SCHI 1358/3-1), the Ministry of the Environment of the State of North Rhine-Westphalia (Dusseldorf, Germany), the Federal Ministry of the Environment (Berlin, Germany), DGUV (German statutory accident assurance) VT 266.1, the European Community's Seventh Framework Program (FP7/2007-2011) under grant agreement number 211250, the German Federal Ministry of Education and Research (BMBF), and the Research Commission of the Medical Faculty of the Heinrich-Heine University of Dusseldorf (12/2011). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilera I, 2013, ENVIRON HEALTH PERSP, V121, P387, DOI 10.1289/ehp.1205281; Asher MI, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-8; Bataille V, 2012, J EUR ACAD DERMATOL, V26, P1067, DOI 10.1111/j.1468-3083.2011.04444.x; Beelen R, 2014, LANCET, V383, P785, DOI 10.1016/S0140-6736(13)62158-3; Beelen R, 2013, ATMOS ENVIRON, V72, P10, DOI 10.1016/j.atmosenv.2013.02.037; Bieber T, 2017, J ALLERGY CLIN IMMUN, V139, pS58, DOI 10.1016/j.jaci.2017.01.008; Bowatte G, 2015, ALLERGY, V70, P245, DOI 10.1111/all.12561; Brunekreef B, 2009, ENVIRON HEALTH PERSP, V117, P1791, DOI 10.1289/ehp.0800467; Cesaroni G, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f7412; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; Dudbridge F, 2016, GENET EPIDEMIOL, V40, P268, DOI 10.1002/gepi.21966; Eeftens M, 2012, ENVIRON SCI TECHNOL, V46, P11195, DOI 10.1021/es301948k; Flohr C, 2009, BRIT J DERMATOL, V161, P846, DOI 10.1111/j.1365-2133.2009.09261.x; Fujii-Kuriyama Y, 2005, BIOCHEM BIOPH RES CO, V338, P311, DOI 10.1016/j.bbrc.2005.08.162; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Haarmann-Stemmann T, 2015, J INVEST DERMATOL, V135, P2572, DOI 10.1038/jid.2015.285; Hidaka T, 2017, NAT IMMUNOL, V18, P64, DOI 10.1038/ni.3614; Hopper JL, 2012, J ALLERGY CLIN IMMUN, V130, P1117, DOI 10.1016/j.jaci.2012.08.003; Huang CC, 2015, BRIT J DERMATOL, V173, P981, DOI 10.1111/bjd.14039; Huls A, 2018, PEDIAT ALLERG IMM-UK, V29, P596, DOI 10.1111/pai.12903; Huls A, 2017, BMC GENET, V18, DOI 10.1186/s12863-017-0586-3; Huls A, 2017, BMC GENET, V18, DOI 10.1186/s12863-017-0519-1; Huls A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157569; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kramer U, 2009, J DERMATOL SCI, V56, P99, DOI 10.1016/j.jdermsci.2009.07.014; Kramer U, 2004, BRIT J DERMATOL, V150, P111, DOI 10.1111/j.1365-2133.2004.05710.x; Krzyzanowski M, 2008, AIR QUAL ATMOS HLTH, V1, P7, DOI 10.1007/s11869-008-0008-9; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Li Q, 2016, INT J ENV RES PUBLIC, V13; Lodge CJ, 2015, ACTA PAEDIATR, V104, P38, DOI 10.1111/apa.13132; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; Pujades-Rodriguez Mar, 2009, BMC Pulm Med, V9, P42, DOI 10.1186/1471-2466-9-42; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Ronmark EP, 2012, BRIT J DERMATOL, V166, P1301, DOI 10.1111/j.1365-2133.2012.10904.x; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Schafer T, 2000, ATOPIC DERMATITIS EP, P155; Schikowski T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-152; Schikowski T, 2014, EUR RESPIR J, V44, P614, DOI 10.1183/09031936.00132213; Schnass W, 2018, INT J HYG ENVIR HEAL, V221, P861, DOI 10.1016/j.ijheh.2018.06.002; Schram ME, 2010, BRIT J DERMATOL, V162, P964, DOI 10.1111/j.1365-2133.2010.09689.x; Tanei R, 2016, GERIATR GERONTOL INT, V16, P75, DOI 10.1111/ggi.12771; Tang KT, 2017, ANN ALLERG ASTHMA IM, V118, P351, DOI 10.1016/j.anai.2016.12.005; Team R.C, 2015, R LANG ENV STAT COMP; Totlandsdal AI, 2012, TOXICOL LETT, V208, P262, DOI 10.1016/j.toxlet.2011.10.025; Vossoughi M, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-5; Yi O, 2012, ENVIRON RES, V113, P40, DOI 10.1016/j.envres.2011.12.012	50	25	26	4	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					378	+		10.1016/j.jaci.2018.09.031	http://dx.doi.org/10.1016/j.jaci.2018.09.031			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30336226				2022-12-18	WOS:000454918300041
J	Laidlaw, TM; Cahill, KN; Cardet, JC; Murphy, K; Cui, J; Dioneda, B; Kothari, P; Raby, BA; Israel, E; Boyce, JA				Laidlaw, Tanya M.; Cahill, Katherine N.; Cardet, Juan Carlos; Murphy, Katherine; Cui, Jing; Dioneda, Brittney; Kothari, Parul; Raby, Benjamin A.; Israel, Elliot; Boyce, Joshua A.			A trial of type 12 purinergic (P2Y(12)) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; double-blind; randomized; placebo-controlled crossover trial; prasugrel; Samter triad; NSAID-exacerbated respiratory disease; leukotrienes; P2Y(12)	PROSTAGLANDIN D-2; P-SELECTIN; P2RY12; CELLS	Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by asthma, recurrent nasal polyposis, and respiratory reactions on ingestion of COX-1 inhibitors. Increased numbers of platelet-leukocyte aggregates are present in the sinus tissue and blood of patients with AERD compared with that of aspirin-tolerant patients, and platelet activation can contribute to aspirin-induced reactions. Objective: We sought to determine whether treatment with prasugrel, which inhibits platelet activation by blocking the type 12 purinergic (P2Y(12)) receptor, would attenuate the severity of sinonasal and respiratory symptoms induced during aspirin challenge in patients with AERD. Methods: Forty patients with AERD completed a 10-week, double-blind, placebo-controlled crossover trial of prasugrel. All patients underwent oral aspirin challenges after 4 weeks of prasugrel and after 4 weeks of placebo. The primary outcome was a change in the provocative dose of aspirin that would elicit an increase in Total Nasal Symptom Score (TNSS) of 2 points. Changes in lung function, urinary eicosanoids, plasma tryptase, platelet-leukocyte aggregates, and platelet activation were also recorded. Results: Prasugrel did not significantly change the mean increase in TNSS of 2 points (79 +/- 15 for patients receiving placebo and 139 +/- 32 for patients receiving prasugrel, P = .10), platelet-leukocyte aggregates, or increases in urinary leukotriene E4 and prostaglandin D-2 metabolite levels during aspirin-induced reactions in the study population as a whole. Five subjects (responders) reacted to aspirin while receiving placebo but did not have any reaction to aspirin challenge after the prasugrel arm. In contrast to prasugrel nonresponders (35 subjects), the prasugrel responders had smaller reaction-induced increases in TNSS; did not have significant aspirin-induced increases in urinary leukotriene E-4, prostaglandin D-2 metabolite, or thromboxane B-2 levels; and did not display increases in serum tryptase levels during aspirin reactions on the placebo arm, all of which were observed in the nonresponders. Conclusion: In the overall study population, prasugrel did not attenuate aspirin-induced symptoms, possibly because it failed to decrease the frequencies of platelet-adherent leukocytes or to diminish aspirin-induced mast cell activation. In a small subset of patients with AERD who had greater baseline platelet activation and milder upper respiratory symptoms during aspirin-induced reactions, P2Y(12) receptor antagonism with prasugrel completely inhibited all aspirin-induced reaction symptoms, suggesting a contribution from P2Y(12) receptor signaling in this subset.	[Laidlaw, Tanya M.; Cahill, Katherine N.; Cui, Jing; Kothari, Parul; Boyce, Joshua A.] Harvard Med Sch, Dept Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA USA; [Laidlaw, Tanya M.; Cahill, Katherine N.; Cui, Jing; Kothari, Parul; Boyce, Joshua A.] Jeff & Penny Vinik Ctr, Boston, MA USA; [Murphy, Katherine] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Dioneda, Brittney] Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA; [Cardet, Juan Carlos; Raby, Benjamin A.; Israel, Elliot] Harvard Med Sch, Dept Med, Boston, MA USA; [Cardet, Juan Carlos; Murphy, Katherine; Israel, Elliot] Brigham & Womens Hosp, Pulm & Crit Care Div, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Laidlaw, TM (corresponding author), Brigham & Womens Hosp, 60 Fenwood Rd,Bldg Transformat Med,Rm 5002M, Boston, MA 02115 USA.	tlaidlaw@bwh.harvard.edu	Raby, Benjamin/AAK-3866-2021	Cahill, Katherine/0000-0002-8549-1835; Cardet, Juan Carlos/0000-0002-9731-4828	National Institutes of Health [U19AI095219, K23HL111113, K23AI118804, K23AI125785, R01HL128241, T32AI00730, AI078908, HL117945, AI52353]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL128241, R01HL117945, K23HL111113, R01HL136209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI118804, R37AI052353, U19AI095219, R01AI136041, K23AI125785, R01AI078908] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants U19AI095219, K23HL111113, K23AI118804, K23AI125785, R01HL128241, T32AI00730, AI078908, HL117945, and AI52353 and by generous contributions from the Vinik and Kaye Families.	Ben Addi A, 2010, J IMMUNOL, V185, P5900, DOI 10.4049/jimmunol.0901799; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; Bunyavanich S, 2012, CLIN EXP ALLERGY, V42, P229, DOI 10.1111/j.1365-2222.2011.03874.x; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Damman P, 2012, J THROMB THROMBOLYS, V33, P143, DOI 10.1007/s11239-011-0667-5; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; Klinkhardt U, 2002, CLIN PHARMACOL THER, V71, P176, DOI 10.1067/mcp.2002.122018; Kupczyk M, 2010, RESP MED, V104, P1404, DOI 10.1016/j.rmed.2010.04.017; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Losol P, 2015, ANN ALLERG ASTHMA IM, V114, P423, DOI 10.1016/j.anai.2015.02.009; MACLOUF J, 1994, ANN NY ACAD SCI, V714, P143, DOI 10.1111/j.1749-6632.1994.tb12038.x; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; MAUGERI N, 1994, THROMB HAEMOSTASIS, V72, P450; Mitsui C, 2016, J ALLERGY CLIN IMMUN, V137, P400, DOI 10.1016/j.jaci.2015.05.041; Muniz VS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139805; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; Osborne JA, 2006, P 31 ANN SAS US GROU; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Stevenson DD, 2000, ANN ALLERG ASTHMA IM, V85, P477, DOI 10.1016/S1081-1206(10)62575-6; Yoshida S, 1998, ANN ALLERG ASTHMA IM, V80, P171, DOI 10.1016/S1081-1206(10)62951-1	26	25	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					316	+		10.1016/j.jaci.2018.06.001	http://dx.doi.org/10.1016/j.jaci.2018.06.001			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29890239	Green Accepted, Bronze			2022-12-18	WOS:000454918300035
J	Huang, HJ; Resch-Marat, Y; Rodriguez-Dominguez, A; Chen, KW; Kiss, R; Zieglmayer, P; Zieglmayer, R; Lemell, P; Horak, F; Valenta, R; Vrtala, S				Huang, Huey-Jy; Resch-Marat, Yvonne; Rodriguez-Dominguez, Azahara; Chen, Kuan-Wei; Kiss, Renata; Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick; Horak, Friedrich; Valenta, Rudolf; Vrtala, Susanne			Underestimation of house dust mite-specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DIAGNOSIS		[Huang, Huey-Jy; Resch-Marat, Yvonne; Rodriguez-Dominguez, Azahara; Chen, Kuan-Wei; Kiss, Renata; Valenta, Rudolf; Vrtala, Susanne] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick; Horak, Friedrich] Vienna Challenge Chamber, Vienna, Austria; [Horak, Friedrich] Allergy Ctr Vienna West, Vienna, Austria; [Valenta, Rudolf] NRC Inst Immunol FMBA Russia, Moscow, Russia	Medical University of Vienna; NRC Institute of Immunology FMBA of Russia	Vrtala, S (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria.	susanne.vrtala@meduniwien.ac.at	Zieglmayer, Petra/AAG-1006-2020	Resch, Yvonne/0000-0002-7933-2547; Chen, Kuan-Wei/0000-0001-5899-5766; Lemell, Patrick/0000-0003-0262-4047; Vrtala, Susanne/0000-0003-4250-8243; Huang, Huey-Jy/0000-0001-5464-0132; Valenta, Rudolf/0000-0001-5944-3365	Austrian Science Fund, Austria (FWF) [DK W 1248-B30, F4602, F4605]; Medical University of Vienna, Vienna, Austria; Megagrant of the Government of the Russian Federation, Russia [14.W03.31.0024]	Austrian Science Fund, Austria (FWF)(Austrian Science Fund (FWF)); Medical University of Vienna, Vienna, Austria; Megagrant of the Government of the Russian Federation, Russia	Supported by the Austrian Science Fund, Austria (FWF; DK W 1248-B30, F4602, and F4605) and the Medical University of Vienna, Vienna, Austria. R.V. is the recipient of a Megagrant of the Government of the Russian Federation, Russia (grant no. 14.W03.31.0024).	Andersson K, 2007, ALLERGY, V62, P897, DOI 10.1111/j.1398-9995.2007.01450.x; Casset A, 2012, INT ARCH ALLERGY IMM, V159, P253, DOI 10.1159/000337654; Dzoro S, 2018, ALLERGY, V73, P115, DOI 10.1111/all.13260; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Ochs HD, 2009, BIOL BLOOD MARROW TR, V15, P84, DOI 10.1016/j.bbmt.2008.10.007; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Sanchez-Borges M, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-017-0145-4; Stringari G, 2014, J ALLERGY CLIN IMMUN, V134, P75, DOI 10.1016/j.jaci.2014.01.042; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896	10	25	25	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1656	+		10.1016/j.jaci.2018.07.010	http://dx.doi.org/10.1016/j.jaci.2018.07.010			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30059698	hybrid			2022-12-18	WOS:000449429800034
J	Altman, MC; Reeves, SR; Parker, AR; Whalen, E; Misura, KM; Barrow, KA; James, RG; Hallstrand, TS; Ziegler, SF; Debley, JS				Altman, Matthew C.; Reeves, Stephen R.; Parker, Andrew R.; Whalen, Elizabeth; Misura, Kira M.; Barrow, Kaitlyn A.; James, Richard G.; Hallstrand, Teal S.; Ziegler, Steven F.; Debley, Jason S.			Interferon response to respiratory syncytial virus by bronchial epithelium from children with asthma is inversely correlated with pulmonary function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; epithelial cells; sequence analysis; RNA; respiratory syncytial virus; type I interferon	BASEMENT-MEMBRANE; RSV BRONCHIOLITIS; IMMUNE-RESPONSES; TISSUE INHIBITOR; PEDIATRIC-AIRWAY; III INTERFERON; IN-VITRO; RIG-I; INFECTION; CELLS	Background: Respiratory viral infection in early childhood, including that from respiratory syncytial virus (RSV), has been previously associated with the development of asthma. Objective: We aimed to determine whether ex vivo RSV infection of bronchial epithelial cells (BECs) from children with asthma would induce specific gene expression patterns and whether such patterns were associated with lung function among BEC donors. Methods: Primary BECs from carefully characterized children with asthma (n = 18) and matched healthy children without asthma (n = 8) were differentiated at an air-liquid interface for 21 days. Air-liquid interface cultures were infected with RSV for 96 hours and RNA was subsequently isolated from BECs. In each case, we analyzed gene expression using RNA sequencing and assessed differences between conditions by linear modeling of the data. BEC donors completed spirometry to measure lung function. Results: RSV infection of BECs from subjects with asthma, compared with uninfected BECs from subjects with asthma, led to a significant increase in expression of 6199 genes. There was significantly greater expression of 195 genes in BECs from children with asthma and airway obstruction (FEV1/forced vital capacity < 0.85 and FEV1 < 100% predicted) than in BECs from children with asthma without obstruction, or in BECs from healthy children. These specific genes were found to be highly enriched for viral response genes induced in parallel with types I and III interferons. Conclusions: BECs from children with asthma and with obstructive physiology exhibit greater expression of types I and III interferons and interferon-stimulated genes than do cells from children with normal lung function, and expression of interferon-associated genes correlates with the degree of airway obstruction. These findings suggest that an exaggerated interferon response to viral infection by airway epithelial cells may be a mechanism leading to lung function decline in a subset of children with asthma.	[Altman, Matthew C.; Parker, Andrew R.] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA; [Hallstrand, Teal S.] Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA USA; [Reeves, Stephen R.; Debley, Jason S.] Univ Washington, Dept Pediat, Div Pulm & Sleep Med, Seattle, WA 98195 USA; [Reeves, Stephen R.; Barrow, Kaitlyn A.; James, Richard G.; Debley, Jason S.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, 1900 Ninth Ave, Seattle, WA 98105 USA; [Altman, Matthew C.; Whalen, Elizabeth; Ziegler, Steven F.] Benaroya Res Inst, Seattle, WA USA; [Misura, Kira M.] Amgen Inc, Thousand Oaks, CA 91320 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Benaroya Research Institute; Amgen	Debley, JS (corresponding author), Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, 1900 Ninth Ave, Seattle, WA 98105 USA.	jason.debley@seattlechildrens.org		Altman, Matthew/0000-0002-1784-8505; Reeves, Stephen/0000-0002-8552-6022; james, richard/0000-0002-2302-7367	National Institutes of Health [R01HL128361, 1U19AI125378]; Amgen, Inc.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL128361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI125378] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amgen, Inc.(Amgen); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (R01HL128361, 1U19AI125378) and Amgen, Inc.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Backman K, 2014, ACTA PAEDIATR, V103, P850, DOI 10.1111/apa.12662; Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Cataldo DD, 2002, CHEST, V122, P1553, DOI 10.1378/chest.122.5.1553; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Dabo AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135970; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Foronjy RF, 2015, MUCOSAL IMMUNOL, V8, P161, DOI 10.1038/mi.2014.54; Hallstrand TS, 2014, CLIN IMMUNOL, V151, P1, DOI 10.1016/j.clim.2013.12.003; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hoffman SJ, 2004, MICROBES INFECT, V6, P767, DOI 10.1016/j.micinf.2004.03.010; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kim SH, 2015, ASIA PAC ALLERGY, V5, P114, DOI 10.5415/apallergy.2015.5.2.114; Kong MYF, 2015, VIRUSES-BASEL, V7, P4230, DOI 10.3390/v7082817; Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058; Lane C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-53; Leigh R, 2015, PHARMACOL THERAPEUT, V148, P185, DOI 10.1016/j.pharmthera.2014.12.005; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; Levy DE, 2011, CURR OPIN VIROL, V1, P476, DOI 10.1016/j.coviro.2011.11.001; Liu P, 2007, J VIROL, V81, P1401, DOI 10.1128/JVI.01740-06; Loo YM, 2008, J VIROL, V82, P335, DOI 10.1128/JVI.01080-07; Lopez-Guisa JM, 2012, J ALLERGY CLIN IMMUN, V129, P990, DOI 10.1016/j.jaci.2011.11.035; Malmstrom K, 2011, THORAX, V66, P157, DOI 10.1136/thx.2010.139246; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mukherjee S, 2013, CURR TOP MICROBIOL, V372, P139, DOI 10.1007/978-3-642-38919-1_7; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Patel DA, 2014, J ALLERGY CLIN IMMUN, V134, P1402, DOI 10.1016/j.jaci.2014.07.013; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Prikk K, 2002, LAB INVEST, V82, P1535, DOI 10.1097/01.LAB.0000035023.53893.B6; Romagnani P, 2012, CLIN CHIM ACTA, V413, P1364, DOI 10.1016/j.cca.2012.02.009; Rusinova I, 2013, NUCLEIC ACIDS RES, V41, pD1040, DOI 10.1093/nar/gks1215; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Shelfoon C, 2016, J ALLERGY CLIN IMMUN, V138, P114, DOI 10.1016/j.jaci.2015.12.1308; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Stevens PT, 2008, CLIN EXP ALLERGY, V38, P1901, DOI 10.1111/j.1365-2222.2008.03093.x; Suzuki R, 2001, J ASTHMA, V38, P477, DOI 10.1081/JAS-100105868; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; Villenave R, 2012, P NATL ACAD SCI USA, V109, P5040, DOI 10.1073/pnas.1110203109; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Zomer-Kooijker K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087162	49	25	26	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					451	459		10.1016/j.jaci.2017.10.004	http://dx.doi.org/10.1016/j.jaci.2017.10.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29106997	Green Accepted, Bronze			2022-12-18	WOS:000440664400014
J	Bloodworth, MH; Rusznak, M; Pfister, CC; Zhang, J; Bastarache, L; Calvillo, SA; Chappell, JD; Boyd, KL; Toki, S; Newcomb, DC; Stier, MT; Zhou, WS; Goleniewska, K; Moore, ML; Hartert, TV; Niswender, KD; Peebles, RS				Bloodworth, Melissa H.; Rusznak, Mark; Pfister, Connor C.; Zhang, Jian; Bastarache, Lisa; Calvillo, Sandra Alvarez; Chappell, James D.; Boyd, Kelli L.; Toki, Shinji; Newcomb, Dawn C.; Stier, Matthew T.; Zhou, Weisong; Goleniewska, Kasia; Moore, Martin L.; Hartert, Tina V.; Niswender, Kevin D.; Peebles, R. Stokes, Jr.			Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INFLAMMATION		[Bloodworth, Melissa H.; Boyd, Kelli L.; Newcomb, Dawn C.; Stier, Matthew T.; Peebles, R. Stokes, Jr.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Rusznak, Mark; Pfister, Connor C.; Zhang, Jian; Toki, Shinji; Newcomb, Dawn C.; Zhou, Weisong; Goleniewska, Kasia; Hartert, Tina V.; Peebles, R. Stokes, Jr.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Dept Med, Nashville, TN 37212 USA; [Bastarache, Lisa] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA; [Calvillo, Sandra Alvarez; Chappell, James D.] Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Pediat, Nashville, TN 37212 USA; [Niswender, Kevin D.] Vanderbilt Univ, Sch Med, Dept Med, Div Diabet Endocrinol & Metab, Nashville, TN 37212 USA; [Moore, Martin L.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Emory University	Peebles, RS (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA.; Peebles, RS (corresponding author), Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Dept Med, Nashville, TN 37212 USA.	stokes.peebles@vanderbilt.edu			Vanderbilt Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research Center [DK058404]; National Center for Research Resources [UL1 RR024975-01]; National Center for Advancing Translational Sciences [2 UL1 TR000445-06];  [R01 AI 124456];  [U19 AI 095227];  [R01 AI 111820];  [2I01BX000624];  [T32 GM07347];  [F30 AI118376]; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F30AI118376, R01AI124456, R01AI111820, U19AI095227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000624] Funding Source: NIH RePORTER	Vanderbilt Ingram Cancer Center; Vanderbilt Digestive Disease Research Center; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); ; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	Supported by grants R01 AI 124456, U19 AI 095227, R01 AI 111820, and 2I01BX000624 (to R.S.P.); T32 GM07347 (to the Vanderbilt MSTP); and F30 AI118376 (to M.H.B.). The VUMC Flow Cytometry Shared Resource is supported by the Vanderbilt Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive Disease Research Center (DK058404). The PheWAS study was supported by the National Center for Research Resources, grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Ahern T, 2013, J EUR ACAD DERMATOL, V27, P1440, DOI 10.1111/j.1468-3083.2012.04609.x; Arita M, 2012, J BIOCHEM, V152, P313, DOI 10.1093/jb/mvs092; Borish L, 2016, ANN ALLERG ASTHMA IM, V117, P108, DOI 10.1016/j.anai.2016.04.022; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Denny JC, 2013, NAT BIOTECHNOL, V31, P1102, DOI 10.1038/nbt.2749; DeVincenzo JP, 2005, J INFECT DIS, V191, P1861, DOI 10.1086/430008; Johnson JE, 2007, MODERN PATHOL, V20, P108, DOI 10.1038/modpathol.3800725; Kabashima K, 2003, NAT IMMUNOL, V4, P694, DOI 10.1038/ni943; Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827; Simonis-Bik AM, 2010, DIABETES, V59, P293, DOI 10.2337/db09-1048; Zhu T, 2015, INT J MOL SCI, V16, P20195, DOI 10.3390/ijms160920195	11	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					683	687		10.1016/j.jaci.2018.01.053	http://dx.doi.org/10.1016/j.jaci.2018.01.053			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29678751	Green Accepted, Bronze			2022-12-18	WOS:000440664400038
J	Chevigne, A; Jacquet, A				Chevigne, Andy; Jacquet, Alain			Emerging roles of the protease allergen Der p 1 in house dust mite-induced airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						House dust mite; allergen; protease activity; Der p 1; airway epithelium; innate immune pathways	INNATE; EPITHELIUM; IMMUNITY		[Chevigne, Andy] Luxembourg Inst Hlth, Dept Infect & Immun Immunopharmacol & Interactom, Strassen, Luxembourg; [Jacquet, Alain] Chulalongkorn Univ, Fac Med, Chula Vaccine Res Ctr, 1873 Rama IV Rd, Bangkok 10330, Thailand	Luxembourg Institute of Health; Chulalongkorn University	Jacquet, A (corresponding author), Chulalongkorn Univ, Fac Med, Chula Vaccine Res Ctr, 1873 Rama IV Rd, Bangkok 10330, Thailand.	alain.j@chula.ac.th	Jacquet, Alain/GQI-0546-2022; Jacquet, Alain/T-8611-2019	Jacquet, Alain/0000-0002-0980-9741; Jacquet, Alain/0000-0002-0980-9741; Chevigne, Andy/0000-0003-4768-6743	Luxembourg Institute of Health (LIH) MESR [20170113]; Luxembourg National Research Fund (FNR) [PRIDE NextImmune-11012546]; Chulalongkorn University [GRB-BSS_83_59_30_24]; Center of Excellence on Medical Biotechnology (CEMB); S&T Postgraduate Education and Research Development Office (PERDO) [SB-60-003-03]; Chulalongkorn Academic Advancement (2nd Century Project-CUAASC)	Luxembourg Institute of Health (LIH) MESR; Luxembourg National Research Fund (FNR)(Luxembourg National Research Fund); Chulalongkorn University(Chulalongkorn University); Center of Excellence on Medical Biotechnology (CEMB); S&T Postgraduate Education and Research Development Office (PERDO); Chulalongkorn Academic Advancement (2nd Century Project-CUAASC)	A.C. was supported by the Luxembourg Institute of Health (LIH) MESR (grants 20170113) and the Luxembourg National Research Fund (FNR; PRIDE NextImmune-11012546). A.J. was supported by Chulalongkorn University (Government Budget GRB-BSS_83_59_30_24), the Center of Excellence on Medical Biotechnology (CEMB), S&T Postgraduate Education and Research Development Office (PERDO, SB-60-003-03) and Chulalongkorn Academic Advancement (2nd Century Project-CUAASC).	Adam E, 2006, J BIOL CHEM, V281, P6910, DOI 10.1074/jbc.M507140200; Cayrol C, 2018, NAT IMMUNOL, V19, P375, DOI 10.1038/s41590-018-0067-5; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Dumez ME, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00138; Jacquet A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071373; Jacquet A, 2011, TRENDS MOL MED, V17, P604, DOI 10.1016/j.molmed.2011.05.014; Kubo M, 2017, IMMUNOL REV, V278, P162, DOI 10.1111/imr.12557; Loxham M, 2018, MUCOSAL IMMUNOL, V11, P404, DOI 10.1038/mi.2017.63; Zhang JH, 2016, J ALLERGY CLIN IMMUN, V138, P1224, DOI 10.1016/j.jaci.2016.05.006	10	25	26	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					398	400		10.1016/j.jaci.2018.05.027	http://dx.doi.org/10.1016/j.jaci.2018.05.027			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29906529	Bronze			2022-12-18	WOS:000440664400006
J	Wechsler, JB; Hirano, I				Wechsler, Joshua B.; Hirano, Ikuo			Biological therapies for eosinophilic gastrointestinal diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; gastroesophageal reflux disease; dysphagia; food allergy; esophageal strictures; esophagitis	THYMIC STROMAL LYMPHOPOIETIN; PLACEBO-CONTROLLED TRIAL; FLUTICASONE PROPIONATE; GENE-EXPRESSION; SWALLOWED FLUTICASONE; CYTOKINE EXPRESSION; ESOPHAGEAL EOSINOPHILIA; ALLERGIC INFLAMMATION; ELIMINATION DIET; BARRIER FUNCTION	The scientific basis and the clinical application of mAb therapies that target specific immunologic pathways for eosinophilic gastrointestinal diseases are areas of active interest. There is a growing recognition of a subset of patients with eosinophilic esophagitis whose disease does not respond well to topical steroids or elimination diets. In addition, long-term use of corticosteroids presents possible risks that are currently being evaluated. Systemic therapy with a biologic agent offers potential advantages as a global approach that could limit the need for multiple, locally active medical therapies and allergen avoidance. The identification of novel biologic strategies is ongoing, and the recent validation of instruments and outcome measures to assess disease activity has proved essential in demonstrating efficacy. Studies using biologics that target IL-13 pathways in the treatment of eosinophilic esophagitis have demonstrated substantial promise.	[Wechsler, Joshua B.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Div Gastroenterol Hepatol & Nutr, Chicago, IL 60611 USA; [Hirano, Ikuo] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Wechsler, JB (corresponding author), Ann & Robert H Lurie Childrens Hosp Chicago, 225 East Chicago Ave, Chicago, IL 60611 USA.	JWechsler@luriechildrens.org			National Institutes of Health Consortium of Eosinophilic Gastrointestinal disease Researchers (CEGIR), Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, the National Center for Advancing Translational Sciences ( [U54 AI117804]; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; NCATS; APFED CURED; EFC; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [K08DK097721]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI117804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK097721] Funding Source: NIH RePORTER	National Institutes of Health Consortium of Eosinophilic Gastrointestinal disease Researchers (CEGIR), Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, the National Center for Advancing Translational Sciences (; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); APFED CURED; EFC; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors acknowledge grant support from the National Institutes of Health Consortium of Eosinophilic Gastrointestinal disease Researchers (CEGIR; grant no. U54 AI117804), which is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, the National Center for Advancing Translational Sciences (NCATS), and is funded through a collaboration between the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, and the NCATS. CEGIR is also supported by patient advocacy groups including APFED CURED and EFC. J.B.W. receives grant support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; grant no. K08DK097721).	Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Andreae DA, 2016, AM J GASTROENTEROL, V111, P1187, DOI 10.1038/ajg.2016.238; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Beppu LY, 2014, J ALLERGY CLIN IMMUN, V134, P1100, DOI 10.1016/j.jaci.2014.04.004; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Brandt EB, 2006, CLIN EXP ALLERGY, V36, P543, DOI 10.1111/j.1365-2222.2006.02456.x; Bullock JZ, 2007, J PEDIATR GASTR NUTR, V45, P22, DOI 10.1097/MPG.0b013e318043c097; Caldwell JM, 2017, MUCOSAL IMMUNOL, V10, P1190, DOI 10.1038/mi.2016.120; Caldwell JM, 2014, J ALLERGY CLIN IMMUN, V134, P1114, DOI 10.1016/j.jaci.2014.07.026; Carlson DA, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2017.47; Cheng E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157376; Cheng E, 2013, GUT, V62, P824, DOI 10.1136/gutjnl-2012-302250; Cianferoni A, 2018, ANN ALLERG ASTHMA IM, V120; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Collins MH, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12470; D'Mello RJ, 2016, MUCOSAL IMMUNOL, V9, P744, DOI 10.1038/mi.2015.98; Davis BP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86355; Dellon ES, 2016, AM COLL GASTR NAT M; Dellon ES, 2017, GASTROENTEROLOGY, V152, P776, DOI 10.1053/j.gastro.2016.11.021; Desreumaux P, 1996, GASTROENTEROLOGY, V110, P768, DOI 10.1053/gast.1996.v110.pm8608886; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Dohil R, 2010, GASTROENTEROLOGY, V139, P418, DOI 10.1053/j.gastro.2010.05.001; Fireman P, 2003, ALLERGY ASTHMA PROC, V24, P79; Forbes E, 2006, J LEUKOCYTE BIOL, V80, P330, DOI 10.1189/jlb.1105643; Foroughi S, 2007, J ALLERGY CLIN IMMUN, V120, P594, DOI 10.1016/j.jaci.2007.06.015; Fulkerson PC, 2014, J IMMUNOL, V193, P4043, DOI 10.4049/jimmunol.1400732; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gela A, 2015, ALLERGY, V70, P161, DOI 10.1111/all.12542; Ghazi A, 2012, EXPERT OPIN BIOL TH, V12, P113, DOI 10.1517/14712598.2012.642359; Golekoh MC, 2016, J PEDIATR-US, V170, P240, DOI 10.1016/j.jpeds.2015.11.026; Greuter T, 2017, AM J GASTROENTEROL, V112, P1527, DOI 10.1038/ajg.2017.202; Guajardo JR, 2018, CLIN REV ALLERG IMMU, V55, P65, DOI 10.1007/s12016-018-8671-6; Gupta SK, 2006, J PEDIATR GASTR NUTR, V42, P22, DOI 10.1097/01.mpg.0000188740.38757.d2; Gurish MF, 2001, J EXP MED, V194, P1243, DOI 10.1084/jem.194.9.1243; Hill DA, 2017, J ALLER CL IMM-PRACT, V5, P369, DOI 10.1016/j.jaip.2016.11.020; Hirano I, 2016, UNITED EUR GASTROENT; Hirano I, 2017, AM COLL GASTR NAT M; Hirano I, 2017, CLIN GASTROENTEROL H, V15, P1173, DOI 10.1016/j.cgh.2017.03.016; Hirano I, 2017, CLIN GASTROENTEROL H, V15, P325, DOI 10.1016/j.cgh.2016.10.022; Hirano I, 2014, GASTROENTEROL CLIN N, V43, P297, DOI 10.1016/j.gtc.2014.02.015; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Issekutz TB, 2001, EUR J IMMUNOL, V31, P860, DOI 10.1002/1521-4141(200103)31:3&lt;860::AID-IMMU860&gt;3.0.CO;2-9; Johnsson M, 2011, J INNATE IMMUN, V3, P594, DOI 10.1159/000331326; Kagalwalla AF, 2017, CLIN GASTROENTEROL H, V15, P1698, DOI 10.1016/j.cgh.2017.05.048; Kim HP, 2018, CLIN GASTROENTEROL H, V16, P1992, DOI 10.1016/j.cgh.2018.03.024; Kuang FL, 2018, J ALLERGY CLIN IMMUN, V141, pAB196, DOI 10.1016/j.jaci.2017.12.622; Kwiatek MA, 2011, GASTROENTEROLOGY, V140, P82, DOI 10.1053/j.gastro.2010.09.037; Lucendo AJ, 2008, AM J GASTROENTEROL, V103, P2184, DOI 10.1111/j.1572-0241.2008.01937.x; Martin LJ, 2018, J ALLERGY CLIN IMMUN, V141, P1690, DOI 10.1016/j.jaci.2017.09.046; Masterson JC, 2014, GUT, V63, P43, DOI 10.1136/gutjnl-2012-303631; Mavi P, 2012, AM J PHYSIOL-GASTR L, V302, pG1347, DOI 10.1152/ajpgi.00013.2012; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Mishra A, 2007, J LEUKOCYTE BIOL, V81, P916, DOI 10.1189/jlb.1106653; Moawad FJ, 2013, AM J GASTROENTEROL, V108, P366, DOI 10.1038/ajg.2012.443; Muir AB, 2016, J PEDIATR GASTR NUTR, V63, P200, DOI 10.1097/MPG.0000000000001100; Nguyen N, 2018, MUCOSAL IMMUNOL, V11, P415, DOI 10.1038/mi.2017.72; Nicodeme F, 2013, CLIN GASTROENTEROL H, V11, P1101, DOI 10.1016/j.cgh.2013.03.020; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Olson AA, 2016, ANN ALLERG ASTHMA IM, V117; Oyoshi MK, 2011, J CLIN INVEST, V121, P2210, DOI 10.1172/JCI43586; Park JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101391; Pelz BJ, 2016, CLIN EXP ALLERGY, V46, P1431, DOI 10.1111/cea.12776; Peterson KA, 2010, DIGEST DIS SCI, V55, P1313, DOI 10.1007/s10620-009-0859-4; Pettipher R, 2012, J PHARMACOL EXP THER, V340, P473, DOI 10.1124/jpet.111.187203; Philpott H, 2016, ALIMENT PHARM THER, V43, P985, DOI 10.1111/apt.13576; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Radonjic-Hoesli S, 2015, ANNU REV PHARMACOL, V55, P633, DOI 10.1146/annurev-pharmtox-010814-124407; Rawson R, 2016, J ALLERGY CLIN IMMUN, V138, P791, DOI 10.1016/j.jaci.2016.02.028; Reed C, 2015, DIGEST LIVER DIS, V47, P197, DOI 10.1016/j.dld.2014.11.009; Remedios M, 2006, GASTROINTEST ENDOSC, V63, P3, DOI 10.1016/j.gie.2005.07.049; Rieder F, 2014, GASTROENTEROLOGY, V146, pe1; Rieder F, 2014, GASTROENTEROLOGY, V146, P1266, DOI 10.1053/j.gastro.2014.01.051; Rochman M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96789; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Rubinstein E, 2011, J PEDIATR GASTR NUTR, V53, P409, DOI 10.1097/MPG.0b013e3182182ff8; Safroneeva E, 2016, GASTROENTEROLOGY, V150, P581, DOI 10.1053/j.gastro.2015.11.004; Satoh T, 2006, J IMMUNOL, V177, P2621, DOI 10.4049/jimmunol.177.4.2621; Schoepfer AM, 2010, AM J GASTROENTEROL, V105, P1062, DOI 10.1038/ajg.2009.657; Sherrill JD, 2014, MUCOSAL IMMUNOL, V7, P718, DOI 10.1038/mi.2013.90; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Shiraishi Y, 2008, J IMMUNOL, V180, P541, DOI 10.4049/jimmunol.180.1.541; Smith SG, 2015, J ALLERGY CLIN IMMUN, V135, P1594, DOI 10.1016/j.jaci.2014.12.1918; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2005, INFLAMM BOWEL DIS, V11, P720, DOI 10.1097/01.MIB.0000172557.39767.53; Straumann A, 2013, ALLERGY, V68, P375, DOI 10.1111/all.12096; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Straumann A, 2011, CLIN GASTROENTEROL H, V9, P400, DOI 10.1016/j.cgh.2011.01.017; Teitelbaum JE, 2002, GASTROENTEROLOGY, V122, P1216, DOI 10.1053/gast.2002.32998; van Rhijn BD, 2015, AM J GASTROENTEROL, V110, P1289, DOI 10.1038/ajg.2015.247; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Wechsler JB, 2018, CLIN GASTROENTEROL H, V16, P1056, DOI 10.1016/j.cgh.2017.12.019; Wechsler JB, 2014, GASTROENTEROL CLIN N, V43, P281, DOI 10.1016/j.gtc.2014.02.006; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Wengrower D, 2012, CAN J GASTROENTEROL, V26, P33, DOI 10.1155/2012/628268; Whelan KA, 2017, GUT, V66, P1197, DOI 10.1136/gutjnl-2015-310341; Yamazaki K, 2006, DIGEST DIS SCI, V51, P1934, DOI 10.1007/s10620-005-9048-2; Youngblood BB, 2018, DIG DIS WEEK M; Youngblood BB, 2018, GASTROENTEROLOGY, V154, pS1358; Zhang X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050037; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	108	25	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					24	+		10.1016/j.jaci.2018.05.018	http://dx.doi.org/10.1016/j.jaci.2018.05.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29859203	Green Accepted, Bronze			2022-12-18	WOS:000437837500003
J	Carroll, DJ; O'Sullivan, JA; Nix, DB; Cao, Y; Tiemeyer, M; Bochner, BS				Carroll, Daniela J.; O'Sullivan, Jeremy A.; Nix, David B.; Cao, Yun; Tiemeyer, Michael; Bochner, Bruce S.			Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating beta(2)-integrin-dependent function in human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; Siglec-8; beta(2)-integrin; apoptosis; phosphoproteomics; reduced nicotinamide adenine dinucleotide phosphate oxidase (NADPH); p38; c-Jun N-terminal kinase (JNK); Akt	NADPH OXIDASE ACTIVATION; N-TERMINAL KINASE; LARGE GENE LISTS; BLOOD EOSINOPHILS; MAP KINASE; CELL-DEATH; APOPTOSIS; NEUTROPHIL; PROTEIN; P38	Background: Siglec-8 is a CD33 subfamily cell-surface receptor selectively expressed on human eosinophils. After cytokine priming, Siglec-8 mAb or glycan ligand binding causes eosinophil apoptosis associated with reactive oxygen species (ROS) production. Most CD33-related Siglecs function as inhibitory receptors, but the ability of Siglec-8 to stimulate eosinophil ROS production and apoptosis suggests that Siglec-8 might instead function as an activating receptor. Objective: We sought to determine the role of IL-5 priming and identify the signaling molecules involved in Siglec-8 function for human eosinophils. Methods: We used an mAb and/or a multimeric synthetic sulfated sialoglycan ligand recognizing Siglec-8 in combinationwith integrin blocking antibodies, pharmacologic inhibitors, phosphoproteomics, andWestern blot analysis to define the necessity of various proteins involved in Siglec-8 function for human eosinophils. Results: Cytokine priming was required to elicit the unanticipated finding that Siglec-8 engagement promotes rapid b2-integrin-dependent eosinophil adhesion. Also novel was the finding that this adhesion was necessary for subsequent ROS production and apoptosis. Siglec-8-mediated ROS was generated through reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation because pretreatment of eosinophils with catalase (an extracellular superoxide scavenger) or NSC 23766 (a Rac GTPase inhibitor) completely inhibited Siglec-8-mediated eosinophil apoptosis. Finally, engagement of Siglec-8 on IL-5-primed eosinophils resulted in increased phosphorylation of Akt, p38, and c-Jun N-terminal kinase 1 that was also b2-integrin dependent; pharmacologic inhibition of these kinases completely prevented Siglec-8mediated eosinophil apoptosis. Conclusions: These data demonstrate that Siglec-8 functions uniquely as an activating receptor on IL-5-primed eosinophils through a novel pathway involving regulation of b2-integrindependent adhesion, NADPH oxidase, and a subset of protein kinases.	[Carroll, Daniela J.; O'Sullivan, Jeremy A.; Cao, Yun; Bochner, Bruce S.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Nix, David B.; Tiemeyer, Michael] Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA	Northwestern University; Feinberg School of Medicine; University System of Georgia; University of Georgia	Bochner, BS (corresponding author), Div Allergy & Immunol, 240 E Huron St,Rm M-306, Chicago, IL 60611 USA.	bruce.bochner@northwestern.edu		O'Sullivan, Jeremy/0000-0002-3862-202X	National Institutes of Health [AI72265, HL107151]; National Institute of General Medical Sciences [P41 GM103490]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041472, R01AI072265, U19AI136443, R56AI072265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103490] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants AI72265 and HL107151 from the National Institutes of Health and P41 GM103490 from the National Institute of General Medical Sciences.	Ali SR, 2014, J EXP MED, V211, P1231, DOI 10.1084/jem.20131853; Angata T, 2001, J BIOL CHEM, V276, P45128, DOI 10.1074/jbc.M108573200; [Anonymous], 2000, J BIOL CHEM, V275, P861; Avril T, 2005, J BIOL CHEM, V280, P19843, DOI 10.1074/jbc.M502041200; Barthel SR, 2008, J LEUKOCYTE BIOL, V83, P1, DOI 10.1189/jlb.0607344; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bochner BS, 2015, J ALLERGY CLIN IMMUN, V135, P598, DOI 10.1016/j.jaci.2014.11.031; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Cao HA, 2011, IMMUNOLOGY, V132, P18, DOI 10.1111/j.1365-2567.2010.03368.x; Detmers PA, 1998, J IMMUNOL, V161, P1921; DRI P, 1991, J IMMUNOL, V147, P613; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Foussias G, 2000, BIOCHEM BIOPH RES CO, V278, P775, DOI 10.1006/bbrc.2000.3866; Han ST, 2014, AM J RESP CELL MOL, V50, P654, DOI 10.1165/rcmb.2013-0181OC; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Hasala H, 2007, PULM PHARMACOL THER, V20, P580, DOI 10.1016/j.pupt.2006.06.004; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; HORIE S, 1994, J IMMUNOL, V152, P5457; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hudson SA, 2009, J PHARMACOL EXP THER, V330, P608, DOI 10.1124/jpet.109.152439; Johansson MW, 2013, CLIN EXP ALLERGY, V43, P292, DOI 10.1111/j.1365-2222.2012.04065.x; Johansson MW, 2013, AM J RESP CELL MOL, V48, P503, DOI 10.1165/rcmb.2012-0150OC; Kano G, 2017, IMMUNOBIOLOGY, V222, P343, DOI 10.1016/j.imbio.2016.09.006; Kano G, 2013, J ALLERGY CLIN IMMUN, V132, P437, DOI 10.1016/j.jaci.2013.03.024; Kato M, 1998, AM J RESP CELL MOL, V18, P675, DOI 10.1165/ajrcmb.18.5.2885; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; Nguyen KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106239; Kitzig F, 2002, BIOCHEM BIOPH RES CO, V296, P355, DOI 10.1016/S0006-291X(02)00885-9; Lynch OT, 1999, BRIT J PHARMACOL, V128, P1149, DOI 10.1038/sj.bjp.0702892; Lynch OT, 2001, BRIT J PHARMACOL, V134, P797, DOI 10.1038/sj.bjp.0704314; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; McMillan SJ, 2014, J BIOL CHEM, V289, P20370, DOI 10.1074/jbc.M114.574624; McMillan SJ, 2013, BLOOD, V121, P2084, DOI 10.1182/blood-2012-08-449983; Na HJ, 2012, CYTOKINE, V57, P169, DOI 10.1016/j.cyto.2011.10.007; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Nutku E, 2005, BIOCHEM BIOPH RES CO, V336, P918, DOI 10.1016/j.bbrc.2005.08.202; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Nutku-Bilir E, 2008, AM J RESP CELL MOL, V38, P121, DOI 10.1165/rcmb.2007-0154OC; Panday A, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.89; Persson C, 2014, AM J RESP CRIT CARE, V189, P628, DOI 10.1164/rccm.201311-2069OE; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Plotnikov A, 2011, BBA-MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012; Rosenberg HF, 2013, NAT REV IMMUNOL, V13, P9, DOI 10.1038/nri3341; Sakamoto K, 2006, J BIOCHEM, V140, P739, DOI 10.1093/jb/mvj204; Simon HU, 2000, ALLERGY, V55, P791, DOI 10.1034/j.1398-9995.2000.00030.x; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Trnka J, 2008, FREE RADICAL BIO MED, V44, P1406, DOI 10.1016/j.freeradbiomed.2007.12.036; Valent P, 2009, BLOOD REV, V23, P157, DOI 10.1016/j.blre.2009.01.001; Villen J, 2008, NAT PROTOC, V3, P1630, DOI 10.1038/nprot.2008.150; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wechsler ME, 2012, J ALLERGY CLIN IMMUN, V130, P563, DOI 10.1016/j.jaci.2012.07.027; Wilkerson EM, 2016, J PROTEOME RES, V15, P1524, DOI 10.1021/acs.jproteome.6b00006; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu HF, 2017, GLYCOBIOLOGY, V27, P657, DOI 10.1093/glycob/cwx026	63	25	26	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2196	2207		10.1016/j.jaci.2017.08.013	http://dx.doi.org/10.1016/j.jaci.2017.08.013			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	28888781	Green Accepted, Bronze			2022-12-18	WOS:000434701600024
J	Kulkarni, HS; Liszewski, MK; Brody, SL; Atkinson, JP				Kulkarni, Hrishikesh S.; Liszewski, M. Kathryn; Brody, Steven L.; Atkinson, John P.			The complement system in the airway epithelium: An overlooked host defense mechanism and therapeutic target?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Complement; allergic rhinitis; properdin; epithelial cells; asthma; ovalbumin; cystic fibrosis; bronchiolitis; pulmonary fibrosis; anaphylatoxins	HUMAN BRONCHIAL EPITHELIUM; TOLL-LIKE RECEPTORS; GENE-EXPRESSION; CELL-LINE; ANAPHYLATOXIN RECEPTORS; PULMONARY-FIBROSIS; DOWN-REGULATION; COMPONENTS; A549; C3		[Kulkarni, Hrishikesh S.; Brody, Steven L.] Washington Univ, Dept Med, Div Pulm & Crit Care Med, St Louis, MO USA; [Kulkarni, Hrishikesh S.; Liszewski, M. Kathryn; Atkinson, John P.] Washington Univ, Dept Med, Div Rheumatol, St Louis, MO USA	Washington University (WUSTL); Washington University (WUSTL)	Atkinson, JP (corresponding author), Washington Univ, Sch Med, Dept Med, Div Rheumatol, 660 South Euclid Ave,Campus Box 8045, St Louis, MO 63110 USA.	j.p.atkinson@wustl.edu		Atkinson, John/0000-0002-2514-3441; Kulkarni, Hrishikesh/0000-0003-4830-5084	National Institutes of Health (NIH) [R01 GM0099111, R01HL122585]; NIH training grants in the Principles of Pulmonary Research [5T32 HL007317]; Immunobiology of Rheumatic Diseases [5T32-AR007279]; National Institute of Arthritis and Musculoskeletal and Skin Diseases; NIH [P30AR048335]; NIH grant for the Washington University Institute of Clinical and Translational Sciences [3UL1 TR000448]; Barnes-Jewish Hospital Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448, UL1TR002345] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL122585, T32HL007317, R01HL122582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048335, R21AR069833, T32AR007279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM099111] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH training grants in the Principles of Pulmonary Research; Immunobiology of Rheumatic Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH grant for the Washington University Institute of Clinical and Translational Sciences; Barnes-Jewish Hospital Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the National Institutes of Health (NIH; R01 GM0099111 to J.P.A. and R01HL122585 to S.L.B.) and NIH training grants in the Principles of Pulmonary Research (5T32 HL007317 to H.S.K., and the Immunobiology of Rheumatic Diseases (5T32-AR007279 to H.S.K.). Research reported in this publication is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the NIH (P30AR048335); an NIH grant for the Washington University Institute of Clinical and Translational Sciences (3UL1 TR000448); and the Hubert C. and Dorothy R. Moog Professorship (to S.L.B.) supported by the Barnes-Jewish Hospital Foundation.	Agrawal A, 2009, PHYSIOL GENOMICS, V40, P1, DOI 10.1152/physiolgenomics.00141.2009; Ajona D, 2007, J IMMUNOL, V178, P5991, DOI 10.4049/jimmunol.178.9.5991; Akaiwa M, 1999, J HISTOCHEM CYTOCHEM, V47, P777, DOI 10.1177/002215549904700607; Ali M, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-4; Barnum SR, 2017, PHARMACOL THERAPEUT, V172, P63, DOI 10.1016/j.pharmthera.2016.11.014; Bidula S, 2015, IMMUNOLOGY, V146, P281, DOI 10.1111/imm.12501; Boesewetter DE, 2006, CELL BIOL TOXICOL, V22, P101, DOI 10.1007/s10565-006-0150-9; Brass DM, 2017, AM J RESP CELL MOL, V56, P784, DOI 10.1165/rcmb.2016-0372OC; Castillon N, 2002, LAB INVEST, V82, P989, DOI 10.1097/01.LAB.0000022221.88025.43; Chen DQ, 2015, NANOSCALE RES LETT, V10, P1, DOI 10.1186/s11671-014-0707-0; Cooper P, 2001, AM J PHYSIOL-LUNG C, V280, pL841, DOI 10.1152/ajplung.2001.280.5.L841; de Astorza B, 2004, INFECT IMMUN, V72, P1767, DOI 10.1128/IAI.72.3.1767-1774.2004; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Fregonese L, 2005, J ALLERGY CLIN IMMUN, V115, P1148, DOI 10.1016/j.jaci.2005.01.068; Goswami MT, 2016, ONCOGENE, V35, P1888, DOI 10.1038/onc.2015.258; Gu HM, 2016, FASEB J, V30, P2336, DOI 10.1096/fj.201500044; Gu HM, 2014, FASEB J, V28, P4223, DOI 10.1096/fj.13-247650; Hackett NR, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-82; Hiemstra PS, 2015, MOL IMMUNOL, V68, P28, DOI 10.1016/j.molimm.2015.07.030; HILL LD, 1993, IMMUNOLOGY, V79, P236; Kesimer M, 2009, FASEB J, V23, P1858, DOI 10.1096/fj.08-119131; Lane AP, 2006, AM J RHINOL, V20, P117, DOI 10.1177/194589240602000122; Leaker BR, 2017, MUCOSAL IMMUNOL, V10, P408, DOI 10.1038/mi.2016.74; Lubbers R, 2017, CLIN EXP IMMUNOL, V188, P183, DOI 10.1111/cei.12952; Luo XY, 2011, J PROTEOMICS, V74, P528, DOI 10.1016/j.jprot.2011.01.011; Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657; Okroj M, 2009, CANCER IMMUNOL IMMUN, V58, P1771, DOI 10.1007/s00262-009-0685-8; Pandya PH, 2016, AM J RESP CELL MOL, V55, P889, DOI 10.1165/rcmb.2015-0237OC; Park EJ, 2009, TOXICOL LETT, V184, P126, DOI 10.1016/j.toxlet.2008.10.028; Peters-Hall JR, 2015, AM J RESP CELL MOL, V53, P22, DOI 10.1165/rcmb.2014-0256RC; Pillai DK, 2014, AM J RESP CELL MOL, V50, P292, DOI 10.1165/rcmb.2013-0188OC; ROTHMAN BL, 1989, AM REV RESPIR DIS, V139, P212, DOI 10.1164/ajrccm/139.1.212; ROTHMAN BL, 1990, J IMMUNOL, V145, P592; Scheetz TE, 2004, PHYSIOL GENOMICS, V17, P69, DOI 10.1152/physiolgenomics.00188.2003; Schlosser RJ, 2010, AM J RHINOL ALLERGY, V24, P21, DOI 10.2500/ajra.2010.24.3399; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Song Mee, 2011, Toxicology and Environmental Health Sciences, V3, P106, DOI 10.1007/s13530-011-0085-2; Staab EB, 2014, INT IMMUNOPHARMACOL, V21, P293, DOI 10.1016/j.intimp.2014.05.008; STRUNK RC, 1988, J CLIN INVEST, V81, P1419, DOI 10.1172/JCI113472; Suzuki H, 2013, J IMMUNOL, V191, P4431, DOI 10.4049/jimmunol.1202242; Vainer ED, 2013, TISSUE ANTIGENS, V82, P26, DOI 10.1111/tan.12138; VanderMeer J, 2004, ARCH OTOLARYNGOL, V130, P1374, DOI 10.1001/archotol.130.12.1374; Varsano S, 2000, THORAX, V55, P364, DOI 10.1136/thorax.55.5.364; VARSANO S, 1995, AM J RESP CRIT CARE, V152, P1087, DOI 10.1164/ajrccm.152.3.7545058; Walters MS, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0094-1; Wang Y, 2015, J IMMUNOL, V195, P1171, DOI 10.4049/jimmunol.1401819; Ying LS, 2016, ONCOTARGET, V7, P86536, DOI 10.18632/oncotarget.13294; Zell S, 2007, CLIN EXP IMMUNOL, V150, P576, DOI 10.1111/j.1365-2249.2007.03507.x; Zhao YX, 2000, INT J MOL MED, V5, P415; Zhou HX, 2016, J IMMUNOL, V196, P3159, DOI 10.4049/jimmunol.1502400; Zhou J, 2012, J INFECT DIS, V206, P495, DOI 10.1093/infdis/jis378; Zimmerman JL, 2000, CRIT CARE MED, V28, P3149, DOI 10.1097/00003246-200009000-00004	52	25	26	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1582	+		10.1016/j.jaci.2017.11.046	http://dx.doi.org/10.1016/j.jaci.2017.11.046			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29339260	Green Accepted, Bronze			2022-12-18	WOS:000432148200005
J	Burbank, AJ; Duran, CG; Pan, YH; Burns, P; Jones, S; Jiang, Q; Yang, C; Jenkins, S; Wells, H; Alexis, N; Kesimer, M; Bennett, WD; Zhou, HB; Peden, DB; Hernandez, ML				Burbank, Allison J.; Duran, Charity G.; Pan, Yinghao; Burns, Patricia; Jones, Susan; Jiang, Qing; Yang, Chao; Jenkins, Sha'Leema; Wells, Heather; Alexis, Neil; Kesimer, Mehmet; Bennett, William D.; Zhou, Haibo; Peden, David B.; Hernandez, Michelle L.			Gamma tocopherol-enriched supplement reduces sputum eosinophilia and endotoxin-induced sputum neutrophilia in volunteers with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; endotoxin; eosinophil; lipopolysaccharide; mucin; mucociliary clearance; neutrophil; tocopherol; vitamin E	REGIONAL PARTICLE DEPOSITION; VITAMIN-E; INHALED ENDOTOXIN; MUCOCILIARY CLEARANCE; AIRWAY NEUTROPHIL; INFLAMMATORY RESPONSE; OXIDATIVE STRESS; ALPHA-TOCOPHEROL; INNATE IMMUNITY; DIETARY-INTAKE	Background: We and others have shown that the gamma tocopherol (gamma T) isoform of vitamin E has multiple anti-inflammatory and antioxidant actions and that gamma T supplementation reduces eosinophilic and endotoxin (LPS)-induced neutrophilic airway inflammation in animal models and healthy human volunteers. Objective: We sought to determine whether gamma T supplementation reduces eosinophilic airway inflammation and acute neutrophilic response to inhaled LPS challenge in volunteers with asthma. Methods: Participants with mild asthma were enrolled in a double-blinded, placebo-controlled crossover study to assess the effect of 1200 mg of gamma T daily for 14 days on sputum eosinophils, mucins, and cytokines. We also assessed the effect on acute inflammatory response to inhaled LPS challenge following gamma T treatment, focusing on changes in sputum neutrophilia, mucins, and cytokines. Mucociliary clearance was measured using gamma scintigraphy. Results: Fifteen subjects with mild asthma completed both arms of the study. Compared with placebo, gamma T notably reduced pre-LPS challenge sputum eosinophils and mucins, including mucin 5AC and reduced LPS-induced airway neutrophil recruitment 6 and 24 hours after challenge. Mucociliary clearance was slowed 4 hours postchallenge in the placebo group but not in the gamma T treatment group. Total sputum mucins (but not mucin 5AC) were reduced at 24 hours postchallenge during gamma T treatment compared with placebo. Conclusions: When compared with placebo, gamma T supplementation for 14 days reduced inflammatory features of asthma, including sputum eosinophils and mucins, as well as acute airway response to inhaled LPS challenge. Larger scale clinical trials are needed to assess the efficacy of gamma T supplements as a complementary or steroid-sparing treatment for asthma.	[Burbank, Allison J.; Duran, Charity G.; Burns, Patricia; Jones, Susan; Jenkins, Sha'Leema; Wells, Heather; Alexis, Neil; Bennett, William D.; Peden, David B.; Hernandez, Michelle L.] Univ N Carolina, Marsico Lung Inst, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA; [Burbank, Allison J.; Alexis, Neil; Peden, David B.; Hernandez, Michelle L.] Univ N Carolina, Marsico Lung Inst, Dept Pediat, Div Allergy Immunol & Rheumatol, Chapel Hill, NC USA; [Pan, Yinghao; Zhou, Haibo] Univ N Carolina, Marsico Lung Inst, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Kesimer, Mehmet] Univ N Carolina, Marsico Lung Inst, Cyst Fibrosis Pulm Res & Treatment Ctr, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Jiang, Qing; Yang, Chao] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Burbank, AJ (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.	allison_burbank@med.unc.edu	, Mehmet Kesimer/AHB-9223-2022; ZHOU, Haibo/M-7373-2017	Peden, David/0000-0003-4526-4627	National Institute of Environmental Health Sciences [R01ES023349, K23-ES021745, P30ES010126, T32ES007126-33, R01ES021900]; National Institute of General Medical Sciences [T32GM086330]; American Academy of Allergy, Asthma & Immunology Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL110906, R01HL103940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, R01ES021900, T32ES007126, K23ES021745, R01ES023349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM086330] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); American Academy of Allergy, Asthma & Immunology Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institute of Environmental Health Sciences grant nos. R01ES023349, K23-ES021745, and P30ES010126. A.J.B. is supported by National Institute of General Medical Sciences grant no. T32GM086330. C.G.D. is supported by National Institute of Environmental Health Sciences grant no. T32ES007126-33. H.Z. and Y.P. are supported by National Institute of Environmental Health Sciences grant no. R01ES021900. M.L.H. was supported by the American Academy of Allergy, Asthma & Immunology Foundation.	Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1396, DOI 10.1016/j.jaci.2006.02.030; Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1185, DOI 10.1016/j.jaci.2005.12.1305; Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Alexis NE, 2001, J ALLERGY CLIN IMMUN, V108, P577; Alexis NE, 2008, ANN ALLERG ASTHMA IM, V100, P206, DOI 10.1016/S1081-1206(10)60444-9; Alexis NE, 2009, J ALLERGY CLIN IMMUN, V124, P1222, DOI 10.1016/j.jaci.2009.07.036; Bennett WD, 2015, J APPL PHYSIOL, V118, P1483, DOI 10.1152/japplphysiol.00404.2014; Bennett WD, 2011, CLIN EXP ALLERGY, V41, P1719, DOI 10.1111/j.1365-2222.2011.03814.x; Bennett WD, 2014, J AEROSOL MED PULM D, V27, P459, DOI 10.1089/jamp.2013.1089; Bennett WD, 2013, J ALLERGY CLIN IMMUN, V131, P912, DOI 10.1016/j.jaci.2012.09.010; Berdnikovs S, 2009, J IMMUNOL, V182, P4395, DOI 10.4049/jimmunol.0803659; Bonser LR, 2016, J CLIN INVEST, V126, P2367, DOI 10.1172/JCI84910; Burbank AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1179, DOI 10.1016/j.jaci.2017.04.030; Centers for Disease Control and Prevention, DAT STAT SURV ASTH S; Christen S, 2002, J LIPID RES, V43, P1978, DOI 10.1194/jlr.D200023-JLR200; Cook-Mills J, 2016, THORAX, V71, P954, DOI 10.1136/thoraxjnl-2016-208494; Devereux G, 2006, AM J RESP CRIT CARE, V174, P499, DOI 10.1164/rccm.200512-1946OC; Dow L, 1996, AM J RESP CRIT CARE, V154, P1401, DOI 10.1164/ajrccm.154.5.8912755; Engelhart MJ, 2002, JAMA-J AM MED ASSOC, V287, P3223, DOI 10.1001/jama.287.24.3223; Fogarty A, 2000, LANCET, V356, P1573, DOI 10.1016/S0140-6736(00)03132-9; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Hekking PPW, 2014, J ALLER CL IMM-PRACT, V2, P671, DOI 10.1016/j.jaip.2014.09.007; Henderson AG, 2014, J CLIN INVEST, V124, P3047, DOI 10.1172/JCI73469; Hernandez M, 2012, J ALLERGY CLIN IMMUN, V129, P259, DOI 10.1016/j.jaci.2011.11.007; Hernandez ML, 2015, J ALLERGY CLIN IMMUN, V135, P379, DOI 10.1016/j.jaci.2014.07.039; Hernandez ML, 2013, FREE RADICAL BIO MED, V60, P56, DOI 10.1016/j.freeradbiomed.2013.02.001; Hernandez ML, 2010, INHAL TOXICOL, V22, P648, DOI 10.3109/08958371003610966; Hoskins A, 2012, ALLERGY, V67, P676, DOI 10.1111/j.1398-9995.2012.02810.x; Jiang Q, 2001, AM J CLIN NUTR, V74, P714; Jiang Q, 2000, P NATL ACAD SCI USA, V97, P11494, DOI 10.1073/pnas.200357097; Jiang Q, 2015, J LIPID RES, V56, P2217, DOI 10.1194/jlr.D061663; Jiang Q, 2014, FREE RADICAL BIO MED, V72, P76, DOI 10.1016/j.freeradbiomed.2014.03.035; Johnson KC, 2002, EUR J CANCER PREV, V11, P253, DOI 10.1097/00008469-200206000-00009; Jones B, 2015, DESIGN ANAL CROSS OV; Lai PS, 2015, CHEST, V148, P1251, DOI 10.1378/chest.15-0098; Lay JC, 2007, J ALLERGY CLIN IMMUN, V120, P719, DOI 10.1016/j.jaci.2007.05.005; Litonjua AA, 2006, AM J CLIN NUTR, V84, P903, DOI 10.1093/ajcn/84.4.903; Marchese ME, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-31; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Miller RL, 2014, J ALLERGY CLIN IMMUN, V134, P1001, DOI 10.1016/j.jaci.2014.07.064; National Heart Lung and Blood Institute, 2007, 3 NAT HEART LUNG BLO; Naziroglu M, 2004, CLIN CHIM ACTA, V344, P63, DOI 10.1016/j.cccn.2004.01.031; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769, DOI 10.1164/ajrccm.161.3.9809071; Pearson PJK, 2004, THORAX, V59, P652, DOI 10.1136/thx.2004.022616; Peden DB, 2011, IMMUNOL REV, V242, P91, DOI 10.1111/j.1600-065X.2011.01035.x; Song KS, 2009, AM J RESP CELL MOL, V41, P40, DOI 10.1165/rcmb.2008-0280OC; Thorne PS, 2015, AM J RESP CRIT CARE, V192, P1287, DOI 10.1164/rccm.201502-0251OC; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401, DOI 10.1164/ajrccm.151.5.7735592; Wagner JG, 2008, CLIN EXP ALLERGY, V38, P501, DOI 10.1111/j.1365-2222.2007.02855.x; Wagner JG, 2007, FREE RADICAL BIO MED, V43, P1176, DOI 10.1016/j.freeradbiomed.2007.07.013; Wagner JG, 2014, FREE RADICAL BIO MED, V68, P101, DOI 10.1016/j.freeradbiomed.2013.11.024; Wagner JG, 2009, TOXICOL PATHOL, V37, P481, DOI 10.1177/0192623309335630; Wang Y, 2012, J NUTR BIOCHEM, V23, P602, DOI 10.1016/j.jnutbio.2011.03.003; Wiser J, 2008, FREE RADICAL BIO MED, V45, P40, DOI 10.1016/j.freeradbiomed.2008.03.002; Yoshikawa S, 2005, EUR J CLIN NUTR, V59, P900, DOI 10.1038/sj.ejcn.1602154	57	25	26	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1231	+		10.1016/j.jaci.2017.06.029	http://dx.doi.org/10.1016/j.jaci.2017.06.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28736267	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000429197800009
J	Qiu, WL; Guo, F; Glass, K; Yuan, GC; Quackenbush, J; Zhou, XB; Tantisira, KG				Qiu, Weiliang; Guo, Feng; Glass, Kimberly; Yuan, Guo Cheng; Quackenbush, John; Zhou, Xiaobo; Tantisira, Kelan G.			Differential connectivity of gene regulatory networks distinguishes corticosteroid response in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pharmacogenomics; gene expression; inhaled corticosteroids; apoptosis; system biology	STEROID-RESISTANT ASTHMA; GLUCOCORTICOID-RECEPTOR; MONONUCLEAR-CELLS; PHARMACOGENETICS; EXPRESSION; PROMOTER; THERAPY; ASSOCIATION; MECHANISMS; DIFFICULT	Background: Variations in drug response between individuals have prevented us from achieving high drug efficacy in treating many complex diseases, including asthma. Genetics plays an important role in accounting for such interindividual variations in drug response. However, systematic approaches for addressing how genetic factors and their regulators determine variations in drug response in asthma treatment are lacking. Objective: We sought to identify key transcriptional regulators of corticosteroid response in asthma using a novel systems biology approach. Methods: We used Passing Attributes between Networks for Data Assimilations (PANDA) to construct the gene regulatory networks associated with good responders and poor responders to inhaled corticosteroids based on a subset of 145 white children with asthma who participated in the Childhood Asthma Management Cohort. PANDA uses gene expression profiles and published relationships among genes, transcription factors (TFs), and proteins to construct the directed networks of TFs and genes. We assessed the differential connectivity between the gene regulatory network of good responders versus that of poor responders. Results: When compared with poor responders, the network of good responders has differential connectivity and distinct ontologies (eg, proapoptosis enriched in network of good responders and antiapoptosis enriched in network of poor responders). Many of the key hubs identified in conjunction with clinical response are also cellular response hubs. Functional validation demonstrated abrogation of differences in corticosteroid-treated cell viability following siRNA knockdown of 2 TFs and differential downstream expression between good responders and poor responders. Conclusions: We have identified and validated multiple TFs influencing asthma treatment response. Our results show that differential connectivity analysis can provide new insights into the heterogeneity of drug treatment effects.	[Qiu, Weiliang; Guo, Feng; Glass, Kimberly; Zhou, Xiaobo; Tantisira, Kelan G.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Qiu, Weiliang; Guo, Feng; Glass, Kimberly; Zhou, Xiaobo; Tantisira, Kelan G.] Harvard Med Sch, Boston, MA USA; [Yuan, Guo Cheng; Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Yuan, Guo Cheng; Quackenbush, John] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Tantisira, Kelan G.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Tantisira, KG (corresponding author), Brigham & Womens Hosp, 181 Longwood Ave, Boston, MA 02115 USA.; Tantisira, KG (corresponding author), Harvard Med Sch, Channing Div Network Med, 181 Longwood Ave, Boston, MA USA.	rekgt@channing.harvard.edu		Zhou, Xiaobo/0000-0002-7127-2869; Glass, Kimberly/0000-0003-4394-5779; Guo, Feng/0000-0002-4506-7618; Quackenbush, John/0000-0002-2702-5879; Qiu, Weiliang/0000-0002-9155-6957	National Institutes of Health [R01 HL092197, K23 HG003983, U01 HL065899, R01 HL111759, P01 HL105339, R01 HL127200, R33 HL120794]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL105339, R01HL111759, R01HL092197, R01HL127200, U01HL065899, R01HL127332, P01HL132825, R33HL120794, K25HL133599] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K23HG003983] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by the National Institutes of Health (grant nos. R01 HL092197, K23 HG003983, U01 HL065899, R01 HL111759, P01 HL105339, R01 HL127200, and R33 HL120794).	ADCOCK IM, 1995, J IMMUNOL, V154, P3500; Al-Hajjaj MS, 2011, ANN THORAC MED, V6, P1, DOI 10.4103/1817-1737.74268; Araujo Ana Carla Sousa de, 2007, J Bras Pneumol, V33, P495; Beste M. T., 2014, SCI TRANSL MED, V6, P16; Breslin MB, 1998, J STEROID BIOCHEM, V67, P369, DOI 10.1016/S0960-0760(98)00138-1; Byrd RP, 2000, POSTGRAD MED, V108, P37, DOI 10.3810/pgm.2000.11.1294; Chang PJ, 2015, AM J RESP CRIT CARE, V191, P54, DOI 10.1164/rccm.201402-0314OC; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Cornejo S, 2015, PEDIATR RES, V78, P505, DOI 10.1038/pr.2015.148; Dahlin A, 2016, PHARMACOGENOMICS J, V16, P151, DOI 10.1038/tpj.2015.34; Dahlin A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129385; Ding J, 2010, AM J HUM GENET, V87, P779, DOI 10.1016/j.ajhg.2010.10.024; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Esposito S, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-31; Geng CD, 2005, J BIOL CHEM, V280, P43264, DOI 10.1074/jbc.M508245200; Glass K, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0551-y; Glass K, 2014, BMC SYST BIOL, V8, DOI 10.1186/s12918-014-0118-y; Glass K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064832; Grundberg E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001279; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Li CS, 2007, EXP MOL MED, V39, P805, DOI 10.1038/emm.2007.87; Liggett SB, 2001, NAT MED, V7, P281, DOI 10.1038/85411; Lima JJ, 2009, CURR OPIN PULM MED, V15, P57, DOI 10.1097/MCP.0b013e32831da8be; Ma Xin-Long, 2010, Orthop Surg, V2, P278, DOI 10.1111/j.1757-7861.2010.00100.x; Maranville JC, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002162; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Melis M, 2002, EUR RESPIR J, V19, P257, DOI 10.1183/09031936.02.00239202; Miller SM, 2013, CURR ALLERGY ASTHM R, V13, P443, DOI 10.1007/s11882-013-0372-x; Nunez BS, 2002, MOL CELL ENDOCRINOL, V189, P191, DOI 10.1016/S0303-7207(01)00676-1; Ortega VE, 2014, CLIN GENET, V86, P12, DOI 10.1111/cge.12377; Ortega VE, 2013, CURR OPIN ALLERGY CL, V13, P399, DOI 10.1097/ACI.0b013e3283630c19; Qiu WL, 2014, HUM MOL GENET, V23, P5017, DOI 10.1093/hmg/ddu191; Reiprich S, 2008, MOL BIOL CELL, V19, P1575, DOI 10.1091/mbc.E07-08-0782; Riffel AK, 2009, MOL PHARMACOL, V76, P1104, DOI 10.1124/mol.109.055699; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Silverman E. S., 2002, THERAPEUTIC TARGETS; Smirnov DA, 2009, NATURE, V459, P587, DOI 10.1038/nature07940; Suzuki M, 2008, ENDOCR PATHOL, V19, P17, DOI 10.1007/s12022-008-9014-6; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tantisira KG, 2012, AM J RESP CRIT CARE, V185, P1286, DOI 10.1164/rccm.201111-2061OC; Trevor JL, 2014, ALLERGY, V69, P817, DOI 10.1111/all.12412; Uddin M, 2010, THORAX, V65, P684, DOI 10.1136/thx.2009.120741; Vazquez-Tello A, 2013, J CLIN IMMUNOL, V33, P466, DOI 10.1007/s10875-012-9828-3; White SR, 2002, CHEST, V122, p278S, DOI 10.1378/chest.122.6_suppl.278S; Yoshida NL, 2002, BIOCHEM BIOPH RES CO, V293, P1254	47	25	25	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1250	1258		10.1016/j.jaci.2017.05.052	http://dx.doi.org/10.1016/j.jaci.2017.05.052			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28736268	Green Accepted, Bronze			2022-12-18	WOS:000429197800011
J	Goldman, DL; Chen, ZG; Shankar, V; Tyberg, M; Vicencio, A; Burk, R				Goldman, David L.; Chen, Zigui; Shankar, Viswanathan; Tyberg, Michael; Vicencio, Alfin; Burk, Robert			Lower airway microbiota and mycobiota in children with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							COLONIZATION; INFECTION		[Goldman, David L.; Tyberg, Michael; Burk, Robert] Childrens Hosp Montefiore, Dept Pediat, Bronx, NY 10467 USA; [Goldman, David L.; Burk, Robert] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; [Shankar, Viswanathan] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; [Chen, Zigui] Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; [Vicencio, Alfin] Cohens Children Med Ctr, Dept Pediat, Queens, NY USA	Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Chinese University of Hong Kong; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York	Goldman, DL (corresponding author), Childrens Hosp Montefiore, Dept Pediat, Bronx, NY 10467 USA.; Goldman, DL (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.	david.goldman@einstein.yu.edu	Chen, Zigui/E-8490-2017; Viswanathan, Shankar/AAX-5281-2020	Chen, Zigui/0000-0002-8577-1298; Viswanathan, Shankar/0000-0003-3349-9090				Durack J, 2017, J ALLERGY CLIN IMMUN, V140, P63, DOI 10.1016/j.jaci.2016.08.055; Eddens T, 2016, AM J RESP CRIT CARE, V194, P807, DOI 10.1164/rccm.201511-2205OC; Fitzpatrick AM, 2010, PEDIAT ALLER IMM PUL, V23, P131, DOI 10.1089/ped.2010.0021; Fitzpatrick ME, 2014, MICROBIOL IMMUNOL, V58, P202, DOI 10.1111/1348-0421.12135; Goldman DL, 2009, MED MYCOL, V47, P445, DOI 10.1080/13693780802641904; Huang YJ, 2015, CURR OPIN PULM MED, V21, P27, DOI 10.1097/MCP.0000000000000124; Morris A, 2009, J CLIN MICROBIOL, V47, P3773, DOI 10.1128/JCM.01712-09; Vargas SL, 2001, CLIN INFECT DIS, V32, P855, DOI 10.1086/319340; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724	9	25	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					808	811		10.1016/j.jaci.2017.09.018	http://dx.doi.org/10.1016/j.jaci.2017.09.018			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29031597				2022-12-18	WOS:000424410800047
J	Pellerin, L; Jenks, JA; Chinthrajah, S; Dominguez, T; Block, W; Zhou, XY; Noshirvan, A; Gregori, S; Roncarolo, MG; Nadeau, KC; Bacchetta, R				Pellerin, Laurence; Jenks, Jennifer Anne; Chinthrajah, Sharon; Dominguez, Tina; Block, Whitney; Zhou, Xiaoying; Noshirvan, Arram; Gregori, Silvia; Roncarolo, Maria Grazia; Nadeau, Kari Christine; Bacchetta, Rosa			Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; oral immunotherapy; T(R)1 cells; LAG3; CD49b; T(H)2 cells; Ara h 1/2	ORAL IMMUNOTHERAPY; ATOPIC-DERMATITIS; FOOD ALLERGY; ANTIGEN; INTERLEUKIN-10; ASSOCIATION; MECHANISMS; EXPRESSION; CHILDREN; DIFFERENTIATION	Background: Peanut allergy (PA) is a life-threatening condition that lacks regulator-approved treatment. Regulatory T type 1 (T(R)1) cells are potent suppressors of immune responses and can be induced in vivo upon repeated antigen exposure or in vitro by using tolerogenic dendritic cells. Whether oral immunotherapy (OIT) leads to antigen-specific T(R)1 cell induction has not been established. Objectives: We sought to determine whether peanut-specific T(R)1 cells can be generated in vitro from peripheral blood of patients with PA at baseline or during OIT and whether they are functional compared with peanut-specific T(R)1 cells induced from healthy control (HC) subjects. Methods: Tolerogenic dendritic cells were differentiated in the presence of IL-10 from PBMCs of patients with PA and HC subjects pulsed with the main peanut allergens of Arachis hypogaea, Ara h 1 and 2, and used as antigen-presenting cells for autologous CD4(+) T cells (CD4(+) T cells coincubated with tolerogenic dendritic cells pulsed with the main peanut allergens [pea-T10 cells]). Pea-T10 cells were characterized by the presence of CD49b(+) lymphocyte-activation gene 3 (LAG3)(+) T(R)1 cells, antigen-specific proliferative responses, and cytokine production. Results: CD49b(+) LAG3(+) T(R)1 cells were induced in pea-T10 cells at comparable percentages from HC subjects and patients with PA. Despite their antigen specificity, pea-T10 cells of patients with PA with or without OIT, as compared with those of HC subjects, were not anergic and had high TH2 cytokine production upon peanut-specific restimulation. Conclusions: Peanut-specific T(R)1 cells can be induced from HC subjects and patients with PA, but those from patients with PA are functionally defective independent of OIT. The unfavorable T(R)1/TH2 ratio is discussed as a possible cause of PA T(R)1 cell impairment.	[Pellerin, Laurence; Jenks, Jennifer Anne; Chinthrajah, Sharon; Dominguez, Tina; Block, Whitney; Zhou, Xiaoying; Noshirvan, Arram; Nadeau, Kari Christine] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Pellerin, Laurence; Jenks, Jennifer Anne; Chinthrajah, Sharon; Dominguez, Tina; Block, Whitney; Zhou, Xiaoying; Noshirvan, Arram; Nadeau, Kari Christine] Stanford Univ, Dept Med, Div Pulm & Crit Care, Stanford, CA 94305 USA; [Pellerin, Laurence; Roncarolo, Maria Grazia; Bacchetta, Rosa] Stanford Univ, Div Stem Cell Transplantat & Regenerat Med, Stanford, CA 94305 USA; [Pellerin, Laurence; Roncarolo, Maria Grazia; Bacchetta, Rosa] Stanford Univ, Dept Pediat, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Gregori, Silvia] Ist Sci San Raffaele, IRCCS, San Raffaele Telethon Inst Gene Therapy SR TIGET, Milan, Italy	Stanford University; Stanford University; Stanford University; Stanford University; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Bacchetta, R (corresponding author), Stanford Sch Med, Dept Pediat, Pediat Stem Cell Transplantat & Regenerat Med, Lorry I Lokey Stem Cell Res Bldg, Stanford, CA 94305 USA.	rosab@stanford.edu	Pellerin, Laurence/AAH-3424-2020; Gregori, Silvia/J-7718-2016	Jenks, Jennifer/0000-0002-6865-5615; Bacchetta, Rosa/0000-0002-0606-6268; Gregori, Silvia/0000-0002-3517-9683; Chinthrajah, Sharon/0000-0003-2467-4256	Child Health Research Institute at Stanford University; Lucile Packard Foundation for Children's Health; Stanford CTSA [UL1 TR001085]; Sean N. Parker Center for Allergy and Asthma Research at Stanford University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001085] Funding Source: NIH RePORTER	Child Health Research Institute at Stanford University; Lucile Packard Foundation for Children's Health; Stanford CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Sean N. Parker Center for Allergy and Asthma Research at Stanford University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by the Child Health Research Institute at Stanford University, Lucile Packard Foundation for Children's Health, Stanford CTSA (grant no. UL1 TR001085), and the Sean N. Parker Center for Allergy and Asthma Research at Stanford University.	Abbas AK, 2013, NAT IMMUNOL, V14, P307, DOI 10.1038/ni.2554; Agace WW, 2008, TRENDS IMMUNOL, V29, P514, DOI 10.1016/j.it.2008.08.003; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Andolfi G, 2012, MOL THER, V20, P1778, DOI 10.1038/mt.2012.71; Asai Y, 2013, J ALLERGY CLIN IMMUN, V132, P239, DOI 10.1016/j.jaci.2013.03.043; BACCHETTA R, 1990, J IMMUNOL, V144, P902; Bacchetta R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00016; Bacchetta R, 2010, HAEMATOL-HEMATOL J, V95, P2134, DOI 10.3324/haematol.2010.025825; Bacher P, 2013, CYTOM PART A, V83A, P692, DOI [10.1002/cyto.a.22317, 10.1002/cyto.22317]; Begin P, 2014, HUM VACC IMMUNOTHER, V10, P2295, DOI 10.4161/hv.29233; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Clemente-Casares X, 2016, NATURE, V530, P434, DOI 10.1038/nature16962; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; Cox A, 2015, CHEM IMMUNOL ALLERGY, V101, P131, DOI 10.1159/000375417; Delgoffe GM, 2015, MOL IMMUNOL, V68, P492, DOI 10.1016/j.molimm.2015.07.026; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; DeVries A, 2015, CURR OPIN ALLERGY CL, V15, P435, DOI 10.1097/ACI.0000000000000201; Gagliani N, 2013, NAT MED, V19, P739, DOI 10.1038/nm.3179; Gianfrani C, 2006, J IMMUNOL, V177, P4178, DOI 10.4049/jimmunol.177.6.4178; Gregori S, 2011, METHODS MOL BIOL, V677, P31, DOI 10.1007/978-1-60761-869-0_3; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Hemler JA, 2015, ANN ALLERG ASTHMA IM, V115, P471, DOI 10.1016/j.anai.2015.10.008; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Kamanaka M, 2006, IMMUNITY, V25, P941, DOI 10.1016/j.immuni.2006.09.013; Kayserova J, 2012, J INVEST ALLERG CLIN, V22, P92; Kim SV, 2013, SCIENCE, V340, P1456, DOI 10.1126/science.1237013; Kulis M, 2015, GASTROENTEROLOGY, V148, P1132, DOI 10.1053/j.gastro.2015.01.034; Kulis M, 2013, ADV DRUG DELIVER REV, V65, P774, DOI 10.1016/j.addr.2012.10.004; Levings MK, 2002, INT ARCH ALLERGY IMM, V129, P263, DOI 10.1159/000067596; Martino D, 2015, J ALLERGY CLIN IMMUN, V135, P1319, DOI 10.1016/j.jaci.2014.12.1933; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Namkung JH, 2011, EXP DERMATOL, V20, P915, DOI [10.1111/j.1600-0625.2010.01148.x, 10.1111/j.1600-0625.2011.01357.x]; Namkung JH, 2011, J DERMATOL SCI, V62, P16, DOI 10.1016/j.jdermsci.2011.01.007; Nguyen LP, 2015, NAT IMMUNOL, V16, P207, DOI 10.1038/ni.3079; Ohkura N, 2013, IMMUNITY, V38, P414, DOI 10.1016/j.immuni.2013.03.002; Pacciani V, 2010, J ALLERGY CLIN IMMUN, V125, P727, DOI 10.1016/j.jaci.2009.12.004; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Passerini L, 2011, EUR J IMMUNOL, V41, P1120, DOI 10.1002/eji.201040909; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Roncarolo MG, 2014, CURR TOP MICROBIOL, V380, P39, DOI 10.1007/978-3-662-43492-5_3; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Srivastava KD, 2016, J ALLERGY CLIN IMMUN, V138, P536, DOI 10.1016/j.jaci.2016.01.047; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Tsuji NM, 2001, IMMUNOLOGY, V103, P458, DOI 10.1046/j.1365-2567.2001.01265.x; Valdor R, 2013, SEMIN IMMUNOL, V25, P313, DOI 10.1016/j.smim.2013.10.010; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, P576, DOI 10.1016/j.jaci.2010.12.1116; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Wisniewski JA, 2015, CLIN EXP ALLERGY, V45, P1201, DOI 10.1111/cea.12537; Yu GP, 2012, INT ARCH ALLERGY IMM, V159, P179, DOI 10.1159/000336391	61	25	25	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					202	+		10.1016/j.jaci.2017.05.045	http://dx.doi.org/10.1016/j.jaci.2017.05.045			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28689791	Bronze			2022-12-18	WOS:000419312200026
J	Hofman, ZLM; de Maat, S; Suffritti, C; Zanichelli, A; van Doorn, C; Sebastian, SAE; Veszeli, N; Csuka, D; Renne, T; Pasterkamp, G; Cicardi, M; Farkas, H; Hack, CE; Maas, C				Hofman, Zonne L. M.; de Maat, Steven; Suffritti, Chiara; Zanichelli, Andrea; van Doorn, Cassandra; Sebastian, Silvie A. E.; Veszeli, Nora; Csuka, Dorottya; Renne, Thomas; Pasterkamp, Gerard; Cicardi, Marco; Farkas, Henriette; Hack, C. Erik; Maas, Coen			Cleaved kininogen as a biomarker for bradykinin release in hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MOLECULAR-WEIGHT KININOGEN; PLASMA; INSTABILITY; ACTIVATION		[Hofman, Zonne L. M.; de Maat, Steven; van Doorn, Cassandra; Sebastian, Silvie A. E.; Pasterkamp, Gerard; Maas, Coen] Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Utrecht, Netherlands; [Hofman, Zonne L. M.; Hack, C. Erik] Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [Suffritti, Chiara; Zanichelli, Andrea; Cicardi, Marco] Luigi Sacco Univ Milan, Dept Biomed & Clin Sci, Milan, Italy; [Suffritti, Chiara; Zanichelli, Andrea; Cicardi, Marco] Luigi Sacco Hosp, Milan, Italy; [Veszeli, Nora; Csuka, Dorottya; Farkas, Henriette] Semmelweis Univ, Dept Internal Med 3, Hungarian Angioedema Ctr, Budapest, Hungary; [Renne, Thomas] Karolinska Inst, Dept Mol Med & Surg, Solna, Sweden; [Renne, Thomas] Univ Hosp, Solna, Sweden; [Renne, Thomas] Univ Med Ctr Hamburg Eppendorf, Inst Clin Chem & Lab Med, Hamburg, Germany	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Milan; Luigi Sacco Hospital; Semmelweis University; Karolinska Institutet; University of Hamburg; University Medical Center Hamburg-Eppendorf	Maas, C (corresponding author), Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Utrecht, Netherlands.	cmaas4@umcutrecht.nl	Suffritti, Chiara/AAE-2940-2020; Levi, Marcel/AAZ-8559-2020; Csuka, Dorottya/F-2224-2010; cicardi, marco/K-9219-2016	Suffritti, Chiara/0000-0002-8872-8842; Csuka, Dorottya/0000-0003-3610-9852; cicardi, marco/0000-0003-1251-225X; Renne, Thomas/0000-0003-4594-5975; Veszeli, Nora/0000-0002-7647-2173; Maas, Coen/0000-0003-4593-0976; zanichelli, andrea/0000-0002-7512-4644	International Patient Organization for C1-Inhibitor Deficiencies (HAEi); Hjart Lungfonden [20140741]; Stockholms Lans Landsting (ALF) [20160375]; Vetenskapsradet [K2013-65X-21462-04-5]; German Research Society [SFB877, TP A11]; European Research Council [ERC-StG-2012-311575_F-12]; Telethon [GGP08223]; ERA-Net E-RARE-1 Research Programme	International Patient Organization for C1-Inhibitor Deficiencies (HAEi); Hjart Lungfonden; Stockholms Lans Landsting (ALF); Vetenskapsradet(Swedish Research Council); German Research Society(German Research Foundation (DFG)); European Research Council(European Research Council (ERC)European Commission); Telethon(Fondazione Telethon); ERA-Net E-RARE-1 Research Programme	This study was supported by a research grant from the International Patient Organization for C1-Inhibitor Deficiencies (HAEi) to C.M. T.R. acknowledges support from Hjart Lungfonden (grant no. 20140741), Stockholms Lans Landsting (ALF, grant no. 20160375), Vetenskapsradet (grant no. K2013-65X-21462-04-5), the German Research Society (grant nos. SFB877 and TP A11), and a European Research Council grant (grant no. ERC-StG-2012-311575_F-12). C.S. and M.C. were supported by Telethon (grant no. GGP08223) and the ERA-Net E-RARE-1 Research Programme within the European 24 Framework 7 titled "Genetics, Pathophysiology, and Therapy of Hereditary Angioedema Type III.''	Banerji A, 2017, NEW ENGL J MED, V376, P717, DOI 10.1056/NEJMoa1605767; Baroso R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163958; Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380; Cugno M, 2017, CLIN EXP ALLERGY, V47, P139, DOI 10.1111/cea.12869; de Maat S, 2013, THROMB HAEMOSTASIS, V110, P458, DOI 10.1160/TH12-11-0792; Faucette R, 2016, ALLERGY, V71, P556; Giard C, 2012, DERMATOLOGY, V225, P62, DOI 10.1159/000340029; Kaplan AP, 2016, CLIN REV ALLERG IMMU, V51, P207, DOI 10.1007/s12016-016-8555-6; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; REDDIGARI S, 1988, BLOOD, V71, P1334; Suffritti C, 2014, CLIN EXP ALLERGY, V44, P1503, DOI 10.1111/cea.12293; Yi JZ, 2007, J PROTEOME RES, V6, P1768, DOI 10.1021/pr060550h	12	25	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1700	+		10.1016/j.jaci.2017.07.012	http://dx.doi.org/10.1016/j.jaci.2017.07.012			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28782632				2022-12-18	WOS:000417206000025
J	Platt, CD; Chou, J; Houlihan, P; Badran, YR; Kumar, L; Bainter, W; Poliani, PL; Perez, CJ; Dent, SYR; Clapham, DE; Benavides, F; Geha, RS				Platt, Craig D.; Chou, Janet; Houlihan, Patrick; Badran, Yousef R.; Kumar, Lalit; Bainter, Wayne; Poliani, P. Luigi; Perez, Carlos J.; Dent, Sharon Y. R.; Clapham, David E.; Benavides, Fernando; Geha, Raif S.			Leucine-rich repeat containing 8A (LRRC8A)-dependent volume-regulated anion channel activity is dispensable for T-cell development and function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Leucine-rich repeat containing 8A; volume-regulated anion channel; thymocyte development	ESSENTIAL COMPONENT; MEMBRANE-PROTEIN; IDENTIFICATION; MUTATION	Background: Leucine-rich repeat containing 8A (LRRC8A) is an ubiquitously expressed transmembrane protein with 17 leucine-rich repeats (LRRs) at its C-terminal end and is an essential component of the volume-regulated anion channel (VRAC), which controls cellular volume. A heterozygous mutation in LRRC8A that truncates the 2 terminal LRRs was reported in a patient with agammaglobulinemia and absent B cells and was demonstrated to exert a dominant negative effect on T-and B-cell development in mice. Lrrc8a(-/-) mice have severely defective T-cell development and function. It is not known whether the T-and B-cell defects caused by LRRC8A deficiency are caused by loss of VRAC activity. Objective: We sought to determine whether VRAC activity is required for normal T-cell development and function. Methods: VRAC activity was examined by using patch-clamp analysis. Flow cytometry was used to examine T-cell development. T-cell proliferation, cytokine secretion, and antibody titers were measured by using standard techniques. Results: We demonstrate that the spontaneous mouse mutant ebouriffe (ebo/ebo) harbors a homozygous 2-bp frameshift mutation in Lrrc8a that truncates the 15 terminal LRRs of LRRC8A. The Lrrc8a(ebo) mutation does not affect protein expression but drastically diminishes VRAC activity in T cells. ebo/ebo mice share features with Lrrc8a(-/-) mice that include curly hair, infertility, reduced longevity, and kidney abnormalities. However, in contrast to Lrrc8a(-/-) mice, ebo/ebo mice have normal T-cell development and function and intact antibody response to T-dependent antigen. Conclusion: LRRC8A-dependent VRAC activity is dispensable for T-cell development and function.	[Platt, Craig D.; Chou, Janet; Badran, Yousef R.; Kumar, Lalit; Bainter, Wayne; Geha, Raif S.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Poliani, P. Luigi] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Perez, Carlos J.; Dent, Sharon Y. R.; Benavides, Fernando] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Smithville, TX USA; [Perez, Carlos J.; Dent, Sharon Y. R.; Benavides, Fernando] Grad Sch Biomed Sci Houston, Houston, TX USA; [Clapham, David E.] Boston Childrens Hosp, Dept Cardiol, Chevy Chase, MD USA; [Clapham, David E.] Howard Hughes Med Inst, Chevy Chase, MD USA	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Brescia; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Geha, RS (corresponding author), One Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Clapham, David/R-5974-2019; Clapham, David/S-1123-2019; Dent, Sharon YR/F-1746-2011; POLIANI, Pietro Luigi/E-8145-2010	Clapham, David/0000-0002-4459-9428; Dent, Sharon YR/0000-0002-4824-3269; POLIANI, Pietro Luigi/0000-0002-5662-8978; Benavides, Fernando/0000-0003-1275-4320	Eleanor and Miles Shore 50th Anniversary Career Development Award;  [AI083503];  [T32 AI007512];  [K08AI116979];  [R21 AI079769];  [NCI/CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007512, K08AI116979, R21AI079769, R01AI083503] Funding Source: NIH RePORTER	Eleanor and Miles Shore 50th Anniversary Career Development Award; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by AI083503 (to R.S.G.), T32 AI007512 (to C.D. P.),K08AI116979 (to J.C.), R21 AI079769, the Eleanor and Miles Shore 50th Anniversary Career Development Award (to L.K.), and NCI/CA016672 (to F.B.).	Bella J, 2008, CELL MOL LIFE SCI, V65, P2307, DOI 10.1007/s00018-008-8019-0; Cahalan M D, 1988, Soc Gen Physiol Ser, V43, P281; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Juntilla MA, 2008, IMMUNOL LETT, V116, P104, DOI 10.1016/j.imlet.2007.12.008; Kumar L, 2014, J EXP MED, V211, P929, DOI 10.1084/jem.20131379; Lalouette A, 1996, BIOL REPROD, V55, P355, DOI 10.1095/biolreprod55.2.355; Pedersen SF, 2015, ACTA PHYSIOL, V213, P868, DOI 10.1111/apha.12450; Qiu ZZ, 2014, CELL, V157, P447, DOI 10.1016/j.cell.2014.03.024; Sawada A, 2003, J CLIN INVEST, V112, P1707, DOI 10.1172/JCI18937; Smits G, 2004, MOL IMMUNOL, V41, P561, DOI 10.1016/j.molimm.2004.04.001; Syeda R, 2016, CELL, V164, P499, DOI 10.1016/j.cell.2015.12.031; von Heijne G, 2006, NAT REV MOL CELL BIO, V7, P909, DOI 10.1038/nrm2063; Voss FK, 2014, SCIENCE, V344, P634, DOI 10.1126/science.1252826	13	25	26	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1651	+		10.1016/j.jaci.2016.12.974	http://dx.doi.org/10.1016/j.jaci.2016.12.974			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28192143	Green Accepted			2022-12-18	WOS:000417206000020
J	Elias, MS; Long, HA; Newman, CF; Wilson, PA; West, A; McGill, PJ; Wu, KC; Donaldson, MJ; Reynolds, NJ				Elias, Martina S.; Long, Heather A.; Newman, Carla F.; Wilson, Paul A.; West, Andrew; McGill, Paul J.; Wu, Keith C.; Donaldson, Michael J.; Reynolds, Nick J.			Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic eczema; dermatitis; skin; proteomic; filaggrin; kallikrein-7; cyclophilin A	STRATUM-CORNEUM; STAPHYLOCOCCUS-AUREUS; PROTEASE ACTIVITY; DERMATITIS; EXPRESSION; GENE; CYCLOSPORINE; CYCLOPHILIN; BARRIER; MUTATIONS	Background: Atopic eczema (AE) is characterized by skin barrier and immune dysfunction. Null mutations in filaggrin (FLG), a key epidermal barrier protein, strongly predispose to AE; however, the precise role of FLG deficiency in AE pathogenesis remains incompletely understood. Objectives: We sought to identify global proteomic changes downstream of FLG deficiency in human epidermal living skinequivalent (LSE) models and validate findings in skin of patients with AE. Methods: Differentially expressed proteins from paired control (nontargeting control short hairpin RNA [shNT]) and FLG knockdown (FLG knockdown short hairpin RNA [shFLG]) LSEs were identified by means of proteomic analysis (liquid chromatography-mass spectrometry) and Ingenuity Pathway Analysis. Expression of key targets was validated in independent LSE samples (quantitative RT-PCR and Western blotting) and in normal and AE skin biopsy specimens (immunofluorescence). Results: Proteomic analysis identified 17 (P <=.05) differentially expressed proteins after FLG knockdown, including kallikrein-7 (KLK7; 2.2-fold), cyclophilin A (PPIA; 0.9-fold), and cofilin-1 (CFL1, 1.3-fold). Differential protein expression was confirmed in shNT/shFLGLSEs; however, only KLK7 was transcriptionally dysregulated. Molecular pathways overrepresented after FLG knockdown included inflammation, protease activity, cell structure, and stress. Furthermore, KLK7 (1.8-fold) and PPIA (0.65-fold) proteins were differentially expressed in lesional biopsy specimens from patients with AE relative to normal skin. Conclusions: For the first time, we show that loss of FLG in the absence of inflammation is sufficient to alter the expression level of proteins relevant to the pathogenesis of AE. These include proteins regulating inflammatory, proteolytic, and cytoskeletal functions. We identify PPIA as a novel protein with levels that are decreased in clinically active AE skin and show that the characteristic upregulation of KLK7 expression in patients with AE occurs downstream of FLG loss. Importantly, we highlight disconnect between the epidermal proteome and transcriptome, emphasizing the utility of global proteomic studies.	[Elias, Martina S.; Long, Heather A.; Wu, Keith C.; Reynolds, Nick J.] Newcastle Univ, Inst Cellular Med, Dermatol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Newman, Carla F.; Wilson, Paul A.; West, Andrew; McGill, Paul J.] GlaxoSmithKline R&D, Stevenage, Herts, England; [Long, Heather A.; Donaldson, Michael J.] Stiefel, Stevenage, Herts, England; [Reynolds, Nick J.] Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England; [Long, Heather A.] Qiagen, Manchester, Lancs, England	Newcastle University - UK; GlaxoSmithKline; Newcastle University - UK	Reynolds, NJ (corresponding author), Newcastle Univ, Inst Cellular Med, Dermatol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	nick.reynolds@ncl.ac.uk		Elias, Martina S/0000-0003-3352-5391; Reynolds, Nick/0000-0002-6484-825X	Newcastle University [KTP007889]; Stiefel (GlaxoSmithKline Company) [KTP007889, BB/K501554/1]; Technology Strategy Board; CASE studentship - Biotechnology and Biological Sciences Research Council (BBSRC); NIHR-Newcastle Biomedical Research Centre; Engineering and Physical Sciences Research Council (EPSRC)/Medical Research Council (MRC) Newcastle Molecular Pathology Node; Medical Research Council [MR/N005872/1] Funding Source: researchfish; MRC [MR/N005872/1] Funding Source: UKRI	Newcastle University; Stiefel (GlaxoSmithKline Company); Technology Strategy Board; CASE studentship - Biotechnology and Biological Sciences Research Council (BBSRC); NIHR-Newcastle Biomedical Research Centre; Engineering and Physical Sciences Research Council (EPSRC)/Medical Research Council (MRC) Newcastle Molecular Pathology Node; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported both through a Knowledge Transfer partnership project (KTP007889) between Newcastle University, Stiefel (a GlaxoSmithKline Company), and the Technology Strategy Board and through a CASE studentship funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and Stiefel (a GlaxoSmithKline Company; BB/K501554/1). The BBSRC and the Technology Strategy Board did not contribute to study design; the collection, analysis/interpretation of data, writing of the report, or decision to submit the article for publication. N.J.R.'s laboratory/research is supported by the NIHR-Newcastle Biomedical Research Centre and the Engineering and Physical Sciences Research Council (EPSRC)/Medical Research Council (MRC) Newcastle Molecular Pathology Node.	Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Amelio I, 2012, J CELL BIOL, V199, P347, DOI 10.1083/jcb.201203134; Bravo-Cordero JJ, 2013, NAT REV MOL CELL BIO, V14, P405, DOI 10.1038/nrm3609; Broccardo CJ, 2011, J ALLERGY CLIN IMMUN, V127, P186, DOI 10.1016/j.jaci.2010.10.033; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; CHATELLARDGRUAZ D, 1994, BIOCHEM J, V303, P863, DOI 10.1042/bj3030863; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Colgan J, 2004, IMMUNITY, V21, P189, DOI 10.1016/j.immuni.2004.07.005; Elias PM, 2014, BBA-MOL CELL BIOL L, V1841, P323, DOI 10.1016/j.bbalip.2013.10.001; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fearon P, 2011, J INVEST DERMATOL, V131, P1085, DOI 10.1038/jid.2010.415; Forrester AR, 2014, J DERMATOL SCI, V73, P10, DOI 10.1016/j.jdermsci.2013.09.001; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; Honma M, 2006, MOL BIOL CELL, V17, P1888, DOI 10.1091/mbc.E05-12-1173; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; KANITAKIS J, 1990, Journal of Dermatological Science, V1, P103, DOI 10.1016/0923-1811(90)90223-Z; Kaur S, 2012, P NATL ACAD SCI USA, V109, P7723, DOI 10.1073/pnas.1118122109; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Komatsu N, 2007, EXP DERMATOL, V16, P513, DOI 10.1111/j.1600-0625.2007.00562.x; Litherland GJ, 2008, J BIOL CHEM, V283, P14221, DOI 10.1074/jbc.M710136200; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; Mildner M, 2006, BIOCHEM BIOPH RES CO, V348, P76, DOI 10.1016/j.bbrc.2006.07.035; Mildner M, 2010, J INVEST DERMATOL, V130, P2286, DOI 10.1038/jid.2010.115; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Monroe KM, 2010, CELL MICROBIOL, V12, P881, DOI 10.1111/j.1462-5822.2010.01478.x; Nigro P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.410; NylanderLundqvist E, 1997, ACTA DERM-VENEREOL, V77, P203; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pendaries V, 2014, J INVEST DERMATOL, V134, P2938, DOI 10.1038/jid.2014.259; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Proud CG, 2004, DNA REPAIR, V3, P927, DOI 10.1016/j.dnarep.2004.03.012; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Rozenblit M, 2014, J ALLERGY CLIN IMMUN, V134, P955, DOI 10.1016/j.jaci.2014.05.024; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Shrestha N, 2012, J BIOL CHEM, V287, P28738, DOI 10.1074/jbc.M112.375915; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Su QZ, 2007, EMBO REP, V8, P265, DOI 10.1038/sj.embor.7400891; Tan SP, 2011, J INVEST DERMATOL, V131, pS39; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Todd C, 1998, AM J PATHOL, V153, P39, DOI 10.1016/S0002-9440(10)65543-5; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Vavrova K, 2014, J INVEST DERMATOL, V134, P746, DOI 10.1038/jid.2013.402; Voegeli R, 2009, BRIT J DERMATOL, V161, P70, DOI 10.1111/j.1365-2133.2009.09142.x; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Wenzel J, 2008, J INVEST DERMATOL, V128, P67, DOI 10.1038/sj.jid.5700945; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Winge MCG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028254; WON YH, 1994, BRIT J DERMATOL, V130, P312, DOI 10.1111/j.1365-2133.1994.tb02926.x; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015	57	25	27	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1299	1309		10.1016/j.jaci.2017.01.039	http://dx.doi.org/10.1016/j.jaci.2017.01.039			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28479159	Green Published, hybrid			2022-12-18	WOS:000414304300010
J	Bahrami, E; Witzel, M; Racek, T; Puchaka, J; Hollizeck, S; Greif-Kohistani, N; Kotlarz, D; Horny, HP; Feederle, R; Schmidt, H; Sherkat, R; Steinemann, D; Gohring, G; Schlegelbeger, B; Albert, MH; Al-Herz, W; Klein, C				Bahrami, Ehsan; Witzel, Maximilian; Racek, Tomas; Puchaka, Jacek; Hollizeck, Sebastian; Greif-Kohistani, Naschla; Kotlarz, Daniel; Horny, Hans-Peter; Feederle, Regina; Schmidt, Heinrich; Sherkat, Roya; Steinemann, Doris; Gohring, Gudrun; Schlegelbeger, Brigitte; Albert, Michael H.; Al-Herz, Waleed; Klein, Christoph			Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-associated bone marrow failure and developmental aberrations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunodeficiency; stem cells; hematopoiesis; rare disease; transplantation	HISTONE H2A DEUBIQUITINASE; STEM-CELL MAINTENANCE; DOUBLE-STRAND BREAKS; LYMPHOCYTE DIFFERENTIATION; EPIGENETIC REGULATION; REFERENCE VALUES; UV-RADIATION; P53 PROTEIN; HEMATOPOIESIS; PHOSPHORYLATION	Background: Myb-like, SWIRM, and MPN domains 1 (MYSM1) is a transcriptional regulator mediating histone deubiquitination. Its role in human immunity and hematopoiesis is poorly understood. Objectives: We sought to investigate the clinical, cellular, and molecular features in 2 siblings presenting with progressive bone marrow failure (BMF), immunodeficiency, and developmental aberrations. Methods: We performed genome-wide homozygosity mapping, whole-exome and Sanger sequencing, immunophenotyping studies, and analysis of genotoxic stress responses. p38 activation, reactive oxygen species levels, rate of apoptosis and clonogenic survival, and growth in immune and nonimmune cells were assessed. The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monitored. Results: We report 2 patients with progressive BMF associated with myelodysplastic features, immunodeficiency affecting B cells and neutrophil granulocytes, and complex developmental aberrations, including mild skeletal anomalies, neurocognitive developmental delay, and cataracts. Whole-exome sequencing revealed a homozygous premature stop codon mutation in the gene encoding MYSM1. MYSM1-deficient cells are characterized by increased sensitivity to genotoxic stress associated with sustained induction of phosphorylated p38 protein, increased reactive oxygen species production, and decreased survival following UV light-induced DNA damage. Both patients were successfully treated with allogeneic HSCT with sustained reconstitution of hematopoietic defects. Conclusions: Here we show that MYSM1 deficiency is associated with developmental aberrations, progressive BMF with myelodysplastic features, and increased susceptibility to genotoxic stress. HSCT represents a curative therapy for patients with MYSM1 deficiency.	[Bahrami, Ehsan; Witzel, Maximilian; Racek, Tomas; Puchaka, Jacek; Hollizeck, Sebastian; Greif-Kohistani, Naschla; Kotlarz, Daniel; Schmidt, Heinrich; Albert, Michael H.; Klein, Christoph] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany; [Horny, Hans-Peter] Ludwig Maximilians Univ Munchen, Inst Pathol, Fac Med, Munich, Germany; [Feederle, Regina] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Core Facil Monoclonal AntibodyDevelopment, Munich, Germany; [Sherkat, Roya] Isfahan Univ Med Sci, Acquired Immunodeficiency Res Ctr, Esfahan, Iran; [Steinemann, Doris; Gohring, Gudrun; Schlegelbeger, Brigitte] Hannover Med Sch, Inst Human Genet, Hannover, Germany; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait; [Al-Herz, Waleed] Al Sabah Hosp, Dept Pediat, Kuwait, Kuwait	University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Isfahan University Medical Science; Hannover Medical School; Kuwait University; Al Sabah Hospital	Klein, C (corresponding author), Dr von Hauner Childrens Hosp, Lindwurmstr 2a, D-80337 Munich, Germany.	christoph.klein@med.uni-muenchen.de	Kotlarz, Daniel/HGA-2077-2022	Kotlarz, Daniel/0000-0002-4576-6769; Hollizeck, Sebastian/0000-0002-9504-3497; sherkat, Roya/0000-0001-6745-8161; Feederle, Regina/0000-0002-3981-367X	BMBF (German PID-NET) [01GM0894]; Leona M. and Harry B. Helmsley Charitable Trust [2015PG-IBD008]; German Research Society [KL 877/11-1, SFB 1054, SFB 1054/1 A05]; German Research Foundation (DFG) through the excellence cluster REBIRTH (DFG) [EXC 62]; European Research Council (ERC) [268608-EXPLORE]; Reinhard-Frank Stiftung; Else Kroner-Fresenius-Stiftung [2013_Kolleg.18]; DZIF/EKFS [TTU 07.801]; Care-for-Rare Foundation [C4R/PrNr.140042]	BMBF (German PID-NET); Leona M. and Harry B. Helmsley Charitable Trust; German Research Society(German Research Foundation (DFG)); German Research Foundation (DFG) through the excellence cluster REBIRTH (DFG); European Research Council (ERC)(European Research Council (ERC)); Reinhard-Frank Stiftung; Else Kroner-Fresenius-Stiftung; DZIF/EKFS; Care-for-Rare Foundation	Supported by grants from the BMBF (German PID-NET, #01GM0894), the Leona M. and Harry B. Helmsley Charitable Trust (#2015PG-IBD008), the German Research Society (Gottfried Wilhelm Leibniz Program [#KL 877/11-1], SFB 1054 [# SFB 1054/1 A05]), German Research Foundation (DFG) through the excellence cluster REBIRTH (DFG #EXC 62), the European Research Council (ERC, Advanced Grant Explore [#268608-EXPLORE]), Reinhard-Frank Stiftung, the Else Kroner-Fresenius-Stiftung (#2013_Kolleg.18), DZIF/EKFS (#TTU 07.801), and the Care-for-Rare Foundation (#C4R/PrNr.140042).	Belle JI, 2016, CELL DEATH DIFFER, V23, P759, DOI 10.1038/cdd.2015.140; Belle JI, 2015, BLOOD, V125, P2344, DOI 10.1182/blood-2014-05-574111; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Gatzka M, 2015, CELL DEATH DIFFER, V22, P1451, DOI 10.1038/cdd.2014.231; Gong XW, 2010, FEBS LETT, V584, P4711, DOI 10.1016/j.febslet.2010.10.057; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang XF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.162; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Jiang XX, 2015, SCI REP-UK, V5, DOI 10.1038/srep13755; Jiang XX, 2011, IMMUNITY, V35, P883, DOI 10.1016/j.immuni.2011.11.010; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Lancini C, 2014, J EXP MED, V211, P1759, DOI 10.1084/jem.20131436; Le Guen T, 2015, J ALLERGY CLIN IMMUN, V136, P1619, DOI 10.1016/j.jaci.2015.06.008; Li P, 2016, SCI REP-UK, V6, DOI 10.1038/srep22211; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Myers KC, 2016, BONE MARROW TRANSPL, V51, P980, DOI 10.1038/bmt.2016.39; Nandakumar V, 2013, P NATL ACAD SCI USA, V110, pE3927, DOI 10.1073/pnas.1308888110; Nicassio F, 2007, CURR BIOL, V17, P1972, DOI 10.1016/j.cub.2007.10.034; Nijnik A, 2012, BLOOD, V119, P1370, DOI 10.1182/blood-2011-05-352666; Nishi R, 2014, NAT CELL BIOL, V16, P1016, DOI 10.1038/ncb3028; Panda S, 2015, IMMUNITY, V43, P647, DOI 10.1016/j.immuni.2015.09.010; Piatosa B, 2010, CYTOM PART B-CLIN CY, V78B, P372, DOI 10.1002/cyto.b.20536; Shamseldin HE, 2013, BLOOD, V122, P3844, DOI 10.1182/blood-2013-09-527127; Shanbhag NM, 2010, CELL, V141, P970, DOI 10.1016/j.cell.2010.04.038; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shimamura A, 2010, BLOOD REV, V24, P101, DOI 10.1016/j.blre.2010.03.002; Triot A, 2014, BLOOD, V123, P3811, DOI 10.1182/blood-2013-11-535419; Wang T, 2013, BLOOD, V122, P2812, DOI 10.1182/blood-2013-03-489641; Won H, 2014, BLOOD, V124, P2647, DOI 10.1182/blood-2013-10-534313; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024	32	25	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1112	1119		10.1016/j.jaci.2016.10.053	http://dx.doi.org/10.1016/j.jaci.2016.10.053			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28115216	Bronze			2022-12-18	WOS:000412172900022
J	Ben-Ali, M; Yang, J; Chan, KW; Ben-Mustapha, I; Mekki, N; Benabdesselem, C; Mellouli, F; Bejaoui, M; Yang, WL; Aissaoui, L; Lau, YL; Barbouche, MR				Ben-Ali, Meriem; Yang, Jing; Chan, Koon Wing; Ben-Mustapha, Imen; Mekki, Najla; Benabdesselem, Chaouki; Mellouli, Fethi; Bejaoui, Mohamed; Yang, Wanling; Aissaoui, Lamia; Lau, Yu Lung; Barbouche, Mohamed-Ridha			Homozygous transcription factor 3 gene (TCF3) mutation is associated with severe hypogammaglobulinemia and B-cell acute lympho blastic leukemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							E2A; PROTEINS		[Ben-Ali, Meriem; Ben-Mustapha, Imen; Mekki, Najla; Benabdesselem, Chaouki; Barbouche, Mohamed-Ridha] Inst Pasteur Tunis, Lab Transmiss Control & Immunobiol Infect LR11IPT, Tunis, Tunisia; [Ben-Ali, Meriem; Ben-Mustapha, Imen; Mekki, Najla; Benabdesselem, Chaouki; Aissaoui, Lamia; Barbouche, Mohamed-Ridha] Univ Tunis El Manar, Tunis, Tunisia; [Yang, Jing; Chan, Koon Wing; Yang, Wanling; Lau, Yu Lung] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China; [Mellouli, Fethi; Bejaoui, Mohamed] Natl Bone Marrow Transplantat Ctr, Dept Pediat, Tunis, Tunisia; [Aissaoui, Lamia] Aziza Othmana Hosp, Dept Hematol, Tunis, Tunisia; [Lau, Yu Lung] Univ Hong Kong, Shenzhen Hosp, Shenzhen Primary Immunodeficiency Diagnost & Ther, Shenzhen, Peoples R China	Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Universite de Tunis-El-Manar; University of Hong Kong; Universite de Tunis-El-Manar; Centre Nationale de Greffe de la Moelle Osseuse; Universite de Tunis-El-Manar; Hopital Aziza Othmana; University of Hong Kong	Lau, YL (corresponding author), Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.; Lau, YL (corresponding author), Univ Hong Kong, Shenzhen Hosp, Shenzhen Primary Immunodeficiency Diagnost & Ther, Shenzhen, Peoples R China.	lauylung@hku.hk; ridha.barbouche@pasteur.rns.tn	mekki, najla/AAA-6564-2019; bejaoui, mohamed/K-2679-2016; Benabdessalem, Chaouki/W-7077-2019; Lau, Yu Lung/C-4322-2009	Benabdessalem, Chaouki/0000-0001-7309-6814; Lau, Yu Lung/0000-0002-4780-0289; MEKKI, NAJLA/0000-0002-5842-9147	Tunisian Ministry of Higher Education, Research and Technology [LR11IPT02]; Society for the Relief of Disabled Children (Hong Kong)	Tunisian Ministry of Higher Education, Research and Technology; Society for the Relief of Disabled Children (Hong Kong)	Supported by the Tunisian Ministry of Higher Education, Research and Technology (LR11IPT02) and the Society for the Relief of Disabled Children (Hong Kong).	BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Berglof A, 2013, EXPERT REV CLIN IMMU, V9, P1205, DOI 10.1586/1744666X.2013.850030; Boisson B, 2013, J CLIN INVEST, V123, P4781, DOI 10.1172/JCI71927; Cobaleda C, 2007, NATURE, V449, P473, DOI 10.1038/nature06159; D'Cruz LM, 2012, EUR J IMMUNOL, V42, P2031, DOI 10.1002/eji.201242497; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; Somasundaram R, 2015, BLOOD, V126, P144, DOI 10.1182/blood-2014-12-575688; Tijchon E, 2013, LEUKEMIA, V27, P541, DOI 10.1038/leu.2012.293; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340	9	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1191	+		10.1016/j.jaci.2017.04.037	http://dx.doi.org/10.1016/j.jaci.2017.04.037			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28532655	Bronze			2022-12-18	WOS:000412172900042
J	Bousquet, J; O'Hehir, RE; Anto, JM; D'Amato, G; Mosges, R; Hellings, PW; Van Eerd, M; Sheikh, A				Bousquet, Jean; O'Hehir, Robyn E.; Anto, Josep M.; D'Amato, Gennaro; Moesges, Ralph; Hellings, Peter W.; Van Eerd, Michiel; Sheikh, Aziz			Assessment of thunderstorm-induced asthma using Google Trends	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Bousquet, Jean] European Innovat Partnership Act & Hlth Ageing Re, MACVIA France, MAalad Chron VIeillissement Actif France, Montpellier, France; [Bousquet, Jean] Univ Versailles St Quentin en Yvelines, INSERM, U1168, Montigny Le Bretonneux, France; [O'Hehir, Robyn E.] Monash Univ, Alfred Hosp, Dept Allergy Immunol & Resp Med, Clayton, Vic, Australia; [O'Hehir, Robyn E.] Monash Univ, Cent Clin Sch, Clayton, Vic, Australia; [O'Hehir, Robyn E.] Monash Univ, Dept Immunol, Melbourne, Vic, Australia; [Anto, Josep M.] ISGLoBAL, Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Anto, Josep M.] IMIM Hosp Mar Res Inst, Barcelona, Spain; [Anto, Josep M.] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [Anto, Josep M.] Univ Pompeu Fabra, Barcelona, Spain; [D'Amato, Gennaro] Univ Naples Federico II, Div Resp & Allerg Dis, Hosp A Cardarelli, Naples, Italy; [Moesges, Ralph] Univ Cologne, Inst Med Stat Informat & Epidemiol, Med Fac, Cologne, Germany; [Hellings, Peter W.] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Clin Immunol, Leuven, Belgium; [Van Eerd, Michiel] Peercode DV, Geldermalsen, Netherlands; [Sheikh, Aziz] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Ctr Med Informat, Asthma UK Ctr Appl Res, Edinburgh, Midlothian, Scotland	Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; Monash University; ISGlobal; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University; Antonio Cardarelli Hospital; University of Naples Federico II; University of Cologne; KU Leuven; University of Edinburgh	Bousquet, J (corresponding author), European Innovat Partnership Act & Hlth Ageing Re, MACVIA France, MAalad Chron VIeillissement Actif France, Montpellier, France.; Bousquet, J (corresponding author), Univ Versailles St Quentin en Yvelines, INSERM, U1168, Montigny Le Bretonneux, France.	jean.bousquet@orange.fr	Bousquet, Jean/O-4221-2019; Anto, J M/H-2676-2014; O'Hehir, Robyn E/H-3627-2011; Hellings, Peter W/I-4068-2018	Anto, J M/0000-0002-4736-8529; O'Hehir, Robyn E/0000-0002-3489-7595; Hellings, Peter W/0000-0001-6898-688X; Sheikh, Aziz/0000-0001-7022-3056; Bousquet, Jean/0000-0002-4061-4766	Almirall; AstraZeneca; Chiesi; GlaxoSmithKline; Meda; Menarini; Merck; MSD; Novartis; Sanofi-Aventis; Takeda; Teva; Uriach; Asthma UK Centre for Applied Research; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre, AUK-AC-2012-01] Funding Source: researchfish	Almirall(Almirall); AstraZeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc); GlaxoSmithKline(GlaxoSmithKline); Meda; Menarini(Menarini Group); Merck(Merck & Company); MSD; Novartis(Novartis); Sanofi-Aventis(Sanofi-Aventis); Takeda(Takeda Pharmaceutical Company Ltd); Teva(Teva Pharmaceutical Industries); Uriach; Asthma UK Centre for Applied Research; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	J. Bousquet has received personal fees from Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Meda, Menarini, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach. A. Sheik has received a grant from the Asthma UK Centre for Applied Research. The rest of the authors declare that they have no relevant conflicts of interest.	Anto JM, 1997, THORAX, V52, P669, DOI 10.1136/thx.52.8.669; BOUSQUET J, 2016, CLIN TRANSL ALLERGY, V6; Bousquet J, 2017, ALLERGY; Cook S, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0023610, 10.1371/journal.pone.0025407]; D'Amato G, 2016, CLIN EXP ALLERGY, V46, P390, DOI 10.1111/cea.12709; Dugas AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056176; Marques JG, 2016, J INVEST ALLERG CLIN, V26, P192, DOI 10.18176/jiaci.0047; Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634; Kang MG, 2015, ALLERGY, V70, P124, DOI 10.1111/all.12528; Konig Volker, 2014, J Allergy (Cairo), V2014, P381983, DOI 10.1155/2014/381983; Olson DR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003256; Ram S, 2015, IEEE J BIOMED HEALTH, V19, P1216, DOI 10.1109/JBHI.2015.2404829; Scales David, 2013, Emerg Health Threats J, V6, P21621, DOI 10.3402/ehtj.v6i0.21621; Willson TJ, 2015, OTOLARYNG HEAD NECK, V152, P228, DOI 10.1177/0194599814560149	14	25	26	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					891	+		10.1016/j.jaci.2017.04.042	http://dx.doi.org/10.1016/j.jaci.2017.04.042			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28579375	Green Accepted, Bronze			2022-12-18	WOS:000409241500038
J	Fukuyama, T; Ganchingco, JR; Mishra, SK; Olivry, T; Rzagalinski, I; Volmer, DA; Baumer, W				Fukuyama, Tomoki; Ganchingco, Joy Rachel; Mishra, Santosh K.; Olivry, Thierry; Rzagalinski, Ignacy; Volmer, Dietrich A.; Baeumer, Wolfgang			Janus kinase inhibitors display broad anti-itch properties: A possible link through the TRPV1 receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGIC DERMATITIS; ATOPIC-DERMATITIS; OCLACITINIB; TRPA1; TOFACITINIB; RESPONSES; EFFICACY; PRURITUS; SAFETY; DOGS		[Fukuyama, Tomoki; Ganchingco, Joy Rachel; Mishra, Santosh K.; Baeumer, Wolfgang] North Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27695 USA; [Fukuyama, Tomoki; Ganchingco, Joy Rachel; Mishra, Santosh K.; Olivry, Thierry; Baeumer, Wolfgang] North Carolina State Univ, Coll Vet Med, Comparat Med Inst, Raleigh, NC 27695 USA; [Olivry, Thierry] North Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC USA; [Rzagalinski, Ignacy; Volmer, Dietrich A.] Saarland Univ, Inst Bioanalyt Chem, Saarbrucken, Germany	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; Saarland University	Baumer, W (corresponding author), North Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27695 USA.; Baumer, W (corresponding author), North Carolina State Univ, Coll Vet Med, Comparat Med Inst, Raleigh, NC 27695 USA.	wolfgang_baeumer@ncsu.edu	Mishra, Santosh/S-7516-2017; Olivry, Thierry/AAV-7869-2021; Volmer, Dietrich/G-7900-2012	Mishra, Santosh/0000-0001-8616-2606; Olivry, Thierry/0000-0003-1399-0034; Volmer, Dietrich/0000-0003-2820-1480; Baumer, Wolfgang/0000-0002-4346-5911; Ganchingco, Joy Rachel/0000-0001-5946-780X; Fukuyama, Tomoki/0000-0003-3510-3272	German Research Foundation (FTICR-MS Facility) [DFG INST 256/356-1]	German Research Foundation (FTICR-MS Facility)	D.A.V. acknowledges support by the German Research Foundation (FTICR-MS Facility, DFG INST 256/356-1).	Bushmakin AG, 2015, J DERMATOL TREAT, V26, P19, DOI 10.3109/09546634.2013.861891; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Cosgrove SB, 2013, VET DERMATOL, V24, P587, DOI 10.1111/vde.12088; Cosgrove SB, 2013, VET DERMATOL, V24, P479, DOI 10.1111/vde.12047; Fukuyama T, 2015, J PHARMACOL EXP THER, V354, P394, DOI 10.1124/jpet.115.223784; Liu BY, 2013, FASEB J, V27, P3549, DOI 10.1096/fj.13-229948; Than JYXL, 2013, J BIOL CHEM, V288, P12818, DOI 10.1074/jbc.M113.450072; Toth BI, 2015, HANDB EXP PHARMACOL, V226, P89, DOI 10.1007/978-3-662-44605-8_6; Yun JW, 2011, J INVEST DERMATOL, V131, P1576, DOI 10.1038/jid.2011.87	9	25	27	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					306	+		10.1016/j.jaci.2016.12.960	http://dx.doi.org/10.1016/j.jaci.2016.12.960			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28131799	Bronze			2022-12-18	WOS:000404542000041
J	Balhara, J; Shan, L; Zhang, J; Muhuri, A; Halayko, AJ; Almiski, MS; Doeing, D; McConville, J; Matzuk, MM; Gounni, AS				Balhara, Jyoti; Shan, Lianyu; Zhang, Jingbo; Muhuri, Anik; Halayko, Andrew J.; Almiski, Muhamad S.; Doeing, Diana; McConville, John; Matzuk, Martin M.; Gounni, Abdelilah S.			Pentraxin 3 deletion aggravates allergic inflammation through a T(H)17-dominant phenotype and enhanced CD4 T-cell survival	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pentraxin 3; allergic inflammation; CD4 T cells; IL-17A; IL-2; survival; B-cell lymphoma 2; signal transducer and activator of transcription 3; dendritic cells; IL-6	DRIVES AIRWAY HYPERRESPONSIVENESS; ADAPTIVE IMMUNE-RESPONSES; INTERLEUKIN (IL)-17; APOPTOSIS; ASTHMA; STAT3; IL-6; LYMPHOCYTES; ACTIVATION; PROMOTES	Background: Pentraxin 3 (PTX3) is a multifunctional molecule that plays a nonredundant role at the crossroads between pathogen clearance, innate immune system, matrix deposition, female fertility, and vascular biology. It is produced at sites of infection and inflammation by both structural and inflammatory cells. However, its role in allergen-induced inflammation remains to be tested. Objective: We sought to determine the effect of Ptx3 deletion on ovalbumin (OVA)-induced allergic inflammation in a murine model of asthma. Methods: Bronchoalveolar lavage fluid was collected from patients with severe asthma and healthy subjects, and the level of PTX3 was determined by using ELISA. Ptx3(+/+) and Ptx3(-/-) mice were sensitized and challenged with OVA and bronchoalveolar lavage fluid, and the lungs were collected for assessing inflammation. Lung tissue inflammation and mucus production were assessed by means of flow cytometry and hematoxylin and eosin and periodic acid-Schiff staining, respectively. flexiVent was used to determine airway resistance to methacholine in these mice. Results: Here we report that mice with severe asthma and OVA-sensitized/challenged mice had increased PTX3 levels in the lungs compared with healthy control mice. Mice lacking PTX3 have exaggerated neutrophilic/eosinophilic lung inflammation, mucus production, and airway hyperresponsiveness in an experimental model of OVA-induced asthma. Furthermore, OVA-exposed lung Ptx(-/-) CD4 T cells exhibit an increased production of IL-17A, an effect that is accompanied by an increased signal transducer and activator of transcription 3 phosphorylation, reduced IL-2 production, and enhanced activation and survival. Also, we observed an increase in numbers of IL-6-and IL-23-producing dendritic cells in OVA-exposed Ptx3(-/-) mice compared with those in wild-type control mice. Conclusion: Altogether, PTX3 deficiency results in augmented airway hyperresponsiveness, mucus production, and IL-17Adominant pulmonary inflammation, suggesting a regulatory role of PTX3 in the development of allergic inflammation.	[Balhara, Jyoti; Shan, Lianyu; Zhang, Jingbo; Muhuri, Anik; Gounni, Abdelilah S.] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Immunol, Winnipeg, MB, Canada; [Halayko, Andrew J.] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Physiol, Winnipeg, MB, Canada; [Almiski, Muhamad S.] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Pathol, Winnipeg, MB, Canada; [Doeing, Diana; McConville, John] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Matzuk, Martin M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Zhang, Jingbo] Third Mil Univ Hosp, Dept Nephrol, Chongqing, Peoples R China	University of Manitoba; University of Manitoba; University of Manitoba; University of Chicago; Baylor College of Medicine	Gounni, AS (corresponding author), Univ Manitoba, Dept Immunol, Coll Med, Fac Hlth Sci,Apotex Ctr 419, 750 McDermot Ave, Winnipeg, MB R3E 0T5, Canada.	abdel.gounni@umanitoba.sca	Gounni, Abdelilah Soussi/AAH-3456-2020	Soussi Gounni, Abdelilah/0000-0002-7282-0388; Gounni, Abdelilah/0000-0003-1265-6560; Halayko, Andrew/0000-0002-7865-4552	Children's Hospital Research Institute of Manitoba; Manitoba Health Research Council Research Chair; Canadian Institute of Health Research (CIHR) [115115]; Eunice Kennedy Shriver National Institute of Child Health and Human [HD033438]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD032067, R01HD033438] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD033438] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060651] Funding Source: NIH RePORTER	Children's Hospital Research Institute of Manitoba; Manitoba Health Research Council Research Chair; Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Eunice Kennedy Shriver National Institute of Child Health and Human; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support for this work was provided by the Children's Hospital Research Institute of Manitoba and Manitoba Health Research Council Research Chair (to A.S.G.), the Children's Hospital Research Institute of Manitoba postdoctoral award (to J.Z.), and the Canadian Institute of Health Research (CIHR; grant no. 115115 to A.S.G.). Ptx3<SUP>-/-</SUP> mice were created with the support of the Eunice Kennedy Shriver National Institute of Child Health and Human grant HD033438.	Akira SZ, 2009, P JPN ACAD B-PHYS, V85, P143, DOI 10.2183/pjab.85.143; Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; Balhara J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00127; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bidere N, 2006, ANNU REV IMMUNOL, V24, P321, DOI 10.1146/annurev.immunol.24.021605.090513; Boggio E, 2014, BLOOD, V123, P1178, DOI 10.1182/blood-2013-07-518167; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Brewer JM, 1999, J IMMUNOL, V163, P6448; Brown V, 2003, THORAX, V58, P311, DOI 10.1136/thorax.58.4.311; Caruso A, 1997, CYTOMETRY, V27, P71, DOI 10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO;2-O; Chambers ES, 2015, J ALLERGY CLIN IMMUN, V136, P628, DOI 10.1016/j.jaci.2015.01.026; Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Cormican L, 2001, CLIN EXP ALLERGY, V31, P731, DOI 10.1046/j.1365-2222.2001.01099.x; Cunha C, 2014, NEW ENGL J MED, V370, P421, DOI 10.1056/NEJMoa1211161; D'Angelo C, 2009, J IMMUNOL, V183, P4609, DOI 10.4049/jimmunol.0900345; Danial NN, 2007, CLIN CANCER RES, V13, P7254, DOI 10.1158/1078-0432.CCR-07-1598; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; ERGER RA, 1995, AM J PHYSIOL-LUNG C, V268, pL117, DOI 10.1152/ajplung.1995.268.1.L117; Finkelman FD, 2010, J IMMUNOL, V184, P1663, DOI 10.4049/jimmunol.0902185; Gu Y, 2008, BRIT J HAEMATOL, V142, P109, DOI 10.1111/j.1365-2141.2008.07161.x; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; Hamzaoui A, 1999, MEDIAT INFLAMM, V8, P237, DOI 10.1080/09629359990405; He H, 2014, INVEST OPHTH VIS SCI, V55, P1647, DOI 10.1167/iovs.13-13094; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Hou WQ, 2014, J VIROL, V88, P8479, DOI 10.1128/JVI.00724-14; Kadkhoda K, 2011, INT IMMUNOL, V23, P239, DOI 10.1093/intimm/dxq476; Kay AB, 1997, CIBA F SYMP, V206, P56; Kay AB., 1997, CIBA F SYMP, V206, P106; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Lam D, 2008, J IMMUNOL, V181, P2925, DOI 10.4049/jimmunol.181.4.2925; Lech M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020118; Lee SY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4179; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Lewkowich IP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003879; Luo HBR, 2008, AM J HEMATOL, V83, P288, DOI 10.1002/ajh.21078; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Mathur AN, 2007, J IMMUNOL, V178, P4901, DOI 10.4049/jimmunol.178.8.4901; Mizutani N, 2014, J IMMUNOL, V192, P1372, DOI 10.4049/jimmunol.1301538; Moalli F, 2011, J IMMUNOL, V186, P5425, DOI 10.4049/jimmunol.1002035; Muller M, 2006, EUR RESPIR J, V28, P513, DOI 10.1183/09031936.06.00118505; Mus AMC, 2010, ARTHRITIS RHEUM-US, V62, P1043, DOI 10.1002/art.27336; Oh HM, 2011, J BIOL CHEM, V286, P30888, DOI 10.1074/jbc.M111.253500; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Pappu R, 2010, J CLIN IMMUNOL, V30, P185, DOI 10.1007/s10875-010-9369-6; Paroni M, 2013, J INFECT DIS, V208, P130, DOI 10.1093/infdis/jis636; Perona-Wright G, 2009, J IMMUNOL, V182, P2808, DOI 10.4049/jimmunol.0803553; Sergejeva S, 2005, AM J RESP CELL MOL, V33, P248, DOI 10.1165/rcmb.2004-0213OC; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zhang J., 2012, J ELECT COMPUT ENG, V2012, P3, DOI DOI 10.1016/J.OMEGA.2012.03.009; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; Zhu HF, 2014, TRANSPL INT, V27, P87, DOI 10.1111/tri.12197; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502	61	25	27	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					950	+		10.1016/j.jaci.2016.04.063	http://dx.doi.org/10.1016/j.jaci.2016.04.063			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27567326	Bronze, Green Published, Green Accepted			2022-12-18	WOS:000397295800027
J	Milara, J; Morell, A; Ballester, B; Armengot, M; Morcillo, E; Cortijo, J				Milara, Javier; Morell, Anselm; Ballester, Beatriz; Armengot, Miguel; Morcillo, Esteban; Cortijo, Julio			MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MUC4; corticosteroid resistance; nasal polyp; chronic rhinosinusitis; glucocorticoid receptor	MEMBRANE-BOUND MUCINS; CORNEAL EPITHELIAL-CELLS; GLUCOCORTICOID-RECEPTOR; GENE-EXPRESSION; RESISTANCE; ACTIVATION; GLYCOPROTEINS; MODULATION; INFECTION; DISEASE	Background: Current evidence suggests that membranete-thered mucins could mediate corticosteroid efficacy, interacting with glucocorticoid receptor (GR) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Mucin 4 (MUC4)-tethered mucin is expressed in nasal polyp (NP) epithelial cells and upregulated under inflammatory conditions. Moreover, MUC4 beta has the capacity to interact with other intracellular proteins. We hypothesized that MUC4 modulates corticosteroid efficacy of patients with CRSwNP. Objective: We sought to analyze the role of MUC4 in corticosteroid effectiveness in different cohorts of patients with CRSwNP and elucidate the possible mechanisms involved. Methods: Eighty-one patients with CRSwNP took oral corticosteroids for 15 days. Corticosteroid resistance was evaluated by using nasal endoscopy. Expression of MUC4 and MUC4b was evaluated by means of real-time PCR, Western blotting, and immunohistochemistry. BEAS-2B knockdown with RNA interference for MUC4 (small interfering RNA [siRNA]MUC4) was used to analyze the role of MUC4 in the antiinflammatory effects of dexamethasone. Results: Twenty-two patients had NPs resistant to oral corticosteroids. MUC4(expression) was upregulated in these patients. In siRNA-MUC4 BEAS-2B airway epithelial cells dexamethasone produced higher anti-inflammatory effects, increased inhibition of phospho-extracellular signal-regulated kinase 1/2, increased mitogen-activated protein kinase phosphatase 1 expression, and increased glucocorticoid response element activation. Immunoprecipitation and immunofluorescence experiments revealed that MUC4 beta forms a complex with GR alpha in the nuclei of NP epithelial cells from corticosteroid- resistant patients. Conclusion: MUC4b participates in the corticosteroid resistance process, inhibiting normal GRa nuclear function. The high expression of MUC4 in patients with CRSwNP might participate in corticosteroid resistance.	[Milara, Javier] Univ Hosp Consortium, Dept Pharm, Valencia, Spain; [Armengot, Miguel] Univ Hosp Consortium, Rhinol Unit, Valencia, Spain; [Cortijo, Julio] Univ Hosp Consortium, Res & Teaching Unit, Valencia, Spain; [Milara, Javier] Jaume I Univ, Fac Med, Dept Pharmacol, Castellon de La Plana, Spain; [Milara, Javier; Morell, Anselm; Morcillo, Esteban; Cortijo, Julio] Univ Valencia, Fac Med, Dept Pharmacol, E-46003 Valencia, Spain; [Armengot, Miguel] Univ Valencia, Fac Med, Dept Med, E-46003 Valencia, Spain; [Milara, Javier; Morell, Anselm; Ballester, Beatriz; Morcillo, Esteban; Cortijo, Julio] Hlth Inst Carlos III, CIBERES, Valencia, Spain; [Morcillo, Esteban] Inst Invest Sanitaria INCLIVA, Valencia, Spain	Universitat Jaume I; University of Valencia; University of Valencia; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Milara, J (corresponding author), Consorcio Hosp Gen Univ, Unidad Invest, Ave Tres Cruces S-N, E-46014 Valencia, Spain.	xmilara@hotmail.com	Armengot, Miguel/E-4664-2016; Llobell, Beatriz Ballester/AAB-3191-2020; Morcillo, Esteban/I-1552-2015	Armengot, Miguel/0000-0001-8258-6292; Morcillo, Esteban/0000-0003-4373-9457; MILARA, JAVIER/0000-0001-6033-4211; Morell, Anselm/0000-0001-7002-7792	CIBERES [CB06/06/0027]; TRACE (Spanish Government) [TRA2009-0311]; Regional Government Prometeo Generalitat Valenciana [II/2013/014];  [SAF2014-55322-P];  [FISPI14/01733];  [FISPI11/02618];  [SAF2015-65368-R]	CIBERES; TRACE (Spanish Government); Regional Government Prometeo Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)); ; ; ; 	Supported by grants SAF2014-55322-P (to J.C.), FISPI14/01733 (to J.M.), FISPI11/02618 (to M.A.), SAF2015-65368-R (to E.M.), CIBERES (CB06/06/0027), TRACE (TRA2009-0311; Spanish Government), and research grants from Regional Government Prometeo II/2013/014 (to J.C., E.M., and J.M.) Generalitat Valenciana.	Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Bai CH, 2007, LARYNGOSCOPE, V117, P2169, DOI 10.1097/MLG.0b013e31813e5fef; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Carraway KL, 2009, FUTURE ONCOL, V5, P1631, DOI [10.2217/fon.09.125, 10.2217/FON.09.125]; Carraway KL, 2007, CURR TOP DEV BIOL, V78, P1, DOI 10.1016/S0070-2153(06)78001-2; Casadevall J, 2000, THORAX, V55, P921, DOI 10.1136/thorax.55.11.921; Choi BR, 2006, EXP MOL MED, V38, P466, DOI 10.1038/emm.2006.55; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Grad W, 2007, MOL CELL ENDOCRINOL, V275, P2, DOI 10.1016/j.mce.2007.05.018; Hamilos DL, 2001, J ALLERGY CLIN IMMUN, V108, P59; Hattori T, 2013, AM J RESP CRIT CARE, V187; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Jonckheere N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032232; Jonckheere N, 2010, BIOCHIMIE, V92, P1, DOI 10.1016/j.biochi.2009.09.018; Jonckheere Nicolas, 2008, Critical Reviews in Oncogenesis, V14, P177; Kim KC, 2012, PULM PHARMACOL THER, V25, P415, DOI 10.1016/j.pupt.2011.12.003; Kim ST, 2011, AM J RHINOL ALLERGY, V25, P303, DOI 10.2500/ajra.2011.25.3627; Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005; Lomako J, 2010, J CELL PHYSIOL, V223, P209, DOI 10.1002/jcp.22028; Ortiz JL, 2010, PULM PHARMACOL THER, V23, P222, DOI 10.1016/j.pupt.2009.11.001; Martinez-Anton A, 2006, CLIN EXP ALLERGY, V36, P448, DOI 10.1111/j.1365-2222.2006.02451.x; Milara J, 2015, J ALLERGY CLIN IMMUN, V135, P470, DOI 10.1016/j.jaci.2014.07.011; Milara J, 2010, AM J RHINOL ALLERGY, V24, P181, DOI 10.2500/ajra.2010.24.3468; Papi A, 2013, J ALLERGY CLIN IMMUN, V132, P1075, DOI 10.1016/j.jaci.2013.05.028; Pauwels B, 2015, EXPERT REV CLIN IMMU, V11, P349, DOI 10.1586/1744666X.2015.1010517; Ramsauer VP, 2006, MOL BIOL CELL, V17, P2931, DOI 10.1091/mbc.E05-09-0895; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Senapati S, 2010, TRENDS BIOCHEM SCI, V35, P236, DOI 10.1016/j.tibs.2009.10.003; Seo KY, 2007, CORNEA, V26, P709, DOI 10.1097/ICO.0b013e31804f5a09; Shin SH, 2014, ALLERGY ASTHMA IMMUN, V6, P149, DOI 10.4168/aair.2014.6.2.149; Ueno K, 2008, AM J RESP CELL MOL, V38, P263, DOI 10.1165/rcmb.2007-0336RC; Valera FCP, 2009, CLIN EXP ALLERGY, V39, P81, DOI 10.1111/j.1365-2222.2008.03144.x; Vandevyver S, 2012, TRAFFIC, V13, P364, DOI 10.1111/j.1600-0854.2011.01288.x; Woo HJ, 2010, ARCH OTOLARYNGOL, V136, P603, DOI 10.1001/archoto.2010.71	37	25	29	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					855	+		10.1016/j.jaci.2016.06.064	http://dx.doi.org/10.1016/j.jaci.2016.06.064			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27639937	Bronze			2022-12-18	WOS:000397295800018
J	Park, S; Lee, EH; Kho, Y				Park, Sangshin; Lee, Eun-Hee; Kho, Younglim			The association of asthma, total IgE, and blood lead and cadmium levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOGLOBULIN-E; SERUM IMMUNOGLOBULIN; ENVIRONMENTAL LEAD; COCKROACH ALLERGEN; DENTAL AMALGAM; EXPOSURE; CHILDREN; MERCURY; SENSITIZATION; PREVALENCE		[Park, Sangshin] Brown Univ, Rhode Isl Hosp, Ctr Int Hlth Res, Warren Alpert Med Sch, Providence, RI 02903 USA; [Park, Sangshin] Brown Univ, Dept Pediat, Warren Alpert Med Sch, Providence, RI 02912 USA; [Lee, Eun-Hee] Far East Univ, Dept Visual Opt & Hlth Sci, Grad Sch Hlth Sci, Eumsung, Chungbuk, South Korea; [Kho, Younglim] Eulji Univ, Dept Hlth Environm & Safety, Sungnam, Kyeonggi, South Korea	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Eulji University	Kho, Y (corresponding author), Eulji Univ, Dept Hlth Environm & Safety, Sungnam, Kyeonggi, South Korea.	ylkho@eulji.ac.kr	Park, Sangshin/K-6889-2014	Park, Sangshin/0000-0003-2407-0962				Airaksinen R, 2011, PUBLIC HEALTH NUTR, V14, P480, DOI 10.1017/S1368980010001485; Bagenstose LM, 1999, IMMUNOL RES, V20, P67, DOI 10.1007/BF02786508; Bant A, 2008, ANN AGR ENV MED, V15, P21; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; Bener A, 2001, ENVIRON INT, V27, P311, DOI 10.1016/S0160-4120(01)00061-7; Grandjean P, 2010, ENVIRON HEALTH PERSP, V118, P1429, DOI 10.1289/ehp.1002289; Heo Y, 1998, TOXICOL SCI, V43, P172, DOI 10.1093/toxsci/43.2.172; Herrstrom P, 1997, INT ARCH OCC ENV HEA, V69, P339, DOI 10.1007/s004200050157; Hirsch T, 2000, CLIN EXP ALLERGY, V30, P529, DOI 10.1046/j.1365-2222.2000.00785.x; Hossny E, 2001, SCI TOTAL ENVIRON, V273, P135, DOI 10.1016/S0048-9697(00)00848-2; Jarup L, 2003, BRIT MED BULL, V68, P167, DOI 10.1093/bmb/ldg032; Jelovcan S, 2003, TOXICOLOGY, V188, P35, DOI 10.1016/S0300-483X(03)00044-1; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Joseph CLM, 2005, ENVIRON HEALTH PERSP, V113, P900, DOI 10.1289/ehp.7453; Karmaus Wilfried, 2005, Environ Health, V4, P5; LEWIS GP, 1972, LANCET, V1, P291; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Lutz PM, 2012, TOXICOLOGY, V291, P43, DOI 10.1016/j.tox.2011.10.013; Lutz PM, 1999, TOXICOLOGY, V134, P63, DOI 10.1016/S0300-483X(99)00036-0; Motosue AM, 2009, J ALLERGY CLIN IMMUN, V123, pS20, DOI 10.1016/j.jaci.2008.12.089; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; PUGH SP, 2011, ENVIRON RES, V111, P81; Razi CH, 2012, ALLERGOL IMMUNOPATH, V40, P51, DOI 10.1016/j.aller.2010.11.004; SNAPP KR, 1989, J DENT RES, V68, P780, DOI 10.1177/00220345890680050501; Sun L, 2003, ENVIRON RES, V92, P124, DOI 10.1016/S0013-9351(02)00090-7; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Weidinger S, 2004, J ALLERGY CLIN IMMUN, V114, P457, DOI 10.1016/j.jaci.2004.04.011; Wells EM, 2014, INT J HYG ENVIR HEAL, V217, P196, DOI 10.1016/j.ijheh.2013.04.010; Wong Suzy L, 2008, Health Rep, V19, P31; Yang SN, 2014, ALLERGY ASTHMA IMMUN, V6, P478, DOI 10.4168/aair.2014.6.6.478	32	25	26	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1701	+		10.1016/j.jaci.2016.04.030	http://dx.doi.org/10.1016/j.jaci.2016.04.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27394912	Bronze			2022-12-18	WOS:000390019300026
J	Riis, JL; Vestergaard, C; Deleuran, MS; Olsen, M				Riis, Jette Lindorff; Vestergaard, Christian; Deleuran, Mette S.; Olsen, Morten			Childhood atopic dermatitis and risk of attention deficit/hyperactivity disorder: A cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NK CELLS; ECZEMA; MATURATION; EXPRESSION; CHILDREN; SUBSETS		[Riis, Jette Lindorff; Vestergaard, Christian; Deleuran, Mette S.] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark; [Olsen, Morten] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark	Aarhus University; Aarhus University	Riis, JL (corresponding author), Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark.	jette_riis@hotmail.com		Vestergaard, Christian/0000-0001-6485-3158; Deleuran, Mette Sondergaard/0000-0003-0593-9925				Awasthi A, 2008, GENES IMMUN, V9, P522, DOI 10.1038/gene.2008.45; Buske-Kirschbaunn A, 2013, PSYCHONEUROENDOCRINO, V38, P12, DOI 10.1016/j.psyneuen.2012.09.017; Chen MH, 2013, J ATTEN DISORD; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Genuneit J, 2014, PEDIAT ALLERG IMM-UK, V25, P51, DOI 10.1111/pai.12152; Juelke K, 2010, BLOOD, V116, P1299, DOI 10.1182/blood-2009-11-253286; Lauritsen MB, 2010, J AUTISM DEV DISORD, V40, P139, DOI 10.1007/s10803-009-0818-0; Lougaris V, 2015, CLIN IMMUNOL, V159, P33, DOI 10.1016/j.clim.2015.04.014; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; Moretta L, 2010, BLOOD, V116, P3689, DOI 10.1182/blood-2010-09-303057; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Schmitt J, 2009, JAMA-J AM MED ASSOC, V301, P724, DOI 10.1001/jama.2009.136; Schmitt J, 2009, J DTSCH DERMATOL GES, V7, P345, DOI 10.1111/j.1610-0387.2008.06967.x; Tsai JD, 2013, ANN EPIDEMIOL, V23, P185, DOI 10.1016/j.annepidem.2012.12.015	16	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					608	610		10.1016/j.jaci.2016.01.027	http://dx.doi.org/10.1016/j.jaci.2016.01.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27025346				2022-12-18	WOS:000380835800040
J	Westernberg, L; Schulten, V; Greenbaum, JA; Natali, S; Tripple, V; McKinney, DM; Frazier, A; Hofer, H; Wallner, M; Sallusto, F; Sette, A; Peters, B				Westernberg, Luise; Schulten, Veronique; Greenbaum, Jason A.; Natali, Sara; Tripple, Victoria; McKinney, Denise M.; Frazier, April; Hofer, Heidi; Wallner, Michael; Sallusto, Federica; Sette, Alessandro; Peters, Bjoern			T-cell epitope conservation across allergen species is a major determinant of immunogenicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cell; epitope; timothy grass allergy; pollen allergy; cross-reactivity; RNA sequencing; sequence conservation; transcriptome	GRASS-POLLEN IMMUNOTHERAPY; CROSS-REACTIVITY; PHLEUM-PRATENSE; ANTIGENS; EXTRACT; T(H)1	Background: Patients with pollen allergies are frequently polysensitized. Pollens contain epitopes that are conserved across multiple species. Objective: We sought to demonstrate that cross-reactive T cells that recognize conserved epitopes show higher levels of expansion than T cells recognizing monospecific epitopes because of more frequent stimulation. Method: RNA was sequenced from 9 pollens, and the reads were assembled de novo into more than 50,000 transcripts. T-cell epitopes from timothy grass (Phleum pratense) were examined for conservation in these transcripts, and this was correlated to their ability to induce T-cell responses. T cells were expanded in vitro with P pratense-derived peptides and tested for cross-reactivity to pollen extracts in ELISpot assays. Results: We found that antigenic proteins are more conserved than nonimmunogenic proteins in P pratense pollen. Additionally, P pratense epitopes that were highly conserved across pollens elicited more T-cell responses in donors with grass allergy than less conserved epitopes. Moreover, conservation of a P pratense peptide at the transcriptomic level correlated with the ability of that peptide to trigger T cells that were cross-reactive with other non-P pratense pollen extracts. Conclusion: We found a correlation between conservation of peptides in plant pollens and their T-cell immunogenicity within P pratense, as well as their ability to induce cross-reactive T-cell responses. T cells recognizing conserved epitopes might be more prominent because they can be stimulated by a broader range of pollens and thereby drive polysensitization in allergic donors. We propose that conserved peptides could potentially be used in diagnostic or immunomodulatory approaches that address the issue of polysensitization and target multiple pollen allergies.	[Westernberg, Luise; Schulten, Veronique; Greenbaum, Jason A.; Tripple, Victoria; McKinney, Denise M.; Frazier, April; Sette, Alessandro; Peters, Bjoern] La Jolla Inst Allergy & Immunol, La Jolla, CA USA; [Hofer, Heidi; Wallner, Michael] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Natali, Sara; Sallusto, Federica] Univ Italian Switzerland, Cellular Immunol Lab, Inst Res Biomed, Bellinzona, Switzerland; [Sallusto, Federica] Univ Italian Switzerland, Ctr Med Immunol, Inst Res Biomed, Bellinzona, Switzerland	La Jolla Institute for Immunology; Salzburg University; Universita della Svizzera Italiana; Universita della Svizzera Italiana	Peters, B (corresponding author), La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.	bpeters@liai.org	Sette, Alessandro/AFO-8916-2022; Wallner, Michael/L-5437-2015	Wallner, Michael/0000-0001-6568-7892; Sallusto, Federica/0000-0003-3750-2752	National Institutes of Allergy and Infectious Diseases [U19AI100275]; European Research Council [323183 PREDICT]; ALK-Abello A/S (Horsholm, Denmark); Helmut Horten Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI100275] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD016262] Funding Source: NIH RePORTER	National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); European Research Council(European Research Council (ERC)European Commission); ALK-Abello A/S (Horsholm, Denmark); Helmut Horten Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported in part by federal funds from the National Institutes of Allergy and Infectious Diseases (grant no. U19AI100275) and the European Research Council (grant no. 323183 PREDICT) in addition to funds from ALK-Abello A/S (Horsholm, Denmark). The Institute for Research in Biomedicine and the Center of Medical Immunology are supported by the Helmut Horten Foundation.	Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Archila LD, 2014, CLIN EXP ALLERGY, V44, P986, DOI 10.1111/cea.12324; Arlehamn CSL, 2015, P NATL ACAD SCI USA, V112, pE147, DOI 10.1073/pnas.1416537112; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Chiu C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004008; Dranitsaris G, 2014, J EVAL CLIN PRACT, V20, P225, DOI 10.1111/jep.12112; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Hannon GJ., 2010, FASTX TOOLKIT; Hejl C, 2009, CLIN EXP ALLERGY, V39, P752, DOI 10.1111/j.1365-2222.2008.03195.x; Jimenez-Lopez JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076066; Kondo Yasuto, 2009, Allergology International, V58, P485, DOI 10.2332/allergolint.09-RAI-0136; Kwok WW, 2010, J ALLERGY CLIN IMMUN, V125, P1407, DOI 10.1016/j.jaci.2010.03.037; Marcucci F, 2010, IMMUNOL INVEST, V39, P635, DOI 10.3109/08820131003796876; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Martinez-Cocera C, 2010, J INVEST ALLERG CLIN, V20, P13; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Oseroff C, 2010, J IMMUNOL, V185, P943, DOI 10.4049/jimmunol.1000405; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Pedrosa M, 2015, CLIN REV ALLERG IMMU, V49, P203, DOI 10.1007/s12016-014-8429-8; Roberts G, 2006, J ALLERGY CLIN IMMUN, V117, P263, DOI 10.1016/j.jaci.2005.09.054; Schulten V, 2014, J ALLERGY CLIN IMMUN, V134, P1076, DOI 10.1016/j.jaci.2014.05.033; Schulten V, 2013, P NATL ACAD SCI USA, V110, P3459, DOI 10.1073/pnas.1300512110; Stringari G, 2014, J ALLERGY CLIN IMMUN, V134, P75, DOI 10.1016/j.jaci.2014.01.042; Wallner M, 2009, ALLERGY, V64, P452, DOI 10.1111/j.1398-9995.2008.01788.x; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683; Weber RW, 2004, CURR ALLERGY ASTHM R, V4, P401, DOI 10.1007/s11882-004-0091-4; Weiskopf D, 2014, J VIROL, V88, P11383, DOI 10.1128/JVI.01108-14	29	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					571	+		10.1016/j.jaci.2015.11.034	http://dx.doi.org/10.1016/j.jaci.2015.11.034			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	26883464	hybrid, Green Accepted			2022-12-18	WOS:000380835800030
J	Pattnaik, B; Bodas, M; Bhatraju, NK; Ahmad, T; Pant, R; Guleria, R; Ghosh, B; Agrawal, A				Pattnaik, Bijay; Bodas, Manish; Bhatraju, Naveen Kumar; Ahmad, Tanveer; Pant, Richa; Guleria, Randeep; Ghosh, Balaram; Agrawal, Anurag			IL-4 promotes asymmetric dimethylarginine accumulation, oxo-nitrative stress, and hypoxic response-induced mitochondrial loss in airway epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-4; ADMA; hypoxic response; mitochondrial transcription factor A; mitochondria	TRANSCRIPTION FACTOR-A; METABOLIC SYNDROME; ARGININE METABOLISM; COPY NUMBER; ASTHMA; INFLAMMATION; EXPRESSION; MODEL	Background: Obesity is known to increase asthma risk and severity. Increased levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are associated with mitochondrial toxicity, asthma, and metabolic syndrome. IL-4 upregulates the expression of protein arginine methyltransferases, which are essential for ADMA formation. Importantly, cross-talk between IL-4, ADMA, and mitochondrial dysfunction could explain how obesity and IL-4 can synergize to exacerbate allergic inflammation. Objective: We sought to investigate how IL-4, a key asthma-associated cytokine, can influenceADMA-related effects on lungs. Methods: BEAS2B (bronchial epithelial) cells were treated with IL-4 followed by ADMA and investigated for oxo-nitrative stress and resultant mitochondrial toxicity after 48 hours by using flow cytometry, confocal imaging, immunoblotting, and fluorimetric assays. Results: IL-4-induced mitotoxicity in BEAS2B cells was significantly higher in the presence of exogenous ADMA. IL-4 treatment led to proteolytic degradation of dimethylarginine dimethylaminohydrolase 2, which catabolizes ADMA. IL-4 pretreatment was associated with increased intracellular ADMA accumulation and increased ADMA-induced mitotoxicity. Airway epithelial cells treated with IL-4 followed by ADMA showed exaggerated oxo-nitrative stress and potent induction of the cellular hypoxic response, despite normoxic conditions. The hypoxic response was associated with reduced mitochondrial function but was reversible by overexpression of the mitochondrial biogenesis factor, mitochondrial transcription factor A. Conclusion: We conclude that IL-4 promotes intracellular ADMA accumulation, leading to mitochondrial loss through oxo-nitrative stress and hypoxic response. This provides a novel understanding of how obesity, with high ADMA levels, and asthma, with high IL-4 levels, might potentiate each other and highlights the potential of mitochondrial-targeted therapeutics in obese subjects with asthma.	[Pattnaik, Bijay; Bodas, Manish; Bhatraju, Naveen Kumar; Ahmad, Tanveer; Pant, Richa; Ghosh, Balaram; Agrawal, Anurag] CSIR, Inst Genom & Integrat Biol, Immunogenet Mol Lab, Mall Rd, Delhi 110007, India; [Pattnaik, Bijay; Bodas, Manish; Bhatraju, Naveen Kumar; Ahmad, Tanveer; Pant, Richa; Ghosh, Balaram; Agrawal, Anurag] CSIR, Inst Genom & Integrat Biol, Ctr Excellence Translat Res Asthma & Lung Dis, Delhi, India; [Guleria, Randeep] All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); All India Institute of Medical Sciences (AIIMS) New Delhi	Agrawal, A (corresponding author), CSIR, Inst Genom & Integrat Biol, Immunogenet Mol Lab, Mall Rd, Delhi 110007, India.	a.agrawal@igib.in	Pattnaik, Bijay Ranjan/GOK-0878-2022; Agrawal, Anurag/GZL-5821-2022; Bodas, Manish/AAE-4016-2020	Pattnaik, Bijay Ranjan/0000-0003-3534-7410; Bodas, Manish/0000-0002-1046-9799; Ahmad, Tanveer/0000-0002-8384-5273; Agrawal, Anurag/0000-0002-0340-5252; Bhatraju, Naveen Kumar/0000-0002-6248-7956	Council of Scientific and Industrial Research (CSIR), India [MLP 5502, BSC 0116, MLP 1201]; Swarnajayanti Fellowship; Department of Science and Technology (DST), India; Department of Science and Technology, Government of India [GAP 0069]; Council of Scientific and Industrial Research, Government of India [MLP 5502, BSC 0116]	Council of Scientific and Industrial Research (CSIR), India(Council of Scientific & Industrial Research (CSIR) - India); Swarnajayanti Fellowship; Department of Science and Technology (DST), India(Department of Science & Technology (India)); Department of Science and Technology, Government of India(Department of Science & Technology (India)); Council of Scientific and Industrial Research, Government of India(Council of Scientific & Industrial Research (CSIR) - India)	Supported by grants from the Council of Scientific and Industrial Research (CSIR), India (MLP 5502, BSC 0116, and MLP 1201); the Swarnajayanti Fellowship; and the Department of Science and Technology (DST), India. Research was supported by grant GAP 0069 (Swarnajayanti Project) from the Department of Science and Technology, Government of India, and grant MLP 5502 and BSC 0116 from the Council of Scientific and Industrial Research, Government of India.	Aggarwal S, 2014, AM J RESP CELL MOL, V50, P614, DOI 10.1165/rcmb.2013-0193OC; Agrawal A, 2014, IMMUNOL ALLERGY CLIN, V34, P785, DOI 10.1016/j.iac.2014.07.004; Agrawal A, 2011, AM J RESP CELL MOL, V44, P270, DOI 10.1165/rcmb.2010-0141TR; Ahmad T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.213; Ahmad T, 2014, EMBO J, V33, P994, DOI 10.1002/embj.201386030; Ahmad T, 2012, AM J RESP CELL MOL, V47, P1, DOI 10.1165/rcmb.2011-0203OC; Ahmad T, 2010, AM J RESP CELL MOL, V42, P3, DOI 10.1165/rcmb.2009-0137RC; Arnandis T, 2012, CELL DEATH DIFFER, V19, P1536, DOI 10.1038/cdd.2012.46; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Boger RH, 2004, J NUTR, V134, p2842S, DOI 10.1093/jn/134.10.2842S; Carraro S, 2013, CHEST, V144, P405, DOI 10.1378/chest.12-2379; Chakrabarty S, 2014, MITOCHONDRION, V15, P52, DOI 10.1016/j.mito.2014.01.002; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Diaz J, 2014, IMMUNOL ALLERGY CLIN, V34, P739, DOI 10.1016/j.iac.2014.07.008; Dillon LM, 2012, IUBMB LIFE, V64, P231, DOI 10.1002/iub.608; duVerle DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019035; Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109; Fiedler L, 2008, CELL ADHES MIGR, V2, P149, DOI 10.4161/cam.2.3.6819; Hiramitsu M, 2014, SCI REP-UK, V4, DOI 10.1038/srep03708; Kips JC, 2001, EUR RESPIR J, V18, p24S, DOI 10.1183/09031936.01.00229601; Klein E, 2010, AM J PHYSIOL-LUNG C, V299, pL816, DOI 10.1152/ajplung.00188.2010; Krishnan J, 2009, CELL METAB, V9, P512, DOI 10.1016/j.cmet.2009.05.005; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Leishangthem Geeta Devi, 2013, ISRN Allergy, V2013, P261297, DOI 10.1155/2013/261297; Li J, 2013, LAB INVEST, V93, P242, DOI 10.1038/labinvest.2012.164; Liu XY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/619207; Mabalirajan Ulaganathan, 2013, J Allergy (Cairo), V2013, P340476, DOI 10.1155/2013/340476; Mabalirajan U, 2010, INT IMMUNOPHARMACOL, V10, P1514, DOI 10.1016/j.intimp.2010.08.025; Mabalirajan U, 2010, J ALLERGY CLIN IMMUN, V125, P626, DOI 10.1016/j.jaci.2009.10.065; Movafagh S, 2015, J CELL BIOCHEM, V116, P696, DOI 10.1002/jcb.25074; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Scharte M, 2006, FEBS LETT, V580, P6399, DOI 10.1016/j.febslet.2006.10.053; Scott JA, 2014, IMMUNOL ALLERGY CLIN, V34, P767, DOI 10.1016/j.iac.2014.07.007; Serafino-Agrusa L, 2015, WORLD J CLIN CASES, V3, P285, DOI 10.12998/wjcc.v3.i3.285; Sharma P, 2008, IMMUNITY, V29, P551, DOI 10.1016/j.immuni.2008.07.019; Singh VP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129850; Staab EB, 2015, J IMMUNOTOXICOL, V12, P273, DOI 10.3109/1547691X.2014.961619; Sun QZ, 2012, J IMMUNOL, V188, P3506, DOI 10.4049/jimmunol.1102635; Takamatsu C, 2002, EMBO REP, V3, P451, DOI 10.1093/embo-reports/kvf099; Townley RG, 2007, ANN ALLERG ASTHMA IM, V99, P215, DOI 10.1016/S1081-1206(10)60656-4; Tran CTL, 2003, ATHEROSCLEROSIS SUPP, V4, P33, DOI 10.1016/S1567-5688(03)00032-1; Vallance P, 2004, ARTERIOSCL THROM VAS, V24, P1023, DOI 10.1161/01.ATV.0000128897.54893.26; Viader A, 2011, J NEUROSCI, V31, P10128, DOI 10.1523/JNEUROSCI.0884-11.2011; Wells SM, 2007, AM J RESP CELL MOL, V36, P520, DOI 10.1165/rcmb.2006-0302SM; Wells SM, 2009, AM J RESP CELL MOL, V40, P179, DOI 10.1165/rcmb.2008-0148OC; Zhu LY, 2010, CELL RES, V20, P676, DOI 10.1038/cr.2010.46	46	25	25	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					130	+		10.1016/j.jaci.2015.11.036	http://dx.doi.org/10.1016/j.jaci.2015.11.036			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26915676	Bronze			2022-12-18	WOS:000379659100015
J	Gil-Krzewska, A; Wood, SM; Murakami, Y; Nguyen, V; Chiang, SCC; Cullinane, AR; Peruzzi, G; Gahl, WA; Coligan, JE; Introne, WJ; Bryceson, YT; Krzewski, K				Gil-Krzewska, Aleksandra; Wood, Stephanie M.; Murakami, Yousuke; Victoria Nguyen; Chiang, Samuel C. C.; Cullinane, Andrew R.; Peruzzi, Giovanna; Gahl, William A.; Coligan, John E.; Introne, Wendy J.; Bryceson, Yenan T.; Krzewski, Konrad			Chediak-Higashi syndrome: Lysosomal trafficking regulator domains regulate exocytosis of lytic granules but not cytokine secretion by natural killer cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chediak-Higashi syndrome; lysosomal trafficking regulator; natural killer cell; cytotoxicity; cytotoxic lymphocyte; lysosomes; lytic granules; exocytosis; immune deficiency	NK-CELL; DISEASE; FUSION; LYST; CYTOTOXICITY; GENE; BIOGENESIS; PHENOTYPE; HUMANS; DEFECT	Background: Mutations in lysosomal trafficking regulator (LYST) cause Chediak-Higashi syndrome (CHS), a rare immunodeficiency with impaired cytotoxic lymphocyte function, mainly that of natural killer (NK) cells. Our understanding of NK cell function deficiency in patients with CHS and how LYST regulates lytic granule exocytosis is very limited. Objective: We sought to delineate cellular defects associated with LYST mutations responsible for the impaired NK cell function seen in patients with CHS. Methods: We analyzed NK cells from patients with CHS with missense mutations in the LYSTARM/HEAT(armadillo/huntingtin, elongation factor 3, protein phosphatase 2A, and the yeast kinase TOR1) or BEACH (beige and Chediak-Higashi) domains. Results: NK cells from patients with CHS displayed severely reduced cytotoxicity. Mutations in the ARM/HEAT domain led to a reduced number of perforin-containing granules, which were significantly increased in size but able to polarize to the immunologic synapse; however, they were unable to properly fuse with the plasma membrane. Mutations in the BEACH domain resulted in formation of normal or slightly enlarged granules that had markedly impaired polarization to the IS but could be exocytosed on reaching the immunologic synapse. Perforin-containing granules in NK cells from patients with CHS did not acquire certain lysosomal markers (lysosome-associated membrane protein 1/2) but were positive for markers of transport vesicles (cation-independent mannose 6-phosphate receptor), late endosomes (Ras-associated binding protein 27a), and, to some extent, early endosomes (early endosome antigen 1), indicating a lack of integrity in the endolysosomal compartments. NK cells from patients with CHS had normal cytokine compartments and cytokine secretion. Conclusion: LYST is involved in regulation of multiple aspects of NK cell lytic activity, ranging from governance of lytic granule size to control of their polarization and exocytosis, as well as regulation of endolysosomal compartment identity. LYST functions in the regulated exocytosis but not in the constitutive secretion pathway.	[Gil-Krzewska, Aleksandra; Murakami, Yousuke; Victoria Nguyen; Peruzzi, Giovanna; Coligan, John E.; Krzewski, Konrad] NIAID, Receptor Cell Biol Sect, Immunogenet Lab, NIH, Rockville, MD USA; [Wood, Stephanie M.; Chiang, Samuel C. C.; Bryceson, Yenan T.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden; [Cullinane, Andrew R.; Gahl, William A.; Introne, Wendy J.] NHGRI, Off Clin Director, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Karolinska Institutet; Karolinska University Hospital; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Krzewski, K (corresponding author), 12441 Parklawn Dr,Twinbrook 2,Rm 205, Rockville, MD 20852 USA.	krzewskikj@niaid.nih.gov	chiang, samuel/M-9267-2016; Chiang, Samuel CC/O-5960-2019; Bryceson, Yenan T/D-2121-2018	Chiang, Samuel CC/0000-0001-6597-6117; Bryceson, Yenan T/0000-0002-7783-9934; Peruzzi, Giovanna/0000-0002-6517-9107	National Institute of Allergy and Infectious Diseases; National Human Genome Research Institute; European Research Council under the European Union's Seventh Framework Programme (FP)/ERC [311335]; Swedish Research Council; Swedish Foundation for Strategic Research; Knut and Alice Wallenberg Foundation; Swedish Cancer Foundation; Swedish Children's Cancer Foundation; Karolinska Institute Research Foundation; Marie Curie FP7 International Incoming Fellowship; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000215, ZIDHG200352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001174, ZIAAI000962] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); European Research Council under the European Union's Seventh Framework Programme (FP)/ERC(European Research Council (ERC)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish Cancer Foundation; Swedish Children's Cancer Foundation; Karolinska Institute Research Foundation(Karolinska Institutet); Marie Curie FP7 International Incoming Fellowship; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Intramural Programs of the National Institute of Allergy and Infectious Diseases (to A.G.-K., Y.M., V.N., K.K., and J.E.C.), and the Intramural Program of National Human Genome Research Institute (to A.R.C., W.A.G., and W.J.I.), the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement no. 311335, the Swedish Research Council, the Swedish Foundation for Strategic Research, the Knut and Alice Wallenberg Foundation, the Swedish Cancer Foundation, the Swedish Children's Cancer Foundation, and the Karolinska Institute Research Foundation (to Y.T.B.), and a Marie Curie FP7 International Incoming Fellowship (to S.M.W.).	ABO T, 1982, J CLIN INVEST, V70, P193, DOI 10.1172/JCI110592; BAETZ K, 1995, J IMMUNOL, V154, P6122; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Bhambhani V, 2013, MOVEMENT DISORD, V28, P127, DOI 10.1002/mds.25386; Brown ACN, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001152; Bryceson YT, 2012, BLOOD, V119, P2754, DOI 10.1182/blood-2011-08-374199; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; Cooper MA, 2004, TRENDS IMMUNOL, V25, P47, DOI 10.1016/j.it.2003.10.012; Cullinane AR, 2013, TRAFFIC, V14, P749, DOI 10.1111/tra.12069; Durchfort N, 2012, TRAFFIC, V13, P108, DOI 10.1111/j.1600-0854.2011.01300.x; Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; HALIOTIS T, 1980, J EXP MED, V151, P1039, DOI 10.1084/jem.151.5.1039; Hammel I, 2010, J CELL MOL MED, V14, P1904, DOI 10.1111/j.1582-4934.2010.01071.x; Holland P, 2014, TRAFFIC, V15, P1390, DOI 10.1111/tra.12227; Huizing M, 2008, ANNU REV GENOM HUM G, V9, P359, DOI 10.1146/annurev.genom.9.081307.164303; Introne WJ, 1993, GENEREVIEWS; Jessen B, 2011, BLOOD, V118, P4620, DOI 10.1182/blood-2011-05-356113; Kaplan J, 2008, CURR OPIN HEMATOL, V15, P22, DOI 10.1097/MOH.0b013e3282f2bcce; Karim MA, 2002, AM J MED GENET, V108, P16, DOI 10.1002/ajmg.10184; KATZ P, 1982, J CLIN INVEST, V69, P1231, DOI 10.1172/JCI110562; KLEIN M, 1980, J EXP MED, V151, P1049, DOI 10.1084/jem.151.5.1049; Klopfenstein DR, 2004, MOL BIOL CELL, V15, P3729, DOI 10.1091/mbc.E04-04-0326; Krzewski K, 2008, CURR OPIN CELL BIOL, V20, P597, DOI 10.1016/j.ceb.2008.05.006; Krzewski K, 2013, EXP CELL RES, V319, P2360, DOI 10.1016/j.yexcr.2013.06.012; Krzewski K, 2013, BLOOD, V121, P4672, DOI 10.1182/blood-2012-08-453738; Krzewski K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00335; Kypri E, 2013, TRAFFIC, V14, P599, DOI 10.1111/tra.12058; Lacy P, 2011, BLOOD, V118, P9, DOI 10.1182/blood-2010-08-265892; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Liu DF, 2011, IMMUNOL CELL BIOL, V89, P728, DOI 10.1038/icb.2010.167; Mentlik AN, 2010, MOL BIOL CELL, V21, P2241, DOI 10.1091/mbc.E09-11-0930; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Perou CM, 1997, J BIOL CHEM, V272, P29790, DOI 10.1074/jbc.272.47.29790; Rak GD, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001151; Reefman E, 2010, J IMMUNOL, V184, P4852, DOI 10.4049/jimmunol.0803954; Robertson MJ, 2002, J LEUKOCYTE BIOL, V71, P173; ROZENSZAJN LA, 1977, ACTA HAEMATOL-BASEL, V57, P279, DOI 10.1159/000207892; Scheffzek K, 2012, FEBS LETT, V586, P2662, DOI 10.1016/j.febslet.2012.06.006; Sepulveda FE, 2015, TRAFFIC, V16, P191, DOI 10.1111/tra.12244; Sibarita JB, 2005, ADV BIOCHEM ENG BIOT, V95, P201, DOI 10.1007/b102215; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; SPICER SS, 1981, FED PROC, V40, P1451; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Stinchcombe JC, 2000, TRAFFIC, V1, P435, DOI 10.1034/j.1600-0854.2000.010508.x; Striegl H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008991; Tewari R, 2010, TRENDS CELL BIOL, V20, P470, DOI 10.1016/j.tcb.2010.05.003; van der Sluijs P, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00359; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Ward DM, 2000, TRAFFIC, V1, P816; Weisfeld-Adams JD, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-46; Westbroek W, 2007, J INVEST DERMATOL, V127, P2674, DOI 10.1038/sj.jid.5700899; Whiteside TL, 2001, CURR PROTOC IMMUNOL; WINDHORST DB, 1966, SCIENCE, V151, P81, DOI 10.1126/science.151.3706.81; Wood SM, 2011, CELL MOL LIFE SCI, V68, P3479, DOI 10.1007/s00018-011-0799-y; Wood SM, 2009, BLOOD, V114, P4117, DOI 10.1182/blood-2009-06-225359	59	25	27	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1165	1177		10.1016/j.jaci.2015.08.039	http://dx.doi.org/10.1016/j.jaci.2015.08.039			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26478006	Bronze, Green Accepted			2022-12-18	WOS:000373351200024
J	Kliewer, KL; Venter, C; Cassin, AM; Abonia, JP; Aceves, SS; Bonis, PA; Dellon, ES; Falk, GW; Furuta, GT; Gonsalves, N; Gupta, SK; Hirano, I; Kagalwalla, A; Leung, J; Mukkada, VA; Spergel, JM; Rothenberg, ME				Kliewer, Kara L.; Venter, Carina; Cassin, Alison M.; Abonia, J. Pablo; Aceves, Seema S.; Bonis, Peter A.; Dellon, Evan S.; Falk, Gary W.; Furuta, Glenn T.; Gonsalves, Nirmala; Gupta, Sandeep K.; Hirano, Ikuo; Kagalwalla, Amir; Leung, John; Mukkada, Vincent A.; Spergel, Jonathan M.; Rothenberg, Marc E.			Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; 6-food elimination diet; wheat; cross-reactivity; gluten	ADULT EOSINOPHILIC ESOPHAGITIS; UNITED-STATES; CHILDREN; IDENTIFICATION; ALLERGY; FOODS; REMISSION; PROTEINS; THERAPY; DISEASE	Eosinophilic esophagitis (EoE), a food antigen-mediated disease, is effectively treated with the dietary elimination of 6 foods commonly associated with food allergies (milk, wheat, egg, soy, tree nuts/peanuts, and fish/shellfish). Because wheat shares homologous proteins (including gluten) with barley and rye and can also be processed with these grains, some clinicians have suggested that barley and rye might also trigger EoE as a result of cross-reaction and/or cross-contamination with wheat. In this article, we discuss the theoretical risks of cross-reactivity and cross-contamination among wheat, barley, and rye proteins (including gluten); assess common practices at EoE treatment centers; and provide recommendations for dietary treatment and future studies of EoE.	[Kliewer, Kara L.; Venter, Carina; Cassin, Alison M.; Abonia, J. Pablo; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA; [Mukkada, Vincent A.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Gastroenterol Hepatol & Nutr, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA; [Aceves, Seema S.] Univ Calif San Diego, Dept Pediat & Med, Div Allergy & Immunol, San Diego, CA 92103 USA; [Aceves, Seema S.] Rady Childrens Hosp, San Diego, CA USA; [Bonis, Peter A.; Leung, John] Tufts Med Ctr, Div Gastroenterol, Boston, MA USA; [Dellon, Evan S.] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA; [Falk, Gary W.] Univ Penn, Hosp Univ Penn, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Furuta, Glenn T.] Univ Colorado, Sch Med, Dept Pediat, Sect Gastroenterol Hepatol & Nutr, Aurora, CO USA; [Gonsalves, Nirmala; Hirano, Ikuo] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA; [Gupta, Sandeep K.] Indiana Univ Sch Med, Riley Hosp Children, Sect Pediat Gastroenterol Hepatol & Nutr, Indianapolis, IN 46202 USA; [Kagalwalla, Amir] Ann & Robert H Lurie Childrens Hosp Chicago, Div Gastroenterol Hepatol & Nutr, Chicago, IL 60611 USA; [Spergel, Jonathan M.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Allergy & Immunol, Philadelphia, PA 19104 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Tufts Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; Northwestern University; Feinberg School of Medicine; Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA.	rothenberg@cchmc.org	Mukkada, Vincent/AAF-6995-2019	Mukkada, Vincent/0000-0003-4225-5506; Gonsalves, Nirmala/0000-0003-0722-6099; Abonia, Juan/0000-0003-3788-6485; Spergel, Jonathan/0000-0002-4658-5353	Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Disease Research (ORDR) [U54 AI117804]; National Center for Advancing Translational Sciences (NCATS); NCATS; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI117804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK100303] Funding Source: NIH RePORTER	Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Disease Research (ORDR); National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by U54 AI117804, which is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Disease Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and funded through collaboration between the NCATS, National Institute of Allergy and Infectious Diseases, and National Institute of Diabetes and Digestive and Kidney Diseases, which have collectively resulted in the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).	Aceves SS, 2014, CLIN GASTROENTEROL H, V12, P1216, DOI 10.1016/j.cgh.2013.09.007; Allen KJ, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-10; Doerfler B, 2015, DIS ESOPHAGUS, V28, P42, DOI 10.1111/dote.12175; FIELD JM, 1982, THEOR APPL GENET, V62, P329, DOI 10.1007/BF00275097; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Hernando A, 2008, EUR J GASTROEN HEPAT, V20, P545, DOI 10.1097/MEG.0b013e3282f46597; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Lee AR, 2007, J HUM NUTR DIET, V20, P423, DOI 10.1111/j.1365-277X.2007.00763.x; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2013, J ALLERGY CLIN IMMUN, V131, P797, DOI 10.1016/j.jaci.2012.12.664; MacCulloch K, 2014, PAED CHILD HEALT-CAN, V19, P305, DOI 10.1093/pch/19.6.305; Mamone G, 2011, EXPERT REV PROTEOMIC, V8, P95, DOI 10.1586/EPR.10.98; Molina-Infante J, 2014, J ALLERGY CLIN IMMUN, V134, P1093, DOI 10.1016/j.jaci.2014.07.023; Pourpak Z, 2005, PEDIAT ALLERG IMM-UK, V16, P262, DOI 10.1111/j.1399-3038.2005.00263.x; SANDIFORD CP, 1995, CLIN EXP ALLERGY, V25, P340, DOI 10.1111/j.1365-2222.1995.tb01052.x; SHEWRY PR, 1986, J CEREAL SCI, V4, P97, DOI 10.1016/S0733-5210(86)80012-1; Simon D, 2005, J ALLERGY CLIN IMMUN, V115, P1090, DOI 10.1016/j.jaci.2005.01.017; Singh J, 2011, J HUM NUTR DIET, V24, P479, DOI 10.1111/j.1365-277X.2011.01160.x; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Tatham AS, 2008, CLIN EXP ALLERGY, V38, P1712, DOI 10.1111/j.1365-2222.2008.03101.x; Thompson T, 2015, J ACAD NUTR DIET, V115, P13, DOI 10.1016/j.jand.2014.10.001; Thompson T, 2010, J AM DIET ASSOC, V110, P937, DOI 10.1016/j.jada.2010.03.014; Wechsler JB, 2014, GASTROENTEROL CLIN N, V43, P281, DOI 10.1016/j.gtc.2014.02.006; Wolf WA, 2014, CLIN GASTROENTEROL H, V12, P1272, DOI 10.1016/j.cgh.2013.12.034	28	25	25	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1011	1014		10.1016/j.jaci.2015.10.040	http://dx.doi.org/10.1016/j.jaci.2015.10.040			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26725190	Green Submitted, Bronze, Green Accepted			2022-12-18	WOS:000373351200005
J	Nassiri, M; Eckermann, O; Babina, M; Edenharter, G; Worm, M				Nassiri, Maria; Eckermann, Oliver; Babina, Magda; Edenharter, Guenter; Worm, Margitta			Serum levels of 9 alpha, 11 beta-PGF(2) and cysteinyl leukotrienes are useful biomarkers of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TRYPTASE; MECHANISMS		[Nassiri, Maria; Babina, Magda; Worm, Margitta] Charite, CCM, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Eckermann, Oliver] ADAC Air Rescue Serv Senftenberg, Senftenberg, Germany; [Edenharter, Guenter] Edenharter Res Berlin, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Nassiri, M (corresponding author), Charite, CCM, Dept Dermatol & Allergy, D-13353 Berlin, Germany.	Margitta.worm@charite.de		Worm, Margitta/0000-0002-3449-1245; Babina, Magda/0000-0002-4500-7615				Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V124, P639, DOI 10.1016/j.jaci.2009.08.035; Peavy RD, 2008, CURR OPIN ALLERGY CL, V8, P310, DOI 10.1097/ACI.0b013e3283036a90; RING J, 1977, LANCET, V1, P466; Sala-Cunill A, 2013, INT ARCH ALLERGY IMM, V160, P192, DOI 10.1159/000339749; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016	9	25	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					312	314		10.1016/j.jaci.2015.07.001	http://dx.doi.org/10.1016/j.jaci.2015.07.001			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26292777	Bronze			2022-12-18	WOS:000367724300027
J	Carlsson, CJ; Vissing, NH; Sevelsted, A; Johnston, SL; Bonnelykke, K; Bisgaard, H				Carlsson, Christian J.; Vissing, Nadja H.; Sevelsted, Astrid; Johnston, Sebastian L.; Bonnelykke, Klaus; Bisgaard, Hans			Duration of wheezy episodes in early childhood is independent of the microbial trigger	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory tract infections; wheezy episodes; pediatrics	BIRTH COHORT; ASTHMA EXACERBATIONS; RESPIRATORY VIRUSES; CHILDREN; DISEASE; INFECTIONS; BACTERIA; EXPOSURE; QUESTION; ILLNESS	Background: Wheezy episodes in young children are often triggered by viral and bacterial respiratory tract infections, but there is little evidence supporting the hypothesis that symptom duration depends on the specific microbial trigger. Objective: We sought to investigate whether the duration of wheezy episodes in young children depends on the microbial trigger. Methods: Two hundred eighty-three children from the Copenhagen Prospective Study on Asthma in Childhood(2000) at-risk birth cohort were prospectively examined for common airway pathogenic bacteria and viruses during acute wheezy episodes in the first 3 years of life. Findings were related to symptomatic duration of episodes, as monitored in daily diary cards from birth. Results: Eight hundred thirty-seven samples were investigated for viruses, bacteria, or both. Both viruses and bacteria were identified in 55% of episodes, bacteria were identified exclusively in 31% of episodes, and viruses were identified exclusively in 10% of episodes. The median duration of acute symptoms was 9 days (interquartile range, 5-16 days), and duration was independent of bacterial or viral species. Conclusions: The duration of wheezy episodes was independent of pathogenic airway bacterial or viral species. This suggests that symptom burden from infections is dependent on other factors, such as environmental exposures or host factors. The common term viral wheeze seems inappropriate in view of the finding of pathogenic bacteria in 86% of wheezy episodes.	[Carlsson, Christian J.; Vissing, Nadja H.; Sevelsted, Astrid; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Copenhagen, Denmark; [Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, MRC & Asthma UK Ctr Allerg Mech Asthma, Airway Dis Infect Sect, Natl Heart & Lung Inst, London SW7 2AZ, England	University of Copenhagen; Imperial College London; University of London; King's College London	Bisgaard, H (corresponding author), Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Carlsson, Christian Jakob/AAK-5022-2020; Johnston, Sebastian Lennox/I-2423-2012; Bisgaard, Hans/N-4761-2016	Carlsson, Christian Jakob/0000-0003-2363-173X; Johnston, Sebastian Lennox/0000-0003-3009-9200; Bisgaard, Hans/0000-0003-4131-7592; Bonnelykke, Klaus/0000-0003-2003-1018; sevelsted, astrid/0000-0001-7117-2334	Lundbeck Foundation [A1694]; Ministry of Health [903516]; Danish Council for Strategic Research [0603-00280B]; Danish Council for Independent Research [10-082884, 271-08-0815]; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish; Asthma UK [CH11SJ] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Ministry of Health; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Lundbeck Foundation(Lundbeckfonden); Asthma UK	The Lundbeck Foundation (grant no. A1694); The Ministry of Health (grant no. 903516); Danish Council for Strategic Research (grant no.0603-00280B); The Danish Council for Independent Research (grant nos. 10-082884 and 271-08-0815), and The Capital Region Research Foundation have provided core support for COPSAC. Thermo Fisher Scientific Inc sponsored the IgE analyses. No pharmaceutical company was involved in the study. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.	American Society for Microbiology, 1999, MANUAL CLIN MICROBIO, P1773; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2012, J ALLERGY CLIN IMMUN, V130, P531, DOI 10.1016/j.jaci.2011.10.047; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kocevar VS, 2004, CHEST, V125, P1680, DOI 10.1378/chest.125.5.1680; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Paganelli R, 1998, ALLERGY, V53, P763; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Skytt N, 2012, J ALLERGY CLIN IMMUN, V130, P403, DOI 10.1016/j.jaci.2012.04.043; Sorensen M, 2007, BIOMARKERS, V12, P38, DOI 10.1080/13547500600943148; Tan WC, 2003, AM J MED, V115, P272, DOI 10.1016/S0002-9343(03)00353-X	21	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1208	+		10.1016/j.jaci.2015.05.003	http://dx.doi.org/10.1016/j.jaci.2015.05.003			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26100088	Bronze, Green Published, Green Submitted			2022-12-18	WOS:000364787200008
J	Hanna, S; Beziat, V; Jouanguy, E; Casanova, JL; Etzioni, A				Hanna, Suheir; Beziat, Vivien; Jouanguy, Emmanuelle; Casanova, Jean Laurent; Etzioni, Amos			A homozygous mutation of RTEL1 in a child presenting with an apparently isolated natural killer cell deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Hanna, Suheir; Etzioni, Amos] Technion Israel Inst Technol, Fac Med, Div Pediat & Immunol, Ruth Rappaport Children Hosp, Haifa, Israel; [Beziat, Vivien; Jouanguy, Emmanuelle; Casanova, Jean Laurent] Imagine Inst, Human Genet Infect Dis Lab, Paris, France; [Casanova, Jean Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, New York, NY 10021 USA; [Casanova, Jean Laurent] Howard Hughes Med Inst, New York, NY USA; [Casanova, Jean Laurent] Necker Hosp Sick Children, Pediat Hematol Immunol Unit, Paris, France	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Howard Hughes Medical Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Hanna, S (corresponding author), Technion Israel Inst Technol, Fac Med, Div Pediat & Immunol, Ruth Rappaport Children Hosp, Haifa, Israel.	etzioni@rambam.health.gov.il	Jouanguy, Emmanuelle/H-7901-2017; Béziat, Vivien/G-2971-2011; Béziat, Vivien/AAT-4097-2021; Casanova, Jean-Laurent/I-3418-2017	Jouanguy, Emmanuelle/0000-0002-7358-9157; Béziat, Vivien/0000-0002-4020-824X; Béziat, Vivien/0000-0002-4020-824X; Casanova, Jean-Laurent/0000-0002-7782-4169				Ballew BJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003695; Ding H, 2004, CELL, V117, P873, DOI 10.1016/j.cell.2004.05.026; Etzioni A, 2005, J PEDIATR-US, V146, P423, DOI 10.1016/j.jpeds.2004.11.022; Fedick A.M., 2014, CLIN GENET; Gineau L, 2012, J CLIN INVEST, V122, P821, DOI 10.1172/JCI61014; Mace EM, 2013, BLOOD, V121, P2669, DOI 10.1182/blood-2012-09-453969; Orange JS, 2013, J ALLERGY CLIN IMMUN, V132, P515, DOI 10.1016/j.jaci.2013.07.020; Orange JS, 2012, J CLIN INVEST, V122, P798, DOI 10.1172/JCI62620; Vannier JB, 2012, CELL, V149, P795, DOI 10.1016/j.cell.2012.03.030; Walne AJ, 2013, AM J HUM GENET, V92, P448, DOI 10.1016/j.ajhg.2013.02.001	10	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1113	1114		10.1016/j.jaci.2015.04.021	http://dx.doi.org/10.1016/j.jaci.2015.04.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26025130	Bronze			2022-12-18	WOS:000362976300037
J	Bleck, B; Kazeros, A; Bakal, K; Garcia-Medina, L; Adams, A; Liu, ML; Lee, RA; Tse, DB; Chiu, A; Grunig, G; Egan, JP; Reibman, J				Bleck, Bertram; Kazeros, Angeliki; Bakal, Keren; Garcia-Medina, Lymaris; Adams, Alexandra; Liu, Mengling; Lee, Richard A.; Tse, Doris B.; Chiu, Amanda; Grunig, Gabriele; Egan, John P., III; Reibman, Joan			Coexpression of type 2 immune targets in sputum-derived epithelial and dendritic cells from asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; sputum; bronchial epithelial cells; dendritic cells; thymic stromal lymphopoietin; IL-33; OX40 ligand; CCL17	THYMIC STROMAL LYMPHOPOIETIN; AIRWAY EPITHELIUM; EXPRESSION; IL-33; INFLAMMATION; RESPONSES; CYTOKINE; INDUCE; IL-25; MITE	Background: Noninvasive sputum sampling has enabled the identification of biomarkers in asthmatic patients. Studies of discrete cell populations in sputum can enhance measurements compared with whole sputum in which changes in rare cells and cell-cell interactions can be masked. Objective: We sought to enrich for sputum-derived human bronchial epithelial cells (sHBECs) and sputum-derived myeloid type 1 dendritic cells (sDCs) to describe transcriptional coexpression of targets associated with a type 2 immune response. Methods: A case-control study was conducted with patients with mild asthma (asthmatic cases) and healthy control subjects. Induced sputum was obtained for simultaneous enrichment of sHBECs and sDCs by using flow cytometry. Quantitative PCR was used to measure mRNA for sHBEC thymic stromal lymphopoietin (TSLP), IL33, POSTN, and IL25 and downstream targets in sDCs (OX40 ligand [OX40L], CCL17, PPP1R14A, CD1E, CD1b, CD80, and CD86). Results: Final analyses for the study sample were based on 11 control subjects and 13 asthmatic cases. Expression of TSLP, IL33, and POSTN mRNA was increased in sHBECs in asthmatic cases (P = .001, P = .05, and P = .04, respectively). Expression of sDC OX40L and CCL17 mRNA was increased in asthmatic cases (P = .003 and P = .0001, respectively). sHBEC TSLP mRNA expression was strongly associated with sDC OX40L mRNA expression (R = 0.65, P = .001) and less strongly with sDC CCL17 mRNA expression. sHBEC IL33 mRNA expression was associated with sDC OX40L mRNA expression (R = 0.42, P = .04) but not sDC CCL17 mRNA expression. Conclusions: Noninvasive sampling and enrichment of select cell populations from sputum can further our understanding of cell-cell interactions in asthmatic patients with the potential to enhance endotyping of asthmatic patients.	[Bleck, Bertram; Kazeros, Angeliki; Bakal, Keren; Garcia-Medina, Lymaris; Adams, Alexandra; Lee, Richard A.; Tse, Doris B.; Chiu, Amanda; Egan, John P., III; Reibman, Joan] NYU, Langone Med Ctr, Dept Med, New York, NY 10016 USA; [Liu, Mengling; Grunig, Gabriele; Reibman, Joan] NYU, Langone Med Ctr, Dept Environm Med, New York, NY 10016 USA; [Liu, Mengling] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA	New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; New York University	Reibman, J (corresponding author), NYU, Sch Med, 550 1st Ave,Rm BH 7N24, New York, NY 10016 USA.	Joan.Reibman@nyumc.org		Liu, Mengling/0000-0001-9758-8522; Reibman, Joan/0000-0001-7878-1511	National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS) [5R01ES010187]; CTSI grant NIH/NCRR [1UL1RR029893-0109]; Stony Wold-Herbert Fund; Colton Family Foundation; Ginsberg/Kanengiser Foundation; Arthur Goldfarb Foundation; NIH/NIEHS [5T32ES007267, 1R01 HL095764-01]	National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); CTSI grant NIH/NCRR; Stony Wold-Herbert Fund; Colton Family Foundation; Ginsberg/Kanengiser Foundation; Arthur Goldfarb Foundation; NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS) grant 5R01ES010187 (to J.R.), CTSI grant NIH/NCRR 1UL1RR029893-0109, the Stony Wold-Herbert Fund, NIH/NIEHS grant 5T32ES007267, 1R01 HL095764-01 (to G.G.), the Colton Family Foundation, Ginsberg/Kanengiser, and the Arthur Goldfarb Foundations.	Alexis NE, 2010, INHAL TOXICOL, V22, P593, DOI 10.3109/08958371003596587; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253, DOI 10.1165/ajrcmb.22.3.3768; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Bhakta Nirav R, 2013, Clin Transl Allergy, V3, P24, DOI 10.1186/2045-7022-3-24; Bleck B, 2008, J CLIN IMMUNOL, V28, P147, DOI 10.1007/s10875-007-9149-0; Bleck B, 2006, J IMMUNOL, V176, P7431, DOI 10.4049/jimmunol.176.12.7431; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Brody SL, 2000, AM J RESP CELL MOL, V23, P45, DOI 10.1165/ajrcmb.23.1.4070; BROERS JLV, 1989, DIFFERENTIATION, V40, P119, DOI 10.1111/j.1432-0436.1989.tb00821.x; Chand HS, 2010, J ALLERGY CLIN IMMUN, V125, P1157, DOI 10.1016/j.jaci.2010.01.020; Cheng DT, 2013, J ALLERGY CLIN IMMUN, V132, P455, DOI 10.1016/j.jaci.2013.05.011; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Chu PG, 2000, MODERN PATHOL, V13, P962, DOI 10.1038/modpathol.3880175; COOPER D, 1985, LAB INVEST, V52, P243; Demedts IK, 2007, EUR RESPIR J, V30, P823, DOI 10.1183/09031936.00111007; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Dua B, 2010, J ALLERGY CLIN IMMUN, V126, P133, DOI 10.1016/j.jaci.2010.04.006; Eiwegger T, 2011, EUR J IMMUNOL, V41, P1535, DOI 10.1002/eji.201141668; Evans MJ, 2001, EXP LUNG RES, V27, P401, DOI 10.1080/019021401300317125; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Grabowski M, 2013, THORAX, V68, P125, DOI 10.1136/thoraxjnl-2012-201895; Hackett NR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018378; Hackett TL, 2011, AM J RESP CELL MOL, V45, P1090, DOI 10.1165/rcmb.2011-0031OC; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; He JQ, 2009, J ALLERGY CLIN IMMUN, V124, P222, DOI 10.1016/j.jaci.2009.04.018; Hsu CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011944; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kaur D, 2012, CHEST, V141, P494, DOI 10.1378/chest.11-1730; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lay JC, 2011, INHAL TOXICOL, V23, P392, DOI 10.3109/08958378.2011.575568; Lefrancais E, 2012, EUR CYTOKINE NETW, V23, P120, DOI 10.1684/ecn.2012.0320; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Liu ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025099; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Masten BJ, 2006, J IMMUNOL, V177, P7784, DOI 10.4049/jimmunol.177.11.7784; McWilliam AS, 1997, J VIROL, V71, P226, DOI 10.1128/JVI.71.1.226-236.1997; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nakamura Y, 2008, J ALLERGY CLIN IMMUN, V122, P1208, DOI 10.1016/j.jaci.2008.09.022; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Petersen BC, 2012, NAT MED, V18, P751, DOI 10.1038/nm.2735; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Schneider E, 2009, J IMMUNOL, V183, P3591, DOI 10.4049/jimmunol.0900328; Seys SF, 2013, CLIN EXP ALLERGY, V43, P1009, DOI 10.1111/cea.12125; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Siddiqui S, 2010, CHEST, V137, P797, DOI 10.1378/chest.09-1839; Suzukawa M, 2012, J IMMUNOL, V189, P3641, DOI 10.4049/jimmunol.1200461; Tan AM, 2010, J IMMUNOL, V184, P3535, DOI 10.4049/jimmunol.0900340; Ten Berge B, 2009, J IMMUNOL METHODS, V351, P13, DOI 10.1016/j.jim.2009.09.009; Tjota MY, 2014, J ALLERGY CLIN IMMUN, V134, P706, DOI 10.1016/j.jaci.2014.06.013; Wills-Karp M, 2012, J EXP MED, V209, P607, DOI 10.1084/jem.20110079; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	68	25	25	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					619	+		10.1016/j.jaci.2014.12.1950	http://dx.doi.org/10.1016/j.jaci.2014.12.1950			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25813919	Bronze			2022-12-18	WOS:000360913300012
J	Garcia, E; Serban, N; Swann, J; Fitzpatrick, A				Garcia, Erin; Serban, Nicoleta; Swann, Julie; Fitzpatrick, Anne			The effect of geographic access on severe health outcomes for pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Geographic access; pediatric asthma; severe health outcomes	POTENTIAL SPATIAL ACCESS; CHILDHOOD ASTHMA; AIR-POLLUTION; CARE PHYSICIANS; NEW-YORK; CHILDREN; ACCESSIBILITY; QUALITY; PREVALENCE; SERVICES	Background: Access to medical care and severe pediatric asthma outcomes vary with geography, but the relationship between them has not been studied. Objective: We sought to evaluate the relationship between geographic access and health outcomes for pediatric asthma. Methods: The severe outcome measures include emergency department (ED) visits and hospitalizations for children with an asthma diagnosis in Georgia and North Carolina. We quantify asthma prevalence, outcome measures, and factors included in the statistical model using multiple data sources. We calculate geographic access to primary and asthma specialist care using optimization models. We estimate the association between outcomes and geographic access in the presence of other factors using logistic regression. The model is used to project the reduction in severe outcomes with improvement in access. Results: The association between access and outcomes for pediatric asthma depends on the type of outcome measure, type of care, and variations in other factors. The expression of this association is also different for the 2 states. Access to primary care plays a larger role than access to specialist care in explaining Georgia ED visits, whereas the reverse applies for hospitalizations. In North Carolina access to both primary and specialist care are statistically significant in explaining the variability in ED visits. Conclusions: The variation in the association between estimated access and outcomes affects the projected reductions of severe outcomes with access improvement. Thus applying one intervention would not have the same level of improvement across geography. Interventions must be tailored to target regions with the potential to deliver the highest effect to gain maximum benefit.	[Garcia, Erin; Serban, Nicoleta; Swann, Julie] Georgia Inst Technol, H Milton Stewart Sch Ind & Syst Engn, Atlanta, GA 30332 USA; [Swann, Julie] Georgia Inst Technol, Sch Publ Policy, Atlanta, GA 30332 USA; [Fitzpatrick, Anne] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Emory University	Serban, N (corresponding author), Georgia Inst Technol, H Milton Stewart Sch Ind & Syst Engn, 755 Ferst Dr NW, Atlanta, GA 30332 USA.	nserban@isye.gatech.edu		Fitzpatrick, Anne/0000-0002-2933-5926; Swann, Julie/0000-0003-2151-4396	National Science Foundation [CMMI-0954283]; Institute of People and Technology (IPaT); Children's Healthcare of Atlanta	National Science Foundation(National Science Foundation (NSF)); Institute of People and Technology (IPaT); Children's Healthcare of Atlanta	Supported in part by a grant from the National Science Foundation (CMMI-0954283) and by a seed grant from the Institute of People and Technology (IPaT) and Children's Healthcare of Atlanta awarded in 2013.	Agency for Healthcare Research and Quality, 2009, HCUP STAT EM DEP DAT; Agency for Healthcare Research and Quality, 2009, HCUP STAT INP DAT SI; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; American Lung Association, 2014, ASTHM CHILDR FACT SH; American Lung Association, ASTHMA; Anselin L, 1953, SPATIAL ECONOMETRICS; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Apparicio P, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-7; Beck AF, 2012, AM J PUBLIC HEALTH, V102, P2308, DOI 10.2105/AJPH.2012.300806; Bissonnette L, 2012, HEALTH PLACE, V18, P841, DOI 10.1016/j.healthplace.2012.03.007; Blackwell AKD, 2007, 2007 GEORG ASTHM SUR; Boudreaux ED, 2003, PEDIATRICS, V111, pE615, DOI 10.1542/peds.111.5.e615; Centers for Disease Control and Prevention, 2011, VIT SIGNS; Centers for Disease Control and Prevention, 2011, ASTHM N CAR 2011; Centers for Disease Control and Prevention, 2010, BEH RISK FACT SURV S; Cheng V, 2012, 2012 GEORGIA ASTHMA; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; Corburn J, 2006, HEALTH PLACE, V12, P167, DOI 10.1016/j.healthplace.2004.11.002; Dales R, 2009, EUR RESPIR J, V34, P316, DOI 10.1183/09031936.00138908; Dean BB, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-96; Delamater PL, 2013, HEALTH PLACE, V24, P30, DOI 10.1016/j.healthplace.2013.07.012; Diette GB, 2001, PEDIATRICS, V108, P432, DOI 10.1542/peds.108.2.432; Diette GB, 1999, J ALLERGY CLIN IMMUN, V103, pS80; Eisner MD, 2002, THORAX, V57, P973, DOI 10.1136/thorax.57.11.973; ESRI, 2002, ARCGIS; Ford JG, 2001, CHEST, V120, P1129, DOI 10.1378/chest.120.4.1129; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gentilli M, 2014, INFORMS NOV 10 2014; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Gulliford M, 2003, ACCESS HLTH CARE; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Jones AP, 1998, J PUBLIC HEALTH MED, V20, P312, DOI 10.1093/oxfordjournals.pubmed.a024774; Kenney GM, 2012, MEDICAID CHIP PARTIC; KHAN AA, 1992, SOCIO ECON PLAN SCI, V26, P275, DOI 10.1016/0038-0121(92)90004-O; Lang DM, 2008, CLEV CLIN J MED, V75, P641, DOI 10.3949/ccjm.75.9.641; Langford M, 2006, PROF GEOGR, V58, P294, DOI 10.1111/j.1467-9272.2006.00569.x; Lin M, 2003, J EPIDEMIOL COMMUN H, V57, P50, DOI 10.1136/jech.57.1.50; Luo W, 2009, HEALTH PLACE, V15, P1100, DOI 10.1016/j.healthplace.2009.06.002; Mackun P., 2011, 2010 CENSUS BRIEFS P; Mayer ML, 2006, PEDIATRICS, V118, P2313, DOI 10.1542/peds.2006-1570; McGrail MR, 2012, INT J HEALTH GEOGR, V11, DOI 10.1186/1476-072X-11-50; Merrill CT, 2006, HOSP STAYS ASTHMA CH; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; National Heart Lung and Blood Institute, 2012, RED ASTHM DISP 2012; Neidell MJ, 2004, J HEALTH ECON, V23, P1209, DOI 10.1016/j.jhealeco.2004.05.002; Nobles M, 2014, ANN APPL STAT, V8, P1922, DOI 10.1214/14-AOAS728; Osborne ML, 1999, CHEST, V115, P85, DOI 10.1378/chest.115.1.85; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rodriguez MA, 2002, ARCH PEDIAT ADOL MED, V156, P269, DOI 10.1001/archpedi.156.3.269; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; Schuurman N, 2010, CAN GEOGR-GEOGR CAN, V54, P29, DOI 10.1111/j.1541-0064.2009.00301.x; Stewart KA, 2010, ARCH PEDIAT ADOL MED, V164, P720, DOI 10.1001/archpediatrics.2010.100; Szilagyi PG, 2006, PEDIATRICS, V117, P486, DOI 10.1542/peds.2005-0340; Talen E, 1998, ENVIRON PLANN A, V30, P595, DOI 10.1068/a300595; Teach SJ, 2006, PEDIATRICS, V117, pS78, DOI 10.1542/peds.2005-2000E; The Commonwealth Fund, STAT HLTH SYST RANK; Zoratti EM, 1998, AM J RESP CRIT CARE, V158, P371, DOI 10.1164/ajrccm.158.2.9608039	58	25	25	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					610	618		10.1016/j.jaci.2015.01.030	http://dx.doi.org/10.1016/j.jaci.2015.01.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	CQ9EA	25794659	Bronze			2022-12-18	WOS:000360913300011
J	Ownby, DR; Tingen, MS; Havstad, S; Waller, JL; Johnson, CC; Joseph, CLM				Ownby, Dennis R.; Tingen, Martha S.; Havstad, Suzanne; Waller, Jennifer L.; Johnson, Christine C.; Joseph, Christine L. M.			Comparison of asthma prevalence among African American teenage youth attending public high schools in rural Georgia and urban Detroit	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Urban; rural; African American; asthma; prevalence; inner-city; high school students; youth	INNER-CITY CHILDREN; RESIDENTIAL SEGREGATION; ALLERGEN EXPOSURE; DISPARITIES; SCHOOLCHILDREN; ADOLESCENTS; POLLUTION; PROGRAM; WHEEZE; CARE	Background: The high prevalence of asthma among urban African American (AA) populations has attracted research attention, whereas the prevalence among rural AA populations is poorly documented. Objective: We sought to compare the prevalence of asthma among AA youth in rural Georgia and urban Detroit, Michigan. Methods: The prevalence of asthma was compared in population-based samples of 7297 youth attending Detroit public high schools and in 2523 youth attending public high schools in rural Georgia. Current asthma was defined as a physician diagnosis and symptoms in the previous 12 months. Undiagnosed asthma was defined as multiple respiratory symptoms in the previous 12 months without a physician diagnosis. Results: In Detroit, 6994 (95.8%) youth were AA compared with 1514 (60.0%) in Georgia. Average population density in high school postal codes was 5628 people/mile(2) in Detroit and 45.1 people/mile(2) in Georgia. The percentages of poverty and of students qualifying for free or reduced lunches were similar in both areas. The prevalence of current diagnosed asthma among AA youth in Detroit and Georgia was similar: 15.0% (95% CI, 14.1-15.8) and 13.7% (95% CI, 12.0-17.1) (P = .22), respectively. The prevalence of undiagnosed asthma in AA youth was 8.0% in Detroit and 7.5% in Georgia (P = .56). Asthma symptoms were reported more frequently among those with diagnosed asthma in Detroit, whereas those with undiagnosed asthma in Georgia reported more symptoms. Conclusions: Among AA youth living in similar socioeconomic circumstances, asthma prevalence is as high in rural Georgia as it is in urban Detroit, suggesting that urban residence is not an asthma risk factor.	[Ownby, Dennis R.; Tingen, Martha S.] Georgia Regents Univ, Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; [Havstad, Suzanne; Johnson, Christine C.; Joseph, Christine L. M.] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA; [Waller, Jennifer L.] Georgia Regents Univ, Med Coll Georgia, Dept Biostat & Epidemiol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University	Ownby, DR (corresponding author), Georgia Regents Univ, Med Coll Georgia, Dept Pediat, Div Allergy Immunol & Rheumatol, 1120 15th St,BG 1019, Augusta, GA 30912 USA.	downby@gru.edu	Kuyucu, Semanur/K-5346-2015		National Heart, Lung, and Blood Institute of the National Institutes of Health [R01HL092412, R01HL06897]; Fund for Henry Ford Hospital; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092412, R01HL068971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI089473] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Fund for Henry Ford Hospital; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (grant nos. R01HL092412 and R01HL06897) and the Fund for Henry Ford Hospital. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Akinbami Lara J, 2011, Natl Health Stat Report, P1; Akinbami Lara J, 2012, NCHS Data Brief, P1; [Anonymous], 2014, BEHAV RISK FACTOR SU; Bashir SA, 2002, AM J PUBLIC HEALTH, V92, P733, DOI 10.2105/AJPH.92.5.733; Beck AF, 2014, PEDIATRICS, V133, P431, DOI 10.1542/peds.2013-2437; Breysse Patrick N, 2010, Proc Am Thorac Soc, V7, P102, DOI 10.1513/pats.200908-083RM; Bryant-Stephens T, 2012, J ASTHMA, V49, P581, DOI 10.3109/02770903.2012.690476; Busse W., 2007, 3 NHLBI US DEP HLTH, P1; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; Byrd RS, 2006, CURR OPIN PULM MED, V12, P68, DOI 10.1097/01.mcp.0000199001.68908.45; CRAIN EF, 1994, PEDIATRICS, V94, P356; Debbink MP, 2011, AM J PUBLIC HEALTH, V101, P1714, DOI 10.2105/AJPH.2011.300152; Donohue KM, 2008, J ALLERGY CLIN IMMUN, V122, P914, DOI 10.1016/j.jaci.2008.08.034; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Higgins PS, 2005, CHEST, V128, P3846, DOI 10.1378/chest.128.6.3846; Iceland J, 2013, DEMOGRAPHY, V50, P97, DOI 10.1007/s13524-012-0136-6; Joseph CLM, 2007, AM J RESP CRIT CARE, V175, P888, DOI 10.1164/rccm.200608-1244OC; Joseph CLM, 2007, J URBAN HEALTH, V84, P60, DOI 10.1007/s11524-006-9121-y; Joseph CLM, 2013, J ADOLESCENT HEALTH, V52, P419, DOI 10.1016/j.jadohealth.2012.07.009; Joseph CLM, 2002, ANN ALLERG ASTHMA IM, V88, P507, DOI 10.1016/S1081-1206(10)62390-3; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Magzamen S, 2010, J ADOLESCENT HEALTH, V46, P583, DOI 10.1016/j.jadohealth.2009.11.203; McGrath RJ, 2011, J COMMUN HEALTH, V36, P495, DOI 10.1007/s10900-010-9333-7; Northridge J, 2010, J URBAN HEALTH, V87, P211, DOI 10.1007/s11524-009-9404-1; Perry TT, 2008, ANN ALLERG ASTHMA IM, V101, P375, DOI 10.1016/S1081-1206(10)60313-4; Pesek RD, 2010, ANN ALLERG ASTHMA IM, V104, P125, DOI 10.1016/j.anai.2009.11.038; Petterson SM, 2012, ANN FAM MED, V10, P503, DOI 10.1370/afm.1431; Roy SR, 2010, J ALLERGY CLIN IMMUN, V125, P636, DOI 10.1016/j.jaci.2009.11.046; Sheehan WJ, 2010, J ALLERGY CLIN IMMUN, V125, P575, DOI 10.1016/j.jaci.2010.01.023; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; Valet RS, 2009, J ALLERGY CLIN IMMUN, V123, P1220, DOI 10.1016/j.jaci.2008.12.1131; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Wen M, 2013, ANN BEHAV MED, V45, pS18, DOI 10.1007/s12160-012-9426-x; Yeatts K, 2003, PEDIATRICS, V111, P1046, DOI 10.1542/peds.111.5.1046	35	25	25	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					595	+		10.1016/j.jaci.2015.02.007	http://dx.doi.org/10.1016/j.jaci.2015.02.007			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	CQ9EA	25825215	Green Accepted			2022-12-18	WOS:000360913300009
J	Hansen, S; Maslova, E; Strom, M; Linneberg, A; Halldorsson, TI; Granstrom, C; Dahl, R; Hoffmann, HJ; Olsen, SF				Hansen, Susanne; Maslova, Ekaterina; Strom, Marin; Linneberg, Allan; Halldorsson, Thorhallur I.; Granstrom, Charlotta; Dahl, Ronald; Hoffmann, Hans Jurgen; Olsen, Sjurdur F.			The long-term programming effect of maternal 25-hydroxyvitamin D in pregnancy on allergic airway disease and lung function in offspring after 20 to 25 years of follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cohort; pregnancy; fetal programming; 25-hydroxyvitamin D; asthma; allergic rhinitis; lung function	VITAMIN-D STATUS; D SUPPLEMENTATION; D DEFICIENCY; D LEVEL; CHILDHOOD; ASTHMA; RISK; ASSOCIATION; EXPRESSION; MATURATION	Background: High prenatal vitamin D status has been linked to decreased risk of atopic diseases in early childhood, but whether such relations persist until adulthood has not been explored. Objective: We sought to examine the association between maternal 25-hydryxovitamin D (25[OH]D) concentrations and outcomes of allergic airway disease and lung function in offspring with 20 to 25 years of follow-up. Methods: In a prospective birth cohort with 965 pregnant women enrolled in 1988-1989, maternal 25(OH)D concentrations were quantified in serum from gestational week 30 (n = 850 [88%]). Offspring were followed in nationwide registries with complete follow-up to the age of 25 years (n = 850 [100%]). Additionally, at age 20 years, outcomes of allergic airway disease and lung function were assessed in a subset of offspring by using blood samples and spirometry (n = 410 [45%]) and a questionnaire (n = 641 [70%]). Results: Exposure to a high maternal 25(OH)D concentration (>= 125 nmol/L) was associated with an increased risk of asthma hospitalizations in offspring (hazard ratio [HR], 1.81; 95% CI, 0.78-4.16) during 25 years of follow-up compared with the reference group (75-<125 nmol/L). Furthermore, there were lower risks of asthma hospitalizations (HR, 0.29; 95% CI, 0.08-1.02) and asthma medication use (HR, 0.58; 95% CI, 0.35-0.95) in those exposed to a low maternal 25(OH)D concentration (<50 nmol/L). In a reduced set of participants, we found no associations between maternal 25(OH)D concentrations and offspring allergen-specific IgE, total IgE, and eosinophil cationic protein levels; self-reported doctor's diagnosis of asthma or hay fever; or lung function at 20 years of age. Conclusions: Our study does not provide support for a protective effect of a high maternal 25(OH)D concentration on outcomes of allergic airway disease and lung function at 20 to 25 years of age. In contrast, a high maternal 25(OH)D concentration might be associated with an increased risk of allergic diseases in offspring.	[Hansen, Susanne; Maslova, Ekaterina; Strom, Marin; Halldorsson, Thorhallur I.; Granstrom, Charlotta; Olsen, Sjurdur F.] Statens Serum Inst, Dept Epidemiol Res, Ctr Fetal Programming, DK-2300 Copenhagen, Denmark; [Linneberg, Allan] Res Ctr Prevent & Hlth, Copenhagen, Denmark; [Linneberg, Allan] Glostrup Univ Hosp, Dept Clin Expt Res, Glostrup, Denmark; [Linneberg, Allan] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, DK-1168 Copenhagen, Denmark; [Halldorsson, Thorhallur I.] Univ Iceland, Fac Food Sci & Nutr, Reykjavik, Iceland; [Halldorsson, Thorhallur I.] Landspitali Univ Hosp, Unit Nutr Res, Reykjavik, Iceland; [Dahl, Ronald] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [Dahl, Ronald; Hoffmann, Hans Jurgen] Aarhus Univ Hosp, Dept Pulm Med & Allergy, Aarhus, Denmark; [Olsen, Sjurdur F.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Statens Serum Institut; University of Copenhagen; University of Copenhagen; University of Iceland; Landspitali National University Hospital; University of Southern Denmark; Odense University Hospital; Aarhus University; Harvard University; Harvard T.H. Chan School of Public Health	Hansen, S (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Ctr Fetal Programming, Artillerivej 5, DK-2300 Copenhagen, Denmark.	suu@ssi.dk	Hansen, Susanne/AAE-7275-2021; Hansen, Susanne/F-1657-2017; Hoffman, Hans Jurgen/I-6969-2018; Halldorsson, Tohrhallur/M-1823-2015	Hoffman, Hans Jurgen/0000-0002-6743-7931; Halldorsson, Tohrhallur/0000-0001-5115-0162; Halldorsson, Thorhallur/0000-0002-3488-0777; Linneberg, Allan/0000-0002-0994-0184; Strom, Marin/0000-0003-1926-6610; Olsen, Sjurdur/0000-0003-3017-7096	Danish Agency for Science, Technology and Innovation [DSF: 09-067124, DSF: 09-063072, DFS: 2101-06-0005, FSS: 09-065631]; Lundbeck Foundation [R13-A907]; Danish Lung Association [2-2010]; Novo Nordisk Foundation	Danish Agency for Science, Technology and Innovation; Lundbeck Foundation(Lundbeckfonden); Danish Lung Association; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	Supported by the Danish Agency for Science, Technology and Innovation (DSF: 09-067124 [Centre for Fetal Programming], DSF: 09-063072 [Danish Obesity Research Centre], DFS: 2101-06-0005, and FSS: 09-065631), the Lundbeck Foundation (R13-A907), and the Danish Lung Association (2-2010). Quantification of vitamin D biomarkers in maternal sera was funded by a grant from the Novo Nordisk Foundation.	Antoniucci DM, 2005, CLIN CHEM, V51, P258; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Bikle D, 2009, J CLIN ENDOCR METAB, V94, P26, DOI 10.1210/jc.2008-1454; Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Chawes BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099856; Chen WJ, 2014, PHARMAZIE, V69, P385, DOI 10.1691/ph.2014.3619; Cremers E, 2011, THORAX, V66, P474, DOI 10.1136/thx.2010.151985; Ford L, 2013, METHODS MOL BIOL, V1065, P245, DOI 10.1007/978-1-62703-616-0_16; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Ginde AA, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.11.036; Goldring ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066627; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Institute of Medicine, 2011, DIET REF RANG CALC V; Jensen Annette Ostergaard, 2010, Clin Epidemiol, V2, P67; Jones AP, 2012, PEDIATRICS, V130, pE1128, DOI 10.1542/peds.2012-1172; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Magnus MC, 2013, PAEDIATR PERINAT EP, V27, P532, DOI 10.1111/ppe.12080; Maslova E, 2014, PEDIAT ALLERG IMM-UK, V25, P706, DOI 10.1111/pai.12295; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI [10.1016/S0091-6749(03)01855-4, 10.1037/mai.2003.1703]; Morales E, 2012, EPIDEMIOLOGY, V23, P64, DOI 10.1097/EDE.0b013e31823a44d3; Moth G, 2007, EUR J CLIN PHARMACOL, V63, P605, DOI 10.1007/s00228-007-0286-4; National Board of Health, 2010, RAT FRAM; Nguyen M, 2004, J STEROID BIOCHEM, V89-90, P93, DOI 10.1016/j.jsbmb.2004.03.054; Nguyen TM, 1996, AM J PHYSIOL-LUNG C, V271, pL392, DOI 10.1152/ajplung.1996.271.3.L392; OLSEN SF, 1995, BRIT J NUTR, V73, P397, DOI 10.1079/BJN19950042; Pichler J, 2002, PEDIATR RES, V52, P12, DOI 10.1203/01.PDR.0000017267.23950.48; Pike KC, 2012, THORAX, V67, P950, DOI 10.1136/thoraxjnl-2012-201888; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P1093, DOI 10.1016/j.jaci.2011.07.015; Shin Youn Ho, 2013, Korean J Pediatr, V56, P439, DOI 10.3345/kjp.2013.56.10.439; Weisse K, 2013, ALLERGY, V68, P220, DOI 10.1111/all.12081; Wills AK, 2013, CLIN EXP ALLERGY, V43, P1180, DOI 10.1111/cea.12172; Zosky Graeme R, 2014, Ann Am Thorac Soc, V11, P571, DOI [10.1513/AnnalsATS.201312-423OC, 10.1513/AnnalsATS.201407-331LE]	35	25	27	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					169	U304		10.1016/j.jaci.2014.12.1924	http://dx.doi.org/10.1016/j.jaci.2014.12.1924			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25649083				2022-12-18	WOS:000357542200019
J	Yu, HS; Kang, MJ; Kwon, JW; Lee, SY; Lee, E; Yang, SI; Jung, YH; Hong, K; Kim, YJ; Lee, SH; Kim, HJ; Kim, HY; Seo, JH; Kim, BJ; Kim, HB; Hong, SJ				Yu, Ho-Sung; Kang, Mi-Jin; Kwon, Ji-Won; Lee, So-Yeon; Lee, Eun; Yang, Song-I.; Jung, Young-Ho; Hong, Kyungmo; Kim, Young-Joon; Lee, Seung-Hwa; Kim, Ha-Jung; Kim, Hyung Young; Seo, Ju-Hee; Kim, Byoung-Ju; Kim, Hyo-Bin; Hong, Soo-Jong			Claudin-1 polymorphism modifies the effect of mold exposure on the development of atopic dermatitis and production of IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA		[Yu, Ho-Sung; Kang, Mi-Jin; Kim, Young-Joon; Lee, Seung-Hwa; Kim, Ha-Jung] Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea; [Kwon, Ji-Won] Seoul Natl Univ, Bundang Hosp, Dept Pediat, Songnam, South Korea; [Kwon, Ji-Won; Lee, So-Yeon; Lee, Eun; Yang, Song-I.; Jung, Young-Ho; Kim, Hyung Young; Seo, Ju-Hee; Kim, Byoung-Ju; Kim, Hyo-Bin; Hong, Soo-Jong] Univ Ulsan, Coll Med, Asan Med Ctr, Res Ctr Standardizat Allerg Dis,Dept Pediat, Seoul, South Korea; [Lee, So-Yeon] Hallym Univ, Coll Med, Hallym Sacred Heart Hosp, Dept Pediat, Anyang, South Korea; [Lee, Eun; Yang, Song-I.; Jung, Young-Ho; Hong, Soo-Jong] Asan Med Ctr, Childhood Asthma Atopy Ctr, Seoul, South Korea; [Hong, Kyungmo] Goucher Coll, Baltimore, MD USA; [Kim, Hyung Young] Pusan Natl Univ, Yangsan Hosp, Dept Pediat, Yangsan, South Korea; [Seo, Ju-Hee] Korea Canc Ctr Hosp, Dept Pediat, Seoul, South Korea; [Kim, Byoung-Ju] Inje Univ, Haeundae Paik Hosp, Dept Pediat, Gimhae, South Korea; [Kim, Hyo-Bin] Inje Univ, Coll Med, Sanggye Paik Hosp, Dept Pediat, Seoul, South Korea	University of Ulsan; Asan Medical Center; Seoul National University (SNU); University of Ulsan; Asan Medical Center; Hallym University; University of Ulsan; Asan Medical Center; Pusan National University; Pusan National University Hospital; National Cancer Center - Korea (NCC); Inje University; Inje University	Yu, HS (corresponding author), Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea.	sjhong@amc.seoul.kr	Hong, Soo-Jong/AAR-1788-2020; Kim, Ha-Jung/AGU-3492-2022	Hong, Soo-Jong/0000-0003-1409-2113; Kim, Byoung-Ju/0000-0003-0271-9417				Balaji H, 2011, J ALLERGY CLIN IMMUN, V128, P92, DOI 10.1016/j.jaci.2011.02.043; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Gupta AK, 2004, J AM ACAD DERMATOL, V51, P785, DOI 10.1016/j.jaad.2003.12.034; Kim WK, 2012, J ALLERGY CLIN IMMUN, V130, P421, DOI 10.1016/j.jaci.2012.04.052; Laidlaw TM, 2011, J ALLERGY CLIN IMMUN, V127, P815, DOI 10.1016/j.jaci.2010.12.1101; Lee JY, 2012, INT ARCH ALLERGY IMM, V157, P363, DOI 10.1159/000328778; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Schutze N, 2010, AM J RESP CRIT CARE, V181, P1188, DOI 10.1164/rccm.200909-1350OC; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Tischer C, 2011, EUR RESPIR J, V37, P1050, DOI 10.1183/09031936.00091210; Tischer CG, 2011, ALLERGY, V66, P1570, DOI 10.1111/j.1398-9995.2011.02712.x	13	25	28	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					827	830		10.1016/j.jaci.2014.10.040	http://dx.doi.org/10.1016/j.jaci.2014.10.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25512082				2022-12-18	WOS:000351065000036
J	Cheung, I; Vadas, P				Cheung, Ingrid; Vadas, Peter			A New Disease Cluster: Mast Cell Activation Syndrome, Postural Orthostatic Tachycardia Syndrome, and Ehlers-Danlos Syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)	FEB 20-24, 2015	Houston, TX	Amer Acad Allergy, Asthma & Immunol					[Cheung, Ingrid; Vadas, Peter] St Michaels Hosp, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto									0	25	25	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2		S		209	AB65	AB65		10.1016/j.jaci.2014.12.1146	http://dx.doi.org/10.1016/j.jaci.2014.12.1146			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	CR2BN					2022-12-18	WOS:000361129600210
J	Hasegawa, K; Sullivan, AF; Tsugawa, Y; Turner, SJ; Massaro, S; Clark, S; Tsai, CL; Camargo, CA				Hasegawa, Kohei; Sullivan, Ashley F.; Tsugawa, Yusuke; Turner, Stuart J.; Massaro, Susan; Clark, Sunday; Tsai, Chu-Lin; Camargo, Carlos A., Jr.		MARC-36 Investigators	Comparison of US emergency department acute asthma care quality: 1997-2001 and 2011-2012	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute asthma; emergency department; guideline; concordance; quality of care; hospitalization; regional variation; time trend	OF-CARE; ADULTS; INDICATORS; HOSPITALS; VISITS; TRENDS; REAL; BAR	Background: It remains unclear whether the quality of acute asthma care in US emergency departments (EDs) has improved over time. Objectives: We investigated changes in concordance of ED asthma care with 2007 National Institutes of Health guidelines, identified ED characteristics predictive of concordance, and tested whether higher concordance was associated with lower risk of hospitalization. Methods: We performed chart reviews in ED patients aged 18 to 54 years with asthma exacerbations in 48 EDs during 2 time periods: 1997-2001 (2 prior studies) and2011-2012 (new study). Concordance with guideline recommendations was evaluated by using item-by-item quality measures and composite concordance scores at the patient and ED levels; these scores ranged from 0 to 100. Results: The analytic cohort comprised 4039 patients (2119 from 1997-2001 vs 1920 from 2011-2012). Over these 16 years, emergency asthma care became more concordant with level A recommendations at both the patient and ED levels (both P<.001). By contrast, concordance with non-level A recommendations (peak expiratory flow measurement and timeliness) decreased at both the patient (median score, 75 [interquartile range, 50-100] to 50 [interquartile range, 33-75], P<.001) and ED (mean score, 67 [SD, 7] to 50 [SD, 16], P<.001) levels. Multivariable analysis demonstrated ED concordance was lower in Southern and Western EDs compared with Midwestern EDs. After adjusting for severity, guideline-concordant care was associated with lower risk of hospitalization (odds ratio, 0.37; 95% CI, 0.26-0.53). Conclusions: Between 1997 and 2012, we observed changes in the quality of emergency asthma care that differed by level of guideline recommendation and substantial interhospital and geographic variations. Greater concordance with guideline-recommended management might reduce unnecessary hospitalizations.	[Hasegawa, Kohei; Sullivan, Ashley F.; Tsai, Chu-Lin; Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Tsugawa, Yusuke] Harvard Interfac Initiat Hlth Policy, Cambridge, England; [Turner, Stuart J.; Massaro, Susan] Novartis Pharmaceut, E Hanover, NJ USA; [Clark, Sunday] Weill Cornell Med Coll, Dept Emergency Med, New York, NY USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Novartis; Cornell University	Hasegawa, K (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, Suite 410,326 Cambridge St, Boston, MA 02114 USA.	khasegawa1@partners.org	Clark, Sunday/AAA-5458-2021; Pallin, Daniel J/H-6382-2013; Shapiro, Nathan/F-1718-2016; Camargo, Carlos A./C-2145-2008	Pallin, Daniel J/0000-0002-8517-9702; Camargo, Carlos A./0000-0002-5071-7654; Tsugawa, Yusuke/0000-0002-1937-4833; Sullivan, D. Matthew/0000-0001-5537-6986; TSAI, CHU-LIN/0000-0003-4639-1513; Crandall, Cameron/0000-0002-4459-8409; Healy, Megan/0000-0001-8145-1898	Novartis Pharmaceuticals Corporation	Novartis Pharmaceuticals Corporation(Novartis)	Supported by a grant from Novartis Pharmaceuticals Corporation to Massachusetts General Hospital (principal investigator: Camargo). The sponsor had no role in the conduct of the study, nor collection, management, or analysis of the data.	Agency for Healthcare research and Quality, UND QUAL MEAS; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Cydulka RK, 2001, ANN EMERG MED, V38, P123, DOI 10.1067/mem.2001.114305; Fonarow GC, 2009, JAMA-J AM MED ASSOC, V302, P792, DOI 10.1001/jama.2009.1180; Ginde AA, 2008, J ALLERGY CLIN IMMUN, V122, P313, DOI 10.1016/j.jaci.2008.04.024; Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530; Griswold SK, 2005, CHEST, V127, P1579, DOI 10.1378/chest.127.5.1579; Hasegawa K, 2013, J ALLER CL IMM-PRACT, V1, P509, DOI 10.1016/j.jaip.2013.05.001; Little R. J., 2019, STAT ANAL MISSING DA, V793; McDermott MF, 2006, ACAD EMERG MED, V13, P345, DOI 10.1197/j.aem.2005.09.006; Morse RB, 2011, JAMA-J AM MED ASSOC, V306, P1454, DOI 10.1001/jama.2011.1385; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Center for Health Statistics, INT CLASS DIS; Nolan T, 2006, JAMA-J AM MED ASSOC, V295, P1168, DOI 10.1001/jama.295.10.1168; Pitts SR, 2010, HEALTH AFFAIR, V29, P1620, DOI 10.1377/hlthaff.2009.1026; Rank MA, 2012, ANN ALLERG ASTHMA IM, V108, P9, DOI 10.1016/j.anai.2011.09.009; Reeves D, 2007, MED CARE, V45, P489, DOI 10.1097/MLR.0b013e31803bb479; Rowe B H, 2001, Respir Care, V46, P1380; Rubin DB, 2004, MULTIPLE IMPUTATION; Schatz M, 2006, CHEST, V130, P43, DOI 10.1378/chest.130.1.43; Sills MR, 2012, PEDIATRICS, V129, pE325, DOI 10.1542/peds.2010-3302; Sills MR, 2011, PEDIATR EMERG CARE, V27, P837, DOI 10.1097/PEC.0b013e31822c1382; Silverman RA, 2003, CHEST, V123, P1472, DOI 10.1378/chest.123.5.1472; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112; Tsai CL, 2013, J ALLER CL IMM-PRACT, V1, P516, DOI 10.1016/j.jaip.2013.06.012; Tsai CL, 2010, AM J EMERG MED, V28, P485, DOI 10.1016/j.ajem.2009.01.041; Tsai CL, 2009, ANN ALLERG ASTHMA IM, V103, P318, DOI 10.1016/S1081-1206(10)60531-5; Tsai CL, 2009, J ALLERGY CLIN IMMUN, V123, P354, DOI 10.1016/j.jaci.2008.10.051; U. S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2020, 2013, HLTH PEOPL 2020; United States Department of Agriculture Economic Research Service, 2013 URB INFL COD; US Census Bureau, CENS REG DIV US; von Hippel PT, 2007, SOCIOL METHODOL, V37, P83, DOI 10.1111/j.1467-9531.2007.00180.x; Williams SC, 2005, NEW ENGL J MED, V353, P255, DOI 10.1056/NEJMsa043778	37	25	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					73	U522		10.1016/j.jaci.2014.08.028	http://dx.doi.org/10.1016/j.jaci.2014.08.028			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25263233	Green Submitted			2022-12-18	WOS:000347298200009
J	Kurukulaaratchy, RJ; Zhang, HM; Patil, V; Raza, A; Karmaus, W; Ewart, S; Arshad, SH				Kurukulaaratchy, Ramesh J.; Zhang, Hongmei; Patil, Veeresh; Raza, Abid; Karmaus, Wilfried; Ewart, Susan; Arshad, S. Hasan			Identifying the heterogeneity of young adult rhinitis through cluster analysis in the Isle of Wight birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cluster analysis; morbidity; rhinitis; wheezing	CHRONIC RHINOSINUSITIS; ASTHMA PHENOTYPES; ALLERGIC RHINITIS; CLINICAL IMMUNOLOGY; EUROPEAN ACADEMY; RISK-FACTOR; CHILDHOOD; ATOPY; PREVALENCE; ENDOTYPES	Background: Rhinitis affects many young adults and often shows comorbidity with asthma. Objective: We hypothesized that young adult rhinitis, like asthma, exhibits clinical heterogeneity identifiable by means of cluster analysis. Methods: Participants in the Isle of Wight birth cohort (n = 1456) were assessed at 1, 2, 4, 10, and 18 years of age. Cluster analysis was performed on those with rhinitis at age 18 years (n 5 468) by using 13 variables defining clinical characteristics. Results: Four clusters were identified. Patients in cluster 1 (n = 128 [27.4%]; ie, moderate childhood-onset rhinitis) had high atopy and eczema prevalence and high total IgE levels but low asthma prevalence. They showed the best lung function at 18 years of age, with normal fraction of exhaled nitric oxide (FENO), low bronchial hyperresponsiveness (BHR), and low bronchodilator reversibility (BDR) but high rhinitis symptoms and treatment. Patients in cluster 2 (n = 199 [42.5%]; ie, mild-adolescence-onset female rhinitis) had the lowest prevalence of comorbid atopy, asthma, and eczema. They had normal lung function and low BHR, BDR, FENO values, and total IgE levels plus low rhinitis symptoms, severity, and treatment. Patients in cluster 3 (n = 59 [12.6%]; ie, severe earliest-onset rhinitis with asthma) had the youngest rhinitis onset plus the highest comorbid asthma (of simultaneous onset) and atopy. They showed the most obstructed lung function with high BHR, BDR, and FENO values plus high rhinitis symptoms, severity, and treatment. Patient 4 in cluster 4 (n = 82 [17.5%]; ie, moderate childhood-onset male rhinitis with asthma) had high atopy, intermediate asthma, and low eczema. They had impaired lung function with high FENO values and total IgE levels but intermediate BHR and BDR. They had moderate rhinitis symptoms. Conclusion: Clinically distinctive adolescent rhinitis clusters are apparent with varying sex and asthma associations plus differing rhinitis severity and treatment needs.	[Kurukulaaratchy, Ramesh J.; Patil, Veeresh; Raza, Abid; Arshad, S. Hasan] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England; [Arshad, S. Hasan] Univ Southampton, Fac Med, Clin & Expt Med, Southampton SO9 5NH, Hants, England; [Zhang, Hongmei; Karmaus, Wilfried] Univ Memphis, Sch Publ Hlth, Div Epidemiol Biostat & Environm Hlth, Memphis, TN 38152 USA; [Ewart, Susan] Michigan State Univ, Large Anim Clin Sci, E Lansing, MI 48824 USA	University of Southampton; University of Memphis; Michigan State University	Arshad, SH (corresponding author), Southampton Gen Hosp, MP 810,South Block,Tremona Rd, Southampton SO9 4XY, Hants, England.	sha@soton.ac.uk		Raza, Abid/0000-0002-7108-3814; Karmaus, Wilfried/0000-0003-2684-1492; Kurukulaaratchy, Ramesh/0000-0002-1588-2400	National Institutes of Health [5 R01 HL082925]; National Institute of Allergy and Infectious Diseases [R01 AI091905]; National Institutes of Health; MRC [G0400473, G0900453] Funding Source: UKRI; Medical Research Council [G0400473, G0900453] Funding Source: researchfish; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091905] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (grant 5 R01 HL082925) and the National Institute of Allergy and Infectious Diseases (award no. R01 AI091905). Disclosure of potential conflict of interest: The authors received research support from the National Institutes of Health.	Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bachert C, 2012, PEDIAT ALLERG IMM-UK, V23, P2, DOI 10.1111/j.1399-3038.2012.01318.x; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; Calinski T., 1974, COMMUN STAT-THEOR M, V3, P1, DOI [DOI 10.1080/03610927408827101, 10.1080/03610927408827101]; de Groot EP, 2012, THORAX, V67, P582, DOI 10.1136/thoraxjnl-2011-201168; Eriksson J, 2011, RESP MED, V105, P1611, DOI 10.1016/j.rmed.2011.06.004; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Jarvis D, 2012, ALLERGY, V67, P91, DOI 10.1111/j.1398-9995.2011.02709.x; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Kurukulaaratchy RJ, 2011, CLIN EXP ALLERGY, V41, P851, DOI 10.1111/j.1365-2222.2011.03765.x; Kurukulaaratchy RJ, 2002, RESP MED, V96, P163, DOI 10.1053/rmed.2001.1236; Martin PE, 2011, J ALLERGY CLIN IMMUN, V127, P1473, DOI 10.1016/j.jaci.2011.02.041; Meltzer Eli O, 2012, Allergy Asthma Proc, V33 Suppl 1, pS113, DOI 10.2500/aap.2012.33.3603; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Punekar YS, 2009, CLIN EXP ALLERGY, V39, P1889, DOI 10.1111/j.1365-2222.2009.03366.x; Raza A, 2012, EUR RESPIR J, V40, P580, DOI 10.1183/09031936.00085111; Roberts G, 2013, ALLERGY, V68, P1102, DOI 10.1111/all.12235; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Sarle W. S, 1983, CUBIC CLUSTERING CRI; Scott M, 2010, THORAX, V65, P258, DOI 10.1136/thx.2009.125443; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; van den Nieuwenhof L, 2010, ALLERGY, V65, P1049, DOI 10.1111/j.1398-9995.2009.02316.x; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Wenzel S, 2012, CLIN EXP ALLERGY, V42, P650, DOI 10.1111/j.1365-2222.2011.03929.x	28	25	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					143	U225		10.1016/j.jaci.2014.06.017	http://dx.doi.org/10.1016/j.jaci.2014.06.017			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25085342	Green Accepted			2022-12-18	WOS:000347298200017
J	Platt, C; Geha, RS; Chou, J				Platt, Craig; Geha, Raif S.; Chou, Janet			Gene hunting in the genomic era: Approaches to diagnostic dilemmas in patients with primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiencies; whole-genome sequencing; whole-exome sequencing; linkage analysis; homozygosity mapping	INTERLEUKIN-2-RECEPTOR GAMMA-CHAIN; HERPES-SIMPLEX ENCEPHALITIS; X-LINKED IMMUNODEFICIENCY; CD40 LIGAND; T-CELL; AUTOSOMAL-DOMINANT; ECTODERMAL DYSPLASIA; DEFECTIVE EXPRESSION; IMMUNE-DEFICIENCY; MENDELIAN DISEASE	There are more than 180 different genetic causes of primary immunodeficiencies identified to date. Approaches for identifying causative mutations can be broadly classified into 3 strategies: (1) educated guesses based on known signaling pathways essential for immune cell development and function, (2) similarity of clinical phenotypes to mouse models, and (3) unbiased genetic approaches. Next-generation DNA sequencing permits efficient sequencing of whole genomes or exomes but also requires strategies for filtering vast amounts of data. Recent studies have identified ways to solve difficult cases, such as diseases with autosomal dominant inheritance, incomplete penetrance, or mutations in noncoding regions. This review focuses on recently identified primary immunodeficiencies to illustrate the strategies, technologies, and potential pitfalls in finding novel causes of these diseases.	Harvard Univ, Sch Med, Boston Childrens Hosp, Div Immunol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pediat, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Chou, J (corresponding author), Boston Childrens Hosp, Div Immunol, Karp Bldg,10th Floor,1 Blackfan Circle, Boston, MA 02115 USA.	janet.chou@childrens.harvard.edu			National Institutes of Health [AI-076210, AI094017, 1 K12 HD052896-01A1]; Dubai Harvard Foundation for Medical Research; Jeffrey Modell Foundation; Manton Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, R03AI094017] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dubai Harvard Foundation for Medical Research; Jeffrey Modell Foundation; Manton Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (AI-076210 and AI094017 to R. S. G. and 1 K12 HD052896-01A1 to J. C.), the Dubai Harvard Foundation for Medical Research (R. S. G.), the Jeffrey Modell Foundation (R. S. G.), and a Manton Foundation Pilot Award (J. C.).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Alkuraya FS, 2010, GENET MED, V12, P236, DOI 10.1097/GIM.0b013e3181ceb95d; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298; Anton IM, 2002, IMMUNITY, V16, P193, DOI 10.1016/S1074-7613(02)00268-6; Arai T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027782; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Baralle D, 2009, EMBO REP, V10, P810, DOI 10.1038/embor.2009.170; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Chou J, 2012, J ALLERGY CLIN IMMUN, V130, P1414, DOI 10.1016/j.jaci.2012.06.012; Chou J, 2012, CURR OPIN ALLERGY CL, V12, P623, DOI 10.1097/ACI.0b013e3283588ca6; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Crequer A, 2012, J CLIN INVEST, V122, P3239, DOI 10.1172/JCI62949; Davydov EV, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001025; de la Fuente MA, 2007, P NATL ACAD SCI USA, V104, P926, DOI 10.1073/pnas.0610275104; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; Fruman DA, 2010, CURR TOP MICROBIOL, V346, P225, DOI 10.1007/82_2010_39; Fu WQ, 2013, NATURE, V493, P216, DOI 10.1038/nature11690; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Gibbs JR, 2006, PLOS GENET, V2, P1511, DOI 10.1371/journal.pgen.0020150; Gonzaga-Jauregui C, 2012, ANNU REV MED, V63, P35, DOI 10.1146/annurev-med-051010-162644; Gu Y, 2006, NAT IMMUNOL, V7, P1182, DOI 10.1038/ni1396; Hahn CN, 2011, NAT GENET, V43, P1012, DOI 10.1038/ng.913; Hanna S, 2011, J ALLERGY CLIN IMMUN, V127, P1433, DOI 10.1016/j.jaci.2011.03.026; Herman M, 2012, J EXP MED, V209, P1567, DOI 10.1084/jem.20111316; Hsu AP, 2013, BLOOD, V121, P3830, DOI 10.1182/blood-2012-08-452763; Hsu AP, 2011, BLOOD, V118, P2653, DOI 10.1182/blood-2011-05-356352; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Janssen R, 2004, J EXP MED, V200, P559, DOI 10.1084/jem.20040773; Kassahn KS, 2011, INTEGR BIOL-UK, V3, P522, DOI 10.1039/c0ib00062k; Knight JC, 2013, TRENDS GENET, V29, P74, DOI 10.1016/j.tig.2012.10.006; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Koss M, 2012, DEV CELL, V22, P913, DOI 10.1016/j.devcel.2012.02.009; Kuhlenbaumer G, 2011, HUM MUTAT, V32, P144, DOI 10.1002/humu.21400; Kutukculer N, 2003, J PEDIATR-US, V142, P194, DOI 10.1067/mpd.2003.41; Lanzi G, 2012, J EXP MED, V209, P29, DOI 10.1084/jem.20110896; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Lupski JR, 2010, NEW ENGL J MED, V362, P1181, DOI 10.1056/NEJMoa0908094; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mao H, 2012, GENES IMMUN, V13, P437, DOI 10.1038/gene.2012.8; McDonald DR, 2007, J ALLERGY CLIN IMMUN, V120, P900, DOI 10.1016/j.jaci.2007.08.035; Meeths M, 2011, BLOOD, V118, P5783, DOI 10.1182/blood-2011-07-369090; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Mooster JL, 2010, J ALLERGY CLIN IMMUN, V126, P127, DOI 10.1016/j.jaci.2010.04.026; Moshous D, 2013, J ALLERGY CLIN IMMUN, V131, P1594, DOI 10.1016/j.jaci.2013.01.042; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ng SB, 2010, HUM MOL GENET, V19, pR119, DOI 10.1093/hmg/ddq390; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; O'Neill LAJ, 2008, IMMUNITY, V29, P12, DOI 10.1016/j.immuni.2008.06.004; Ombrello MJ, 2012, NEW ENGL J MED, V366, P330, DOI 10.1056/NEJMoa1102140; Pabst O, 1999, DEVELOPMENT, V126, P2215; Pelak K, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001111; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Puel A, 2004, CURR OPIN IMMUNOL, V16, P34, DOI 10.1016/j.coi.2003.11.013; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Recher M, 2013, CLIN IMMUNOL, V146, P84, DOI 10.1016/j.clim.2012.11.007; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Sancho-Shimizu V, 2011, J CLIN INVEST, V121, P4889, DOI 10.1172/JCI59259; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Shiow LR, 2008, NAT IMMUNOL, V9, P1307, DOI 10.1038/ni.1662; Stone EA, 2005, GENOME RES, V15, P978, DOI 10.1101/gr.3804205; Talkowski ME, 2011, AM J HUM GENET, V88, P469, DOI 10.1016/j.ajhg.2011.03.013; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Weidberg H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002355; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	78	25	33	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					262	268		10.1016/j.jaci.2013.08.021	http://dx.doi.org/10.1016/j.jaci.2013.08.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24100122	Green Accepted			2022-12-18	WOS:000341370800003
J	Gepp, B; Lengger, N; Bublin, M; Hemmer, W; Breiteneder, H; Radauer, C				Gepp, Barbara; Lengger, Nina; Bublin, Merima; Hemmer, Wolfgang; Breiteneder, Heimo; Radauer, Christian			Chimeras of Bet v 1 and Api g 1 reveal heterogeneous IgE responses in patients with birch pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bet v 1.0101; Api g 1.0101; patient-specific IgE repertoire; chimera-based technology; IgE epitope mapping; birch pollen allergy	MUTATIONAL EPITOPE ANALYSIS; SITE-DIRECTED MUTAGENESIS; MAJOR CELERY ALLERGEN; APPLE MALUS-DOMESTICA; CROSS-REACTIVITY; RECOMBINANT ALLERGENS; BINDING EPITOPES; MOLECULAR CHARACTERIZATION; CHERRY ALLERGEN; FOOD ALLERGENS	Background: Characterization of IgE-binding epitopes of allergens and determination of their patient-specific relevance is crucial for the diagnosis and treatment of allergy. Objective: We sought to assess the contribution of specific surface areas of the major birch pollen allergen Bet v 1.0101 to binding IgE of individual patients. Methods: Four distinct areas of Bet v 1 representing in total 81% of its surface were grafted onto the scaffold of its homolog, Api g 1.0101, to yield the chimeras Api-Bet-1 to Api-Bet-4. The chimeras were expressed in Escherichia coli and purified. IgE binding of 64 sera from Bet v 1-sensitized subjects with birch pollen allergy was determined by using direct ELISA. Specificity was assessed by means of inhibition ELISA. Results: rApi g 1.0101, Api-Bet-1, Api-Bet-2, Api-Bet-3, and Api-Bet-4 bound IgE from 44%, 89%, 80%, 78%, and 48% of the patients, respectively. By comparing the amount of IgE binding to the chimeras and to rApi g 1.0101, 81%, 70%, 75%, and 45% of the patients showed significantly enhanced IgE binding to Api-Bet-1, Api-Bet-2, Api-Bet-3, and Api-Bet-4, respectively. The minority (8%) of the sera revealed enhanced IgE binding exclusively to a single chimera, whereas 31% showed increased IgE binding to all 4 chimeras compared with rApi g 1.0101. The chimeras inhibited up to 70% of IgE binding to rBet v 1.0101, confirming the specific IgE recognition of the grafted regions. Conclusion: The Bet v 1-specific IgE response is polyclonal, and epitopes are spread across the entire Bet v 1 surface. Furthermore, the IgE recognition profile of Bet v 1 is highly patient specific.	[Gepp, Barbara; Lengger, Nina; Bublin, Merima; Breiteneder, Heimo; Radauer, Christian] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Hemmer, Wolfgang] Floridsdorfer Allergiezentrum, Vienna, Austria	Medical University of Vienna	Breiteneder, H (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	heimo.breiteneder@meduniwien.ac.at	Radauer, Christian/AAN-6260-2021	Radauer, Christian/0000-0001-9920-4449; Bublin, Merima/0000-0002-7191-9431	Austrian Science Fund [SFB-F4608, P22559-B11]; Austrian Science Fund (FWF) [P 22559] Funding Source: researchfish	Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by grants SFB-F4608 (to H. B.) and P22559-B11 (to C. R.) from the Austrian Science Fund.	Aalberse RC, 2011, ALLERGY, V66, P1261, DOI 10.1111/j.1398-9995.2011.02656.x; Albrecht M, 2009, J ALLERGY CLIN IMMUN, V124, P328, DOI 10.1016/j.jaci.2009.05.031; Bauermeister K, 2009, J ALLERGY CLIN IMMUN, V124, P1273, DOI 10.1016/j.jaci.2009.07.033; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Ganglberger E, 2000, FASEB J, V14, P2177, DOI 10.1096/fj.99-1000com; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Gieras A, 2011, J IMMUNOL, V186, P5333, DOI 10.4049/jimmunol.1000804; Hecker J, 2012, ALLERGY, V67, P1530, DOI 10.1111/all.12045; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; Holm J, 2004, J IMMUNOL, V173, P5258, DOI 10.4049/jimmunol.173.8.5258; Holm J, 2011, J BIOL CHEM, V286, P17569, DOI 10.1074/jbc.M110.194878; Jutel M, 2011, ALLERGY, V66, P725, DOI 10.1111/j.1398-9995.2011.02589.x; Karisola P, 2002, J BIOL CHEM, V277, P22656, DOI 10.1074/jbc.M201076200; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; King TP, 2001, J IMMUNOL, V166, P6057, DOI 10.4049/jimmunol.166.10.6057; Klinglmayr E, 2009, ALLERGY, V64, P647, DOI 10.1111/j.1398-9995.2008.01844.x; Liu JJ, 2006, PHYSIOL MOL PLANT P, V68, P3, DOI 10.1016/j.pmpp.2006.06.004; Ma Y, 2006, INT ARCH ALLERGY IMM, V139, P53, DOI 10.1159/000089756; Mirza O, 2000, J IMMUNOL, V165, P331, DOI 10.4049/jimmunol.165.1.331; Mittag D, 2006, MOL IMMUNOL, V43, P268, DOI 10.1016/j.molimm.2005.02.008; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Neudecker P, 2003, BIOCHEM J, V376, P97, DOI 10.1042/BJ20031057; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Radauer C, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-286; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Schirmer T, 2005, J MOL BIOL, V351, P1101, DOI 10.1016/j.jmb.2005.06.054; Spangfort MD, 2003, J IMMUNOL, V171, P3084, DOI 10.4049/jimmunol.171.6.3084; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Wangorsch A, 2007, MOL IMMUNOL, V44, P2518, DOI 10.1016/j.molimm.2006.12.023; Willumsen N, 2012, CLIN EXP ALLERGY, V42, P1227, DOI 10.1111/j.1365-2222.2012.04009.x	36	25	25	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					188	194		10.1016/j.jaci.2013.12.1073	http://dx.doi.org/10.1016/j.jaci.2013.12.1073			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24529686	Green Published, hybrid			2022-12-18	WOS:000338930300024
J	Savage, WJ; Hamilton, RG; Tobian, AAR; Milne, GL; Kaufman, RM; Savage, JH; Borge, PD; Ness, PM				Savage, William J.; Hamilton, Robert G.; Tobian, Aaron A. R.; Milne, Ginger L.; Kaufman, Richard M.; Savage, Jessica H.; Borge, P. Dayand; Ness, Paul M.			Defining risk factors and presentations of allergic reactions to platelet transfusion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PATIENT; PLASMA; IGA		[Savage, William J.; Kaufman, Richard M.; Savage, Jessica H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Hamilton, Robert G.; Tobian, Aaron A. R.; Ness, Paul M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Milne, Ginger L.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Borge, P. Dayand] Amer Red Cross, Baltimore, MD USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Johns Hopkins University; Vanderbilt University; American Red Cross	Savage, WJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.	wjsavage@partners.org	Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL107828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI093152] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR001079] Funding Source: Medline; NHLBI NIH HHS [R21HL107828, R21 HL107828] Funding Source: Medline; NIAID NIH HHS [K23 AI093152] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnold DM, 2007, ARCH INTERN MED, V167, P853, DOI 10.1001/archinte.167.8.853; Arshad SH, 2001, J INVEST ALLERG CLIN, V11, P94; BRANCH D R, 1979, Journal of the American Medical Association, V241, P495, DOI 10.1001/jama.241.5.495; Duffield-Lillico AJ, 2009, CANCER PREV RES, V2, P322, DOI 10.1158/1940-6207.CAPR-09-0005; Heddle NM, 2002, TRANSFUSION, V42, P556, DOI 10.1046/j.1537-2995.2002.00094.x; Morishita K, 2000, TRANSFUSION, V40, P120, DOI 10.1046/j.1537-2995.2000.40010120.x; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanders RP, 2007, TRANSFUSION, V47, P621, DOI 10.1111/j.1537-2995.2007.01163.x; SANDLER SG, 1994, BLOOD, V84, P2031; Savage WJ, 2011, TRANSFUSION, V51, P1716, DOI 10.1111/j.1537-2995.2010.03009.x; Sheikh SI, 2013, CLIN THER, V35, P1582, DOI 10.1016/j.clinthera.2013.08.009; The Trial to Reduce Alloimmunization to Platelets Study Group, 1997, N ENGL J MED, V337, P1861; VYAS GN, 1968, LANCET, V2, P312; WESTHOFF CM, 1992, TRANSFUSION, V32, P576, DOI 10.1046/j.1537-2995.1992.32692367205.x	14	25	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1772	+		10.1016/j.jaci.2014.03.030	http://dx.doi.org/10.1016/j.jaci.2014.03.030			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24794681	Green Accepted			2022-12-18	WOS:000336672500038
J	Brigida, I; Sauer, AV; Ferrua, F; Giannelli, S; Scaramuzza, S; Pistoia, V; Castiello, MC; Barendregt, BH; Cicalese, MP; Casiraghi, M; Brombin, C; Puck, J; Muller, K; Notarangelo, LD; Montin, D; van Montfrans, JM; Roncarolo, MG; Traggiai, E; van Dongen, JJM; van der Burg, M; Aiuti, A				Brigida, Immacolata; Sauer, Aisha V.; Ferrua, Francesca; Giannelli, Stefania; Scaramuzza, Samantha; Pistoia, Valentina; Castiello, Maria Carmina; Barendregt, Barbara H.; Cicalese, Maria Pia; Casiraghi, Miriam; Brombin, Chiara; Puck, Jennifer; Muller, Klaus; Notarangelo, Lucia Dora; Montin, Davide; van Montfrans, Joris M.; Roncarolo, Maria Grazia; Traggiai, Elisabetta; van Dongen, Jacques J. M.; van der Burg, Mirjam; Aiuti, Alessandro			B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gene therapy; adenosine deaminase-deficient severe combined immunodeficiency; B-cell development; antibodies	SEVERE COMBINED IMMUNODEFICIENCY; GENE-THERAPY; BONE-MARROW; IMMUNE RECONSTITUTION; ENZYME REPLACEMENT; AUTOANTIBODY PRODUCTION; REFERENCE VALUES; SCID PATIENTS; T-CELL; TRANSPLANTATION	Background: Adenosine deaminase (ADA) deficiency causes severe cellular and humoral immune defects and dysregulation because of metabolic toxicity. Alterations in B-cell development and function have been poorly studied. Enzyme replacement therapy (ERT) and hematopoietic stem cell (HSC) gene therapy (GT) are therapeutic options for patients lacking a suitable bone marrow (BM) transplant donor. Objective: We sought to study alterations in B-cell development in ADA-deficient patients and investigate the ability of ERT and HSC-GT to restore normal B-cell differentiation and function. Methods: Flow cytometry was used to characterize B-cell development in BM and the periphery. The percentage of gene-corrected B cells was measured by using quantitative PCR. B cells were assessed for their capacity to proliferate and release IgM after stimulation. Results: Despite the severe peripheral B-cell lymphopenia, patients with ADA-deficient severe combined immunodeficiency showed a partial block in central BM development. Treatment with ERT or HSC-GT reverted most BM alterations, but ERT led to immature B-cell expansion. In the periphery transitional B cells accumulated under ERT, and the defect in maturation persisted long-term. HSC-GT led to a progressive improvement in B-cell numbers and development, along with increased levels of gene correction. The strongest selective advantage for ADA-transduced cells occurred at the transition from immature to naive cells. B-cell proliferative responses and differentiation to immunoglobulin secreting IgM after B-cell receptor and Toll-like receptor triggering were severely impaired after ERT and improved significantly after HSC-GT. Conclusions: ADA-deficient patients show specific defects in B-cell development and functions that are differently corrected after ERT and HSC-GT.	[Brigida, Immacolata; Sauer, Aisha V.; Giannelli, Stefania; Scaramuzza, Samantha; Pistoia, Valentina; Castiello, Maria Carmina; Roncarolo, Maria Grazia; Aiuti, Alessandro] Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy TIGET, I-20132 Milan, Italy; [Aiuti, Alessandro] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy; [Ferrua, Francesca; Cicalese, Maria Pia; Casiraghi, Miriam] Ist Sci San Raffaele, Pediat Immunohematol & Bone Marrow Transplantat U, I-20132 Milan, Italy; [Castiello, Maria Carmina; Roncarolo, Maria Grazia] Univ Vita Salute San Raffaele, Milan, Italy; [Barendregt, Barbara H.; van Dongen, Jacques J. M.; van der Burg, Mirjam] Univ Med Ctr, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Brombin, Chiara] Univ Vita Salute San Raffaele, CUSSB, Milan, Italy; [Puck, Jennifer] Univ Calif San Francisco, Div Allergy Immunol & Bone Marrow Transplantat, Dept Pediat, San Francisco, CA 94143 USA; [Muller, Klaus] Juliane Marie Ctr, Pediat Clin, Copenhagen, Denmark; [Notarangelo, Lucia Dora] Spedali Civil Brescia, Childrens Hosp, Pediat Oncohematol & BMT Unit, I-25125 Brescia, Italy; [Montin, Davide] Univ Turin, Dept Pediat, I-10124 Turin, Italy; [van Montfrans, Joris M.] Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands; [Traggiai, Elisabetta] Novartis Inst Res Biomed, Basel, Switzerland	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Rome Tor Vergata; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Erasmus University Rotterdam; Erasmus MC; Vita-Salute San Raffaele University; University of California System; University of California San Francisco; Hospital Spedali Civili Brescia; University of Turin; Utrecht University; Utrecht University Medical Center; Novartis	Aiuti, A (corresponding author), TIGET, Via Olgettina 58, I-20132 Milan, Italy.	aiuti.alessandro@hsr.it	Müller, Klaus G/B-7241-2015; Scaramuzza, Samantha/AAN-2204-2020; Brombin, Chiara/AAB-9926-2019; Ferrua, Francesca/K-4340-2016; Castiello, Maria Carmina/K-9767-2016; AIUTI, ALESSANDRO/K-3918-2016; van Dongen, Jacques J.M./F-8537-2015	Müller, Klaus G/0000-0002-5278-1983; Scaramuzza, Samantha/0000-0003-2903-3650; Brombin, Chiara/0000-0002-8215-6206; Ferrua, Francesca/0000-0002-5695-4490; Castiello, Maria Carmina/0000-0003-2581-9648; AIUTI, ALESSANDRO/0000-0002-5398-1717; van Dongen, Jacques J.M./0000-0001-7686-0021; Brigida, Immacolata/0000-0002-0338-2230; Montin, Davide/0000-0001-8953-2182; RONCAROLO, Maria Grazia/0000-0002-2193-9186; van Dongen, Jacques J.M./0000-0002-3650-7087	Italian TELETHON foundation (TIGET Core grant A1); European Commission: Advanced Cell-based Therapies for the treatment of Primary Immuno-Deficiency [HEALTH-F5-2010-261387]; Italian Ministero della Salute [RF-2009-1485896 conv.055]; UCSF CTSI, NIH NCATS [1UL1 RR024131]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI105776, R01AI078248, N01AI030070] Funding Source: NIH RePORTER	Italian TELETHON foundation (TIGET Core grant A1)(Fondazione Telethon); European Commission: Advanced Cell-based Therapies for the treatment of Primary Immuno-Deficiency; Italian Ministero della Salute(Ministry of Health, Italy); UCSF CTSI, NIH NCATS; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Italian TELETHON foundation (TIGET Core grant A1), the European Commission: Advanced Cell-based Therapies for the treatment of Primary Immuno-Deficiency (HEALTH-F5-2010-261387, CELL-PID), and Italian Ministero della Salute (RF-2009-1485896 conv.055). J.P. acknowledges support from the UCSF CTSI, NIH NCATS 1UL1 RR024131.	Aiuti A, 2002, NAT MED, V8, P423, DOI 10.1038/nm0502-423; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Booth C, 2009, BIOL-TARGETS THER, V3, P349; Cancrini C, 2010, HAEMATOL-HEMATOL J, V95, P1778, DOI 10.3324/haematol.2010.025098; Cancro MP, 2009, NAT REV IMMUNOL, V9, P657, DOI 10.1038/nri2621; Candotti F, 2012, BLOOD, V120, P3635, DOI 10.1182/blood-2012-02-400937; Cassani B, 2010, J EXP MED, V207, P1525, DOI 10.1084/jem.20091928; Chan B, 2005, CLIN IMMUNOL, V117, P133, DOI 10.1016/j.clim.2005.07.006; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Cuss AK, 2006, J IMMUNOL, V176, P1506, DOI 10.4049/jimmunol.176.3.1506; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Ferrua F, 2010, CURR OPIN ALLERGY CL, V10, P551, DOI 10.1097/ACI.0b013e32833fea85; Gangi-Peterson L, 1999, J CLIN INVEST, V103, P833, DOI 10.1172/JCI4320; Gaspar HB, 2011, SCI TRANSL MED, V3, DOI [10.1126/scitranslmed.3002716, 10.1126/scitranslmed.3002715]; Hassan A, 2012, BLOOD, V120, P3615, DOI 10.1182/blood-2011-12-396879; Hershfield MS, 2005, EUR J IMMUNOL, V35, P25, DOI 10.1002/eji.200425738; Hirschorn R, 2006, PRIMARY IMMUNODEFICI, P169; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Kohn DB, 2008, BONE MARROW TRANSPL, V41, P199, DOI 10.1038/sj.bmt.1705895; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Malacarne F, 2005, EUR J IMMUNOL, V35, P3376, DOI 10.1002/eji.200526248; Marie-Cardine A, 2008, CLIN IMMUNOL, V127, P14, DOI 10.1016/j.clim.2007.11.013; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Noordzij JG, 2002, PEDIATR RES, V51, P159, DOI 10.1203/00006450-200202000-00007; Noordzij JG, 2002, BLOOD, V100, P2145; NOTARANGELO LD, 1992, EUR J PEDIATR, V151, P811, DOI 10.1007/BF01957930; Ozsahin H, 1997, BLOOD, V89, P2849, DOI 10.1182/blood.V89.8.2849; Pers JO, 2005, ANN NY ACAD SCI, V1050, P34, DOI 10.1196/annals.1313.004; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Sauer AV, 2012, J CLIN INVEST, V122, P2141, DOI 10.1172/JCI61788; Sauer AV, 2012, BLOOD, V119, P1428, DOI 10.1182/blood-2011-07-366781; Sauer AV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00265; Selleri S, 2011, J ALLERGY CLIN IMMUN, V127, P1368, DOI 10.1016/j.jaci.2011.03.004; Serana F, 2010, J IMMUNOL, V185, P7713, DOI 10.4049/jimmunol.1001770; Shlomchik MJ, 2008, IMMUNITY, V28, P18, DOI 10.1016/j.immuni.2007.12.004; Skimoyama RK, 1999, MOL GENET METAB, V68, P455, DOI 10.1006/mgme.1999.2937; Su TT, 2002, J IMMUNOL, V168, P2101, DOI 10.4049/jimmunol.168.5.2101; Suryani S, 2010, BLOOD, V115, P519, DOI 10.1182/blood-2009-07-234799; Tangye SG, 2006, SEMIN IMMUNOL, V18, P305, DOI 10.1016/j.smim.2006.04.004; Traggiai E, 2008, STEM CELLS, V26, P562, DOI 10.1634/stemcells.2007-0528; van Zelm MC, 2005, J IMMUNOL, V175, P5912, DOI 10.4049/jimmunol.175.9.5912; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wehr C, 2004, CLIN IMMUNOL, V113, P161, DOI 10.1016/j.clim.2004.05.010; Zhu XJ, 2009, BLOOD, V114, P5362, DOI 10.1182/blood-2009-05-217513	44	25	26	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					799	+		10.1016/j.jaci.2013.12.1043	http://dx.doi.org/10.1016/j.jaci.2013.12.1043			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24506932	Green Accepted			2022-12-18	WOS:000332397600024
J	Hilger, C; Kler, S; Arumugam, K; Revets, D; Muller, CP; Charpentier, C; Lehners, C; Morisset, M; Hentges, F				Hilger, Christiane; Kler, Stephanie; Arumugam, Karthik; Revets, Dominique; Muller, Claude P.; Charpentier, Catherine; Lehners, Christiane; Morisset, Martine; Hentges, Francois			Identification and isolation of a Fel d 1-like molecule as a major rabbit allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; cross-reactivity; Fel d 1; IgE; inhibition; lipophilin; molecular modeling; Ory c 3; rabbit; secretoglobin	CAT ALLERGEN; ENDOTOXIN EXPOSURE; SENSITIZATION; POPULATION; LIPOPHILIN; DIAGNOSIS; ANIMALS; HAIR; FORM	Background: Rabbits are increasingly kept as domestic pets. Several rabbit allergens have been characterized. However, their sequences are still elusive, and none of these molecules are available for diagnosis. Objective: We sought to isolate major allergens from the rabbit Oryctolagus cuniculus and to investigate their importance in sensitized patients. Methods: Proteins were extracted from rabbit hair, and IgE-reactive proteins were purified by using sequential chromatography. Allergens were characterized by means of N-terminal sequencing and mass spectrometry. IgE reactivity to a new allergen was analyzed in sera of 35 patients sensitized to rabbits in a domestic setting. A model of the crystal structure of the isolated proteins was constructed. Results: A new IgE-reactive allergen, Ory c 3, was identified as rabbit lipophilin. The molecule that belongs to the secretoglobin family is a heterodimer of 18 to 19 kDa composed of 2 polypeptide chains, CL2 and AL. CL2 has a predicted N-linked glycosylation site confirmed by using mass spectrometry. Of the 35 patients with rabbit allergy studied, 27 (77%) had IgE to both the glycosylated and deglycosylated Ory c 3 heterodimer. Allergenicity of Ory c 3 was confirmed by using skin prick tests and the basophil activation assay. Modeling of the structure revealed a marked homology to Fel d 1, the major cat allergen. However, no IgE cross-reactivity was detected between Fel d 1 and Ory c 3. Conclusion: The rabbit lipophilin heterodimer AL-CL2 has been identified as a major rabbit allergen. After Fel d 1, Ory c 3 is the second mammalian secretoglobin shown to be a major allergen.	[Hilger, Christiane; Kler, Stephanie; Hentges, Francois] CRP Sante, Lab Immunogenet & Allergol, L-1526 Luxembourg, Luxembourg; [Arumugam, Karthik] CRP Sante, Lab Retrovirol, L-1526 Luxembourg, Luxembourg; [Revets, Dominique; Muller, Claude P.] CRP Sante, Dept Immunol, L-1526 Luxembourg, Luxembourg; [Charpentier, Catherine] Ctr Hosp Luxembourg, Dept Pneumol, Luxembourg, Luxembourg; [Lehners, Christiane; Morisset, Martine; Hentges, Francois] Ctr Hosp Luxembourg, Natl Unit Immunol Allergol, Luxembourg, Luxembourg	Luxembourg Institute of Health; Luxembourg Institute of Health; Luxembourg Institute of Health; Luxembourg Hospital Center; Luxembourg Hospital Center	Hilger, C (corresponding author), CRP Sante, Lab Immunogenet & Allergol, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.	christiane.hilger@crp-sante.lu	; Morisset, Martine/A-3084-2017	Hilger, Christiane/0000-0001-9455-5442; Morisset, Martine/0000-0002-4028-703X	Ministry of Higher Education and Research of Luxembourg	Ministry of Higher Education and Research of Luxembourg	Supported by the Ministry of Higher Education and Research of Luxembourg.	Adedoyin J, 2007, J ALLERGY CLIN IMMUN, V119, P640, DOI 10.1016/j.jaci.2006.11.637; AOYAMA K, 1992, BRIT J IND MED, V49, P41; Azzarolo AM, 2004, COMP BIOCHEM PHYS B, V138, P111, DOI 10.1016/j.cbpc.2004.02.012; Baker J, 2001, CLIN EXP ALLERGY, V31, P303, DOI 10.1046/j.1365-2222.2001.00973.x; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Emara M, 2011, J BIOL CHEM, V286, P13033, DOI 10.1074/jbc.M111.220657; Gaffin JM, 2009, CURR OPIN ALLERGY CL, V9, P128, DOI 10.1097/ACI.0b013e32832678b0; Glasgow BJ, 2002, ADV EXP MED BIOL, V506, P573; Gronlund H, 2010, INT ARCH ALLERGY IMM, V151, P265, DOI 10.1159/000250435; Hilger C, 2011, CLIN EXP ALLERGY, V41, P899, DOI 10.1111/j.1365-2222.2011.03726.x; Hilger C, 2012, CURR ALLERGY ASTHM R, V12, P438, DOI 10.1007/s11882-012-0283-2; Hilger C, 2012, J ALLERGY CLIN IMMUN, V129, P1149, DOI 10.1016/j.jaci.2011.10.017; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; Kaiser L, 2007, J MOL BIOL, V370, P714, DOI 10.1016/j.jmb.2007.04.074; Lehrer RI, 2000, ANN NY ACAD SCI, V923, P59; Liccardi G, 2011, ALLERGY, V66, P1500, DOI 10.1111/j.1398-9995.2011.02675.x; Caballero ML, 2012, ANN ALLERG ASTHMA IM, V108, P178, DOI 10.1016/j.anai.2012.01.007; MORIZE I, 1987, J MOL BIOL, V194, P725, DOI 10.1016/0022-2836(87)90250-6; Noss I, 2008, APPL ENVIRON MICROB, V74, P5621, DOI 10.1128/AEM.00619-08; Phillips JF, 2009, J ALLERGY CLIN IMMUN, V123, P513, DOI 10.1016/j.jaci.2008.09.019; PRICE JA, 1988, ALLERGY, V43, P39, DOI 10.1111/j.1398-9995.1988.tb02042.x; Prodhomme EJF, 2010, J PROTEOME RES, V9, P5598, DOI 10.1021/pr100407w; Reininger R, 2007, CLIN EXP ALLERGY, V37, P116, DOI 10.1111/j.1365-2222.2006.02611.x; Remington SG, 2008, INVEST OPHTH VIS SCI, V49, P2856, DOI 10.1167/iovs.07-1496; Renstrom A, 2011, ALLERGY, V66, P1081, DOI 10.1111/j.1398-9995.2011.02591.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salo PM, 2009, J ALLERGY CLIN IMMUN, V124, P185, DOI 10.1016/j.jaci.2009.05.012; Samadi S, 2010, OCCUP ENVIRON MED, V67, P486, DOI 10.1136/oem.2009.051342; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; Virtanen Tuomas, 2008, Clin Allergy Immunol, V21, P201; Vredegoor DW, 2012, J ALLERGY CLIN IMMUN, V130, P904, DOI 10.1016/j.jaci.2012.05.013; WARNER JA, 1991, ALLERGY, V46, P481, DOI 10.1111/j.1398-9995.1991.tb00610.x; Zahradnik E, 2011, INT ARCH ALLERGY IMM, V155, P225, DOI 10.1159/000319839	33	25	25	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					759	766		10.1016/j.jaci.2013.04.034	http://dx.doi.org/10.1016/j.jaci.2013.04.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	23763973				2022-12-18	WOS:000332397600018
J	Wysocki, K; Park, SY; Bleecker, E; Busse, W; Castro, M; Chung, KF; Gaston, B; Erzurum, S; Israel, E; Teague, WG; Moore, CG; Wenzel, S				Wysocki, Kenneth; Park, Seo Young; Bleecker, Eugene; Busse, William; Castro, Mario; Chung, Kian Fan; Gaston, Benjamin; Erzurum, Serpil; Israel, Elliot; Teague, W. Gerald; Moore, Charity G.; Wenzel, Sally			Characterization of factors associated with systemic corticosteroid use in severe asthma: Data from the Severe Asthma Research Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NITRIC-OXIDE; INFLAMMATION		[Wysocki, Kenneth; Park, Seo Young; Moore, Charity G.; Wenzel, Sally] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Bleecker, Eugene] Wake Forest Univ, Winston Salem, NC 27109 USA; [Busse, William] Univ Wisconsin, Madison, WI USA; [Castro, Mario] Washington Univ, St Louis, MO USA; [Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, London, England; [Gaston, Benjamin] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Erzurum, Serpil] Cleveland Clin, Cleveland, OH 44106 USA; [Israel, Elliot] Brigham & Womens Hosp, Boston, MA 02115 USA; [Teague, W. Gerald] Univ Virginia, Charlottesville, VA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Imperial College London; Case Western Reserve University; Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; University of Virginia	Wysocki, K (corresponding author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.	wenzelse@upmc.edu	Chung, Kian Fan/I-8456-2019; Wysocki, Kenneth/AAO-9523-2020; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Wenzel, Sally/0000-0002-4242-0164; Patterson, Charity/0000-0002-0060-0124	NCATS NIH HHS [UL1 TR000448, UL1 TR000427, UL1 TR000454, KL2 TR000455, UL1 TR000005, UL1 TR000439] Funding Source: Medline; NCRR NIH HHS [M01 RR02635, M01 RR03186, KL2RR025009, 1 UL1RR024992, 1UL1RR024153, 1 UL1RR025008, UL1 RR024153, M01 RR007122-14, UL1 RR025011, 1UL1RR025011, 1 UL1RR024989, UL1 RR024992] Funding Source: Medline; NHLBI NIH HHS [U10 HL109250, HL69155, HL69167, R01 HL069170, U10 HL109257, R01 HL069174, HL69116, HL69174, HL69170, R01 HL069167, HL091762, HL69130, HL69349] Funding Source: Medline; NINR NIH HHS [T32NR009759, T32 NR009759] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000455, UL1TR000448, UL1TR000005, UL1TR000427, UL1TR000439, UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153, UL1RR025011, UL1RR025008, KL2RR025009, M01RR007122, M01RR002635, M01RR003186, UL1RR024992, UL1RR024989] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069155, R01HL069349, R01HL069116, R01HL069170, R01HL091762, R01HL069130, U10HL109257, R01HL069167, R01HL069174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [T32NR009759] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Alfarano C, 2005, NUCLEIC ACIDS RES, V33, pD418, DOI 10.1093/nar/gki051; Chung KF, 2012, CURR OPIN PULM MED, V18, P35, DOI 10.1097/MCP.0b013e32834d09a5; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Yamamoto M, 2012, CLIN EXP ALLERGY, V42, P760, DOI 10.1111/j.1365-2222.2011.03860.x; Yeh KH, 2011, J ASTHMA, V48, P546, DOI 10.3109/02770903.2011.581733	9	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					915	918		10.1016/j.jaci.2013.10.031	http://dx.doi.org/10.1016/j.jaci.2013.10.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24332222	Green Accepted			2022-12-18	WOS:000332397600047
J	Seshadri, S; Rosati, M; Lin, DC; Carter, RG; Norton, JE; Choi, AW; Suh, L; Kato, A; Chandra, RK; Harris, KE; Chu, HW; Peters, AT; Tan, BK; Conley, DB; Grammer, LC; Kern, RC; Schleimer, RP				Seshadri, Sudarshan; Rosati, Mariel; Lin, David C.; Carter, Roderick G.; Norton, James E.; Choi, Andrew Wonho; Suh, Lydia; Kato, Atsushi; Chandra, Rakesh K.; Harris, Kathleen E.; Chu, Hong Wei; Peters, Anju T.; Tan, Bruce K.; Conley, David B.; Grammer, Leslie C.; Kern, Robert C.; Schleimer, Robert P.			Regional differences in the expression of innate host defense molecules in sinonasal mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC RHINOSINUSITIS; PARANASAL SINUSES; EPITHELIAL-CELLS; INFLAMMATION; IMMUNITY		[Seshadri, Sudarshan; Rosati, Mariel; Lin, David C.; Carter, Roderick G.; Norton, James E.; Choi, Andrew Wonho; Suh, Lydia; Kato, Atsushi; Harris, Kathleen E.; Peters, Anju T.; Grammer, Leslie C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Chandra, Rakesh K.; Tan, Bruce K.; Conley, David B.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA; [Chu, Hong Wei] Natl Jewish Hlth, Dept Med, Denver, CO USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; National Jewish Health	Seshadri, S (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu	Seshadri, Sudarshan/J-5544-2016	Seshadri, Sudarshan/0000-0003-4910-8664; Chandra, Rakesh/0000-0002-3612-0026; Grammer, Leslie/0000-0001-6860-2014; Kato, Atsushi/0000-0001-9144-3138	NHLBI NIH HHS [R01 HL 078860, R37 HL068546, R01 HL078860] Funding Source: Medline; NIAID NIH HHS [P01 AI106683, R01 AI072570] Funding Source: Medline; NIDCD NIH HHS [K23DC012067] Funding Source: Medline; PHS HHS [R37 GK068546] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570, P01AI106683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Avila PC, 2008, ALLERGY ALLERGIC DIS; Baines KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018426; Chu HW, 2007, J IMMUNOL, V179, P3995, DOI 10.4049/jimmunol.179.6.3995; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Laudien M, 2011, RHINOLOGY, V49, P107, DOI 10.4193/Rhino10.036; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; McGillivary G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013224; Ooi EH, 2008, AM J RHINOL, V22, P13, DOI 10.2500/ajr.2008.22.3127; Ramanathan M, 2008, AM J RHINOL, V22, P115, DOI 10.2500/ajr.2008.22.3136; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045	11	25	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1227	1230		10.1016/j.jaci.2013.05.042	http://dx.doi.org/10.1016/j.jaci.2013.05.042			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23895899	Green Accepted			2022-12-18	WOS:000326235600030
J	Mintz-Cole, RA; Brandt, EB; Bass, SA; Gibson, AM; Reponen, T; Hershey, GKK				Mintz-Cole, Rachael A.; Brandt, Eric B.; Bass, Stacey A.; Gibson, Aaron M.; Reponen, Tiina; Hershey, Gurjit K. Khurana			Surface availability of beta-glucans is critical determinant of host immune response to Cladosporium cladosporioides	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mold; Cladosporium cladosporioides; beta-glucans; asthma; Dectin-1	CHRONIC MUCOCUTANEOUS CANDIDIASIS; HYPER-IGE SYNDROME; FUNGAL-INFECTION; ASPERGILLUS-FUMIGATUS; DENDRITIC CELLS; MOLD EXPOSURE; DECTIN-1; ASTHMA; RECOGNITION; RECEPTOR	Background: It is well accepted that mold exposure is a major contributor to the development of asthma, and beta-glucans are often used as a surrogate for mold exposure in the environment. Beta-glucans are an important component of mold spores and are recognized by the immune system by their receptor, Dectin-1. Cladosporium cladosporioides spores have a high beta-glucan content, but the beta-glucans are not available on the surface of live spores. Objective: We sought to determine whether altering the exposure of beta-glucans in C cladosporioides through heat killing could alter the immune response through binding to Dectin-1. Methods: In a murine model of mold-induced asthma, mice were repeatedly exposed to either live or heat-killed C cladosporioides and the phenotype was determined by the measurement of airway hyperresponsiveness, airway inflammation, and cytokine production. Pro-inflammatory cytokines from dendritic cells were measured by using quantitative PCR and ELISA. Results: Live C cladosporioides induced robust airway hyperresponsiveness, eosinophilia, and a predominately T(H)2 response, while heat-killed C cladosporioides induceda strong T(H)17 response and neutrophilic inflammation, but very mild airway hyperresponsiveness. Heat killing of C cladosporioides spores effectively exposed beta-glucans on the surface of the spores and increased binding to Dectin-1. In the absence of Dectin-1, heat-killed spores induced a predominantly T(H)2 response analogous to live spores. Furthermore, the production of T(H)17-skewing IL-6, IL-23, and TNF-alpha by dendritic cells in response to heat-killed C cladosporioides was dependent onDectin-1. Conclusions: The host immune response to C cladosporioides is dependent on the surface availability of beta-glucans rather than the total beta-glucan content.	[Mintz-Cole, Rachael A.; Brandt, Eric B.; Bass, Stacey A.; Gibson, Aaron M.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA; [Reponen, Tiina] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org		Brandt, Eric/0000-0003-0617-4100; Khurana Hershey, Gurjit/0000-0001-6663-977X	NIAID [2U19AI70235-06]; NHBLI [F30 HL103087]; NIEHS [T32 E5010956]; Centers for Disease Control and Prevention; National Institutes of Health; US HUD; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL103087, R01HL097135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971, P30DK078392] Funding Source: NIH RePORTER	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHBLI; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US HUD; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIAID grant no. 2U19AI70235-06 (to G.K.K.H.), NHBLI grant no. F30 HL103087 (to R.A.M.C.), and NIEHS grant no. T32 E5010956 (to E.B.B.).; Disclosure of potential conflict of interest: R. A. Mintz-Cole has been supported by a Ruth L. Kirschstein NRSA Individual Fellowship. T. Reponen has received one or more grants from or has one or more grants pending with the US HUD (contract from the Centers for Disease Control and Prevention). G. K. Khurana Hershey has received one or more grants from or has one or more grants pending with the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Aimanianda V, 2009, NATURE, V460, P1117, DOI 10.1038/nature08264; Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Beijer L, 2003, EUR RESPIR J, V21, P317, DOI 10.1183/09031936.03.00283603; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Cunha C, 2010, BLOOD, V116, P5394, DOI 10.1182/blood-2010-04-279307; Dennehy KM, 2009, EUR J IMMUNOL, V39, P1379, DOI 10.1002/eji.200838543; Douwes J, 2005, INDOOR AIR, V15, P160, DOI 10.1111/j.1600-0668.2005.00333.x; Eduard W, 2009, CRIT REV TOXICOL, V39, P799, DOI 10.3109/10408440903307333; Fei MJ, 2011, P NATL ACAD SCI USA, V108, P5360, DOI 10.1073/pnas.1015476108; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Fuller GLJ, 2007, J BIOL CHEM, V282, P12397, DOI 10.1074/jbc.M609558200; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Gehring U, 2001, ENVIRON HEALTH PERSP, V109, P139, DOI 10.2307/3434766; Goodridge HS, 2009, J IMMUNOL, V182, P1146, DOI 10.4049/jimmunol.182.2.1146; Gow NAR, 2007, J INFECT DIS, V196, P1565, DOI 10.1086/523110; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hohl TM, 2005, PLOS PATHOG, V1, P232, DOI 10.1371/journal.ppat.0010030; Hu W, 2011, IMMUNITY, V35, P1010, DOI 10.1016/j.immuni.2011.10.013; Iossifova Y, 2008, INDOOR AIR, V18, P225, DOI 10.1111/j.1600-0668.2008.00526.x; Iossifova Y, 2008, OPEN ALLERGY J, V1, P26; Iossifova YY, 2009, ANN ALLERG ASTHMA IM, V102, P131, DOI 10.1016/S1081-1206(10)60243-8; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Lewkowich IP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003879; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mintz-Cole RA, 2012, J IMMUNOL, V189, P3609, DOI 10.4049/jimmunol.1200589; O'Driscoll B Ronan, 2005, BMC Pulm Med, V5, P4, DOI 10.1186/1471-2466-5-4; Osorio F, 2008, EUR J IMMUNOL, V38, P3274, DOI 10.1002/eji.200838950; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Rivera A, 2005, INFECT IMMUN, V73, P7170, DOI 10.1128/IAI.73.11.7170-7179.2005; Saijo S, 2007, NAT IMMUNOL, V8, P39, DOI 10.1038/ni1425; Sivaprasad U, 2011, J ALLERGY CLIN IMMUN, V127, P254, DOI 10.1016/j.jaci.2010.10.009; Steele C, 2005, PLOS PATHOG, V1, P323, DOI 10.1371/journal.ppat.0010042; Tassi I, 2009, EUR J IMMUNOL, V39, P1369, DOI 10.1002/eji.200839313; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Tischer C, 2011, EUR RESPIR J, V38, P812, DOI 10.1183/09031936.00184010; Werner JL, 2011, INFECT IMMUN, V79, P3966, DOI 10.1128/IAI.05493-11; Werner JL, 2009, J IMMUNOL, V182, P4938, DOI 10.4049/jimmunol.0804250	43	25	25	1	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					159	U266		10.1016/j.jaci.2013.01.003	http://dx.doi.org/10.1016/j.jaci.2013.01.003			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23403046	Green Accepted			2022-12-18	WOS:000321052300021
J	Roussel, L; Farias, R; Rousseau, S				Roussel, Lucie; Farias, Raquel; Rousseau, Simon			IL-33 is expressed in epithelia from patients with cystic fibrosis and potentiates neutrophil recruitment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Roussel, Lucie; Farias, Raquel; Rousseau, Simon] McGill Univ, Meakins Christie Labs, Heath Ctr, Res Inst, Montreal, PQ, Canada	McGill University	Roussel, L (corresponding author), McGill Univ, Meakins Christie Labs, Heath Ctr, Res Inst, Montreal, PQ, Canada.	simon.rousseau@mcgill.ca	Farias, Raquel/ABB-7985-2020	Farias, Raquel/0000-0003-1729-2997; Rousseau, Simon/0000-0002-8773-575X				Alves JC, 2010, NAT MED, V16, P708, DOI 10.1038/nm.2156; Berube J, 2010, J BIOL CHEM, V285, P22299, DOI 10.1074/jbc.M109.098566; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Palmer G, 2011, NAT REV RHEUMATOL, V7, P321, DOI 10.1038/nrrheum.2011.53; Rowe SM, 2008, AM J RESP CRIT CARE, V178, P822, DOI 10.1164/rccm.200712-1894OC; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Trinh NT, 2012, EUR RESP J	9	25	25	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					913	916		10.1016/j.jaci.2012.10.019	http://dx.doi.org/10.1016/j.jaci.2012.10.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23219168				2022-12-18	WOS:000315587800040
J	Penton, PC; Wang, XM; Amatullah, H; Cooper, J; Godri, K; North, ML; Khanna, N; Scott, JA; Chow, CW				Penton, Patricia Castellanos; Wang, Xiaomin; Amatullah, Hajera; Cooper, Josephine; Godri, Krystal; North, Michelle L.; Khanna, Nivedita; Scott, Jeremy A.; Chow, Chung-Wai			Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airways hyperresponsiveness; Syk; asthma; pollution; mouse	EPITHELIAL-CELLS; ELEMENTARY SCHOOLCHILDREN; ALLERGIC RHINITIS; BRONCHIAL-ASTHMA; MURINE MODEL; SYK-KINASE; ARGINASE 1; INFLAMMATION; ACTIVATION; EXPRESSION	Background: Asthma is a chronic inflammatory disease characterized by airways hyperresponsiveness (AHR), reversible airflow obstruction, airway remodeling, and episodic exacerbations caused by air pollutants, such as particulate matter (PM; PM <2.5 mu m in diameter [PM2.5]) and ozone (O-3). Spleen tyrosine kinase (Syk), an immunoregulatory kinase, has been implicated in the pathogenesis of asthma. Objective: We sought to evaluate the effect of Syk inhibition on AHR in a chronic mouse model of allergic airways inflammation and pollutant exposure. Methods: We used a 12-week chronic ovalbumin (OVA) sensitization and challenge mouse model of airways inflammation followed by exposure to PM2.5 plus O-3. Respiratory mechanics and methacholine (MCh) responsiveness were assessed by using the flexiVent system. The Syk inhibitor NVP-QAB-205 was nebulized intratracheally by using a treatment-based protocol 15 minutes before assessment of MCh responsiveness. Results: Syk expression increased significantly in the airway epithelia of OVA-sensitized and OVA-challenged (OVA/OVA) mice compared with OVA-sensitized but PBS-challenged (OVA/PBS) control mice. OVA/OVA mice exhibited AHR to MCh, which was attenuated by a single administration of NVP-QAB-205 (0.3 and 3 mg/kg). PM2.5 plus O-3 significantly augmented AHR to MCh in the OVA/OVA mice, which was abrogated by NVP-QAB-205. Total inflammatory cell counts were significantly higher in the bronchoalveolar lavage fluid from OVA/OVA than OVA/PBS mice and were unaffected by PM2.5 plus O-3 or NVP-QAB-205. Conclusion: NVP-QAB-205 reduced AHR and the enhanced response to PM2.5 plus O-3 to normal levels in an established model of chronic allergic airways inflammation, suggesting that Syk inhibitors have promise as a therapy for asthma. (J Allergy Clin Immunol 2013;131:512-20.)	[Penton, Patricia Castellanos; Wang, Xiaomin; North, Michelle L.; Khanna, Nivedita; Chow, Chung-Wai] Univ Toronto, Fac Med, Dept Med, Div Respirol, Toronto, ON M5G 1L7, Canada; [Amatullah, Hajera; North, Michelle L.; Khanna, Nivedita] Univ Toronto, Fac Med, Dalla Lana Sch Publ Hlth, Div Occupat & Environm Hlth, Toronto, ON M5G 1L7, Canada; [Amatullah, Hajera; North, Michelle L.; Khanna, Nivedita] Univ Toronto, Gage Occupat & Environm Hlth Unit, Toronto, ON M5G 1L7, Canada; [Cooper, Josephine; Godri, Krystal; Chow, Chung-Wai] Univ Toronto, Fac Sci Appl, So Ontario Ctr Atmospher Aerosol Res, Toronto, ON M5G 1L7, Canada; [Scott, Jeremy A.] Lakehead Univ, Dept Hlth Sci, Thunder Bay, ON P7B 5E1, Canada; [Chow, Chung-Wai] Univ Hlth Network, Multiorgan Transplant Programme, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Lakehead University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Chow, CW (corresponding author), Univ Toronto, Univ Hlth Network, 101 Coll St,TMDT 2-406, Toronto, ON M5G 1L7, Canada.	cw.chow@utoronto.ca	Scott, Jeremy A/D-2965-2009; Chow, Chung-Wai/AAP-5533-2020; North, Michelle/C-3164-2014	Scott, Jeremy A/0000-0002-7513-6768; Chow, Chung-Wai/0000-0001-9344-8522; Godri Pollitt, Krystal/0000-0001-7332-2228; North, Michelle/0000-0003-3565-6387	GlaxoSmithKline Collaborative and Innovative Research Fund; Ontario Graduate Scholarship in Science and Technology; Canada Graduate Scholarship-Doctoral Award	GlaxoSmithKline Collaborative and Innovative Research Fund; Ontario Graduate Scholarship in Science and Technology; Canada Graduate Scholarship-Doctoral Award	Supported by the GlaxoSmithKline Collaborative and Innovative Research Fund, an Ontario Graduate Scholarship in Science and Technology (to P. C. P.), and a Canada Graduate Scholarship-Doctoral Award (to M.L.N.).	Akhtar US, 2010, INHAL TOXICOL, V22, P37, DOI 10.3109/08958378.2010.518377; Akhtar US, 2010, ENVIRON SCI ENG, P427, DOI 10.1007/978-3-642-12278-1_22; Baraldo S, 2011, EUR RESPIR J, V38, P575, DOI 10.1183/09031936.00168210; Barnes PJ, 2010, TRENDS PHARMACOL SCI, V31, P335, DOI 10.1016/j.tips.2010.04.009; Carlsten C, 2011, OCCUP ENVIRON MED, V68, P291, DOI 10.1136/oem.2010.055152; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Dales R, 2009, EUR RESPIR J, V34, P316, DOI 10.1183/09031936.00138908; Dales R, 2008, ENVIRON HEALTH PERSP, V116, P1423, DOI 10.1289/ehp.10943; Dales R, 2009, J OCCUP ENVIRON MED, V51, P654, DOI 10.1097/JOM.0b013e3181a0363c; Duta F, 2006, HISTOCHEM CELL BIOL, V126, P495, DOI 10.1007/s00418-006-0188-z; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Halwani R, 2010, CURR OPIN PHARMACOL, V10, P236, DOI 10.1016/j.coph.2010.06.004; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168, DOI 10.1152/jappl.1992.72.1.168; Hayer J, 2002, DRUGS FUTURE, V27, P280; He JQ, 2008, EUR RESPIR J, V32, P755, DOI 10.1183/09031936.00129107; Hirota JA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-120; Ilies M, 2010, J MED CHEM, V53, P4266, DOI 10.1021/jm100306a; Jackson DJ, 2010, J ALLERGY CLIN IMMUN, V125, P1178, DOI 10.1016/j.jaci.2010.04.021; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Lau C, 2008, J IMMUNOL, V180, P870, DOI 10.4049/jimmunol.180.2.870; Lau C, 2011, PROTEIN PEPTIDE LETT, V18, P518, DOI 10.2174/092986611794927910; Liu L, 2009, ENVIRON HEALTH PERSP, V117, P668, DOI 10.1289/ehp11813; Locke NR, 2007, AM J RESP CELL MOL, V36, P625, DOI 10.1165/rcmb.2006-0083OC; Masuda ES, 2008, PULM PHARMACOL THER, V21, P461, DOI 10.1016/j.pupt.2007.06.002; Matsubara S, 2006, AM J RESP CELL MOL, V34, P426, DOI 10.1165/rcmb.2005-0298OC; Matsubara S, 2006, AM J RESP CRIT CARE, V173, P56, DOI 10.1164/rccm.200503-361OC; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Moore WJ, 2010, EXPERT OPIN THER PAT, V20, P1703, DOI 10.1517/13543776.2010.534459; Murphy DM, 2010, CHEST, V137, P1417, DOI 10.1378/chest.09-1895; North ML, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-19; North ML, 2009, AM J PHYSIOL-LUNG C, V296, pL911, DOI 10.1152/ajplung.00025.2009; Penard-Morand C, 2010, EUR RESPIR J, V36, P33, DOI 10.1183/09031936.00116109; Plant PJ, 2012, AM J RESP CELL MOL, V46, P532, DOI 10.1165/rcmb.2011-0293OC; Pohunek P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/j.1399-3038.2005.00239.x; Proud D, 2006, AM J RESP CELL MOL, V35, P513, DOI 10.1165/rcmb.2006-0199TR; Riccaboni M, 2010, DRUG DISCOV TODAY, V15, P517, DOI 10.1016/j.drudis.2010.05.001; Roche WR, 1998, AM J RESP CRIT CARE, V157, pS191, DOI 10.1164/ajrccm.157.5.rsaa-5; Ruzza P, 2009, EXPERT OPIN THER PAT, V19, P1361, DOI 10.1517/13543770903207039; Stenton GR, 2002, J IMMUNOL, V169, P1028, DOI 10.4049/jimmunol.169.2.1028; Stenton GR, 2000, J IMMUNOL, V164, P3790, DOI 10.4049/jimmunol.164.7.3790; Thomson Errol M, 2009, Inhal Toxicol, V21 Suppl 1, P74, DOI 10.1080/08958370902962309; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; Wang XM, 2006, J IMMUNOL, V177, P6859, DOI 10.4049/jimmunol.177.10.6859; Wang XM, 2012, J PHARMACOL EXP THER, V340, P277, DOI 10.1124/jpet.111.186429; Weinblatt ME, 2010, NEW ENGL J MED, V363, P1303, DOI 10.1056/NEJMoa1000500	47	25	27	0	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					512	+		10.1016/j.jaci.2012.07.039	http://dx.doi.org/10.1016/j.jaci.2012.07.039			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22981792	Bronze			2022-12-18	WOS:000314661500031
J	Shemer, A; Cardinale, I; Krueger, JG; Guttman-Yassky, E				Shemer, Avner; Cardinale, Irma; Krueger, James G.; Guttman-Yassky, Emma			Residual genomic signature of atopic dermatitis despite clinical resolution with narrowband UVB	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SKIN		[Cardinale, Irma; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10021 USA; Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10021 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; [Shemer, Avner] Tel Hashomer Hosp, Dept Dermatol, Tel Aviv, Israel; [Shemer, Avner] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Guttman-Yassky, Emma] Mt Sinai Sch Med, Dept Dermatol, New York, NY USA	Rockefeller University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Tel Aviv University; Icahn School of Medicine at Mount Sinai	Shemer, A (corresponding author), Tel Hashomer Hosp, Dept Dermatol, Tel Aviv, Israel.	eguttman@rockefeller.edu			NCRR NIH HHS [UL1 RR024143, 5UL1RR024143-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Balato N, 2011, DERMATITIS, V22, P320, DOI 10.2310/6620.2011.11038; Behshad R, 2008, ARCH DERMATOL, V144, P84, DOI 10.1001/archdermatol.2007.22; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Hino R, 2007, BRIT J DERMATOL, V156, P830, DOI 10.1111/j.1365-2133.2007.07774.x; Jung K, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Jung K, 2011, J ALLERGY CLIN IMMUN, V127, P420, DOI 10.1016/j.jaci.2010.10.043; Rico L, 2005, ENDOCRINOLOGY, V146, P4167, DOI 10.1210/en.2005-0156; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Suarez-Farinas M, 2011, J INVEST DERMATOL, V131, P391, DOI 10.1038/jid.2010.280; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Verkman AS, 2009, J EXP BIOL, V212, P1707, DOI 10.1242/jeb.024125	12	25	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					577	579		10.1016/j.jaci.2012.11.010	http://dx.doi.org/10.1016/j.jaci.2012.11.010			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23265860				2022-12-18	WOS:000314661500038
J	Geroldinger-Simic, M; Kinaciyan, T; Nagl, B; Baumgartner-Durchschlag, U; Huber, H; Ebner, C; Lidholm, J; Bartel, D; Vieths, S; Jahn-Schmid, B; Bohle, B				Geroldinger-Simic, Marija; Kinaciyan, Tamar; Nagl, Birgit; Baumgartner-Durchschlag, Ursula; Huber, Hans; Ebner, Christof; Lidholm, Jonas; Bartel, Detlef; Vieths, Stefan; Jahn-Schmid, Beatrice; Bohle, Barbara			Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birch pollen allergy; food allergy; oral allergy syndrome; Bet v 1; Mal d 1; IgE; T cells	BET V 1; T-CELL RESPONSES; FOOD ALLERGENS; SUBLINGUAL IMMUNOTHERAPY; CROSS-REACTIVITY; MAJOR ALLERGEN; APPLE ALLERGEN; BET-V-1; SENSITIZATION; INDIVIDUALS	Background: Antibodies and T cells specific for the major birch pollen allergen Bet v 1 cross-react with structurally related food allergens, such as Mal d 1 in apple. Objective: We sought to evaluate the effects of oral uptake of Mal d 1 on the allergen-specific immune response in patients with birch pollen allergy. Methods: Patients received 50 mu g of rBet v 1 sublingually on 2 consecutive days outside of the birch pollen season. One year later, equal amounts of rMal d 1 were administered. Blood samples were collected before and after oral exposure, as well as before and after the intermediate birch pollen season. Allergen-specific IgE levels were determined by using ImmunoCAP. Proliferation of allergen-stimulated PBMCs was assessed, as well as the expression of IL-5, IL-13, IL-10, IFN-gamma, and forkhead box protein 3 (Foxp3) in isolated T cells (real-time PCR). Allergen-specific T-cell lines were analyzed for epitope recognition. Results: Orally administered Bet v 1 transiently reduced Bet v 1-specific serum IgE levels, as well as Bet v 1- and Mal d 1-induced T-cell proliferation, and enhanced the expression of IL-5, IL-10, and Foxp3. Orally applied Mal d 1 significantly decreased Bet v 1- and Mal d 1-specific IgE levels and induced IL-5 and IL-10 but no Foxp3 expression. In contrast to Bet v 1, Mal d 1 triggered IFN-gamma production and T cells with a different epitope repertoire. Inhalation of birch pollen significantly enhanced allergen-specific IgE levels, T-cell proliferation, and IL-5, IL-10, IL-13, and Foxp3 expression. Conclusion: Two sublingual administrations of 50 mu g of Mal d 1 were well tolerated and induced transient immune responses seen during peripheral tolerance development. Thus recombinant Mal d 1 might be suitable and relevant for sublingual treatment of birch pollen-related apple allergy. (J Allergy Clin Immunol 2013;131:94-102.)	[Geroldinger-Simic, Marija; Nagl, Birgit; Jahn-Schmid, Beatrice; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria; [Kinaciyan, Tamar] Med Univ Vienna, Dept Dermatol, DIAID, A-1090 Vienna, Austria; [Baumgartner-Durchschlag, Ursula; Huber, Hans] Biomay AG, Vienna, Austria; [Ebner, Christof] Allergy Clin Reumannpl, Vienna, Austria; [Lidholm, Jonas] Thermo Fisher Sci, Uppsala, Sweden; [Bartel, Detlef; Vieths, Stefan] Paul Ehrlich Inst, Div Allergol, Langen, Germany; [Bohle, Barbara] Med Univ Vienna, Christian Doppler Lab Immunomodulat, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Thermo Fisher Scientific; Paul Ehrlich Institute; Medical University of Vienna	Bohle, B (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Waehringer Guertel 18-20,AKH 3Q, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at		Lidholm, Jonas/0000-0002-7779-3411; Bohle, Barbara/0000-0002-5105-7985; Kinaciyan, Tamar/0000-0002-8238-2561	Austrian Science Fund [SFB-F1807-B13]; Christian Doppler Research Association; Biomay AG, Vienna, Austria; Monsanto Company; Pioneer Hi-Bred International; Austrian National Bank; Austrian Science Foundation; Austrian Science Fund; Christian Doppler Laboratory; Schattauer Allergologie Handbuch; Elsevier Nahrungsmittelallergie und Intoleranzen	Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association; Biomay AG, Vienna, Austria; Monsanto Company; Pioneer Hi-Bred International; Austrian National Bank; Austrian Science Foundation(Austrian Science Fund (FWF)); Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Laboratory; Schattauer Allergologie Handbuch; Elsevier Nahrungsmittelallergie und Intoleranzen	Supported by the Austrian Science Fund, project SFB-F1807-B13; the Christian Doppler Research Association; and Biomay AG, Vienna, Austria.; H. Huber is employed by Biomay AG. J. Lidholm is employed by Thermo Fischer Scientific. S. Vieths has consultant arrangements with the Food Allergy Resource and Research Program, the Institute for Product Quality, and Fresenius Academy; is employed by Johann Wolfgang Goethe-Universitat; has provided expert testimony for the Medical University of Vienna; has received grants from Monsanto Company and Pioneer Hi-Bred International; has received payment for lectures from Deutsche Dermatologische Gesellschaft, the Spanish Society of Allergy and Clinical Immunology, Westdeutsche Arbeitsgemeinschaft fur Padiatrische Pneumologie and Allergologie e. V., Gesellschaft fur Padiatrische Allergologie und Umweltmedizin, and the American Academy of Asthma, Allergy & Immunology; has received royalties from Schattauer Allergologie Handbuch and Elsevier Nahrungsmittelallergie und Intoleranzen; and has received travel expenses from the German Research Foundation, the Federal Institute for Risk Assessment, the Austrian Society for Allergology and Immunology, the French Society of Allergology, the European Directorate for the Quality of Medicines and Health Care, the European Academy of Allergy and Clinical Immunology, the World Allergy Organization, the Technical University of Munich, Deutscher Allergie und Asthmabund, Association Monegasque pour le Perfectionnement des Connaissances des Medecins, and the Federal Office of Consumer Protection and Food Safety. B. Jahn-Schmid receives research support from the Austrian National Bank and the Austrian Science Foundation. B. Bohle receives research support from the Austrian Science Fund and the Christian Doppler Laboratory. The rest of the authors declare that they have no relevant conflicts of interest.	Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bohle B, 2006, J ALLERGY CLIN IMMUN, V118, P242, DOI 10.1016/j.jaci.2006.03.011; CRIMI E, 1990, J ALLERGY CLIN IMMUN, V85, P1014, DOI 10.1016/0091-6749(90)90045-6; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Gabrielsson S, 1998, SCAND J IMMUNOL, V48, P429; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Grindebacke H, 2009, J CLIN IMMUNOL, V29, P752, DOI 10.1007/s10875-009-9312-x; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; Klinglmayr E, 2009, ALLERGY, V64, P647, DOI 10.1111/j.1398-9995.2008.01844.x; Kopac P, 2012, ALLERGY, V67, P280, DOI 10.1111/j.1398-9995.2011.02744.x; LOFKVIST T, 1994, ALLERGY, V49, P100, DOI 10.1111/j.1398-9995.1994.tb00808.x; Matthes A, 2009, J AGR FOOD CHEM, V57, P10548, DOI 10.1021/jf901938q; Mauro M, 2011, INT ARCH ALLERGY IMM, V156, P416, DOI 10.1159/000323909; Mittag D, 2006, MOL IMMUNOL, V43, P268, DOI 10.1016/j.molimm.2005.02.008; Mothes-Luksch N, 2006, 25 C EUR AC ALL CLIN, P294; Mutschlechner S, 2010, J ALLERGY CLIN IMMUN, V125, P711, DOI 10.1016/j.jaci.2009.10.052; Radauer C, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-286; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Sancho AI, 2006, J AGR FOOD CHEM, V54, P5917, DOI 10.1021/jf060880m; Schimek EM, 2005, J ALLERGY CLIN IMMUN, V116, P1327, DOI 10.1016/j.jaci.2005.09.007; Schulten V, 2011, MOL NUTR FOOD RES, V55, P1484, DOI 10.1002/mnfr.201100234; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Wosinska-Becler K, 2004, CLIN EXP ALLERGY, V34, P123, DOI 10.1111/j.1365-2222.2004.01850.x	32	25	25	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					94	102		10.1016/j.jaci.2012.06.039	http://dx.doi.org/10.1016/j.jaci.2012.06.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	22921871				2022-12-18	WOS:000312961200011
J	Kreiner-Moller, E; Sevelsted, A; Vissing, NH; Schoos, AMM; Bisgaard, H				Kreiner-Moller, Eskil; Sevelsted, Astrid; Vissing, Nadja Hawwa; Schoos, Ann-Marie Malby; Bisgaard, Hans			Infant acetaminophen use associates with early asthmatic symptoms independently of respiratory tract infections: The Copenhagen Prospective Study on Asthma in Childhood 2000 (COPSAC(2000)) cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PARACETAMOL USE		[Kreiner-Moller, Eskil] Univ Copenhagen, Fac Hlth Sci, COPSAC, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark; Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Gentofte, Denmark	University of Copenhagen; University of Copenhagen	Kreiner-Moller, E (corresponding author), Univ Copenhagen, Fac Hlth Sci, COPSAC, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark.	bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011; Schoos, Ann-Marie Malby/AAO-7677-2020	Bisgaard, Hans/0000-0003-4131-7592; Schoos, Ann-Marie Malby/0000-0002-5827-0885; Kreiner, Eskil/0000-0003-1204-2438; sevelsted, astrid/0000-0001-7117-2334				Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Eyers S, 2011, CLIN EXP ALLERGY, V41, P482, DOI 10.1111/j.1365-2222.2010.03691.x; Lesko SM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e20; Lowe AJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4616; McBride JT, 2011, PEDIATRICS, V128, P1181, DOI 10.1542/peds.2011-1106; Schnabel E, 2010, J ALLERGY CLIN IMMUN, V126, P1071, DOI 10.1016/j.jaci.2010.08.023; Skytt N, 2012, J ALLERGY CLIN IMMUN, V130, P403, DOI 10.1016/j.jaci.2012.04.043	9	25	26	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1434	1436		10.1016/j.jaci.2012.09.017	http://dx.doi.org/10.1016/j.jaci.2012.09.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23102919				2022-12-18	WOS:000311641100033
J	Baptist, AP; Dever, SI; Greenhawt, MJ; Polmear-Swendris, N; McMorris, MS; Clark, NM				Baptist, Alan P.; Dever, Sara I.; Greenhawt, Matthew J.; Polmear-Swendris, Nancy; McMorris, Marc S.; Clark, Noreen M.			A self-regulation intervention can improve quality of life for families with food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN		[Baptist, Alan P.; Dever, Sara I.; Greenhawt, Matthew J.; Polmear-Swendris, Nancy; McMorris, Marc S.] Univ Michigan, Div Allergy & Clin Immunol, Ann Arbor, MI 48109 USA; [Baptist, Alan P.; Clark, Noreen M.] Univ Michigan, Ctr Managing Chron Dis, Sch Publ Hlth, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Baptist, AP (corresponding author), Univ Michigan, Div Allergy & Clin Immunol, Ann Arbor, MI 48109 USA.	abaptist@med.umich.edu		Greenhawt, Matthew/0000-0002-2365-9372				Clark NM, 2001, HEALTH EDUC BEHAV, V28, P769, DOI 10.1177/109019810102800608; Clark NM, 2007, CHEST, V132, P88, DOI 10.1378/chest.06-2539; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; Glanz K., 2015, HLTH BEHAV THEORY RE; King RM, 2009, ALLERGY, V64, P461, DOI 10.1111/j.1398-9995.2008.01843.x; Klinnert MD, 2008, CURR ALLERGY ASTHM R, V8, P195, DOI 10.1007/s11882-008-0033-7; LeBovidge JS, 2008, ANN ALLERG ASTHMA IM, V101, P160, DOI 10.1016/S1081-1206(10)60204-9; LeBovidge JS, 2009, J ALLERGY CLIN IMMUN, V124, P1282, DOI 10.1016/j.jaci.2009.08.045	8	25	26	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					263	265		10.1016/j.jaci.2012.03.029	http://dx.doi.org/10.1016/j.jaci.2012.03.029			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22541244				2022-12-18	WOS:000306644800038
J	Bogiatzi, SI; Guillot-Delost, M; Cappuccio, A; Bichet, JC; Chouchane-Mlik, O; Donnadieu, MH; Barillot, E; Hupe, P; Chlichlia, K; Efremidou, EI; Aractingi, S; Bayrou, O; Soumelis, V				Bogiatzi, Sofia I.; Guillot-Delost, Maude; Cappuccio, Antonio; Bichet, Jean-Christophe; Chouchane-Mlik, Olfa; Donnadieu, Marie-Helene; Barillot, Emmanuel; Hupe, Philippe; Chlichlia, Katerina; Efremidou, Eleni I.; Aractingi, Selim; Bayrou, Olivier; Soumelis, Vassili			Multiple-checkpoint inhibition of thymic stromal lymphopoietin-induced T(H)2 response by T(H)17-related cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; T(H)17; dendritic cells; T cells; autoimmunity; allergy	TH17 CELLS; TSLP; DIFFERENTIATION; INTERLEUKIN-17; INFLAMMATION; DISORDERS; SCLEROSIS; DISEASE; ALLERGY; ASTHMA	Background: The interplay between allergy and autoimmunity has been a matter of long debate. Epidemiologic studies point to a decreased frequency of allergy in patients with autoimmune diseases. However, recent studies suggest that IL-17 and related cytokines, which play a central role in autoimmunity, might also promote allergy. Objective: To address this controversy, we systematically studied the interactions between T(H)17-related cytokines and the thymic stromal lymphopoietin (TSLP)-mediated proallergic pathway. Methods: We used human primary dendritic cells (DCs), T cells, and skin explants. A novel geometric representation and multivariate ANOVA were used to analyze the T-H cytokine profile. Results: We show that IL-17A specifically inhibits TSLP production but increases proinflammatory IL-8 production in human skin explants exposed to TNF-alpha and IL-4. This inhibitory activity was confirmed in cultured skin explants of atopic dermatitis lesions. At the T-cell level, T(H)17-polarizing cytokines (IL-1 beta, IL-6, TGF-beta, and IL-23) inhibited T(H)2 differentiation induced by TSLP-activated DCs. This led to a global dominance of a T(H)17-polarizing environment over TSLP-activated DCs, as revealed by clustering and computational analysis. Conclusions: Our data indicate that T(H)17-related cytokines are negative regulators of the TSLP immune pathway. This might explain the decreased frequency of allergy in patients with autoimmunity and suggests new means of manipulating proallergic responses. (J Allergy Clin Immunol 2012; 130:233-40.)	[Soumelis, Vassili] Inst Curie, INSERM, U932, F-75005 Paris, France; [Soumelis, Vassili] Ctr Clin Invest, INSERM, Villejuif, France; [Bichet, Jean-Christophe] Hop La Pitie Salpetriere, Dept Chirurg, Paris, France; [Cappuccio, Antonio; Barillot, Emmanuel; Hupe, Philippe] Inst Curie Bioinformat & Biol Syst, Paris, France; [Cappuccio, Antonio; Barillot, Emmanuel; Hupe, Philippe] Paris Tech, Ecole Mines Paris, Fontainebleau, France; [Hupe, Philippe] CNRS, Unite Mixte Rech 144, Paris, France; [Chlichlia, Katerina] Democritus Univ Thrace, Dept Mol Biol & Genet, Mol Immunol Lab, Alexandroupolis, Greece; [Efremidou, Eleni I.] Democritus Univ Thrace, Sch Med, Dept Surg 1, Univ Gen Hosp Alexandroupolis, Alexandroupolis, Greece; [Aractingi, Selim; Bayrou, Olivier] Hop Tenon, Serv Dermatol Allergol, F-75970 Paris, France; [Bogiatzi, Sofia I.; Chouchane-Mlik, Olfa] Inst Curie, Serv Pathol, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; MINES ParisTech; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite; Universite Paris Cite; Democritus University of Thrace; Democritus University of Thrace; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Soumelis, V (corresponding author), Inst Curie, INSERM, U932, 26 Rue Ulm, F-75005 Paris, France.	vassili.soumelis@curie.net	Hupe, Philippe/T-8793-2017; EFFRAIMIDOU, ELENI/AAF-4168-2021; Chlichlia, Katerina/Q-3948-2019	Hupe, Philippe/0000-0001-8468-3424; EFFRAIMIDOU, ELENI/0000-0003-0129-5835; BARILLOT, Emmanuel/0000-0003-2724-2002; Cappuccio, Antonio/0000-0002-8266-2344; Chlichlia, Katerina/0000-0003-4952-0675; Aractingi, Selim/0000-0002-7766-2673	Association pour la Recherche contre le Cancer (ARC); Fondation pour la Recherche Medicale (FRM); Agence Nationale de la Recherche (ANR); European Community; INSERM Center of Clinical Investigation [CBT507 IGR-Curie]; La Ligue Contre le Cancer	Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR)); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); European Community(European Commission); INSERM Center of Clinical Investigation; La Ligue Contre le Cancer(Ligue nationale contre le cancer)	Supported by research grants from Association pour la Recherche contre le Cancer (ARC), Fondation pour la Recherche Medicale (FRM), Agence Nationale de la Recherche (ANR), the European Community 6th framework program, and the INSERM Center of Clinical Investigation, CBT507 IGR-Curie. M.G.-D. is supported by a grant from La Ligue Contre le Cancer.	Antonysamy MA, 1999, J IMMUNOL, V162, P577; Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x; Beriou G, 2010, J IMMUNOL, V185, P46, DOI 10.4049/jimmunol.1000356; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Caffarelli C, 2004, INT ARCH ALLERGY IMM, V134, P288, DOI 10.1159/000079166; Chambers J., 1983, GRAPHICAL METHODS DA, DOI DOI 10.1201/9781351072304; Dahlquist G, 2000, J PEDIATR-US, V137, P470, DOI 10.1067/mpd.2000.109109; Dambacher J, 2009, GUT, V58, P1207, DOI 10.1136/gut.2007.130112; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Gilliet M, 2003, J EXP MED, V197, P1059, DOI 10.1084/jem.20030240; HENSELER T, 1995, J AM ACAD DERMATOL, V32, P982, DOI 10.1016/0190-9622(95)91336-X; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Krzanowski W.J., 1988, PRINCIPLES MULTIVARI; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Ponsonby AL, 2006, CLIN EXP IMMUNOL, V146, P463, DOI 10.1111/j.1365-2249.2006.03235.x; Rabin RL, 2008, CLIN EXP IMMUNOL, V153, P19, DOI 10.1111/j.1365-2249.2008.03679.x; Rodenburg RJT, 1998, J LEUKOCYTE BIOL, V63, P606, DOI 10.1002/jlb.63.5.606; Rudwaleit M, 2002, ANN RHEUM DIS, V61, P968, DOI 10.1136/ard.61.11.968; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Sheikh A, 2003, J ALLERGY CLIN IMMUN, V111, P131, DOI 10.1067/mai.2003.8; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Soumelis V, 2007, M S-MED SCI, V23, P692, DOI 10.1051/medsci/20072389692; STROMBERG LGE, 1995, J ALLERGY CLIN IMMUN, V96, P188, DOI 10.1016/S0091-6749(95)70007-2; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; Tremlett HL, 2002, QJM-INT J MED, V95, P753, DOI 10.1093/qjmed/95.11.753; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Xu G, 2010, ALLERGY, V65, P581, DOI 10.1111/j.1398-9995.2009.02252.x; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	33	25	26	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					233	+		10.1016/j.jaci.2012.04.038	http://dx.doi.org/10.1016/j.jaci.2012.04.038			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22664159				2022-12-18	WOS:000306644800032
J	Kucuk, ZY; Strait, R; Khodoun, MV; Mahler, A; Hogan, S; Finkelman, FD				Kucuk, Zeynep Yesim; Strait, Richard; Khodoun, Marat V.; Mahler, Ashley; Hogan, Simon; Finkelman, Fred D.			Induction and suppression of allergic diarrhea and systemic anaphylaxis in a murine model of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgA; IgE; IgG; J chain; polymeric immunoglobulin receptor	IMMUNOGLOBULIN-A; DEFICIENT MICE; ANTIGEN; IGE; HYPERSENSITIVITY; TRANSPORT; MOUSE; CELLS	Background: The clinical manifestations of food allergy include diarrhea and systemic anaphylaxis (shock), which can occur together or by themselves in different subjects. Although ingested food antigens need to be absorbed to induce shock, it is not known whether they need to be absorbed to induce diarrhea. Objective: We sought to identify mechanisms that determine whether food allergy induces diarrhea versus shock and determine whether diarrhea requires absorption of ingested antigens. Methods: These issues were studied in mice in active, passive, and hybrid immunization models. The active model was used to determine the allergic diarrhea susceptibility of J chain-and polymeric immunoglobulin receptor-deficient mice, which are unable to secrete IgA. The hybrid model was used to determine whether intravenously administered antigen-specific IgG antibody, which is not secreted into the gut, can protect against allergic diarrhea, as well as shock. Results: Shock, but not diarrhea, was induced in naive mice by using intravenous IgE anti-trinitrophenyl (TNP) antibody, followed by oral TNP-BSA, whereas both were induced in mice presensitized with intraperitoneal ovalbumin/alum plus oral ovalbumin. More TNP-BSA was required to induce shock than diarrhea in presensitized mice, and intravenous IgG anti-TNP antibody, which is not secreted into the gut, protected these mice against both diarrhea and shock. Consistent with this, chicken ovalbumin-immunized J chain-and polymeric immunoglobulin receptor-deficient mice, which have high serum IgA levels but little intestinal IgA, resisted diarrhea induction. Conclusion: Intestinal immunity and oral antigen dose determine whether diarrhea, systemic anaphylaxis, or both are induced, and ingested antigen must be absorbed to induce either response. (J Allergy Clin Immunol 2012;129:1343-8.)	[Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH 45220 USA; [Khodoun, Marat V.] Cincinnati Vet Affairs Med Ctr, Dept Res, Cincinnati, OH 45220 USA; [Kucuk, Zeynep Yesim; Hogan, Simon] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH USA; [Strait, Richard; Mahler, Ashley] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Emergency Med, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Immunobiol, Cincinnati, OH USA; [Khodoun, Marat V.; Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH 45221 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Finkelman, FD (corresponding author), Cincinnati Vet Affairs Med Ctr, Dept Med, 3200 Vine St, Cincinnati, OH 45220 USA.	ffinkelman@pol.net			Department of Veterans Affairs; National Institutes of Health (NIH) [R01 AI073553]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073553, R21AI079947] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a Department of Veterans Affairs Merit Award (to F. D. F.), National Institutes of Health (NIH) grant R01 AI073553 (to S. H.), and an NIH T32 Training Grant (to Z.Y.K.).	ALIZADEH H, 1986, J IMMUNOL, V137, P2555; Berin MC, 2009, MUCOSAL IMMUNOL, V2, P24, DOI 10.1038/mi.2008.72; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; BRANDTZAEG P, 1987, ANN ALLERGY, V59, P21; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; FORBES D, 1988, AM J PHYSIOL, V255, pG201, DOI 10.1152/ajpgi.1988.255.2.G201; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; HENDRICKSON BA, 1995, J EXP MED, V182, P1905, DOI 10.1084/jem.182.6.1905; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Johansen FE, 1999, J EXP MED, V190, P915, DOI 10.1084/jem.190.7.915; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1494; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Strait RT, 2011, J ALLERGY CLIN IMMUN, V127, P982, DOI 10.1016/j.jaci.2011.01.034; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Wang J, 2011, J CLIN INVEST, V121, P827, DOI [10.1172/JCI45434, 10.1186/1710-1492-7-S1-S7]	24	25	26	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1343	1348		10.1016/j.jaci.2012.03.004	http://dx.doi.org/10.1016/j.jaci.2012.03.004			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22465213	Green Accepted, Bronze			2022-12-18	WOS:000303418000025
J	Eakin, MN; Rand, CS; Bilderback, A; Bollinger, ME; Butz, A; Kandasamy, V; Riekert, KA				Eakin, Michelle N.; Rand, Cynthia S.; Bilderback, Andrew; Bollinger, Mary E.; Butz, Arlene; Kandasamy, Veni; Riekert, Kristin A.			Asthma in Head Start children: Effects of the Breathmobile program and family communication on asthma outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; intervention; communication; quality of life; interaction; barriers	INNER-CITY CHILDREN; AFRICAN-AMERICAN CHILDREN; EMERGENCY-DEPARTMENT; HEALTH DISPARITIES; LOW-INCOME; MANAGEMENT; EDUCATION; CONCORDANCE; CHILDHOOD; ADHERENCE	Background: Asthma morbidity and mortality rates are high among young inner-city children. Lack of routine primary care provider visits, poor access to care, and poor patient-physician communication might be contributing factors. Objective: This study evaluated the effects of providing Breathmobile services only, a Facilitated Asthma Communication Intervention (FACI) only, or both Breathmobile plus FACI on asthma outcomes relative to standard care. Methods: Children with asthma (n = 322; mean age, 4 years; 53% male; 97% African American) were recruited from Head Start programs in Baltimore City and randomized into 4 groups. Outcome measures included symptom-free days (SFDs), urgent care use (emergency department visits and hospitalizations), and medication use (courses of oral steroids and proportion taking an asthma controller medication), as reported by caregivers at baseline, 6-month, and 12-month assessments. Generalized estimating equations models were conducted to examine the differential treatment effects of the Breathmobile and FACI compared with standard care. Results: Children in the combined treatment group (Breathmobile plus FACI) had an increase of 1.7 (6.6%) SFDs that was not maintained at 12 months. In intent-to-treat analyses the FACI-only group had an increase in the number of emergency department visits at 6 months, which was not present at 12 months or in the post hoc as-treated analyses. No significant differences were found between the intervention groups compared with those receiving standard care on all other outcome measures. Conclusions: Other than a slight improvement in SFDs at 6 months in the Breathmobile plus FACI group, the intervention components did not result in any significant improvements in asthma management or asthma morbidity. (J Allergy Clin Immunol 2012; 129: 664-70.)	[Eakin, Michelle N.; Rand, Cynthia S.; Bilderback, Andrew; Kandasamy, Veni; Riekert, Kristin A.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Johns Hopkins Sch Med, Baltimore, MD 21224 USA; [Butz, Arlene] Johns Hopkins Sch Med, Div Gen Pediat & Adolescent Med, Baltimore, MD USA; [Bollinger, Mary E.] Univ Maryland, Sch Med, Div Pediat Pulmonol Allergy, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Riekert, KA (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, Johns Hopkins Sch Med, 5501 Hopkins Bayview Circle,4B-74, Baltimore, MD 21224 USA.	kriekert@jhmi.edu		Kandasamy, Veni/0000-0001-6969-6884	National Institute of Nursing Research, National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073833] Funding Source: NIH RePORTER	National Institute of Nursing Research, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	C. S. Rand has consultant arrangements with TEVA and is an advisor for the Merck Foundation. A. Butz receives research support from the National Institute of Nursing Research, National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Akinbami Lara, 2006, Adv Data, P1; [Anonymous], 2007, J ALLERGY CLIN IMMUN, V120, pS94, DOI 10.1016/j.jaci.2007.09.029; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bokhour BG, 2008, PATIENT EDUC COUNS, V70, P376, DOI 10.1016/j.pec.2007.11.007; Bollinger ME, 2010, ANN ALLERG ASTHMA IM, V105, P274, DOI 10.1016/j.anai.2010.07.012; Bravata DM, 2007, 0407005 AG HEALTHC R; Brown JV, 2002, J PEDIATR PSYCHOL, V27, P677, DOI 10.1093/jpepsy/27.8.677; Butz AM, 2007, J ASTHMA, V44, P739, DOI 10.1080/02770900701595683; Canino G, 2009, J ALLERGY CLIN IMMUN, V123, P1209, DOI 10.1016/j.jaci.2009.02.043; Cegala DJ, 2000, ARCH FAM MED, V9, P57, DOI 10.1001/archfami.9.1.57; Celano MP, 2010, J ASTHMA, V47, P317, DOI 10.3109/02770900903580850; D'Souza-Vazirani D, 2005, ARCH PEDIAT ADOL MED, V159, P167, DOI 10.1001/archpedi.159.2.167; Diette GB, 2007, CHEST, V132, p802S, DOI 10.1378/chest.07-1909; Garwick AW, 2010, PUBLIC HEALTH NURS, V27, P329, DOI 10.1111/j.1525-1446.2010.00862.x; Halm EA, 2006, CHEST, V129, P573, DOI 10.1378/chest.129.3.573; Johnson CE, 2006, J ASTHMA, V43, P9, DOI 10.1080/02770900500446831; Jones CA, 2004, CHEST, V125, P924, DOI 10.1378/chest.125.3.924; Jones CA, 2000, J ALLERGY CLIN IMMUN, V105, pS103, DOI 10.1016/S0091-6749(00)90737-1; Jones CA, 2007, J ALLERGY CLIN IMMUN, V119, P1445, DOI 10.1016/j.jaci.2007.02.031; Jones Craig A, 2005, Dis Manag, V8, P205, DOI 10.1089/dis.2005.8.205; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Li P, 2009, CURR OPIN PEDIATR, V21, P783, DOI 10.1097/MOP.0b013e328332537d; Liao O, 2006, J SCHOOL HEALTH, V76, P313, DOI 10.1111/j.1746-1561.2006.00119.x; McDaniel M, 2006, PEDIATRICS, V117, pE868, DOI 10.1542/peds.2005-1721; Murray NG, 2007, J SCHOOL HEALTH, V77, P589, DOI 10.1111/j.1746-1561.2007.00238.x; Nelson KA, 2011, ARCH PEDIAT ADOL MED, V165, P520, DOI 10.1001/archpediatrics.2011.57; Otsuki M, 2009, PEDIATRICS, V124, P1513, DOI 10.1542/peds.2008-2961; Quint DM, 2009, CLIN PEDIATR EMERG M, V10, P115, DOI 10.1016/j.cpem.2009.03.003; Rand CS, 2000, J ALLERGY CLIN IMMUN, V105, P83, DOI 10.1016/S0091-6749(00)90182-9; Riekert KA, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e214; Sarver N, 2009, J AM ACAD NURSE PRAC, V21, P54, DOI 10.1111/j.1745-7599.2008.00375.x; Scott L, 2011, J ALLERGY CLIN IMMUN, V128, P56, DOI 10.1016/j.jaci.2011.03.020; Small M, 2010, ADV THER, V27, P591, DOI 10.1007/s12325-010-0054-1; Smith LA, 2008, PEDIATRICS, V122, P760, DOI 10.1542/peds.2007-2750; Vargas PA, 2004, J ALLERGY CLIN IMMUN, V114, P499, DOI 10.1016/j.jaci.2004.05.025; Wilson SR, 1996, J ASTHMA, V33, P239, DOI 10.3109/02770909609055365	36	25	25	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					664	670		10.1016/j.jaci.2011.10.013	http://dx.doi.org/10.1016/j.jaci.2011.10.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	904IW	22104603	Green Accepted			2022-12-18	WOS:000301189300009
J	Freeman, AF; Ding, L; Holland, SM; Uzel, G				Freeman, Alexandra F.; Ding, Li; Holland, Steven M.; Uzel, Gulbu			Plasma metalloproteinase levels are dysregulated in signal transducer and activator of transcription 3 mutated hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MATRIX METALLOPROTEINASES; STAT3; MUTATIONS		[Freeman, Alexandra F.; Ding, Li; Holland, Steven M.; Uzel, Gulbu] NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; NIAID, Biostat Res Branch, Div Clin Res, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Freeman, AF (corresponding author), NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.	guzel@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000646-16] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Grimbacher B, 1999, AM J HUM GENET, V65, P735, DOI 10.1086/302547; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Lagente V, 2010, J MOL CELL CARDIOL, V48, P440, DOI 10.1016/j.yjmcc.2009.09.017; Lopez-Otin C, 2009, CELL CYCLE, V8, P3657, DOI 10.4161/cc.8.22.9956; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Paulson ML, 2008, CURR OPIN ALLERGY CL, V8, P527, DOI 10.1097/ACI.0b013e3283184210; Pradhan-Palikhe P, 2010, SCAND J IMMUNOL, V72, P150, DOI 10.1111/j.1365-3083.2010.02418.x; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Thrailkill KM, 2005, CLIN CHEM LAB MED, V43, P1392, DOI 10.1515/CCLM.2005.238; Vallania F, 2009, P NATL ACAD SCI USA, V106, P5117, DOI 10.1073/pnas.0900473106	10	25	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1124	1127		10.1016/j.jaci.2011.07.046	http://dx.doi.org/10.1016/j.jaci.2011.07.046			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21872914	Green Accepted			2022-12-18	WOS:000296578200035
J	Cookson, W; Moffatt, M; Strachan, DP				Cookson, William; Moffatt, Miriam; Strachan, David P.			Genetic risks and childhood-onset asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; childhood; genetic; familial; population; risk; genome-wide association	DNA METHYLATION; DISEASE RISK; ASSOCIATION; GENOME; VARIANTS; LOCI; AGE; BIRTH	Recent large-scale genome-wide association studies have successfully identified several genetic loci that influence asthma susceptibility. The loci thus far identified confer a high population attributable risk for childhood-onset disease and have provided a better understanding of the primary mechanisms underlying asthma and a clear focus for new therapies to treat the disease. The loci are of limited utility for diagnostic or predictive genetic testing. This review considers different aspects of genetic risk, including individual, population, and familial risks, and explores how these different measures interact and how the next generation of genetic studies might be best designed. (J Allergy Clin Immunol 2011;128:266-70.)	[Cookson, William] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Div Resp Sci, London SW3 6LY, England; [Strachan, David P.] St Georges Univ London, Div Populat Hlth Sci & Educ, London, England	Imperial College London; St Georges University London	Cookson, W (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Div Resp Sci, London SW3 6LY, England.	w.cookson@imperial.ac.uk	Cookson, William/HHC-1790-2022		European Community; Wellcome Trust; Medical Research Council [G1000758, G1000758B, G0801056B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	European Community(European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the European Community Framework 6 Program and the Wellcome Trust.	Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Biesecker LG, 2010, NAT GENET, V42, P13, DOI 10.1038/ng0110-13; Binia A, 2011, J HUM GENET, V56, P97, DOI 10.1038/jhg.2010.134; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; Blakemore AIF, 2010, ANN NY ACAD SCI, V1214, P180, DOI 10.1111/j.1749-6632.2010.05880.x; Blakey JD, 2009, THORAX, V64, P381, DOI 10.1136/thx.2008.102053; Boks MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006767; Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602; Clarke R, 2009, NEW ENGL J MED, V361, P2518, DOI 10.1056/NEJMoa0902604; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; DeWan AT, 2010, J ALLERGY CLIN IMMUN, V126, P871, DOI 10.1016/j.jaci.2010.06.051; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Edwards AGK, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001865.pub2; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Ferreira MAR, 2011, EUR J HUM GENET, V19, P458, DOI 10.1038/ejhg.2010.191; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hadley David, 2009, BMC Proc, V3 Suppl 7, pS55; Haga SB, 2008, NEW ENGL J MED, V358, P2184, DOI 10.1056/NEJMc086053; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Heijmans BT, 2007, HUM MOL GENET, V16, P547, DOI 10.1093/hmg/ddm010; Hemminki K, 2007, CARCINOGENESIS, V28, P648, DOI 10.1093/carcin/bgl182; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hunter DJ, 2008, NEW ENGL J MED, V358, P105, DOI 10.1056/NEJMp0708162; Kraft P, 2009, NAT REV GENET, V10, P264, DOI 10.1038/nrg2516; LI X, 2009, J ALLERGY CLIN IMMUN, V125, pE11; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Liu JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010028; Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Weedon MN, 2008, NAT GENET, V40, P575, DOI 10.1038/ng.121	42	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					266	272		10.1016/j.jaci.2011.06.026	http://dx.doi.org/10.1016/j.jaci.2011.06.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21807248				2022-12-18	WOS:000293280800002
J	Kohan, M; Muro, AF; Bader, R; Berkman, N				Kohan, Martin; Muro, Andres F.; Bader, Reem; Berkman, Neville			The extra domain A of fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway remodeling; asthma; EDA-containing fibronectin; fibroblast; fibrosis; myofibroblast	MURINE MODEL; SUBEPITHELIAL FIBROSIS; TGF-BETA; BRONCHOALVEOLAR LAVAGE; SMOOTH-MUSCLE; MILD ASTHMA; IN-VITRO; LUNG; EXPRESSION; FIBROBLASTS	Background: Asthma is characterized by airway inflammation, airway remodeling, and airway hyperresponsiveness (AHR). Myofibroblast differentiation and subepithelial fibrosis are key features of airway remodeling. Extra domain A (EDA)-containing fibronectin (EDA-FN), an alternatively spliced form of the extracellular matrix protein fibronectin, has been implicated in fibroblast differentiation during wound healing and tissue fibrosis. Objectives: We sought to investigate the role of EDA-FN in airway remodeling using a murine model of chronic allergen-induced experimental asthma. Methods: EDA(-/-) and wild-type (WT) mice were sensitized and exposed to inhaled ovalbumin (OVA) or saline for 5 weeks. EDA-FN expression was evaluated by means of PCR and immunostaining. Peribronchial fibrosis, smooth muscle area, mucus-producing cell numbers, bronchoalveolar cell counts, and lung function were assessed in WT and EDA(-/-) mice. Fibroblast activation and differentiation were evaluated ex vivo by using OVA-treated WT and EDA(-/-) lung fibroblasts. Results: Exposure to OVA increased EDA-FN expression in lung tissue and primary lung fibroblasts. OVA-treated EDA(-/-) mice showed reduced airway fibrosis and AHR and impaired expression of TGF-beta 1 and IL-13 without changes in airway inflammation or other aspects of remodeling. Lung fibroblasts from OVA-treated EDA(-/-) mice exhibited reduced proliferation, migration, a-smooth muscle actin expression, and collagen deposition and impaired TGF-b1 and IL-13 release compared with that seen in WT mice. Conclusions: EDA-FN is essential for the development of OVA-induced airway fibrosis and AHR. The effect of the EDA domain on airway fibrosis after OVA challenge is through activation and differentiation of fibroblasts. Fibroblast activation and airway fibrosis are necessary for the development of AHR. (J Allergy Clin Immunol 2011;127:439-46.)	[Kohan, Martin; Bader, Reem; Berkman, Neville] Hadassah Hebrew Univ, Inst Pulmonol, Med Ctr, IL-91120 Jerusalem, Israel; [Muro, Andres F.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	Hebrew University of Jerusalem; Hadassah University Medical Center; International Center for Genetic Engineering & Biotechnology (ICGEB)	Berkman, N (corresponding author), Hadassah Hebrew Univ, Inst Pulmonol, Med Ctr, POB 12000, IL-91120 Jerusalem, Israel.	Neville@hadassah.org.il	Muro, Andrés F/K-3156-2016	Muro, Andrés F/0000-0002-9628-0494	Israel Science Foundation [1408/08]; Chief Scientist Office of the Ministry of Health, Israel [4921]	Israel Science Foundation(Israel Science Foundation); Chief Scientist Office of the Ministry of Health, Israel	Supported by grants from the Israel Science Foundation (1408/08) and the Chief Scientist Office of the Ministry of Health, Israel (4921) to N.B.	Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BALZA E, 1988, FEBS LETT, V228, P42, DOI 10.1016/0014-5793(88)80580-5; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Botero JE, 2008, ORAL MICROBIOL IMMUN, V23, P291, DOI 10.1111/j.1399-302X.2007.00427.x; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chauhan AK, 2004, GENE, V324, P55, DOI 10.1016/j.gene.2003.09.026; Chiappara G, 2001, CURR OPIN ALLERGY CL, V1, P85, DOI 10.1097/00130832-200102000-00015; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Christie PE, 2004, EUR RESPIR J, V24, P107, DOI 10.1183/09031936.04.00013303; Dekkers BGJ, 2010, AM J RESP CRIT CARE, V181, P556, DOI 10.1164/rccm.200907-1065OC; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fernandes DJ, 2006, CURR DRUG TARGETS, V7, P567, DOI 10.2174/138945006776818700; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Gupta S, 2004, J BIOL CHEM, V279, P5821, DOI 10.1074/jbc.M310979200; Hynes RO, 1990, FIBRONECTINS, P546; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Jones RC, 2000, CELL TISSUE RES, V300, P263, DOI 10.1007/s004419900100; Kohan M, 2007, CLIN EXP ALLERGY, V37, P1444, DOI 10.1111/j.1365-2222.2007.02801.x; Kohan M, 2010, FASEB J, V24, P4503, DOI 10.1096/fj.10-154435; Kohan M, 2009, AM J RESP CELL MOL, V41, P290, DOI 10.1165/rcmb.2008-0307OC; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Larsen K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-11; Le Saux CJ, 2008, J BIOL CHEM, V283, P5760, DOI 10.1074/jbc.M701572200; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lim DH, 2009, AM J PHYSIOL-LUNG C, V296, pL210, DOI 10.1152/ajplung.90275.2008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Locke NR, 2007, AM J RESP CELL MOL, V36, P625, DOI 10.1165/rcmb.2006-0083OC; Martin JG, 2000, EUR RESPIR J, V16, P349, DOI 10.1034/j.1399-3003.2000.16b25.x; MARX J, 1995, SCIENCE, V268, P1276, DOI 10.1126/science.7761848; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; Meerschaert J, 1999, AM J RESP CRIT CARE, V159, P619, DOI 10.1164/ajrccm.159.2.9806053; Miller M, 2006, AM J PHYSIOL-LUNG C, V290, pL162, DOI 10.1152/ajplung.00252.2005; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Muro AF, 2008, AM J RESP CRIT CARE, V177, P638, DOI 10.1164/rccm.200708-1291OC; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; Ngo P, 2006, METH MOL B, V341, P103; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627, DOI 10.1164/ajrccm.161.2.9902094; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Puxeddu I, 2006, J ALLERGY CLIN IMMUN, V117, P103, DOI 10.1016/j.jaci.2005.08.057; ROCHE WR, 1989, LANCET, V1, P520; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Shiba K, 2002, CHEST, V122, P1622, DOI 10.1378/chest.122.5.1622; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sugiura H, 2007, AM J RESP CELL MOL, V37, P424, DOI 10.1165/rcmb.2007-0089OC; Tattersfield AE, 2002, LANCET, V360, P1313, DOI 10.1016/S0140-6736(02)11312-2; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; Trifilieff A, 2000, AM J PHYSIOL-LUNG C, V279, pL1120, DOI 10.1152/ajplung.2000.279.6.L1120; Westergren-Thorsson G, 2002, INT J BIOCHEM CELL B, V34, P1256, DOI 10.1016/S1357-2725(02)00058-4; White ES, 2008, J PATHOL, V216, P1, DOI 10.1002/path.2388; Wilson MS, 2009, MUCOSAL IMMUNOL, V2, P103, DOI 10.1038/mi.2008.85; ZuritaSalinas CS, 1996, FEMS IMMUNOL MED MIC, V15, P123, DOI 10.1111/j.1574-695X.1996.tb00062.x	57	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					439	U1681		10.1016/j.jaci.2010.10.021	http://dx.doi.org/10.1016/j.jaci.2010.10.021			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21167578	Bronze			2022-12-18	WOS:000286808000018
J	Newell, A; Dadi, H; Goldberg, R; Ngan, BY; Grunebaum, E; Roifman, CM				Newell, Andrea; Dadi, Harjit; Goldberg, Rachel; Ngan, Bo-Yee; Grunebaum, Eyal; Roifman, Chaim M.			Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EPSTEIN-BARR VIRUS; KINASE; SELECTION		[Newell, Andrea; Dadi, Harjit; Goldberg, Rachel; Grunebaum, Eyal; Roifman, Chaim M.] Hosp Sick Children, Dept Pediat, Canadian Ctr Primary Immunodeficiency, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada; [Ngan, Bo-Yee] Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; [Ngan, Bo-Yee] Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Newell, A (corresponding author), Hosp Sick Children, Dept Pediat, Canadian Ctr Primary Immunodeficiency, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca						ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CRAWFORD DH, 1980, LANCET, V1, P1355, DOI 10.1016/S0140-6736(80)91800-0; Jakob T, 2008, J ALLERGY CLIN IMMUN, V121, P179, DOI 10.1016/j.jaci.2007.07.018; ROIFMAN CM, 1989, J EXP MED, V170, P2177, DOI 10.1084/jem.170.6.2177; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; TOSATO G, 1985, J IMMUNOL, V135, P959; Turul T, 2009, EUR J PEDIATR, V168, P87, DOI 10.1007/s00431-008-0718-x; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730	9	25	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					517	520		10.1016/j.jaci.2010.09.016	http://dx.doi.org/10.1016/j.jaci.2010.09.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21094993				2022-12-18	WOS:000286808000028
J	van Nieuwaal, NHG; Lasfar, W; Meijer, Y; Kentie, PA; Flinterman, AE; Pasmans, SGAM; Knulst, AC; Hoekstra, MO				van Nieuwaal, Nancy H. G.; Lasfar, Wafae; Meijer, Yolanda; Kentie, Petra A.; Flinterman, Annebeth E.; Pasmans, Suzanne G. A. M.; Knulst, Andre C.; Hoekstra, Maarten O.			Utility of peanut-specific IgE levels in predicting the outcome of double-blind, placebo-controlled food challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SKIN PRICK; ALLERGY; CHILDREN		[van Nieuwaal, Nancy H. G.; Lasfar, Wafae; Meijer, Yolanda; Kentie, Petra A.; Flinterman, Annebeth E.] Wilhelmina Childrens Hosp, Ctr Pediat Allergol, Utrecht, Netherlands; [Pasmans, Suzanne G. A. M.; Knulst, Andre C.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands; [Hoekstra, Maarten O.] Radboud Univ Nijmegen, Med Ctr, Dept Gen Pediat, NL-6525 ED Nijmegen, Netherlands	Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen	van Nieuwaal, NHG (corresponding author), Wilhelmina Childrens Hosp, Ctr Pediat Allergol, Utrecht, Netherlands.	M.O.Hoekstra@umcutrecht.nl	Pasmans, Suzanne/AAI-6016-2021	Pasmans, Suzanne/0000-0003-1018-4475; Knulst, Andre/0000-0002-1056-3179				BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x	9	25	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1391	1392		10.1016/j.jaci.2010.01.057	http://dx.doi.org/10.1016/j.jaci.2010.01.057			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20304474				2022-12-18	WOS:000278831000031
J	Hollingsworth, JW; Free, ME; Li, ZW; Andrews, LN; Nakano, H; Cook, DN				Hollingsworth, John W.; Free, Meghan E.; Li, Zhuowei; Andrews, Laura Novack; Nakano, Hideki; Cook, Donald N.			Ozone activates pulmonary dendritic cells and promotes allergic sensitization through a Toll-like receptor 4-dependent mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IL-10; B7-1		[Hollingsworth, John W.; Li, Zhuowei] Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Durham, NC 27706 USA; [Free, Meghan E.; Andrews, Laura Novack; Nakano, Hideki; Cook, Donald N.] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hollingsworth, JW (corresponding author), Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Durham, NC 27706 USA.	cookd@niehs.nih.gov	Cook, Donald/E-5079-2019	Cook, Donald/0000-0002-0052-3755	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016126, R21ES016659, ZIAES102025] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA ES102025-04] Funding Source: Medline; NIEHS NIH HHS [ES16126, ES16659, R21 ES016659, R01 ES016126] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Alexis NE, 2009, J ALLERGY CLIN IMMUN, V124, P1222, DOI 10.1016/j.jaci.2009.07.036; Bhatia S, 2006, IMMUNOL LETT, V104, P70, DOI 10.1016/j.imlet.2005.11.019; Chen XQ, 2006, RESPIRATION, V73, P34, DOI 10.1159/000087457; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; GARANTZIOTIS S, 2009, AM J RESP CRIT CARE; Hollingsworth JW, 2004, AM J RESP CRIT CARE, V170, P126, DOI 10.1164/rccm.200311-1499OC; Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620, DOI 10.1165/ajrcmb.22.5.3912; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lay JC, 2007, J ALLERGY CLIN IMMUN, V120, P719, DOI 10.1016/j.jaci.2007.05.005; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; STEINMAN RM, 1978, P NATL ACAD SCI USA, V75, P5132, DOI 10.1073/pnas.75.10.5132; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC	13	25	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1167	1170		10.1016/j.jaci.2010.03.001	http://dx.doi.org/10.1016/j.jaci.2010.03.001			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20394980	Green Accepted			2022-12-18	WOS:000277686700033
J	Mandala, WL; MacLennan, JM; Gondwe, EN; Ward, SA; Molyneux, ME; MacLennan, CA				Mandala, Wilson L.; MacLennan, Jenny M.; Gondwe, Esther N.; Ward, Steven A.; Molyneux, Malcolm E.; MacLennan, Calman A.			Lymphocyte subsets in healthy Malawians: Implications for immunologic assessment of HIV infection in Africa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lymphocyte subsets; immunophenotyping; flow cytometry; CD4 lymphocyte count; Africa; HIV; AIDS	REFERENCE VALUES; ANTIRETROVIRAL THERAPY; BLOOD-LYMPHOCYTES; REFERENCE RANGES; FLOW-CYTOMETRY; ENUMERATION; CHILDREN; POPULATION; CHILDHOOD; ADULTS	Background: CD4(+)T lymphocyte measurements are the most important indicator of mortality in HIV-infected individuals in resource-limited settings. There is currently a lack of comprehensive immunophenotyping data from African populations to guide the immunologic assessment of HIV infection. Objective: To quantify variation in absolute and relative lymphocyte subsets with age in healthy Malawians. Methods: Lymphocyte subsets in peripheral blood of 539 healthy HIV-uninfected Malawians stratified by age were enumerated by How cytometry. Results: B and T-lymphocyte and T-lymphocyte subset absolute concentrations peaked in early childhood then decreased to adult levels, whereas lymphocyte subset proportions demonstrated much less variation with age. Adult lymphocyte subsets were similar to those in developed countries. In contrast, high B-lymphocyte and CD8(+)T-lymphocyte levels among children under 2 years, relative to those in developed countries, resulted in low CD4(+)T-lymphocyte percentages that varied little between 0 and 5 years (35% to 39%). The CD4(+)T-lymphocyte percentages in 35% of healthy children under 1 year and 18% of children age I to 3 years were below the World Health Organization threshold defining immunodeficiency in HIV-infected children in resource-limited settings. Thirteen percent of healthy children under 18 months old had a CD4:CD8T-lymphocyte ratio <1.0, which is commonly associated with HIV infection. All immunologic parameters except absolute natural killer lymphocyte concentration varied significantly with age, and percentage and overall absolute CD4(+)T-lymphocyte counts were higher in females than males. Conclusion: Although lymphocyte subsets in Malawian adults are similar to those from developed countries, CD4(+)T-lymphocyte percentages in young children are comparatively low. These findings need to be considered when assessing the severity of HIV-related immunodeficiency in African children under 3 years. (J Allergy Clin Immunol 2010;125:203-8.)	[MacLennan, Calman A.] Univ Birmingham, Med Res Council, Ctr Immune Regulat, Sch Immun & Infect,Coll Med & Dent Sci,Inst Biome, Birmingham B15 2TT, W Midlands, England; [Gondwe, Esther N.; MacLennan, Calman A.] Univ Birmingham, Clin Immunol Serv, Sch Immun & Infect, Birmingham B15 2TT, W Midlands, England; [Mandala, Wilson L.; MacLennan, Jenny M.; Gondwe, Esther N.; Molyneux, Malcolm E.; MacLennan, Calman A.] Univ Malawi, Malawi Liverpool Wellcome Trust Clin Res Programm, Zomba, Malawi; [MacLennan, Calman A.] Univ Malawi, Dept Microbiol, Coll Med, Zomba, Malawi; [Mandala, Wilson L.; Gondwe, Esther N.; Ward, Steven A.; Molyneux, Malcolm E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L69 3BX, Merseyside, England; [MacLennan, Calman A.] Univ Liverpool, Div Med Microbiol, Sch Infect & Host Def, Liverpool L69 3BX, Merseyside, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Birmingham; University of Birmingham; University of Malawi; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; University of Liverpool	MacLennan, CA (corresponding author), Univ Birmingham, Med Res Council, Ctr Immune Regulat, Sch Immun & Infect,Coll Med & Dent Sci,Inst Biome, Wolfson Dr, Birmingham B15 2TT, W Midlands, England.	c.maclennan@bham.ac.uk	MacLennan, Calman A/L-9343-2014; Ward, Steve/G-6003-2015	MacLennan, Calman A/0000-0001-9694-0846; Ward, Steve/0000-0003-2331-3192; Mandala, Wilson/0000-0001-9386-9239	Gates Malaria Partnership PhD studentship; Wellcome Trust; GlaxoSmithKline Clinical Research Fellowship; Medical Research Council [G9818340B] Funding Source: researchfish	Gates Malaria Partnership PhD studentship; Wellcome Trust(Wellcome TrustEuropean Commission); GlaxoSmithKline Clinical Research Fellowship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by a Gates Malaria Partnership PhD studentship (W.L.M.). a Wellcome Trust Research Fellowship (C.A.M.), a Wellcome Trust Programme Grant (M.E.M.) and a GlaxoSmithKline Clinical Research Fellowship (C.A.M.).	[Anonymous], 2008, GUID US ANT THER MAL; Bonilla FA, 1997, J PEDIATR-US, V130, P347; Colonna-Romano G, 2006, REJUV RES, V9, P149, DOI 10.1089/rej.2006.9.149; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Dunn DT, 2006, AIDS, V20, P1289, DOI 10.1097/01.aids.0000232237.20792.68; Dunn DT, 2003, LANCET, V362, P1605, DOI 10.1016/S0140-6736(03)14793-9; Embree J, 2001, PEDIATR INFECT DIS J, V20, P397, DOI 10.1097/00006454-200104000-00006; *GEN WHO, 2006, ANT THER HIV INF INF; Gibb DM, 2008, AIDS, V22, P97, DOI 10.1097/01.aids.0000302262.51286.a5; Glencross D, 2002, CYTOMETRY, V50, P69, DOI 10.1002/cyto.10068; Harries AD, 2006, LANCET, V367, P1870, DOI 10.1016/S0140-6736(06)68809-0; Janossy G, 2000, BRIT J HAEMATOL, V111, P1198, DOI 10.1046/j.1365-2141.2000.02433.x; JONES DS, 1993, PEDIATR INFECT DIS J, V12, P222, DOI 10.1097/00006454-199303000-00010; Karita E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004401; Kassa E, 1999, AIDS, V13, P381, DOI 10.1097/00002030-199902250-00011; Kassu A, 2001, CLIN DIAGN LAB IMMUN, V8, P1171, DOI 10.1128/CDLI.8.6.1171-1176.2001; Kibaya RS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003327; Lugada ES, 2004, CLIN DIAGN LAB IMMUN, V11, P29, DOI 10.1128/CDLI.11.1.29-34.2004; MacLennan CA, 2008, CYTOM PART B-CLIN CY, V74B, pS90, DOI 10.1002/cyto.b.20411; MacLennan CA, 2007, BRIT MED J, V335, P190, DOI 10.1136/bmj.39268.719780.BE; O'Gorman MRG, 2008, CYTOM PART B-CLIN CY, V74B, pS19, DOI 10.1002/cyto.b.20398; *PENTA, 2008, PENTA GUID US ANT TH; SANSONI P, 1993, BLOOD, V82, P2767; Santagostino A, 1999, HAEMATOLOGICA, V84, P499; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sherman GG, 1999, J IMMUNOL METHODS, V222, P209, DOI 10.1016/S0022-1759(98)00172-0; Tsegaye A, 2003, CLIN IMMUNOL, V109, P338, DOI 10.1016/j.clim.2003.08.008; Urassa WK, 2003, J IMMUNOL METHODS, V277, P65, DOI 10.1016/S0022-1759(03)00174-1; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; Whitby L, 2002, CYTOMETRY, V50, P102, DOI 10.1002/cyto.10094; Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, 2009, GUID US ANT AG PED H; Zijenah LS, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-6	32	25	25	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					203	208		10.1016/j.jaci.2009.10.010	http://dx.doi.org/10.1016/j.jaci.2009.10.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19944455	Green Published, hybrid			2022-12-18	WOS:000273660500025
J	Penders, J; Thijs, C; Mommers, M; Stobberingh, EE; Dompeling, E; Reijmerink, NE; van den Brandt, PA; Kerkhof, M; Koppelman, GH; Postma, DS				Penders, John; Thijs, Carel; Mommers, Monique; Stobberingh, Ellen E.; Dompeling, Edward; Reijmerink, Naomi E.; van den Brandt, Piet A.; Kerkhof, Marjan; Koppelman, Gerard H.; Postma, Dirkje S.			Host-microbial interactions in childhood atopy: Toll-like receptor 4 (TLR4), CD14, and fecal Escherichia coli	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; Toll-like receptor 4; CD14; gene-environment interaction; Escherichia coli; intestinal microbiota	INTESTINAL MICROFLORA; GENE; POLYMORPHISMS; DERMATITIS; VARIANTS; CHILDREN; INFANCY	Background: Perturbations in the gut microbiota have been linked to atopic diseases. However, the development of atopic diseases depends not only on environmental factors (like microbial stimulation) but also on genetic factors. It is likely that particularly gene-environmental interactions in early life determine the development of atopy. Objective We examine the interaction between detection of fecal Escherichia coli and genetic variations in the CD14 and Toll-like receptor 4 (TLR4) genes in relation to atopic manifestations. Methods: Within the Child, Parent and Health: Lifestyle and Genetic Constitution (KOALA) Birth Cohort Study, fecal samples of 957 one-month-old infants were collected and quantitatively screened for E coli. Fourteen haplotype-tagging polymorphisms in the genes TLR4 and CD14 were genotyped in 681 of the 957 children. Atopic outcomes were parentally reported eczema in the first 2 years of life and clinically diagnosed eczema and allergic sensitization at age 2 years. Multiple logistic regression was used to evaluate a multiplicative model of interaction. Results: Most of the single nucleotide polymorphisms (SNPs) showed no significant interaction with E coli exposure for both eczema and allergic sensitization. A borderline significant multiplicative interaction was found between E coli and the rs2569190 (CD14/-159) SNP regarding allergic sensitization. Furthermore, a statistically significant multiplicative interaction was found for the TLR4 SNP rs10759932 (P for interaction = .001). E coli colonization was associated with a decreased risk of sensitization only in children with the rs10759932 TT genotype (adjusted odds ratio, 0.31; 95% CI, 0.14-0.68) and not in children with the minor C allele. This interaction remained statistically significant after controlling for multiple testing. Conclusion: The current study is the first to address the potential effect-modifying role of genetic variations in the relationship between the intestinal microbiota and allergy development. (J Allergy Clin Immunol 2010;125:231-6.)	[Penders, John; Thijs, Carel; Mommers, Monique] Maastricht Univ, Dept Epidemiol, Nutr & Toxicol Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands; [Penders, John; Thijs, Carel; Mommers, Monique] Maastricht Univ, Care & Publ Hlth Res Inst, NL-6200 MD Maastricht, Netherlands; [van den Brandt, Piet A.] Maastricht Univ, Dept Epidemiol, Res Inst Growth & Dev, NL-6200 MD Maastricht, Netherlands; [Penders, John; Stobberingh, Ellen E.] Univ Hosp Maastricht, Dept Med Microbiol, Maastricht, Netherlands; [Dompeling, Edward] Univ Hosp Maastricht, Dept Pediat Pulmonol, Maastricht, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, NL-9713 AV Groningen, Netherlands; [Reijmerink, Naomi E.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands; [Reijmerink, Naomi E.; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9713 AV Groningen, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9713 AV Groningen, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); University of Groningen; University of Groningen; University of Groningen; University of Groningen	Penders, J (corresponding author), Maastricht Univ, Dept Epidemiol, Nutr & Toxicol Res Inst Maastricht, POB 616, NL-6200 MD Maastricht, Netherlands.	j.penders@epid.unimaas.nl	Thijs, Carel/H-8340-2019; Koppelman, Gerard/AAG-9187-2020; Penders, John/A-1280-2011	Thijs, Carel/0000-0001-6646-5458; Penders, John/0000-0001-9146-5919; van den Brandt, Piet/0000-0001-8781-8099; Koppelman, Gerard/0000-0001-8567-3252	Netherlands Asthma Foundation [3.2.07.022]; Netherlands Organisation for Health Research and Development (ZonMw) [912-03-031]	Netherlands Asthma Foundation; Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	Supported by the Netherlands Asthma Foundation (grant no. 3.2.07.022) and The Netherlands Organisation for Health Research and Development (ZonMw; grant no. 912-03-031).	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bottema RWB, 2008, EUR RESPIR J, V32, P593, DOI 10.1183/09031936.00162407; Chen YC, 2005, CANCER RES, V65, P11771, DOI 10.1158/0008-5472.CAN-05-2078; Cheng I, 2007, CANCER EPIDEM BIOMAR, V16, P352, DOI 10.1158/1055-9965.EPI-06-0429; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Enquobahrie DA, 2008, AM J CARDIOL, V101, P1683, DOI 10.1016/j.amjcard.2008.02.052; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Koppelman GH, 2006, CURR ALLERGY ASTHM R, V6, P103, DOI 10.1007/s11882-006-0047-y; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kummeling I, 2005, PEDIATR ALLERGY IMMU, V16, P679, DOI 10.1111/j.1399-3038.2005.00333.x; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Sambrook J, 2001, MOL CLONING LAB MANU; Sepp E, 2005, CLIN EXP ALLERGY, V35, P1141, DOI 10.1111/j.1365-2222.2005.02315.x; Simhan HN, 2008, AM J OBSTET GYNECOL, V199; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Vercelli D, 2003, CURR OPIN ALLERGY CL, V3, P343, DOI 10.1097/01.all.0000092603.76804.e4; Watanabe S, 2003, J ALLERGY CLIN IMMUN, V111, P587, DOI 10.1067/mai.2003.105; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	29	25	27	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					231	236		10.1016/j.jaci.2009.10.011	http://dx.doi.org/10.1016/j.jaci.2009.10.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109750	Green Submitted, Bronze			2022-12-18	WOS:000273660500029
J	Pincus, M; Keil, T; Rucke, M; Bruenahl, C; Magdorf, K; Klapp, BF; Douglas, AJ; Paus, R; Wahn, U; Arck, P				Pincus, Maike; Keil, Thomas; Ruecke, Mirjam; Bruenahl, Christian; Magdorf, Klaus; Klapp, Burghard F.; Douglas, Alison J.; Paus, Ralf; Wahn, Ulrich; Arck, Petra			Fetal origin of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SUSCEPTIBILITY; COHORT; STRESS		[Pincus, Maike; Bruenahl, Christian; Magdorf, Klaus; Wahn, Ulrich] Charite, Med Ctr, Dept Pediat, Div Pneumol & Immunol, D-13353 Berlin, Germany; [Keil, Thomas] Charite, Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Ruecke, Mirjam; Klapp, Burghard F.; Arck, Petra] Charite, Med Ctr, Ctr Internal Med & Dermatol, D-13353 Berlin, Germany; [Bruenahl, Christian; Douglas, Alison J.] Univ Edinburgh, Sch Biomed Sci, Ctr Integrat Physiol, Edinburgh EH8 9YL, Midlothian, Scotland; [Paus, Ralf] Med Univ Lubeck, Dept Dermatol, Lubeck, Germany; [Paus, Ralf] Univ Manchester, Sch Translat Med, Dermatol Sci Grp, Manchester M13 9PL, Lancs, England; [Arck, Petra] McMaster Univ, Brain Body Inst, Hamilton, ON, Canada	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Edinburgh; University of Lubeck; University of Manchester; McMaster University	Pincus, M (corresponding author), Charite, Med Ctr, Dept Pediat, Div Pneumol & Immunol, D-13353 Berlin, Germany.	petra.arck@charite.de	Arck, Petra C/D-7094-2013; Paus, Ralf/F-6243-2011; Paus, Ralf/B-5279-2015	Arck, Petra/0000-0002-2932-926X; Paus, Ralf/0000-0002-3492-9358				Arck PC, 2008, REPROD BIOMED ONLINE, V17, P101, DOI 10.1016/S1472-6483(10)60300-8; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; DODD JM, 2006, COCHRANE DB SYST REV, V25; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Pepe GJ, 1998, HUM REPROD UPDATE, V4, P406, DOI 10.1093/humupd/4.4.406; Pincus-Knackstedt MK, 2006, J IMMUNOL, V177, P8484, DOI 10.4049/jimmunol.177.12.8484; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032	9	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					273	275		10.1016/j.jaci.2009.10.057	http://dx.doi.org/10.1016/j.jaci.2009.10.057			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109756				2022-12-18	WOS:000273660500038
J	Borger, P; Miglino, N; Baraket, M; Black, JL; Tamm, M; Roth, M				Borger, Peter; Miglino, Nicola; Baraket, Melissa; Black, Judith L.; Tamm, Michael; Roth, Michael			Impaired translation of CCAAT/enhancer binding protein alpha mRNA in bronchial smooth muscle cells of asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; bronchial smooth muscle cell hyperplasia; C/EBP alpha; messenger RNA translation	NF-KAPPA-B; C/EBP-ALPHA; EXPRESSION; BETA	Background: Bronchial smooth muscle (BSM) cells of asthmatic patients have an impaired expression of CCAAT/enhancer binding protein (C/EBP) alpha, which is associated with increased proliferation. Objective: We sought to assess the translational regulation of CEBPA mRNA in cultured BSM cells of healthy control subjects (n = 11) and asthmatic patients (n = 12). Methods: Translation efficiency was studied by using a translation control reporter system driven by the control elements present in the CEBPA mRNA. Translation efficiency was determined by the ratio of 2 artificial hemagglutinin (HA.11) proteins: p23 and p12. We also analyzed levels of proteins that control translation of CEBPA mRNA, namely heterogeneous nuclear ribonucleoprotein E2, calreticulin, eukaryotic translation initiation factor (eIF4E), and 4E binding protein. Results: Compared with healthy control subjects, BSM cells of asthmatic patients proliferate faster (2.1-fold) and are primed for IL-6 secretion., Real-time RT-PCR showed that BSM cells of asthmatic patients express normal levels of CEBPA mRNA, whereas they express lower levels of C/EBP alpha (p42). Transient transfections with the translation control reporter system construct showed a disturbed p12/p23 ratio in BSM cells of asthmatic patients relative to healthy control subjects, which coincided with lower levels of eIF4E. Conclusion: BSM cells of asthmatic patients have normal levels of CEBPA mRNA but inadequately reinitiate the translation into C/EBP alpha Impaired translation control upstream of eIF4E might underlie the observed increased proliferation and priming of BSM cells of asthmatic patients. (J Allergy Clin Immunol 2009;123:639-45.)	[Borger, Peter; Miglino, Nicola; Tamm, Michael; Roth, Michael] Univ Basel, Dept Biomed, CH-4031 Basel, Switzerland; [Roth, Michael] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia	University of Basel; University of Sydney; Woolcock Institute of Medical Research	Borger, P (corresponding author), Univ Basel, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland.	pieter.borger@unibas.ch	Black, Judith L/C-6559-2008; Roth, Michael/H-8657-2019	Roth, Michael/0000-0002-8139-2821	Swiss National Foundation [SNF32-116022]; Nora van Meeuven-Hafliger Stiftung; National Health and Medical Research Council of Australia; Anonymous Charitable Trust; Rebecca Cooper Foundation	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Nora van Meeuven-Hafliger Stiftung; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Anonymous Charitable Trust; Rebecca Cooper Foundation	Supported by a grant of the Swiss National Foundation (grant no. SNF32-116022) and the Nora van Meeuven-Hafliger Stiftung. J.L.B. is supported by the National Health and Medical Research Council of Australia.; Disclosure of potential conflict of interest: J. L. Black has received research support from the National Health and Medical Research Council (Australia), the Anonymous Charitable Trust, and the Rebecca Cooper Foundation. The rest of the authors have declared that they have no conflict of interest.	Azzola A, 2004, TRANSPLANTATION, V77, P275, DOI 10.1097/01.TP.0000101822.50960.AB; Borger P, 2002, J ALLERGY CLIN IMMUN, V110, P841, DOI 10.1067/mai.2002.130047; Borger P, 1999, J INFECT DIS, V180, P1267, DOI 10.1086/315027; Borger P, 2006, AM J RESP CRIT CARE, V174, P367, DOI 10.1164/rccm.200501-082PP; Borger P, 2007, J ALLERGY CLIN IMMUN, V119, P98, DOI 10.1016/j.jaci.2006.07.056; Burgess JK, 2003, AM J RESP CRIT CARE, V167, P71, DOI 10.1164/rccm.200205-416OC; Calkhoven CF, 2000, GENE DEV, V14, P1920; Calkhoven CF, 2002, TRENDS MOL MED, V8, P577, DOI 10.1016/S1471-4914(02)02424-3; Chen J, 2005, J BIOL CHEM, V280, P16354, DOI 10.1074/jbc.M411134200; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Eickelberg O, 1999, CIRCULATION, V99, P2276, DOI 10.1161/01.CIR.99.17.2276; Grunstein MM, 2005, J ALLERGY CLIN IMMUN, V116, P94, DOI 10.1016/j.jaci.2005.03.046; Halayko AJ, 2004, AM J RESP CELL MOL, V31, P266, DOI 10.1165/rcmb.2003-0272OC; Hamilton TL, 2006, BIOCHEM SOC T, V34, P12, DOI 10.1042/BST0340012; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Ma XF, 2002, AM J PHYSIOL-LUNG C, V283, pL1181, DOI 10.1152/ajplung.00389.2001; MATHEWS MB, 2000, ORIGINS PRINCIPLES T, P1; MIGLINO N, 2007, EUR RESP J S51, V30, pE1667; Nerlov C, 2004, NAT REV CANCER, V4, P394, DOI 10.1038/nrc1363; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Stephens NL, 2003, RESP PHYSIOL NEUROBI, V137, P125, DOI 10.1016/S1569-9048(03)00142-3; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; Trian T, 2007, J EXP MED, V204, P3173, DOI 10.1084/jem.20070956; *WHO NHLBI WORKSH, 1995, PUBL NIH; Wiesenthal V, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj029; Wiesenthal V, 2006, NAT PROTOC, V1, P1531, DOI 10.1038/nprot.2006.274; Zhong J, 2006, J CELL PHYSIOL, V207, P540, DOI 10.1002/jcp.20605	31	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					639	645		10.1016/j.jaci.2008.11.006	http://dx.doi.org/10.1016/j.jaci.2008.11.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19121862				2022-12-18	WOS:000264731200023
J	Mazuc, E; Villoutreix, BO; Malbec, O; Roumier, T; Fleury, S; Leonetti, JP; Dombrowicz, D; Daedron, M; Martineau, P; Dariavach, P				Mazuc, Elsa; Villoutreix, Bruno O.; Malbec, Odile; Roumier, Thomas; Fleury, Sebastien; Leonetti, Jean-Paul; Dombrowicz, David; Daedron, Marc; Martineau, Pierre; Dariavach, Piona			A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy and inflammation; anaphylactic shock; degranulation; druglike compound; mast cells/basophils; tyrosine kinase Syk	FC-EPSILON-RI; AFFINITY IGE RECEPTOR; GAMMA-RIII; SYK; PROTEIN; SLP-76; ACTIVATION; DEGRANULATION; ANTIBODIES; SUBSTRATE	Background: The spleen tyrosine kinase (Syk) is recognized as a potential pharmaceutical target for the treatment of type I hypersensitivity reactions including allergic rhinitis, urticaria, asthma, and anaphylaxis because of its critical position upstream of immunoreceptor signaling complexes that regulate inflammatory responses in leukocytes. Objective: Our aim was to improve the selectivity of anti-Syk therapies by impeding the interaction of Syk with its cellular partners, instead of targeting its catalytic site. Methods: We have previously studied the inhibitory effects of the anti-Syk intracellular antibody G4G11 on Fc is an element of RI-induced release of allergic mediators. A compound collection was screened by using an antibody displacement assay to identify functional mimics of G4G11 that act as potential inhibitors of the allergic response. The effects of the selected druglike compounds on mast cell activation were evaluated in vitro and in vivo. Results: We discovered compound 13, a small molecule that inhibits Fc is an element of RI-induced mast cell degranulation in vitro and anaphylactic shock in vivo. Importantly, compound 13 was efficient when administered orally to mice. Structural analysis, docking, and site-directed mutagenesis allowed us to identify the binding cavity of this compound, located at the interface between the 2 Src homology 2 domains and the interdomain A of Syk. Conclusion: We have isolated a new class of druglike compounds that modulate the interaction of Syk with some of its macromolecular substrates implicated in the degranulation pathway in mast cells.	[Dariavach, Piona] CRLC Val Aurelle, IRCM, INSERM, U896, F-34298 Montpellier 5, France; [Mazuc, Elsa; Martineau, Pierre; Dariavach, Piona] Univ Montpellier I, F-34006 Montpellier, France; [Mazuc, Elsa; Martineau, Pierre; Dariavach, Piona] Univ Montpellier 2, F-34095 Montpellier 5, France; [Villoutreix, Bruno O.] Univ Paris 05, INSERM, U648, F-75270 Paris 06, France; [Malbec, Odile; Daedron, Marc] INSERM, U760, F-75654 Paris 13, France; [Malbec, Odile; Daedron, Marc] Inst Pasteur, Paris, France; [Roumier, Thomas; Fleury, Sebastien; Dombrowicz, David] Univ Lille 2, INSERM, U547, F-59800 Lille, France; [Roumier, Thomas; Fleury, Sebastien; Dombrowicz, David] Inst Pasteur, Lille, France; [Leonetti, Jean-Paul] Ctr Natl Rech Sci, UMR 5236, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Dariavach, P (corresponding author), CRLC Val Aurelle, IRCM, INSERM, U896, Batiment Rech,208 Rue Apothicaires, F-34298 Montpellier 5, France.	piona.dariavach@valdorel.fnclcc.fr	Martineau, Pierre/N-4386-2017; Villoutreix, Bruno/I-4565-2015; Dombrowicz, David/F-7044-2013	Martineau, Pierre/0000-0002-7993-7183; Villoutreix, Bruno/0000-0002-6456-7730; Dombrowicz, David/0000-0002-0485-8923; Fleury, Sebastien/0000-0002-0679-3086				An Jianghong, 2004, Genome Inform, V15, P31; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; Coopman PJ, 2006, CANCER LETT, V241, P159, DOI 10.1016/j.canlet.2005.11.004; Costello PS, 1996, ONCOGENE, V13, P2595; Dauvillier S, 2002, J IMMUNOL, V169, P2274, DOI 10.4049/jimmunol.169.5.2274; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Frank R, 1996, Methods Mol Biol, V66, P149; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Kambayashi T, 2007, J ALLERGY CLIN IMMUN, V119, P544, DOI 10.1016/j.jaci.2007.01.017; Kettner A, 2003, MOL CELL BIOL, V23, P2395, DOI 10.1128/MCB.23.7.2395-2406.2003; LATOUR S, 1992, J IMMUNOL, V149, P2155; Laurie ATR, 2005, BIOINFORMATICS, V21, P1908, DOI 10.1093/bioinformatics/bti315; Law CL, 1996, MOL CELL BIOL, V16, P1305; Lobato MN, 2003, TRENDS MOL MED, V9, P390, DOI 10.1016/S1471-4914(03)00163-1; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Nadler M J, 2000, Adv Immunol, V76, P325; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Peneff C, 2000, J IMMUNOL METHODS, V236, P105, DOI 10.1016/S0022-1759(99)00228-8; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; QI Q, 2007, SCI STKE, V396, pPE39; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Saitoh S, 2003, J EXP MED, V198, P831, DOI 10.1084/jem.20030574; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Silverman MA, 2006, MOL CELL BIOL, V26, P1826, DOI 10.1128/MCB.26.5.1826-1838.2006; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Venkatachalam CM, 2003, J MOL GRAPH MODEL, V21, P289, DOI 10.1016/S1093-3263(02)00164-X; Wen RR, 2002, J IMMUNOL, V169, P6743, DOI 10.4049/jimmunol.169.12.6743; Wilson BS, 2002, MOL IMMUNOL, V38, P1259, DOI 10.1016/S0161-5890(02)00073-1; Wong WSF, 2004, BBA-PROTEINS PROTEOM, V1697, P53, DOI 10.1016/j.bbapap.2003.11.013; Wu JN, 2004, J IMMUNOL, V172, P6768, DOI 10.4049/jimmunol.172.11.6768	36	25	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					188	194		10.1016/j.jaci.2008.04.026	http://dx.doi.org/10.1016/j.jaci.2008.04.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18539317	Green Submitted			2022-12-18	WOS:000257605100030
J	Weber, RW				Weber, Richard W.			Guidelines for using pollen cross-reactivity in formulating allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Weber, RW (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	weberr@njc.org						Judd W.S., 1999, PLANT SYSTEMATICS PH; Mothes N, 2004, INT ARCH ALLERGY IMM, V135, P357, DOI 10.1159/000082332; Weber RW, 2007, ANN ALLERG ASTHMA IM, V99, P203, DOI 10.1016/S1081-1206(10)60654-0; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683	4	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					219	221		10.1016/j.jaci.2008.05.034	http://dx.doi.org/10.1016/j.jaci.2008.05.034			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18602577				2022-12-18	WOS:000257605100043
J	Dijkstra, A; Koppelman, GH; Vonk, JM; Bridnenberg, M; Schouten, JP; Postma, DS				Dijkstra, Antoon; Koppelman, Gerard H.; Vonk, Judith M.; Bridnenberg, Marcel; Schouten, Jan P.; Postma, Dirkje S.			Pharmacogenomics and outcome of asthma: No clinical application for long-term steroid effects by CRHR1 polymorphisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LUNG-FUNCTION DECLINE; ASSOCIATION		[Dijkstra, Antoon; Postma, Dirkje S.] Univ Med Ctr Groningen, Dept Pulmonol, NL-9713 AV Groningen, Netherlands; [Koppelman, Gerard H.] Univ Med Ctr Groningen, Beatrix Children Hosp, Dept Pediat Pulmonol & Pediat Allergol, NL-9713 AV Groningen, Netherlands; [Vonk, Judith M.; Schouten, Jan P.] Univ Med Ctr Groningen, Dept Epidemiol, NL-9713 AV Groningen, Netherlands; [Bridnenberg, Marcel] Univ Med Ctr Groningen, Dept Genet, NL-9713 AV Groningen, Netherlands; Univ Groningen, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen	Dijkstra, A (corresponding author), Univ Med Ctr Groningen, Dept Pulmonol, NL-9713 AV Groningen, Netherlands.	d.s.postma@int.umcg.nl	Koppelman, Gerard/AAG-9187-2020; Vonk, Judith M/ABA-3009-2020; Vonk, Judith/K-8477-2019	Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547; Koppelman, Gerard/0000-0001-8567-3252				Agelaki S, 2002, INFECT IMMUN, V70, P6068, DOI 10.1128/IAI.70.11.6068-6074.2002; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Theoharides TC, 1998, ENDOCRINOLOGY, V139, P403, DOI 10.1210/en.139.1.403; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Wechsler ME, 2006, PEDIATR ANN, V35, P660, DOI 10.3928/0090-4481-20060901-10; Weiss Scott T, 2004, Proc Am Thorac Soc, V1, P364, DOI 10.1513/pats.200409-043MS; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190	9	25	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1510	1513		10.1016/j.jaci.2008.04.015	http://dx.doi.org/10.1016/j.jaci.2008.04.015			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18539200	Bronze			2022-12-18	WOS:000256771700032
J	Clarke, E; Rahman, N; Page, N; Rolph, MS; Stewart, GJ; Jones, GJ				Clarke, Emily; Rahman, Nusrat; Page, Natalie; Rolph, Michael S.; Stewart, Graeme J.; Jones, Graham J.			Functional characterization of the atopy-associated gene PHF11	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PHF11; atopic dermatitis; asthma; atopy; T(H)1; T(H)2; small interfering RNA; nuclearfactor kappa B	NF-KAPPA-B; MESSENGER-RNA DECAY; CHROMOSOME 13Q14; GAMMA PRODUCTION; T-CELLS; DERMATITIS; DIFFERENTIATION; POLYMORPHISMS; PREDOMINANCE; EXPRESSION	Background: Polymorphisms in the plant homeodomain finger protein 11 gene (PHF11) are associated with increased total serum IgE levels, asthma, and severe atopic dermatitis (AD) in children. Although PHF11 includes a plant homeodomain, a motif often found in transcriptional regulators, the function of PHF11 has not been investigated. Objective: We sought to test (1) whether PHF-11 regulates the transcription of genes involved in allergic disorders and (2) whether polymorphisms in PHF11 predict changes in the expression or function of this gene. Methods: Microarray analysis was used to examine the expression of PHF11 in different immune cell subsets, and the function of PHF11 was tested by using small interfering RNA-induced knockdown or overexpression of PHF11 in primary CD4(+) T cells or Jurkat T cells. Genotype-dependent effects on PHF11 expression were tested by using an allele-specific gene expression, and the transcriptional activity of PHF11 was determined by using luciferase hybrid gene reporter assays and in vitro DNA-binding electromobility shift assays. Results: PHF11 expression was higher in T(H)1 cells relative to that in T(H)2 cells, and knockdown of PHF11 expression reduced expression of the T(H)1-type cytokines IFN-gamma and IL-2. The G-allele of a 3' untranslated region polymorphism associated with AD was correlated with reduced abundance of PHF11 RNA in T(H)1 cells, as well as an increase in a PHF11 isoform lacking exon II. Evidence was also found for a physical and functional interaction between PHF11 and the p65 subunit of nuclear factor kappa B. Conclusion: PHF11 is a regulator of T(H)1-type cytokine gene expression. The reduction in PHF11 expression seen with an AD-associated genotype could contribute to the strong TH2 responses that characterize many allergic individuals.	[Clarke, Emily; Rahman, Nusrat; Page, Natalie; Stewart, Graeme J.; Jones, Graham J.] Univ Sydney, Westmead Millennium Inst, Inst Immunol & Allergy Res, Westmead, NSW 2145, Australia; [Rolph, Michael S.] Garvan Inst Med Res, Darlinghurst, NSW, Australia	University of Sydney; Westmead Institute for Medical Research; Garvan Institute of Medical Research	Jones, GJ (corresponding author), Univ Sydney, Westmead Millennium Inst, Inst Immunol & Allergy Res, Westmead, NSW 2145, Australia.	graham_jones@wmi.usyd.edu.au						Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Aronica MA, 1999, J IMMUNOL, V163, P5116; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chtanova T, 2004, J IMMUNOL, V173, P68, DOI 10.4049/jimmunol.173.1.68; Chtanova T, 2005, J IMMUNOL, V175, P7837, DOI 10.4049/jimmunol.175.12.7837; Dieckhoff K, 2005, EXP DERMATOL, V14, P17, DOI 10.1111/j.0906-6705.2005.00241.x; Hohler T, 2005, J IMMUNOL, V175, P5457, DOI 10.4049/jimmunol.175.8.5457; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Jang N, 2005, GENES IMMUN, V6, P262, DOI 10.1038/sj.gene.6364169; Jones G, 2006, BRIT J DERMATOL, V154, P467, DOI 10.1111/j.1365-2133.2005.07080.x; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Katsunuma T, 2004, INT ARCH ALLERGY IMM, V134, P240, DOI 10.1159/000078772; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Liu SM, 2006, J ALLERGY CLIN IMMUN, V118, P496, DOI 10.1016/j.jaci.2006.04.040; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; Meier T, 1998, EUR J NEUROSCI, V10, P3141, DOI 10.1046/j.1460-9568.1998.00320.x; Nakazawa M, 1997, J ALLERGY CLIN IMMUN, V99, P673, DOI 10.1016/S0091-6749(97)70030-7; Owen HR, 2007, J MOL BIOL, V366, P725, DOI 10.1016/j.jmb.2006.11.099; Page NS, 2006, INT ARCH ALLERGY IMM, V141, P331, DOI 10.1159/000095459; Pan Q, 2006, GENE DEV, V20, P153, DOI 10.1101/gad.1382806; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tahvanainen J, 2006, J IMMUNOL METHODS, V310, P30, DOI 10.1016/j.jim.2005.11.024; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	31	25	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1148	1154		10.1016/j.jaci.2008.02.028	http://dx.doi.org/10.1016/j.jaci.2008.02.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18405956				2022-12-18	WOS:000255961700011
J	Cresswell, KM; Sheikh, A				Cresswell, Kathrin M.; Sheikh, Aziz			Information technology-based approaches to reducing repeat drug exposure in patients with known drug allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						drug allergies; information technology; patient safety; systems approach	PHYSICIAN ORDER ENTRY; PRESCRIBING ERRORS; COMPUTER-SYSTEMS; SAFETY FEATURES; PREVENTION; MANAGEMENT; EVENTS	There is increasing interest internationally in ways of reducing the high disease burden resulting from errors in medicine management. Repeat exposure to drugs to which patients have a known allergy has been a repeatedly identified error, often with disastrous consequences. Drug allergies are immunologically mediated reactions that are characterized by specificity and recurrence on reexposure. These repeat reactions should therefore be preventable. We argue that there is insufficient attention being paid to studying and implementing system-based approaches to reducing the risk of such accidental reexposure. Drawing on recent and ongoing research, we discuss a number of information technology-based interventions that can be used to reduce the risk of recurrent exposure. Proven to be effective in this respect are interventions that provide real-time clinical decision support; also promising are interventions aiming to enhance patient recognition, such as bar coding, radiofrequency identification, and biometric technologies.	[Cresswell, Kathrin M.; Sheikh, Aziz] Univ Edinburgh, Div Commun Hlth Sci Gen Practice, Allergy & Resp Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, Div Commun Hlth Sci Gen Practice, Allergy & Resp Res Grp, 20 W Richmond St, Edinburgh EH8 9DX, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056				Adkinson NF, 2002, J ALLERGY CLIN IMMUN, V109, pS461, DOI 10.1067/mai.2002.122214; Adkinson NF, 2006, ALLERGY, P157; Alrasbi M, 2007, ALLERGY, V62, P838, DOI 10.1111/j.1398-9995.2007.01434.x; [Anonymous], 1999, Ann Allergy Asthma Immunol, V83, P665; [Anonymous], [No title captured]; BACHELDOR B, TAGS TRACK SURG PATI; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Cohen M.R., 2000, MED ERRORS CAUSES PR; Coombs RRA., 1968, CLIN ASPECTS IMMUNOL, V2, P575; CZERNOWALOW M, SA PIL BIOM HEALTHC; DALTON J, USING RFID TECHNOLOG; Dzik S, 2007, TRANSFUSION, V47, p125S, DOI 10.1111/j.1537-2995.2007.01367.x; *E HLTH INS, PAT INF POW PRESCR; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Fernando B, 2004, BMJ-BRIT MED J, V328, P1171, DOI 10.1136/bmj.328.7449.1171; Franklin BD, 2007, QUAL SAF HEALTH CARE, V16, P279, DOI 10.1136/qshc.2006.019497; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gomes E., 2005, ALLERGY CLIN IMMUNOL, V17, P9; HEAD B, EYES HAVE IT IDENTIF; Hsieh TC, 2004, J AM MED INFORM ASSN, V11, P482, DOI 10.1197/jamia.M1556; KOHL G, REC GO DIG BIOM INT; Kuperman GJ, 2003, J BIOMED INFORM, V36, P70, DOI 10.1016/S1532-0464(03)00063-7; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; Marconi M, 2000, Immunohematology, V16, P82; McDonald CJ, 2006, ANN INTERN MED, V144, P510, DOI 10.7326/0003-4819-144-7-200604040-00010; *MED HEALTHC PROD, 2007, MON SAF QUAL MED YEL; *MED NEWS TOD, HOR BLUE SHIELD NEW; *MOR RFID, VERICHIP CORP ALZH C; Morris CJ, 2005, QUAL SAF HEALTH CARE, V14, P164, DOI 10.1136/qshc.2004.011866; *NAT PAT SAF AG, 2007, NAT REP LEARN SYST; *NAT PAT SAF AG, 2007, STAND WRISTB IMPR PA; National Patient Safety Agency, 2007, SAF DOS MED SAF INC; *NEC SEC SOL, BIOM BEC PART HEALTH; Pagliari C, 2007, BMJ-BRIT MED J, V335, P330, DOI 10.1136/bmj.39279.482963.AD; Patterson ES, 2002, J AM MED INFORM ASSN, V9, P540, DOI 10.1197/jamia.M1061; *PREC DYN CORP, RFID TECHN INT 100 A; Siminerio LM, 2000, DIABETES, V49, pA173; Turner CL, 2003, TRANSFUSION, V43, P1200, DOI 10.1046/j.1537-2995.2003.00428.x; Vervloet D, 1998, BRIT MED J, V316, P1511, DOI 10.1136/bmj.316.7143.1511; WESSEL R, RFID BANDS JACOBI ME; WESSEL R, GERMAN CLIN USES RFI	43	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1112	1117		10.1016/j.jaci.2007.12.1180	http://dx.doi.org/10.1016/j.jaci.2007.12.1180			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18313132				2022-12-18	WOS:000255961700006
J	Karwot, R; Maxeiner, JH; Schmitt, S; Scholtes, P; Hausding, M; Lehr, HA; Glimcher, LH; Finotto, S				Karwot, Roman; Maxeiner, Joachim H.; Schmitt, Steffen; Scholtes, Petra; Hausding, Michael; Lehr, Hans A.; Glimcher, Laurie H.; Finotto, Susetta			Protective role of nuclear factor of activated T cells 2 in CD8(+) long-lived memory T cells in an allergy model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NFATc2; CD8(+) T cells; IL-2; IL-10; IFN-gamma; IL-17; long-lived memory cells; CD8(+) CD122(+)(IL-2R beta)(+)CD127(IL-7R alpha)(+) T cells; allergy; model of human allergic asthma	IFN-GAMMA PRODUCTION; MICE LACKING; EXPRESSION; ASTHMA; TRANSCRIPTION; IL-10; DIFFERENTIATION; HOMEOSTASIS; CYTOKINES; PROTEINS	Background: The transcriptional regulation of cytokines released and controlled by memory T cells is not well understood. Defective IFN-gamma production in allergic asthma correlates in human beings with the risk of wheezing in childhood. Objective: To understand the role of the transcription factor nuclear factor of activated T cells 2 (NFATc2) in memory and effector T cells in the airways in experimental allergic asthma. Methods: We used murine models of allergic asthma and adoptive cell transfer of fluorescence-activated sorted cells in a disease model. Results: Mice lacking NFATc2 developed an increase in airway hyperresponsiveness (AHR), remodeling, and serum IgE levels on ovalbumin sensitization. This phenotype was associated with CD8(+)CD122(-) T cells deficient in IFN-gamma production in the airways. The origin of this phenotype in NFATc2((-/-)) mice was related to an expanded population of lung CD8(+)CD122(+) (IL-2R beta chain) CD127(hi) (IL-7 receptor [R] alpha chain(+)) long-lived memory cells. Adoptive transfer of ovalbumin-specific CD8(+) NFATc2((-/-)) T cells enhanced the AHR generated by NFATc2((-/-)) CD4(+) T cells in immunodeficient mice, increased IL-17, and reduced IFN-gamma production in the reconstituted mice. Depletion of the memory CD8(+)CD122(+)IL-7R(high) T-cell population corrected the defect in IFN-gamma production by lung NFATc2((-/-)) CD8(+)CD122(+) cells and abrogated the increased AHR observed in NFATc2((-/-)) CD8(+) T-cell-reconstituted mice with a severe combined immunodeficiency disorder. Conclusion: Taken together, our results suggest that NFATc2 expression in long-lived memory CD8(+) T cells controls IL-2 and IFN-gamma production in lung CD8(+) T cells, which then limits T(H)17 and T(H)2 development in the airways during allergen challenge.	[Karwot, Roman; Maxeiner, Joachim H.; Scholtes, Petra; Hausding, Michael; Finotto, Susetta] Johannes Gutenberg Univ Mainz, Lab Cellular & Mol Lung Immunol, Med Clin 1, D-55131 Mainz, Germany; [Schmitt, Steffen] Johannes Gutenberg Univ Mainz, Fluorescence Activated Cell Sorting Core Facil, D-55131 Mainz, Germany; [Lehr, Hans A.] Univ Lausanne, CHU Vaudois, Inst Pathol, CH-1015 Lausanne, Switzerland; [Glimcher, Laurie H.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Glimcher, Laurie H.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Finotto, S (corresponding author), Johannes Gutenberg Univ Mainz, Lab Cellular & Mol Lung Immunol, Med Clin 1, Obere Zahlbacher Str 63,Room 1-359, D-55131 Mainz, Germany.	finotto@mail.uni-mainz.de	Finotto, Susetta/H-2753-2019		NIAID NIH HHS [AI31541] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031541, U01AI031541] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Endharti AT, 2005, J IMMUNOL, V175, P7093, DOI 10.4049/jimmunol.175.11.7093; Finotto S, 2005, INT IMMUNOL, V17, P993, DOI 10.1093/intimm/dxh281; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Hu XY, 2006, IMMUNITY, V24, P563, DOI 10.1016/j.immuni.2006.02.014; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009; Kalia V, 2006, CURR OPIN IMMUNOL, V18, P255, DOI 10.1016/j.coi.2006.03.020; Klein M, 2006, J IMMUNOL, V177, P6667, DOI 10.4049/jimmunol.177.10.6667; Klonowski KD, 2005, SEMIN IMMUNOL, V17, P219, DOI 10.1016/j.smim.2005.02.004; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Maxeiner JH, 2007, NAT PROTOC, V2, P105, DOI 10.1038/nprot.2007.8; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567; Rifa'i M, 2004, J EXP MED, V200, P1123, DOI 10.1084/jem.20040395; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Srinivasan M, 2007, J IMMUNOL, V179, P3734, DOI 10.4049/jimmunol.179.6.3734; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Trifari S, 2006, J IMMUNOL, V177, P7451, DOI 10.4049/jimmunol.177.10.7451; Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548; Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892	28	25	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					992	999		10.1016/j.jaci.2007.12.1172	http://dx.doi.org/10.1016/j.jaci.2007.12.1172			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18329088				2022-12-18	WOS:000254884000026
J	Saxon, A; Kepley, C; Zhang, K				Saxon, Andrew; Kepley, Chris; Zhang, Ke			"Accentuate the negative, eliminate the positive": Engineering allergy therapeutics to block allergic reactivity through negative signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IgE therapeutics; immune response modifiers; allergy therapy; Fc gamma RII; Fc epsilon RI; mast cells; basophils	FC-EPSILON-RI; HUMAN MAST-CELLS; GAMMA-RII; IGE; COAGGREGATION; INHIBITION; ASTHMA	By targeting the dominant-negative signaling receptor Fc gamma RIIb expressed on proallergic cells, we have developed 2 novel platforms for the treatment of IgE-mediated allergic disease. First is a genetically engineered bifunctional human fusion protein GE2, which is comprised of the Fc portions of human IgE and IgG1 with an interposed flexible linker designed as a long-term parenteral allergen-nonspecific therapy. GE2 blocks the effector phase of the IgE response in vitro in mice and human subjects and in vivo in the skin and airway and systemically in mice and monkeys. Whether reactivity against human GE2 in human subjects will limit its applicability remains to be determined. The second platform is designed to provide a safer form of allergen-specific immunotherapy and consists of genetically engineered chimeric human Fc gamma-allergen proteins, with Fc gamma-Fel d 1 as the prototype. The allergen portion binds to specific IgE on Fc epsilon Rs, whereas the Fc gamma portion coaggregates inhibitory Fc gamma RIIb and drives inhibition of allergic reactivity. Fc gamma-Fel d 1 blocked human mast cell Fel d 1-induced allergic reactivity in vitro and in vivo in murine models while functioning as an immunogen but not as an allergen.	[Saxon, Andrew; Zhang, Ke] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; [Kepley, Chris] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA	University of California System; University of California Los Angeles; Virginia Commonwealth University	Saxon, A (corresponding author), Univ Calif Los Angeles, Dept Med, 52-262 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	asaxon@mednet.ucla.edu			NIAID NIH HHS [AI-15251] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015251, R21AI015251] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen LC, 2007, J ALLERGY CLIN IMMUN, V120, P462, DOI 10.1016/j.jaci.2007.04.019; ARLEN H, 1944, CAPITOL RECORDS; DACRON M, 1997, ANNU REV IMMUNOL, V15, P203; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; Kepley CL, 2003, CLIN IMMUNOL, V108, P89, DOI 10.1016/S1521-6616(03)00155-4; Malbec O, 1998, J IMMUNOL, V160, P1647; MERTSCHING E, 2007, J ALLERGY CLIN IMMUN; Munitz A, 2007, J ALLERGY CLIN IMMUN, V119, P1382, DOI 10.1016/j.jaci.2007.01.031; Oliver JM, 2000, IMMUNOPHARMACOLOGY, V48, P269, DOI 10.1016/S0162-3109(00)00224-1; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; Schelegle ES, 2001, AM J PATHOL, V158, P333, DOI 10.1016/S0002-9440(10)63973-9; Suzuki H, 1997, J IMMUNOL, V159, P5881; Tam SW, 2004, ALLERGY, V59, P772, DOI 10.1111/j.1398-9995.2004.00332.x; Terada T, 2006, CLIN IMMUNOL, V120, P45, DOI 10.1016/j.clim.2005.12.010; Van Scott MR, 2005, J APPL PHYSIOL, V99, P2080, DOI 10.1152/japplphysiol.00537.2005; Van Scott MR, 2004, J APPL PHYSIOL, V96, P1433, DOI 10.1152/japplphysiol.01128.2003; Yamada T, 2003, J BIOL CHEM, V278, P32818, DOI 10.1074/jbc.M304590200; Zhang K, 2004, J ALLERGY CLIN IMMUN, V114, P321, DOI 10.1016/j.jaci.2004.03.058; Zhao W, 2006, J IMMUNOL, V177, P694, DOI 10.4049/jimmunol.177.1.694; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	23	25	31	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					320	325		10.1016/j.jaci.2007.10.017	http://dx.doi.org/10.1016/j.jaci.2007.10.017			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18086492				2022-12-18	WOS:000253337800004
J	Miller, M; Ramsdell, J; Friedman, PJ; Cho, JY; Renvall, M; Broide, DH				Miller, Marina; Ramsdell, Joe; Friedman, Paul J.; Cho, Jae Youn; Renvall, Marian; Broide, David H.			Computed tomographic scan-diagnosed chronic obstructive pulmonary disease-emphysema: Eotaxin-1 is associated with bronchodilator response and extent of emphysema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eosinophil; eotaxin; cytokines; chemokines	AIR-FLOW LIMITATION; SPUTUM EOSINOPHILIA; INFLAMMATION; ASTHMA; REVERSIBILITY; INTERLEUKIN-5; EXPRESSION	Background: Bronchodilator responses are a hallmark of asthma and a subset of chronic obstructive pulmonary disease (COPD). We evaluated subjects with COPD and computed tomographic (CT) scan evidence of emphysema to determine the biomarker profile associated with a bronchodilator response. Objective: We investigated whether subjects with COPD and a bronchodilator response had increased levels of bronchoalveolar lavage (BAL) fluid eosinophil biomarkers, T(H)2 cytokines, CC chemokines, and serum allergen-specific IgE. Methods: All patients with COPI) and control subjects (n = 31) had chest CT scans to detect emphysema and subsequent pulmonary function studies, BAL for biomarkers, and serum IgE measurements. Results: CT scan score, FEV1, carbon monoxide single-breath diffusion capacity, and BAL fluid neutrophil biomarker levels were similar in subjects with COPD who had or did not have a bronchodilator response of greater than 12%. In contrast, levels of BAL fluid eosinophil biomarkers (eosinophil cationic protein [ECP] and eotaxin-D were greater in patients with COPD with a bronchodilator response, whereas TH2 cytokines were not detectable in any patients with COPD. BAL fluid ECP and eotaxin-1 levels correlated with CT scan extent of emphysema. Immunostaining of COPD lung sections from a separate cohort of subjects with COPD and healthy subjects demonstrated epithelial expression of eotaxin-1 but no lung expression of IL-4 or IL-5. Conclusion: Subjects with COPD diagnosed on the basis of the presence of emphysema on CT scan who have a bronchodilator response have increased levels of BAL ECP and eotaxin-1 but not TH2 cytokines. Clinical implications: Eosinophil biomarkers (ECP-1 and eotaxin-1) might identify a subset of subjects with COPD with emphysema on CT scans who have a bronchodilator response and an increased extent of emphysema on CT scanning.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, Biomed Sci Bldg,Room 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.	dbroide@ucsd.edu		Broide, David/0000-0001-8405-9090	NCRR NIH HHS [MO1RR000827] Funding Source: Medline; NHLBI NIH HHS [HL72342] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072342] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P814; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524; MULLER NL, 1988, CHEST, V94, P782, DOI 10.1378/chest.94.4.782; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773, DOI 10.1164/ajrccm.162.5.9910112; Pauwels R A, 2001, Respir Care, V46, P798; Perng DW, 2004, CHEST, V126, P375, DOI 10.1378/chest.126.2.375; SUR S, 1995, J ALLERGY CLIN IMMUN, V96, P661, DOI 10.1016/S0091-6749(95)70265-2; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; VEREBEY KG, 1982, J ANAL TOXICOL, V6, P294, DOI 10.1093/jat/6.6.294; Vignola AM, 2004, EUR RESPIR J, V24, P910, DOI 10.1183/09031936.04.00032603; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322	20	25	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1118	1125		10.1016/j.jaci.2007.08.045	http://dx.doi.org/10.1016/j.jaci.2007.08.045			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17983873				2022-12-18	WOS:000250973400021
J	Palmer, K; Green, TD; Roberts, JL; Sajaroff, E; Cooney, M; Parrott, R; Chen, DF; Reinsmoen, NL; Buckley, RH				Palmer, Kricia; Green, Todd D.; Roberts, Joseph L.; Sajaroff, Elisa; Cooney, Myriah; Parrott, Roberta; Chen, Dong-Feng; Reinsmoen, Nancy L.; Buckley, Rebecca H.			Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						severe combined immunodeficiency; transplacentally transferred maternal T cells; graft-versus-host disease	TRANSPLANTATION; AMPLIFICATION; DEFICIENCY; GAMMOPATHY; PHENOTYPE; CLONING	The persistence of transplacentally transferred maternal T cells is common in infants with severe combined immunodeficiency (SCID), occurring in more than half of patients with SCID undergoing transplantation at our institution. These T cells respond poorly to mitogens in vitro but can cause cutaneous graft-versus-host disease; however, other effects of these cells are unknown. We describe 2 infants with SCID who had unusual problems associated with transplacentally transferred maternal T cells. Patient 1 was a 5-month-old girl with Janus kinase 3-deficient SCID who had 4% circulating CD3+ T cells but no lymphocyte proliferative response to mitogens. Although the number of T cells increased after 2 nonchemoablated, T cell-depleted, haploidentical, paternal bone marrow transplantations, T-cell function failed to develop, and she became pancytopenic. Restriction fragment length polymorphism studies of How cytometry-sorted blood T cells revealed all to be of maternal origin. A subsequent nonchemoablated, T cell-depleted maternal transplantation resulted in normal T-cell function and marrow recovery. Patient 2 was a 9-month-old girl with IL-7R alpha-deficient SCID who presented with autoimmune pancytopenia. She had 8% blood T cells (all CD45RO(+)) but no response to mitogens. High-resolution HLA sequence-specific priming typing detected both maternal haplotypes, indicating the presence of maternal cells. Her pancytopenia resolved after treatment with rituximab and was thought to be due to host B-cell activation by transplacentally acquired maternal T cells. Persistent transplacentally acquired maternal T cells in infants with SCID can mediate immunologic functions despite failing respond to mitogens in vitro. We present evidence that these cells can cause allograft rejection and immune cytopenias.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Pediat Allergy & Immunol, Durham, NC 27706 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27706 USA	Duke University; Duke University; Duke University	Buckley, RH (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Box 2898, Durham, NC 27710 USA.	buck1003@mc.duke.edu	Buckley, Rebecca/AAB-1578-2019		NCRR NIH HHS [5M01-RR-00030] Funding Source: Medline; NIAID NIH HHS [5R01-AI042951-08, 5R01-AI047605-06] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047605, R01AI042951] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; FRIEDMAN NJ, 1991, PEDIAT ALLERG IMMUNO, V2, P111; GHORY P, 1986, J CLIN IMMUNOL, V6, P161, DOI 10.1007/BF00918749; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; KADOWAKI JI, 1965, LANCET, V2, P1152; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KENT EF, 1990, J CLIN IMMUNOL, V10, P106, DOI 10.1007/BF00918192; KNOBLOCH C, 1991, J IMMUNOL, V146, P4157; Kobrynski LJ, 2006, J PEDIAT HEMATOL ONC, V28, P53; LEDEIST F, 1987, J IMMUNOL, V138, P423; Lo YMD, 1996, BLOOD, V88, P4390; Muller SM, 2001, BLOOD, V98, P1847, DOI 10.1182/blood.V98.6.1847; Niehues T, 1996, ARCH DIS CHILD, V74, P340, DOI 10.1136/adc.74.4.340; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; Plebani A, 1998, J ALLERGY CLIN IMMUN, V101, P131, DOI 10.1016/S0091-6749(98)70207-6; POLLACK MS, 1982, NEW ENGL J MED, V307, P662, DOI 10.1056/NEJM198209093071106; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Roberts JL, 2004, BLOOD, V103, P2009, DOI 10.1182/blood-2003-06-2104; Scaradavou A, 1996, BLOOD, V88, P1494, DOI 10.1182/blood.V88.4.1494.bloodjournal8841494; Tezcan I, 2005, J PEDIATR-US, V146, P137, DOI 10.1016/j.jpeds.2004.09.010; THOMPSON LF, 1984, J IMMUNOL, V133, P2513	23	25	26	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					423	428		10.1016/j.jaci.2007.02.047	http://dx.doi.org/10.1016/j.jaci.2007.02.047			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17481714	Bronze			2022-12-18	WOS:000248654900031
J	Andrews, AL; Bucchieri, F; Arima, K; Izuhara, K; Holgate, ST; Davies, DE; Holloway, JW				Andrews, Allison-Lynn; Bucchieri, Fabio; Arima, Kazuhiko; Izuhara, Kenji; Holgate, Stephen T.; Davies, Donna E.; Holloway, John W.			Effect of IL-13 receptor alpha 2 levels on the biological activity of IL-13 variant R110Q	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IL-13R alpha 2; IL-13; polymorphisms	GERMAN MULTICENTER ATOPY; PROMOTER POLYMORPHISM; INTERLEUKIN-13 GENE; BRONCHIAL-ASTHMA; IGE SYNTHESIS; ALPHA CHAIN; B-CELLS; CLONING; IDENTIFICATION; RECEPTORS	Background: IL-13 is a key cytokine associated with the asthmatic phenotype. IL-13 signals via its cognate receptor, a complex of IL-13 receptor (11,4311) a I chain with IL-4 receptor a; however, a second protein, 11,IL-13R alpha 2, also binds IL-13. Recently a polymorphic variant of IL-13 (R110Q) has been shown to be associated with atopy. Objective: To investigate the binding properties of this IL-13 variant to its cognate receptors. Methods: We used surface plasmon resonance to measure the binding kinetics of R110Q to its receptors. Primary human fibroblasts were grown from endobronchial biopsies obtained from volunteers. Receptor levels were measured by fluorescence-activated cell sorting. Results: There was no significant difference in the binding of R110Q with soluble human IL-13R alpha 1 compared with IL-13 (32 +/- 5 nmol/L and 36 +/- 7 nmol/L, respectively; P =.625). However, a small but significant difference was observed in the binding of R110Q to soluble human 11,IL-13R alpha 2 compared with IL-13 (840 +/- 87 pmol/L and 1.1 +/- .05 nmot/L, respectively; P =.04). We observed that primary human lung fibroblasts expressed different levels of 11,IL-13R alpha 2. Eotaxin release from fibroblasts expressing low IL-13R alpha 2 levels was significantly higher in response to R110Q compared with IL-13. This was not evident in cells that had high baseline 11,IL-13R alpha 2 levels. Conclusion: These results suggest that relatively small changes in functional properties of a ligand combined with variation in receptor levels in vivo can result in significant differences in responsiveness. Clinical implications: Expression of R110Q and low IL-13R alpha 2 levels can result in important biological differences that may have clinical relevance in an atopic environment.	Univ Southampton, Southampton Gen Hosp, Infect Inflammat & Repair Div, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Human Genet Div, Sch Med, Southampton SO16 6YD, Hants, England; Univ Palermo, Human Anat Sect, Dept Expt Med, I-90133 Palermo, Italy; Saga Med Sch, Dept Biomol Sci, Saga 84001, Japan	University of Southampton; University of Southampton; University of Palermo; Saga University	Holloway, JW (corresponding author), Univ Southampton, Southampton Gen Hosp, Infect Inflammat & Repair Div, MP810,Level F,S Block, Southampton SO16 6YD, Hants, England.	J.W.Holloway@soton.ac.uk	Holloway, John W/B-5424-2009; Arima, Kazuhiko/I-8962-2014; Davies, Donna E/H-2993-2012; Bucchieri, Fabio/F-8877-2012	Holloway, John W/0000-0001-9998-0464; Arima, Kazuhiko/0000-0002-0607-8787; Davies, Donna/0000-0002-5117-2991; BUCCHIERI, Fabio/0000-0002-0209-8668	MRC [G0800766] Funding Source: UKRI; Asthma UK [RF06/01] Funding Source: researchfish; Medical Research Council [G0800766] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Andrews AL, 2002, J BIOL CHEM, V277, P46073, DOI 10.1074/jbc.M209560200; Andrews AL, 2006, J ALLERGY CLIN IMMUN, V118, P858, DOI 10.1016/j.jaci.2006.06.041; Arima K, 2005, J BIOL CHEM, V280, P24915, DOI 10.1074/jbc.M502571200; Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044; Chomarat P, 1998, Int Rev Immunol, V17, P1, DOI 10.3109/08830189809084486; Cookson WOC, 2000, HUM MOL GENET, V9, P2359, DOI 10.1093/hmg/9.16.2359; de Vries JE, 1999, J ALLERGY CLIN IMMUN, V103, pS492, DOI 10.1016/S0091-6749(99)70166-1; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Hummelshoj T, 2003, EUR J IMMUNOGENET, V30, P355, DOI 10.1046/j.1365-2370.2003.00416.x; Izuhara K, 2006, CURR MED CHEM, V13, P2291, DOI 10.2174/092986706777935140; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Liu X, 2004, J ALLERGY CLIN IMMUN, V113, P489, DOI 10.1016/j.jaci.2003.12.037; Lordan JL, 2002, J IMMUNOL, V169, P407, DOI 10.4049/jimmunol.169.1.407; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Oshima Y, 2000, J BIOL CHEM, V275, P14375, DOI 10.1074/jbc.275.19.14375; Pantelidis P, 2000, GENES IMMUN, V1, P341, DOI 10.1038/sj.gene.6363679; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Vercelli D, 2003, CURR OPIN IMMUNOL, V15, P609, DOI 10.1016/j.coi.2003.09.005; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; Wang M, 2003, HUM GENET, V113, P387, DOI 10.1007/s00439-003-1001-x; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	37	25	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					91	97		10.1016/j.jaci.2007.04.026	http://dx.doi.org/10.1016/j.jaci.2007.04.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17560640				2022-12-18	WOS:000248066400013
J	Bohm, A; Fodinger, M; Wimazal, F; Haas, OA; Mayerhofer, M; Sperr, WR; Esterbauer, H; Valent, P				Boehm, Alexandra; Foedinger, Manuela; Wimazal, Friedrich; Haas, Oskar A.; Mayerhofer, Matthias; Sperr, Wolfgang R.; Esterbauer, Harald; Valent, Peter			Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mastocytosis; eosinophilia; targets; KIT D816V; FIP1L1/PDGFR alpha	IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; POLYMERASE-CHAIN-REACTION; MAST-CELL DISEASE; C-KIT; FIP1L1-PDGFRA FUSION; IMATINIB MESYLATE; CLASSIFICATION; DISORDERS; THERAPY; LEUKEMIA	Background: In a group of patients with systemic mastocytosis (SM), marked and sustained eosinophilia is detectable (SM-eo). Objective: Although the molecular defect has been defined in some cases, little is known about the impact and clinical correlates of eosinophilia. Methods: In a cohort of 63 patients with SM, we identified 9 with permanent eosinophilia (> 1500/mu L). According to the World Health Organization classification, 2 bad indolent SM, I had smoldering SM, 2 had SM with associated chronic eosinophilic leukemia (SM-CEL), and 4 had aggressive SM. Results: SM-eo was found to be associated with a significantly reduced probability of overall and event-free survival compared with SM without eosinophilia (P < .05). In the 2 patients with SM-CEL, a CHIC2 deletion was found. By contrast, no KIT mutation at codon 816 was detectable in these patients. In the other patients with SM-eo, KIT D816V was demonstrable. The 2 patients with SM-CEL had cardiomyopathy, whereas other organ systems remained largely unaffected. By contrast, in all other patients with SM-eo, organopathy, if recorded, affected the bone marrow, liver, or/and skeletal system, but not the heart, even when eosinophilia persisted for many years. Conclusions: The biochemical basis of eosinophilia in SM is variable and predictive for the type of organopathy. Clinical implications: In SM eosinophilia is of prognostic significance but is not a final diagnosis and is not invariably associated with cardiomyopathy. The latter might be restricted to cases with an associated primary eosinophilic disorder	Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria; Med Univ Vienna, Clin Inst Med & Chem Lab Diagnost, Vienna, Austria; CCRI, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Saint Anna Children's Hospital	Valent, P (corresponding author), Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	peter.valent@meduniwien.ac.at	Gamperl, Susi/V-2715-2019; Test, Test/Y-7921-2019; Sperr, Mast/V-4767-2019; Valent, Peter/B-8533-2016; Haas, Oskar/AAM-5794-2020; Test, PV/U-9451-2019	Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Sperr, Wolfgang/0000-0003-3288-8027; Esterbauer, Harald/0000-0001-7343-7455				Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; AUSTEN KF, 1992, NEW ENGL J MED, V326, P639, DOI 10.1056/NEJM199202273260912; Bain BJ, 2004, AM J HEMATOL, V77, P82, DOI 10.1002/ajh.20088; Bain BJ, 2004, BLOOD, V104, P3836, DOI 10.1182/blood-2004-07-2680; Bain BJ, 2001, WHO CLASSIFICATION T, P29; CHRISTEN R, 1989, KLIN WOCHENSCHR, V67, P358, DOI 10.1007/BF01741392; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Corradi D, 2004, HUM PATHOL, V35, P1160, DOI 10.1016/j.humpath.2004.05.008; Escribano L, 2002, ANN HEMATOL, V81, P677, DOI 10.1007/s00277-002-0575-z; Escribano L, 2004, CYTOM PART B-CLIN CY, V58B, P1, DOI 10.1002/cyto.b.10072; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; Feger F, 2002, INT ARCH ALLERGY IMM, V127, P110, DOI 10.1159/000048179; Florian S, 2006, LEUKEMIA RES, V30, P1201, DOI 10.1016/j.leukres.2005.11.014; Fodinger M, 1999, DIAGN MOL PATHOL, V8, P80, DOI 10.1097/00019606-199906000-00004; Fritsche-Polanz R, 2001, BRIT J HAEMATOL, V113, P357, DOI 10.1046/j.1365-2141.2001.02783.x; Gotlib J, 2005, ACTA HAEMATOL-BASEL, V114, P7, DOI 10.1159/000085559; HARNDEN DG, 1981, CYTOGENET CELL GENET, V31, P5; Hauswirth AW, 2002, LEUKEMIA RES, V26, P601, DOI 10.1016/S0145-2126(01)00172-2; Hauswirth AW, 2004, LEUKEMIA RES, V28, P249, DOI 10.1016/S0145-2126(03)00259-5; Horny HP, 2004, J CLIN PATHOL, V57, P604, DOI 10.1136/jcp.2003.014860; HORNY HP, 1990, BRIT J HAEMATOL, V76, P186, DOI 10.1111/j.1365-2141.1990.tb07870.x; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Klion AD, 2004, BLOOD, V103, P4050, DOI 10.1182/blood-2003-11-3850; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Kluin-Nelemans HC, 2003, BLOOD, V102, P4270, DOI 10.1182/blood-2003-05-1699; Konig M, 2002, BRIT J HAEMATOL, V116, P758, DOI 10.1046/j.0007-1048.2002.03340.x; LAWRENCE JB, 1991, AM J MED, V91, P612, DOI 10.1016/0002-9343(91)90214-I; LENNERT K, 1979, HISTOPATHOLOGY, V3, P349, DOI 10.1111/j.1365-2559.1979.tb03017.x; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Metcalfe DD, 1991, J INVEST DERMATOL, V96, p2S; Mitterbauer-Hohendanner G, 2004, LEUKEMIA, V18, P1102, DOI 10.1038/sj.leu.2403376; Muller AMS, 2006, ANN HEMATOL, V85, P1, DOI 10.1007/s00277-005-1084-7; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NUNODA S, 1991, Heart and Vessels, V6, P116, DOI 10.1007/BF02058759; Pallisgaard N, 1998, BLOOD, V92, P574, DOI 10.1182/blood.V92.2.574; Pardanani A, 2004, BLOOD, V104, P3038, DOI 10.1182/blood-2004-03-0787; Pardanani A, 2003, BLOOD, V102, P3093, DOI 10.1182/blood-2003-05-1627; Pardanani A, 2003, BLOOD, V101, P3391, DOI 10.1182/blood-2002-10-3103; Schernthaner GH, 2001, BLOOD, V98, P3784, DOI 10.1182/blood.V98.13.3784; Sperr WR, 2001, LEUKEMIA RES, V25, P529, DOI 10.1016/S0145-2126(01)00041-8; Sperr WR, 2002, INT ARCH ALLERGY IMM, V127, P140, DOI 10.1159/000048186; Sperr WR, 2000, LEUKEMIA LYMPHOMA, V37, P473, DOI 10.3109/10428190009058500; Tefferi A, 2005, ACTA HAEMATOL-BASEL, V114, P52, DOI 10.1159/000085562; Tefferi A, 2004, CURR OPIN HEMATOL, V11, P58, DOI 10.1097/00062752-200401000-00009; Tefferi Ayalew, 2004, Curr Hematol Rep, V3, P197; TRAVIS WD, 1988, CANCER, V62, P965, DOI 10.1002/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M; Valent P, 1996, WIEN KLIN WOCHENSCHR, V108, P385; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2003, HEMATOL ONCOL CLIN N, V17, P1227, DOI 10.1016/S0889-8588(03)00089-3; Valent P, 2003, LEUKEMIA RES, V27, P635, DOI 10.1016/S0145-2126(02)00168-6; Valent P, 2001, WHO CLASSIFICATION T, P291	52	25	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					192	199		10.1016/j.jaci.2007.03.015	http://dx.doi.org/10.1016/j.jaci.2007.03.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17451799				2022-12-18	WOS:000248066400028
J	Nie, ZY; Nelson, CS; Jacoby, DB; Fryer, AD				Nie, Zhenying; Nelson, Cole S.; Jacoby, David B.; Fryer, Allison D.			Expression and regulation of intercellular adhesion molecule-1 on airway parasympathetic nerves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intercellular adhesion molecule 1; TNF-alpha; nuclear factor kappa B; dexamethasone; asthma; parasympathetic nerve; human; guinea pig	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; CHALLENGED GUINEA-PIGS; MUSCARINIC RECEPTOR FUNCTION; SMOOTH-MUSCLE-CELLS; MAJOR BASIC-PROTEIN; ICAM-1 EXPRESSION; INFLAMMATORY RESPONSE; EOSINOPHIL ADHESION; ENDOTHELIAL-CELLS	Background: Eosinophils cluster along airway nerves in patients with asthma and release eosinophil major basic protein, an antagonist of inhibitory M2 muscarinic receptors on nerves. Blocking M2 function increases bronchoconstriction, leading to airway hyperreactivity. Intercellular adhesion molecule-1 (ICAM-1) mediates eosinophil adhesion to nerves. Objective: We investigated mechanisms of ICAM-1 expression by parasympathetic nerves. Methods: ICAM-1 expression was examined by immunocytochemistry of lung sections from ovalbumin-sensitized and challenged guinea pigs. ICAM-1 was measured in parasympathetic nerves isolated from subjects and guinea pigs and in human neuroblastoma cells by real-time RT-PCR, immunocytochemistry, and Western blot. Results: ICAM-1 was not detected in control airway parasympatheric nerves in vivo or in cultured cells. ICAM-1 was expressed throughout antigen-challenged guinea pig lung tissue and was selectively decreased by dexamethasone only in nerves. ICAM-1 was induced in human and guinea pig parasympathetic nerves by TNF-alpha and IFN-gamma and was inhibited by dexamethasone and by an inhibitor of nuclear factor-kappa B (NF-kappa B). In neuroblastoma cell lines TNF-alpha and IFN-gamma-induced ICAM-1 was blocked by an inhibitor of NF-kappa B but not by inhibitors of mitogen-activated protein kinases. Dexamethasone did not inhibit ICAM-1 expression in neuroblastoma cells. Conclusions: ICAM-1 induced in nerves by antigen challenge and proinflammatory cytokines is sensitive to dexamethasone. ICAM-1 expression is also sensitive to inhibitors of NF-kappa B. Neuroblastoma cells mimic many, but not all, characteristics of ICAM-1 expression in parasympathetic nerves. Clinical implications: Dexamethasone and NF-kappa B inhibitors could prevent eosinophils from adhering to nerves by blocking ICAM-1 expression on parasympathetic nerves, thus protecting inhibitory M2 muscarinic receptors and making this pathway a potential target for asthma treatment.	Oregon Hlth & Sci Univ, Div Physiol & Pharmacol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Pulm & Crit Care Med, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Fryer, AD (corresponding author), Mail Code L334,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	fryera@ohsu.edu	Fryer, Allison/F-2420-2014	Fryer, Allison/0000-0003-1712-9831; Jacoby, David/0000-0003-2195-9512	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055543, R01HL061013, R01HL054659] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61013, HL54659, HL55543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamko DJ, 1999, J EXP MED, V190, P1465, DOI 10.1084/jem.190.10.1465; Amrani Y, 1999, J IMMUNOL, V163, P2128; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Bourke E, 1999, J IMMUNOL, V163, P2113; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Carr MJ, 2002, AM J RESP CRIT CARE, V165, P1071, DOI 10.1164/ajrccm.165.8.2108065; Chaudhary P, 2006, J NEUROIMMUNOL, V175, P87, DOI 10.1016/j.jneuroim.2006.03.007; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; Chihara J, 1999, J ALLERGY CLIN IMMUN, V103, pS452, DOI 10.1016/S0091-6749(99)70161-2; Costello RW, 1997, AM J PHYSIOL-LUNG C, V273, pL93, DOI 10.1152/ajplung.1997.273.1.L93; ELBON CL, 1995, AM J RESP CELL MOL, V12, P320, DOI 10.1165/ajrcmb.12.3.7873198; Eum SY, 2003, J ALLERGY CLIN IMMUN, V111, P1049, DOI 10.1067/mai.2003.1416; Evans CM, 2001, AM J RESP CRIT CARE, V163, P1484, DOI 10.1164/ajrccm.163.6.2007047; Evans CM, 1997, J CLIN INVEST, V100, P2254, DOI 10.1172/JCI119763; FRYER AD, 1992, J CLIN INVEST, V90, P2292, DOI 10.1172/JCI116116; FRYER AD, 1984, BRIT J PHARMACOL, V83, P973, DOI 10.1111/j.1476-5381.1984.tb16539.x; Fryer AD, 2006, J CLIN INVEST, V116, P228, DOI 10.1172/JCI25423; FRYER AD, 1991, J APPL PHYSIOL, V71, P2255, DOI 10.1152/jappl.1991.71.6.2255; Heijink IH, 2004, CLIN EXP ALLERGY, V34, P1356, DOI 10.1111/j.1365-2222.2004.02037.x; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Holden NS, 2004, EUR J BIOCHEM, V271, P785, DOI 10.1111/j.1432-1033.2004.03982.x; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; Jenny NS, 2006, J THROMB HAEMOST, V4, P107, DOI 10.1111/j.1538-7836.2005.01678.x; KEITH RG, 1985, CAN J SURG, V28, P207; KOWALZICK L, 1995, DERMATOLOGY, V190, P14, DOI 10.1159/000246627; Krunkosky TM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-12; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Lin FS, 2005, J CELL PHYSIOL, V202, P464, DOI 10.1002/jcp.20142; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; Miao H, 1997, CLIN HEMORHEOL MICRO, V17, P325; Milici AJ, 1998, LAB INVEST, V78, P1239; MINETTE PAH, 1989, J APPL PHYSIOL, V67, P2461, DOI 10.1152/jappl.1989.67.6.2461; PANETTIERI RA, 1995, J IMMUNOL, V154, P2358; Pazdrak K, 2004, GASTROENTEROLOGY, V127, P1096, DOI 10.1053/j.gastro.2004.07.008; Radhakrishnan VV, 2004, ACTA NEUROL SCAND, V109, P71, DOI 10.1034/j.1600-0404.2003.00179.x; Sawatzky DA, 2002, AM J PHYSIOL-LUNG C, V282, pL1279, DOI 10.1152/ajplung.00279.2001; SOTER NA, 1989, ALLERGY, V44, P16, DOI 10.1111/j.1398-9995.1989.tb02449.x; Steiner E, 2006, J CELL SCI, V119, P459, DOI 10.1242/jcs.02773; Thomas PS, 2001, IMMUNOL CELL BIOL, V79, P132, DOI 10.1046/j.1440-1711.2001.00980.x; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; VERBOUT NG, 2007, IN PRESS AM J PHYSL; Walsh MT, 2004, AM J RESP CELL MOL, V30, P333, DOI 10.1165/rcmb.2003-0188OC; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Yost BL, 2005, AM J PHYSIOL-LUNG C, V289, pL627, DOI 10.1152/ajplung.00377.2004	47	25	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1415	1422		10.1016/j.jaci.2007.03.005	http://dx.doi.org/10.1016/j.jaci.2007.03.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17418379				2022-12-18	WOS:000247232800017
J	Borger, P; Matsumoto, H; Boustany, S; Gencay, MMC; Burgess, JK; King, GG; Black, JL; Tamm, M; Roth, M				Borger, Peter; Matsumoto, Hisako; Boustany, Sarah; Gencay, Mikael M. C.; Burgess, Janette K.; King, Greg G.; Black, Judith L.; Tamm, Michael; Roth, Michael			Disease-specific expression and regulation of CCAAT/enhancer-binding proteins in asthma and chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; chronic obstructive pulmonary disease; remodeling; CCAAT/enhancer-binding proteins	SMOOTH-MUSCLE-CELLS; C/EBP-DELTA GENE; GLUCOCORTICOID-RECEPTOR; TRANSCRIPTION FACTOR; ALPHA; COPD; ACTIVATION; PROLIFERATION; ACETYLATION; ADIPOCYTE	Background: CCAAT/enhancer-binding proteins (C/EBPs) control cell proliferation; lack of C/EBP alpha correlates with increased proliferation of bronchial smooth muscle cells (BSMCs) of asthmatic patients. Objective: We sought to assess disease-specific expression of C/EBP alpha, beta, delta, and epsilon and the effects of budesonide (10(-8) mol/L) and formoterol (10(-8) mol/L). Methods: Expression and function of C/EBP alpha, beta, delta, and epsilon BSMCs of control subjects (n = 9), asthmatic patients (n = 12), and patients with chronic obstructive pulmonary disease (COPD; n = 10) were determined. Results: The control group expressed C/EBP alpha, beta, delta, and epsilon, which were upregulated by serum (5%). Budesonide completely inhibited C/EBP alpha and beta expression; formoterol increased C/EBP alpha expression (2-fold). C/EBP delta and epsilon expression were not affected by the drugs. The asthmatic group did not appropriately express C/EBP alpha. Basal levels of C/EBP beta, delta, and epsilon were upregulated by serum (5%). Budesonide and formoterol increased C/EBP beta levels (3.4-fold and 2.5-fold, respectively), leaving C/EBP alpha, delta, and epsilon levels unaffected. The COPD group normally expressed C/EBP alpha, beta, and epsilon, which were upregulated by serum treatment (5%). Basal levels of C/EBP,5 were downregulated by serum in 7 of 10 BSMC lines. Budesonide inhibited C/EBPa and P expression, upregulated C/EBP delta (3.2-fold), and had no effect on C/EBP epsilon. Formoterol upregulated C/EBP alpha expression (3-fold) but not the other C/EBPs. Protein analysis and electrophoretic mobility shift assay confirmed the disease-specific expression pattern of C/EBP alpha in asthmatic patients and C/EBP delta in patients with COPD. Conclusions: The expression and regulation of C/EBPs in BSMCs of asthmatic patients and patients with COPD seems disease specific. Budesonide and formoterol modulate C/EBP expression in a drug- and disease-specific pattern. Clinical implications: The data could provide a method to discriminate between asthma and COPD at an early disease stage.	Univ Basel Hosp, Dept Res & Pneumol, Dept Internal Med, CH-4031 Basel, Switzerland; Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia	University of Basel; University of Sydney; Woolcock Institute of Medical Research; University of Sydney	Borger, P (corresponding author), Univ Basel, Dept Res, Hebelstr 20, CH-4031 Basel, Switzerland.	pieter.borger@unibas.ch	Roth, Michael/H-8657-2019; Burgess, Janette/M-7117-2019; Burgess, Janette K/A-3597-2010; Black, Judith L/C-6559-2008	Roth, Michael/0000-0002-8139-2821; 				Aoshiba K, 2004, CLIN REV ALLERG IMMU, V27, P35, DOI 10.1385/CRIAI:27:1:035; Barnes PJ, 2005, EXPERT OPIN THER TAR, V9, P1111, DOI 10.1517/14728222.9.6.1111; Borger P, 2002, J ALLERGY CLIN IMMUN, V110, P841, DOI 10.1067/mai.2002.130047; Borger P, 1998, J ALLERGY CLIN IMMUN, V101, P231, DOI 10.1016/S0091-6749(98)70388-4; Borger P, 2006, AM J RESP CRIT CARE, V174, P367, DOI 10.1164/rccm.200501-082PP; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Dahl M, 2005, EUR RESPIR J, V26, P67, DOI 10.1183/09031936.05.00135704; Demedts IK, 2005, CURR OPIN PHARMACOL, V5, P257, DOI 10.1016/j.coph.2004.12.005; Didon L, 2005, CHEST, V127, P1341, DOI 10.1378/chest.127.4.1341; Doherty DE, 2004, AM J MED, V117, p11S, DOI 10.1016/j.amjmed.2004.10.017; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; JOHNSON PRA, 1995, AM J PHYSIOL, V269, P514; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kumon Y, 2002, SCAND J IMMUNOL, V56, P504, DOI 10.1046/j.1365-3083.2002.01169.x; LEE JH, 2001, AM J RESP CRIT CARE, V163, pA269; MacNee William, 2005, Proc Am Thorac Soc, V2, P258, DOI 10.1513/pats.200504-045SR; McNagny K, 2002, J EXP MED, V195, pf43, DOI 10.1084/jem.20020636; Nerlov C, 2004, NAT REV CANCER, V4, P394, DOI 10.1038/nrc1363; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Penner G, 2002, AM J PHYSIOL-REG I, V282, pR439, DOI 10.1152/ajpregu.00512.2001; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rodrigues E, 2003, EUR J BIOCHEM, V270, P556, DOI 10.1046/j.1432-1033.2003.03413.x; Rolli-Derkinderen M, 2003, J BIOL CHEM, V278, P18859, DOI 10.1074/jbc.M211696200; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Rudiger JJ, 2002, FASEB J, V16, P177, DOI 10.1096/fj.01-0226com; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Spurzem JR, 2005, SEMIN RESP CRIT CARE, V26, P142, DOI 10.1055/s-2005-869535; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Williams LJS, 2000, J BIOL CHEM, V275, P30232, DOI 10.1074/jbc.M001286200; Zhang WH, 2001, J BIOL CHEM, V276, P40373, DOI 10.1074/jbc.C100505200	40	25	25	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					98	105		10.1016/j.jaci.2006.07.056	http://dx.doi.org/10.1016/j.jaci.2006.07.056			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208590				2022-12-18	WOS:000243622200015
J	Loza, MJ; Peters, SP; Foster, S; Khan, IU; Penn, RB				Loza, Matthew J.; Peters, Stephen P.; Foster, Susan; Khan, Islam U.; Penn, Raymond B.			beta-Agonist enhances type 2 T-cell survival and accumulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; T cells; apoptosis; cytokines; signal transduction; beta-adrenergic receptor; prostaglandin E-2; EP receptor; lupus; asthma; heart failure; inflammation; cyclic AMP protein-dependent kinase	SYSTEMIC-LUPUS-ERYTHEMATOSUS; PROTEIN-KINASE; PHOSPHORYLATION; BAD; CYTOKINES; ASTHMA; CORTICOSTEROIDS; PROLIFERATION; INFLAMMATION; LYMPHOCYTES	Background: Neurohumoral modulation of immune system function is poorly understood. beta-Adrenergic receptor ligands; (beta-agonists) subserve numerous physiologic processes but also function as pathogenic or therapeutic agents in numerous diseases with inflammatory components. Objectives: We sought to establish the effects of beta-agonists and prostaglandin E-2 (PGE(2)) on antigen-dependent and antigen-independent accumulation of IL-13(+) (type 2) and IFN-gamma(+) (type 1) T cells. We also sought to clarify the mechanisms mediating the effects of these G protein-coupled receptor agonists. Methods: Effects of beta-agonists or PGE(2) on T-cell subtype accumulation were assessed in peripheral blood lymphocytes cultured with alpha CD3/CD28 or IL-2 by using flow cytometry. The role of cyclic AMP-dependent protein kinase (PKA) in mediating agonist effects was assessed by means of characterization of (1) phosphorylation of an intracellular PKA substrate and (2) T cells from patients with lupus possessing a natural defect in PKA activation. Results: beta-Agonists, in contrast to PGE(2), increased IL-2-induced accumulation of human type 2 T cells, an effect attributable to differential activation of PKA affecting regulation of cell proliferation and apoptosis. In T cells from patients with lupus; exhibiting defective PKA activation, both beta-agonists and PGE(2) promoted an increase in type 2 T-cell accumulation. Conclusion: G(s)-coupled receptors have the capacity to elicit prosurvival signaling in type 2 T cells, which, in most instances, is obscured by concomitant and antimitogenic PKA activation. Clinical implications: beta-Agonists and other G(s)-coupled receptor agonists have the potential to regulate T-cell development to affect disease pathogenesis or the efficacy of therapies, and variability of effect relates to the ability to stimulate PKA activity.	Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Internal Med, Winston Salem, NC 27157 USA	Wake Forest University	Penn, RB (corresponding author), Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rpenn@wfubmc.edu		Loza, Matthew/0000-0002-8609-118X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058506, R29HL058506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039501] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR07122] Funding Source: Medline; NHLBI NIH HHS [HL58506] Funding Source: Medline; NIAMS NIH HHS [AR39501] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aaronson DW, 2006, J ALLERGY CLIN IMMUN, V117, P40, DOI 10.1016/j.jaci.2005.08.060; ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; Amerio P, 2002, CLIN EXP RHEUMATOL, V20, P535; Aringer M, 2001, RHEUMATOLOGY, V40, P876, DOI 10.1093/rheumatology/40.8.876; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Colavita AM, 2000, CLIN CHEST MED, V21, P263, DOI 10.1016/S0272-5231(05)70265-3; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Giembycz MA, 2006, EUR RESPIR J, V27, P1286, DOI 10.1183/09031936.06.00112605; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; KAMMER GM, 1994, J CLIN INVEST, V94, P422, DOI 10.1172/JCI117340; Khan IU, 2001, J IMMUNOL, V166, P7600, DOI 10.4049/jimmunol.166.12.7600; Laxminarayana D, 1999, J IMMUNOL, V162, P5639; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Loza M, 2003, MOL BIOTECHNOL, V23, P245, DOI 10.1385/MB:23:3:245; Loza MJ, 2006, J ALLERGY CLIN IMMUN, V117, pS252, DOI 10.1016/j.jaci.2005.12.996; Loza MJ, 2005, CLIN EXP ALLERGY, V35, P8, DOI 10.1111/j.1365-2222.2004.02148.x; Loza MJ, 2004, INT IMMUNOL, V16, P23, DOI 10.1093/intimm/dxh001; Loza MJ, 2003, EUR J IMMUNOL, V33, P939, DOI 10.1002/eji.200323643; Loza MJ, 2001, NAT IMMUNOL, V2, P917, DOI 10.1038/ni1001-917; Loza MJ, 2006, BLOOD, V107, P2052, DOI 10.1182/blood-2005-08-3265; Malissein E, 2003, BIOCHIMIE, V85, P733, DOI 10.1016/S0300-9084(03)00140-8; Marshall GD, 2004, ANN ALLERG ASTHMA IM, V93, pS11, DOI 10.1016/S1081-1206(10)61482-2; Matsumori A, 2004, CURR OPIN PHARMACOL, V4, P171, DOI 10.1016/j.coph.2003.11.003; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Mehra VC, 2005, J LEUKOCYTE BIOL, V78, P805, DOI 10.1189/jlb.0405182; Morimoto S, 2001, AUTOIMMUNITY, V34, P19, DOI 10.3109/08916930108994122; Nagy G, 2000, IMMUNOL LETT, V74, P207, DOI 10.1016/S0165-2478(00)00265-0; Pankuweit S, 2002, HERZ, V27, P669, DOI 10.1007/s00059-002-2421-4; Perussia B, 2003, TRENDS IMMUNOL, V24, P235, DOI 10.1016/S1471-4906(03)00080-2; Perussia Bice, 2005, Methods Mol Med, V107, P147; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Remington TL, 2005, CURR OPIN PULM MED, V11, P74, DOI 10.1097/01.mcp.0000146784.56834.ff; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; Turner M O, 1998, Can Respir J, V5, P261; Valks DM, 2002, J MOL CELL CARDIOL, V34, P749, DOI 10.1006/jmcc.2002.2014; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8	37	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					235	244		10.1016/j.jaci.2006.09.019	http://dx.doi.org/10.1016/j.jaci.2006.09.019			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208607				2022-12-18	WOS:000243622200033
J	Sampson, HA				Sampson, H. A.			A phase II, randomized, double-blind, parallel-group, placebo-controlled, oral food challenge trial of XOLAIR (R) (omalizumab) in peanut allergy (TOPS)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 23-27, 2007	San Diego, CA	Amer Acad Allergy, Asthma & Immunol					[Sampson, H. A.] Mt Sinai Sch Med, New York, NY USA	Icahn School of Medicine at Mount Sinai									0	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1		1		461	S117	S117		10.1016/j.jaci.2006.11.440	http://dx.doi.org/10.1016/j.jaci.2006.11.440			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	238PT					2022-12-18	WOS:000251460400461
J	Antas, PRZ; Ding, L; Hackman, J; Reeves-Hammock, L; Shintani, AK; Schiffer, J; Holland, SM; Sterling, TR				Antas, PRZ; Ding, L; Hackman, J; Reeves-Hammock, L; Shintani, AK; Schiffer, J; Holland, SM; Sterling, TR			Decreased CD4(+) lymphocytes and innate immune responses in adults with previous extrapulmonary tuberculosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; extrapulmonary tuberculosis; cytokines; innate immunity; CD4(+) lymphocytes	TUMOR-NECROSIS-FACTOR; MYCOBACTERIUM-TUBERCULOSIS; INTERFERON-GAMMA; FACTOR-ALPHA; CELL COUNTS; IFN-GAMMA; SUSCEPTIBILITY; INFECTION; MANIFESTATIONS; INTERLEUKIN-10	Background: CD4(+) lymphocytes control Mycobacterium tuberculosis infection through cytokine-mediated macrophage activation. Extrapulmonary tuberculosis is presumably a marker of immunodeficiency, but cytokine responses have not been well studied in such patients. Objective: Assess immune defects in persons with previous extrapulmonary tuberculosis. Methods: In vitro cytokine responses of PBMCs from HIV-seronegative adults with previous extrapulmonary tuberculosis (n = 10) were compared with responses from persons with previous pulmonary tuberculosis (n = 24) and latent M tuberculosis infection (n = 30) in a case-control study. Results: Patients and controls did not differ according to age, sex, race, or monocytes. The median time between tuberculosis diagnosis and study entry was 72 and 122 weeks in extrapulmonary and pulmonary patients, respectively (P = .2). Median CD4+ counts were 660, 814, and 974 lymphocytes/mm(3) in extrapulmonary, pulmonary, and latently infected patients, respectively (P = .03). At 48 hours, median unstimulated cytokine levels were uniformly lower in extrapulmonary patients than both sets of controls. These differences persisted after controlling for CD4(+) count by linear regression analysis. Despite lower unstimulated levels, median TNF-alpha response was higher in patients with extrapulmonary and pulmonary tuberculosis than latently infected persons after stimulation with PHA 1% (P = .006) and PHA + IL-12 (1 ng/mL; P = .02); IL-10 remained low in patients with extrapulmonary tuberculosis after the same stimuli (P = .04 and .06, respectively). There was no primary immunodeficiency in the IL-12/23-1FN-gamma axis. Conclusion: HIV-seronegative adults with previous extrapulmonary tuberculosis had lower CD4+ lymphocytes and unstimulated cytokine production. This suggests a subtle abnormality in innate immune function. Clinical implications: These characteristics could identify persons at risk for severe tuberculosis manifestations.	Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; NIH, Lab Clin Infect Dis, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Baltimore City Hlth Dept Eastern Chest Clin, Baltimore, MD USA; Nashville Metropolitan Hlth Dept TB Clin, Nashville, TN USA	Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH) - USA; Johns Hopkins University	Sterling, TR (corresponding author), Vanderbilt Univ, Med Ctr, Div Infect Dis, A2209 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	timothy.sterling@vanderbilt.edu	ANTAS, PRZ/AAF-6021-2019	ANTAS, PRZ/0000-0002-6168-9185	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000647, K23AI001654, Z01AI000647] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00052] Funding Source: Medline; NIAID NIH HHS [K23-AI01654] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920; BARNES PF, 1990, J IMMUNOL, V145, P149; Bean AGD, 1999, J IMMUNOL, V162, P3504; Bekker LG, 1998, J INFECT DIS, V178, P580, DOI 10.1086/517479; Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002; Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614; Byrne P, 2004, EUR J IMMUNOL, V34, P2579, DOI 10.1002/eji.200425092; *CDCP AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; Cooley W.W., 1971, MULTIVARIATE DATA AN; Dorman SE, 2004, LANCET, V364, P2113, DOI 10.1016/S0140-6736(04)17552-1; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; Goldfeld AE, 1998, JAMA-J AM MED ASSOC, V279, P226, DOI 10.1001/jama.279.3.226; Gonzalez OY, 2003, INT J TUBERC LUNG D, V7, P1178; Greenwood CMT, 2000, AM J HUM GENET, V67, P405, DOI 10.1086/303012; Jalapathy KV, 2004, FEMS IMMUNOL MED MIC, V40, P139, DOI 10.1016/S0928-8244(03)00303-1; Jones BE, 1997, CLIN INFECT DIS, V24, P988, DOI 10.1093/clinids/24.5.988; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC; Mohan AK, 2004, CLIN INFECT DIS, V39, P295, DOI 10.1086/421494; Nance S, 2005, EUR J IMMUNOL, V35, P1928, DOI 10.1002/eji.200425762; Ong A, 2004, CLIN INFECT DIS, V38, P25, DOI 10.1086/380448; RIEDER HL, 1990, AM REV RESPIR DIS, V141, P347, DOI 10.1164/ajrccm/141.2.347; Schaible UE, 2000, SEMIN IMMUNOL, V12, P527, DOI 10.1006/smim.2000.0272; Shafer RW, 1996, CLIN INFECT DIS, V22, P683, DOI 10.1093/clinids/22.4.683; SINGH SPN, 1983, J INFECT DIS, V148, P676, DOI 10.1093/infdis/148.4.676; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; Stenger S, 1999, CURR OPIN MICROBIOL, V2, P89, DOI 10.1016/S1369-5274(99)80015-0; Sterling TR, 2001, CLIN INFECT DIS, V33, P976, DOI 10.1086/322670; Sutherland I, 1976, Adv Tuberc Res, V19, P1; Swaminathan S, 2000, Indian Pediatr, V37, P489; Tosi MF, 2005, J ALLERGY CLIN IMMUN, V116, P241, DOI 10.1016/j.jaci.2005.05.036; TVERDAL A, 1986, EUR J RESPIR DIS, V69, P355; Uppal SS, 2004, CYTOM PART B-CLIN CY, V61B, P20, DOI 10.1002/cyto.b.20018; WALLGREN A, 1948, Tubercle, V29, P245, DOI 10.1016/S0041-3879(48)80033-4; *WHO, 2005, WHOHTMTB2005349; Yang ZH, 2004, CLIN INFECT DIS, V38, P199, DOI 10.1086/380644	42	25	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					916	923		10.1016/j.jaci.2006.01.042	http://dx.doi.org/10.1016/j.jaci.2006.01.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630952				2022-12-18	WOS:000236862800029
J	Wenzel, S; Szefler, SJ				Wenzel, S; Szefler, SJ			Managing severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						corticosteroids; severe asthma; difficult to control asthma; refractory asthma; childhood asthma; adult asthma	RISK-FACTORS; PHENOTYPES; EXACERBATIONS; ADULTS		Natl Jewish Med & Res Ctr, Div Pulm Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Boulder, CO 80309 USA; Natl Jewish Med & Res Ctr, Div Pediat Clin Pharmacol & Allergy, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Div Pulm Med, 1400 Jackson St,Rm J313, Denver, CO 80206 USA.	szeflers@njc.org						Chung KF, 1999, EUR RESPIR J, V13, P1198; Colice GL, 2005, J ALLERGY CLIN IMMUN, V115, P200, DOI 10.1016/j.jaci.2004.07.065; Covar RA, 2005, J ALLERGY CLIN IMMUN, V115, P700, DOI 10.1016/j.jaci.2005.01.034; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Oba Y, 2004, J ALLERGY CLIN IMMUN, V114, P265, DOI 10.1016/j.jaci.2004.05.049; Payne DNR, 2001, J ASTHMA, V38, P189, DOI 10.1081/JAS-100000106; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; SZEFLER SJ, 2001, SEVERE ASTHMA MULTID; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 2004, AM J RESP CRIT CARE, V170, P579, DOI 10.1164/rccm.2407005	13	25	27	4	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					508	511		10.1016/j.jaci.2005.12.1316	http://dx.doi.org/10.1016/j.jaci.2005.12.1316			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522447				2022-12-18	WOS:000236263100003
J	Rowe, BH; Carnargo, CA				Rowe, BH; Carnargo, CA		MARC Investigators	The use of magnesium sulfate in acute asthma: Rapid uptake of evidence in North American emergency departments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; treatment; emergency department; magnesium; severe	INTRAVENOUS MAGNESIUM	Background: Systematic reviews of approximately 13 randomized trials support treatment with intravenous magnesium sulfate (MgSO4) in patients with severe acute asthma; however, little is known about its actual clinical use. Objective: We sought to examine the use of intravenous MgSO4 in the emergency department (ED) and physician attitudes toward its use. Methods: Data for MgSO4 use were obtained from observational cohort studies of ED patients with acute asthma. Investigators were asked about MgSO4 through a brief Internet-based survey. The main outcomes were the percentage of sites reporting MgSO4 use and patient factors that potentially modified the use of this agent. Results: Among 9745 ED patients with acute asthma, 240 (2.5%) received MgSO4, Increasing age, previous intubation, higher initial respiratory rate, lower initial PEF, higher number of beta-agonists in the ED, and use of systemic corticosteroids were associated with MgSO4 use (P < .01). Overall, 103 (87%) of 119 potential sites completed the survey. Most (92%) respondents stated their EDs had MgSO4 available, and 64% had recently used it. More respondents listed severity (96%) and failure to respond to initial beta-agonists (87%) as factors prompting their use of MgSO4. Other factors, such as age, sex, and duration of exacerbation, less commonly influenced MgSO4 use. Conclusion: Most ED physicians accept the efficacy of MgSO4 in acute asthma. Despite this belief and the ready availability of MgSO4, its ED use remains uncommon (2.5% of cases). In both practice and theory, emergency physicians appear to appropriately restrict its use to patients with severe acute asthma.	Univ Alberta, Dept Emergency Med, Edmonton, AB T6G 2B7, Canada; Capital Hlth, Edmonton, AB, Canada; Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab,Dept Med, Boston, MA 02115 USA	University of Alberta; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Rowe, BH (corresponding author), Univ Alberta, Dept Emergency Med, 1G1-43,WMC,8440-112th St, Edmonton, AB T6G 2B7, Canada.	brian.rowe@ualberta.ca	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NHLBI NIH HHS [HL-63841, HL-63253] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063841, R03HL063253] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alter HJ, 2000, ANN EMERG MED, V36, P191, DOI 10.1067/mem.2000.109170; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Camargo CA, 2002, J ALLERGY CLIN IMMUN, V109, pS156, DOI 10.1016/S0091-6749(02)81593-7; CATES CJ, 2005, COCHRANE LIBR; EDMONDS ML, 2005, COCHRANE LIBR; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; *NAT HEART LUNG, 1997, 974051 NAT HEART LUN; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ram FSF, 2005, COCHRANE DB SYST REV, DOI [10.1002/146514858.CD004360.pub2, 10.1002/14651858.CD004360.pub3, 10.1002/14651858.CD003137.pub2]; Rowe BH, 2000, ANN EMERG MED, V36, P181, DOI 10.1067/mem.2000.105659; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262	12	25	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					53	58		10.1016/j.jaci.2005.09.033	http://dx.doi.org/10.1016/j.jaci.2005.09.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387584				2022-12-18	WOS:000235687100009
J	Matheu, V; Perez-Rodriguez, E; Sanchez-Machin, I; de la Torre, F; Garcia-Robaina, JC				Matheu, V; Perez-Rodriguez, E; Sanchez-Machin, I; de la Torre, F; Garcia-Robaina, JC			Major and minor determinants are high-performance skin tests in beta-lactam allergy diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Lund Univ, S-22184 Lund, Sweden	Lund University	Matheu, V (corresponding author), Lund Univ, BMC 111, S-22184 Lund, Sweden.		Matheu, Victor/AAU-3043-2020; Machín, María Inmaculada Sánchez/ABF-6003-2020	Matheu, Victor/0000-0002-0469-800X; Sanchez-Machin, Inmaculada/0000-0003-0109-8735				Bousquet PJ, 2005, J ALLERGY CLIN IMMUN, V115, P1314, DOI 10.1016/j.jaci.2005.02.026; Gruchalla RS, 2000, LANCET, V356, P1505, DOI 10.1016/S0140-6736(00)02885-3; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x	3	25	26	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1167	1168		10.1016/j.jaci.2005.08.010	http://dx.doi.org/10.1016/j.jaci.2005.08.010			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275398	Bronze			2022-12-18	WOS:000235686700039
J	Heinemann, A; Sturm, GJ; Ofner, M; Sturm, EM; Weller, C; Peskar, BA; Hartnell, A				Heinemann, A; Sturm, GJ; Ofner, M; Sturm, EM; Weller, C; Peskar, BA; Hartnell, A			Stem cell factor stimulates the chemotaxis, integrin upregulation, and survival of human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; chemoattractants; allergy; stem cell factor; c-kit	C-KIT LIGAND; AIRWAY INFLAMMATION; KINASE INHIBITORS; HISTAMINE-RELEASE; PERIPHERAL-BLOOD; IL-4 PRODUCTION; LAVAGE FLUID; MAP KINASE; MAST-CELLS; RESPONSES	Background: Little is known about the mechanisms that regulate the selective recruitment of basophils to sites of allergic inflammation. Objective: Here we examine the role of stem cell factor (SCF) in the regulation of basophil function. Methods: Human basophils were isolated from peripheral blood, and their migration was investigated in chemotaxis assays. Apoptosis was detected by means of annexin V and propidium iodide staining. The expression of cell-surface molecules was measured by means of flow cytometry. Results: SCF amplified the chemotactic responsiveness of human peripheral blood basophils to the chemoattractants eotaxin, monocyte chemotactic protein 2 and macrophage inflammatory protein 1 alpha, and C5a, without being chemotactic or chemokinetic by itself. SCF synergized with chemoattractants in causing basophil upregulation of the integrin CD11b, and this effect was inhibited by a c-kit antibody, the tyrosine kinase inhibitor imatinib mesylate (STI-571), and a phosphatidylinositol 3 kinase inhibitor but not by inhibitors of p38 mitogen-activated protein kinase or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase. Basophils bound fluorescence-labeled SCF and expressed its receptor, c-kit, which was markedly upregulated in culture for 24 to 48 hours in the presence of IL-3. Moreover, SCF prolonged basophil survival in concert with IL-3 by delaying apoptosis. These effects of SCF were selective for basophils because chemotaxis and CD11b upregulation of eosinophils or neutrophils were unchanged. Conclusion: SCF might be an important selective modulator of basophil function through a phosphatidylinositol 3 kinase-dependent pathway.	Med Univ Graz, Dept Expt & Clin Pharmacol, A-8010 Graz, Austria; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, London SW7 2AZ, England	Medical University of Graz; Imperial College London	Heinemann, A (corresponding author), Med Univ Graz, Dept Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemann@meduni-graz.at		Heinemann, Akos/0000-0002-8554-2372; Sturm, Eva/0000-0003-4898-884X				Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Bryan SA, 2002, AM J RESP CRIT CARE, V165, P1602, DOI 10.1164/rccm.200111-059OC; COLOMBO M, 1992, J IMMUNOL, V149, P599; COUTURIER C, 1990, EUR J IMMUNOL, V20, P999, DOI 10.1002/eji.1830200508; Falcone FH, 2000, BLOOD, V96, P4028; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finotto S, 2001, J ALLERGY CLIN IMMUN, V107, P279, DOI 10.1067/mai.2001.113049; Frenz AM, 1997, INFLAMM RES, V46, P35, DOI 10.1007/s000110050045; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; Heinemann A, 2000, J IMMUNOL, V165, P7224, DOI 10.4049/jimmunol.165.12.7224; Heinemann A, 2003, PHARMACOLOGY, V67, P49, DOI 10.1159/000066786; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kapur R, 2002, BLOOD, V100, P1287, DOI 10.1182/blood.V100.4.1287.h81602001287_1287_1293; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Li LX, 1998, J IMMUNOL, V161, P5079; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; Lukacs NW, 1996, J IMMUNOL, V156, P3945; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MEININGER CJ, 1992, BLOOD, V79, P958; NAGAI S, 1995, BIOCHEM BIOPH RES CO, V208, P576, DOI 10.1006/bbrc.1995.1377; Nilsson G, 1998, ALLERGY, V53, P874, DOI 10.1111/j.1398-9995.1998.tb03994.x; Oliveira SHP, 2001, AM J PHYSIOL-LUNG C, V280, pL1242, DOI 10.1152/ajplung.2001.280.6.L1242; Olsson N, 2000, J ALLERGY CLIN IMMUN, V105, P455, DOI 10.1067/mai.2000.104380; Rainger GE, 1997, CURR BIOL, V7, P316, DOI 10.1016/S0960-9822(06)00155-2; REID DM, 1993, NEUROSCIENCE, V56, P529, DOI 10.1016/0306-4522(93)90353-H; Schroeder JT, 2001, J ALLERGY CLIN IMMUN, V107, P265, DOI 10.1067/mai.2001.112846; Stubbs VEL, 2002, J BIOL CHEM, V277, P26012, DOI 10.1074/jbc.M201803200; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Ueda S, 2002, INT J HEMATOL, V76, P427, DOI 10.1007/BF02982808; Ueda S, 2002, BLOOD, V99, P3342, DOI 10.1182/blood.V99.9.3342; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WATANABE A, 1992, INT ARCH ALLERGY IMM, V98, P308, DOI 10.1159/000236203; YAMAGUCHI M, 1992, CLIN EXP ALLERGY, V22, P379, DOI 10.1111/j.1365-2222.1992.tb03099.x; Yoshimura C, 2001, J ALLERGY CLIN IMMUN, V108, P215, DOI 10.1067/mai.2001.116575; Yuan Q, 1997, J EXP MED, V186, P313, DOI 10.1084/jem.186.2.313; Zheng XY, 2002, IMMUNOLOGY, V107, P306, DOI 10.1046/j.1365-2567.2002.01517.x	36	25	29	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					820	826		10.1016/j.jaci.2005.06.008	http://dx.doi.org/10.1016/j.jaci.2005.06.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210056				2022-12-18	WOS:000235686600016
J	Radhakrishnan, S; Iijima, K; Kobayashi, T; Kita, H; Pease, LR				Radhakrishnan, S; Iijima, K; Kobayashi, T; Kita, H; Pease, LR			Dendritic cells activated by cross-linking B7-DC (PD-L2) block inflammatory airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inflammatory lung disease; dendritic cells; immunotherapy; antibody; B7-DC; PD-L2; T(H)1; T(H)2	RETRACTED ARTICLE. SEE; INHALED ANTIGEN; TH2 RESPONSES; MOUSE MODEL; VOL. 184; T-CELLS; ANTIBODY; INDUCTION; MOLECULE	Background: Allergic asthma is an increasing clinical problem that might be addressed with immunologically based interventions. A novel human antibody that activates human and mouse dendritic cells (DCs) by cross-linking B7-DC has strong immunomodulatory properties and blocks antigen-induced inflammatory lung disease in mice. Objective: We sought to evaluate the ability of activated DCs to mediate an antibody-induced protective response against inflammatory lung disease. Methods: An adoptive transfer strategy was used to test the ability of antibody treatments to activate DCs, inducing a protective response against inflammatory lung disease in mice presensitized to ovalbumin (OVA). After transfer of activated DCs, recipient mice were exposed repeatedly to airway antigen and evaluated for changes in immune reactivity and airway inflammatory disease. Results: Animals presensitized to OVA receiving either systemic treatments with B7-DC cross-linking antibody (XAb) or adoptively transferred antibody-activated DCs were completely protected from airway inflammatory responses normally induced by repeated exposure to OVA. Lymphocytes isolated from spleens or lung-draining lymph nodes of treated animals were highly responsive to OVA and secreted TNF-alpha, IFN-gamma, and IL-10. In contrast, IL-4 was not produced by cells isolated from animals receiving B7-DC XAb. Conclusion: Activation of DCs with B7-DC XAb ex vivo before adoptive transfer into presensitized mice is sufficient to protect animals completely from inflammatory lung disease induced by subsequent repeated airway exposure to the offending antigen. This finding is consistent with our hypothesis that in vivo administration of B7-DC XAb modulates the immune response by activating endogenous DCs.	Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Pease, LR (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	pease.larry@mayo.edu			NCI NIH HHS [R01 CA104996] Funding Source: Medline; NIAID NIH HHS [R01 AI49235] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049235] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; Hammad H, 2004, AM J PATHOL, V164, P263, DOI 10.1016/S0002-9440(10)63116-1; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; Kuipers H, 2004, J LEUKOCYTE BIOL, V76, P1028, DOI 10.1189/jlb.0604325; Kuipers H, 2003, J IMMUNOL, V171, P3645, DOI 10.4049/jimmunol.171.7.3645; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 2000, J IMMUNOL, V164, P2937, DOI 10.4049/jimmunol.164.6.2937; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466; Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360; Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025; Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830; Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661, DOI 10.1164/ajrccm.155.2.9032210	21	25	50	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					668	674		10.1016/j.jaci.2005.04.038	http://dx.doi.org/10.1016/j.jaci.2005.04.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159641				2022-12-18	WOS:000235686500031
J	Beuther, DA; Sutherland, ER				Beuther, DA; Sutherland, ER			Obesity and pulmonary function testing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							FAT DISTRIBUTION; ASTHMA; WOMEN		Univ Colorado, Ctr Hlth Sci, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sutherland, ER (corresponding author), Univ Colorado, Ctr Hlth Sci, Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	sutherlande@njc.org	Sutherland, Everett Rand/B-7666-2008	Beuther, David/0000-0002-5021-5734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004385] Funding Source: NIH RePORTER; NHLBI NIH HHS [K23 HL-04385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Biring MS, 1999, AM J MED SCI, V318, P293, DOI 10.1097/00000441-199911000-00002; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Chen Y, 1999, AM J EPIDEMIOL, V150, P255, DOI 10.1093/oxfordjournals.aje.a009996; COLLINS LC, 1995, CHEST, V107, P1298, DOI 10.1378/chest.107.5.1298; KAUFMAN BJ, 1959, J CLIN INVEST, V38, P500, DOI 10.1172/JCI103827; Lazarus R, 1997, CHEST, V111, P891, DOI 10.1378/chest.111.4.891; Litonjua AA, 1999, AM J RESP CRIT CARE, V159, P1574, DOI 10.1164/ajrccm.159.5.9803063; REFSUM HE, 1990, INT J OBESITY, V14, P175; SHARP JT, 1964, J APPL PHYSIOL, V19, P959, DOI 10.1152/jappl.1964.19.5.959; Tantisira KG, 2001, THORAX, V56, P64	10	25	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1100	1101		10.1016/j.jaci.2004.12.1141	http://dx.doi.org/10.1016/j.jaci.2004.12.1141			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867878				2022-12-18	WOS:000229055100039
J	Yoshida, M; Watson, RM; Rerecich, T; O'Byrne, PM				Yoshida, M; Watson, RM; Rerecich, T; O'Byrne, PM			Different profiles of T-cell IFN-gamma and IL-12 in allergen-induced early and dual responders with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen challenge; T(H)1 and T(H)2 cytokines	BRONCHOALVEOLAR LAVAGE; AIRWAY INFLAMMATION; INTERFERON-GAMMA; MESSENGER-RNA; CYTOKINE EXPRESSION; ATOPIC ASTHMA; INTERLEUKIN-12; RESPONSES; MICE; EOSINOPHILS	Background: IFN-gamma and IL-12 are anti-inflammatory cytokines released from various cells, including T cells. Allergen inhalation by atopic subjects with asthma results in 2 bronchoconstrictor phenotypes, termed isolated early and dual responders. Persistence of allergen-induced airway response and inflammation is a distinctive feature of dual responders. Objective: To evaluate the roles of IFN-gamma and IL-12 in resolving allergen-induced airway inflammation by comparing T lymphocytes (CD4(+) and CD8(+) cells) producing these cytokines in isolated early and dual responders. Methods: Twenty-four subjects with asthma (12 isolated early and 12 dual responders) were challenged with inhaled allergen. Peripheral blood and induced sputum were taken before and 1 day, 3 days, and 7 days after challenge. Frequency of IFN-gamma, IL-12, IL-4, and IL-13 producing CD4(+) and CD8(+) cells was assessed by using How cytometry. Results: After allergen, both CD4(+) and CD8(+) IFN-gamma positive cells in peripheral blood significantly decreased in dual responders only, whereas CD4(+) and CD8(+) IFN-gamma positive cells in induced sputum significantly increased in isolated early responders only. By contrast, IL-12 positive cells in peripheral blood significantly increased after allergen challenge only in isolated early responders. The ratio of CD4(+) and CD8(+) IL-4/ IFN-gamma positive cells in peripheral blood significantly decreased in isolated early responders by 3 days and had recovered by 7 days. Conclusion: These results suggest that contrasting profiles of IFN-gamma and IL-12 production may be responsible for different time courses of allergen-induced airway responses between isolated early and dual responders.	McMaster Univ, Dept Med, Hlth Sci Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Firestone Inst Resp Hlth, Hamilton, ON L8S 4L8, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University	O'Byrne, PM (corresponding author), McMaster Univ, Dept Med, Hlth Sci Ctr, Room 3W10,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X				American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, pS78; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; Bodey KJ, 1999, ALLERGY, V54, P1083, DOI 10.1034/j.1398-9995.1999.00889.x; BOGUNIEWICZ M, 1993, CLIN EXP ALLERGY, V23, P785, DOI 10.1111/j.1365-2222.1993.tb00367.x; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Camporota L, 1999, CLIN EXP ALLERGY, V29, P1298; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hogan SP, 1998, J IMMUNOL, V161, P1501; Krug N, 2001, AM J RESP CELL MOL, V25, P125, DOI 10.1165/ajrcmb.25.1.4194; Lack G, 1996, J IMMUNOL, V157, P1432; MOQBEL R, 1995, J IMMUNOL, V155, P4939; Morita M, 1996, EUR CYTOKINE NETW, V7, P725; MORRIS SC, 1994, J IMMUNOL, V152, P1047; Nouri-Aria KT, 2000, CLIN EXP ALLERGY, V30, P1709, DOI 10.1046/j.1365-2222.2000.00998.x; Nouri-Aria KT, 2001, J ALLERGY CLIN IMMUN, V108, P205, DOI 10.1067/mai.2001.117175; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Purello-D'Ambrosio F, 1999, J INVEST ALLERG CLIN, V9, P262; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; Tang CB, 2001, J IMMUNOL, V166, P1471, DOI 10.4049/jimmunol.166.3.1471; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; Yoshida M, 2002, AM J RESP CRIT CARE, V166, P451, DOI 10.1164/rccm.200202-095OC	27	25	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1004	1009		10.1016/j.jaci.2005.02.003	http://dx.doi.org/10.1016/j.jaci.2005.02.003			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867858				2022-12-18	WOS:000229055100016
J	Suissa, S; Ernst, P				Suissa, S; Ernst, P			Bias in observational study of the effectiveness of nasal corticosteroids in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cohort studies; biases; drug effectiveness; databases; nasal corticosteroids	ALLERGIC RHINITIS; INHALED CORTICOSTEROIDS; INTRANASAL STEROIDS; IMMORTAL TIME; REGULAR USE; RISK; PREVENTION; HOSPITALIZATION; MORTALITY; EMERGENCY	Background: A recent observational study suggests that intranasal corticosteroids used to treat allergic rhinitis are effective at preventing asthma outcomes, such as emergency visits. The approach to data analysis may have led to biased results because of misclassification of immortal time. Objective: To illustrate the bias in the cohort approach and to present the proper time-dependent analysis by replicating the recent study using data from another source. Methods: From an existing cohort of 30,569 patients with asthma age 5 to 44 years and identified from the Saskatchewan Health databases (1975-1997), we formed the cohort of all subjects who were in the source population between January 1, 1989, and December 31, 1991. Subjects were followed to the first asthma hospitalization. All prescriptions dispensed during follow-up were identified. We replicated the time-fixed approach to data analysis used in the recent study and compared it with time-dependent approaches. Results: The cohort included 20,173 subjects, of whom 1849 were hospitalized for asthma between January 1, 1989, and December 31, 1991. The time-fixed approach misclassified more than 5000 person-years of follow-up, corresponding to 44% of the exposed person-time. As a result, the rate ratio of asthma hospitalization after any use of nasal corticosteroids (NCSs) was 0.57 by the biased time-fixed approach compared with 1.13 by the proper time-dependent approach. The time-fixed approach produced a paradoxical protective effect of NCS with I or less canisters dispensed per year (odds ratio, 0.47), which was further exaggerated when the cohort was extended to 5 years (odds ratio, 0.33). Adjusted time-dependent analyses found no protective effect, even when NCSs were dispensed regularly (rate ratio, 1.10; 95% CI, 0.54-2.21). Conclusion: The time-fixed approach to the analysis of the effectiveness of NCSs on asthma outcomes leads, by its inherent misclassification of immortal time, to a considerable exaggeration of the protective effect of these medications in preventing severe asthma exacerbations.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Suissa, S (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Epidemiol, 687 Pine Ave W,Ross 4-29, Montreal, PQ H3A 1A1, Canada.	samy.suissa@clinepi.mcgill.ca						Adams RJ, 2002, J ALLERGY CLIN IMMUN, V109, P636, DOI 10.1067/mai.2002.123237; Adams RJ, 2001, PEDIATRICS, V107, P706, DOI 10.1542/peds.107.4.706; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V101, pS427, DOI 10.1016/S0091-6749(98)70154-X; Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; Borish L, 2003, J ALLERGY CLIN IMMUN, V112, P1021, DOI 10.1016/j.jaci.2003.09.015; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Downey W, 2000, PHARMACOEPIDEMIOLOGY, V3rd, P325; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391, DOI 10.1164/ajrccm.162.4.9912033; PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6; Rothman K., 1998, MODERN EPIDEMIOLOGY; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; Sin DD, 2001, AM J RESP CRIT CARE, V164, P580, DOI 10.1164/ajrccm.164.4.2009033; Soriano JB, 2002, EUR RESPIR J, V20, P819, DOI 10.1183/09031936.02.00301302; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; Suissa S, 2004, EUR RESPIR J, V23, P391, DOI 10.1183/09031936.04.00062504; Suissa S, 2003, AM J RESP CRIT CARE, V168, P49, DOI 10.1164/rccm.200210-1231OC; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; Walker AM, 1991, OBSERVATION INFERENC; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315, DOI 10.1164/ajrccm.151.2.7842184; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Yawn BP, 1999, J ALLERGY CLIN IMMUN, V103, P54, DOI 10.1016/S0091-6749(99)70525-7	33	25	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					714	719		10.1016/j.jaci.2004.12.1118	http://dx.doi.org/10.1016/j.jaci.2004.12.1118			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805989	Bronze			2022-12-18	WOS:000228373400008
J	Park, HS; Kim, SH; Sampson, AP; Lee, KW; Park, CS				Park, HS; Kim, SH; Sampson, AP; Lee, KW; Park, CS			The HLA-DPB1*0301 marker might predict the requirement for leukotriene receptor antagonist in patients with aspirin-intolerant asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Ajou Univ, Sch Med, Dept Allergy & Rheumatol, Suwon, South Korea; Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Southampton, Hants, England; Hallym Univ, Hallym Inst Genome Applicat, Anyang, South Korea; Soonchunhyang Univ Hosp, Asthma Genom Ctr, Bucheon, South Korea	Ajou University; University of Southampton; Hallym University; Soonchunhyang University; Soonchunhyang University Hospital	Park, CS (corresponding author), Ajou Univ, Sch Med, Dept Allergy & Rheumatol, Suwon, South Korea.	hspark@madang.ajou.ac.kr	Park, Hae-Sim/S-7974-2019; Sampson, Anthony/C-1112-2011	Park, Hae-Sim/0000-0003-2614-0303				Asano K, 2002, PHARMACOGENETICS, V12, P565, DOI 10.1097/00008571-200210000-00009; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Choi JH, 2004, J ALLERGY CLIN IMMUN, V113, P562, DOI 10.1016/j.jaci.2003.12.012; Currie GP, 2003, BRIT J CLIN PHARMACO, V56, P422, DOI 10.1046/j.1365-2125.2003.01952.x; Dekker JW, 1997, CLIN EXP ALLERGY, V27, P574, DOI 10.1046/j.1365-2222.1997.540848.x; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; Mastalerz L, 2002, EUR J CLIN INVEST, V32, P949, DOI 10.1046/j.1365-2362.2002.01088.x; Wechsler ME, 2002, CURR OPIN ALLERGY CL, V2, P395, DOI 10.1097/00130832-200210000-00005	8	25	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					688	689		10.1016/j.jaci.2004.05.051	http://dx.doi.org/10.1016/j.jaci.2004.05.051			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15446291	Bronze			2022-12-18	WOS:000223799600033
J	Bunder, R; Mittermann, I; Herz, U; Focke, M; Wegmann, M; Valenta, R; Renz, H				Bunder, R; Mittermann, I; Herz, U; Focke, M; Wegmann, M; Valenta, R; Renz, H			Induction of autoallergy with an environmental allergen mimicking a self protein in a murine model of experimental allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						autoallergy; antigens; peptides; epitopes; autoantibodies; lung inflammation; cross-reactivity	ATOPIC-DERMATITIS; ASPERGILLUS-FUMIGATUS; IGE AUTOREACTIVITY; MOUSE MODEL; CELLS; INFLAMMATION; AUTOANTIGENS; INDIVIDUALS; COMPLEX	Background: Allergy and autoimmunity are traditionally considered as 2 exclusive entities related to the development of either T(H)2-dominated or T(H)1-dominated immune responses. Objective: This study investigated whether allergic sensitization to a foreign antigen mimicking a self protein can induce allergy accompanied by an autoimmune response. Methods: BALB/c mice were sensitized to human alpha-NAC, an evolutionary conserved component of the nascent polypeptide-associated complex, recently identified as an IgE-reactive autoantigen in patients with severe forms of atopy. By using nitrocellulose-blotted murine lung and skin extracts, purified recombinant human as well as murine alpha-NAC and murine alpha-NAC-derived synthetic peptides, the IgE, IgG1, and IgG2a antibody responses were measured, and their epitope specificity was mapped. Results: Cross-reactivity of IgE and IgG antibodies with murine alpha-NAC was found in mice sensitized with human alpha-NAC. The biological relevance of the antibody response was demonstrated by the induction of immediate skin reactions in sensitized mice and by the fact that skin sensitivity could be passively transferred with serum to naive mice. Antigen challenge of sensitized mice resulted in airway inflammation accompanied by eosinophil and neutrophil accumulation, airway hyperresponsiveness to methacholine and perivasculitis of lung veins. Conclusion: Our data demonstrate that sensitization with a foreign antigen mimicking self can induce an allergic immune response of a mixed T(H)2 and T(H)1 profile that is associated with autoreactivity. Cross-sensitization to self may represent an important pathomechanism involved in the maintenance of severe and chronic forms of allergy.	Univ Marburg, Dept Clin Chem & Mol Diagnost, Cent Lab, D-35033 Marburg, Germany; Med Univ Vienna, Dept Pathophysiol, Vienna, Austria	Philipps University Marburg; Medical University of Vienna	Renz, H (corresponding author), Univ Marburg, Dept Clin Chem & Mol Diagnost, Cent Lab, Baldinger Str, D-35033 Marburg, Germany.	renzh@med.uni-marburg.de		Wegmann, Michael/0000-0002-1658-1554; Mittermann, Irene/0000-0002-6240-6730; Valenta, Rudolf/0000-0001-5944-3365				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Fluckiger S, 2002, EUR J IMMUNOL, V32, P10, DOI 10.1002/1521-4141(200201)32:1<10::AID-IMMU10>3.0.CO;2-I; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kinaciyan T, 2002, J ALLERGY CLIN IMMUN, V109, P717, DOI 10.1067/mai.2002.123303; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Liew FY, 2002, NAT REV IMMUNOL, V2, P55, DOI 10.1038/nri705; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; Mossabeb R, 2002, J INVEST DERMATOL, V119, P820, DOI 10.1046/j.1523-1747.2002.00518.x; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567; Seiberler S, 1999, INT ARCH ALLERGY IMM, V120, P117, DOI 10.1159/000024229; Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V98, P913, DOI 10.1016/S0091-6749(96)80007-8; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	25	25	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					422	428		10.1016/j.jaci.2004.05.029	http://dx.doi.org/10.1016/j.jaci.2004.05.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316527				2022-12-18	WOS:000223405600034
J	Korpi, A; Mantyjarvi, R; Rautiainen, J; Kaliste, E; Kalliokoski, P; Renstrom, A; Pasanen, AL				Korpi, A; Mantyjarvi, R; Rautiainen, J; Kaliste, E; Kalliokoski, P; Renstrom, A; Pasanen, AL			Detection of mouse and rat urinary aeroallergens with an improved ELISA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						air sampling; ELISA; laboratory animal allergy; Rat n 1; Mus m 1; rat; mouse; allergen	LABORATORY-ANIMAL ALLERGENS; ASSESS AIRBORNE RAT; EXPOSURE; AIR; WORKERS; SENSITIZATION; VENTILATION; REDUCTION; ENDOTOXIN; CHILDREN	Background: Risk analysis of laboratory animal work presupposes allergen monitoring with sensitive methods. Commercial ELISA kits have recently become available for the detection of mouse (Mus m 1) and rat (Rat n 1) urinary allergen from settled dust samples and air samples with high allergen levels. Objective: Our aims were to enhance the sensitivities of the commercial ELISA kits for low aeroallergen levels (less than 1 ng/m(3)) and to test these methods with air samples collected from an animal facility. Methods: Personal and stationary air samples were collected from an animal facility during various tasks of laboratory animal work and from various premises of the animal facility. Results: The sensitivities of the ELISA assays were improved with a careful choice of analysis parameters and reagents. The detection limits of 0.1 ng/m(3) for Mus m 1 and 0.8 ng/m(3) for Rat n 1 were established. The sensitized assays enabled detection of mouse and rat aeroallergens also from premises in which animals or dirty cages were not present during sampling. Conclusion: These sensitive assays will help to perform risk assessment in laboratory animal work. However, there remains a lack of standardized analytic procedures and occupational exposure limits for laboratory animal allergens.	Univ Kuopio, Dept Environm Sci, Res & Dev Unit Environm Hlth, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland; Univ Kuopio, Natl Lab Anim Ctr, FIN-70211 Kuopio, Finland; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; Karolinska Institutet	Korpi, A (corresponding author), Univ Kuopio, Dept Environm Sci, Res & Dev Unit Environm Hlth, Bioteknia 2,POB 1627, FIN-70211 Kuopio, Finland.		Tuluc, Petronel/C-2527-2011					Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; BARTLEY DL, 1998, APPL OCCUP ENV HYG, V13, P274; BOTHAM PA, 1995, OCCUP ENVIRON MED, V52, P129, DOI 10.1136/oem.52.2.129; Bush R K, 2001, ILAR J, V42, P55; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; Emenius G, 2001, ALLERGY, V56, P771, DOI 10.1034/j.1398-9995.2001.056008771.x; GORDON S, 1994, CLIN EXP ALLERGY, V24, P1070, DOI 10.1111/j.1365-2222.1994.tb02745.x; Gordon S, 2001, ILAR J, V42, P37; Gordon S, 1997, CLIN EXP ALLERGY, V27, P744, DOI 10.1046/j.1365-2222.1997.640844.x; GORDON S, 1999, LAB ANIMAL HDB, V13, P17; Harrison D J, 2001, ILAR J, V42, P17; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; Hollander A, 1998, SCAND J WORK ENV HEA, V24, P228, DOI 10.5271/sjweh.303; Hollander A, 1999, ALLERGY, V54, P142, DOI 10.1034/j.1398-9995.1999.00630.x; Hollander A, 1997, CLIN EXP ALLERGY, V27, P617; JONES RB, 1995, AM IND HYG ASSOC J, V56, P398, DOI 10.1202/0002-8894(1995)056<0398:TEORHO>2.0.CO;2; Kacergis JB, 1996, AM IND HYG ASSOC J, V57, P634, DOI 10.1202/0002-8894(1996)057<0634:AQIAAF>2.0.CO;2; Lieutier-Colas F, 2002, CLIN EXP ALLERGY, V32, P1424, DOI 10.1046/j.1365-2745.2002.01502.x; Lieutier-Colas F, 2001, CLIN EXP ALLERGY, V31, P1449, DOI 10.1046/j.1365-2222.2001.01180.x; NIEUWENHUIJSEN M, 1994, OCCUP ENVIRON MED, V51, P593, DOI 10.1136/oem.51.9.593; Nieuwenhuijsen MJ, 1995, ANN OCCUP HYG, V39, P819, DOI 10.1016/0003-4878(95)00042-9; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; PRICE JA, 1988, CLIN ALLERGY, V18, P95, DOI 10.1111/j.1365-2222.1988.tb02848.x; Renstrom A, 1997, CLIN EXP ALLERGY, V27, P1314; Renstrom A, 1999, ALLERGY, V54, P150, DOI 10.1034/j.1398-9995.1999.00631.x; Renstrom A, 2002, CLIN EXP ALLERGY, V32, P1769, DOI 10.1046/j.1365-2222.2002.01545.x; Renstrom A, 2002, J ENVIRON MONITOR, V4, P619, DOI 10.1039/b202756a; Renstrom A, 2001, LAB ANIM-UK, V35, P42, DOI 10.1258/0023677011911363; Renstrom A, 2001, ALLERGY, V56, P964, DOI 10.1034/j.1398-9995.2001.00899.x; Renstrom A, 1997, J ALLERGY CLIN IMMUN, V100, P649, DOI 10.1016/S0091-6749(97)70169-6; RENSTROM A, 1997, ALLERGY LAB ANIMALS; Thulin H, 2002, ANN OCCUP HYG, V46, P61, DOI 10.1093/annhyg/mef022; Wickman M, 1999, CLIN EXP ALLERGY, V29, P626; Wood R A, 2001, ILAR J, V42, P12	35	25	26	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					677	682		10.1016/j.jaci.2003.11.039	http://dx.doi.org/10.1016/j.jaci.2003.11.039			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100673				2022-12-18	WOS:000220956600015
J	Kasahara, Y; Kaneko, H; Fukao, T; Terada, T; Asano, T; Kasahara, K; Kondo, N				Kasahara, Y; Kaneko, H; Fukao, T; Terada, T; Asano, T; Kasahara, K; Kondo, N			Hyper-IgM syndrome with putative dominant negative mutation in activation-induced cytidine deaminase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hyper-IgM syndrome; activation-induced cytidine deaminase; dominant negative mutation	X-LINKED IMMUNODEFICIENCY; AUTOSOMAL RECESSIVE FORM; CD40 LIGAND; MESSENGER-RNA; DEFECTIVE EXPRESSION; B-CELLS; DEFICIENCY; AID; APOBEC-1; ANTIBODY	Background: Hyper-IgM immunodeficiency is an immunologic disorder characterized by normal or increased serum IgM levels and reduced serum IgG and IgA levels caused by the disruption of Ig class switching in B cells. The gene encoding activation-induced cytidine deaminase (AID) is responsible for the autosomal recessive form of hyper-IgM syndrome. Objective: To investigate the relationship between the AID gene mutation and the clinical phenotype, we analyzed the AID gene in a female Japanese patient with the autosomal recessive form of hyper-IgM syndrome. Methods: Genomic DNA and cDNA were extracted from neutrophils and analyzed by means of PCR. The AID gene was expressed as a glutathione S-transferase fusion protein. RTPCR was performed after stimulation of the patient's PBMCs with phorbol myristate acetate and TGF-beta. Results: Despite significantly low serum IgG levels, our patient had not shown a predisposition to any severe infections, even without Ig replacement therapy. We identified a point mutation resulting in the stop codon in exon 5 of the AID gene (R190X) in the patient. No other mutations of the AID gene were detected in the patient. The same mutation was not detected in other members of her family. The mutant allele fused with the glutathione S-transferase protein was expressed stably at the same level as the normal allele. The AID gene expression in the patient was induced by phorbol myristate acetate and TGF-beta. Conclusion: The mutation of the AID gene is assumed to be of the dominant negative form. This is the first report of a dominant negative form of the mutation in vivo.	Gifu Univ, Sch Med, Dept Pediat, Gifu 5008705, Japan	Gifu University	Kaneko, H (corresponding author), Gifu Univ, Sch Med, Dept Pediat, 40 Tsukasa Machi, Gifu 5008705, Japan.							ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757; CALLARD RE, 1994, J IMMUNOL, V153, P3295; Carlow DC, 1999, BIOCHEMISTRY-US, V38, P12258, DOI 10.1021/bi990819t; CONLEY ME, 1994, J CLIN INVEST, V94, P1404, DOI 10.1172/JCI117476; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURANDY A, 1993, EUR J IMMUNOL, V23, P2294, DOI 10.1002/eji.1830230936; Durandy A, 1997, J IMMUNOL, V158, P2576; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; Kaneko H, 2000, EXP CLIN IMMUNOGENET, V17, P173, DOI 10.1159/000019136; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kondo N, 1997, SCAND J IMMUNOL, V45, P227, DOI 10.1046/j.1365-3083.1997.d01-387.x; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Longacre A, 2000, CELL, V102, P541, DOI 10.1016/S0092-8674(00)00075-1; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Minegishi Y, 2000, CLIN IMMUNOL, V97, P203, DOI 10.1006/clim.2000.4956; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muto T, 2000, GENOMICS, V68, P85, DOI 10.1006/geno.2000.6268; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; Oka K, 1997, J BIOL CHEM, V272, P1456, DOI 10.1074/jbc.272.39.24387; Papavasiliou FN, 2002, J EXP MED, V195, P1193, DOI 10.1084/jem.20011858; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Tashita H, 1998, J CLIN INVEST, V101, P677, DOI 10.1172/JCI1672; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2	28	25	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					755	760		10.1016/S0091-6749(03)01860-8	http://dx.doi.org/10.1016/S0091-6749(03)01860-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564357				2022-12-18	WOS:000185831200016
J	Shin, HD; Park, BL; Jung, JH; Wang, HJ; Park, HS; Choi, BW; Hong, SJ; Lee, YM; Kim, YH; Park, CS				Shin, HD; Park, BL; Jung, JH; Wang, HJ; Park, HS; Choi, BW; Hong, SJ; Lee, YM; Kim, YH; Park, CS			Association of thromboxane A2 receptor (TBXA2R) with atopy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENE; POLYMORPHISM; A(2)		SNP Genet Inc, Dept Genet Epidemiol, Seoul, South Korea; Soonchunhyang Univ, Asthma Genome Res Grp, Seoul, South Korea; Ajou Univ, Seoul, South Korea; Univ Ulsan, Seoul, South Korea; Choong Ang Univ Hosp, Seoul, South Korea	SNP Genetics; Soonchunhyang University; Ajou University; University of Ulsan	Shin, HD (corresponding author), SNP Genet Inc, Dept Genet Epidemiol, Seoul, South Korea.		Park, Hae-Sim/S-7974-2019	Park, Choon-Sik/0000-0003-2977-0255; Lee, Young Mok/0000-0003-4039-0456; Park, Hae-Sim/0000-0003-2614-0303				Devillier P, 1997, FUNDAM CLIN PHARM, V11, P2, DOI 10.1111/j.1472-8206.1997.tb00163.x; Leung TF, 2002, PEDIAT ALLERG IMM-UK, V13, P10, DOI 10.1034/j.1399-3038.2002.01033.x; Makridakis NM, 2001, BIOTECHNIQUES, V31, P1374, DOI 10.2144/01316md05; NUSING RM, 1993, J BIOL CHEM, V268, P25253; Tanaka H, 1999, RESP MED, V93, P891, DOI 10.1016/S0954-6111(99)90055-0; Tanaka K, 2002, BIOCHEM BIOPH RES CO, V292, P776, DOI 10.1006/bbrc.2002.6713; Unoki M, 2000, HUM GENET, V106, P440, DOI 10.1007/s004390000267	7	25	26	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					454	457		10.1067/mai.2003.1641	http://dx.doi.org/10.1067/mai.2003.1641			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897758				2022-12-18	WOS:000184650600036
J	Vadas, P; Perelman, B				Vadas, P; Perelman, B			Activated charcoal forms non-IgE binding complexes with peanut proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut; complex; activated; ara h1; ara h2; charcoal; allergy IgE; anaphylaxis; ELISA	ALLERGY; ABSORPTION	Background: Conventional management of peanut-induced anaphylaxis is composed of administration of epinephrine, antihistamine, and steroid and stabilization of airway, ventilatory, and circulatory function. Therapies directed toward slowing or preventing further absorption of peanut protein from the gastrointestinal tract after accidental ingestion have not been a routine part of management. Objective: The purpose of this study was to determine the ability of activated charcoal to complex with peanut protein, thereby preventing its binding to either peanut-specific IgE or peanut-specific IgG. Methods: Peanut protein was coincubated with micronized activated charcoal suspension at pH 3.5 or 7.4. Peanut protein complexed with charcoal was removed by centrifugation. Binding of residual peanut protein to peanut-specific IgG was measured by a sandwich ELISA assay. Also, ability of uncomplexed peanut protein to bind to peanut-specific IgE was determined by Western blot and by skin prick testing in subjects with peanut allergy. Results: Activated charcoal (AC) formed complexes with peanut protein, effectively competing for binding with peanut-specific IgG in a sandwich ELISA assay. AC complexed efficiently with peanut protein at both neutral and acidic pH in as little as 60 seconds. AC was also able to remove IgE-binding peanut allergens from solution as determined by Western blot and by skin prick testing in subjects with peanut allergy. A ratio of 200 mg of AC to 1 mg peanut protein was required for complete removal of peanut protein from solution. AC was able to complex with peanut protein within food matrices such as ice cream and chocolate. Conclusion: The data presented herein show that AC removes both IgE-binding and IgG-binding peanut proteins from solution rapidly at both neutral and acidic pH. These data suggest that administration of AC may be useful as an adjunct to slow or to prevent further absorption of peanut protein from the gastrointestinal tract after accidental ingestion by individuals with peanut allergy.	Univ Toronto, St Michaels Hosp, Dept Med, Div Clin Immunol & Allergy, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Vadas, P (corresponding author), Univ Toronto, St Michaels Hosp, Dept Med, Div Clin Immunol & Allergy, 30 Bond St, Toronto, ON M5B 1W8, Canada.							Allison T B, 1997, Prehosp Emerg Care, V1, P73, DOI 10.1080/10903129708958791; Am Acad Clin Toxicology, 1999, J TOXICOL-CLIN TOXIC, V37, P731; Bowden CA, 1997, DRUG SAFETY, V16, P9, DOI 10.2165/00002018-199716010-00002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clarke MCA, 1998, CLIN EXP ALLERGY, V28, P1251, DOI 10.1046/j.1365-2222.1998.00386.x; Crockett Richard, 1996, Journal of Emergency Medicine, V14, P335, DOI 10.1016/0736-4679(96)00030-3; Gittelman MA, 1999, PEDIATR EMERG CARE, V15, P359, DOI 10.1097/00006565-199910000-00017; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P1240, DOI [10.1111/j.1365-2222.1997.tb01167.x, 10.1046/j.1365-2222.1997.1520954.x]; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Krenzelok E P, 1996, Dis Mon, V42, P509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laine K, 1996, PHARMACOL TOXICOL, V79, P270, DOI 10.1111/j.1600-0773.1996.tb00272.x; Lapatto-Reiniluoto O, 1999, BRIT J CLIN PHARMACO, V48, P148, DOI 10.1046/j.1365-2125.1999.00995.x; Manoguerra AS, 1997, CRIT CARE CLIN, V13, P709, DOI 10.1016/S0749-0704(05)70365-1; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; Rance F, 1999, PEDIATR PULM, P165; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1	18	25	25	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					175	179		10.1067/mai.2003.1480	http://dx.doi.org/10.1067/mai.2003.1480			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847495				2022-12-18	WOS:000184010600026
J	Escoubet-Lozach, L; Glass, CK; Wasserman, SI				Escoubet-Lozach, L; Glass, CK; Wasserman, SI			The role of transcription factors in allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						gene transcription; transcription factors; nuclear receptors; allergic inflammation; coactivators; compressors	ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; COLONY-STIMULATING FACTOR; SMOOTH-MUSCLE CELLS; GLUCOCORTICOID-RECEPTOR; SIGNAL TRANSDUCER; GENE-EXPRESSION; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); MURINE MODEL; MICE LACKING	The induction of allergic inflammation and the expression of allergic disorders are dependent on the coordinated regulation of numerous genes. The products of these genes determine lymphocyte phenotype, immunologic responsiveness, eosinophil and mast cell development, activation, migration and life span, adhesion molecule expression, cytokine synthesis, cell-surface receptor display, and processes governing fibrosis and tissue repair. Although the expression of gene products involved in these processes is regulated at multiple levels (eg, transcription, mRNA processing, translation, phosphorylation, and degradation), transcription represents an essential and often the most important determinant of their contribution to cellular function. Signal-dependent and cell type-specific regulation of gene expression is generally achieved by means of combinatorial interactions between sequence-specific transcription factors that recruit chromatin remodeling machinery and general transcription factors to promoter and enhancer regions of RNA polymerase II-dependent genes. As targets of signal-transduction pathways, transcription factors integrate the response of the cell to the myriad of inputs it receives. This integration can be accomplished by the effect of signaling cascades on the activation status or subcellular locus of transcription factors or by transcription factor dimerization induced by means of ligand binding. This review will identify the major families of transcription factors important in allergic mechanisms and discuss their interactions, their mechanisms of action, and their interrelated and competitive actions, as well as implications for therapy of allergic disorders.	Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Rheumatol Allergy & Immunol, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wasserman, SI (corresponding author), Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, Stein Clin Res Bldg,Rm 244,9500 Gilman Dr,Mail Co, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Azuma M, 2000, ARTHRITIS RHEUM, V43, P1756, DOI 10.1002/1529-0131(200008)43:8<1756::AID-ANR12>3.0.CO;2-H; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Bureau F, 2000, J IMMUNOL, V165, P5822, DOI 10.4049/jimmunol.165.10.5822; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CHRISTIANRITTER KK, 1994, AM J PATHOL, V144, P171; Christodoulopoulos P, 2001, J ALLERGY CLIN IMMUN, V107, P586, DOI 10.1067/mai.2001.114883; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V105, P211, DOI 10.1016/S0091-6749(00)90068-X; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V106, P479; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2000, J BIOL CHEM, V275, P36703, DOI 10.1074/jbc.M004045200; DEMOLY P, 1992, AM J RESP CELL MOL, V7, P128, DOI 10.1165/ajrcmb/7.2.128; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Donovan CE, 1999, J IMMUNOL, V163, P6827; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Elholm M, 2001, J BIOL CHEM, V276, P21410, DOI 10.1074/jbc.M101073200; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X; Gosset P, 2001, J ALLERGY CLIN IMMUN, V107, P114, DOI 10.1067/mai.2001.111126; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; Hamilos DL, 2001, J ALLERGY CLIN IMMUN, V108, P59; Hamilos DL, 2000, J ALLERGY CLIN IMMUN, V106, P213, DOI 10.1067/mai.2000.109269; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Hidi R, 2000, J IMMUNOL, V164, P412, DOI 10.4049/jimmunol.164.1.412; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Hoontrakoon R, 2002, AM J RESP CELL MOL, V26, P404, DOI 10.1165/ajrcmb.26.4.4517; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Huang TJ, 2001, BRIT J PHARMACOL, V134, P1029, DOI 10.1038/sj.bjp.0704344; Huber MA, 2002, J BIOL CHEM, V277, P1268, DOI 10.1074/jbc.M109358200; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL302, DOI 10.1152/ajplung.00158.2001; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kraft M, 2001, J ALLERGY CLIN IMMUN, V107, P602, DOI 10.1067/mai.2001.113760; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Malaviya R, 2002, J IMMUNOL, V168, P421, DOI 10.4049/jimmunol.168.1.421; Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Miyata S, 1999, CLIN EXP ALLERGY, V29, P114; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Muller CW, 1996, NAT STRUCT BIOL, V3, P224, DOI 10.1038/nsb0396-224; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Nakamura Y, 2000, J ALLERGY CLIN IMMUN, V105, P1146, DOI 10.1067/mai.2000.107045; Natarajan C, 2002, GENES IMMUN, V3, P59, DOI 10.1038/sj.gene.6363832; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Pastore S, 2000, J INVEST DERMATOL, V115, P1134, DOI 10.1046/j.1523-1747.2000.00149.x; PAWANKAR R, 2001, CURR OPIN ALLERGY CL, V1, P1; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Poynter ME, 2002, AM J PATHOL, V160, P1325, DOI 10.1016/S0002-9440(10)62559-X; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SCHMITZ J, 1994, J EXP MED, V179, P1349, DOI 10.1084/jem.179.4.1349; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; Setoguchi K, 2001, J CLIN INVEST, V108, P1667; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; Soussi-Gounni A, 2001, J ALLERGY CLIN IMMUN, V107, P575, DOI 10.1067/mai.2001.114238; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Striz I, 1999, AM J PHYSIOL-LUNG C, V277, pL58, DOI 10.1152/ajplung.1999.277.1.L58; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Sugiyama H, 2000, EUR J IMMUNOL, V30, P3363, DOI 10.1002/1521-4141(2000012)30:12<3363::AID-IMMU3363>3.0.CO;2-B; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283, DOI 10.1164/ajrccm.160.4.9809065; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Toru H, 1996, INT IMMUNOL, V8, P1367; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Valapour M, 2002, J ALLERGY CLIN IMMUN, V109, P238, DOI 10.1067/mai.2002.121145; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; Viola JPB, 1998, BLOOD, V91, P2223, DOI 10.1182/blood.V91.7.2223.2223_2223_2230; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Westin S, 2000, ADV PHARMACOL, V47, P89; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; Yamashita M, 2000, BRIT J PHARMACOL, V129, P367, DOI 10.1038/sj.bjp.0703044; Yamazaki F, 2002, J DERMATOL SCI, V28, P227, DOI 10.1016/S0923-1811(01)00171-2; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Yokozeki H, 2000, J EXP MED, V191, P995, DOI 10.1084/jem.191.6.995; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; ZANGRILLI JG, 1995, AM J RESP CRIT CARE, V151, P1346, DOI 10.1164/ajrccm.151.5.7537586; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	155	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					553	564		10.1067/mai.2002.128076	http://dx.doi.org/10.1067/mai.2002.128076			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373260	Bronze			2022-12-18	WOS:000178501900002
J	Davoine, F; Lavigne, S; Chakir, J; Ferland, C; Boulay, ME; Laviolette, M				Davoine, F; Lavigne, S; Chakir, J; Ferland, C; Boulay, ME; Laviolette, M			Expression of Fc gamma RIII (CD16) on human peripheral blood eosinophils increases in allergic conditions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; CD16; allergic rhinitis; asthma; hypereosinophilia; allergen challenge; IL-5 receptor; CD11b; IL-12p35	HOUSE-DUST MITE; IL-12; ACTIVATION; ANTIBODIES; ADHESION; DISEASE; ALPHA; MAC-1; IFN; IGE	Background: Blood eosinophils have mRNA for FcgammaRIIIB (CD16) but no or minimal spontaneous CD16 expression. Because IFN-gamma and chemotactic factors induce eosinophil CD16 expression in vitro, we postulated that blood eosinophils could express CD16. Objective: Blood of nonallergic controls and subjects with allergic rhinitis, allergic and nonallergic asthma, or hypereosinophilia of various etiologies were analyzed for leukocyte CD16 surface expression. Methods: CD16(+) eosinophils were identified on the basis of physico-optic characteristics, major basic protein, CD49b expression, and sorting by flow cytometry and microscope examination. Results: Subjects with allergic rhinitis and subjects with asthma had higher median percentages of CD16(+) eosinophils (8.1% [1% to 48.6%] and 7.3% [1.4% to 31.1%], respectively) than nonallergic controls and nonallergic asthmatics (3% [0% to 11%] and 4.6% [2.9% to 5.1%], respectively). In subjects with hypereosinophilia, CD16(+) eosinophils were increased only in a case of drug allergy. When subjects with mild allergic asthma were challenged with a relevant aeroallergen, blood CD16(+) eosinophils further increased during or after the late-phase response (6 to 48 hours after challenge; mean +/- SEM, 9.4% +/- 2.5% to 20.0% +/- 3.0%). CD16(+) eosinophils expressed more IL-5 receptor but less CD11b and IL-12p35 than did CD16(-) eosinophils. Conclusion: Upregulation of blood CD16(+) eosinophils in allergic conditions and its association with a modified phenotype suggest that CD16 receptor could play a role in eosinophil activation in allergy.	Univ Laval, Hop Laval,Ctr Rech, Inst Cardiol & Pneumol, Unite Rech Pneumol, Ste Foy, PQ G1V 4G5, Canada	Laval University	Laviolette, M (corresponding author), Univ Laval, Hop Laval,Ctr Rech, Inst Cardiol & Pneumol, Unite Rech Pneumol, 2725 Chemin St Foy, Ste Foy, PQ G1V 4G5, Canada.							[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; CALHOUN W J, 1992, American Review of Respiratory Disease, V145, pA638; CANONICA GW, 1989, ALLERGY, V44, P1, DOI 10.1111/j.1398-9995.1989.tb00438.x; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Duchateau J, 1997, CLIN EXP ALLERGY, V27, P296, DOI 10.1111/j.1365-2222.1997.tb00708.x; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Grewe M, 1998, J IMMUNOL, V161, P415; Guilbert M, 1999, AM J RESP CELL MOL, V21, P97, DOI 10.1165/ajrcmb.21.1.3517; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HARTNELL A, 1992, J IMMUNOL, V148, P1471; HARTNELL A, 1990, IMMUNOLOGY, V69, P264; Hogan SP, 1998, EUR J IMMUNOL, V28, P413; HUIZINGA TWJ, 1990, J IMMUNOL, V144, P1432; Iwamoto I, 1996, AM J RESP CRIT CARE, V154, P1257, DOI 10.1164/ajrccm.154.5.8912732; Juniper EF, 1991, HISTAMINE METHACHOLI; KANEKO M, 1995, J CLIN INVEST, V95, P2813, DOI 10.1172/JCI117986; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Lavigne S, 1997, CYTOMETRY, V29, P197, DOI 10.1002/(SICI)1097-0320(19971101)29:3<197::AID-CYTO2>3.0.CO;2-9; Matsumoto K, 1998, AM J RESP CELL MOL, V18, P860, DOI 10.1165/ajrcmb.18.6.3159; Nahm DH, 1998, ANN ALLERG ASTHMA IM, V80, P411, DOI 10.1016/S1081-1206(10)62993-6; NAZIRUDDIN B, 1992, J IMMUNOL, V149, P3702; NEELEY SP, 1993, AM J RESP CELL MOL, V8, P633, DOI 10.1165/ajrcmb/8.6.633; Nutku E, 2000, J ALLERGY CLIN IMMUN, V106, P288, DOI 10.1067/mai.2000.107932; Roche N, 1997, EUR RESPIR J, V10, P719; Rose G, 1996, J ALLERGY CLIN IMMUN, V97, P1071, DOI 10.1016/S0091-6749(96)70260-9; SALMON JE, 1990, J CLIN INVEST, V85, P1287, DOI 10.1172/JCI114566; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Shibasaki M, 1997, J ASTHMA, V34, P235, DOI 10.3109/02770909709068194; Tame A, 1996, CLIN EXP ALLERGY, V26, P43, DOI 10.1111/j.1365-2222.1996.tb00055.x; Tang T, 1997, J EXP MED, V186, P1853, DOI 10.1084/jem.186.11.1853; VALERIUS T, 1990, J IMMUNOL, V145, P2950; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; Zhu XD, 1998, J IMMUNOL, V161, P2574	38	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					463	469		10.1067/mai.2002.121952	http://dx.doi.org/10.1067/mai.2002.121952			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897993				2022-12-18	WOS:000174586400013
J	Rinne, J; Simola, M; Malmberg, H; Haahtela, T				Rinne, J; Simola, M; Malmberg, H; Haahtela, T			Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antihistamine; budesonide; cetirizine; corticosteroids; early intervention; perennial rhinitis	ALLERGIC RHINITIS; DOUBLE-BLIND; BECLOMETHASONE DIPROPIONATE; NASAL BUDESONIDE; CORTICOSTEROIDS; TERFENADINE; EFFICACY; ASTHMA	Background: Perennial rhinitis is a common disease that has many similarities with bronchial asthma. Early treatment with inhaled steroids has improved asthma symptoms, lung function, and bronchial hyperreactivity, but it has not been studied in perennial rhinitis. Objective: The main objective was to determine whether early introduction of long-term daily intranasal steroid treatment would have a positive effect on the clinical course and outcome of perennial rhinitis compared with the effect of an antihistamine. A secondary objective was to compare the clinical efficacy of intranasal budesonide and oral cetirizine. Methods: One hundred forty-three adult patients with newly detected perennial allergic or nonallergic eosinophilic rhinitis of I to 3 years' duration were randomized to receive budesonide dry powder, 400 mug (delivered dose of 280 mug) intranasally, or cetirizine, 10 mg orally, once daily for 1 year. At the end of the double-blind treatment period, medication was stopped, and the patients were followed for another year, during which time they could use 14-day courses of intranasal budesonide as needed to control rhinitis relapses. The main outcome measures were the time to first relapse and the number of relapses during the second year. Nasal symptom scores, nasal smear eosinophilia, and nasal peak expiratory flow were used to compare the clinical efficacy of the 2 treatments. Results: During the randomized phase of the study, budesonide was significantly more effective than cetirizine in relieving nasal symptoms. Nasal peak expiratory flow improved significantly in budesonide-treated patients compared with in patients receiving cetirizine. After discontinuation of randomized treatment, 38% of budesonide-treated and 56% of cetirizine-treated patients had a relapse within the first month (P = .04). The median time to first relapse was longer in budesonide-treated patients than in cetirizine-treated patients (62 vs 20 days), although the difference was not significant. Fourteen-day courses of budesonide provided effective control of relapses; the mean number of relapses was 4.0 versus 5.4 in the groups previously treated with budesonide or cetirizine, respectively. Both treatments were well tolerated throughout the study. Conclusions: Budesonide is significantly more effective than cetirizine in controlling perennial rhinitis. After stopping treatment, budesonide better prevents relapses for I to 2 months compared with cetirizine. Periodic therapy with budesonide may be sufficient to control symptoms in most patients who have relapses.	Skin & Allergy Hosp, Div Allergy, Helsinki 00029, Finland; Univ Helsinki, Eye & Ear Hosp, Helsinki, Finland	University of Helsinki	Rinne, J (corresponding author), Skin & Allergy Hosp, Div Allergy, Box 160, Helsinki 00029, Finland.							Andersson Morgan, 1995, Rhinology (Utrecht), V33, P18; BASRAN GS, 1995, AM J RHINOL, V9, P285, DOI 10.2500/105065895781808838; Bertrand B., 1996, Rhinology (Utrecht), V34, P91; Bousquet J, 1998, CLIN EXP ALLERGY, V28, P49; BUNNAG C, 1992, ALLERGY, V47, P313, DOI 10.1111/j.1398-9995.1992.tb02060.x; DAY JH, 1990, ANN ALLERGY, V64, P445; Drebotg S, 1989, ALLERGY S10, V44, P22; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; LAU SK, 1990, ASIAN PAC J ALLERGY, V8, P109; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391, DOI 10.1164/ajrccm.162.4.9912033; MELTZER EO, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02736.x; MELZER EO, 1993, CLIN ASPECTS, P66; PEDERSEN B, 1991, ALLERGY, V46, P582, DOI 10.1111/j.1398-9995.1991.tb00627.x; ROBINSON AC, 1989, CLIN EXP ALLERGY, V19, P569, DOI 10.1111/j.1365-2222.1989.tb02437.x; RoweJones JM, 1997, ALLERGY, V52, P20, DOI 10.1111/j.1398-9995.1997.tb04818.x; SOVIJARVI ARA, 1993, CHEST, V104, P164, DOI 10.1378/chest.104.1.164; SPENCER CM, 1993, DRUGS, V46, P1055, DOI 10.2165/00003495-199346060-00008; Stempel DA, 1998, AM J MANAG CARE, V4, P89; Stern MA, 1998, ANN ALLERG ASTHMA IM, V81, P354, DOI 10.1016/S1081-1206(10)63128-6; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; van Zoest JGCM, 2000, PEDIATR ALLERGY IMMU, V11, P256, DOI 10.1034/j.1399-3038.2000.00079.x; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Vignola AM, 1998, ALLERGY, V53, P833, DOI 10.1111/j.1398-9995.1998.tb03988.x; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624	26	25	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					426	432		10.1067/mai.2002.121703	http://dx.doi.org/10.1067/mai.2002.121703			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897986				2022-12-18	WOS:000174586400007
J	Lordan, JL; Davies, DE; Wilson, SJ; Dent, G; Corkhill, A; Jaffar, Z; Roberts, K; Djukanovic, R; Holgate, ST				Lordan, JL; Davies, DE; Wilson, SJ; Dent, G; Corkhill, A; Jaffar, Z; Roberts, K; Djukanovic, R; Holgate, ST			The role of CD28-B7 costimulation in allergen-induced cytokine release by bronchial mucosa from patients with moderately severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; costimulation; CTLA-4; CD28; T cell; allergen; explant; inflammation; IL	T-CELL COSTIMULATION; MURINE MODEL; AIRWAY EOSINOPHILIA; IMMUNE-RESPONSES; ANTIGEN; CD80; INTERLEUKIN-5; LIGAND; CTLA-4; B7-2	Background: T cells play an important role in airway inflammation in asthma through the release of T(H)2 cytokines. Optimal T-cell activation by antigen-presenting cells requires costimulatory signaling, such as the interaction of CD80, CD86, or both with CD28. In patients with mild allergic asthma, the fusion protein cytotoxic T-lymphocyte antigen 4Ig (CTLA-4Ig), which inhibits CD28-mediated signaling, blocks the release of IL-5 and IL-13 from bronchial explant cultures exposed to the allergen Dermatophagoides pteronyssinus. Objectives: To assess costimulation in more severe forms of atopic asthma, we have compared the ability of CTLA-4Ig to block allergen-induced cytokine responses of bronchial explants and PBMCs from patients with moderately severe asthma. Methods: Bronchial explants and PBMCs were cultured in vitro, and cytokine expression was measured by means of quantitative RT-PCR and ELISA. Results: Constitutive mRNA transcripts for IL-5, IL-13, and GM-CSF were detected in the tissue explants, but only IL-5 mRNA increased significantly with allergen stimulation. Consistent with increased transcription, allergen-stimulated IL-5 protein release into explant supernatants, but this was not blocked by CTLA-4Ig. Allergen did not induce GM-CSF release, and IL-13 protein could not be detected in the explant supernatants under any condition. In contrast, allergen enhanced production of IL-5 and IL-13 by PBMC cultures from the same subjects, and this was inhibited effectively by CTLA-4Ig. Conclusions: These data suggest that IL-5 production in the airways of subjects with moderately severe asthma is largely independent of CD28-mediated costimulation. The different requirements for CD28-mediated costimulation in PBMC cultures and bronchial tissue cultures emphasizes the importance of the tissue microenvironment in pulmonary inflammatory responses in severe asthma.	Univ Southampton, Sch Med, Resp Cell & Mol Biol Div, Southampton, Hants, England	University of Southampton	Davies, DE (corresponding author), Southampton Gen Hosp, D Level Ctr Block, Southampton SO16 6YD, Hants, England.		Davies, Donna E/H-2993-2012; Dent, Gordon/O-3197-2013	Dent, Gordon/0000-0001-9419-2952; Davies, Donna/0000-0002-5117-2991; Djukanovic, Ratko/0000-0001-6039-5612				Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; Bashian GG, 1997, AM J RESP CELL MOL, V17, P235, DOI 10.1165/ajrcmb.17.2.2739; Booms P, 1997, J ALLERGY CLIN IMMUN, V99, P330, DOI 10.1016/S0091-6749(97)70050-2; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; DENT G, 2001, AM J RESP CRIT CARE, V163, pA600; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; Gause WC, 1997, J IMMUNOL, V159, P1055; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; Harris N, 1997, J EXP MED, V185, P177, DOI 10.1084/jem.185.1.177; Hidi R, 2000, J IMMUNOL, V164, P412, DOI 10.4049/jimmunol.164.1.412; Higgins LM, 1999, J IMMUNOL, V162, P486; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Jaffar Z, 1999, AM J RESP CELL MOL, V20, P153, DOI 10.1165/ajrcmb.20.1.3255; Jaffar ZH, 1999, J IMMUNOL, V163, P6283; Keane-Myers AM, 1998, J IMMUNOL, V160, P1036; Krinzman SJ, 1996, J CLIN INVEST, V98, P2693, DOI 10.1172/JCI119093; Larche M, 1998, J IMMUNOL, V161, P6375; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; Park CS, 1998, EUR RESPIR J, V12, P872, DOI 10.1183/09031936.98.12040872; Salvi S, 1999, AM J RESP CELL MOL, V20, P984, DOI 10.1165/ajrcmb.20.5.3463; Sato J, 1999, INT ARCH ALLERGY IMM, V119, P197, DOI 10.1159/000024195; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; *WHO NHLBI, 1995, NIH PUBL; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zhang S, 1996, J PATHOL, V180, P95; Zhang YQ, 1996, INT IMMUNOL, V8, P37, DOI 10.1093/intimm/8.1.37	36	25	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					976	981		10.1067/mai.2001.119740	http://dx.doi.org/10.1067/mai.2001.119740			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742276				2022-12-18	WOS:000172938400014
J	Wagner, B; Buck, D; Hafner, C; Sowka, S; Niggemann, B; Scheiner, O; Breiteneder, HJ				Wagner, B; Buck, D; Hafner, C; Sowka, S; Niggemann, B; Scheiner, O; Breiteneder, HJ			Hev b 7 is a Hevea brasiliensis protein associated with latex allergy in children with spina bifida	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hev b 7; latex allergy; spina bifida; children; immunoblots	NATURAL-RUBBER LATEX; HEALTH-CARE WORKERS; ELONGATION-FACTOR; IGE REACTIVITY; RISK-FACTORS; SENSITIZATION; CLONING; HEV-B-7; PATATIN; PREVALENCE	Background: In addition to their disease-associated handicaps, patients with spina bifida (SD) are at high risk of developing latex allergy. Individuals with SB represent a special group of latex-allergic patients, inasmuch as their IgE-binding patterns differ from those of other populations of latex-allergic individuals. Two allergens strongly associated with latex allergy in patients with SB-Hev b 1 and Hev b 3-have already been identified. Objective: We intended to identify a predominant IgE-binding band-in addition to Hev b 1 and 3-at 43 kDa in a study population of 38 latex-allergic (IgE antibodies to latex and symptoms on provocation with latex gloves) and 15 latex-sensitized (IgE antibodies to latex but no symptoms on provocation) children with SB (mean age, 12.3 years) and to determine its frequency of recognition. Methods: Sera of latex-sensitized or latex-allergic patients with SB were tested on latex C extract containing natural Hev b 1, Hev b 3, and Hev b 7 and with the recombinant 43-kDa Hev b 7 in immunoblot and inhibition studies. Results: Natural Hev b 1 was recognized by 82% and natural Hev b 3 by 79% of the latex-allergic children with SB. In addition to some other proteins, 15 (39.5%) of 38 latex-allergic and 2 (13%) of 5 latex-sensitized children with SB revealed IgE binding to a 43-kDa band in the latex protein extract. We identified this 43-kDa IgE-binding band as natural Hev b 7 by immunoblotting and inhibition experiments using recombinant Hev b 7. Conclusion: From these data, we conclude that Hev b 7, the patatinlike Hevea latex protein, is the third SB-associated latex allergen. Future immunotherapy for latex-allergic individuals with SB will have to include Hev b 7 in addition to Hev b 1 and Hev b 3.	Univ Vienna, Dept Pathophysiol, Vienna, Austria; Childrens Hosp, Virchow Clin, Berlin, Germany	University of Vienna	Breiteneder, HJ (corresponding author), AKH EBO 3Q, Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.							ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; AXEN R, 1998, N ENGL REG ALLERGY P, V53, P513; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; Buck D, 2000, PEDIATR ALLERGY IMMU, V11, P111, DOI 10.1034/j.1399-3038.2000.00039.x; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V100, P684, DOI 10.1016/S0091-6749(97)70174-X; Cremer R, 1998, EUR J PEDIATR, V157, P13, DOI 10.1007/s004310050758; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; Kirpalani HM, 2000, ARCH DIS CHILD, V83, P293, DOI 10.1136/adc.83.4.293; KONZ KR, 1995, J ALLERGY CLIN IMMUN, V95, P950, DOI 10.1016/S0091-6749(95)70094-3; Kostyal DA, 1998, CLIN EXP IMMUNOL, V112, P355; Mazon A, 2000, ANN ALLERG ASTHMA IM, V84, P207, DOI 10.1016/S1081-1206(10)62757-3; Michael T, 1996, CLIN EXP ALLERGY, V26, P934; Moller M, 1998, ALLERGY, V53, P289, DOI 10.1111/j.1398-9995.1998.tb03889.x; Nieto A, 1996, J ALLERGY CLIN IMMUN, V98, P501, DOI 10.1016/S0091-6749(96)70082-9; Niggemann B, 1998, J ALLERGY CLIN IMMUN, V102, P665, DOI 10.1016/S0091-6749(98)70285-4; Niggemann B, 2000, J ALLERGY CLIN IMMUN, V106, P1201; Niggemann B, 2000, INT ARCH ALLERGY IMM, V121, P98, DOI 10.1159/000024304; NOETZEL MJ, 1989, CLIN PERINATOL, V16, P311, DOI 10.1016/S0095-5108(18)30634-1; Seppala U, 2000, ALLERGY, V55, P266, DOI 10.1034/j.1398-9995.2000.00392.x; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; Sowka S, 1999, J ALLERGY CLIN IMMUN, V104, P1302, DOI 10.1016/S0091-6749(99)70028-X; Szepfalusi Z, 1999, J PEDIATR-US, V134, P344, DOI 10.1016/S0022-3476(99)70461-0; Wagner B, 1999, J ALLERGY CLIN IMMUN, V104, P1084, DOI 10.1016/S0091-6749(99)70093-X; YASSIN MS, 1994, ANN ALLERGY, V72, P245; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; Yeang HY, 2000, J INVEST ALLERG CLIN, V10, P215; Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342	28	25	30	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					621	627						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590391				2022-12-18	WOS:000171760300024
J	Schubert, MS				Schubert, MS			Antileukotriene therapy for allergic fungal sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Arizona, Coll Med, Dept Med, Phoenix, AZ USA; Allergy Asthma Clin, Phoenix, AZ 85013 USA	University of Arizona	Schubert, MS (corresponding author), Allergy Asthma Clin, 31 W Camelback Rd, Phoenix, AZ 85013 USA.							DAHIEN B, 1998, AM J RESP CRIT CARE, V157, P1187; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; GEORGITIS JW, 1995, INT ARCH ALLERGY IMM, V106, P416, DOI 10.1159/000236875; Hamilos DL, 2000, J ALLERGY CLIN IMMUN, V106, P213, DOI 10.1067/mai.2000.109269; Khan DA, 2000, J ALLERGY CLIN IMMUN, V106, P1096, DOI 10.1067/mai.2000.110929; Kupferberg SB, 1996, ARCH OTOLARYNGOL, V122, P1381, DOI 10.1001/archotol.1996.01890240087019; Mabry RL, 1998, OTOLARYNG HEAD NECK, V119, P648, DOI 10.1016/S0194-5998(98)70027-0; OGINO S, 1993, ACTA OTO-LARYNGOL, P85; Parnes S M, 2000, Ear Nose Throat J, V79, P18; Schubert MS, 2000, ANN ALLERG ASTHMA IM, V85, P90, DOI 10.1016/S1081-1206(10)62445-3; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P387, DOI 10.1016/S0091-6749(98)70125-3	12	25	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					466	467		10.1067/mai.2001.117592	http://dx.doi.org/10.1067/mai.2001.117592			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544470	Bronze			2022-12-18	WOS:000171215400022
J	Shearer, WT; Lugg, DJ; Rosenblatt, HM; Nickolls, PM; Sharp, RM; Reuben, JM; Ochs, HD				Shearer, WT; Lugg, DJ; Rosenblatt, HM; Nickolls, PM; Sharp, RM; Reuben, JM; Ochs, HD			Antibody responses to bacteriophage phi X-174 in human subjects exposed to the Antarctic winter-over model of spaceflight	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						spaceflight model; Antarctic winter; phi X-174 antibody responses	CELL-MEDIATED-IMMUNITY; PROTEIN-KINASE-C; SPACE-FLIGHT; INTERFERON-PRODUCTION; SLEEP-DEPRIVATION; DURATION MISSIONS; HUMORAL IMMUNITY; MICROGRAVITY; DEFICIENCY; LEUKOCYTES	Background: It has been proposed that exposure to long-term spaceflight conditions (stress, isolation, sleep disruption, containment, microbial contamination, and solar radiation) or to ground-based models of spaceflight will alter human immune responses, but specific antibody responses hale not been fully evaluated. Objective: We sought to determine whether exposure to the 8-month Antarctic winter-over model of spaceflight would alter human antibody responses. Methods: During the 1999 Australian National Antarctic Research Expeditions, 11 adult study subjects at Casey, Antarctica, and 7 control subjects at Macquarie Island, sub-Antarctica, received primary and secondary immunizations with the T cell-dependent neoantigen bacteriophage phiX-174. Periodic plasma samples were analyzed for specific antibody function. Results: All of the subjects from Casey, Antarctica cleared bacteriophage phiX-174 normally by 1 week after primary immunization, and all had normal primary and secondary antibody responses, including immunologic memory amplification and snitch from IgM to IgG antibody production. One subject showed a high normal pattern, and one subject had a low normal pattern. The control subjects from Macquarie Island also had normal immune responses to bacteriophage phiX-174. Conclusions: These data do not support the hypothesis that de novo specific antibody responses of subjects become defective during the conditions of the Antarctic winter-over. Because the Antarctic winter-over model of spaceflight lacks the important factors of microgravity and solar radiation, caution must be used in interpreting these data to anticipate normal antibody responses in long-term spaceflight.	Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Washington, Seattle, WA 98195 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Washington; University of Washington Seattle	Shearer, WT (corresponding author), Texas Childrens Hosp, Baylor Coll Med, 6621 Fannin St,MC 1-3291, Houston, TX 77030 USA.			Shearer, William/0000-0002-2483-2130				Aguilar Laura K., 1999, Current Opinion in Oncology, V11, P96, DOI 10.1097/00001622-199903000-00004; ARMSTRONG JW, 1995, EXP CELL RES, V216, P160, DOI 10.1006/excr.1995.1020; BECHLER B, 1992, BIOTECHNOL BIOENG, V40, P991, DOI 10.1002/bit.260400815; BERNSTEIN LJ, 1985, J PEDIATR-US, V107, P352, DOI 10.1016/S0022-3476(85)80505-9; CHAPES SK, 1992, J LEUKOCYTE BIOL, V52, P104, DOI 10.1002/jlb.52.1.104; COGOLI A, 1993, J LEUKOCYTE BIOL, V54, P259, DOI 10.1002/jlb.54.3.259; DICK EC, 1977, ANTARCT J US, V12, P2; DINGES DF, 1995, ADV NEUROIMMUNOL, V5, P97, DOI 10.1016/0960-5428(95)00002-J; DINGES DF, 1994, J CLIN INVEST, V93, P1930, DOI 10.1172/JCI117184; Dinges DF, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P1; Fogelman I, 2000, J INFECT DIS, V182, P435, DOI 10.1086/315739; GLASER R, 1986, BEHAV NEUROSCI, V100, P675, DOI 10.1037/0735-7044.100.5.675; GMUNDER FK, 1990, BIOL CELL, V70, P33, DOI 10.1016/0248-4900(90)90358-A; GMUNDER FK, 1994, AVIAT SPACE ENVIR MD, V65, P419; JACKSON CG, 1979, NEW ENGL J MED, V300, P1124, DOI 10.1056/NEJM197905173002002; Kajioka EH, 2000, RADIAT RES, V153, P587, DOI 10.1667/0033-7587(2000)153[0587:AEOWBP]2.0.CO;2; Kajioka EH, 1999, IN VIVO, V13, P525; KIECOLTGLASER JK, 1986, J BEHAV MED, V1, P5; KONSTANTINOVA IV, 1993, J LEUKOCYTE BIOL, V54, P189, DOI 10.1002/jlb.54.3.189; Konstantinova IV, 1991, IMMUNE SYSTEM SPACE; LEBLANC AD, 1990, J BONE MINER RES, V5, P843; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; MEEHAN R, 1988, J CLIN IMMUNOL, V8, P397, DOI 10.1007/BF00917156; MEEHAN RT, 1992, IMMUNOLOGY, V76, P491; Mehta SK, 2000, J MED VIROL, V61, P235, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;235::AID-JMV10&gt;3.0.CO;2-4; MULLER HK, 1995, PATHOLOGY, V27, P186; MULLER HK, 1995, IMMUNOL CELL BIOL, V73, P316, DOI 10.1038/icb.1995.48; NIEMAN DC, 1990, INT J SPORTS MED, V11, P467, DOI 10.1055/s-2007-1024839; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; Pitson G A, 1996, Arctic Med Res, V55, P118; PYUN KH, 1989, CLIN IMMUNOL IMMUNOP, V51, P252, DOI 10.1016/0090-1229(89)90024-X; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; SCHMITT DA, 1993, J LEUKOCYTE BIOL, V54, P209, DOI 10.1002/jlb.54.3.209; SCHMITT DA, 1995, BRAIN BEHAV IMMUN, V9, P70, DOI 10.1006/brbi.1995.1007; SHEARER WT, 1985, NEW ENGL J MED, V312, P1151, DOI 10.1056/NEJM198505023121804; SHEARER WT, IN PRESS ENCY SPACE; SONNENFELD G, 1992, J INTERFERON RES, V12, P75, DOI 10.1089/jir.1992.12.75; Taylor G R, 1997, Adv Space Biol Med, V6, P1, DOI 10.1016/S1569-2574(08)60076-3; TAYLOR GR, 1992, J LEUKOCYTE BIOL, V51, P129, DOI 10.1002/jlb.51.2.129; TAYLOR GR, 1993, J LEUKOCYTE BIOL, V54, P202, DOI 10.1002/jlb.54.3.202; Tingate TR, 1997, IMMUNOL CELL BIOL, V75, P275, DOI 10.1038/icb.1997.42; UMETSU DT, 1994, J ALLERGY CLIN IMMUN, V93, P543, DOI 10.1016/0091-6749(94)90365-4; VOSS EW, 1984, SCIENCE, V225, P214, DOI 10.1126/science.6729476; Wedgwood R J, 1975, Birth Defects Orig Artic Ser, V11, P331; WILLIAMS DL, 1986, J CLIN LAB IMMUNOL, V20, P43; WOODS KM, 1994, EXP CELL RES, V211, P171, DOI 10.1006/excr.1994.1074	46	25	26	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					160	164		10.1067/mai.2001.112269	http://dx.doi.org/10.1067/mai.2001.112269			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11150006				2022-12-18	WOS:000166533300026
J	Larsen, GL				Larsen, GL			Differences between adult and childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma pathogenesis; airway function; airway hyperresponsiveness; airway inflammation; cytokines; leukotrienes	MANAGEMENT PROGRAM CAMP; LONG-TERM TREATMENT; AIRWAY RESPONSIVENESS; 14-YEAR-OLD CHILDREN; NEURAL CONTROL; MILD ASTHMA; INFLAMMATION; RESPONSES; INFANTS; HYPERRESPONSIVENESS	During the last 2 decades, we have gained new insights into the pathogenesis of asthma; consequently, new therapeutic agents and approaches to therapy have emerged. Nevertheless, significant gaps remain in our understanding of this disease. Important new treatment issues affect childhood (the usual time of asthma onset), and researchers have recently described increases in asthma incidence in children. Yet, most clinical studies have been performed with adults, and our knowledge about major determinants of childhood asthma remains incomplete. Major challenges in pediatric asthma include methods of easily assessing Lung function and noninvasive methods of assessing asthma's inflammatory nature. Research that addresses the mechanisms responsible for disease onset is also critical to decrease the prevalence of asthma. What we know about adult asthma cannot be used in the treatment of children without further study, but it is now clear that effective treatment should begin during childhood.	Univ Colorado, Sch Med, Natl Jewish Med & Res Ctr, Dept Pediat,Div Pediat Pulm Med, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Larsen, GL (corresponding author), Univ Colorado, Sch Med, Natl Jewish Med & Res Ctr, Dept Pediat,Div Pediat Pulm Med, Room J112,1400 Jackson St, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Barnes PJ, 1996, CLIN EXP ALLERGY, V26, P738; BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BRUGMAN SM, 1995, CLIN CHEST MED, V16, P637; BUSSE W, 1995, AM J RESP CRIT CARE, V151, P1635, DOI 10.1164/ajrccm.151.5.7735626; Busse WW, 1997, AM J RESP CRIT CARE, V156, P314, DOI 10.1164/ajrccm.156.1.9612121; COLASURDO GN, 1994, AM J PHYSIOL-LUNG C, V267, pL739, DOI 10.1152/ajplung.1994.267.6.L739; COLASURDO GN, 1994, ASTHMA RHINITIS, P1044; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; Gelfand AS, 1997, PEDIATR PULM, V23, P198, DOI 10.1002/(SICI)1099-0496(199703)23:3&lt;198::AID-PPUL5&gt;3.0.CO;2-K; Grigg J, 1996, EUR RESPIR J, V9, pS16; Haahtela T, 1997, CLIN EXP ALLERGY, V27, P351; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Haley KJ, 1998, AM J RESP CRIT CARE, V157, P1; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Lanz MJ, 1997, PEDIATR PULM, V24, P305; Larsen GL, 1999, J PEDIATR-US, V135, pS21; Larsen GL, 1999, J ALLERGY CLIN IMMUN, V103, P371, DOI 10.1016/S0091-6749(99)70458-6; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; *NAT ASTHM ED PREV, 1997, NIH PUBL; Persson CGA, 1997, LANCET, V350, P1021, DOI 10.1016/S0140-6736(96)02335-5; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; RICHARDS W, 1965, AM J DIS CHILD, V110, P4, DOI 10.1001/archpedi.1965.02090030010003; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; TEPPER RS, 1992, PEDIATR PULM, V13, P6, DOI 10.1002/ppul.1950130104; TEPPER RS, 1987, J APPL PHYSIOL, V62, P1155, DOI 10.1152/jappl.1987.62.3.1155; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	43	25	25	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3		S			S153	S157						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	357XB	10984396				2022-12-18	WOS:000089525400007
J	Shim, JJ; Dabbagh, K; Takeyama, K; Burgel, PR; Dao-Pick, TP; Ueki, IF; Nadel, JA				Shim, JJ; Dabbagh, K; Takeyama, K; Burgel, PR; Dao-Pick, TP; Ueki, IF; Nadel, JA			Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway epithelium; mucin production; IL-4 expression; ovalbumin sensitization	DIMETHYLSULFONIUM AGENT; IGE PRODUCTION; HYPERPLASIA; SUPPRESSION; EXPRESSION; ASTHMA	Background: IL-4 and IL-13 play a putative role in mucus hypersecretion in asthma. Suplatast tosilate prevents the synthesis of T-H2 cytokines. Objective: Because suplatast tosilate inhibits T-H2 cytokines but does not inhibits IFN-gamma production, we examined the effect of suplatast on IL-4- or IL-13- and ovalbumin (OVA)-induced mucin synthesis in NCI-H292 cells in vitro and in bronchi of pathogen-free BALB/c mice in vivo. Methods: In vitro, NCI-H292 cells were preincubated with suplatast tosilate (0.1-100 mu g/mL) 1 hour before adding human recombinant IL-4 (10 ng/mL). In vivo, mouse recombinant IL-4 or IL-13 (250 ng per/mouse) was instilled intranasally in mice pretreated with suplatast tosilate (50 mg(.)kg(-1.)d(-1)). Mucous glycoconjugates were stained with Alcian blue (AB)/periodic acid-Schiff (PAS) stain. To evaluate effects of suplatast tosilate on goblet-cell metaplasia in OVA-sensitized mice, animals were pretreated with suplatast tosilate (1-50 mg(.)kg(-1.)d(-1)) intragastrically, IL-4 and IL-13 were measured, and allergic inflammatory cells were analyzed in bronchoalveolar lavage fluid of OVA-sensitized mice. Results: Pretreatment with suplastast did not prevent IL-4- or IL-13-induced increase in mucous glycoconjugate production in NCI-H292 cells or in mice. OVA sensitization increased AB/PAS-stained area of the epithelium (48.1% +/- 2.4%, P < .01 compared with control mice). Suplatast tosilate inhibited OVA-induced goblet-cell metaplasia in airway epithelium in a dose-dependent fashion; 50 mg(.)kg(-1.)d(-1) decreased the AB/PAS area to 22.7% +/- 2.7% (P < .05 compared with OVA sensitization alone). Pre-treatment with suplatast tosilate also prevented OVA-induced increase in IL-4 and IL-13 levels and decreased the number of lymphocytes and eosinophils in bronchoalveolar lavage fluid (P < .05 compared with values of mice given OVA alone), Conclusion: These results indicate that suplatast tosilate prevents allergen-induced goblet-cell metaplasia and the recruitment of eosinophils and lymphocytes into the airways, These results suggest that this effect is due to the prevention of the production of T-H2 cytokines in airways.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Nadel, JA (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 505 Parnassus Ave,Room M-1325, San Francisco, CA 94143 USA.			Burgel, Pierre Regis/0000-0003-0903-9828				AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cohn L, 1999, J IMMUNOL, V162, P6178; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Iijima H, 1999, AM J RESP CRIT CARE, V160, P331, DOI 10.1164/ajrccm.160.1.9809059; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Lou YP, 1998, AM J RESP CRIT CARE, V157, P1927, DOI 10.1164/ajrccm.157.6.9709113; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; Taniguchi H, 1996, EUR J PHARMACOL, V318, P447, DOI 10.1016/S0014-2999(96)00810-2; Temann UA, 1997, AM J RESP CELL MOL, V16, P471, DOI 10.1165/ajrcmb.16.4.9115759; THORNTON DJ, 1989, ANAL BIOCHEM, V182, P160, DOI 10.1016/0003-2697(89)90735-5; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YAMAYA H, 1995, LIFE SCI, V56, P1647, DOI 10.1016/0024-3205(95)00132-P; YANAGIHARA Y, 1993, JPN J PHARMACOL, V61, P23, DOI 10.1254/jjp.61.23; YANAGIHARA Y, 1993, JPN J PHARMACOL, V61, P31, DOI 10.1254/jjp.61.31	18	25	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					739	745		10.1067/mai.2000.105221	http://dx.doi.org/10.1067/mai.2000.105221			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756224				2022-12-18	WOS:000086604100012
J	Soldatova, LN; Paupore, EJ; Burk, SH; Pastor, RW; Slater, JE				Soldatova, LN; Paupore, EJ; Burk, SH; Pastor, RW; Slater, JE			The stability of house dust mite allergens in glycerinated extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dust mite; monoclonal antibody; allergen; ELISA; immunoblot; stability; allergy; allergen extract	SITE-DIRECTED MUTAGENESIS; DILUTION; DER-P-2	Background: Mite allergen vaccines are important diagnostic and immunotherapeutic reagents. Previous studies on mite allergen stability under different storage conditions have yielded contradictory results, Objective: We sought to compare, over a 12-month period, the stability of mite allergens reconstituted in 50% glycerol and stored at different temperatures and to examine the role of protease inhibitors in enhancing allergen stability. Methods: Lyophilized allergen extracts were reconstituted in 50% glycerol, with and without protease inhibitors, and stored at -70 degrees C, -20 degrees C, 4 degrees C, or 37 degrees C for 12 months. At 6 and 12 months, the extracts were compared with freshly dissolved extracts by competition ELISA with pooled allergic sera, 2-site ELISA with mite-specific mAbs, and immunoblot analyses, Results: The overall potencies of the stored extracts measured by competition ELISA were stable at -20 degrees C and 4 degrees C. As determined by means of the immunoblot and 2-site ELISA, Der fl levels decreased at 4 degrees C. Levels of Der f 2, Der p 1, and Der p 2 decreased in at least one of the allergen-specific assays. Storage at 37 degrees C led to overall loss of potency and allergen content, whereas storage at -70 degrees C was associated with a moderate loss of potency that increased with multiple freeze-thaw cycles, Protease inhibitors had no effect on allergen stability. Conclusion: Although overall potency of the extracts, as measured by competition ELISA, was preserved at -20 degrees C and 4 degrees C, allergen-specific assays indicated loss of allergens. These findings suggest that the competition ELISA is insensitive to decreases in the concentrations of individual allergens.	US FDA, CBER, DBPAP,Div Allergen Prod & Parasitol, Lab Immunobiochem, Rockville, MD 20852 USA; US FDA, CBER, Div Allergen Prod & Parasitol, Biophys Lab, Rockville, MD 20852 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Soldatova, LN (corresponding author), US FDA, CBER, DBPAP,Div Allergen Prod & Parasitol, Lab Immunobiochem, 1401 Rockville Pike,HFM-422, Rockville, MD 20852 USA.							ACKLAND J, 1984, J ALLERGY CLIN IMMUN, V74, P848, DOI 10.1016/0091-6749(84)90189-1; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; Chapman MD, 1999, J ALLERGY CLIN IMMUN, V103, pS122; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; DEGROOT MH, 1975, PROBABILITY STAT; ESCH RE, 1992, P EHRLICH I BUNDESAM, V91, P171; FERNANDESCALDES E, 1999, ALLERGENS ALLERGEN I, P181; Hakkaart GAJ, 1998, ALLERGY, V53, P165, DOI 10.1111/j.1398-9995.1998.tb03865.x; Liu T, 1998, ANN ALLERG ASTHMA IM, V80, P177, DOI 10.1016/S1081-1206(10)62952-3; NAERDAL A, 1983, CLIN ALLERGY, V13, P149, DOI 10.1111/j.1365-2222.1983.tb02582.x; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; Niemeijer NR, 1996, ANN ALLERG ASTHMA IM, V76, P535, DOI 10.1016/S1081-1206(10)63274-7; PLATTSMILLS TAE, 1997, ALLERGY ALLERGIC DIS, P888; Rosenbaum MR, 1996, AM J VET RES, V57, P1447; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; THOMAS WR, 1993, CLIN EXP ALLERGY, V23, P350, DOI 10.1111/j.1365-2222.1993.tb00338.x; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; THOMAS WR, 1997, P EHRLICH I BUNDESAM, V91, P87; TURKELTAUB PC, 1989, ALLERGOL IMMUNOPATH, V17, P53	20	25	26	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					482	488		10.1067/mai.2000.104549	http://dx.doi.org/10.1067/mai.2000.104549			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719297	Bronze			2022-12-18	WOS:000088946700013
J	Howard, TD; Meyers, DA; Bleecker, ER				Howard, TD; Meyers, DA; Bleecker, ER			Mapping susceptibility genes for asthma and allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; genome screens; candidate genes	SKIN-TEST REACTIVITY; GENOME-WIDE SEARCH; SERUM IGE LEVELS; BRONCHIAL HYPERRESPONSIVENESS; UNDERLYING ASTHMA; ATOPY; LINKAGE; MARKERS; ASSOCIATION; CHILDREN	Allergy and asthma are related conditions caused by a complex interaction of genetic factors and environmental influences. With family data from several different populations, linkage analysis has been performed and used to identify regions of the genome that contain susceptibility genes for these conditions, To date, 4 genome screens have been completed and have successfully identified several chromosomal locations that are likely to contain asthma and allergy genes. Many of these regions contain potential biologic candidate genes that modulate immunologic responses or airways inflammation. By focusing on the common regions that have been replicated in these 4 genome screens, the major susceptibility genes for asthma and allergy should be identified, This will lead to an improved understanding of pathogenic factors that lead to development or progression of asthma and allergic diseases.	Univ Maryland, Ctr Genet Asthma & Complex Dis, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Bleecker, ER (corresponding author), Univ Maryland, Ctr Genet Asthma & Complex Dis, 108 N Greene St,Suite 119, Baltimore, MD 21201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049602, R01HL048341] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01-HL49602, R01-HL48341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amelung PJ, 1999, AM J RESP CRIT CARE, V159, pA646; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; COOKSON WOCM, 1989, LANCET, V1, P1292; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; Folster-Holst R, 1998, HUM GENET, V102, P236, DOI 10.1007/s004390050685; HALONEN M, 1992, AM REV RESPIR DIS, V146, P666; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; KOPPELMAN GH, 1998, AM J HUM GENET, V63, pA295; LIFE P, 1995, EUR J IMMUNOL, V25, P333, DOI 10.1002/eji.1830250205; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Rosenwasser LJ, 1997, AM J RESP CRIT CARE, V156, pS152, DOI 10.1164/ajrccm.156.4.12tac-14; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; STINE OC, 1998, AM J RESP CRIT CARE, V157, pA855; *US PUBL HLTH SERV, 1977, US DHHS PHS NIH PUBL; VERCELLI D, 1996, GENETICS ASTHMA, P181; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; WIESCH DG, 1996, GENETICS ASTHMA, P421; WILLADSEN S, 1998, AM J HUM GENET, V63, P1821	32	25	27	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S477	S481		10.1016/S0091-6749(00)90046-0	http://dx.doi.org/10.1016/S0091-6749(00)90046-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669527				2022-12-18	WOS:000085439600004
J	Bush, RK; Sanchez, H; Geisler, D				Bush, RK; Sanchez, H; Geisler, D			Molecular cloning of a major Alternaria alternata allergen, rAlt a 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alternaria alternata; recombinant allergens; rAlt a 2	NUTRITION EXAMINATION SURVEY; 2ND NATIONAL-HEALTH; FUNGAL ALLERGENS; ALT; PURIFICATION; ASTHMA; REACTIVITY	Background: Sensitivity to the fungus Alternaria alternata is a common cause of asthma, Epidemiologic studies from a variety of locations worldwide indicate that A alternata sensitivity is closely linked with the development of asthma. Furthermore, A alternata sensitivity has been associated with severe and potentially fatal attacks of asthma, Objective: The diagnosis of A alternata sensitivity is hampered by the lack of standardized and well-characterized allergenic extracts. Molecular cloning of allergens offers the possibility of providing large quantities of purified, well-characterized allergens not only for diagnostic purposes but also for studying the pathogenesis of A alternata sensitivity, We used molecular cloning to identify, purify, and produce a majors alternata allergen in quantity. Methods: We prepared messenger (m)RNA from A alternata to produce a complementary (c)DNA library The library was screened for A alternata allergens by using sera from A alternata-sensitive individuals. A recombinant allergen was isolated, the cDNA sequence was determined, and the protein was expressed in Pichia pastoris, Results: A unique A alternata allergen, rAlt a 2, was identified. A 2.2-kb cDNA sequence was obtained that has homology with a common transposable region and mouse RNA-dependent eukaryote initiation factor-2 a-kinase but no homology to any known allergen, No N-glycosylation sites were found in the cDNA sequence. The recombinant allergen was recognized by IgE antibodies in the sera of 16 of 26 (61%) individuals allergic to A alternata, which defines Alt a 2 as a major allergen. Conclusions: We have molecularly cloned a unique major A alternata allergen, rAlt a 2. Identification and expression of the recombinant allergen should enhance the development of standardized A alternata allergenic extracts and provide stable reagents for investigating the pathogenesis of A alternata sensitivity.	William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison	Bush, RK (corresponding author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.							ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; AUKRUST L, 1982, Allergy (Copenhagen), V37, P36; Barnes CS, 1996, ADV EXP MED BIOL, V409, P197; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; Breitenbach M, 1997, INT ARCH ALLERGY IMM, V113, P114, DOI 10.1159/000237521; BUDD TW, 1983, J ALLERGY CLIN IMMUN, V71, P277, DOI 10.1016/0091-6749(83)90081-7; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; Bush RK, 1996, IMMUNOL ALLERGY CLIN, V16, P535, DOI 10.1016/S0889-8561(05)70260-5; DEARDS MJ, 1991, MOL IMMUNOL, V28, P409, DOI 10.1016/0161-5890(91)90154-C; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Guss J, 1998, J ALLERGY CLIN IMMUN, V101, pS84; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HELM RM, 1988, J ALLERGY CLIN IMMUN, V81, P651, DOI 10.1016/0091-6749(88)91035-4; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; Larsen JN, 1996, J ALLERGY CLIN IMMUN, V97, P577; Lee S.B., 1990, PCR PROTOCOLS GUIDE, P282, DOI [10.1016/B978-0-12-372180-8.50038-X, DOI 10.1016/B978-0-12-372180-8.50038-X]; MANIATIS T, 1982, MOL CLONING LABORATO, P196; NYHOLM L, 1983, J ALLERGY CLIN IMMUN, V71, P461, DOI 10.1016/0091-6749(83)90462-1; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PARIS S, 1991, J ALLERGY CLIN IMMUN, V88, P902, DOI 10.1016/0091-6749(91)90247-L; PATNEY SC, 1981, P NATL ACAD SCI USA, V78, P7350; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PORTNOY J, 1990, ANN ALLERGY, V65, P109; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P773, DOI 10.1016/0091-6749(93)90197-N; SCHONWALD PHILIPP, 1938, JOUR ALLERGY, V9, P175, DOI 10.1016/S0021-8707(38)90512-X; STEWART GA, 1995, ASTHMA RHINITIS, P898; VIJAY HM, 1984, INT ARCH ALLER A IMM, V74, P256, DOI 10.1159/000233554; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; ZHANG L, 1995, INT ARCH ALLERGY IMM, V108, P254, DOI 10.1159/000237161	33	25	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				665	671		10.1016/S0091-6749(99)70340-4	http://dx.doi.org/10.1016/S0091-6749(99)70340-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482844				2022-12-18	WOS:000082870000032
J	Frew, AJ; White, PJ				Frew, AJ; White, PJ			Sublingual immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; HOUSE-DUST-MITE; ALLERGEN-SPECIFIC IMMUNOTHERAPY; GRASS-POLLEN IMMUNOTHERAPY; LOCAL NASAL IMMUNOTHERAPY; DOUBLE-BLIND TRIAL; SUMMER HAY-FEVER; ORAL IMMUNOTHERAPY; DERMATOPHAGOIDES-PTERONYSSINUS; CLINICAL EFFICACY		Univ Southampton, Sch Med, Dept Med, Southampton, Hants, England; Univ Southampton, Sch Med, Dept Primary Med Care, Southampton, Hants, England	University of Southampton; University of Southampton	Frew, AJ (corresponding author), Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.		Yusuf, M Osman/AAI-1142-2020; Kelly, Frank J/C-6125-2009; Smith, Helen E/M-2449-2016	Yusuf, M Osman/0000-0002-8067-1204; Kelly, Frank J/0000-0003-2558-8392; Smith, Helen E/0000-0003-1883-6124				ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; ANDRI L, 1993, J ALLERGY CLIN IMMUN, V91, P987, DOI 10.1016/0091-6749(93)90211-W; Andri L, 1996, J ALLERGY CLIN IMMUN, V97, P34, DOI 10.1016/S0091-6749(96)70280-4; [Anonymous], 1986, Br Med J (Clin Res Ed), V293, P948; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P292, DOI 10.1016/S0091-6749(05)80091-0; *BRIT SOC ALL CLIN, 1993, CLIN EXP ALLERGY  S3, V23, P1; Chanez P, 1996, ALLERGY, V51, P850; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; FELL P, 1990, EUR J CLIN PHARMACOL, V38, P77, DOI 10.1007/BF00314808; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; LENG X, 1990, ANN ALLERGY, V64, P27; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; Litwin A, 1997, J ALLERGY CLIN IMMUN, V100, P30, DOI 10.1016/S0091-6749(97)70191-X; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LOFKVIST T, 1994, ALLERGY, V49, P100, DOI 10.1111/j.1398-9995.1994.tb00808.x; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OHMAN JL, 1989, J ALLERGY CLIN IMMUN, V84, P133, DOI 10.1016/0091-6749(89)90313-8; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; PERONI DG, 1995, ALLERGY, V50, P925, DOI 10.1111/j.1398-9995.1995.tb02500.x; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; REID M J, 1990, Journal of Allergy and Clinical Immunology, V85, P180; REID MJ, 1992, J ALLERGY CLIN IMMUN, P89; REILLY DT, 1986, LANCET, V2, P881; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; Spiegelberg HL, 1997, ALLERGY, V52, P964, DOI 10.1111/j.1398-9995.1997.tb02415.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Tari MG, 1997, ALLERGY, V52, P65, DOI 10.1111/j.1398-9995.1997.tb02547.x; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Wheeler AW, 1997, ALLERGY, V52, P602, DOI 10.1111/j.1398-9995.1997.tb01038.x	47	25	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				267	270		10.1016/S0091-6749(99)70362-3	http://dx.doi.org/10.1016/S0091-6749(99)70362-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452740				2022-12-18	WOS:000082364800009
J	Tashkin, DP; Nathan, RA; Howland, WC; Minkwitz, MC; Simonson, SG; Bonuccelli, CM				Tashkin, DP; Nathan, RA; Howland, WC; Minkwitz, MC; Simonson, SG; Bonuccelli, CM			An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; leukotrienes; leukotriene receptor antagonist; pulmonary function; subset analyses; zafirlukast	TO-MODERATE ASTHMA; RECEPTOR ANTAGONIST; 5-LIPOXYGENASE INHIBITOR; MONTELUKAST MK-0476; LEUKOTRIENE; THERAPY; MULTICENTER; ICI-204,219; AGENTS; TRIAL	Background: Consensus asthma guidelines recommend antileukotriene agents as alternative therapy to existing anti-inflammatory medications; however the full therapeutic potential of these medications has not yet been determined. Objective: The purpose of this study was to assess the efficacy and safety of the oral leukotriene receptor antagonist zafirlukast (20 mg twice daily) in subgroups of patients who have asthma with the use of integrated data from four 13-week trials. Methods: The trials had comparable designs, entry criteria, and clinical assessments. Patient subgroups were characterized by demographic and baseline asthma characteristics. Analysis of covariance models were tested for overall treatment effect and for interactions between treatment and subgroup characteristics. Results: Patients with mild-to-moderate asthma (12 to 76 years old) who were treated with albuterol alone mere randomized (n(Z) = 879; n(P) = 605) and included in subset analyses. Significant overall treatment effects, favoring zafirlukast, were noted for measures of daytime and nighttime symptoms, beta(2)-agonist use, and pulmonary function (P < .05). A significant, quantitative, treatment-by-age interaction was noted for beta(2)-agonist use (P < .03), suggesting greater reductions in rescue medication use with increasing patient age. Compared with placebo, similar size and/or direction of response was noted with zafirlukast in the various subgroups, indicating a benefit with zafirlukast regardless of subgroup. Significant treatment-by-strata interactions (P < .05), favoring zafirlukast, were noted for various outcome measures in subgroups with the greatest amount of baseline beta(2)-agonist use (>8 puffs/day) and with greater baseline peak flow variability (greater than or equal to 20%) and baseline airflow obstruction (FEV1/forced vital capacity ratio, <0.70). The overall treatment failure rate was significantly lower in the zafirlukast group compared with the placebo group (P < .003). No associations were observed between any adverse events and subgroups defined by demographic characteristics. Conclusions: Exploratory subset analyses showed that zafirlukast is similarly efficacious in patients with asthma who have differing demographic characteristics and degrees of subjective symptoms. Additionally, zafirlukast appears to be incrementally beneficial in patients with more moderate disease, defined by a greater requirement for as-needed rescue medication and more abnormal pulmonary function at baseline. Over 13 weeks, zafirlukast was well tolerated and demonstrated a safety profile clinically indistinguishable from placebo.	Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Asthma & Allergy Assoc PC, Colorado Springs, CO USA; HealthQuest Therapy & Res Inst Inc, Austin, TX USA; Zeneca Pharmaceut, Wilmington, DE USA	University of California System; University of California Los Angeles	Tashkin, DP (corresponding author), Univ Calif Los Angeles, Dept Med, Room 32-176 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.							[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894, DOI 10.1164/ajrccm.154.4.8887582; Enright PL, 1997, CHEST, V112, P895, DOI 10.1378/chest.112.4.895; Fish JE, 1997, CLIN THER, V19, P675, DOI 10.1016/S0149-2918(97)80092-6; Fleming TR, 1995, DRUG INF J, V29, p1681S; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; Liu MC, 1996, J ALLERGY CLIN IMMUN, V98, P859, DOI 10.1016/S0091-6749(96)80002-9; *MED EC, 1998, PHYS DESK REF, P3148; *NAT ASTHM ED PREV, 1997, NIH PUBL; *NAT CTR HLTH STAT, 1995, DHHS PUBL; NATHAN RA, 1995, J ALLERGY CLIN IMMUN, V95, P388; Nathan RA, 1998, J ALLERGY CLIN IMMUN, V102, P935, DOI 10.1016/S0091-6749(98)70331-8; Nathan RA, 1996, J ASTHMA, V33, P353, DOI 10.3109/02770909609068181; Nelson DA, 1997, ANN ALLERG ASTHMA IM, V78, P21, DOI 10.1016/S1081-1206(10)63365-0; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; QUACKENBOSS JJ, 1991, AM REV RESPIR DIS, V143, P323, DOI 10.1164/ajrccm/143.2.323; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Reiss TF, 1996, J ALLERGY CLIN IMMUN, V98, P528, DOI 10.1016/S0091-6749(96)70086-6; Smith LJ, 1996, ARCH INTERN MED, V156, P2181, DOI 10.1001/archinte.156.19.2181; Smith LJ, 1998, ANN ALLERG ASTHMA IM, V81, P43, DOI 10.1016/S1081-1206(10)63108-0; SPECTOR S, 1995, AM J RESP CRIT CARE, V151, pA379; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; Spector SL, 1997, DRUGS, V54, P369, DOI 10.2165/00003495-199754030-00002; *USDA, 1995, PUBL USDA	29	25	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				246	254		10.1016/S0091-6749(99)70498-7	http://dx.doi.org/10.1016/S0091-6749(99)70498-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949315				2022-12-18	WOS:000078630100011
J	Gibson, PG				Gibson, PG			Use of induced sputum to examine airway inflammation in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Festschrift Meeting in Honor of Jerry Dolovich	MAY   24, 1997	HAMILTON, CANADA	McMaster Univ, Fac Hlth Sci, Astra Canada			BRONCHIAL HYPERRESPONSIVENESS; HEALTHY-SUBJECTS; CHILDREN	Airway inflammation is important in the pathogenesis of asthma, during which it may lead to symptomatic exacerbations and increases in asthma severity, as well as contribute to future decline in asthma status. The use of induced sputum has emerged as an important and useful technique to study airway inflammation. It has particular advantages in the study of childhood asthma because it is noninvasive and allows samples to be collected on repeated occasions in children over 7 years of age. The results of cell counts are reliable when the sputum is processed in a standardized manner involving selection from saliva, cell dispersion, and quantitative cytology. Children with asthma have increased eosinophils and mast cells, which may persist even with high doses of inhaled corticosteroid therapy. During a severe exacerbation of asthma, there is an intense and heterogeneous inflammatory response involving eosinophil and neutrophil accumulation and activation. Characterization of the relevance of airway inflammation in children with asthma is important.	John Hunter Hosp, Dept Resp Med, Newcastle, NSW, Australia	John Hunter Hospital	Gibson, PG (corresponding author), John Hunter Hosp, Dept Resp Med, Locked Bag 1 Hunter Reg Mail Ctr,Lookout Rd, New Lambton Hts, NSW 2305, Australia.		gibson, peter/G-6194-2014	gibson, peter/0000-0001-5865-489X				BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; *INT CONS REP DIAG, 1992, NHLBI PUBL; PIN I, 1993, EUR RESPIR J, V6, P1249; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; PIZZICHINI E, 1996, AM J RESP CRIT CARE, V154, P808; RIEDLER J, 1994, EUR RESPIR J, V7, P998; Twaddell SH, 1996, EUR RESPIR J, V9, P2104, DOI 10.1183/09031936.96.09102104; WARNER JO, 1992, ARCH DIS CHILD, V67, P240	14	25	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					S100	S101		10.1016/S0091-6749(98)70039-9	http://dx.doi.org/10.1016/S0091-6749(98)70039-9			2	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819317				2022-12-18	WOS:000077033400035
J	Charous, BL; Halpern, EF; Steven, GC				Charous, BL; Halpern, EF; Steven, GC			Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IgE; hydroxychloroquine; antiinflammatory agents; asthma therapy; antimalarial	CORTICOSTEROID-DEPENDENT ASTHMA; OCULAR SAFETY; CHLOROQUINE; INHIBITION; DISEASE; METHOTREXATE; BUDESONIDE; TRIAL	Background: Although antiinflammatory therapy is accepted as the cornerstone of asthma treatment, available systemic immunosuppressive agents are not widely used because of justified concerns over potential toxicity Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma. Objective: We sought to assess the effectiveness of HCQ in subjects with moderate symptomatic asthma. Methods: Symptomatic asthmatic subjects receiving stable doses of at least 6 puffs of inhaled corticosteroid per day with daily need for beta(2)-adrenergic agonists were studied. After baseline run-in, these subjects were randomized to 30 weeks of HCQ (n = 8) or placebo (n = 9). Objective measures included change from baseline mean FEV1, morning and evening peak flows, beta(2)-agonist use, IgE level, and need for rescue corticosteroids. Subjective symptom scores from bidaily diaries were also obtained. Results: In the treatment group, mean FEV1 at the last 2 visits on therapy increased by 10.8 % (P <.05), morning peak flows rose 16.2% (P <.03), evening peak flows rose 14.2% (P <.04), and beta(2)-agonist use fell 18.6% (P <.03), Mean IgE level declined 48% from WO to 125 IU/mL (P <.05). In the placebo group no significant change in these parameters occurred. Comparison of changes in these objective measures between the treatment and placebo groups failed to reach significance in the small population studied. Corticosteroid rescue interventions were required in 4 patients receiving placebo and 2 receiving HCQ. HCQ was well tolerated without notable side effects. Conclusions: Although the size of our sample population precludes definitive conclusions, these findings extend previous open-label observations. The late improvement in the HCQ group is consistent with its known slow onset of action. Further studies are warranted to confirm the antiasthmatic and antiallergic effects of HCQ and to investigate its potential as a disease modifying agent.	Milwaukee Med Clin, Allergy & Resp Care Ctr, Milwaukee, WI 53217 USA		Charous, BL (corresponding author), Milwaukee Med Clin, Allergy & Resp Care Ctr, 3003 W Good Hope Rd, Milwaukee, WI 53217 USA.							ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ANDERSSON P, 1982, BRIT J PHARMACOL, V77, P301, DOI 10.1111/j.1476-5381.1982.tb09299.x; AYITEYSMITH E, 1974, J PHARM PHARMACOL, V26, P208, DOI 10.1111/j.2042-7158.1974.tb09258.x; BERLOW BA, 1991, J ALLERGY CLIN IMMUN, V87, P710, DOI 10.1016/0091-6749(91)90393-3; BERNSTEIN HN, 1991, ANN OPHTHALMOL, V23, P292; Bernstein IL, 1996, J ALLERGY CLIN IMMUN, V98, P317, DOI 10.1016/S0091-6749(96)70156-2; CHAROUS BL, 1990, ANN ALLERGY, V65, P53; Demoly P, 1997, AM J RESP CRIT CARE, V155, P1825, DOI 10.1164/ajrccm.155.6.9196081; EASTERBROOK M, 1993, SEMIN ARTHRITIS RHEU, V23, P62, DOI 10.1016/S0049-0172(10)80009-5; FOX RI, 1988, AM J MED, V85, P62, DOI 10.1016/0002-9343(88)90365-8; GESHICKTER CF, 1955, SOUTH MED J, V48, P497; HOGG JC, 1992, AM REV RESPIR DIS, V145, P7; HURST NP, 1987, ANN RHEUM DIS, V46, P750, DOI 10.1136/ard.46.10.750; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; KERSTJENS HAM, 1995, AM J RESP CRIT CARE, V151, P360, DOI 10.1164/ajrccm.151.2.7842192; KROGSTAD DJ, 1987, NEW ENGL J MED, V317, P542, DOI 10.1056/NEJM198708273170905; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; *NAT HEART LUNG BL, 1995, DAT FACT SHEET; O'Connor B. J., 1996, Journal of Allergy and Clinical Immunology, V97, P250; Ramirez MA, 1925, AM J ROENTGENOL RADI, V14, P322; Roberts J A, 1988, Pulm Pharmacol, V1, P59, DOI 10.1016/0952-0600(88)90012-9; SEGGEV J, 1993, J IMMUNOL, V150, P62; SHAUKU H, 1991, J ALLERGY CLIN IMMUN, V87, P258; SHERMAN BV, 1992, J ALLERGY CLIN IMMUN, V89, P286; SPERBER K, 1993, AIDS RES HUM RETROV, V9, P91, DOI 10.1089/aid.1993.9.91; TSAI WP, 1990, AIDS RES HUM RETROV, V6, P481, DOI 10.1089/aid.1990.6.481; VALLERAND H, 1992, LANCET, V339, P1551, DOI 10.1016/0140-6736(92)91325-3; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WALLACE DJ, 1990, AM J MED, V89, P322, DOI 10.1016/0002-9343(90)90345-E; WEISSMANN G, 1964, FED PROC, V23, P1038; Welch K. E., 1997, Journal of Allergy and Clinical Immunology, V99, pS187	32	25	28	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					198	203		10.1016/S0091-6749(98)70086-7	http://dx.doi.org/10.1016/S0091-6749(98)70086-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723661				2022-12-18	WOS:000075537100008
J	Pauls, JD; Cross, D				Pauls, JD; Cross, D			Food-dependent exercise-induced anaphylaxis to corn	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA; Univ Calgary, Dept Med, Calgary, AB, Canada	Scripps Research Institute; University of Calgary	Pauls, JD (corresponding author), Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA.							BRUCE R A, 1963, Pediatrics, V32, P742; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; Volcheck GW, 1997, MAYO CLIN PROC, V72, P140, DOI 10.4065/72.2.140	3	25	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				853	854		10.1016/S0091-6749(98)70317-3	http://dx.doi.org/10.1016/S0091-6749(98)70317-3			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648717	Bronze			2022-12-18	WOS:000074414200024
J	Bollinger, ME; Wood, RA; Chen, PH; Eggleston, PA				Bollinger, ME; Wood, RA; Chen, PH; Eggleston, PA			Measurement of cat allergen levels in the home by use of an amplified ELISA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FEL-D-I; MITE		Univ Maryland, Sch Med, Div Allergy & Immunol, Dept Pediat, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Bollinger, ME (corresponding author), Univ Maryland, Sch Med, Div Pediat Allergy & Immunol, 120 Penn St, Baltimore, MD 21201 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007, U01AI030773] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07007, AI 30773] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; BOLLINGER ME, 1996, J ALLRGY CLIN IMMUNO, V97, P997; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Larsson P. H., 1996, Journal of Allergy and Clinical Immunology, V97, P421, DOI 10.1016/S0091-6749(96)81173-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6	7	25	26	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				124	125		10.1016/S0091-6749(98)70203-9	http://dx.doi.org/10.1016/S0091-6749(98)70203-9			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449511	hybrid			2022-12-18	WOS:000071539800019
J	Nayak, AS; Anderson, P; Charous, BL; Williams, K; Simonson, S				Nayak, AS; Anderson, P; Charous, BL; Williams, K; Simonson, S			Equivalence of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients symptomatic on low-dose inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Asthma & Allergy Res Associates, Normal, IL USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Milwaukee Med Clin, Milwaukee, WI USA; Zeneca Pharmaceut, Wilmington, DE USA	University of Arkansas System; University of Arkansas Medical Sciences									0	25	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			965	S233	S233						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800961
J	Raschal, S; Siegel, JN; Huml, J; Richmond, GW				Raschal, S; Siegel, JN; Huml, J; Richmond, GW			Hypogammaglobulinemia and anemia 18 years after thymoma resection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hypogammaglobulinemia; Good's syndrome; thymoma; immunodeficiency		Immunodeficiency with a thymoma (Good's syndrome) is a rare condition occurring in 7% to 13% of patients with adult-onset hypogammaglobulinemia. In 80% of cases, hypogammaglobulinemia is detected within 5 years of the identification of the thymoma. A 70-year-old man was found to have hypogammaglobulinemia 18 years after a thymoma had been resected. Cellular immunophenotyping revealed there were no detectable B cells, decreased CD4(+) cells, and increased CD8(+) cells. Both CD4(+) and CD8(+) subsets expressed increased populations of CD38(+) DR+ cells and CD45RO(+) cells. The CD8(+) CD28(+) population was markedly reduced. Inducible cytokine production by the patient's peripheral blood mononuclear cells revealed decreased IL-2, IL-10, and interferon-gamma production. These data suggest that patients with Good's syndrome have activated memory T cells that have dysregulated cytokine production.	Rush Med Coll, Dept Immunol Microbiol, Chicago, IL 60612 USA; Rush Med Coll, Dept Internal Med, Chicago, IL 60612 USA; Dupage Hosp, Winfield, IL USA	Rush University; Rush University	Richmond, GW (corresponding author), Univ Consultants Allergy & Immunol, 1725 W Harrison St,Suite 207, Chicago, IL 60612 USA.							GOOD RA, 1954, B U MINNESOTA HOSP, V2, P1; HAYWARD AR, 1982, CLIN EXP IMMUNOL, V48, P437; LITWIN SD, 1977, NATURE, V266, P57, DOI 10.1038/266057a0; MORETTA L, 1977, EUR J IMMUNOL, V7, P696, DOI 10.1002/eji.1830071009; OCHS HD, 1996, IMMUNOLOGIC DISORDER, P296; PEARL ER, 1978, J IMMUNOL, V120, P1169; Souquet R, 1970, Poumon Coeur, V26, P1203; Te VELDE K., 1966, ANN INTERN MED, V65, P554; WALDMANN TA, 1995, SAMTERS IMMUNOLOGIC, P387	9	25	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				846	848		10.1016/S0091-6749(97)70283-5	http://dx.doi.org/10.1016/S0091-6749(97)70283-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438496				2022-12-18	WOS:000071353600020
J	Zweiman, B; Atkins, PC; Moskovitz, A; vonAllmen, C; Ciliberti, M; Grossman, S				Zweiman, B; Atkins, PC; Moskovitz, A; vonAllmen, C; Ciliberti, M; Grossman, S			Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: Effects of cetirizine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						late-phase response; cutaneous allergic response; neutrophils; eosinophils lactoferrin; eosinophil cationic protein; cetirizine	MESSENGER-RNA EXPRESSION; EOSINOPHIL RECRUITMENT; ATOPIC SUBJECTS; PAF-ACETHER; HUMAN-SKIN; CHALLENGE; RELEASE; INVIVO; REACTIVITY; HISTAMINE	Background: In some previous studies, the antihistamine cetirizine has inhibited both developing (at 6 hours) and established (at 24 hours) gross late-phase skin reactions (LPR) to pollen antigens, possibly relevant to clinical drug effects. However, the effects of cetirizine at the histologic level require further definition. Objective: To characterize cetirizine effects an gross and histologic inflammatory events from 20 minutes to 24 hours af ter intradermal antigen challenge in sensitive patients. Methods: Gross and histologic responses to intradermal pollen antigen, codeine, histamine, and buffer diluent were assessed during randomized 7-day treatments with cetirizine and placebo. Accumulated neutrophils, eosinophils, activated (EG2(+)) eosinophils, and T lymphocytes were quantitated. The degrees of extracellular deposition of lactoferrin from neutrophils and eosinophilic cationic protein (ECP) from eosinophils were also assessed. Results: During placebo treatment, wheal-and-flare responses were significantly greater to antigen at 20 minutes (p < 0.01) and induration at 6 hours (p < 0.01) at antigen challenge sites than at buffer diluent sites. During cetirizine treatment, these wheal-and-hare responses to antigen were inhibited significantly (p < 0.01) but gross LPRs were not affected. During placebo treatment, significantly-more cells per high-power field were found in antigen sites than in buffer sites of neutrophils at 20 minutes (p < 0.01) and 24 hours; than in eosinophils at 20 minutes, 6 hours, and 24 hours (p < 0.01 for each); than in EG2(+) cells at 20 minutes (p = 0.004), 6 hours (p = 0.001), and 24 hours (p = 0.02); and at T lymphocyte sites at 24 hours (p = 0.001). Extracellular deposition of lactoferrin and ECP was significantly greater at antigen sites than at buffer sites at 6 and 24 hours. Cetirizine treatment had no significant effect on these responses. Conclusion: Neutrophils, eosinophils, and T lymphocytes were persistently more common at antigen sites than at buffer sites through 24 hours. Many of these neutrophils and eosinophils were activated, releasing more lactoferrin and ECP into the extracellular dermis for at least 24 hours after antigen challenge. Cetirizine inhibited gross immediate responses to antigen, but not the gross LPR nor the cellular inflammatory responses seen in such LPR sites.	PFIZER CENT RES,NEW YORK,NY	Pfizer	Zweiman, B (corresponding author), UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL DIV,512 JOHNSON PAVIL,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NIAID NIH HHS [R01 AI 14332] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS P, 1995, J ALLERGY CLIN IMMUN, V95, P384; BIERMAN CW, 1991, J ALLERGY CLIN IMMUN, V87, P1013, DOI 10.1016/0091-6749(91)90425-N; CHARLESWORTH EN, 1992, J PHARMACOL EXP THER, V262, P964; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CIPRANDI G, 1995, J ALLERGY CLIN IMMUN, V95, P612, DOI 10.1016/S0091-6749(95)70324-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; FADEL R, 1990, J ALLERGY CLIN IMMUN, V86, P314, DOI 10.1016/S0091-6749(05)80093-4; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FREW AJ, 1988, J IMMUNOL, V141, P4158; JOHNSEN FL, 1994, J IMMUNOL METHODS, V175, P23; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; SLOTT RI, 1973, J ALELRGY CLIN IMMUN, V51, P263; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; VARNEY V, 1992, CLIN EXP ALLERGY, V22, P43, DOI 10.1111/j.1365-2222.1992.tb00113.x; WASSERFALLEN JB, 1993, J ALLERGY CLIN IMMUN, V91, P1189, DOI 10.1016/0091-6749(93)90322-7; ZWEIMAN B, 1990, J IMMUNOL, V144, P3953	20	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					341	347		10.1016/S0091-6749(97)70247-1	http://dx.doi.org/10.1016/S0091-6749(97)70247-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314346	hybrid			2022-12-18	WOS:A1997XX47900011
J	Isolauri, E; Pelto, L; Nuutila, J; Majamaa, H; Lilius, EM; Salminen, S				Isolauri, E; Pelto, L; Nuutila, J; Majamaa, H; Lilius, EM; Salminen, S			Altered expression of IgG and complement receptors indicates a significant role of phagocytes in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						complement receptors; atopic dermatitis; Fc receptors; food allergy; hypersensitivity	SYSTEMIC LUPUS-ERYTHEMATOSUS; PERIPHERAL-BLOOD; FC-RECEPTOR; POLYMORPHONUCLEAR LEUKOCYTES; RHEUMATOID-ARTHRITIS; CR-1 EXPRESSION; ACTIVATION; INFLAMMATION; PATIENT; IMMUNE	Background: Strict dietary precautions against allergic sensitization may benefit a group of predisposed children. Objective, To develop new strategies for identifying these children, a better understanding of the processes that initiate sensitization and regulate and perpetuate the inflammatory response is needed, Methods: We measured the expression of the receptors for the constant (Fc) region of IgG (Fc gamma RI, Fc gamma RII, and Fc gamma RIII) and that for the complement fragments C3b and C3bi (CRI and CR3) in neutrophils and monocytes from 39 children with atopic dermatitis, 17 disease control patients with acute infections, and 17 healthy control subjects. The capacity of phagocytes to produce reactive oxygen species was also determined, To find the best way of discriminating the patients with atopic dermatitis from control subjects, a stepwise logistic binary regression model was made, Results: The stepwise logistic regression analysis was based on differences in individual receptor expression between the study groups, Because acute infections strongly affected receptor expression in both neutrophils and monocytes, to avoid diagnostic bias, children with acute infections were excluded from the analysis, The combination of the receptors CR1 in neutrophils and Fc gamma R1 and Fc gamma RII in monocytes was the best indicator of atopic dermatitis. A significant correlation between the expression of CRI in neutrophils and in monocytes, as well as reactive oxygen species production of phagocytes, and the severity of the eczema was detected, Conclusions: These results suggest that a distinct receptor profile of phagocytic cells can be characterized in patients with atopic dermatitis, providing a new direction to the search for early identification of children predisposed to allergic sensitization.	UNIV TURKU,DEPT BIOCHEM & FOOD CHEM,FIN-20520 TURKU,FINLAND; UNIV TAMPERE,DEPT PAEDIAT,FIN-33101 TAMPERE,FINLAND	University of Turku; Tampere University	Isolauri, E (corresponding author), UNIV TURKU,DEPT PEDIAT,FIN-20520 TURKU,FINLAND.							BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BUYON JP, 1988, CLIN IMMUNOL IMMUNOP, V46, P141, DOI 10.1016/0090-1229(88)90014-1; CLARK MR, 1990, J CLIN INVEST, V86, P341, DOI 10.1172/JCI114706; ENENKEL B, 1991, EUR J IMMUNOL, V21, P659, DOI 10.1002/eji.1830210318; *EUR TASK FORC AT, 1993, DERMATOLOGY, V186, P23; FARGEAS MJ, 1995, GASTROENTEROLOGY, V109, P53, DOI 10.1016/0016-5085(95)90268-6; FYFE A, 1987, CLIN EXP IMMUNOL, V67, P300; GADD SJ, 1992, RHEUMATOL INT, V12, P153, DOI 10.1007/BF00274935; GRAY AB, 1993, J LEUKOCYTE BIOL, V53, P591, DOI 10.1002/jlb.53.5.591; HANIFIN JM, 1987, MONOGR ALLERGY, V21, P116; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Lilius E., 1987, BIOLUMINESCENCE CHEM, P53; Majamaa H, 1996, J ALLERGY CLIN IMMUN, V97, P985, DOI 10.1016/S0091-6749(96)80074-1; MCCARTHY D, 1992, ANN RHEUM DIS, V51, P307, DOI 10.1136/ard.51.3.307; MCCARTHY DA, 1992, ANN RHEUM DIS, V51, P13, DOI 10.1136/ard.51.1.13; MIR A, 1988, CLIN EXP IMMUNOL, V73, P461; Mishima Kengo, 1992, Tokai Journal of Experimental and Clinical Medicine, V17, P41; Owens M. A., 1995, FLOW CYTOMETRY PRINC; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SANDERSON IR, 1993, GASTROENTEROLOGY, V104, P622, DOI 10.1016/0016-5085(93)90436-G; SIMMS HH, 1989, J CLIN INVEST, V83, P252, DOI 10.1172/JCI113867; SZUCS G, 1994, SCAND J IMMUNOL, V40, P481, DOI 10.1111/j.1365-3083.1994.tb03493.x; TELLADO JM, 1993, SURGERY, V113, P624; UNKELESS JC, 1992, INFLAMMATION BASIC P, P497; VINDENES H, 1994, J TRAUMA, V36, P161, DOI 10.1097/00005373-199402000-00001; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; WILSON JG, 1986, ARTHRITIS RHEUM, V29, P739, DOI 10.1002/art.1780290606; WRIGHT SD, 1992, INFLAMMATION BASIC P, P477; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7	30	25	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					707	713		10.1016/S0091-6749(97)70034-4	http://dx.doi.org/10.1016/S0091-6749(97)70034-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155839				2022-12-18	WOS:A1997WY60000020
J	Booms, P; Cheung, D; Timmers, MC; Zwinderman, AH; Sterk, PJ				Booms, P; Cheung, D; Timmers, MC; Zwinderman, AH; Sterk, PJ			Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway hyperresponsiveness; glucocorticosteroids; budesonide; methacholine; excessive air-way narrowing; maximal-response plateau	BRONCHIAL RESPONSIVENESS; MICROVASCULAR LEAKAGE; PLASMA EXUDATION; THERAPY; DISEASE; HYPERRESPONSIVENESS; BRONCHOCONSTRICTION; CORTICOSTEROIDS; HYPOTHESIS; MUSCLE	Background: Patients with asthma who have moderate to severe airway hyperresponsiveness often demonstrate progressive, unlimited airway narrowing in response to inhaled bronchoconstrictor stimuli, which is likely to be due to inflammatory changes within the airway wall, It is unknown whether regular therapy with inhaled steroids can limit this excessive response. Objective: We investigated the effect of inhaled budesonide on the development of a plateau on the dose-response curve to methacholine in patients with asthma who did not show such a plateau before the study. Methods: Thirty-one atopic patients with asthma (age, 19 to 31 years; FEV(1) > 70% of predicted value; PC20 < 8 mg/ml) with documented absence of a maximal-response plateau to methacholine on two occasions during the run-in period, participated in a double-blind, placebo-controlled, parallel study, Standardized methacholine challenges were performed at -1, 0, 4, 8, and 12 weeks of treatment with inhaled budesonide, 800 mu g two times a day, or corresponding placebo, and after a 2-week washout period, Airway response was measured by FEV(1) (percent fall from baseline), A maximal-response plateau was considered if three or more consecutive data points fell within a 5% response range. Results: Thirty patients completed the study. There was a steady increase in the number of budesonide-treated patients exhibiting a maximal-response plateau on the dose-response curve from zero of 15 patients at run-in to nine of 14 patients at week 12, as compared with four of 16 patients in the placebo group (p = 0.03, chi square test). This was accompanied by a significant improvement in PC20 in the budesonide group as compared with the placebo group (p < 0.01 at week 12), whereas the changes in FEV(1) were not significantly different between the groups (p = 0.77 at week 12). Conclusion: Regular treatment with the inhaled corticosteroid budesonide limits maximal airway narrowing in response to methacholine by introducing a plateau on the dose-response curve in patients with asthma, who were initially characterized by the absence of a plateau. This indicates that inhaled steroids are likely to reduce the hazard of unlimited airway narrowing in asthma.	LEIDEN UNIV HOSP, LUNG FUNCT LAB, DEPT PULMONOL, NL-2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MED STAT, NL-2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC			Sterk, P.J./AAK-8175-2020; Booms, Patrick/AAN-8717-2020					BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; BEL EH, 1991, AM REV RESPIR DIS, V143, P109, DOI 10.1164/ajrccm/143.1.109; BEL EH, 1991, THORAX, V46, P9, DOI 10.1136/thx.46.1.9; BOSCHETTO P, 1991, AM REV RESPIR DIS, V143, P605, DOI 10.1164/ajrccm/143.3.605; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; BRAMLEY AM, 1994, EUR RESPIR J, V7, P337, DOI 10.1183/09031936.94.07020337; CHEUNG D, 1997, IN PRESS AM REV RESP, V155; DANDURAND RJ, 1993, J APPL PHYSIOL, V74, P538, DOI 10.1152/jappl.1993.74.2.538; DEPEE S, 1991, EUR RESPIR J, V4, P421; Gibbons WJ, 1996, AM J RESP CRIT CARE, V153, P582, DOI 10.1164/ajrccm.153.2.8564102; GREIFF L, 1994, EUR RESPIR J, V7, P1120; GUSTAFSSON B, 1989, THORAX, V44, P24, DOI 10.1136/thx.44.1.24; JAMES A, 1992, AM REV RESPIR DIS, V146, P895, DOI 10.1164/ajrccm/146.4.895; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; KIMURA K, 1992, AM REV RESPIR DIS, V146, P1301, DOI 10.1164/ajrccm/146.5_Pt_1.1301; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; MACKLEM PT, 1990, ANN ALLERGY, V64, P113; MACKLEM PT, 1986, AM REV RESPIR DIS, V134, P812; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922, DOI 10.1164/ajrccm/145.4_Pt_1.922; PERSSON CGA, 1991, EUR RESPIR J, V4, P1268; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RODWELL LT, 1992, EUR RESPIR J, V5, P953; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; SONT JK, 1989, EUR RESPIR J S5, V2, pS302; STERK PJ, 1989, EUR RESPIR J, V2, P267; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; STERK PJ, 1985, AM REV RESPIR DIS, V132, P272; STERK PJ, 1992, RESP MED, V86, P391, DOI 10.1016/S0954-6111(06)80005-3; STERK PJ, 1994, EUR RESPIR J, V7, P220, DOI 10.1183/09031936.94.07020220; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71	37	25	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					330	337		10.1016/S0091-6749(97)70050-2	http://dx.doi.org/10.1016/S0091-6749(97)70050-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058688				2022-12-18	WOS:A1997WM42200009
J	Alonso, L; Marcos, ML; Blanco, JG; Navarro, JA; Juste, S; Garces, MD; Perez, R; Carretero, PJ				Alonso, L; Marcos, ML; Blanco, JG; Navarro, JA; Juste, S; Garces, MD; Perez, R; Carretero, PJ			Anaphylaxis caused by linseed (flaxseed) intake	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											Alonso, L (corresponding author), HOSP GEN YAGUE,SECC ALERGOL,E-09005 BURGOS,SPAIN.							BERNSTEIN DI, 1988, ALLERGY PRINCIPLES P, P1197; Black WC, 1930, J AMER MED ASSOC, V94, P1064, DOI 10.1001/jama.1930.27120400002014d; Grant LR, 1931, J ALLERGY, V3, P469; MERIER P, 1990, SCHWEIZ MED WOCHENSC, V120, P314; NOWIER M, 1975, BR J IND MED, V32, P147; SUHONEN R, 1983, ALLERGY, V38, P363, DOI 10.1111/j.1398-9995.1983.tb04132.x; WILLIAM R, 1988, ALLERGY PRINCIPLES P, P312	7	25	25	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					469	470		10.1016/S0091-6749(96)70175-6	http://dx.doi.org/10.1016/S0091-6749(96)70175-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757228				2022-12-18	WOS:A1996VC99500030
J	Frew, AJ; StPierre, J; Teran, LM; Trefilieff, A; Madden, J; Peroni, D; Bodey, KM; Walls, AF; Howarth, PH; Carroll, MP; Holgate, ST				Frew, AJ; StPierre, J; Teran, LM; Trefilieff, A; Madden, J; Peroni, D; Bodey, KM; Walls, AF; Howarth, PH; Carroll, MP; Holgate, ST			Cellular and mediator responses twenty-four hours after local endobronchial allergen challenge of asthmatic airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; local allergen challenge; adhesion molecules; bronchoalveolar large; T lymphocytes; eosinophils	SEGMENTAL ANTIGEN CHALLENGE; LYMPHOCYTES-T; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; EOSINOPHILS; BIOPSIES	The effects of acute allergen exposure on bronchoalveolar lavage cells and mediators and mucosal inflammatory cells were evaluated in 10 subjects with atopic asthma who underwent lavage and biopsy 24 hours segmental endobronchial allergen challenge. Increased numbers of bronchoalveolar lavage eosinophils were retrieved from the allergen-challenged sites compared with the saline-challenged sites (mean 21.4 vs 1.5 x 10(3) cells/ml; p < 0.02). Numbers of neutrophils and proportions of CD4(+), CD8(+), CD25(+), and HLA-DR(+) T cells were similar at the saline- and allergen-challenged sites. In contrast to the bronchoalveolar lavage findings, eosinophil numbers were not increased in the bronchial submucosa or epithelium. There was also no significant difference in neutrophils, mast cells, CD3(+), CD4(+), or CD8(+) T cells in the submucosa after allergen challenge, but the number of activated (CD25(+)) T lymphocytes in the mucosa did increase after allergen challenge. Allergen challenge did not significant change in endothelial expression of P-selectin, E-selectin, intercellular adhesion molecule-1, or vascular cell adhesion molecule-1. CD11a(+) and very late antigen-4(+) cell numbers were similar in the saline- and allergen-challenged sites. This study suggests that in patients with very mild asthma, local allergen challenge induces persistent bronchoalveolar lavage eosinophilia, but the recruitment process seems to have diminished or ceased by 24 hours.			Frew, AJ (corresponding author), UNIV MED,SOUTHAMPTON GEN HOSP,CTR BLOCK,D FLOOR,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Peroni, Diego G/K-4002-2018; Teran, Luis/AAI-9815-2021; Kelly, Frank J/C-6125-2009; Peroni, Diego/K-8795-2016	Kelly, Frank J/0000-0003-2558-8392; Peroni, Diego/0000-0002-0234-1373; Howarth, Peter/0000-0003-0619-7927; Teran, Luis Manuel/0000-0003-1806-1779				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DUPUIS R, 1992, J ALLERGY CLIN IMMUN, V89, P850, DOI 10.1016/0091-6749(92)90441-4; DURHAM SR, 1990, RESP MED, V84, P263, DOI 10.1016/S0954-6111(08)80050-9; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; GRATZIOU C, 1992, AM REV RESPIR DIS, V145, P1259, DOI 10.1164/ajrccm/145.6.1259; GRATZIOU C, 1995, IN PRESS AM J RESP C, V152; KELLY RW, 1986, PROSTAG LEUKOTR ESS, V24, P1, DOI 10.1016/0262-1746(86)90201-5; KRUG N, 1995, IN PRESS AM J RESP C; KYANAUNG U, 1991, AM J RESP CELL MOL, V5, P445, DOI 10.1165/ajrcmb/5.5.445; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; POBER JS, 1986, J IMMUNOL, V137, P1893; TERAN LM, 1995, IN PRESS AM J RESP C; TWENTYMAN OP, 1994, CLIN EXP ALLERGY, V24, P245, DOI 10.1111/j.1365-2222.1994.tb00226.x; WALLS AF, 1990, CLIN EXP ALLERGY, V20, P581, DOI 10.1111/j.1365-2222.1990.tb03153.x; ZANGRILLI JG, 1995, AM J RESP CRIT CARE, V151, P1346, DOI 10.1164/ajrccm.151.5.7537586; 1991, J ALLERGY CLIN IMMUN, V88, P808	25	25	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					133	143		10.1016/S0091-6749(96)70235-X	http://dx.doi.org/10.1016/S0091-6749(96)70235-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765827				2022-12-18	WOS:A1996VA69200016
J	Schwartz, E; Shapiro, R; Shina, S; Bank, I				Schwartz, E; Shapiro, R; Shina, S; Bank, I			Delayed expansion of V delta 2(+) and V delta 1(+) gamma delta T cells after acute Plasmodium falciparum and Plasmodium vivax malaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						malaria; T lymphocytes; gamma delta T cells; P-falciparum; P-vivax	PERIPHERAL-BLOOD; LYMPHOCYTES; MEROZOITES; BEARING; SUBSET	T lymphocytes that express T-cell receptors encoded by the gamma and delta T-cell receptor genes (gamma delta T cells), and preferentially those expressing the V gamma 9 and V delta 2 gene segments, are activated by microbial and parasitic organisms in vitro and have been implicated in the pathogenesis of the fever and rigors during acute malaria. We have found, in a cohort of nine nonimmune patients who contracted malaria during travel to endemic areas (five with Plasmodium falciparum and four with P. vivax infections) that gamma delta T lymphocytes expanded to comprise 17.92% +/- 11% of the peripheral blood mononuclear cells (vs 3.08% +/- 2.4% gamma delta cells in normal control subjects). Although V delta 2(+) cells predominated among the gamma delta subset, gamma delta lymphocytes expressing the V delta 1 gene segment also expanded significantly in some patients. Importantly, the gamma delta cells continued to expand for 2 months after the infection, and the mean level of gamma delta cells peaked during the second month after the acute clinical syndrome, when patients were free of symptoms. Thus although gamma delta T cells may contribute to the pathogenesis of the acute clinical syndrome, our findings suggest that gamma delta lymphocytes could also play a role in generating an immune response to plasmodia.	CHAIM SHEBA MED CTR,DEPT MED,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,CTR GEOG MED,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,IMMUNOREGULAT LAB,IL-52621 TEL HASHOMER,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine			Bank, I./I-7153-2012					BANK I, 1986, NATURE, V322, P179, DOI 10.1038/322179a0; BANK I, 1993, CLIN IMMUNOL IMMUNOP, V67, P17, DOI 10.1006/clin.1993.1040; BENDER A, 1993, INT ARCH ALLERGY IMM, V100, P12, DOI 10.1159/000236381; CHANG WL, 1992, IMMUNOL LETT, V32, P273, DOI 10.1016/0165-2478(92)90061-R; GOERLICH R, 1991, EUR J IMMUNOL, V21, P2613, DOI 10.1002/eji.1830211045; GOODIER M, 1993, T ROY SOC TROP MED H, V87, P692, DOI 10.1016/0035-9203(93)90299-6; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HO M, 1990, IMMUNOL LETT, V25, P139, DOI 10.1016/0165-2478(90)90105-Y; HO M, 1994, INFECT IMMUN, V62, P855, DOI 10.1128/IAI.62.3.855-862.1994; KABELITZ D, 1993, INT ARCH ALLERGY IMM, V102, P1, DOI 10.1159/000236544; LANGHORNE J, 1992, IMMUNOL TODAY, V13, P298, DOI 10.1016/0167-5699(92)90041-5; MCGREGOR IA, 1989, PRINCIPLES PRACTICE, V1, P559; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; PERERA MK, 1994, J EXP MED, V179, P311, DOI 10.1084/jem.179.1.311; ROUSSILHON C, 1990, J INFECT DIS, V162, P283, DOI 10.1093/infdis/162.1.283-a; STRUCHLER B, 1985, PARASITOL TODAY, V5, P39; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175	19	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1387	1392		10.1016/S0091-6749(96)70208-7	http://dx.doi.org/10.1016/S0091-6749(96)70208-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648036				2022-12-18	WOS:A1996VD60700028
J	VanMetre, TE; Rosenberg, GL; Vaswani, SK; Ziegler, SR; Adkinson, NF				VanMetre, TE; Rosenberg, GL; Vaswani, SK; Ziegler, SR; Adkinson, NF			Pain and dermal reaction caused by injected glycerin in immunotherapy solutions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glycerin; human serum albumin saline; immunotherapy solution; potency; dose; pain; erythema; induration; bruising	STORAGE; POTENCY	Background: Fifty percent glycerin preserves immunotherapy solution potency for at least 3 years but must be diluted before injection to reduce glycerin-induced pain and inflammation. We studied pain, erythema, induration, and bruises caused by glycerin (0% to 30%). Methods: In 15 healthy subjects we compared, in double-blind fashion, pain scores, injection site erythema, induration, and bruising caused by subcutaneous injections in randomized order of 0.1, 0.5, and 1 ml of glycerin 0%, 10%, 20%, and 30%. Results: Injection volume did not significantly influence pain scores from diluent alone (0% glycerin) (p > 0.1). Pain scores of subjects given glycerin (0.1 to 1 ml 10% to 30%) increased significantly as both injection volume (p < 0.001) and glycerin concentration (p < 0.001) increased. Pain scores correlated with total glycerin dose administered (volume x concentration) (r(s) = 0.67, p < 0.0005) but varied widely, from minimal to severe, in those given the same dose. injection site erythema, induration, and bruising occurred in some subjects with significant positive correlations between total glycerin dose and both frequency and diameters of erythema and induration. However, these dermal reactions were of trivial clinical importance. Conclusion: Injected glycerin produces pain that is proportional to total injected dose of glycerin, but individual variation in perceived discomfort is substantial. Total glycerin doses of less than 0.05 ml rarely produce clinically important pain.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS ASTHMA & ALLERGY CTR,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine								ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; BAER H, 1974, DEV BIOL STAND, V24, P115; CENTER JG, 1974, J ALLERGY CLIN IMMUN, V54, P305, DOI 10.1016/0091-6749(74)90016-5; Glantz S, 2016, PRIMER APPL REGRESSI; NELSON HS, 1981, J ALLERGY CLIN IMMUN, V67, P64, DOI 10.1016/0091-6749(81)90047-6; SIEGEL S, 1956, NONPARAMETRIC STAT; SWINYARD EA, 1980, GOODMAN GILMANS PHAR, P951; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANMETRE TE, 1993, ALLERGY PRINCIPLES P, P1498; Zar J.H, 1999, BIOSTAT ANAL, V4th	10	25	27	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1033	1039		10.1016/S0091-6749(96)70254-3	http://dx.doi.org/10.1016/S0091-6749(96)70254-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626978	hybrid			2022-12-18	WOS:A1996UL26100001
J	MURRAY, AB; MILNER, RA				MURRAY, AB; MILNER, RA			THE ACCURACY OF FEATURES IN THE CLINICAL HISTORY FOR PREDICTING ATOPIC SENSITIZATION TO AIRBORNE ALLERGENS IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYPERSENSITIVITY DIAGNOSIS; INTERVIEWS; CLINICAL HISTORY; SKIN TESTS; ALLERGENS; CHILDREN	SKIN-PRICK TESTS; HOUSE DUST MITE; ASTHMATIC-CHILDREN; DIAGNOSIS; RAST; HISTAMINE; PROVOCATION; CHALLENGE	Background: The clinical history is given considerable weight when on decides which allergens are responsible for a patients symptoms, and in research studies the clinical history has been used as the ''gold standard'' with which different tests for allergy are compared. Objectives: To determine whether standardized questions accurately predict replies to detailed questions asked by an experienced allergist, and to assess the utility of certain standardized questions for predicting sensitization to individual allergen groups. Methods: Trained interviews put standardized questions to parents of 1160 children, aged 1 to 17 years, who had respiratory symptoms and had been newly referred to the allergy clinic of a children's hospital. For the first 151 of the subjects the answers were compared with those elicited by questions asked by a pediatric allergist. Skin prick tests and pollen counts were performed by a technologist. Results: The standardized questions had an accuracy for predicting the allergist's history of 93% to 97% for all questions except one. The standardized questions with the highest accuracy for predicting the skin test results to the appropriate allergens were the following: for mite, improvement in symptoms when outdoors (66.8%);and when in dry areas (69.4%), and aggravation during house cleaning (65.9%) and when bed making (70.6%); for dog, symptoms when with dogs (80.6%); for cat, symptoms when with cats (77.3%); for tree pollen, symptoms worse in April (70.8%) and when among trees in March and April (80.8%); and for grass pollen, exacerbation in June (69.2%) and during lawn mowing (71.2%). Although specificity was generally above 80%, sensitivity was variable, ranging from 11% to 56%. Conclusions: The standardized questions accurately predicted a detailed history obtained by an experienced allergist. Because standardized questions are reproducible they are the preferred method of history taking for research projects. Because several of the standardized questions have a high specificity they are useful for excluding sensitization to individual allergen groups, but because they have only a modes sensitivity, they are less helpful for detecting those who are sensitized to individual allergen groups.	UNIV BRITISH COLUMBIA,DEPT PAEDIAT,VANCOUVER,BC,CANADA	University of British Columbia								ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; ADLER TR, 1985, J ALLERGY CLIN IMMUN, V75, P31, DOI 10.1016/0091-6749(85)90008-9; AHLSTEDT S, 1974, CLIN ALLERGY, V4, P131, DOI 10.1111/j.1365-2222.1974.tb01370.x; BOOTH BH, 1993, ALLERGIC DIS DIAGNOS, P195; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; BRAND PLP, 1993, J ALLERGY CLIN IMMUN, V91, pS60; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; CRAWFORD LV, 1982, PEDIAT ALLERGIC DIS, P36; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; FERGUSON AC, 1986, CAN MED ASSOC J, V134, P1365; FINNERTY JP, 1989, CLIN EXP ALLERGY, V19, P51, DOI 10.1111/j.1365-2222.1989.tb02343.x; GARCIAORTEGA P, 1989, CLIN EXP ALLERGY, V19, P529, DOI 10.1111/j.1365-2222.1989.tb02428.x; KJELLMAN NIM, 1988, ALLERGY, V43, P277, DOI 10.1111/j.1398-9995.1988.tb00900.x; LINDGREN S, 1988, J ALLERGY CLIN IMMUN, V82, P196, DOI 10.1016/0091-6749(88)90999-2; MURRAY AB, 1983, CAN MED ASSOC J, V129, P828; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; MURRAY AB, 1983, PEDIATRICS, V71, P418; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P21, DOI 10.1016/0091-6749(83)90542-0; NEGRINI AC, 1985, ALLERGY, V40, P238, DOI 10.1111/j.1398-9995.1985.tb00227.x; NIEMEIJER NR, 1993, ALLERGY, V48, P498, DOI 10.1111/j.1398-9995.1993.tb01105.x; NOLTE H, 1990, ALLERGY, V45, P213, DOI 10.1111/j.1398-9995.1990.tb00486.x; OSTERGAARD PA, 1990, ALLERGY, V45, P231, DOI 10.1111/j.1398-9995.1990.tb00488.x; PEPYS J, 1975, Clinical Allergy, V5, P431, DOI 10.1111/j.1365-2222.1975.tb01882.x; PETERSSON G, 1986, ALLERGY, V41, P398, DOI 10.1111/j.1398-9995.1986.tb00319.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; ROWE MS, 1986, J ALLERGY CLIN IMMUN, V77, P14; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SHAPIRO GG, 1988, PEDIATRICS, V82, P935; Solomon W. R., 1988, ALLERGY PRINCIPLES P, P312; STAFANGER G, 1986, ALLERGY, V41, P110, DOI 10.1111/j.1398-9995.1986.tb00286.x; TANSER AR, 1984, BRIT J DIS CHEST, V78, P135, DOI 10.1016/0007-0971(84)90113-X; VANMETRE TE, 1988, ALLERGY PRINCIPLES P, P1327; WEVER AMJ, 1993, CLIN EXP ALLERGY, V23, P976, DOI 10.1111/j.1365-2222.1993.tb00286.x; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V84, P730	35	25	25	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				588	596		10.1016/S0091-6749(95)70256-3	http://dx.doi.org/10.1016/S0091-6749(95)70256-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499674				2022-12-18	WOS:A1995TG52800003
J	CUSTOVIC, A; TAGGART, SCO; NIVEN, RM; WOODCOCK, A				CUSTOVIC, A; TAGGART, SCO; NIVEN, RM; WOODCOCK, A			EVALUATING EXPOSURE TO MITE ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							ANTIGEN		WYTHENSHAWE HOSP,NW LUNG CTR,MANCHESTER M23 9LT,LANCS,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital			Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Niven, Robert/0000-0003-2249-960X; Woodcock, Ashley/0000-0002-5428-8578				COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; LUCZYNSKA CM, 1989, IMMUNOL METHODS, V18, P227; MILLS TAE, 1993, J ALLERGY CLIN IMMUN, V89, P1046; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; SPORIK R, 1990, LANCET, V336, P1507, DOI 10.1016/0140-6736(90)93213-9; Warner J, 1990, PEDIATR ALLERGY IMMU, V1, P79; WARNER JO, 1991, LANCET, V337, P1038, DOI 10.1016/0140-6736(91)92695-X	7	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					134	135		10.1016/S0091-6749(95)70044-7	http://dx.doi.org/10.1016/S0091-6749(95)70044-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622757				2022-12-18	WOS:A1995RK38300019
J	GREIFF, L; PERSSON, CGA; SVENSSON, C; ENANDER, I; ANDERSSON, M				GREIFF, L; PERSSON, CGA; SVENSSON, C; ENANDER, I; ANDERSSON, M			LORATADINE REDUCES ALLERGEN-INDUCED MUCOSAL OUTPUT OF ALPHA(2)-MACROGLOBULIN AND TRYPTASE IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIRWAY; ALLERGY; ANTIHISTAMINE; EPITHELIUM; HUMAN; INFLAMMATION; MAST CELL; MICROCIRCULATION; PERMEABILITY; PLASMA EXUDATION	HYDROSTATIC-PRESSURE; HISTAMINE-RELEASE; MAST-CELLS; CHALLENGE; EXUDATION; PLASMA; CETIRIZINE; ASTHMA; NOSE	Background: Despite the wide use of antihistamines in the treatment of allergic rhinitis, little is known about effects of these drugs on airway mucosal indices, which specifically reflect either mast cell release activity (tryptase) or microvascular-epithelial exudation of bulk plasma (alpha(2)-macroglobulin). Objective: This study, involving subjects with seasonal allergic rhinitis, examines the effects of loratadine treatment on allergen-induced nasal mucosal output of typtase and alpha(2)-macroglobulin. Effects on nasal symptoms and eosinophils are also examined. Methods: Placebo and loratadine (20 mg) were given ovally once daily for 5 days at 6-week intervals. Nasal diluent and allergen challenges were carried out on day 5. The mucosa was lavaged with saline solution after each challenge, and nasal lavage fluid levels of tryptase and alpha(2)-macroglobulin were determined. Nasal symptoms were scored, and nasal peak expiratory flow rates were measured. Superficial cells (eosinophils) were obtained with a blush device before and 24 hours after the allergen challenges. Results: Allergen dose-dependently increased the nasal symptoms and the lavage fluid levels of alpha(2)-macroglobulin and tryptase. Allergen also reduced the nasal peak expiratory pow rates. Loratadine inhibited the exudation of alpha(2)-macroglobulin and reduced tryptase levels, nasal symptoms, and obstruction, but did not affect the number of eosinophils. Conclusion: The inhibitory effects of loratadine on nasal lavage fluid levels of alpha(2)-macroglobulin suggest that histamine, through effects on microvascular H-1-receptors, mediates allergen challenge-induced exudation of bulk plasma in acute allergic rhinitis. The reduced lavage fluid levels of tryptase suggest either that loratadine directly attenuates mast cell release activity or that loratadine, through inhibition of the exudation process, simply attenuates luminal entry of tissue solutes (in this case, tryptase).	UNIV LUND HOSP,DEPT CLIN PHARMACOL,S-22185 LUND,SWEDEN; PHARMACIA DIAGNOST AB,S-75182 UPPSALA,SWEDEN	Lund University; Skane University Hospital; Pfizer; Pharmacia Corporation	GREIFF, L (corresponding author), UNIV LUND HOSP,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,S-22185 LUND,SWEDEN.							ANDERSSON M, 1991, ALLERGY, V46, P540, DOI 10.1111/j.1398-9995.1991.tb00618.x; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; DOUGLAS WW, 1987, PHARMACOL BASIS THER, P605; ENANDER I, 1991, J IMMUNOL METHODS, V138, P39, DOI 10.1016/0022-1759(91)90062-K; ENERBACK L, 1989, INT ARCH ALLER A IMM, V88, P209, DOI 10.1159/000234788; FADEL R, 1987, CLIN ALLERGY, V17, P209; GUSTAFSSON BG, 1991, CLIN EXP ALLERGY, V21, P121, DOI 10.1111/j.1365-2222.1991.tb00813.x; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JAMES K, 1990, IMMUNOL TODAY, V1, P163; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; PERSSON CGA, 1992, THORAX, V47, P993, DOI 10.1136/thx.47.12.993; PERSSON CGA, 1990, INT ARCH ALLER A IMM, V92, P148, DOI 10.1159/000235206; PERSSON CGA, IN PRESS EUR RESPIR; PERSSON CGA, 1993, AM REV RESPIR DIS, V147, P833; PIPKORN U, 1988, J IMMUNOL METHODS, V112, P37, DOI 10.1016/0022-1759(88)90030-0; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; SALOMONSSON P, 1992, AM REV RESPIR DIS, V146, P1535, DOI 10.1164/ajrccm/146.6.1535; SCHULMAN ES, 1983, EUR RESPIR J S128, V64, P52; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1981, J IMMUNOL, V26, P1290; SVENSSON C, 1992, CLIN EXP ALLERGY, V22, P411, DOI 10.1111/j.1365-2222.1992.tb03103.x; SVENSSON C, 1983, ALLERGY, V48, P91	26	25	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					97	103		10.1016/S0091-6749(95)70038-2	http://dx.doi.org/10.1016/S0091-6749(95)70038-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7542675	Bronze			2022-12-18	WOS:A1995RK38300013
J	BIRCHER, AJ; HEDIN, H; BERGLUND, A				BIRCHER, AJ; HEDIN, H; BERGLUND, A			PROBABLE GRADE-IV DEXTRAN-INDUCED ANAPHYLACTIC REACTION DESPITE HAPTEN INHIBITION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							ANTIBODIES		PHARMACIA AB,HOSP CARE,S-75182 UPPSALA,SWEDEN	Pfizer; Pharmacia Corporation	BIRCHER, AJ (corresponding author), UNIV BASEL HOSP,DEPT DERMATOL,ALLERGY UNIT,CH-4031 BASEL,SWITZERLAND.							HEDIN H, 1982, INT ARCH ALLER A IMM, V68, P122, DOI 10.1159/000233080; ILLIEVICH UM, 1989, ALLERGOLOGIE, V12, P326; KRAFT D, 1982, ALLERGY, V37, P481, DOI 10.1111/j.1398-9995.1982.tb02331.x; LJUNGSTROM KG, 1993, INFUSIONSTHERAPIE, V20, P206; RING J, 1991, CLIN REV ALLERG, V9, P397	5	25	25	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					633	634		10.1016/S0091-6749(95)70327-6	http://dx.doi.org/10.1016/S0091-6749(95)70327-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7531733				2022-12-18	WOS:A1995QH69700017
J	ENGLER, RJM; DAVIS, WS				ENGLER, RJM; DAVIS, WS			RUSH HYMENOPTERA VENOM IMMUNOTHERAPY - SUCCESSFUL TREATMENT IN A PATIENT WITH SYSTEMIC MAST-CELL DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							YELLOW JACKET VENOM; BEE VENOM; MASTOCYTOSIS; ANAPHYLAXIS; DISORDERS; HISTAMINE		UNIV BETHESDA,SCH MED,DEPT MED,BETHESDA,MD; UNIV BETHESDA,SCH MED,PEDIAT UNIFORMED SERV,BETHESDA,MD		ENGLER, RJM (corresponding author), WALTER REED ARMY MED CTR,ALLERGY IMMUNOL SERV,WASHINGTON,DC 20307, USA.							BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; DJURUP R, 1985, J ALLERGY CLIN IMMUN, V76, P46, DOI 10.1016/0091-6749(85)90803-6; FRIEDMAN BS, 1989, AM J MED, V87, P649; GARRIGA MM, 1988, J ALLERGY CLIN IMMUN, V82, P425, DOI 10.1016/0091-6749(88)90015-2; KEFFER JM, 1989, J ALLERGY CLIN IMMUN, V83, P595, DOI 10.1016/0091-6749(89)90071-7; KETTELHUT BV, 1991, J INVEST DERMATOL, V96, pS15, DOI 10.1111/1523-1747.ep12468942; MALLING HJ, 1985, ALLERGY, V40, P373, DOI 10.1111/j.1398-9995.1985.tb00250.x; METCALFE DD, 1991, J INVEST DERMATOL S3, V96, P64; MUELLER U, 1990, ALLERGY, V45, P597; MUELLER UR, 1983, J ALLERGY CLIN IMMUN, V72, P685; PRICE LA, 1987, J ALLERGY CLIN IMMUN, V79, P407, DOI 10.1016/0091-6749(87)90162-X; REISMAN RE, 1988, ANN ALLERGY, V61, P383; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001	14	25	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				556	559		10.1016/0091-6749(94)90213-5	http://dx.doi.org/10.1016/0091-6749(94)90213-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083461				2022-12-18	WOS:A1994PG90700016
J	TOUQUI, L; HERPINRICHARD, N; GENE, RM; JULLIAN, E; ALJABI, D; HAMBERGER, C; VARGAFTIG, BB; DESSANGE, JF				TOUQUI, L; HERPINRICHARD, N; GENE, RM; JULLIAN, E; ALJABI, D; HAMBERGER, C; VARGAFTIG, BB; DESSANGE, JF			EXCRETION OF PLATELET-ACTIVATING FACTOR-ACETYLHYDROLASE AND PHOSPHOLIPASE A(2) INTO NASAL FLUIDS AFTER ALLERGENIC CHALLENGE - POSSIBLE ROLE IN THE REGULATION OF PLATELET-ACTIVATING-FACTOR RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; PAF; LYSO-PAF; ACETYLHYDROLASE; PHOSPHOLIPASE A(2)	ZYMOSAN PERITONITIS; RABBIT PLATELETS; AIRWAY CHALLENGE; ACID; 1-0-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; INDIVIDUALS; RHINITIS; ESTERASE; ASSAY; URINE	Platelet activating factor (PAF), a proinflammatory mediator synthesized through a phospholipase A(2) (PLA(2))-dependent reaction, is hydrolyzed into its inactive metabolite, lyso-PAF; by a specific acetylhydrolase. Previous studies have shown that allergen challenge of patients with allergic rhinitis leads to an incr ease of the concentrations of lyso-PAF in nasal lavage fluid (NLF), whereas PAF is detected only marginally. PAF-hydrolyzing enzymes are expected to be released on allergenic challenge, to account for the reduced concentrations of PAF in NLF. Here, we show that allergen challenge of patients with allergic rhinitis; induces an increase of acetylhydrolase-like activity in NLF; which peaks: within 10 minutes and returns to basal values 1 hour later. Acetyhydrolase hydrolyzed exogenous PAF with a complete loss of its ability to induce platelet aggr egation. Allergen challenge also led to a parallel release of a PLA(2) in nasal fluids. This enzyme preferentially hydrolyzes negatively char ged phospholipids (phosphatidic acid monomethyl ester and phosphatidylgylcerol) versus phosphatidylcholine. More interestingly the hydrolysis of phosphatidic acid monomethyl ester and phosphatidylglycerol by NLF was completely abolished by the addition of ethylenediaminetetraacetic acid which had no effect on the hydrolysis of PAF; indicating that the PLA(2) secreted in nasal fluids is not involved in the degradation of PAF. Finally, our results show that allergen-induced increase in the concentrations of lyso-PAF and prostaglandin D-2 occurred with a kinetic similar to that of tosyl-L-arginine-methyl-ester esterase, suggesting that mast cells are implicated in this process. Although no direct relationship was demonstrated between the absence of PAF and the increase of acetylhydrolase levels in NLF we suggest a potential role for this enzyme in the inactivation of PAF if the latter is released in the nasal lumen.	INST PASTEUR,CTR BIOL MED SPECIALISEE,UNITE IMMUNOALLERGOL,PARIS,FRANCE; INST PASTEUR,CTR BIOL MED SPECIALISEE,CYTOL LAB,PARIS,FRANCE; INST PASTEUR,CTR BIOL MED SPECIALISEE,RADIOIMMUNOANAL LAB,PARIS,FRANCE; HOP COCHIN,DEPT PNEUMOL,F-75674 PARIS,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP	TOUQUI, L (corresponding author), INST PASTEUR,INSERM,U285,UNITE PHARMACOL CELLULAIRE,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Vargaftig, Bernardo Boris B.B.J./C-3323-2013					BEAVEN VH, 1971, CLIN CHIM ACTA, V32, P67, DOI 10.1016/0009-8981(71)90465-7; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BENVENISTE J, 1982, THROMB RES, V25, P275; BILLAH MM, 1983, BIOCHEM BIOPH RES CO, V113, P51, DOI 10.1016/0006-291X(83)90430-8; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOMBALASKI JS, 1991, J IMMUNOL, V146, P3904; BOMBALASKI JS, 1985, J LEUKOCYTE BIOL, V38, P649; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CARAMELO C, 1984, BIOCHEM BIOPH RES CO, V120, P789, DOI 10.1016/S0006-291X(84)80176-X; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; FARR RS, 1983, FED PROC, V42, P3120; GANS KR, 1989, AGENTS ACTIONS, V27, P341, DOI 10.1007/BF01972817; KRAMER RM, 1987, BIOCHEM J, V248, P779, DOI 10.1042/bj2480779; LUNDY SR, 1990, J IMMUNOL, V144, P2671; MADONNA A, 1989, AM REV RESPIR DIS, V140, P142; MESLIER N, 1988, AM REV RESPIR DIS, V137, P617, DOI 10.1164/ajrccm/137.3.617; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PRUZANSKI W, 1986, J INVEST DERMATOL, V15, P791; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; SANCHEZCRESPO M, 1983, AM J PHYSIOL, V244, pF706, DOI 10.1152/ajprenal.1983.244.6.F706; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; SHIBA KS, 1985, CLIN CHEM, V31, P1215; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; TESSON F, 1993, EUR J PHARM-ENVIRON, V248, P27, DOI 10.1016/0926-6917(93)90021-H; TOUQUI L, 1987, BIOCHEM J, V241, P555, DOI 10.1042/bj2410555; VADAS P, 1985, LIFE SCI, V36, P579, DOI 10.1016/0024-3205(85)90640-X	31	25	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					109	119		10.1016/0091-6749(94)90077-9	http://dx.doi.org/10.1016/0091-6749(94)90077-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027488				2022-12-18	WOS:A1994NX39300014
J	SLATER, JE; TRYBUL, DE				SLATER, JE; TRYBUL, DE			AFFINITY PURIFICATION OF LATEX ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; RUBBER; IMMEDIATE HYPERSENSITIVITY; IGE; MONOCLONAL ANTIBODIES; RAST; RAST INHIBITION; IMMUNOBLOTS; AFFINITY PURIFICATION	CONTACT URTICARIA; RUBBER; ANAPHYLAXIS	Latex extracts are complex mixtures of antigenic peptides. We attempted to raise monoclonal antibodies to latex and to use these antibodies to purify latex antigens. A monoclonal antibody, CRI-C, was raised by standard techniques. Peptides of nonammoniated latex (NAL) and ammoniated latex were electrophoretically separated and transferred for immunoblots. CRI-C was covalently attached to an agarose column. NAL was passed over the column, and purified antigen was then eluted. The eluate was analyzed by sodium dodecylsulfate-polyacrylamide gel electrophoresis and RAST inhibition with sera from health care workers and children with spina bifida. CRI-C recognized a single band in ammoniated latex immunoblots and several distinct bands in NAL. The affinity-purified antigen of CRI-C (C-Ag) had multiple bands of less than 20 kd and was 3.9 times more potent in RAST inhibition than NAL when sera from patients with spina bifida were used However, when health care workers' sera were used, there was no significant difference in the inhibitory potency of NAL and C-Ag. CRI-C appears to recognize a distinct and important epitope in the IgE immune response to latex of patients with spina bifida.	CHILDRENS RES INST,CTR CANC & TRANSPLANT BIOL,WASHINGTON,DC; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT PEDIAT,WASHINGTON,DC 20052	George Washington University	SLATER, JE (corresponding author), CHILDRENS NATL MED CTR,DEPT ALLERGY & IMMUNOL,111 MICHIGAN AVE NW,WASHINGTON,DC 20010, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029428] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29428-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		LIGHT DR, 1989, J BIOL CHEM, V264, P18589; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1990, ANN ALLERGY, V65, P411; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1992, ANN ALLERGY, V68, P203; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P226; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1989, CONTACT DERMATITIS, V20, P360, DOI 10.1111/j.1600-0536.1989.tb03173.x	11	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					644	649		10.1016/S0091-6749(94)70076-1	http://dx.doi.org/10.1016/S0091-6749(94)70076-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	8151064				2022-12-18	WOS:A1994ND14000011
J	BECK, LA; SCHALL, TJ; BEALL, LD; LEOPOLD, D; BICKEL, C; BAROODY, F; NACLERIO, RM; SCHLEIMER, RP				BECK, LA; SCHALL, TJ; BEALL, LD; LEOPOLD, D; BICKEL, C; BAROODY, F; NACLERIO, RM; SCHLEIMER, RP			DETECTION OF THE CHEMOKINE RANTES AND ACTIVATION OF VASCULAR ENDOTHELIUM IN NASAL POLYPS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	2				234	234						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MV317					2022-12-18	WOS:A1994MV31700430
J	SALVAGGIO, JE; BURGE, HA; CHAPMAN, JA				SALVAGGIO, JE; BURGE, HA; CHAPMAN, JA			EMERGING CONCEPTS IN MOLD ALLERGY - WHAT IS THE ROLE OF IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CLADOSPORIUM-HERBARUM; ALTERNARIA ALLERGENS; INDUCED ASTHMA; DOUBLE-BLIND; EXTRACTS; HYPOSENSITIZATION; DIAGNOSIS; CHILDREN; POLLEN		TULANE UNIV,MED CTR,NEW ORLEANS,LA 70118	Tulane University								AAS K, 1980, ALLERGY, V35, P443, DOI 10.1111/j.1398-9995.1980.tb01791.x; AUKRUST L, 1979, INT ARCH ALLER A IMM, V58, P371; AUKURST L, 1979, INT ARCH ALLER A IMM, V60, P68; Blackley CH, 1873, EXPT RES CAUSES NATU; BURGE HA, 1989, IMMUNOL ALLERGY CLIN, V9, P307; BURGE HA, 1989, MYCOTAXON, V34, P55; BURGE HA, 1986, GRANA, V25, P247, DOI 10.1080/00173138609427726; Burge HA, 1987, ATMOS ENVIRON, V39, P840; CANTANI A, 1988, ALLERGOL IMMUNOPATH, V16, P1; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; ESCH R, IN PRESS J ALLERGY C; FEINBERG SM, 1935, WISC MED J, V34, P254; FROSTAD AB, 1983, CLIN ALLERGY, V13, P337, DOI 10.1111/j.1365-2222.1983.tb02609.x; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Kendrick B., 1985, 5 KINGDOM; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LIACOPOULOS P, 1975, PROG ALLERGY, V18, P97; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MALLING HJ, 1988, ALLERGY, V43, P228; METZGER WJ, 1983, J ALLERGY CLIN IMMUN, V71, P119, DOI 10.1016/0091-6749(83)90245-2; MUILENBERG ML, 1989, IMMUNOL ALLERGY CLIN, V9, P245; OSTERGAARD PA, 1986, ALLERGY, V41, P588; Prince H, 1934, TEXAS J MED, V30, P34; REED C, 1979, J ALLERGY CLIN IMMUN, V61, P227; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SHANK RC, 1981, MYCOTOXINS N NITROSO, P1; SOLOMON WR, 1970, J ALLERGY, V45, P1, DOI 10.1016/0021-8707(70)90012-2; WONGTIM S, IN PRESS J ALLERGY C; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; 1990, POLLEN SPORE REPORT	34	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					217	222		10.1016/0091-6749(93)90164-B	http://dx.doi.org/10.1016/0091-6749(93)90164-B			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349931				2022-12-18	WOS:A1993LT46900001
J	THEOHARIDES, TC				THEOHARIDES, TC			HYDROXYZINE FOR INTERSTITIAL CYSTITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							HISTAMINE; RELEASE				THEOHARIDES, TC (corresponding author), TUFTS UNIV,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,136 HARRISON AVE,BOSTON,MA 02111, USA.		Theoharides, Theoharis C/E-5596-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042409, R01DK044816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44816, DK42409] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		RATNER V, 1992, J WOMENS HEALTH, V1, P63; SANT GR, 1991, MONOGR UROL, V12, P37; SIMONS FER, 1984, J ALLERGY CLIN IMMUN, V73, P69, DOI 10.1016/0091-6749(84)90486-X; Theoharides T C, 1991, Semin Urol, V9, P74; THEOHARIDES TC, 1985, BIOCHEM PHARMACOL, V34, P1389, DOI 10.1016/0006-2952(85)90675-6; TING S, 1985, J ALLERGY CLIN IMMUN, V75, P63, DOI 10.1016/0091-6749(85)90013-2	6	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					686	687		10.1016/0091-6749(93)90277-M	http://dx.doi.org/10.1016/0091-6749(93)90277-M			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436783				2022-12-18	WOS:A1993KN54800019
J	GRIFFITH, IJ; LUSSIER, A; GARMAN, R; KOURY, R; YEUNG, H; POLLOCK, J				GRIFFITH, IJ; LUSSIER, A; GARMAN, R; KOURY, R; YEUNG, H; POLLOCK, J			CDNA CLONING OF CRY-J-I, THE MAJOR ALLERGEN OF CRYPTOMERIA-JAPONICA (JAPANESE CEDAR)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																		GRIFFITH, 1991, INT ARCH ALLERGY CLI, V96, P296; Wing R. A., 1989, Plant Molecular Biology, V14, P17, DOI 10.1007/BF00015651; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X	3	25	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				339	339						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100791
J	DOCKHORN, R; GROSSMAN, J; POSNER, M; ZINNY, M; TINKLEMAN, D				DOCKHORN, R; GROSSMAN, J; POSNER, M; ZINNY, M; TINKLEMAN, D			A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF IPRATROPIUM BROMIDE NASAL SPRAY VERSUS PLACEBO IN PATIENTS WITH THE COMMON COLD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON INTRANASAL ANTICHOLINERGIC TREATMENT OF NASAL DISORDERS	MAR   06, 1991	SAN FRANCISCO, CA	BOEHRINGER INGELHEIM PHARM		COMMON COLD; RHINORRHEA; IPRATROPIUM BROMIDE; NASAL DISCHARGE		Ipratropium bromide (IB) has been found to reduce secretions in the upper respiratory tract; this is accomplished through competitive inhibition of acetylcholine at muscarinic receptors that control rhinorrhea production. This study compared the safety and efficacy of IB with placebo in the symptomatic relief of rhinorrhea in patients with the common cold. Human subjects with symptoms of a common cold, primarily rhinorrhea, were enrolled and treated with either IB (84 mug / nostril) or placebo; each was administered as two sprays per nostril, four times a day, for 4 days. Primary efficacy analyses were in-clinic measurements of nasal discharge weights over a 3-hour period after administration on days 1 and 2 and assessment of rhinorrhea symptoms by use of a subjective patient-completed visual analog rating scale. IB significantly reduced rhinorrhea an average of 18% over placebo for days 1 and 2 (p = 0.01). Visual analog scale scores showed an average improvement in rhinorrhea of 22% over placebo (p = 0.001). When patients with relatively minor rhinorrhea (baseline weight of nasal discharge less-than-or-equal-to 1.0 gm) were excluded, IB produced an average reduction in nasal discharge of 23% over placebo for days 1 and 2 (p = 0.003).	ALBANY ALLERGY & ASTHMA SERV,ALBANY,NY									BORUM P, 1978, Rhinology (Utrecht), V16, P225; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; GAFFEY MJ, 1987, AM REV RESPIR DIS, V135, P241; GAFFEY MJ, 1988, ANTIMICROB AGENTS CH, V32, P1644, DOI 10.1128/AAC.32.11.1644; KIRKEGAARD J, 1987, J ALLERGY CLIN IMMUN, V79, P585, DOI 10.1016/S0091-6749(87)80153-7; KIRKEGAARD J, 1988, ACTA OTOLARYNGOL S, V449, P93; MILFORD CA, 1990, J LARYNGOL OTOL, V104, P123, DOI 10.1017/S0022215100112022; Mygind N, 1989, Rhinol Suppl, V9, P37; Mygind N, 1990, AM J RHINOL, V4, P1; ODWYER TP, 1988, J LARYNGOL OTOL, V102, P799, DOI 10.1017/S0022215100106498; SIMONS FER, 1987, J ALLERGY CLIN IMMUN, V80, P239, DOI 10.1016/0091-6749(87)90025-X	11	25	27	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	2	S			1076	1082		10.1016/0091-6749(92)90126-M	http://dx.doi.org/10.1016/0091-6749(92)90126-M			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD635	1460211				2022-12-18	WOS:A1992KD63500009
J	TOWNLEY, RG				TOWNLEY, RG			ANTIALLERGIC PROPERTIES OF THE 2ND-GENERATION H1-ANTIHISTAMINES DURING THE EARLY AND LATE REACTIONS TO ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANTIGEN CHALLENGE; ANTIHISTAMINES; PLATELET-ACTIVATING FACTOR; ASTHMA; BRONCHOCONSTRICTION; AZELASTINE; CETIRIZINE; KETOTIFEN; TERFENADINE	PLATELET-ACTIVATING-FACTOR; RECEPTOR ANTAGONIST; MEDIATOR RELEASE; TERFENADINE; BRONCHOCONSTRICTION; CETIRIZINE; ASTHMA; POTENT	Some of the second-generation H-1 antihistamines reduce the bronchoconstrictor response after exercise and antigen challenge. For example, terfenadine causes a slight but significant increase in forced expiratory volume after 1 second. At doses of 120 and 240 mg, terfenadine has a protective effect against asthma induced by ultrasonic nebulized distilled water and cold air hyperventilation challenge. Certain other newer antihistamines, such as ketotifen, azelastine, and cetirizine, have additional antiallergy properties. These effects include inhibition of eosinophil, basophil, and neutrophil migration and platelet-activating factor-induced eosinophil accumulation in skin. The ability of cetirizine (and perhaps other antihistamines) to inhibit these responses al usual therapeutic doses may be useful in investigating the late allergic reaction.			TOWNLEY, RG (corresponding author), CREIGHTON UNIV,SCH MED,DEPT MED,CTR ALLERG DIS,DIV ALLERGY,OMAHA,NE 68178, USA.							BEWTRA AK, 1989, ANN ALLERGY, V62, P299; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; FADEL R, 1990, J ALLERGY CLIN IMMUN, V86, P314, DOI 10.1016/S0091-6749(05)80093-4; HENNOCQ E, 1988, LANCET, V1, P1378; HOPP RJ, 1988, ANN ALLERGY, V61, P13; HOPP RJ, 1991, CHEST, V100, P994, DOI 10.1378/chest.100.4.994; MARGOLSKEE DJ, 1991, ANN NY ACAD SCI, V629, P148; NABE M, 1989, CLIN EXP ALLERGY, V19, P515, DOI 10.1111/j.1365-2222.1989.tb02426.x; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PATEL KR, 1988, 8TH INT C ALL CLIN I; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; SANJAR S, 1989, EOSINOPHILS ASTHMA, P201; TOGIAS AG, 1989, ANN ALLERGY, V63, P467; TOWNLEY RG, 1991, J ALLERGY CLIN IMMUN, V87, pA281	15	25	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	2	S			720	725		10.1016/0091-6749(92)90158-X	http://dx.doi.org/10.1016/0091-6749(92)90158-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV009	1383311				2022-12-18	WOS:A1992JV00900004
J	MELTZER, EO; ORGEL, HA; ELLIS, EF; EIGEN, HN; HEMSTREET, MPB				MELTZER, EO; ORGEL, HA; ELLIS, EF; EIGEN, HN; HEMSTREET, MPB			LONG-TERM COMPARISON OF 3 COMBINATIONS OF ALBUTEROL, THEOPHYLLINE, AND BECLOMETHASONE IN CHILDREN WITH CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ASTHMA THERAPY; CHILDREN; ALBUTEROL; THEOPHYLLINE; BECLOMETHASONE DIPROPIONATE	INHALED CORTICOSTEROIDS; BRONCHIAL HYPERREACTIVITY; SODIUM CROMOGLYCATE; ORAL THEOPHYLLINE; CHILDHOOD ASTHMA; ALLERGIC-ASTHMA; DIPROPIONATE; AEROSOL; RESPONSIVENESS; MANAGEMENT	Three combination regimens, (1) inhaled albuterol (ALB) with oral theophylline (THEO), (2) inhaled ALB with inhaled beclomethasone dipropionate (BDP), or (3) inhaled ALB, inhaled BDP, and oral THEO, were evaluated and compared as optimal pharmacotherapy for chronic asthma in 111 children. In this double-blind, parallel-group, multicenter study, children, aged 6 to 16 years with moderately severe asthma (unstable despite daily medications), were treated with one of the combinations for 12 weeks. Patients were evaluated every 4 weeks by spirometry and serum THEO measurement. Patients kept daily symptom diaries, measured peak flow rates twice daily, and recorded adverse events. Treatment groups did not differ in disease or demographic characteristics at study entry. All three combination treatments provided and maintained significant improvement in FVC, FEV1, and FEF25%-75% volume points, and compared with that of pretreatment, with no significant differences between treatments. Throughout the 12-week treatment period, however, patients receiving BDP had lower symptom scores, fewer had more than one asthma attack, fewer required "bursts" of prednisone (p = 0.001), and fewer required rescue medication (p = 0.009). Significantly more patients receiving BDP said that they felt better than they did at the beginning of the study compared with the number of patients not receiving BDP (p = 0.002). Adverse events were similar among treatment groups.	UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093; NEMOURS CHILDRENS CLIN,JACKSONVILLE,FL; RILEY HOSP CHILDREN,DEPT PEDIAT,INDIANAPOLIS,IN; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN 46202; UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL 35294; CHILDRENS HOSP,DIV CLIN & DEV IMMUNOL,BIRMINGHAM,AL	University of California System; University of California San Diego; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; University of Alabama System; University of Alabama Birmingham	MELTZER, EO (corresponding author), ALLERGY & ASTHMA MED GRP & RES CTR,3444 KEARNY VILLA RD,SUITE 100,SAN DIEGO,CA 92123, USA.							BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1982, LANCET, V1, P299; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BRENNER M, 1988, CLIN ALLERGY, V18, P143, DOI 10.1111/j.1365-2222.1988.tb02853.x; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CANNY GJ, 1988, ANN ALLERGY, V60, P11; CLARK TJH, 1985, J ALLERGY CLIN IMMUN, V76, P340; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CRANE J, 1989, LANCET, V1, P917; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; EDMUNDS AT, 1979, BRIT J DIS CHEST, V73, P149, DOI 10.1016/S0007-0971(79)80124-2; FURUKAWA CT, 1988, J ALLERGY CLIN IMMUN, V81, P83, DOI 10.1016/0091-6749(88)90224-2; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GODFREY S, 1981, ANN ALLERGY, V47, P423; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GODFREY S, 1974, J PEDIATR, V87, P465; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HARGREAVE FE, 1989, J ALLERGY CLIN IMMUN, V83, P525, DOI 10.1016/0091-6749(89)90033-X; KEMP JP, 1989, J ALLERGY CLIN IMMUN, V83, P697, DOI 10.1016/0091-6749(89)90085-7; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KERSHNAR H, 1978, PEDIATRICS, V62, P189; KONIG P, 1988, J ALLERGY CLIN IMMUN, V82, P297, DOI 10.1016/0091-6749(88)91015-9; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; NASPITZ CK, 1987, CHILDHOOD ASTHMA, P249; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; Polgar G, 1971, PULMONARY FUNCTION T; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; RAPPAPORT L, 1989, AM J DIS CHILD, V143, P368, DOI 10.1001/archpedi.1989.02150150126032; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P361, DOI 10.1016/0091-6749(87)90047-9; SHEFFER AL, 1991, J ALLERGY CLIN IMMUN, V88, P425; SLY RM, 1984, ANN ALLERGY, V53, P20; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; 1991, J ALLERGY CLIN IMMUN, V87, P202; 1987, J ALLERGY CLIN IMMUN, V87, P202	37	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					2	11		10.1016/S0091-6749(06)80005-9	http://dx.doi.org/10.1016/S0091-6749(06)80005-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1629506				2022-12-18	WOS:A1992JE25500001
J	OKAYAMA, M; BARANIUK, JN; HAUSFELD, JN; MERIDA, M; KALINER, MA				OKAYAMA, M; BARANIUK, JN; HAUSFELD, JN; MERIDA, M; KALINER, MA			CHARACTERIZATION AND AUTORADIOGRAPHIC LOCALIZATION OF HISTAMINE H1 RECEPTORS IN HUMAN NASAL TURBINATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HUMAN NASAL MUCOSA; H1 RECEPTORS; [3H]PYRILAMINE; AUTORADIOGRAPHY; HISTAMINE; VASCULAR PERMEABILITY; NASAL SECRETION	H-1 RECEPTORS; SMOOTH-MUSCLE; BINDING; <MEPYRAMINE-H-3; ANTIHISTAMINE; METHACHOLINE; ENDOTHELIUM; SECRETIONS; MEMBRANES; INVITRO	To examine the localization of histamine H-1 receptors (H1R) in human nasal mucosa, the autoradiographic distribution of H1R was studied in human nasal inferior turbinates. Cryostat sections were incubated with various concentration of [H-3]pyrilamine in saturation-binding studies and with 1 nmol/L of [H-3]pyrilamine for autoradiography. Nonspecific binding was determined by adding 2-mu-mol/L of pyrilamine. Scatchard analysis demonstrated high-affinity binding sites with a maximum binding capacity of H1R of 193 +/- 46 fmol/mg of protein, and dissociation constant was 0.6 +/- 0.1 nmol/L. Autoradiograms indicated H1R exist exclusively on the endothelium of vessels. No specific labeling could be observed in the submucosal glands or epithelium. These results extend and support our previous finding that histamine directly causes vascular permeability through H1R and stimulates nasal glandular secretion indirectly through reflexes.	NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20891; GEORGETOWN UNIV,LUNG BIOL LABS,WASHINGTON,DC 20007; WASHINGTON HOSP CTR,DEPT OTOLARYNGOL,WASHINGTON,DC 20010; GEORGETOWN UNIV,DEPT OTOLARYNGOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT PEDIAT,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Georgetown University; MedStar Washington Hospital Center; Georgetown University; Georgetown University				Baraniuk, James Nicholas/0000-0002-1866-4177				BISGAARD H, 1987, CLIN SCI, V73, P217, DOI 10.1042/cs0730217; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; CARMANKRZAN M, 1983, AGENTS ACTIONS, V13, P162, DOI 10.1007/BF01967322; CASALE TB, 1985, BIOCHEM PHARMACOL, V34, P3285, DOI 10.1016/0006-2952(85)90347-8; CASALE TB, 1985, INT J IMMUNOPHARMACO, V7, P639, DOI 10.1016/0192-0561(85)90147-X; CHANG RSL, 1979, J PHARMACOL EXP THER, V209, P437; CORRADO OJ, 1986, THORAX, V41, P863, DOI 10.1136/thx.41.11.863; Garrison J. C., 1990, PHARMACOL BASIS THER, P574; HAVAS TE, 1986, J ALLERGY CLIN IMMUN, V78, P856, DOI 10.1016/0091-6749(86)90230-7; HELTIANU C, 1982, J CELL BIOL, V93, P357, DOI 10.1083/jcb.93.2.357; HIDE M, 1988, EUR J PHARMACOL, V148, P161, DOI 10.1016/0014-2999(88)90560-2; HILEY CR, 1978, ACTA OTO-LARYNGOL, V85, P444; HILL SJ, 1977, NATURE, V270, P361, DOI 10.1038/270361a0; ICHIMURA K, 1985, ACTA OTO-LARYNGOL, V99, P610, DOI 10.3109/00016488509182268; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P3655; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULLOL J, 1992, J ALLERGY CLIN IMMUN, V89, P584, DOI 10.1016/0091-6749(92)90326-W; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; ROGERS AW, 1984, PRACTICAL AUTORADIOG; SATOH H, 1984, EUR J PHARMACOL, V97, P321, DOI 10.1016/0014-2999(84)90468-0; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SERTL K, 1987, AM REV RESPIR DIS, V135, P456; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; TODA N, 1987, CIRC RES, V61, P280, DOI 10.1161/01.RES.61.2.280; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOSAKA K, 1985, Kumamoto Medical Journal, V38, P37; TRAN VT, 1978, P NATL ACAD SCI USA, V75, P6290, DOI 10.1073/pnas.75.12.6290; VANDEVOORDE J, 1983, EUR J PHARMACOL, V87, P113, DOI 10.1016/0014-2999(83)90056-0; WESCOTT S, 1983, INFLAMMATION, V7, P291, DOI 10.1007/BF00917266	31	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1144	1150		10.1016/0091-6749(92)90298-G	http://dx.doi.org/10.1016/0091-6749(92)90298-G			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1607549				2022-12-18	WOS:A1992HZ74800009
J	BURKE, LA; HALLSWORTH, MP; LITCHFIELD, TM; DAVIDSON, R; LEE, TH				BURKE, LA; HALLSWORTH, MP; LITCHFIELD, TM; DAVIDSON, R; LEE, TH			IDENTIFICATION OF THE MAJOR ACTIVITY DERIVED FROM CULTURED HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS, WHICH ENHANCES EOSINOPHIL VIABILITY, AS GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						GM-CSF; EOSINOPHILS; MONOCYTES; ASTHMA; ALLERGY; LYMPHOCYTES	ALVEOLAR MACROPHAGES; SCHISTOSOMA-MANSONI; FC-RECEPTORS; HUMAN-NEUTROPHILS; IGE; MONOCYTES; RELEASE; INVITRO; ASTHMA; LEUKOTRIENE-C4	Eosinophils (EOSs) cultured in the presence of 50% peripheral blood mononuclear cell (PBMC)-derived culture supernatants remained 67% +/- 7% (mean +/- SEM; n = 5) viable for 7 days. In the absence of PBMC supernatant, only 15% +/- 7% of cells remained viable for 7 days. PBMC supernatants from six atopic individuals, with eosinophilia, and six normal subjects, with no eosinophilia, were compared for EOS viability-enhancing activity with the same target EOSs. Optimal conditions for the production of viability-enhancing activity by mononuclear cells were established as a 24-hour culture period, with a concentration of 2 x 10(6) cells per milliliter. Comparison of monocyte-enriched and lymphocyte-enriched culture supernatants for the production of the EOS viability-enhancing activity indicated that both cell types released the factor. C-18 Sep-Pak separation of the PBMC culture supernatant yielded a major EOS viability-enhancing activity in the aqueous eluent, suggesting a hydrophilic molecule. This major activity was neutralized by a specific antibody to granulocyte/macrophage colony-stimulating factor but was unaffected by specific antibodies to interleukin-3 and interleukin-5. A second, minor viability-enhancing activity was observed in the 100% methanol fraction, indicating the presence of a more hydrophobic molecule. The supernatants from the PBMCs of the atopic individuals consistently enhanced EOS survival to a greater extent than supernatants from the PBMCs of the normal, nonatopic individuals.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT ALLERGY & ALLIED RESP DISORDERS,LONDON SE1 9RT,ENGLAND; HOSP TROP DIS,LONDON NW1 0PE,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON CL, 1981, J IMMUNOL, V126, P2470; ATKINSON YH, 1988, IMMUNOLOGY, V64, P519; BEGLEY CG, 1986, BLOOD, V68, P162; Boyum A, 1968, SCAND J CLIN LAB S97, V21, P7; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; CARROLL MP, 1985, J ALLERGY CLIN IMMUN, V75, P290, DOI 10.1016/0091-6749(85)90060-0; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; DESSAINT JP, 1979, CELL IMMUNOL, V46, P24, DOI 10.1016/0008-8749(79)90242-9; DESSEIN AJ, 1986, J IMMUNOL, V136, P3829; DIPERSIO JF, 1980, BLOOD, V56, P717; ELSAS P, 1987, ANN INST PASTEUR IMM, V138, P97, DOI 10.1016/S0769-2625(87)80099-5; ELSAS PX, 1990, EUR J IMMUNOL, V20, P1143, DOI 10.1002/eji.1830200530; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KAY AB, 1981, CLIN EXP IMMUNOL, V44, P576; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MELEWICZ FM, 1982, CLIN EXP IMMUNOL, V49, P364; MELEWICZ FM, 1981, J IMMUNOL, V126, P1592; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; NICOLA NA, 1979, BLOOD, V54, P614; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; THORNE KJI, 1986, EUR J IMMUNOL, V16, P1143, DOI 10.1002/eji.1830160919; VADAS MA, 1984, J IMMUNOL, V133, P202; VADAS MA, 1979, J IMMUNOL, V122, P1228; VEITH MC, 1983, J EXP MED, V157, P1828, DOI 10.1084/jem.157.6.1828; WEISBART RH, 1987, BLOOD, V69, P18; WEISBART RH, 1985, NATURE, V314, P316; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844	32	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					226	235		10.1016/0091-6749(91)90333-J	http://dx.doi.org/10.1016/0091-6749(91)90333-J			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880323				2022-12-18	WOS:A1991GB22500012
J	BERNSTEIN, JA; ZEISS, CR; GREENBERGER, PA; PATTERSON, R; MARHOUL, JF; SMITH, LL				BERNSTEIN, JA; ZEISS, CR; GREENBERGER, PA; PATTERSON, R; MARHOUL, JF; SMITH, LL			IMMUNOBLOT ANALYSIS OF SERA FROM PATIENTS WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS - CORRELATION WITH DISEASE-ACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LAKESIDE VET ADM MED CTR, 400 E ONTARIO, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY IMMUNOL SECT, CHICAGO, IL 60611 USA	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498; Bernstein, Jonathan/0000-0002-3476-1196	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APTER AJ, 1989, J ALLERGY CLIN IMMUN, V84, P367, DOI 10.1016/0091-6749(89)90422-3; BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8; BAUR X, 1985, SCHWEIZ MED WSCHR, V115, P757; BAUR X, 1989, J ALLERGY CLIN IMMUN, V83, P839, DOI 10.1016/0091-6749(89)90023-7; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROUWER J, 1988, INT ARCH ALLER A IMM, V85, P244, DOI 10.1159/000234510; BRUMMUND W, 1987, J CLIN MICROBIOL, V25, P5, DOI 10.1128/JCM.25.1.5-9.1987; FORMAN SR, 1978, J ALLERGY CLIN IMMUN, V62, P131, DOI 10.1016/0091-6749(78)90096-9; GREENBERGER PA, 1988, CLIN CHEST MED, V9, P599; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; GUTT L, 1986, J ALLERGY CLIN IMMUN, V78, P98, DOI 10.1016/0091-6749(86)90120-X; HARVEY C, 1986, CLIN EXP IMMUNOL, V65, P206; HARVEY C, 1987, CLIN EXP IMMUNOL, V70, P247; KAUFFMAN HF, 1984, J ALLERGY CLIN IMMUN, V74, P741, DOI 10.1016/0091-6749(84)90239-2; KHAN ZU, 1984, INT ARCH ALLER A IMM, V73, P205, DOI 10.1159/000233468; KURUP VP, 1988, INT ARCH ALLER A IMM, V86, P176, DOI 10.1159/000234568; KURUP VP, 1989, J CLIN MICROBIOL, V27, P1312, DOI 10.1128/JCM.27.6.1312-1316.1989; KURUP VP, 1986, J ALLERGY CLIN IMMUN, V78, P1166, DOI 10.1016/0091-6749(86)90267-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG PSC, 1988, INT ARCH ALLER A IMM, V85, P416, DOI 10.1159/000234544; LONGBOTTOM JL, 1983, CLIN EXP IMMUNOL, V53, P354; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P18, DOI 10.1016/0091-6749(86)90109-0; LONGBOTTOM JL, 1983, J ALLERGY CLIN IMMUN, V72, P668, DOI 10.1016/0091-6749(83)90627-9; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P9, DOI 10.1016/0091-6749(86)90108-9; PATTERSON R, 1977, AM J MED, V63, P257, DOI 10.1016/0002-9343(77)90240-6; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; PIECHURA JE, 1983, IMMUNOLOGY, V49, P657; RICKETTI AJ, 1984, J ALLERGY CLIN IMMUN, V74, P68, DOI 10.1016/0091-6749(84)90089-7; RICKETTI AJ, 1983, J ALLERGY CLIN IMMUN, V72, P386, DOI 10.1016/0091-6749(83)90504-3; ROSENBERG M, 1977, J PEDIATR-US, V91, P914, DOI 10.1016/S0022-3476(77)80889-5; TAYLOR ML, 1988, J ALLERGY CLIN IMMUN, V81, P537, DOI 10.1016/0091-6749(88)90193-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLENBECK I, 1984, INT ARCH ALLER A IMM, V73, P166, DOI 10.1159/000233459; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917	34	25	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				532	539		10.1016/S0091-6749(05)80209-X	http://dx.doi.org/10.1016/S0091-6749(05)80209-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229814				2022-12-18	WOS:A1990EG45400013
J	MITTMAN, RJ; BERNSTEIN, DI; STEINBERG, DR; ENRIONE, M; BERNSTEIN, IL				MITTMAN, RJ; BERNSTEIN, DI; STEINBERG, DR; ENRIONE, M; BERNSTEIN, IL			PROGESTERONE-RESPONSIVE URTICARIA AND EOSINOPHILIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,ML SUITE 563,CINCINNATI,OH 45267	University of Cincinnati								BASSOL S, 1984, FERTIL STERIL, V42, P216; BEESON PB, 1977, MAJOR PROBLEMS INTER, V14, P210; BJORNSON BH, 1985, J CLIN INVEST, V76, P924, DOI 10.1172/JCI112091; CONRAD MJ, 1974, PHYSIOL CHEM PHYS M, V6, P11; COOPER BJ, 1976, ARCH INTERN MED, V136, P1366; FARAH FS, 1971, J ALLERGY CLIN IMMUN, V48, P257, DOI 10.1016/0091-6749(71)90025-X; GARZA R, 1975, ANAL LETT, V8, P225; GAULTIER C, 1987, BIOMED PHARMACOTHER, V41, P186; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GUY WH, 1951, AMA ARCH DERM SYPH, V63, P377, DOI 10.1001/archderm.1951.01570030091012; HANING RV, 1984, FERTIL STERIL, V42, P882; HILL DJ, 1986, J ALLERGY CLIN IMMUN, V78, P122, DOI 10.1016/0091-6749(86)90124-7; KAPLAN AP, 1985, ALLERGY, P439; KATZEN DR, 1982, AM J DIS CHILD, V140, P62; LEECH SH, 1981, ANN ALLERGY, V46, P201; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MEGGS WJ, 1984, NEW ENGL J MED, V311, P1236, DOI 10.1056/NEJM198411083111907; MIDGLEY AR, 1967, J CLIN ENDOCR METAB, V27, P295, DOI 10.1210/jcem-27-2-295; Nye L, 1975, Clin Allergy, V5, P13; ODELL WD, 1967, J CLIN INVEST, V46, P248, DOI 10.1172/JCI105527; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; PARISH WE, 1985, URTICARIAS, P79; PHILLIPS EW, 1949, ANN INTERN MED, V30, P364, DOI 10.7326/0003-4819-30-2-364; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SLATER JE, 1987, J ALLERGY CLIN IMMUN, V80, P285, DOI 10.1016/0091-6749(87)90033-9; SLATER JE, 1987, OBSTET GYNECOL, V4, P542; TAYLOR KM, 1972, J NEUROCHEM, V19, P1343, DOI 10.1111/j.1471-4159.1972.tb01459.x; ZONDEK B, 1945, J ALLERGY, V16, P1, DOI 10.1016/0021-8707(45)90035-9	28	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					304	310		10.1016/0091-6749(89)90412-0	http://dx.doi.org/10.1016/0091-6749(89)90412-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2778236				2022-12-18	WOS:A1989AR19900005
J	MCFADDEN, ER				MCFADDEN, ER			THERAPY OF ACUTE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106	Case Western Reserve University	MCFADDEN, ER (corresponding author), UNIV HOSP CLEVELAND,DEPT MED,CTR AIRWAY DIS,2074 ABINGTON RD,CLEVELAND,OH 44106, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR0080] Funding Source: Medline; NHLBI NIH HHS [HL 37117] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER AB, 1983, J PEDIATR-US, V102, P465, DOI 10.1016/S0022-3476(83)80679-9; BENZVI Z, 1983, AM REV RESPIR DIS, V127, P101, DOI 10.1164/arrd.1983.127.1.101; BLOOMFIELD P, 1979, BRIT MED J, V1, P848, DOI 10.1136/bmj.1.6167.848; BOHN D, 1984, CRIT CARE MED, V12, P892, DOI 10.1097/00003246-198410000-00012; BOWLER SD, 1987, EUR J RESPIR DIS, V70, P280; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EDMUNDS AT, 1981, THORAX, V36, P534, DOI 10.1136/thx.36.7.534; ELENBAAS RM, 1985, DRUG INTEL CLIN PHAR, V19, P567, DOI 10.1177/106002808501900714; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; FANTA CH, 1986, AM J MED, V80, P5, DOI 10.1016/0002-9343(86)90041-0; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; FUGLSANG G, 1986, EUR J RESPIR DIS, V69, P109; GLAZEBROOK KN, 1985, NEW ZEAL MED J, V98, P590; GREIF J, 1985, ANN ALLERGY, V55, P504; GROSS NJ, 1984, AM REV RESPIR DIS, V129, P856, DOI 10.1164/arrd.1984.129.5.856; HARRISON BA, 1983, AUST NZ J MED, V13, P29, DOI 10.1111/j.1445-5994.1983.tb04543.x; HASKELL RJ, 1983, ARCH INTERN MED, V143, P1324, DOI 10.1001/archinte.143.7.1324; HUDGEL DW, 1974, ANN INTERN MED, V80, P622, DOI 10.7326/0003-4819-80-5-622; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; KNOWLES GK, 1973, LANCET, V2, P1356; KONIG P, 1983, ARCH INTERN MED, V143, P1361, DOI 10.1001/archinte.143.7.1361; KURLAND G, 1979, J ALLERGY CLIN IMMUN, V63, P407, DOI 10.1016/0091-6749(79)90214-8; LAWFORD P, 1978, BRIT MED J, V1, P84, DOI 10.1136/bmj.1.6105.84; LEWIS JE, 1985, ANN ALLERGY, V55, P472; LINDGREN S, 1987, EUR J RESPIR DIS, V70, P93; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; LUKSZA AR, 1982, BRIT J DIS CHEST, V76, P15, DOI 10.1016/0007-0971(82)90003-1; MATSON JR, 1978, J PEDIATR-US, V92, P776, DOI 10.1016/S0022-3476(78)80150-4; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCFADDEN ER, 1976, AM J MED, V60, P52, DOI 10.1016/0002-9343(76)90533-7; MCFADDEN ER, 1981, J ALLERGY CLIN IMMUN, V68, P91, DOI 10.1016/0091-6749(81)90164-0; MCFADDEN ER, 1983, ALLERGY PRINCIPLES P, V2, P843; MIKHAIL MS, 1987, CLIN PEDIATR, V26, P419, DOI 10.1177/000992288702600808; MOLER FW, 1988, J ALLERGY CLIN IMMUN, V81, P1101, DOI 10.1016/0091-6749(88)90876-7; NELSON HS, 1986, J ALLERGY CLIN IMMUN, V77, P771, DOI 10.1016/0091-6749(86)90372-6; OSLER W, 1892, PRINCIPLES PRACTICE, P499; OSMAN J, 1987, BRIT J DIS CHEST, V81, P232, DOI 10.1016/0007-0971(87)90155-0; PAKES GE, 1980, DRUGS, V20, P237, DOI 10.2165/00003495-198020040-00001; PANCORBO S, 1983, CLIN PHARMACY, V2, P45; PARRY WH, 1976, AM J DIS CHILD, V130, P39, DOI 10.1001/archpedi.1976.02120020041006; PIERCE RJ, 1981, CHEST, V79, P506, DOI 10.1378/chest.79.5.506; PLISS LB, 1981, ANN EMERG MED, V10, P353, DOI 10.1016/S0196-0644(81)80235-1; POPA V, 1986, CLIN CHEST MED, V7, P313; RAIMONDI AC, 1986, CHEST, V89, P832, DOI 10.1378/chest.89.6.832; REBUCK AS, 1987, AM J MED, V82, P59, DOI 10.1016/0002-9343(87)90378-0; REISMAN J, 1988, J ALLERGY CLIN IMMUN, V81, P16, DOI 10.1016/0091-6749(88)90214-X; ROBERTSON CF, 1985, J PEDIATR-US, V106, P672, DOI 10.1016/S0022-3476(85)80101-3; ROSSING TH, 1983, AM J MED, V75, P781, DOI 10.1016/0002-9343(83)90407-2; ROSSING TH, 1981, AM REV RESPIR DIS, V123, P190; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; SCHWARTZ AL, 1980, AM J DIS CHILD, V134, P474, DOI 10.1001/archpedi.1980.02130170024009; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; STORR J, 1987, LANCET, V1, P879; TANAKA RM, 1982, CHEST, V82, P439; TARALA RA, 1980, BRIT J CLIN PHARMACO, V10, P393; TINKELMAN DG, 1983, ANN ALLERGY, V50, P398; TURPEINEN M, 1984, ARCH DIS CHILD, V59, P666, DOI 10.1136/adc.59.7.666; UDEN DL, 1985, ANN EMERG MED, V14, P229, DOI 10.1016/S0196-0644(85)80445-5; VANRENTERGHEM D, 1987, ANN ALLERGY, V59, P313; WARD MJ, 1985, BRIT J DIS CHEST, V79, P374, DOI 10.1016/0007-0971(85)90071-3; WILLIAMS S, 1977, THORAX, V32, P555, DOI 10.1136/thx.32.5.555; WILLIAMS SJ, 1981, THORAX, V36, P629, DOI 10.1136/thx.36.8.629; WOOD DW, 1973, ANN ALLERGY, V31, P607; YOUNGCHAIYUD P, 1987, EUR J RESPIR DIS, V70, P284	64	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					151	158		10.1016/0091-6749(89)90318-7	http://dx.doi.org/10.1016/0091-6749(89)90318-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2668380				2022-12-18	WOS:A1989AL83600003
J	KAPLAN, AP; ANDERSON, JA; VALENTINE, MD; LOCKEY, RF; PIERSON, WE; ZWEIMAN, B; KALINER, MA; LICHTENSTEIN, LM; LIEBERMAN, PL; SETTIPANE, GA; SHEFFER, AL; YUNGINGER, JW				KAPLAN, AP; ANDERSON, JA; VALENTINE, MD; LOCKEY, RF; PIERSON, WE; ZWEIMAN, B; KALINER, MA; LICHTENSTEIN, LM; LIEBERMAN, PL; SETTIPANE, GA; SHEFFER, AL; YUNGINGER, JW			BETA-ADRENERGIC BLOCKERS, IMMUNOTHERAPY, AND SKIN TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											KAPLAN, AP (corresponding author), AMER ACAD ALLERGY & IMMUNOL,611 E WELLS ST,MILWAUKEE,WI 53202, USA.							AWAI LE, 1984, ANN ALLERGY, V53, P48; BERKELMAN RL, 1986, ANN INTERN MED, V104, P134, DOI 10.7326/0003-4819-104-1-134_1; BICKELL WH, 1984, ANN EMERG MED, V13, P189, DOI 10.1016/S0196-0644(84)80611-3; FRALEY DS, 1980, SOUTHERN MED J, V73, P238, DOI 10.1097/00007611-198002000-00030; FRANKISH C, 1985, CLIN INVEST MED, V8, pA42; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V80, P698, DOI 10.1016/0091-6749(87)90290-9; HAMILTON G, 1985, CAN MED ASSOC J, V133, P122; HANNAWAY PJ, 1983, NEW ENGL J MED, V308, P1536; HEPNER M, 1987, J ALLERGY CLIN IMMUN, V79, P133; INGALL M, 1984, JAMA-J AM MED ASSOC, V251, P1432, DOI 10.1001/jama.1984.03340350026019; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; LEMANSKE RF, 1985, ALLERGY, P199; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P630; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; SCHOENE RB, 1981, JAMA-J AM MED ASSOC, V245, P1460, DOI 10.1001/jama.245.14.1460; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TOOGOOD JH, 1987, CAN MED ASSOC J, V136, P929; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103	21	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					129	130		10.1016/0091-6749(89)90186-3	http://dx.doi.org/10.1016/0091-6749(89)90186-3			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2569002				2022-12-18	WOS:A1989AG12000017
J	SCHROECKENSTEIN, DC; MEIERDAVIS, S; GRAZIANO, FM; FALOMO, A; BUSH, RK				SCHROECKENSTEIN, DC; MEIERDAVIS, S; GRAZIANO, FM; FALOMO, A; BUSH, RK			OCCUPATIONAL SENSITIVITY TO ALPHITOBIUS-DIAPERINUS (PANZER) (LESSER MEALWORM)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM S MIDDLETON MEM VET ADM HOSP,MED SERV,ALLERGY SECT,2500 OVERLOOK TERRACE,MADISON,WI 53705; UNIV WISCONSIN,DEPT MED,ALLERGY CLIN IMMUNOL SECT,MADISON,WI 53706	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K07AI000652] Funding Source: NIH RePORTER; NIAID NIH HHS [KO7-AI00652] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN DI, 1983, J ALLERGY CLIN IMMUN, V72, P475, DOI 10.1016/0091-6749(83)90584-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGE PS, 1980, CLIN ALLERGY, V10, P355, DOI 10.1111/j.1365-2222.1980.tb02119.x; BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P90, DOI 10.1016/0091-6749(86)90119-3; FRANKLAND AW, 1965, BRIT J IND MED, V22, P157; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OKUUMURA GT, 1967, CALIF VECTOR VIEWS, V14, P19; PERLMAN F, 1961, J ALLERGY, V32, P93, DOI 10.1016/0021-8707(61)90061-2; PERLMAN F, 1958, J ALLERGY, V29, P302, DOI 10.1016/0021-8707(58)90037-6; PETRY RW, 1985, J ALLERGY CLIN IMMUN, V75, P268, DOI 10.1016/0091-6749(85)90056-9; PHILLIPS JK, 1984, INSECT MANAGEMENT FO, P279; SHELDON J. M., 1941, JOUR ALLERGY, V12, P493, DOI 10.1016/S0021-8707(41)90228-9; SHULMAN S, 1967, ANNU REV ENTOMOL, V12, P323, DOI 10.1146/annurev.en.12.010167.001543; SPIEKSMA FTM, 1986, J ALLERGY CLIN IMMUN, V77, P108, DOI 10.1016/0091-6749(86)90331-3; STEVENSON DD, 1967, J ALLERGY, V39, P274, DOI 10.1016/0021-8707(67)90091-3; TEE RD, 1985, J ALLERGY CLIN IMMUN, V76, P826, DOI 10.1016/0091-6749(85)90756-0; WIDE L, 1967, LANCET, V2, P1105; WIRTZ RA, 1984, ANNU REV ENTOMOL, V29, P47, DOI 10.1146/annurev.en.29.010184.000403; WITTICH F. W., 1940, JOUR ALLERGY, V12, P42, DOI 10.1016/S0021-8707(40)90390-2; 1986, USDA AGR HDB, V500, P34	22	25	26	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1081	1088		10.1016/0091-6749(88)90147-9	http://dx.doi.org/10.1016/0091-6749(88)90147-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	2462582				2022-12-18	WOS:A1988R631100018
J	ARROYAVE, CM; GIAMBRONE, MJ; RICH, KC; WALASZEK, M				ARROYAVE, CM; GIAMBRONE, MJ; RICH, KC; WALASZEK, M			THE FREQUENCY OF ANTINUCLEAR ANTIBODY (ANA) IN CHILDREN BY USE OF MOUSE KIDNEY (MK) AND HUMAN EPITHELIAL-CELLS (HEP-2) AS SUBSTRATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, CHILDRENS MEM HOSP, DIV RHEUMATOL, CHICAGO, IL 60614 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University								ALSPAUGH MA, 1976, ARTHRITIS RHEUM-US, V19, P216, DOI 10.1002/art.1780190214; ARROYAVE CM, 1982, B MED HOSP INFANT M, V39, P160; CHUDWIN DS, 1983, AM J DIS CHILD, V137, P1103, DOI 10.1001/archpedi.1983.02140370063021; CHUDWIN DS, 1981, J PEDIATR-US, V98, P213, DOI 10.1016/S0022-3476(81)80637-3; DABICH L, 1974, J PEDIATR-US, V85, P770, DOI 10.1016/S0022-3476(74)80338-0; FESSEL WJ, 1978, AM J MED, V64, P80, DOI 10.1016/0002-9343(78)90181-X; GLADMAN DD, 1978, J RHEUMATOL, V5, P142; MADDISON PJ, 1981, MEDICINE, V60, P87, DOI 10.1097/00005792-198103000-00002; NAKAMURA RM, 1974, IMMUNOPATHOLOGY CLIN; NOTMAN DD, 1975, ANN INTERN MED, V83, P464, DOI 10.7326/0003-4819-83-4-464; OHLSSON C, UNPUB DIFFERENT IMMU; OSBORN TG, 1984, ARTHRITIS RHEUM, V27, P1286, DOI 10.1002/art.1780271111; PACHMAN LM, 1980, J PEDIATR-US, V96, P226, DOI 10.1016/S0022-3476(80)80807-9; PETTY RE, 1980, ARTHRITIS RHEUM, V20, P260; PINCUS T, 1969, NEW ENGL J MED, V281, P701, DOI 10.1056/NEJM196909252811304; REICHLIN M, 1981, CLIN EXP IMMUNOL, V44, P1; REICHLIN M, 1972, NEW ENGL J MED, V286, P908, DOI 10.1056/NEJM197204272861702; RIPPEY JH, 1985, DIAGN CLIN IMMUNOL, V3, P43; ROTHFIELD NF, 1976, MANUAL CLIN IMMUNOLO, P647; SINGSEN BH, 1977, J PEDIATR-US, V90, P893, DOI 10.1016/S0022-3476(77)80555-6; TAN EM, 1966, J IMMUNOL, V96, P464; TAN EM, 1967, J CLIN INVEST, V46, P735, DOI 10.1172/JCI105574; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1003, DOI 10.1002/art.1780250814	23	25	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				741	744		10.1016/0091-6749(88)90073-5	http://dx.doi.org/10.1016/0091-6749(88)90073-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3263996				2022-12-18	WOS:A1988R170800005
J	WARNER, JA; MACGLASHAN, DW; PETERS, SP; KAGEYSOBOTKA, A; LICHTENSTEIN, LM				WARNER, JA; MACGLASHAN, DW; PETERS, SP; KAGEYSOBOTKA, A; LICHTENSTEIN, LM			THE PHARMACOLOGIC MODULATION OF MEDIATOR RELEASE FROM HUMAN BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI020136, R01AI020253] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20253, AI 20136, AI 07290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BISCAARD H, 1982, PROSTAGLANDINS, V23, P797; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAMMARSTROM S, 1977, BIOCHIM BIOPHYS ACTA, V487, P517, DOI 10.1016/0005-2760(77)90221-1; HAYES EC, 1983, J IMMUNOL, V131, P429; LEWIS RA, 1980, P NATL ACAD SCI US, V77, P310; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1131; LICHTENSTEIN LM, 1968, SCIENCE, V161, P192; MACGLASHAN DW, 1983, J IMMUNOL, V130, P4; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1980, J IMMUNOL, V124, P2519; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARONE G, 1980, CLIN IMMUNOL IMMUNOP, V17, P117, DOI 10.1016/0090-1229(80)90079-3; MARONE G, 1983, INT ARCH ALLERGY APP, V65, P339; MARONE G, 1979, J IMMUNOL, V123, P166; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Orange R P, 1969, Adv Immunol, V10, P105, DOI 10.1016/S0065-2776(08)60416-2; PEACHELL PT, 1988, J IMMUNOL, V140, P571; PETERS SP, 1985, AM REV RESPIR DIS, V132, P367; PETERS SP, 1981, NATURE, V292, P455, DOI 10.1038/292455a0; RAZIN E, 1984, J IMMUNOL, V133, P3282; ROUZER CA, 1982, J EXP MED, V155, P720, DOI 10.1084/jem.155.3.720; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1985, INT ARCH ALLER A IMM, V77, P241, DOI 10.1159/000233799; SCHULMAN ES, 1988, J CLIN INVEST, V81, P918, DOI 10.1172/JCI113403; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Volverk JJ, 1974, BIOCHEMISTRY-US, V13, P1446; WARNER JA, 1985, ANN ALLERGY, V55, P275	31	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				432	438		10.1016/0091-6749(88)90016-4	http://dx.doi.org/10.1016/0091-6749(88)90016-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	2459175				2022-12-18	WOS:A1988Q322900017
J	BRITTON, J; CHINN, S; BURNEY, P; PAPACOSTA, AO; TATTERSFIELD, A				BRITTON, J; CHINN, S; BURNEY, P; PAPACOSTA, AO; TATTERSFIELD, A			SEASONAL-VARIATION IN BRONCHIAL REACTIVITY IN A COMMUNITY POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT COMMUNITY MED, LONDON, ENGLAND	University of London; King's College London	BRITTON, J (corresponding author), CITY HOSP, RESP MED UNIT, HUCKNALL RD, NOTTINGHAM NG5 1PB, ENGLAND.		Britton, John R/G-9705-2011	Burney, Peter/0000-0001-8635-5678				ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; AYRES JG, 1986, THORAX, V41, P111, DOI 10.1136/thx.41.2.111; Baker R, 1978, GLIM SYSTEM RELEASE; BLYTHE ME, 1976, BRIT J DIS CHEST, V70, P3, DOI 10.1016/0007-0971(76)90003-6; BOOTH S, 1965, ARCH ENVIRON HEALTH, V10, P152, DOI 10.1080/00039896.1965.10663974; BRITTON J, 1986, EUR J RESPIR DIS, V68, P233; BRITTON J, 1986, THORAX, V41, P128, DOI 10.1136/thx.41.2.128; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; CAREY MJ, 1986, BRIT MED J, V293, P843, DOI 10.1136/bmj.293.6551.843; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; Check W A, 1982, JAMA, V247, P2071, DOI 10.1001/jama.247.15.2071; CHINN S, 1987, THORAX, V42, P45, DOI 10.1136/thx.42.1.45; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTES JE, 1979, LUNG FUNCTION ASSESS, P369; DERRICK EH, 1972, AUST NZ J MED, V2, P235, DOI 10.1111/j.1445-5994.1972.tb03068.x; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GREENBURG L, 1964, ARCH ENVIRON HEALTH, V8, P642, DOI 10.1080/00039896.1964.10663734; GREGORY PH, 1952, NATURE, V170, P414, DOI 10.1038/170414a0; HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976; HARRIES MG, 1985, LANCET, V1, P1063; INMAN WHW, 1969, LANCET, V2, P279; JENKINS CR, 1984, AM REV RESPIR DIS, V130, P879; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; KHOT A, 1983, BRIT MED J, V287, P1257, DOI 10.1136/bmj.287.6401.1257; KHOT A, 1984, BRIT MED J, V289, P233, DOI 10.1136/bmj.289.6439.233; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P466; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MANN JS, 1985, CLIN SCI         S12, V69, pP34; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; REED S, 1985, THORAX, V40, P897, DOI 10.1136/thx.40.12.897; RIBON A, 1972, ANN ALLERGY, V30, P276; ROSENTHAL RR, 1979, CHEST, V75, P228, DOI 10.1378/chest.75.2.228; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; TARLO S, 1979, CLIN ALLERGY, V9, P293, DOI 10.1111/j.1365-2222.1979.tb01556.x; Tromp S W, 1968, Rev Allergy, V22, P1027; WELLIVER RC, 1983, J ALLERGY CLIN IMMUN, V72, P341, DOI 10.1016/0091-6749(83)90497-9; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1983, SPSSX USERS GUIDE, P601	43	25	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					134	139		10.1016/0091-6749(88)90063-2	http://dx.doi.org/10.1016/0091-6749(88)90063-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392365				2022-12-18	WOS:A1988P400400022
J	HOFFMAN, DR; GUENTHER, DM				HOFFMAN, DR; GUENTHER, DM			OCCUPATIONAL ALLERGY TO AVIAN PROTEINS PRESENTING AS ALLERGY TO INGESTION OF EGG-YOLK	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PERMANENTE MED GRP,DEPT ALLERGY,SAN FRANCISCO,CA	Permanente Medical Groups	HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27858, USA.							BOYER RS, 1974, AM REV RESPIR DIS, V109, P630; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUNNINGHAM AS, 1976, PEDIATRICS, V58, P436; EDWARDS JH, 1983, CLIN ALLERGY, V13, P427, DOI 10.1111/j.1365-2222.1983.tb02618.x; FINK JN, 1980, MANUAL CLIN IMMUNOLO, P829; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; HARGREAVE FE, 1966, LANCET, V1, P44; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; Korn D S, 1968, JAMA, V205, P114, DOI 10.1001/jama.205.1.114; LUTSKY I, 1984, J ALLERGY CLIN IMMUN, V73, P56, DOI 10.1016/0091-6749(84)90484-6; MAATBLEEKER F, 1985, ANN ALLERGY, V54, P245; PAGGIARO PL, 1979, CLIN ALLERGY, V9, P571, DOI 10.1111/j.1365-2222.1979.tb00481.x; PEARSALL H R, 1960, Bull Mason Clin, V14, P127; PLESSNER M, 1960, Arch Mal Prof, V21, P67; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001	17	25	25	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					484	488		10.1016/0091-6749(88)90921-9	http://dx.doi.org/10.1016/0091-6749(88)90921-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3339198				2022-12-18	WOS:A1988M099300019
J	BRONSKY, E; BUCHOLTZ, GA; BUSSE, WW; CHERVINSKY, P; CONDEMI, J; GHAFOURI, MA; HUDSON, L; LAKSHMINARAYAN, S; LOCKEY, R; REESE, ME; RENNARD, SI; SEGAL, A; SMOLLEY, L; SPECTOR, S; STABLEIN, JJ; VANAS, A; WILSON, A				BRONSKY, E; BUCHOLTZ, GA; BUSSE, WW; CHERVINSKY, P; CONDEMI, J; GHAFOURI, MA; HUDSON, L; LAKSHMINARAYAN, S; LOCKEY, R; REESE, ME; RENNARD, SI; SEGAL, A; SMOLLEY, L; SPECTOR, S; STABLEIN, JJ; VANAS, A; WILSON, A			COMPARISON OF INHALED ALBUTEROL POWDER AND AEROSOL IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GLAXO INC,CLIN INVEST,RES TRIANGLE PK,NC 27709	GlaxoSmithKline								DUNCAN D, 1977, BRIT J CLIN PHARMACO, V4, P669, DOI 10.1111/j.1365-2125.1977.tb00428.x; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; HARTLEY JPR, 1977, BRIT J CLIN PHARMACO, V4, P673, DOI 10.1111/j.1365-2125.1977.tb00429.x; HARTLEY JPR, 1979, BRIT J DIS CHEST, V73, P271, DOI 10.1016/0007-0971(79)90051-2; HETZEL MR, 1977, CLIN ALLERGY, V7, P563, DOI 10.1111/j.1365-2222.1977.tb01486.x; LATIMER KM, 1982, CAN MED ASSOC J, V127, P857; LITTNER MR, 1983, ANN ALLERGY, V50, P309; MCFADDEN ER, 1981, J ALLERGY CLIN IMMUN, V68, P91, DOI 10.1016/0091-6749(81)90164-0; PATERSON IC, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76-a; SPECTOR SL, 1977, J ALLERGY CLIN IMMUN, V59, P280, DOI 10.1016/0091-6749(77)90048-3	10	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					741	747		10.1016/0091-6749(87)90205-3	http://dx.doi.org/10.1016/0091-6749(87)90205-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3553277				2022-12-18	WOS:A1987H434900008
J	CLOUD, M; ENAS, G; KEMP, J; PLATTSMILLS, T; ALTMAN, L; TOWNLEY, R; TINKELMAN, D; KING, T; MIDDLETON, E; SHEFFER, A; MCFADDEN, E				CLOUD, M; ENAS, G; KEMP, J; PLATTSMILLS, T; ALTMAN, L; TOWNLEY, R; TINKELMAN, D; KING, T; MIDDLETON, E; SHEFFER, A; MCFADDEN, E			EFFICACY AND SAFETY OF LY171883 IN PATIENTS WITH MILD CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285	Eli Lilly									0	25	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					256	256						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810					2022-12-18	WOS:A1987F881000549
J	KOENIG, JQ; MARSHALL, SG; HORIKE, M; SHAPIRO, GG; FURUKAWA, CT; BIERMAN, CW; PIERSON, WE				KOENIG, JQ; MARSHALL, SG; HORIKE, M; SHAPIRO, GG; FURUKAWA, CT; BIERMAN, CW; PIERSON, WE			THE EFFECTS OF ALBUTEROL ON SULFUR DIOXIDE-INDUCED BRONCHOCONSTRICTION IN ALLERGIC ADOLESCENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KOENIG, JQ (corresponding author), UNIV WASHINGTON,DEPT ENVIRONM HLTH,SC34,SEATTLE,WA 98195, USA.				NIEHS NIH HHS [5 R01 ES 02366] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002366] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOOIJNOORD H, 1969, BRONCHITIS, P316; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; GOLDMAN M, 1970, J APPL PHYSIOL, V28, P113, DOI 10.1152/jappl.1970.28.1.113; HARRIES MG, 1981, LANCET, V1, P5; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; KOENIG JQ, 1982, J ALLERGY CLIN IMMUN, V69, P339, DOI 10.1016/0091-6749(82)90143-9; KOENIG JQ, 1980, ENVIRON RES, V22, P145, DOI 10.1016/0013-9351(80)90126-7; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; LINN WS, 1983, AM REV RESPIR DIS, V127, P278; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SHEPPARD D, 1981, AM REV RESPIR DIS, V124, P257; SNASHALL PD, 1982, THORAX, V37, P118, DOI 10.1136/thx.37.2.118; TAM E, 1983, AM REV RESPIR DIS, V127, P257; TAN WC, 1982, THORAX, V37, P671, DOI 10.1136/thx.37.9.671; TASHKIN DP, 1985, BRONCHIAL ASTHMA MEC, P604; 1982, EPA600882029C	18	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					54	58		10.1016/S0091-6749(87)80016-7	http://dx.doi.org/10.1016/S0091-6749(87)80016-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3805547				2022-12-18	WOS:A1987F881000012
J	FOX, RW; LOCKEY, RF; BUKANTZ, SC; SERBOUSEK, D				FOX, RW; LOCKEY, RF; BUKANTZ, SC; SERBOUSEK, D			THE TREATMENT OF MILD TO SEVERE CHRONIC IDIOPATHIC URTICARIA WITH ASTEMIZOLE - DOUBLE-BLIND AND OPEN TRIALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV S FLORIDA,COLL MED,DIV ALLERGY IMMUNOL,TAMPA,FL 33612	State University System of Florida; University of South Florida	FOX, RW (corresponding author), JAMES A HALEY VET ADM MED CTR,13000 BRUCE B DOWNS BLVD,VAR 111D,TAMPA,FL 33612, USA.							AWOUTERS FHL, 1983, ARZNEIMITTEL-FORSCH, V33-1, P381; BATEMAN DN, 1983, EUR J CLIN PHARMACOL, V25, P547, DOI 10.1007/BF00542126; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; CRISTOL JL, 1984, NER ALLERGY P, V5, P334; DAMSEAUX M, 1981, CLIN RES REP, V43, P1; HOWARTH PH, 1985, J ALLERGY CLIN IMMUN, V75, P166, DOI 10.1016/0091-6749(85)90383-5; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; KAPLAN AP, 1983, ALLERGY PRINCIPLES P, P1341; KRAUSE LB, 1984, LANCET, V1, P929; MATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177; MATTHEWS KP, 1974, MED CLIN N AM, V58, P185; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; WILSON JD, 1982, CLIN ALLERGY, V12, P131	13	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1159	1166		10.1016/0091-6749(86)90266-6	http://dx.doi.org/10.1016/0091-6749(86)90266-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3097109				2022-12-18	WOS:A1986F302600012
J	HENDELES, L; WEINBERGER, M				HENDELES, L; WEINBERGER, M			SELECTION OF A SLOW-RELEASE THEOPHYLLINE PRODUCT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,DEPT PEDIAT,DIV CLIN PHARMACOL,GAINESVILLE,FL 32610; UNIV IOWA,DIV PEDIAT ALLERGY & PULM,IOWA CITY,IA 52242	State University System of Florida; University of Florida; University of Iowa	HENDELES, L (corresponding author), UNIV FLORIDA,COLL PHARM,J HILLIS MILLER HLTH CTR,DIV CLIN PHARMACOKINET,BOX J-486,GAINESVILLE,FL 32610, USA.							BAKER JR, 1985, J ALLERGY CLIN IMMUN, V75, P106; FAGERSTROM PO, 1983, INT J CLIN PHARM TH, V21, P359; GINCHANSKY E, 1977, J PEDIATR-US, V91, P655, DOI 10.1016/S0022-3476(77)80527-1; HALTOM JR, 1985, J PEDIATR-US, V107, P805, DOI 10.1016/S0022-3476(85)80425-X; HENDELES L, 1985, CHEST, V87, P758, DOI 10.1378/chest.87.6.758; HENDELES L, 1984, CLIN PHARMACOKINET, V9, P95, DOI 10.2165/00003088-198409020-00001; HENDELES L, 1977, AM J HOSP PHARM, V34, P525, DOI 10.1093/ajhp/34.5.525; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; JONKMAN JHG, 1980, EUR J CLIN PHARMACOL, V17, P379, DOI 10.1007/BF00558452; KARIM A, 1985, CLIN PHARMACOL THER, V38, P77, DOI 10.1038/clpt.1985.138; Karim A, 1985, Am Pharm, VNS25, P4; KARIM A, 1985, CLIN PHARMACOL THER, V38, P642, DOI 10.1038/clpt.1985.238; LAGAS M, 1983, EUR J CLIN PHARMACOL, V24, P761, DOI 10.1007/BF00607084; LEEDS NH, 1982, J CLIN PHARMACOL, V22, P196, DOI 10.1002/j.1552-4604.1982.tb02162.x; MILAVETZ G, 1986, J ALLERGY CLIN IMMUN, V77, P146; MYHRE KI, 1983, BRIT J CLIN PHARMACO, V15, P683, DOI 10.1111/j.1365-2125.1983.tb01550.x; OSMAN MA, 1983, BIOPHARM DRUG DISPOS, V4, P63, DOI 10.1002/bdd.2510040109; PEDERSEN S, 1985, CLIN ALLERGY, V15, P253, DOI 10.1111/j.1365-2222.1985.tb02282.x; PEDERSEN S, 1982, ALLERGY, V37, P531, DOI 10.1111/j.1398-9995.1982.tb02336.x; PEDERSEN S, 1984, PEDIATRICS, V74, P534; ROGERS RJ, 1985, J PEDIATR-US, V106, P496, DOI 10.1016/S0022-3476(85)80690-9; SALLENT J, 1985, American Review of Respiratory Disease, V131, pA235; SCOTT PH, 1981, J PEDIATR-US, V99, P476, DOI 10.1016/S0022-3476(81)80354-X; SHARGEL L, 1981, J PHARM SCI, V70, P599, DOI 10.1002/jps.2600700606; SIPS AP, 1984, EUR J CLIN PHARMACOL, V26, P405, DOI 10.1007/BF00548776; SPANGLER DL, 1980, ANN ALLERGY, V45, P355; SPANGLER DL, 1978, ANN ALLERGY, V40, P6; TABACHNIK E, 1982, J PEDIATR-US, V100, P489, DOI 10.1016/S0022-3476(82)80467-8; TALSETH T, 1981, ANN ALLERGY, V46, P279; WAXLER SH, 1950, JAMA-J AM MED ASSOC, V143, P736, DOI 10.1001/jama.1950.02910430028010; WEINBERGER M, 1981, J PEDIATR-US, V99, P145, DOI 10.1016/S0022-3476(81)80982-1; WEINBERGER M, 1978, NEW ENGL J MED, V299, P852, DOI 10.1056/NEJM197810192991603; WEINBERGER MM, 1984, PHARMACOTHERAPY, V4, P181; WELLING PG, 1975, CLIN PHARMACOL THER, V17, P475	34	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				743	751		10.1016/0091-6749(86)90055-2	http://dx.doi.org/10.1016/0091-6749(86)90055-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3534055				2022-12-18	WOS:A1986E568400013
J	SALARI, H; BORGEAT, P; BRAQUET, P; SIROIS, P				SALARI, H; BORGEAT, P; BRAQUET, P; SIROIS, P			STUDIES ON THE BIOSYNTHESIS OF LEUKOTRIENES IN GUINEA-PIG LUNG INVITRO BY USE OF HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU LAVAL,ENDOCRINOL MOLEC LAB,RECH LEUCOTRIENES GRP,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; CHU SHERBROOKE,DEPT PEDIAT,SHERBROOKE J1H 5N4,QUEBEC,CANADA	Laval University; University of Sherbrooke								AHARONY D, 1983, BIOCHEM BIOPH RES CO, V117, P574, DOI 10.1016/0006-291X(83)91239-1; BISGAARD H, 1984, PROSTAG OTH LIPID M, V28, P620, DOI 10.1016/0090-6980(84)90135-7; BORGEAT P, 1981, PROSTAG LEUKOTR ESS, V6, P557, DOI 10.1016/0161-4630(81)90117-8; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BORGEAT P, 1984, J ALLERGY CLIN IMMUN, V74, P310, DOI 10.1016/0091-6749(84)90122-2; BORGEAT P, 1981, J MED CHEM, V24, P121, DOI 10.1021/jm00134a001; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; ENGINEER DM, 1978, BRIT J PHARMACOL, V62, P61, DOI 10.1111/j.1476-5381.1978.tb07006.x; FOLCO G, 1981, BIOCHEM PHARMACOL, V30, P2491, DOI 10.1016/0006-2952(81)90349-X; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HARPER TW, 1984, J BIOL CHEM, V259, P4437; HEDQVIST P, 1980, ACTA PHYSIOL SCAND, V110, P331, DOI 10.1111/j.1748-1716.1980.tb06676.x; JUBIZ W, 1982, J BIOL CHEM, V257, P6106; Kellaway CH, 1940, Q J EXP PHYSIOL CMS, V30, P121; LEWIS RA, 1974, J EXP MED, V140, P1133, DOI 10.1084/jem.140.5.1133; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; LIU Y, 1985, BIOCHEM BIOPH RES CO, V129, P268, DOI 10.1016/0006-291X(85)91432-9; MORRIS HR, 1980, NATURE, V285, P104, DOI 10.1038/285104a0; MORRIS HR, 1980, PROSTAG OTH LIPID M, V19, P185, DOI 10.1016/0090-6980(80)90019-2; MORRIS HR, 1979, AGENTS ACTIONS     S, V6, P27; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; PIPER PJ, 1982, BRIT J PHARMACOL, V77, P267, DOI 10.1111/j.1476-5381.1982.tb09295.x; PIPER PJ, 1979, BRIT J PHARMACOL, V67, P67; POWELL WS, 1982, J BIOL CHEM, V257, P9465; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; RITCHIE DM, 1981, AGENTS ACTIONS, V11, P396, DOI 10.1007/BF01982477; ROBINSON C, 1984, BIOCHEM PHARMACOL, V33, P395, DOI 10.1016/0006-2952(84)90231-4; SALARI H, 1985, PROSTAGLANDINS LEUKO, P511; SAMUELSSON B, 1982, ADV PROSTAG THROMB L, V9, P1; SAMUELSSON B, 1975, ANNU REV BIOCHEM, V44, P669, DOI 10.1146/annurev.bi.44.070175.003321; SIROIS P, 1981, PROSTAG LEUKOTR ESS, V7, P327, DOI 10.1016/0161-4630(81)90137-3; SIROIS P, PHARMACOLOGY; WEICHMAN BM, 1982, J PHARMACOL EXP THER, V221, P295	36	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					720	727		10.1016/0091-6749(86)90417-3	http://dx.doi.org/10.1016/0091-6749(86)90417-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3009590	Bronze			2022-12-18	WOS:A1986C390300015
J	CARTIER, A; CHAN, H; MALO, JL; PINEAU, L; CHANYEUNG, M				CARTIER, A; CHAN, H; MALO, JL; PINEAU, L; CHANYEUNG, M			OCCUPATIONAL ASTHMA CAUSED BY EASTERN WHITE CEDAR (THUJA-OCCIDENTALIS) WITH DEMONSTRATION THAT PLICATIC ACID IS PRESENT IN THIS WOOD DUST AND IS THE CAUSAL AGENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VANCOUVER GEN HOSP, DIV RESP, DEPT MED, VANCOUVER V5Z 1M9, BC, CANADA	University of British Columbia	CARTIER, A (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.							[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BERNSTEIN IL, 1981, CLIN CHEST MED, V2, P255; BURGE PS, 1979, THORAX, V34, P308, DOI 10.1136/thx.34.3.308; CARTIER A, 1984, CLIN ALLERGY, V14, P193, DOI 10.1111/j.1365-2222.1984.tb02652.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V73, P574, DOI 10.1016/0091-6749(84)90513-X; CHANYEUNG M, 1978, J OCCUP ENVIRON MED, V20, P323; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; CHANYEUNG M, UNPUB ANIMAL MODEL R; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; GARDNER JAF, 1959, CAN J CHEM, V37, P1703, DOI 10.1139/v59-246; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MOIRA CY, 1984, AM REV RESPIR DIS, V130, P1038; PARKES WR, 1982, OCCUPATIONAL LUNG DI, P415; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; VEDAL S, 1984, AM REV RESPIR DIS, V129, P152	20	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					639	645		10.1016/0091-6749(86)90359-3	http://dx.doi.org/10.1016/0091-6749(86)90359-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3958393				2022-12-18	WOS:A1986A938100019
J	HOMBURGER, HA; MAUER, K; SACHS, MI; OCONNELL, EJ; JACOB, GL; CARON, J				HOMBURGER, HA; MAUER, K; SACHS, MI; OCONNELL, EJ; JACOB, GL; CARON, J			SERUM IGG4 CONCENTRATIONS AND ALLERGEN-SPECIFIC IGG4 ANTIBODIES COMPARED IN ADULTS AND CHILDREN WITH ASTHMA AND NONALLERGIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55905; KALLESTAD LABS INC,CHASKA,MN	Mayo Clinic	HOMBURGER, HA (corresponding author), MAYO CLIN & MAYO FDN,DEPT LAB MED,CLIN IMMUNOL SECT,160 HILTON BLDG,ROCHESTER,MN 55905, USA.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; BACH MK, 1971, J EXP MED, V133, P772, DOI 10.1084/jem.133.4.772; BERRY JB, 1977, CLIN ALLERGY, V7, P401, DOI 10.1111/j.1365-2222.1977.tb01470.x; BRIGHTON WD, 1980, CLIN ALLERGY, V10, P97, DOI 10.1111/j.1365-2222.1980.tb02085.x; BRUYNZEEL PLB, 1979, INT ARCH ALLER A IMM, V58, P344, DOI 10.1159/000232211; BRYANT DH, 1975, J ALLERGY CLIN IMMUN, V56, P417, DOI 10.1016/0091-6749(75)90060-3; BRYANT DH, 1973, BRIT MED J, V4, P589, DOI 10.1136/bmj.4.5892.589; DEVEY M E, 1975, Clinical Allergy, V5, P353, DOI 10.1111/j.1365-2222.1975.tb01874.x; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; FAGAN DL, 1982, J ALLERGY CLIN IMMUN, V70, P399, DOI 10.1016/0091-6749(82)90031-8; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; GREY HM, 1964, J EXP MED, V120, P253, DOI 10.1084/jem.120.2.253; GWYNN CM, 1982, LANCET, V1, P254; GWYNN CM, 1979, CLIN ALLERGY, V9, P119, DOI 10.1111/j.1365-2222.1979.tb01530.x; GWYNN CM, 1978, LANCET, V1, P910; HEINER DC, 1980, J ALLERGY CLIN IMMUN, V65, P201; HOMBURGER HA, 1983, FED PROC, V42, P441; MERRETT J, 1984, CLIN EXP IMMUNOL, V56, P645; NELSON HS, 1977, J ALLERGY CLIN IMMUN, V60, P266, DOI 10.1016/0091-6749(77)90142-7; OVARY Z, 1963, J EXP MED, V117, P951, DOI 10.1084/jem.117.6.951; OVARY Z, 1965, J IMMUNOL, V94, P410; OWNBY DR, 1984, J ALLERGY CLIN IMMUN, V73, P466, DOI 10.1016/0091-6749(84)90356-7; PARISH W E, 1971, Clinical Allergy, V1, P369, DOI 10.1111/j.1365-2222.1971.tb00788.x; PARISH W E, 1973, P71; PARISH WE, 1970, LANCET, V2, P591; PARISH WE, 1981, BRIT J DERMATOL, V105, P223, DOI 10.1111/j.1365-2133.1981.tb01210.x; PARISH WE, 1974, PROGR IMMUNOLOGY 2, V4, P19; PEPYS J, 1979, CLIN ALLERGY, V9, P645, DOI 10.1111/j.1365-2222.1979.tb00491.x; REID RT, 1970, J IMMUNOL, V104, P935; SHAKIB F, 1979, CLIN ALLERGY, V9, P597, DOI 10.1111/j.1365-2222.1979.tb00485.x; SHAKIB F, 1977, BRIT J DERMATOL, V97, P59, DOI 10.1111/j.1365-2133.1977.tb15428.x; STANWORTH D R, 1973, Clinical Allergy, V3, P37, DOI 10.1111/j.1365-2222.1973.tb01307.x; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; VANTOORENENBERGEN AW, 1982, INT ARCH ALLER A IMM, V67, P117, DOI 10.1159/000233000; VANTOORENENBERGEN AW, 1982, CLIN ALLERGY, V12, P451; VANTOORENENBERGEN AW, 1981, INT ARCH ALLER A IMM, V65, P432, DOI 10.1159/000232784; VIJAY HM, 1977, INT ARCH ALLER A IMM, V53, P78, DOI 10.1159/000231734; VIJAY HM, 1978, INT ARCH ALLER A IMM, V56, P517, DOI 10.1159/000232067; VIJAY HM, 1975, NEW ENGL J MED, V292, P1079	39	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					427	434		10.1016/0091-6749(86)90176-4	http://dx.doi.org/10.1016/0091-6749(86)90176-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	3512662				2022-12-18	WOS:A1986A536700005
J	WANG, SR; YANG, CM; WANG, SSM; HAN, SH; CHIANG, BN				WANG, SR; YANG, CM; WANG, SSM; HAN, SH; CHIANG, BN			ENHANCEMENT OF A23187-INDUCED PRODUCTION OF THE SLOW-REACTING SUBSTANCE ON PERIPHERAL LEUKOCYTES FROM SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									YANG MING MED COLL, TAIPEI, TAIWAN		WANG, SR (corresponding author), VET GEN HOSP, DEPT MED, ALLERGY IMMUNOL & RHEUMATOL SECT, TAIPEI 112, TAIWAN.							ADAMS GK, 1977, NATURE, V270, P255, DOI 10.1038/270255a0; ADAMS GK, 1979, J IMMUNOL, V122, P555; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BACH MK, 1978, J IMMUNOL, V120, P998; BORGEAT P, 1981, J MED CHEM, V24, P121, DOI 10.1021/jm00134a001; BOURNE HR, 1972, J IMMUNOL, V108, P695; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; CHAND N, 1979, AGENTS ACTIONS, V9, P133, DOI 10.1007/BF02024724; Conover W. J., 1979, LA7677MS LOS AL SCI; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P213; CONROY MC, 1976, J IMMUNOL, V116, P1677; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FINDLAY SR, 1980, J IMMUNOL, V124, P238; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HAMMARSTROM S, 1983, ANNU REV BIOCHEM, V52, P355, DOI 10.1146/annurev.bi.52.070183.002035; HAYES EC, 1983, J IMMUNOL, V131, P429; HEDQVIST P, 1980, ACTA PHYSIOL SCAND, V110, P331, DOI 10.1111/j.1748-1716.1980.tb06676.x; HEMADY Z, 1983, J ALLERGY CLIN IMMUN, V71, P324, DOI 10.1016/0091-6749(83)90087-8; ISHIZAKA K, 1971, Clinical Allergy, V1, P9, DOI 10.1111/j.1365-2222.1971.tb02444.x; ISHIZAKA K, 1970, CLIN EXP IMMUNOL, V6, P25; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; JAKSCHIK BA, 1977, J IMMUNOL, V119, P618; JORG A, 1982, J EXP MED, V155, P390, DOI 10.1084/jem.155.2.390; LEWIS RA, 1975, J IMMUNOL, V114, P87; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MATHEWS WR, 1981, ANAL BIOCHEM, V118, P96, DOI 10.1016/0003-2697(81)90162-7; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MORRIS HG, 1983, J ALLERGY CLIN IMMUN, V71, P266, DOI 10.1016/0091-6749(83)90080-5; MORRIS HR, 1979, BRIT J PHARMACOL, V67, P179, DOI 10.1111/j.1476-5381.1979.tb08664.x; ORANGE RP, 1971, J EXP MED, V134, pS136; ORANGE RP, 1973, J IMMUNOL, V110, P760; PATTERSON R, 1981, J ALLERGY CLIN IMMUN, V67, P444, DOI 10.1016/0091-6749(81)90097-X; REED CE, 1968, J ALLERGY, V42, P238, DOI 10.1016/S0021-8707(68)90119-6; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TUNG R, 1982, J IMMUNOL, V128, P2067; WANG SR, 1978, CELL IMMUNOL, V36, P28, DOI 10.1016/0008-8749(78)90247-2; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; Yecies L D, 1979, Monogr Allergy, V14, P155; YECIES LD, 1979, J IMMUNOL, V122, P2083	42	25	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					465	471		10.1016/0091-6749(86)90181-8	http://dx.doi.org/10.1016/0091-6749(86)90181-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	3081616				2022-12-18	WOS:A1986A536700010
J	BASCOM, R; PIPKORN, U; GLEICH, G; LICHTENSTEIN, LM; NACLERIO, RM				BASCOM, R; PIPKORN, U; GLEICH, G; LICHTENSTEIN, LM; NACLERIO, RM			EFFECT OF SYSTEMIC STEROIDS ON EOSINOPHILS (EOS) AND MAJOR BASIC-PROTEIN (MBP) DURING NASAL ANTIGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	2	S			246	246						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD38					2022-12-18	WOS:A1986AZD3800497
J	PATTERSON, R; GRAMMER, LC; SHAUGHNESSY, MA				PATTERSON, R; GRAMMER, LC; SHAUGHNESSY, MA			IMMUNOTHERAPY - PARAMETERS OF ASSESSMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY IMMUNOL SECT, CHICAGO, IL 60611 USA	Northwestern University				Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; Cooke RA, 1922, J IMMUNOL, V7, P219; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; DESWARTE RD, 1985, ALLERGIC DISEASES DI; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P448, DOI 10.1016/0091-6749(83)90580-8; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; GRAMMER LC, 1985, ALLERGIC DISEASES DI; GREENBERGER P, 1978, ANN INTERN MED, V89, P234, DOI 10.7326/0003-4819-89-2-234; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; NORMAN PS, 1978, IMMUNOLOGICAL DISEAS, P832; PATTERSON R, 1983, ALLERGY PRINCIPLES P, P1119; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	21	25	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					394	397		10.1016/0091-6749(85)90660-8	http://dx.doi.org/10.1016/0091-6749(85)90660-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	4019962				2022-12-18	WOS:A1985APE8900024
J	BORISH, L; MATLOFF, SM; FINDLAY, SR				BORISH, L; MATLOFF, SM; FINDLAY, SR			RADIOGRAPHIC CONTRAST MEDIA-INDUCED NONCARDIOGENIC PULMONARY-EDEMA - CASE-REPORT AND REVIEW OF THE LITERATURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											BORISH, L (corresponding author), NEW ENGLAND MED CTR,DEPT MED,DIV ALLERGY,BOSTON,MA 02111, USA.							ANSELL G, 1970, INVEST RADIOL, V5, P374, DOI 10.1097/00004424-197011000-00002; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; BODEN WE, 1982, CHEST, V81, P759, DOI 10.1378/chest.81.6.759; CAMERON JD, 1974, RADIOLOGY, V111, P89, DOI 10.1148/111.1.89; COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; DAVIES P, 1975, BMJ-BRIT MED J, V2, P434, DOI 10.1136/bmj.2.5968.434; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FISHER HW, 1972, RADIOLOGY, V103, P497; GONSETTE RE, 1980, INVEST RADIOL, V15, P26; GREENBERGER PA, 1981, J ALLERGY CLIN IMMUN, V67, P185, DOI 10.1016/0091-6749(81)90059-2; GREGANTI MA, 1979, RADIOLOGY, V132, P583, DOI 10.1148/132.3.583; LANG JH, 1976, INVEST RADIOL, V11, P303, DOI 10.1097/00004424-197607000-00007; LASSER EC, 1977, RADIOLOGY, V125, P1; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MCCLENNAN BL, 1972, RADIOLOGY, V105, P383, DOI 10.1148/105.2.383; OROURKE JN, 1973, J ALLERGY CLIN IMMUN, V51, P99, DOI 10.1016/S0091-6749(73)80046-6; RAININKO R, 1979, ACTA RADIOL DIAGN, V20, P410, DOI 10.1177/028418517902000302; RING J, 1978, CLIN EXP IMMUNOL, V32, P105; ROCKOFF SD, 1972, INVEST RADIOL, V7, P177; SHEHADI WH, 1982, RADIOLOGY, V143, P11, DOI 10.1148/radiology.143.1.7063711; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; TILL G, 1977, FED PROC, V36, P1264; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832	23	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					104	107		10.1016/0091-6749(84)90095-2	http://dx.doi.org/10.1016/0091-6749(84)90095-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6376598				2022-12-18	WOS:A1984SZ64800016
J	KONIG, P				KONIG, P			THE USE OF CROMOLYN IN THE MANAGEMENT OF HYPERREACTIVE AIRWAYS AND EXERCISE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KONIG, P (corresponding author), UNIV MISSOURI,MED CTR,SCH MED,DEPT CHILD HLTH,COLUMBIA,MO 65201, USA.							ALTOUNYAN REC, 1969, DISODIUM CROMOGLYCAT, P47; BRESLIN FJ, 1980, AM REV RESPIR DIS, V122, P11; BUNDGAARD A, 1982, CLIN ALLERGY, V12, P605; CLARKE PS, 1982, J ASTHMA, V19, P91, DOI 10.3109/02770908209104741; CORKEY C, 1982, AM REV RESPIR DIS, V125, P623; CUMMINGS NP, 1980, J ALLERGY CLIN IMMUN, V65, P183; DAVIES SE, 1968, BRIT MED J, V3, P593, DOI 10.1136/bmj.3.5618.593; DICKSON W, 1969, DISODIUM CROMOGLYCAT, P105; EASTON JG, 1981, J ALLERGY CLIN IMMUN, V67, P388, DOI 10.1016/0091-6749(81)90084-1; FABBRI LM, 1983, ANN ALLERGY, V50, P195; FELDMAN CH, 1982, AM REV RESPIR DIS, V125, P191; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1975, J PEDIATR-US, V87, P465, DOI 10.1016/S0022-3476(75)80663-9; GRIFFIN MP, 1983, J ALLERGY CLIN IMMUN, V71, P331, DOI 10.1016/0091-6749(83)90088-X; JONES RS, 1979, MAST CELL ITS ROLE H, P287; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; KENNEDY JD, 1980, BRIT MED J, V281, P1458, DOI 10.1136/bmj.281.6253.1458; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440, DOI 10.1164/arrd.1983.128.3.440; NUMEROSO R, 1983, RESPIRATION, V44, P109, DOI 10.1159/000194536; PATEL KR, 1982, THORAX, V37, P663, DOI 10.1136/thx.37.9.663; PATEL KR, 1976, J ALLERGY CLIN IMMUN, V57, P285, DOI 10.1016/0091-6749(76)90084-1; PATEL KR, 1983, BRIT MED J, V282, P606; RAK S, 1983, J ALLERGY CLIN IMMUN, V71, P149, DOI 10.1016/0091-6749(83)90367-6; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; SHEPPARD D, 1981, AM REV RESPIR DIS, V124, P257; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927	26	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					686	689		10.1016/0091-6749(84)90306-3	http://dx.doi.org/10.1016/0091-6749(84)90306-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6425391	Bronze			2022-12-18	WOS:A1984SS04600013
J	NICKLAS, RA; WHITEHURST, VE; DONOHOE, RF; BALAZS, T				NICKLAS, RA; WHITEHURST, VE; DONOHOE, RF; BALAZS, T			CONCOMITANT USE OF BETA-ADRENERGIC AGONISTS AND METHYLXANTHINES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									US FDA,NATL CTR DRUGS & BIOL,ROCKVILLE,MD 20857; US FDA,DIV DRUG BIOL,WASHINGTON,DC 20204	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)								AUSTIN KF, 1975, AM REV RESPIR DIS, V112, P432; BALAZS T, 1976, Annals of Clinical and Laboratory Science, V6, P467; BALAZS T, 1972, RECENT ADV STUDIES C, P770; BANNER AS, 1979, ARCH INTERN MED, V139, P434, DOI 10.1001/archinte.139.4.434; BARCLAY J, 1981, BRIT J CLIN PHARMACO, V11, P203, DOI 10.1111/j.1365-2125.1981.tb01125.x; BLUMENTHAL I, 1980, J INT MED RES, V8, P400, DOI 10.1177/030006058000800606; BOURNE HR, 1972, J IMMUNOL, V108, P695; Brittain R T, 1970, Adv Drug Res, V5, P197; Brown EA, 1940, NEW ENGL J MED, V223, P843, DOI 10.1056/NEJM194011212232103; CAMPBELL AH, 1976, MED J AUSTRALIA, V1, P386, DOI 10.5694/j.1326-5377.1976.tb140697.x; CAMPBELL IA, 1977, THORAX, V32, P424, DOI 10.1136/thx.32.4.424; Chasin M, 1976, Adv Cyclic Nucleotide Res, V7, P225; FORMGREN H, 1971, ACTA ALLERGOL, V26, P81, DOI 10.1111/j.1398-9995.1971.tb01283.x; FORMGREN H, 1970, SCAND J RESPIR DIS, V51, P203; FORMGREN H, 1970, SCAND J RESPIR DIS, V51, P195; GALANT SP, 1979, J ALLERGY CLIN IMMUN, V61, P73; GANDEVIA B, 1957, LANCET, V1, P956; GLASS P, 1973, CURR THER RES CLIN E, V15, P141; GRANT IWB, 1983, BRIT MED J, V286, P374, DOI 10.1136/bmj.286.6362.374; GREEFHORST APM, 1983, EUR J CLIN PHARMACOL, V24, P173, DOI 10.1007/BF00613813; GREEN M, 1980, J PHARM SCI, V69, P441, DOI 10.1002/jps.2600690420; HENDELES L, 1978, AM J DIS CHILD, V132, P876; HENDELES L, 1979, NEW ENGL J MED, V300, P1217; Hoak J C, 1972, Recent Adv Stud Cardiac Struct Metab, V1, P127; HUDSON LD, 1977, CHEST, V72, P401; INMAN WHW, 1969, LANCET, V2, P279; JACK D, 1971, POSTGRAD MED J, V47, P8; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JACOBS MH, 1976, JAMA-J AM MED ASSOC, V235, P1983, DOI 10.1001/jama.235.18.1983; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; Joseph X, 1981, Fundam Appl Toxicol, V1, P443, DOI 10.1016/S0272-0590(81)80025-5; JOSEPHSON GW, 1979, JAMA-J AM MED ASSOC, V242, P639, DOI 10.1001/jama.242.7.639; JOSEPHSON GW, 1980, CHEST, V78, P429, DOI 10.1378/chest.78.3.429; JOSEPHSON GW, 1981, AM REV RESPIR DIS, V124, P765; KENDALL MJ, 1982, BRIT J CLIN PHARMACO, V14, P821, DOI 10.1111/j.1365-2125.1982.tb02043.x; KINNEY EL, 1978, JAMA-J AM MED ASSOC, V240, P2247, DOI 10.1001/jama.1978.03290210029010; LAL S, 1981, POSTGRAD MED S, V47, P89; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; LEHR D, 1981, CARDIAC TOXICOLOGY, P75; LEOPOLD D, 1979, J INT MED RES, V7, P52; LONNERHOLM G, 1981, BRIT MED J, V282, P1029, DOI 10.1136/bmj.282.6269.1029; MARLIN GE, 1979, CURR MED RES OPIN, V6, P92, DOI 10.1185/03007997909115915; MILEI J, 1976, ARCH I CARDIOL MEX, V46, P347; NEVILLE A, 1977, BRIT MED J, V1, P413, DOI 10.1136/bmj.1.6058.413; NEVILLE E, 1982, BRIT MED J, V285, P796, DOI 10.1136/bmj.285.6344.796; OGILVIE RI, 1978, CLIN PHARMACOKINET, V3, P267, DOI 10.2165/00003088-197803040-00002; PARKER CW, 1973, J CLIN INVEST, V52, P1336, DOI 10.1172/JCI107305; PATEL AK, 1981, CHEST, V80, P661, DOI 10.1378/chest.80.6.661; PERSSON H, 1970, ACTA MED SCAND S, V512, P11; PHILLIPS PJ, 1980, BRIT J CLIN PHARMACO, V9, P483, DOI 10.1111/j.1365-2125.1980.tb05844.x; RONA G, 1959, ARCH PATHOL, V67, P443; ROSNER F, 1981, THORAX, V36, P245, DOI 10.1136/thx.36.4.245; ROSSING TH, 1981, AM REV RESPIR DIS, V123, P190; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; SACKNER MA, 1975, CHEST, V68, P616, DOI 10.1378/chest.68.5.616; SHENFIELD GM, 1982, DRUGS, V23, P462, DOI 10.2165/00003495-198223060-00003; SHIM C, 1980, ANN INTERN MED, V93, P428; SMITH JA, 1980, CHEST, V78, P816, DOI 10.1378/chest.78.6.816; SNIDER GL, 1972, J AMER MED ASSOC, V221, P682, DOI 10.1001/jama.221.7.682; SUTHERLAND DC, 1981, LANCET, V2, P988; SVEDMYR K, 1982, ALLERGY, V37, P101, DOI 10.1111/j.1398-9995.1982.tb01883.x; SVEDMYR K, 1982, ALLERGY, V37, P119, DOI 10.1111/j.1398-9995.1982.tb01885.x; SVEDMYR N, 1977, Scandinavian Journal of Respiratory Diseases Supplementum, V101, P125; SVEDMYR N, 1978, PHARMACOL THER PT B, V3, P397, DOI 10.1016/S0306-039X(78)90005-3; SVEDMYR N, 1979, ACTA PHARMACOL TOX, V44, P47; SVEDMYR N, 1977, SCAND J RESPIR DIS, V101, P13; TASHKIN DP, 1975, CHEST, V68, P155, DOI 10.1378/chest.68.2.155; TATTERSFIELD AE, 1969, NEW ENGL J MED, V281, P1323, DOI 10.1056/NEJM196912112812402; TAYLOR MW, 1976, BRIT MED J, V1, P22, DOI 10.1136/bmj.1.6000.22; THIRINGER G, 1975, SCAND J RESPIR DIS, V56, P93; THIRINGER G, 1976, SCAND J RESPIR DIS, V57, P17; VICK J, UNPUB EFFECT CAFFEIN; WALKER SR, 1972, CLIN PHARMACOL THER, V13, P861; WATANABE AM, 1974, CIRC RES, V35, P316, DOI 10.1161/01.RES.35.2.316; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1975, CLIN PHARMACOL THER, V17, P585; WHITEHURST VE, 1983, J AM COLL TOXICOL, V2, P147, DOI 10.3109/10915818309140676; WHITEHURST VE, 1983, TOXICOLOGIST, V3, P53; WHITSETT TL, 1981, BRIT J CLIN PHARMACO, V12, P195; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703; WYATT R, 1978, J PEDIATR-US, V92, P125, DOI 10.1016/S0022-3476(78)80093-6; 1963, PRACTITIONER, V190, P253	82	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					20	24		10.1016/0091-6749(84)90479-2	http://dx.doi.org/10.1016/0091-6749(84)90479-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6141197				2022-12-18	WOS:A1984SB99000003
J	BERNSTEIN, DI; ROACH, DE; MCGRATH, KG; LARSEN, RS; ZEISS, CR; PATTERSON, R				BERNSTEIN, DI; ROACH, DE; MCGRATH, KG; LARSEN, RS; ZEISS, CR; PATTERSON, R			THE RELATIONSHIP OF AIRBORNE TRIMELLITIC ANHYDRIDE CONCENTRATIONS TO TRIMELLITIC ANHYDRIDE INDUCED SYMPTOMS AND IMMUNE-RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; THREE M CO,DEPT MED,ST PAUL,MN 55101	Northwestern University; 3M					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; CHEMLIK F, 1974, J ALLERGY CLIN IMMUN, V54, P180; FINK JN, 1973, J ALLERGY CLIN IMMUN, V52, P309, DOI 10.1016/0091-6749(73)90051-1; GILSON JC, 1976, THORAX, V31, P621; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; PEPYS J, 1969, MONOGR ALLERGY, V4, P69; SALE SR, 1981, J ALLERGY CLIN IMMUN, V68, P188, DOI 10.1016/0091-6749(81)90182-2; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	11	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	6					709	713		10.1016/0091-6749(83)90634-6	http://dx.doi.org/10.1016/0091-6749(83)90634-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RW048	6643875				2022-12-18	WOS:A1983RW04800013
J	CHAND, N; NOLAN, K; DIAMANTIS, W; PERHACH, JL; SOFIA, RD				CHAND, N; NOLAN, K; DIAMANTIS, W; PERHACH, JL; SOFIA, RD			INHIBITION OF LEUKOTRIENE (SRS-A)-MEDIATED ALLERGIC BRONCHOSPASM BY AZELASTINE, A NOVEL ORALLY EFFECTIVE ANTIASTHMATIC DRUG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																		1981, ARZNEIM FORSCH, V31, P1184; 1981, AGENTS ACTIONS, V11, P396; 1981, ARZNEIM FORSCH, V31, P1196	3	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					149	149		10.1016/0091-6749(83)90365-2	http://dx.doi.org/10.1016/0091-6749(83)90365-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ462		Bronze			2022-12-18	WOS:A1983PZ46200242
J	MJORNDAL, TO; CHESROWN, SE; FREY, MJ; REED, BR; LAZARUS, SC; GOLD, WM				MJORNDAL, TO; CHESROWN, SE; FREY, MJ; REED, BR; LAZARUS, SC; GOLD, WM			EFFECT OF BETA-ADRENERGIC STIMULATION ON EXPERIMENTAL CANINE ANAPHYLAXIS INVIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT MED M997,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136, HL-19156, HL-19604] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKASU A, 1960, INT ARCH ALLERGY APP, V16, P32; ASSEM ESK, 1971, INT ARCH ALLER A IMM, V40, P576, DOI 10.1159/000230439; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BALL JH, 1972, J CLIN INVEST, V51, P2124, DOI 10.1172/JCI107019; BARNETT DB, 1978, AM REV RESPIR DIS, V118, P723, DOI 10.1164/arrd.1978.118.4.723; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; CHIESA A, 1975, AM REV RESPIR DIS, V111, P148; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EVANS GH, 1973, J PHARMACOL EXP THER, V186, P114; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GOLD WM, 1977, J APPL PHYSIOL, V43, P271, DOI 10.1152/jappl.1977.43.2.271; GOLD WM, 1972, J APPL PHYSIOL, V33, P496, DOI 10.1152/jappl.1972.33.4.496; GREENSPON L W, 1981, American Review of Respiratory Disease, V123, P52; KALINER MA, 1971, BIOCHIM BIOPHYS ACTA, V252, P160, DOI 10.1016/0304-4165(71)90104-8; KESSLER GF, 1974, INT ARCH ALLER A IMM, V47, P313, DOI 10.1159/000231225; KRELL RD, 1976, J ALLERGY CLIN IMMUN, V58, P664, DOI 10.1016/0091-6749(76)90178-0; LANDS A. M., 1967, LIFE SCI, V6, P2241, DOI 10.1016/0024-3205(67)90031-8; LAZARUS SC, 1979, J APPL PHYSIOL, V46, P919, DOI 10.1152/jappl.1979.46.5.919; Lehmann EL., 1998, NONPARAMETRICS STAT, V1 st, P79; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTA E, 1975, EUR J PHARMACOL, V30, P79, DOI 10.1016/0014-2999(75)90206-X; MURAD F, 1971, P NATL ACAD SCI USA, V68, P736, DOI 10.1073/pnas.68.4.736; NILSSON HT, 1973, XENOBIOTICA, V3, P615, DOI 10.3109/00498257309151550; NISAM MR, 1978, J APPL PHYSIOL, V44, P455, DOI 10.1152/jappl.1978.44.3.455; ORANGE RP, 1971, FED PROC, V30, P1725; ORANGE RP, 1971, J EXP MED          S, V134, P136; PERSSON H, 1970, ACTA MED SCAND S, V512, P11; SCHILD H., 1936, QUART JOUR EXP PHYSIOL, V26, P165; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; SNAPPER JR, 1980, AM REV RESPIR DIS, V122, P775, DOI 10.1164/arrd.1980.122.5.775; SORENBY L, 1975, EUR J PHARMACOL, V30, P140, DOI 10.1016/0014-2999(75)90092-8; STEINER AL, 1972, J BIOL CHEM, V247, P1106; UVNAS B, 1967, ACTA PHYSIOL SCAND, V70, P269, DOI 10.1111/j.1748-1716.1967.tb03625.x; WANNER A, 1975, J APPL PHYSIOL, V39, P950, DOI 10.1152/jappl.1975.39.6.950; WASSERMAN MA, 1974, J PHARMACOL EXP THER, V189, P445; Zar JH, 1974, BIOSTATISTICAL ANAL	36	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					62	70		10.1016/0091-6749(83)90548-1	http://dx.doi.org/10.1016/0091-6749(83)90548-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6185556				2022-12-18	WOS:A1983PZ46100010
J	ODRISCOLL, BRC; LEE, TH; CROMWELL, O; KAY, AB				ODRISCOLL, BRC; LEE, TH; CROMWELL, O; KAY, AB			IMMUNOLOGICAL RELEASE OF NEUTROPHIL CHEMOTACTIC ACTIVITY FROM HUMAN-LUNG TISSUE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; KAY AB, 1971, J IMMUNOL, V107, P899; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PAPAGEORGIOU N, 1983, J ALLERGY CLIN IMMUN, V72, P75, DOI 10.1016/0091-6749(83)90055-6; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; SHEARD P, 1970, INT ARCH ALLER A IMM, V38, P217, DOI 10.1159/000230274; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TURNBULL LW, 1976, IMMUNOLOGY, V31, P797	13	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	6					695	701		10.1016/0091-6749(83)90632-2	http://dx.doi.org/10.1016/0091-6749(83)90632-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RW048	6643874				2022-12-18	WOS:A1983RW04800011
J	RICKETTI, AJ; GREENBERGER, PA; PATTERSON, R				RICKETTI, AJ; GREENBERGER, PA; PATTERSON, R			IMMEDIATE-TYPE REACTIONS IN PATIENTS WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASICH JE, 1981, J ALLERGY CLIN IMMUN, V68, P98, DOI 10.1016/0091-6749(81)90165-2; GOLBERT TM, 1980, ALLERGIC DISEASES DI, P409; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; HOEHNE JH, 1973, CHEST, V63, P177, DOI 10.1378/chest.63.2.177; MCCARTHY DS, 1971, CLIN ALLERGY, V7, P415; NOBLE WC, 1963, J GEN MICROBIOL, V32, P397, DOI 10.1099/00221287-32-3-397; PATTERSON R, 1968, University of Michigan Medical Center Journal, V34, P8; PEPYS J, 1969, MONOGR ALLERGY, V4, P20; RADIN RC, CLIN ALLERGY; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1976, J CHRON DIS, V30, P1; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SLAVIN RG, 1969, AM J MED, V47, P306, DOI 10.1016/0002-9343(69)90156-9; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917	16	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					541	545		10.1016/0091-6749(83)90434-7	http://dx.doi.org/10.1016/0091-6749(83)90434-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6853923				2022-12-18	WOS:A1983QV13900004
J	FRETWELL, MD; ALTMAN, LC				FRETWELL, MD; ALTMAN, LC			EXACERBATION OF A LUPUS-ERYTHEMATOSUS LIKE SYNDROME DURING TREATMENT OF NON C1-ESTERASE-INHIBITOR DEPENDENT ANGIOEDEMA WITH DANAZOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT MED,DIV ALLERGY & INFECT DIS,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIAID NIH HHS [AI-07044] Funding Source: Medline; NIDCR NIH HHS [DE-02600] Funding Source: Medline; NIGMS NIH HHS [GM-24990] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE002600] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABLIN, 1974, J IMMUNOL, V113, P705; ANDREWS MC, 1975, AM J OBSTET GYNECOL, V121, P817; CAPELL PT, 1973, J CLIN ENDOCR METAB, V37, P752, DOI 10.1210/jcem-37-5-752; CHAPEL TA, 1971, AM J OBSTET GYNECOL, V110, P366, DOI 10.1016/0002-9378(71)90730-7; COHEN SH, 1978, ANN INTERN MED, V88, P429, DOI 10.7326/0003-4819-88-3-429_1; DUBOIS EL, 1974, LUPUS ERYTHEMATOSUS; EIDINGER D, 1972, J EXP MED, V136, P1098, DOI 10.1084/jem.136.5.1098; FAHEY JL, 1965, J IMMUNOL, V94, P84; FONG JSC, 1970, J LAB CLIN MED, V76, P836; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; HOOPER B, 1972, CLIN EXP IMMUNOL, V12, P79; INMAN RD, 1978, ARTHRITIS RHEUM, V21, P849, DOI 10.1002/art.1780210718; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MELEZ KA, 1980, ARTHRITIS RHEUM, V23, P41, DOI 10.1002/art.1780230108; PINCUS T, 1969, NEW ENGL J MED, V281, P701, DOI 10.1056/NEJM196909252811304; ROTHFIELD NF, 1976, MANUAL CLIN IMMUNOLO, P647; ROUBINIAN JR, 1979, ARTHRITIS RHEUM, V22, P1399, DOI 10.1002/art.1780221215; ROUBINIAN JR, 1977, J CLIN INVEST, V59, P1066, DOI 10.1172/JCI108729; SHERINS RJ, 1971, J CLIN ENDOCR METAB, V32, P522, DOI 10.1210/jcem-32-4-522; STEINBERG AD, 1979, ARTHRITIS RHEUM, V22, P1170, DOI 10.1002/art.1780221103; STERN R, 1977, ARTHRITIS RHEUM, V20, P18, DOI 10.1002/art.1780200103; ZICCARDI RJ, 1980, CLIN IMMUNOL IMMUNOP, V15, P465, DOI 10.1016/0090-1229(80)90058-6; ZUBLER RH, 1976, J IMMUNOL, V116, P232	23	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					306	310		10.1016/S0091-6749(82)80008-0	http://dx.doi.org/10.1016/S0091-6749(82)80008-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	6977562				2022-12-18	WOS:A1982NF69700008
J	MAHMOOD, T; WALL, H; SOBUS, S; STECHSCHULTE, DJ; ABDOU, NI				MAHMOOD, T; WALL, H; SOBUS, S; STECHSCHULTE, DJ; ABDOU, NI			MODULATION OF VENOM-INDUCED LEUKOCYTE HISTAMINE-RELEASE BY MONONUCLEAR-CELLS - EFFECT OF VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV KANSAS,MED CTR,DIV ALLERGY CLIN IMMUNOL & RHEUMATOL,KANSAS CITY,KS 66103; VET ADM MED CTR,KANSAS CITY,MO	University of Kansas; University of Kansas Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIAID NIH HHS [AI-15360] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARVILOMMI H, 1975, NATURE, V257, P144, DOI 10.1038/257144a0; BAMZAI AK, 1978, J ALLERGY CLIN IMMUN, V62, P137, DOI 10.1016/0091-6749(78)90097-0; CASE RL, 1981, J ALLERGY CLIN IMMUN, V68, P399, DOI 10.1016/0091-6749(81)90139-1; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FINDLAY SR, 1977, J ALLERGY CLIN IMMUN, V60, P230, DOI 10.1016/0091-6749(77)90135-X; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; IDA S, 1980, CLIN EXP IMMUNOL, V41, P380; IRONS JS, 1975, J ALLERGY CLIN IMMUN, V56, P64, DOI 10.1016/0091-6749(75)90035-4; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LEVY DA, 1967, J ALLERGY, V39, P124; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; MAINI RN, 1971, CLIN EXP IMMUNOL, V9, P449; MARTINEZ JD, 1979, J ALLERGY CLIN IMMUN, V64, P485, DOI 10.1016/0091-6749(79)90057-5; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NORMAN PS, 1978, ALLERGY, V33, P62; PATERSON NAM, 1981, J ALLERGY CLIN IMMUN, V67, P435, DOI 10.1016/0091-6749(81)90096-8; REISMAN RE, 1979, CLIN ALLERGY, V9, P303, DOI 10.1111/j.1365-2222.1979.tb01557.x; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SAGAWA A, 1978, J CLIN INVEST, V62, P789, DOI 10.1172/JCI109190; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; THUESON DO, 1979, J IMMUNOL, V123, P626; WARDLEY RC, 1976, IMMUNOL COMMUN, V5, P637, DOI 10.3109/08820137609033872; Winer BJ, 1971, STATISTICAL PRINCIPL, P261; YUNGINGER JW, 1978, J ALLERGY CLIN IMMUN, V61, P93, DOI 10.1016/0091-6749(78)90231-2	29	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					445	451		10.1016/0091-6749(82)90007-0	http://dx.doi.org/10.1016/0091-6749(82)90007-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6183307				2022-12-18	WOS:A1982PT74400007
J	MARX, JJ; GRAY, RL				MARX, JJ; GRAY, RL			COMPARISON OF THE ENZYME-LINKED IMMUNOSORBENT-ASSAY AND DOUBLE IMMUNODIFFUSION TEST FOR THE DETECTION AND QUANTITATION OF ANTIBODIES IN FARMERS LUNG-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MARX, JJ (corresponding author), MARSHFIELD MED FDN INC,510 N ST JOSEPH AVE,MARSHFIELD,WI 54449, USA.							BAMDAD S, 1980, CLIN ALLERGY, V10, P161, DOI 10.1111/j.1365-2222.1980.tb02093.x; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; FLAHERTY DK, 1974, J LAB CLIN MED, V84, P298; HOLMBERG K, 1980, J INFECT DIS, V141, P656, DOI 10.1093/infdis/141.5.656; KURUP VP, 1977, INFECT IMMUN, V15, P608, DOI 10.1128/IAI.15.2.608-613.1977; MANTYJARVI RA, 1980, CLIN ALLERGY, V10, P187, DOI 10.1111/j.1365-2222.1980.tb02096.x; MARX JJ, 1978, J ALLERGY CLIN IMMUN, V62, P185, DOI 10.1016/0091-6749(78)90105-7; MARX JJ, 1975, J CLIN MICROBIOL, V1, P480, DOI 10.1128/JCM.1.5.480-482.1975; MOORE VL, 1975, J LAB CLIN MED, V85, P540; NIELSEN KH, 1973, J IMMUNOL METHODS, V3, P301, DOI 10.1016/0022-1759(73)90025-2; OJANEN TH, 1980, ALLERGY, V35, P537, DOI 10.1111/j.1398-9995.1980.tb01801.x; PATTERSON R, 1976, AM REV RESPIR DIS, V114, P315; Pepys J, 1969, Monogr Allergy, V4, P1; ROBERTS RC, 1977, J LAB CLIN MED, V90, P1076; ROBERTS RC, 1976, J ALLERGY CLIN IMMUN, V57, P518, DOI 10.1016/0091-6749(76)90002-6; ROBERTS RC, 1977, AM REV RESPIR DIS, V116, P1075; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; TREUHAFT MW, 1979, AM REV RESPIR DIS, V119, P571; WENZEL FJ, 1974, AM REV RESPIR DIS, V109, P464; [No title captured]	21	25	25	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	2					109	113		10.1016/0091-6749(82)90237-8	http://dx.doi.org/10.1016/0091-6749(82)90237-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PB591	6808046				2022-12-18	WOS:A1982PB59100006
J	DAVIS, RS; REMIGIO, LK; SCHOCKET, AL; BOCK, SA				DAVIS, RS; REMIGIO, LK; SCHOCKET, AL; BOCK, SA			EVALUATION OF A PATIENT WITH BOTH AQUAGENIC AND CHOLINERGIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,SCH MED,DENVER,CO 80202	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	DAVIS, RS (corresponding author), NATL JEWISH HOSP & RES CTR,DEPT PEDIAT,DENVER,CO 80206, USA.							BONNETBLANC JM, 1979, DERMATOLOGICA, V158, P468, DOI 10.1159/000250799; CHALAMID.SL, 1971, ARCH DERMATOL, V104, P541, DOI 10.1001/archderm.104.5.541; DAMAN L, 1978, J ALLERGY CLIN IMMUN, V61, P273, DOI 10.1016/0091-6749(78)90203-8; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; Hopkins JG, 1938, ARCH DERMATOL SYPH, V38, P679, DOI 10.1001/archderm.1938.01480170003001; HULLIGER L, 1967, LANCET, V1, P1304; ILLIG L, 1969, HAUTARZT, V20, P167; JOHNSTON T G, 1959, J Am Med Assoc, V169, P23; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KOUNIS NG, 1975, ANN ALLERGY, V35, P243; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P159; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MOOREROBINSON M, 1968, BRIT J DERMATOL, V80, P794, DOI 10.1111/j.1365-2133.1968.tb11948.x; MORGAN JK, 1953, J INVEST DERMATOL, V21, P173, DOI 10.1038/jid.1953.87; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; SHELLEY WB, 1964, JAMA-J AM MED ASSOC, V189, P895; SIGLER RW, 1979, J ALLERGY CLIN IMMUN, V63, P35, DOI 10.1016/0091-6749(79)90159-3; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; TROMOVITCH TA, 1967, CALIF MED, V106, P400; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P366, DOI 10.1016/0091-6749(71)90083-2; WARIN RP, 1974, MAJOR PROBLEMS DERMA, P142; Zaruba F, 1967, Cesk Dermatol, V42, P381	24	25	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					479	483		10.1016/0091-6749(81)90202-5	http://dx.doi.org/10.1016/0091-6749(81)90202-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	7310013	Bronze			2022-12-18	WOS:A1981MU79000011
J	GRANT, JA; FINDLAY, SR; THUESON, DO; FINE, DP; KRUEGER, GG				GRANT, JA; FINDLAY, SR; THUESON, DO; FINE, DP; KRUEGER, GG			LOCAL HEAT URTICARIA-ANGIOEDEMA - EVIDENCE FOR HISTAMINE-RELEASE WITHOUT COMPLEMENT ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV UTAH,MED CTR,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	GRANT, JA (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ALLERGY,GALVESTON,TX 77550, USA.				NCRR NIH HHS [RR-73, RR-64] Funding Source: Medline; NIAID NIH HHS [AI-12621] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLOW M, 1975, LANCET, V2, P248; Beaven MA., 1975, HDB PSYCHOPHARMACOLO, V1, P253; BENTLEYPHILLIPS CB, 1976, LANCET, V2, P63; BLACK AK, 1979, LANCET, V2, P964; DAMAN L, 1978, J ALLERGY CLIN IMMUN, V61, P273, DOI 10.1016/0091-6749(78)90203-8; DELORME P, 1969, J ALLERGY, V43, P284, DOI 10.1016/0021-8707(69)90149-X; Duke WW, 1924, J AMER MED ASSOC, V83, P3, DOI 10.1001/jama.1924.02660010007002; Duke WW, 1925, J AMER MED ASSOC, V84, P736, DOI 10.1001/jama.1925.02660360018008; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; GRANT JA, 1975, J IMMUNOL, V114, P1101; GREAVES MW, 1974, BRIT J DERMATOL, V90, P289, DOI 10.1111/j.1365-2133.1974.tb06404.x; Hopkins JG, 1938, ARCH DERMATOL SYPH, V38, P679, DOI 10.1001/archderm.1938.01480170003001; Horton BT, 1936, J AMER MED ASSOC, V107, P1263, DOI 10.1001/jama.1936.02770420001001; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; LEIGH IM, 1975, BRIT J DERMATOL, V92, P191, DOI 10.1111/j.1365-2133.1975.tb03057.x; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; METZGER WJ, 1976, J ALLERGY CLIN IMMUN, V57, P605, DOI 10.1016/0091-6749(76)90012-9; RAPP HJ, 1970, MOL BASIS COMPLEMENT; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1977, FED PROC, V36, P1736; SOTER NA, 1979, INT J DERMATOL, V18, P517, DOI 10.1111/j.1365-4362.1979.tb01963.x; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; THUESON DO, 1979, J IMMUNOL, V123, P626; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WEISS NS, 1976, ANN ALLERGY, V37, P55; WILLIS I, 1974, ARCH DERMATOL, V110, P389, DOI 10.1001/archderm.110.3.389; WISE RD, 1978, ARCH DERMATOL, V114, P1079, DOI 10.1001/archderm.114.7.1079	29	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					75	77		10.1016/0091-6749(81)90049-X	http://dx.doi.org/10.1016/0091-6749(81)90049-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	6161144				2022-12-18	WOS:A1981KZ17300014
J	KULCZYCKI, A				KULCZYCKI, A			ROLE OF IMMUNOGLOBULIN-E AND IMMUNOGLOBULIN-E RECEPTORS IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOWARD HUGHES MED INST,CLIN IMMUNOL LAB,ST LOUIS,MO	Howard Hughes Medical Institute	KULCZYCKI, A (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI015322, R01AI016946] Funding Source: NIH RePORTER; NIAID NIH HHS [P50 AI 15322, R01 AI 16946] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1976, MOL BIOL ASPECTS ACU; BARKER WC, 1980, J MOL EVOL, V15, P113, DOI 10.1007/BF01732665; BECKER KE, 1973, J EXP MED, V138, P394, DOI 10.1084/jem.138.2.394; BENNICH H, 1977, INT ARCH ALLER A IMM, V53, P459, DOI 10.1159/000231784; BENNICH H, 1974, PROGR IMMUNOLOGY 2, V1; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CONRAD DH, 1976, J IMMUNOL, V116, P319; CONRAD DH, 1975, J IMMUNOL, V114, P1688; CREWS FT, 1980, BIOCHEM BIOPH RES CO, V93, P42, DOI 10.1016/S0006-291X(80)80243-9; CUEVAS M, 1977, CLIN ALLERGY, V7, P515, DOI 10.1111/j.1365-2222.1977.tb01482.x; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; DORRINGTON KJ, 1978, IMMEDIATE HYPERSENSI; FARAH FS, 1960, J EXP MED, V112, P1211, DOI 10.1084/jem.112.6.1211; FORD RM, 1969, MED J AUSTRALIA, V1, P628, DOI 10.5694/j.1326-5377.1969.tb92346.x; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HAMBURGER RN, 1975, SCIENCE, V189, P389, DOI 10.1126/science.1145208; HEMPSTEAD BL, 1981, BIOCHEM BIOPH RES CO, V98, P815, DOI 10.1016/0006-291X(81)91184-0; HEMPSTEAD BL, 1979, J IMMUNOL, V123, P2283; HENDERSON LL, 1971, J ALLERGY CLIN IMMUN, V48, P361, DOI 10.1016/0091-6749(71)90082-0; HOLOWKA D, 1980, J RECEPTOR RES, V1, P41, DOI 10.3109/10799898009039254; ISERSKY C, 1978, J IMMUNOL, V121, P549; ISERSKY C, 1974, J IMMUNOL, V112, P1909; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; ISHIZAKA K, 1969, J IMMUNOL, V103, P588; ISHIZAKA K, 1967, J IMMUNOL, V99, P610; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; ISHIZAKA T, 1978, J ALLERGY CLIN IMMUN, V61, P320, DOI 10.1016/0091-6749(78)90054-4; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; JOHANSSON SGO, 1972, PROG CLIN IMMUNOL, V1, P165; KANELLOPOULOS JM, 1980, J BIOL CHEM, V255, P9060; KANG B, 1978, ANN ALLERGY, V41, P333; KANG F, 1976, J ALLERGY CLINICAL I, V58, P357; KENNERLY DA, 1979, J EXP MED, V150, P1039, DOI 10.1084/jem.150.4.1039; KOZAK PP, 1980, ANN ALLERGY, V45, P167; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; KULCZYCKI A, 1976, J IMMUNOL, V117, P661; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; KULCZYCKI A, 1979, J BIOL CHEM, V254, P3194; KULCZYCKI A, 1979, J BIOL CHEM, V254, P3187; KULCZYCKI A, MOL IMMUNOL; LIDOR Y, 1980, ANN ALLERGY, V44, P296; LIM DT, 1980, ANN ALLERGY, V44, P267; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; MIYAMOTO T, 1980, ALLERGIC DISEASE DIA, P107; MORRISONSMITH J, 1969, BRIT MED J, V2, P723; MURRAY AB, 1980, ANN ALLERGY, V45, P347; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; NAGAYA H, 1979, ANN ALLERGY, V43, P267; NEZLIN RS, 1973, IMMUNOCHEMISTRY, V10, P681, DOI 10.1016/0019-2791(73)90211-5; OGAWA M, 1969, NEW ENGL J MED, V281, P1217, DOI 10.1056/NEJM196911272812204; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SIRAGANIAN RP, 1975, IMMUNOCHEMISTRY, V12, P149, DOI 10.1016/0019-2791(75)90111-1; SMITH JM, 1978, ALLERGY PRINCIPLES P, P635; STANWORTH DR, 1968, LANCET, V2, P17; SULLIVAN AL, 1971, J EXP MED, V134, P1403, DOI 10.1084/jem.134.6.1403; SULLIVAN TJ, 1980, CLIN IMMUNOLOGY, V1, P115; SUZUKI T, 1980, BIOCHEMISTRY-US, V19, P6037, DOI 10.1021/bi00567a014; TAKATSU K, 1975, J IMMUNOL, V114, P1838; TURNERWARWICK M, 1974, PROGR IMMUNOLOGY 2, V4, P283; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VANASPEREN PP, 1980, MED J AUSTRALIA, V2, P266; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7	71	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					5	14		10.1016/0091-6749(81)90116-0	http://dx.doi.org/10.1016/0091-6749(81)90116-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	7240599				2022-12-18	WOS:A1981LY10100002
J	MATHEWS, KP				MATHEWS, KP			MANAGEMENT OF URTICARIA AND ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MATHEWS, KP (corresponding author), UNIV MICHIGAN,MED CTR,SCH MED,DEPT INTERNAL MED,DIV ALLERGY,ANN ARBOR,MI 48109, USA.				NIAID NIH HHS [AI 14950-03] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; ALPER CA, 1970, J CLIN INVEST, V49, P1975, DOI 10.1172/JCI106417; ALPERT E, 1971, NEW ENGL J MED, V285, P185, DOI 10.1056/NEJM197107222850401; BALLOW M, 1975, LANCET, V2, P248; BECKER LC, 1973, JOHNS HOPKINS MED J, V133, P38; BENTLEYPHILLIPS CB, 1978, J INVEST DERMATOL, V71, P266, DOI 10.1111/1523-1747.ep12515101; CHODIRKER WB, 1979, CLIN ALLERGY, V9, P201, DOI 10.1111/j.1365-2222.1979.tb01542.x; COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; CURD JG, 1979, J ALLERGY CLIN IMMUN, V63, P173; CZARNETZKI BM, 1976, J INVEST DERMATOL, V67, P276, DOI 10.1111/1523-1747.ep12514261; DAMAN L, 1978, J ALLERGY CLIN IMMUN, V60, P273; DOEGLAS HMG, 1975, ARCH DERMATOL, V111, P979, DOI 10.1001/archderm.111.8.979; Donaldson V H, 1977, Trans Assoc Am Physicians, V90, P174; EFTEKHARI N, 1979, BRIT J DERMATOL, V101, P20; FARAH FS, 1971, J ALLERGY CLIN IMMUN, V48, P257, DOI 10.1016/0091-6749(71)90025-X; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; GLOVSKY MM, 1976, J ALLERGY CLIN IMMUN, V57, P134, DOI 10.1016/0091-6749(76)90032-4; GRAHAM DT, 1950, JAMA-J AM MED ASSOC, V143, P1936; GREAVES MW, 1978, LANCET, V1, P880; GREAVES MW, 1974, CLIN ALLERGY, V4, P265, DOI 10.1111/j.1365-2222.1974.tb01384.x; Hugli T E, 1978, Contemp Top Mol Immunol, V7, P181; ISAACS NJ, 1971, J ALLERGY CLIN IMMUN, V48, P73, DOI 10.1016/0091-6749(71)90089-3; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; JUHLIN L, 1977, ANN ALLERGY, V39, P356; KAPLAN AP, 1977, J ALLERGY CLIN IMMUN, V60, P324, DOI 10.1016/0091-6749(77)90113-0; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; LAURELL AB, 1977, INT ARCH ALLER A IMM, V54, P434, DOI 10.1159/000231859; Lewis T., 1927, BLOOD VESSELS HUMAN; LIEBERMAN P, 1977, ARCH INTERN MED, V137, P440, DOI 10.1001/archinte.137.4.440; MAIBACH HI, 1975, ARCH DERMATOL, V111, P726, DOI 10.1001/archderm.111.6.726; MARDER RJ, 1976, AM J MED, V61, P560, DOI 10.1016/0002-9343(76)90338-7; MATHEWS KP, 1974, MED CLIN N AM, V58, P185, DOI 10.1016/S0025-7125(16)32187-3; MATHEWS KP, 1979, J ALLERGY CLIN IMMUN, V63, P186; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; MATTHEWS CNA, 1978, BRIT J DERMATOL, V99, P455, DOI 10.1111/j.1365-2133.1978.tb06188.x; MCDUFFIE FC, 1973, MAYO CLIN PROC, V48, P340; MUCKLE TJ, 1979, BRIT J DERMATOL, V100, P87, DOI 10.1111/j.1365-2133.1979.tb03572.x; PATON WDM, 1957, PHARMACOL REV, V9, P269; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; RORSMAN H, 1962, ACTA ALLERGOL, V17, P168, DOI 10.1111/j.1398-9995.1962.tb02937.x; SCHOCKET AL, 1979, J ALLERGY CLIN IMMUN, V63, P172; SHEFFER AL, 1979, J ALLERGY CLIN IMMUN, V64, P275, DOI 10.1016/0091-6749(79)90144-1; SHELDON JM, 1954, J ALLERGY, V25, P525, DOI 10.1016/S0021-8707(54)90034-9; SHELLEY WB, 1964, JAMA-J AM MED ASSOC, V189, P895; SISSONS JGP, 1974, LANCET, V2, P1350; SOTER NA, 1974, J INVEST DERMATOL, V63, P485, DOI 10.1111/1523-1747.ep12680443; SOTER NA, 1980, J ALLERGY CLIN IMMUN, V66, P358, DOI 10.1016/0091-6749(80)90114-1; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WARIN RP, 1976, BRIT J DERMATOL, V94, P401, DOI 10.1111/j.1365-2133.1976.tb06117.x; WARIN RP, 1974, URTICARIA; 1964, BRIT MED J, V2, P643	53	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	5					347	357		10.1016/0091-6749(80)90113-X	http://dx.doi.org/10.1016/0091-6749(80)90113-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KQ965	6160171				2022-12-18	WOS:A1980KQ96500002
J	NORMAN, PS; ISHIZAKA, K; LICHTENSTEIN, LM; ADKINSON, NF				NORMAN, PS; ISHIZAKA, K; LICHTENSTEIN, LM; ADKINSON, NF			TREATMENT OF RAGWEED HAY-FEVER WITH UREA-DENATURED ANTIGEN-E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239; JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,DIV BASIC IMMUNOL,BALTIMORE,MD 21239	Johns Hopkins University; Johns Hopkins University	NORMAN, PS (corresponding author), GOOD SAMARITAN HOSP,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI004866, R01AI011202, R37AI004866, R37AI008270, R01AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 04866, AI 08270, AI 11202] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FURAKAWA CT, 1979, J ALLERGY CLIN IMMUN, V63, P145; ISHIZAKA K, 1975, J IMMUNOL, V114, P110; KING TP, 1964, BIOCHEMISTRY, V3, P456; KING TP, 1974, IMMUNOCHEMISTRY, V11, P82; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; MARSH DG, 1975, ANTIGENS, V3, P271; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TAKATSU K, 1976, J IMMUNOL, V116, P1257; TAKATSU K, 1976, J IMMUNOL, V117, P1211; TAKATSU K, 1975, J IMMUNOL, V115, P1469; TIJO AH, 1979, J IMMUNOL, V122, P2131; WIDE L, 1969, ACTA ENDOCRINOL-COP, VS 63, P207	20	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	4					336	341		10.1016/0091-6749(80)90030-5	http://dx.doi.org/10.1016/0091-6749(80)90030-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KM254	6158532				2022-12-18	WOS:A1980KM25400012
J	PATTERSON, R; TSAO, CH; SUSZKO, IM				PATTERSON, R; TSAO, CH; SUSZKO, IM			HETEROGENEITY OF BRONCHIAL LUMEN MAST-CELLS WHICH ARE HOMOGENEOUS BY ELECTRON-MICROSCOPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Northwestern University	PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,CHICAGO,IL 60611, USA.							MURATA F, 1974, AM J ANAT, V139, P335, DOI 10.1002/aja.1001390304; PATTERSON R, 1976, J LAB CLIN MED, V87, P1016; PATTERSON R, 1978, J CLIN INVEST, V62, P519, DOI 10.1172/JCI109155; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; PATTERSON R, 1977, J CLIN INVEST, V59, P217, DOI 10.1172/JCI108631; PATTERSON R, 1972, CLIN EXP IMMUNOL, V10, P267; PATTERSON R, 1974, CLIN EXP IMMUNOL, V16, P223; PRUZANSKY JJ, 1966, J ALLERGY, V38, P315, DOI 10.1016/0021-8707(66)90028-1; Selye H, 1965, MAST CELLS; TOMITA Y, 1974, INT ARCH ALLER A IMM, V47, P261, DOI 10.1159/000231219; TSAO C, 1976, INT ARCH ALLER A IMM, V52, P315, DOI 10.1159/000231697; YURT RW, 1977, J IMMUNOL, V118, P1201	12	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	4					278	284		10.1016/0091-6749(80)90156-6	http://dx.doi.org/10.1016/0091-6749(80)90156-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JN548	6153665				2022-12-18	WOS:A1980JN54800007
J	NAGEL, JE; WHITE, C; LIN, MS; FIREMAN, P				NAGEL, JE; WHITE, C; LIN, MS; FIREMAN, P			IGE SYNTHESIS IN MAN .2. COMPARISON OF TETANUS AND DIPHTHERIA IGE ANTIBODY IN ALLERGIC AND NON-ALLERGIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BARSOUM AL, 1977, Z IMMUNITATSFORSCH, V152, P388, DOI 10.1016/S0340-904X(77)80071-7; BAZARAL M, 1971, J IMMUNOL, V107, P794; BUCKLEY CE, 1970, J IMMUNOL, V105, P964; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHIORAZZI N, 1977, J IMMUNOL, V118, P48; GERRARD JW, 1974, J PEDIATR-US, V85, P660, DOI 10.1016/S0022-3476(74)80510-X; GRUNDBACHER FJ, 1976, EXPERIENTIA, V32, P1063, DOI 10.1007/BF01933973; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; HAMAOKA T, 1974, J IMMUNOL, V113, P958; ISHIZAKA K, 1972, J IMMUNOL, V109, P84; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; KIMOTO M, 1977, J IMMUNOL, V118, P840; KISHIMOTO T, 1973, J IMMUNOL, V111, P720; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; LEVINE BB, 1966, J IMMUNOL, V96, P719; NAGEL J, 1977, J IMMUNOL, V118, P334; OPREE W, 1972, ACTA ALLERGOL, V27, P247, DOI 10.1111/j.1398-9995.1972.tb01423.x; ORGEL HA, 1974, J ALLERGY CLIN IMMUN, V53, P213, DOI 10.1016/0091-6749(74)90083-9; STANNEGARD O, 1970, IMMUNOLOGY, V18, P775; TADA T, 1971, J IMMUNOL, V106, P1002	23	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	5					308	314		10.1016/0091-6749(79)90124-6	http://dx.doi.org/10.1016/0091-6749(79)90124-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GU943	107210	Bronze			2022-12-18	WOS:A1979GU94300003
J	BAMZAI, AK; KRETSCHMER, RR				BAMZAI, AK; KRETSCHMER, RR			ENHANCEMENT OF ANTIGEN-INDUCED LEUKOCYTE HISTAMINE-RELEASE BY A MONONUCLEAR CELL-DERIVED FACTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MICHAEL REESE HOSP & MED CTR,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,CHICAGO,IL 60616; UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637	Michael Reese Hospital & Medical Center; University of Chicago								AUSTEN KF, 1974, FED PROC, V33, P2256; BLAESE RM, 1971, J CLIN INVEST, V55, P2331; BLAST RC, 1970, FED P, V29, P501; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; BUSSE WW, 1976, SCIENCE, V194, P737, DOI 10.1126/science.185696; COLTEN HR, 1972, J CLIN INVEST, V51, P1927, DOI 10.1172/JCI106998; DAVID JR, 1972, PROG ALLERGY, V16, P302; DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; GALLI SJ, 1977, LANCET, V2, P409; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; GRANT JA, 1975, J IMMUNOL, V114, P1101; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; HOOK WA, 1974, INFECT IMMUN, V9, P903, DOI 10.1128/IAI.9.5.903-908.1974; HOOK WA, 1976, J IMMUNOL, V117, P594; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; KELLY MT, 1971, J CLIN INVEST, V50, P1044, DOI 10.1172/JCI106575; KOOPMAN WJ, 1970, J IMMUNOL, V105, P1096; LAPIN JH, 1958, BLOOD, V13, P1001, DOI 10.1182/blood.V13.10.1001.1001; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1131; LUCKASEN JR, 1974, ARCH DERMATOL, V110, P375, DOI 10.1001/archderm.110.3.375; MAINI RN, 1971, CLIN EXP IMMUNOL, V9, P449; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; PASS F, 1966, ANN ALLERGY, V24, P426; PATTERSON R, 1975, CLIN EXP IMMUNOL, V19, P335; PLAUT M, 1975, J CLIN INVEST, V55, P856, DOI 10.1172/JCI107997; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SARACLAR Y, 1977, J ALLERGY CLIN IMMUN, V60, P301, DOI 10.1016/0091-6749(77)90109-9; SNEDECOR GW, 1953, STATISTICAL METHODS, P138; SPITZ E, 1972, J ALLERGY CLIN IMMUN, V49, P337, DOI 10.1016/0091-6749(72)90132-7; STADECKER MJ, 1976, J IMMUNOL, V116, P1646; STRANNEGARD IL, 1976, INT ARCH ALLER A IMM, V50, P684, DOI 10.1159/000231547; THUESON DO, 1977, FED PROC, V36, P1300; VAZ N, 1974, PROG IMMUNOL, V2, P377; WAKSMAN BH, 1976, CELL IMMUNOL, V21, P161, DOI 10.1016/0008-8749(76)90337-3; WARD PA, 1975, J IMMUNOL, V114, P1523	41	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	3					137	142		10.1016/0091-6749(78)90097-0	http://dx.doi.org/10.1016/0091-6749(78)90097-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FP554	79584				2022-12-18	WOS:A1978FP55400002
J	GALANT, SP; GRONCY, CE; DURISETI, S; STRICK, L				GALANT, SP; GRONCY, CE; DURISETI, S; STRICK, L			EFFECT OF METAPROTERENOL IN CHRONIC ASTHMATIC-CHILDREN RECEIVING THERAPEUTIC DOSES OF THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,DEPT PEDIAT,IRVINE,CA 92664; SUNAIR HOME ASTHMAT CHILDREN,TUJUNGA,CA	University of California System; University of California Irvine								BRANDON ML, 1976, JAMA-J AM MED ASSOC, V235, P736, DOI 10.1001/jama.235.7.736; CAMPBELL AB, 1976, J PEDIATR-US, V89, P1020; ELLIS EF, 1976, PEDIATRICS, V58, P542; HURST A, 1973, ANN ALLERGY, V31, P460; KOPTEZKY MT, 1974, J ALLERGY CLIN IMMUN, V53, P1; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MIDDLETON E, 1973, ADV INT MED, V19, P177; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; SOUHRADA JF, 1976, PEDIATR CLIN N AM, V23, P249; TAYLOR WF, 1965, ANN ALLERGY, V23, P437; TINKELMAN DG, 1977, JAMA-J AM MED ASSOC, V237, P553, DOI 10.1001/jama.237.6.553; TINKELMAN DG, 1977, J ALLERGY CLIN IMMUN, V59, P109, DOI 10.1016/0091-6749(77)90211-1; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1974, NEW ENGL J MED, V291, P151, DOI 10.1056/NEJM197407182910310; WEINBERGER MM, P INT S CLINICAL PHA	15	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	2					73	79		10.1016/0091-6749(78)90228-2	http://dx.doi.org/10.1016/0091-6749(78)90228-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EL413	340493				2022-12-18	WOS:A1978EL41300002
J	MILLER, MM; FISH, JE; PATTERSON, R				MILLER, MM; FISH, JE; PATTERSON, R			METHACHOLINE AND PHYSOSTIGMINE AIRWAY REACTIVITY IN ASTHMATIC AND NON-ASTHMATIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MED,PULM DIS SECT,CHICAGO,IL 60611	Northwestern University; Northwestern University								BELL C, 1966, BIOCHEM PHARMACOL, V15, P1085, DOI 10.1016/0006-2952(66)90273-5; CARLYLE RF, 1963, BRIT J PHARM CHEMOTH, V21, P137, DOI 10.1111/j.1476-5381.1963.tb01509.x; COX B, 1970, J PHARM PHARMACOL, V22, P231, DOI 10.1111/j.2042-7158.1970.tb08505.x; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; GOODMAN LS, 1970, PHARMACOLOGIC BASIS; MILLER MM, 1977, INT ARCH ALLER A IMM, V53, P349, DOI 10.1159/000231771; MILLER MM, 1976, J LAB CLIN MED, V88, P995; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NADEL J A, 1973, P29; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; Snedecor G.W., 1980, STAT METHODS, V7; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429	16	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	2					116	120		10.1016/0091-6749(77)90036-7	http://dx.doi.org/10.1016/0091-6749(77)90036-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR448	874211				2022-12-18	WOS:A1977DR44800005
J	SPECTOR, SL; GARZAGOMEZ, M				SPECTOR, SL; GARZAGOMEZ, M			DOSE-RESPONSE EFFECTS OF ALBUTEROL AEROSOL COMPARED WITH ISOPROTERENOL AND PLACEBO AEROSOLS - RESPONSE TO ALBUTEROL, ISOPROTERENOL, AND PLACEBO AEROSOLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,DENVER,CO 80206	National Jewish Health								ALLIOTT RJ, 1972, BMJ-BRIT MED J, V1, P539, DOI 10.1136/bmj.1.5799.539; GANDEVIA B, 1973, MED J AUSTRALIA, V1, P273, DOI 10.5694/j.1326-5377.1973.tb119742.x; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; PALMER KNV, 1969, LANCET, V1, P591; PATERSON JW, 1968, LANCET, V2, P426; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; SHIM C, 1975, ANN INTERN MED, V83, P208, DOI 10.7326/0003-4819-83-2-208; SNIDER GL, 1972, J AMER MED ASSOC, V221, P682, DOI 10.1001/jama.221.7.682; SPECTOR SL, 1972, J ALLERGY CLIN IMMUN, V49, P128; SPECTOR SL, 1976, J ALLERGY CLIN IMMUN, V57, P499, DOI 10.1016/0091-6749(76)90067-1; SPECTOR SL, 1974, NOV P WORLD C ASTHM; SPECTOR SL, 1975, NEW DIRECTIONS ASTHM, P483; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; TATTERSFIELD AE, 1969, NEW ENGL J MED, V281, P1323, DOI 10.1056/NEJM196912112812402; VANMETRE TE, 1969, J ALLERGY, V43, P101, DOI 10.1016/0021-8707(69)90130-0; WINER BJ, 1971, STATISTICAL PRINCIPL, P539	18	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					280	286		10.1016/0091-6749(77)90048-3	http://dx.doi.org/10.1016/0091-6749(77)90048-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	321502	Bronze			2022-12-18	WOS:A1977DB88600002
J	GLEICH, GJ; LEIFERMAN, KM; JONES, RT; HOOTON, ML; BAER, H				GLEICH, GJ; LEIFERMAN, KM; JONES, RT; HOOTON, ML; BAER, H			ANALYSIS OF POTENCY OF EXTRACTS OF JUNE GRASS POLLEN BY THEIR INHIBITORY CAPACITIES IN RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERGIC DIS RES LAB,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,ALLERGIC DIS RES LAB,DEPT IMMUNOL,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,ALLERGIC DIS RES LAB,DEPT MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,ALLERGIC DIS RES LAB,DEPT MICROBIOL,ROCHESTER,MN 55901; US FDA,BUR BIOL,ROCKVILLE,MD	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; US Food & Drug Administration (FDA)								BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BECKER EL, 1948, J ALLERGY, V19, P317, DOI 10.1016/0021-8707(48)90112-9; BELIN L, 1972, INT ARCH ALLER A IMM, V42, P329, DOI 10.1159/000230616; DIXON WJ, 1969, INTRO STATISTICAL AN, P222; ELSAYED S, 1973, IMMUNOCHEMISTRY, V10, P701, DOI 10.1016/0019-2791(73)90214-0; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; MARSH DG, 1974, ALLERGOLOGIE, P381; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1	11	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					31	38		10.1016/0091-6749(76)90104-4	http://dx.doi.org/10.1016/0091-6749(76)90104-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	947976				2022-12-18	WOS:A1976BX74200004
J	NEMOTO, T; AOKI, H; IKE, A; YAMADA, K; KONDO, T; KOBAYASHI, S; INAGAWA, T				NEMOTO, T; AOKI, H; IKE, A; YAMADA, K; KONDO, T; KOBAYASHI, S; INAGAWA, T			SERUM PROSTAGLANDIN LEVELS IN ASTHMATIC-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GUNMA UNIV,SCH MED,DEPT INTERN MED 1,MAEBASHI 371,JAPAN; ONO PHARM CO LTD,RES INST,MISHIMA,JAPAN	Gunma University; Ono Pharmaceutical Co Ltd								ANGGARD E, 1965, BIOCHEM PHARMACOL, V14, P1507, DOI 10.1016/0006-2952(65)90004-3; BERGSTROM S, 1972, 3RD C PROST FERT CON; BYGDEMAN M, 1971, ANN NY ACAD SCI, V180, P473, DOI 10.1111/j.1749-6632.1971.tb53215.x; CALDWELL BV, 1971, J CLIN ENDOCR METAB, V33, P171, DOI 10.1210/jcem-33-2-171; CUTHBERT MF, 1971, P ROY SOC MED, V64, P15, DOI 10.1177/003591577106400108; HORTON EW, 1969, PHYSIOL REV, V49, P122, DOI 10.1152/physrev.1969.49.1.122; JAFFE BM, 1971, SCIENCE, V171, P494, DOI 10.1126/science.171.3970.494; JUBIZ W, 1972, PROSTAGLANDINS, V2, P477; KITAMURA S, 1973, FED PROC, V32, P341; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; PIPER P, 1971, ANN NY ACAD SCI, V180, P363, DOI 10.1111/j.1749-6632.1971.tb53205.x; SWEATMAN WJ, 1968, NATURE, V217, P69, DOI 10.1038/217069a0; WUTHIER RE, 1966, J LIPID RES, V7, P558	13	25	25	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	2					89	94		10.1016/0091-6749(76)90028-2	http://dx.doi.org/10.1016/0091-6749(76)90028-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BE952	1249354				2022-12-18	WOS:A1976BE95200001
J	SOLOMON, WR				SOLOMON, WR			VOLUMETRIC STUDIES OF AEROALLERGEN PREVALENCE .1. POLLENS OF WEEDY FORBS AT A MIDWESTERN STATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH MED,DEPT INTERN MED,ALLERGY SECT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								Gregory P.H., 1973, MICROBIOLOGY ATMOSPH, V2nd; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; HYDE H. A., 1959, ACTA ALLERGOL, V13, P186, DOI 10.1111/j.1398-9995.1959.tb02764.x; Johansen DA., 1940, PLANT MICROTECHNIQUE; OGDEN EC, 1960, J ALLERGY, V31, P307, DOI 10.1016/0021-8707(60)90067-8; OGDEN EC, 1966, 6 U STAT NEW YORK PR; SHELDON JM, 1959, 6 U MICH RES I PROGR; SOLOMON WR, 1969, J ALLERGY, V44, P25, DOI 10.1016/0021-8707(69)90045-8; SOLOMON WR, 1970, J ALLERGY, V45, P99; SOLOMON WR, 1968, J ALLERGY, V41, P290, DOI 10.1016/0021-8707(68)90034-8; SOLOMON WR, 1967, MANUAL CLINICAL AL 1, pCH16; SOLOMON WR, TO BE PUBLISHED; WALDBOTT GL, 1931, J DETROIT COLL MED S, V2, P3; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; [No title captured]	15	25	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					318	327		10.1016/0091-6749(76)90088-9	http://dx.doi.org/10.1016/0091-6749(76)90088-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	944204				2022-12-18	WOS:A1976BM68900005
J	KOLOTKIN, BM; LEE, CK; TOWNLEY, RG				KOLOTKIN, BM; LEE, CK; TOWNLEY, RG			DURATION AND SPECIFICITY OF SODIUM CROMOLYN ON ALLERGEN INHALATION CHALLENGES IN ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,DEPT MED,OMAHA,NB 68178	Creighton University								ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; ANAND SC, 1972, ANN ALLERGY, V30, P64; BOOIJNOO.H, 1970, J ALLERGY, V46, P1, DOI 10.1016/0021-8707(70)90055-9; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; COX JSG, 1970, RESPIRATION, V27, P292, DOI 10.1159/000192762; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; COX JSG, 1970, REV CHEMISTRY PHARMA, pCH2; FERRIS BG, 1965, AM REV RESPIR DIS, V91, P252; HERXHEIMER H, 1969, BMJ-BRIT MED J, V2, P220, DOI 10.1136/bmj.2.5651.220; MOLK L, 1972, ANN ALLERGY, V30, P321; ORR T S C, 1970, Clinical and Experimental Immunology, V7, P745; PEPYS J, 1968, LANCET, V2, P134; RYO UY, 1971, J ALLERGY, V47, P96; SHEARD P, 1970, INT ARCH ALLER A IMM, V38, P217, DOI 10.1159/000230274	15	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	5					288	297		10.1016/0091-6749(74)90108-0	http://dx.doi.org/10.1016/0091-6749(74)90108-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S9114	4207119				2022-12-18	WOS:A1974S911400006
J	MENDES, E; RAPHAEL, A; MOTA, NGS; MENDES, NF				MENDES, E; RAPHAEL, A; MOTA, NGS; MENDES, NF			CELL-MEDIATED-IMMUNITY IN LEPROSY AND TRANSFER OF DELAYED-HYPERSENSITIVITY REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SAO PAULO, FAC MED, HOSP CLIN, DEPT CLIN MED, SECCAO ALERGIA, SAO PAULO, BRAZIL	Universidade de Sao Paulo								BECHELLI LM, 1966, ACTA LEPROLOGICA, V25, P1; BUCK AA, 1963, AM J HYG, V77, P305, DOI 10.1093/oxfordjournals.aje.a120321; BULLOCK WE, 1972, NEW ENGL J MED, V287, P1053, DOI 10.1056/NEJM197211232872101; BULLOCK WE, 1968, NEW ENGL J MED, V278, P298, DOI 10.1056/NEJM196802082780603; DIERKS RE, 1968, P SOC EXP BIOL MED, V127, P391, DOI 10.3181/00379727-127-32698; GUINTO R S, 1962, Int J Lepr, V30, P152; GUINTO RS, 1963, ANNUAL REPORT L WOOD, P3; HAN S H, 1971, International Journal of Leprosy and Other Mycobacterial Diseases, V39, P1; JOB CK, 1967, BRIT MED B, V23, P80; KOOIJ R, 1958, Int J Lepr, V26, P24; LAWRENCE HS, 1949, P SOC EXP BIOL MED, V71, P516, DOI 10.3181/00379727-71-17242; LAWRENCE HS, 1972, NEW ENGL J MED, V287, P1092, DOI 10.1056/NEJM197211232872110; Lim, 1972, CLIN IMMUNOL IMMUNOP, V1, P122, DOI 10.1016/0090-1229(72)90012-8; LIMA SO, 1952, CLIN TISIOL, V7, P65; MENDES E, 1971, J ALLERGY, V47, P17, DOI 10.1016/S0091-6749(71)80313-5; MENDES NF, 1971, J ALLERGY CLIN IMMUN, V48, P40, DOI 10.1016/0091-6749(71)90054-6; NELSON DS, 1971, CLIN EXP IMMUNOL, V9, P33; PARADISI ER, 1969, NEW ENGL J MED, V280, P859, DOI 10.1056/NEJM196904172801604; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; ROTBERG Abrahao, 1938, Revista Brasileira de Leprologia, V6, P245; SHEAGREN JN, 1969, ANN INTERN MED, V70, P295, DOI 10.7326/0003-4819-70-2-295; Turk J L, 1971, Adv Immunol, V13, P209, DOI 10.1016/S0065-2776(08)60185-6; TURK JL, 1969, LANCET, V2, P243; WALDORF DS, 1966, LANCET, V2, P773; WONG P C, 1971, International Journal of Leprosy and Other Mycobacterial Diseases, V39, P7; 1969, N ENGL J MED, V280, P896; 1968, N ENGL J MED, V278, P333	27	25	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	4					223	229		10.1016/0091-6749(74)90084-0	http://dx.doi.org/10.1016/0091-6749(74)90084-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S6732	4835734				2022-12-18	WOS:A1974S673200005
J	SCHUR, S; HYDE, JS; WYPYCH, JI				SCHUR, S; HYDE, JS; WYPYCH, JI			EGG-WHITE SENSITIVITY AND ATOPIC ECZEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RUSH MED CTR,DIV ALLERGY & CLIN IMMUNOL,CHICAGO,IL 60612; BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY	Rush University; Buffalo General Medical Center								ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; BLEUMINK E, 1969, INT ARCH ALLER A IMM, V35, P1; BLEUMINK E, 1971, INT ARCH ALLER A IMM, V40, P72, DOI 10.1159/000230396; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214, DOI 10.1001/archpedi.1966.02090120082007; CLENDENNING WE, 1973, J INVEST DERMATOL, V61, P233, DOI 10.1111/1523-1747.ep12676481; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; LOWELL FC, 1967, J AMER MED ASSOC, V202, P875, DOI 10.1001/jama.202.9.875; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; RATNER B, 1952, AMA AM J DIS CHILD, V83, P309, DOI 10.1001/archpedi.1952.02040070055006; ROSTENBERG A, 1971, IMMUNOLOGICAL DISEAS; Sokal Robert R., 1969, BIOMETRY; STIFLER WC, 1965, J PEDIATR-US, V66, P235; WIDE L, 1967, LANCET, V2, P1105	16	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	3					174	179		10.1016/0091-6749(74)90054-2	http://dx.doi.org/10.1016/0091-6749(74)90054-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U0308	4851796				2022-12-18	WOS:A1974U030800006
J	CHAI, H; GILBERT, A				CHAI, H; GILBERT, A			EFFECT OF ALTERNATE-DAY PREDNISONE ON WHITE BLOOD COUNT IN CHILDREN WITH CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS ASTHMA RES INST & HOSP,HOSP SERV,DENVER,CO 80204									DAUGHADAY WH, 1948, BLOOD, V3, P1342, DOI 10.1182/blood.V3.12.1342.1342; Dougherty TF, 1944, ENDOCRINOLOGY, V35, P1; HUDSON G, 1964, BRIT J HAEMATOL, V10, P122, DOI 10.1111/j.1365-2141.1964.tb00685.x; NOWELL PC, 1961, CANCER RES, V21, P1518; WINTROBE MM, 1967, CLINICAL HEMATOLOGY	5	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	2					65	70		10.1016/S0091-6749(73)80001-6	http://dx.doi.org/10.1016/S0091-6749(73)80001-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O7913	4683860				2022-12-18	WOS:A1973O791300001
J	CRIEP, LH				CRIEP, LH			ALLERGIC VASCULAR PURPURA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ACKROYD JF, 1953, AM J MED, V14, P605, DOI 10.1016/0002-9343(53)90377-5; Alexander HL, 1927, ARCH DERMATOL SYPH, V16, P322, DOI 10.1001/archderm.1927.02380030069007; BROWN A, 1946, Glasgow Med J, V27, P84; CARMEL WJ, 1956, NEW ENGL J MED, V255, P770, DOI 10.1056/NEJM195610182551608; CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; CLARK WG, 1950, BLOOD, V5, P320, DOI 10.1182/blood.V5.4.320.320; CRIEP LH, 1951, ANN INTERN MED, V34, P1219, DOI 10.7326/0003-4819-34-5-1219; CRIEP LH, 1969, CLINICAL IMMUNOLOGY; DAMESHEK W, 1953, BLOOD, V8, P282, DOI 10.1182/blood.V8.3.282.282; LOCKEY SD, 1967, PERSONAL COMMUNICATI; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; OSLER W, 1914, BRIT MED J, V1, P517; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SIEGEL J M, 1954, Postgrad Med, V15, P46; SNYDER RD, 1968, ANN ALLERGY, V26, P328; STEFANINI M, 1954, J CLIN INVEST, V33, P967; Stefanini M, 1955, HEMORRHAGIC DISORDER; WINTROBE M, 1967, CLINICAL HEMATOLOGY, P912	18	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	1					7	&		10.1016/0091-6749(71)90049-2	http://dx.doi.org/10.1016/0091-6749(71)90049-2			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J8503	4996879				2022-12-18	WOS:A1971J850300002
J	LASTER, CE; GLEICH, GJ				LASTER, CE; GLEICH, GJ			CHEMOTAXIS OF EOSINOPHILS AND NEUTROPHILS BY AGGREGATED IMMUNOGLOBULINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; COHEN S, 1971, J EXP MED, V133, P133, DOI 10.1084/jem.133.1.133; COHEN SG, 1963, P SOC EXP BIOL MED, V113, P29, DOI 10.3181/00379727-113-28266; ISHIKAWA T, 1971, J ALLERGY, V47, P101; ISHIZAKA T, 1967, J IMMUNOL, V99, P82; KAY A B, 1971, Federation Proceedings, V30, P682; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; KELLER HU, 1967, P SOC EXP BIOL MED, V126, P677; LACHMANN PJ, 1970, IMMUNOLOGY, V19, P895; LITT M, 1964, ANN NY ACAD SCI, V116, P964, DOI 10.1111/j.1749-6632.1964.tb52562.x; MACY NE, 1968, P SOC EXP BIOL MED, V128, P1098; WARD PA, 1965, J EXP MED, V122, P327, DOI 10.1084/jem.122.2.327; WARD PA, 1969, J IMMUNOL, V102, P93; WARD PA, 1969, AM J PATHOL, V54, P121; ZOLOV DM, 1969, INT ARCH ALLER A IMM, V35, P179, DOI 10.1159/000230170	16	25	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	5					297	&		10.1016/0091-6749(71)90031-5	http://dx.doi.org/10.1016/0091-6749(71)90031-5			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K7978	5285780				2022-12-18	WOS:A1971K797800007
J	Renert-Yuval, Y; Del Duca, E; Pavel, AB; Fang, M; Lefferdink, R; Wu, JN; Diaz, A; Estrada, YD; Canter, T; Zhang, N; Wagner, A; Chamlin, S; Krueger, JG; Guttman-Yassky, E; Paller, AS				Renert-Yuval, Yael; Del Duca, Ester; Pavel, Ana B.; Fang, Milie; Lefferdink, Rachel; Wu, Jianni; Diaz, Aisleen; Estrada, Yeriel D.; Canter, Talia; Zhang, Ning; Wagner, Annette; Chamlin, Sarah; Krueger, James G.; Guttman-Yassky, Emma; Paller, Amy S.			The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; maturation; pediatric; biomarkers; epidermal barrier; normal skin; T(H)2; T(H)22	T-CELLS; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; DENDRITIC CELLS; MAST-CELL; IMMUNE; RECEPTOR; BARRIER; CYTOKINE; ACTIVATION	Background: Although atopic dermatitis (AD) often presents in infancy and persists into adulthood, comparative characterization of AD skin among different pediatric age groups is lacking. Objective: We sought to define skin biopsy profiles of lesional and nonlesional AD across different age groups (0-5-year-old infants with disease duration <6 months, 6-11-year-old children, 12-17-year-old adolescents, >= 18-year-old adults) versus age appropriate controls. Methods: We performed gene expression analyses by RNA-sequencing and real-time PCR (RT-PCR) and protein expression analysis using immunohistochemistry. Results: T(H)2/T(H)22 skewing, including IL-13, CCL17/thymus and activation-regulated chemokine, IL-22, and S100As, characterized the common AD signature, with a global pathway-level enrichment across all ages. Nevertheless, specific cytokines varied widely. For example, IL-33, IL-1RL1/IL-33R, and IL-9, often associated with early atopic sensitization, showed greatest upregulations in infants. T(H)17 inflammation presented a 2-peak curve, with highest increases in infants (including IL-17A and IL-17F), followed by adults. T(H)1 polarization was uniquely detected in adults, even when compared with adolescents, with significant upregulation in adults of IFN-gamma and CXCL9/CXCL10/CXCL11. Although all AD age groups had barrier abnormalities, only adults had significant decreases in filaggrin expression. Despite the short duration of the disease, infant AD presented robust downregulations of multiple barrier-related genes in both lesional and nonlesional skin. Clinical severity scores significantly correlated with T(H)2/T(H)22-related markers in all pediatric age groups. Conclusions: The shared signature of AD across ages is T(H)2/T(H)22-skewed, yet differential expression of specific T(H)2/T(H)22-related genes, other T-H pathways, and barrier-related genes portray heterogenetic, age-specific molecular fingerprints.	[Renert-Yuval, Yael; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Renert-Yuval, Yael; Del Duca, Ester; Pavel, Ana B.; Wu, Jianni; Diaz, Aisleen; Estrada, Yeriel D.; Zhang, Ning; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA; [Renert-Yuval, Yael; Del Duca, Ester; Pavel, Ana B.; Wu, Jianni; Diaz, Aisleen; Estrada, Yeriel D.; Zhang, Ning; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA; [Del Duca, Ester] Magna Graecia Univ Catanzaro, Dept Dermatol, Catanzaro, Italy; [Pavel, Ana B.] Univ Mississippi, Dept Biomed Engn, Oxford, MS USA; [Fang, Milie; Lefferdink, Rachel; Canter, Talia; Wagner, Annette; Chamlin, Sarah; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, 676 N St Clair,Ste 1600, Chicago, IL 60611 USA	Rockefeller University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Magna Graecia University of Catanzaro; University of Mississippi; Northwestern University; Feinberg School of Medicine	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA.; Paller, AS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, 676 N St Clair,Ste 1600, Chicago, IL 60611 USA.; Paller, AS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pediat, 676 N St Clair,Ste 1600, Chicago, IL 60611 USA.	Emma.Guttman@mountsinai.org; apaller@northwestern.edu	Del Duca, Ester/AAC-2711-2022; Renert-Yuval, Yael/AAP-5414-2020	Del Duca, Ester/0000-0001-7948-8536; Renert Yuval, Dr. Yael/0000-0002-2876-3048; Canter, Talia/0000-0002-9999-1013	LEO Foundation; National Center for Advancing Translational Sciences, National Institutes of Health, through Rockefeller University [UL1TR001866]; North western University Skin Biology and Diseases Resource-based Center, National Institute of Arthritis and Musculoskeletal and Skin [P30AR075049]	LEO Foundation(LEO Pharma); National Center for Advancing Translational Sciences, National Institutes of Health, through Rockefeller University; North western University Skin Biology and Diseases Resource-based Center, National Institute of Arthritis and Musculoskeletal and Skin	This study was supported by a research grant from the LEO Foundation. Y.R.-Y. was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Rockefeller University (grant no. UL1TR001866). R.L. received salary support as a fellow from the National Psoriasis Foundation. Tissue collection was supported by the North western University Skin Biology and Diseases Resource-based Center, National Institute of Arthritis and Musculoskeletal and Skin (grant no. #P30AR075049).	Agrawal A, 2007, J IMMUNOL, V178, P6912, DOI 10.4049/jimmunol.178.11.6912; Al-Temimi MH, 2012, J AM COLL SURGEONS, V215, P503, DOI 10.1016/j.jamcollsurg.2012.06.004; Alexander H, 2018, J INVEST DERMATOL, V138, P2295, DOI 10.1016/j.jid.2018.09.001; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Black A, 2012, EUR J IMMUNOL, V42, P311, DOI 10.1002/eji.201141847; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P1329, DOI 10.1016/j.jaci.2014.06.032; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2018, ANN ALLERG ASTHMA IM, V120, P34, DOI 10.1016/j.anai.2017.09.055; Cayrol C, 2018, IMMUNOL REV, V281, P154, DOI 10.1111/imr.12619; Charfeddine C, 2020, J HUM GENET, V65, P397, DOI 10.1038/s10038-019-0711-4; Charrad R, 2017, LUNG, V195, P749, DOI 10.1007/s00408-017-0058-6; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Cork MJ, 2020, BRIT J DERMATOL, V182, P85, DOI 10.1111/bjd.18476; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Czarnowicki T, 2020, J ALLERGY CLIN IMMUN, V145, P215, DOI 10.1016/j.jaci.2019.09.031; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; Davidson WF, 2019, J ALLERGY CLIN IMMUN, V143, P894, DOI 10.1016/j.jaci.2019.01.003; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Bruin-Weller M, 2018, BRIT J DERMATOL, V178, P1083, DOI 10.1111/bjd.16156; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Fang H, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0384-y; Floudas A, 2017, J IMMUNOL, V199, P707, DOI 10.4049/jimmunol.1602185; Fujio K, 2017, CURR TOP MICROBIOL, V410, P29, DOI 10.1007/82_2017_59; Gao GG, 2017, BBA-MOL CELL BIOL L, V1862, P1197, DOI 10.1016/j.bbalip.2017.06.009; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Giuliani N, 2001, EXP GERONTOL, V36, P547, DOI 10.1016/S0531-5565(00)00220-5; Glines KR, 2019, EXPERT OPIN PHARMACO, V20, P621, DOI 10.1080/14656566.2018.1561868; Guttman-Yassky E, 2019, JAMA DERMATOL, V155, P1358, DOI 10.1001/jamadermatol.2019.2983; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Guttman-Yassky E, 2018, J INVEST DERMATOL, V138, P1467, DOI 10.1016/j.jid.2018.02.037; Guttman-Yassky E, 2016, J ALLERGY CLIN IMMUN, V137, P301, DOI 10.1016/j.jaci.2015.11.001; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Ito Y, 2009, ANN ALLERG ASTHMA IM, V103, P160, DOI 10.1016/S1081-1206(10)60170-6; Kabashima K, 2018, J ALLERGY CLIN IMMUN, V142, P1121, DOI 10.1016/j.jaci.2018.03.018; Kagami S, 2005, CLIN EXP IMMUNOL, V141, P459, DOI 10.1111/j.1365-2249.2005.02875.x; Kato A, 2014, J DERMATOL SCI, V74, P229, DOI 10.1016/j.jdermsci.2014.02.009; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Knolle J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01640; Kovarova M, 2006, J EXP MED, V203, P1161, DOI 10.1084/jem.20051701; Kumar A, 2006, IMMUNITY, V25, P213, DOI 10.1016/j.immuni.2006.06.015; Laberge S, 1998, J ALLERGY CLIN IMMUN, V102, P645, DOI 10.1016/S0091-6749(98)70282-9; Lai Chester, 2015, Lancet, V385 Suppl 1, pS59, DOI 10.1016/S0140-6736(15)60374-9; Laudanska H, 2003, Rocz Akad Med Bialymst, V48, P123; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564; Mihara R, 2019, J DERMATOL, V46, P662, DOI 10.1111/1346-8138.14934; Mold JE, 2010, SCIENCE, V330, P1695, DOI 10.1126/science.1196509; Morita E, 2010, ALLERGY, V65, P1166, DOI 10.1111/j.1398-9995.2010.02361.x; Nakazato J, 2008, PEDIAT ALLERG IMM-UK, V19, P605, DOI 10.1111/j.1399-3038.2007.00692.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Ochs HD, 2009, J ALLERGY CLIN IMMUN, V123, P977, DOI 10.1016/j.jaci.2009.03.030; Okamura T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7329; Pan Y, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109705; Pelaia C, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01514; Pitt JM, 2012, J IMMUNOL, V189, P4079, DOI 10.4049/jimmunol.1201061; Renert-Yuval Y, 2019, DERMATOL CLIN, V37, P205, DOI 10.1016/j.det.2018.12.007; Renert-Yuval Y, 2018, CURR OPIN ALLERGY CL, V18, P356, DOI 10.1097/ACI.0000000000000455; Saeki H, 2016, J DERMATOL, V43, P1117, DOI 10.1111/1346-8138.13392; Saluja R, 2015, MOL IMMUNOL, V63, P80, DOI 10.1016/j.molimm.2014.06.018; Sanyal RD, 2019, ANN ALLERG ASTHMA IM, V122, P99, DOI 10.1016/j.anai.2018.08.024; Sato T, 2013, J DERMATOL SCI, V70, P204, DOI 10.1016/j.jdermsci.2013.02.003; Seo S, 2016, IRAN J ALLERGY ASTHM, V15, P138; Silverberg JI, 2017, DERMATOL CLIN, V35, P283, DOI 10.1016/j.det.2017.02.002; Silverberg NB, 2015, CUTIS, V96, P359; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Simpson EL, 2020, JAMA DERMATOL, V156, P44, DOI 10.1001/jamadermatol.2019.3336; Simpson EL, 2018, J AM ACAD DERMATOL, V78, P863, DOI 10.1016/j.jaad.2018.01.017; Simpson EL, 2012, SEMIN CUTAN MED SURG, V31, pS6, DOI 10.1016/j.sder.2012.08.001; Smith SH, 2017, J INVEST DERMATOL, V137, P2110, DOI 10.1016/j.jid.2017.05.004; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V136, P1277, DOI 10.1016/j.jaci.2015.06.032; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Sun Y, 2017, SEMIN CELL DEV BIOL, V62, P170, DOI 10.1016/j.semcdb.2016.09.005; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Toki S, 2020, ALLERGY, V75, P1606, DOI 10.1111/all.14196; Tsai TF, 2019, J DERMATOL, V46, P825, DOI 10.1111/1346-8138.15048; Turkish AR, 2005, J BIOL CHEM, V280, P14755, DOI 10.1074/jbc.M500025200; Vandeghinste N, 2018, J INVEST DERMATOL, V138, P1555, DOI 10.1016/j.jid.2018.01.036; Vasileva E, 2018, TISSUE BARRIERS, V6, DOI 10.1080/21688370.2018.1539596; Ventura Maria Teresa, 2017, Clin Mol Allergy, V15, P21, DOI 10.1186/s12948-017-0077-0; Vukmanovic-Stejic M, 2018, J ALLERGY CLIN IMMUN, V142, P844, DOI 10.1016/j.jaci.2017.10.032; Wollenberg A, 2019, J ALLERGY CLIN IMMUN, V143, P135, DOI 10.1016/j.jaci.2018.05.029; Xu R, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/328146; Xu X, 2018, NAT IMMUNOL, V19, P547, DOI 10.1038/s41590-018-0112-4; Yi L, 2017, MUCOSAL IMMUNOL, V10, P1491, DOI 10.1038/mi.2017.10; Zadeh SA, 2017, EXP DERMATOL, V26, P352, DOI 10.1111/exd.13272; Zhang GQ, 2014, IRAN J ALLERGY ASTHM, V13, P11; Zhou LS, 2019, J ALLERGY CLIN IMMUN, V144, P144, DOI 10.1016/j.jaci.2019.01.015	93	24	24	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2021	148	1					148	163		10.1016/j.jaci.2021.01.001	http://dx.doi.org/10.1016/j.jaci.2021.01.001		JUL 2021	16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE3IE	33453290	Green Accepted			2022-12-18	WOS:000669906700023
J	Tang, HHF; Lang, A; Teo, SM; Judd, LM; Gangnon, R; Evans, MD; Lee, KE; Vrtis, R; Holt, PG; Lemanske, RF; Jackson, DJ; Holt, KE; Inouye, M; Gern, JE				Tang, Howard H. F.; Lang, Anna; Teo, Shu Mei; Judd, Louise M.; Gangnon, Ronald; Evans, Michael D.; Lee, Kristine E.; Vrtis, Rose; Holt, Patrick G.; Lemanske, Robert F., Jr.; Jackson, Daniel J.; Holt, Kathryn E.; Inouye, Michael; Gern, James E.			Developmental patterns in the nasopharyngeal microbiome during infancy are associated with asthma risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiome; children; asthma; development; birth cohort	RESPIRATORY SYNCYTIAL VIRUS; ALLERGIC SENSITIZATION; RHINOVIRUS ILLNESSES; PATHOGENIC BACTERIA; AIRWAY MICROBIOME; CHILDHOOD; INFECTION; COLONIZATION; SEVERITY; CHILDREN	Background: Studies indicate that the nasal microbiome may correlate strongly with the presence or future risk of childhood asthma. Objectives: In this study, we tested whether developmental trajectories of the nasopharyngeal microbiome in early life and the composition of the microbiome during illnesses were related to risk of childhood asthma. Methods: Children participating in the Childhood Origins of Asthma study (N = 285) provided nasopharyngeal mucus samples in the first 2 years of life, during routine healthy study visits (at 2, 4, 6, 9, 12, 18, and 24 months of age), and during episodes of respiratory illnesses, all of which were analyzed for respiratory viruses and bacteria. We identified developmental trajectories of early-life microbiome composition, as well as predominant bacteria during respiratory illnesses, and we correlated these with presence of asthma at 6, 8, 11, 13, and 18 years of age. Results: Of the 4 microbiome trajectories identified, a Staphylococcus-dominant microbiome in the first 6 months of life was associated with increased risk of recurrent wheezing by age 3 years and asthma that persisted throughout childhood. In addition, this trajectory was associated with the early onset of allergic sensitization. During wheezing illnesses, detection of rhinoviruses and predominance of Moraxella were associated with asthma that persisted throughout later childhood. Conclusion: In infancy, the developmental composition of the microbiome during healthy periods and the predominant microbes during acute wheezing illnesses are both associated with the subsequent risk of developing persistent childhood asthma.	[Tang, Howard H. F.; Teo, Shu Mei; Inouye, Michael] Baker Heart & Diabet Inst, Cambridge Baker Syst Genom Initiat, Melbourne, Vic, Australia; [Tang, Howard H. F.; Teo, Shu Mei; Inouye, Michael] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England; [Tang, Howard H. F.] Univ Melbourne, Sch Biosci, Melbourne, Vic, Australia; [Lang, Anna; Vrtis, Rose; Lemanske, Robert F., Jr.; Jackson, Daniel J.; Gern, James E.] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Gangnon, Ronald; Evans, Michael D.; Lee, Kristine E.] Univ Wisconsin, Dept Biomed Informat, Madison, WI USA; [Judd, Louise M.; Holt, Kathryn E.] Monash Univ, Cent Clin Sch, Dept Infect Dis, Melbourne, Vic, Australia; [Holt, Patrick G.] Childrens Telethon Inst, Perth, WA, Australia; [Holt, Patrick G.] Univ Western Australia, Perth, WA, Australia; [Holt, Kathryn E.] London Sch Hyg & Trop Med, Dept Infect Biol, London, England; [Inouye, Michael] Alan Turing Inst, London, England; [Lang, Anna] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA; [Evans, Michael D.] Univ Minnesota, Clin & Translat Sci Inst, Minneapolis, MN USA	University of Cambridge; University of Melbourne; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Monash University; University of Western Australia; University of London; London School of Hygiene & Tropical Medicine; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities	Gern, JE (corresponding author), K4-918 CSC,600 Highland Ave, Madison, WI 53562 USA.	gern@medicine.wisc.edu	; Holt, Patrick/H-1548-2011	Gangnon, Ronald/0000-0003-2587-6714; Inouye, Michael/0000-0001-9413-6520; Holt, Patrick/0000-0003-1193-0935; Evans, Michael/0000-0001-7449-3993; Judd, Louise/0000-0003-3613-4839	National Institutes of Health, National Heart, Lung, and Blood Institute [PO1 HL70381]; National Center for Advancing Translational Sciences [UL1TR000427]; Office of the National Institutes of Health Director [UG3/UH3 OD023282]; Australian National Health and Medical Research Council [1049539]; Australian National Health and Medical Research Council PhD scholarship	National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Office of the National Institutes of Health Director; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian National Health and Medical Research Council PhD scholarship(National Health and Medical Research Council (NHMRC) of Australia)	Supported by National Institutes of Health, National Heart, Lung, and Blood Institute (grant PO1 HL70381) , the National Center for Advancing Translational Sciences (grant UL1TR000427) , and the Office of the National Institutes of Health Director (grant no. UG3/UH3 OD023282) . M.I. was supported by the Australian National Health and Medical Research Council (grant 1049539) . H.H.F.T. was supported by an Australian National Health and Medical Research Council PhD scholarship.	Altman MC, 2019, NAT IMMUNOL, V20, P637, DOI 10.1038/s41590-019-0347-8; Anderson HM, 2017, J ALLERGY CLIN IMMUN, V139, P692, DOI 10.1016/j.jaci.2016.07.031; [Anonymous], 2015, GEN ESTIMATION EQUAT; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Baldry M, 2018, J INFECT DIS, V218, P1009, DOI 10.1093/infdis/jiy259; Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P1283, DOI 10.1164/rccm.201407-1240OC; Bin LH, 2012, J ALLERGY CLIN IMMUN, V130, P683, DOI 10.1016/j.jaci.2012.06.019; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bochkov YA, 2014, J CLIN MICROBIOL, V52, P2461, DOI 10.1128/JCM.00075-14; Bosch AATM, 2017, AM J RESP CRIT CARE, V196, P1582, DOI 10.1164/rccm.201703-0554OC; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Davis MF, 2015, J ALLERGY CLIN IMMUN, V135, P811, DOI 10.1016/j.jaci.2014.10.052; Dumas O, 2019, J ALLERGY CLIN IMMUN, V143, P1371, DOI 10.1016/j.jaci.2018.08.043; Folsgaard NV, 2013, AM J RESP CRIT CARE, V187, P589, DOI 10.1164/rccm.201207-1297OC; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Gern JE, 2012, J INFECT DIS, V206, P1342, DOI 10.1093/infdis/jis504; Hasegawa K, 2019, JAMA PEDIATR, V173, P544, DOI 10.1001/jamapediatrics.2019.0384; Huang YJ, 2014, ANN AM THORAC SOC, V11, pS78; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jackson DJ, 2009, J ALLERGY CLIN IMMUN, V124, P949, DOI 10.1016/j.jaci.2009.07.024; Jones AL, 2016, J ALLERGY CLIN IMMUN, V137, P1247, DOI 10.1016/j.jaci.2016.01.010; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Kim BS, 2018, ALLERGY, V73, P644, DOI 10.1111/all.13331; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Mansbach JM, 2016, J ALLERGY CLIN IMMUN, V137, P1909, DOI 10.1016/j.jaci.2016.01.036; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pattaroni C, 2018, CELL HOST MICROBE, V24, P857, DOI 10.1016/j.chom.2018.10.019; Piters WAAD, 2016, AM J RESP CRIT CARE, V194, P1104, DOI 10.1164/rccm.201602-0220OC; Powell EA, 2019, EBIOMEDICINE, V46, P486, DOI 10.1016/j.ebiom.2019.07.034; Rosas-Salazar C, 2018, J ALLERGY CLIN IMMUN, V142, P1447, DOI 10.1016/j.jaci.2017.10.049; Rosas-Salazar C, 2016, J INFECT DIS, V214, P1924, DOI 10.1093/infdis/jiw456; Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049; Shilts MH, 2016, MICROB ECOL, V71, P233, DOI 10.1007/s00248-015-0663-y; Singh AM, 2010, J ALLERGY CLIN IMMUN, V125, P491, DOI 10.1016/j.jaci.2009.11.026; Spaulding AR, 2013, CLIN MICROBIOL REV, V26, P422, DOI 10.1128/CMR.00104-12; Teo SM, 2018, CELL HOST MICROBE, V24, P341, DOI 10.1016/j.chom.2018.08.005; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Thorsen J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12989-7; Vrtis R, 2018, J ALLERGY CLIN IMMUN, V141, P822, DOI 10.1016/j.jaci.2017.09.027; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Wang R, 2007, NAT MED, V13, P1510, DOI 10.1038/nm1656; Zahran HS, 2018, MMWR-MORBID MORTAL W, V67, P149, DOI 10.15585/mmwr.mm6705e1	51	24	24	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2021	147	5					1683	1691		10.1016/j.jaci.2020.10.009	http://dx.doi.org/10.1016/j.jaci.2020.10.009		MAY 2021	9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RY1MN	33091409	Green Published, Bronze, Green Submitted			2022-12-18	WOS:000647680800018
J	Heymann, PW; Platts-Mills, TAE; Woodfolk, JA; Borish, L; Murphy, DD; Carper, HT; Conaway, MR; Steinke, JW; Muehling, L; Teague, WG; Kennedy, JL; Irani, AM; McGraw, MD; Early, SV; Wheatley, LM; Adams, AP; Turner, RB				Heymann, Peter W.; Platts-Mills, Thomas A. E.; Woodfolk, Judith A.; Borish, Larry; Murphy, Deborah D.; Carper, Holliday T.; Conaway, Mark R.; Steinke, John W.; Muehling, Lyndsey; Teague, W. Gerald; Kennedy, Joshua L.; Irani, Anne-Marie; McGraw, Matthew D.; Early, Stephen V.; Wheatley, Lisa M.; Adams, Amy P.; Turner, Ronald B.			Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; rhinovirus; IgE; allergy; viral infection; anti-IgE; omalizumab	VIRAL-INFECTIONS; TYPE-2 INFLAMMATION; OMALIZUMAB; EXACERBATIONS; RISK; SENSITIZATION; ILLNESSES; CELLS	Background: Rhinovirus frequently causes asthma exacerbations among children and young adults who are allergic. The interaction between allergen and rhinovirus-induced symptoms and inflammation over time is unclear. Objective: Our aim was to compare the response to an experimental inoculation with rhinovirus-16 in allergic asthmatics with the response in healthy controls and to evaluate the effects of administrating omalizumab before and during the infection. Methods: Two clinical trials were run in parallel. In one of these trials, the response to an experimental inoculation with rhinovirus-16 among asthmatics with high levels of total IgE was compared to the response in healthy controls. The other trial compared the effects of administering omalizumab versus placebo to asthmatics in a randomized, double-blind placebo-controlled investigation. The primary outcome for both trials compared lower respiratory tract symptoms (LRTSs) between study groups over the first 4 days of infection. Results: Frequent comparisons of symptoms, lung function, and blood eosinophil counts revealed differences that were more pronounced among allergic asthmatics than among controls by days 2 and 3 after virus inoculation. Additionally, an augmentation of upper respiratory tract symptom scores and LRTS scores occurred among the atopic asthmatics versus the controls during the resolution of symptoms (P < .01 for upper respiratory symptom tract scores and P < .001 for LRTS scores). The beneficial effects of administering omalizumab on reducing LRTSs and improving lung function were strongest over the first 4 days. Conclusions: LRTSs and blood eosinophil counts were augmented and lung function was reduced among allergic asthmatics early after rhinovirus inoculation but increased late in the infection during symptom resolution. The effect of administering omalizumab on the response to rhinovirus was most pronounced during the early/innate phase of the infection.	[Heymann, Peter W.; Platts-Mills, Thomas A. E.; Woodfolk, Judith A.; Borish, Larry; Murphy, Deborah D.; Carper, Holliday T.; Steinke, John W.; Muehling, Lyndsey] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Heymann, Peter W.; Murphy, Deborah D.; Carper, Holliday T.; Teague, W. Gerald] Univ Virginia, Div Pediat Resp Med, Charlottesville, VA USA; [Conaway, Mark R.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA; [Early, Stephen V.] Univ Virginia, Div Pediat Otolaryngol, Charlottesville, VA USA; [Adams, Amy P.] Univ Virginia, Dept Pharm, Charlottesville, VA USA; [Turner, Ronald B.] Univ Virginia, Dept Pediat Infect Dis, Charlottesville, VA USA; [Kennedy, Joshua L.] Univ Arkansas Med Sci, Div Allergy & Immunol, Little Rock, AR 72205 USA; [Irani, Anne-Marie] Virginia Commonwealth Univ, Div Pediat Allergy & Immunol, Richmond, VA USA; [McGraw, Matthew D.] Univ Rochester, Div Pediat Pulmonol, Rochester, NY 14627 USA; [Wheatley, Lisa M.] NIAID, Allergy Asthma & Airways Biol Branch, Div Allergy Immunol & Transplantat, 9000 Rockville Pike, Bethesda, MD 20892 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Arkansas System; University of Arkansas Medical Sciences; Virginia Commonwealth University; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Heymann, PW (corresponding author), Univ Virginia, Med Ctr, Asthma & Allerg Dis Ctr, POB 800386, Charlottesville, VA 22908 USA.	pwh5a@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health (NIH) [U01-AI100799, R01-AI20565]; Novartis Pharmaceuticals Corp; University of Virginia Children's Health Research Center;  [R01-AI052196];  [U01 AI123337];  [T32-AI007496];  [KO8AI121345];  [KL2-KL2TR000063];  [UL1TR000039];  [COBRE-P20GM121293];  [P20GM103625]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis Pharmaceuticals Corp(Novartis); University of Virginia Children's Health Research Center; ; ; ; ; ; ; ; 	Supported by the National Institutes of Health (NIH) (grants U01-AI100799 [to J.A. Woodfolk, L. Borish, T.A.E. Platts-Mills, and P. W. Heymann (Heymann and PlattsMills -co-principal investigators)] and R01-AI20565 [to T.A.E. Platts-Mills (principal investigator)]), Novartis Pharmaceuticals Corp, and the University of Virginia Children's Health Research Center. Funding for authors related to our study of rhinovirus and asthma also includes grants R01-AI052196 (to J.A. Woodfolk); U01 AI123337 (to L. Borish); T32-AI007496 (to L. Muehling); and KO8AI121345, KL2-KL2TR000063, and UL1TR000039 and COBRE-P20GM121293 and P20GM103625 (to J.L. Kennedy).	Agrawal R, 2014, CLIN EXP ALLERGY, V44, P1266, DOI 10.1111/cea.12390; Arruda E, 1996, J CLIN MICROBIOL, V34, P1277, DOI 10.1128/JCM.34.5.1277-1279.1996; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; DeMore JP, 2009, J ALLERGY CLIN IMMUN, V124, P245, DOI 10.1016/j.jaci.2009.05.030; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025; Esquivel A, 2017, AM J RESP CRIT CARE, V196, P985, DOI 10.1164/rccm.201701-0120OC; Genentech, 2007, OM XOL FULL PRESCR I; Grunberg K, 1999, AM J RESP CRIT CARE, V160, P1375; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Hansel TT, 2017, EBIOMEDICINE, V19, P128, DOI 10.1016/j.ebiom.2017.03.033; Heymann Peter W, 2005, Pediatr Infect Dis J, V24, pS217, DOI 10.1097/01.inf.0000188164.33856.f9; Heymann PW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178096; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kennedy JL, 2014, AM J RESP CRIT CARE, V189, P532, DOI 10.1164/rccm.201310-1767OC; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lehman EL, 1975, NONPARAMETRICS STAT; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Pineros YSS, 2019, AM J RESP CRIT CARE, V199, P508, DOI 10.1164/rccm.201803-0461OC; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049; Silkoff PE, 2018, J ALLERGY CLIN IMMUN, V141, P1220, DOI 10.1016/j.jaci.2017.06.027; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Turner RB, 1999, JAMA-J AM MED ASSOC, V281, P1797, DOI 10.1001/jama.281.19.1797; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396	35	24	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					545	554		10.1016/j.jaci.2020.01.035	http://dx.doi.org/10.1016/j.jaci.2020.01.035			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32018030	Green Accepted, Bronze			2022-12-18	WOS:000569168900008
J	Buchheit, KM; Dwyer, DF; Ordovas-Montanes, J; Katz, HR; Lewis, E; Vukovic, M; Lai, JY; Bankova, LG; Bhattacharyya, N; Shalek, AK; Barrett, NA; Boyce, JA; Laidlaw, TM				Buchheit, Kathleen M.; Dwyer, Daniel F.; Ordovas-Montanes, Jose; Katz, Howard R.; Lewis, Erin; Vukovic, Marko; Lai, Juying; Bankova, Lora G.; Bhattacharyya, Neil; Shalek, Alex K.; Barrett, Nora A.; Boyce, Joshua A.; Laidlaw, Tanya M.			IL-5R alpha marks nasal polyp IgG4-and IgE-expressing cells in aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; chronic rhinosinusitis; nasal polyposis; plasma cell; interleukin-5; IgG4; IgE; IL-5R alpha	HUMAN B-CELLS; CHRONIC RHINOSINUSITIS; CYTOKINE PRODUCTION; PROSTAGLANDIN D-2; CHAIN EXPRESSION; INTERLEUKIN-5; ACTIVATION; DIFFERENTIATION; RECEPTOR; ASTHMA	Background: The cause of severe nasal polyposis in aspirin-exacerbated respiratory disease (AERD) is unknown. Elevated antibody levels have been associated with disease severity in nasal polyps, but upstream drivers of local antibody production in nasal polyps are undetermined. Objective: We sought to identify upstream drivers and phenotypic properties of local antibody-expressing cells in nasal polyps from subjects with AERD. Methods: Sinus tissue was obtained from subjects with AERD, chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), CRS without nasal polyps, and controls without CRS. Tissue antibody levels were quantified via ELISA and immunohistochemistry and were correlated with disease severity. Antibody-expressing cells were profiled with single-cell RNA sequencing, flow cytometry, and immunofluorescence, with IL-5R alpha function determined through IL-5 stimulation and subsequent RNA sequencing and quantitative PCR. Results: Tissue IgE and IgG4 levels were elevated in AERD compared with in controls (P<.01 for IgE and P<.001 for IgG4 vs CRSwNP). Subjects with AERD whose nasal polyps recurred rapidly had higher IgE levels than did subjects with AERD, with slower regrowth (P=.005). Single-cell RNA sequencing revealed increased IL5RA, IGHG4, and IGHE in antibody-expressing cells from patients with AERD compared with antibody-expressing cells from patients with CRSwNP. There were more IL-5R alpha(+) plasma cells in the polyp tissue from those with AERD than in polyp tissue from those with CRSwNP (P=.026). IL-5 stimulation of plasma cells in vitro induced changes in a distinct set of transcripts. Conclusions: Our study identifies an increase in antibody-expressing cells in AERD defined by transcript enrichment of IL5RA and IGHG4 or IGHE, with confirmed surface expression of IL-5Ra and functional IL-5 signaling. Tissue IgE and IgG4 levels are elevated in AERD, and higher IgE levels are associated with faster nasal polyp regrowth. Our findings suggest a role for IL-5R alpha(+) antibody-expressing cells in facilitating local antibody production and severe nasal polyps in AERD.	[Buchheit, Kathleen M.; Dwyer, Daniel F.; Katz, Howard R.; Bankova, Lora G.; Barrett, Nora A.; Boyce, Joshua A.; Laidlaw, Tanya M.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Bhattacharyya, Neil] Harvard Med Sch, Dept Surg, Boston, MA 02115 USA; [Buchheit, Kathleen M.; Dwyer, Daniel F.; Katz, Howard R.; Lewis, Erin; Lai, Juying; Bankova, Lora G.; Barrett, Nora A.; Boyce, Joshua A.; Laidlaw, Tanya M.] Brigham & Womens Hosp, Div Allergy & Clin Immunol, Boston, MA 02115 USA; [Bhattacharyya, Neil] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA; [Ordovas-Montanes, Jose; Vukovic, Marko; Shalek, Alex K.] MIT, Inst Med Engn & Sci, Dept Chem, Cambridge, MA 02139 USA; [Ordovas-Montanes, Jose; Vukovic, Marko; Shalek, Alex K.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Ordovas-Montanes, Jose; Vukovic, Marko; Shalek, Alex K.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA USA; [Ordovas-Montanes, Jose] Boston Childrens Hosp, Div Gastroenterol, Cambridge, MA USA; [Shalek, Alex K.] Harvard Massachusetts Inst Technol Div Hlth Sci &, Cambridge, MA USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts Eye & Ear Infirmary; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Laidlaw, TM (corresponding author), Brigham & Womens Hosp, 60 Fenwood Rd,Bldg Transformat Med,Rm 5002M, Boston, MA 02115 USA.	tlaidlaw@bwh.harvard.edu			National Institutes of Health [K23HL111113, K23AI139352, R01HL128241, T32AI00730, AI078908, HL117945, R37AI052353, R01AI136041, R01HL136209, R01AI130109, R01AI134989, K08AI132723, U19AI095219]; AAAAI Foundation Faculty Development Award; Searle Scholars Program; Beckman Young Investigator Program [5U24AI118672]; Pew-Stewart Scholars; Sloan Fellowship in Chemistry; Bill and Melinda Gates Foundation; Howard Hughes Medical Institute Damon Runyon Cancer Research Foundation Fellowship [DRG-2274-16]; Richard and Susan Smith Family Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AAAAI Foundation Faculty Development Award; Searle Scholars Program; Beckman Young Investigator Program; Pew-Stewart Scholars; Sloan Fellowship in Chemistry; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Howard Hughes Medical Institute Damon Runyon Cancer Research Foundation Fellowship; Richard and Susan Smith Family Foundation	Supported by the National Institutes of Health (grants K23HL111113, K23AI139352, R01HL128241, T32AI00730, AI078908, HL117945, R37AI052353, R01AI136041, R01HL136209, R01AI130109, R01AI134989, K08AI132723, and U19AI095219) and generous contributions from the Vinik and Kaye Families. L.G.B. was supported, in part, by the AAAAI Foundation Faculty Development Award. A.K.S. was supported, in part, by the Searle Scholars Program; the Beckman Young Investigator Program; grant 5U24AI118672; the Pew-Stewart Scholars; a Sloan Fellowship in Chemistry; and the Bill and Melinda Gates Foundation. J.O.M. was supported by a Howard Hughes Medical Institute Damon Runyon Cancer Research Foundation Fellowship (DRG-2274-16) and by the Richard and Susan Smith Family Foundation.	Adjobimey T, 2010, ANN TROP MED PARASIT, V104, P455, DOI 10.1179/136485910X12786389891407; Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Barternes KR, 2005, J ALLERGY CLIN IMMUN, V116, P827, DOI 10.1016/j.jaci.2005.07.014; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Bhattacharyya N, 2007, LARYNGOSCOPE, V117, P1834, DOI 10.1097/MLG.0b013e3180caa19d; Bhattacharyya N, 2009, ANN OTO RHINOL LARYN, V118, P185, DOI 10.1177/000348940911800305; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; Cassese G, 2003, J IMMUNOL, V171, P1684, DOI 10.4049/jimmunol.171.4.1684; Chiles TC, 2004, J IMMUNOL, V173, P2901, DOI 10.4049/jimmunol.173.5.2901; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; Crestani E, 2007, J ALLERGY CLIN IMMUN, V120, P820, DOI 10.1016/j.jaci.2007.05.033; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Emslie D, 2008, J EXP MED, V205, P409, DOI 10.1084/jem.20072049; Erwin EA, 2016, J ALLERGY CLIN IMMUN, V138, P625, DOI 10.1016/j.jaci.2016.01.048; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gevaert P, 2003, ALLERGY, V58, P371, DOI 10.1034/j.1398-9995.2003.00110.x; Gevaert P, 2009, ALLERGY, V64, P725, DOI 10.1111/j.1398-9995.2008.01885.x; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hayashi H, 2016, J ALLERGY CLIN IMMUN, V137, P1585, DOI 10.1016/j.jaci.2015.09.034; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HITOSHI Y, 1990, J IMMUNOL, V144, P4218; Horikawa K, 2006, IMMUNOLOGY, V118, P497, DOI 10.1111/j.1365-2567.2006.02382.x; Hulse KE, 2015, CLIN EXP ALLERGY, V45, P328, DOI 10.1111/cea.12472; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Jeannin P, 1998, J IMMUNOL, V160, P3555; Johns CB, 2014, AM J RHINOL ALLERGY, V28, P287, DOI 10.2500/ajra.2014.28.4054; Kormelink TG, 2012, ALLERGY, V67, P1165, DOI 10.1111/j.1398-9995.2012.02866.x; Koyama T, 2019, ALLERGOL INT, V68, P216, DOI 10.1016/j.alit.2018.09.002; Laidlaw TM, 2019, LARYNGOSCOPE, V129, pE61, DOI 10.1002/lary.27564; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; McMains KC, 2006, AM J RHINOL, V20, P573, DOI 10.2500/ajr.2006.20.2913; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Ordovas-Montanes J, 2018, NATURE, V560, P649, DOI 10.1038/s41586-018-0449-8; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Poposki JA, 2017, IMMUN INFLAMM DIS, V5, P233, DOI 10.1002/iid3.161; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Shamji MH, 2019, J ALLERGY CLIN IMMUN, V143, P1067, DOI 10.1016/j.jaci.2018.09.039; Smith KA, 2015, LARYNGOSCOPE, V125, P1547, DOI 10.1002/lary.25180; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Swierczynska-Krepa M, 2014, J ALLERGY CLIN IMMUN, V134, P883, DOI 10.1016/j.jaci.2014.02.041; SZCZEKLIK A, 1992, CLIN EXP ALLERGY, V22, P283, DOI 10.1111/j.1365-2222.1992.tb03084.x; TAKATSU K, 1980, J IMMUNOL, V124, P2414; Takatsu K, 1998, CYTOKINE GROWTH F R, V9, P25, DOI 10.1016/S1359-6101(97)00034-8; Takeda K, 2019, J ALLERGY CLIN IMMUN, V143, P1163, DOI 10.1016/j.jaci.2018.07.006; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Tuttle KL, 2018, J ALLER CL IMM-PRACT, V6, P1045, DOI 10.1016/j.jaip.2018.01.038; Van Roey GA, 2017, J ALLERGY CLIN IMMUN, V140, P89, DOI 10.1016/j.jaci.2016.11.015; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2009, LARYNGOSCOPE, V119, P1753, DOI 10.1002/lary.20484; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Yang ZY, 2014, CURR OPIN IMMUNOL, V28, P64, DOI 10.1016/j.coi.2014.02.001; Zhou JB, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-72	66	24	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1574	1584		10.1016/j.jaci.2020.02.035	http://dx.doi.org/10.1016/j.jaci.2020.02.035			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32199912	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000539157800013
J	Niespodziana, K; Borochova, K; Pazderova, P; Schlederer, T; Astafyeva, N; Baranovskaya, T; Barbouche, MR; Beltyukov, E; Berger, A; Borzova, E; Bousquet, J; Bumbacea, RS; Bychkovskaya, S; Caraballo, L; Chung, KF; Custovic, A; Docena, G; Eiwegger, T; Evsegneeva, I; Emelyanov, A; Errhalt, P; Fassakhov, R; Fayzullina, R; Fedenko, E; Fomina, D; Gao, ZS; Giavina-Bianchi, P; Gotua, M; Greber-Platzer, S; Hedlin, G; Ilina, N; Ispayeva, Z; Idzko, M; Johnston, SL; Kalayci, O; Karaulov, A; Karsonova, A; Khaitov, M; Kovzel, E; Kowalski, ML; Kudlay, D; Levin, M; Makarova, S; Matricardi, PM; Nadeau, KC; Namazova-Baranova, L; Naumova, O; Nazarenko, O; O'Byrne, PM; Osier, F; Pampura, AN; Panaitescu, C; Papadopoulos, NG; Park, HS; Pawankar, R; Pohl, W; Renz, H; Riabova, K; Sampath, V; Sekerel, BE; Sibanda, E; Siroux, V; Sizyakina, LP; Sun, JL; Szepfalusi, Z; Umanets, T; Van Bever, HPS; van Hage, M; Vasileva, M; von Mutius, E; Wang, JY; Wong, GWK; Zaikov, S; Zidarn, M; Valenta, R				Niespodziana, Katarzyna; Borochova, Kristina; Pazderova, Petra; Schlederer, Thomas; Astafyeva, Natalia; Baranovskaya, Tatiana; Barbouche, Mohamed-Ridha; Beltyukov, Evgeny; Berger, Angelika; Borzova, Elena; Bousquet, Jean; Bumbacea, Roxana S.; Bychkovskaya, Snezhana; Caraballo, Luis; Chung, Kian Fan; Custovic, Adnan; Docena, Guillermo; Eiwegger, Thomas; Evsegneeva, Irina; Emelyanov, Alexander; Errhalt, Peter; Fassakhov, Rustem; Fayzullina, Rezeda; Fedenko, Elena; Fomina, Daria; Gao, Zhongshan; Giavina-Bianchi, Pedro; Gotua, Maia; Greber-Platzer, Susanne; Hedlin, Gunilla; Ilina, Natalia; Ispayeva, Zhanat; Idzko, Marco; Johnston, Sebastian L.; Kalayci, Omer; Karaulov, Alexander; Karsonova, Antonina; Khaitov, Musa; Kovzel, Elena; Kowalski, Marek L.; Kudlay, Dmitry; Levin, Michael; Makarova, Svetlana; Matricardi, Paolo Maria; Nadeau, Kari C.; Namazova-Baranova, Leyla; Naumova, Olga; Nazarenko, Oleksandr; O'Byrne, Paul M.; Osier, Faith; Pampura, Alexander N.; Panaitescu, Carmen; Papadopoulos, Nikolaos G.; Park, Hae-Sim; Pawankar, Ruby; Pohl, Wolfgang; Renz, Harald; Riabova, Ksenja; Sampath, Vanitha; Sekerel, Bulent E.; Sibanda, Elopy; Siroux, Valerie; Sizyakina, Ludmila P.; Sun, Jin-Lyu; Szepfalusi, Zsolt; Umanets, Tetiana; Van Bever, Hugo P. S.; van Hage, Marianne; Vasileva, Margarita; von Mutius, Erika; Wang, Jiu-Yao; Wong, Gary W. K.; Zaikov, Sergii; Zidarn, Mihaela; Valenta, Rudolf			Toward personalization of asthma treatment according to trigger factors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; wheeze; rhinovirus; allergen; microarray	ALLERGEN; SENSITIZATION; CHILDREN; IMMUNOTHERAPY; INFECTIONS; RESPONSES; ANTIBODY; EPITOPE; ATOPY; RISK	Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma.	[Niespodziana, Katarzyna; Borochova, Kristina; Pazderova, Petra; Schlederer, Thomas; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20,3Q, A-1090 Vienna, Austria; [Astafyeva, Natalia] Saratov State Med Univ, Dept Clin Immunol & Allergol, Saratov, Russia; [Baranovskaya, Tatiana] Belarusian Med Acad Post Diploma Studies, Minsk, BELARUS; [Barbouche, Mohamed-Ridha] Inst Pasteur Tunis, Dept Immunol, Tunis, Tunisia; [Beltyukov, Evgeny] Ural State Med Univ, Dept Fac Therapy Endocrinol Allergol & Immunol, Ekaterinburg, Russia; [Berger, Angelika] Med Univ Vienna, Comprehens Ctr Pediat, Dept Pediat & Adolescent Med, Div Neonatol Pediat Intens Care & Neuropediat, Vienna, Austria; [Borzova, Elena] Russian Med Acad Continuous Profess Educ, Dept Clin Allergol & Immunol, Moscow, Russia; [Borzova, Elena] Pirogov Russian Natl Res Med Univ, Dept Clin Genet, Res & Clin Inst Pediat, Moscow, Russia; [Borzova, Elena] IV Sechenov First State Med Univ, Dept Dermatol & Venereol, Moscow, Russia; [Bousquet, Jean] Univ Hosp, Montpellier, France; [Bousquet, Jean] MACVIA France, Montpellier, France; [Bousquet, Jean] Univ Med Berlin, Charite, Berlin, Germany; [Bousquet, Jean] Humboldt Univ, Berlin, Germany; [Bousquet, Jean] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany; [Bumbacea, Roxana S.] Univ Med & Pharm Carol Davila, Dept Allergol & Clin Immunol, Bucharest, Romania; [Bychkovskaya, Snezhana] Krasnoyarsk Med Univ, Dept Pediat, Kransnoyarsk, Russia; [Caraballo, Luis] Univ Cartagena, Inst Immunol Res, Cartagena De Indias, Colombia; [Chung, Kian Fan; Custovic, Adnan; Johnston, Sebastian L.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Chung, Kian Fan; Custovic, Adnan; Johnston, Sebastian L.] MRC, London, England; [Chung, Kian Fan; Custovic, Adnan; Johnston, Sebastian L.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Docena, Guillermo] Univ Nacl La Plata, Fac Ciencias Exactas, La Plata, Argentina; [Eiwegger, Thomas] Hosp Sick Children, Res Inst, Translat Med Program, Toronto, ON, Canada; [Eiwegger, Thomas] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Eiwegger, Thomas] Univ Toronto, Hosp Sick Children, Dept Paedriatr, Div Immunol & Allergy,Food Allergy & Anaphylaxis, Toronto, ON, Canada; [Eiwegger, Thomas] Univ Toronto, Hosp Sick Children, Dept Immunol, Div Immunol & Allergy,Food Allergy & Anaphylaxis, Toronto, ON, Canada; [Evsegneeva, Irina; Fomina, Daria; Karaulov, Alexander; Karsonova, Antonina; Riabova, Ksenja; Valenta, Rudolf] Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergy, Lab Immunopathol, Moscow, Russia; [Emelyanov, Alexander] North Western Med Univ, Dept Resp Med & Allergy, St Petersburg, Russia; [Errhalt, Peter] Univ Hosp Krems, Dept Pneumol, Krems, Austria; [Errhalt, Peter] Karl Landsteiner Univ Hlth Sci, Dept Pneumol, Krems, Austria; [Fassakhov, Rustem] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia; [Fayzullina, Rezeda] Bashkir State Med Univ, Fac Pediat, Ufa, Russia; [Fedenko, Elena; Ilina, Natalia; Khaitov, Musa; Kudlay, Dmitry; Valenta, Rudolf] NRC Inst Immunol FMBA Russia, Moscow, Russia; [Fomina, Daria] Clin Hosp 52, City Moscow Ctr Allergy & Immunol, Moscow, Russia; [Gao, Zhongshan] Zhejiang Univ, Allergy Res Ctr, Hangzhou, Peoples R China; [Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil; [Gotua, Maia] David Tvildiani Med Univ, Ctr Allergy & Immunol, Tbilisi, Georgia; [Greber-Platzer, Susanne; Szepfalusi, Zsolt] Med Univ Vienna, Comprehens Ctr Pediat, Dept Pediat & Adolescent Med, Div Pediat Pulmonol Allergol & Endocrinol, Vienna, Austria; [Hedlin, Gunilla] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Hedlin, Gunilla] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Ispayeva, Zhanat] Kazakh Natl Med Univ, Allergol Dept, Alma Ata, Kazakhstan; [Idzko, Marco] Med Univ Vienna, Dept Pneumol, Vienna, Austria; [Kalayci, Omer; Sekerel, Bulent E.] Hacettepe Univ, Pediat Allergy & Asthma Unit, Sch Med, Ankara, Turkey; [Kovzel, Elena] Nazarbayev Univ, Republ Diagnost Ctr, Dept Clin Immunol Allergol Pulmonol, Corp Fund Univ Med Ctr, Nur Sultan, Kazakhstan; [Kowalski, Marek L.] Med Univ Lodz, Dept Allergy & Immunol, Lodz, Poland; [Levin, Michael] Univ Cape Town, Div Asthma & Allergy, Cape Town, South Africa; [Makarova, Svetlana] Natl Med Res Ctr Childrens Hlth, Dept Prevent Pediat, Moscow, Russia; [Matricardi, Paolo Maria] Charite Univ Med Berlin, Dept Pediat Pulmonol Immunol & Intens Care Med, Berlin, Germany; [Nadeau, Kari C.; Sampath, Vanitha] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Namazova-Baranova, Leyla] Russian Natl Res Med Univ MoH RF, Dept Pediat, Moscow, Russia; [Naumova, Olga] Natl Acad Med Sci Ukraine, Ctr Allerg Dis Upper Resp Ways, Kiev, Ukraine; [Nazarenko, Oleksandr] Natl Med Acad Postgrad Educ, Dept Clin & Lab Allergol & Immunol, Kiev, Ukraine; [O'Byrne, Paul M.] McMaster Univ, Michael G DeGroote Sch Med, Firestone Inst Resp Hlth, Dept Med, Hamilton, ON, Canada; [Osier, Faith] KEMRI Wellcome Trust Res Programme KWTRP, Kilifi, Kenya; [Pampura, Alexander N.] Pirogov Russian Natl Res Med Univ, Dept Allergol & Clin Immunol, Russian Minist Hlth, Res & Clin Inst Pediat, Moscow, Russia; [Panaitescu, Carmen] Cty Clin Emergency Hosp Pius Branzeu, OncoGen Ctr, Timisoara, Romania; [Panaitescu, Carmen] Univ Med & Pharm V Babes, Timisoara, Romania; [Papadopoulos, Nikolaos G.] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Papadopoulos, Nikolaos G.] Natl Kapodistrian Univ Athens, Allergy Dept, Pediat Clin 2, Athens, Greece; [Park, Hae-Sim] Ajou Univ, Dept Allergy & Clin Immunol, Sch Med, Suwon, South Korea; [Pawankar, Ruby] Nippon Med Sch, Dept Pediat, Tokyo, Japan; [Pohl, Wolfgang] Hietzing Hosp, Pulm Dept, Vienna, Austria; [Pohl, Wolfgang] Hietzing Hosp, Karl Landsteiner Inst Clin & Expt Pulmol, Vienna, Austria; [Renz, Harald] Philipps Univ Marburg, Univ Giessen & Marburg Lung Ctr UGMLC, German Ctr Lung Res DZL Marburg, Inst Lab Med, Marburg, Germany; [Sibanda, Elopy] Twin Palms Med Ctr, Asthma Allergy & Immune Dysfunct Clin, Harare, Zimbabwe; [Sibanda, Elopy] Natl Univ Sci & Technol, Med Sch, Dept Pathol, Bulawayo, Zimbabwe; [Siroux, Valerie] Univ Grenoble Alpes, IAB, Team Environm Epidemiol Appl Reprod & Resp Hlth, CNRS,Inserm, Grenoble, France; [Sizyakina, Ludmila P.] Rostov Med Univ, Dept Allergol & Immunol, Rostov Na Donu, Russia; [Sun, Jin-Lyu] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Allergy & Clin Immunol, Beijing, Peoples R China; [Umanets, Tetiana] Natl Acad Med Sci, Inst Pediat Obstet & Gynecol, Dept Resp Dis & Resp Allergy Children, Kiev, Ukraine; [Van Bever, Hugo P. S.] Natl Univ Singapore, Dept Paediat, Singapore, Singapore; [van Hage, Marianne; Valenta, Rudolf] Karolinska Inst, Dept Med, Div Immunol & Allergy, Stockholm, Sweden; [van Hage, Marianne] Univ Hosp, Dept Med, Div Immunol & Allergy, Stockholm, Sweden; [Vasileva, Margarita] Reg Clin Hosp, Ctr Allergol & Clin Immunol, Khabarovsk, Russia; [von Mutius, Erika] Ludwig Maximilian Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; [von Mutius, Erika] Helmholtz Ctr Munich, Inst Asthma & Allergy Prevent, Munich, Germany; [von Mutius, Erika] German Ctr Lung Res, Munich, Germany; [Wang, Jiu-Yao] Natl Cheng Kung Univ Hosp, Coll Med, Ctr Allergy & Clin Immunol Res ACIR, Dept Pediat, Tainan, Taiwan; [Wong, Gary W. K.] Chinese Univ Hong Kong, Fac Med, Dept Paediat, Hong Kong, Peoples R China; [Zaikov, Sergii] Shupyk Natl Med Acad Postgrad Educ, Dept Phtihisiatry & Pulmonol, Kiev, Ukraine; [Zidarn, Mihaela] Univ Clin Pulm & Allerg Dis Golnik, Golnik, Slovenia; [Zidarn, Mihaela] Univ Ljubljana, Fac Med, Ljubljana, Slovenia; [Valenta, Rudolf] Karl Landsteiner Univ, Krems, Austria	Medical University of Vienna; Razumovsky Saratov State Medical University; Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Ural State Medical University; Medical University of Vienna; Pirogov Russian National Research Medical University; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Berlin Institute of Health; Carol Davila University of Medicine & Pharmacy; Krasnoyarsk State Medical University; Universidad de Cartagena; Imperial College London; University of London; King's College London; National University of La Plata; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Sechenov First Moscow State Medical University; Kazan Federal University; Bashkir State Medical University; NRC Institute of Immunology FMBA of Russia; Zhejiang University; Universidade de Sao Paulo; Medical University of Vienna; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Asfendiyarov Kazakh National Medical University; Medical University of Vienna; Hacettepe University; Nazarbayev University; Medical University Lodz; University of Cape Town; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Stanford University; National Academy of Medical Sciences of Ukraine; Shupyk National Healthcare University of Ukraine; McMaster University; Ministry of Health of the Russian Federation; Pirogov Russian National Research Medical University; Victor Babes University of Medicine & Pharmacy, Timisoara; University of Manchester; National & Kapodistrian University of Athens; Ajou University; Nippon Medical School; Hietzing Hospital; Hietzing Hospital; Philipps University Marburg; National University of Science & Technology - Zimbabwe; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Rostov State Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; National Academy of Medical Sciences of Ukraine; Institute of Pediatrics, Obstetrics & Gynecology of the National Academy of Medical Sciences of Ukraine; National University of Singapore; Karolinska Institutet; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Cheng Kung University; National Cheng Kung University Hospital; Chinese University of Hong Kong; Shupyk National Healthcare University of Ukraine; University Clinic Golnik; University of Ljubljana	Valenta, R (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20,3Q, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Ksenja, Riabova/AAU-2490-2021; Fedenko, Elena S./P-6912-2015; Emelyanov, Alexander/P-6774-2014; Gotua, Maia/ABA-1648-2021; Karaulov, Alexander V/C-2482-2016; Fassakhov, Rustem/C-5712-2018; Karsonova, Antonina V./U-8600-2017; Namazova-Baranova, Leyla/HDN-1442-2022; Beltyukov, Evgeny/AAI-1608-2020; Makarova, Svetlana/R-9616-2019; Wong, Gary WK/AAY-9207-2020; Khaitov, Musa/AAC-1516-2021; Fedenko, Elena/AAH-9814-2020; Namazova-Baranova, Leyla/C-9485-2019; Fomina, Daria/AAJ-8545-2020; Greber-Platzer, Susanne/AAT-1972-2021; Sizyakina, Ludmila/AAC-5392-2021; Evsegneeva, Irina V/U-7067-2017; Custovic, Adnan/A-2435-2012; Levin, Michael/AAT-2370-2020	Ksenja, Riabova/0000-0003-0520-0936; Fedenko, Elena S./0000-0003-3358-5087; Emelyanov, Alexander/0000-0002-8574-6869; Karaulov, Alexander V/0000-0002-1930-5424; Karsonova, Antonina V./0000-0002-8697-9816; Beltyukov, Evgeny/0000-0003-2485-2243; Makarova, Svetlana/0000-0002-3056-403X; Wong, Gary WK/0000-0001-5939-812X; Khaitov, Musa/0000-0003-4961-9640; Fedenko, Elena/0000-0003-3358-5087; Namazova-Baranova, Leyla/0000-0002-2209-7531; Fomina, Daria/0000-0002-5083-6637; Greber-Platzer, Susanne/0000-0002-3706-8370; Evsegneeva, Irina V/0000-0002-6624-1363; Custovic, Adnan/0000-0001-5218-7071; Levin, Michael/0000-0003-2439-7981; Kudlay, Dmitry/0000-0003-1878-4467; Errhalt, Peter/0000-0003-3556-4917; Pampura, Alexander/0000-0001-5039-8473; Berger, Angelika/0000-0001-8775-2405; Valenta, Rudolf/0000-0001-5944-3365; O'Byrne, Paul/0000-0003-0979-281X; Fassakhov, Rustem/0000-0001-9322-2689; Borzova, Elena/0000-0003-1587-9137; Bousquet, Jean/0000-0002-4061-4766; Zaikov, Sergii/0000-0002-9276-0490	Austrian Science Foundation (FWF); AstraZeneca; Innovation fund Denmark; Virtus Respiratory Research; Concert Pharmaceuticals; Virion Health; National Institute of Allergy and Infectious Diseases; Regeneron; FARE; Sanofi; Astellas; AImmune Therapeutics; DBV Technologies; ImmuneWorks; National Heart, Lung, and Blood Institute, NIEHS; Medimmune; Novartis; GSK; Nutricia; Boehringer Ingelheim; Gerolymatos International SA; Astra Zeneca; Chiesi; French National Research Agency (ANR); Thermo Fisher Scientific; OM Pharma S. A., B_ohringer Ingelheim International GmbH; Nestl~e Deutschland AG; Takeda; Viravaxx, Vienna, Austria;  [14];  [W03.31.0024]; MRC [MR/K002449/2, MR/S025340/1] Funding Source: UKRI	Austrian Science Foundation (FWF)(Austrian Science Fund (FWF)); AstraZeneca(AstraZeneca); Innovation fund Denmark; Virtus Respiratory Research; Concert Pharmaceuticals; Virion Health; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Regeneron(Regeneron); FARE; Sanofi; Astellas(Astellas Pharmaceuticals); AImmune Therapeutics; DBV Technologies; ImmuneWorks; National Heart, Lung, and Blood Institute, NIEHS; Medimmune(AstraZenecaMedimmune); Novartis(Novartis); GSK(GlaxoSmithKline); Nutricia(Danone Nutricia); Boehringer Ingelheim(Boehringer Ingelheim); Gerolymatos International SA; Astra Zeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc); French National Research Agency (ANR)(French National Research Agency (ANR)); Thermo Fisher Scientific; OM Pharma S. A., B_ohringer Ingelheim International GmbH; Nestl~e Deutschland AG; Takeda(Takeda Pharmaceutical Company Ltd); Viravaxx, Vienna, Austria; ; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Disclosure of potential conflict of interest K. Niespodziana receives grant support (grant no. P29398) from the Austrian Science Foundation (FWF). K. F. Chung has received honoraria for participating in advisory board meetings of GlaxoSmithKline (GSK), AstraZeneca, Novartis, Merck, Boehringer Ingelheim, and Teva regarding treatments for asthma and chronic obstructive pulmonary disease and has also been renumerated for speaking engagements. A. Custovic reports personal fees from Novartis, Regeneron, Thermo Fisher Scientific, Philips, and Sanofi, outside the submitted work. T. Eiwegger reports other fees fromDBV, grants from Innovation fund Denmark, and other fees from Regeneron, outside the submitted work; is the Co-PI or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the Allergy and Anaphylaxis Program Sickkids; is on local advisory board for ALK; and serves as associate editor for Allergy. S. L. Johnston reports board memberships of Therapeutic Frontiers and Virtus Respiratory Research and personal fees from Myelo Therapeutics GmbH, Concert Pharmaceuticals, Bayer, Synairgen, Novartis, Boehringer Ingelheim, Chiesi, Gerson Lehrman Group, resTORbio, Bioforce, MateriaMedical Holdings, PrepBio Pharma, Pulmotect, Virion Health, and Lallemand Pharma, outside the submitted work. K. C. Nadeau reports grants and other fees from the National Institute of Allergy and Infectious Diseases; other fees from Novartis; personal fees and other fees from Regeneron; grants and other fees from FARE; grants from EAT; other fees from Sanofi, Astellas, Nestle, BeforeBrands, Alladapt, ForTra, Genentech, AImmune Therapeutics, and DBV Technologies; personal fees from AstraZeneca, ImmuneWorks, and Cour; grants from Allergenis and Ukko; and other fees from AnaptysBio, Adare Pharmaceuticals, Stallergenes-Greer, the National Heart, Lung, and Blood Institute, NIEHS, EPA, and WAO Center of Excellence, outside the submitted work. P. M. O'Byrne reports grants and personal fees from AstrZeneca and Medimmune; grants from Novartis; and personal fees from GSK and Chiesi, outside the submitted work. N. G. Papadopoulos reports personal fees from Novartis, Nutricia, HAL, Menarini/FAES Farma, Sanofi, Mylan/Meda, Biomay, AstraZeneca, GSK, MSD, ASIT Biotech, and Boehringer Ingelheim and grants from Gerolymatos International SA and Capricare, outside the submitted work. W. Pohl reports personal fees from Astra Zeneca, Chiesi, GSK, Meda, Sanofi, Novartis, Teva, and Boehringer Ingelheim, outside the submitted work. V. Siroux reports grants from Aviesan Itmo sant~ee publique, the Scientific committee ``AGIR for chronic diseases,'' and the French National Research Agency (ANR), during the conduct of the study. M. van Hage reports personal fees from Thermo Fisher Scientific, ALK, and Biomay AG, Vienna, Austria, outside the submitted work. E. von Mutius reports personal fees from OM Pharma S. A., B_ohringer Ingelheim International GmbH, Peptinnovate Ltd, Pharmaventures Ltd, and Nestl~e Deutschland AG, outside the submitted work. In addition, E.; von Mutius has a patent application number LU101064, Barn dust extract for the prevention and treatment of diseases, pending; a patent publication number EP2361632: Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders; with royalties paid to Protectimmun GmbH, a patent publication number EP 1411977: Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases; licensed to Protectimmun GmbH, a patent publication number EP1637147: Stable dust extract for allergy protection; and a patent publication number EP 1964570: Pharmaceutical compound to protect against allergies and inflammatory diseases licensed to Protectimmun GmbH. M. Zidarn reports personal fees from Takeda and Novartis, outside the submitted work. R. Valenta receives grant support from the Austrian Science Foundation (FWF) and Viravaxx, Vienna, Austria. Furthermore, R. Valenta is a recipient of a megagrant of the Government of the Russian Federation (grant no. 14.W03.31.0024) and serves as a consultant forViravaxx, Vienna, Austria. In addition, S. L. Johnston, K. Niespodziana, and R. Valenta are authors of patent/patent applications related to the subject of the study. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2019, GLOB ASTHM REP 2018; Belgrave DCM, 2018, LANCET RESP MED, V6, P526, DOI 10.1016/S2213-2600(18)30099-7; Bossios A, 2008, CLIN EXP ALLERGY, V38, P1615, DOI 10.1111/j.1365-2222.2008.03058.x; Caminati M, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0192-5; Chung KF, 2019, ALLERGY, V74, P1649, DOI 10.1111/all.13771; Cipriani F, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00103; Contreras RD, 2020, J OCCUP ENVIRON HYG, V17, P30, DOI 10.1080/15459624.2019.1691219; Dhami S, 2017, ALLERGY, V72, P1825, DOI 10.1111/all.13208; Ewaltl E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27022-y; Froidure A, 2016, EUR RESPIR J, V47, P304, DOI 10.1183/13993003.01824-2014; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Hansel TT, 2013, LANCET, V381, P861, DOI 10.1016/S0140-6736(12)62202-8; Heffler E, 2019, EXPERT REV CLIN IMMU, V12, P1; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Incorvaia C, 2017, EBIOMEDICINE, V17, P16, DOI 10.1016/j.ebiom.2017.02.023; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Lee H, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00804-2019; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Megremis S, 2018, AM J RESP CRIT CARE, V198, P1490, DOI 10.1164/rccm.201803-0575OC; Nakauchi M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030216; Niespodziana K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04591-0; Niespodziana K, 2015, EBIOMEDICINE, V2, P64, DOI 10.1016/j.ebiom.2014.11.012; Niespodziana K, 2012, FASEB J, V26, P1001, DOI 10.1096/fj.11-193557; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Seth D, 2019, PEDIATR CLIN N AM, V66, P967, DOI 10.1016/j.pcl.2019.06.012; Skrindo I, 2015, PEDIAT ALLERG IMM-UK, V26, P239, DOI 10.1111/pai.12366; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; van Wijk RG, 2013, GLOBAL ATLAS ASTHMA, P18; Wickman M, 2017, EBIOMEDICINE, V26, P91, DOI 10.1016/j.ebiom.2017.11.009; Wisniewski JA, 2016, ALLERGY ASTHMA PROC, V37, P475, DOI 10.2500/aap.2016.37.3994; Xepapadaki P, 2018, PEDIAT ALLERG IMM-UK, V29, P383, DOI 10.1111/pai.12881; Zhou SS, 2018, J THORAC DIS, V10, P2059, DOI 10.21037/jtd.2018.03.103; Zieglmayer P, 2016, EBIOMEDICINE, V11, P43, DOI 10.1016/j.ebiom.2016.08.022	37	24	28	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1529	1534		10.1016/j.jaci.2020.02.001	http://dx.doi.org/10.1016/j.jaci.2020.02.001			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32081759	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000539157800005
J	Sarrabay, G; Mechin, D; Salhi, A; Boursier, G; Rittore, C; Crow, Y; Rice, G; Tran, TA; Cezar, R; Duffy, D; Bondet, V; Boudhane, L; Broca, C; Kant, BP; VanGijn, M; Grandemange, S; Richard, E; Apparailly, F; Touitou, I				Sarrabay, Guillaume; Mechin, Deborah; Salhi, Aicha; Boursier, Guilaine; Rittore, Cecile; Crow, Yanick; Rice, Gillian; Tu-Anh Tran; Cezar, Renaud; Duffy, Darragh; Bondet, Vincent; Boudhane, Lakhdar; Broca, Christophe; Kant, Benjamin P.; VanGijn, Marielle; Grandemange, Sylvie; Richard, Eric; Apparailly, Florence; Touitou, Isabelle			PSMB10, the last immunoproteasome gene missing for PRAAS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Sarrabay, Guillaume; Mechin, Deborah; Boursier, Guilaine; Rittore, Cecile; Tu-Anh Tran; Cezar, Renaud; Broca, Christophe; Grandemange, Sylvie; Apparailly, Florence; Touitou, Isabelle] Univ Montpellier, IRMB, INSERM, CHU Montpellier, Montpellier, France; [Sarrabay, Guillaume; Mechin, Deborah; Boursier, Guilaine; Rittore, Cecile; Grandemange, Sylvie; Touitou, Isabelle] Univ Montpellier, Dept Med Genet Rare Dis & Personalized Med, Rare & Autoinflammatory Dis Unit, CHU Montpellier, Montpellier, France; [Salhi, Aicha] Alger Med Univ, Dept Dermatol, Algiers, Algeria; [Crow, Yanick] Paris Descartes Univ, Inst Imagine, Lab Neurogenet & Neuroinflammat, Paris, France; [Rice, Gillian] Univ Manchester, Div Evolut & Genom Sci, Sch Biol Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Tu-Anh Tran; Cezar, Renaud] Univ Montpellier, Dept Immunol, CHU Nimes, Nimes, France; [Tu-Anh Tran] Univ Hosp Nimes, Dept Paediat, Nimes, France; [Duffy, Darragh; Bondet, Vincent] Inst Pasteur, ICD Unit, INSERM, U1223, Paris, France; [Kant, Benjamin P.; VanGijn, Marielle] Univ Med Ctr Utrecht, Dept Genet, Utrecht, Netherlands; [Richard, Eric] Univ Montpellier, Inst Rech Cancerol Montpellier, INSERM, U1194,Inst Reg Canc Montpellier, Montpellier, France; [Apparailly, Florence] Univ Hosp Lapeyronie, Clin Dept Osteoarticular Dis & Biotherapy, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; UDICE-French Research Universities; Universite Paris Cite; University of Manchester; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Nimes; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Utrecht University; Utrecht University Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Montpellier	Sarrabay, G (corresponding author), Univ Montpellier, IRMB, INSERM, CHU Montpellier, Montpellier, France.; Sarrabay, G (corresponding author), Univ Montpellier, Dept Med Genet Rare Dis & Personalized Med, Rare & Autoinflammatory Dis Unit, CHU Montpellier, Montpellier, France.	guillaume.sarrabay@inserm.fr	APPARAILLY, Florence/AAU-5489-2020	APPARAILLY, Florence/0000-0003-1762-084X; Grandemange, Sylvie/0000-0002-8373-6798; Sarrabay, Guillaume/0000-0002-9943-9368	Institut National de la Sante et Recherche Medicale; University of Montpellier; French Ministry of Health; European INSAID project; E-Rare-3 program [9003037603]	Institut National de la Sante et Recherche Medicale; University of Montpellier; French Ministry of Health; European INSAID project; E-Rare-3 program	This work was supported by Institut National de la Sante et Recherche Medicale, the University of Montpellier, the French Ministry of Health, the European INSAID project, and the E-Rare-3 program (grant no. 9003037603).	Agarwal AK, 2010, AM J HUM GENET, V87, P866, DOI 10.1016/j.ajhg.2010.10.031; Davidson S, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0748-y; de Jesus AA, 2019, J ALLERGY CLIN IMMUN, V143, P1939, DOI 10.1016/j.jaci.2018.12.1012; Eijkelenboom A, 2016, J MOL DIAGN, V18, P851, DOI 10.1016/j.jmoldx.2016.06.010; Ladi E, 2019, J MED CHEM, V62, P7032, DOI 10.1021/acs.jmedchem.9b00509; Manthiram K, 2017, NAT IMMUNOL, V18, P832, DOI 10.1038/ni.3777; O'Roak BJ, 2012, SCIENCE, V338, P1619, DOI 10.1126/science.1227764; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Poli MC, 2018, AM J HUM GENET, V102, P1126, DOI 10.1016/j.ajhg.2018.04.010; Rodero MP, 2017, J EXP MED, V214, P1547, DOI 10.1084/jem.20161451; Treise I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24199-0; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	12	24	24	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					1015	+		10.1016/j.jaci.2019.11.024	http://dx.doi.org/10.1016/j.jaci.2019.11.024			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31783057	Green Submitted, Bronze			2022-12-18	WOS:000518756700044
J	Lowe, KE; Mansfield, KE; Delmestri, A; Smeeth, L; Roberts, A; Abuabara, K; Prieto-Alhambra, D; Langan, SM				Lowe, Katherine E.; Mansfield, Kathryn E.; Delmestri, Antonella; Smeeth, Liam; Roberts, Amanda; Abuabara, Katrina; Prieto-Alhambra, Daniel; Langan, Sinead M.			Atopic eczema and fracture risk in adults: A population-based cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic eczema; fracture; osteoporosis; population based; severity	BONE-MINERAL DENSITY; ORAL CORTICOSTEROIDS; DERMATITIS; OSTEOPOROSIS; GUIDELINES; EXPOSURE; CHILDREN; HEALTH	Background: Limited evidence suggests increased fracture risk in people with atopic eczema. Any link could have substantial effect; atopic eczema is common, and fractures have associated morbidity and mortality. Objective: We sought to examine whether atopic eczema is associated with fracture and whether fracture risk varies with eczema severity. Methods: We performed a matched cohort study set in primary care (Clinical Practice Research Datalink GOLD 1998-2016) and linked hospital admissions data (Hospital Episode Statistics), including adults (>18 years old) with atopic eczema matched (by age, sex, general practice, and cohort entry date) with up to 5 individuals without eczema. We estimated hazard ratios (HRs) from stratified Cox regression comparing risk of major osteoporotic (hip, pelvis, spine, wrist, and proximal humerus) fractures individually and any fracture in those with and without atopic eczema. Results: We identified 526,808 people with atopic eczema and 2,569,030 people without atopic eczema. Those with eczema had increased risk of hip (HR, 1.10; 99% CI, 1.06-1.14), pelvic (HR, 1.10; 99% CI, 1.02-1.19), spinal (HR, 1.18; 99% CI, 1.10-1.27), and wrist (HR, 1.07; 99% CI, 1.03,-1.11) fractures. We found no evidence of increased proximal humeral (HR, 1.06; 99% CI, 0.97-1.15) fracture risk. Fracture risk increased with increasing eczema severity, with the strongest associations in people with severe eczema (compared with those without) for spinal (HR, 2.09; 99% CI, 1.66-2.65), pelvic (HR, 1.66; 99% CI, 1.26-2.20), and hip (HR, 1.50; 99% CI, 1.30-1.74) fractures. Associations persisted after oral glucocorticoid adjustment. Conclusions: People with atopic eczema have increased fracture risk, particularly major osteoporotic fractures.	[Lowe, Katherine E.; Mansfield, Kathryn E.; Smeeth, Liam; Langan, Sinead M.] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, Keppel St, London WC1E 7HT, England; [Delmestri, Antonella; Prieto-Alhambra, Daniel] Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Abuabara, Katrina] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Langan, Sinead M.] Hlth Data Res UK, London, England; [Lowe, Katherine E.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA; [Roberts, Amanda] Nottingham Support Grp Carers Children Eczema, Nottingham, England	University of London; London School of Hygiene & Tropical Medicine; University of Oxford; University of California System; University of California San Francisco; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus	Mansfield, KE (corresponding author), London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, Keppel St, London WC1E 7HT, England.	kathryn.mansfield@ac.uk	Smeeth, Liam/X-5862-2018	Smeeth, Liam/0000-0002-9168-6022; Langan, Sinead/0000-0002-7022-7441; Lowe, Katherine/0000-0003-4111-1789; Delmestri, Antonella/0000-0003-0388-3403	Wellcome Trust [205039/Z/16/Z]; Health Data ResearchUK - UK Medical Research Council [LOND1]; Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission); Health Data ResearchUK - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by a Wellcome Trust Senior Research Fellowship in Clinical Science to SML (reference 205039/Z/16/Z). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funders. This work was also supported by Health Data ResearchUK (reference LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome Trust.	AALTOKORTE K, 1995, BRIT J DERMATOL, V133, P403, DOI 10.1111/j.1365-2133.1995.tb02668.x; AaltoKorte K, 2008, BRIT J DERMATOL, V136, P172; Abrahamsen B, 2009, OSTEOPOROSIS INT, V20, P1633, DOI 10.1007/s00198-009-0920-3; Abuabara K, 2017, J INVEST DERMATOL, V137, P1655, DOI 10.1016/j.jid.2017.03.029; [Anonymous], HOSP EP STAT; Armour KJ, 2003, METH MOLEC MED, V80, P353; Carroll CL, 2005, PEDIATR DERMATOL, V22, P192, DOI 10.1111/j.1525-1470.2005.22303.x; Cho H, 2018, OSTEOPOROSIS INT, V29, P2163, DOI 10.1007/s00198-018-4564-z; Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657-017-0324-5; Curry SJ, 2018, JAMA-J AM MED ASSOC, V319, P2521, DOI 10.1001/jama.2018.7498; Delmas PD, 2005, J BONE MINER RES, V20, P557, DOI 10.1359/JBMR.041214; Donaldson LJ, 2008, J EPIDEMIOL COMMUN H, V62, P174, DOI 10.1136/jech.2006.056622; Drucker AM, 2018, BRIT J DERMATOL, V178, P768, DOI 10.1111/bjd.15928; Garg N, 2015, JAMA DERMATOL, V151, P33, DOI 10.1001/jamadermatol.2014.2098; Garg NK, 2015, J ALLERGY CLIN IMMUN, V135, P1085, DOI 10.1016/j.jaci.2014.10.043; Haeck IM, 2009, BRIT J DERMATOL, V161, P1248, DOI 10.1111/j.1365-2133.2009.09327.x; Haeck I, 2012, CHEM IMMUNOL ALLERGY, V96, P96, DOI 10.1159/000331893; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; HippisleyCox J, 2012, BMJ-BRIT MED J, V345, P1; Hon KLE, 2006, CLIN EXP DERMATOL, V31, P187, DOI 10.1111/j.1365-2230.2005.02002.x; Jordan H, 2004, J EPIDEMIOL COMMUN H, V58, P250, DOI 10.1136/jech.2003.013011; Kanis JA, 2004, BONE, V35, P375, DOI 10.1016/j.bone.2004.03.024; Kanis JA, 2009, BONE, V44, P734, DOI 10.1016/j.bone.2009.01.373; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; National Clinical Guideline Centre, 2012, OSTEOPOROSIS ASSESSI; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1176, DOI 10.1111/j.1468-3083.2012.04636.x; Rothman KJ, 2010, EUR J EPIDEMIOL, V25, P223, DOI 10.1007/s10654-010-9437-5; Scottish Intercollegiate Guidelines Network, 2015, SIGN 142 MAN OST PRE; Silverberg JI, 2015, J INVEST DERMATOL, V135, P56, DOI 10.1038/jid.2014.325; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; van Staa TP, 2006, ARTHRITIS RHEUM-US, V54, P3104, DOI 10.1002/art.22117; van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383; Van Staa TP, 2005, J BONE MINER RES, V20, P1486, DOI 10.1359/jbmr.2005.20.8.1486; Van Staa TP, 2003, GASTROENTEROLOGY, V125, P1591, DOI 10.1053/j.gastro.2003.09.027; Van Staa TP, 2000, PHARMACOEPIDEM DR S, V9, P359, DOI 10.1002/1099-1557(200009/10)9:5<359::AID-PDS507>3.0.CO;2-E; Vandenbroucke J, 2015, AM J EPIDEMIOL, V182, P826, DOI 10.1093/aje/kwv225; Wollenberg A, 2018, J EUR ACAD DERMATOL, V32, P850, DOI 10.1111/jdv.14888; Wu CK, 2017, PLOS ONE, V12, P1	39	24	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					563	+		10.1016/j.jaci.2019.09.015	http://dx.doi.org/10.1016/j.jaci.2019.09.015			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31757515	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000512887400019
J	Ross, KR; Gupta, R; DeBoer, MD; Zein, J; Phillips, BR; Mauger, DT; Li, C; Myers, RE; Phipatanakul, W; Fitzpatrick, AM; Ly, NP; Bacharier, LB; Jackson, DJ; Celedon, JC; Larkin, A; Israel, E; Levy, B; Fahy, JV; Castro, M; Bleecker, ER; Meyers, D; Moore, WC; Wenzel, SE; Jarjour, NN; Erzurum, SC; Teague, WG; Gaston, B				Ross, Kristie R.; Gupta, Ritika; DeBoer, Mark D.; Zein, Joe; Phillips, Brenda R.; Mauger, David T.; Li, Chun; Myers, Ross E.; Phipatanakul, Wanda; Fitzpatrick, Anne M.; Ly, Ngoc P.; Bacharier, Leonard B.; Jackson, Daniel J.; Celedon, Juan C.; Larkin, Allyson; Israel, Elliot; Levy, Bruce; Fahy, John, V; Castro, Mario; Bleecker, Eugene R.; Meyers, Deborah; Moore, Wendy C.; Wenzel, Sally E.; Jarjour, Nizar N.; Erzurum, Serpil C.; Teague, W. Gerald; Gaston, Benjamin			Severe asthma during childhood and adolescence: A longitudinal study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; lung function; eosinophilia; adolescence	LUNG-FUNCTION; SEX; TESTOSTERONE; OBESITY; DEHYDROEPIANDROSTERONE; PERSISTENCE; REMISSION; FEATURES; GENDER; GROWTH	Background: Morbidity and mortality associated with childhood asthma are driven disproportionately by children with severe asthma. However, it is not known from longitudinal studies whether children outgrow severe asthma. Objective: We sought to study prospectively whether well-characterized children with severe asthma outgrow their asthma during adolescence. Methods: Children with asthma were assessed at baseline with detailed questionnaires, allergy tests, and lung function tests and were reassessed annually for 3 years. The population was enriched for children with severe asthma, as assessed by the American Thoracic Society/European Respiratory Society guidelines, and subject classification was reassessed annually. Results: At baseline, 111 (59%) children had severe asthma. Year to year, there was a decrease in the proportion meeting the criteria for severe asthma. After 3 years, only 30% of subjects met the criteria for severe asthma (P < .001 compared with enrollment). Subjects experienced improvements in most indices of severity, including symptom scores, exacerbations, and controller medication requirements, but not lung function. Surprisingly, boys and girls were equally likely to has resolved asthma (33% vs 29%). The odds ratio in favor of resolution of severe asthma was 2.75 (95% CI, 1.02-7.43) for those with a peripheral eosinophil count of greater than 436 cells/mu L. Conclusions: In longitudinal analysis of this well-characterized cohort, half of the children with severe asthma no longer had severe asthma after 3 years; there was a stepwise decrease in the proportion meeting severe asthma criteria. Surprisingly, asthma severity decreased equally in male and female subjects. Peripheral eosinophilia predicted resolution. These data will be important for planning clinical trials in this population.	[Ross, Kristie R.; Li, Chun; Myers, Ross E.; Gaston, Benjamin] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [DeBoer, Mark D.; Teague, W. Gerald] Univ Virginia, Dept Pediat, Charlottesville, VA USA; [Zein, Joe; Erzurum, Serpil C.] Cleveland Clin, Dept Pathobiol, Lerner Res Inst, Cleveland, OH 44106 USA; [Zein, Joe; Erzurum, Serpil C.] Cleveland Clin, Dept Pulm & Crit Care Med, Resp Inst, Cleveland, OH 44106 USA; [Phillips, Brenda R.; Mauger, David T.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Med Ctr, Asthma Inst, Pittsburgh, PA USA; [Celedon, Juan C.; Larkin, Allyson] UPMC, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA USA; [Phipatanakul, Wanda; Israel, Elliot; Levy, Bruce] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Fitzpatrick, Anne M.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Ly, Ngoc P.; Fahy, John, V] Univ Calif San Francisco, Dept Pediat, San Francisco Sch Med, San Francisco, CA USA; [Bacharier, Leonard B.; Castro, Mario] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Jackson, Daniel J.; Jarjour, Nizar N.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Bleecker, Eugene R.; Meyers, Deborah] Univ Arizona Hlth Sci, Dept Med, Tucson, AZ USA; [Moore, Wendy C.] Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27103 USA; [Gupta, Ritika] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University of Virginia; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; Emory University; University of California System; University of California San Francisco; Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; University of Arizona; University of Arizona Health Sciences; Wake Forest University; Wake Forest Baptist Medical Center; Case Western Reserve University	Gaston, B (corresponding author), Wells Ctr Pediat Res, 1044 West Walnut Stree, Indianapolis, IN 46202 USA.	begaston@iu.edu	Gupta, Ritika/GZL-2385-2022	Wenzel, Sally/0000-0002-4242-0164; Bacharier, Leonard/0000-0003-0432-2704; Myers, Ross/0000-0002-9494-3653	 [1U10HL109250]		Supported by grant 1U10HL109250 (SARP III) and SARP ClinicalTrials.gov number NCT01606826.	Al-Alwan A, 2014, AM J RESP CRIT CARE, V189, P1494, DOI 10.1164/rccm.201401-0178OC; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; Berry CE, 2016, AM J RESP CRIT CARE, V194, P607, DOI 10.1164/rccm.201604-0753OC; Cephus JY, 2017, CELL REP, V21, P2487, DOI 10.1016/j.celrep.2017.10.110; Chen YC, 2016, J ASTHMA, V54, P279; Chipps BE, 2018, J ALLERGY CLIN IMMUN, V141, P1590, DOI 10.1016/j.jaci.2017.07.014; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; DeBoer MD, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0612-x; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Forno E, 2017, AM J RESP CRIT CARE, V195, P314, DOI 10.1164/rccm.201605-1039OC; Fuseini H, 2018, J IMMUNOL, V201, P1843, DOI 10.4049/jimmunol.1800293; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Han MLK, 2018, AM J RESP CRIT CARE, V198, P850, DOI 10.1164/rccm.201801-0168WS; Holguin F, 2013, AM J RESP CRIT CARE, V187, P153, DOI 10.1164/rccm.201207-1270OC; Huang TTK, 2001, OBES RES, V9, P283, DOI 10.1038/oby.2001.35; Kouloumenta V, 2016, BRIT J PHARMACOL, V149, P1083; Koziol-White CJ, 2012, BBA-MOL BASIS DIS, V1822, P1638, DOI 10.1016/j.bbadis.2012.06.012; Lang A, 2008, ALLERGY, V63, P1054, DOI 10.1111/j.1398-9995.2008.01672.x; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; MARTIN TR, 1987, J APPL PHYSIOL, V63, P2042, DOI 10.1152/jappl.1987.63.5.2042; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McGeachie MJ, 2016, NEW ENGL J MED, V374, P1842, DOI 10.1056/NEJMoa1513737; Mendoza-Milla C, 2013, EUR RESPIR J, V42, P1309, DOI 10.1183/09031936.00027412; Mohan SS, 2015, CLIN ENDOCRINOL, V83, P268, DOI 10.1111/cen.12738; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Phipatanakul W, 2017, AM J RESP CRIT CARE, V195, P1439, DOI 10.1164/rccm.201607-1453OC; Rosanbalm S, 2015, GETTING SANKEY BAR C; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Svartberg J, 2007, EUR J EPIDEMIOL, V22, P107, DOI 10.1007/s10654-006-9095-9; Tantisira KG, 2008, AM J RESP CRIT CARE, V178, P325, DOI 10.1164/rccm.200708-1174OC; Teague WG, 2018, J ALLER CL IMM-PRACT, V6, P545, DOI 10.1016/j.jaip.2017.05.032; Tse SM, 2016, J ALLERGY CLIN IMMUN, V138, P1561, DOI 10.1016/j.jaci.2016.04.005; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246; Wu TJ, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0135-9; Xu L, 2014, EXP LUNG RES, V40, P211, DOI 10.3109/01902148.2013.879966; Zein JG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157301	38	24	24	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					140	+		10.1016/j.jaci.2019.09.030	http://dx.doi.org/10.1016/j.jaci.2019.09.030			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31622688	hybrid			2022-12-18	WOS:000505590800021
J	Krusche, J; Twardziok, M; Rehbach, K; Bock, A; Tsang, MS; Schroder, PC; Kumbrink, J; Kirchner, T; Xing, YH; Riedler, J; Dalphin, JC; Pekkanen, J; Lauener, R; Roponen, M; Li, J; Wong, CK; Wong, GWK; Schaub, B; Ege, M; Depner, M; Illi, S; Loss, GJ; Renz, H; Pfefferle, PI; Kabesch, M; Genuneit, J; Karvonen, AM; Hyvarinen, A; Kirjavainen, PV; Remes, S; Braun-Fahrlander, C; Roduit, C; Frei, R; Kaulek, V; Dalphin, ML; Divaret-Chauveau, A; Doekes, G				Krusche, Johanna; Twardziok, Monika; Rehbach, Katharina; Boeck, Andreas; Tsang, Miranda S.; Schroeder, Paul C.; Kumbrink, Joerg; Kirchner, Thomas; Xing, Yuhan; Riedler, Josef; Dalphin, Jean-Charles; Pekkanen, Juha; Lauener, Roger; Roponen, Marjut; Li, Jing; Wong, Chun K.; Wong, Gary W. K.; Schaub, Bianca; Ege, Markus; Depner, Martin; Illi, Sabina; Loss, Georg; Renz, Harald; Pfefferle, Petra I.; Kabesch, Michael; Genuneit, Jon; Karvonen, Anne M.; Hyvarinen, Anne; Kirjavainen, Pirkka V.; Remes, Sami; Braun-Fahrlander, Charlotte; Roduit, Caroline; Frei, Remo; Kaulek, Vincent; Dalphin, Marie-Laure; Divaret-Chauveau, Amandine; Doekes, Gert		PASTURE Study	TNF-alpha-induced protein 3 is a key player in childhood asthma development and environment-mediated protection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						A20; asthma; childhood; immune development; environment; farming; inflammatory; TNFAIP3; LPS; protection	EARLY-LIFE; EXPOSURE; ENDOTOXIN; INDUCTION; ALLERGY; DUST; RISK	Background: Childhood asthma prevalence is significantly greater in urban areas compared with rural/farm environments. Murine studies have shown that TNF-alpha-induced protein 3 (TNFAIP3; A20), an anti-inflammatory regulator of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) signaling, mediates environmentally induced asthma protection. Objective: We aimed to determine the role of TNFAIP3 for asthma development in childhood and the immunomodulatory effects of environmental factors. Methods: In a representative selection of 250 of 2168 children from 2 prospective birth cohorts and 2 cross-sectional studies, we analyzed blood cells of healthy and asthmatic children from urban and rural/farm environments from Europe and China. PBMCs were stimulated ex vivo with dust from "asthma-protective'' farms or LPS. NF-kappa B signaling-related gene and protein expression was assessed in PBMCs and multiplex gene expression assays (NanoString Technologies) in isolated dendritic cells of schoolchildren and in cord blood mononuclear cells from newborns. Results: Anti-inflammatory TNFAIP3 gene and protein expression was consistently decreased, whereas proinflammatory Toll-like receptor 4 expression was increased in urban asthmatic patients (P < .05), reflecting their increased inflammatory status. Ex vivo farm dust or LPS stimulation restored TNFAIP3 expression to healthy levels in asthmatic patients and shifted NF-kappa B signaling-associated gene expression toward an anti-inflammatory state (P < .001). Farm/rural children had lower expression, indicating tolerance induction by continuous environmental exposure. Newborns with asthma at school age had reduced TNFAIP3 expression at birth, suggesting TNFAIP3 as a possible biomarker predicting subsequent asthma. Conclusion: Our data indicate TNFAIP3 as a key regulator during childhood asthma development and its environmentally mediated protection. Because environmental dust exposure conferred the anti-inflammatory effects, it might represent a promising future agent for asthma prevention and treatment.	[Krusche, Johanna; Twardziok, Monika; Rehbach, Katharina; Boeck, Andreas; Schroeder, Paul C.; Schaub, Bianca; Ege, Markus; Depner, Martin; Illi, Sabina] Univ Hosp, Dr von Hauner Childrens Hosp, Dept Pediat, Pediat Allergol, Munich, Germany; [Krusche, Johanna; Schaub, Bianca; Ege, Markus; Pfefferle, Petra I.] German Ctr Lung Res DZL, Giessen, Germany; [Kumbrink, Joerg; Kirchner, Thomas] Ludwig Maximilians Univ Munchen, Inst Pathol, Fac Med, Munich, Germany; [Tsang, Miranda S.] Chinese Univ Hong Kong, Inst Chinese Med, Hong Kong, Hong Kong, Peoples R China; [Kumbrink, Joerg; Kirchner, Thomas] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany; [Xing, Yuhan; Wong, Gary W. K.] Chinese Univ Hong Kong, Dept Paediat, Fac Med, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Austria; [Riedler, Josef] Paracelsus Med Private Univ Salzburg, Teaching Hosp, Salzburg, Austria; [Dalphin, Jean-Charles; Karvonen, Anne M.; Hyvarinen, Anne; Kirjavainen, Pirkka V.; Kaulek, Vincent] Univ Franche Comte, Univ Hosp Besancon, UMR CNRS Chronoenvironment 6249, Besancon, France; [Pekkanen, Juha] Natl Inst Hlth & Welf THL, Dept Hlth Secur, Kuopio, Finland; [Pekkanen, Juha; Roduit, Caroline] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; [Lauener, Roger] Childrens Hosp Eastern Switzerland, St Gallen, Switzerland; [Lauener, Roger] Univ Zurich, Zurich, Switzerland; [Lauener, Roger] Univ St Gallen, Sch Med, St Gallen, Switzerland; [Lauener, Roger] Christine Kuhne Ctr Allergy Care & Educ CK CARE, Davos, Switzerland; [Roponen, Marjut] Univ Eastern Finland, Dept Environm & Biol Sci, Kuopio, Finland; [Li, Jing; Loss, Georg] Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Affiliated Hosp 1, Dept Allergy & Clin Immunol, Guangzhou, Guangdong, Peoples R China; [Wong, Chun K.; Renz, Harald] Chinese Univ Hong Kong, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; [Pfefferle, Petra I.] Philipps Univ, Fachbereich Med, CBBM, ZTI, Marburg, Germany; [Kabesch, Michael] KUNO Childrens Univ Hosp Regensburg, Dept Pediat Pneumol & Allergy, Campus St Hedwig, Regensburg, Germany; [Genuneit, Jon] Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, Germany; [Remes, Sami] Kuopio Univ Hosp, Dept Pediat, Kuopio, Finland; [Braun-Fahrlander, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Braun-Fahrlander, Charlotte] Univ Basel, Basel, Switzerland; [Roduit, Caroline] Univ Zurich, Childrens Hosp, Zurich, Switzerland; [Frei, Remo] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Dalphin, Marie-Laure; Divaret-Chauveau, Amandine] Univ Besanon, Univ Hosp, Dept Pediat, Besancon, France; [Doekes, Gert] Univ Utrecht, IRAS, Div Environm Epidemiol, Utrecht, Netherlands	University of Munich; University of Munich; Chinese University of Hong Kong; Helmholtz Association; German Cancer Research Center (DKFZ); Chinese University of Hong Kong; Prince of Wales Hospital; Paracelsus Private Medical University; Universite de Franche-Comte; CHU Besancon; Finland National Institute for Health & Welfare; University of Helsinki; University of Zurich; University of St Gallen; University of Eastern Finland; Guangzhou Medical University; Chinese University of Hong Kong; Philipps University Marburg; Ulm University; Kuopio University Hospital; University of Eastern Finland; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University Children's Hospital Zurich; University of Zurich; Swiss Institute of Allergy & Asthma Research; University of Zurich; Universite de Franche-Comte; CHU Besancon; Utrecht University	Wong, GWK (corresponding author), Chinese Univ Hong Kong, Dept Paediat, Fac Med, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.; Schaub, B (corresponding author), Univ Childrens Hosp, Dr von Haunersches Kinderspital, Dept Allergy Immunol, Lindwurmstr 4, D-80337 Munich, Germany.	wingkinwong@cuhk.edu.hk; Bianca.Schaub@med.uni-muenchen.de	Tsang, Miranda Sin-Man/T-6485-2017; Schaub, Bianca/B-9935-2019; Genuneit, Jon/I-9323-2012; riedler, josef/AAQ-4666-2020; Xing, Yuhan/AAG-2610-2019; Kirjavainen, Pirkka/AAX-8069-2020; Kabesch, Michael/AAB-5701-2020; Wong, Gary WK/AAY-9207-2020; Frei, Remo/AAI-9180-2020; Kirjavainen, Pirkka/AAW-6833-2021; Kabesch, Michael/GZM-1583-2022; Roduit, Caroline/S-4928-2017	Schaub, Bianca/0000-0003-1652-8873; Genuneit, Jon/0000-0001-5764-1528; Xing, Yuhan/0000-0002-2373-5101; Wong, Gary WK/0000-0001-5939-812X; Kirjavainen, Pirkka/0000-0001-6119-8768; Ege, Markus/0000-0001-6643-3923; Loss, Georg/0000-0003-1090-812X; Hyvarinen, Anne/0000-0002-2823-0866; Roduit, Caroline/0000-0002-5988-0570; Divaret-Chauveau, Amandine/0000-0002-2492-9864	EFRAIM EU FP7 [KBBE-2007-1, DFG SCHA 997/3-1, DFG-SCHA 997/7-1, SFB TR22, DFG-SCHA 997/8-1]; Comprehensive Pneumology Center; EKFS; Academy of Finland; CK-CARE/Kuhne Foundation, Davos, Switzerland; PHRC IR University Hospital of Besancon, France; International (Regional) Cooperation and Exchange Program (Cooperation Research-NSFC-AFDFG) by the National Natural Science Foundation of China [81261130023]; FoFoLe	EFRAIM EU FP7; Comprehensive Pneumology Center; EKFS; Academy of Finland(Academy of Finland); CK-CARE/Kuhne Foundation, Davos, Switzerland; PHRC IR University Hospital of Besancon, France; International (Regional) Cooperation and Exchange Program (Cooperation Research-NSFC-AFDFG) by the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); FoFoLe	This work was supported by EFRAIM EU FP7-(grants KBBE-2007-1, DFG SCHA 997/3-1 [to B.S. and P.C.S.], DFG-SCHA 997/7-1 [to B.S., M.T., and J.K.], SFB TR22, and DFG-SCHA 997/8-1 [to B.S.]); the Comprehensive Pneumology Center (to B.S.); FoFoLe (to K.R.); EKFS (to B.S. and A.B.); the Academy of Finland (to M.R.); CK-CARE/Kuhne Foundation, Davos, Switzerland (to R.L. and C.R.); PHRC IR University Hospital of Besancon, France (to J.-C.D.); and the International (Regional) Cooperation and Exchange Program (Cooperation Research-NSFC-AFDFG) by the National Natural Science Foundation of China (grant 81261130023 [to J.L.]).	Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Butte MJ, 2008, MOL IMMUNOL, V45, P3567, DOI 10.1016/j.molimm.2008.05.014; Campbell E, 2000, J IMMUNOL, V164, P1096, DOI 10.4049/jimmunol.164.2.1096; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Feng ML, 2016, CHEST, V149, P1030, DOI 10.1016/j.chest.2015.12.028; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Global Initiative for Asthma, 2022, GLOB STRAT ASTHM MAN; Groothuis-Oudshoorn K., 2009, J STAT SOFTW, V45, P1; Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425; Kaario H, 2016, SCAND J IMMUNOL, V83, P18, DOI 10.1111/sji.12389; Krautenbacher N, 2019, ALLERGY, V74, P1364, DOI 10.1111/all.13745; Liu J, 2011, ALLERGY, V66, P1020, DOI 10.1111/j.1398-9995.2011.02573.x; Martikainen MV, 2015, ALLERGY, V70, P1278, DOI 10.1111/all.12682; Martikainen MV, 2018, PEDIAT ALLERG IMM-UK, V29, P815, DOI 10.1111/pai.12975; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Noss I, 2008, APPL ENVIRON MICROB, V74, P5621, DOI 10.1128/AEM.00619-08; R Development Core Team, 2016, R FDN STAT COMP, DOI DOI 10.1007/978-3-540-74686-7; Raedler D, 2015, J ALLERGY CLIN IMMUN, V135, P81, DOI 10.1016/j.jaci.2014.07.046; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x; Sansom DM, 2003, TRENDS IMMUNOL, V24, P314, DOI 10.1016/S1471-4906(03)00111-X; Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Seeley JJ, 2017, J LEUKOCYTE BIOL, V101, P107, DOI 10.1189/jlb.3MR0316-118RR; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Vatanen T, 2016, CELL, V165, P842, DOI 10.1016/j.cell.2016.04.007; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	33	24	25	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1684	+		10.1016/j.jaci.2019.07.029	http://dx.doi.org/10.1016/j.jaci.2019.07.029			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31381928	Green Accepted, Bronze			2022-12-18	WOS:000500694900025
J	Li, ZP; Zeng, M; Deng, YH; Zhao, JM; Zhou, XX; Trudeau, JB; Goldschmidt, E; Moore, JA; Chu, HW; Zhang, WT; Yin, SK; Liu, Z; Di, YP; Lee, SE; Wenzel, SE				Li, Zhipeng; Zeng, Ming; Deng, Yanhan; Zhao, Jinming; Zhou, Xiuxia; Trudeau, John B.; Goldschmidt, Ezequiel; Moore, John A.; Chu, Hongwei; Zhang, Weitian; Yin, Shankai; Liu, Zheng; Di, Y. Peter; Lee, Stella E.; Wenzel, Sally E.			15-Lipoxygenase 1 in nasal polyps promotes CCL26/eotaxin 3 expression through extracellular signal-regulated kinase activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						15-Lipoxygenase 1; CCL26; epithelial cell; nasal polyps; chronic rhinosinusitis; extracellular signal-regulated kinase	AIRWAY EPITHELIAL-CELLS; CHRONIC RHINOSINUSITIS; PROTEIN; DIFFERENTIATION; EOTAXIN-2; IL-4; PROSTAGLANDIN; INFLAMMATION; MEPOLIZUMAB; GENERATION	Background: 15-Lipoxygenase 1 (15LO1) is expressed in airway epithelial cells in patients with type 2-high asthma in association with eosinophilia. Chronic rhinosinusitis with nasal polyps (CRSwNP) is also associated with type 2 inflammation and eosinophilia. CCL26/eotaxin 3 has been reported to be regulated by 15LO1 in lower airway epithelial cells. However, its relation to 15LO1 in patients with CRSwNP or mechanisms for its activation are unclear. Objective: We sought to evaluate 15LO1 and CCL26 expression in nasal epithelial cells (NECs) from patients with CRSwNP and healthy control subjects (HCs) and determine whether 15LO1 regulates CCL26 in NECs through extracellular signal-regulated kinase (ERK) activation. Methods: 15LO1, CCL26, and phosphorylated ERK were evaluated in NECs from patients with CRSwNP and HCs. 15LO1/CCL26 and CCL26/cytokeratin 5 were colocalized by means of immunofluorescence. IL-13-stimulated NECs were cultured at an air-liquid interface with or without 15-lipoxygenase 1 gene (ALOX15) Dicer-substrate short interfering RNAs (DsiRNA) transfection, a specific 15LO1 enzymatic inhibitor, and 2 ERK inhibitors. Expression of 15LO1 and CCL26 mRNA and protein was analyzed by using quantitative RT-PCR, Western blotting, and ELISA. Results: 15LO1 expression was increased in nasal polyp (NP) epithelial cells compared with middle turbinate epithelial cells from patients with CRSwNP and HCs. 15LO1 expression correlated with CCL26 expression and colocalized with CCL26 expression in basal cells of the middle turbinate and NPs from patients with CRSwNP. In primary NECs in vitro, IL-13 induced 15LO1 and CCL26 expression. 15LO1 knockdown and inhibition decreased IL-13-induced ERK phosphorylation and CCL26 expression. ERK inhibition (alone) similarly decreased IL-13-induced CCL26. Phosphorylated ERK expression was increased in NECs from CRSwNP subjects and positively correlated with both 15LO1 and CCL26 expression. Conclusions: 15LO1 expression is increased in NP epithelial cells and contributes to CCL26 expression through ERK activation. 15LO1 could be considered a novel therapeutic target for CRSwNP.	[Li, Zhipeng; Zhang, Weitian; Yin, Shankai] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Otolaryngol Head & Neck Surg, Shanghai, Peoples R China; [Zeng, Ming; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China; [Deng, Yanhan] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Resp & Crit Care Med, Wuhan, Hubei, Peoples R China; [Goldschmidt, Ezequiel] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Moore, John A.; Lee, Stella E.] Univ Pittsburgh, Med Ctr, Mercy Hosp, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA; [Chu, Hongwei] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Li, Zhipeng; Zeng, Ming; Deng, Yanhan; Zhao, Jinming; Zhou, Xiuxia; Trudeau, John B.; Di, Y. Peter; Wenzel, Sally E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Asthma Inst UPMC, Pittsburgh, PA 15261 USA	Shanghai Jiao Tong University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Jewish Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wenzel, SE (corresponding author), 130 Desoto St, Pittsburgh, PA 15261 USA.; Lee, SE (corresponding author), 1400 Locust St, Pittsburgh, PA 15219 USA.	lees6@upmc.edu; swenzel@pitt.edu	Lee, Stella/AAI-6029-2021; deng, yanhan/HHD-0477-2022; Di, Yuanpu Peter/H-4191-2016	Wenzel, Sally/0000-0002-4242-0164; Di, Yuanpu Peter/0000-0003-2028-2087; Zhao, Jinming/0000-0003-4700-9734	National Institutes of Health (NIH) [HL069174, HL064937, AI40600, P01 AI106684]; National Heart, Lung, and Blood Institute (NHLBI) [U10 HL109152, HL125128]; National Natural Science Foundation of China [81870700, 81502339]; Shanghai Science and Technology Committee grant [16ZR1426100]; Shanghai Jiaotong University Medical School grant [BXJ201637]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL125128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI106684] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee grant; Shanghai Jiaotong University Medical School grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (NIH; HL069174, HL064937, AI40600, and P01 AI106684); the National Heart, Lung, and Blood Institute (NHLBI; U10 HL109152, and HL125128); a generous donation from the Dellenback Family; the National Natural Science Foundation of China (81870700 and 81502339); a Shanghai Science and Technology Committee grant (16ZR1426100); and a Shanghai Jiaotong University Medical School grant (BXJ201637).	Abonyo BO, 2005, AM J PHYSIOL-LUNG C, V289, pL478, DOI 10.1152/ajplung.00032.2005; Albano GD, 2015, J ALLERGY CLIN IMMUN, V135, P1144, DOI 10.1016/j.jaci.2015.02.006; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Bartels Joachim, 1997, Rhinology (Utrecht), V35, P171; Cho DY, 2013, INT FORUM ALLERGY RH, V3, P376, DOI 10.1002/alr.21133; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Coleman JM, 2012, THORAX, V67, P1061, DOI 10.1136/thoraxjnl-2012-201634; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Henriquez-Henriquez M, 2010, REV NEUROLOGIA, V50, P109, DOI 10.33588/rn.5002.2009082; Hulse KE, 2015, CLIN EXP ALLERGY, V45, P328, DOI 10.1111/cea.12472; Keller ET, 2004, BIOCHEM PHARMACOL, V68, P1049, DOI 10.1016/j.bcp.2004.04.024; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Kristjansson RP, 2019, NAT GENET, V51, P267, DOI 10.1038/s41588-018-0314-6; Li CW, 2011, J ALLERGY CLIN IMMUN, V127, P765, DOI 10.1016/j.jaci.2010.12.011; Li YY, 2014, J ALLERGY CLIN IMMUN, V134, P1282, DOI 10.1016/j.jaci.2014.07.038; Li ZP, 2014, IRAN J ALLERGY ASTHM, V13, P412; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Min JY, 2017, J ALLERGY CLIN IMMUN, V139, P130, DOI 10.1016/j.jaci.2016.07.020; Olze H, 2006, RHINOLOGY, V44, P145; Ordovas-Montanes J, 2018, NATURE, V560, P649, DOI 10.1038/s41586-018-0449-8; Pearlman AN, 2008, CURR OPIN OTOLARYNGO, V16, P226, DOI 10.1097/MOO.0b013e3282fdcc9a; Pelcman B, 2015, BIOORG MED CHEM LETT, V25, P3024, DOI 10.1016/j.bmcl.2015.05.004; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Spencer LA, 2006, P NATL ACAD SCI USA, V103, P3333, DOI 10.1073/pnas.0508946103; Stevens WW, 2016, J ALLER CL IMM-PRACT, V4, P565, DOI 10.1016/j.jaip.2016.04.012; Sun QZ, 2012, J IMMUNOL, V188, P3506, DOI 10.4049/jimmunol.1102635; Tian P, 2019, INT FORUM ALLERGY RH, V9, P311, DOI 10.1002/alr.22250; Trakul N, 2005, CELL RES, V15, P19, DOI 10.1038/sj.cr.7290258; Trudeau J, 2006, J ALLERGY CLIN IMMUN, V117, P1446, DOI 10.1016/j.jaci.2006.01.049; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P16; van Wetering S, 2007, MOL IMMUNOL, V44, P803, DOI 10.1016/j.molimm.2006.04.008; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Wenzel SE, 2017, CELL, V171, P628, DOI 10.1016/j.cell.2017.09.044; Wenzel SE, 2002, J IMMUNOL, V169, P4613, DOI 10.4049/jimmunol.169.8.4613; Xie M, 2015, J ALLERGY CLIN IMMUN, V135, P386, DOI 10.1016/j.jaci.2014.08.023; Yao T, 2009, LARYNGOSCOPE, V119, P1053, DOI 10.1002/lary.20191; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yu XM, 2014, STAT BIOPHARM RES, V4, P1; Zhao JM, 2017, AM J RESP CELL MOL, V57, P692, DOI 10.1165/rcmb.2017-0031OC; Zhao JM, 2011, P NATL ACAD SCI USA, V108, P14246, DOI 10.1073/pnas.1018075108; Zhao JM, 2009, AM J RESP CRIT CARE, V179, P782, DOI 10.1164/rccm.200811-1744OC	49	24	25	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1228	+		10.1016/j.jaci.2019.06.037	http://dx.doi.org/10.1016/j.jaci.2019.06.037			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31301373	Green Accepted, Bronze			2022-12-18	WOS:000495004700015
J	Sawada, Y; Honda, T; Nakamizo, S; Nakajima, S; Nonomura, Y; Otsuka, A; Egawa, G; Yoshimoto, T; Nakamura, M; Narumiya, S; Kabashima, K				Sawada, Yu; Honda, Tetsuya; Nakamizo, Satoshi; Nakajima, Saeko; Nonomura, Yumi; Otsuka, Atsushi; Egawa, Gyohei; Yoshimoto, Tomohiro; Nakamura, Motonobu; Narumiya, Shuh; Kabashima, Kenji			Prostaglandin E-2 (PGE(2))-EP2 signaling negatively regulates murine atopic dermatitis-like skin inflammation by suppressing thymic stromal lymphopoietin expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prostaglandin E-2; prostaglandin E-2 receptor; thymic stromal lymphopoietin; IL-33; protease-activated receptor 2	INNATE LYMPHOID-CELLS; PROSTANOID RECEPTORS; IMMUNE-RESPONSE; CYTOKINE; EP4; SENSITIZATION; BARRIER; ALLERGY; IL-33; ROLES	Background: Atopic dermatitis (AD) is a common and chronic inflammatory skin disease of type 2 immunity. Keratinocyte-derived cytokines, including thymic stromal lymphopoietin (TSLP) and IL-33, are considered to induce the development of AD. Production of prostanoids, a family of lipid mediators, is increased in AD lesions. However, their physiologic functions remain to be clarified. Objectives: We sought to elucidate the functions of prostanoids in the development of AD. Methods: The roles of prostanoids were investigated in a mouse model of AD induced by repeated application of hapten and PAM212, a keratinocyte cell line. Results: Application of indomethacin, which blocks prostanoid synthesis, leads to enhanced TSLP and IL-33 production in the skin, increased serum IgE levels, and exacerbation of skin inflammation in this AD model. The skin inflammation was attenuated in TSLP receptor-deficient mice but not in IL-33-deficient mice, and the indomethacin-enhanced type 2 immune responses were abolished in TSLP receptor-deficient mice. Indomethacin increased protease-activated receptor 2-mediated TSLP production in keratinocytes in vitro, and prostaglandin E-2 reversed the increase in TSLP levels through its receptor, the prostaglandin E2 receptor (EP2), by downregulating surface expression of protease-activated receptor 2. Administration of an EP2 agonist canceled indomethacin-enhanced TSLP production and type 2 immune responses in the skin, whereas an EP2 antagonist caused an enhancement of TSLP production and type 2 immune responses in the skin. Conclusion: Prostaglandin E-2-EP2 signaling negatively regulates murine AD-like skin inflammation by suppressing TSLP expression.	[Sawada, Yu; Honda, Tetsuya; Nakamizo, Satoshi; Nakajima, Saeko; Nonomura, Yumi; Otsuka, Atsushi; Egawa, Gyohei; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Narumiya, Shuh] Kyoto Univ, Grad Sch Med, Dept Drug Discovery Med, Kyoto, Japan; [Sawada, Yu; Nakamura, Motonobu] Univ Occupat & Environm Hlth, Dept Dermatol, Kitakyushu, Fukuoka, Japan; [Yoshimoto, Tomohiro] Hyogo Coll Med, Lab Allerg Dis, Inst Adv Med Sci, Nishinomiya, Hyogo, Japan; [Kabashima, Kenji] ASTAR, Singapore Immunol Network SIgN, Biopolis, Singapore; [Kabashima, Kenji] ASTAR, SRIS, Biopolis, Singapore	Kyoto University; Kyoto University; University of Occupational & Environmental Health - Japan; Hyogo College of Medicine; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR)	Honda, T; Kabashima, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawahara, Kyoto 6068507, Japan.	hontetsu@kuhp.kyoto-u.ac.jp; kaba@kuhp.kyoto-u.ac.jp	Nakajima, Saeko/AAB-1577-2021; Nakamizo, Satoshi/ABH-2121-2021	Nakamizo, Satoshi/0000-0001-9332-0369; Egawa, Gyohei/0000-0002-6101-4719; Nakajima, Saeko/0000-0003-0831-1447; Otsuka, Atsushi/0000-0001-7365-947X	Japan Society for the Promotion of Science KAKENHI [JP19K08790, JP15H05906, 263395]; Japan Agency for Medical Research and Development (AMED) [19ek0410062s0201, 16ek0410011h0003, 16he0902003h0002]; Practical Research Project for Allergic Diseases and Immunology from AMED [19ek0410040h0003]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Practical Research Project for Allergic Diseases and Immunology from AMED	Supported by grants from the Japan Society for the Promotion of Science KAKENHI (JP19K08790 and JP15H05906 [to T.H.] and 263395 [to K.K.]), the Japan Agency for Medical Research and Development (AMED; 19ek0410062s0201 [to T.H.] and 16ek0410011h0003 and 16he0902003h0002 [to K.K.]), and the Practical Research Project for Allergic Diseases and Immunology from AMED (19ek0410040h0003; to S.N.).	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1; Boguniewicz M, 2018, ANN ALLERG ASTHMA IM, V120, P10, DOI 10.1016/j.anai.2017.10.039; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Buchmann BB, 2009, EP2 receptor WO, Patent No. [2009/ 007421 A1, 15, 2009007421]; Carpino N, 2004, MOL CELL BIOL, V24, P2584, DOI 10.1128/MCB.24.6.2584-2592.2004; Chan S, 1996, J ALLERGY CLIN IMMUN, V97, P85, DOI 10.1016/S0091-6749(96)70286-5; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; FOGH K, 1989, J ALLERGY CLIN IMMUN, V83, P450, DOI 10.1016/0091-6749(89)90132-2; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; He R, 2010, J ALLERGY CLIN IMMUN, V126, P784, DOI 10.1016/j.jaci.2010.07.006; Honda T, 2015, ALLERGOL INT, V64, P11, DOI 10.1016/j.alit.2014.08.002; Honda T, 2010, CURR DRUG TARGETS, V11, P1605, DOI 10.2174/1389450111009011605; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kitagaki H, 1997, J IMMUNOL, V159, P2484; Komatsu H, 2013, J VET MED SCI, V75, P255, DOI 10.1292/jvms.12-0365; Laouini D, 2005, J ALLERGY CLIN IMMUN, V116, P390, DOI 10.1016/j.jaci.2005.03.042; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Maric J, 2018, J ALLERGY CLIN IMMUN, V141, P1761, DOI 10.1016/j.jaci.2017.09.050; Matsushima Y, 2011, MOL IMMUNOL, V49, P304, DOI 10.1016/j.molimm.2011.08.023; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Nagamachi M, 2007, J EXP MED, V204, P2865, DOI 10.1084/jem.20070773; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nomura T, 2018, INT IMMUNOL, V30, P419, DOI 10.1093/intimm/dxy015; Okano M, 2009, J ALLERGY CLIN IMMUN, V123, P868, DOI 10.1016/j.jaci.2009.01.047; Otsuka A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2740; Paller AS, 2017, J ALLERGY CLIN IMMUN, V140, P633, DOI 10.1016/j.jaci.2017.07.006; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Simpson EL, 2019, J AM ACAD DERMATOL, V80, P1013, DOI 10.1016/j.jaad.2018.11.059; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Takai T, 2012, ALLERGOL INT, V61, P3, DOI 10.2332/allergolint.11-RAI-0395; Tatsuno K, 2015, J INVEST DERMATOL, V135, P3017, DOI 10.1038/jid.2015.318; Watanabe K, 2000, CANCER LETT, V156, P57, DOI 10.1016/S0304-3835(00)00440-7; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Yasuda K, 2012, P NATL ACAD SCI USA, V109, P3451, DOI 10.1073/pnas.1201042109; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399; YUSPA SH, 1980, CANCER RES, V40, P4694; Zaslona Z, 2014, J ALLERGY CLIN IMMUN, V133, P379, DOI 10.1016/j.jaci.2013.07.037	50	24	28	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1265	+		10.1016/j.jaci.2019.06.036	http://dx.doi.org/10.1016/j.jaci.2019.06.036			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31301371	Bronze			2022-12-18	WOS:000495004700018
J	Holt, PG; Mok, D; Panda, D; Renn, L; Fabozzi, G; deKlerk, NH; Kusel, MMH; Serralha, M; Hollams, EM; Holt, BJ; Sly, PD; Rabin, RL				Holt, Patrick G.; Mok, Danny; Panda, Debasis; Renn, Lynnsey; Fabozzi, Giulia; deKlerk, Nick H.; Kusel, Merci M. H.; Serralha, Michael; Hollams, Elysia M.; Holt, Barbara J.; Sly, Peter D.; Rabin, Ronald L.			Developmental regulation of type 1 and type 3 interferon production and risk for infant infections and asthma development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type 1 and type 3 interferons; persistent wheeze; asthma development; infant respiratory tract infections; febrile lower respiratory tract infections; hygiene hypothesis; innate immune development	RESPIRATORY SYNCYTIAL VIRUS; SENSITIZATION; LIFE; PHENOTYPES; VARIABLES; IMMUNITY; AIRWAY; ATOPY	Background: Virus-associated febrile lower respiratory tract infections (fLRIs) during infancy have been identified as risk factors for persistent wheeze development. We hypothesized that variations in innate immune defense capacity during this period, as exemplified by production of type 1 and 3 interferons (T1/3IFNs), might be an underlying determinant of risk. Objective: We sought to investigate relationships between postnatal development of innate interferon response capacity and susceptibility to early infections and persistent wheeze. Methods: We studied a subset of subjects from a birth cohort at high risk for asthma/allergy and determined the capacity of cord blood cells (n = 151) to produce any of a panel of 17 T1/3IFNs in response to the viral mimic polyinosinic-polycytidylic acid using a sensitive PCR assay. We investigated relationships between neonatal interferon responses and lower respiratory tract infection history during infancy, wheezing history to 5 age years, and ensuing maturation of innate immune capacity by age 4 years (n = 160) and 10 years (n = 125). Results: Although cohort subjects produced an average of 2.6 +/- 0.3 of the 17 innate interferons tested at birth, 24% showed no T1/3IFN production. This nonproducer subgroup showed increased risk for infant fLRIs (odds ratio, 2.62; 95% CI, 1.14-6.06; P =.024) and persistent wheeze (odds ratio, 4.24; 95% CI, 1.60-11.24; P =.004) at age 5 years relative to those producing 1 or more T1/3IFNs, whereas risk for infant wheezy lower respiratory tract infections or "ransient early wheeze'' was unaffected. Moreover, infants who experienced fLRIs subsequently demonstrated accelerated development of T1/3IFN response capacity between 1 and 4 years of age. Conclusions: T1/3IFN response capacity appears strongly developmentally constrained at birth. Infants in whom this negative regulation is strongest manifest increased risk for severe respiratory tract infections during infancy and subsequent persistent wheeze.	[Holt, Patrick G.; Mok, Danny; deKlerk, Nick H.; Kusel, Merci M. H.; Serralha, Michael; Hollams, Elysia M.; Holt, Barbara J.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Panda, Debasis; Renn, Lynnsey; Fabozzi, Giulia; Rabin, Ronald L.] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA; [Sly, Peter D.] Univ Queensland, Child Hlth Res Ctr, Brisbane, Qld, Australia	Telethon Kids Institute; University of Western Australia; US Food & Drug Administration (FDA); University of Queensland	Holt, PG (corresponding author), Telethon Kids Inst, 100 Roberts Rd, Subiaco, WA 6008, Australia.	Patrick.Holt@telethonkids.org.au	Sly, Peter D/F-1486-2010; Serralha, Michael/CAA-0940-2022; Holt, Patrick/H-1548-2011	Sly, Peter D/0000-0001-6305-2201; Rabin, Ronald/0000-0003-3496-0504; Mok, Danny/0000-0001-7425-6891; Holt, Patrick/0000-0003-1193-0935; Hollams, Elysia/0000-0002-3481-6396; Serralha, Michael/0000-0002-0121-2879	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council of Australia. R.L.R. is an inventor of the technology to measure expression of IFN-alpha and IFN-lambda subtypes and has derived royalty income from it.	Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Dinarello CA, 2004, J ENDOTOXIN RES, V10, P201, DOI 10.1179/096805104225006129; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hillyer P, 2012, IMMUNOL CELL BIOL, V90, P774, DOI 10.1038/icb.2011.109; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Kusel MMH, 2012, EUR RESPIR J, V39, P876, DOI 10.1183/09031936.00193310; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Makris S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00259; Mejias A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001549; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schreiber G, 2015, TRENDS IMMUNOL, V36, P139, DOI 10.1016/j.it.2015.01.002; Siegrist C A, 2000, Int Rev Immunol, V19, P195, DOI 10.3109/08830180009088505; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Wack A, 2015, NAT IMMUNOL, V16, P802, DOI 10.1038/ni.3212; WALTER SD, 1987, AM J EPIDEMIOL, V125, P319, DOI 10.1093/oxfordjournals.aje.a114532; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC	28	24	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1176	+		10.1016/j.jaci.2018.08.035	http://dx.doi.org/10.1016/j.jaci.2018.08.035			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30217468				2022-12-18	WOS:000460272900037
J	Takeda, K; Sakakibara, S; Yamashita, K; Motooka, D; Nakamura, S; El Hussien, MA; Katayama, J; Maeda, Y; Nakata, M; Hamada, S; Standley, DM; Hayama, M; Shikina, T; Inohara, H; Kikutani, H				Takeda, Kazuya; Sakakibara, Shuhei; Yamashita, Kazuo; Motooka, Daisuke; Nakamura, Shota; El Hussien, Marwa Ali; Katayama, Jun; Maeda, Yohei; Nakata, Masanobu; Hamada, Shigeyuki; Standley, Daron M.; Hayama, Masaki; Shikina, Takashi; Inohara, Hidenori; Kikutani, Hitoshi			Allergic conversion of protective mucosal immunity against nasal bacteria in patients with chronic rhinosinusitis with nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis with nasal polyposis; IgE; human mAb; high-throughput immunoglobulin analysis; T(H)2 inflammation	STAPHYLOCOCCUS-AUREUS ENTEROTOXIN; CLASS SWITCH RECOMBINATION; B-CELLS; IGE; EXPRESSION; GENERATION; RESPONSES; SUPERANTIGENS; COLONIZATION; CARBOHYDRATE	Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is characterized by eosinophilic inflammation and polyposis at the nose and paranasal sinus and a high concentration of IgE in nasal polyps (NPs). The causative antigen and pathogenesis of CRSwNP remain unknown. Objective: We aimed to identify reactive allergens of IgE antibodies produced locally in NPs of patients with CRSwNP. We also attempted to unravel the differentiation pathway of IgE-producing B cells in NPs. Methods: IgE reactivity of patients with CRSwNP was investigated by characterizing single cell-derived mAbs. T-cell response against identified allergens was investigated in vitro. NP-infiltrating lymphocytes were characterized by using flow cytometry. Immunoglobulins expressed in NPs were analyzed by using high-throughput DNA sequencing for immunoglobulin. Results: About 20% of isolated IgE antibodies derived from NP-residing plasmablasts specifically recognized surface determinants of nasal bacteria, such as Staphylococcus aureus, Streptococcus pyogenes, and Haemophilus influenzae. A T(H)2 response against S pyogenes was observed in patients with CRSwNP. Flow cytometric analysis revealed sizable germinal center B-like cell and plasmablast subsets expressing IgE on the cell surface in NPs. High-throughput DNA sequencing immunoglobulin analysis highlighted the clonal connectivity of IgE with IgG and IgA(1). The I epsilon-C alpha(1) circle transcript was detected in NPs. Conclusions: In patients with CRSwNP, nasal bacteria-reactive B cells differentiate into IgE-producing B cells through IgG/IgA1-IgE class switching, suggesting that allergic conversion of the mucosal response against nasal bacteria underlies disease pathogenesis.	[Takeda, Kazuya; Sakakibara, Shuhei; El Hussien, Marwa Ali; Katayama, Jun; Kikutani, Hitoshi] Osaka Univ, Immunol Frontier Res Ctr, Lab Immune Regulat, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan; [Yamashita, Kazuo; Standley, Daron M.] Osaka Univ, Immunol Frontier Res Ctr, Lab Syst Immunol, Osaka, Japan; [Motooka, Daisuke; Nakamura, Shota] Osaka Univ, Genome Informat Res Ctr, Dept Infect Metagen, Osaka, Japan; [Standley, Daron M.] Osaka Univ, Genome Informat Res Ctr, Dept Genome Informat, Osaka, Japan; [Hamada, Shigeyuki] Osaka Univ, Res Inst Microbial Dis, Thailand Japan Res Collaborat Ctr Emerging & Reem, Osaka, Japan; [Takeda, Kazuya; Maeda, Yohei; Hayama, Masaki; Shikina, Takashi; Inohara, Hidenori] Osaka Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Osaka, Japan; [Nakata, Masanobu] Osaka Univ, Grad Sch Dent, Dept Oral & Mol Microbiol, Osaka, Japan; [Yamashita, Kazuo] KOTAI Biotechnol, Suita, Osaka, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Osaka University	Sakakibara, S; Kikutani, H (corresponding author), Osaka Univ, Immunol Frontier Res Ctr, Lab Immune Regulat, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	sakakibara@ifrec.osaka-u.ac.jp; kikutani@biken.osaka-u.ac.jp	Nakamura, Shota/E-3033-2010	Nakamura, Shota/0000-0003-2058-5942; Sakakibara, Shuhei/0000-0003-3157-5870; Nakata, Masanobu/0000-0003-1686-5415; Hayama, Masaki/0000-0002-7952-0206	Kishimoto Foundation; Japan Society for the Promotion of Science (JSPS) [15K20201, 26861378]; Research Foundation for Microbial Diseases of Osaka University, Interdisciplinary Research Grant (FY2015-2016)	Kishimoto Foundation; Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Research Foundation for Microbial Diseases of Osaka University, Interdisciplinary Research Grant (FY2015-2016)	Supported by Kishimoto Foundation; Japan Society for the Promotion of Science (JSPS), Grants-in-Aid for Young Scientists (B) nos. 15K20201 and 26861378; and the Research Foundation for Microbial Diseases of Osaka University, Interdisciplinary Research Grant (FY2015-2016).	Baba S, 2014, CLIN EXP ALLERGY, V44, P701, DOI 10.1111/cea.12287; Bachert C, 2007, Chem Immunol Allergy, V93, P214, DOI 10.1159/000100897; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Cao PP, 2014, CLIN EXP ALLERGY, V44, P690, DOI 10.1111/cea.12304; Chaaban MR, 2013, AM J RHINOL ALLERGY, V27, P473, DOI 10.2500/ajra.2013.27.3981; Cheng KJ, 2017, EXP THER MED, V13, P321, DOI 10.3892/etm.2016.3951; Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163; Corriveau MN, 2009, AM J RHINOL ALLERGY, V23, P461, DOI 10.2500/ajra.2009.23.3367; Costalonga M, 2009, MUCOSAL IMMUNOL, V2, P85, DOI 10.1038/mi.2008.67; Fokkens Wytske J, 2012, Rhinol Suppl, V23, P1; Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; HAMADA S, 1983, ZBL BAKT-INT J MED M, V256, P37, DOI 10.1016/S0174-3031(83)80051-1; Haniuda K, 2016, NAT IMMUNOL, V17, P1109, DOI 10.1038/ni.3508; Hotomi M, 2005, VACCINE, V23, P1294, DOI 10.1016/j.vaccine.2004.08.042; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Huvenne W, 2013, INT ARCH ALLERGY IMM, V161, P304, DOI 10.1159/000350329; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kinoshita K, 2001, P NATL ACAD SCI USA, V98, P12620, DOI 10.1073/pnas.221454398; Krohn IK, 2017, ALLERGY, V72, P985, DOI 10.1111/all.13136; Kurono Y, 1999, J INFECT DIS, V180, P122, DOI 10.1086/314827; Lefranc MP, 2005, NUCLEIC ACIDS RES, V33, pD593, DOI 10.1093/nar/gki065; Mahdavinia M, 2016, CLIN EXP ALLERGY, V46, P21, DOI 10.1111/cea.12666; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Niederfuhr A, 2009, ARCH OTOLARYNGOL, V135, P131, DOI 10.1001/archoto.2008.531; Patou J, 2008, J ALLERGY CLIN IMMUN, V121, P110, DOI 10.1016/j.jaci.2007.08.059; Pauwels B, 2015, EXPERT REV CLIN IMMU, V11, P349, DOI 10.1586/1744666X.2015.1010517; Perreau M, 2014, J EXP MED, V211, P2033, DOI 10.1084/jem.20140039; Sabharwal H, 2006, J INFECT DIS, V193, P129, DOI 10.1086/498618; Sakakibara S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16681-y; Sasama Jan, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P2, DOI 10.1097/00020840-200502000-00003; Sejima T, 2012, ALLERGOL INT, V61, P115, DOI 10.2332/allergolint.10-OA-0290; Shah SA, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0121-8; Stevens WW, 2016, J ALLER CL IMM-PRACT, V4, P565, DOI 10.1016/j.jaip.2016.04.012; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Tokunaga T, 2015, ALLERGY, V70, P995, DOI 10.1111/all.12644; Uhliarova B, 2014, J MED MICROBIOL, V63, P28, DOI 10.1099/jmm.0.068320-0; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Wan YZ, 2016, EUR ARCH OTO-RHINO-L, V273, P391, DOI 10.1007/s00405-015-3498-8; Wang M, 2008, ACTA OTO-LARYNGOL, V128, P901, DOI 10.1080/00016480701760122; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Yang ZY, 2016, ELIFE, V5, DOI 10.7554/eLife.21238; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382; Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593; Zhang YN, 2016, J ALLERGY CLIN IMMUN, V137, P462, DOI 10.1016/j.jaci.2015.07.025; Zielinski CE, 2011, IMMUNOL REV, V240, P40, DOI 10.1111/j.1600-065X.2010.01000.x	52	24	27	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1163	+		10.1016/j.jaci.2018.07.006	http://dx.doi.org/10.1016/j.jaci.2018.07.006			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30053529	Bronze			2022-12-18	WOS:000460272900036
J	Bolcas, PE; Brandt, EB; Zhang, ZH; Myers, JMB; Ruff, BP; Hershey, GKK				Bolcas, Paige E.; Brandt, Eric B.; Zhang, Zhonghua; Myers, Jocelyn M. Biagini; Ruff, Brandy P.; Hershey, Gurjit K. Khurana			Vitamin D supplementation attenuates asthma development following traffic-related particulate matter exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; asthma; diesel exhaust particle; house dust mite; traffic pollution; allergen; prevention	DOUBLE-BLIND; D DEFICIENCY; CHILDHOOD ASTHMA; CONTROLLED-TRIAL; CELLS; INFLAMMATION; PREVENTION; PREGNANCY; CHILDREN; IL-17A	Background: Recent literature suggests that children who are vitamin D deficient are uniquely susceptible to the effects of traffic-related air pollution (TRAP) exposure. This is highly significant because large segments of the population reside in zones of high TRAP exposure. Objective: We sought to determine whether vitamin D supplementation mitigates the effect of TRAP exposure on asthma development, asthma exacerbation, and/or airway inflammation and to determine the timing of vitamin D supplementation that confers maximal health benefit. Methods: Using established mouse models of asthma, we examined the effect of prenatal and postnatal vitamin D supplementation on asthma development, as well as the utility of vitamin D as a treatment for established asthma in the context of diesel exhaust particle (DEP) exposure. Results: DEP and allergen coexposure resulted in increased airway hyperresponsiveness (AHR) and accumulation of pathogenic T(H)2/T(H)17 cells in the lungs of vitamin D-deficient mice compared with control mice. Prenatal and postnatal vitamin D supplementation significantly attenuated the development of AHR and decreased pulmonary accumulation of T(H)2/T(H)17 cells after coexposure to TRAP and allergen but not to allergen alone. Restoration of normal vitamin D status had no effect on AHR once asthma was already established. Conclusions: Our data establish that vitamin D confers protection against asthma development specifically in the context of TRAP exposure. Although vitamin D replacement did not reverse established asthma, restoration of normal vitamin D status in early life significantly attenuated the development of AHR in the setting of DEP-exacerbated allergic asthma and reduced numbers of lung T(H)2/T(H)17 cells, which portend the development of severe asthma.	[Myers, Jocelyn M. Biagini; Hershey, Gurjit K. Khurana] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Bolcas, Paige E.; Brandt, Eric B.; Zhang, Zhonghua; Myers, Jocelyn M. Biagini; Ruff, Brandy P.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA; [Bolcas, Paige E.] Cincinnati Childrens Hosp Med Ctr, Grad Program Immunol, Cincinnati, OH 45229 USA; [Bolcas, Paige E.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org	zhang, zh/GWV-4677-2022	Brandt, Eric/0000-0003-0617-4100	National Institutes of Health [AI1070235-11]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant AI1070235-11 (to G.K.K.H.).	Alessandrini F, 2006, J ALLERGY CLIN IMMUN, V117, P824, DOI 10.1016/j.jaci.2005.11.046; Appatova AS, 2008, J ENVIRON PLANN MAN, V51, P631, DOI 10.1080/09640560802208173; Bar Yoseph R, 2015, PEDIATR PULM, V50, P747, DOI 10.1002/ppul.23076; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Cabana MD, 2014, J ALLERGY CLIN IMMUN, V133, P27, DOI 10.1016/j.jaci.2013.10.026; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Chambers ES, 2015, J ALLERGY CLIN IMMUN, V136, P628, DOI 10.1016/j.jaci.2015.01.026; Chawes BL, 2016, JAMA-J AM MED ASSOC, V315, P353, DOI 10.1001/jama.2015.18318; De Grove KC, 2017, J ALLERGY CLIN IMMUN, V139, P246, DOI 10.1016/j.jaci.2016.03.044; Fawaz L, 2016, CLIN IMMUNOL, V166, P59, DOI 10.1016/j.clim.2016.02.011; Feng HX, 2017, J ALLERGY CLIN IMMUN, V139, P1508, DOI 10.1016/j.jaci.2016.06.065; Grinshpun SA, 2014, AEROSOL AIR QUAL RES, V14, P1344, DOI 10.4209/aaqr.2013.11.0334; Hamzaoui A, 2014, IMMUNOBIOLOGY, V219, P873, DOI 10.1016/j.imbio.2014.07.009; Helth Effects Institute,, 2010, 17 HEI; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Kerley CP, 2016, PEDIAT ALLERG IMM-UK, V27, P404, DOI 10.1111/pai.12547; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Litonjua AA, 2014, CONTEMP CLIN TRIALS, V38, P37, DOI 10.1016/j.cct.2014.02.006; Lodovici M, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/487074; Manners S, 2014, J ALLERGY CLIN IMMUN, V134, P63, DOI 10.1016/j.jaci.2013.10.047; Martineau AR, 2015, THORAX, V70, P451, DOI 10.1136/thoraxjnl-2014-206449; Mitchell DM, 2012, ENDOCR PRACT, V18, P914, DOI 10.4158/EP12072.OR; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Robinson RK, 2018, J ALLERGY CLIN IMMUN, V141, P1074, DOI 10.1016/j.jaci.2017.04.038; Rosser F, 2014, AM J RESP CRIT CARE, V190, P1190, DOI 10.1164/rccm.201408-1568LE; Spira-Cohen A, 2010, J EXPO SCI ENV EPID, V20, P446, DOI 10.1038/jes.2009.34; Stevens T, 2009, TOXICOL SCI, V107, P522, DOI 10.1093/toxsci/kfn248; Tachimoto H, 2016, ALLERGY, V71, P1001, DOI 10.1111/all.12856; Vahdaninia M, 2017, J ALLER CL IMM-PRACT, V5, P771, DOI 10.1016/j.jaip.2016.09.024; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Yepes-Nunez JJ, 2018, ALLERGY, V73, P37, DOI 10.1111/all.13241; Yetley EA, 2008, AM J CLIN NUTR, V88, p558S, DOI 10.1093/ajcn/88.2.558S	36	24	25	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					386	+		10.1016/j.jaci.2018.04.042	http://dx.doi.org/10.1016/j.jaci.2018.04.042			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29936100	Bronze, Green Accepted			2022-12-18	WOS:000454918300042
J	Altman, MC; Whalen, E; Togias, A; O'Connor, GT; Bacharier, LB; Bloomberg, GR; Kattan, M; Wood, RA; Presnell, S; LeBeau, P; Jaffee, K; Visness, CM; Busse, WW; Gern, JE				Altman, Matthew C.; Whalen, Elizabeth; Togias, Alkis; O'Connor, George T.; Bacharier, Leonard B.; Bloomberg, Gordon R.; Kattan, Meyer; Wood, Robert A.; Presnell, Scott; LeBeau, Petra; Jaffee, Katy; Visness, Cynthia M.; Busse, William W.; Gern, James E.			Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergens; transcriptomics; natural killer cells; dendritic cells	INNATE LYMPHOID-CELLS; T-CELLS; PERIPHERAL-BLOOD; DENDRITIC CELLS; NK-CELL; EXPRESSION ANALYSIS; MURINE MODEL; GAMMA; GENE; INFLAMMATION	Background: Childhood asthma in inner-city populations is a major public health burden, and understanding early-life immune mechanisms that promote asthma onset is key to disease prevention. Children with asthma demonstrate a high prevalence of aeroallergen sensitization and T(H)2-type inflammation; however, the early-life immune events that lead to T(H)2 skewing and disease development are unknown. Objective: We sought to use RNA sequencing of PBMCs collected at age 2 years to determine networks of immune responses that occur in children with allergy and asthma. Methods: In an inner-city birth cohort with high asthma risk, we compared gene expression using RNA sequencing in PBMCs collected at age 2 years between children with 2 or more aeroallergen sensitizations, including dust mite, cockroach, or both, by age 3 years and asthma by age 7 years (cases) and matched control subjects who did not have any aeroallergen sensitization or asthma by age 7 years. Results: PBMCs from the cases showed higher levels of expression of natural killer (NK) cell-related genes. After cockroach or dust mite allergen but not tetanus antigen stimulation, PBMCs from the cases compared with the control subjects showed differential expression of 244 genes. This gene set included upregulation of a densely interconnected NK cell-like gene network reflecting a pattern of cell activation and induction of inflammatory signaling molecules, including the key T(H)2-type cytokines IL9, IL13, and CCL17, as well as a dendritic cell-like gene network, including upregulation of CD1 lipid antigen presentation molecules. The NK cell-like response was reproducible in an independent group of children with later-onset allergic sensitization and asthma and was found to be specific to only those children with both aeroallergen sensitization and asthma. Conclusion: These findings provide important mechanistic insight into an early-life immune pathway involved in T(H)2 polarization, leading to the development of allergic asthma.	[Altman, Matthew C.; Whalen, Elizabeth; Presnell, Scott] Benaroya Res Inst, Syst Immunol Div, 1201 Ninth Ave, Seattle, WA 98101 USA; [Altman, Matthew C.] Univ Washington, Dept Med, Seattle, WA USA; [Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Bacharier, Leonard B.; Bloomberg, Gordon R.] Washington Univ, Sch Med, St Louis, MO USA; [Kattan, Meyer] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [LeBeau, Petra; Jaffee, Katy; Visness, Cynthia M.] Rho, Chapel Hill, NC USA; [Busse, William W.; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA	Benaroya Research Institute; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Boston University; Washington University (WUSTL); Columbia University; Johns Hopkins University; Rho; University of Wisconsin System; University of Wisconsin Madison	Altman, MC (corresponding author), Benaroya Res Inst, Syst Immunol Div, 1201 Ninth Ave, Seattle, WA 98101 USA.	maltman@benaroyaresearch.org		LeBeau, Petra/0000-0002-0883-9922; Altman, Matthew/0000-0002-1784-8505; Bacharier, Leonard/0000-0003-0432-2704; Presnell, Scott/0000-0001-9203-6403	National Institute of Allergy and Infectious Diseases, National Institutes of Health [NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, UM2AI117870]; National Center for Research Resources, National Institutes of Health [RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, UL1TR000040, UL1TR001079, 5UL1RR024992-02]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002345, UL1TR001079, UL1TR000040] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992, M01RR000533, UL1RR025771, UL1RR024156, M01RR000052, M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM2AI117870, N01AI025496, UM1AI114271] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract nos. NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, and UM2AI117870. Additional support was provided by the National Center for Research Resources, National Institutes of Health, under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, UL1TR000040, UL1TR001079, and 5UL1RR024992-02.	Abbas AR, 2005, GENES IMMUN, V6, P319, DOI 10.1038/sj.gene.6364173; Afgan E, 2016, NUCLEIC ACIDS RES, V44, pW3, DOI 10.1093/nar/gkw343; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Bolen CR, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-258; Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chikina M, 2015, BIOINFORMATICS, V31, P1584, DOI 10.1093/bioinformatics/btv015; CRAIN EF, 1994, PEDIATRICS, V94, P356; Deniz G, 2002, EUR J IMMUNOL, V32, P879, DOI 10.1002/1521-4141(200203)32:3<879::AID-IMMU879>3.0.CO;2-2; Deniz G, 2013, J ALLERGY CLIN IMMUN, V132, P527, DOI 10.1016/j.jaci.2013.07.030; Di Santo JP, 2008, EUR J IMMUNOL, V38, P2948, DOI 10.1002/eji.200838830; Duvall MG, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam5446; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Harizi H, 2013, CELL MOL IMMUNOL, V10, P213, DOI 10.1038/cmi.2013.1; Havstad S, 2014, J ALLERGY CLIN IMMUN, V134, P722, DOI 10.1016/j.jaci.2014.01.022; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; Hoshino T, 1999, J IMMUNOL, V162, P5070; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jacobs B, 2012, CURR MED CHEM, V19, P1771, DOI 10.2174/092986712800099857; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Krejsek J, 1998, ALLERGY, V53, P73, DOI 10.1111/j.1398-9995.1998.tb03776.x; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lin SJ, 2003, ALLERGY, V58, P67, DOI 10.1034/j.1398-9995.2003.t01-1-23697.x; Liu RJ, 2015, NUCLEIC ACIDS RES, V43, pE97, DOI 10.1093/nar/gkv412; Loza MJ, 2002, BLOOD, V99, P1273, DOI 10.1182/blood.V99.4.1273; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Manners S, 2014, J ALLERGY CLIN IMMUN, V134, P63, DOI 10.1016/j.jaci.2013.10.047; Mathias CB, 2014, CLIN EXP ALLERGY, V44, P589, DOI 10.1111/cea.12271; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; O'Connor GT, 2018, J ALLERGY CLIN IMMUN, V141, P1468, DOI 10.1016/j.jaci.2017.06.040; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Ple C, 2010, SCAND J IMMUNOL, V72, P118, DOI 10.1111/j.1365-3083.2010.02419.x; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Ruedler D, 2014, LANCET RESP MED, V2, P647, DOI 10.1016/S2213-2600(14)70129-8; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shen-Orr SS, 2013, CURR OPIN IMMUNOL, V25, P571, DOI 10.1016/j.coi.2013.09.015; Shim JU, 2014, ALLERGY ASTHMA IMMUN, V6, P444, DOI 10.4168/aair.2014.6.5.444; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Smedley D, 2015, NUCLEIC ACIDS RES, V43, pW589, DOI 10.1093/nar/gkv350; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; TIMONEN T, 1985, CLIN EXP IMMUNOL, V59, P85; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Van Elssen CHMJ, 2011, BLOOD, V118, P2473, DOI 10.1182/blood-2010-09-307835; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; WARREN HS, 1995, J IMMUNOL, V154, P5144; Wei HM, 2005, J ALLERGY CLIN IMMUN, V115, P841, DOI 10.1016/j.jaci.2004.11.026; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wingett D, 2003, J LEUKOCYTE BIOL, V74, P531, DOI 10.1189/jlb.0303103; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhong Y, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-89	66	24	25	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1856	1866		10.1016/j.jaci.2018.02.019	http://dx.doi.org/10.1016/j.jaci.2018.02.019			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29518416	Green Accepted, Bronze			2022-12-18	WOS:000452315800020
J	Grayson, MH; Feldman, S; Prince, BT; Patel, PJ; Matsui, EC; Apter, AJ				Grayson, Mitchell H.; Feldman, Scott; Prince, Benjamin T.; Patel, Priya J.; Matsui, Elizabeth C.; Apter, Andrea J.			Advances in asthma in 2017: Mechanisms, biologics, and genetics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway hyperreactivity; asthma biomarkers; asthma phenotypes; genetics; environment; respiratory viruses; allergens; eosinophils; helper T cells; B cells; innate lymphoid cells; neutrophils; biologic therapies; microbiome	CHILDHOOD ASTHMA; POOLED ANALYSIS; DOUBLE-BLIND; AIRWAY; LUNG; SENSITIZATION; ADULTS; INTERVENTION; RISK; INFLAMMATION	This review summarizes some of the most significant advances in asthma research over the past year. We first focus on novel discoveries in the mechanism of asthma development and exacerbation. This is followed by a discussion of potential new biomarkers, including the use of radiographic markers of disease. Several new biologics have become available to the clinician in the past year, and we summarize these advances and how they can influence the clinical delivery of asthma care. After this, important findings in the genetics of asthma and heterogeneity in phenotypes of the disease are explored, as is the role the environment plays in shaping the development and exacerbation of asthma. Finally, we conclude with a discussion of advances in health literacy and how they will affect asthma care.	[Grayson, Mitchell H.; Prince, Benjamin T.] Ohio State Univ, Coll Med, Div Allergy & Immunol, Dept Pediat,Nationwide Childrens Hosp, Columbus, OH USA; [Feldman, Scott; Patel, Priya J.; Apter, Andrea J.] Univ Penn, Sch Med, Dept Med, Sect Allergy & Immunol,Div Pulm Allergy Crit Care, Philadelphia, PA 19104 USA; [Matsui, Elizabeth C.] Univ Texas Austin, Dept Populat Hlth, Dell Med Sch, Austin, TX 78712 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of Pennsylvania; University of Texas System; University of Texas Austin	Grayson, MH (corresponding author), 700 Childrens Dr, Columbus, OH 43205 USA.	wheeze@allergist.com	Grayson, Mitchell/AAX-3674-2020	Grayson, Mitchell/0000-0002-4673-2122; Matsui, Elizabeth/0000-0001-8134-5593	National Institutes of Health (NIH); Research Institute at Nationwide Children's Hospital; NIH; Patient-Centered Outcomes Research Institute; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Institute at Nationwide Children's Hospital(Ohio State University); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Patient-Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	M. H. Grayson has been on the advisory board for AstraZeneca; has received research funds from the National Institutes of Health (NIH) and the Research Institute at Nationwide Children's Hospital; is an Associate Editor for the Annals of Allergy, Asthma, and Immunology; and is on the Board of Directors of the American Board of Allergy and Immunology, the Asthma and Allergy Foundation of America, and the American Academy of Allergy, Asthma & Immunology. A. J. Apter has received research funds from the NIH and Patient-Centered Outcomes Research Institute, consults for UpToDate, and is an Associate Editor of the Journal of Allergy and Clinical Immunology. The rest of the authors declare that they have no relevant conflicts of interest.	Alam R, 2017, J ALLERGY CLIN IMMUN, V140, P1004, DOI 10.1016/j.jaci.2016.12.963; Albers FC, 2017, J ALLERGY CLIN IMMUN, V140, P1464, DOI 10.1016/j.jaci.2017.06.010; Anderson HM, 2017, J ALLERGY CLIN IMMUN, V139, P790, DOI 10.1016/j.jaci.2016.05.033; Andersson CK, 2017, J ALLERGY CLIN IMMUN, V139, P1819, DOI 10.1016/j.jaci.2016.09.022; Andre-Gregoire G, 2018, J ALLERGY CLIN IMMUN, V142, P824, DOI 10.1016/j.jaci.2017.09.049; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bousquet J, 2017, J ALLERGY CLIN IMMUN, V140, P891, DOI 10.1016/j.jaci.2017.04.042; Burbank AJ, 2018, J ALLERGY CLIN IMMUN, V141, P1231, DOI 10.1016/j.jaci.2017.06.029; Cephus JY, 2017, CELL REP, V21, P2487, DOI 10.1016/j.celrep.2017.10.110; Chairakaki AD, 2018, J ALLERGY CLIN IMMUN, V142, P542, DOI 10.1016/j.jaci.2017.08.032; Chen E, 2017, J ALLERGY CLIN IMMUN, V140, P828, DOI 10.1016/j.jaci.2016.11.040; Chen J, 2018, J ALLERGY CLIN IMMUN, V142, P207, DOI 10.1016/j.jaci.2017.08.015; Chen W, 2017, J ALLERGY CLIN IMMUN, V140, P571, DOI 10.1016/j.jaci.2016.11.030; Cheung DS, 2018, J ALLERGY CLIN IMMUN, V142, P1206, DOI 10.1016/j.jaci.2017.11.026; Chipps BE, 2018, J ALLERGY CLIN IMMUN, V141, pAB16, DOI 10.1016/j.jaci.2017.12.049; Cho M, 2018, J ALLERGY CLIN IMMUN, V142, P530, DOI 10.1016/j.jaci.2017.09.019; Choi S, 2017, J ALLERGY CLIN IMMUN, V140, P690, DOI 10.1016/j.jaci.2016.11.053; Clemmer GL, 2015, J ALLERGY CLIN IMMUN, V136, P274, DOI 10.1016/j.jaci.2015.03.029; Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064; D'Amato G, 2017, J ALLERGY CLIN IMMUN, V139, P1786, DOI 10.1016/j.jaci.2017.03.003; DeBoer EM, 2017, J ALLERGY CLIN IMMUN, V139, P21, DOI 10.1016/j.jaci.2016.11.004; Ebmeier S, 2017, LANCET, V390, P935, DOI [10.1016/S0140-6736(17)31448-4, 10.1016/s0140-6736(17)31448-4]; Farne HA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010834.pub3; Fazlollahi M, 2018, J ALLERGY CLIN IMMUN, V142, P834, DOI 10.1016/j.jaci.2018.02.020; Forno E, 2017, J ALLERGY CLIN IMMUN, V140, P996, DOI 10.1016/j.jaci.2016.12.967; Gaffin JM, 2018, J ALLERGY CLIN IMMUN, V141, P2249, DOI 10.1016/j.jaci.2017.08.028; Gern JE, 2017, J ALLERGY CLIN IMMUN, V140, P836, DOI 10.1016/j.jaci.2016.10.052; Ghosh A, 2018, AM J RESP CRIT CARE, V198, P67, DOI 10.1164/rccm.201710-2033OC; Gold DR, 2017, J ALLERGY CLIN IMMUN, V140, P933, DOI 10.1016/j.jaci.2017.04.024; Halterman JS, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2017.4938; Hansen S, 2017, J ALLERGY CLIN IMMUN, V139, P104, DOI 10.1016/j.jaci.2016.02.042; Hekking PP, 2018, J ALLERGY CLIN IMMUN, V141, P1280, DOI 10.1016/j.jaci.2017.06.037; Hentschke I, 2017, SCI REP-UK, V7, DOI 10.1038/srep43426; Iribarren C, 2017, J ALLERGY CLIN IMMUN, V139, P1678, DOI 10.1016/j.jaci.2016.12.953; Iribarren C, 2017, J ALLERGY CLIN IMMUN, V139, P1489, DOI 10.1016/j.jaci.2016.07.038; Jo A, 2018, J ALLERGY CLIN IMMUN, V142, P294, DOI 10.1016/j.jaci.2018.01.040; Kast JI, 2017, CLIN EXP IMMUNOL, V190, P351, DOI 10.1111/cei.13042; Keet CA, 2017, J ALLERGY CLIN IMMUN, V140, P822, DOI 10.1016/j.jaci.2017.01.036; KleinJan A, 2018, J ALLERGY CLIN IMMUN, V142, P76, DOI 10.1016/j.jaci.2017.08.042; Kothari PH, 2018, J ALLERGY CLIN IMMUN, V141, P2282, DOI 10.1016/j.jaci.2017.11.057; Laffont S, 2017, J EXP MED, V214, P1581, DOI 10.1084/jem.20161807; Lefaudeux D, 2017, J ALLERGY CLIN IMMUN, V139, P1797, DOI 10.1016/j.jaci.2016.08.048; Lieberman PL, 2017, J ALLERGY CLIN IMMUN, V140, P1734, DOI 10.1016/j.jaci.2017.07.013; Lieberman PL, 2016, J ALLERGY CLIN IMMUN, V138, P913, DOI 10.1016/j.jaci.2016.03.030; Liu WM, 2017, J ALLERGY CLIN IMMUN, V139, P1548, DOI 10.1016/j.jaci.2016.08.032; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007; Loser S, 2017, J ALLERGY CLIN IMMUN, V139, P1496, DOI 10.1016/j.jaci.2016.07.033; Lukkarinen M, 2017, J ALLERGY CLIN IMMUN, V140, P988, DOI 10.1016/j.jaci.2016.12.991; Matsui EC, 2017, JAMA-J AM MED ASSOC, V317, P1027, DOI 10.1001/jama.2016.21048; McGeachie MJ, 2018, J ALLERGY CLIN IMMUN; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Mishra A, 2018, J ALLERGY CLIN IMMUN, V142, P1066, DOI 10.1016/j.jaci.2017.10.044; Mosteller M, 2017, J ALLERGY CLIN IMMUN, V139, P797, DOI 10.1016/j.jaci.2016.05.032; Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501; Nyenhuis SM, 2017, J ALLERGY CLIN IMMUN, V140, P257, DOI 10.1016/j.jaci.2016.10.024; O'Connor GT, 2018, J ALLERGY CLIN IMMUN, V141, P1468, DOI 10.1016/j.jaci.2017.06.040; Oliveria JP, 2018, J ALLERGY CLIN IMMUN, V141, P1495, DOI 10.1016/j.jaci.2017.11.013; Oliveria JP, 2017, J ALLERGY CLIN IMMUN, V140, P590, DOI 10.1016/j.jaci.2016.12.981; Olsen SF, 2008, AM J CLIN NUTR, V88, P167, DOI 10.1093/ajcn/88.1.167; Peng H, 2018, J ALLERGY CLIN IMMUN, V142, P582, DOI 10.1016/j.jaci.2017.09.031; Pepper AN, 2017, J ALLER CL IMM-PRACT, V5, P909, DOI 10.1016/j.jaip.2017.04.038; Polosa R, 2016, NEW ENGL J MED, V375, P2608, DOI 10.1056/NEJMc1613869; Qiao YK, 2017, J ALLERGY CLIN IMMUN, V139, P82, DOI 10.1016/j.jaci.2016.03.029; Qiu WL, 2018, J ALLERGY CLIN IMMUN, V141, P1250, DOI 10.1016/j.jaci.2017.05.052; Rabito FA, 2017, J ALLERGY CLIN IMMUN, V140, P565, DOI [10.1016/j.jaci.2016.10.019, 10.1016/j.jaci.2016.12.221]; Ricciardolo FLM, 2017, J ALLERGY CLIN IMMUN, V140, P395, DOI 10.1016/j.jaci.2016.10.034; Rigas D, 2017, J ALLERGY CLIN IMMUN, V139, P1468, DOI 10.1016/j.jaci.2016.08.034; Rosas-Salazar C, 2018, J ALLERGY CLIN IMMUN; Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049; Schoos AMM, 2017, J ALLERGY CLIN IMMUN, V140, P1693, DOI 10.1016/j.jaci.2017.01.041; Sehmi R, 2018, J ALLERGY CLIN IMMUN, V141, P1529, DOI 10.1016/j.jaci.2018.01.008; Semprini R, 2017, J ALLERGY CLIN IMMUN, V139, P1687, DOI 10.1016/j.jaci.2016.11.041; Shen XF, 2018, J ALLERGY CLIN IMMUN, V141, P1929, DOI 10.1016/j.jaci.2018.01.005; SHETH JS, 2017, AM J RESP CRIT CARE, V195; Shim SS, 2018, J ALLERGY CLIN IMMUN; Silkoff PE, 2017, J ALLERGY CLIN IMMUN, V140, P710, DOI 10.1016/j.jaci.2016.11.038; Sinclair C, 2017, SCIENCE, V357, P1014, DOI 10.1126/science.aaj2155; Soones TN, 2017, J ALLERGY CLIN IMMUN, V139, P804, DOI 10.1016/j.jaci.2016.05.043; Stokholm J, 2018, J ALLERGY CLIN IMMUN, V141, P1598, DOI 10.1016/j.jaci.2017.07.044; Sverrild A, 2017, J ALLERGY CLIN IMMUN, V140, P407, DOI 10.1016/j.jaci.2016.10.046; Sweerus K, 2017, J ALLERGY CLIN IMMUN, V139, P72, DOI 10.1016/j.jaci.2016.02.035; Tanaka A, 2018, J ALLERGY CLIN IMMUN, V141, P2316, DOI 10.1016/j.jaci.2018.01.050; Tashkin DP, 2017, J ALLERGY CLIN IMMUN, V139, P49, DOI 10.1016/j.jaci.2016.11.010; Aung T, 2018, JAMA CARDIOL, V3, P225, DOI 10.1001/jamacardio.2017.5205; Trivedi A, 2017, J ALLERGY CLIN IMMUN, V139, P1, DOI 10.1016/j.jaci.2016.11.009; Vroman H, 2018, J ALLERGY CLIN IMMUN, V141, P1620, DOI 10.1016/j.jaci.2017.08.012; Wallrapp A, 2017, NATURE, V549, P351, DOI 10.1038/nature24029; Wang P, 2018, J ALLERGY CLIN IMMUN, V141, P1259, DOI 10.1016/j.jaci.2017.05.053; Weinstein SF, 2018, J ALLERGY CLIN IMMUN, V142, P171, DOI 10.1016/j.jaci.2017.11.051; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5; Wisniewski JA, 2018, J ALLERGY CLIN IMMUN, V141, P2048, DOI 10.1016/j.jaci.2017.08.020; Wypych TP, 2018, J ALLERGY CLIN IMMUN, V141, P1395, DOI 10.1016/j.jaci.2017.09.001; Yancey SW, 2017, J ALLERGY CLIN IMMUN, V139, P1167, DOI 10.1016/j.jaci.2016.08.008; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Zhang ZH, 2017, J ALLERGY CLIN IMMUN, V139, P54, DOI 10.1016/j.jaci.2016.02.031	95	24	28	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1423	1436		10.1016/j.jaci.2018.08.033	http://dx.doi.org/10.1016/j.jaci.2018.08.033			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30213625	Bronze			2022-12-18	WOS:000449429800005
J	Xia, MC; Harb, H; Saffari, A; Sioutas, C; Chatila, TA				Xia, Mingcan; Harb, Hani; Saffari, Arian; Sioutas, Constantinos; Chatila, Talal A.			A Jagged 1-Notch 4 molecular switch mediates airway inflammation induced by ultrafine particles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway hyperresponsiveness; allergic airway inflammation; alveolar macrophages; aryl hydrocarbon receptor; asthma-Jagged 1; Notch; Notch 4; traffic-related particulate matter; ultrafine particles	DIESEL EXHAUST PARTICLES; REGULATORY T-CELLS; DENDRITIC CELLS; IN-VIVO; POLLUTION EXPOSURE; PARTICULATE MATTER; AMBIENT ULTRAFINE; LOS-ANGELES; MACROPHAGES; ASTHMA	Background: Exposure to traffic-related particulate matter promotes asthma and allergic diseases. However, the precise cellular and molecular mechanisms by which particulate matter exposure acts to mediate these effects remain unclear. Objective: We sought to elucidate the cellular targets and signaling pathways critical for augmentation of allergic airway inflammation induced by ambient ultrafine particles (UFP). Methods: We used in vitro cell-culture assays with lung-derived antigen-presenting cells and allergen-specific T cells and in vivo mouse models of allergic airway inflammation with myeloid lineage-specific gene deletions, cellular reconstitution approaches, and antibody inhibition studies. Results: We identified lung alveolar macrophages (AM) as the key cellular target of UFP in promoting airway inflammation. Aryl hydrocarbon receptor-dependent induction of Jagged 1 (Jag1) expression in AM was necessary and sufficient for augmentation of allergic airway inflammation by UFP. UFP promoted T(H)2 and T(H)17 cell differentiation of allergen-specific T cells in a Jag1- and Notch 4-dependent manner. Treatment of mice with an anti-Notch 4 antibody abrogated exacerbation of allergic airway inflammation induced by UFP. Conclusion: UFP exacerbate allergic airway inflammation by promoting a Jag1-Notch 4-dependent interaction between AM and allergen-specific T cells, leading to augmented T-H cell differentiation.	[Xia, Mingcan; Harb, Hani; Chatila, Talal A.] Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, Div Immunol, Boston, MA 02115 USA; [Saffari, Arian; Sioutas, Constantinos] Univ Southern Calif, Dept Civil & Environm Engn, Los Angeles, CA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Southern California	Chatila, TA (corresponding author), Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, Div Immunol, Boston, MA 02115 USA.	talal.chatila@childrens.harvard.edu	Harb, Hani/HGB-7333-2022; Sioutas, Constantinos/R-1968-2019; Harb, Hani/J-6517-2019	Harb, Hani/0000-0001-8218-2538; Harb, Hani/0000-0001-8218-2538; Chatila, Talal/0000-0001-7439-2762; Sioutas, Constantinos/0000-0001-5146-0857	National Institutes of Health [2R01AI065617, R01AI115699]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065617, R01AI115699] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants 2R01AI065617 and R01AI115699 (to T.A.C.).	Abram CL, 2014, J IMMUNOL METHODS, V408, P89, DOI 10.1016/j.jim.2014.05.009; Adar Sara D, 2014, Curr Environ Health Rep, V1, P258; Bailis W, 2013, IMMUNITY, V39, P148, DOI 10.1016/j.immuni.2013.07.006; Blaeser F, 2003, J EXP MED, V198, P1189, DOI 10.1084/jem.20030471; Blank F, 2013, AM J RESP CELL MOL, V49, P67, DOI 10.1165/rcmb.2012-0387OC; Blumenthal RL, 2001, J ALLERGY CLIN IMMUN, V107, P258, DOI 10.1067/mai.2001.112845; Bowatte G, 2015, ALLERGY, V70, P245, DOI 10.1111/all.12561; Brandt EB, 2015, CURR OPIN PEDIATR, V27, P724, DOI 10.1097/MOP.0000000000000286; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Brunst KJ, 2015, AM J RESP CRIT CARE, V192, P421, DOI 10.1164/rccm.201407-1314OC; Charbonnier LM, 2015, NAT IMMUNOL, V16, P1162, DOI 10.1038/ni.3288; CHELEN CJ, 1995, J CLIN INVEST, V95, P1415, DOI 10.1172/JCI117796; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Coleman MM, 2013, AM J RESP CELL MOL, V48, P773, DOI 10.1165/rcmb.2012-0263OC; de Haar C, 2008, J ALLERGY CLIN IMMUN, V121, P1246, DOI 10.1016/j.jaci.2008.01.010; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Duan W, 2008, J IMMUNOL, V181, P8650, DOI 10.4049/jimmunol.181.12.8650; Fine PM, 2008, J AIR WASTE MANAGE, V58, P234, DOI 10.3155/1047-3289.58.2.234; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Garbi N, 2017, PFLUG ARCH EUR J PHY, V469, P561, DOI 10.1007/s00424-017-1965-3; Gehring U, 2015, LANCET RESP MED, V3, P933, DOI 10.1016/S2213-2600(15)00426-9; Hardy CL, 2013, J IMMUNOL, V191, P5278, DOI 10.4049/jimmunol.1203131; Herner JD, 2006, ENVIRON SCI TECHNOL, V40, P1925, DOI 10.1021/es052315q; Hiraiwa K, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/619523; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Katakura T, 2004, J IMMUNOL, V172, P1407, DOI 10.4049/jimmunol.172.3.1407; Khreis H, 2017, ENVIRON INT, V100, P1, DOI 10.1016/j.envint.2016.11.012; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Kopf M, 2015, NAT IMMUNOL, V16, P36, DOI 10.1038/ni.3052; Li N, 2016, J ALLERGY CLIN IMMUN, V138, P386, DOI 10.1016/j.jaci.2016.02.023; Li N, 2010, AM J PHYSIOL-LUNG C, V299, pL374, DOI 10.1152/ajplung.00115.2010; Li N, 2009, ENVIRON HEALTH PERSP, V117, P1116, DOI 10.1289/ehp.0800319; Mancini SJC, 2005, BLOOD, V105, P2340, DOI 10.1182/blood-2004-08-3207; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Massoud AH, 2016, NAT MED, V22, P1013, DOI 10.1038/nm.4147; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Miniati D, 2010, AM J PHYSIOL-LUNG C, V298, pL169, DOI 10.1152/ajplung.00188.2009; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Miyata R, 2011, TOXICOL APPL PHARM, V257, P209, DOI 10.1016/j.taap.2011.09.007; Moon KA, 2007, INT IMMUNOL, V19, P1371, DOI 10.1093/intimm/dxm108; Moriyama Y, 2008, INT IMMUNOL, V20, P763, DOI 10.1093/intimm/dxn034; Murata A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108535; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Saffari A, 2016, ATMOS ENVIRON, V133, P112, DOI 10.1016/j.atmosenv.2016.03.022; Sakamoto K, 2005, EXP CELL RES, V302, P281, DOI 10.1016/j.yexcr.2004.09.016; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Shirmohammadi F, 2016, SCI TOTAL ENVIRON, V541, P1083, DOI 10.1016/j.scitotenv.2015.09.133; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; Stone EA, 2009, ATMOS ENVIRON, V43, P4205, DOI 10.1016/j.atmosenv.2009.05.030; Tachdjian R, 2009, J EXP MED, V206, P2191, DOI 10.1084/jem.20091480; Tindemans I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00419; Uyttendaele H, 2000, MICROVASC RES, V60, P91, DOI 10.1006/mvre.2000.2254; Walisser JA, 2005, P NATL ACAD SCI USA, V102, P17858, DOI 10.1073/pnas.0504757102; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; Xia MC, 2015, J ALLERGY CLIN IMMUN, V136, P441, DOI 10.1016/j.jaci.2015.02.014	64	24	25	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1243	+		10.1016/j.jaci.2018.03.009	http://dx.doi.org/10.1016/j.jaci.2018.03.009			31	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29627423	Green Accepted, Bronze			2022-12-18	WOS:000446327300023
J	Evans, MD; Esnault, S; Denlinger, LC; Jarjour, NN				Evans, Michael D.; Esnault, Stephane; Denlinger, Loren C.; Jarjour, Nizar N.			Sputum cell IL-1 receptor expression level is a marker of airway neutrophilia and airflow obstruction in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; sputum samples; type 1; type 2; type 17; lymphocyte; partial least squares; neutrophil; IL-1 receptor; pulmonary function	CD4(+) T-CELLS; BRONCHOALVEOLAR LAVAGE FLUID; INFLAMMATION; INTERLEUKIN-1; PHENOTYPES; RELEASE; TH17; DIFFERENTIATION; IDENTIFICATION; ACTIVATION	Background: Various clinical, biologic, or physiologic markers of asthma have been used to identify patient clusters and potential targets for therapy. However, these identifiers frequently overlap among the different asthma groups. For instance, both eosinophil and neutrophil counts are often increased in the airways of asthmatic patients despite their typical association with type 2 and type 17 immune response, respectively. Objectives: We sought to determine whether inflammatory gene expression is related to patterns of airway inflammation and lung function and identify molecular markers for neutrophilic asthma. Methods: Expression levels of 17 genes characterizing type 1, type 2, and type 17 lymphocytes were measured in sputum samples from 48 participants with asthma. The relationships between gene expression levels and sputum cell differentials or measures of pulmonary function were examined by using partial least squares regression. Results: Gene expression levels were strongly associated with cell differentials, explaining 71% of variation in eosinophil counts and 64% of variation in neutrophil counts. The 3 genes with the strongest relationships to sputum neutrophil counts were IL1R1 (standardized regression coefficient [beta] = +0.27, P = .005), IL1RAP (beta = +0.32, P = .0004), and IL4R (beta = +0.29, P = .002). Higher expression levels of IL1R1, IL1RAP, and IL4R were associated with reduced FEV1/forced vital capacity ratio (beta = -0.11, -0.08, and -0.10; P = .005, .07, and .05). Conclusion: IL-1 receptor appears to be a marker of neutrophilic inflammation and airflow obstruction in patients with asthma, who have a wide range of disease severity. The IL-1 pathway might contribute to airway neutrophilia and is a potential therapeutic target in patients with neutrophilic asthma.	[Evans, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA; [Esnault, Stephane; Denlinger, Loren C.; Jarjour, Nizar N.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Allergy Pulm & Crit Care Med, 600 Highland Ave,CSC K4-928, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jarjour, NN (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Allergy Pulm & Crit Care Med, 600 Highland Ave,CSC K4-928, Madison, WI 53792 USA.	NJarjour@uwhealth.org	Esnault, Stephane/AAJ-4511-2020; Esnault, Stephane/AAO-4712-2020	Esnault, Stephane/0000-0001-7238-8671; Evans, Michael/0000-0001-7449-3993	National Institutes of Health [R01 HL069116, U10 HL109168, P01 HL088594, UL1 RR025011, UL1 TR000427]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069116, U10HL109168, P01HL088594] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the Severe Asthma Research Program grants R01 HL069116 and U10 HL109168, Program Project grant P01 HL088594, and Clinical and Translational Research Center grants UL1 RR025011 and UL1 TR000427 from the National Institutes of Health.	Abdi Herve, 2013, Methods Mol Biol, V930, P549, DOI 10.1007/978-1-62703-059-5_23; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Bellehumeur C, 2009, HUM REPROD, V24, P2193, DOI 10.1093/humrep/dep192; BORISH L, 1992, J IMMUNOL, V149, P3078; Broide DH, 2000, BLOOD, V95, P263; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Chambers ES, 2015, J ALLERGY CLIN IMMUN, V136, P628, DOI 10.1016/j.jaci.2015.01.026; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Denlinger LC, 2013, AM J RESP CRIT CARE, V187, P28, DOI 10.1164/rccm.201204-0750OC; Denlinger LC, 2011, AM J RESP CRIT CARE, V184, P1007, DOI 10.1164/rccm.201103-0585OC; Denlinger LC, 2009, AM J RESP CRIT CARE, V179, P265, DOI 10.1164/rccm.200802-293OC; Dhimolea E, 2010, MABS-AUSTIN, V2, P3, DOI 10.4161/mabs.2.1.10328; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; DOKTER WHA, 1992, BLOOD, V80, P2721; Dragon S, 2007, AM J PHYSIOL-LUNG C, V292, pL1023, DOI 10.1152/ajplung.00306.2006; Edwards RH, 2015, MBIO, V6, DOI 10.1128/mBio.00441-15; Esnault S, 2012, CLIN EXP ALLERGY, V42, P1756, DOI 10.1111/j.1365-2222.2012.04060.x; Esnault S, 2016, J ALLERGY CLIN IMMUN, V137, P767, DOI 10.1016/j.jaci.2015.05.053; Friendly M, 2002, AM STAT, V56, P316, DOI 10.1198/000313002533; Fujisawa T, 2009, J IMMUNOL, V183, P6236, DOI 10.4049/jimmunol.0900614; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hernandez ML, 2015, J ALLERGY CLIN IMMUN, V135, P379, DOI 10.1016/j.jaci.2014.07.039; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; JARJOUR NN, 1995, AM J RESP CRIT CARE, V152, P1474, DOI 10.1164/ajrccm.152.5.7582279; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Josse J, 2016, J STAT SOFTW, V70; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Konno S, 1996, INT ARCH ALLERGY IMM, V109, P73, DOI 10.1159/000237234; Krause K, 2012, CURR OPIN ALLERGY CL, V12, P477, DOI 10.1097/ACI.0b013e3283574d0c; Kuo CHS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02135-2016; Lee JH, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/567351; Lee WW, 2010, BLOOD, V115, P530, DOI 10.1182/blood-2009-08-236521; Liu H, 2008, J IMMUNOL, V180, P7948, DOI 10.4049/jimmunol.180.12.7948; Liu WM, 2017, J ALLERGY CLIN IMMUN, V139, P1548, DOI 10.1016/j.jaci.2016.08.032; Hoang LT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111640; Menzella F, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/2049-6958-10-1; Mevik B-H, LS PARTIAL LEAST SQU; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Netea MG, 2015, ANNU REV IMMUNOL, V33, P49, DOI 10.1146/annurev-immunol-032414-112306; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Pascoe S, 2006, 16 ANN C EUR RESP SO; Patel OP, 2015, ALLERGY RHINOL, V6, pE101, DOI 10.2500/ar.2015.6.0124; Peng Bo, 2007, BMC Proc, V1 Suppl 1, pS156; Prause O, 2003, EUR J PHARMACOL, V462, P193, DOI 10.1016/S0014-2999(03)01341-4; R Core Team, R LANG ENV STAT COMP; Raedler D, 2015, J ALLERGY CLIN IMMUN, V135, P81, DOI 10.1016/j.jaci.2014.07.046; Raffin C, 2011, J IMMUNOL, V187, P5196, DOI 10.4049/jimmunol.1101742; Rosenkranz MA, 2016, BRAIN BEHAV IMMUN, V58, P18, DOI 10.1016/j.bbi.2016.03.024; Roussel L, 2010, J IMMUNOL, V184, P4531, DOI 10.4049/jimmunol.0903162; Schmitz N, 2003, EUR J IMMUNOL, V33, P991, DOI 10.1002/eji.200323801; Seys SF, 2013, CLIN EXP ALLERGY, V43, P1009, DOI 10.1111/cea.12125; Seys SF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0524-y; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Strine TW, 2008, J ASTHMA, V45, P123, DOI 10.1080/02770900701840238; Suwara MI, 2014, MUCOSAL IMMUNOL, V7, P684, DOI 10.1038/mi.2013.87; TAKII T, 1992, EUR J IMMUNOL, V22, P1221, DOI 10.1002/eji.1830220517; TAYLORROBINSON AW, 1994, IMMUNOLOGY, V81, P216; Thomas SS, 2003, J INDIAN MED ASSOC, P284; Vazquez-Tello A, 2013, J CLIN IMMUNOL, V33, P466, DOI 10.1007/s10875-012-9828-3; Wei T., CORRPLOT VISUALIZATI; Whelan R, 2004, EUR RESPIR J, V24, P559, DOI 10.1183/09031936.04.00133803; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	73	24	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					415	423		10.1016/j.jaci.2017.09.035	http://dx.doi.org/10.1016/j.jaci.2017.09.035			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29103994	Green Accepted, Bronze			2022-12-18	WOS:000440664400011
J	Ruiz-Garcia, R; Vargas-Hernandez, A; Chinn, IK; Angelo, LS; Cao, TN; Coban-Akdemir, Z; Jhangiani, SN; Meng, QC; Forbes, LR; Muzny, DM; Allende, LM; Ehlayel, MS; Gibbs, RA; Lupski, JR; Uzel, G; Orange, JS; Mace, EM				Ruiz-Garcia, Raquel; Vargas-Hernandez, Alexander; Chinn, Ivan K.; Angelo, Laura S.; Cao, Tram N.; Coban-Akdemir, Zeynep; Jhangiani, Shalini N.; Meng, Qingchang; Forbes, Lisa R.; Muzny, Donna M.; Allende, Luis M.; Ehlayel, Mohammed S.; Gibbs, Richard A.; Lupski, James R.; Uzel, Gulbu; Orange, Jordan S.; Mace, Emily M.			Mutations in PI3K110 delta cause impaired natural killer cell function partially rescued by rapamycin treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer cell deficiency; combined immunodeficiency; cytotoxicity; activated phosphoinositide 3-kinase delta syndrome; phosphoinositide 3-kinase signaling	LYTIC GRANULE CONVERGENCE; ALDRICH-SYNDROME PROTEIN; 3-KINASE DELTA SYNDROME; NK-CELLS; PRIMARY IMMUNODEFICIENCY; IMMUNOLOGICAL SYNAPSE; MENDELIAN DISORDERS; ACTIN ACCUMULATION; SIGNALING PATHWAYS; F-ACTIN	Background: Heterozygous gain-of-function mutations in PI3K110 delta lead to lymphadenopathy, lymphoid hyperplasia, EBV and cytomegalovirus viremia, and sinopulmonary infections. Objective: The known role of natural killer (NK) cell function in the control of EBV and cytomegalovirus prompted us to investigate the functional and phenotypic effects of PI3K110 delta mutations on NK cell subsets and cytotoxic function. Methods: Mutations in patients were identified by using whole-exome or targeted sequencing. We performed NK cell phenotyping and functional analysis of patients' cells using flow cytometry, standard Cr-51 cytotoxicity assays, and quantitative confocal microscopy. Results: PI3K110 delta mutations led to an altered NK cell developmental phenotype and cytotoxic dysfunction. Impaired NK cell cytotoxicity was due to decreased conjugate formation with susceptible target cells and abrogated activation of cell machinery required for target cell killing. These defects were restored partially after initiation of treatment with rapamycin in 3 patients. Conclusion: We describe novel NK cell functional deficiency caused by PI3K110 delta mutation, which is a likely contributor to the severe viremia observed in these patients. Rapamycin treatment partially restores NK cell function, providing a further rationale for its use in patients with this disease.	[Ruiz-Garcia, Raquel; Vargas-Hernandez, Alexander; Chinn, Ivan K.; Angelo, Laura S.; Cao, Tram N.; Forbes, Lisa R.; Orange, Jordan S.; Mace, Emily M.] Texas Childrens Hosp, Ctr Human Immunobiol, Houston, TX 77030 USA; [Ruiz-Garcia, Raquel; Allende, Luis M.] Hosp Univ 12 Octubre, Serv Immunol, Madrid, Spain; [Vargas-Hernandez, Alexander; Chinn, Ivan K.; Angelo, Laura S.; Forbes, Lisa R.; Lupski, James R.; Orange, Jordan S.; Mace, Emily M.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Coban-Akdemir, Zeynep; Jhangiani, Shalini N.; Meng, Qingchang; Muzny, Donna M.; Gibbs, Richard A.; Lupski, James R.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Coban-Akdemir, Zeynep; Gibbs, Richard A.; Lupski, James R.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Ehlayel, Mohammed S.] Hamad Med Corp, Sect Pediat Allergy & Immunol, Dept Pediat, Doha, Qatar; [Ehlayel, Mohammed S.] Weill Cornell Med Coll, Dept Pediat, Ar Rayyan, Qatar; [Uzel, Gulbu] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	Baylor College of Medicine; Hospital Universitario 12 de Octubre; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Hamad Medical Corporation; Qatar Foundation (QF); Weill Cornell Medical College Qatar; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Mace, EM (corresponding author), FC330-11,1102 Bates Ave, Houston, TX 77030 USA.	mace@bcm.edu	Ruiz-García, Raquel/AAE-6659-2021	Ruiz-Garcia, Raquel/0000-0002-8403-3613; /0000-0001-9586-8539; orange, jordan/0000-0001-7117-7725; Mace, Emily/0000-0003-0226-7393; Chinn, Ivan/0000-0001-5684-5457	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [R01AI067946, R01 AI120989]; Jeffrey Modell Foundation; American Society of Hematology Junior Scholar Award; NIH/National Human Genome Research Institute (NHGRI)/National Heart, Lung, and Blood Institute (NHLBI) [U54HG006542]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [UM1HG008898, U54HG006542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI120989, R01AI067946] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Jeffrey Modell Foundation; American Society of Hematology Junior Scholar Award; NIH/National Human Genome Research Institute (NHGRI)/National Heart, Lung, and Blood Institute (NHLBI); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grants R01AI067946 and R01 AI120989 (to J.S.O.), the Jeffrey Modell Foundation, the American Society of Hematology Junior Scholar Award (to E.M.M.), and NIH/National Human Genome Research Institute (NHGRI)/National Heart, Lung, and Blood Institute (NHLBI) grant U54HG006542 to the Baylor Hopkins Center for Mendelian Genomics.	Angelo LS, 2015, IMMUNOL RES, V62, P341, DOI 10.1007/s12026-015-8664-y; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Banerjee PP, 2010, J IMMUNOL METHODS, V355, P1, DOI 10.1016/j.jim.2010.02.003; Billadeau DD, 2003, NAT IMMUNOL, V4, P557, DOI 10.1038/ni929; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; Briercheck EL, 2015, J IMMUNOL, V194, P1832, DOI 10.4049/jimmunol.1401224; Cerboni C, 1998, EUR J IMMUNOL, V28, P1005, DOI 10.1002/(SICI)1521-4141(199803)28:03<1005::AID-IMMU1005>3.0.CO;2-O; Chen X, 2007, P NATL ACAD SCI USA, V104, P6329, DOI 10.1073/pnas.0611655104; Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Coulter TI, 2017, J ALLERGY CLIN IMMUN, V139, P597, DOI 10.1016/j.jaci.2016.06.021; Dornan GL, 2017, P NATL ACAD SCI USA, V114, P1982, DOI 10.1073/pnas.1617244114; Eldomery MK, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0412-6; Elgizouli M, 2016, CLIN EXP IMMUNOL, V183, P221, DOI 10.1111/cei.12706; Elkaim E, 2016, J ALLERGY CLIN IMMUN, V138, P210, DOI 10.1016/j.jaci.2016.03.022; Guo HL, 2008, J EXP MED, V205, P2419, DOI 10.1084/jem.20072327; Ham H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00002; Ham H, 2013, J IMMUNOL, V190, P3661, DOI 10.4049/jimmunol.1202792; Hayakawa Y, 2006, J IMMUNOL, V176, P1517, DOI 10.4049/jimmunol.176.3.1517; Horowitz A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006702; Hsu HT, 2016, J CELL BIOL, V215, P875, DOI 10.1083/jcb.201604136; James AM, 2013, BLOOD, V121, P2627, DOI 10.1182/blood-2012-06-437012; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Jiang K, 2002, J IMMUNOL, V168, P3155, DOI 10.4049/jimmunol.168.7.3155; Kotecha N., 2010, CURR PROTOC CYTOM, DOI DOI 10.1002/0471142956.CY1017S53; Lucas CL, 2016, NAT REV IMMUNOL, V16, P702, DOI 10.1038/nri.2016.93; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Lupski JR, 2013, GENOME MED, V5, DOI 10.1186/gm461; Mace EM, 2014, IMMUNOL CELL BIOL, V92, P245, DOI 10.1038/icb.2013.96; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; Mentlik AN, 2010, MOL BIOL CELL, V21, P2241, DOI 10.1091/mbc.E09-11-0930; Mizesko MC, 2013, J ALLERGY CLIN IMMUN, V131, P840, DOI 10.1016/j.jaci.2012.12.1568; Orange JS, 2006, CURR OPIN ALLERGY CL, V6, P399, DOI 10.1097/ACI.0b013e3280106b65; Orange JS, 2013, J ALLERGY CLIN IMMUN, V132, P515, DOI 10.1016/j.jaci.2013.07.020; Orange JS, 2011, J CLIN INVEST, V121, P1535, DOI 10.1172/JCI44862; Orange JS, 2006, CLIN IMMUNOL, V118, P1, DOI 10.1016/j.clim.2005.10.011; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Sanborn KB, 2010, METHODS MOL BIOL, V612, P127, DOI 10.1007/978-1-60761-362-6_9; Sanborn KB, 2009, J IMMUNOL, V182, P6969, DOI 10.4049/jimmunol.0804337; Segovis CM, 2009, J IMMUNOL, V182, P6933, DOI 10.4049/jimmunol.0803840; Stray-Pedersen A, 2017, J ALLERGY CLIN IMMUN, V139, P232, DOI 10.1016/j.jaci.2016.05.042; Tassi I, 2007, IMMUNITY, V27, P214, DOI 10.1016/j.immuni.2007.07.014; Upshaw JL, 2006, NAT IMMUNOL, V7, P524, DOI 10.1038/ni1325; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Voss M, 2017, CLIN IMMUNOL, V177, P29, DOI 10.1016/j.clim.2015.11.004; Willmann KL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6360; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555; Zhang KJ, 2013, J CLIN IMMUNOL, V33, P673; Zhang MG, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005629	51	24	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					605	+		10.1016/j.jaci.2017.11.042	http://dx.doi.org/10.1016/j.jaci.2017.11.042			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29330011	Green Accepted, Bronze			2022-12-18	WOS:000440664400027
J	Sarkar, K; Han, SS; Wen, KK; Ochs, HD; Dupre, L; Seidman, MM; Vyas, YM				Sarkar, Koustav; Han, Seong-Su; Wen, Kuo-Kuang; Ochs, Hans D.; Dupre, Loic; Seidman, Michael M.; Vyas, Yatin M.			R-loops cause genomic instability in T helper lymphocytes from patients with Wiskott-Aldrich syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; Wiskott-Aldrich syndrome; X-linked thrombocytopenia; T(H)1/T(H)2 differentiation; R-loops; DNA damage; genomic instability	X-LINKED THROMBOCYTOPENIA; DNA TOPOISOMERASE-I; TRANSCRIPTIONAL PAUSE SITES; DOUBLE-STRAND BREAKS; SYNDROME PROTEIN; ACTIN POLYMERIZATION; GENE-TRANSCRIPTION; RNA/DNA HYBRIDS; WASP GENE; B-CELLS	Background: Wiskott-Aldrich syndrome (WAS), X-linked thrombocytopenia (XLT), and X-linked neutropenia, which are caused by WAS mutations affecting Wiskott-Aldrich syndrome protein (WASp) expression or activity, manifest in immunodeficiency, autoimmunity, genomic instability, and lymphoid and other cancers. WASp supports filamentous actin formation in the cytoplasm and gene transcription in the nucleus. Although the genetic basis for XLT/WAS has been clarified, the relationships between mutant forms of WASp and the diverse features of these disorders remain ill-defined. Objective: We sought to define how dysfunctional gene transcription is causally linked to the degree of T-H cell deficiency and genomic instability in the XLT/WAS clinical spectrum. Methods: In human T(H)1- or T(H)2-skewing cell culture systems, cotranscriptional R-loops (RNA/DNA duplex and displaced single-stranded DNA) and DNA double-strand breaks (DSBs) were monitored in multiple samples from patients with XLT and WAS and in normal T cells depleted of WASp. Results: WASp deficiency provokes increased R-loops and R-loop-mediated DSBs in T(H)1 cells relative to T(H)2 cells. Mechanistically, chromatin occupancy of serine 2-unphosphorylated RNA polymerase II is increased, and that of topoisomerase 1, an R-loop preventing factor, is decreased at R-loop-enriched regions of IFNG and TBX21 (T(H)1 genes) in T(H)1 cells. These aberrations accompany increased unspliced (intron-retained) and decreased spliced mRNA of IFNG and TBX21 but not IL13 (T(H)2 gene). Significantly, increased cellular load of R-loops and DSBs, which are normalized on RNaseH1-mediated suppression of ectopic R-loops, inversely correlates with disease severity scores. Conclusion: Transcriptional R-loop imbalance is a novel molecular defect causative in TH1 immunodeficiency and genomic instability in patients with WAS. The study proposes that cellular R-loop load could be used as a potential biomarker for monitoring symptom severity and prognostic outcome in the XLT-WAS clinical spectrum and could be targeted therapeutically.	[Sarkar, Koustav; Han, Seong-Su; Wen, Kuo-Kuang; Vyas, Yatin M.] Carver Coll Med, Div Pediat Hematol Oncol, Iowa City, IA USA; [Sarkar, Koustav; Han, Seong-Su; Wen, Kuo-Kuang; Vyas, Yatin M.] Univ Iowa, Stead Family Childrens Hosp, Iowa City, IA 52242 USA; [Ochs, Hans D.] Univ Washington, Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA 98195 USA; [Dupre, Loic] INSERM, Ctr Physiopathol Toulouse Purpan, UMR1043, Toulouse, France; [Dupre, Loic] Univ Toulouse III Paul Sabatier, Toulouse, France; [Dupre, Loic] CNRS, UMR5282, Toulouse, France; [Dupre, Loic] Ludwig Boltzmann Inst Rare & Undiagnosed Dis, Vienna, Austria; [Dupre, Loic] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Seidman, Michael M.] NIA, Lab Mol Gerontol, NIH, Biomed Res Ctr, Baltimore, MD 21224 USA; [Sarkar, Koustav] SRM Univ & Res Inst, Dept Biotechnol, Madras 603203, Tamil Nadu, India	University of Iowa; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); SRM Institute of Science & Technology Chennai	Vyas, YM (corresponding author), Univ Iowa, Carver Coll Med, Stead Family Childrens Hosp, Div Pediat Hematol Oncol, Iowa City, IA 52242 USA.	yatin-vyas@uiowa.edu	dupre, loic/L-8174-2014; Sarkar, Koustav/ABE-6071-2021	dupre, loic/0000-0002-7278-6503; SARKAR, KOUSTAV/0000-0002-0696-6688; Han, Seong-Su/0000-0001-9824-6751; Vyas, Yatin/0000-0002-4595-0267	National Institutes of Health (NIH) [R01AI084957]; Intramural Research Program of the NIH, the National Institute on Aging grant [Z01AG000746-08]; DeJoria Wiskott-Aldrich Research Fund; NATIONAL CANCER INSTITUTE [P30CA086862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000746, ZIAAG000577, Z01AG000746] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the NIH, the National Institute on Aging grant; DeJoria Wiskott-Aldrich Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by National Institutes of Health (NIH) grant R01AI084957 (to Y.M.V.), the Intramural Research Program of the NIH, the National Institute on Aging grant Z01AG000746-08 (to M.M.S.), and the DeJoria Wiskott-Aldrich Research Fund (to H.D.O.).	Aguilera A, 2012, MOL CELL, V46, P115, DOI 10.1016/j.molcel.2012.04.009; Albert MH, 2010, BLOOD, V115, P3231, DOI 10.1182/blood-2009-09-239087; Ancliff PJ, 2006, BLOOD, V108, P2182, DOI 10.1182/blood-2006-01-010249; Bai XM, 2016, BLOOD, V128, P1723, DOI 10.1182/blood-2016-03-703579; Baranello L, 2016, CELL, V165, P357, DOI 10.1016/j.cell.2016.02.036; Belotserkovskii BP, 2011, BIOPHYS J, V100, P675, DOI 10.1016/j.bpj.2010.12.3709; Bhatia V, 2014, NATURE, V511, P362, DOI 10.1038/nature13374; Bredemeyer AL, 2008, NATURE, V456, P819, DOI 10.1038/nature07392; Broccoli S, 2004, MOL MICROBIOL, V52, P1769, DOI 10.1111/j.1365-2958.2004.04092.x; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Chedin F, 2016, TRENDS GENET, V32, P828, DOI 10.1016/j.tig.2016.10.002; Chen PB, 2015, NAT STRUCT MOL BIOL, V22, P999, DOI 10.1038/nsmb.3122; Costantino L, 2015, CURR OPIN CELL BIOL, V34, P39, DOI 10.1016/j.ceb.2015.04.008; Davis AJ, 2014, DNA REPAIR, V17, P21, DOI 10.1016/j.dnarep.2014.02.020; De I, 2015, NAT STRUCT MOL BIOL, V22, P138, DOI 10.1038/nsmb.2951; De Meester J, 2010, J LEUKOCYTE BIOL, V88, P1031, DOI 10.1189/jlb.0410197; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Dominguez-Sanchez MS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002386; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; El Hage A, 2010, GENE DEV, V24, P1546, DOI 10.1101/gad.573310; Felipe-Abrio I, 2015, EMBO J, V34, P236, DOI 10.15252/embj.201488544; Garcia-Rubio ML, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005674; Ginno PA, 2013, GENOME RES, V23, P1590, DOI 10.1101/gr.158436.113; Ginno PA, 2012, MOL CELL, V45, P814, DOI 10.1016/j.molcel.2012.01.017; Groh M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004630; Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047; Hatchi E, 2015, MOL CELL, V57, P636, DOI 10.1016/j.molcel.2015.01.011; Herrera-Moyano E, 2014, GENE DEV, V28, P735, DOI 10.1101/gad.234070.113; Huang W, 2005, J IMMUNOL, V174, P2602, DOI 10.4049/jimmunol.174.5.2602; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Husain A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10549; Imai K, 2004, BLOOD, V103, P456, DOI 10.1182/blood-2003-05-1480; Jangi M, 2017, P NATL ACAD SCI USA, V114, pE2347, DOI 10.1073/pnas.1613181114; Jin YZ, 2004, BLOOD, V104, P4010, DOI 10.1182/blood-2003-05-1592; Kawanishi S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081808; Kim H, 2010, NAT STRUCT MOL BIOL, V17, P1279, DOI 10.1038/nsmb.1913; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Krol K, 2017, ONCOTARGET, V8, P24988, DOI 10.18632/oncotarget.15332; Kuntziger T, 2011, CELL CYCLE, V10, P1356, DOI 10.4161/cc.10.9.15442; Kurosaki T, 2016, J CELL SCI, V129, P461, DOI 10.1242/jcs.181008; Kuznetsov NV, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0481-6; Lafouresse F, 2012, IMMUNOLOGY, V137, P183, DOI 10.1111/j.1365-2567.2012.03620.x; Li M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7720; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Lim YW, 2015, ELIFE, V4, DOI 10.7554/eLife.08007; Looi CY, 2014, INT IMMUNOL, V26, P341, DOI 10.1093/intimm/dxt072; Mayer A, 2010, NAT STRUCT MOL BIOL, V17, P1272, DOI 10.1038/nsmb.1903; Miyamoto K, 2013, SCIENCE, V341, P1002, DOI 10.1126/science.1240376; Moulding DA, 2007, J EXP MED, V204, P2213, DOI 10.1084/jem.20062324; Nadel J, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0040-6; Nguyen TN, 2006, NAT METHODS, V3, P135, DOI 10.1038/nmeth0206-135; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Paulsen RD, 2009, MOL CELL, V35, P228, DOI 10.1016/j.molcel.2009.06.021; Richard P, 2017, J MOL BIOL, V429, P3168, DOI 10.1016/j.jmb.2016.08.031; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; Rodriguez-Mesa E, 2012, DEV DYNAM, V241, P608, DOI 10.1002/dvdy.23742; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Sadhukhan S, 2014, J IMMUNOL, V193, P150, DOI 10.4049/jimmunol.1302923; Santos-Pereira JM, 2015, NAT REV GENET, V16, P583, DOI 10.1038/nrg3961; Sanz LA, 2016, MOL CELL, V63, P167, DOI 10.1016/j.molcel.2016.05.032; Sarkar K, 2015, BLOOD, V126, P1670, DOI 10.1182/blood-2015-05-646182; Sarkar K, 2014, BLOOD, V124, P3409, DOI 10.1182/blood-2014-07-587642; Schwab RA, 2015, MOL CELL, V60, P351, DOI 10.1016/j.molcel.2015.09.012; Skourti-Stathaki K, 2014, NATURE, V516, P436, DOI 10.1038/nature13787; Skourti-Stathaki K, 2014, GENE DEV, V28, P1384, DOI 10.1101/gad.242990.114; Skourti-Stathaki K, 2011, MOL CELL, V42, P794, DOI 10.1016/j.molcel.2011.04.026; Sollier J, 2015, TRENDS CELL BIOL, V25, P514, DOI 10.1016/j.tcb.2015.05.003; Sollier J, 2014, MOL CELL, V56, P777, DOI 10.1016/j.molcel.2014.10.020; Stirling PC, 2012, GENE DEV, V26, P163, DOI 10.1101/gad.179721.111; Stork CT, 2016, ELIFE, V5, DOI 10.7554/eLife.17548; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Taylor MD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000813; Teitell MA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001336; Tresini M, 2015, NATURE, V523, P53, DOI 10.1038/nature14512; Trifari S, 2006, J IMMUNOL, V177, P7451, DOI 10.4049/jimmunol.177.10.7451; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Verboon JM, 2015, CURR BIOL, V25, P804, DOI 10.1016/j.cub.2015.01.052; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; Wahba L, 2011, MOL CELL, V44, P978, DOI 10.1016/j.molcel.2011.10.017; Westerberg LS, 2010, J EXP MED, V207, P1145, DOI 10.1084/jem.20091245; Wickramasinghe VO, 2016, MOL CELL, V61, P496, DOI 10.1016/j.molcel.2016.02.001; Xia PY, 2014, J EXP MED, V211, P2119, DOI 10.1084/jem.20140169; Yang YZ, 2014, MOL CELL, V53, P484, DOI 10.1016/j.molcel.2014.01.011; Yeo G, 2004, J COMPUT BIOL, V11, P377, DOI 10.1089/1066527041410418; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919; Zhang X, 2016, BLOOD, V127, P3180, DOI 10.1182/blood-2015-06-652636	87	24	27	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					219	234		10.1016/j.jaci.2017.11.023	http://dx.doi.org/10.1016/j.jaci.2017.11.023			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29248492	Bronze, Green Accepted			2022-12-18	WOS:000437837500025
J	Pavord, ID				Pavord, Ian D.			Biologics and chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Biologics; chronic obstructive pulmonary diseases	EOSINOPHILIC AIRWAY INFLAMMATION; RANDOMIZED CONTROLLED-TRIAL; NECROSIS-FACTOR-ALPHA; PLACEBO-CONTROLLED TRIAL; CONTROLLED PHASE-3 TRIAL; SHORT-TERM RESPONSE; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; INHALED CORTICOSTEROIDS; SPUTUM-EOSINOPHILIA	The presence of airway inflammation in patients with chronic obstructive pulmonary disease (COPD) provides a rationale for biological agents targeting specific inflammatory pathways. This approach has been strikingly effective in patients with other chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, and asthma. However, there are important and unresolved challenges in COPD, including our incomplete understanding of heterogeneity of the lower airway inflammatory response and how these contribute to the clinical expression of disease. As a result, progress has been slow, and there have been many failures. One notable exception is the targeting of eosinophilic airway inflammation with anti-IL-5, which has an acknowledged and important role in the treatment of severe eosinophilic asthma. Recent phase III studies have shown a reduction in exacerbations of around 20% in patients with COPD and clear evidence of a blood eosinophil count-dependent beneficial effect. The demonstration of clinical efficacy linked to a clinically accessible biomarker raises the possibility of precision biomarker-directed use of biological agents in patients with COPD. The hope is that this will be an exemplar for the future development of biological agents in patients with COPD.	[Pavord, Ian D.] Nuffield Dept Med, Resp Med Unit, NDM Res Bldg,Old Rd Campus, Oxford OX3 7FZ, England; [Pavord, Ian D.] Nuffield Dept Med, Oxford Resp NIHR BRC, NDM Res Bldg,Old Rd Campus, Oxford OX3 7FZ, England	University of Oxford; University of Oxford	Pavord, ID (corresponding author), Nuffield Dept Med, Resp Med Unit, NDM Res Bldg,Old Rd Campus, Oxford OX3 7FZ, England.; Pavord, ID (corresponding author), Nuffield Dept Med, Oxford Resp NIHR BRC, NDM Res Bldg,Old Rd Campus, Oxford OX3 7FZ, England.	ian.pavord@ndm.ox.ac.uk			AstraZeneca; Boehringer Ingelheim; Aerocrine; Almirall; Novartis; Teva; Chiesi; GlaxoSmithKline	AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Aerocrine; Almirall(Almirall); Novartis(Novartis); Teva(Teva Pharmaceutical Industries); Chiesi(Chiesi Pharmaceuticals Inc); GlaxoSmithKline(GlaxoSmithKline)	In the last 5 years, I. D. Pavord has received speakers' honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, and GlaxoSmithKline and payments for organizing educational events from AstraZeneca and Teva; has received honoraria for attending advisory panels with Genentech, Regeneron, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva, Merck, Sanofi, Circassia, Chiesi, and Knopp; has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Teva, and Chiesi; and has received a grant from Chiesi to support a phase 2 clinical trial in Oxford.	Aaron SD, 2013, THORAX, V68, P142, DOI 10.1136/thoraxjnl-2012-202432; Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Bafadhel M, 2012, RESPIRATION, V83, P36, DOI 10.1159/000330667; Bafadhel M, 2018, LANCET RESP MED, V6, P117, DOI 10.1016/S2213-2600(18)30006-7; Bafadhel M, 2017, LANCET RESP MED, V5, P913, DOI 10.1016/S2213-2600(17)30445-9; Bafadhel M, 2017, LANCET RESP MED, V5, P747, DOI 10.1016/S2213-2600(17)30217-5; Bafadhel M, 2014, EUR RESPIR J, V44, P789, DOI 10.1183/09031936.00062614; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC; Barnes PJ, 2017, CLIN SCI, V131, P1541, DOI 10.1042/CS20160487; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 2005, THORAX, V60, P193, DOI 10.1136/thx.2004.032516; Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0; Brusselle GG, 2013, NAT MED, V19, P977, DOI 10.1038/nm.3300; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Calverley PM, 2015, AM J RESP CRIT CARE, V191; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064; Dentener MA, 2008, RESPIRATION, V76, P275, DOI 10.1159/000117386; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; Global Initiative for Chronic Obstructive Lung Disease, 2017, GLOB STRAT DIAGN MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Guarascio AJ, 2013, CLINICOECONOMIC OUTC, V5, P235, DOI 10.2147/CEOR.S34321; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Han MLK, 2014, AM J RESP CRIT CARE, V189, P1503, DOI 10.1164/rccm.201402-0207OC; Hanania NA, 2016, LANCET RESP MED, V4, P781, DOI 10.1016/S2213-2600(16)30265-X; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449, DOI 10.1164/ajrccm.155.2.9032177; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Lange P, 2015, NEW ENGL J MED, V373, P111, DOI 10.1056/NEJMoa1411532; Mahler DA, 2004, CHEST, V126, P926, DOI 10.1378/chest.126.3.926; Matera MG, 2010, PULM PHARMACOL THER, V23, P121, DOI 10.1016/j.pupt.2009.10.007; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Pavord ID, 2017, NEW ENGL J MED, V377, P1613, DOI 10.1056/NEJMoa1708208; Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6; Pavord ID, 2016, THORAX, V71, P118, DOI 10.1136/thoraxjnl-2015-207021; Pavord ID, 2013, LANCET RESP MED, V1, P84, DOI 10.1016/S2213-2600(12)70049-8; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Rennard SI, 2007, AM J RESP CRIT CARE, V175, P926, DOI 10.1164/rccm.200607-995OC; Rennard SI, 2015, AM J RESP CRIT CARE, V191, P1001, DOI 10.1164/rccm.201405-0992OC; Rogliani P, 2015, PULM PHARMACOL THER, V31, P15, DOI 10.1016/j.pupt.2015.01.005; Sakao S, 2001, AM J RESP CRIT CARE, V163, P420, DOI 10.1164/ajrccm.163.2.2006031; Siddiqui SH, 2015, AM J RESP CRIT CARE, V192, P523, DOI 10.1164/rccm.201502-0235LE; Singh D, 2014, EUR RESPIR J, V44, P1697, DOI 10.1183/09031936.00162414; Siva R, 2007, EUR RESPIR J, V29, P906, DOI 10.1183/09031936.00146306; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; Staton TL, 2016, BIOMARK MED, V10, P165, DOI 10.2217/bmm.15.116; Suissa S, 2008, PULM PHARMACOL THER, V21, P234, DOI 10.1016/j.pupt.2007.03.003; Suissa S, 2013, THORAX, V68, P1029, DOI 10.1136/thoraxjnl-2012-202872; Wedzicha JA, 2008, AM J RESP CRIT CARE, V177, P19, DOI 10.1164/rccm.200707-973OC; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048	63	24	25	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					1983	1991		10.1016/j.jaci.2018.04.020	http://dx.doi.org/10.1016/j.jaci.2018.04.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29729941	Bronze			2022-12-18	WOS:000434701600003
J	Cooles, FAH; Anderson, AE; Lendrem, DW; Norris, J; Pratt, AG; Hilkens, CMU; Isaacs, JD				Cooles, Faye A. H.; Anderson, Amy E.; Lendrem, Dennis W.; Norris, Julie; Pratt, Arthur G.; Hilkens, Catharien M. U.; Isaacs, John D.			The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Cooles, Faye A. H.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; NHS Fdn Trust, Newcastle Tyne Hosp, Natl Inst Hlth Res, Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England; Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK	Cooles, FAH (corresponding author), Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.	faye.cooles@newcastle.ac.uk	Lendrem, Dennis/L-9273-2019; Lendrem, Dennis/H-2590-2013	Isaacs, John/0000-0002-6103-7056; Cooles, Faye/0000-0002-8529-3337; Lendrem, Dennis/0000-0001-6268-5509; Hilkens, Catharien/0000-0003-2283-8886; Pratt, Arthur/0000-0002-9909-8209; Anderson, Amy/0000-0003-0532-623X	Medical Research Council; JWG Patterson Foundation; National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust and Newcastle University; MRC [MR/M003183/1, G1001518] Funding Source: UKRI; Medical Research Council [G1001518, MR/M003183/1] Funding Source: researchfish; National Institute for Health Research [CL-2016-01-002] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); JWG Patterson Foundation; National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust and Newcastle University; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the Medical Research Council and JWG Patterson Foundation. The research was supported by the National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust and Newcastle University. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Brkic Z, 2016, ANN RHEUM DIS, V75, P1567, DOI 10.1136/annrheumdis-2015-207392; de Jong TD, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1191-y; de Jong TD, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0564-y; Ferreira RC, 2014, DIABETES, V63, P2538, DOI 10.2337/db13-1777; Guiducci C, 2010, NATURE, V465, P937, DOI 10.1038/nature09102; Lubbers J, 2013, ANN RHEUM DIS, V72, P776, DOI 10.1136/annrheumdis-2012-202753; Narendra SC, 2014, J LEUKOCYTE BIOL, V95, P661, DOI 10.1189/jlb.0613320; Raterman HG, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3819; Shimane K, 2009, ANN RHEUM DIS, V68, P377, DOI 10.1136/ard.2007.085704	9	24	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					445	448		10.1016/j.jaci.2017.08.026	http://dx.doi.org/10.1016/j.jaci.2017.08.026			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28987811	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000419312200060
J	Dubiela, P; Aina, R; Polak, D; Geiselhart, S; Humeniuk, P; Bohle, B; Alessandri, S; Del Conte, R; Cantini, F; Borowski, T; Bublin, M; Hoffmann-Sommergruber, K				Dubiela, Pawel; Aina, Roberta; Polak, Dominika; Geiselhart, Sabine; Humeniuk, Piotr; Bohle, Barbara; Alessandri, Stefano; Del Conte, Rebecca; Cantini, Francesca; Borowski, Tomasz; Bublin, Merima; Hoffmann-Sommergruber, Karin			Enhanced Pru p 3 IgE-binding activity by selective free fatty acid-interaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LIPID TRANSFER PROTEIN; ALLERGENS; PRU-P-3		[Dubiela, Pawel; Aina, Roberta; Polak, Dominika; Geiselhart, Sabine; Humeniuk, Piotr; Bohle, Barbara; Bublin, Merima; Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Alessandri, Stefano] Dept Statist, Florence, Italy; [Del Conte, Rebecca; Cantini, Francesca] Univ Florence, CERM, Florence, Italy; [Del Conte, Rebecca; Cantini, Francesca] Univ Florence, Dept Chem, Florence, Italy; [Borowski, Tomasz] Polish Acad Sci, Jerzy Haber Inst Catalysis & Surface Chem, Krakow, Poland	Medical University of Vienna; University of Florence; University of Florence; Polish Academy of Sciences; Jerzy Haber Institute of Catalysis & Surface Chemistry	Hoffmann-Sommergruber, K (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria.	karin.hoffmann@muv.ac.at	Humeniuk, Piotr/HCH-4108-2022; Borowski, Tomasz/E-8569-2016; Alessandri, Stefano/Q-6314-2019	Borowski, Tomasz/0000-0002-3450-3576; Alessandri, Stefano/0000-0001-8228-7559; Bohle, Barbara/0000-0002-5105-7985; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Geiselhart, Sabine/0000-0002-4749-3485; Dubiela, Pawel/0000-0001-8537-4404	Austrian Science Fund (FWF) [DK W 1248-B13, SFB F4603]; European Union (iNEXT) [653706]; PL-Grid Infrastructure; Marie-Curie project CARAMEL within the 7th European Community Framework Programme [626572]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); European Union (iNEXT); PL-Grid Infrastructure; Marie-Curie project CARAMEL within the 7th European Community Framework Programme	This work was funded by the Austrian Science Fund (FWF): grant number DK W 1248-B13 to P.D. and grant number SFB F4603 to K.H.-S. Further support came from the Horizon 2020 Programme of the European Union (iNEXT grant, project no. 653706). This research was also supported in part by PL-Grid Infrastructure and by the Marie-Curie project CARAMEL within the 7th European Community Framework Programme (grant no. 626572 to R.A.).	Abdullah SU, 2016, SCI REP-UK, V6, DOI 10.1038/srep30279; Bublin M, 2014, J ALLERGY CLIN IMMUN, V134, P521, DOI 10.1016/j.jaci.2014.04.015; Case D.A., 2014, AMBER 14; Dalvit C, 2001, J BIOMOL NMR, V21, P349, DOI 10.1023/A:1013302231549; Frisch M. J., 2016, GAUSSIAN 16 REV C01; Gaier S, 2008, MOL NUTR FOOD RES, V52, pS220, DOI 10.1002/mnfr.200700274; Garcia-Casado G, 2003, J ALLERGY CLIN IMMUN, V112, P599, DOI 10.1037/mai.2003.1638; Hauser Michael, 2010, Allergy Asthma Clin Immunol, V6, P1, DOI 10.1186/1710-1492-6-1; Liu F, 2015, J EXP BOT, V66, P5663, DOI 10.1093/jxb/erv313; Offermann LR, 2015, J AGR FOOD CHEM, V63, P9150, DOI 10.1021/acs.jafc.5b03534; Pasquato N, 2006, J MOL BIOL, V356, P684, DOI 10.1016/j.jmb.2005.11.063; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Vassilopoulou E, 2006, J ALLERGY CLIN IMMUN, V118, P473, DOI 10.1016/j.jaci.2006.04.057; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010	14	24	24	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1728	+		10.1016/j.jaci.2017.06.016	http://dx.doi.org/10.1016/j.jaci.2017.06.016			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28712832	Green Published, hybrid			2022-12-18	WOS:000417206000036
J	Tindemans, I; Lukkes, M; de Bruijn, MJW; Li, BWS; van Nimwegen, M; Amsen, D; KleinJan, A; Hendriks, RW				Tindemans, Irma; Lukkes, Melanie; de Bruijn, Marjolein J. W.; Li, Bobby W. S.; van Nimwegen, Menno; Amsen, Derk; KleinJan, Alex; Hendriks, Rudi W.			Notch signaling in T cells is essential for allergic airway inflammation, but expression of the Notch ligands Jagged 1 and Jagged 2 on dendritic cells is dispensable	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; Notch signaling; Gata-3; T(H)2 immunity; T(H)1 immunity; house dust mite; Jagged; recombination signal-binding protein for immunoglobulin J(k) region; cytokines	HOUSE-DUST MITE; FOLLICULAR-HELPER-CELLS; MEDIATED-IMMUNITY; GATA3 EXPRESSION; TYPE-2 IMMUNITY; TH2 IMMUNITY; DIFFERENTIATION; RESPONSES; RESPONSIVENESS; INDUCTION	Background: Allergic asthma is characterized by a T(H)2 response induced by dendritic cells (DCs) that present inhaled allergen. Although the mechanisms by which they instruct T(H)2 differentiation are still poorly understood, expression of the Notch ligand Jagged on DCs has been implicated in this process. Objective: We sought to establish whether Notch signaling induced by DCs is critical for house dust mite (HDM)-driven allergic airway inflammation (AAI) in vivo. Methods: The induction of Notch ligand expression on DC subsets by HDM was quantified by using quantitative real-time PCR. We used an HDM-driven asthma mouse model to compare the capacity of Jagged 1 and Jagged 2 single-and double-deficient DCs to induce AAI. In addition, we studied AAI in mice with a T cell-specific deletion of recombination signal-binding protein for immunoglobulin Jk region (RBPJk), a downstream effector of Notch signaling. Results: HDM exposure promoted expression of Jagged 1, but not Jagged 2, on DCs. In agreement with published findings, in vitro-differentiated and HDM-pulsed Jagged 1 and Jagged 2 double-deficient DCs lacked the capacity to induce AAI. However, after in vivo intranasal sensitization and challenge with HDM, DC-specific Jagged 1 or Jagged 2 single-or double-deficient mice had eosinophilic airway inflammation and a T(H)2 cell activation phenotype that was not different from that in control littermates. In contrast, RBPJk-deficient mice did not experience AAI and airway hyperreactivity. Conclusion: Our results show that the Notch signaling pathway in T cells is crucial for the induction of T(H)2-mediated AAI in an HDM-driven asthma model but that expression of Jagged 1 or Jagged 2 on DCs is not required.	[Tindemans, Irma; Lukkes, Melanie; de Bruijn, Marjolein J. W.; Li, Bobby W. S.; van Nimwegen, Menno; KleinJan, Alex; Hendriks, Rudi W.] Erasmus MC, Dept Pulm Med, Rm Ee2251a,POB 2040, NL-3000 CA Rotterdam, Netherlands; [Amsen, Derk] Sanquin, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Hendriks, RW (corresponding author), Erasmus MC, Dept Pulm Med, Rm Ee2251a,POB 2040, NL-3000 CA Rotterdam, Netherlands.	r.hendriks@erasmusmc.nl			Lung Foundation Netherlands [3.2.12.087, 3.2.12.067]	Lung Foundation Netherlands	Supported in part by Lung Foundation Netherlands grants 3.2.12.087 and 3.2.12.067.	Adler SH, 2003, J IMMUNOL, V171, P2896, DOI 10.4049/jimmunol.171.6.2896; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Amsen D, 2007, IMMUNITY, V27, P89, DOI 10.1016/j.immuni.2007.05.021; Amsen D, 2015, TRENDS IMMUNOL, V36, P802, DOI 10.1016/j.it.2015.10.007; Bailis W, 2013, IMMUNITY, V39, P148, DOI 10.1016/j.immuni.2013.07.006; Ballesteros-Tato A, 2016, IMMUNITY, V44, P259, DOI 10.1016/j.immuni.2015.11.017; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Dullaers M, 2017, J ALLERGY CLIN IMMUN, V140, P76, DOI 10.1016/j.jaci.2016.09.020; Fang TC, 2007, IMMUNITY, V27, P100, DOI 10.1016/j.immuni.2007.04.018; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Helbig C, 2012, P NATL ACAD SCI USA, V109, P9041, DOI 10.1073/pnas.1206044109; Helft J, 2015, IMMUNITY, V42, P1197, DOI 10.1016/j.immuni.2015.05.018; Huang HZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059482, 10.1371/journal.pone.0076982, 10.1371/journal.pone.0071808]; Jang S, 2010, J IMMUNOL, V185, P5835, DOI 10.4049/jimmunol.1000175; Kang JH, 2009, AM J RESP CRIT CARE, V179, P875, DOI 10.1164/rccm.200806-893OC; King IL, 2009, J EXP MED, V206, P1001, DOI 10.1084/jem.20090313; Krawczyk CM, 2008, J IMMUNOL, V180, P7931, DOI 10.4049/jimmunol.180.12.7931; Laky K, 2015, IMMUNITY, V42, P80, DOI 10.1016/j.immuni.2014.12.027; Lambrecht Bart N, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS236, DOI 10.1513/AnnalsATS.201405-218AW; Li YY, 2015, IMMUNOLOGY, V144, P127, DOI 10.1111/imm.12357; Lindell DM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003129; Maekawa Y, 2003, IMMUNITY, V19, P549, DOI 10.1016/S1074-7613(03)00270-X; Mukherjee S, 2014, J IMMUNOL, V192, P996, DOI 10.4049/jimmunol.1301991; Okamoto M, 2012, INT ARCH ALLERGY IMM, V157, P65, DOI 10.1159/000324836; Okamoto M, 2009, J IMMUNOL, V183, P2995, DOI 10.4049/jimmunol.0900692; Ong CT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002823; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Pletinckx K, 2011, EUR J IMMUNOL, V41, P3479, DOI 10.1002/eji.201141631; Rudd BD, 2007, J IMMUNOL, V178, P5820, DOI 10.4049/jimmunol.178.9.5820; Scheinman EJ, 2009, J BIOL CHEM, V284, P3037, DOI 10.1074/jbc.M807302200; Skokos D, 2007, J EXP MED, V204, P1525, DOI 10.1084/jem.20062305; Tsai JJ, 2016, IMMUNOBIOLOGY, V221, P1319, DOI 10.1016/j.imbio.2016.04.002; Tu LL, 2005, J EXP MED, V202, P1037, DOI 10.1084/jem.20050923; Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001; Worsley AGF, 2008, EUR J IMMUNOL, V38, P1043, DOI 10.1002/eji.200737335	37	24	27	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1079	1089		10.1016/j.jaci.2016.11.046	http://dx.doi.org/10.1016/j.jaci.2016.11.046			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28111308	Bronze, Green Submitted			2022-12-18	WOS:000412172900019
J	Niehues, H; Schalkwijk, J; van Vlijmen-Willems, IMJJ; Rodijk-Olthuis, D; van Rossum, MM; Wladykowski, E; Brandner, JM; van den Bogaard, EHJ; Zeeuwen, PLJM				Niehues, Hanna; Schalkwijk, Joost; van Vlijmen-Willems, Ivonne M. J. J.; Rodijk-Olthuis, Diana; van Rossum, Michelle M.; Wladykowski, Ewa; Brandner, Johanna M.; van den Bogaard, Ellen H. J.; Zeeuwen, Patrick L. J. M.			Epidermal equivalents of filaggrin null keratinocytes do not show impaired skin barrier function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ICHTHYOSIS VULGARIS; ATOPIC-DERMATITIS; STRATUM-CORNEUM; DEFICIENCY; INVOLUCRIN; KNOCKDOWN; PSORIASIS		[Niehues, Hanna; Schalkwijk, Joost; van Vlijmen-Willems, Ivonne M. J. J.; Rodijk-Olthuis, Diana; van Rossum, Michelle M.; van den Bogaard, Ellen H. J.; Zeeuwen, Patrick L. J. M.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Dermatol, Nijmegen, Netherlands; [Wladykowski, Ewa; Brandner, Johanna M.] Univ Hosp Hamburg Eppendorf, Dept Dermatol & Venerol, Hamburg, Germany	Radboud University Nijmegen; University of Hamburg; University Medical Center Hamburg-Eppendorf	van den Bogaard, EHJ (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Dermatol, Nijmegen, Netherlands.	Ellen.vandenBogaard@radboudumc.nl; Patrick.Zeeuwen@radboudumc.nl	Niehues, Hanna/P-5071-2015; Rossum, M.M./L-4614-2015; Schalkwijk, Joost/R-7509-2019; van den Bogaard, Ellen H./P-6212-2015; van Vlijmen-Willems, Ivonne MJJ/P-5336-2015; Zeeuwen, Patrick/N-1779-2013; Schalkwijk, Joost/N-1774-2013	Niehues, Hanna/0000-0002-6954-6955; Schalkwijk, Joost/0000-0002-1308-1319; van den Bogaard, Ellen H./0000-0003-4846-0287; van Vlijmen-Willems, Ivonne MJJ/0000-0002-3522-2573; Zeeuwen, Patrick/0000-0002-6878-2438; 	TOP grant of The Netherlands Organization for Health Research and Development (ZonMw) [91211052]; Deutsche Forschungsgemeinschaft [Br-1982-4]	TOP grant of The Netherlands Organization for Health Research and Development (ZonMw); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This study is funded by a TOP grant (grant no. 91211052) of The Netherlands Organization for Health Research and Development (ZonMw) awarded to J.S. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The work of J.M.B. was supported by the Deutsche Forschungsgemeinschaft (grant no. Br-1982-4).	Bergboer JGM, 2011, AM J PATHOL, V178, P1470, DOI 10.1016/j.ajpath.2010.12.017; Gruber R, 2015, AM J PATHOL, V185, P2777, DOI 10.1016/j.ajpath.2015.06.021; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Jakasa I, 2011, J INVEST DERMATOL, V131, P540, DOI 10.1038/jid.2010.307; Jones AL, 2016, J ALLERGY CLIN IMMUN, V137, P1247, DOI 10.1016/j.jaci.2016.01.010; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kuchler S, 2011, ATLA-ALTERN LAB ANIM, V39, P471, DOI 10.1177/026119291103900508; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mildner M, 2010, J INVEST DERMATOL, V130, P2286, DOI 10.1038/jid.2010.115; Niehues H, 2016, BRIT J DERMATOL, V174, P795, DOI 10.1111/bjd.14284; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pendaries V, 2014, J INVEST DERMATOL, V134, P2938, DOI 10.1038/jid.2014.259; Perusquia-Ortiz AM, 2013, J EUR ACAD DERMATOL, V27, P1552, DOI 10.1111/jdv.12079; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; van den Bogaard EH, 2013, J CLIN INVEST, V123, P917, DOI 10.1172/JCI65642; van Drongelen V, 2013, EXP DERMATOL, V22, P807, DOI 10.1111/exd.12271; VANDUIJNHOVEN JLP, 1992, ARCH DERMATOL RES, V284, P167, DOI 10.1007/BF00372711; Vavrova K, 2014, J INVEST DERMATOL, V134, P746, DOI 10.1038/jid.2013.402; Yokouchi M, 2015, J DERMATOL SCI, V77, P28, DOI 10.1016/j.jdermsci.2014.11.007; Zeeuwen PLJM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002301	21	24	24	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1979	+		10.1016/j.jaci.2016.09.016	http://dx.doi.org/10.1016/j.jaci.2016.09.016			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27742393	hybrid			2022-12-18	WOS:000402724600028
J	Paluel-Marmont, C; Bellon, N; Barbet, P; Leclerc-Mercier, S; Hadj-Rabia, S; Dupont, C; Bodemer, C				Paluel-Marmont, Colombe; Bellon, Nathalia; Barbet, Patrick; Leclerc-Mercier, Stephanie; Hadj-Rabia, Smail; Dupont, Christophe; Bodemer, Christine			Eosinophilic esophagitis and colonic mucosal eosinophilia in Netherton syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN; SERIES		[Paluel-Marmont, Colombe; Bellon, Nathalia; Dupont, Christophe] Necker Enfants Malad Hosp, AP HP, Dept Pediat Digest Funct Explorat Gastroenterol &, Paris, France; [Paluel-Marmont, Colombe; Bellon, Nathalia; Barbet, Patrick; Hadj-Rabia, Smail; Dupont, Christophe; Bodemer, Christine] Descartes Sorbonne Paris Cite Univ, Paris, France; [Bellon, Nathalia; Leclerc-Mercier, Stephanie; Hadj-Rabia, Smail; Bodemer, Christine] Necker Enfants Malad Hosp, AP HP, Dept Dermatol, Referral Ctr Genodermatoses MAGEC,Imagine Inst, Paris, France; [Barbet, Patrick; Leclerc-Mercier, Stephanie] Necker Enfants Malad Hosp, AP HP, Dept Pathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Bodemer, C (corresponding author), Descartes Sorbonne Paris Cite Univ, Paris, France.; Bodemer, C (corresponding author), Necker Enfants Malad Hosp, AP HP, Dept Dermatol, Referral Ctr Genodermatoses MAGEC,Imagine Inst, Paris, France.	christine.bodemer@aphp.fr	Leclerc-Mercier, Stéphanie/AAP-1057-2021	Hadj-Rabia, Smail/0000-0001-6801-7106	Sodilac, France; Danone Baby Nutrition and United Pharmaceuticals; Fondation Pierre Fabre; Roche Posay; Expanscience: Skin and neonates; Atopic dermatitis; Novartis	Sodilac, France; Danone Baby Nutrition and United Pharmaceuticals(Danone Nutricia); Fondation Pierre Fabre; Roche Posay; Expanscience: Skin and neonates; Atopic dermatitis; Novartis(Novartis)	C. Dupont has received board membership from Nutricia Baby Nutrition, DBV Technologies, Nestle; consultancy fees from Sodilac, France; payment for lectures from Danone Baby Nutrition and United Pharmaceuticals; and stock options from DBV Technologies. His institution has a patent with DBV Technologies. C. Bodemer's institution has received a grant from Fondation Pierre Fabre (Atopic dermaitis). She has received payment for lectures from la Roche Posay (Atopic Dermatitis and Microbioma), Expanscience: Skin and neonates; Atopic dermatitis, and Novartis: Inflammatory skin diseases in children; and travel expenses from Sanofi, Bioderma, and Novartis.	Behjati S, 2009, J PEDIATR GASTR NUTR, V49, P208, DOI 10.1097/MPG.0b013e31818de373; Hannula-Jouppi K, 2014, J ALLERGY CLIN IMMUN, V134, P985, DOI 10.1016/j.jaci.2014.07.008; Hovnanian A, 2013, CELL TISSUE RES, V351, P289, DOI 10.1007/s00441-013-1558-1; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Leclerc-Mercier S, 2016, AM J DERMATOPATH, V38, P83, DOI 10.1097/DAD.0000000000000425; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Masterson JC, 2011, CURR OPIN GASTROEN, V27, P515, DOI 10.1097/MOG.0b013e32834b314c	8	24	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					2003	+		10.1016/j.jaci.2016.10.045	http://dx.doi.org/10.1016/j.jaci.2016.10.045			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28025013	Bronze			2022-12-18	WOS:000402724600037
J	Dietz, K; Jimenez, MD; Gollwitzer, ES; Chaker, AM; Zissler, UM; Radmark, OP; Baarsma, HA; Konigshoff, M; Schmidt-Weber, CB; Marsland, BJ; Esser-von Bieren, J				Dietz, Katharina; Jimenez, Marta de los Reyes; Gollwitzer, Eva S.; Chaker, Adam M.; Zissler, Ulrich M.; Radmark, Olof P.; Baarsma, Hoeke A.; Koenigshoff, Melanie; Schmidt-Weber, Carsten B.; Marsland, Benjamin J.; Esser-von Bieren, Julia			Age dictates a steroid-resistant cascade of Wnt5a, transglutaminase 2, and leukotrienes in inflamed airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Age; airway remodeling; airway inflammation; allergy; asthma; bronchial epithelial cells; house dust mite; leukotrienes; lipid mediators; nasal polyps; secretory phospholipase A(2); transglutaminase 2; Wnt5a	SECRETED PHOSPHOLIPASE A(2); MOUSE ASTHMA MODEL; SMOOTH-MUSCLE-CELLS; EPITHELIAL-CELLS; TISSUE TRANSGLUTAMINASE; CYSTEINYL LEUKOTRIENES; EICOSANOID PRODUCTION; OXIDATIVE STRESS; DNA METHYLATION; EXPRESSION	Background: Airway remodeling is a detrimental and refractory process showing age-dependent clinical manifestations that are mechanistically undefined. The leukotriene (LT) and wingless/integrase (Wnt) pathways have been implicated in remodeling, but age-specific expression profiles and common regulators remained elusive. Objective: We sought to study the activation of the LT and Wnt pathways during early-or late-onset allergic airway inflammation and to address regulatory mechanisms and clinical relevance in normal human bronchial epithelial cells (NHBEs) and nasal polyp tissues. Methods: Mice were sensitized with house dust mite (HDM) allergens from days 3, 15, or 60 after birth. Remodeling factors in murine bronchoalveolar lavage fluid, lung tissue, or human nasal polyp tissue were analyzed by means of Western blotting, immunoassays, or histology. Regulatory mechanisms were studied in cytokine/HDM-stimulated NHBEs and macrophages. Results: Bronchoalveolar lavage fluid LT levels were increased in neonatal and adult but reduced in juvenile HDM-sensitized mice. Lungs of neonatally sensitized mice showed increased 5-lipoxygenase levels, whereas adult mice expressed more group 10 secretory phospholipase A(2), Wnt5a, and transglutaminase 2 (Tgm2). Older mice showed colocalization of Wnt5a and LT enzymes in the epithelium, a pattern also observed in human nasal polyps. IL-4 promoted epithelial Wnt5a secretion, which upregulated macrophage Tgm2 expression, and Tgm2 inhibition in turn reduced LT release. Tgm2, group 10 secretory phospholipase A(2), and LT enzymes in NHBEs and nasal polyps were refractory to corticosteroids. Conclusion: Our findings reveal age differences in LT and Wnt pathways during airway inflammation and identify a steroid-resistant cascade of Wnt5a, Tgm2, and LTs, which might represent a therapeutic target for airway inflammation and remodeling.	[Dietz, Katharina; Jimenez, Marta de los Reyes; Chaker, Adam M.; Zissler, Ulrich M.; Schmidt-Weber, Carsten B.; Esser-von Bieren, Julia] Tech Univ Munich, Ctr Allergy & Environm ZAUM, German Ctr Lung Res DZL, Munich, Germany; [Dietz, Katharina; Jimenez, Marta de los Reyes; Chaker, Adam M.; Zissler, Ulrich M.; Schmidt-Weber, Carsten B.; Esser-von Bieren, Julia] Helmholtz Ctr Munich, D-80802 Munich, Germany; [Gollwitzer, Eva S.; Marsland, Benjamin J.] Univ Lausanne, CHUV, Serv Pneumol, Fac Biol & Med, Lausanne, Switzerland; [Chaker, Adam M.] Tech Univ Munich, Klinikum Rechts Isar, Dept Otolaryngol, Allergy Sect, Munich, Germany; [Radmark, Olof P.] Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, Stockholm, Sweden; [Baarsma, Hoeke A.; Koenigshoff, Melanie] German Ctr Lung Res DZL, Helmholtz Zentrum Munchen, CPC, Munich, Germany; [Baarsma, Hoeke A.; Koenigshoff, Melanie] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Munich, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Technical University of Munich; Karolinska Institutet; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Esser-von Bieren, J (corresponding author), Helmholtz Ctr Munich, D-80802 Munich, Germany.; Esser-von Bieren, J (corresponding author), Tech Univ Munich, Ctr Allergy & Environm ZAUM, D-80802 Munich, Germany.	Julia.esser@tum.de	Zissler, Ulrich Matthias/AAP-2878-2020; Schmidt-Weber, Carsten B./AAU-1621-2021; Zissler, Ulrich Matthias/GSD-3514-2022; Zissler, Ulrich/GRO-1107-2022	Zissler, Ulrich Matthias/0000-0003-4826-3419; Schmidt-Weber, Carsten B./0000-0002-3203-8084; Zissler, Ulrich Matthias/0000-0003-4826-3419; Chaker, Adam/0000-0002-5117-4073; Baarsma, Hoeke/0000-0002-0792-0374; Esser-von Bieren, Julia/0000-0003-1898-9382	German Center for Lung Research (DZL) [82DZL00302]; Else Kroner-Fresenius-Stiftung [2015_A195]; Allergopharma; PLS Design; Zeller AG; ALK-Abello; GlaxoSmithKline; Technical University of Munich; HAL-Allergy; Mundipharma; Lofarma	German Center for Lung Research (DZL); Else Kroner-Fresenius-Stiftung; Allergopharma; PLS Design; Zeller AG; ALK-Abello; GlaxoSmithKline(GlaxoSmithKline); Technical University of Munich; HAL-Allergy; Mundipharma; Lofarma	Supported by the German Center for Lung Research (DZL; 82DZL00302) and by the Else Kroner-Fresenius-Stiftung (grant 2015_A195). C.B.S.-W. received grant support from Allergopharma, PLS Design as well as Zeller AG and received speaker honoraria from Allergopharma. A.M.C. reports giving lectures sponsored by Allergopharma, ALK-Abello, and GlaxoSmithKline and received grant support or consultant arrangements via Technical University of Munich with Allergopharma, ALK-Abello, HAL-Allergy, Mundipharma, Lofarma, Zeller AG, and Novartis.	BALTER MS, 1989, J IMMUNOL, V142, P602; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Berair R, 2014, DRUGS, V74, P1345, DOI 10.1007/s40265-014-0250-4; Boyce JA, 2015, AM J RESP CRIT CARE, V191, P496, DOI 10.1164/rccm.201501-0073ED; Bozyk PD, 2011, STEM CELLS DEV, V20, P1995, DOI 10.1089/scd.2010.0494; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Campisi A, 2008, J NEUROSCI RES, V86, P1297, DOI 10.1002/jnr.21579; Carnieli DS, 2011, PEDIATR PULM, V46, P650, DOI 10.1002/ppul.21436; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Chan JKW, 2013, AM J RESP CELL MOL, V48, P114, DOI 10.1165/rcmb.2012-0108OC; Cummings HE, 2013, J IMMUNOL, V191, P5807, DOI 10.4049/jimmunol.1302187; Curro M, 2014, AMINO ACIDS, V46, P759, DOI 10.1007/s00726-013-1569-y; Dorscheid DR, 2003, J ALLERGY CLIN IMMUN, V111, P360, DOI 10.1067/mai.2003.117; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; Durrani SR, 2011, J ALLERGY CLIN IMMUN, V128, P439, DOI 10.1016/j.jaci.2011.06.002; Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039; Esser-von Bieren Julia, 2013, PLoS Pathog, V9, pe1003771, DOI 10.1371/journal.ppat.1003771; Florian MC, 2013, NATURE, V503, P392, DOI 10.1038/nature12631; Frischer T, 2000, ALLERGY, V55, P773, DOI 10.1034/j.1398-9995.2000.00773.x; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Hallstrand TS, 2011, CLIN EXP ALLERGY, V41, P801, DOI 10.1111/j.1365-2222.2010.03676.x; Hallstrand TS, 2007, AM J RESP CRIT CARE, V176, P1072, DOI 10.1164/rccm.200707-1088OC; Hallstrand TS, 2016, J ALLERGY CLIN IMMUN, V137, P268, DOI 10.1016/j.jaci.2015.05.026; Hallstrand TS, 2012, PULM PHARMACOL THER, V25, P432, DOI 10.1016/j.pupt.2012.02.004; Hallstrand TS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008583; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Henderson WR, 2007, J EXP MED, V204, P865, DOI 10.1084/jem.20070029; Henderson WR, 2011, J BIOL CHEM, V286, P28049, DOI 10.1074/jbc.M111.235812; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Hewitson JP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004676; Holmes D, 2012, NAT REV DRUG DISCOV, V11, P737, DOI 10.1038/nrd3858; Hosoki K, 2014, BIOCHEM BIOPH RES CO, V449, P351, DOI 10.1016/j.bbrc.2014.05.033; Jame AJ, 2007, CLIN EXP ALLERGY, V37, P880, DOI 10.1111/j.1365-2222.2007.02733.x; Kariyawasam HH, 2009, J ALLERGY CLIN IMMUN, V124, P454, DOI 10.1016/j.jaci.2009.06.022; Keillor JW, 2015, TRENDS PHARMACOL SCI, V36, P32, DOI 10.1016/j.tips.2014.10.014; Kumawat K, 2016, CELL MOL LIFE SCI, V73, P567, DOI 10.1007/s00018-015-2076-y; Kumawat K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094801; Kumawat K, 2013, FASEB J, V27, P1631, DOI 10.1096/fj.12-217539; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lezmi G, 2015, AM J RESP CRIT CARE, V192, P164, DOI 10.1164/rccm.201411-1958OC; Li CG, 2002, DEV BIOL, V248, P68, DOI 10.1006/dbio.2002.0729; Lovinsky-Desir S, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-9; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; MacRedmond RE, 2013, J STEROIDS HORM SCI, V5, P134; Maiuri L, 2008, J IMMUNOL, V180, P7697, DOI 10.4049/jimmunol.180.11.7697; Malmstrom K, 2015, ANN ALLERG ASTHMA IM, V114, P90, DOI 10.1016/j.anai.2014.09.019; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; McKeage K, 2013, DRUGS, V73, P195, DOI 10.1007/s40265-013-0016-4; Myneni VD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.238; O'Reilly R, 2013, J ALLERGY CLIN IMMUN, V131, P1024, DOI 10.1016/j.jaci.2012.08.044; Ochkur SI, 2013, AM J RESP CELL MOL, V49, P1074, DOI 10.1165/rcmb.2013-0009OC; Oh K, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-35; Olsen KC, 2014, AM J RESP CELL MOL, V50, P737, DOI 10.1165/rcmb.2013-0092OC; Olsen KC, 2011, AM J RESP CRIT CARE, V184, P699, DOI 10.1164/rccm.201101-0013OC; Papasotiriou M, 2012, NEPHRON CLIN PRACT, V121, pC60, DOI 10.1159/000341116; Park KS, 2010, J CANCER RES CLIN, V136, P493, DOI 10.1007/s00432-009-0681-6; Park SJ, 2015, YONSEI MED J, V56, P426, DOI 10.3349/ymj.2015.56.2.426; Patel M, 2014, J ALLER CL IMM-PRACT, V2, P751, DOI 10.1016/j.jaip.2014.06.001; Perng DW, 2006, AM J RESP CELL MOL, V34, P101, DOI 10.1165/rcmb.2005-0068OC; Provost V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043544; Reuter S, 2016, LAB INVEST, V96, P177, DOI 10.1038/labinvest.2015.143; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Shin DM, 2004, J BIOL CHEM, V279, P15032, DOI 10.1074/jbc.M308734200; Shin DM, 2008, FASEB J, V22, P2498, DOI 10.1096/fj.07-095455; Trian T, 2015, AM J RESP CRIT CARE, V191, P538, DOI 10.1164/rccm.201409-1582OC; Trischler J, 2016, AM J RESP CELL MOL, V54, P584, DOI 10.1165/rcmb.2014-0425OC; Uhlik J, 2014, INT ARCH ALLERGY IMM, V164, P289, DOI 10.1159/000366278; Vijay R, 2015, J EXP MED, V212, P1851, DOI 10.1084/jem.20150632; Wadsworth SJ, 2010, J ALLERGY CLIN IMMUN, V126, P366, DOI 10.1016/j.jaci.2010.05.015; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831; Yamaguchi M, 2016, J LEUKOCYTE BIOL, V100, P131, DOI 10.1189/jlb.3A0815-372R; Zissler UM, 2016, MUCOSAL IMMUNOL, V9, P917, DOI 10.1038/mi.2015.110; Zissler UM, 2016, ALLERGY, V71, P475, DOI 10.1111/all.12828	73	24	24	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1343	+		10.1016/j.jaci.2016.07.014	http://dx.doi.org/10.1016/j.jaci.2016.07.014			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27554815	Green Accepted, Bronze			2022-12-18	WOS:000398771800029
J	Hasegawa, K; Mansbach, JM; Ajami, NJ; Petrosino, JF; Freishtat, RJ; Teach, SJ; Piedra, PA; Camargo, CA				Hasegawa, Kohei; Mansbach, Jonathan M.; Ajami, Nadim J.; Petrosino, Joseph F.; Freishtat, Robert J.; Teach, Stephen J.; Piedra, Pedro A.; Camargo, Carlos A., Jr.			Serumcathelicidin, nasopharyngeal microbiota, and disease severity among infants hospitalized with bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RESPIRATORY SYNCYTIAL VIRUS; ANTIMICROBIAL PEPTIDE; CHILDREN		[Hasegawa, Kohei; Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Mansbach, Jonathan M.] Boston Childrens Hosp, Dept Med, Boston, MA USA; [Ajami, Nadim J.; Petrosino, Joseph F.] Baylor Coll Med, Dept Mol Virol & Microbiol, Alkek Ctr Metagen & Microbiome Res, Houston, TX 77030 USA; [Freishtat, Robert J.; Teach, Stephen J.] Childrens Natl Med Ctr, Div Emergency Med, Washington, DC 20010 USA; [Freishtat, Robert J.; Teach, Stephen J.] Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol & Pediat, Houston, TX 77030 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Baylor College of Medicine; Children's National Health System; Children's National Health System; Baylor College of Medicine	Hasegawa, K (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA.	khasegawa1@partners.org	Camargo, Carlos A./C-2145-2008; Petrosino, Joseph F./AAF-1621-2019	Camargo, Carlos A./0000-0002-5071-7654; Freishtat, Robert/0000-0002-7411-2342; Hasegawa, Kohei/0000-0002-5739-7999	National Institutes of Health (Bethesda, Md) [U01 AI-087881, R01 AI-114552, R01 AI-108588, R21 HL-129909]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL129909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI114552, U01AI087881, R01AI108588] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [UG3OD023253] Funding Source: NIH RePORTER	National Institutes of Health (Bethesda, Md)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the National Institutes of Health (Bethesda, Md; grant nos. U01 AI-087881, R01 AI-114552, R01 AI-108588, and R21 HL-129909). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Hasegawa K, 2016, EUR RESPIR J, V48, P1329, DOI 10.1183/13993003.00152-2016; Hilchie AL, 2013, NAT CHEM BIOL, V9, P761, DOI [10.1038/NCHEMBIO.1393, 10.1038/nchembio.1393]; Kovach MA, 2012, J IMMUNOL, V189, P304, DOI 10.4049/jimmunol.1103196; Mansbach JM, 2016, J ALLERGY CLIN IMMUN, V137, P1909, DOI 10.1016/j.jaci.2016.01.036; Mansbach JM, 2012, J ALLERGY CLIN IMMUN, V130, P1007, DOI 10.1016/j.jaci.2012.07.044; Marsh RL, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0182-1; Neumann A, 2014, BIOCHEM J, V464, P3, DOI 10.1042/BJ20140778; Piters WAAD, 2016, AM J RESP CRIT CARE, V194, P1104, DOI 10.1164/rccm.201602-0220OC; Pound LD, 2015, DIABETES, V64, P4135, DOI 10.2337/db15-0788; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742	10	24	25	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1383	1386		10.1016/j.jaci.2016.09.037	http://dx.doi.org/10.1016/j.jaci.2016.09.037			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27845236	Green Accepted, Bronze			2022-12-18	WOS:000398771800036
J	Liang, Y; Xing, XY; Beamer, MA; Swindell, WR; Sarkar, MK; Roberts, LW; Voorhees, JJ; Kahlenberg, JM; Harms, PW; Johnston, A; Gudjonsson, JE				Liang, Yun; Xing, Xianying; Beamer, Maria A.; Swindell, William R.; Sarkar, Mrinal K.; Roberts, Liza Wolterink; Voorhees, John J.; Kahlenberg, J. Michelle; Harms, Paul W.; Johnston, Andrew; Gudjonsson, Johann E.			Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pustular skin disorders; neutrophils; inflammation; transcriptomic profiling; 6-transmembrane epithelial antigens of prostate; IL-1; IL-36; CXCL1; CXCL8	GENERALIZED EXANTHEMATOUS PUSTULOSIS; BARDET-BIEDL-SYNDROME; GENE-EXPRESSION; HUMAN NEUTROPHILS; STEAP PROTEINS; PSORIASIS; IL36RN; SYSTEM; CELLS; INSTABILITY	Background: Pustular skin disorders are a category of difficult-to-treat and potentially life-threatening conditions that involve the appearance of neutrophil-rich pustules. The molecular basis of most pustular skin conditions has remained unknown. Objective: We sought to investigate the molecular basis of 3 pustular skin disorders: generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP), and acute generalized exanthematous pustulosis (AGEP). Methods: Microarray analyses were performed to profile genome-wide gene expression of skin biopsy specimens obtained from patients with GPP, PPP, or AGEP and healthy control subjects. Functional enrichment, gene network, and k-means clustering analyses were used to identify molecular pathways dysregulated in patients with these disorders. Immunohistochemistry and immunofluorescence were used to determine protein localization. Quantitative RT-PCR and ELISA were used to determine transcript and secreted cytokine levels. Small interfering RNA was used to decrease transcript levels. Results: Molecules and pathways related to neutrophil chemotaxis emerged as common alterations in patients with GPP, PPP, and AGEP, which is consistent with the pustular phenotypes. Expression of two 6-transmembrane epithelial antigens of the prostate (STEAP) proteins, STEAP1 and STEAP4, was increased in patients' skin and colocalized with IL-36 gamma around neutrophilic pustules. STEAP1/4 expression clustered with and positively correlated with that of IL-1, the IL-36 family proteins, and CXCL1/8. STEAP4 expression was activated by cytokines and suppressed by inhibition of mitogen-activated protein kinase kinase 1/2, whereas STEAP1 expression appeared less prone to such dynamic regulation. Importantly, STEAP1/4 knockdown resulted in impaired induction of a broad spectrum of proinflammatory cytokines, including IL-1, IL-36, and the neutrophil chemotaxins CXCL1 and CXCL8. STEAP1/4 knockdown also reduced the ability of keratinocytes to induce neutrophil chemotaxis. Conclusion: Transcriptomic changes in 3 pustular skin disorders, GPP, PPP, and AGEP, converged on neutrophil chemotaxis and diapedesis and cytokines known to drive neutrophil-rich inflammatory processes, including IL-1 and members of the IL-36 family. STEAP1 and STEAP4 positively regulate the induction of proinflammatory neutrophil-activating cytokines.	[Liang, Yun; Xing, Xianying; Beamer, Maria A.; Sarkar, Mrinal K.; Roberts, Liza Wolterink; Voorhees, John J.; Harms, Paul W.; Johnston, Andrew; Gudjonsson, Johann E.] Univ Michigan, Dept Dermatol, 6427 Med Sci 1,1301 Catherine St, Ann Arbor, MI 48109 USA; [Kahlenberg, J. Michelle] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI 48109 USA; [Harms, Paul W.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Swindell, William R.] Ohio Univ, Heritage Coll Osteopath Med, Athens, OH 45701 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; Ohio University	Gudjonsson, JE (corresponding author), Univ Michigan, Dept Dermatol, 6427 Med Sci 1,1301 Catherine St, Ann Arbor, MI 48109 USA.	johanng@med.umich.edu	Voorhees, John/AAM-9966-2020	Voorhees, John/0000-0003-1856-785X; Kahlenberg, J. Michelle/0000-0002-4006-8945; Sarkar, Mrinal/0000-0001-8505-4259; Harms, Paul/0000-0002-0802-2883	University of Michigan Babcock Endowment Fund; National Institutes of Health (NIH) [K08-AR060802, R01-AR069071]; A. Alfred Taubman Medical Research Institute Kenneth and Frances Eisenberg Emerging Scholar Award; Doris Duke Charitable Foundation [2013106]; Novartis; NIH [K01 AR064765]; National Psoriasis Foundation USA; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the NIH [K08AR063668]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR060802, R01AR069071, K08AR063668, K01AR064765, T32AR007197] Funding Source: NIH RePORTER	University of Michigan Babcock Endowment Fund; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); A. Alfred Taubman Medical Research Institute Kenneth and Frances Eisenberg Emerging Scholar Award; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Novartis(Novartis); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Psoriasis Foundation USA; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the NIH; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported in part by the University of Michigan Babcock Endowment Fund (to A.J., Y.L, X.X., M.K.S., J.J.V., and J.E.G.), National Institutes of Health (NIH) awards K08-AR060802 and R01-AR069071 (to J.E.G.), the A. Alfred Taubman Medical Research Institute Kenneth and Frances Eisenberg Emerging Scholar Award (to J.E.G.), the Doris Duke Charitable Foundation Grant no. 2013106 (to J.E.G.), and Novartis (J.E.G.). A.J. is supported by NIH grant K01 AR064765 and the National Psoriasis Foundation USA. J.M.K. was partially supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the NIH under award no. K08AR063668.	Aguirre JD, 2012, J BIOL CHEM, V287, P13541, DOI 10.1074/jbc.R111.312181; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bissonnette R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158190; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Campregher C, 2008, GUT, V57, P780, DOI 10.1136/gut.2007.141556; Capon F, 2013, J INVEST DERMATOL, V133, P2503, DOI 10.1038/jid.2013.361; Challita-Eid PM, 2007, CANCER RES, V67, P5798, DOI 10.1158/0008-5472.CAN-06-3849; Chen XH, 2010, INT J MOL MED, V25, P361, DOI 10.3892/ijmm_00000353; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; Fedorowicz G, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-23; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; Forsythe E, 2013, EUR J HUM GENET, V21, P8, DOI 10.1038/ejhg.2012.115; Gomes IM, 2012, MOL CANCER RES, V10, P573, DOI 10.1158/1541-7786.MCR-11-0281; Harbort CJ, 2015, BLOOD, V126, P2842, DOI 10.1182/blood-2015-05-645424; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Henry CM, 2016, CELL REP, V14, P708, DOI 10.1016/j.celrep.2015.12.072; Hodgin JB, 2010, AM J PATHOL, V177, P1674, DOI 10.2353/ajpath.2010.090746; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Johnston A, 2011, J INVEST DERMATOL, V131, P329, DOI 10.1038/jid.2010.313; Korber A, 2013, J INVEST DERMATOL, V133, P2634, DOI 10.1038/jid.2013.214; Komatsu K, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-63; Krawchuk D, 2010, DEV BIOL, V347, P133, DOI 10.1016/j.ydbio.2010.08.015; Langley RGB, 2005, ANN RHEUM DIS, V64, P18, DOI 10.1136/ard.2004.033217; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Mengesha Yebabe M, 2002, Am J Clin Dermatol, V3, P389, DOI 10.2165/00128071-200203060-00003; Moldes M, 2001, J BIOL CHEM, V276, P33938, DOI 10.1074/jbc.M105726200; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; Nakai N, 2015, JAMA DERMATOL, V151, P311, DOI 10.1001/jamadermatol.2014.3002; Navarini AA, 2013, J INVEST DERMATOL, V133, P1904, DOI 10.1038/jid.2013.44; O'Rourke MP, 2002, DEV BIOL, V248, P143, DOI 10.1006/dbio.2002.0730; Ohgami RS, 2006, BLOOD, V108, P1388, DOI 10.1182/blood-2006-02-003681; Ohgami RS, 2005, NAT GENET, V37, P1264, DOI 10.1038/ng1658; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Petrak J, 2005, INT J BIOCHEM CELL B, V37, P1173, DOI 10.1016/j.biocel.2004.12.007; Prince LR, 2011, CURR OPIN PHARMACOL, V11, P397, DOI 10.1016/j.coph.2011.06.007; Reichel CA, 2009, ARTERIOSCL THROM VAS, V29, P1787, DOI 10.1161/ATVBAHA.109.193268; Richardson DR, 2010, P NATL ACAD SCI USA, V107, P10775, DOI 10.1073/pnas.0912925107; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saletta F, 2010, MOL PHARMACOL, V77, P443, DOI 10.1124/mol.109.061028; Schmitz ML, 2016, TRENDS PHARMACOL SCI, V37, P101, DOI 10.1016/j.tips.2015.10.004; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; Scott AM, 2007, CELL DEATH DIFFER, V14, P23, DOI 10.1038/sj.cdd.4402026; Setta-Kaffetzi N, 2013, J INVEST DERMATOL, V133, P1366, DOI 10.1038/jid.2012.490; Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803; Srinivasan G, 2012, J IMMUNOL, V189, P1911, DOI 10.4049/jimmunol.1200892; Tayeh MK, 2008, HUM MOL GENET, V17, P1956, DOI 10.1093/hmg/ddn093; Taylor PR, 2014, NAT IMMUNOL, V15, P143, DOI 10.1038/ni.2797; Wang JS, 2006, CELL MOL IMMUNOL, V3, P255; Wang L., 2010, APPL ACOUST, V1, P1; Wellen KE, 2007, CELL, V129, P537, DOI 10.1016/j.cell.2007.02.049; Xue ML, 2007, IMMUNOL CELL BIOL, V85, P525, DOI 10.1038/sj.icb.7100082	61	24	25	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1217	1227		10.1016/j.jaci.2016.10.021	http://dx.doi.org/10.1016/j.jaci.2016.10.021			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27884600	Green Accepted			2022-12-18	WOS:000398771800017
J	Naeem, AS; Tommasi, C; Cole, C; Brown, SJ; Zhu, YN; Way, B; Owen, SAGW; Moffatt, M; Cookson, WO; Harper, JI; Di, WL; Brown, SJ; Reinheckel, T; O'Shaughnessy, RFL				Naeem, Aishath S.; Tommasi, Cristina; Cole, Christian; Brown, Stuart J.; Zhu, Yanan; Way, Benjamin; Owen, Saffron A. G. Willis; Moffatt, Miriam; Cookson, William O.; Harper, John I.; Di, Wei-Li; Brown, Sara J.; Reinheckel, Thomas; O'Shaughnessy, Ryan F. L.			A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; skin barrier; filaggrin; regulatory associated protein of the MTOR complex 1; protease	GENOME-WIDE ASSOCIATION; OF-FUNCTION MUTATIONS; CHRONIC HAND ECZEMA; RETINOIC ACID; ICHTHYOSIS VULGARIS; TERMINAL DIFFERENTIATION; SUSCEPTIBILITY LOCI; STRATUM-CORNEUM; RARE MUTATIONS; TH2 CYTOKINES	Background: Filaggrin, which is encoded by the filaggrin gene (FLG), is an important component of the skin's barrier to the external environment, and genetic defects in FLG strongly associate with atopic dermatitis (AD). However, not all patients with AD have FLG mutations. Objective: We hypothesized that these patients might possess other defects in filaggrin expression and processing contributing to barrier disruption and AD, and therefore we present novel therapeutic targets for this disease. Results: We describe the relationship between the mechanistic target of rapamycin complex 1/2 protein subunit regulatory associated protein of the MTOR complex 1 (RAPTOR), the serine/threonine kinase V-Akt murine thymoma viral oncogene homolog 1 (AKT1), and the protease cathepsin H (CTSH), for which we establish a role in filaggrin expression and processing. Increased RAPTOR levels correlated with decreased filaggrin expression in patients with AD. In keratinocyte cell cultures RAPTOR upregulation or AKT1 short hairpin RNA knockdown reduced expression of the protease CTSH. Skin of CTSH-deficient mice and CTSH short hairpin RNA knockdown keratinocytes showed reduced filaggrin processing, and the mouse had both impaired skin barrier function and a mild proinflammatory phenotype. Conclusion: Our findings highlight a novel and potentially treatable signaling axis controlling filaggrin expression and processing that is defective in patients with AD.	[Naeem, Aishath S.; Tommasi, Cristina; Brown, Stuart J.; Zhu, Yanan; Way, Benjamin; Harper, John I.; Di, Wei-Li; O'Shaughnessy, Ryan F. L.] UCL Inst Child Hlth, Immunobiol & Dermatol, London, England; [Naeem, Aishath S.; Tommasi, Cristina; Brown, Stuart J.; Zhu, Yanan; Way, Benjamin; Harper, John I.; Di, Wei-Li; O'Shaughnessy, Ryan F. L.] UCL Inst Child Hlth, Livingstone Skin Res Ctr, London, England; [Cole, Christian] Univ Dundee, Computat Biol, Sch Life Sci, Dundee DD1 4HN, Scotland; [Brown, Sara J.] Univ Dundee, Med Res Inst, Ctr Dermatol & Genet Med, Dundee DD1 4HN, Scotland; [Owen, Saffron A. G. Willis; Moffatt, Miriam; Cookson, William O.] Imperial Coll, Natl Heart & Lung Inst, London, England; [Reinheckel, Thomas] Albert Ludwigs Univ, BIOSS Ctr Biol Signalling Studies, Inst Mol Med & Cell Res, Freiburg, Germany	University of London; University College London; University of London; University College London; University of Dundee; University of Dundee; Imperial College London; University of Freiburg	O'Shaughnessy, RFL (corresponding author), UCL Inst Child Hlth, Immunobiol, 30 Guilford St, London WC1N 1EH, England.	r.oshaughnessy@ucl.ac.uk	Cookson, William/HHC-1790-2022; Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Brown, Stuart John/0000-0001-9455-6701; O'Shaughnessy, Ryan/0000-0002-3701-0267; Way, Benjamin/0000-0002-4624-5463; Willis-Owen, Saffron/0000-0003-2633-1150; Cole, Christian/0000-0002-2560-2484; Tommasi, Cristina/0000-0002-4314-5088	Great Ormond Street Hospital Children's Charity; British Skin Foundation studentship; Centre for Dermatology and Genetic Medicine, University of Dundee Wellcome Trust Strategic Award [098439/Z/12/Z]; Wellcome Trust [106865/Z/15/Z]; Manknell Charitable Trust	Great Ormond Street Hospital Children's Charity; British Skin Foundation studentship; Centre for Dermatology and Genetic Medicine, University of Dundee Wellcome Trust Strategic Award; Wellcome Trust(Wellcome TrustEuropean Commission); Manknell Charitable Trust	R.F.L.O. is funded by the Great Ormond Street Hospital Children's Charity. A.S.N. is funded by a British Skin Foundation studentship (2018s). C.C. is funded as part of the Centre for Dermatology and Genetic Medicine, University of Dundee Wellcome Trust Strategic Award (098439/Z/12/Z). S.J.B. is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (106865/Z/15/Z) and a research grant from the Manknell Charitable Trust.	ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; ASSELINEAU D, 1995, DIFFERENTIATION, V58, P297, DOI 10.1046/j.1432-0436.1995.5840297.x; Balgi AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021549; Bonnart C, 2010, J CLIN INVEST, V120, P871, DOI 10.1172/JCI41440; Brasch F, 2002, AM J RESP CELL MOL, V26, P659, DOI 10.1165/ajrcmb.26.6.4744; Brown SJ, 2008, J INVEST DERMATOL, V128, P1591, DOI 10.1038/sj.jid.5701206; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Buhling F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026247; Burgess JA, 2009, J ASTHMA, V46, P429, DOI 10.1080/02770900902846356; Byrne C, 2010, METHODS MOL BIOL, V585, P271, DOI 10.1007/978-1-60761-380-0_19; Callard RE, 2007, TRENDS IMMUNOL, V28, P294, DOI 10.1016/j.it.2007.05.003; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; D'Angelo ME, 2010, J BIOL CHEM, V285, P20514, DOI 10.1074/jbc.M109.094573; de Veer SJ, 2014, TRENDS MOL MED, V20, P166, DOI 10.1016/j.molmed.2013.11.005; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; Diepgen TL, 2012, ACTA DERM-VENEREOL, V92, P251, DOI 10.2340/00015555-1256; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Egberts F, 2004, J CELL SCI, V117, P2295, DOI 10.1242/jcs.01075; Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Faiz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057245; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Flentke GR, 2004, DEV DYNAM, V229, P886, DOI 10.1002/dvdy.10489; Grahovac M, 2010, BRIT J DERMATOL, V162, P217, DOI 10.1111/j.1365-2133.2009.09522.x; Gruber R, 2015, AM J PATHOL, V185, P2777, DOI 10.1016/j.ajpath.2015.06.021; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Jakasa I, 2006, BRIT J DERMATOL, V155, P104, DOI 10.1111/j.1365-2133.2006.07319.x; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Kasraie S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/942375; KAWADA A, 1995, INT J BIOCHEM CELL B, V27, P175, DOI 10.1016/1357-2725(94)00072-J; KAWADA A, 1995, J BIOCHEM, V118, P332, DOI 10.1093/oxfordjournals.jbchem.a124911; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Lambert C, 2014, ARTHRITIS RHEUMATOL, V66, P960, DOI 10.1002/art.38315; Le QT, 2011, J IMMUNOL, V187, P1912, DOI 10.4049/jimmunol.1001806; Li M, 2013, BRIT J DERMATOL, V168, P1335, DOI 10.1111/bjd.12206; Li XD, 2010, INVEST OPHTH VIS SCI, V51, P5019, DOI 10.1167/iovs.09-4523; List K, 2003, J CELL BIOL, V163, P901, DOI 10.1083/jcb.200304161; Matsui T, 2011, EMBO MOL MED, V3, P320, DOI 10.1002/emmm.201100140; Modena BD, 2016, TRANSL RES, V174, P98, DOI 10.1016/j.trsl.2016.02.011; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; O'Shaughnessy RFL, 2007, CANCER RES, V67, P8207, DOI 10.1158/0008-5472.CAN-07-0755; O'Shaughnessy RFL, 2007, J BIOL CHEM, V282, P17297, DOI 10.1074/jbc.M610386200; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; ROSENTHAL DS, 1992, J INVEST DERMATOL, V98, P343, DOI 10.1111/1523-1747.ep12499802; Ruzicka T, 2008, BRIT J DERMATOL, V158, P808, DOI 10.1111/j.1365-2133.2008.08487.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Sevilla LM, 2013, J INVEST DERMATOL, V133, P361, DOI 10.1038/jid.2012.281; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Sully K, 2013, ONCOGENE, V32, P3254, DOI 10.1038/onc.2012.338; Sun C, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001178; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Vavrova K, 2014, J INVEST DERMATOL, V134, P746, DOI 10.1038/jid.2013.402; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317	63	24	26	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1228	1241		10.1016/j.jaci.2016.09.052	http://dx.doi.org/10.1016/j.jaci.2016.09.052			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27913303	Green Published, hybrid			2022-12-18	WOS:000398771800018
J	Andersen, YMF; Egeberg, A; Gislason, GH; Skov, L; Knop, FK; Thyssen, JP				Andersen, Yuki M. F.; Egeberg, Alexander; Gislason, Gunnar H.; Skov, Lone; Knop, Filip K.; Thyssen, Jacob P.			Adult atopic dermatitis and the risk of type 2 diabetes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ISCHEMIC-STROKE; ECZEMA		[Andersen, Yuki M. F.; Egeberg, Alexander; Skov, Lone; Thyssen, Jacob P.] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Copenhagen, Denmark; [Andersen, Yuki M. F.; Egeberg, Alexander; Gislason, Gunnar H.] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Cardiol, Copenhagen, Denmark; [Gislason, Gunnar H.] Danish Heart Fdn, Copenhagen, Denmark; [Gislason, Gunnar H.] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark; [Knop, Filip K.] Univ Copenhagen, Gentofte Hosp, Ctr Diabet Res, Hellerup, Denmark; [Thyssen, Jacob P.] Univ Copenhagen, Herlev & Gentofte Hosp, Natl Allergy Res Ctr, Hellerup, Denmark	University of Copenhagen; University of Copenhagen; University of Southern Denmark; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen	Andersen, YMF (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Copenhagen, Denmark.; Andersen, YMF (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Dept Cardiol, Copenhagen, Denmark.	yuki.maria.fukuda.andersen.01@regionh.dk	Knop, Filip K/GQI-2604-2022; Thyssen, Jacob/ABD-8517-2020; Gislason, Gunnar/B-7561-2009; Egeberg, Alexander/AFO-3479-2022; Skov, Lone/W-3575-2018	Knop, Filip K/0000-0002-2495-5034; Gislason, Gunnar/0000-0002-0548-402X; Egeberg, Alexander/0000-0001-8257-1816; Andersen, Yuki/0000-0001-6131-2815; Skov, Lone/0000-0002-4784-9680; Thyssen, Jacob Pontoppidan/0000-0003-3770-1743	Lundbeck Foundation; Pfizer; Eli Lilly; Novo Nordisk Foundation; Lundbeck Foundation [R139-2012-12679] Funding Source: researchfish; Novo Nordisk Fonden [NNF12OC1015957] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Pfizer(Pfizer); Eli Lilly(Eli Lilly); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Fonden(Novo Nordisk Foundation)	Y.M.F.A. and J.P.T. are supported by an unrestricted grant from the Lundbeck Foundation. J.P.T.'s spouse is currently employed at Novo Nordisk. A. E. has received research funding and/or consultancy and speaker honoraria from Pfizer and Eli Lilly. G.H.G. and F.K.K. are supported by unrestricted research grants from the Novo Nordisk Foundation.	Andersen YMF, 2016, J ALLERGY CLIN IMMUN, V138, P310, DOI 10.1016/j.jaci.2016.01.015; Lee JK, 2002, BIOCHEM BIOPH RES CO, V295, P771, DOI 10.1016/S0006-291X(02)00679-4; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Proudfoot LE, 2013, BRIT J DERMATOL, V169, P901, DOI 10.1111/bjd.12505; Silverberg JI, 2015, ALLERGY, V70, P1300, DOI 10.1111/all.12685; Silverberg JI, 2015, J ALLERGY CLIN IMMUN, V135, P721, DOI 10.1016/j.jaci.2014.11.023; Su VYF, 2014, ANN MED, V46, P84, DOI 10.3109/07853890.2013.870018; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X	8	24	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1057	1059		10.1016/j.jaci.2016.08.049	http://dx.doi.org/10.1016/j.jaci.2016.08.049			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27771322	Bronze			2022-12-18	WOS:000397295800046
J	Cabral-Marques, O; Ramos, RN; Schimke, LF; Khan, TA; Amaral, EP; Bomfim, CCB; Reis, O; Franca, TT; Arslanian, C; Lima, JDCC; Weber, CW; Ferreira, JF; Tavares, FS; Sun, J; Lima, MRD; Seelaender, M; Calich, VLG; Barbuto, JAM; Costa-Carvalho, BT; Riemekasten, G; Seminario, G; Bezrodnik, L; Notarangelo, L; Torgerson, TR; Ochs, HD; Condino-Neto, A				Cabral-Marques, Otavio; Ramos, Rodrigo Nalio; Schimke, Lena F.; Khan, Taj Ali; Amaral, Eduardo Pinheiro; Barbosa Bomfim, Caio Cesar; Reis Junior, Osvaldo; Franca, Tabata Takahashi; Arslanian, Christina; Carola Correia Lima, Joanna Darck; Weber, Cristina Worm; Ferreira, Janaira Fernandes; Tavares, Fabiola Scancetti; Sun, Jing; D'Imperio Lima, Maria Regina; Seelaender, Marilia; Garcia Calich, Vera Lucia; Marzagao Barbuto, Jose Alexandre; Costa-Carvalho, Beatriz Tavares; Riemekasten, Gabriela; Seminario, Gisela; Bezrodnik, Liliana; Notarangelo, Luigi; Torgerson, Troy R.; Ochs, Hans D.; Condino-Neto, Antonio			Human CD40 ligand deficiency dysregulates the macrophage transcriptome causing functional defects that are improved by exogenous IFN-gamma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Macrophages; CD40 ligand; opportunistic infections; IFN-gamma	HYPER-IGM SYNDROME; CHRONIC GRANULOMATOUS-DISEASE; X-LINKED IMMUNODEFICIENCY; LARGE GENE LISTS; INTERFERON-GAMMA; DENDRITIC CELLS; BONE-MARROW; MENDELIAN SUSCEPTIBILITY; MYCOBACTERIAL DISEASE; 1ST REPORT	Background: CD40 ligand (CD40L) deficiency predisposes to opportunistic infections, including those caused by fungi and intracellular bacteria. Studies of CD40L-deficient patients reveal the critical role of CD40L-CD40 interaction for the function of T, B, and dendritic cells. However, the consequences of CD40L deficiency on macrophage function remain to be investigated. Objectives: We sought to determine the effect of CD40L absence on monocyte-derived macrophage responses. Methods: After observing the improvement of refractory disseminated mycobacterial infection in a CD40L-deficient patient by recombinant human IFN-gamma (rhIFN-gamma) adjuvant therapy, we investigated macrophage functions from CD40L-deficient patients. We analyzed the killing activity, oxidative burst, cytokine production, and in vitro effects of rhIFN-g and soluble CD40 ligand (sCD40L) treatment on macrophages. In addition, the effect of CD40L absence on the macrophage transcriptome before and after rhIFN-gamma treatment was studied. Results: Macrophages from CD40L-deficient patients exhibited defective fungicidal activity and reduced oxidative burst, both of which improved in the presence of rhIFN-gamma but not sCD40L. In contrast, rhIFN-gamma and sCD40L ameliorate impaired production of inflammatory cytokines. Furthermore, rhIFN-gamma reversed defective control of Mycobacterium tuberculosis proliferation by patients' macrophages. The absence of CD40L dysregulated the macrophage transcriptome, which was improved by rhIFN-gamma. Additionally, rhIFN-gamma increased expression levels of pattern recognition receptors, such as Toll-like receptors 1 and 2, dectin 1, and dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin in macrophages from both control subjects and patients. Conclusion: Absence of CD40L impairs macrophage development and function. In addition, the improvement of macrophage immune responses by IFN-gamma suggests this cytokine as a potential therapeutic option for patients with CD40L deficiency.	[Cabral-Marques, Otavio; Ramos, Rodrigo Nalio; Schimke, Lena F.; Amaral, Eduardo Pinheiro; Barbosa Bomfim, Caio Cesar; Franca, Tabata Takahashi; Arslanian, Christina; D'Imperio Lima, Maria Regina; Garcia Calich, Vera Lucia; Marzagao Barbuto, Jose Alexandre; Condino-Neto, Antonio] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508 Sao Paulo, Brazil; [Cabral-Marques, Otavio; Schimke, Lena F.; Riemekasten, Gabriela] Univ Lubeck, Dept Rheumatol, Lubeck, Germany; [Khan, Taj Ali] Kohat Univ Sci & Technol, Dept Microbiol, Kohat, Pakistan; [Reis Junior, Osvaldo] Univ Estadual Campinas, Cent Lab High Performance Technol LaCTAD, Sao Paulo, Brazil; [Carola Correia Lima, Joanna Darck; Seelaender, Marilia] Univ Sao Paulo, Canc Metab Res Grp, Inst Biomed Sci, BR-05508 Sao Paulo, Brazil; [Weber, Cristina Worm] Pediat Allergy & Immunol Clin, Caxias Do Sul, Brazil; [Ferreira, Janaira Fernandes] Albert Sabin Hosp, Fortaleza, Ceara, Brazil; [Tavares, Fabiola Scancetti] Hop Base Dist Fed Brasilia, Pediat Unit, Pediat Immunol Clin, Brasilia, DF, Brazil; [Sun, Jing] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Marzagao Barbuto, Jose Alexandre] Univ Sao Paulo, Cell & Mol Therapy Ctr, NETCEM, BR-05508 Sao Paulo, Brazil; [Costa-Carvalho, Beatriz Tavares] Univ Fed Sao Paulo, Div Allergy Immunol & Rheumatol, Dept Pediat, Sao Paulo, Brazil; [Seminario, Gisela; Bezrodnik, Liliana] Ricardo Gutierrez Childrens Hosp, Immunol, Buenos Aires, DF, Argentina; [Notarangelo, Luigi] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Torgerson, Troy R.; Ochs, Hans D.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Torgerson, Troy R.; Ochs, Hans D.] Seattle Childrens Res Inst, Seattle, WA USA	Universidade de Sao Paulo; University of Lubeck; Kohat University of Science & Technology; Universidade Estadual de Campinas; Universidade de Sao Paulo; University System of Ohio; University of Cincinnati; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Hospital de Ninos Doctor Ricardo Gutierrez; Instituto Nacional de Saude Dr. Ricardo Jorge; University of Buenos Aires; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Condino-Neto, A (corresponding author), Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, 1730 Lineu Prestes Ave, BR-05508000 Sao Paulo, SP, Brazil.	condino@icb.usp.br	Condino-Neto, Antonio/D-4762-2012; Seelaender, Marilia Cerqueira Leite/B-9101-2011; Marques, Otavio Cabral/C-8090-2012; Barbuto, Jose A. M./H-5299-2011; D'Império Lima, Maria Regina/I-4747-2012; Lima, Joanna/AAZ-5251-2021; Calich, Vera/G-8367-2011; Ramos, Rodrigo N/K-3553-2012; Bomfim, Caio/AAD-8361-2020; Pinheiro Amaral, Eduardo/M-2456-2014	Condino-Neto, Antonio/0000-0002-1069-3117; Seelaender, Marilia Cerqueira Leite/0000-0002-9999-8020; Barbuto, Jose A. M./0000-0001-9526-6781; D'Império Lima, Maria Regina/0000-0002-4683-7709; Calich, Vera/0000-0002-2170-5099; Ramos, Rodrigo N/0000-0003-1249-4733; Bomfim, Caio/0000-0003-1998-9237; Franca, Tabata Takahashi/0000-0001-8950-0877; Carola Correia Lima, Joanna Darck/0000-0001-6804-8666; Cabral Marques, Otavio/0000-0002-3183-6236; Pinheiro Amaral, Eduardo/0000-0001-5465-8113	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2012/50515-4, 2012/51745-3]; Jeffrey Modell Foundation	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Jeffrey Modell Foundation	Supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (grant 2012/50515-4 to O.C.-M. and grant 2012/51745-3 to A.C.-N.) and the Jeffrey Modell Foundation.	Abzug MJ, 2004, PEDIATR INFECT DIS J, V23, P769, DOI 10.1097/01.inf.0000134314.65398.bf; Al-Muhsen S, 2008, J ALLERGY CLIN IMMUN, V122, P1043, DOI 10.1016/j.jaci.2008.10.037; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Amaral EP, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004188; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bemiller LS, 1995, BLOOD CELL MOL DIS, V21, P239, DOI 10.1006/bcmd.1995.0028; Beyer M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045466; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; BORREGAARD N, 1983, EUR J CLIN INVEST, V13, P243, DOI 10.1111/j.1365-2362.1983.tb00095.x; Bustamante J, 2014, SEMIN IMMUNOL, V26, P454, DOI 10.1016/j.smim.2014.09.008; Bustamante J, 2011, NAT IMMUNOL, V12, P213, DOI 10.1038/ni.1992; Cabral-Marques O, 2014, J CLIN IMMUNOL, V34, P146, DOI 10.1007/s10875-013-9980-4; Cabral-Marques O, 2012, J CLIN IMMUNOL, V32, P212, DOI 10.1007/s10875-011-9623-6; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Covarrubias A, 2013, CELL RES, V23, P984, DOI 10.1038/cr.2013.88; De Kleer I, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00423; de Oliveira EB, 2015, PEDIATR BLOOD CANCER, V62, P2101, DOI 10.1002/pbc.25674; den Dunnen JT, 2000, HUM MUTAT, V15, P7; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Dong CS, 2013, GENE, V519, P279, DOI 10.1016/j.gene.2013.02.015; EZEKOWITZ RAB, 1990, BLOOD, V76, P2443; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; FloresRomo L, 1997, J EXP MED, V185, P341, DOI 10.1084/jem.185.2.341; Fontana S, 2003, BLOOD, V102, P4099, DOI 10.1182/blood-2003-04-1244; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Gao XF, 2011, INT J INFECT DIS, V15, pE594, DOI 10.1016/j.ijid.2011.05.002; Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Gisela SA, 2013, J CLIN IMMUNOL, V33, pS108; Heeschen C, 2003, NEW ENGL J MED, V348, P1104, DOI 10.1056/NEJMoa022600; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Hensman J, 2015, BIOINFORMATICS, V31, P3881, DOI 10.1093/bioinformatics/btv483; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jain A, 1999, J CLIN INVEST, V103, P1151, DOI 10.1172/JCI5891; Kelleher P, 2006, EUR RESPIR J, V27, P1307, DOI 10.1183/09031936.06.00021705; KIM HS, 1994, J IMMUNOL, V153, P2951; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; LU CY, 1979, NATURE, V282, P327, DOI 10.1038/282327a0; Malik N, 1996, J IMMUNOL, V156, P3952; Marciano BE, 2004, CLIN INFECT DIS, V39, P692, DOI 10.1086/422993; Marodi L, 2006, INFECT IMMUN, V74, P1999, DOI 10.1128/IAI.74.4.1999-2006.2006; Marodi L, 2002, CLIN EXP IMMUNOL, V128, P1, DOI 10.1046/j.1365-2249.2002.01873.x; MARODI L, 1994, J IMMUNOL, V153, P5643; Marques OC, 2012, J ALLERGY CLIN IMMUN, V129, P778, DOI 10.1016/j.jaci.2011.10.026; Mavroudi I, 2011, THESCIENTIFICWORLDJO, V11, P2011, DOI 10.1100/2011/671453; Pina A, 2006, J LEUKOCYTE BIOL, V79, P1202, DOI 10.1189/jlb.0106052; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Roesler J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034296; Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460; SAELAND S, 1992, EXP HEMATOL, V20, P24; Soeiro-Pereira PV, 2012, BRIT J PHARMACOL, V166, P1617, DOI 10.1111/j.1476-5381.2011.01764.x; Solanilla A, 2000, BLOOD, V95, P3758; Subauste CS, 1999, J IMMUNOL, V162, P6690; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Taschner PEM, 2011, HUM MUTAT, V32, P507, DOI 10.1002/humu.21427; Uronen H, 2000, CLIN EXP IMMUNOL, V121, P346, DOI 10.1046/j.1365-2249.2000.01307.x; Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101; Wang LL, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/683160; Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537; Weber M, 2015, BRIT J CANCER, V113, P510, DOI 10.1038/bjc.2015.212; WESTON WL, 1977, AM J DIS CHILD, V131, P1241, DOI 10.1001/archpedi.1977.02120240059011; WILSON CB, 1990, REV INFECT DIS, V12, pS410; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0	68	24	24	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					900	+		10.1016/j.jaci.2016.07.018	http://dx.doi.org/10.1016/j.jaci.2016.07.018			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27554817	Bronze			2022-12-18	WOS:000397295800023
J	Kohn, DB; Kuo, CY				Kohn, Donald B.; Kuo, Caroline Y.			New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hematopoietic stem cell transplantation; gammaretroviral vector; lentiviral vector; gene editing; site-specific endonuclease; zinc finger nuclease; CRISPR/Cas9	CHRONIC GRANULOMATOUS-DISEASE; HEMATOPOIETIC-CELLS; LENTIVIRAL VECTORS; STEM-CELLS; RETROVIRAL VECTORS; RECONSTITUTION; ADA; TRANSPLANTATION; DEFICIENCY; ACTIVATION	The most severe primary immune deficiency diseases (PIDs) have been successfully treated with allogeneic hematopoietic stem cell transplantation for more than 4 decades. However, such transplantations have the best outcomes when there is a well matched donor available because immune complications, such as graft- versus- host disease, are greater without a matched sibling donor. Gene therapy has been developed as a method to perform autologous transplantations of a patient's own stem cells that are genetically corrected. Through an iterative bench- to- bedside and- back process, methods to efficiently add new copies of the relevant gene to hematopoietic stem cells have led to safe and effective treatments for several PIDs, including forms of severe combined immune deficiency, Wiskott- Aldrich syndrome, and chronic granulomatous disease. New methods for gene editing might allow additional PIDs to be treated by gene therapy because they will allow the endogenous gene to be repaired and expressed under its native regulatory elements, which are essential for genes involved in cell processes of signaling, activation, and proliferation. Gene therapy is providing exciting new treatment options for patients with PIDs, and advances are sure to continue.	[Kohn, Donald B.; Kuo, Caroline Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90024 USA; [Kohn, Donald B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA; [Kohn, Donald B.] Univ Calif Los Angeles, David Geffen Sch Med, Eli & Edythe Broad Ctr Stem Cell Res & Regenerat, Los Angeles, CA 90024 USA; [Kohn, Donald B.] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kohn, DB (corresponding author), 3165 Terasaki Life Sci Bldg, Los Angeles, CA 90095 USA.	dkohn1@mednet.ucla.edu		Kuo, Caroline/0000-0002-9302-0187	National Institutes of Health; California Institute for Regenerative Medicine; Doris Duke Charitable Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD034610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	D. B. Kohn is a member of the scientific advisory boards for Kite Pharma and Orchard Therapeutics; has received grants from the National Institutes of Health, the California Institute for Regenerative Medicine, and the Doris Duke Charitable Foundation; has patents through the University of California- Los Angeles; and has received royalties from patents licensed from UCLA to Orchard Therapeutics and BioMarin. C. Y. Kuo declares that she has no relevant conflicts of interest.	Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253; Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Aiuti A, 2007, J CLIN INVEST, V117, P2233, DOI 10.1172/JCI31666; Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Brown MP, 1998, NAT MED, V4, P1253, DOI 10.1038/3233; Candotti F, 2012, BLOOD, V120, P3635, DOI 10.1182/blood-2012-02-400937; Carbonaro DA, 2014, MOL THER, V22, P607, DOI 10.1038/mt.2013.265; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Charrier S, 2007, GENE THER, V14, P415, DOI 10.1038/sj.gt.3302863; Chhabra A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aae0501; Cicalese MP, 2016, BLOOD, V128, P45, DOI 10.1182/blood-2016-01-688226; Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726; De Ravin SS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8856; De Ravin SS, 2016, NAT BIOTECHNOL, V34, P424, DOI 10.1038/nbt.3513; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; Fischer A, 2004, NEW ENGL J MED, V350, P2526; Gaspar HB, 2006, MOL THER, V14, P505, DOI 10.1016/j.ymthe.2006.06.007; Gaspar HB, 2011, SCI TRANSL MED, V3, DOI [10.1126/scitranslmed.3002716, 10.1126/scitranslmed.3002715]; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Gaspar HB, 2015, MOL THER, V23, pS102, DOI 10.1016/S1525-0016(16)33866-7; GATTI RA, 1968, LANCET, V2, P1366; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2014, NEW ENGL J MED, V371, P1407, DOI 10.1056/NEJMoa1404588; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hacein-Bey-Abina S, 2010, NEW ENGL J MED, V363, P355, DOI 10.1056/NEJMoa1000164; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Joglekar AV, 2013, MOL THER, V21, P1705, DOI 10.1038/mt.2013.106; Kang EM, 2010, BLOOD, V115, P783, DOI 10.1182/blood-2009-05-222760; Kang HJ, 2011, MOL THER, V19, P2092, DOI 10.1038/mt.2011.166; Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353; Marangoni F, 2009, MOL THER, V17, P1073, DOI 10.1038/mt.2009.31; Merling RK, 2015, MOL THER, V23, P147, DOI 10.1038/mt.2014.195; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Modlich U, 2009, MOL THER, V17, P1919, DOI 10.1038/mt.2009.179; MORITZ T, 1994, J CLIN INVEST, V93, P1451, DOI 10.1172/JCI117122; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Naldini L, 2016, SCIENCE, V353, P1101, DOI 10.1126/science.aah6192; NOLTA JA, 1992, EXP HEMATOL, V20, P1065; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Pagovich OE, 2016, MOL THER, V24, pS298, DOI 10.1016/S1525-0016(16)33563-8; Palchaudhuri R, 2016, NAT BIOTECHNOL, V34, P738, DOI 10.1038/nbt.3584; PARKMAN R, 1978, NEW ENGL J MED, V298, P922, DOI 10.1056/NEJM197804272981701; Porteus MH, 2003, SCIENCE, V300, P763, DOI 10.1126/science.1078395; Santilli G, 2011, MOL THER, V19, P122, DOI 10.1038/mt.2010.226; Shaw KL, 2014, MOL THER, V22, pS107; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0	52	24	30	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					726	732		10.1016/j.jaci.2017.01.007	http://dx.doi.org/10.1016/j.jaci.2017.01.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	28270364	Green Accepted, Bronze			2022-12-18	WOS:000397295800002
J	Balbino, B; Sibilano, R; Starkl, P; Marichal, T; Gaudenzio, N; Karasuyama, H; Bruhns, P; Tsai, M; Reber, LL; Galli, SJ				Balbino, Bianca; Sibilano, Riccardo; Starkl, Philipp; Marichal, Thomas; Gaudenzio, Nicolas; Karasuyama, Hajime; Bruhns, Pierre; Tsai, Mindy; Reber, Laurent L.; Galli, Stephen J.			Pathways of immediate hypothermia and leukocyte infiltration in an adjuvant-free mouse model of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rodents; mouse model; mast cells/basophils; monocytes/macrophages neutrophils; antibodies; Fc receptors; allergy; inflammation; anaphylaxis	PLATELET-ACTIVATING-FACTOR; IGG-MEDIATED ANAPHYLAXIS; MAST-CELL DEGRANULATION; FC-GAMMA RIII; SYSTEMIC-ANAPHYLAXIS; IMMUNOGLOBULIN-E; DEFICIENT MICE; AIRWAY HYPERRESPONSIVENESS; CHRONIC ASTHMA; IN-VIVO	Background: Conflicting results have been obtained regarding the roles of Fc receptors and effector cells in models of active systemic anaphylaxis (ASA). In part, this might reflect the choice of adjuvant used during sensitization because various adjuvants might differentially influence the production of particular antibody isotypes. Objective: We developed an "adjuvant-free'' mouse model of ASA and assessed the contributions of components of the "classical'' and "alternative'' pathways in this model. Methods: Mice were sensitized intraperitoneally with ovalbumin at weekly intervals for 6 weeks and challenged intraperitoneally with ovalbumin 2 weeks later. Results: Wild-type animals had immediate hypothermia and late-phase intraperitoneal inflammation in this model. These features were reduced in mice lacking the IgE receptor Fc epsilon RI, the IgG receptor Fc gamma RIII or the common gamma-chain FcR gamma. Fc gamma RIV blockade resulted in a partial reduction of inflammation without any effect on hypothermia. Depletion of monocytes/macrophages with clodronate liposomes significantly reduced the hypothermia response. By contrast, depletion of neutrophils or basophils had no significant effects in this ASA model. Both the hypothermia and inflammation were dependent on platelet-activating factor and histamine and were reduced in 2 types of mast cell (MC)-deficient mice. Finally, engraftment of MC-deficient mice with bone marrow-derived cultured MCs significantly exacerbated the hypothermia response and restored inflammation to levels similar to those observed in wild-type mice. Conclusion: Components of the classical and alternative pathways contribute to anaphylaxis in this adjuvant-free model, with key roles for MCs and monocytes/macrophages.	[Balbino, Bianca; Bruhns, Pierre; Reber, Laurent L.] Inst Pasteur, Dept Immunol, Unit Antibodies Therapy & Pathol, 25 Rue Docteur Roux, F-75015 Paris, France; [Balbino, Bianca; Bruhns, Pierre; Reber, Laurent L.] INSERM, U1222, Paris, France; [Balbino, Bianca] Univ Paris 06, Paris, France; [Sibilano, Riccardo; Starkl, Philipp; Marichal, Thomas; Gaudenzio, Nicolas; Tsai, Mindy; Reber, Laurent L.; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, CCSR Room 3255B,269 Campus Dr, Stanford, CA 94305 USA; [Sibilano, Riccardo; Starkl, Philipp; Gaudenzio, Nicolas; Tsai, Mindy; Reber, Laurent L.; Galli, Stephen J.] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Sch Med, Stanford, CA 94305 USA; [Karasuyama, Hajime] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Galli, Stephen J.] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Immune Regulat, Tokyo, Japan; [Starkl, Philipp] Austrian Acad Sci, Res Ctr Mol Med, CeMM, Vienna, Austria; [Starkl, Philipp] Med Univ Vienna, Dept Med, Lab Infect Biol, Vienna, Austria; [Marichal, Thomas] Univ Liege, GIGA Res, Liege, Belgium; [Marichal, Thomas] Univ Liege, Fac Vet Med, Liege, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Stanford University; Stanford University; Stanford University; Tokyo Medical & Dental University (TMDU); Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna; University of Liege; University of Liege	Reber, LL (corresponding author), Inst Pasteur, Dept Immunol, Unit Antibodies Therapy & Pathol, 25 Rue Docteur Roux, F-75015 Paris, France.; Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, CCSR Room 3255B,269 Campus Dr, Stanford, CA 94305 USA.	laurent.reber@pasteur.fr; sgalli@stanford.edu	Bruhns, Pierre/F-5567-2013; Reber, Laurent L/K-4148-2014; Karasuyama, Hajime/A-7966-2011	Bruhns, Pierre/0000-0002-4709-8936; Reber, Laurent L/0000-0003-3384-6769; Karasuyama, Hajime/0000-0003-0689-0836; Tsai, Mindy/0000-0002-8421-4721; Gaudenzio, Nicolas/0000-0002-5648-509X; Starkl, Philipp/0000-0001-7521-129X	Pasteur-Paris University (PPU) International PhD Program; Lucile Packard Foundation for Children's Health; Stanford National Institutes of Health (NIH)/NCRR CTSA [UL1 RR025744]; Max Kade Fellowship of the Max Kade Foundation; Schroedinger Fellowship of the Austrian Science Fund (FWF) [J3399-B21]; European Commission Marie Sklodowska-Curie Individual Fellowship [H2020-MSCA-IF-2014655153]; Marie Curie International Outgoing Fellowship for Career Development [299954]; "Charge de recherches'' fellowship of the Belgian National Fund for Scientific Research (F.R. S-FNRS); French "Fondation pour la Recherche Medicale FRM"; European Research Council (ERC)-Seventh Framework Program [ERC-2013-CoG 616050]; Institut National de la Sante et de la Recherche Medicale (INSERM); Institut Pasteur; Stanford Pediatric Research Fund of the Lucile Packard Foundation for Children's Health; Stanford CTSA (National Institutes of Health) [UL1 RR025744]; NIH [K99AI110645, AI023990, CA072074, AI070813, AR067145, U19 AI104209, NS 080062]; European Commission Marie SklodowskaCurie Individual Fellowship [H2020-MSCA-IF-2014 656086]; French "Institut National de la Sante et de la Recherche Medicale'' (INSERM); Tobacco-Related Disease Research Program at the University of California; Department of Pathology, Stanford University School of Medicine; Austrian Academy of Sciences; NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023990, R01AI070813, K99AI110645, U19AI104209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067145] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [15H05786] Funding Source: KAKEN	Pasteur-Paris University (PPU) International PhD Program; Lucile Packard Foundation for Children's Health; Stanford National Institutes of Health (NIH)/NCRR CTSA; Max Kade Fellowship of the Max Kade Foundation; Schroedinger Fellowship of the Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); European Commission Marie Sklodowska-Curie Individual Fellowship; Marie Curie International Outgoing Fellowship for Career Development; "Charge de recherches'' fellowship of the Belgian National Fund for Scientific Research (F.R. S-FNRS)(Fonds de la Recherche Scientifique - FNRS); French "Fondation pour la Recherche Medicale FRM"(Fondation pour la Recherche Medicale); European Research Council (ERC)-Seventh Framework Program; Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut Pasteur(European Commission); Stanford Pediatric Research Fund of the Lucile Packard Foundation for Children's Health; Stanford CTSA (National Institutes of Health); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Commission Marie SklodowskaCurie Individual Fellowship; French "Institut National de la Sante et de la Recherche Medicale'' (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Tobacco-Related Disease Research Program at the University of California; Department of Pathology, Stanford University School of Medicine; Austrian Academy of Sciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	B.B. was supported by a stipend from the Pasteur-Paris University (PPU) International PhD Program. R.S. was supported by the Lucile Packard Foundation for Children's Health and the Stanford National Institutes of Health (NIH)/NCRR CTSA award number UL1 RR025744. P.S. was supported by a Max Kade Fellowship of the Max Kade Foundation and the Austrian Academy of Sciences and a Schroedinger Fellowship of the Austrian Science Fund (FWF; J3399-B21) and is supported by a European Commission Marie Sklodowska-Curie Individual Fellowship (H2020-MSCA-IF-2014655153). T.M. was supported by the Marie Curie International Outgoing Fellowship for Career Development (299954) and supported by a "Charge de recherches'' fellowship of the Belgian National Fund for Scientific Research (F.R. S-FNRS). N.G. was the recipient of a fellowship from the French "Fondation pour la Recherche Medicale FRM.'' P.B. acknowledges support from the European Research Council (ERC)-Seventh Framework Program (ERC-2013-CoG 616050), the Institut National de la Sante et de la Recherche Medicale (INSERM), and the Institut Pasteur. L.L.R. acknowledges support from the French "Fondation pour la Recherche Medicale FRM,'' the Stanford Pediatric Research Fund of the Lucile Packard Foundation for Children's Health and the Stanford CTSA (National Institutes of Health grant UL1 RR025744), NIH grant K99AI110645, the European Commission Marie SklodowskaCurie Individual Fellowship (H2020-MSCA-IF-2014 656086), and the French "Institut National de la Sante et de la Recherche Medicale'' (INSERM). S.J.G. acknowledges support from NIH grants AI023990, CA072074, AI070813, AR067145, U19 AI104209, and NS 080062; the Tobacco-Related Disease Research Program at the University of California; and the Department of Pathology, Stanford University School of Medicine.	Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Beutier H, 2016, J ALLERGY CLIN IMMUN; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Cunningham AF, 2004, EUR J IMMUNOL, V34, P2986, DOI 10.1002/eji.200425403; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Forster A, 2015, J ALLERGY CLIN IMMUN, V135, P1077, DOI 10.1016/j.jaci.2014.10.005; Galli SJ, 2015, ADV IMMUNOL, V126, P45, DOI 10.1016/bs.ai.2014.11.002; Gaudenzio N, 2015, JOVE-J VIS EXP, DOI 10.3791/52753; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Gutierrez DA, 2015, CELL METAB, V21, P678, DOI 10.1016/j.cmet.2015.04.013; Jiao DL, 2014, CELL IMMUNOL, V289, P97, DOI 10.1016/j.cellimm.2014.03.018; Jonsson F, 2013, J LEUKOCYTE BIOL, V94, P643, DOI 10.1189/jlb.1212623; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Joulia R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7174; JOUVINMARCHE E, 1989, IMMUNOGENETICS, V29, P92, DOI 10.1007/BF00395856; Kasprick A, 2015, EUR J IMMUNOL, V45, P1462, DOI 10.1002/eji.201444769; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V132, P1375, DOI 10.1016/j.jaci.2013.09.008; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; LAZAR G, 1994, AGENTS ACTIONS, V41, pC97, DOI 10.1007/BF02007784; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Makabe-Kobayashi Y, 2002, J ALLERGY CLIN IMMUN, V110, P298, DOI 10.1067/mai.2002.125977; Malbec O, 2007, J IMMUNOL, V178, P6465, DOI 10.4049/jimmunol.178.10.6465; Marichal T, 2013, IMMUNITY, V39, P963, DOI 10.1016/j.immuni.2013.10.005; Maurer M, 2004, NATURE, V432, P512, DOI 10.1038/nature03085; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V124, P639, DOI 10.1016/j.jaci.2009.08.035; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Million M, 1997, EUR J PHARMACOL, V334, P67, DOI 10.1016/S0014-2999(97)01142-4; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Nakae S, 2007, J ALLERGY CLIN IMMUN, V120, P48, DOI 10.1016/j.jaci.2007.02.046; Nigrovic PA, 2008, AM J PATHOL, V173, P1693, DOI 10.2353/ajpath.2008.080407; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Piliponsky AM, 2010, AM J PATHOL, V176, P926, DOI 10.2353/ajpath.2010.090342; Reber LL, 2015, MUCOSAL IMMUNOL, V8, P444, DOI 10.1038/mi.2014.131; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Reber LL, 2012, TRENDS IMMUNOL, V33, P613, DOI 10.1016/j.it.2012.09.008; Rodewald HR, 2012, IMMUNITY, V37, P13, DOI 10.1016/j.immuni.2012.07.007; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; Shibamoto T, 2008, PHARMACOLOGY, V82, P114, DOI 10.1159/000141516; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P625, DOI 10.1016/j.jaci.2009.08.025; Smit JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028917; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wang MF, 2014, LIFE SCI, V116, P98, DOI 10.1016/j.lfs.2014.09.010; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Yu M, 2011, J CLIN INVEST, V121, P3133, DOI 10.1172/JCI43598	67	24	24	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					584	+		10.1016/j.jaci.2016.05.047	http://dx.doi.org/10.1016/j.jaci.2016.05.047			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27555460	Green Accepted, Bronze			2022-12-18	WOS:000397002400024
J	Koch, K; Weller, K; Werner, A; Maurer, M; Altrichter, S				Koch, Katja; Weller, Karsten; Werner, Andreas; Maurer, Marcus; Altrichter, Sabine			Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CETIRIZINE		[Koch, Katja; Weller, Karsten; Maurer, Marcus; Altrichter, Sabine] Charite, ChariteCrossOver CCO, Ctr Space Med, Dept Dermatol & Allergy, Berlin, Germany; [Werner, Andreas] Charite, ChariteCrossOver CCO, Ctr Space Med, Dept Physiol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Maurer, M (corresponding author), Charite, ChariteCrossOver CCO, Ctr Space Med, Dept Dermatol & Allergy, Berlin, Germany.	marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X; Dr. Werner, Andreas/0000-0001-9719-5139; Weller, Karsten/0000-0003-4437-0313; Altrichter, Sabine/0000-0001-9955-385X				Abajian M, 2014, IMMUNOL ALLERGY CLIN, V34, P73, DOI 10.1016/j.iac.2013.09.010; Altrichter S, 2015, J DERMATOL, V42, P422, DOI 10.1111/1346-8138.12765; Altrichter S, 2014, J DERMATOL SCI, V75, P88, DOI 10.1016/j.jdermsci.2014.04.007; Dickinson RE, 2011, BLOOD, V118, P2656, DOI 10.1182/blood-2011-06-360313; Horikawa T, 2009, CURR ALLERGY ASTHM R, V9, P273, DOI 10.1007/s11882-009-0038-x; LGSM Shaffer, 2009, ISCN 2009 INT SYSTEM, DOI DOI 10.1007/S00439-009-0726-6; Magerl M, 2012, BRIT J DERMATOL, V166, P1095, DOI 10.1111/j.1365-2133.2012.10822.x; Nakamizo S, 2012, J EUR ACAD DERMATOL, V26, P114, DOI 10.1111/j.1468-3083.2011.04017.x; Thiede C, 1999, BONE MARROW TRANSPL, V23, P1055, DOI 10.1038/sj.bmt.1701779; ZUBERBIER T, 1994, J AM ACAD DERMATOL, V31, P978, DOI 10.1016/S0190-9622(94)70267-5; Zuberbier T, 1996, DERMATOLOGY, V193, P324, DOI 10.1159/000246281; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313; ZUBERBIER T, 1995, ACTA DERM-VENEREOL, V75, P147	13	24	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1483	+		10.1016/j.jaci.2016.05.026	http://dx.doi.org/10.1016/j.jaci.2016.05.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27496595	Bronze			2022-12-18	WOS:000389542700040
J	Zhou, YJ; Bacharier, LB; Isaacson-Schmid, M; Baty, J; Schechtman, KB; Sajol, G; Wylie, K; Storch, GA; Castro, M; Beigelman, A				Zhou, Yanjiao; Bacharier, Leonard B.; Isaacson-Schmid, Megan; Baty, Jack; Schechtman, Kenneth B.; Sajol, Geneline; Wylie, Kristine; Storch, Gregory A.; Castro, Mario; Beigelman, Avraham			Azithromycin therapy during respiratory syncytial virus bronchiolitis: Upper airway microbiome alterations and subsequent recurrent wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VIRAL BRONCHIOLITIS; ASTHMA; INFECTION		[Zhou, Yanjiao] Jackson Lab Genom Med, Farmington, CT USA; [Bacharier, Leonard B.; Isaacson-Schmid, Megan; Wylie, Kristine; Storch, Gregory A.; Beigelman, Avraham] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Baty, Jack; Schechtman, Kenneth B.] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; [Sajol, Geneline; Castro, Mario] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63178 USA	Jackson Laboratory; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Beigelman, A (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.	beigelman_a@kids.wustl.edu		Bacharier, Leonard/0000-0003-0432-2704	NCATS NIH HHS [KL2 TR000450, UL1 TR000448, UL1 TR002345] Funding Source: Medline; NCI NIH HHS [P30 CA091842] Funding Source: Medline; NHLBI NIH HHS [R01 HL061895, R01 HL130876, R01 HL092486] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448, KL2TR000450] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL130876, R01HL092486, R01HL061895] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Beigelman A, 2015, J ALLERGY CLIN IMMUN, V135, P1171, DOI 10.1016/j.jaci.2014.10.001; Beigelman A, 2014, J ALLERGY CLIN IMMUN, V133, P603, DOI 10.1016/j.jaci.2013.12.001; Beigelman A, 2013, CURR OPIN ALLERGY CL, V13, P211, DOI 10.1097/ACI.0b013e32835eb6ef; Beigelman A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-90; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Friedlander AL, 2010, CHEST, V138, P1202, DOI 10.1378/chest.10-0196; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Zhou Y, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0099-x	11	24	24	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1215	1219		10.1016/j.jaci.2016.03.054	http://dx.doi.org/10.1016/j.jaci.2016.03.054			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27339392	Bronze, Green Accepted			2022-12-18	WOS:000385499400035
J	Jeppesen, AN; Christiansen, CF; Froslev, T; Sorensen, HT				Jeppesen, Anni Norgaard; Christiansen, Christian Fynbo; Froslev, Trine; Sorensen, Henrik Toft			Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylactic; epidemiology; incidence; intensive care unit; prognosis; shock	COMORBIDITY INDEX; MORTALITY; MANAGEMENT; MORBIDITY; TRENDS	Background: Anaphylactic shock (AS) is an acute, potentially life-threatening hypersensitivity reaction. There are limited population-based data on changes in the hospitalization rate and prognosis of AS. Objectives: We sought to examine the proportion of patients with AS admitted to an intensive care unit (ICU), the prognosis of AS, and time trends in AS hospitalization rates in Denmark from 1995 through 2012. Methods: We performed a population-based cohort study in Denmark from 1995 through 2012 (cumulative population, 7.1 million) using the Danish National Patient Registry and the Danish Civil Registration System. Outcomes included time trends in first-time AS hospitalization rates, percentage admitted to an ICU, and 30-day mortality overall and stratified by year. Results: We included 6,707 patients with a first-time hospitalization for AS during 103,747,997 person-years of observation time. The average AS hospitalization rate was 64.6 (95% CI, 63.1-66.2) per 1,000,000 person-years. From 1995 to 2012, the annual AS hospitalization rate increased more than 2-fold (rate ratio, 2.6; 95% CI, 2.2-3.0). However, the annual hospitalization rate in children increased 10-fold (rate ratio, 10.75; 95% CI, 5.59-20.67). Only 0.7% of patients died within 30 days after admission (50 deaths), and most fatal AS cases occurred among patients aged 30 years or older. During the 2005-2012 period, 14.5% of patients hospitalized with AS were admitted to an ICU. Conclusion: The AS hospitalization rate increased from 1995 to 2012; however, the 30-day mortality was less than 1%.	[Jeppesen, Anni Norgaard; Christiansen, Christian Fynbo; Froslev, Trine; Sorensen, Henrik Toft] Aarhus Univ Hosp, Dept Clin Epidemiol, Norrebrogade 44,Bygn 30, DK-8000 Aarhus C, Denmark; [Jeppesen, Anni Norgaard] Aarhus Univ Hosp, Res Ctr Emergency Med, Norrebrogade 44,Bygn 30, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Jeppesen, AN (corresponding author), Aarhus Univ Hosp, Res Ctr Emergency Med, Norrebrogade 44,Bygn 30, DK-8000 Aarhus C, Denmark.	anni.jeppesen@clin.au.dk	Christiansen, Christian Fynbo/B-5870-2014; Christiansen, Christian/ABE-9423-2021; Sorensen, Henrik Toft/Z-6181-2019	Christiansen, Christian Fynbo/0000-0002-0727-953X; Christiansen, Christian/0000-0002-0727-953X; Sorensen, Henrik Toft/0000-0003-4299-7040	Aarhus University Research Foundation; Program for Clinical Research Infrastructure (PROCRIN); Novo Nordisk Foundation; Lundbeck Foundation [R155-2014-2647] Funding Source: researchfish; Novo Nordisk Fonden [NNF14SA0015794] Funding Source: researchfish	Aarhus University Research Foundation; Program for Clinical Research Infrastructure (PROCRIN); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Fonden(Novo Nordisk Foundation)	Supported by Aarhus University Research Foundation and the Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation.	Blichert-Hansen Linea, 2013, Clin Epidemiol, V5, P9, DOI 10.2147/CLEP.S37763; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christiansen CF, 2011, ACTA ANAESTH SCAND, V55, P962, DOI 10.1111/j.1399-6576.2011.02480.x; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Gibbison B, 2012, ANAESTHESIA, V67, P833, DOI 10.1111/j.1365-2044.2012.07159.x; Gonzalez-Perez A, 2010, J ALLERGY CLIN IMMUN, V125, P1098, DOI 10.1016/j.jaci.2010.02.009; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; Law M, 2005, BRIT MED J, V330, P1187, DOI 10.1136/bmj.38435.582975.AE; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Ma L, 2014, J ALLERGY CLIN IMMUN, V133, P1075, DOI 10.1016/j.jaci.2013.10.029; Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895-4356(02)00591-7; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Simon MR, 2008, ALLERGY, V63, P1077, DOI 10.1111/j.1398-9995.2008.01737.x; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; SORENSEN HT, 1989, ALLERGY, V44, P288, DOI 10.1111/j.1398-9995.1989.tb01071.x; Strid Jennie Maria Christin, 2013, Clin Epidemiol, V5, P345, DOI 10.2147/CLEP.S47679; Techapornroong M, 2010, ASIAN PAC J ALLERGY, V28, P262; Tejedor Alonso MA, 2012, CLIN EXP ALLERGY, V42, P578, DOI 10.1111/j.1365-2222.2012.03930.x; Thygesen SK, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-83	26	24	24	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1143	1147		10.1016/j.jaci.2015.10.027	http://dx.doi.org/10.1016/j.jaci.2015.10.027			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26691436	Bronze			2022-12-18	WOS:000373351200021
J	O'Connor, C; Kelleher, M; Hourihane, JO				O'Connor, Cathal; Kelleher, Maeve; Hourihane, Jonathan O'B			Calculating the effect of population-level implementation of the Learning Early About Peanut Allergy (LEAP) protocol to prevent peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LINE BIRTH COHORT; INFANTS; RISK		[O'Connor, Cathal; Kelleher, Maeve; Hourihane, Jonathan O'B] Natl Univ Ireland Univ Coll Cork, Paediat & Child Hlth, Cork, Ireland	University College Cork	Hourihane, JO (corresponding author), Natl Univ Ireland Univ Coll Cork, Paediat & Child Hlth, Cork, Ireland.	J.Hourihane@ucc.ie		O'Connor, Cathal/0000-0001-7084-5293				Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fleischer DM, 2015, J ALLERGY CLIN IMMUN, V136, P258, DOI 10.1016/j.jaci.2015.06.001; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; O'Donovan SM, 2015, PUBLIC HEALTH NUTR, V18, P2864, DOI 10.1017/S136898001500018X; O'Donovan SM, 2015, INT J EPIDEMIOL, V44, P764, DOI 10.1093/ije/dyu157	6	24	24	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1263	1264		10.1016/j.jaci.2015.11.029	http://dx.doi.org/10.1016/j.jaci.2015.11.029			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26874368	Bronze			2022-12-18	WOS:000373351200040
J	Gonem, S; Hardy, S; Buhl, N; Hartley, R; Soares, M; Kay, R; Costanza, R; Gustafsson, P; Brightling, CE; Owers-Bradley, J; Siddiqui, S				Gonem, Sherif; Hardy, Steven; Buhl, Niels; Hartley, Ruth; Soares, Marcia; Kay, Richard; Costanza, Rino; Gustafsson, Per; Brightling, Christopher E.; Owers-Bradley, John; Siddiqui, Salman			Characterization of acinar airspace involvement in asthmatic patients by using inert gas washout and hyperpolarized (3)helium magnetic resonance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; small airways; acinus; physiology	SMALL-AIRWAY-OBSTRUCTION; HE-3 DIFFUSION; APPARENT DIFFUSION; LUNG-FUNCTION; EMPHYSEMA; STANDARDIZATION; ADULTS; MODEL; MRI; COEFFICIENT	Background: The multiple-breath inert gas washout parameter acinar ventilation heterogeneity (Sacin) is thought to be a marker of acinar airway involvement but has not been validated by using quantitative imaging techniques in asthmatic patients. Objective: We aimed to use hyperpolarized (3)Hediffusion magnetic resonance at multiple diffusion timescales and quantitative computed tomographic (CT) densitometry to determine the nature of acinar airway involvement in asthmatic patients. Methods: Thirty-seven patients with asthma and 17 age-matched healthy control subjects underwent spirometry, body plethysmography, multiple-breath inert gas washout (with the tracer gas sulfur hexafluoride), and hyperpolarized He-3 diffusion magnetic resonance. A subset of asthmatic patients (n = 27) underwent quantitative CT densitometry. Results: Ninety-four percent (16/17) of patients with an increased S-acin had Global Initiative for Asthma treatment step 4 to 5 asthma, and 13 of 17 had refractory disease. The apparent diffusion coefficient (ADC) of He-3 at 1 second was significantly higher in patients with S-acin-high asthma compared with that in healthy control subjects (0.024 vs 0.017, P<.05). Sacin correlated strongly with ADCs at 1 second (R = 0.65, P<.001) but weakly with ADCs at 13 ms (R = 0.38, P<.05). ADCs at both 13 ms and 1 second correlated strongly with the mean lung density expiratory/inspiratory ratio, a CT marker of expiratory air trapping (R = 0.77, P<.0001 for ADCs at 13 ms; R = 0.72, P<.001 for ADCs at 1 second). Conclusion: Sacin is associated with alterations in long-range diffusion within the acinar airways and gas trapping. The precise anatomic nature and mechanistic role in patients with severe asthma requires further evaluation.	[Gonem, Sherif; Hartley, Ruth; Soares, Marcia; Brightling, Christopher E.; Siddiqui, Salman] Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England; [Hardy, Steven; Buhl, Niels; Owers-Bradley, John] Univ Nottingham, Dept Phys & Astron, Nottingham NG7 2RD, England; [Kay, Richard] Novartis Pharmaceut, Basel, Switzerland; [Costanza, Rino] Chiesi UK, Cheadle, England; [Gustafsson, Per] Cent Hosp Skovde, Dept Paediat, Skovde, Sweden	University of Leicester; University of Nottingham; Novartis; Chiesi Pharmaceuticals Inc	Siddiqui, S (corresponding author), Glenfield Hosp, NIHR Resp Biomed Res Unit, Groby Rd, Leicester LE3 9QP, Leics, England.	ss338@le.ac.uk		Kay, Richard/0000-0002-8132-0721; Soares, Marcia/0000-0002-0205-6927; brightling, chris/0000-0002-9345-4903; Siddiqui, Salman/0000-0003-3770-7870	National Institute for Health Research (NIHR); Chiesi Farmaceutici S. P. A.; Novartis Pharmaceuticals; Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (FP7 European Union grant); Engineering and Physical Sciences Research Council [1201567] Funding Source: researchfish; National Institute for Health Research [CL-2014-11-002, NF-SI-0512-10018] Funding Source: researchfish	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Chiesi Farmaceutici S. P. A.; Novartis Pharmaceuticals(Novartis); Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (FP7 European Union grant); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); National Institute for Health Research(National Institute for Health Research (NIHR))	This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR, or the Department of Health. This work was partly funded through research collaborations with Chiesi Farmaceutici S. P. A. and Novartis Pharmaceuticals. Additional funding was received from the Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (funded through an FP7 European Union grant).	[Anonymous], 2008, BRIT GUID MAN ASTHM; Balzar S, 2002, EUR RESPIR J, V20, P254, DOI 10.1183/09031936.02.00261102; Boudreau M, 2013, MAGN RESON MED, V69, P211, DOI 10.1002/mrm.24224; Brightling CE, 2012, CLIN EXP ALLERGY, V42, P638, DOI 10.1111/j.1365-2222.2011.03917.x; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chen XJ, 2000, P NATL ACAD SCI USA, V97, P11478, DOI 10.1073/pnas.97.21.11478; Chrystyn H, 1999, ALLERGY, V54, P82, DOI 10.1111/j.1398-9995.1999.tb04393.x; CRAWFORD ABH, 1985, J APPL PHYSIOL, V59, P838, DOI 10.1152/jappl.1985.59.3.838; Criee CP, 2011, RESP MED, V105, P959, DOI 10.1016/j.rmed.2011.02.006; Dirksen A, 1999, AM J RESP CRIT CARE, V160, P1468, DOI 10.1164/ajrccm.160.5.9901055; Durand E, 2002, MAGNET RESON MED, V47, P75, DOI 10.1002/mrm.10047; Dutrieue B, 2000, J APPL PHYSIOL, V89, P1859, DOI 10.1152/jappl.2000.89.5.1859; European Respiratory Society, 1993, EUR RESPIR J, V6, P3; Farah CS, 2012, J ALLERGY CLIN IMMUN, V130, P61, DOI 10.1016/j.jaci.2012.02.015; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; Faul JL, 1997, EUR RESPIR J, V10, P301, DOI 10.1183/09031936.97.10020301; FINUCANE KE, 1969, J APPL PHYSIOL, V26, P330, DOI 10.1152/jappl.1969.26.3.330; Gelb AF, 2002, CHEST, V121, P715, DOI 10.1378/chest.121.3.715; Gelb AF, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Gelb AF, 2014, J ALLERGY CLIN IMMUN, V133, P263, DOI 10.1016/j.jaci.2013.09.045; Gierada DS, 2009, J MAGN RESON IMAGING, V30, P801, DOI 10.1002/jmri.21912; Global Strategy for Asthma Management and Prevention (2021), GLOB STRAT ASTHM MAN; Gonem S, 2014, CLIN EXP ALLERGY, V44, P499, DOI 10.1111/cea.12257; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Gupta S, 2014, J ALLERGY CLIN IMMUN, V133, P729, DOI 10.1016/j.jaci.2013.09.039; Hajari AJ, 2012, J APPL PHYSIOL, V112, P937, DOI 10.1152/japplphysiol.00768.2011; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hanon S, 2014, RESP MED, V108, P1601, DOI 10.1016/j.rmed.2014.07.019; Heaney LG, 2010, THORAX, V65, P787, DOI 10.1136/thx.2010.137414; Horsley AR, 2008, THORAX, V63, P135, DOI 10.1136/thx.2007.082628; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Kaushik SS, 2011, MAGN RESON MED, V65, P1155, DOI 10.1002/mrm.22697; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Mata JF, 2007, J APPL PHYSIOL, V102, P1273, DOI 10.1152/japplphysiol.00418.2006; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; McDonough JE, 2011, NEW ENGL J MED, V365, P1567, DOI 10.1056/NEJMoa1106955; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; PAIVA M, 1984, J APPL PHYSIOL, V56, P418, DOI 10.1152/jappl.1984.56.2.418; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Peces-Barba G, 2003, EUR RESPIR J, V22, P14, DOI 10.1183/09031936.03.00084402; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Robinson PD, 2013, EUR RESPIR J, V41, P507, DOI 10.1183/09031936.00069712; Robinson PD, 2009, RESPIRATION, V78, P339, DOI 10.1159/000225373; Saam BT, 2000, MAGN RESON MED, V44, P174, DOI 10.1002/1522-2594(200008)44:2<174::AID-MRM2>3.0.CO;2-4; Salerno M, 2002, RADIOLOGY, V222, P252, DOI 10.1148/radiol.2221001834; Thompson BR, 2013, J ALLERGY CLIN IMMUN, V131, P1322, DOI 10.1016/j.jaci.2013.01.054; Usmani OS, 2012, RESPIRATION, V84, P441, DOI 10.1159/000343629; Verbanck S, 1999, AM J RESP CRIT CARE, V159, P1545, DOI 10.1164/ajrccm.159.5.9809017; Verbanck S, 2004, AM J RESP CRIT CARE, V170, P414, DOI 10.1164/rccm.200401-037OC; Verbanck S, 1997, J APPL PHYSIOL, V83, P1907, DOI 10.1152/jappl.1997.83.6.1907; VERBANCK S, 1988, RESP PHYSIOL, V73, P273, DOI 10.1016/0034-5687(88)90072-2; Verbanck S, 2007, J APPL PHYSIOL, V103, P249, DOI 10.1152/japplphysiol.01384.2006; Verbanck S, 2010, J APPL PHYSIOL, V108, P793, DOI 10.1152/japplphysiol.01230.2009; Walker C, 2012, CURR OPIN PULM MED, V18, P42, DOI 10.1097/MCP.0b013e32834db255; Wang CB, 2006, MAGN RESON MED, V56, P296, DOI 10.1002/mrm.20944; Wang CB, 2008, J MAGN RESON IMAGING, V28, P80, DOI 10.1002/jmri.21408; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; Waters B, 2006, AM J RESP CRIT CARE, V173, P847, DOI 10.1164/rccm.200411-1595OC; Weibel ER, 2009, SWISS MED WKLY, V139, P375, DOI smw-12270; Woods JC, 2006, MAGN RESON MED, V56, P1293, DOI 10.1002/mrm.21076; Yablonskiy DA, 2002, P NATL ACAD SCI USA, V99, P3111, DOI 10.1073/pnas.052594699; Yablonskiy DA, 2014, MAGN RESON MED, V71, P486, DOI 10.1002/mrm.24729	65	24	24	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					417	425		10.1016/j.jaci.2015.06.027	http://dx.doi.org/10.1016/j.jaci.2015.06.027			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26242298	Green Submitted, Bronze			2022-12-18	WOS:000369235500010
J	Scott, J; Harris, GJ; Pinder, EM; Macfarlane, JG; Hellyer, TP; Rostron, AJ; Morris, AC; Thickett, DR; Perkins, GD; McAuley, DF; Widdrington, JD; Wiscombe, S; Baudouin, SV; Roy, AI; Linnett, VC; Wright, SE; Ruchaud-Sparagano, MH; Simpson, AJ				Scott, Jonathan; Harris, Graham J.; Pinder, Emma M.; Macfarlane, James G.; Hellyer, Thomas P.; Rostron, Anthony J.; Morris, Andrew Conway; Thickett, David R.; Perkins, Gavin D.; McAuley, Daniel F.; Widdrington, John D.; Wiscombe, Sarah; Baudouin, Simon V.; Roy, Alistair I.; Linnett, Vanessa C.; Wright, Stephen E.; Ruchaud-Sparagano, Marie-Helene; Simpson, A. John			Exchange protein directly activated by cyclic AMP (EPAC) activation reverses neutrophil dysfunction induced by beta(2)-agonists, corticosteroids, and critical illness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Neutrophil; beta(2)-agonist; cyclic AMP; exchange protein directly activated by cyclic AMP; hospital-acquired infection	RAP1; IDENTIFICATION; PHAGOCYTOSIS; SALBUTAMOL; GTPASES	Background: Neutrophils play a role in the pathogenesis of asthma, chronic obstructive pulmonary disease, and pulmonary infection. Impaired neutrophil phagocytosis predicts hospital-acquired infection. Despite this, remarkably few neutrophil-specific treatments exist. Objectives: We sought to identify novel pathways for the restoration of effective neutrophil phagocytosis and to activate such pathways effectively in neutrophils from patients with impaired neutrophil phagocytosis. Methods: Blood neutrophils were isolated from healthy volunteers and patients with impaired neutrophil function. In healthy neutrophils phagocytic impairment was induced experimentally by using beta(2)-agonists. Inhibitors and activators of cyclic AMP (cAMP)-dependent pathways were used to assess the influence on neutrophil phagocytosis in vitro. Results: beta(2)-Agonists and corticosteroids inhibited neutrophil phagocytosis. Impairment of neutrophil phagocytosis by beta(2)-agonists was associated with significantly reduced RhoA activity. Inhibition of protein kinase A (PKA) restored phagocytosis and RhoA activity, suggesting that cAMP signals through PKA to drive phagocytic impairment. However, cAMP can signal through effectors other than PKA, such as exchange protein directly activated by cyclic AMP (EPAC). An EPAC-activating analog of cAMP (8CPT-2Me-cAMP) reversed neutrophil dysfunction induced by beta(2)-agonists or corticosteroids but did not increase RhoA activity. 8CPT-2Me-cAMP reversed phagocytic impairment induced by Rho kinase inhibition but was ineffective in the presence of Rap-1 GTPase inhibitors. 8CPT-2Me-cAMP restored function to neutrophils from patients with known acquired impairment of neutrophil phagocytosis. Conclusions: EPAC activation consistently reverses clinical and experimental impairment of neutrophil phagocytosis. EPAC signals through Rap-1 and bypasses RhoA. EPAC activation represents a novel potential means by which to reverse impaired neutrophil phagocytosis.	[Scott, Jonathan; Harris, Graham J.; Pinder, Emma M.; Macfarlane, James G.; Hellyer, Thomas P.; Rostron, Anthony J.; Widdrington, John D.; Wiscombe, Sarah; Ruchaud-Sparagano, Marie-Helene; Simpson, A. John] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Morris, Andrew Conway] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; [Thickett, David R.] Univ Birmingham, Queen Elizabeth Hosp, Ctr Translat Inflammat Res, Birmingham B15 2TH, W Midlands, England; [Perkins, Gavin D.] Univ Warwick, Warwick Med Sch, Clin Trials Unit, Coventry CV4 7AL, W Midlands, England; [Perkins, Gavin D.] Univ Warwick, Heart England Fdn Trust, Coventry CV4 7AL, W Midlands, England; [McAuley, Daniel F.] Queens Univ Belfast, Ctr Infect & Immun, Hlth Sci Bldg, Belfast BT7 1NN, Antrim, North Ireland; [McAuley, Daniel F.] Royal Victoria Hosp, Reg Intens Care Unit, Belfast BT12 6BA, Antrim, North Ireland; [Baudouin, Simon V.] Royal Victoria Infirm, Dept Anaesthet, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Roy, Alistair I.] Sunderland Royal Hosp, Integrated Crit Care Unit, Sunderland, Durham, England; [Linnett, Vanessa C.] Queen Elizabeth Hosp, Intens Care Unit, Gateshead, England; [Wright, Stephen E.] Freeman Rd Hosp, Intens Care Unit, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham; University of Warwick; Heart of England NHS Foundation Trust; University of Warwick; Queens University Belfast; Newcastle University - UK; Sunderland Royal Hospital; Newcastle Freeman Hospital; Newcastle University - UK	Simpson, AJ (corresponding author), Newcastle Univ, Sch Med, Inst Cellular Med, 3rd Floor,William Leech Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.simpson@ncl.ac.uk	Perkins, Gavin/E-7613-2010; Morris, Andrew Conway/B-8644-2012	Morris, Andrew Conway/0000-0002-3211-3216; Simpson, John/0000-0003-4731-7294; Perkins, Gavin/0000-0003-3027-7548; Rostron, Anthony/0000-0002-9336-1723; Scott, Jonathan/0000-0003-3102-4294; thickett, david/0000-0002-5456-6080; Hellyer, Thomas P/0000-0001-5346-7411; McAuley, Daniel/0000-0002-3283-1947	Newcastle University; National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre; Academy of Medical Sciences (AMS) [AMS-SGCL13-Conway-Morris] Funding Source: researchfish; Medical Research Council [MR/L002736/1, G1100196] Funding Source: researchfish; National Institute for Health Research [DHCS/06/06/010, CL-2013-01-001, CL-2013-14-007, NF-SI-0514-10139] Funding Source: researchfish; MRC [MR/L002736/1, G1100196] Funding Source: UKRI	Newcastle University; National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre(National Institute for Health Research (NIHR)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by Newcastle University and the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre. G.D.P. is Director of Research for the Intensive Care Foundation and an NIHR Senior Investigator.	Breckler M, 2011, CELL SIGNAL, V23, P1257, DOI 10.1016/j.cellsig.2011.03.007; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Diviani D, 2011, AM J PHYSIOL-HEART C, V301, pH1742, DOI 10.1152/ajpheart.00569.2011; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Hoenderdos K, 2013, AM J RESP CELL MOL, V48, P531, DOI 10.1165/rcmb.2012-0492TR; Horvat SJ, 2012, FASEB J, V26, P3670, DOI 10.1096/fj.11-201020; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; IGNARRO LJ, 1974, J EXP MED, V139, P1395, DOI 10.1084/jem.139.6.1395; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jones SL, 2002, J LEUKOCYTE BIOL, V71, P1042; Kamanova J, 2008, J IMMUNOL, V181, P5587, DOI 10.4049/jimmunol.181.8.5587; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kim JG, 2012, J BIOL CHEM, V287, P5145, DOI 10.1074/jbc.M111.257634; Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205; Morris AC, 2011, BLOOD, V117, P5178, DOI 10.1182/blood-2010-08-304667; Morris AC, 2009, AM J RESP CRIT CARE, V180, P19, DOI 10.1164/rccm.200812-1928OC; Perkins GD, 2007, THORAX, V62, P36, DOI 10.1136/thx.2006.059410; Perkins GD, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-113; Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; STEVENS MG, 1991, VET IMMUNOL IMMUNOP, V28, P45, DOI 10.1016/0165-2427(91)90042-B; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006; Wittchen ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073070	25	24	25	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					535	544		10.1016/j.jaci.2015.07.036	http://dx.doi.org/10.1016/j.jaci.2015.07.036			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26388312	Bronze, Green Published			2022-12-18	WOS:000369235500023
J	Suri, R; Periselneris, J; Lanone, S; Zeidler-Erdely, PC; Melton, G; Palmer, KT; Andujar, P; Antonini, JM; Cohignac, V; Erdely, A; Jose, RJ; Mudway, I; Brown, J; Grigg, J				Suri, Reetika; Periselneris, Jimstan; Lanone, Sophie; Zeidler-Erdely, Patti C.; Melton, Geoffrey; Palmer, Keith T.; Andujar, Pascal; Antonini, James M.; Cohignac, Vanessa; Erdely, Aaron; Jose, Ricardo J.; Mudway, Ian; Brown, Jeremy; Grigg, Jonathan			Exposure to welding fumes and lower airway infection with Streptococcus pneumoniae	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Occupational disease; welding fumes; platelet-activating factor receptor; Streptococcus pneumoniae; pneumonia; bacterial adhesion and infection	ACTIVATING-FACTOR RECEPTOR; INHALATION EXPOSURE; DEFENSE RESPONSES; LUNG INFLAMMATION; CIGARETTE-SMOKE; DISEASE; INJURY; CELLS; BINDING	Background: Welders are at increased risk of pneumococcal pneumonia. The mechanism for this association is not known. The capacity of pneumococci to adhere to and infect lower airway cells is mediated by host-expressed platelet-activating factor receptor (PAFR). Objective: We sought to assess the effect of mild steel welding fumes (MS-WF) on PAFR-dependent pneumococcal adhesion and infection to human airway cells in vitro and on pneumococcal airway infection in a mouse model. Methods: The oxidative potential of MS-WF was assessed by their capacity to reduce antioxidants in vitro. Pneumococcal adhesion and infection of A549, BEAS-2B, and primary human bronchial airway cells were assessed by means of quantitative bacterial culture and expressed as colony-forming units (CFU). After intranasal instillation of MS-WF, mice were infected with Streptococcus pneumoniae, and bronchoalveolar lavage fluid (BALF) and lung CFU values were determined. PAFR protein levels were assessed by using immunofluorescence and immunohistochemistry, and PAFR mRNA expression was assessed by using quantitative PCR. PAFR was blocked by CV-3988, and oxidative stress was attenuated by N-acetylcysteine. Results: MS-WF exhibited high oxidative potential. In A549 and BEAS-2B cells MS-WF increased pneumococcal adhesion and infection and PAFR protein expression. Both CV-3988 and N-acetylcysteine reduced MS-WF-stimulated pneumococcal adhesion and infection of airway cells. MS-WF increased mouse lung PAFR mRNA expression and increased BALF and lung pneumococcal CFU values. In MS-WF-exposed mice CV-3988 reduced BALF CFU values. Conclusions: Hypersusceptibility of welders to pneumococcal pneumonia is in part mediated by the capacity of welding fumes to increase PAFR-dependent pneumococcal adhesion and infection of lower airway cells.	[Suri, Reetika; Grigg, Jonathan] Queen Mary Univ London, Blizard Inst, London, England; [Periselneris, Jimstan; Jose, Ricardo J.; Brown, Jeremy] Royal Free & Univ Coll Med Sch, Rayne Inst, Dept Med, Ctr Inflammat & Tissue Repair, London, England; [Lanone, Sophie; Andujar, Pascal; Cohignac, Vanessa] Fac Med, INSERM, U955, Equipe 4, Creteil, France; [Zeidler-Erdely, Patti C.; Antonini, James M.; Erdely, Aaron] NIOSH, Hlth Effects Lab Div, Morgantown, WV USA; [Melton, Geoffrey] Welding Inst, Cambridge CB1 6AL, England; [Palmer, Keith T.] Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton SO9 5NH, Hants, England; [Mudway, Ian] Kings Coll London, Fac Life Sci & Med, Analyt & Environm Sci Div, MRC PHE Ctr Environm & Hlth, London WC2R 2LS, England	University of London; Queen Mary University London; University of London; King's College London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); The Welding Institute (TWI); University of Southampton; University of London; King's College London	Grigg, J (corresponding author), Blizard Inst, London E1 2AT, England.	j.grigg@qmul.ac.uk	Periselneris, Jimstan/AAQ-2747-2020; Lanone, Sophie/I-4042-2016; Andujar, Pascal/A-2395-2013	Lanone, Sophie/0000-0003-2509-8799; Suri, Reetika/0000-0001-5509-2502; Mudway, Ian/0000-0003-1239-5014; Andujar, Pascal/0000-0002-9408-7033; Brown, Jeremy/0000-0002-5650-5361; Grigg, Jonathan/0000-0003-3109-6028; Jose, Ricardo Jorge Paixao/0000-0003-3645-6862	Colt Foundation [CF/05/12]; Wellcome Trust [097216/Z/11/Z]; Medical Research Council [MR/K00168X/1]; MRC [MR/K00168X/1, MC_PC_15015, MC_UP_A620_1018, MC_UU_12011/5] Funding Source: UKRI; Medical Research Council [MC_UP_A620_1018, MC_PC_15015, MC_UU_12011/5, U1475000005] Funding Source: researchfish; National Institute for Health Research [ACF-2009-18-029] Funding Source: researchfish	Colt Foundation; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by Colt Foundation grant number CF/05/12. R.J.J. is supported by Wellcome Trust grant 097216/Z/11/Z, and J.P. is supported by Medical Research Council grant MR/K00168X/1.	Andujar P, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-23; Antonini JM, 2007, TOXICOL APPL PHARM, V223, P234, DOI 10.1016/j.taap.2007.06.020; Antonini JM, 2009, INHAL TOXICOL, V21, P182, DOI 10.1080/08958370802360661 ; Antonini JM, 2006, J OCCUP ENVIRON HYG, V3, P194, DOI 10.1080/15459620600584352; Antonini JM, 2004, TOXICOL APPL PHARM, V200, P206, DOI 10.1016/j.taap.2004.04.022; Badding MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101310; COGGON D, 1994, LANCET, V344, P41, DOI 10.1016/S0140-6736(94)91056-1; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; Duitman J, 2012, P NATL ACAD SCI USA, V109, P9113, DOI 10.1073/pnas.1202641109; Godri KJ, 2010, ENVIRON SCI TECHNOL, V44, P8295, DOI 10.1021/es1016284; Grigg J, 2012, THORAX, V67, P908, DOI 10.1136/thoraxjnl-2011-200835; Han SG, 2005, AM J RESP CRIT CARE, V172, P1541, DOI 10.1164/rccm.200409-1222OC; Health and Safety Executive (HSE), 2014, PNEUM VACC EMPL EXP; Iovino F, 2013, CELL MICROBIOL, V15, P870, DOI 10.1111/cmi.12129; Kelly Frank, 2011, Res Rep Health Eff Inst, P73; Kim JY, 2005, OCCUP ENVIRON MED, V62, P157, DOI 10.1136/oem.2004.014795; Koh DH, 2015, OCCUP MED-OXFORD, V65, P72, DOI 10.1093/occmed/kqu136; McNeilly JD, 2004, TOXICOL APPL PHARM, V196, P95, DOI 10.1016/j.taap.2003.11.021; Messier EM, 2013, AM J RESP CELL MOL, V48, P559, DOI 10.1165/rcmb.2012-0295OC; Miller ML, 2007, J INFECT DIS, V195, P581, DOI 10.1086/510626; Mushtaq N, 2011, J ALLERGY CLIN IMMUN, V127, P1236, DOI 10.1016/j.jaci.2010.11.039; Palmer KT, 2009, THORAX, V64, P983, DOI 10.1136/thx.2009.114280; Palmer KT, 2003, AM J EPIDEMIOL, V157, P227, DOI 10.1093/aje/kwf188; Patterson L, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.21.21138; Phalen RF, 2006, TOXICOL SCI, V92, P126, DOI 10.1093/toxsci/kfj182; Registrar General, 1971, DEC SUPPL ENGL WAL 1; ROBERTSON DN, 1986, EUR J PHARMACOL, V123, P91, DOI 10.1016/0014-2999(86)90692-8; Smani Y, 2012, J BIOL CHEM, V287, P26901, DOI 10.1074/jbc.M112.344556; Suri R, 2014, RESP MED, V108, P898, DOI 10.1016/j.rmed.2014.03.003; Swords WE, 2000, MOL MICROBIOL, V37, P13, DOI 10.1046/j.1365-2958.2000.01952.x; Toren K, 2011, THORAX, V66, DOI 10.1136/thoraxjnl-2011-200707; van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4; Wong A, 2010, INT J INFECT DIS, V14, pE796, DOI 10.1016/j.ijid.2010.02.2268; Zimmer AT, 2002, J AEROSOL SCI, V33, P519, DOI 10.1016/S0021-8502(01)00189-6	34	24	27	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					527	+		10.1016/j.jaci.2015.06.033	http://dx.doi.org/10.1016/j.jaci.2015.06.033			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26277596	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000369235500022
J	Alexandrova, E; Miglino, N; Hashim, A; Nassa, G; Stellato, C; Tamm, M; Baty, F; Brutsche, M; Weisz, A; Borger, P				Alexandrova, Elena; Miglino, Nicola; Hashim, Adnan; Nassa, Giovanni; Stellato, Claudia; Tamm, Michael; Baty, Florent; Brutsche, Martin; Weisz, Alessandro; Borger, Pieter			Small RNA profiling reveals deregulated phosphatase and tensin homolog (PTEN)/phosphoinositide 3-kinase (PI3K)/Akt pathway in bronchial smooth muscle cells from asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Small noncoding RNA; asthma; smooth muscle cells; phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt pathway	ACTIVATED RECEPTOR-GAMMA; MICRORNA EXPRESSION; THERAPEUTIC TARGET; PROTEIN-RECEPTOR; MOLD ALLERGEN; MURINE MODEL; GENE; PTEN; IDENTIFICATION; POLYMORPHISMS	Background: Aberrant expression of small noncoding RNAs (sncRNAs), microRNAs (miRNAs) and PIWI-interacting RNAs (piRNAs) in particular, define several pathologic processes. Asthma is characterized by airway hyperreactivity, chronic inflammation, and airway wall remodeling. Asthma-specific miRNA profiles were reported for bronchial epithelial cells, whereas sncRNA expression in asthmatic bronchial smooth muscle (BSM) cells is almost completely unexplored. Objective: We sought to determine whether the primary BSM sncRNA expression profile is altered in asthmatic patients and identify targets of differentially expressed sncRNAs. Methods: Small RNA sequencing was used for sncRNA profiling in BSMcells (from 8 asthmatic and 6 nonasthmatic subjects). sncRNA identification and differential expression analysis was performed with iMir software. Experimentally validated miRNA targets were identified by using Ingenuity Pathway Analysis, and putative piRNA targets were identified by using miRanda software. Results: BSM cells from asthmatic patients showed abnormal expression of 32 sncRNAs (26 miRNAs, 5 piRNAs, and 1 small nucleolar RNA). Target prediction for deregulated miRNAs and piRNAs revealed experimentally validated and predicted mRNA targets expressed in the BSM cells. Thirty-eight of these mRNAs represent major targets for deregulated miRNAs and might play important roles in the pathophysiology of asthma. Interestingly, 6 of these mRNAs were previously associated with asthma, considered as novel therapeutic targets for treatment of this disease, or both. Signaling pathway analysis revealed involvement of 38 miRNA-targeted mRNAs in increased cell proliferation through phosphatase and tensin homolog and phosphoinositide 3-kinase/Akt signaling pathways. Conclusions: BSM cells of asthmatic patients are characterized by aberrant sncRNA expression that recapitulates multiple pathologic phenotypes of these cells.	[Alexandrova, Elena; Hashim, Adnan; Nassa, Giovanni; Stellato, Claudia; Weisz, Alessandro] Univ Salerno, Dept Med & Surg, Lab Mol Med & Genom, I-840811 Baronissi, Italy; [Alexandrova, Elena] Univ Salerno, Genomix4Life Srl, I-840811 Baronissi, Italy; [Miglino, Nicola; Tamm, Michael; Borger, Pieter] Univ Basel, Dept Biomed, CH-4031 Basel, Switzerland; [Baty, Florent; Brutsche, Martin] Kantonsspital St Gallen, Div Mol Pathol & Med Genom, St Gallen, Switzerland; [Weisz, Alessandro] SS Giovanni Dio & Ruggi Aragona Schuola Med Saler, Mol Pathol & Med Genom Unit, Salerno, Italy	University of Basel; Kantonsspital St. Gallen	Borger, P (corresponding author), Univ Basel, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland.	aweisz@unisa.it; pieter.borger@unibas.ch	Hashim, Adnan/Y-8924-2019; Weisz, Alessandro/A-1317-2014; Nassa, Giovanni/AAB-2059-2022; Alexandrova, Elena/Y-7455-2019; Alexandrova, Elena A/K-7241-2016	Weisz, Alessandro/0000-0003-0455-2083; Alexandrova, Elena/0000-0002-6220-6229; Alexandrova, Elena A/0000-0002-6220-6229; Brutsche, Martin/0000-0002-1612-3609; Stellato, Claudia/0000-0003-1513-3263; Nassa, Giovanni/0000-0001-7453-1240	Swiss National Science Foundation [310030_133109]; Italian Association for Cancer Research (AIRC) [IG-13176]; Ministry of Education, University and Research [PON_03PE_00146_1]; Ministry of Health [GR-2011-02347781]; National Research Council (CNR Flagship Project InterOmics); "Mario e Valeria Rindi'' fellowship of the Italian Foundation for Cancer Research (FIRC)	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministry of Education, University and Research; Ministry of Health; National Research Council (CNR Flagship Project InterOmics); "Mario e Valeria Rindi'' fellowship of the Italian Foundation for Cancer Research (FIRC)(Fondazione AIRC per la ricerca sul cancro)	Supported by the Swiss National Science Foundation (grant 310030_133109); the Italian Association for Cancer Research (AIRC, grant IG-13176); the Ministry of Education, University and Research (grant PON_03PE_00146_1); the Ministry of Health (Young Researchers grant GR-2011-02347781); and the National Research Council (CNR Flagship Project InterOmics). G.N. is supported by a "Mario e Valeria Rindi'' fellowship of the Italian Foundation for Cancer Research (FIRC).	Agrawal T, 2012, EXP MOL PATHOL, V93, P74, DOI 10.1016/j.yexmp.2012.04.004; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berk Barkin, 2005, Farmaco (Lausanne), V60, P974, DOI 10.1016/j.farmac.2005.08.011; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Borisov NM, 2014, ONCOTARGET, V5, P10198, DOI 10.18632/oncotarget.2548; Bracken CP, 2009, CELL MOL LIFE SCI, V66, P1682, DOI 10.1007/s00018-009-8750-1; Brock M, 2009, CIRC RES, V104, P1184, DOI 10.1161/CIRCRESAHA.109.197491; Burge SW, 2013, NUCLEIC ACIDS RES, V41, pD226, DOI 10.1093/nar/gks1005; Chen CZ, 2013, IMMUNOL REV, V253, P112, DOI 10.1111/imr.12060; Comer BS, 2015, AM J RESP CELL MOL, V52, P438, DOI 10.1165/rcmb.2014-0129OC; Enright AJ, 2004, GENOME BIOL, V5; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Garofalo M, 2011, ANNU REV PHARMACOL, V51, P25, DOI 10.1146/annurev-pharmtox-010510-100517; Giurato G, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-362; Gou LT, 2014, CELL RES, V24, P680, DOI 10.1038/cr.2014.41; Hashim A, 2014, ONCOTARGET, V5, P9901, DOI 10.18632/oncotarget.2476; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Holgate ST, 2005, BRIT J PHARMACOL, V145, P1009, DOI 10.1038/sj.bjp.0706272; Hosgood HD, 2009, RESP MED, V103, P1866, DOI 10.1016/j.rmed.2009.06.016; Hu RX, 2014, FASEB J, V28, P2347, DOI 10.1096/fj.13-247247; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Kariyawasam HH, 2008, AM J RESP CRIT CARE, V177, P1074, DOI 10.1164/rccm.200709-1376OC; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Keglowich L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089875; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027; Lakshmi SS, 2008, NUCLEIC ACIDS RES, V36, pD173, DOI 10.1093/nar/gkm696; Larner-Svensson HM, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-68; Leonardo TR, 2012, NAT CELL BIOL, V14, P1114, DOI 10.1038/ncb2613; Litonjua AA, 2008, AM J RESP CRIT CARE, V178, P688, DOI 10.1164/rccm.200709-1363OC; Machado RD, 2012, SCIENTIFICA CAIRO, V2012; Malenfant S, 2013, PULM CIRC, V3, P278, DOI 10.4103/2045-8932.114752; Mattick JS, 2009, BIOESSAYS, V31, P51, DOI 10.1002/bies.080099; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Mestdagh P, 2014, NAT METHODS, V11, P809, DOI [10.1038/NMETH.3014, 10.1038/nmeth.3014]; Miglino N, 2012, EUR RESPIR J, V40, P788, DOI 10.1183/09031936.00189811; Miglino Nicola, 2012, Open Respir Med J, V6, P1, DOI 10.2174/1874306401206010001; Narala VR, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-90; Ni ZH, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-47; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; Oh SH, 2009, RESP MED, V103, P1020, DOI 10.1016/j.rmed.2009.01.015; Park S, 2008, J KOREAN MATH SOC, V45, P1, DOI 10.1080/02770900701247319; Perry MM, 2014, AM J RESP CELL MOL, V50, P7, DOI 10.1165/rcmb.2013-0067OC; Pinkerton M, 2013, J ALLERGY CLIN IMMUN, V132, P217, DOI 10.1016/j.jaci.2013.03.006; Plank M, 2013, CLIN EXP ALLERGY, V43, P981, DOI [10.1111/cea.12135, 10.1111/cea.12170]; Rebane A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0424-x; Rebane A, 2013, J ALLERGY CLIN IMMUN, V132, P15, DOI 10.1016/j.jaci.2013.04.011; Rizzo F, 2014, HEPATOLOGY, V60, P798, DOI 10.1002/hep.27267; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Ross RJ, 2014, NATURE, V505, P353, DOI 10.1038/nature12987; Rouget C, 2010, NATURE, V467, P1128, DOI 10.1038/nature09465; Schnall-Levin M, 2011, GENOME RES, V21, P1395, DOI 10.1101/gr.121210.111; Severin J, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r39; Smit LAM, 2011, J ALLERGY CLIN IMMUN, V128, P185, DOI 10.1016/j.jaci.2011.04.007; Suojalehto H, 2014, INT ARCH ALLERGY IMM, V163, P168, DOI 10.1159/000358486; Thompson EE, 2007, J ALLERGY CLIN IMMUN, V119, P1423, DOI 10.1016/j.jaci.2007.03.029; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Trifilieff A, 2003, BRIT J PHARMACOL, V139, P163, DOI 10.1038/sj.bjp.0705232; Tumaneng K, 2012, NAT CELL BIOL, V14, P1322, DOI 10.1038/ncb2615; Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215; Weiss LA, 2005, AM J RESP CRIT CARE, V172, P67, DOI 10.1164/rccm.200411-1555OC; Williams AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005889; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056914	68	24	27	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					58	67		10.1016/j.jaci.2015.05.031	http://dx.doi.org/10.1016/j.jaci.2015.05.031			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26148798	Bronze			2022-12-18	WOS:000367724300044
